MINUTES OF 324th MEETING OF REGISTRATION BOARD
HELD ON 24th to 26th January, 2023

Item No.	Detail of Item	Page No
I.	Confirmation of Minutes of 322nd meeting of Registration Board…….	3
II	Confirmation of Minutes of 323rd meeting of Registration Board……	3
III.	Division of Pharmaceutical Evaluation & Registration ----------	
	Pharmaceutical Evaluation Cell (PEC) ----------	4-1745
	Registration-I Section ----------	1746-1757
	Registration-II Section ----------	1757-1764
	Post Registration-I Section ----------	1764-1769
	Post Registration-II Section ----------	1769-1770
	Export Facilitation Desk----------	1770-1774
	Post Registration-I Section (Additional Agenda)----------	1774
	Import & Vet-I Section ----------	1775
	Import & Vet-II Section ----------	1776-1781
IV.	Division of Biological Evaluation & Research	1782-1877
V.	Division of Quality Assurance & Laboratory Testing	1877-1896
VI.	Additional Agenda	1896-2094
VII.	Miscellaneous Cases	2094-20297

Drug Regulatory Authority of Pakistan
T.F. Complex, Mauve Area, G-9/4
Islamabad

324th meeting of Registration Board was held on 24th to 26th January, 2023 in the Committee Room, Drug Regulatory Authority of Pakistan, G-9/4, Islamabad.

The meeting was chaired by Dr. Obaidullah, Chairman Registration Board DRAP. The meeting started with recitation of the Holy Verses.

Chairman, Registration Board inform the Board that Dr. Noor us Saba, Director, Biological Division is going to be retired on 3rd February, 2023 and it is her last meeting as Director, Biological Division. Members of Registration Board appreciated the work done by Dr. Noor us Saba and wishes for her best future life.

Following members attended the meeting:

1.	Ch. Zeeshan Nazir Bajar, Additional Director (BE&R/PE&R), DRAP.	Member/ Secretary
2.	Lt. Gen.(R) Prof. Dr. Karamat A. Karamat (HI-M.SI-M), Former Surgeon General Pakistan.	Co-opted Member
3.	Mr. Iftikhar A. Chaudhary, Hospital Pharmacist, Lahore	Member
4.	Dr. Qurban Ali, Ex-Director General, National Veterinary Laboratories, Islamabad	Co-opted Member (online)
5.	Dr. Noor us Saba, Director, Biological Evaluation & Research Division, DRAP	Member
6.	Dr. Muhammad Akram, Animal Husbandry Commissioner, M/o NFS&R	Co-opted Member
7.	Mr. Muhammad Hafez Ur Rehman, Rep. of Director DTL Govt. of Punjab Rawalpindi	Member
8.	Mr. Muhammad Aslam, Deputy Draftsman-I, Ministry of law & Justice, Islamabad.	Member
9.	Mr. Ghulam Mujtaba, Deputy Director, Representative of IPO	Member
10.	Dr. Imran Khan, Director, DTL, Peshawar	Member (online)
11.	Mr. Ajmal Sohail Asif, Director, QA&LT Division	Member
12.	Mr. Babar Khan, Representative of Division of MD&MD	Member

Mr. Nadeem Alamgir (Pharma Bureau), Dr. Izhar Hussain, Mr. Hamid Raza, Mr. Uzair Nagra & Mr. Jalal-ud-Din (PPMA) and Mr. Ziaulhaq & Mr. Amir (PCDA) attended the meeting as observers.

Director, BE&R was assisted by respective Additional Director and Assistant Directors for presentation of the agenda.

Item No. I: Confirmation of Minutes of 322nd meetings of Registration Board.

322nd meeting of Registration Board was held on 8th & 10th November, 2022. Accordingly, draft minutes of 322nd meeting of Registration Board were circulated among the members on 9th December, 2022 for perusal/approval/comments (if any) by 14th December, 2022 at 10:00am. Mr. Iftikhar Ahmad, Member (Registration Board) thorough email dated 13th December, 2022 approved the minutes. Rest of the members did not pass any comment. Hence minutes of 322nd meeting of RB stand approved.

Accordingly, fair minutes of 322nd meeting of RB were processed for perusal/approval of Chairman, Registration Board. After approval from Chairman Registration Board, fair minutes of 323rd meeting of Registration Board were circulated among relevant Divisions / Sections for implementation / compliance of decisions.

Decision: Registration Board noted the information and unanimously confirmed the minutes of 322nd meeting of Registration Board.

Item No. II: Confirmation of Minutes of 323rd meetings of Registration Board.

323rd meeting of Registration Board was held on 6th to 8th December, 2022. Accordingly, draft minutes of 323rd meeting of Registration Board were circulated among the members on 04th January, 2023 for perusal/approval/comments (if any) by 09th January, 2023 at 10:00am. Mr. Hafeez ur Rehman, DTL, Rawalpindi through email on 07th January, 2023 responded and ***"Please proceed"***. Mr. Iftikhar Ahmed, Member Registration Board through email on 09th January2023 responded as ***"Approved"*** minutes of the meeting. Rest of the members did not give any comments. Rest of the members did not pass any comment. Hence minutes of 323rd meeting of RB stand approved.

Accordingly, fair minutes of 323rd meeting of RB were processed for perusal/approval of Chairman, Registration Board. After approval from Chairman Registration Board, fair minutes of 323rd meeting of Registration Board were circulated among relevant Divisions / Sections for implementation / compliance of decisions.

Decision: Registration Board noted the information and unanimously confirmed the minutes of 323rd meeting of Registration Board.

Item No. III Division of Pharmaceutical Evaluation & Registration

Pharmaceutical Evaluation Cell (PEC)

Sr. No	Name of Evaluator	Title
1.	Mr. Farooq Aslam	Evaluator PEC-I
2.	Mr. Ammar Ashraf Awan	Evaluator PEC-II
3.	Mr. Muhammad Haseeb Tariq	Evaluator PEC-III
4.	Mst.Farzana Raja	Evaluator PEC-IV
5.	Mst. Iqra Aftab	Evaluator PEC-V
6.	Mr. Ishtiaq Shafique	Evaluator PEC-VI
7.	Mr. Muhammad Usman	Evaluator PEC-VIII
8.	Mr. Adil Saeed	Evaluator PEC-IX
9.	Mst. Najia Saleem	Evaluator PEC-X
10.	Dr. Farhadullah	Evaluator PEC-XI
11.	Mr. Shahid Nawaz	Evaluator PEC-XIII
12.	Mst. Saima Hussain	Evaluator PEC-XV
13.	Mr. Akbar Ali	Evaluator PEC-XVI
14.	Mr. Zia Ullah	Evaluator PEC-XVII
15.	Mr. Muneeb Ahmed	Evaluator PEC-XVIII
16.	Mst. Sana Kanwal	Evaluator PEC-XX

Evaluator PEC-I (Farooq Aslam)

Case No. I: Registration applications submitted on Form 5F (Human Import):
Priority Applications:
As per Decision of 257th meeting of Registration Board the registration applications for New molecules / New formulations / Anticancer etc. will be considered out of queue.

1.	Name, address of Applicant / Importer	M/s Lab Diagnostic System (SMC) Pvt. Ltd. plot 36-A, PSIC Taxila, Rawalpindi.
	Details of Drug Sale License of importer	License No: 01-374-0006-96845D Address: Lab Diagnostic Systems Pvt. Ltd. 36-A, PSIC, SIE, Taxila Rawalpindi Godown: N/A Validity: 04/08/2024 Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	M/s Naprod Life Sciences Pvt. Ltd. Plot No. G-17/1, MIDC Tarapur, Boisar, Dist Palghar 401506, Mahaashtra state, India
	Name, address of manufacturer(s)	M/s Naprod Life Sciences Pvt. Ltd. Plot No. G-17/1, MIDC Tarapur, Boisar, Dist Palghar 401506, Mahaashtra state, India
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy GMP certificate no. New-WHO-GMp/CERT/KD/111021/11/40081 valid till 27/04/2025 issued by FDA M.H India. • Original legalized CoPP (No. COPPP/CERT/KD/114093/2022/11/41431/203265 dated 20/07/2022) issued by Food and Drug Administration M.H India. The applied product is available in the market of exporting country for free sale. The facilities and operations conform to WHO GMP. The certificate is valid till 27/04/2025. The certificate is issued for 10mL and 50mL filled volume (1mg/mL).	
	Details of letter of authorization / sole agency agreement: • Copy of letter of authorization is submitted from Naprod Life Sciences Pvt. Ltd. wherein M/s Lab Diagnostic Systems (SMC) is authorize for registration for 10mg/10mL cisplatin injection.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No.27755 : 30/09/2022
	Details of fee submitted	PKR 150,000/- : 12/09/2022
	The proposed proprietary name / brand name	Cisplab 10mg/10mL injection

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Cisplatin……1mg
	Pharmaceutical form of applied drug	Solution for IV injection
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	BP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Cisplatin 1mg/mL Sterile Concentrate (10mg/10mL, 50mg/50mL, 100mg/100mL), PL 04515/0026, MHRA Approved.
	For generic drugs (me-too status)	Cisplatin Injection 10mg by M/s Highnoon
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, detail of impurities and validations studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Sun Pharmaceutical Industris Ltd., A-7/A-8, MIDC, Industrial Area, Ahmednagar, 414111, Maharashtra, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 25oC±2 and 60%RH±5% for 72 months of 3 batches • Accelerated stability study is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: (AH-3-08013, AH-3-08014, AH-3-08015)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, compatibility studies of excipients with drug substance manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, detail of impurities and the validation studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not submitted.
	Analytical method validation/verification of product	The firm has submitted analytical method verification / validation studies for drug substance and drug product including linearity, accuracy, specificity, force degradation, precision etc.
	Container closure system of the drug product	Type I amber colored glass vial
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and65%RH±5% for 24 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: (NN7282, NN7287, NN7297)
Evaluation by PEC-I:		
Observations		**Response**
Please provide evidence of approval of the applied formulation by the reference regulatory authorities as specified by Registration Board in its 275th meeting and same strength and filled volume.		Cisplatin 1mg/mL Sterile Concentrate (10mg/10mL, 50mg/50mL, 100mg/100mL), PL 04515/0026, MHRA Approved.
Provide pharmaceutical equivalence studies against the reference / innovator's product (same strength and same filled volume) by performing the quality tests along with the detail of batch number, expiry, date of manufacturing, name of manufacturer etc.		*Please note that the pharmaceutical equivalence of 50mg/50mL is same for 10mg/10mL as the basic strength of product is 1mg/mL, only filled volume is different.*
Please provide detail of method of administration along with the accompanying diluents used for preparation of solution for IV administration. Provide compatibility studies of diluents with the applied formulation as well.		Submitted. Compatibility studies is submitted in 1000mL 0.9%Sodium chloride (after 12 hour storage at room temperature), 1000mL mixture of 0.9% sodium chloride (after 12 hour storage at room temperature), and 5% glucose (1:1), 1000mL 0.9% Sodium Chloride and Mannitol 5% (1:1) (after 12 hour storage at room temperature).
Decision: Approved as per Policy for inspection of manufacturer abroad. Registration letter will be issued upon submission of Pharmaceutical equivalence studies against the innovator/reference product of same fill volume and strength. • **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.** • **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**		
2.	Name, address of Applicant / Importer	M/s Lab Diagnostic System (SMC) Pvt. Ltd. plot 36-A, PSIC Taxila, Rawalpindi.
	Details of Drug Sale License of importer	License No: 01-374-0006-96845D Address: Lab Diagnostic Systems Pvt. Ltd. 36-A, PSIC, SIE, Taxila Rawalpindi Godown: N/A Validity: 04/08/2024

		Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	M/s Naprod Life Sciences Pvt. Ltd. Plot No. G-17/1, MIDC Tarapur, Boisar, Dist Palghar 401506, Mahaashtra state, India
	Name, address of manufacturer(s)	M/s Naprod Life Sciences Pvt. Ltd. Plot No. G-17/1, MIDC Tarapur, Boisar, Dist Palghar 401506, Mahaashtra state, India
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy GMP certificate no. New-WHO-GMp/CERT/KD/111021/11/40081 valid till 27/04/2025 issued by FDA M.H India. • Original legalized CoPP (No. COPPP/CERT/KD/114093/2022/11/41431/203268 dated 20/07/2022) issued by Food and Drug Administration M.H India. The applied product is available in the market of exporting country for free sale. The facilities and operations conform to WHO GMP. The certificate is valid till 27/04/2025. The certificate is issued for 10mL and 50mL filled volume (1mg/mL).	
	Details of letter of authorization / sole agency agreement: • Copy of letter of authorization is submitted from Naprod Life Sciences Pvt. Ltd. wherein M/s Lab Diagnostic Systems (SMC) is authorize for registration for 50mg/50mL cisplatin injection.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No.26941 : 23/09/2022
	Details of fee submitted	PKR 150,000/- : 12/09/2022
	The proposed proprietary name / brand name	Cisplab 50mg/50mL injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Cisplatin……1mg
	Pharmaceutical form of applied drug	Solution for IV injection
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	BP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	Cisplatin injction 50mg by M/s Atco

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, detail of impurities and validations studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Sun Pharmaceutical Industries Ltd., A-7/A-8, MIDC, Industrial Area, Ahmednagar, 414111, Maharashtra, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 25oC±2 and 60%RH±5% for 72 months of 3 batches • Accelerated stability study is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: (AH-3-08013, AH-3-08014, Ah-3-08015)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, compatibility studies of excipients with drug substance manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, detail of impurities and the validation studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against the reference product Platinol 50mg/50mL by performing all the quality tests (Batch number: 5F05063).
	Analytical method validation/verification of product	The firm has submitted analytical method verification / validation studies for drug substance and drug product including linearity, accuracy, specificity, force degradation, precision etc.
	Container closure system of the drug product	Type I amber colored glass vial
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and65%RH±5% for 24 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches

		Batches: (NN7283, NN7288, NN7298)
Evaluation by PEC-I:		
Observations		**Response**
Provide pharmaceutical equivalence studies against the reference / innovator's product (same strength and same filled volume) by performing the quality tests along with the detail of batch number, expiry, date of manufacturing, name of manufacturer etc.		Pharmaceutical equivalence is established against the reference product Platinol 50mg/50mL by performing all the quality tests (Batch number: 5F05063).
Please provide detail of method of administration along with the accompanying diluents used for preparation of solution for IV administration. Provide compatibility studies of diluents with the applied formulation as well.		Submitted. Compatibility studies is submitted in 1000mL 0.9%Sodium chloride (after 12 hour storage at room temperature), 1000mL mixture of 0.9% sodium chloride (after 12 hour storage at room temperature), and 5% glucose (1:1), 1000mL 0.9% Sodium Chloride and Mannitol 5% (1:1) (after 12 hour storage at room temperature).
Decision: Approved as per Policy for inspection of manufacturer abroad. • **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.** • **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**		

3.	Name, address of Applicant / Importer	M/s Himmel Pharmaceuticals (Pvt) Ltd. 793-D, Block "C", Faisal Town Lahore.
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174D **Address:** 793-D, Block C, Faisal Town District Lahore. **Validity:** 06-02-2022 **Status:** License to sell drugs as a distributor **Address of Go-down:** NA
	Name and address of marketing authorization holder (abroad)	M/s AqVia GmbH Kaiser-Wilhelm Str. 89 20355 Hamburg Germany.
	Name, address of manufacturer(s)	M/s AqVia GmbH Werkstr.21 23942 Dassow Germany.
	Name of exporting country	Germany
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate) **CoPP:** Firm has submitted Original, Legalized CoPP (Certificate# AQV/230720/34) issued on 23-07-2020 by Behörde für Justiz und Verbraucherschutz der Freien und Hansestadt Hamburg Abteilung V4 Pharmaziewesen und Medizinprodukte Billstraße 80 20539 Hamburg Germany. The CoPP confirms the free sale status of the applied product and GMP status of the manufacturer through periodic inspections every 2 years.	
	Details of letter of authorization / sole agency agreement Firm has submitted copy of letter of authorization dated 17-07-2020 from AqVida GmbH Kaiser-Wilhelm Str-89 20355 Hamburg Germany. The letter specifies irinotecan HCl AqVida 20mg/ml concentrate for solution for infusion with filling size of 0mg/2ml, 100mg.5ml and 300mg/15ml.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)

		☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy No 10480: 25-04-2022
	Details of fee submitted	PKR 150,000/-: 25-06-2021
	The proposed proprietary name / brand name	IRINOTECAN HCl AqVida 100mg/5mL concentrate for solution for infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Irinotecan hydrochloride as trihydrate ……..20mg
	Pharmaceutical form of applied drug	Clear yellow solution not more coloured than GT3, free of visible particles
	Pharmacotherapeutic Group of (API)	Other Antineoplastic agents
	Reference to Finished product specifications	In-House
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved.
	For generic drugs (me-too status)	Irinotel 100mg Injection by Atco pharma International (Reg#045763)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Laurus Labs Limited Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhpatnam Andhra Pradesh India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC / 60% RH. The stability study data is till 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of

		specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	Type I Amber Glass vial
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted long term stability data of 3 batches for 36 months at 30±2°C, 75±5%RH and 6 months at 40°C±75%RH for three batches.
Evaluation by PEC-I:		
Sr. No.	**Observations**	**Response**
1	Submit valid copy of Drug Sale License.	The firm has submitted revised Form 5F with change of address of the applicant which is as follows; **Name and address of applicant:** M/s Himmel Pharmaceuticals (pvt) Ltd., ground floor, 6-Judicial colony Phase-1 (ext), Shahrah Nazaria e Paksitan Lahore. **Details of new DSL:** **License No:** 05-352-0065-016174D **Address:** ground floor, 6-Judicial colony Phase-1 (ext), Shahrah Nazaria e Paksitan Lahore. **Validity:** 06-02-2024 **Status:** License to sell drugs as a distributor **Address of Go-down:** NA
2	Submit complete label claim as per the innovator's product in section 1.5.2 along with submission of requisite fee since you have only mentioned 100mg/5ml which does not correspond with the label claim of innovator's product.	The submitted label claim is different from the innovator's product. Each ml contains: Irinotecan as hydrochloride trihydrate ……..20mg Innovator's label claim: Each ml contains: Irinotecan hydrochloride trihydrate ……..20mg
3	Since Irinotecan HCl injection is diluted preferably in 5% Dextrose injection or 0.9% Sodium chloride Injection prior to IV Infusion, therefore, compatibility studies of the drug product with the diluents are required.	Submitted.
4	Submit pharmaceutical equivalence against the innovator's / reference product.	Pharmaceutical equivalence is submitted against reference product Campto 100mg/5mL Mfg by Pfizer Germany by performing quality tests. Batch number: D6A167
5	Provide reference of the specifications of drug product since you have not provided any reference while the drug product monograph is available in USP as well as JP pharmacopoeia. The firm has submitted comparison of USP and In-House specifications.	

Comparison			
Sr#	**Parameters**	**USP Specs**	**Manufacturer's Specs**
1	Appearance	-	Clear yellow solution not more colored than GY3, free of visible particles
2	pH	3.0–3.8	3.0–3.8
3	Extractable volume	≥ nominal volume	≥ nominal volume
4	Identity of irinotecan (HPLC)*	-	Positive
6	Assay of irinotecan hydrochloride, trihydrate [mg/ml] (HPLC)	90.0%-110.0%	95.0–105.0 %
7	Sub visible particles ≥ 10 µm ≥ 25 µm	-	≤ 6000/container ≤ 600/container
8	Related substances (HPLC) [%] 7-Ethyl-10-hydroxy-camptothecin	NMT 0.2	NMT 0.2
	Individual unknown	NMT 0.2	NMT 0.2
	Total unknown	NMT 0.2	NMT 0.2
	Total impurities	NMT1.0	NMT1.0
9	Sterility	Sterile	Complies with Ph. Eur
10	Bacterial endotoxins	≤ 0.83 Units/mg	≤ 11.00 EU/ml

Decision: Approved as per Policy for inspection of manufacturer abroad with following label claim:
"Each ml contains:
Irinotecan hydrochloride trihydrate ……. 20mg"

- **Registration letter will be issued upon submission of full fee for correction/pre-approval change in product label claim and DSL address, as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**
- **Furthermore Board decided that drug product specifications will be granted on the basis of comparison between manufacturer specifications and pharmacopoeial specifications, presented at the time of issuance registration letter.**

4.	Name, address of Applicant / Importer	M/s Al-Habib Pharmaceutical Plot # 81, Block B, SMCHS, Karachi.
	Details of Drug Sale License of importer	License No: 1245 Address: Al-Habib Pharmaceuticals 81-B Block SMCHS, Karachi Validity: 18/05/2022 Godown: 1. Plot no. 10 sector 25 KIA, Karachi 2. HT-8, Landhi Industrial Area, Karachi. Status: Drug License by way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s Qilu Pharmaceutical (Hainan) Co., Ltd., No. 273-A, Nanhai Avenue, National High-Tech Zone, Haikou, 570314, China.
	Name, address of manufacturer(s)	M/s Qilu Pharmaceutical (Hainan) Co., Ltd., No. 273-A, Nanhai Avenue, National High-Tech Zone, Haikou, 570314, China.
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy of DML No. Qiong20150030 valid till 22/1/2025 issued by National Medical Products Administration China is submitted. • Copy of GMP certificate no. HI20170029 valid till 22/10/2022 issued by Hainan provincial Food and Drug Administration. • Firm has submitted original, legalized COPP certificate (No. 20210042) dated 02-02-2021 valid till 02/03/2023 issued by Hainan Medical Product Administration, China. The applied product is available for free sale in the market of exporting country. The facilities and operations conform to WHO-GMP. The COPP is valid till 02-03-2023.	
	Details of letter of authorization / sole agency agreement:	

	• Legalized letter of authorization is submitted whereby M/s Qilu Pharmaceutical (Hainan) Co., Ltd., Has authorized M/s Al-Habib Pharmacueticlas as a sole agent and distributor of differnet product including the applied product.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5510 : 28-02-2022
	Details of fee submitted	PKR 150,000/-: 15-02-2022
	The proposed proprietary name / brand name	Iriton Injection 100mg/5mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Irinotecan Hydrochloride trihydrate……. 20mg
	Pharmaceutical form of applied drug	Sterile, pale yellow, clear aqueous solution for further dilution in recommended diluents for IV administration.
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	AS per SRO
	The status in reference regulatory authorities	MHRA Approved.
	For generic drugs (me-too status)	EFIXANO 100MG by M/s Ghani Brothers
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Qilu Pharmaceutical Co., Ltd., No. 243 Gongyebei road, Jinan China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 25oC±2 and 60%RH±5% for 24 months of 3 batches Batches: 307001GV, 30700GV, 307003GV
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability. The qualitative composition of the applied product is similar to the reference product therefore, the firm has not submitted compatibility studies of excipients with the drug substance.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against the reference product Camptosar by M/s Pfizer USFDA approved (including physical and chemical tests). Batch number: HM60A (100mg/5mL) against the applied strength (batch number: 2B4E10309004) Batch number: obay1 (40mg/2mL) against applied strengths (Batch number : 1001003, 1010014, E1103001)
	Analytical method validation/verification of product	The firm has submitted analytical method validations/ verification studies for the drug substance as well as for the drug product including specificity, accuracy, precision, linearity, LOD / LOQ (for impurities), system suitability etc.
	Container closure system of the drug product	Brown colored type I glass vial with butyl rubber stopper and aluminium-Plastic cap.
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and 65%RH±5% for 36 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: EB3E7001, EB3E7001, EB3E7001 (40mg/2mL) EB4E7005, EB4E7006, EB4E7007 (100mg/5mL)

Evaluation by PEC:

•

Sr. No.	Observations	Response
1	Please submit Quality over all summary for the applied product as per WHO-PD template.	Submitted.
2	Since Irinotecan HCl injection is diluted preferably in 5% Dextrose injection or 0.9% Sodium chloride Injection prior to IV Infusion, therefore, compatibility studies of the drug product with the diluents are required.	Compatibility studies are submitted for 5% Dextrose as well as 0.9% Sodium Chloride by making final dilution equal to 0.12mg/ml to 2.8mg/ml. The solution is stable for 24 hours when stored at room temperature. At refrigerated condition, the solution is stable for 48 hours when dilute with Dextrose 5%. However, refrigerated storage is not recommended when the product is diluted with 0.9% Sodium Chloride. Since the product does not contain any antibacterial preservative therefore the product preferably, be used immediately after reconstitution.

3	Provide detail of process validation for the applied strength of drug product.	The firm has submitted process validation protocol and process validation report for the applied strengths.
4	Provide pharmaceutical equivalence studies for the applied product against the innovator's / reference product by performing the quality tests along with the details of mfg date, expiry, batch number etc of the reference product.	Pharmaceutical equivalence is established against the reference product Camptosar by M/s Pfizer USFDA approved (including physical and chemical tests). Batch number: HM60A (100mg/5mL) against the applied strength (batch number: 2B4E10309004) Batch number: obay1 (40mg/2mL) against applied strengths (Batch number : 1001003, 1010014, E1103001)
5	Please provide complete protocol and method of terminal sterilization for the applied product.	Submitted. (By HP).
6	Provide detail method and preparation of dilution for conducting the tests for specificity parameter of analytical method verification / validation studies along with the acceptance criteria.	Report for specificity testing along with the acceptance criteria is submitted.
Decision: Registration Board approved the product subject to compliance of current Import Policy for Finished Drugs.		

5.	Name, address of Applicant / Importer	M/s Al-Habib Pharmaceutical Plot # 81, Block B, SMCHS, Karachi.
	Details of Drug Sale License of importer	License No: 1245 Address: Al-Habib Pharmaceuticals 81-B Block SMCHS, Karachi Validity: 18/05/2022 Godown: 1. Plot no. 10 sector 25 KIA, Karachi 2. HT-8, Landhi Industrial Area, Karachi. Status: Drug License by way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s Qilu Pharmaceutical (Hainan) Co., Ltd., No. 273-A, Nanhai Avenue, National High-Tech Zone, Haikou, 570314, China.
	Name, address of manufacturer(s)	M/s Qilu Pharmaceutical (Hainan) Co., Ltd., No. 273-A, Nanhai Avenue, National High-Tech Zone, Haikou, 570314, China.
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy of DML No. Qiong20150030 valid till 22/1/2025 issued by National Medical Products Administration China is submitted. • Copy of GMP certificate no. HI20170029 valid till 22/10/2022 issued by Hainan provincial Food and Drug Administration. • Firm has submitted original, legalized COPP certificate (No. 20210044) dated 02-03-2021 valid till 02/03/2023 issued by Hainan Medical Product Administration, China. The applied product is available for free sale in the market of exporting country. The facilities and operations conform to WHO-GMP. The COPP is valid till 02-03-2023.	
	Details of letter of authorization / sole agency agreement: • Legalized letter of authorization is submitted whereby M/s Qilu Pharmaceutical (Hainan) Co., Ltd., Has authorized M/s Al-Habib Pharmacueticlas as a sole agent and distributor of differnet product including the applied product.	
	Status of the applicant	☐ Manufacturer ☒ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5509 : 28-02-2022
	Details of fee submitted	PKR 150,000/-: 15-02-2022
	The proposed proprietary name / brand name	Iriton Injection 40mg/2mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Irinotecan Hydrochloride trihydrate……. 20mg
	Pharmaceutical form of applied drug	Sterile, pale yellow, clear aqueous solution for further dilution in recommended diluents for IV administration.
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	AS per SRO
	The status in reference regulatory authorities	MHRA Approved.
	For generic drugs (me-too status)	CYTOTECAN INJECTION 40MG by M/s CCL
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Qilu Pharmaceutical Co., Ltd., No. 243 Gongyebei road, Jinan China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 25oC±2 and 60%RH±5% for 24 months of 3 batches

		Batches: 307001GV, 30700GV, 307003GV
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability. The qualitative composition of the applied product is similar to the reference product therefore, the firm has not submitted compatibility studies of excipients with the drug substance.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against the reference product Camptosar by M/s Pfizer USFDA approved (including physical and chemical tests). Batch number: HM60A (100mg/5mL) against the applied strength (batch number: 2B4E10309004) Batch number: obay1 (40mg/2mL) against applied strengths (Batch number : 1001003, 1010014, E1103001)
	Analytical method validation/verification of product	The firm has submitted analytical method validations/ verification studies for the drug substance as well as for the drug product including specificity, accuracy, precision, linearity, LOD / LOQ (for impurities), system suitability etc.
	Container closure system of the drug product	Brown colored type I glass vial with butyl rubber stopper and aluminium-Plastic cap.
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and 65%RH±5% for 36 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: EB3E7001, EB3E7001, EB3E7001 (40mg/2mL) EB4E7005, EB4E7006, EB4E7007 (100mg/5mL)

Evaluation by PEC:

Sr. No.	Observations	Response
1	Please submit Quality over all summary for the applied product as per WHO-PD template.	Submitted.
2	Since Irinotecan HCl injection is diluted preferably in 5% Dextrose injection or 0.9% Sodium chloride Injection prior to IV Infusion, therefore, compatibility studies of the drug product with the diluents are required.	Compatibility studies are submitted for 5% Dextrose as well as 0.9% Sodium Chloride by making final dilution equal to 0.12mg/ml to 2.8mg/ml. The solution is stable for 24 hours when stored at room temperature. At refrigerated condition, the solution is stable for 48 hours when dilute with Dextrose 5%. However, refrigerated storage is not recommended when the product is diluted with 0.9% Sodium Chloride. Since the product does not contain any antibacterial preservative therefore the product preferably, be used immediately after reconstitution.

3	Provide detail of process validation for the applied strength of drug product.	The firm has submitted process validation protocol and process validation report for the applied strengths.
4	Provide pharmaceutical equivalence studies for the applied product against the innovator's / reference product by performing the quality tests along with the details of mfg date, expiry, batch number etc of the reference product.	Pharmaceutical equivalence is established against the reference product Camptosar by M/s Pfizer USFDA approved (including physical and chemical tests). Batch number: HM60A (100mg/5mL) against the applied strength (batch number: 2B4E10309004) Batch number: obay1 (40mg/2mL) against applied strengths (Batch number : 1001003, 1010014, E1103001)
5	Please provide complete protocol and method of terminal sterilization for the applied product.	Submitted. (By HP).
6	Provide detail method and preparation of dilution for conducting the tests for specificity parameter of analytical method verification / validation studies along with the acceptance criteria.	Report for specificity testing along with the acceptance criteria is submitted.
7	Please submit form 5F for 40mg/2mL since the submitted form 5F is for the other strength of the applied formulation that IS 100MG/5Ml.	Submitted.
Decision: Registration Board approved the product as per Import Policy for Finished Drugs.		

6.	Name, address of Applicant / Importer	M/s A.J. Mirza Pharma (Pvt.) Ltd., 1st Floor, Shafi Court, Merewether Road, Civil Lines, Karachi. Pakistan.
	Details of Drug Sale License of importer	**License No:** DHODSK(Drugs)/-587 **Address:** 1st Floor, Shafi Court, Civil Lines, Merewether Road, Karachi, Pakistan. **Address of Godown:** 2nd floor Shafi Court, Civil lines Merewether road, Karachi. **Validity:** 22/12/2022* **Status: B**y way of whole sale *The firm has submitted copy of receipt for renewal of DSL dated 09/12/2022.
	Name and address of marketing authorization holder (abroad)	Jiangsu Hansoh Pharmaceutical Group Co. Ltd. No. 5, Dongjin Road Economic and Technical Development one, Lianyungang Jiangsu China.
	Name, address of manufacturer(s)	Jiangsu Hansoh Pharmaceutical Group Co. Ltd. No. 5, Dongjin Road Economic and Technical Development one, Lianyungang Jiangsu China.
	Name of exporting country	China.
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate) **CoPP:** Firm has submitted original, legalized CoPP (No. 20210592) dated 23-11-2021 for Fulvestrant Injection 0.25gm/5ml. The certificate confirms the free sale status of the product along with GMP status of the manufacturer.	
	Details of letter of authorization / sole agency agreement Firm has submitted copy of Letter of authorization dated 10-09-2021. The agreement is valid for 6 years and specifies Fulvestrant Injection 250mg/5ml pack size.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)

	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy No 5103: 23-02-2022
	Details of fee submitted	PKR 150,000/-: 10-02-2022
	The proposed proprietary name / brand name	**Vestrant Injection 250mg/5mL**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml pre-filled syringe contains: Fulvestrant ……..250mg
	Pharmaceutical form of applied drug	Clear colourless to yellow liquid for IM injection
	Pharmacotherapeutic Group of (API)	Estrogen receptor antagonist
	Reference to Finished product specifications	Not mentioned
	Proposed Pack size	250mg/5ml (2 syringes in a carton)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	Not submitted
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Jiangsu Hansoh Pharmaceutical Group Co. Ltd. Kaiti Road, Dapu Industrial Park, Economic and Technical Development Zone, Lianyungang Jiangsu China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 2 - 8°C. The stability study data is till 24 months. Batches: 2019051, 20190502, 20190503

	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against the reference product Faslodex Injection. Batch number: NX027
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	5ml type I clear glass barrel with PRTC luer-lock adaptor.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted long term stability data of 3 batches for 12 months at 2 – 8°C and 6 months at 25°C±60%RH for three batches. The storage conditions for the innovator's product is 2 to 8ºC.
Evaluation by PEC-I:		
1	Submit valid copy of Drug Sale License.	**License No:** DHODSK(Drugs)/-587 **Address:** 1st Floor, Shafi Court, Civil Lines, Merewether Road, Karachi, Pakistan. **Address of Godown:** 2nd floor Shafi Court, Civil lines Merewether road, Karachi. **Validity:** 22/12/2022* **Status: B**y way of whole sale *The firm has submitted copy of receipt for renewal of DSL dated 09/12/2022.
2	Specify the proposed brand name since you have mentioned "NA".	Vestrant Injection 250mg/5mL
3	Submit complete stability study data of 3 batches of the drug product till claimed shelf life according to the conditions of Zone-IVA.	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 2 - 8°C. The stability study data is till 24 months. Batches: 2019051, 20190502, 20190503
4	Provide reference of the specifications of drug product since you have not provided any reference along with the copy of monograph if available.	In-House
5	Provide pharmaceutical equivalence studies against the reference / innovator's product along with the detail of manufacturer, expiry, date of manufacturing, approval status in reference regulatory authorities etc.	Firm has submitted pharmaceutical equivalence against the reference product Faslodex Injection. Batch number: NX027
6	Terminal sterilization has not been adopted for manufacturing of the applied product and sterile filtration followed by aseptic filling have been selected as sterilization method, please justify with experimental data.	The firm has referred EMA public assessment report of the reference product that is Faslodex. *The manufacturing process for the finished product follows conventional pharmaceutical practices which include a solution compounding step, sterile filtration and aseptic filling into syringes followed by steering. Process is carried out under an inert gas overlay, which*

		has been shown to minimize formation of the oxidative degradation. Sterility is assured by filtration and aseptic filling. Terminal sterilization by heat or irradiation has been shown to be unsuitable for this product. Detail of filter: Material: Polytetrafluoroethylene (PTFE) Pore diameter: 0.2um Ref: EMA Public assessment report https://www.ema.europa.eu/en/documents/assessment-report/faslodex-epar-public-assessment-report_en.pdf
Decision: Approved as per Policy for inspection of manufacturer abroad with innovator's specifications. The Board further decided that the firm shall submit Rs. 7,500/- for as pre-registration variation fee for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.		
7.	Name, address of Applicant / Importer	M/s AMB HK Enterprises (pvt) Ltd., 2nd floor Plaza 60 commercial, Block-K, Phase 1, DHA, Lahore.
	Details of Drug Sale License of importer	License No: 05-352-0058-066904D Address: AMB HK Enterprises (Pvt) Ltd., 2nd floor, plaza 60 commercial, Bock-K, Phase-1, DHA, Lahore. Validity: 24-02-2023 Godown: N/A Status: License to sell drugs as a Distributor
	Name and address of marketing authorization holder (abroad)	M/s Livzon (Group) Pharmaceutical Factory, No. 38 Chuangye road north, Jinan district, Zhuhai, China.
	Name, address of manufacturer(s)	M/s Livzon (Group) Pharmaceutical Factory, No. 38 Chuangye road north, Jinan district, Zhuhai, China.
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy of DML No. Yue 20160261 valid till 05/08/2025 issued by National Medical Products Administration, Guangdong China is submitted. • Copy of GMP certificate no. GD20170696 valid till 19/04/2022 issued CFDA. • Firm has submitted original, legalized COPP certificate (No. Guangdong 20210333) dated 09-10-2021 valid till 08/10/2023 issued by Medical Product Administration of Guangdong Province, China. The applied product is available for free sale in the market of exporting country. The facilities and operations conform to WHO-GMP. The COPP is valid till 02-03-2023.	
	Details of letter of authorization / sole agency agreement:	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 4539 : 17-02-2022

	Details of fee submitted	PKR 150,000/-: 11-01-2022
	The proposed proprietary name / brand name	Vorizole 0.1g for injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Voriconazole……..100mg (Lyophilized powder)
	Pharmaceutical form of applied drug	
	Pharmacotherapeutic Group of (API)	Anti-fungal for systemic use
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	Rs. 650/- for 1's
	The status in reference regulatory authorities	
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Shenzhen Haibin Pharamceutical Co., Ltd., No. 2003, Shatoujiao Shenyan road, Yantian District, Shenzen.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 30oC±2 and 65%RH±5% for 24 months of 3 batches Batches: 71806904, 71806905, 71809901
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, detail of impurities (including impurity D and F) analytical procedures (for impurities as well), validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	

	Analytical method validation/verification of product	The firm has submitted analytical method validations/ verification studies for the drug substance as well as for the drug product including specificity, accuracy, precision, linearity, LOD / LOQ (for impurities), system suitability etc.
	Container closure system of the drug product	Low borosilicate glass vial s with chlorinated butyl rubber stopper coated with polytetrafluoroethylene film.
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and 65%RH±5% for 24 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: 190301, 190302, 190303

Evaluation by PEC:

Sr. No.	Observations
1	Please provide evidence of approval of the applied in same strength is reference regulatory authorities as approved in 275th meeting of Registration Board.
2	Provide pharmaceutical equivalence studies for the applied product against the innovator's / reference product along with the detail of batch number, expiry, date of manufacturing, approval status if reference country etc.
3	Compatibility study of excipient with the drug substance are required.
4	Since the product is lyophilized powder for infusion and the detail of accompanying reconstitution diluents have not been provided. Please detail of method of administration along with the detail of all the diluents used for reconstitution along with the compatibility studies of the formulation with the diluents.
5	As per submitted dossier, the specifications for the drug product are USP while the product is not present in USP, please clarify and submit Rs. 7,500/- fee for revision of specifications as per notification number No.F.7-11/2021-B&A/DRAP dated 07-05-2021.
6	Analytical method is not provided with the submitted dossier, please provide detailed analytical method for the drug product including the specifications.
7	Provide product specific sole agency agreement for the applied product.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

8.	Name, address of Applicant / Importer	M/s AMB HK Enterprises (pvt) Ltd., 2nd floor Plaza 60 commercial, Block-K, Phase 1, DHA, Lahore.
	Details of Drug Sale License of importer	License No: 05-352-0058-066904D Address: AMB HK Enterprises (Pvt) Ltd., 2nd floor, plaza 60 commercial, Bock-K, Phase-1, DHA, Lahore. Validity: 24-02-2023 Godown: N/A Status: License to sell drugs as a Distributor
	Name and address of marketing authorization holder (abroad)	M/s Hebei Tiancheng Pharmaceutcal Co.,Ltd., No. 18, Jinguang street, Economic &Technological Development zone, Changzhou City, Hebei Province, China. (Headd Office)
	Name, address of manufacturer(s)	M/s Hebei Tiancheng Pharmaceutcal Co.,Ltd., No. 51, Jinguang street, Economic &Technological Development zone, Changzhou City, Hebei Province, China.
	Name of exporting country	China

	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy of DML No. HEBEI20150098 valid till 12/11/2025 issued by Hebei Medicla Products Administrtaion is submitted. • Copy of GMP certificate no. HE20180059 valid till 16/07/2023 issued Hebei FDA.	
	Details of letter of authorization / sole agency agreement:	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 30343 : 26-10-2022
	Details of fee submitted	PKR 150,000/-: 19-06-2022
	The proposed proprietary name / brand name	Movtin Injection 1g IV Powder for injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Creatine Phsphate Injection……1g
	Pharmaceutical form of applied drug	
	Pharmacotherapeutic Group of (API)	
	Reference to Finished product specifications	
	Proposed Pack size	1’s
	Proposed unit price	Rs. 1200/- for 1’s
	The status in reference regulatory authorities	
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	M/s Hebei Tiancheng Pharmaceutcal Co.,Ltd., east of Jingsi street, west area of Lingang economic & technological development zone, Canghzhou, Hebei province, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general

		properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 30oC±2 and 65%RH±5% for 24 months of 3 batches Batches: 20171102, 20171103, 20171104
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, detail of impurities analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	The firm has submitted analytical method validations/ verification studies for the drug substance as well as for the drug product including specificity, accuracy, precision, linearity, LOD / LOQ (for impurities), system suitability etc.
	Container closure system of the drug product	Low borosilicate glass vial s with Halogenated butyl rubber stopper
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and 65%RH±5% for 24 months of 3 batches Batch numbers: F11812091, F11812101, F11812111 • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: 110331, 1103311, 1104011

Evaluation by PEC:

•

Sr. No.	Observations
1	Please provide evidence of approval of the applied in same strength is reference regulatory authorities as approved in 275th meeting of Registration Board.
2	Provide pharmaceutical equivalence studies for the applied product against the innovator's / reference product along with the detail of batch number, expiry, date of manufacturing, approval status if reference country etc.
3	Compatibility study of excipient with the drug substance are required.
4	Since the product is powder for injection and the detail of accompanying reconstitution diluents have not been provided. Please detail of method of administration along with the detail of all the diluents used for reconstitution along with the compatibility studies of the formulation with the diluents.
5	As per submitted dossier, the specifications for the drug product are BP while the product is not present in BP, please clarify and submit Rs. 7,500/- fee for revision of specifications as per notification number No.F.7-11/2021-B&A/DRAP dated 07-05-2021.
6	Provide product specific sole agency agreement for the applied product.

7	Provide evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.	
8	Provide original, legalized and valid CoPP confirming the free sale of the applied product in exporting country and GMP status of the manufacturing facility.	
Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.		
9.	Name, address of Applicant / Importer	M/s AMB HK Enterprises (pvt) Ltd., 2nd floor Plaza 60 commercial, Block-K, Phase 1, DHA, Lahore.
	Details of Drug Sale License of importer	License No: 05-352-0058-066904D Address: AMB HK Enterprises (Pvt) Ltd., 2nd floor, plaza 60 commercial, Bock-K, Phase-1, DHA, Lahore. Validity: 24-02-2023 Godown: N/A Status: License to sell drugs as a Distributor
	Name and address of marketing authorization holder (abroad)	M/s Hainan Hualon Pharmacetical Co., Ltd., No. 8 Sanheng road, Pharmaceutical valley, national hi-tech industrial development zone, Haikou, Hainan, 570311, China
	Name, address of manufacturer(s)	
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Firm has submitted original, legalized COPP certificate (No. Hainan20210069) dated 12-05-2021 valid till 12-05-2023 issued by Medical Product Administration of Guangdong Province, China. The applied product is available for free sale in the market of exporting country. The facilities and operations conform to WHO-GMP. The COPP is valid till 12-05-2023.	
	Details of letter of authorization / sole agency agreement: • Copy of Foreign Agency Agreement is submitted. M/s Hainan Hualon Pharmaceutical co., Ltd., has authorized M/s AMB HK Enterprises (private) ltd., for distribution of different products including the applied product.	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 29849 : 21-10-2022
	Details of fee submitted	PKR 150,000/-: 24-11-2021
	The proposed proprietary name / brand name	Metachlor V Lotion 50mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Chlorhexidine gluconate…….1.2mg Metronidaole……...0.2mg

	Pharmaceutical form of applied drug	Vagina lotion
	Pharmacotherapeutic Group of (API)	Anti-infective / antiseptic
	Reference to Finished product specifications	In-House
	Proposed Pack size	1's
	Proposed unit price	Rs. 445/- per 1's (50mL)
	The status in reference regulatory authorities	
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and product.
	Name, address of drug substance manufacturer	Metronidazole: M/s Wuhan Wuyao Pharmaceutical Co., Ltd., No. 18 Wangfen road, Fuchi town, Yangxin county Huangshi city, Hubei province, China. Chlorhexidine: Jiu Tai Pharmaceutical Co., Ltd., No. 41 Tai'anli, Taihe district, Jinzhou city, Liaoning province, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Metronidazole: • Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 30oC±2 and 65%RH±5% for 60 months of 3 batches Batches: C04-W1312630, C04-W1312631, C04-W1312632 Chlorhexidien: • Real time stability studies have been conducted at 40oC±2 RH 75%±5 for 36 months of 3 batches • Accelerated stability study is conducted at 30oC±2 and 65%RH±5% for 48 months of 3 batches Batches: 211201211202211203
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, detail of impurities analytical procedures, validation of analytical procedures, batch analysis, justification of specifications,

		reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	The firm has submitted analytical method validations/ verification studies for the drug substance as well as for the drug product including specificity, accuracy, precision, linearity, LOD / LOQ (for impurities), system suitability etc.
	Container closure system of the drug product	HDPE bottle
	Stability study data of drug product, shelf life and storage conditions	• Real time stability studies have been conducted at 30oC±2 and 65%RH±5% for 36 months of 3 batches • Accelerated stability studies is conducted at 40oC±2 and 75%RH±5% for 6 months of 3 batches Batches: 110320200302, 20200307, 20200313

Evaluation by PEC:

Sr. No.	Observations
1	Please provide evidence of approval of the applied in same strength is reference regulatory authorities as approved in 275th meeting of Registration Board.
2	Provide evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
3	Provide relevant details of the product including batch number, expiry, date of manufacturing, approval status in reference country against which the pharmaceutical equivalence studies have been performed.
4	Compatibility study of excipient with the drug substance are required.
5	Provide product specific sole agency agreement for the applied product.
6	Provide analytical method validation studies for the applied product.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Case No. II: Registration applications submitted on Form 5F (Human, local manufacturing)
Priority Applications (New molecules / New Formulations / Anti-Cancer):

10.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22878 dated 12/08/2022
	Details of fee submitted	PKR 75,000/-: dated 27/07/2022

	The proposed proprietary name / brand name	Manidlow tablet 20mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Manidipine hydrochloride…..20mg
	Pharmaceutical form of applied drug	Uncoated immediate release Oral tablet
	Pharmacotherapeutic Group of (API)	Anti-hypertensive
	Reference to Finished product specifications	JP
	Proposed Pack size	10;s, 20's, 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PMDA Japan Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 68/2021-DRAP(FID-385689549774-222) issued on the basis of inspection conducted on 06/08/2021.
	Section approval	Tablet general section (revised)
	Name and address of API manufacturer.	M/s Xuchang Hensheng Pharmaceutical Co., Ltd., Jian an Fine Chemical Industry Park, Xuchang City, Henan Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 75% ± 5%RH for 42 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (20160701, 20161001, 20161002)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product. Excipients used in applied product are same as used in the innovator's product therefore, compatibility

		studies of excipients with the drug substance are not required.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is established against the innovator's product that is Calslot 20mg tablet, PMDA Approved by performing assay, content uniformity, dissolution identification etc. (Batch number: FD021). Comparative dissolution profile is submitted against the innovator's product in all the three recommended dissolution media. The value of f2 are well within the limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, Robustness, system suitability etc.

STABILITY STUDY DATA			
Manufacturer of API	M/s Xuchang Hensheng Pharmaceutical Co., Ltd., Jian an Fine Chemical Industry Park, Xuchang City, Henan Province, China.		
API Lot No.	20210601 (99.76)		
Description of Pack (Container closure system)	Alu-Alu blister packed in hardcard secondary unit cartom		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD/PR21-106/T1/S1	RD/PR21-106/T1/S2	RD/PR21-106/T1/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	11-2021	11-2021	11-2021
Date of Initiation	23-12-2021	23-12-2021	23-12-2021
No. of Batches	03		

Administrative Portion		
1	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has not submitted any response
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. HA20180002 valid till 12/01/2023 issued by Henan Province Food and Drug Administration.
3	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP attested invoice no. HS20210801 dated 14/09/2021 issued vide Dy. No. 14689 dated 30/09/2021 is submitted.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted

6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

This is a dihydropyridine-based calcium antagonist that specifically binds to membrane voltage-gated L-type calcium channels and reduces the influx of calcium into cells, thereby relaxing coronary and peripheral smooth muscle results in lowering of blood pressure.

The usual adult dosage is 10 to 20 mg of manidipine hydrochloride orally administered once daily after breakfast. However, administration should be started at 5 mg daily, and the dose should be increased gradually as necessary. The firm has not applied for 5mg strength.

Sr. No.	Observations	Response
1	Provide detailed method of analysis for drug substance for routine analysis along with the analytical method verification studies performed by drug product manufacturer including specificity, accuracy and precision.	Detailed method of analysis and analytical method verification studies for drug substance performed by drug product manufacturer are submitted.
2	As per submitted stability studies of drug substance from drug substance manufacturer, tests for heavy metals and Arsenic content have not been including in stability testing, please clarify.	The firm has submitted revised stability summary sheets of the same batches as submitted with initially submitted dossier containing the results of Arsenic content an heavy metal test without any clarification.
3	Provide complete batch manufacturing record for the applied product along with the justification for the dispensed quantity of the drug substance.	The firm has submitted complete batch manufacturing record.
4	Documents confirming import of the drug substance endorsed from DRAP field office are required.	Copy of DRAP attested invoice no. HS20210801 dated 14/09/2021 issued vide Dy. No. 14689 dated 30/09/2021 is submitted.
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin is required.	Copy of GMP certificate no. HA20180002 valid till 12/01/2023 issued by Henan Province Food and Drug Administration.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

11.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22662 dated 22/08/2022

	Details of fee submitted	PKR 75,000/-: dated 27/07/2022
	The proposed proprietary name / brand name	Manidlow tablet 10mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Manidipine hydrochloride…..10mg
	Pharmaceutical form of applied drug	Uncoated immediate release Oral tablet
	Pharmacotherapeutic Group of (API)	Anti-hypertensive
	Reference to Finished product specifications	JP
	Proposed Pack size	10;s, 20's, 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PMDA Japan Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 68/2021-DRAP(FID-385689549774-222) issued on the basis of inspection conducted on 06/08/2021.
	Section approval	Tablet general section (revised)
	Name and address of API manufacturer.	M/s Xuchang Hensheng Pharmaceutical Co., Ltd., Jian an Fine Chemical Industry Park, Xuchang City, Henan Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 75% ± 5%RH for 42 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (20160701, 201610001, 20161002)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure

		system and stability studies of drug product. Excipients used in applied product are same as used in the innovator's product therefore, compatibility studies of excipients with the drug substance are not required.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is established against the reference product that is Manidipine HCl by M/s Sawai 10mg tablet, PMDA Approved by performing assay, content uniformity, dissolution identification etc. (Batch number: 721Y02). Comparative dissolution profile is submitted against the reference product in all the three recommended dissolution media. The value of f2 are well within the limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, Robustness, system suitability etc.

STABILITY STUDY DATA

Manufacturer of API	M/s Xuchang Hensheng Pharmaceutical Co., Ltd., Jian an Fine Chemical Industry Park, Xuchang City, Henan Province, China.
API Lot No.	20210601 (99.76)
Description of Pack (Container closure system)	Alu-Alu blister packed in hardcard secondary unit cartom
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	RD/PR21-117/T1/S1	RD/PR21-117/T1/S2	RD/PR21-117/T1/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	11-2021	11-2021	11-2021
Date of Initiation	23-12-2021	23-12-2021	23-12-2021
No. of Batches	03		

Administrative Portion

1	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has not submitted any response
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. HA20180002 valid till 12/01/2023 issued by Henan Province Food and Drug Administration.
3	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP attested invoice no. HS20210801 dated 14/09/2021 issued vide Dy. No. 14689 dated 30/09/2021 is submitted.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

This is a dihydropyridine-based calcium antagonist that specifically binds to membrane voltage-gated L-type calcium channels and reduces the influx of calcium into cells, thereby relaxing coronary and peripheral smooth muscle results in lowering of blood pressure.

The usual adult dosage is 10 to 20 mg of manidipine hydrochloride orally administered once daily after breakfast. However, administration should be started at 5 mg daily, and the dose should be increased gradually as necessary. The firm has not applied for 5mg strength.

Sr. No.	Observations	Response
1	Provide detailed method of analysis for drug substance for routine analysis along with the analytical method verification studies performed by drug product manufacturer including specificity, accuracy and precision.	Detailed method of analysis and analytical method verification studies for drug substance performed by drug product manufacturer are submitted.
2	As per submitted stability studies of drug substance from drug substance manufacturer, tests for heavy metals and Arsenic content have not been including in stability testing, please clarify.	The firm has submitted revised stability summary sheets of the same batches as submitted with initially submitted dossier containing the results of Arsenic content an heavy metal test without any clarification.
3	Provide complete batch manufacturing record for the applied product along with the justification for the dispensed quantity of the drug substance.	Submitted.
4	Documents confirming import of the drug substance endorsed from DRAP field office are required.	Copy of DRAP attested invoice no. HS20210801 dated 14/09/2021 issued vide Dy. No. 14689 dated 30/09/2021 is submitted.
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin is required.	Copy of GMP certificate no. HA20180002 valid till 12/01/2023 issued by Henan Province Food and Drug Administration.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

12.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24209 dated 28/08/2022
	Details of fee submitted	PKR 75,000/-: dated 22/08/2022
	The proposed proprietary name / brand name	Cilnid tablet 10mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Cilnidipine…….10mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Calcium channel blocker / anti-hypertensive
	Reference to Finished product specifications	JP
	Proposed Pack size	10's, 20's, 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Atelec tablets (5mg, 10mg, 20mg), PMDA Japan approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 68/2021-DRAP(FID-385689549774-222) issued on the basis of inspection conducted on 06/08/2021.
	Section approval	Tablet general section (revised)
	Name and address of API manufacturer.	M/s Pure chemical Private limited, Plot no. 4717 GIDC estate, Ankleshwar 393002, Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (CLD150501P2. CLD150602P2, CLD150603P2)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of

		specification, reference standard, container closure system and stability studies of drug product. Excipients used in applied product are same as used in the innovator's product therefore, compatibility studies of excipients with the drug substance are not required.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is established against the innovator's product that is Atelec 10mg tablet, PMDA Approved by performing assay, content uniformity, dissolution identification etc. (Batch number: K837). Comparative dissolution profile is submitted against the innovator's product in all the three recommended dissolution media. The value of f2 are well within the limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, Robustness, system suitability etc.

STABILITY STUDY DATA			
Manufacturer of API	M/s Pure chemical Private limited, Plot no. 4717 GIDC estate, Ankleshwar 393002, Gujarat India.		
API Lot No.	CLD201703P8E (99.59)		
Description of Pack (Container closure system)	Alu-Alu blister packed in hard cardboard unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD/PR21-092/T1/S1	RD/PR21-092/T1/S2	RD/PR21-092/T1/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	09-2021	09-2021	09-2021
Date of Initiation	20-09-2021	20-09-2021	20-09-2021
No. of Batches	03		

Administrative Portion		
1	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has not submitted any response
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 21012385 valid till 03/01/2024 issued by Food and Drug Control Administration Gujarat India.
3	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice number EXP/015/21-22 dated 09/07/2021 cleared on 02/08/2021vide dy. No. 11436/2021.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator-I:

Antihypertensive effect with once-daily administration. This drug is a dual-action type Ca antagonist that blocks not only L-type Ca channels but also N-type Ca channels. It is thought that the increase in heart rate, suppression of stress-induced hypertension, and dilation of renal arterioles are exhibited.

Sr. No.	Observations	Response
1	The analytical method used for analysis of drug substance is in-house while the official monograph is available in JP, clarification is required. Moreover, the dilution prepared for analysis of drug substance is 0.02mg/mL as per analytical method verification studies the range is established from 0.08mg/mL to 0.12mg/mL concentration. The concentration of the dilution used for analysis is outside the established range, please clarify. Moreover, in the testing of accuracy parameter for analytical method verification studies of drug substance, the recovery of the dilution having concentration 80%, is out of acceptable limits, please justify.	• *Drug substance has been tested as per JP specs. There was a typo error of reference in shared analytical method, which has been amended and reference copy is attached.* • *LOD and LOQ is calculated for the method used in testing of substance. Our method is verified / validated to detect upto a limit of LOD 0.00317mg/mL and quantity limit LOQ 0.00962mg/mL. Dilution is prepared as 0.02mg/mL which is within the range of LOD and LOQ.* The firm has submitted method verification report. • The firm has submitted analytical method verification report wherein the out of specs results of accuracy parameter for 80% dilution have not been addressed.
2	Please provide analytical method verification studies considering the analytical method provided in JP along with the detail of all the dilutions prepared for drug product.	Submitted. Linearity is established from 0.08mg/mL to 0.12mg/mL and the dilution used for assay determination is outside the range (i.e upper limit).
3	Provide complete batch manufacturing record for the applied product along with the justification for the dispensed quantity of the drug substance.	Submitted.
4	Documents confirming import of the drug substance endorsed from DRAP field office are required.	Copy of invoice number EXP/015/21-22 dated 09/07/2021 cleared on 02/08/2021vide dy. No. 11436/2021.
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin is required.	Copy of GMP certificate No. 21012385 valid till 03/01/2024 issued by Food and Drug Control Administration Gujarat India.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **The Board further decided that the applicant shall submit analytical method verification / validation studies for drug substance as well as for drug product according to relevant JP monograph before the issuance of registration letter.**

13.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.

	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals (pvt) Ltd. 28-km Ferozepur rod, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24208 dated 28/08/2022
	Details of fee submitted	PKR 75,000/-: dated 22/08/2022
	The proposed proprietary name / brand name	Cilnid tablet 5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Cilnidipine…….5mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Calcium channel blocker / anti-hypertensive
	Reference to Finished product specifications	JP
	Proposed Pack size	10's, 20's, 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Atelec tablets (5mg, 10mg, 20mg), PMDA Japan approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 68/2021-DRAP(FID-385689549774-222) issued on the basis of inspection conducted on 06/08/2021.
	Section approval	Tablet general section (revised)
	Name and address of API manufacturer.	M/s Pure chemical Private limited, Plot no. 4717 GIDC estate, Ankleshwar 393002, Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and

		justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (CLD150501P2. CLD150602P2, CLD150603P2)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product. Excipients used in applied product are same as used in the innovator's product therefore, compatibility studies of excipients with the drug substance are not required.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is established against the innovator's product that is Atelec 5mg tablet, PMDA Approved by performing assay, content uniformity, dissolution identification etc. (Batch number: F260). Comparative dissolution profile is submitted against the innovator's product in all the three recommended dissolution media. The value of f2 are well within the limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, Robustness, system suitability etc.

STABILITY STUDY DATA			
Manufacturer of API	M/s Pure chemical Private limited, Plot no. 4717 GIDC estate, Ankleshwar 393002, Gujarat India.		
API Lot No.	CLD201703P8E (99.59)		
Description of Pack (Container closure system)	Alu-Alu blister packed in hard cardboard unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD/PR21-096/T1/S1	RD/PR21-096/T1/S2	RD/PR21-096/T1/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	09-2021	09-2021	09-2021
Date of Initiation	20-09-2021	20-09-2021	20-09-2021
No. of Batches	03		

Administrative Portion		
1	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has not submitted any response

2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 21012385 valid till 03/01/2024 issued by Food and Drug Control Administration Gujarat India.
3	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice number EXP/015/21-22 dated 09/07/2021 cleared on 02/08/2021vide dy. No. 11436/2021.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Antihypertensive effect with once-daily administration. This drug is a dual-action type Ca antagonist that blocks not only L-type Ca channels but also N-type Ca channels. It is thought that the increase in heart rate, suppression of stress-induced hypertension, and dilation of renal arterioles are exhibited.

Sr. No.	Observations	Response
1	The analytical method used for analysis of drug substance is in-house while the official monograph is available in JP, clarification is required. Moreover, the dilution prepared for analysis of drug substance is 0.02mg/mL as per analytical method verification studies the range is established from 0.08mg/mL to 0.12mg/mL concentration. The concentration of the dilution used for analysis is outside the established range, please clarify. Moreover, in the testing of accuracy parameter for analytical method verification studies of drug substance, the recovery of the dilution having concentration 80%, is out of acceptable limits, please justify.	• *Drug substance has been tested as per JP specs. There was a typo error of reference in shared analytical method, which has been amended and reference copy is attached.* • *LOD and LOQ is calculated for the method used in testing of substance. Our method is verified / validated to detect upto a limit of LOD 0.00317mg/mL and quantity limit LOQ 0.00962mg/mL. Dilution is prepared as 0.02mg/mL which is within the range of LOD and LOQ.* The firm has submitted method verification report. • The firm has submitted analytical method verification report wherein the out of specs results of accuracy parameter for 80% dilution have not been addressed.
2	Please provide analytical method verification studies considering the analytical method provided in JP along with the detail of all the dilutions prepared for drug product.	Submitted. Linearity is established from 0.08mg/mL to 0.12mg/mL and the dilution used for assay determination is outside the range (i.e upper limit).
3	Provide complete batch manufacturing record for the applied product along with the justification for the dispensed quantity of the drug substance.	Submitted.
4	Documents confirming import of the drug substance endorsed from DRAP field office are required.	Copy of invoice number EXP/015/21-22 dated 09/07/2021 cleared on 02/08/2021vide dy. No. 11436/2021.

5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin is required.	Copy of GMP certificate No. 21012385 valid till 03/01/2024 issued by Food and Drug Control Administration Gujarat India.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **The Board further decided that the applicant shall submit analytical method verification / validation studies for drug substance as well as for drug product according to relevant JP monograph before the issuance of registration letter.**

14.	Name, address of Applicant / Marketing Authorization Holder	M/s Horizon Healthcare Pvt., Ltd., Plot # 33, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s Horizon Healthcare Pvt., Ltd., Plot # 33, Sundar Industrial Estate Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12206 dated 19-05-2022
	Details of fee submitted	PKR 75,000/-: dated 11-05-2022
	The proposed proprietary name / brand name	Ibufam Tablet 800mg/26.6mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Ibuprofen…….800mg Famotidine……...26.6mg
	Pharmaceutical form of applied drug	Immediate release film coated tablet
	Pharmacotherapeutic Group of (API)	NSAID / Histamine H2 receptor antagonist
	Reference to Finished product specifications	Innovators specifications
	Proposed Pack size	As per SRO
	Proposed unit price	AS per SRO
	The status in reference regulatory authorities	USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 103/2020-DRAP (AD-1998036-5147) issued on the basis of inspection conducted on 18/06/2020 Is submitted,
	Name and address of API manufacturer.	**Ibuprofen:**

		M/s Zenith Chemical Industries (pvt) ltd. 16 kilometer off Ferozepur road, behind Wapda grid station, 1 kilometer of Chandrai road Lahore. **Famotidine:** M/s Vaasavaa Pharmaceuticals (p) Ltd., plot no. C-216 & 217, MIDC Chinocholi, Solapur, Maharashtra 413 255, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, impurity testing for impurity A-G, analytical procedure and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Ibuprofen:** • Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months • Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: ZIBU11-001, ZIBU11-002, ZIBU11-003 **Ibuprofen:** • Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months • Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: FM-IV/05/001, FM-IV/05/002, FM-IV/05/003
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence of the applied product s established against the reference product that is Duexis tablet, USFDA Approved by performing the quality tests (Batch number: PTBF-001). Comparative dissolution profile s submitted against the same reference product in 0.1N HCl (pH 1.2), Acetate Buffer (pH 4.5), Phosphate

		buffer (pH 6.8) and Potassium Phosphate buffer (pH 7.2). Values of F2 found to be within the specified limits.
	Analytical method validation/verification of product	Method validation studies are submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	**Ibuprofen:** M/s Zenith Chemical Industries (pvt) ltd. 16 kilometer off Ferozepur road, behind Wapda grid station, 1 kilometer of Chandrai road Lahore. **Famotidine:** M/s Vaasavaa Pharmaceuticals (p) Ltd., plot no. C-216 & 217, MIDC Chinocholi, Solapur, Maharashtra 413 255, India.		
API Lot No.	Ibuprofen: ZIBU21-087 (99.57) Famotidine: FAM-1221226 (99.83)		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.	IBF-001	IBF-002	IBF-003
Batch Size	5000 tab	5000 tab	5000 tab
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	16-02-2022	17-02-2022	16-02-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Ibuprofen:** Copy of GMP certificate no. 75/2021-DRAP(AD-2027105-531) dated 24/09/2021 issued on the basis of inspection conducted on 14/07/2021. **Famotidine:** Copy of GMP certificate No. 6100728 valid till 19/07/2022 issued by Food and Drug Administration Maharashtra India.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Ibuprofen:** Copy of Invoice number 00027/1121 dated 20/11/2021 is submitted. **Famotidine:** Copy of invoice number EP/21-22/118 dated 01/06/2021 cleared on 29/12/2021 vide dy. No. 19841/2021-DRAP.

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

The product is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers who require the use of Ibuprofen.

Sr. No.	**Observations**	**Response**
1	Provide analytical method verification studies including specificity, accuracy and precision performed by drug product manufacturer for Ibuprofen drug substance.	The analytical method verification report for Ibuprofen drug substance is provided performed by M/s Horizon Pharmacaeuticals.
2	Justify the selection of dissolution specification / parameters for the applied product since as per the available literature of the reference product, change in the dissolution specifications is proposed.	*Our dissolution parameters and specification meet the FDA reference ID 2909903 of FDA approved reference product DUEXIS Tablet. As the FDA recommendation the change of dissolution sampling time point. Hence, we taken the changed time point of dissolution as per FDA.*
3	Provide complete batch manufacturing record of the applied product along with the justification of the dispensed quantity of the drug substances considering the assay values.	The firm has submitted complete batch manufacturing record for the applied productis submitted along with the calcualtions.
4	The strengths of the dilutions prepared for analytical method validation studies (for Linearity), do not correspond to the strength of dilution as described in analytical method of the applied product that is 0.2mg/mL and 0.0066mg/mL for Ibuprofen and Famotidine respectively. Moreover, clarification is required regarding the final column load for concentration 01 to concentration 06 since the calculated strength of the concentration is different than the provided final column load. Furthermore, clarify the terms mentioned in validation report Target concentration and Load.	*The procedure for dilution preparation in analytical method validation report of linearity test was unintentionally written wrong. Therefore, we corrected the procedure of linearity test in report. The detailed corrected report analytical method validation has been attached.* *The Target concentration is the concentration that which we use for quantification for our analyte of interest with accuracy and precision while column load is amount of analyte which is injected to column.*
5	Provide detail of accuracy testing along with the acceptance criteria and preparation of dilutions.	Submitted.
6	Provide GMP certificate of Ibuprofen D.S manufacturer.	Copy of GMP certificate no. 75/2021-DRAP(AD-2027105-531) dated 24/09/2021 issued on the basis of inspection conducted on 14/07/2021.
7	Submitted stability data is till 3rd month time point, provide 06 months stability data of the applied product.	Submitted.

Decision: Deferred for consideration on its turn since applied formulation is already registered in name of M/s Global Pharmaceuticals vide registration no. 109397 and brand name Famoprofen tablet, hence instant application do not qualify for the prioriy consideration as new drug product.		
15.	Name, address of Applicant / Marketing Authorization Holder	M/s Horizon Healthcare Pvt., Ltd., Plot # 33, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s Horizon Healthcare Pvt., Ltd., Plot # 33, Sundar Industrial Estate Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12999 dated 27-05-2022
	Details of fee submitted	PKR 75,000/-: dated 11-05-2022
	The proposed proprietary name / brand name	**Lefazon tablet 600mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Lefamulin as Acetate……..600mg
	Pharmaceutical form of applied drug	Antibacterial
	Pharmacotherapeutic Group of (API)	Immediate release film coated tablet
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Xenelta 600mg tablet, USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 103/2020-DRAP (AD-1998036-5147) issued on the basis of inspection conducted on 18/06/2020 Is submitted.
	Name and address of API manufacturer.	M/s Kaifeng Pharmaceutical (Group) Company Limited, No. 1, Yunan street, Kaifeng Henan, Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, impurity testing for impurity A-G, analytical procedure and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: • Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: 200211, 200308, 200415
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence and CDP is submitted against the reference product Xenelta 600mg tablet, USFDA Approved (Batch number: 12345). Results of pharmaceutical equivalence are comparable. F2 values for CDP testing are within the acceptable limits.
	Analytical method validation/verification of product	Method validation studies are submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	M/s Kaifeng Pharmaceutical (Group) Company Limited, No. 1, Yunan street, Kaifeng Henan, Province, China.		
API Lot No.	HF220115 (98.94)		
Description of Pack (Container closure system)	Alu-Alu Blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.	LA-001	LA-002	LA-003
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	17-02-2022	18-02-2022	19 -02-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of Drug Production License no. Yu20150031 valid till 31/12/2025 issued by FDA Henan Province is submitted. Copy of GMP certificate no. HA20190069 valid till 2/09/2024 issued by CFDA.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice number CIN20220101L01 dated 20/01/2022 cleared on 25/01/2022 vide dy. No. 1328/2022-DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

The applied product is indicated for the treatment of adults with community acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

Sr. No.	**Observations**	**Response**
1	Provide detail of preparation of final dilution for assay of drug substance and correlate the strength of the final dilution with the established linearity range.	*The details of preparation of the final dilution of assay of drug substance are provided in method validation detailed report. Our target concentration correlate with linearity range at 2nd concentration for linearity preparations.* Range: 0.15mg/mL, 0.30mg/mL, 0.45mg/mL, 0.60mg/mL, 0.75mg/mL, 0.90mg/mL, 1.05mg/mL,
2	Submitted stability data is till 3rd month time point, provide 06 months stability data of the applied product.	Submitted.
3	Provide complete batch manufacturing record for the applied product.	Submitted.
4	Dissolution medium selected for the applied product is 0.1N HCl and as per submitted CDP results the drug product gives more than 80% release in 45 minutes while in the final product dissolution specification, drug release should be more than 80% in 60 minutes. Justify the selection of 60 minutes time point for sampling instead of fixing it at 45 minutes.	*Our specification of dissolution is NLT 80% (Q) at 60 minutes. The results provided in CDP report are not meet the USP criteria of dissolution at S_1 stage. Thus, the results of CDP are the average of 12 units and meets the criteria of S_2 stage. Also, the FDA provided sampling time point is 60 minutes. Hence, we followed the FDA approved reference product time point.*

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. III: Export facilitation

In Pursuance od decision of 133rd meeting of the Authroity held on 13th April, 2022, wherein it was decided that for each 100,000/- USD worth of export of medicine during a fiscal year, one molecule will be considered on prority.

a. Registration applications submitted on Form 5F:

16.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Name, address of Manufacturing site.	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 20205 dated 15/07/2022
	Details of fee submitted	PKR 75,000/-: dated 04/07/2022
	The proposed proprietary name / brand name	**MOXETIN Oral solution 4mg/ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml of oral solution contains: Atomoxetine as hydrochloride…….4mg
	Pharmaceutical form of applied drug	Clear colourless solution
	Pharmacotherapeutic Group of (API)	Psychoanaleptic.
	Reference to Finished product specifications	Innovator specification
	Proposed Pack size	30ml & 100ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	STRATTERA 4mg/ml Oral solution by Eli Lilly and Company Limited, Austria Approved MHRA Approved.
	For generic drugs (me-too status)	Not available
	GMP status of the Finished product manufacturer	New GMP granted on 07/10/2021
	Section approval	Syrup/ suspension oral (General antibiotic) approved.
	Name and address of API manufacturer.	M/s ZCL Chemicals Limited Plot No. 3102/B, GIDC Estate Ankleshwar-393002, Dist.-Bharuch, Gujarat, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure

		system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Atomoxetine HCL is tested on USP specifications. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (ATOP150214, ATOP150314 & ATOP150414)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure, its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator's product that is STRATTERA 4mg/ml Oral solution (Batch No: A473913A) by Eli Lilly and Company Limited by performing quality tests (Appearance, Identification, pH, Assay,)
	Analytical method validation/verification of product	Method validation studies have been submitted including specificity, linearity, accuracy, precision, repeatability, intermediate precision, robustness, range and justification of system suitability

STABILITY STUDY DATA

Manufacturer of API	M/s ZCL Chemicals Limited Plot No. 3102/B, GIDC Estate Ankleshwar-393002, Dist.-Bharuch, Gujarat, India.		
API Lot No.	ATO2501020		
Description of Pack (Container closure system)	Packed in white LDPE bag, then another black bag placed in aluminium bag, and sealed with tie seal. Finally, the bag is placed in HDPE container.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3, 6, 9 ,12,18 & 24 (Months)		
Batch No.	21SB(B)-164-01	21SB(B)-165-02	21SB(B)-166-03
Batch Size	(66 bottle) 2000ml	(66 bottle) 2000ml	(66 bottle) 2000ml
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	20-10-2021	20-10-2021	20-10-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted by the firm
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. 21072771 valid till 06/07/2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Purchase invoice No. 2221129 attested by AD I&E DRAP, Karachi dated 26.08.2021 is submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Indications:

Strattera is used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children from 6 years of age, adolescents and adults as part of a comprehensive treatment program.

Sr. No.	Observations	Firm's response
1	• Submitted drug substance analytical procedure for Assay test from drug substance manufacturer is not as per USP monograph. • Submitted drug substance analytical procedure for Assay test from drug product manufacturer is different from that applied by drug substance manufacturer. • Analytical method verification studies performed by M/s Genix Pharma shall be submitted.	Drug product manufacturer has adopted USP method for analysis of drug substance and analytical method verifications studies from drug product manufacturer according to USP are submitted.
2	Submit valid working standard COA applied for the drug substance analysis by M/s Genix Pharma.	The analytical report from M/s Genix pharma is Submitted. Report no. AMV-RR-003/01/23
3	Test for content of antimicrobial preservative & efficacy of preservative, as recommended by ICH Q1 (R2) guidelines & USP chapter <51>, has not been included in the finished product specifications. You are required to submit justification in this regard. Test for content of antimicrobial preservative & efficacy of preservative, as recommended by ICH Q1 (R2) guidelines, has not been performed during stability studies, justify.	*We conducted this test in development stage initially and not a part of routine analysis, that is why it is not included in finished product SOP. Although we have separate SOP of antimicrobial preservative test.* Sop No. QC/SOP/SY/032 dated 14-06-2022 is submitted. M/s Genix Pharma has stated that thy had performed the preservative test at initial time point and will be performed at final time point htat is 24th month. Moreover, M/s Genix Pharma has submitted preservative efficacy test report for Moxetine Oral solution for

		all the three batches at initial time point. Document no. QC/RFT/077
4	Please provide detail of batch size of the stability batches in terms of number of units / bottles.	66 bottles (2000 mL)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Vide letter No. F.1-6/2019-PR-I(EFD) dated 29/12/2022

17.	Name, address of Applicant / Marketing Authorization Holder	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Name, address of Manufacturing site.	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12655 dated 24/05/2022
	Details of fee submitted	PKR 30,000/-: dated 23/04/2022
	The proposed proprietary name / brand name	**Vonzin 20mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vonoprazan as fumarate…….20mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Potassium competitive acid blocker / anti-ulcer
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	AS per SRO
	Proposed unit price	AS per SRO
	The status in reference regulatory authorities	PMDA Japan

	For generic drugs (me-too status)	Vonzan by Getz Pharma
	GMP status of the Finished product manufacturer	Copy GMP certificate No F.11-96/2021-DRAP-97 issued on the basis of inspection conducted on 11/11/2021.
	Section approval	Tablet General Section
	Name and address of API manufacturer.	M/s XianQiang Pharmaceutical Co., Ltd., No. 6, Industry avenue, conghua economy development zone, Guangzhou, Guangdong province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards , container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 75% ± 5%RH for 24 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (TAK09R150701, TAK09R150702, TAK09R150703,)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is submitted against Voniza tablet 20mg by M/s Hilton Pharma by performing all the quality tests. (Batch number 138864). Comparative dissolution profile is submitted against the same brand that is Voniza in all the three media 0.1N HCl, acetate buffer and phosphate buffer. Fs values are within the acceptable limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, LOD/LOQ, Robustness, Solution stability, system suitability
STABILITY STUDY DATA		

Manufacturer of API	M/s XianQiang Pharmaceutical Co., Ltd., No. 6, Industry avenue, conghua economy development zone, Guangzhou, Guangdong province, China.		
API Lot No.	TAK09R210101		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T031	T032	T033
Batch Size	1200 tablets	1200 tablets	1200 tablets
Manufacturing Date	08-2021	09-2021	09-2021
Date of Initiation	01-09-2021	02-09-2021	03-09-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any response.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of drug manufacturing certificate (no. Yue20160016) issued on 24/12/2020 valid till 23/12/2025 issued by NMPA. Copy of GMP certificate (No.20210620) issued Guangdong Pharmaceutical Industry Association is submitted valid till 19/06/2026.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Copy of form 6, license to import drugs for clinical trial, examination, test or analysis. copy of invoice number EAC20210220017 dated 17/02/2021.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	Provide analytical method verification studies performed by drug product manufacturer.	Analytical method verification / validation report is submitted including accuracy, precision, specificity etc.
2	Please provide document confirming import of drug substance (invoice etc) endorsed from DRAP field office.	The firm has submitted Copy of form 6, license to import drugs for clinical trial, examination, test or analysis.

		copy of invoice number EAC20210220017 dated 17/02/2021.
3	Justify the selection of Phosphate buffer as dissolution media for dissolution testing since innovator has used different media.	0.05M Acetate Buffer (pH 4.5) has been used by the innovator for dissolution testing while the firm has selected Phosphate buffer (pH 6.8). The firm has stated that initially they had conducted dissolution studies in all the three media that is 0.1N HCl, acetate buffer and phosphate buffer and the applied product was found to be least soluble in 6.8 pH medium. Therefore, they had selected the Phosphate Buffer as dissolution media. The firm has stated that they had revised the dissolution specifications and conducted dissolution testing according to revised dissolution specs as per innovator (Acetate Buffer as dissolution media). The results of dissolution testing on stability batches are submitted.
4	Provide valid GMP certificate of drug substance manufacturer issued by relevant authority.	Copy of drug manufacturing certificate (no. Yue20160016) issued on 24/12/2020 valid till 23/12/2025 issued by NMPA. Copy of GMP certificate (No.20210620) issued Guangdong Pharmaceutical Industry Association is submitted valid till 19/06/2026.
5	As per submitted specifications, Disintegration time for the applied product is 30 minutes while the dissolution limits are NLT 75% in 15 minutes, please revise the specification for D.T along with the submission of applicable fee.	The firm has not revise the specifications for disintegration (D.T) and has referred to USP general chapter <701>.
6	Provide batch size of trial batches.	1200 tablets
7	Please justify the dispensed quantity of drug substance considering the assay on As-is basis.	The quantity of drug substance dispensed on the basis of 100 percent potency while it should have been calculated on As-is based assay value.
8	Since pharmaceutical equivalence and CDP studies are required to be performed against the reference / innovator's product while you have submitted the said studies against Voniza tablet, please clarify.	*The innovator's product was not available at the time of product development stage therefore, the said studies were conducted against comparator's product.*

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufacturer shall consider potency adjustment on basis of Assay results of drug substance on "as is basis" for dispensing of commercial batches.**
- **Registration letter will be issued upon submission of Rs. 7,500/- fee for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.**

18.	Name, address of Applicant / Marketing Authorization Holder	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Name, address of Manufacturing site.	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11267 dated 11/05/2022
	Details of fee submitted	PKR 30,000/-: dated 17/04/2022
	The proposed proprietary name / brand name	**Vonzin 10mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vonoprazan as fumarate…….10mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Potassium competitive acid blocker / anti-ulcer
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PMDA Japan
	For generic drugs (me-too status)	Vonzan by Getz Pharma
	GMP status of the Finished product manufacturer	Copy GMP certificate No F.11-96/2021-DRAP-97 issued on the basis of inspection conducted on 11/11/2021.
	Section approval	Tablet General Section
	Name and address of API manufacturer.	M/s XianQiang Pharmaceutical Co., Ltd., No. 6, Industry avenue, conghua economy development zone, Guangzhou, Guangdong province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards , container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 75% ± 5%RH for 24

		months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (TAK09R150701, TAK09R150702, TAK09R150703,)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is submitted against Voniza tablet 10mg by M/s Hilton Pharma by performing all the quality tests. (Batch number 138849). Comparative dissolution profile is submitted against the same brand that is Voniza in all the three media 0.1N HCl, acetate buffer and phosphate buffer. Fs values are within the acceptable limits.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, LOD/LOQ, Robustness, Solution stability, system suitability

STABILITY STUDY DATA

Manufacturer of API	M/s XianQiang Pharmaceutical Co., Ltd., No. 6, Industry avenue, conghua economy development zone, Guangzhou, Guangdong province, China.		
API Lot No.	TAK09R210101		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T029	T028	T030
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	24-08-2021	23-08-2021	25-08-2021
No. of Batches	03		

Administrative Portion

1	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any response.
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of drug manufacturing certificate (no. Yue20160016) issued on 24/12/2020 valid till 23/12/2025 issued by NMPA. Copy of GMP certificate (No.20210620) issued Guangdong Pharmaceutical Industry Association is submitted valid till 19/06/2026.

3	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Copy of form 6, license to import drugs for clinical trial, examination, test or analysis. copy of invoice number EAC20210220017 dated 17/02/2021.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	Provide analytical method verification studies performed by drug product manufacturer.	Analytical method verification / validation report is submitted including accuracy, precision, specificity etc.
2	Please provide document confirming import of drug substance (invoice etc) endorsed from DRAP field office.	The firm has submitted Copy of form 6, license to import drugs for clinical trial, examination, test or analysis. copy of invoice number EAC20210220017 dated 17/02/2021.
3	Justify the selection of Phosphate buffer as dissolution media for dissolution testing since innovator has used different media.	0.05M Acetate Buffer (pH 4.5) has been used by the innovator for dissolution testing while the firm has selected Phosphate buffer (pH 6.8). The firm has stated that initially they had conducted dissolution studies in all the three media that is 0.1N HCl, acetate buffer and phosphate buffer and the applied product was found to be least soluble in 6.8 pH medium. Therefore, they had selected the Phosphate Buffer as dissolution media. The firm has stated that they had revised the dissolution specifications and conducted dissolution testing according to revised dissolution specs as per innovator (Acetate Buffer as dissolution media). The results of dissolution testing on stability batches are submitted.
4	Provide valid GMP certificate of drug substance manufacturer issued by relevant authority.	Copy of drug manufacturing certificate (no. Yue20160016) issued on 24/12/2020 valid till 23/12/2025 issued by NMPA. Copy of GMP certificate (No.20210620) issued Guangdong Pharmaceutical Industry Association is submitted valid till 19/06/2026.
5	As per submitted specifications, Disintegration time for the applied product is 30 minutes while the dissolution limits are NLT 75% in 15 minutes, please revise the specification for D.T along with the submission of applicable fee.	The firm has not revise the specifications for disintegration (D.T) and has referred to USP general chapter <701>.

6	Provide batch size of trial batches.	1200 tablets
7	Please justify the dispensed quantity of drug substance considering the assay on As-is basis.	The quantity of drug substance dispensed on the basis of 100 percent potency while it should have been calculated on As-is based assay value.
8	Since pharmaceutical equivalence and CDP studies are required to be performed against the reference / innovator's product while you have submitted the said studies against Voniza tablet, please clarify.	*The innovator's product was not available at the time of product development stage therefore, the said studies were conducted against comparator's product.*

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufacturer shall consider potency adjustment on basis of Assay results of drug substance on "as is basis" for dispensing of commercial batches.**
- **Registration letter will be issued upon submission of Rs. 7,500/- fee for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.**

Vide letter no. F.1-6/2019-PR-I(EFD dated 29/12/2022.

19.	Name, address of Applicant / Marketing Authorization Holder	M/s Sami Pharmaceuticals, F-95, Off Hub river Road, S.I.T.E, Karachi.
	Name, address of Manufacturing site.	M/s Sami Pharmaceuticals, F-95, Off Hub river Road, S.I.T.E, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 23369 dated 18/08/2022
	Details of fee submitted	PKR 30,000/-: dated 22/06/2022
	The proposed proprietary name / brand name	**Vozan 10mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vonoprazan as Fumarate……10mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Potassium competitive acid blocker/anti-ulcer
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7's, 14's, 28's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PMDA Japan approved.

	For generic drugs (me-too status)	Vonozan by Getz Pharma
	GMP status of the Finished product manufacturer	Inspection date: 26-03-2020 & 13-04-2020 Based on the areas inspected, people met, processes observed and intention of the firm for continuous improvement at the time of inspection it is concluded that the firm is operating at a Good level of GMP compliance.
	Section approval	Tablet Section (General/General Antibiotic)
	Name and address of API manufacturer.	M/s Ami life Sciences private limited, block no. 82/B, ECP road,AT & Post, Karakhadi-391450, Taluka, Padra, District Vadodara. Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months • Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (VPF/30051020, VPF/30031020, VPF/30041020)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution profile is submitted against Vonozan 10mg tablet mfg by Getz Pharma, (Batch number 003FF8) in all thre recommended media that is 0.1N HCL, acetate buffer and phosphate buffer. F2 values have not been calculated since more than 85% release is observed within 15 minutes. Pharmaceutical equivalence is established against the same brand by performing all the quality tests.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, LOD/LOQ, Robustness, Solution stability, system suitability
STABILITY STUDY DATA		

Manufacturer of API	M/s Ami life Sciences private limited, block no. 82/B, ECP road,AT & Post, Karakhadi-391450, Taluka, Padra, District Vadodara. Gujarat India.		
API Lot No.	VPF/30021020		
Description of Pack (Container closure system)	Alu-pvc foil acked in secondary unit carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Lab-01	Lab-02	Lab-03
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	25-11-2021	25-11-2021	25-11-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted by the firm
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. S-GMP & GLP/21032496 valid till 04/03/2023 issued by Food & Drugs Control Administration.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no. EXP/I/21-22/0168 dated 06/07/2021 cleared on 16/01/2021 vide dy. No. 2275/21.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator-I:

Sr. No.	Observations	Response
1	Provide documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no. EXP/I/21-22/0168 dated 06/07/2021 cleared on 16/01/2021 vide dy. No. 2275/21.
2	Please justify the selection of dissolution parameters for the applied product. Specifications of Tripak tablets (USFDA approved): USP II, 50rpm, 900mL, 37^0C, 0.05M Acetate Buffer (4.5), 15minutes) Applied product:	The firm has stated that the dissolution specifications of the innovator's product approved by PMDA Japan are not revealed therefore, the specifications were developed In-House. The dissolution specifications of Tripak are revealed in the literature. The firm has submitted test results of 3 batches according to

	USP II, 50rpm, 900mL, 37^0C, Phosphate Buffer, 30 minutes	dissolution specification as revealed in the literature.
3	Provide valid GMP certificate of drug substance manufacturer.	Copy of GMP certificate no. S-GMP & GLP/21032496 valid till 04/03/2023 issued by Food & Drugs Control Administration.
4	Provide complete BMR of the applied product along with the justification of the dispensed quantity of drug substance.	Submitted.
5	Since pharmaceutical equivalence and CDP studies are required to be performed against the reference / innovator's product while you have submitted the said studies against Vonozan tablet, please clarify.	The firm has stated that the innovator product was not available in Pakistan and due to failure in arranging the product, they had conducted comparative analysis with the comparator's product.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Registration letter will be issued upon submission of Rs. 7,500/- fee for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.**

20.	Name, address of Applicant / Marketing Authorization Holder	M/s Sami Pharmaceuticals, F-95, Off Hub river Road, S.I.T.E, Karachi.
	Name, address of Manufacturing site.	M/s Sami Pharmaceuticals, F-95, Off Hub river Road, S.I.T.E, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 23370 dated 18/08/2022
	Details of fee submitted	PKR 30,000/-: dated 22/06/2022
	The proposed proprietary name / brand name	**Vozan 20mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vonoprazan as Fumarate……20mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Potassium competitive acid blocker/anti-ulcer
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7's, 14's, 28's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PMDA Japan approved.

	For generic drugs (me-too status)	Vonozan by Getz Pharma
	GMP status of the Finished product manufacturer	Inspection date: 26-03-2020 & 13-04-2020 Based on the areas inspected, people met, processes observed and intention of the firm for continuous improvement at the time of inspection it is concluded that the firm is operating at a Good level of GMP compliance.
	Section approval	Tablet Section (General/General Antibiotic)
	Name and address of API manufacturer.	M/s Ami life Sciences private limited, block no. 82/B, ECP road,AT & Post, Karakhadi-391450, Taluka, Padra, District Vadodara. Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months • Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (VPF/30051020, VPF/30031020, VPF/30041020)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution profile is submitted against Vonozan 10mg tablet mfg by Getz Pharma, (Batch number 004FF9) in all the recommended media that is 0.1N HCL, acetate buffer and phosphate buffer. F2 values have not been calculated since more than 85% release is observed within 15 minutes. Pharmaceutical equivalence is established against the same brand by performing all the quality tests.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, LOD/LOQ, Robustness, Solution stability, system suitability
STABILITY STUDY DATA		

Manufacturer of API	M/s Ami life Sciences private limited, block no. 82/B, ECP road,AT & Post, Karakhadi-391450, Taluka, Padra, District Vadodara. Gujarat India.		
API Lot No.	VPF/30021020		
Description of Pack (Container closure system)	Alu-pvc foil packed in secondary unit carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Lab-01	Lab-01	Lab-01
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	13-12-2021	13-12-2021	13-12-2021
No. of Batches	03		

Administrative Portion

1	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted ay response.
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. S-GMP & GLP/21032496 valid till 04/03/2023 issued by Food & Drugs Control Administration.
3	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no. EXP/I/21-22/0168 dated 06/07/2021 cleared on 16/01/2021 vide dy. No. 2275/21.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	Provide documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no. EXP/I/21-22/0168 dated 06/07/2021 cleared on 16/01/2021 vide dy. No. 2275/21.
2	Please justify the selection of dissolution parameters for the applied product. Specifications of Tripak tablets (USFDA approved): USP II, 50rpm, 900mL, 37^0C, 0.05M Acetate Buffer (4.5), 15minutes) Applied product:	The firm has stated that the dissolution specifications of the innovator's product approved by PMDA Japan are not revealed therefore, the specifications were developed In-House. The dissolution specifications of Tripak are revealed in the literature. The firm has submitted test results of 3 batches according to

	USP II, 50rpm, 900mL, 37^0C, Phosphate Buffer, 30 minutes	dissolution specification as revealed in the literature.
3	Provide valid GMP certificate of drug substance manufacturer.	Copy of GMP certificate no. S-GMP & GLP/21032496 valid till 04/03/2023 issued by Food & Drugs Control Administration.
4	Provide complete BMR of the applied product along with the justification of the dispensed quantity of drug substance.	Submitted.
5	Since pharmaceutical equivalence and CDP studies are required to be performed against the reference / innovator's product while you have submitted the said studies against Vonozan tablet, please clarify.	The firm has stated that the innovator product was not available in Pakistan and due to failure in arranging the product, they had conducted comparative analysis with the comparator's product.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Registration letter will be issued upon submission of Rs. 7,500/- fee for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.**

Vide letter no. F.1-6/2019-PR-I(EFD) dated 06/10/2022.

21.	Name, address of Applicant / Marketing Authorization Holder	M/s PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi.
	Name, address of Manufacturing site.	M/s PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 156 dated 03/01/2022
	Details of fee submitted	PKR 30,000/-: dated 26/10/2021
	The proposed proprietary name / brand name	**Erli Plus 5/850mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin……5mg Metformin HCl……..850mg
	Pharmaceutical form of applied drug	Film coated immediate release tablet
	Pharmacotherapeutic Group of (API)	Anti-diabetic
	Reference to Finished product specifications	Innovator's specs
	Proposed Pack size	As per SRO
	Proposed unit price	AS per SRO

	The status in reference regulatory authorities	Synjardy 5/850mg tablet
	For generic drugs (me-too status)	Xenglu-Met by Hilton Pharma
	GMP status of the Finished product manufacturer	GMP certificate no. 119/2020-DRAP(K) dated 17/09/2020 issued on the basis of inspection conducted on 16/09/2020.
	Section approval	Tablet General Section
	Name and address of API manufacturer.	**Empagliflozin:** M/s Jiangsu Yongan Pharmaceutical co., Limited., No. 18, 237 provincial road, economic development zone, Huaian, Jiangsu. **Metformin HCl:** M/s Shouguang Fukang Pharmaceutical co. ltd., North-east of Dongwaihuan road, Dongchend Industrial area, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	**Empagliflozin:** • Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (130701, 130702, 130801) **Metformin:** • Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-72611405016, A-72611405017, A-72611405018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product. Excipients used in applied product are same as used in the innovator's product therefore, compatibility studies of excipients with the drug substance are not required.

	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence is submitted against the innovator's product that is Synjardy 5/850mg EMA approved, by performing all the quality tests including the tests for impurities (batch number: 905509). Comparative dissolution profile is submitted against the same innovator's product in all the three recommended media. F2 values have not been calculated since 85% drugs have been release within 15 minutes.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, Robustness, system suitability etc.

STABILITY STUDY DATA

Manufacturer of API	**Empagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Limited, No. 18, 237 provincial road, economic development zone, Huaian Jiangsu, China. **Metformin HCl:** M/s Shouguang Fukang Pharmaceutical co. ltd., North-east of Dongwaihuan road, Dongchend Industrial area, China.
API Lot No.	Empgliflozn (5920) Metformin (6415)
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	20PD-3316-02-T	20PD-3316-03-T	20PD-3316-04-T
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	22-09-2020	22-09-2020	22-09-2020
No. of Batches	03		

Administrative Portion

1	Reference of previous approval of applications with stability study data of the firm (if any)	Another strength of the same formulation that is 12.5mg/850mg was approved in 322nd meeting.
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** Copy of GMP certificate valid till 14/01/2024 issued by Huai'an Pharmaceutical Industry association, China. Copy of drug manufacturing license number Su20160324 valid till 06/12/2025 issued by Jiangsu Medical Producs Administration China. **Metformin HCl;** Copy of GMP certificate No. SD20190888 valid till 12/03/2024 issued by CFDA.
3	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Copy of attested invoice number ZY19100801G/W dated 18/10/2019 cleared on 22/10/2019 vide dy. No. 11623. **Metformin HCl;**

		Copy of attested invoice number 419FK08Z092-2 dated 10/10/2019 dy. No. 11552 dated 21/10/2019.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	The submitted analytical method verifications studies for Empagliflozin drug substance are from drug substance manufacturer while the said studies by drug product manufacturer are required.	Submitted.
2	Titration method is adopted for analysis of Metformin HCl while HPLC method has been described for the estimation of Metformin in latest edition of USP, please clarify. Moreover, analytical method verification studies are required for Metformin drug substance according to latest USP monograph performed by drug product manufacturer.	The firm has submitted that they had used the method available in USP at the time of development of the applied product. Now the firm has submitted revised methof for assay estimation of Metformin according to latest edition of USP and performed the verification studies.
3	Provide results of pharmaceutical equivalence studies against the reference / innovator's product by performing all the quality tests along with the results of comparative dissolution profile against reference / innovator's product. Moreover, provide batch number, expiry and date of manufacturing of the innovator's / reference product.	Pharmaceutical equivalence is submitted against the innovator's product that is Synjardy 5/850mg EMA approved, by performing all the quality tests including the tests for impurities (batch number: 905509). Comparative dissolution profile is submitted against the same innovator's product in all the three recommended media. F2 values have not been calculated since 85% drugs have been release within 15 minutes.
4	Justify the dissolution parameters since the selected RPM is 75 while as per USFDA dissolution data base, the RPM should be 50 for the applied formulation.	The firm has referred to Empagliflozin tablet's literature review where the speed 75rpm is selected while as per the assessment report of Synjardy tablet, the rotational speed is 50 RPM.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufacturer shall adopt dissolution specifications (i.e., paddle speed of 50rpm) as per the innovator product for the commercial batches.**
- **Registration letter will be issued upon submission of analytical method verification studies**

for Metformin HCl drug substance according to latest edition of USP monograph along with fee of Rs. 7,500/- for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.

b. Registration applications submitted on Form 5D

Sr. No.	Name & Address of Manufacturer / Applicant	Brand Name (Proprietary Name + Dosage Form + Strength), Composition, Pharmacological Group, Finished Product Specification	Type of Form, Initial Diary & Date, Fee (including differential fee), Demanded Price / Pack size	International Availability GMP Inspection Report Date & Remarks
22.	PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi. Date of submission of stability data: 25/06/2021	Erli Plus 5/500mg tablet Each film coated tablet contains: Empagliflozin……5mg Metformin HCl…...500mg Anti-diabetic In-House	Form 5D Dy. No.916 dated 10/01/2017 Rs. 50,000/- (copy of challan) As per SRO As per SRO Duplicate dossier	USFDA Approved. Copy of GMP certificate No. 119/2020-DRAP(K) issued on the basis of inspection conducted on 16/09/2020.
23.	PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi. Date of submission of stability data: 21/06/2021	Erli Plus 5/1000mg tablet Each film coated tablet contains: Empagliflozin……5mg Metformin HCl…...1000mg Anti-diabetic In-House	Form 5D Dy. No.914 dated 10/01/2017 Rs. 50,000/- (copy of challan) As per SRO As per SRO Duplicate dossier	
24.	PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi. Date of submission of stability data: 21/06/2021	Erli Plus 12.5/500mg tablet Each film coated tablet contains: Empagliflozin……12.5mg Metformin HCl……500mg Anti-diabetic In-House	Form 5D Dy. No.915 dated 10/01/2017 Rs. 50,000/- (copy of challan) As per SRO As per SRO Duplicate dossier	
25.	PharmEvo (pvt.) Ltd., Plot no. A-29, North Wetern Industrial zone, port Qasim, Karachi. Date of submission of stability data: 21/06/2021	Erli Plus 12.5/1000mg tablet Each film coated tablet contains: Empagliflozin……12.5mg Metformin HCl……1000mg Anti-diabetic In-House	Form 5D Dy. No.913 dated 10/01/2017 Rs. 50,000/- (copy of challan) As per SRO As per SRO Duplicate dossier	

Remarks of Evaluator:

The firm has submitted analytical method validation studeis for drug product including accuracy, linearity, specificity, robustness, precision etc.

Initislly the firm had applied for brnad name Empagmin anf then requested to change the name as Erli plus.

STABILITY STUDY DATA

Name of API manufaturer	**Empagliflozin:** M/s Jiangsu Yongan Pharmaceutical co., Limited., No. 18, 237 provincial road, economic development zone, Huaian, Jiangsu. **Metformin HCl:**

	M/s Shouguang Fukang Pharmaceutical co. ltd., North-east of Dongwaihuan road, Dongchend Industrial area, China.		
API lot number	Empgliflozn (5920) Metformin (6415)		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Accelerated: 40˚C ± 2˚C / 75% ± 5%RH Real Time: 30˚C ± 2˚C / 65% ± 5%RH		
Time Period	Accelerated: 6 Months Real Time: 6 Months		
Frequency	Real Time: 0,3 & 6 (months) Accelerated: 0, 3, 6 (months)		
Erli Plus 5/500mg tablet			
Batch No.	20PD-3309-01-T	20PD-3309-02-T	20PD-3309-03-T
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	07-2020	07-2020	07-2020
Date of Initiation	03-09-2020	03-09-2020	03-09-2020
No. of Batches	03		
Erli Plus 5/1000mg tablet			
Batch No.	20PD-3239-06-T	20PD-3239-07-T	20PD-3239-08-T
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	06-2020	06-2020	06-2020
Date of Initiation	20-07-2020	20-07-2020	20-07-2020
No. of Batches	03		
Erli Plus 12.5/500mg tablet			
Batch No.	20PD-3212-01-T	20PD-3212-02-T	20PD-3212-03-T
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	03-09-2020	03-09-2020	03-09-2020
No. of Batches	03		
Erli Plus 12.5/1000mg tablet			
Batch No.	20PD-3235-02-T	20PD-3235-03-T	20PD-3235-04-T
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	06-2020	06-2020	06-2020
Date of Initiation	20-07-2020	20-07-2020	20-07-2020
No. of Batches	03		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT			
1.	Reference of previous approval of applications with stability study data of the firm		
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted	
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Firm has submitted copy of method used for analysis of API from both API Manufacturer and Finished Product manufacturer	

4.	Stability study data of API from API manufacturer	**Empagliflozin:** • Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (130701, 130702, 130801) **Metformin:** • Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-72611405016, A-72611405017, A-72611405018)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** Copy of GMP certificate valid till 14/01/2024 issued by Huai'an Pharmaceutical Industry association, China. Copy of drug manufacturing license number Su20160324 valid till 06/12/2025 issued by Jiangsu Medical Producs Administration China. **Metformin HCl;** Copy of GMP certificate No. SD20190888 valid till 12/03/2024 issued by CFDA.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Copy of attested invoice number ZY19100801G/W dated 18/10/2019 cleared on 22/10/2019 vide dy. No. 11623. **Metformin HCl;** Copy of attested invoice number 419FK08Z092-2 dated 10/10/2019 dy. No. 11552 dated 21/10/2019.
7.	Protocols followed for conduction of stability study	Firm has submitted protocols followed for conduction of stability study
8.	Method used for analysis of FPP	Firm has provided detailed method for analysis of finished product (In-House).
9.	Drug-excipients compatibility studies (where applicable)	Firm has used same excipients as that of the innovator's product therefore compatibility studies are not required
10.	Complete batch manufacturing record of three stability batches.	Firm has provided Batch Manufacturing Record for all the batches of applied products.
11.	Record of comparative dissolution data (where applicable)	**Erli Plus 5/500mg tablet** CDP is submitted against Xenglu-Met 5/500mg (batch number 136760) tablet mfg by M/s Hilton Pharmaceutical in all the three recommended media. F2 values have not been calculated since more than 85% of drug has been released within 15 minutes. **Erli Plus 5/1000mg tablet** CDP is submitted against Diampa-M 5/1000 5 (batch number 001FD8) tablet mfg by M/s Getz Pharma in all the three recommended media. F2 values have not been calculated since more than 85% of drug has been released within 15 minutes. **Erli Plus 12.5/500mg tablet** CDP is submitted against Xenglu-Met 12.5/500mg (batch number 137089) tablet mfg by M/s Hilton Pharmaceutical in all the three recommended media. F2 values have not been calculated since more than 85% of drug has been released within 15 minutes

		Erli Plus 12.5/1000mg tablet CDP is submitted against Diampa-M 12.5/1000 5 (batch number 0797D2) tablet mfg by M/s Getz Pharma in all the three recommended media. F2 values have not been calculated since more than 85% of drug has been released within 15 minutes.
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted documents like chromatograms, raw data sheets, COA, summary data sheets for the stability studies
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted certificate of compliance and audit trail reports for HPLC analysis for all the three batches .
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for both stability chambers for accelerated as well as real time stability studies.

Evaluation by PEC:

Sr. no.	Shortcomings communicated	Response by the firm
1	The submitted analytical method verifications studies for Empagliflozin drug substance are from drug substance manufacturer while the said studies by drug product manufacturer are required.	Submitted.
2	Titration method is adopted for analysis of Metformin HCl drug substance while HPLC method has been described for the estimation of Metformin in latest edition of USP, please clarify. Moreover, analytical method verification studies are required for Metformin drug substance according to latest USP monograph performed by drug product manufacturer.	The firm has submitted that they had used the method available in USP at the time of development of the applied product. Now the firm has submitted revised meth of for assay estimation of Metformin according to latest edition of USP and performed the verification studies.
3	Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	The firm has stated that the reference brand was not readily available at the time of development therefore, the pharmaceutical studies have been performed against comparator's product.
4	Justify the dissolution parameters since the selected RPM is 75 while as per USFDA dissolution data base, the RPM should be 50 for the applied formulation.	The firm has referred to Empagliflozin tablet's literature review where the speed 75rpm is selected while as per the assessment report of Synjardy tablet, the rotational speed is 50 RPM.

Decision: Registration Board approved the applications of Erli Plus 5/500mg tablet, Erli Plus 5/1000mg tablet, Erli Plus 12.5/500mg & Erli Plus 12.5/1000mg tablet with Innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufacturer shall adopt dissolution specifications (i.e., paddle speed of 50rpm) as per the innovator product for the commercial batches.**
- **Registration letter will be issued upon submission of analytical method verification studies for Metformin HCl drug substance according to latest edition of USP monograph along with fee of Rs. 7,500/- for each strength for revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.**

Case No. III: Deferred Cases:

I. Cases submitted on Form 5F:

26.	Name, address of Applicant / Marketing Authorization Holder	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Name, address of Manufacturing site.	M/s Welmark Pharmaceuticals, plot # 122, Block B, Phase V, Indusrial Estate Hattar, Haripur, KPK.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 32854 dated 02/12/2021
	Details of fee submitted	PKR 30,000/-: dated 25/11/2021
	The proposed proprietary name / brand name	**Tapentawel tablet 75mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Tapentadol as hydrochloride…..75mg
	Pharmaceutical form of applied drug	Immediate release film coated tablet
	Pharmacotherapeutic Group of (API)	Analgesic, opioids
	Reference to Finished product specifications	Innovators specifications
	Proposed Pack size	10’s
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	Tapento tablet by M/s Sami Pharmaceuticals, Reg. No. 093064
	GMP status of the Finished product manufacturer	Copy GMP certificate No F.11-96/2021-DRAP-97 issued on the basis of inspection conducted on 11/11/2021.
	Section approval	Tablet General Section
	Name and address of API manufacturer.	M/s Precise Chemipharma Pvt Limited, C384, TTC Industrial area, MIDC, Pawne village, Nawi Mumbai, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of

		manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards , container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (6001012013, 6002012013, 6003012013)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence data is submitted against the comparator's product that is Tapento IR 75mg Tablet by M/s Sami Pharmaceuticals by performing all the quality tests. (Batch number: 003F) Comparative dissolution profile is submitted against the same product that is Tapento IR 75mg tablet by M/s Sami Pharmaceuticals. The values of F2 are within the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, precision, specificity, LOD/LOQ, Robustness, Solution stability, system suitability

STABILITY STUDY DATA

Manufacturer of API	87.375mg per tablet		
API Lot No.	060034102019		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T013	T014	T015
Batch Size	1500 tab	1500 tab	1500 tab
Manufacturing Date	01/2021	01/2021	01/2021
Date of Initiation	27/01/2021	28/01/2021	29/01/2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted by the firm.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 6102090 issued valid till 28/09/2022 by FDA Maharashtra.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of attested invoice No. EXPS/0002082/2019-20 dated 26/12/2019 dy. No. 128 dated 09/01/2020 is submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations
1	As per submitted analytical method for Tapentadol HCl drug substance, the HPLC method is used for assay while analytical method validation report shows UV-performance for validation/verification studies. Please clarify and submit protocol and complete validation/verification studies for analytical method of drug substance. Moreover, correlate the strengths of dilution prepared for calculation of assay with the strengths of dilutions prepared for performing testing of linearity parameter in analytical method verification studies. Furthermore, please state that whether you have used same method of analysis as used by the manufacturer of drug substance or otherwise. Provide method of analysis of drug substance from drug substance manufacturer.
2	Provide certificate of analysis of the batch of drug substance used for product development from drug substance manufacturer as well as from the drug product manufacturer.
3	Provide pharmaceutical equivalence data against innovator's / reference product. The submitted data is against the comparator's product.
4	Justification is required for selection of dissolution parameters including dissolution medium (0.1N HCl), RPM, time etc.
5	Justify the amount of drug substance that is 87.375/tablet dispensed for potency adjustment by providing detail of calculations along considering the assay value i.e 99.8%.

Decision of 321st meeting: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months of issuance of minutes of 322nd meeting. In case Pharmaceutical Evaluation Cell doses not receive any response from the firm within the given time, the case will be placed before Registration Board for decision.

Sr. No.	Observations	Response
1	As per submitted analytical method for Tapentadol HCl drug substance, the HPLC method is used for assay while analytical method validation report shows UV-performance for validation/verification studies. Please clarify and submit protocol and complete validation/verification studies for analytical method of drug substance.	The firm has stated that the analysis and analytical validation / verifications have been performed by using HPLC. Complete protocol and results have been submitted. *We prepared stock solution, then we furhter diluted the concentration. The concentration for assay method is 0.2mg/mL and the linearity range is from 0.24, 0.2, 0.16, 0.12, 0.1, 0.08, 0.04, 0.02mg/mL respectively.*

	Moreover, correlate the strengths of dilution prepared for calculation of assay with the strengths of dilutions prepared for performing testing of linearity parameter in analytical method verification studies. Furthermore, please state that whether you have used same method of analysis as used by the manufacturer of drug substance or otherwise. Provide method of analysis of drug substance from drug substance manufacturer.	The method of analysis is used by drug product manufacturer is different from the method used by drug substance mnafuatcruer for estimation of Tapentadol D.S. The drug substance manufacturer has used titration method for analysis of drug substance while the applicant has developed HPLC method for analysis of D.S. The firm has submitted analytical method validation report.
2	Provide certificate of analysis of the batch of drug substance used for product development from drug substance manufacturer as well as from the drug product manufacturer.	COAs from drug product and drug substance manufacturer are submitted for the batch used for product development. Batch number: 060034102019 Mfg date: Oct, 2019 Expiry: Sep, 2022
3	Provide pharmaceutical equivalence data against innovator's / reference product. The submitted data is against the comparator's product.	The firm has stated that during the pandemic, the innovator's product pack was not available due to closure of international flights and shipments so the sad studies were performed against the comparator's product with the detail given in the following. Pharmaceutical equivalence data is submitted against the comparator's product that is Tapento IR 75mg Tablet by M/s Sami Pharmaceuticals by performing all the quality tests. (Batch number: 003F) Comparative dissolution profile is submitted against the same product that is Tapento IR 75mg tablet by M/s Sami Pharmaceuticals. The values of F2 are within the acceptable range.
4	Justification is required for selection of dissolution parameters including dissolution medium (0.1N HCl), RPM, time etc.	The firm has referred FDA's dissolution guidance, 2018 document and stated that in-house method was developed for dissolution testing.
5	Justify the amount of drug substance that is 87.375/tablet dispensed for potency adjustment by providing detail of calculations along considering the assay value i.e 99.8%.	The dispensed quantity is according to 100% assay (As-Is) value while 99.8% assay (As-is) should have been considered. However, the firm has submitted revised calculations for potency adjustment considering the assay on as-is 99.8%.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Furthermore, the firm shall submit revised calculations for potency adjustment considering the assay value on As-Is basis for commercial batches.**

27.	Name, address of Applicant / Marketing Authorization Holder	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.
	Name, address of Manufacturing site.	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30788 dated 31/10/2022
	Details of fee submitted	PKR 30,000/-: dated 31/10/2022
	The proposed proprietary name / brand name	Colmate 4.5 MIU powder for injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate as sodium……..4.5 MIU
	Pharmaceutical form of applied drug	White Lyophilized Powder for solution for IV injection
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Colitin Link 4,500,000 IU powder for injection vial, TGA Australia approved.
	For generic drugs (me-too status)	Colistim 4.5MIU by Biocare Pharmaceutica,
	GMP status of the Finished product manufacturer	DML issued vide letter No.F.1-10/2019-Lic dated 29/04/2022.
	Section approval	Dry Powder Vial Section (General)
	Name and address of API manufacturer.	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China. Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference

		standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months • Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (CMS1707001, CMS1707002, CMS1707003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity, , system suitability etc for drug substance and drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China.		
API Lot No.	CMS2106002		
Description of Pack (Container closure system)	Type I glass vial packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TRL01	TRL02	TRL03
Batch Size	1000 vials		
Manufacturing Date	03-2022		
Date of Initiation			
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals.

		**The firm has not provided any document related to borrowing of API.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Not submitted**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	Provide documents of approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..
2	Provide analytical method verification studies (including accuracy, specificity and precision) for drug substance performed by drug product manufacturer.	Submitted. Test results for specificity is not provided.
3	Provide pharmaceutical equivalence studies against innovator's / reference product by performing all the quality tests.	Pharmaceutical equivalence study report is submitted without providing other details, batch numbers, expiry etc.
4	Provide documents confirming import of drug substance (invoice, clearance certificate etc) attested from DRAP.	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals. **The firm has not provided any document related to borrowing of API.
5	Provide exact date of initiation of stability studies and detail of batch sizes.	Submitted.
6	Provide stability summary sheets containing results till 6 months along with the all the chromatograms along with raw data sheets for accelerated and real time stability. • The firm has not submitted the stability summary sheets. • The data submitted is not comprehendible.	

Strength	Accelerated (%)			Real time (%)		
	0	3	6	0	3	6
1 MIU	103.78	102.2	102.07	102.19	102.4	103.01
	103.33	100.53	101.42	105.55	101.48	102.81
	102.8	100.53	105.53	101.21	101.48	102.41
2 MIU	103.78	102.2	102.07	102.19	102.4	103.01
	103.33	100.53	101.42	105.55	101.48	102.81
	102.8	100.53	105.53	101.21	101.48	102.41
4.5 MIU	103.78	102.2	102.07	102.19	102.4	103.01
	103.33	100.53	101.42	105.55	101.48	102.81
	102.8	100.53	105.53	101.21	101.48	102.41

Decision of 323rd meeting:
The Board was apprised as under:

- As per submitted stability data, the assay results of accelerated and real time stability studies at initial time points are different while the results should be the same for all the three batches.
- The results of assay for all the three batches are exactly same on respective time points throughout the stability studies which is not practically possible.

The Board decided to defer the case for clarification / scientific justification of the above mentioned observations along with the submission of Pharmaceutical Equivalence studies against the reference / innovator's product.

Submission by the firm:

The firm has submitted revised stability summary sheet along with raw data sheets and has stated that in previously submitted data there was a printing error.

Batch No.	TRL01	TRL02	TRL03
Batch Size	1000 vials	1000 vials	1000 vials
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	10-03-2022	10-03-2022	10-03-2022
No. of Batches	03		

The firm has submitted Pharmaceutical equivalence against Colistim Powder for Injection 4.5 MIU MFG by M/s Xellia Pharmaceuticals marketed by M/s Mukhtar Enterprises by performing quality tests.
Batch number 3159481
Mfg date: 03/2022
ExP: 02/2024

Decision of 324th meeting: Approved with label claim for USP specifications as decided in 323rd meeting of Registration Board.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

28.		
	Name, address of Applicant / Marketing Authorization Holder	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.
	Name, address of Manufacturing site.	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30787 dated 31/10/2022
	Details of fee submitted	PKR 30,000/-: dated 30/10/2022
	The proposed proprietary name / brand name	**Colmate 2 MIU powder for injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate as sodium……..2 MIU
	Pharmaceutical form of applied drug	White Lyophilized Powder for solution for IV injection

	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved.
	For generic drugs (me-too status)	Colistim 2MIU by M/s Biopharmaseutica.
	GMP status of the Finished product manufacturer	DML issued vide letter No.F.1-10/2019-Lic dated 29/04/2022.
	Section approval	Dry Powder Vial Section (General)
	Name and address of API manufacturer.	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (CMS1707001, CMS1707002, CMS1707003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity, , etc for drug substance and drug product.
STABILITY STUDY DATA		

Manufacturer of API	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China.		
API Lot No.	CMS2106002		
Description of Pack (Container closure system)	Type I glass vial packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.			
Batch Size			
Manufacturing Date			
Date of Initiation			
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals. **The firm has not provided any document related to borrowing of API.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Not submitted**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator-I:

Sr. No.	Observations	Response
1	Provide documents of approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..

2	Provide analytical method verification studies (including accuracy, specificity and precision) for drug substance performed by drug product manufacturer.	Submitted. Test results for specificity is not provided.
3	Provide pharmaceutical equivalence studies against innovator's / reference product by performing all the quality tests.	Pharmaceutical equivalence study report is submitted without providing other details, batch numbers, expiry etc.
4	Provide documents confirming import of drug substance (invoice, clearance certificate etc) attested from DRAP.	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals. **The firm has not provided any document related to borrowing of API.
5	Provide exact date of initiation of stability studies and detail of batch sizes.	Submitted.
6	Provide stability summary sheets containing results till 6 months along with the all the chromatograms along with raw data sheets for accelerated and real time stability for all the 3 strengths of the applied product.	• The firm has not submitted the stability summary sheets. • The firm has not provided chromatograms. • The data submitted is not comprehendible.

Decision of 323rd meeting:

The Board was apprised as under:

- As per submitted stability data, the assay results of accelerated and real time stability studies at initial time points are different while the results should be the same for all the three batches.
- The results of assay for all the three batches are exactly same on respective time points throughout the stability studies which is not practically possible.

The Board decided to defer the case for clarification / scientific justification of the above mentioned observations along with the submission of Pharmaceutical Equivalence studies against the reference / innovator's product.

Submission by the firm:

The firm has submitted revised stability summary sheet along with raw data sheets and has stated that in previously submitted data there was a printing error.

Batch No.	TRL01	TRL02	TRL03
Batch Size	1000 vials	1000 vials	1000 vials
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	09-03-2022	09-03-2022	09-03-2022
No. of Batches	03		

The firm has submitted Pharmaceutical equivalence against Colistim Powder for Injection 2MIU MFG by M/s Xellia Pharmaceuticals marketed by M/s Mukhtar Enterprises by performing quality tests.
Batch number: 3155427
Mfg date: 08/2021
ExP: 07/2023

Decision of 324th meeting: Approved with label claim for USP specifications as decided in 323rd meeting of Registration Board.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

29.	Name, address of Applicant / Marketing Authorization Holder	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.

	Name, address of Manufacturing site.	M/s May & Baker (pvt) Ltd., 45km, Dina Nath, Multan road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30039 dated 24/10/2022
	Details of fee submitted	PKR 30,000/-: dated 18/10/2022
	The proposed proprietary name / brand name	**Colmate 1 MIU powder for injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate as sodium……..1 MIU
	Pharmaceutical form of applied drug	White Lyophilized Powder for solution for IV injection
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved
	For generic drugs (me-too status)	Colistim 1MIU by Biocare Pharmaceutica,
	GMP status of the Finished product manufacturer	DML issued vide letter No.F.1-10/2019-Lic dated 29/04/2022.
	Section approval	Dry Powder Vial Section (General)
	Name and address of API manufacturer.	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, residual solvents, specifications, analytical procedures

		and its complete validation studies, batch analysis and justification of specification, details of reference standards, container closure system and stability studies of drug substance.
	Stability studies	• Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months • Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (CMS1707001, CMS1707002, CMS1707003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity, , system suitability etc for drug substance and drug product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., No. 8. Nangang road Jiangyin Industrial Concentration zone, Fuqing, Fuzhou city, Fujian province, China.		
API Lot No.	CMS2106002		
Description of Pack (Container closure system)	Type I glass vial packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TRL01	TRL02	TRL03
Batch Size	1000 vials	1000 vials	1000 vials
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	08-03-2022	08-03-2022	08-03-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	No response is submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals. **The firm has not provided any document related to borrowing of API.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Not submitted**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator-I:

Sr. No.	Observations	Response
1	Provide documents of approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. FJ200003 valid till 21/09/2022 issued by Fujian Food and Drug Administration China..
2	Provide analytical method verification studies (including accuracy, specificity and precision) for drug substance performed by drug product manufacturer.	Submitted. Test for specificity is not provided.
3	Provide pharmaceutical equivalence studies against innovator's / reference product by performing all the quality tests.	Pharmaceutical equivalence study report is submitted without providing other details, batch numbers, expiry etc.
4	Provide documents confirming import of drug substance (invoice, clearance certificate etc) attested from DRAP.	Copy of clearance certificate no. 2761/2021-ADC(I&E) dated 16/08/2021 issued for M/s Vision Pharmaceuticals Islamabad. The material has been borrowed from M/s Vision Pharmaceuticals. **The firm has not provided any document related to borrowing of API.
5	Provide exact date of initiation of stability studies and detail of batch sizes.	Submitted.
6	Provide stability summary sheets containing results till 6 months along with the all the chromatograms along with raw data sheets for accelerated and real time stability.	• The firm has not submitted the stability summary sheets. • The firm has not provided chromatograms. • The data submitted is not comprehendible.

Decision of 323rd meeting:
The Board was apprised as under:

- As per submitted stability data, the assay results of accelerated and real time stability studies at initial time points are different while the results should be the same for all the three batches.
- The results of assay for all the three batches are exactly same on respective time points throughout the stability studies which is not practically possible.

The Board decided to defer the case for clarification / scientific justification of the above mentioned observations along with the submission of Pharmaceutical Equivalence studies against the reference / innovator's product.

Submission by the firm:
The firm has submitted revised stability summary sheet along with raw data sheets and has stated that in previously submitted data there was a printing error.

Batch No.	TRL01	TRL02	TRL03
Batch Size	1000 vials	1000 vials	1000 vials
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	08-03-2022	08-03-2022	08-03-2022
No. of Batches	03		

The firm has submitted Pharmaceutical equivalence against Colistim Powder for Injection 1MIU MFG by M/s Pharmasol Pvt. Ltd. by performing quality tests.
Batch number KC076
Mfg date: 05/22
ExP: 04/24

Decision of 324th meeting: Approved with label claim for USP specifications as decided in 323rd meeting of Registration Board.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. IV: Registration applications submitted on Form 5 (Human, local manufacturing):

30.	**Name and address of manufacture / Applicant**	**M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore**
	Brand Name + Dosage Form and Strength	**Fluno 0.025% W/W Cream**
	Composition	Each Gram Contains: Fluocinolone acetonide……0.25mg (0.025% w/w)
	Dairy No. date of R &I fee	Dy. No. 44270 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Corticosteroid
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	15g, 20g, 30g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Synalar Cream (Fluocinolone Acetonide Ph.Eur. 0.025% wlw) MHRA Approvd.
	Me-too-status	Synalar Cream 0.025% (Reg. No. 2510)
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020.	

	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter.		
31.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Lotriwin Cream
	Composition	Each gram Contains: Betamethasone as Dipropionate…0.5mg (0.05%w/w) Clotrimazole…10mg (1%w/w)
	Dairy No. date of R &I fee	Dy. No. 44292 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Corticosteroid+Antifungal
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	5g, 10g, 15g; As per SRO
	Approval status of product in Reference Regulatory Authorities	LOTRIDERM 0.05% w/w /1.0% w/w Cream, (MHRA Approved)
	Me-too-status	Lotricort-G Cream (Reg. No. 41697)
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter.		
32.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Bifomit 1% W/W Cream
	Composition	Each Gram Contains: Bifonazole…10mg (1%w/w)
	Dairy No. date of R &I fee	Dy. No. 44290 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Antifungal
	Type of form	Form-5
	Finished product specifications	In-House
	Pack size and Demand Price	15g, 30g, 45g; As per SRO
	Approval status of product in Reference Regulatory Authorities	CANESTEN ONCE DAILY BIFONAZOLE ANTIFUNGAL CREAM 1% bifonazole 10mg/g cream tube, TGA Australia approved.
	Me-too-status	MYCOSPOR CRM (BIFONAZOLE 1%) Reg. no. 7484
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020.	

	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved with innovator's specifications. Frim shall submit fee of Rs. 7500/- revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.		
33.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Vanesten 2% W/W Cream
	Composition	Each gm contains: Clotrimazole…….20mg (2% w/w)
	Dairy No. date of R &I fee	Dy. No. 44289 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Antifungal
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	15g, 35g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Canesten Thrush External Cream 2% w/w cream of UK-MHR
	Me-too-status	Benastin 2% Cream (Clotrimazole 20 mg) Reg. no. 73439
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		
34.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Vanesten V 10% W/W Cream
	Composition	Each gm contains: Clotrimazole…….100mg
	Dairy No. date of R &I fee	Dy. No. 44271 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Antifungal
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	5g, 10g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Canesten 10% w/w Vaginal Cream (Clotrimazole) MHRA Approved.
	Me-too-status	Vaginex-1 Cream (Clotrimazole 10%) , Reg. No. 22368
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		

35.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Betawit N Cream
	Composition	Each Gram Contains: Betamethasone as Valerate…1mg (0.1% w/w) Neomycin Sulphate……5mg (0.5% w/w)
	Dairy No. date of R &I fee	Dy. No. 44291 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Corticosteroids + antibiotic
	Type of form	Form-5
	Finished product specifications	In-House
	Pack size and Demand Price	15g, 30g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Betnovate-N 0.1% / 0.5% w/w Cream, MHRA Apprved.
	Me-too-status	Betnovate N Cream, Reg. no. 254
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter.		
36.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Hydronin 4% W/W Cream
	Composition	Each gm of Cream contains: Hydroquinone ……..40mg (4% w/w)
	Dairy No. date of R &I fee	Dy. No. 44276 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Ultraviolet Blocking agent
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	10g, 15g, 30g, 45g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Could not be confirmed.
	Me-too-status	Hyderquin Cream 4% of Atco Laboratories Pvt. Ltd.
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.		
37.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore

	Brand Name + Dosage Form and Strength	Hydronin 2% W/W Cream
	Composition	Each gm of Cream contains: Hydroquinone ……..20mg (2% w/w)
	Dairy No. date of R &I fee	Dy. No. 44277 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Ultraviolet Blocking agent
	Type of form	Form-5
	Finished product specifications	USP
	Pack size and Demand Price	10g, 15g, 30g, 45g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Symba Skin Toner Cream (hydroquinone 2% W/W) of UK-MHRA
	Me-too-status	Grace Cream-2% (hydroquinone 2%), Reg. No. 39549
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		
38.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Valacin 2% W/W Vaginal Cream
	Composition	Each gram contains: Clindamycin (as phosphate)……20mg (2%w/w)
	Dairy No. date of R &I fee	Dy. No. 44267 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Antibacterial
	Type of form	Form-5
	Finished product specifications	In-House
	Pack size and Demand Price	40g; as per SRO
	Approval status of product in Reference Regulatory Authorities	Dalacin Vaginal Cream 2% (clindamycin as phosphate 20g) (MHRA Approved)
	Me-too-status	DALACIN Vaginal CREAM (CLINDAMYCIN PHOSPHATE 2% W/W) Reg. No. 18574
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
	The firm has applied for In-House specifications while Clindamycin Phosphate Vaginal Cream is present in USP.	
Decision: Approved with USP specifications. Frim shall submit fee of Rs. 7500/- revision of specifications as per notification No.F.7-11/2021-B&A/DRAP dated 07-05-2021.		
39.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Valacin-T 1% Lotion

	Composition	Each ml contains: Clindamycin (as Phosphate)……10 mg (1%w/v)
	Dairy No. date of R &I fee	Dy. No. 44266 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Anti-Bacterial
	Type of form	Form-5
	Finished product specifications	In-House
	Pack size and Demand Price	30ml, 60ml; As per SRO
	Approval status of product in Reference Regulatory Authorities	Dalacin T Topical Lotion MHRA Approved
	Me-too-status	Dalacin T Lotion 1%, Reg. No. 13582
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		
40.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Diclowim 1% W/W Gel
	Composition	Each gram of gel Contains: Diclofenac diethylamine 11.6mg equivalent to Diclofenac sodium…10mg
	Dairy No. date of R &I fee	Dy. No. 44285 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	NSAIDS
	Type of form	Form-5
	Finished product specifications	BP
	Pack size and Demand Price	25g, 50g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Voltarol 1.16% Emulgel, Gel MHRA Approved.
	Me-too-status	Ronset Gel, Reg. No. 33012
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated 07-06-2022. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		
41.	Name and address of manufacture / Applicant	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore
	Brand Name + Dosage Form and Strength	Ketowit 2.5% W/W Gel
	Composition	Each gram contains: Ketoprofen…25mg (2.5%w/w)
	Dairy No. date of R &I fee	Dy. No. 44275 dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	NSAIDs
	Type of form	Form-5
	Finished product specifications	BP

	Pack size and Demand Price	15g, 20g, 30g; as per SRO
	Approval status of product in Reference Regulatory Authorities	Ketoprofen 2.5% w/w (25mg Ketoprofen per gram) Gel MHRA Approved.
	Me-too-status	Ketoflex Gel 2.5%, Re. No. 18518
	GMP Status	The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.
	Remark of the Evaluator-I: The firm was asked for evidence of approval of required manufacturing facility vide shortcoming letter dated 06-03-2020. The firm has submitted renewal letter for DML no. F.1-10/2012-Lic dated07-06-202. The firm his granted Cream / Ointment / Lotion / Gel (General) NEW section.	
Decision: Approved.		

Case No. V: Registration applications submitted on Form 5F

42.	Name, address of Applicant / Marketing Authorization Holder	M/s Jaskan Pharmaceuticals (Pvt) Ltd. 50-Sundar Industrial Estate, Lahore.
	Name, address of Manufacturing site.	M/s Jaskan Pharmaceuticals (Pvt) Ltd. 50-Sundar Industrial Estate, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of dated 18-02-2021 based on the inspection dated 26-10-2020.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter for grant of additional section dated 12-03-2021 specifying Injectable Ampoule (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30256: 05-11-2021
	Details of fee submitted	PKR 30,000/-: 08-10-2021
	The proposed proprietary name / brand name	**MECOKAN Injection 500mcg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1 ml ampoule Contains: Mecobalamin……500mcg
	Pharmaceutical form of applied drug	Almost red colour solution filled in amber glass ampoule.
	Pharmacotherapeutic Group of (API)	Vitamin B12
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	1ml x 10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Mecobalamin 500mcg Injection **(PMDA** Japan Approved)

	For generic drugs (me-too status)	Mecomax Injection by Global Pharma
	Name and address of API manufacturer.	Mahima Life Sciences Pvt Ltd. BST Road, Ganaur-131101, Distt. Sonepat (Haryana)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40^{o}C ± 2^{o}C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30^{o}C ± 2^{o}C / 65% ± 5% RH for 48 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has performed pharmaceutical equivalence against the product Mabil 500 mcg injection by Sami Pharma
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and validation studies of the drug product.

STABILITY STUDY DATA	
Manufacturer of API	Mahima Life Sciences Pvt Ltd. BST Road, Ganaur-131101, Distt. Sonepat (Haryana)
API Lot No.	MLMCB-040121
Description of Pack (Container closure system)	Glass ampoule
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months)

	Real Time: 0, 3, 6 (Months)		
Batch No.	OG-01	OG-02	OG-03
Batch Size	1000 Ampoules	1000 Ampoules	1000 Ampoules
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	18-05-2021	18-05-2021	18-05-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. 12/55-2Drug1-2020/7030 dated 26-10-2020 issued by Haryana Food and Drug Administration. The certificate is valid till 12-09-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice number EP/21-22/032 dated 15/04/2021 cleared on 24/04/2021 vide dy. No. 6205/2021-DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC:

1	Justify Japanese pharmacopoeia specifications as mentioned in module 1 since no monograph for the mecobalamin injection is available in JP pharmacopoeia. Revise your specifications along with submission of requisite fee.	The firm has revised the specification to innovator's spec along with the submission of Rs. 7,500/- vide challan number 0673860677 dated 18/02/2022.
2	Submit data in section 3.2.S.4.1 and 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."	Submitted.
3	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted*	The firm has submitted analytical method verification report of drug substance performed by drug product manufacturer.
4	Justify the use of reference standard from Vital labs which is neither the drug substance manufacturer nor any reference lab.	*M/s Vital Laboratories Pvt. Ltd. is manufacturer of Mecobalamin reference standard.*

5	Justify your master formulation in which sodium chloride, sodium dihydrogen phosphate, acetic acid and water for injection is used as excipient, since the innovator has only used D-mannitol and pH regulator.	The firm has stated that results from stability studies show that the formulation is stable. The firm has provided method of tonicity determination for the applied formulation in response.
6	Justify why complete tests as mentioned in general monographs for such preparations are not performed during pharmaceutical; equivalence studies.	The firm has submitted pharmaceutical equivalence by performing quality test using HPLC method against comparator's product that is Methycobal injection 500 mcg injection by Hilton Pharma.
7	Submit detailed process validation protocols which are to be based on critical quality attributes identified during product development studies to optimize your manufacturing process.	Process validation protocol is submitted by M/s Jaskan Pharmaceuticals for the applied product. Batch number: 40762
8	Provide specifications of the excipients in section 3.2.P.4.	The applicant has submitted specifications for all the excipients used in the formulation.
9	Justify your drug product specifications in the light of recommendations of general monographs of official pharmacopoeia, since you have not included important tests like particulate matter, uniformity of dosage unit etc which are recommended in general monograph of USP.	The firm has revised the specifications which includes pH of solution, filled volume, leakage test, BET, sterility tets, particulate matter, assay but have not performed the test on finished product.
10	Justify the use of UV method for assay testing in pharmaceutical equivalence studies, since HPLC method is used by drug substance manufacturer as well as innovator's product. Justify the analytical method for assay and identification test based on UV method, since the drug substance manufacturer's method as well as the innovator product analytical method is based on HPLC testing.	The firm has developed HPLC method for analysis of drug substance along with the analytical method validation studies.
11	Provide detailed method of analysis of the drug product in section 3.2.P.5.2.	Submitted.
12	Justify how three batches having batch size of 100 ampoule is manufactured. Also provide the specifications of the equipment including maximum and minimum capacity to justify the manufacturing of sterile product.	The firm has submitted that the batch size for stability batches is 1000 ampoules.
13	Provide COA of reference standard actually used in the analysis of drug product.	Submitted.
14	Justify why photostability studies are not performed for the drug product.	The firm has performed photo stability studies of the drug substance and submitted the results.
15	Provide approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. 12/55-2Drug1-2020/7030 dated 26-10-2020 issued by Haryana Food and Drug Administration. The certificate is valid till 12-09-2022.
16	Provide Documents for the procurement of API with approval from DRAP.	Copy of invoice number EP/21-22/032 dated 15/04/2021 cleared on 24/04/2021 vide dy. No. 6205/2021-DRAP.

17	Provide Compliance Record of HPLC software 21CFR & audit trail reports on product testing instead of mentioning NA.	The firm has stated tha the testing is done at HPLC by using EZ Chrom Elite but has not submitted the compliance report.
18	Specify the details how the manufacturing and analysis of the product was carried out without exposure to light. Further also provide evidence of light resistant vessels to carry out analysis as recommended in JP monograph.	Manufacturing is done in light resistant SS vessels, all the operations are done in red diffused light havig 4-8 Ix, for optical checking Ix may be increase to 40-60 IX after sterility tests. Ampoules are packed in light resistant plastic. For testing in Qc lab amber colored glass ware wrapped with aluminium foil are used.
Decision: Approved. Registration letter will be issued upon submission of Pharmaceutical equivalence studies against the innovator/reference product. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		

Case No, VI: Deferred cases (Import):

43.	Name and address of Applicant	M/s Himmel Pharmaceuticals Pvt. Limited 793-D Block C Faisal Town Lahore Pakistan
	Product License Holder & Manufacturer	M/s BEACON Pharmaceuticals Limited Plant address: Kathali, Bhaluka, Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel Dhaka, Bangladesh
	Name of exporting country	Bangladesh
	Type of Form	Form 5-A
	Diary No. & Date of R& I	Dy. No 7363 Dated 20-02-2019
	Fee including differential fee	Rs. 100,000/- Dated 20-02-2019
	Brand Name +Dosage Form + Strength	**Lapanix 250mg Tablet**
	Composition	Each film coated tablet contains: Lapatinib Ditosylate INN 398mg eq. to Lapatinib….250mg
	Finished Product Specification	In-house
	Pharmacological Group	Anti-cancer
	Shelf life	24 Months
	Pack size & Demanded Price	150's & As per SRO
	International availability	Tyverb® 250 mg film-coated tablets (UK)
	Me-too status	TYKERB TABLETS 250MG of M/s Gsk Karachi
	Stability studies	Firm has submitted long term (24 months) at 30+2oC, 65+5%RH & accelerated (06 months) stability data at 40+ 2oC, 75+ 5% RH for three batches.
	Detail of certificates attached	Original Legalized CoPP (Certificate#. DA/6-110/2016/22466 issued on 14-10-2018 by Govt. of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration declaring the free sale of applied product and GMP compliant status of the manufacturer i.e., M/s BEACON Pharmaceuticals Limited. Original product specific letter of authorization from product license holder is submitted.

	Remarks of the Evaluator.	Reference formulation Each film-coated tablet contains lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib while applied Each film coated tablet contains: Lapatinib Ditosylate INN 398mg eq. to Lapatinib….250mg
	Decision of 293rd meeting: Deferred for revision of composition as per reference product along with submission of requisite fee for the revision. Submission by the firm: The firm has submitted several references from RRAs confirming the monohydrate for of the salt of the applied product that is Lapatinib Ditosylate monhydrtae. Hoever, the API used for manufacturing of the applied product is Lpatinib Ditosylate.	
	Decision of 308th meeting: The Board deferred the case for clarification since the reference product contains Lapatinib Ditosylate Monohydrate while the applied product is manufactured by using Lapatinib Ditosylate. Submission by the firm: The firm has submitted attested copy of declaration from the API manufacturer stating that the API manufacturer had provided the API as Lapatinib Ditosylate to M/s Beacon Pharmaceuticals ltd Bangladesh (the drug product manufacturer).	
	Decision of 312th meeting: The Board deferred the case for further deliberation since the API used for manufacturing of reference product is lapatinib ditosylate monohydrate while the applied product is manufactured by using lapatinib ditosylate. Submission by the firm: The firm has submitted that the drug substance used for the manufacturing of the applied product is Lapatinib Ditosylate. A declaration letter from Drug Substance manufacturer is also submitted stating that the drug substance which has been supplied to finished product manufacturer is Lapatinib Ditosylate. It is worthy to bring the fact before the Board that the drug substance falls in BCS Class II (low solubility/high permeability) (Sourse: USFDA Biopharamceutical review of the innovator's product). Decision of 313th meeting: The Board deferred the case for further deliberation since the API used for manufacturing of reference product is lapatinib ditosylate monohydrate while the applied product is manufactured by using lapatinib ditosylate. Submission by the firm: The firm has submitted the General information on drug substance from drug substance manfuactruer that is M/s Qilu AntiBiotic (Linyi) Pharmaceuticals Ltd, China. The firm has stated that the API used in the manufacturing of the applied product is Lapatinib Ditosylate monohydrate as per the structure of the API from DMf.	
	Decision of 324th meeting: Deferred for submission of scientific evidence regarding the salt form of the drug substance used in the manufacturing of stability batches since the applicant in previous submission had claimed that they had used "Lapatinib ditosylate" for manufacturing of drug product whereas innovator product is of "Lapatinib ditosylate monohydrate."	

Item No. 2: Agenda of Evaluator PEC-II (Mr. Ammar Ashraf)

Case no. 01 Priority registration of Isoflurane Inhalational Solution

DRAP in its 143rd meeting of Authority held on 05th August, 2022, keeping in view of essentiality, criticality of isoflurane and pursuance from Government of Punjab to ensure its availability in Pakistan decided that registration application of Isoflurane shall be considered "out of queue" by the Registration Board.

PHARMA LIMITED. Sy. Nos. 7-70, 70/1 & 70/2, Digwal (D), Kohir (M), SANGAREDDY (D), Telangana State, India.

Available applications of Isoflurane 100ml & 250ml liquid for inhalation, are presented below:

44.	**Name, address of Applicant / Importer**	**M/s Highsea pharmaceuticals. 2nd floor, 39 commercial cavalry ground, Lahore**
	Details of Drug Sale License of importer	**License No:** 05-352-0058-100282D **Address:** 2nd floor,39-commercial area, cavalary ground Lahore. **Address of Godown:** NA **Validity:** 01-12-2027 **Status:** Drug Licence by way of Distributor.
	Name and address of marketing authorization holder (abroad)	M/s Fujian Highsea United Pharmaceutical Co., Ltd No. 15, Zone D, Mingxi Economic Development Zone, Mingxi Country, Fujian Province, 365200 China
	Name, address of manufacturer(s)	M/s Fujian Highsea United Pharmaceutical Co., Ltd No. 15, Zone D, Mingxi Economic Development Zone, Mingxi Country, Fujian Province, 365200 China
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate) • Copy of COPP (Certificate# Fujian20220009) issued by Fujian Medical Products Administration valid till 15-06-2024. • Free Sale status: The COPP endorses the free sale status of the applied product in exporting country • GMP: The COPP declares GMP compliant status of the manufacturer on bais of periodic inspections conducted on yearly basis.	
	Details of letter of authorization / sole agency agreement Copy "Confidentiality agreement" dated 10-8-2022, issued between M/s Fujian Highsea United Pharmaceutical Co., Ltd., and of M/s Highsea Pharmaceutica for the applied product of "Isoflurane 100ml & Sevoflurane 250ml".	
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy.No 25071 dated 05-09-2022	Dy. No 25071 dated 05-09-2022
	Details of fee submitted	Rs.150,000/- dated 23-08-2022
	The proposed proprietary name / brand name	**Alslar inhalation solution 100ml**

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml contains: Isoflurane …… 100% v/v
	Pharmaceutical form of applied drug	Liquid for Inhalation
	Pharmacotherapeutic Group of (API)	General Anaesthetic
	Reference to Finished product specifications	USP
	Proposed Pack size	100ml
	Proposed unit price	M.R.P. 3990/100ml bottle
	The status in reference regulatory authorities	Approved by US FDA
	For generic drugs (me-too status)	Forane of M/s Getz Pharma.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Name: Fujian Highsea United Pharmaceutical Co., Ltd Address: No. 15, Zone D, Mingxi Economic Development Zone, Mingxi, Fujian 365200 China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Submitted.
	Module-III Drug Product:	Firm has submitted data of drug product, including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence Studies	Not submitted
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	Soda lime glass moulded pharmaceutical bottle (brown), medicinal polypropylene cap lined with low density polyethylene gasket

	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40ºC ±2ºC / 75% ± 5% RH for 6 months. The Long term stability study data is conducted at 25ºC ±2ºC / 60% ± 5% RH for 36 months.
	Claimed shelf life	36 months.

Remarks of Evaluator:

Section#	Observations	Firm's response
1.4.2	Notarized copy of letter of authorization/Sole agency agreement from the market authorization holder shall be submitted for applied product	It is under process in the Pakistan embassy in Beijing China and will be submitted on receipt. Firm has submitted undertaking in this regard.
3.2.P.2.2.1	Pharmaceutical equivalence of the applied drug shall be established with the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted	Pharmaceutical equivalence studies against the product of M/s Baxter (Batch#N063M522) has been submitted.
3.2.P.3.5	Submit process validation reports including the protocols and results for critical process steps shall be provided	Submitted.
3.2.P.8.3	Submitted long term stability studies data of drug product is not as per Zone IVa conditions.	Firm has submitted long term stability studies data as per Zone IVa conditions for 24 months.

Decision: Approved as per Policy for inspection of Manufacturer abroad. Registration letter will be issued upon submission of legalized Original CoPP & Noatrized copy of letter of authorisation.

Case no. 02 Registration applications on Form 5F (Human)

a. New cases:

45.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Enzon Pharma Labs Pvt Ltd. 5km Off Raiwind Manga Road, Lahore**
	Name, address of Manufacturing site.	M/s Fynk Pharmaceuticals. 19km G.T. Road Kalashah Kaku, Lahore, Pakistan
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ **Is involved in none of the above (contract giver)**
	Status of application	☐ New Drug Product (NDP) ☒ **Generic Drug Product (GDP)**
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Evidence of manufacturing facility	DML renewal letter declaring section of "Dry Powder Injection" (General) section.
	Dy. No. and date of submission	Dy.No 28457 dated 15-10-2021

	Details of fee submitted	Rs.50,000/- dated 20-04-2021 & Rs.25,000/- dated 01-09-2021
	The proposed proprietary name / brand name	**Enzop 40mg Dry Powder Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Omeprazole as Sodium …… 40mg
	Pharmaceutical form of applied drug	Dry powder injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitors ATC Code: A02BC01
	Reference to Finished product specifications	Manufacturer Specifications
	Proposed Pack size	7's, 10's, 14's, 20's, 30's, 50's, 60's, 100's
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	Approved by US FDA
	For generic drugs (me-too status)	Risek 40 mg of M/s Getz Pharma
	GMP status of the Finished product manufacturer	New license granted on 20/10/2021 to M/s Enzon
	Name and address of API manufacturer.	M/s Vision Pharmaceuticals (Pvt) Ltd. Plot No. 22-23, industrial Triangle, kahuta Road, Islamabad-Pakistan
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Drug substances is tested at in-house specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	--

	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY STUDY DATA				
Manufacturer of API	M/s Vision Pharmaceuticals (Pvt) Ltd. Plot No. 22-23, industrial Triangle, kahuta Road, Islamabad-Pakistan			
API Lot No.	ABC082021001/B			
Description of Pack (Container closure system)	Glass vial			
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH			
Time Period	Real time: 24 months Accelerated: 6 months			
Frequency	Accelerated: 3 & 6 (Months) Real Time: 3, 6, 9, 12, 18 & 24 (Months)			
Batch No.	F-042	F-043	F-044	
Batch Size	17390 vials	26085 vials	17390 vials	
Manufacturing Date	02-2019	02-2019	02-2019	
No. of Batches	03			
Administrative Portion				
7.	Reference of previous approval of applications with stability study data of the firm (if any)	Not applicable		
8.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate submitted		
9.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Purchase invoice: GE035/2018 , attested by DRAP, dated 03/07/2018 is submitted		
10.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
11.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted		
12.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted		

Remarks of Evaluator:

Section#	Observations
1.3	Form 5F has been submitted from the *M/s* Fynk Pharmaceuticals instead of M/s Enzon.
3.2.S	• Role of Mannitol in the "Omeprazole sodium/Lyophilized powder shall be justified against the innovator product composition. • Submitted drug substance details are of "Omeprazole sodium lyophiliized powder (38%w/w) whereas drug product composition declares the use of • Omeprazole sodium lyophilized powder (35%w/w).
3.2.P.1	• Equivalency of Omeprazole sodium lyophilized powder (35%) to the claimed strength of 40 mg of Omeprazole is not correct. • Details of accompanying reconstitution diluent are not as per innovator product.
3.2.P.2.2.1	Pharmaceutical equivalence studies against the reference product shall be submitted.

3.2.P.2.5	The said section declares the "Sterile water for injection" as compatible diluent for reconstitution which is contrary to the recommendations of innovator product literature.
3.2.P.2.5	The said section declares the "Sterile water for injection" as compatible diluent for reconstitution which is contrary to the recommendations of innovator product literature.
3.2.P.3.2	Declaration of "Sterile water of injection" as ingredient in the composition table shall be justified.
3.2.P.3.5	Justification shall be submitted for not including test of "Filled weight per vial" in the process validation studies.
3.2.P.5.1	Limits of pH test in drug product specifications are not as per innovator product. Limits of Assay test shall be justified.
3.2.P.5.4	Batch release COAs of stability batches shall be submitted.
3.2.P.8.3	• Documents confirming procurement of drug substance shall be submitted. • Justification shall be submitted for not performing sterility testing at the last time point of accelerated stability studies. • Results of pH test during stability studies are out of the range recommended by the innovator drug product. • Submit complete analytical record for the performance of stability studies of drug product. • Record digital data logger of stability chambers shall be submitted. • Complete batch manufacturing record of stability batches shall be submitted.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

46.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore**
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	GMP certificate issued on 17-07-2020
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 24-06-2019 which specifies Ophthalmic general section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 6373 dated 08-03-2022
	Details of fee submitted	Rs.30,000/- dated 03-02-2022
	The proposed proprietary name / brand name	**Latano-T Eye Drops**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml Contains: Latanoprost …… 50mcg Timolol Maleate 6.8mg Eq. to Timolol …… 5mg
	Pharmaceutical form of applied drug	Ophthalmic Drops
	Pharmacotherapeutic Group of (API)	Ophthalmologicals, antiglaucoma preparations and miotics, prostaglandin analogues. ATC code: S01EE01.
	Reference to Finished product specifications	In-House specification
	Proposed Pack size	1 x 2.5 ml

	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Xalacom Approved by US FDA
	For generic drugs (me-too status)	Xalatan Eye Drop 2.5ml by Pfizer Laboratories (Pvt) Ltd.
	Name and address of API manufacturer.	Cayman Pharma s r.o. ul. Práce 657, 277 11 Neratovice Czech Republic FDC limited
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions duration of Stability studies)	**Latanoprost:** Long-term stability studies were performed at a storage temperature of -18°C for 24 months. Accelerated stability studies were performed at a temperature of +5 °C for 6 months. **Timolol maleate:** Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40ºC ±2ºC / 75% ± 5% RH for 6 months. The Long term stability study data is conducted at 30ºC ±2ºC / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence Studies s against the reference product of "Xalatan Eye Drop" 2.5ml by Pfizer Laboratories (Pvt) Ltd.
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and the drug product.
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long term conditions.

STABILITY STUDY DATA	
Manufacturer of APIs	Cayman Pharma s r.o. ul. Práce 657, 277 11 Neratovice Czech Republic
API Lot No.	Batch # 2008S004
Description of Pack (Container closure system)	Eye Drops is available as 2.5 mL sterile solution in 5 mL LDPE bottle with polypropylene dropping nozzle with HDPE Cap

Stability Storage Condition		Real time: 5°C ± 3°C Accelerated: 25°C ± 2°C / 60% RH ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3,6 (Months)		
Batch No.		PDGN0012021	PDGN0022021	PDGN0032021
Batch Size		5 liter	5 liter	5 liter
Manufacturing Date		07/2021	07/2021	07/2021
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
#	**Documents To Be Provided**	**Status**		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of EUDRA GMP certificate (Certificate Ref. No. ***016/2021/API***) valid upto 19-10-2021.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	N/A		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data pf stability batches along with batch manufacturing record and analytical record.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted.		
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)		

Remarks of Evaluator:

Section#	**Observations**	**Firm's response**
3.2. S.4	The specifications submitted from drug substance manufacturer are not as per USP monograph of "Latanoprost" for the test of Optical rotation & water content, Latanoprost related compound E test missing. Specifications different between API & Product manufacturer.	Specifications as per USP Kindly see the attachment **Optical Rotation:** **USP:** 31 º – 38º **Manufacturer:** 31º – 38 º Manufacturer's COA as per USP-42, It may be typo mistake in the lower limit of Optical Rotation, but the results are within limits of USP-42. **Water Contents:** **USP:** 2% **Manufacturer:** 0.5% USP-42 gives the wide range of Water Contents while Manufacturer is following the narrow range and results fall in the USP-42 Limits. **Latanoprost Related Compound E:** Manufacturer performed the test of related Compound E as in COA **(e) Latanoprost Free Acid** but the range is narrow.

		USP: NMT 0.2% **Manufacturer:** NMT 0.15% USP-42 gives the wide range for Assay Determination while Manufacturer is following narrow range which falls in the range of USP-42.	
3.2.S.5	COA of working standard of Timolol maleate declares validity date as 08-01-2021.	The updated COA of Working Standard For Timolol Maleate is submitted, valid till October, 2025.	
3.2.P.2.1	Finish product specifications for pH and Osmolarity are not as per reference product	Finish product specifications for pH and Osmolarity are as per reference product	
3.2.P.3.2	Manufacturing process includes step of terminal sterilization, which is not recommended by the reference product.	No terminal sterilization, Aseptic area manufacturing tank under LAF and aseptic Blowing, filling/Sealing multiple filtration cartage assembling 0.65um+ 0.45um +0.22um in manufacturing for filtration of solution and 0.22 in filling BFS machine which already mention in BMR so our product are sterile by filtration and aseptic process.	
3.2.3.5	Process validation protocol is missing.	Submitted.	
3.2.P.5.3	• Clarification shall be submitted for applying same chromatographic conditions except UV detector wavelength for the method validation studies of both APIs in the product.	• Because both APIs are very soluble in same diluent that why the diluent and other chromatographic conditions are same like flow rate, injection volume and column. So, both APIs can be detected in single injection.	
3.2.P.6	• COAs of primary/working standards shall be submitted.	Submitted.	
3.2.P.8	• Documents confirming import of APIs shall be submitted. • Complete analytical record for the performance of stability studies shall be submitted including chromatograms, raw data sheets etc..	Firm has submitted following: Copy of commercial invoice# FOZ-11/2021 attested by AD I&E, DRAP, Lahore dated 24-02-2021 for import of 7gm of Latanoprost. Copy of commercial invoice# 9510004244 attested by AD I&E, DRAP dated 15-06-2021 for import of 0.5Kg of Timolol maleate. Analytical record for stability studies.	

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 75,00/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

b. Deferred cases:

47.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Indus Pharma (Pvt.) Ltd. Plot No. 26,27 & 63-67, Sector 27, Korangi Industrial Area, Karachi**

	Name, address of Manufacturing site.	M/s Nabiqasim Industries Pvt Ltd. 17/24, Korangi Industrial Area, Karachi, Pakistan
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 31870 dated 19-11-2021
	Details of fee submitted	Rs.75,000/- dated 14-10-2021
	The proposed proprietary name / brand name	**Indaz IV 500mg Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: (Lyophilized powder for injection) Azithromycin Dihydrate Eq. to Azithromycin ……. 500mg
	Pharmaceutical form of applied drug	Intravenous Sterile Dry Powder for Injection
	Pharmacotherapeutic Group of (API)	Antibacterial for systemic use (macrolide)
	Reference to Finished product specifications	USP
	Proposed Pack size	1×1's
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	Approved by MHRA of UK
	For generic drugs (me-too status)	Romycin Injection by M/s NabiQasim Industries.
	GMP status of the Finished product manufacturer	Firm has submitted copy of GMP certificate issued on basis of inspection conducted on 19-09-2020, wherein Small Volume Lyophilized injectables section is declared.
	Name and address of API manufacturer.	M/s Zhejiang Guobong Pharmaceutical Co., Ltd. No. 6, Weiwu Road, Hangzhou Gulf Shangyuu Economic and Technological Development Zone, Zheijnag, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the Zezot injection
	Analytical method validation/verification of product	Method verification studies have submitted

STABILITY STUDY DATA

Manufacturer of API	M/s Zhejiang Guobong Pharmaceutical Co., Ltd. No. 6, Weiwu Road, Hangzhou Gulf Shangyuu Economic and Technological Development Zone, Zheijnag, China.		
API Lot No.	103-200642-21		
Description of Pack (Container closure system)	Glass Vial with rubber stopper sealed with flip off seal and packed in unit carton (1×1's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	394DS01	394DS02	394DS03
Batch Size	300 vials	300 vials	300 vials
Manufacturing Date	01-2021	01-2021	01-2021
No. of Batches	03		

Documents submitted along with stability data.

1.	Reference of previous approval of applications with stability study data of the firm (if any)	--
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. ZJ20180112 issued by Shandong Food and Drug Administration valid till 04/09/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice GBPH2020 attested by AD DRAP I&E, Karachi dated 07-09-2020 for import of 100Kg of Azithromycin dihydrate (batch# 103-200642-21)
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	N/A
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	N/A

Remarks of Evaluator[II]:
Firm had initially submitted trial batches data, while subsequently firm has submitted stability studies data of three commercial batches detailed as below:

Description of Pack (Container closure system)	Glass Vial with rubber stopper sealed with flip off seal and packed in unit carton (1×1's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RYD001	RYD002	
Batch Size	20,300 vials	20,300 vials	
Manufacturing Date	04-2021	10-2021	
No. of Batches	03		

- Firm has not submitted following for new stability studies data:
  i. Fee for revision of stability studies data.
  ii. COA of relevant batch of API used for preparation of newly submitted stability batches.
  iii. Complete batch manufacturing record.
  iv. Details of drug substance used for the preparation of stability batches including evidence of procurement of Drug substance.
  v. Digital data logger record for stability chambers.

Decision of 321st meeting: Deferred for submission of following:

i. Full fee of Rs. 75,000/- for revision of stability studies data as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021
ii. COA of relevant batch of API used for preparation of newly submitted stability batches.
iii. Complete batch manufacturing record.
iv. Details of drug substance used for the preparation of stability batches including evidence of procurement of Drug substance.

Firms response: Firm has submitted following:

- Fee of RS. 75,000/- vide deposit slip#25218030.
- COA of "Azithromycin (as dihydrate powder) of two batches from M/s Nabiqasim (Batch# 2010-6091-FP023 & 129-210516-1).
- Batch Manufacturing Record of Stability Batches i.e., batch# RYD001 & RYD002.
- Commercial invoice# NSK20PK128 for import of 100Kgs of Azithromycin attested y AD FDRAP I&E Karachi dated 10-12-2020.

Decision of 324th meeting: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Nabiqasim Industries Pvt Ltd. 17/24, Korangi Industrial Area, Karachi, Pakistan.

48.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Indus Pharma (Pvt.) Ltd. Plot No. 26,27 & 63-67, Sector 27, Korangi Industrial Area, Karachi**
	Name, address of Manufacturing site.	M/s Stallion Pharmaceuticals, PVT, Ltd., 581-Sundar Industrial Estate, Raiwind Road Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale

		☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 27810 dated 07-10-2021
	Details of fee submitted	Rs.75,000/- dated 27-09-2021
	The proposed proprietary name / brand name	**Tazit 2.25gm Sterile Dry Powder for Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Piperacillin Sodium Equivalent to Piperacillin ……. 2.0 g Tazobactam Sodium Equivalent to Tazobactam ……. 0.25 g
	Pharmaceutical form of applied drug	Intravenous Sterile Dry Powder for Injection
	Pharmacotherapeutic Group of (API)	First Generation Beta Lactam Antibiotics (Penicillin)
	Reference to Finished product specifications	USP
	Proposed Pack size	1×1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved.
	For generic drugs (me-too status)	Tanzo 2.25 g Injection by M/s Bosch, Reg. No. 039593
	GMP status of the Finished product manufacturer	Firm has submitted copy of GMP certificate issued on basis of inspection conducted on 22-09-2020, wherein Dry powder injectable Penicillin section is declared.
	Name and address of API manufacturer.	M/s Shandong /Anxin Pharmaceutical Co., Ltd. 849, Dongjia Town, Licheng District, Jinan, Shandong, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls and its verification studies, batch analysis and

		justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Tanzo 4.5 g Injection by M/s Bosch Pharma by performing quality tests (Identification, Assay and Uniformity of dosage form).
	Analytical method validation/verification of product	Method verification studies have submitted

STABILITY STUDY DATA			
Manufacturer of API	M/s Shandong /Anxin Pharmaceutical Co., Ltd. 849, Dongjia Town, Licheng District, Jinan, Shandong, China		
API Lot No.	KA1007150016		
Description of Pack (Container closure system)	Glass Vial with rubber stopper sealed with flip off seal and packed in unit carton (1×1's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	N5001	N5002	N5003
Batch Size	42,50 vials	41,60 vials	63,80 vials
Manufacturing Date	03-2015	03-2015	04-2015
Date of Initiation	25-05-2015	26-05-2015	12-06-2015
No. of Batches	03		

Documents submitted along with stability data.		
	Reference of previous approval of applications with stability study data of the firm (if any)	--
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 2018001 issued by Shandong Food and Drug Administration valid till 24/07/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice attested by AD DRAP I&E, Lahore dated 11-02-2015 for import of 100Kg of Piperacillin sodium: Tazobactam sodium (8:1)
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	N/A
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	N/A
49.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Indus Pharma (Pvt.) Ltd. Plot No. 26,27 & 63-67, Sector 27, Korangi Industrial Area, Karachi**

	Name, address of Manufacturing site.	M/s Stallion Pharmaceuticals, PVT, LTD. 581-Sundar Industrial Estate, Raiwind Road Lahore, Punjab 54000.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 27811 dated 07-10-2021
	Details of fee submitted	Rs.75,000/- dated 27-09-2021
	The proposed proprietary name / brand name	**Tazit 4.5gm Sterile Dry Powder for Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Piperacillin Sodium USP Equivalent to Piperacillin ……. 4.0 g Tazobactam Sodium USP Equivalent to Tazobactam ……. 0.50 g
	Pharmaceutical form of applied drug	Intravenous Sterile Dry Powder for Injection
	Pharmacotherapeutic Group of (API)	First Generation Beta Lactam Antibiotics (Penicillin)
	Reference to Finished product specifications	USP
	Proposed Pack size	1×1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved.
	For generic drugs (me-too status)	Tanzo 4.5 g Injection by M/s Bosch, Reg. No. 039439
	GMP status of the Finished product manufacturer	Firm has submitted copy of GMP certificate issued on basis of inspection conducted on 22-09-2020, wherein Dry powder injectable Penicillin section is declared.
	Name and address of API manufacturer.	M/s Shandong / (Previously Qilu Pharmaceuticals Co. Ltd) Anxin Pharmaceutical Co., Ltd. 849, Dongjia Town, Licheng District, Jinan, Shandong, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and

		justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Tanzo 4.5 g Injection by M/s Bosch Pharma by performing quality tests (Identification, Assay and Uniformity of dosage form).
	Analytical method validation/verification of product	Method verification studies have submitted

STABILITY STUDY DATA			
Manufacturer of API	M/s Shandong / (Previously Qilu Tianhe Pharmaceuticals Co. Ltd) Anxin Pharmaceutical Co., Ltd. 849, Dongjia Town, Licheng District, Jinan, Shandong, China		
API Lot No.	KA1007150016		
Description of Pack (Container closure system)	Glass Vial with rubber stopper sealed with flip off seal and packed in unit carton (1×1's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	P5001	P5002	P5003
Batch Size	8,600 vials	8,600 vials	10,630 vials
Manufacturing Date	03-2015	03-2015	04-2015
Date of Initiation	16-04-2015	16-04-2015	04-06-2015
No. of Batches	03		

Documents submitted along with stability data.		
	Reference of previous approval of applications with stability study data of the firm (if any)	--
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 2018001 issued by Shandong Food and Drug Administration valid till 24/07/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice attested by AD DRAP I&E, Lahore dated 11-02-2015 for import of 100Kg of Piperacillin sodium: Tazobactam sodium (8:1)

	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	N/A
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	N/A

Remarks of EvaluatorII:

Section#	**Observation**	**Firm's response**
3.2. S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance by Drug Product manufacturer shall be submitted.	Submitted.
3.2.S.4.3	Analytical method verification studies from the drug product manufacturer shall be submitted.	Submitted.
3.2. S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	Submitted.
3.2.P.2.2.1	Pharmaceutical equivalence studies against the innovator product shall be submitted.	Pharmaceutical equivalence has been submitted against the Tanzo Injection of M/s Bosch.
3.2.P.2.6	Compatibility studies with the reconstitution diluent shall be submitted.	Compatibility studies with water for injection have been submitted.
3.2.P.5.3	Test of specificity parameter has not been submitted in the analytical method verification studies.	Submitted.
3.2.P.8.3	Significant change i.e., more than 5% in the Assay results of Tazobactam has been reported in the accelerated stability studies data of batch# N5001 & N5002 of "2.25gm Injection." Firm has submitted following justification: We placed three consecutive batches of Talzon Sterile Dry Powder Injection 2.25g N500 I, N5002 and N5003 in 2015 from the respective supplier Shandlong, Pharmaceutical Co. Ltd. (Previously Qilu) for accelerated stability study at 40°C ± 2°C temperature and 75% ± 5% humidity and shelf life stability study at 30°C ± 2°C temperature and 65% ± 5%, humidity in which a slightly significant change was observed in N5001 and N5002 which might vary from analyst to analyst etc. Due to this significant change, we re-placed three consecutive batches of Talzon Sterile Dry Powder Injection 2.25g N900 I, N9002 and 1 9003 in 2019 from Shandong, Pharmaceutical Co. Ltd. (Previously Qilu) in which the results of the accelerated stability study and the shelf life stability are within limits and were found to be satisfactory. In addition, we are then placed one batch from the same supplier each year and-the results of all batches are within limits and deemed satisfactory. The details of new stability studies data submitted by firm for 2.25gm strength is as under:	

Description of Pack (Container closure system)	Glass Vial with rubber stopper sealed with flip off seal and packed in unit carton (1×1's)
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 24 months

	Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	N9001	N9002	N9003
Batch Size	8,330 vials	8,330 vials	12,500 vials
Manufacturing Date	01-2019	04-2019	10-2019
Date of Initiation	23-01-2019	23-04-2019	08-11-2019

Documents submitted along with stability data.	
Reference of previous approval of applications with stability study data of the firm (if any)	--
Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 2018001 issued by Shandong Food and Drug Administration valid till 24/07/2023.
Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted for the relevant batch of API used for preparation of newly submitted drub product stability batches.
Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted for time duration of newly submitted stability batches.

- Firm has not submitted following for new stability studies data:
    i. Fee for revision of stability studies data.
    ii. COA of relevant batch of API used for preparation of newly submitted stability batches.
    iii. Complete batch manufacturing record.
    iv. Submitted stability studies record does not show performance of sterility testing.

Decision of 321st meeting: Registration Board deferred the applications of Tazit 2.25gm Sterile Dry Powder for Injection & Tazit 4.5gm Sterile Dry Powder for Injection for submission of following:

i. Full fee of Rs. 75,000/- for revision of stability studies data as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021
ii. COA of relevant batch of API used for preparation of newly submitted stability batches.
iii. Complete batch manufacturing record.
iv. Microbial reports for performance of sterility testing during stability studies.

Firms response: Firm has submitted following:

- Fee of RS. 75,000/- vide deposit slip#4303205195
- COA of "Piperacillin sodium & Tazobactum sodium sterile powder from M/s Qilu Antibiotics & M/s Stallion of two batches (Batch# HF8086D2 & HF8116D1).
- Batch Manufacturing Record of revised Stability Batches.
- Microbial reports for performance of sterility testing

Decision of 324th meeting: Registration Board approved the applications of Tazit 2.25gm Sterile Dry Powder for Injection & Tazit 4.5gm Sterile Dry Powder for Injection. Registration Board further authorized its Chairman for issuance of registration letter upon capacity assessment of manufacturing and testing facility of M/s Stallion Pharmaceuticals (Pvt.) Ltd.

Case no. 03 Deferred cases Registration applications on Form 5F (Human)

50.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Limited 30 km, Multan Road, Lahore, Pakistan**
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Limited. 30 km, Multan Road, Lahore, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 24064 dated 01-09-2021
	Details of fee submitted	Rs.75,000/- dated 30-07-2021
	The proposed proprietary name / brand name	**Trilin 5/2.5/1000 mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated extended-release tablet contains: Empagliflozin …….. 5mg Linagliptin …… 2.5 mg (as immediate release coating) Metformin HCl …… 1000mg (as extended release core)
	Pharmaceutical form of applied drug	Film-coated extended-release tablet
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** sodium-glucose co-transporter 2 (SGLT2) inhibitors **Linagliptin:** dipeptidyl peptidase-4 (DPP-4) inhibitors **Metformin HCl:** antihyperglycemic drug
	Reference to Finished product specifications	Innovator
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy® XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Available
	Evidence of manufacturing facility	GMP certificate granted on basis of inspection conducted on 18.06.2020 endorses tablet general section.
	GMP status of the Finished product manufacturer	GMP certificate granted on basis of inspection conducted on 18.06.2020.

	Name and address of API manufacturer.	**Linagliptin:** **M/s Lee Pharma Limited, India** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Empagliflozin:** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Metformin Hydrochloride:** Shandong Keyuan Pharmaceutical Co., Ltd. Keyuan Street, Shandong shanghe Economic Zone, Jinan city, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies of Drug substance	**Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Trijardy XR Tablets approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablets 12.5/2.5/1000mg approved by US-FDA inAcid media

		(pH 1.2) , Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8)
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA

Manufacturer of API	**Linagliptin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Empagliflozin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Metformin Hydrochloride:** M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India.		
API Lot No.	**Empagliflozin:** L-E-202000409-D01-E06-01 **Linagliptin:** L-20200219-D01-L09-01 **Metformin HCl:** 2018MPC0633		
Description of Pack (Container closure system)	Alu-Alu. Blisters with aluminum foil having leaflet and packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 03 months Accelerated: 03 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TLM00110P	TLM00210P	TLM00310P
Batch Size	5000 tab	5000 tab	5000 tab
Manufacturing Date	10-2020	10-2020	10-2020
No. of Batches	02		

51.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Limited 30 km, Multan Road, Lahore, Pakistan**
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Limited. 30 km, Multan Road, Lahore, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 30929 dated 11-11-2021
	Details of fee submitted	Rs.75,000/- dated 30-07-2021
	The proposed proprietary name / brand name	**Trilin 10/5/1000 mg Tablet**

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated extended-release tablet contains: Empagliflozin …….. 10mg Linagliptin …… 5 mg (as immediate release coating) Metformin HCl …… 1000mg (as extended release core)
	Pharmaceutical form of applied drug	Film-coated extended-release tablet
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** sodium-glucose co-transporter 2 (SGLT2) inhibitors **Linagliptin:** dipeptidyl peptidase-4 (DPP-4) inhibitors **Metformin HCl:** antihyperglycemic drug
	Reference to Finished product specifications	Innovator
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy® XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Available
	Evidence of manufacturing facility	GMP certificate granted on basis of inspection conducted on 18.06.2020 endorses tablet general section.
	GMP status of the Finished product manufacturer	GMP certificate granted on basis of inspection conducted on 18.06.2020.
	Name and address of API manufacturer.	**Linagliptin:** **M/s Lee Pharma Limited, India** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Empagliflozin:** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Metformin Hydrochloride:** Shandong Keyuan Pharmaceutical Co., Ltd. Keyuan Street, Shandong shanghe Economic Zone, Jinan city, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical

		procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies of Drug substance	**Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Trijardy XR Tablets 25/25/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablets 12.5/2.5/1000mg approved by US-FDA in Acid media (pH 1.2) , Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8)
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA

Manufacturer of API	**Linagliptin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Empagliflozin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Metformin Hydrochloride:** M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India.		
API Lot No.	**Empagliflozin:** L-E-202000409-D01-E06-01 **Linagliptin:** L-20200219-D01-L09-01 **Metformin HCl:** 2018MPC0633		
Description of Pack (Container closure system)	Alu-Alu. Blisters with aluminum foil having leaflet and packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 03 months Accelerated: 03 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TEL00110P	TEL 00210P	TEL 00310P

Batch Size		5000 tab	5000 tab	5000 tab
Manufacturing Date		10-2020	10-2020	10-2020
No. of Batches		02		
52.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Limited 30 km, Multan Road, Lahore, Pakistan**		
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Limited. 30 km, Multan Road, Lahore, Pakistan		
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)		
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales		
	Dy. No. and date of submission	Dy.No 31873 dated 19-11-2021		
	Details of fee submitted	Rs.75,000/- dated 30-07-2021		
	The proposed proprietary name / brand name	**Trilin 25/5/1000 mg Tablet**		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated extended-release tablet contains: Empagliflozin …….. 25mg Linagliptin …… 5 mg (as immediate release coating) Metformin HCl …… 1000mg (as extended release core)		
	Pharmaceutical form of applied drug	Film-coated extended-release tablet		
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** sodium-glucose co-transporter 2 (SGLT2) inhibitors **Linagliptin:** dipeptidyl peptidase-4 (DPP-4) inhibitors **Metformin HCl:** antihyperglycemic drug		
	Reference to Finished product specifications	Innovator		
	Proposed Pack size	As per SRO		
	Proposed unit price	As per SRO		
	The status in reference regulatory authorities	Trijardy® XR Tablets by M/s Boehringer Ingelheim, FDA Approved.		
	For generic drugs (me-too status)	Not Available		
	Evidence of manufacturing facility	GMP certificate granted on basis of inspection conducted on 18.06.2020 endorses tablet general section.		
	GMP status of the Finished product manufacturer	GMP certificate granted on basis of inspection conducted on 18.06.2020.		

	Name and address of API manufacturer.	**Linagliptin:** **M/s Lee Pharma Limited, India** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Empagliflozin:** HuaiNan ShunLong Pharmaceutical CO, LTD. No. 9 Yongxing Road, Econonmic and Technological Development Development Zone, Huainan City, Anhui Province China. **Metformin Hydrochloride:** Shandong Keyuan Pharmaceutical Co., Ltd. Keyuan Street, Shandong shanghe Economic Zone, Jinan city, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies of Drug substance	**Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Trijardy XR Tablets 10/5/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablets 12.5/2.5/1000mg approved by US-FDA in

		Acid media (pH 1.2) , Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8)
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA

Manufacturer of API	**Linagliptin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Empagliflozin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Metformin Hydrochloride:** M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India.		
API Lot No.	**Empagliflozin:** L-E-202000409-D01-E06-01 **Linagliptin:** L-20200219-D01-L09-01 **Metformin HCl:** 2018MPC0633		
Description of Pack (Container closure system)	Alu-Alu. Blisters with aluminum foil having leaflet and packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 03 months Accelerated: 03 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TML00110P	TML 00210P	TML 00310P
Batch Size	5000 tab	5000 tab	5000 tab
Manufacturing Date	10-2020	10-2020	10-2020
No. of Batches	02		

53.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Limited 30 km, Multan Road, Lahore, Pakistan**
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Limited. 30 km, Multan Road, Lahore, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 31874 dated 19-11-2021
	Details of fee submitted	Rs.75,000/- dated 30-07-2021
	The proposed proprietary name / brand name	**Trilin 12.5/2.5/1000 mg Tablet**

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated extended-release tablet contains: Empagliflozin …….. 12.5mg Linagliptin …… 2.5 mg (as immediate release coating) Metformin HCl …… 1000mg (as extended release core)
	Pharmaceutical form of applied drug	Film-coated extended-release tablet
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** sodium-glucose co-transporter 2 (SGLT2) inhibitors **Linagliptin:** dipeptidyl peptidase-4 (DPP-4) inhibitors **Metformin HCl:** antihyperglycemic drug.
	Reference to Finished product specifications	In-House
	Proposed Pack size	8 x 4's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy® XR Tablets 12.5mg/2.5mg/1000mg by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Available
	Evidence of manufacturing facility	GMP certificate granted on basis of inspection conducted don 07-03-02019 declares availability of tablet general section.
	GMP status of the Finished product manufacturer	GMP certificate granted on basis of inspection conducted don 07-03-02019.
	Name and address of API manufacturer.	**Linagliptin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Empagliflozin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Metformin Hydrochloride:** M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies of Drug substance	**Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months

		Linagliptin: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Trijardy XR Tablets 12.5/2.5/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablets 12.5/2.5/1000mg approved by US-FDA inAcid media (pH 1.2) , Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8)
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA

Manufacturer of API	**Linagliptin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Empagliflozin:** M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China **Metformin Hydrochloride:** M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India.		
API Lot No.	**Empagliflozin:** L-E-202000409-D01-E06-01 **Linagliptin:** L-20200219-D01-L09-01 **Metformin HCl:** 2018NPC0633		
Description of Pack (Container closure system)	Alu-Alu. Blisters with aluminum foil having leaflet and packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 03 months Accelerated: 03 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TLE0010P	TLE0020P	TLE0030P
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	10-2020	10-2020	10-2020
No. of Batches	02		
Documents submitted along with stability data			

<table>
<tr><td>1.</td><td>Reference of previous approval of applications with stability study data of the firm (if any)</td><td></td></tr>
<tr><td>2.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>• Copy of DML (Certificate# Liao20150233) issued by Liaoning FDA, valid upto 20-12-2022 for M/s Fuxin Long Rui

• Firm had provided copy of GMP certificate (NEW-WHO-GMP/CERT/KD/17230/2015/11/10384) issued by Food & Drug Administration Maharashtra, India valid upto: 18-04-2017</td></tr>
<tr><td>3.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of commercial invoice attested by AD I&E DRAP, Lahore, has been submitted.
Empagliflozin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>L-E-202000409-D01-E06-01</td><td>SY200061201</td><td>0.35kgs</td><td>20-06-2020</td></tr>
</table>
Linagliptin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>L-20200219-D01-L09-01</td><td>SY200714-F</td><td>0.125kgs</td><td>28-07-2020</td></tr>
</table></td></tr>
<tr><td>4.</td><td>Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>5.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>--</td></tr>
<tr><td>6.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).</td><td>Digital data logger record has been submitted for temperature & humidity conditions of both accelerated and long-term stability chambers.</td></tr>
<tr><td colspan="3">Remarks of Evaluator^{II}:
<table>
<tr><th>Section#</th><th>Observations</th><th>Firm’s response</th></tr>
<tr><td>1.3</td><td>Valid GMP inspection report shall be submitted for M/s Pacific Pharmaceuticals, 30-Km, Multan Road, Lahore.</td><td>GMP certificate submitted issued on basis of inspection conducted on 14-09-2021</td></tr>
<tr><td>1.6.5</td><td>Valid GMP certificate of M/s Auro laboratories, shall be submitted.</td><td>Firm has submitted Certificate No: ES/083/15 issued by AEMPS of Spain, valid upto April, 2017.

Submitted GMP certificate is still not valid.</td></tr>
<tr><td>3.2.S.4.1</td><td>Justification shall be submitted for the test of optical rotation of Empagliflozin.</td><td>It is tested as per supplier specifications.</td></tr>
<tr><td>3.2.S.4.3</td><td>Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug</td><td>Submitted.</td></tr>
</table></td></tr>
</table>

	Product manufacturer shall be submitted for Empagliflozin & Linagliptin.	
3.2.P.2.1	• Innovator product has used Polyethylene oxide as extended release polymer, whereas you have used HPMC 15000 for the same purpose. Justification shall be submitted for this variation along with drug excipient compatibility study. • Dissolution limits defined in the "Quality Target product Profile" are different from that recommended by US FDA for the Innovator product i.e., Trijardy XR tablets.	• Composition is according to innovator, Product is stable, no variations in result observed were found during all study. • Compatibility study report has been submitted. • Dissolution Limits in CDP are updated according to USFDA and updated Protocol, Report has been submitted.
3.2.P.5.1	• Submitted drug product specifications does not include test for "Uniformity of Dosage Unit" by way of content uniformity for Empagliflozin & Linagliptin. • Dissolution time points for metformin HCl & Linagliptin are not as recommended by US FDA for the innovator product i.e., Trijardy XR tablets.	Firm has submitted revised drug product specification including test of content uniformity whereas the dissolution specifications for Empagliflozin & Linagliptin are still not as recommended by US FDA for innovator product. Firm has proposed dissolution limits of NLT Q in 60 minutes for both Empagliflozin & Linagliptin whereas US FDA has recommended 45 minutes & 30 minutes time point for Empagliflozin & Linagliptin respectively.
3.2.P.5.2	• Submitted analytical procedure for dissolution test does not mention details for standard solution preparation. • Standard concentration for each API does not equate with the sample concentrations in the analytical procedure of Assay test.	Firm has revised analytical procedure for the details of standard solution preparation and concentration of standard and sample solution, whereas the stability data had been submitted as per previous method.
3.2.P.5.3	The concentration range applied for the linearity test of Linagliptin, does not cover the specified concertation for Assay test.	Revised method validation report has been submitted.
3.2.P.5.4	Submitted Batch analysis COA does not include test of content uniformity for Empagliflozin & Linagliptin. Dissolution time points for Linagliptin & Metformin HCl are not as recommended by US FDA for the innovator product i.e., Trijardy XR tablets.	Firm has submitted revised drug product specification including test of content uniformity whereas the dissolution specifications for Empagliflozin & Linagliptin are still not as recommended by US FDA for innovator product. Firm has proposed dissolution limits of NLT Q in 60 minutes for both Empagliflozin & Linagliptin whereas US FDA has recommended 45 minutes & 30 minutes time point for Empagliflozin & Linagliptin respectively.
3.2.P.6	• Submitted COA of working standard of Metformin HCl declares retest date as May 2021, whereas stability studies have also been performed subsequent to this date. • Submitted COA of working standard of Empagliflozin declares retest date as March 2021, whereas stability studies have also been performed subsequent to this date.	No justification has been submitted.
3.2.P.8.3	• Documents confirming import of Metformin HCl shall be submitted. • Analytical record i.e., raw data sheets, chromatograms & COAs shall be submitted for complete stability studies at both accelerated and long-term conditions.	• Firm has submitted commercial invoice attested by AD DRAP I&E, Lahore 11-12-2018 for import of 1000Kg Metformin HCl. • Firm has submitted raw data sheet for the stability studies. • Audit trail reports on product testing have not been submitted.

	• Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted. • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	• Details of data logger have been submitted.
• Submit clarification regarding not ensuring the dissolution profile at in-process stage of Metformin HCl extended release core prior to proceeding for Active coating of other drug substances. • Submitted BMR declare dispensing of Empagliflozin & Linagliptin as per 100% content of desired label claim. Justification shall be submitted that how dispensed quantity will produce 100% content of Empagliflozin & Linagliptin, when both APIs are being included by way of Active coating and how the wastage of coating solution will be compensated.		Not replied. Firm has submitted a document titled "Additional Raw/Packaging materials Requisition Form" 01-10-2020 wherein dispensing of Empagliflozin & Linagliptin for batch# 00110P,00210P,003 has been declared with the reason as "To produce 100% content of Empagliflozin & Linagliptin, overages required for coating solution.

Decision of 321st meeting: Registration Board deferred the applications of Trilin 12.5/2.5/1000 mg Tablet, Trilin 25/5/1000 mg Tablet, Trilin 10/5/1000 mg Tablet & Trilin 5/2.5/1000 mg Tablet for following:

- Valid GMP certificate of M/s Auro Laboratories Ltd., K-56, MIDC tarapur, Boiser, Dist, Thane, Maharashtra, India, shall be submitted.
- Dissolution specifications for Empagliflozin & Linagliptin are not as recommended by US FDA for innovator product. Firm has proposed dissolution limits of NLT Q in 60 minutes for both Empagliflozin & Linagliptin whereas US FDA has recommended 45 minutes & 30 minutes time point for Empagliflozin & Linagliptin respectively. Justification shall be submitted in this regard.
- Submitted COA of working standard of Metformin HCl declares retest date as May 2021, whereas stability studies have also been performed subsequent to this date. Justification shall be submitted in this regard.
- Submitted COA of working standard of Empagliflozin declares retest date as March 2021, whereas stability studies have also been performed subsequent to this date. Justification shall be submitted in this regard.
- Submit clarification regarding not ensuring the dissolution profile at in-process stage of Metformin HCl extended release core prior to proceeding for Active coating of other drug substances.
- Submit batch wise details of each strength for the dispensing of Linagliptin & Empagliflozin for ensuring the 100% content as per label claim.
- HPLC chromatograms shall be submitted for complete stability studies of each strength.
- Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.

Response by Firm:

Sr.#	Deficiency	Firm's response
1.	Valid GMP certificate of M/s Auro Laboratories Ltd., K-56, MIDC Tarapur, Boiser, Dist., Thane, Maharashtra, India, shall be submitted.	**GMP certificate#** NEW-WHO-GMP/CERT/KD/10938212021/11/38620 valid till 26-12-2024 issued by FDA Maharashtra has been submitted.
2.	Dissolution specifications for Empagliflozin & Linagliptin are not as recommended by US FDA for innovator product. Firm has proposed dissolution limits of NLT Q in 60 minutes for both Empagliflozin & Linagliptin whereas US FDA has recommended 45 minutes & 30 minutes time point for Empagliflozin & Linagliptin respectively. Justification shall be submitted in this regard.	Firm has referred to the US FDA Dissolution database for setting the dissolution limits initially and has now submitted revised drug product test methods for each strength wherein dissolution limits of 45 minutes & 30 minutes time point have been declared for Empagliflozin & Linagliptin respectively.
3.	Submitted COA of working standard of Metformin HCl declares retest date	

		as May 2021, whereas stability studies have also been performed subsequent to this date. Justification shall be submitted in this regard.	The subsequent stability testing is performed using a valid working standard, which was standardized on May 2021. Firm has submitted valid COAs of working standard.
	4.	Submitted COA of working standard of Empagliflozin declares retest date as March 2021, whereas stability studies have also been performed subsequent to this date. Justification shall be submitted in this regard.	
	5.	Submit clarification regarding not ensuring the dissolution profile at in-process stage of Metformin HCl extended release core prior to proceeding for Active coating of other drug substances.	Pacific has already registered product with same formulation of core and have its history data that is sufficient to ensure dissolution profile of Metformin HCl. In case of Trilin, BMR will be revised for commercial batches.
	6.	Submit batch wise details of each strength for the dispensing of Linagliptin & Empagliflozin for ensuring the 100% content as per label claim.	Firm has submitted "Additional Raw material requisite Form" against which additional quantity of Empagliflozin and Linagliptin has been issued for coating solution of each batch of every strength.
	7.	HPLC chromatograms shall be submitted for complete stability studies of each strength.	Submitted.
	8.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Submitted.

Decision: Registration Board approved the applications of Trilin 5/2.5/1000 mg Tablet, Trilin 10/5/1000 mg Tablet, Trilin 25/5/1000 mg Tablet & Trilin 12.5/2.5/1000 mg Tablet.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case no. 04 Registration Applications on Form 5.

a. Deferred cases:

54.	**Name and address of manufacturer / Applicant**	**M/s Wellborne Pharmachem and Biologicals, Plot No.51/1 – 52/1, Phase-II, Industrial Estate, Hattar**
	Brand Name + Dosage Form + Strength	**Bromep 40mg capsules**
	Composition	Each capsule contains: Omeprazole (as 22.5%w/w enteric coated pellets) …….. 40mg Source of pellets: M/s Spansules Formulations, India
	Diary No. Date of R& I & fee	Dy. No. 359; 23-12-2015; Rs.20,000/- (23-12-2015)
	Pharmacological Group	Antacid
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As fixed by government
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Acizole Capsule 40mg by M/s Cirin Pharmaceuticals, (Reg# 034369)
	GMP status	Last GMP inspection was conducted on 27-6-2018 concluded good GMP.
	Remarks of Evaluator II: Fee of Rs. 80,000/- for import of pellets shall be submitted.	

	Decision of 285th meeting: Deferred for submission of fee of Rs. 80,000/- for import of pellets.	
	Firm's reply: Firm has requested for change of source of pellets to M/s Vision Pharmaceuticals, Islamabad along with fee of Rs. 30,000/- vide deposit slip#845065420513.	
	Decision of 324th meeting: Approved with source of pellets from M/s Vision Pharmaceuticals, Islamabad.	
55.	**Name and address of manufacturer / Applicant**	**M/s Jinnah Pharmaceuticals Pvt Ltd. 13 km, Lahore Road, Multan**
	Brand Name + Dosage Form + Strength	**Jaydallin Syrup**
	Composition	Each 5ml Contains: Aminophylline…….32mg Diphenhydramine…….8mg Ammonium Chloride……30mg Menthol……0.98mg
	Diary No. Date of R& I & fee	Dy.No 16225 dated 06-03-2019 Rs. 20,000/- 07-03-2019
	Pharmacological Group	bronchodilator
	Type of Form	Form 5
	Finished product Specifications	Mfg
	Pack size & Demanded Price	Rs.69 for 120ml,
	Approval status of product in Reference Regulatory Authorities	Could not be confirmed
	Me-too status (with strength and dosage form)	Hydryllin Syrup by M/s Searle, Pakistan
	GMP status	The panel recommended renewal of DML, inspection date 03/05/2019.
	Remarks of Evaluator II: RRA Status could not be confirmed	
	Decision of 290th meeting: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
	Firm's reply: Firm has submitted following revised composition along with fee of Rs. 30,000/- vide deposit slip#399998694: Each 5ml Contains: Aminophylline…….32mg Diphenhydramine…….8mg Ammonium Chloride……30mg	
	Decision of 324th meeting: Deferred for evidence of approval of revised formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
56.	**Name and address of manufacturer / Applicant**	**M/s Evolution Pharmaceuticals (Pvt.) Ltd. Plot #: 25 & 26, Street No. S-3, RCCI, National Industrial Zone, Rawat, Islamabad**
	Brand Name + Dosage Form + Strength	Vofen Sachet 600mg
	Composition	Each sachet contains: Ibuprofen…….600mg
	Diary No. Date of R& I & fee	Dy No. 9332: 13.03.2018 PKR 20,000/-: 13.03.2018
	Pharmacological Group	Propionic acid derivatives
	Type of Form	Form 5
	Finished product Specifications	Manufaturer's specifications
	Pack size & Demanded Price	20's; As per SRO
	Approval status of product in Reference Regulatory Authorities	Brufen® 600mg Effervescent Granules. **MHRA** approved
	Me-too status (with strength and dosage form)	Brufen 600mg Sachet Reg. No. 44414
	GMP status	Last GMP inspection report dated 25.102.2018 declaring following recommendations: As the operations have not started as of yet at M/s Evolution Pharmaceuticals, Rawat GMP status can only be ascertained upon

		the start of active production, however: Keeping in view the facility inspected the firm has requisite for manufacturing of pharmaceuticals.
	Remarks of Evaluator II:	
	Decision of 289th meeting: Deferred for further deliberation.	
	Firm's reply: Firm has submitted that me-too product is effervescent granules. The me too product available is Radifen effervescent granules 600mg in sachet form registered by M/s Radiant Pharma, Lahore (Reg.#088775)	
	Decision of 324th meeting: Approved with Innovator's specifications as per following label claim: **"Each sachet contains:** **Ibuprofen (as effervescent granules) ……. 600mg"** **The firm shall submit fee for correction/pre-approval change in product composition as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
57.	**Name and address of manufacturer / Applicant**	**M/s Evolution Pharmaceuticals (Pvt.) Ltd. Plot #: 25 & 26, Street No. S-3, RCCI, National Industrial Zone, Rawat, Islamabad**
	Brand Name + Dosage Form + Strength	Meconic Capsule 500mcg
	Composition	Each capsule contains: Mecobalamin …….500mcg
	Diary No. Date of R& I & fee	Dy No. 9102: 12.03.2018 PKR 20,000/-: 12.03.2018
	Pharmacological Group	Vitamin B12 (cyanocobalamin and analogues)
	Type of Form	Form 5
	Finished product Specifications	The firm has claimed innovator's specifications
	Pack size & Demanded Price	20's, 30's, 50's, 100's; As per SRO
	Approval status of product in Reference Regulatory Authorities	**Could not be confirmed**
	Me-too status (with strength and dosage form)	Cobamin capsules. Reg. No. 22643
	GMP status	Last GMP inspection report dated 25.102.2018 declaring following recommendations: As the operations have not started as of yet at M/s Evolution Pharmaceuticals, Rawat GMP status can only be ascertained upon the start of active production, however: Keeping in view the facility inspected the firm has requisite for manufacturing of pharmaceuticals.
	Remarks of Evaluator II:	
	Decision of 289th meeting: Deferred for Proof of International availability of same dosage form with same strength in reference regulatory authority as defined in 275th meeting of the Registration Board.	
	Firm's reply: Firm has submitted requested for revision of dosage form and has submitted following revised composition along with fee of Form 5 and fee of Rs. 30,000/- vide deposit slip# 03235098: "Each sugar coated tablet contains: Mecobalamin ……. 500mcg"	
	Decision of 324th meeting: Approved as per following label claim with JP specifications: **"Meconic tablet 500mcg** **Each sugar coated tablet contains:** **Mecobalamin ……. 500mcg"**	
58.	**Name and address of manufacturer / Applicant**	**M/s Evolution Pharmaceuticals (Pvt.) Ltd.** Plot #: 25/26, St.#S-3, RCCI, Industrial Estate, Rawat,Islamabad
	Brand Name + Dosage Form + Strength	**Movate Lotion 0.1% w/w**
	Composition	Each gram contains: Mometasone furoate…1mg
	Diary No. Date of R& I & fee	Diary No:14569, 11/09/2017, Rs: 20,000/-
	Pharmacological Group	Corticosteroid, potent (group III)
	Type of Form	Form 5
	Finished product Specifications	BP

	Pack size & Demanded Price	20ml/ As per SRO
	Approval status of product in Reference Regulatory Authorities	Elocon Scalp Lotion 0.1% w/w by M/s Merck Sharp & Dohme (MHRA Approved)
	Me-too status (with strength and dosage form)	Hivate Lotion 0.1% by M/s Saffron (Reg#046430)
	GMP status	Last GMP inspection report dated 25.102.2018 declaring following recommendations: As the operations have not started as of yet at M/s Evolution Pharmaceuticals, Rawat GMP status can only be ascertained upon the start of active production, however: Keeping in view the facility inspected the firm has requisite for manufacturing of pharmaceuticals.
	Remarks of Evaluator: • Confirmed as w/w formulation in MHRA. • Firm has also applied in w/w composition.	
	Decision of 281st meeting: Registration Board deferred the case in the light of decision of 248th meeting of Registration Board, for confirmation and verification of segregated dispensing booths, cleaning validation and controls studies for processes and adequate system to minimize the potential risk of cross contamination.	
	Firm's reply: Firm has referred to the GMP inspection report conducted on 06-08-2020 & 19-08-2020 wherein availability of two dispensing booths has been confirmed. Frim has also the section approval for "Topical section general (Cream/ointment, gel , Solution/Lotion) section" vide letter No. F.1-14/2008-Lic dated 10-7-2017.	
	Decision of 324th meeting: Approved.	
59.	**Name and address of manufacturer / Applicant**	**M/s Evolution Pharmaceuticals (Pvt.) Ltd.** Plot #: 25/26, St.#S-3, RCCI, Industrial Estate, Rawat,Islamabad
	Brand Name + Dosage Form + Strength	**Betanex Lotion 0.1% w/w**
	Composition	Each gram contains: Betamethasone (as valerate) …1mg
	Diary No. Date of R& I & fee	Diary No:14565, 11/09/2017, Rs: 20,000/-
	Pharmacological Group	Corticosteroids, potent (group III)
	Type of Form	Form 5
	Finished product Specifications	BP
	Pack size & Demanded Price	60ml/ As per SRO
	Approval status of product in Reference Regulatory Authorities	Betnovate Lotion 0.1% w/w by M/s Glaxo Wellcome UK Limited (MHRA Approved)
	Me-too status (with strength and dosage form)	Betnovate Lotion 0.1% by M/s GSK (Reg#000253)
	GMP status	Last GMP inspection report dated 25.102.2018 declaring following recommendations: As the operations have not started as of yet at M/s Evolution Pharmaceuticals, Rawat GMP status can only be ascertained upon the start of active production, however: Keeping in view the facility inspected the firm has requisite for manufacturing of pharmaceuticals.
	Remarks of Evaluator: • Confirmed as w/w formulation in MHRA. • Firm has also applied in w/w composition.	
	Decision of 281st meeting: Registration Board deferred the case referring to the decision of 248th meeting of Registration Board stating as under: "Products containing steroidal topical preparations like eye/ear drops, sterile eye ointment, external preparations i.e. cream/ointment/gel, lotions, spray/aerosols, suppositories, vaginal preparation, intra oral preparations, nasal drops etc. shall be permitted for manufacturing in general facility/area provided that manufacturers shall have segregated dispensing booths, cleaning validation and controls studies for processes and adequate system to minimize the potential risk of cross contamination." Registration Board directed the firm to submit clarification regarding confirmation of separate dispensing booth for applied product.	

	Firm's reply: Firm has referred to the GMP inspection report conducted on 06-08-2020 & 19-08-2020 wherein availability of two dispensing booths have been confirmed.	
	Decision of 324th meeting: Approved.	
60.	Name and address of manufacturer / Applicant	M/s Usawa Pharmaceuticals. 146 S.I.Z. Risalpur, KPK, Pakistan By M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Usven 500mg Injection
	Composition	Each Vial Contains: Vancomycin as HCl ……500mg
	Diary No. Date of R& I & fee	Dy. No.12456 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Tricyclic Glycopeptide
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	VANCOCIN CP vancomycin 500mg (as hydrochloride) powder for injection vial. TGA approved
	Me-too status	Vanzy 500mg Injection. Reg. No. 81901
	GMP status	M/s Usawa Pharmaceuticals was inspected on 08.01.2019, wherein satisfactory level of GMP was reported M/s Bio-lab was inspected on 08.07.2021, 15.07.2021, 30.07.2021 and 03.08.2021 wherein renewal of DML / regularization of layout plan, grant of additional section as well as change in section was recommended
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Had adjusted the weight of API as per salt factor in the master formula. Revised Vancomycin as HCl to Vancomycin HCl in the master formula. • Mentioned the excipients in the master formula/ composition. • Submitted complete manufacturing outlines. • Enclosure of Form 5 from point 16 onwards was missing. Submitted it. • Submitted Rs. 75000 (challan- 3626024049)
	Decision of 321st meeting: Deferred for the following; • Confirmation of manufacturing method for the applied formulation whether through lyophilization process or otherwise. • Latest GMP certificate/last inspection report conducted within last three years for contract acceptor.	
	Firm's response: • Firm has submitted Lyophilisation is being performed at M/s Bio-Labs and has also submitted manufacturing method by way of Lyophilisation. • Firm has submitted copy of GMP certificate of M/s Bio-Labs dated 21-05-2019 based on the inspection dated 23-04-2019. The GMP certificate specifies Lyophilized vial (General) section.	
	Decision of 324th meeting: Approved as per following label claim: **"Each lyophilized vial contains:** **Vancomycin as HCl ……500mg"** **The firm shall submit fee for correction/pre-approval change in product manufacturing method as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
61.	Name and address of manufacturer / Applicant	M/s Usawa Pharmaceuticals. 146 S.I.Z. Risalpur, KPK, Pakistan By

		M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Usven 1g Injection
	Composition	Each Vial Contains: Vancomycin as HCl ……..…1g
	Diary No. Date of R& I & fee	Dy. No.12454 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Tricyclic Glycopeptide
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	VANCOCIN CP vancomycin 1g (1,000,000IU as hydrochloride) powder for injection vial. TGA approved
	Me-too status	Vanzy 1g Injection. Reg. No. 81902
	GMP status	M/s Usawa Pharmaceuticals was inspected on 08.01.2019, wherein satisfactory level of GMP was reported M/s M/s Bio-lab was inspected on 08.07.2021, 15.07.2021, 30.07.2021 and 03.08.2021 wherein renewal of DML / regularization of layout plan, grant of additional section as well as change in section was recommended
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Had adjusted the weight of API as per salt factor in the master formula. Revised Vancomycin as HCl to Vancomycin HCl in the master formula. • Mentioned the excipients in the master formula/ composition. • Submitted Rs. 75000 (challan- 6159809290)
	Decision of 321st meeting: Deferred for the following; • Confirmation of manufacturing method for the applied formulation whether through lyophilization process or otherwise. • Latest GMP certificate/last inspection report conducted within last three years for contract acceptor.	
	Firm's response: • Firm has submitted Lyophilisation is being performed at M/s Bio-Labs and has also submitted manufacturing method by way of Lyophilisation. • Firm has submitted copy of GMP certificate of M/s Bio-Labs dated 21-05-2019 based on the inspection dated 23-04-2019. The GMP certificate specifies Lyophilized vial (General) section.	
	Decision of 324th meeting: Approved as per following label claim: **"Each lyophilized vial contains:** **Vancomycin as HCl ……1gm"** **The firm shall submit fee for correction/pre-approval change in product manufacturing method as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
62.	Name and address of manufacturer / Applicant	M/s Usawa Pharmaceuticals. 146 S.I.Z. Risalpur, KPK, Pakistan By M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Awacol 11MU IV Injection
	Composition	Each Vial Contains: Colistimethate Sodium (Lyophilized Powder) ……1MIU
	Diary No. Date of R& I & fee	Dy. No.12455 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Antibiotic (polymyxin)

	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Colistimethate Sodium 1 Million I.U. Powder for Solution for Injection (lyophilized powder in glass vial). Approved by **MHRA**
	Me-too status	Colistat powder for Injection. Reg. No. 76160
	GMP status	M/s Usawa Pharmaceuticals was inspected on 08.01.2019, wherein satisfactory level of GMP was reported M/s Usawa Pharmaceuticals was inspected on 08.07.2021, 15.07.2021, 30.07.2021 and 03.08.2021 wherein renewal of DML / regularization of layout plan, grant of additional section as well as change in section was recommended
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Did not provide chemical name of the API at serial No. 03. Later on, submitted it. • Had mentioned Colistimethate Sodium eq. to Colistimethate and mentioned its weight as 85.68mg in master formula. Then, mentioned Colistimethate Sodium…1MIU and revised 85.68mg to 90mg (for 7% water contents and 4%overage). Then, revised Colistimethate Sodium…90mg (for 7% water contents and 4%overage to Colistimethate Sodium…80mg. But the label claim in the revised documents is Colistimethate Sodium eq. to Colistimethate….1MIU. Then, once again submitted the label claim "Each Vial Contains: Colistimethate Sodium (Lyophilized Powder)…1MIU" shall be considered. • Also mentioned water for injection, and lyophilization process. • Added packing process to the manufacturing outlines. • Revised brand Awacol 11MU to Awacol 1MIU. • Submitted Rs. 7500 (challan- 557752858924)
	Decision of 321st meeting: Registration Board deferred the case for submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.	
	Firm's response: Firm has submitted BMR of three production batches i.e., batch# 22B041, 22E032, 22J104 with manufacturing date 02-2022, 05-2022 & 09-2022 respectively.	
	Decision of 324th meeting: Deferred for the submission of data by M/s Bio-Labs against the Form 5F applications of applied formulation, presented in instant meeting.	
63.	Name and address of manufacturer / Applicant	M/s MBL Pharma. B-77-A, H.I.T.E, Hub, Pakistan
	Brand Name + Dosage Form + Strength	Cinamin 500mcg IM /IV Injection
	Composition	Each 2ml Contains: Cyanocobalamin……500mcg
	Diary No. Date of R& I & fee	Dy.No 14173 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Vitamin b12
	Type of Form	Form-5
	Finished product Specifications	USP

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too status (with strength and dosage form)	
	GMP status	Last inspection report conducted on 31-5-2022 recommends renewal of DML.
	Remarks of the Evaluator [II]: • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board.	
	Decision of 323rd meeting: Deferred for following: Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm. Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
	Reply by the firm: The firm has revised the formulation from Cyanocobalamin 500mcg/2mL ampoule to Cyanocobalamin 1000mcg/1mL ampoule along with the relevant annexures and submitted following me-too and RRA references. **Me-Too:** Vitamin B12 Injection (1mL ampoule ; 1000mcg/mL) by /s Amros Pharmaceutical (Reg. No. 26880) ***RRA:*** *Cyanocobalamin Injection 1mg/1mL ampoule "Nichiiko" (by M/s Nichi-Iko Co., Ltd., Japan), PMDA Japan Approved.* https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_3136402A3190_1_02#CONTRAINDICATIONS The firm has not submitted any fee.	
	Decision of 324th meeting: Approved as per following label claim: **"Each ml ampoule contains:** **Cyanocobalamin……1000mcg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
64.	Name and address of manufacturer / Applicant	M/s MBL Pharma. B-77-A, H.I.T.E, Hub, Pakistan
	Brand Name + Dosage Form + Strength	Pritim 150mg Tablet
	Composition	Each Extended Release Tablet Contains: Itopride Hcl…150mg
	Diary No. Date of R& I & fee	Dy.No 14175 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Prokinetic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	--
	Me-too status (with strength and dosage form)	Itoride SR Tablets of Amarant Karachi (Reg # 073484)
	GMP status	Last inspection report conducted on 31-5-2022 recommends renewal of DML.
	Remarks of the Evaluator [II]: • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	

	Decision of 323rd meeting: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
	Reply by the firm: The firm has revised the formulation from Itopride 150mg ER tablet to Itorpride 50mg film coated tablet as per the reference product. Each film coated tablet contains: Itopride HCl……50mg **Me-too:** ITP of M/s Sami Pharmaceuticals **RRA:** Ganaton film coated tablet 50mg of M/s Abbott Laboratories (PMDA) Japan Approved. The firm has not submitted any fee for the revision.	
	Decision of 324th meeting: Approved as per following label claim: **"Each film coated tablet contains:** **Itopride HCl……50mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
65.	Name and address of manufacturer / Applicant	M/s MBL Pharma. B-77-A, H.I.T.E, Hub, Pakistan
	Brand Name + Dosage Form + Strength	Kerolac 30mg/ml Injection
	Composition	Each ml Contains: Ketorolac Tromethamine……30mg
	Diary No. Date of R& I & fee	Dy.No 14174 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	US-FDA Approved.
	Me-too status (with strength and dosage form)	Tromit Injection of Standpharm (Reg.# 049960)
	GMP status	Last inspection report conducted on 31-5-2022 recommends renewal of DML.
	Remarks of the Evaluator II: • Submit reference for drug product specifications. • Firm has not mentioned terminal sterilization step in the manufacturing process. • Firm has submitted revised specifications as USP without submission of fee.	
	Decision of 323rd meeting: Deferred for clarification regarding method of sterilisation proposed for applied formulation along with fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
	Reply by firm: The firm has stated that terminal sterilization will not be method of sterilization for the applied product. The product will be sterilized by way of filtration followed by aseptic filling.	
	Decision of 324th meeting: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product manufacturing procedure as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

b. Applications on Form 5 with Stability studies data:

66.	**Name and address of manufacturer / Applicant**	**M/s The Schazoo Zaka Pvt Ltd. Lahore Kalalwala, Zaka ur Rehman State, Plot No.1, 20-km Lahore-Jaranwala Road, Shikhupura**
	Brand Name +Dosage Form + Strength	Dexlanz 30mg Capsule

	Composition	Each Capsule Contains: Dual Delayed Release Pellets of Dexlansoprazole Eq. to Dexlansoprazole…30mg
	Diary No. Date of R& I & fee	Dy.No 929 dated 08-01-2019 Rs.20,000/- Dated 07-01-2019
	Pharmacological Group	Proton Pump inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacturers specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulator Authorities	Dexilant Delayed Release Capsule 30mg of USFDA approved
	Me-too status	Lansodex Capsule 30mg of M/S Getz Pharma
	GMP status	Last GMP inspection conducted on 05-01-2018 and report concludes that firm had maintained conformance to cGMP.
	Remarks of the Evaluator.	Source of pellets (In case of imported source remaining Rs: 80000/- fee) Submit Stability studies along with requisite documents. Submit complete manufacturing method.
	Previous Registration Board deferred the case for submission of stability study data as per the guidelines provided in 278th meeting of Registration Board**. (M-295).**	

STABILITY STUDY DATA			
Drug	Dexlanz 30mg Capsule		
Name of Manufacturer	M/s The Schazoo Zaka Pvt Ltd. Lahore Kalalwala, Zaka ur Rehman State, Plot No.1, 20-km Lahore-Jaranwala Road, Shikhupura		
Manufacturer of API	M/s vision Pharmaceuticals (Pvt) Ltd.		
API Lot No.	DLP467		
Description of Pack (Container closure system)	Alu/Alu blister		
Stability Storage Condition	Real time : 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (month) Real Time: 0, 3, 6 (month)		
Batch No.	DXC-T1-19	DXC-T2-19	DXC-T3-19
Batch Size	1200 Capsules	1200 Capsules	1200 Capsules
Manufacturing Date	09-11-2019	09-11-2019	09-11-2019
Date of Initiation	Accelerated: 14-05-2020 Real 14-05-2020	Accelerated: 14-05-2020 Real 14-05-2020	Accelerated: 14-05-2020 Real 14-05-2020
No. of Batches	03		
Date of Submission	19-01-2021(2232)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**

<table>
<tr><td>1.</td><td>Reference of previous approval of applications with stability study data of the firm (if available)</td><td></td></tr>
<tr><td>2.</td><td>Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.</td><td>Copy of COA of Dexlansoprazole Dual delayed release pellets (Batch# DLP467) from M/s vision Pharmaceuticals (Pvt) Ltd.is submitted.

Copy of COA (Batch# DLP467) from M/s The Schazoo Zaka Pvt Ltd. is submitted</td></tr>
<tr><td>3.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Dissolution testing method not included</td></tr>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td>The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 36 Months (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Copy of GMP certificate on the basis of evaluation conducted on 11-02-2019 and valid till 10-02-2022</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Local source</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Assay is conducted by UV method</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td></td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Dexlanz 30mg Capsule</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>DXC-T1-19</td><td>1200 Capsule</td><td>09-11-2019</td></tr>
<tr><td>DXC-T2-19</td><td>1200 Capsule</td><td>09-11-2019</td></tr>
<tr><td>DXC-T3-19</td><td>1200 Capsule</td><td>09-11-2019</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>No</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>COA raw data sheets are not submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>No</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>No</td></tr>
<tr><td colspan="3">REMARKS OF EVALUATOR</td></tr>
<tr><td colspan="3"><table><tr><td>S.NO</td><td>Shortcomings communicated</td><td>Reply</td></tr></table></td></tr>
</table>

1.	In analytical testing method of FPP, Assay is conducted by UV method while drug substance and innovator conducted assay by HPLC Clarification is required.	Approved assay method of Dexlanz contains assay testing by both methods (HPLC& UV spectrophotometric). UV spectrophotometric In-house method has been validated so this approved method is being used for assay testing of Dexlanz capsule. ***(Analytical testing method include only UV spectrophotometric method)***
2.	Reference of previous approval of applications with stability study data of the firm (if available).	
3.	Method used for analysis of API by Finished Product manufacturer does not include dissolution testing of delayed release pellets. Clarification is required.	For dissolution testing of API, manufacturer method was used by finished product manufacturer as it is integral test.
4.	Record of comparative dissolution.	Protocols and report of Pharmaceutical equivalence of Dexlanz 30mg Capsule Batch # DXC-T1-19 with Razodex capsule Batch # 070C47 of M/s GETS Pharma submitted. (***Finished product dissolution is two pH Acid stage 0.1N HCl and buffer stage pH 7.0 but comparative dissolution not separately submitted.)***
5.	Raw data sheets, COA are not submitted.	
6.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not applicable as the API and finished product is tested by UV spectrophotometric method.

Decision: Registration Board discussed the fact that the applied formulation is non-pharacopoeial hence the drug product Assay method shall primarily be based upon the analytical method proposed by the drug substance manufacturer therefore Board deferred the case for submission of afresh stability studies data wherein Assay analysis of drug product shall be performed with analytical procedure based upon HPLC.

67.	**Name and address of manufacturer / Applicant**	**M/s The Schazoo Zaka Pvt Ltd. Lahore Kalalwala, Zaka ur Rehman State, Plot No.1, 20-km Lahore-Jaranwala Road, Shikhupura**
	Brand Name +Dosage Form + Strength	Dexlanz 60mg Capsule
	Composition	Each Capsule Contains: Dual Delayed Release Pellets of Dexlansoprazole Eq. to Dexlansoprazole…60mg
	Diary No. Date of R& I & fee	Dy.No 930 dated 08-01-2019 Rs.20,000/- Dated 07-01-2019
	Pharmacological Group	Proton Pump inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacturers specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulator Authorities	Dexilant Delayed Release Capsule 30mg of USFDA approved
	Me-too status	Lansodex Capsule 30mg of M/S Getz Pharma
	GMP status	Last GMP inspection conducted on 05-01-2018 and report concludes that firm had maintained conformance to cGMP.
	Remarks of the Evaluator.	Source of pellets (In case of imported source remaining Rs: 80000/- fee) Submit Stability studies along with requisite documents

		Submit complete manufacturing method
	Previous Registration Board deferred the case for submission of stability study data as per the guidelines provided in 278th meeting of Registration Board**. (M-295)**	

STABILITY STUDY DATA			
Drug	Dexlanz 60mg Capsule		
Name of Manufacturer	M/s The Schazoo Zaka Pvt Ltd. Lahore Kalalwala, Zaka ur Rehman State, Plot No.1, 20-km Lahore-Jaranwala Road, Shikhupura		
Manufacturer of API	M/s vision Pharmaceuticals (Pvt) Ltd.		
API Lot No.	DLP467		
Description of Pack (Container closure system)	Alu/Alu blister		
Stability Storage Condition	Real time : 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated:0,3,6 (month) Real: 0, 3, 6 (month)		
Batch No.	DZC-T1-19	DZC-T2-19	DZC-T3-19
Batch Size	1200 Capsules	1200 Capsules	1200 Capsules
Manufacturing Date	09-11-2019	09-11-2019	09-11-2019
Date of Initiation	Accelerated: 22-01-2020 Real: 01-04-2020	Accelerated: 22-01-2020 Real:01-04-2020	Accelerated: 22-01-2020 Real: 01-04-2020
No. of Batches	03		
Date of Submission	19-01-2021(2233)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**
1.	Reference of previous approval of applications with stability study data of the firm (if available)	
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA of Dexlansoprazole Dual delayed release pellets (Batch# DLP467) from M/s vision Pharmaceuticals (Pvt) Ltd.is submitted. Copy of COA (Batch# DLP467) from M/s The Schazoo Zaka Pvt Ltd. is submitted
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Dissolution testing method not included
4.	Stability study data of API from API manufacturer	The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 36 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate on the basis of evaluation conducted on 11-02-2019 and valid till 10-02-2022

6.	Documents for the procurement of API with approval from DRAP (in case of import).	Local source
7.	Protocols followed for conduction of stability study	Yes
8.	Method used for analysis of FPP	Assay is conducted by UV method
9.	Drug-excipients compatibility studies	….
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted copy of Trial batch manufacturing record. Details are as under:

Dexlanz 60mg Capsule		
Batch No.	**Bach size**	**Mfg. Started**
DZC-T1-19	1200 Capsule	09-11-2019
DZC-T2-19	1200 Capsule	09-11-2019
DZC-T3-19	1200 Capsule	09-11-2019

11.	Record of comparative dissolution	No
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	COA raw data sheets are not submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	No
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	No

REMARKS OF EVALUATOR

S.NO	Shortcomings communicated	Reply
1.	In analytical testing method of FPP, Assay is conducted by UV method while drug substance and innovator conducted assay by HPLC Clarification is required.	Approved assay method of Dexlanz contains assay testing by both methods (HPLC& UV spectrophotometric). UV spectrophotometric In-house method has been validated so this approved method is being used for assay testing of Dexlanz capsule. ***(Analytical testing method include only UV spectrophotometric method)***
2.	Reference of previous approval of applications with stability study data of the firm (if available).	Firm has referred of previous inspection report of Daclatasvir tablet
3.	Method used for analysis of API by Finished Product manufacturer does not include dissolution testing of delayed release pellets. Clarification is required.	For dissolution testing of API, manufacturer method was used by finished product manufacturer as it is integral test.
4.	Record of comparative dissolution.	Protocols and report of Pharmaceutical equivalence of Dexlanz 30mg Capsule Batch # DXC-T1-19 with Razodex capsule Batch # 070C47 of M/s GETS Pharma submitted. (***Finished product dissolution is two pH Acid stage 0.1N HCl and buffer stage pH 7.0 but comparative dissolution not separately submitted.)***
5.	Raw data sheets, COA are not submitted.	Submitted

6.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not applicable as the API and finished product is tested by UV spectrophotometric method.

Decision: Registration Board discussed the fact that the applied formulation is non-pharacopoeial hence the drug product Assay method shall primarily be based upon the analytical method proposed by the drug substance manufacturer therefore Board deferred the case for submission of afresh stability studies data wherein Assay analysis of drug product shall be performed with analytical procedure based upon HPLC.

Case no. 05 Registration Applications of Anti-Cancer drug products considered on priority:

68.	**Name, address of Applicant / Importer**	**M/s AJ Mirza Pharma (Pvt.) Ltd., 1st Floor, Shafi Court, Merewether Road, Civil Lines, Karachi. Pakistan.**
	Details of Drug Sale License of importer	**License No: 132** **Address:** 1st Floor, Shafi Court, Civil Lines, Merewether Road, Karachi, Pakistan. **Address of Godown:** Plot No.44, Sector27, orangei Industrial Area, Karachi **Validity:** 22.12.2022. **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Cipla Ltd, S-103 to S-105 S-107 to S-112, L- 138 L-147, L-147/1 to L-147/3, & L-147/A, & L-147/A, L-150 Verna Industrial Estate Verna Goa.
	Name, address of manufacturer(s)	M/s Cipla Ltd, S-103 to S-105 S-107 to S-112, L- 138 L-147, L-147/1 to L-147/3, & L-147/A, & L-147/A, L-150 Verna Industrial Estate Verna Goa.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. 789/MFG/WHO-GMP/DFDA/2020/178(3)) valid up to 19-05-2022 issued by Directorate of Food & Drug Administration, India the Applied product is available for free sale in exporting country. The facilities and operations conform WHO-GMP as per CoPP as well as GMP status of the manufacturing site through periodic inspection every year.
	Details of letter of authorization / sole agency agreement	Copy of Letter of Authorization is attached. M/s Cipla Ltd. Cipla house, Peninsula Business Park, Gantaptrao Kadam Marg, Lower Parel, Mumbai India authorizes M/s A.J. Miza Pharma (Pvt) Ltd., 1st Floor Shafi Court, Merewether Road, Civil Lines Karachi to register, Import & Distribute IMATIB 400mg Capsule. The authorization letter is valid till 13-06-2023.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale

		☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy.No 33135 dated 18-11-2022
	Details of fee submitted	Rs.75,000/- dated 15-11-2022
	The proposed proprietary name / brand name	**IMATIB 400mg Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Hard Gelatin capsule contains: Imatinib Mesylate Ph. Eur. equivalent to Imatinib 400mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	As per Innovator's Specs.
	Proposed Pack size	30's / Unit Pack
	Proposed unit price	As Per Current SRO
	The status in reference regulatory authorities	IMATINIB 400mg Hard Gelatin Capsule (AS MESILATE), • Denmark By Denish Medicine Agency, • Germany by Federal Institute for Drugs and Medical Devices • MHRA of UK
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	NA
	Name, address of drug substance manufacturer	M/s Cipla Limited-Bommasandra Plot No. 285, 286 and 287 Bommasandra – Jigani Link Road Industrial Area,KIADB 4th Phase, Bommasandra Bangalore 560 105, INDIA
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 30°C ± 2°C. The stability study data is till 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of

		specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP studies have been submitted against reference product i.e., Glivec 400mg tablet in three dissolution mediums of pH 1.2, 4.5 & 6.8 Firm has aslo ssubmitted bioequivalence studies against the same product
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	PVC/PE/PVDC film - Blister foil
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40°C ±2°C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30°C ±2°C / 75% ± 5% RH. The real time stability study data of 3 batches is for 24 months.

Evaluation by PEC:

Section#	Observations	Firm's response
1.3.1	Copy of valid DSL shall be submitted as the submitted DSL was valid till 22-12-2022 .	Firm has submitted copy of receiving of renewal application of DSL.
1.3.3	• Original legalized and valid COPP shall be submitted as submitted COPP was valid till 19-05-2022. • Valid GMP certificate/DML of the drug product manufacturer declaring the approval of required manufacturing facility of "Hard Gelatin Capsule (Cytotoxic) section", shall be submitted.	• Firm has submitted legalized valid COPP (No. 789/MFG/WHO-GMP/DFDA/2022/58) valid up to 13-06-2025 issued by Directorate of Food & Drug Administration, Govt. of Goa. • Firm has legalized GMP certificate issued dated 22-06-2022 by Directorate of Food & Drug Administration, Govt. of Goa in the name of M/s Cipla Ltd, S-103 to S-105 S-107 to S-112, L-138 L-147, L-147/1 to L-147/3, & L-147/A, & L-147/A, L-150 Verna Industrial Estate Verna declaring availability of hard Gelatin capsule section (Cytotoxic).
1.6.5	Valid GMP certificate/DML of the drug substance manufacturer shall be submitted.	Firm has referred to the US FDA database of Drug Establishment Current Registration Site, declaring expiration date of 31-12-2023 for M/s Cipla Limited-Bommasandra Plot No. 285, 286 and 287 Bommasandra – Jigani Link Road Industrial Area,KIADB 4th Phase, Bommasandra Bangalore 560 105, India
3.2.P.2.2.1	Justification shall be submitted for performing Pharmaceutical equivalence and CDP studies against the "Glivec 400mg tablets", whereas applied formulation is in capsule dosage form.	Firm has submitted that our applied product is already registered in Norway, Denmark & Germany based upon the similar comparison between tablet vs capsule for CDP and Bioequivalence studies as provided for registration in Pakistan.

ASSESSMENT REPORT OF BIOEQUIVALENCE STUDY OF IMATINIB MESILATE CAPSULES 400 MG

M/s AJ Mirza Pharma (Pvt.) Ltd., 1st Floor, Shafi Court, Merewether Road, Civil Lines, Karachi. Pakistan have applied for marketing authorization of **IMATIB 400mg Capsule** (Imatinib Mesylate equivalent to 400mg Imatinib). The applied product is manufactured by M/s Cipla Ltd, S-103 to S-105 S-107 to S-112, L- 138 L-147, L-147/1 to L-147/3, & L-147/A, & L-147/A, L-150 Verna Industrial Estate Verna Goa, India. The application was submitted on Form 5-F along with requisite data in module 3 along with Bioequivalence study reports. The assessment report of Bioequivalence study is provided below:

DETAILS OF THE MA APPLICATION:

Name, address of Applicant / Importer	M/s AJ Mirza Pharma (Pvt.) Ltd., 1st Floor, Shafi Court, Merewether Road, Civil Lines, Karachi. Pakistan.

Name, address of manufacturer(s) abroad	M/s Cipla Ltd, S-103 to S-105 S-107 to S-112, L- 138 L-147, L-147/1 to L-147/3, & L-147/A, & L-147/A, L-150 Verna Industrial Estate Verna Goa.
Name of exporting country	India
The proposed proprietary name / brand name	IMATIB 400mg Capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Hard Gelatin capsule contains: Imatinib Mesylate equivalent to Imatinib 400mg
Pharmaceutical form of applied drug	Hard Gelatin Capsule
Pharmacotherapeutic Group of (API)	Anti-cancer (L01EA01)

DETAILS OF THE BIOEQUIVALENCE STUDY DESIGN:

Study Design:	Open-label, randomized, single-dose, two-treatment, two-sequence, two-period, two-way cross-over bioequivalence study
Study Population:	healthy male and/or post- menopausal and/or surgically sterile female volunteers
Type of Study:	Fed
Sample size:	30
Test Product (Treatment A):	**Imatinib Mesilate Capsules 400 mg** *Lot No: J35336*; (Cipla Ltd., India)
Dose:	1 x 400 mg
Mode of Administration:	Oral under fed conditions
Reference Product (Treatment B):	**GLIVEC® 400 mg Tablets** *Lot No: S0094*; (Novartis Europharm Limited, U.K.)
Dose:	1 x 400 mg
Mode of Administration:	Oral under fed conditions
Duration of treatment:	Single dose of 400mg of either the test product or the reference product was administered and plasma samples were collected over a 72-hour interval after dosing.
Washout period	22 days between each drug administration
Dosing dates:	Period 1: August 25, 2013 Period 2: September 16, 2013
Analyte:	Imatinib, N-desmethyl imatinib
Bioanalytical method:	The bioanalytical method used to measure concentrations of imatinib in human plasma were sensitive, selective, accurate and reproducible. Stability of the analytes were demonstrated during sample processing and long-term storage
Criteria for Evaluation:	**Bioequivalence:** To establish bioequivalence, the calculated 90% CI for the ratio of geometric means for AUC_t and C_{max} for imatinib should fall within 80.00%-125.00%. **Safety:** Safety was evaluated by vital signs measurement, clinical laboratory tests (including hematology, urine analysis, and serum chemistry tests), physical examinations and adverse events reported by subjects who received a drug treatment.
Statistical Methods:	Descriptive statistics (min, max, median, mean, standard deviation and coefficient of variability) of all pharmacokinetic parameters were provided for the test and reference products.

DETAILS OF BIOEQUIVALENCE STUDY SITES:

Clinical Facility:	Bio Pharma Services Inc. 4000 Weston Road Toronto, Ontario, Canada, M9L 3A2
Clinical Laboratory:	Gamma-Dynacare Medical Laboratories 115 Midair Court Brampton, Ontario, Canada, L6T 5M3
Analytical Laboratory:	inVentivHealth Clinical 2500 rue Einstein Quebec, QC, Canada G1P 0A2
Pharmacokinetic, Statistical and Report Issuing Facility:	Bio Pharma Services Inc. 4000 Weston Road Toronto, Ontario, Canada, M9L 3A2

BRIEF OF THE BIOEQUIVALENCE:

Title of Study:
A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Imatinib Mesilate 400 mg Capsules (Cipla Ltd., India) and GLIVEC® 400 mg Film-Coated Tablets (Novartis Europharm Limited, U.K.) in Healthy Male and/or Post-Menopausal and/or Surgically Sterile Female Volunteers under Fed Conditions

Objectives:
This study is aimed to determine bioequivalence between the test (imatinib mesylate 400 mg capsules of Cipla Limited, India) and the reference (GLIVEC® 400 mg film-coated tablets (Novartis Europharm Limited, U.K) products at single dose in healthy, male and/or postmenopausal and/or surgically sterile female subjects under fed conditions (high-fat-high-calorie meal).

Methodology:
This study was an open-label, randomized, single-dose, two-treatment, two-sequence, two-period, two-way cross-over bioequivalence study was conducted in 30 healthy, male and/or postmenopausal and/or surgically sterile female subjects. After an overnight fast of at least 10 hours prior to dosing, subjects were given high-fat, high-calorie breakfast 30 minutes after the start of breakfast, as per randomization sequence the subjects were administered single oral dose of either test or reference product with 240 mL of water on each occasion. The dosing of 28 subjects were done for period I and for period II as per the randomization schedule. The two treatment days were separated with a washout period of 22 days. A total of 26 blood samples (6 mL each) were collected from the subjects per period during the study.

Number of Subjects (planned and analyzed):
Thirty (30) subjects were enrolled and dosed in Period 1. Twenty-six (26) subjects completed the study in its entirety. Samples from twenty-eight (28) subjects were analyzed by the bioanalytical laboratory. Data from twenty-six (26) subjects was included in the pharmacokinetic and statistical analysis

Diagnosis and main criteria for inclusion:
Subjects met the following inclusion criteria within 21 days prior to Period 1 dosing:

1. Healthy, non-smoking (for at least 6 months prior to first drug administration), male and/or postmenopausal and/or surgically sterile female (Refer to inclusion criteria number 12 for additional female inclusion criteria requirements) volunteers, 18-55 years of age.
2. BMI that is within 18.5-30.0 kg/m², inclusive.
3. Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the Principal Investigator/Sub-Investigator.
4. Systolic blood pressure between 95-140 mmHg, inclusive, diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the Principal Investigator/Sub-Investigator.
5. Clinical laboratory values within BPSI's acceptable range, unless values are deemed by the Principal Investigator/Sub-Investigator as "Not Clinically Significant".
6. Ability to comprehend and be informed of the nature of the study, as assessed by BPSI staff. Capable of giving written informed consent prior to receiving any study medication. Must be able to communicate effectively with clinic staff.

7. Ability to fast for at least 10 hours and consume a high-fat, high-calorie meal, as well as standard meals.
8. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.
9. Agree not to have a tattoo or body piercing until the end of the study.
10. Agree not to drive or operate heavy machinery if feeling dizzy or drowsy following drug administration until full mental alertness is regained.
11. Agree to limit exposure to sunlight and UV light by wearing protective clothing and using a sunscreen with a high protection factor during the study.
12. Female subjects must fulfill at least one of the following:
    - Be surgically sterile (total hysterectomy, bilateral oophorectomy, bilateral salpingooophorectomy, or bilateral tubal ligation/coagulation) for at least 6 months [confirmed by medical/operative report].
    - Post-menopausal for a minimum of 1 year, confirmed by FSH and 17β-estradiol tests.
13. Men who are able to father children must agree to use medically acceptable methods of contraception during the study and for 30 days after the end of the study.

SUMMARY – CONCLUSIONS:

Bioequivalence Results:

The calculated 90% confidence interval for the ratio of geometric means for AUCt and Cmax for imatinib fell within 80.00%-125.00%.

Table 3: Comparative Bioequivalence Data of Test and Reference formulations of Imatinib

Pharmacokinetic Parameter	Test/Reference Ratio of Geometric Means (90% Confidence Interval)	Intra-Subject CV (%)
AUC_t	98.81% (93.52% – 104.39%)	11.64%
AUC_{inf}	99.39% (94.03% – 105.07%)	11.76%
C_{max}	89.04% (81.73% – 97.00%)	18.22%

Test: Imatinib 400 mg capsules
Reference: GLIVEC® 400 mg film-coated tablets

Therefore, in this study, bioequivalence was demonstrated between Imatinib Mesilate Capsules 400 mg (Cipla Ltd., India) and GLIVEC® 400 mg Film-Coated Tablets (Novartis Europharm Limited, U.K.) when administered in normal, healthy, male and/or post-menopausal and/or surgically sterile female volunteers under fed conditions.

Safety Results:

A total of 5 mild and 1 moderate AEs were experienced by the subjects after taking the Test product A. A total of 7 mild and 1 moderate AEs were experienced by the subjects after taking the Reference product B. A total of 10 mild AEs associated with clinical laboratory tests were experienced by the subjects at post-study. No serious adverse events were reported during the conduct of this study. Both the Test product and Reference product were well tolerated by all subjects.

Therefore; it has been concluded that the test: Imatinib mesylate 400 mg capsule of Cipla Ltd., India, is bioequivalent to the reference: GLIVEC® 400 mg film-coated tablets (Novartis Europharm Limited, U.K, in healthy, male and/or post- menopausal and/or surgically sterile female subjects under fed conditions.

Decision: Registration Board deliberated and considered the following points:

- **Firm has submitted Bioequivalence studies of applied formulation against the referenc product i.e., GLIVEC® 400 mg film-coated tablets.**
- **The applied formulatin was approved by reference regulatory authorities e.g., MHRA of UK, Danish Medicine Agency of Denmark, on the basis of same "Bioequivalence studies" as cited in instant case.**
- **The presented Bioequivalence study is acceptable considering the international guidelines of "Bioequivalence studies" for the pharmaceutical alternatives.**

Based upon above cited considerations Registration Board decided to approve the instant application as per policy of inspection of manufacturer abroad.

Case No. XIII: Cases related to Import Policy Order

Federal Government has issued Import Policy Order, 2020 vide S.R.O. 902 (I)/2020 dated 25th September, 2020 wherein it has been mentioned in APPENDIX-G as below:

"LIST OF ITEMS NOT IMPORTABLE FROM INDIA
(Omitted vide SRO 927(I)/2019 dated 9th August, 2019)"

Drug Regulatory Authority of Pakistan in its 70th meeting held on 5th September, 2019 decided as under:

Decision:-

The Authority decided as follows:

1. Clearance certificate will be issued by DRAP for those consignments, for which contracts / LCs / bill of ladings were established prior to revised Import Policy Orders dated 09-08-2019.

2. Division of Legal Affairs will issue clarification of revised order dated 02-09-2019 that:-
a. The word "therapeutic products" and "therapeutic good" carry the same meaning.
b. Conditions & requirements for import from India shall remain same as were in practice prior to 09-8-2019.

3. Division of Legal Affairs will recommend to the Ministry of Commerce to re-instate the clause (ii) Appendix-G in Paragraph 5, sub-paragraph (B), of Import Policy Order.

69.	Name and address of Applicant	M/s Hakimsons (Impex) (pvt) Ltd. Hakimsons building 19, Wet Wharf road, Karachi.
	Detail of Drug Sale License	Address:. Hakimsons (Impex) (pvt) Ltd. Hakimsons building 19, Wet Wharf road, Karachi. Validity: 15/09/2017 Status: Drug sale license by the way of wholesale
	Name and address of manufacturer	M/s Bharat serums and vaccines limited, plot No k-27, Jambivili Village, Anand Nagar, Additional MIDC, Ambernnath (East), Thane 421501
	Name and address of marketing authorization holder	M/s Bharat serums and vaccines limited, plot No k-27, Jambivili Village, Anand Nagar, Additional MIDC, Ambernnath (East), Thane 421501
	Name of exporting country	India
	Type of Form	Form 5-A
	Diary No. & Date of R& I	Dy. No. 2124 Dated 02/12/2014
	Fee including differential fee	Rs. 50,000/- Dated 01/12/2014
	Brand Name +Dosage Form + Strength	AMPHOLIP IV Injection 50mg/10ml (Amphotericcin B lipid complex Injection)
	Composition	Each ml contains: Amphotericin B ……. 5mg Lipids: • Dimyristoylphosphatidylcholine [DMPC]….. 3.4mg • Dimyristophosphatidylglycerol [DMPG as sodium salt]…1.5mg
	Finished Product Specification	In House
	Pharmacological Group	Antifungal
	Shelf life	24 months
	Demanded Price	Rs 16,600/-
	Pack size	1's (10ml vial)
	International availability	Abelcet 5mg/mL Concentrate for Suspension for Infusion by M/s Teva Pharma B.V., MHRA Approved
	Me-too status	Amphogen 50 by Ms Ferozsons, (Reg # 045800) (Imported)

	Detail of certificates attached	Original legalized CoPP (certificate No.COPP/CERT/ KD/ 16842/ 2014/11/6613/29059) certified by food and Drug Administration Maharashtra state, Mumbai, India Valid till 01/04/2016 confirms that the facilities and operations conform to GMP as recommended by WHO at the time of inspection as per CoPP.
	Remarks of the Evaluator.	• Storage conditions: 2-8°C • The firm has claimed In House manufacturing specifications while the product is present in USP/BP.
	Decision of 289th meeting: The Registration Board deferred the case for clarification whether Anti-Fungals are importable from India or otherwise.	
	Decision of 308th meeting: The Board decided to refer the case to DRAP's Authority in light of its decision regarding importability from India.	
	Evaluation by PEC: The Authority in its 128th meeting held on 14-12-2021, while considering the agenda item of "**IMPORT OF ANTI-FUNGAL DRUGS FROM INDIA",** decided as under: "The Authority noted that antimicrobials is a broader category which includes antibiotics, antifungals, antiprotozoals, and antivirals. While, antibiotics are antibacterial substance and are used to treat or prevent bacterial infections, therefore, clarified that anti-fungal products do not fall under definition of antibiotics and are importable from India as per Import Policy Order, 2016 subject to other conditions and requirements as per aforesaid order."	
	Decision of 324th meeting: Deferred for clarification of the dosage form for applied formulation whether liposomal or otherwise .	

Case no. 06 Registration Applications of Import drug products:

a. Deferred cases:

70.	**Name, address of Applicant / Importer**	**M/s Medical Equipment & System 60/61 FCC, Syed Maratib Ali Road, Gulberg IV District Lahore, Pakistan**
	Details of Drug Sale License of importer	License No: 05-352-0065-069537D Address: House No 59-C/III, Gulberg III District Lahore Address of Godown: NA Validity: 14-04-2-23 Status: License to sell drugs as distributor Renewal: Firm has submitted a receipt of renewal but it does not contain any date
	Name and address of marketing authorization holder (abroad)	M/s Guerbet BP 57400,F-95943 Roissy CdG Cedex
	Name, address of manufacturer(s)	M/s Guertbet BP 57400,F-95943 Roissy CdG Cedex (Responsible for manufacturing and Batch releasing)
	Name of exporting country	France
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized **copy** of CoPP certificate (No. 034191) dated 23-06-2020 issued CCI PARIS ILE-DE-FRANCE for Lipiodol Ultra Fluide(480mg I/ml) solution injectable . The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned as France. Furthermore the CoPP was valid till 22-06-2022.**
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from. The letter species that the manufacturer appoints M/s **Medical Equipment & System** register their products in Pakistan. The authorization letter is valid till 11-04-2023.


	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Form-5F Dy. No. 22519: 1-07-2021
	Details of fee submitted	PKR 50,000/-: 09-05-2019
	The proposed proprietary name / brand name	LIPIODOL Injection 10ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 10ml of ampoule contains:4800mg of iodine Lipiodol in the form of ethyl ester of iodised fatty acids of poppy seed oil contains 48% w/v 480mg of iodine per ml)
	Pharmaceutical form of applied drug	White lyophilized mass packed in moulded amber type-I vials.
	Pharmacotherapeutic Group of (API)	Non-water-soluble x-ray contrast media
	Reference to Finished product specifications	In house
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Injection **(USFDA** Approved).
	For generic drugs (me-too status)	**Not applicable as it is an innovator product**
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Manufacture: M/s SIMAFEX Address: 16 avenue des Fours a Chauz MARANS, 17230 France
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls,

		impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at $5^oC \pm 3^oC$. The stability study data is till 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not submitted as The product is innovator.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	USP type-I glass
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at $40^oC \pm 2^oC$ / 75% ± 5% RH for 6 months. The real time stability study data is conducted at $30^oC \pm 2^oC$ / 75% ± 5% RH. The real time stability study data of 2 batches is for 12 months while the stability study data for 3rd batch is for 9 months only.

Evaluation by PEC VI:

Sr no	Short coming	Reply
1	• Different API and finish product manufacturers are written in your application. Please specify the one which is actually manufacturing API and finish product. Also submit valid GMP certificate of both manufacturers.	The firm has submitted valid GMP certificate of M/s Guerbet 16-24 rue Jean Chaptal, Aulnay Sous Bois, 93600, France issued by EudraGMP. Valid till 2024 The firm has submitted valid GMP certificate of M/s Simafex 16, Avenue des Fours a Chaux, Marans, 1720, France issued by EudraGMP. Valid till 2024
2	• Letter of authorization/agreement is required clearly showing the validity.	Similar product was considered in M-291st meeting in September 2019 from Applicant: M/s A & Z Health Services. Suit No. 2, Block 27, Industrial & Trade Center, G-9/4, Islamabad, Pakistan." MAH: M/s Guerbet BP 57400, F-95943, Roissy CdG CEDEX" Brand name: Lipiodol Ultra-Fluide (480mg I/ml) Solution for Injection

3	• 3.2.S.4 Control of Drug Substance /3.2.P.5 Control of Drug Product. You are following In-house specifications, although the product is present in pharmacopoeia. Justification is required.	



GUERBET — **ETHYL ESTER OF IODIZED FATTY ACIDS OF POPPY SEED OIL (EEIFA)**

February 2019 — **Report no. 2_19_00396-1.0** — **Page 5 sur 7**

3.2.S.4.5 Justification of Specifications — **Confidential**

Appendix 1: Comparison between Lipiodol Ultra Fluid internal monograph, British Pharmacopoeia monograph "Iodised oil fluid injection" and US Pharmacopoeia monograph "Ethiodized oil injection"

	GUERBET specifications	BP monograph "iodised oil fluid injection"	USP monograph "ethiodized oil injection"
CHARACTERS			
- Appearance	Clear, pale yellow to oil	Straw-coloured or yellow, oily liquid	-
- Solubility(*)			
. Water	-	Practically insoluble	-
. Chloroform	-	Soluble	-
. Ether	-	Soluble	-
. Petroleum Spirit	-	Soluble	-
IDENTIFICATION			
- Identification	IR	Iodine vapor	Iodine vapor
TESTS OF PURITY			
- Density at 20 °C	1.268 to 1.290 g/mL	1.28 to 1.30	1.280 to 1.293 at 15°C
- Viscosity at 20 °C	34 to 70 mPa.s	-	50 to 100 cP at 15°C
- Absorbance			
. at 420 nm	NMT 0.60	-	-
. at 460 nm	NMT 0.50	-	-
- Acid value	NMT 1.0	NMT 1.2	NMT 1.3
- Free iodine	NMT 100 ppm	NMT 500 ppm	No blue color
- Water content	NMT 0.06 % w/w	-	-
ASSAY			
Iodine content (potentiometry)	37.0 to 39.0 % w/w	37.0 to 39.0 % w/w	35.2 to 38.9 % w/w

NMT = Not More Than

(*) According to EP chapter 1 "General Notices", "the statements under the heading Characters are not to be interpreted in a strict sense and are not requirements".
Therefore, solubility is not routinely tested as it is under the heading Characters.

Decision of 316th: Deferred for clarification regarding sole agency agreement of applied product since same product was considered in 291st meeting of Registration Board from applicant M/s A & Z Health Services. Suit No. 2, Block 27, Industrial & Trade Center, G-9/4, Islamabad, Pakistan."


Evaluation by PEC VI: M/s Medical equipment and systems has submitted NOC from M/s A & Z. The NOC states "We M/s : A&Z health services, Suit #2, Block 27 I&T center, G-9/4 Islamabad do hereby state and undertake that we have no objection if the product LIPIDOL ULTRA FLUID register on the name M/s Medical Equipment & Systems 60/61, FCC Syed Maratib Ali Road, Gulberg IV Lahore."

Decision of 320th meeting: Deferred for further deliberation upon marketing status of the applied product.

Firm's response: Firm has submitted following:

- Letter from M/s Guerbet in name of M/s A&Z Health services, declaring "termination of purchase, distribution and marketing of contrast media agreemen" weith effect from 03-03-2020.
- NOC from M/s A & Z. The NOC states "We M/s A&Z health services, Suit #2, Block 27 I&T Center, G-9/4 Islamabad do hereby state and undertake that we have no objection if the product LIPIDOL ULTRA FLUID register on the name M/s Medical Equipment & Systems 60/61, FCC Syed Maratib Ali Road, Gulberg IV Lahore. We further undertake that to withdraw our all rights and claim on this registration that was discussed in 249th meeting."

M/s Medical Equipment & System has also submitted a letter with subject "Counterfeit Lipiodol Ultra Fluid in Pakistan", which is reproduced as under:



MEDICAL EQUIPMENT & SYSTEMS

60/61, F.C.C. Syed Maratib Ali Road, Gulberg IV Lahore.
Ph: (92) (42) 35870538, 35878483, 35778086
Fax: (92) (42) 35870537
www.me-systems.org

To,
The Additional Director,
Pharmaceutical Evaluation and Registraion,,
Ministry of National Health Service Regulation & Coordination,
Islamabad.

Subject: Counterfeit Lipiodol Ultra Fluid in Pakistan

We,M/s: **Medical Equipment & Systems (MES), with registered address at 60/61 FCC Syed aratib ali road, Lahore, Pakistan**, are appointed by Guerbet Asia Pacific Limited as the distributor to import and sales of Lipiodol Ultra Fluid in Pakistan. We have also been authorized by Guerbet to act as the market authorization holder for the product. Currently the application is being under review and we have already imported and distributed Lipiodol Ultra Fluid in Pakistan from Guerbet's subsidiary, Guerbet Asia Pacific Ltd with its office in Hong Kong.

We have recently discovered that there are Lipiodol Ultra Fluid in the market being sold to some large hospitals in Pakistan, we therefore informed and checked with Guerbet regarding the batch. It has been confirmed by Guerbet that the said batch of Lipiodol Ultra Fluid has not been manufactured by Guerbet nor was sold in the Pakistan market through us. It seems as though it is being sold via other channels.

We therefore have reasonable ground to believe that those Lipiodol Ultra-Fluid is counterfeit product and reported the matter to Guerbet. Guerbet has conducted preliminary search in its production data base and confirmed that the batches have not been manufactured by Guerbet.

Guerbet is concerned of the safety of the counterfeit Lipiodol Ultra Fluid and is hereby authorized us to submit the findings to your authority. Please see attached herewith a letter issued by Guerbet on the counterfeit Lipiodol Ultra Fluid for your information and further action.

Thank you for your attention.

Yours faithfully,

Sheharyar Umer
Director

Decision of 324th meeting: Registration Board approved the instant application of "LIPIODOL Injection 10ml" of M/s Medical Equipment & Systems, as per policy of inspection of manufacturer abroad.

Furthermore, Registration Board acceded with the request for withdrawal of registration application of "Lipiodol Ultra-Fluide (480mg I/ml) Solution for Injection" from M/s A&Z health services submitted vide Dy. No 38087 dated 19-11-2018 and declared it as disposed of.

71.	Name, address of Applicant / Importer	M/s Sitech Pharmaceuticals Pvt Ltd. SF 07 and 09 Floor Shahnaz Arcade 158- Main Shaheede Millat Road, BYJCHS, Karachi, Pakistan
	Details of Drug Sale License of importer	License No: 1141 Address: Ground floor House No. 43-2B-1 Waja Abdul Sattar Masti khan Road block-6 P.E.C.H.S Karachi. Address of Godown: SF 07 and 09, 4th Floor Shahnaz Arcade 158- Main Shaheed e Millat Road, BYJCHS, Karachi, Pakistan Validity: 16 November 2023 Status: License to sell drugs by way of Wholesale. Validity: 01-01-2022.
	Name and address of marketing authorization holder (abroad)	Derma Pharma S.A.R.L. 25, Rue la Boetie, 75008 Paris – France
	Name, address of manufacturer(s)	**Manufacturer:** Laboratorio Farmaceutico S.I.T S.r.l Via Cavour 70, 27035 Mede (PV), Italy **Exporter:** Medexport Italia

		Via Alcide De Gasperi 35, 00165 Rome (RM), Italy
	Name of exporting country	Italy
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of legalized CoPP certificate (No. 036387) issued by Chamber de Commerce et d Industrie de Region paris Iie-de-France dated 06-August-2020**.** The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspections. The name of importing country on CoPP is mentioned as Pakistan. **Applicant of Certificate:** DB-Pharma -1 Bis, rue du Commandant Riviere-94210 La Varenne Saint -Hilaire.
	Details of letter of authorization / sole agency agreement	Letter of authorization issued by Laboratorio Farmeceutico SIT Specialita Igienico terapeutiche S.r.l Italy in name of M/s Sitech pharmaceuticals for the import of marketing of Dedrogyl 15mg/100mml oral soulton drops in Pakistan, being exported from M/s Consorzio medexport italia.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy.No 7174 dated 04-03-2021
	Details of fee submitted	Rs.100,000/- dated 24-02-2021
	The proposed proprietary name / brand name	**Dedrogyl 10 ml oral drops**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml contains: Calcifediol as monohydrate…15mg
	Pharmaceutical form of applied drug	Oral Drops Solution
	Pharmacotherapeutic Group of (API)	Vitamin D
	Reference to Finished product specifications	Eu. Ph. Current Edition
	Proposed Pack size	1's
	Proposed unit price	As per Pricing Policy
	The status in reference regulatory authorities	Approved by ANSM of France

	For generic drugs (me-too status)	--
	Module-II (Quality Overall Summary)	Firm has submitted summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Carbogen Amcis B.V. Nieuweweg 2A, Veenendaal, 3901BE, Netherlands
	Module-III Drug Substance:	Firm has submitted Certificate of Suitability (R1-CEP 1998-059 - Rev 08) issued by EDQM on 07-01-2022.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturers, manufacturing process and control of critical steps validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, characterization of impurities, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Amber glass-type III
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40^{o}C ±2^{o}C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30^{o}C ±2^{o}C / 65% ± 5% RH for 36 months

Evaluation by PEC:

Initially the application was submitted from M/s Sitech Pharmaceuticals Pvt Ltd. dated 04-03-2021, while subsequently M/s Angelini Pharmaceuticals (Pvt) Ltd. has submitted the new Form 5F of same product to be imported from the same principal along with the documents detailed below:

Name, address of Applicant / Importer	M/s Angelini Pharmaceuticals (Pvt) Ltd. 44 Commercial Imperial Block, Paragon City Barki Road, Lahore, Pakistan
Details of Drug Sale License of importer	License No: 05-352-0068-047191D Address: 44 Commercial Imperial Block, Paragon City, Barki Road, Lahore, Pakistan Address of Godown: Same as above Validity: 16 November 2023

	Status: License to sell drugs as distributor
Dy. No. and date of submission	Dy.No 31443 dated 15-11-2021
Details of fee submitted	Rs.75,000/- dated 22-10-2021
Details of Letter of Withdrawal from M/s Sitech	Firm has submitted copy of letter from M/s Sitech Pharmaceutical Pvt. Ltd., dated 11-10-2021 stating that "We SiTech Pharmaceuticals (Pvt.) Ltd withdrew from our application of registration of Dedrogyl 10ml oral drops in favor of Angelini Pharmaceuticals (Pvt} Ltd."
Details of NOC from M/s Sitech	Firm has submitted copy of letter from M/s Sitech Pharmaceutical Pvt. Ltd., dated 06-05-2021 stating that "We have submitted our application for registration of drug Dedrogyl 10ml oral drops (Calcifediol l5mg/l00ml) to DRAP Pharma Evaluation Cell on February 24, 2021. Now the exporter and our principal M/s Medexport Italia Rome, Italy has requested to withdraw the application, and instead will be resubmitted by their new distributor/importer M/s. Angelini Pharmaceuticals (Pvt) Ltd. having office at 44 Commercial Imperial Block, Paragon City, Barki Road Lahore. This decision is with our mutual understanding and consent. We have no objection for this and DRAP may process the registration application of drug Dedrogyl 10ml oral drops (Calcifediol 15mg/100ml) submitted by new distributor. We would be grateful, if you please consider & process application of above product submitted by M/s. Angelini Pharmaceuticals (Pvt) Ltd."
Details of letter of authorization / sole agency agreement from Exporter	Letter of authorization issued by Laboratorio Farmeceutico SIT Specialita Igienico terapeuti S.r.l Italy in name of M/s Angelini Pharmaceuticals (Pvt) Ltd. 44 Commercial Imperial Block, Paragon City Barki Road, Lahore, Pakistan for the import of marketing of Dedrogyl 15mg/100mml oral soulton drops in Pakistan, being exported from M/s Medexport italia. An authorization letter from M/s Med Export Italia has also been submitted stating as under: "We hereby confirm that our previous authorization to M/s SiTech Pharmaceuticals (Pvt) Ltd. located at SF - 07, 4th Floor, Shahnaz Arcade 158, Shaheed-e-Millat Road, BYJCHS, Karachi Pakistan is no longer valid and now M/s Angelini Pharmaceuticals (Pvt}

	Ltd. having office at 44 Commercial Imperial Block, Paragon City, Barki Road, Lahore, Pakistan is authorized to import, distribute, market and also handle regulatory matters of this product in the territory of Pakistan."

The letter of authorizations has been issued form the drug product manufacturer i.e., Laboratorio Farmaceutico S.I.T S.r.l Via Cavour 70, 27035 Mede (PV), Italy and Exporter i.e., M/s Medexport Italia Via Alcide De Gasperi 35, 00165 Rome (RM), Italy while submitted COPP mentions Market Authorization holder as Derma Pharma S.A.R.L. 25, Rue la Boetie, 75008 Paris – France.

Decision of 320th meeting: Registration Board decided as follows:

a. Acceded the request of M/s Sitech Pharmaceutical Pvt. Ltd. for withdrawal of their submitted application of Dedrogyl 10 ml oral drops dated 04-03-2021 vide Dy. No 7174 and declared it as disposed of.

b. Deferred the application of M/s Angelini Pharmaceuticals (Pvt) Ltd. 44 Commercial Imperial Block, Paragon City Barki Road, Lahore, Pakistan for submission of complete dossier of applied product.

Response by firm: M/s Angelini Pharmaceuticals (Pvt) Ltd. 44 Commercial Imperial Block, Paragon City Barki Road, Lahore has submitted complete dossier on Form 5F details of which are as under:

	Name, address of Applicant / Importer	M/s Angelini Pharmaceuticals (Pvt) Ltd. 44 Commercial Imperial Block, Paragon C Barki Road, Lahore, Pakistan
	Details of Drug Sale License of importer	License No: 05-352-0068-047191D Address: 44 Commercial Imperial Block, Paragon City, Barki Road, Lahore, Pakistan Address of Godown: Same as above Validity: 16 November 2023 Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	Derma Pharma S.A.R.L. 25, Rue la Boetie, 75008 Paris – France
	Name, address of manufacturer(s)	**Manufacturer:** Laboratorio Farmaceutico S.I.T S.r.l Via Cavour 70, 27035 Mede (PV), Italy **Exporter:** Medexport Italia Via Alcide De Gasperi 35, 00165 Rome (RM), Italy
	Name of exporting country	Italy
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of legalized CoPP certificate (No. 036387) issued by Chamber de Commerce et d Industrie de Region paris Iie-de-France dated 06-August-2020**.** The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspections. The name of importing country on CoPP is mentioned as Pakistan.

		Applicant of Certificate: DB-Pharma -1 Bis, rue du Commandant Riviere-94210 La Varenne Saint -Hilaire.
	Details of letter of authorization / sole agency agreement	Letter of authorization issued by Laboratorio Farmeceutico SIT Specialita Igienico terapeutiche S.r.l Italy in name of M/s Sitech pharmaceuticals for the import of marketing of Dedrogyl 15mg/100mml oral soulton drops in Pakistan, being exported from M/s Consorzio medexport italia.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy.No 33806 dated 23-11-2022
	Details of fee submitted	Rs.75,000/- dated 22-10-2021
	The proposed proprietary name / brand name	**Dedrogyl 10 ml oral drops**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml contains: Calcifediol as monohydrate…15mg
	Pharmaceutical form of applied drug	Oral Drops Solution
	Pharmacotherapeutic Group of (API)	Vitamin D
	Reference to Finished product specifications	Eu. Ph. Current Edition
	Proposed Pack size	1's
	Proposed unit price	As per Pricing Policy
	The status in reference regulatory authorities	Approved by ANSM of France
	For generic drugs (me-too status)	--

	Module-II (Quality Overall Summary)	Firm has submitted summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Carbogen Amcis B.V. Nieuweweg 2A, Veenendaal, 3901BE, Netherlands
	Module-III Drug Substance:	Firm has submitted Certificate of Suitability (R1-CEP 1998-059 - Rev 08) issued by EDQM on 07-01-2022.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturers, manufacturing process and control of critical steps validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, characterization of impurities, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Amber glass-type III
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40^{o}C ±2^{o}C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30^{o}C ±2^{o}C / 65% ± 5% RH for 36 months

Decision of 324th meeting: Registration Board approved the instant application of Dedrogyl 10 ml oral drops of M/s Angelini Pharmaceuticals (Pvt) Ltd as per policy of inspection of manufacturer abroad.

Item No. 3: Agenda of Evaluator PEC-III (Dr. Haseeb Tariq)

Case No. 01 Registration applications of Export facilitation cases

a. New Cases

72.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s AGP Limited, B-23-C, S.I.T.E., Karachi, Pakistan**
	Name, address of Manufacturing site.	M/s Sante (Pvt) Ltd. A-97, SITE Super Highway Karachi.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) (Firm has submitted copy of contract manufacturing agreement between Sante (Pvt) Ltd and AGP dated 19-04-2022).
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s Sante (Pvt) Ltd. dated 08-03-2022 issued on the basis of inspection dated 07-03-2022. The GMP certificate specifies Sterile ophthalmic drops (General) section.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of Drug Manufacturing License of M/s Sante (Pvt) Ltd dated 20-09-2021 specifying Sterile ophthalmic drops (General) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12287: 20-05-2022
	Details of fee submitted	PKR 75,000/-: 18-04-2022
	The proposed proprietary name / brand name	**RIGIX Eye Drops**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Cetirizine (as HCl)…….2.4mg
	Pharmaceutical form of applied drug	Clear transparent solution filled in LDPE bottles.
	Pharmacotherapeutic Group of (API)	Antiallergics
	Reference to Finished product specifications	Manufacturer's specifications
	Proposed Pack size	5ml
	Proposed unit price	As per DRAP approved MRP
	The status in reference regulatory authorities	Zerivate ophthalmic solution **(USFDA** Approved)
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	Praveen Laboratories Pvt. Ltd. Plot No. 1, Block No. 206, Moje Jolwa, Tal Palsana, Dist. Surat, Gujarat, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information

		related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Trizin Ophthalmic solution by Navana Pharma Bangladesh.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	Praveen Laboratories Pvt. Ltd. Plot No. 1, Block No. 206, Moje Jolwa, Tal Palsana, Dist. Surat, Gujarat, India.		
API Lot No.	MK40120056		
Description of Pack (Container closure system)	LDPE bottles		
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	TAA-P01	TAA-P02	TAA-P03

Batch Size	6.0 Litres	6.0 Litres	6.0 Litres
Manufacturing Date	03-2021	03-2021	03-2021
Date of Initiation	30-04-2021	30-04-2021	30-04-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate No. S-GMP/21092927 issued by Food and Drug Control Administration Gujrat State India valid till 19-09-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared by AD (I&E) DRAP dated 21-12-2020 specifying purchase of 1000 Kg cetirizine hydrochloride by M/s AGP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record and raw data sheets, HPLC chromatograms etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted by the firm
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

Sr. No	Shortcomings communicated	Response by the firm
1.	Submit complete label claim in module 1 as per the reference product.	Complete label claim as per reference/ innovator product is provided by the firm.
2.	Verification studies of analytical method of drug substances from drug product manufacturer is required.	Verification studies of analytical method of drug substance from drug product manufacturer is provided by the firm.
3.	Submit COA of reference standard actually used in the analysis of drug substance and drug product.	CoA of reference standard (Batch No. MK40120032) used in analysis is provided by the firm.
4.	Justify why the pharmaceutical equivalence studies does not include complete tests as recommended by the innovator's product.	Revised pharmaceutical equivalence study report is submitted by the firm.
5.	Justify why pharmaceutical equivalence studies are not performed against innovator / reference product.	As already mentioned in PE report (Page No. 324 of Volume 2) due to unavailability of innovator's product Zerviate Ophthalmic Solution in Pakistan, however, the study is conducted on generic product Trizin Ophthalmic Solution manufactured by Navana Pharmaceuticals Ltd., Bangladesh.
6.	Submit image / picture of the outer pack and primary container of the comparator product revealing the details of brand name, manufacturer, batch# and expiry date as per the decision of 322nd meeting of Registration Board and notified vide notification No. 14-1/2022-PEC dated 16th January 2023.	Firm has submitted the picture of pack of the comparator product against which PE studies were conducted.
7.	Submit preservative effectiveness studies.	Data of preservative effectiveness study is provided by the firm
8.	Justify why terminal sterilization is not performed for the applied drug product.	Sante private limited has a qualified Aseptic facility, and as our primary containers are sterile LDPE plastic bottles along with sterile LDPE

		nozzle and sterile HDPE caps so the terminal sterilization is not required. Batch has been sterilized aseptically via 0.22 micron filter under the LAF into the sanitized filling tank.
9.	Justify the process validation protocols without any step for validation of method of sterilization.	Revised validation protocol is submitted by the firm
10.	Justify the drug product specifications submitted in section 3.2.P.5.1 which does not contains the test of assay of benzalkonium chloride, EDTA, particulate appearance, specific gravity and viscosity as performed by the innovator's product.	Specification has been revised including tests: Assay of Benzalkonium Chloride, Particulate Appearance, Particulate Matter, Specific Gravity and Viscosity. Test will be performed on next station (24th Month APR-2023). However no fee is submitted by the firm.
11.	Justify the wide pH limit of 4.0 – 8.0 since the innovator's product recommends that pH should be approximately 7.0 and your batch analaysis results also depicts results between 6.9 to 7.1.	As per <USP 771>, normal tears have a pH about 7.4. the eye can tolerate products over a range of pH values from 3.0 – 8.6. This justification is already provided in Section 3.2.P.5.6 (Justification of Specifications).
12.	You have mentioned that for stability batches the API used is of lot number MK40120123 while in section 3.2.S.4.4 you have submitted COA of batch MK40120056.	The API used in stability batches is of lot number MK40120123. The CoA of the said batch is provided by the firm.
13.	Justify why water loss test is not performed during stability studies.	Data of water loss test is submitted by the firm
14.	Submit stability study data of three batches along with raw data sheets showing calculation of results of assay coupled with relevant chromtaograms with proper sequence and tagging so that further evaluation could be carried out.	Stability study data of three batches along with raw data sheets showing calculation of results of assay coupled with relevant chromatograms with proper sequence and tagging is submitted by the firm
15.	Submit stability study data in section 3.2.P.8.3 as per the 6 points checklist as mentioned in the CTD guidance document, since you have randomly submitted the data without following the recommendations of guidance document.	Data as per CTD guidance document is is now submitted by the firm
16.	Submit batch size in terms of number of units.	Batch Size: 1,132 packs (6.0 liter), Pack Size: 5mL

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. 02 Registration applications of New Sections

b. Deferred Cases

73.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Titlis Pharma (Pvt) Ltd. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore.**
	Name, address of Manufacturing site.	M/s Titlis Pharma (Pvt) Ltd. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer

		☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate dated 05-11-2020 issued on the basis of inspection dated 30-09-2020.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of grant of additionall section under Drug Manufacturing License (DML No. 000779) dated 10-05-2022. The letter specifies following section: 1. Tablet Section-II (General) 2. Dry powder suspension (General) 3. Dry powder sachet section (General)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22073: 03-08-2022
	Details of fee submitted	PKR 30,000/- : 15-07-2022
	The proposed proprietary name / brand name	**CIPROLIS 125mg/5ml Dry Suspension**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml of reconstituted suspension contains: Ciprofloxacin HCl……125mg
	Pharmaceutical form of applied drug	Light pinkgranular powder with strawberry flavoured filled in 60ml amber color glass bottle
	Pharmacotherapeutic Group of (API)	Fluoroquinolones
	Reference to Finished product specifications	USP
	Proposed Pack size	60ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**Registration Board in its 269th meeting decided as under:** Keeping in view the following statement written in Qualitative and quantitative composition "2.5 mL suspension after reconstitution (1/2 measuring spoon) contains 125 mg ciprofloxacin" and domestic conditions for difficulties in dispensing 250mg/5ml suspension for children under 2 years of age, Registration Board decided to approve the formulation of ciprofloxacin 125mg/5ml granules and solvent for oral suspension as per reference product approved by USFDA and MHRA.
	For generic drugs (me-too status)	Novidat suspension by Sami
	Name and address of API manufacturer.	M/s Vision Pharmaceuticals (Pvt.) Ltd. Plot# 22-23, Industrial triangle, Kahuta road, Islamabad
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications,

		analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40ºC ± 2ºC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30ºC ± 2ºC / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator product Novidat suspension of Sami Pharmaceuticals. Firm has submitted results of CDP for their product against the comparator product Novidat suspension of Sami Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA	
Manufacturer of API	M/s Vision Pharmaceuticals (Pvt.) Ltd. Plot# 22-23, Industrial triangle, Kahuta road, Islamabad
API Lot No.	CPX1279
Description of Pack (Container closure system)	Amber color glass bottle
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months)

	Real Time: 0, 3, 6 (Months)		
Batch No.	CP-03	CP-04	CP-05
Batch Size	100 Bottles	100 Bottles	100 Bottles
Manufacturing Date	11-2021	11-2021	11-2021
Date of Initiation	27-11-2021	27-11-2021	27-11-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate of M/s Vision Pharmaceuticals dated 25-02-2019 based on the inspection dated 11-02-2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Evaluation by PEC:

- The label claim of the applied product is not in line with the reference product in terms of salt form as well as equivalency, revise the label claim along with submission of full fee of registration.
- Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required." You have only submitted the specifications of API from the drug product manufacturer.
- Provide verification studies of drug substance from drug product manufacturer.
- Justify the assay testing of drug substance using UV method contrary to that recommended by the innovator's product.
- Submmit COA of relevant batch of API i.e. Lot No. CPX1279 from Vision pharmaceuticals in section 3.2.S.4.4.
- Submit COA of reference standard / working standard actually used in the analysis of drug substance.
- Justify the stability study data of ciprofloxacin micro-pellets from Vision pharmaceuticals initiated in 2013 and completed in 2016 in which ciprofloxacin base is mentioned, while M/s Vision pharmaceuticals was manufacturing ciprofloxacin pellets using ciprofloxacin HCl before Registration Board took the decision to revise the salt form to ciprofloxacin base in its 290th meeting which was held on 3rd - 4th July, 2019. Justify how the salt form in stability study data of previous batches was changed.
- Justify the use of sugar and poly succar ultra DM as sweetner while you are already using taste masked granules in your formulation.
- Justify the use of xanthan gum as suspending agent along with granules in the formulation while the reference product contains no suspending agent.
- Justify how 71.429mg/1ml of ciprofloxacin granules is equivalent to 25mg ciprofloxacin base per ml.

- Justify the use of sodium benzoate anhydrous in your formulation while the pH is already controlled by the drug substance manufacturer at pellets stage and pH test is specified in COA of drug substance. Furthermore, the reference product contains oil based diluent for which pH is not required to be controlled.
- Justify the use of citric acid in your formulation as buffering agent which is not used by the reference product and the reference product contains oil based diluent for which pH is not required to be controlled.
- Justify the use of flavour in your formulation while you are already using taste masked granules.
- Justify the use of aerosil in your formulation.
- Provide details about the diluent which to be used with the applied product in section 3.2.P.1.
- Provide complete module 3.2.P for the diluent which will be used in the administration of applied product as per the decision of 290th and 313th meeting of Registration Board.
- Justify why the qualitative composition of applied product is different from that of innovator's product, and also provide compatibility studies.
- Justify why pharmaceutical equivalence studies are not conducted against the innovator's product.
- Provide microbiological attributes of the applied product in section 3.2.P.2.5 as per USP monograph.
- Submit preservative effectiveness studies in section 3.2.P.2.5.
- Submit compatibility studies of the applied product along with recommended diluent.
- Justify the pH test in your specification since no such test is recommended in USP monograph.
- Justify why Microbial Enumeration Tests is not mentioned in your specifications while it is recommended by USP.
- Justify the analytical method of assay and dissolution test in which initial reconstitution with water is mentioned while USP recommends to use the particular diluent for this purpose. Justify how your analytical method complies USP monograph.
- Justify why identification test using diode array detector is not performed and mentioned in analytical method.
- Justify why you are using different column in assay test as that recommended by USP.
- Submit evidence of diode array detector which is required for identification test as per USP monograph.
- Submit evidence of column oven which is required to maintain column temperature at 40° and 30° for assay and dissolution test.
- Submit evidence of autosampler with HPLC having capacity to maintain 10° which is required to perform assay and dissolution test as per USP monograph.
- Provide details of the exact concentrations of the solutions and its preparation method which are used to perform accuracy, and precision studies in analytical method verification studies.
- Justify how you are using ciprofloxacin HCl manufactured by Shangyu Jingxin pharmaceuticals for the testing of your product.
- The stability chromatograms for assay testing depicts that ciprofloxacin HCl is tested while the applied product contains ciprofloxacin base. Clarification is required in this regard.
- Justify the manufacturing of stability batches in November 2021 while your section was approved on 10-05-2022.
- Provide stability study data in a proper sequence using separators to segregate the data of each time point and each batch along with relevant raw data sheets.
- Clarification regarding reconstitution diluent used for the product development and stability studies.
- Submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following:
    - Reference of previous approval of applications with stability study data of the firm (if any)
    - Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.
    - Documents for the procurement of API with approval from DRAP (in case of import).
    - Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
    - Compliance Record of HPLC software 21CFR & audit trail reports on product testing.

- Record of Digital data logger for temperature and humidity monitoring of both stability chambers.

Decision of 323rd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response by the firm:

Sr. No	Reason for deferment	Response by the firm
1.	The label claim of the applied product is not line with the reference product in terms of salt form as well as an equivalency, revise the label claim along with submission of full fee of registration.	We revised the label claim as per innovator i.e. Ciprolis 125mg/5ml Dry Powder Suspension Each 1 ml suspension after reconstitution contains 25 mg ciprofloxacin Each 5 ml suspension after reconstitution (1 measuring spoon) contains 125 mg ciprofloxacin
2.	Submit data in section 3.2.S.4.1 as per guidance document approved in Registration Board which specifies that ''Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance/ Active Pharmaceutical Ingredient by both Drug Substance & Drug Product manufacturer is required.*you have only submitted the specifications of API from the drug product manufacturer.	Firm has submitted copies of the Drug substance specifications and analytical procedures from drug product manufacturer as well.
3.	Provide verification studies of drug substance from drug product manufacturer	Frim has submitted verification studies of the drug substance from drug product manufacturer
4.	Justify the assay testing of drug substance using UV method contrary to that recommended by the innovator's product.	Our API manufacturer (Vision Pharmaceuticals) have performed analytical method validation for Ciprofloxacin TM Micro pellets 35% including the parameters specificity, Accuracy and Recovery, Linearity and Range, Ruggedness, Robustness, Precision, and Repeatability. Moreover, we have also performed analytical verification of our API manufacturer, the testing method including the parameters specificity, Accuracy, and recovery, and repeatability. As the testing method (UV based) is a completely reliable and validated method. So, we used the said method for our API testing,
5.	Submit COA of relevant batch of API i.e. Lot No. CPX1279 from Vision pharmaceuticals in section 3.2.S.4.4.	Submitted by the firm.
6.	Submit COA of reference standard/working standard actually used in the analysis of drug substance.	Previously, we were using reference standard/working standard of Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed: Working Standard for Ciprofloxacin Suspension Molecular weight of Ciprofloxacin HCL = 367.81

		Molecular weight of Ciprofloxacin Base = 331.34 Factor= 331.34/367.81 = 0.901 1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base We hereby confirmed that currently we are using working standard of Ciprofloxacin Base from Vision Pharma (Pvt) Limited (COA Copy attached) Moreover, we have also manufactured 3 new batches (Batch numbers: CP-10, CP-11, and CP-12) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of "0" month and accelerated stability testing of "1.5" month after reconstitution with diluent: as per innovator's specifications / dissolution parameters.
7.	Justification for changed salt form in stability study data of previous batch as the stability study data of ciprofloxacin micro-pellets from Vision Pharmaceuticals initiated in 2013 and completed in 2016 in which ciprofloxacin base is mentioned, while M/s Vision pharmaceuticals was manufacturing ciprofloxacin pellets using ciprofloxacin HCL before Registration Board took the decision to revise the salt form to ciprofloxacin base in its 290th meeting which was held on 3rd-4th July, 2019.	''Vision Pharmaceuticals got registration for both Ciprofloxacin base and Ciprofloxacin HCL in 2014 and started manufacturing of Ciprofloxacin base after registration for its market demand. Later on Drug Registration Board in its 290th meeting instructed all manufacturers to manufacturer Ciprofloxacin Dry powder suspension using Ciprofloxacin Base. As Vision Pharma was already manufacturing Ciprofloxacin Base. Therefore, Ciprofloxacin base is mentioned in given stability study data which was used in our product development'' Registration Certificated and stability study reports of most recent batch are enclosed for your reference.
8.	Justify the use of sugar and poly Succar ultra DM as sweetner while you are already used taste masked granules in your formulation.	Coating material of granules is not enough to mask the bitterness of ciprofloxacin completely. As suspension form is developed for children; therefore, it is necessary to mask the bitterness as well as to produce a sweet taste to make it palatable. As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 125/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
9.	Justify the for use of Xanthan gum as suspending agent along with the granules	The coating material used in the granulation of Ciprofloxacin is not enough to suspend the active ingredient in the product when reconstituted,

	in the formulation while reference product contains no suspending agent.	therefore we used Xanthan Gum for equal dispersion of active material after reconstitution to avoid unequal dose. As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 125/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
10.	Justify for how 71.429mg/ml of ciprofloxacin granules is equivalent to 25mg Ciprofloxacin base per ml.	We are using 35% TM Pellets which mean: 100mg of pellets contains 35mg of Ciprofloxacin base 1mg pellets = 35/100 = 0.35mg of ciprofloxacin base 71.429mg pellets = 25mg of Ciprofloxacin Base Therefore, it is justified that 71.429 mg/ml of ciprofloxacin granules is equivalent to 25mg of ciprofloxacin base per ml.
11.	Justification for use of sodium benzoate anhydrous in formulation while the pH is already controlled by the drug substance manufacturer at pellets stage and pH in COA of drug substance. Furthermore, the reference product contains oil based diluent for which pH test is not required to be controlled.	As product has to keep for five days after reconstitution, we used Sodium Benzoate as antifungal preservative in the product to avoid any contamination in the liquid form ➢ As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 125/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. ➢ Moreover, it is remarkable that we have developed the diluent as per 290th & 313 minutes of meeting of Drug Registration Board/Innovators formulation, kept it on stability and after reconstitution it was observed that our pH is stable as per the prescribed range which is 7.0-9.5%
12.	Justify the use of citric acid in formulation as buffering agent which is not used by the reference product and the reference product contains oil based diluent for which pH is not required to be controlled.	Citric acid was used in the formulation as buffering agent to maintain the pH range 7.0-9.5. We have performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability (Reports are attached). It is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Ciprolis 125mg/5ml suspension. Moreover it is remarkable that we have developed the diluent as per 290th & 313 minutes of meeting of Drug Registration Board/Innovators formulation, kept it on stability and after reconstitution it was

		observed that our pH is stable as per the prescribed range which is 7.0-9.5%
13.	Justify the use of flavor in formulation while you are already used taste masked granules.	Taste masking ingredients don't impart any flavor, they are used just to mask the bitterness, Moreover, use of flavor makes the product more palatable. Whereas, as per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 125/5ML Dry Powder suspension. Their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
14.	Justify the use of aerosil in formulation.	As aerosil is glidant which is used as anti-caking agent in dry powder suspension. Aerosil keep the granules in free-flowing form throughout its shelf life. This is an inert material which doesn't impart any change in our formulation. Whereas, as per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 125/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
15.	Provide details about the diluent which is to be used with the applied product in section 3.2.P.1	We have developed a diluent as per 290th & 313 minutes of meeting of Drug Registration Board; truly according to Innovators composition; which is as followed; 1. Sugar 2.5 gm (1%) 2. Sodium Benzoate 250mg (0.001%) 3. Soya Lecithin Powder 250mg (0.001%) 4. Triglyceride 250mg (0.001%) Procedure: Heat the water upto 60℃ and add the sugar with continuous stirring until sugar is dissolved Cook the above solution till boiled to prepare the sugar solution till boiled to prepared the sugar solution, then off the flame. Add Soya Lecithin powder in above solution and stir for 30 minutes

		Add triglyceride in step 4 and stir for one hour Firm has Liquid Syrup (General) Section in which this diluent is manufactured.
16.	Provide Complete module 3.2.P for the diluent which will be used in the administration of the applied product as per the decision of 290th and 313th meeting of Registration Board.	We have developed a diluent after receiving deficiency letter of Ciprolis 125mg/5ml Dry Powder Suspension on 22nd November 2022 as per 290th & 313th minutes of the meeting of Drug Registration Board; truly according to Innovators composition along with 3 new batches of Ciprolis 125mg/5ml Dry Powder Suspension (Batch numbers: CP-10, CP-11 and CP-12) for performance of stability studies. We have performed complete stability testing of "0" month and accelerated stability testing of "1.5" month on these 3 new batches as per innovator's specifications / dissolution parameters. Results are complying with innovator's specifications. Moreover, we have also performed long-run stability testing of 12th month of previous batches (Batch numbers: CP-03, CP-04, and CP-05) after reconstitution with the diluent as per innovator's specifications / dissolution parameters and results are complying with innovator's specifications. Complete BMRs of new batches along with diluent, complete testing along with COA and stability study Reports and chromatograms are provided by the firm.
17.	Justify why the qualitative composition of applied product is different from that of innovator's product.	All the excipients used in our formulation are **inert** and compatible. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
18.	Justify why the pharmaceutical equivalence studies are not conducted against the innovator's product	We have performed Pharmaceutical equivalence studies of Ciprolis (Ciprofloxacin) 125mg/5ml Suspension against the reference product Novidat Dry Powder Suspension 125mg/5ml manufactured by Sami Pharmaceuticals As the innovator product is not available in Pakistan therefore, pharmaceutical equivalence of Ciprolis (Ciprofloxacin) 125mg/5ml Suspension was performed against the reference product Novidat Dry Powder Suspension 125mg/5ml manufactured by Sami Pharmaceuticals.
19.	Provide Microbial attributes of applied Drug product in section 3.2.P.2.5	Submitted by the firm
20.	Submit Preservative effectiveness studies in section 3.2.P.2.5.	Submitted by the firm
21.	Submit Compatibility study of applied product along with recommended diluent.	Submitted by the firm

22.	Justify the pH test in your specification since no such test is recommended in USP monograph.	We are performing all the test as per USP monograph and truly followed USP monograph However, we are also performing additional test for pH as a quality attributes in order to be more stringent
23.	Justify why Microbial Enumeration Tests is not mentioned in specification while it is recommended by USP	We have revised our method and test for Microbial Enumeration has been performed as recommended by USP (COA and revised method are enclosed) We have performed our finished product method as per USP which covers Microbial Enumeration Test Moreover, we have also performed Microbial Preservative test, which shows that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Ciprolis 125mg/5ml. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. (Complete method and Microbial Preservative test are enclosed)
24.	Justify the analytical method of assay and dissolution test in which initial reconstitution with water is mentioned while USP recommends to use the particular diluent for this purpose. Justify how your analytical method complies USP monograph.	We have developed a diluent as per 290th & 313 minutes of meeting of Drug Registration Board; which is truly according to Innovators composition and performed finished product test as per USP method after reconstitution with diluent and found that results are fully comply with USP requirements (Revised method of analysis and finished product COA after reconstitution with diluent are attached) Stability studies of CIPROLIS 125MG/5ML after reconstitution with diluent are also provided by the firm.
25.	Justify why the identification test using diode array detector is not performed and mentioned in analytical method.	Sample and standard were analyzed under same chromatographic conditions and found that the results were closely comparable. It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.
26.	Justify why you are using different column in assay test as that recommended by USP	The column used for analysis of Ciprofloxacin suspension have chemically same specification i.e. packing L1 with same particle size, the difference is only the length of column, USP require 15cm while we are using 25cm, remaining specifications are same as USP requirements. Sample and standard were analyzed under same chromatographic conditions and found that the results were closely comparable. It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification,

<table>
<tr><td></td><td></td><td>Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.
Column oven invoice along with specifications is provided by the firm.</td></tr>
<tr><td>27.</td><td>Submit evidence of diode array detector which is required for identification test as per USP monograph.</td><td>Sample and standard were analyzed under same chromatographic conditions found that the results were closely comparable.
It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.</td></tr>
<tr><td>28.</td><td>Submit evidence of column oven which is required to maintain column temperature to 40℃ and 30℃ for assay and dissolution test.</td><td>Sample and standard were analyzed under same chromatographic conditions (including the same injection volume) and found that the results were closely comparable.
It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.
Moreover, we have capacity to maintain column temperature t 40℃ and 30℃ for assay and dissolution test
Column oven invoice along with specifications is provided by the firm.</td></tr>
<tr><td>29.</td><td>Submit evidence of auto sampler with HPLC having capacity to maintain 10° which is required to perform assay and dissolution test as per USP monograph.</td><td>We don’t have auto sampler with HPLC but still we have capacity to maintain 10° which is required to perform assay and dissolution test as per USP monograph.</td></tr>
<tr><td>30.</td><td>Details about the exact concentrations of the solutions and its preparation method which are used for perform accuracy, and precision studies in analytical method verification studies.</td><td>The exact concentrations of the solutions and its preparation method is as followed:

Specificity
Concentration:<table><tr><td>Standard</td><td>Sample</td></tr><tr><td>0.1mg/ml</td><td>0.1mg/ml</td></tr><tr><td>0.01%</td><td>0.01%</td></tr></table>
Method to prepare analytical solution:
➢ Standard
Weight taken:250gm ➔ 25ml diluent
5ml ➔ 50ml mobile phase
➢ Sample
Weight taken: 5.5250gm ➔ 100ml diluent
5ml ➔ 50ml mobile phase
Repeatability
Concentration:<table><tr><td>Standard</td><td>Sample</td></tr><tr><td>0.1mg/ml</td><td>0.1mg/ml</td></tr><tr><td>0.01%</td><td>0.01%</td></tr></table>
Method to prepare analytical solution:</td></tr>
</table>

		➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 5.5250gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase Accuracy For 100% Concentration: Standard | Sample 0.1mg/ml | 0.1mg/ml 0.01% | 0.01% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 5.5250gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase For 75% Concentration: Standard | Sample 0.1mg/ml | 0.075mg/ml 0.01% | 0.0075% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 4.144gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase For 50% Concentration: Standard | Sample 0.1mg/ml | 0.05mg/ml 0.01% | 0.005% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 2.625gm ➔ 100ml diluent 5ml ➔ 50ml mobile phas (Detailed analytical method is attached for your reference
31.	Justify how you are using Ciprofloxacin HCl Manufactured by Shangyu Jingxin Pharmaceuticals for the testing of your product.	Previously, we were using Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed: Working Standard for Ciprofloxacin Suspension Molecular weight of Ciprofloxacin HCL= 367.81 Molecular weight of Ciprofloxacin Base = 331.34 Factor= 331.34/367.81 = 0.901 1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base

<table>
<tr><td></td><td></td><td>We hereby confirmed that currently we are using Ciprofloxacin Base from Vision Pharma (Pvt) Limited (COA Copy attached)
Moreover, we have also manufactured 3 new batches (Batch numbers: CP-10, CP-11, and CP-12) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of “0” month and accelerated stability testing of “1.5” month after reconstitution with diluent: as per innovator’s specifications / dissolution parameters.
Reports and stability chromatograms are provided by the firm.</td></tr>
<tr><td>32.</td><td>The stability chromatograms for assay testing depicts that ciprofloxacin HCl is tested while the applied product contains ciprofloxacin base. Clarification is required in this regard.</td><td>Previously, we were using Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed:
Working Standard for Ciprofloxacin Suspension
Molecular weight of Ciprofloxacin HCL = 367.81
Molecular weight of Ciprofloxacin Base = 331.34
Factor= 331.34/367.81 = 0.901
1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base
We hereby confirmed that currently we are using Ciprofloxacin Base from Vision Pharma (Pvt) Limited (COA Copy attached)
Moreover, we have also manufactured 3 new batches (Batch numbers: CP-10, CP-11, and CP-12) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of “0” month and accelerated stability testing of “1.5” month after reconstitution with diluent: as per innovator’s specifications / dissolution parameters.
Reports and stability chromatograms are provided by the firm.</td></tr>
<tr><td>33.</td><td>Justify the manufacturing of stability batches in November 2021 while your section was approved on 10-05-2022</td><td>Development of Trial Batches of Ciprolis 125mg/5ml suspension was performed in our product development (R & D) section.
Our R&D Lab has been inspected/ endorsed by the DRAP Panel of Inspectors; with following remarks
<table><tr><th>Q #</th><th>Question</th><th>Observation by Panel</th></tr><tr><td>17.</td><td>Do You have Product development (R&D) Section?</td><td>Yes, The Firm has product development (R&D) section for product development, manufacturing &</td></tr></table></td></tr>
</table>

		testing facility for trial Batches.

The above stated report was based on PSI conducted for Delanso Capsule where the inspection was carried out on 02-05-2019 and the PSI report was discussed in the Board in 289th meeting.

34.	Provide stability study data in a proper sequence using separators along with relevant raw data sheet	Firm has submitted data with proper sequence
35.	Stability study data in section 3.2.P.8.3 as per the checklist approved by registration Board in its 296th meeting and the CTD guidance document, which includes the following; Reference of previous approval of applications with stability study data of the firm (if any) Approval of API/DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin. Documents for the procurement of API with the approval from DRAP (in case of import) Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc. Compliance Record of HPLC software 21CFR & audit trail reports on product testing Record of digital data logger for temperature and humidity monitoring of both stability chamber	Firm has submitted data as per checklist

Decision of 324th meeting: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufcaturer shall declare the shelf life of the diluent, to be used with commercial batches.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 30,000/- for submission of revised stability studies data, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**
- **Accelerated and long term stability studies data till third month time point of newl manufactured stability batches i.e., (**Batch numbers: CP-10, CP-11, and CP-12**) as per USP**

	monograph along with in-use stability data with the reconstituioton diluent as recommended by Innovator.	
74.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Titlis Pharma (Pvt) Ltd. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore.**
	Name, address of Manufacturing site.	M/s Titlis Pharma (Pvt) Ltd. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate dated 05-11-2020 issued on the basis of inspection dated 30-09-2020.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of grant of additionall section under Drug Manufacturing License (DML No. 000779) dated 10-05-2022. The letter specifies following section: 1. Tablet Section-II (General) 2. Dry powder suspension (General) 3. Dry powder sachet section (General)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22072: 03-08-2022
	Details of fee submitted	PKR 30,000/- : 15-07-2022
	The proposed proprietary name / brand name	**CIPROLIS 250mg/5ml Dry Suspension**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml of reconstituted suspension contains: Ciprofloxacin HCl……..250mg
	Pharmaceutical form of applied drug	Light pinkgranular powder with strawberry flavoured filled in 60ml amber color glass bottle
	Pharmacotherapeutic Group of (API)	Fluoroquinolones
	Reference to Finished product specifications	USP
	Proposed Pack size	60ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**MHRA** Approved
	For generic drugs (me-too status)	Novidat suspension by Sami
	Name and address of API manufacturer.	M/s Vision Pharmaceuticals (Pvt.) Ltd. Plot# 22-23, Industrial triangle, Kahuta road, Islamabad
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and

		stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator product Novidat suspension of Sami Pharmaceuticals. Firm has submitted results of CDP for their product against the comparator product Novidat suspension of Sami Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s Vision Pharmaceuticals (Pvt.) Ltd. Plot# 22-23, Industrial triangle, Kahuta road, Islamabad		
API Lot No.	CPX1279		
Description of Pack (Container closure system)	Amber color glass bottle		
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	CP-06	CP-07	CP-08

Batch Size	100 Bottles	100 Bottles	100 Bottles
Manufacturing Date	11-2021	11-2021	11-2021
Date of Initiation	27-11-2021	27-11-2021	27-11-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate of M/s Vision Pharmaceuticals dated 25-02-2019 based on the inspection dated 11-02-2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Evaluation by PEC:

- The label claim of the applied product is not in line with the reference product in terms of salt form as well as equivalency, revise the label claim along with submission of full fee of registration.
- Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required." You have only submitted the specifications of API from the drug product manufacturer.
- Provide verification studies of drug substance from drug product manufacturer.
- Justify the assay testing of drug substance using UV method contrary to that recommended by the innovator's product.
- Submmit COA of relevant batch of API i.e. Lot No. CPX1279 from Vision pharmaceuticals in section 3.2.S.4.4.
- Submit COA of reference standard / working standard actually used in the analysis of drug substance.
- Justify the stability study data of ciprofloxacin micro-pellets from Vision pharmaceuticals initiated in 2013 and completed in 2016 in which ciprofloxacin base is mentioned, while M/s Vision pharmaceuticals was manufacturing ciprofloxacin pellets using ciprofloxacin HCl before Registration Board took the decision to revise the salt form to ciprofloxacin base in its 290th meeting which was held on 3rd - 4th July, 2019. Justify how the salt form in stability study data of previous batches was changed.
- Justify the use of sugar and poly succar ultra DM as sweetner while you are already using taste masked granules in your formulation.
- Justify the use of xanthan gum as suspending agent along with granules in the formulation while the reference product contains no suspending agent.
- Justify how 71.429mg/1ml of ciprofloxacin granules is equivalent to 25mg ciprofloxacin base per ml.
- Justify the use of sodium benzoate anhydrous in your formulation while the pH is already controlled by the drug substance manufacturer at pellets stage and pH test is specified in COA of drug substance. Furthermore, the reference product contains oil based diluent for which pH is not required to be controlled.

- Justify the use of citric acid in your formulation as buffering agent which is not used by the reference product and the reference product contains oil based diluent for which pH is not required to be controlled.
- Justify the use of flavour in your formulation while you are already using taste masked granules.
- Justify the use of aerosil in your formulation.
- Provide details about the diluent which to be used with the applied product in section 3.2.P.1.
- Provide complete module 3.2.P for the diluent which will be used in the administration of applied product as per the decision of 290th and 313th meeting of Registration Board.
- Justify why the qualitative composition of applied product is different from that of innovator's product, and also provide compatibility studies.
- Justify why pharmaceutical equivalence studies are not conducted against the innovator's product.
- Provide microbiological attributes of the applied product in section 3.2.P.2.5 as per USP monograph.
- Submit preservative effectiveness studies in section 3.2.P.2.5.
- Submit compatibility studies of the applied product along with recommended diluent.
- Justify the pH test in your specification since no such test is recommended in USP monograph.
- Justify why Microbial Enumeration Tests is not mentioned in your specifications while it is recommended by USP.
- Justify the analytical method of assay and dissolution test in which initial reconstitution with water is mentioned while USP recommends to use the particular diluent for this purpose. Justify how your analytical method complies USP monograph.
- Justify why identification test using diode array detector is not performed and mentioned in analytical method.
- Justify why you are using different column in assay test as that recommended by USP.
- Submit evidence of diode array detector which is required for identification test as per USP monograph.
- Submit evidence of column oven which is required to maintain column temperature at 40° and 30° for assay and dissolution test.
- Submit evidence of autosampler with HPLC having capacity to maintain 10° which is required to perform assay and dissolution test as per USP monograph.
- Provide details of the exact concentrations of the solutions and its preparation method which are used to perform accuracy, and precision studies in analytical method verification studies.
- Justify how you are using ciprofloxacin HCl manufactured by Shangyu Jingxin pharmaceuticals for the testing of your product.
- The stability chromatograms for assay testing depicts that ciprofloxacin HCl is tested while the applied product contains ciprofloxacin base. Clarification is required in this regard.
- Justify the manufacturing of stability batches in November 2021 while your section was approved on 10-05-2022.
- Provide stability study data in a proper sequence using separators to segregate the data of each time point and each batch along with relevant raw data sheets.
- Clarification regarding reconstitution diluent used for the product development and stability studies.
- Submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following:
    - Reference of previous approval of applications with stability study data of the firm (if any)
    - Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.
    - Documents for the procurement of API with approval from DRAP (in case of import).
    - Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
    - Compliance Record of HPLC software 21CFR & audit trail reports on product testing.
    - Record of Digital data logger for temperature and humidity monitoring of both stability chambers.

Decision of 323rd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response by the firm:

Sr. No	Reason for deferment	Response by the firm
1.	The label claim of the applied product is not line with the reference product in terms of salt form as well as an equivalency, revise the label claim along with submission of full fee of registration.	We revised the label claim as per innovator i.e. Ciprolis 250mg/5ml Dry Powder Suspension Each 1 ml suspension after reconstitution contains 50 mg ciprofloxacin Each 5 ml suspension after reconstitution (1 measuring spoon) contains 250 mg ciprofloxacin
2.	Submit data in section 3.2.S.4.1 as per guidance document approved in Registration Board which specifies that ''Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance/ Active Pharmaceutical Ingredient by both Drug Substance & Drug Product manufacturer is required.*you have only submitted the specifications of API from the drug product manufacturer.	Firm has submitted copies of the Drug substance specifications and analytical procedures from drug product manufacturer as well.
3.	Provide verification studies of drug substance from drug product manufacturer	Frim has submitted verification studies of the drug substance from drug product manufacturer
4.	Justify the assay testing of drug substance using UV method contrary to that recommended by the innovator's product.	Our API manufacturer (Vision Pharmaceuticals) have performed analytical method validation for Ciprofloxacin TM Micro pellets 35% including the parameters specificity, Accuracy and Recovery, Linearity and Range, Ruggedness, Robustness, Precision, and Repeatability. Moreover, we have also performed analytical verification of our API manufacturer, the testing method including the parameters specificity, Accuracy, and recovery, and repeatability. As the testing method (UV based) is a completely reliable and validated method. So, we used the said method for our API testing,
5.	Submit COA of relevant batch of API i.e. Lot No. CPX1279 from Vision pharmaceuticals in section 3.2.S.4.4.	Submitted by the firm
6.	Submit COA of reference standard/working standard actually used in the analysis of drug substance.	Previously, we were using reference standard/working standard of Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed: Working Standard for Ciprofloxacin Suspension Molecular weight of Ciprofloxacin HCL = 367.81 Molecular weight of Ciprofloxacin Base = 331.34 Factor= 331.34/367.81 = 0.901

		1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base We hereby confirmed that currently we are using working standard of Ciprofloxacin Base from Vision Pharma (Pvt) Limited (COA Copy attached) Moreover, we have also manufactured 3 new batches (Batch numbers: CP-13, CP-14, and CP-15) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of "0" month and accelerated stability testing of "1.5" month after reconstitution with diluent: as per innovator's specifications / dissolution parameters. Reports and stability chromatograms are provided by the firm.
7.	Justification for changed salt form in stability study data of previous batch as the stability study data of ciprofloxacin micro-pellets from Vision Pharmaceuticals initiated in 2013 and completed in 2016 in which ciprofloxacin base is mentioned, while M/s Vision pharmaceuticals was manufacturing ciprofloxacin pellets using ciprofloxacin HCL before Registration Board took the decision to revise the salt form to ciprofloxacin base in its 290th meeting which was held on 3rd-4th July, 2019.	''Vision Pharmaceuticals got registration for both Ciprofloxacin base and Ciprofloxacin HCL in 2014 and started manufacturing of Ciprofloxacin base after registration for its market demand. Later on Drug Registration Board in its 290th meeting instructed all manufacturers to manufacturer Ciprofloxacin Dry powder suspension using Ciprofloxacin Base. As Vision Pharma was already manufacturing Ciprofloxacin Base. Therefore, Ciprofloxacin base is mentioned in given stability study data which was used in our product development'' Registration Certificated and stability study reports of most recent batch are enclosed for your reference.
8.	Justify the use of sugar and poly Succar ultra DM as sweetner while you are already used taste masked granules in your formulation.	Coating material of granules is not enough to mask the bitterness of ciprofloxacin completely. As suspension form is developed for children; therefore, it is necessary to mask the bitterness as well as to produce a sweet taste to make it palatable. As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are **inert**, and are compatible with active pharmaceutical ingredient of CIPROLIS 250/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
9.	Justify the for use of Xanthan gum as suspending agent along with the granules in the formulation while reference product contain no suspending agent.	The coating material used in the granulation of Ciprofloxacin is not enough to suspend the active ingredient in the product when reconstituted, therefore we used Xanthan Gum for equal dispersion of active material after reconstitution to avoid unequal dose.

		As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 250/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
10.	Justify for how 142.857mg/ml of ciprofloxacin granules is equivalent to 50mg Ciprofloxacin base per ml.	We are using 35% TM Pellets which mean: 100mg of pellets contains 35mg of Ciprofloxacin base 1mg pellets = 35/100 = 0.35mg of ciprofloxacin base 142.857 mg pellets = 50mg of Ciprofloxacin Base Therefore, it is justified that 142.857 mg/ml of ciprofloxacin granules is equivalent to 50mg of ciprofloxacin base per ml.
11.	Justification for use of sodium benzoate anhydrous in formulation while the pH is already controlled by the drug substance manufacturer at pellets stage and pH in COA of drug substance. Furthermore, the reference product contains oil based diluent for which pH test is not required to be controlled.	As product has to keep for five days after reconstitution, we used Sodium Benzoate as antifungal preservative in the product to avoid any contamination in the liquid form As per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 250/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. Moreover, it is remarkable that we have developed the diluent as per 290th & 313 minutes of meeting of Drug Registration Board/Innovators formulation, kept it on stability and after reconstitution it was observed that our pH is stable as per the prescribed range which is 7.0-9.5%
12.	Justify the use of citric acid in formulation as buffering agent which is not used by the reference product and the reference product contains oil based diluent for which pH is not required to be controlled.	Citric acid was used in the formulation as buffering agent to maintain the pH range 7.0-9.5. We have performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability (Reports are attached). It is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Ciprolis 250mg/5ml suspension. Moreover it is remarkable that we have developed the diluent as per 290th & 313 minutes of meeting of Drug Registration Board/Innovators formulation, kept it on stability and after reconstitution it was observed that our pH is stable as per the prescribed range which is 7.0-9.5%
13.	Justify the use of flavor in formulation while you are already used taste masked granules.	Taste masking ingredients don't impart any flavor, they are used just to mask the bitterness,

		Moreover, use of flavor makes the product more palatable. Whereas, as per literature review and study of Hand Book for Pharmaceutical Excipients , it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 250/5ML Dry Powder suspension. Their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
14.	Justify the use of aerosil in formulation.	As aerosil is glidant which is used as anti-caking agent in dry powder suspension. Aerosil keep the granules in free-flowing form throughout its shelf life. This is an inert material which doesn't impart any change in our formulation. Whereas, as per literature review and study of Hand Book for Pharmaceutical Excipients , it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of CIPROLIS 250/5ML Dry Powder suspension. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
15.	Provide details about the diluent which is to be used with the applied product in section 3.2.P.1	We have developed a diluent as per 290th & 313 minutes of meeting of Drug Registration Board; truly according to Innovators composition; which is as followed; 1. Sugar 2.5 gm (1%) 2. Sodium Benzoate 250mg (0.001%) 3. Soya Lecithin Powder 250mg (0.001%) 4. Triglyceride 250mg (0.001%) Procedure: Heat the water upto 60℃ and add the sugar with continuous stirring until sugar is dissolved Cook the above solution till boiled to prepare the sugar solution till boiled to prepared the sugar solution, then off the flame. Add Soya Lecithin powder in above solution and stir for 30 minutes Add triglyceride in step 4 and stir for one hour Firm has Liquid Syrup (General) section in which this diluent was manufactured.

16.	Provide Complete module 3.2.P for the diluent which will be used in the administration of the applied product as per the decision of 290th and 313th meeting of Registration Board.	We have developed a diluent after receiving deficiency letter of Ciprolis 250mg/5ml Dry Powder Suspension on 22nd November 2022 as per 290th & 313th minutes of the meeting of Drug Registration Board; truly according to Innovators composition along with 3 new batches of Ciprolis 250mg/5ml Dry Powder Suspension (Batch numbers: CP-13, CP-14 and CP-15) for performance of stability studies. We have performed complete stability testing of "0" month and accelerated stability testing of "1.5" month on these 3 new batches as per innovator's specifications / dissolution parameters. Results are complying with innovator's specifications. Moreover, we have also performed long-run stability testing of 12th month of previous batches (Batch numbers: CP-06, CP-07, and CP-08) after reconstitution with the diluent as per innovator's specifications / dissolution parameters and results are complying with innovator's specifications. Complete BMRs of new batches along with diluent, complete testing along with COA and stability study Reports and chromatograms are provided by the firm.
17.	Justify why the qualitative composition of applied product is different from that of innovator's product.	All the excipients used in our formulation are inert and compatible. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. We have also performed Drug Excipients Compatibility studies concluded that all the excipients are inert and has no harsh effect on product stability.
18.	Justify why the pharmaceutical equivalence studies are not conducted against the innovator's product	We have performed Pharmaceutical equivalence studies of Ciprolis (Ciprofloxacin) 250mg/5ml Suspension against the reference product Novidat Dry Powder Suspension 250mg/5ml manufactured by Sami Pharmaceuticals As the innovator product is not available in Pakistan therefore, pharmaceutical equivalence of Ciprolis (Ciprofloxacin) 250mg/5ml Suspension was performed against the reference product Novidat Dry Powder Suspension 250mg/5ml manufactured by Sami Pharmaceuticals.
19.	Provide Microbial attributes of applied Drug product in section 3.2.P.2.5	Submitted by the firm
20.	Submit Preservative effectiveness studies in section 3.2.P.2.5.	Submitted by the firm
21.	Submit Compatibility study of applied product along with recommended diluent.	Submitted by the firm
22.	Justify the pH test in your specification since no such test is recommended in USP monograph.	We are performing all the test as per USP monograph and truly followed USP monograph

		However, we are also performing additional test for pH as a quality attributes in order to be more stringent
23.	Justify why Microbial Enumeration Tests is not mentioned in specification while it is recommended by USP	We have revised our method and test for Microbial Enumeration has been performed as recommended by USP (COA and revised method are enclosed) We have performed our finished product method as per USP which covers Microbial Enumeration Test Moreover, we have also performed Microbial Preservative test, which shows that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Ciprolis 250mg/5ml. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies. Complete method and Microbial Preservative test are provided by the firm.
24.	Justify the analytical method of assay and dissolution test in which initial reconstitution with water is mentioned while USP recommends to use the particular diluent for this purpose. Justify how your analytical method complies USP monograph.	We have developed a diluent as per 290th & 313 minutes of meeting of Drug Registration Board; which is truly according to Innovators composition and performed finished product test as per USP method after reconstitution with diluent and found that results are fully comply with USP requirements (Revised method of analysis and finished product COA after reconstitution with diluent are attached) Stability studies of CIPROLIS 250MG/5ML after reconstitution with diluent are also provided by the firm.
25.	Justify why the identification test using diode array detector is not performed and mentioned in analytical method.	Sample and standard were analyzed under same chromatographic conditions and found that the results were closely comparable. It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.
26.	Justify why you are using different column in assay test as that recommended by USP	The column used for analysis of Ciprofloxacin suspension have chemically same specification i.e. packing L1 with same particle size, the difference is only the length of column, USP require 15cm while we are using 25cm, remaining specifications are same as USP requirements. Sample and standard were analyzed under same chromatographic conditions and found that the results were closely comparable. It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above

<table>
<tr><td></td><td></td><td>said validation parameters complied with the Relative Standard Deviation limits.
Column oven invoice along with specifications is provided by the firm.</td></tr>
<tr><td>27.</td><td>Submit evidence of diode array detector which is required for identification test as per USP monograph.</td><td>Sample and standard were analyzed under same chromatographic conditions found that the results were closely comparable.
It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.</td></tr>
<tr><td>28.</td><td>Submit evidence of column oven which is required to maintain column temperature t 40℃ and 30℃ for assay and dissolution test.</td><td>Sample and standard were analyzed under same chromatographic conditions (including the same injection volume) and found that the results were closely comparable.
It is remarkable that we have performed analytical method validation in which we did extensive testing taking different concentrations under heading of Limit of Detection, Limit of Quantification, Linearity, Accuracy and Recovery. Results of above said validation parameters complied with the Relative Standard Deviation limits.
Moreover, we have capacity to maintain column temperature t 40℃ and 30℃ for assay and dissolution test
Column oven invoice along with specifications is provided by the firm.</td></tr>
<tr><td>29.</td><td>Submit evidence of auto sampler with HPLC having capacity to maintain 10° which is required to perform assay and dissolution test as per USP monograph.</td><td>We don’t have auto sampler with HPLC but still we have capacity to maintain 10* which is required to perform assay and dissolution test as per USP monograph.</td></tr>
<tr><td>30.</td><td>Details about the exact concentrations of the solutions and its preparation method which are used for perform accuracy, and precision studies in analytical method verification studies.</td><td>The exact concentrations of the solutions and its preparation method is as followed:
Specificity
Concentration:
<table>
<tr><td>Standard</td><td>Sample</td></tr>
<tr><td>0.1mg/ml</td><td>0.1mg/ml</td></tr>
<tr><td>0.01%</td><td>0.01%</td></tr>
</table>
Method to prepare analytical solution:
➢ Standard
Weight taken:250gm ➔ 25ml diluent
5ml ➔ 50ml mobile phase
➢ Sample
Weight taken: 5.5250gm ➔ 100ml diluent
5ml ➔ 50ml mobile phase
Repeatability
Concentration:
<table>
<tr><td>Standard</td><td>Sample</td></tr>
<tr><td>0.1mg/ml</td><td>0.1mg/ml</td></tr>
<tr><td>0.01%</td><td>0.01%</td></tr>
</table>
Method to prepare analytical solution:
➢ Standard
Weight taken: 250gm ➔ 25ml diluent
5ml ➔ 50ml mobile phase</td></tr>
</table>

		➢ Sample Weight taken: 5.5250gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase Accuracy For 100% Concentration: Standard: 0.1mg/ml, 0.01% Sample: 0.1mg/ml, 0.01% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 5.5250gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase For 75% Concentration: Standard: 0.1mg/ml, 0.01% Sample: 0.075mg/ml, 0.0075% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 4.144gm ➔ 100ml diluent 5ml ➔ 50ml mobile phase For 50% Concentration: Standard: 0.1mg/ml, 0.01% Sample: 0.05mg/ml, 0.005% Method to prepare analytical solution: ➢ Standard Weight taken: 250gm ➔ 25ml diluent 5ml ➔ 50ml mobile phase ➢ Sample Weight taken: 2.625gm ➔ 100ml diluent 5ml ➔ 50ml mobile phas Detailed analytical method is provided by the firm.
31.	Justify how you are using Ciprofloxacin HCl Manufactured by Shangyu Jingxin Pharmaceuticals for the testing of your product.	Previously, we were using Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed: Working Standard for Ciprofloxacin Suspension Molecular weight of Ciprofloxacin HCL = 367.81 Molecular weight of Ciprofloxacin Base = 331.34 Factor= 331.34/367.81 = 0.901 1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base

<table>
<tr><td></td><td></td><td>We hereby confirmed that currently we are using Ciprofloxacin Base from Vision Pharma (Pvt) Limited (COA Copy attached)
Moreover, we have also manufactured 3 new batches (Batch numbers: CP-13, CP-14, and CP-15) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of “0” month and accelerated stability testing of “1.5” month after reconstitution with diluent: as per innovator’s specifications / dissolution parameters.
Reports and stability chromatograms are provided by the firm.</td></tr>
<tr><td>32.</td><td>The stability chromatograms for assay testing depicts that ciprofloxacin HCl is tested while the applied product contains ciprofloxacin base. Clarification is required in this regard.</td><td>Previously, we were using Ciprofloxacin HCL manufactured by Shangyu Jingxin pharmaceuticals for the testing of our product by applying correction factor, the calculation is as followed:
Working Standard for Ciprofloxacin Suspension
Molecular weight of Ciprofloxacin HCL = 367.81
Molecular weight of Ciprofloxacin Base = 331.34
Factor= 331.34/367.81 = 0.901
1mg of Ciprofloxacin HCL is equivalent to 0.901mg of ciprofloxacin base
We hereby confirmed that currently we are using Ciprofloxacin Base from Vision Pharma (Pvt) Limited.
Moreover, we have also manufactured 3 new batches (Batch numbers: CP-13, CP-14, and CP-15) along with diluent and performed all the analysis by using the working standard of ciprofloxacin base (by Vision Pharmaceuticals (Pvt) Ltd, Batch no 200973). We have performed complete stability testing of “0” month and accelerated stability testing of “1.5” month after reconstitution with diluent: as per innovator’s specifications / dissolution parameters.
Reports and stability chromatograms are provided by the firm.</td></tr>
<tr><td>33.</td><td>Justify the manufacturing of stability batches in November 2021 while your section was approved on 10-05-2022</td><td>Development of Trial Batches of Ciprolis 250mg/5ml suspension was performed in our product development (R & D) section.
Our R&D Lab has been inspected/ endorsed by the DRAP Panel of Inspectors; with following remarks
<table><tr><th>Q #</th><th>Question</th><th>OBSERVATION BY PANEL</th></tr><tr><td>17.</td><td>Do You have Product development (R&D) Section?</td><td>Yes, The Firm has product development (R&D) section for product development, manufacturing &</td></tr></table></td></tr>
</table>

		testing facility for trial Batches.

The above stated report was based on PSI conducted for Delanso Capsule where the inspection was carried out on 02-05-2019 and the PSI report was discussed in the Board in 289th meeting.

34.	Provide stability study data in a proper sequence using separators along with relevant raw data sheet	Firm has submitted data with proper sequence
35.	Stability study data in section 3.2.P.8.3 as per the checklist approved by registration Board in its 296th meeting and the CTD guidance document, which includes the following; Reference of previous approval of applications with stability study data of the firm (if any) Approval of API/DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin. Documents for the procurement of API with the approval from DRAP (in case of import) Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc. Compliance Record of HPLC software 21CFR & audit trail reports on product testing Record of digital data logger for temperature and humidity monitoring of both stability chamber	Firm has submitted data as per checklist

Decision of 324th meeting: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufcaturer shall declare the shelf life of the diluent, to be used with commercial batches.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 30,000/- for submission of revised stability studies data, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**
- **Accelerated and long term stability studies data till third month time point of newl manufactured stability batches i.e., (Batch numbers: CP-13, CP-14, and CP-15) as per USP monograph along with in-use stability data with the reconstituioton diluent as recommended by Innovator.**

Case No. 03 Registration applications of Form 5F cases

a. New cases of local manufacturing

75.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Gray's Pharmaceutical Plot # 2, Street # N-3, National Industrial Zone, Rawat Islamabad**
	Name, address of Manufacturing site.	M/s Gray's Pharmaceutical Plot # 2, Street # N-3, National Industrial Zone, Rawat Islamabad
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of issued on the basis of inspection dated 05-05-2017.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of issuance of Drug Manufacturing License of M/s Gray's Pharmaceuticals dated 22-06-2011 specifying Dry powder injection (Ceph) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 26125: 21-09-2021
	Details of fee submitted	PKR 30,000/-: 12-07-2021
	The proposed proprietary name / brand name	**Nezone Injection 2g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone sodium eq. to Ceftriaxone… 2g
	Pharmaceutical form of applied drug	Almost white to off white colored powder filled in glass vial.
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA approved
	For generic drugs (me-too status)	Oxidil Injection by Sami
	Name and address of API manufacturer.	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications,

		analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Cefxone 2g Injection by Bosch Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.		
API Lot No.	0151NJ81HE		
Description of Pack (Container closure system)	Glass vials		
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	TDI001	TDI002	TDI003
Batch Size	2000 Vials	2000 Vials	2000 Vials
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	25-02-2021	26-02-2021	26-02-2021

No. of Batches		03
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. SD20170590) issued by China Food and Drug Administration, valid till 30-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 09-02-2021 specifying import of 20Kg ceftriaxone. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

- Capacity assessment of the firm was conducted by the panel on 31-10-2022 wherein panel concluded that firm has sufficient manufvaturing capacity for manufacturing of Dry powder injection (Cephalosporin), Dry powder for suspension (Cephalosporin) & Capsule (Cephalosporin).
- Firm has not performed pharmaceutical equivalence studies against the innovator's / reference product since it is not registered in Pakistan..

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

76.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Leama Chemi Pharma Pvt Ltd. 37-A, Hayatabad Industrial Estate, Peshawar**
	Name, address of Manufacturing site.	M/s Gray's Pharmaceutical Plot # 2, Street # N-3, National Industrial Zone, Rawat Islamabad
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of issued on the basis of inspection dated 05-05-2017.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of issuance of Drug Manufacturing License of M/s Gray's Pharmaceuticals dated 22-06-2011 specifying Dry powder injection (Ceph) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 26129: 21-09-2021
	Details of fee submitted	PKR 75,000/-: 13-07-2021
	The proposed proprietary name / brand name	**Limaxone Injection 2g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone sodium eq. to Ceftriaxone… 2g
	Pharmaceutical form of applied drug	Almost white to off white colored powder filled in glass vial.
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA approved
	For generic drugs (me-too status)	Oxidil Injection by Sami
	Name and address of API manufacturer.	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard

		or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Cefxone 2g Injection by Bosch Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.		
API Lot No.	0151NJ81HE		
Description of Pack (Container closure system)	Glass vials		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 35% RH Accelerated: 40˚C ± 2˚C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	TDI001	TDI002	TDI003
Batch Size	2000 Vials	2000 Vials	2000 Vials
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	25-02-2021	26-02-2021	26-02-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. SD20170590) issued by China Food and Drug Administration, valid till 30-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 09-02-2021 specifying import of 20Kg ceftriaxone. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

- Capacity assessment of the firm was conducted by the panel on 31-10-2022 wherein panel concluded that firm has sufficient manufvaturing capacity for manufacturing of Dry powder injection (Cephalosporin), Dry powder for suspension (Cephalosporin) & Capsule (Cephalosporin).
- Firm has not performed pharmaceutical equivalence studies against the innovator's / reference product since it is not registered in Pakistan..

Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
77.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Alliance Pharmaceutical Pvt Ltd. 112 A, Hayatabad Industrial Estate, Peshawar**
	Name, address of Manufacturing site.	M/s Gray's Pharmaceutical Plot # 2, Street # N-3, National Industrial Zone, Rawat Islamabad
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of issued on the basis of inspection dated 05-05-2017.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of issuance of Drug Manufacturing License of M/s Gray's Pharmaceuticals dated 22-06-2011 specifying Dry powder injection (Ceph) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 26134: 21-09-2021
	Details of fee submitted	PKR 75,000/-: 29-06-2021
	The proposed proprietary name / brand name	**Rocexon Injection 2g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone sodium eq. to Ceftriaxone… 2g
	Pharmaceutical form of applied drug	Almost white to off white colored powder filled in glass vial.
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA approved
	For generic drugs (me-too status)	Oxidil Injection by Sami
	Name and address of API manufacturer.	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Cefxone 2g Injection by Bosch Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.		
API Lot No.	0151NJ81HE		
Description of Pack (Container closure system)	Glass vials		
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	TDI001	TDI002	TDI003
Batch Size	2000 Vials	2000 Vials	2000 Vials
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	25-02-2021	26-02-2021	26-02-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. SD20170590) issued by China Food and Drug Administration, valid till 30-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 09-02-2021 specifying import of 20Kg ceftriaxone. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

- Capacity assessment of the firm was conducted by the panel on 31-10-2022 wherein panel concluded that firm has sufficient manufvaturing capacity for manufacturing of Dry powder injection (Cephalosporin), Dry powder for suspension (Cephalosporin) & Capsule (Cephalosporin).
- Firm has not performed pharmaceutical equivalence studies against the innovator's / reference product since it is not registered in Pakistan..

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

78.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Akson Pharmaceuticals Pvt Ltd. Plot No.9-B/1 & 2, Sector D-1,Old industrial Estate Mirpur Azad Kashmir**
	Name, address of Manufacturing site.	M/s Gray's Pharmaceutical Plot # 2, Street # N-3, National Industrial Zone, Rawat Islamabad
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of issued on the basis of inspection dated 05-05-2017.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of issuance of Drug Manufacturing License of M/s Gray's Pharmaceuticals dated 22-06-2011 specifying Dry powder injection (Ceph) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 26136: 21-09-2021
	Details of fee submitted	PKR 75,000/-: 29-06-2021
	The proposed proprietary name / brand name	**Trophin Injection 2g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone sodium eq. to Ceftriaxone… 2g
	Pharmaceutical form of applied drug	Almost white to off white colored powder filled in glass vial.
	Pharmacotherapeutic Group of (API)	Antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA approved
	For generic drugs (me-too status)	Oxidil Injection by Sami
	Name and address of API manufacturer.	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard

		or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Cefxone 2g Injection by Bosch Pharmaceuticals.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	M/s. Qilu Antibiotics Pharmaceutical CO. Ltd. No. 849 Dongjia Town Licheng District Jinan Shanding Province China.		
API Lot No.	0151NJ81HE		
Description of Pack (Container closure system)	Glass vials		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 35% RH Accelerated: 40˚C ± 2˚C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	TDI001	TDI002	TDI003
Batch Size	2000 Vials	2000 Vials	2000 Vials
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	25-02-2021	26-02-2021	26-02-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. SD20170590) issued by China Food and Drug Administration, valid till 30-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 09-02-2021 specifying import of 20Kg ceftriaxone. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC[3]:

- Capacity assessment of the firm was conducted by the panel on 31-10-2022 wherein panel concluded that firm has sufficient manufvaturing capacity for manufacturing of Dry powder injection (Cephalosporin), Dry powder for suspension (Cephalosporin) & Capsule (Cephalosporin).
- Firm has not performed pharmaceutical equivalence studies against the innovator's / reference product since it is not registered in Pakistan..

Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
79.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Genetics Pharmaceuticals (Private) Limited** **539-A Sunder Industrial Estate, Lahore Pakistan**
	Name, address of Manufacturing site.	M/s Cunningham Pharmaceuticals (Pvt.) Limited, Plot No. 81- Sundar Industrial Estate, Raiwind road, Lahore
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 25692 dated 15-09-2021
	Details of fee submitted	PKR 75,000/-: dated 08-06-2021
	The proposed proprietary name / brand name	GENXONE Dry Powder Injection 500mg (IM)
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Ceftriaxone (as Sodium)…….500mg
	Pharmaceutical form of applied drug	white to yellowish orange crystalline powder for solution for injection
	Pharmacotherapeutic Group of (API)	Semi- synthetic Broad spectrum Antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's (1 vial)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	ROCEPHIN 5OOmg IM Injection F-Hoffmann-La Roche Ltd. Basel, Switzerland
	For generic drugs (me-too status)	CEFZONE Injection 500mg by M/s Bosch Pharmaceuticals (Pvt.) Ltd. Reg. No. 017656
	GMP status of the Finished product manufacturer	01-04-2019
	Name and address of API manufacturer.	M/s Zhuhai United Laboratories Trading Company Limited. (No.2428 Anji Road, Sanzao Town, Jinwan District, Zhuhai, Guangdong-519090, P.R. China).
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container

		closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ceftriaxone as Sodium is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (180004, 180019, 180040)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is ROCEPHIN 500mg Injection by Bosch Pharmaceuticals (Pvt.) Ltd. by performing quality tests (Identification, Assay by HPLC, Average Weight, Weight Variation, Particulate matter in injection, Water Content, pH , Endotoxin Test, Sterility Test).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificty.

STABILITY STUDY DATA

Manufacturer of API	Zhuhai United Laboratories Trading Company Limited. (No.2428 Anji Road, Sanzao Town, Jinwan District, Zhuhai, Guangdong-519090, P.R. China).		
API Lot No.	3051807878		
Description of Pack (Container closure system)	Clear Glass vial with rubber stopper having pilfered proof aluminium seal and orange plastic top Packed in unit Carton with 2ml Lidocaine HCl.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 3, 6 (Months) Real Time: 0, 1, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	180076	180088	180090
Batch Size	16666 vials	16666 vials	16666 vials

Manufacturing Date	11-2018	12-2018	12-2018
Date of Initiation	23-11-2018	24-12-2018	24-12-2018
No. of Batches	03		

Administrative Portion

13.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
14.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. GD20180909) issued by CFDA China. The certificate is valid till 05-12-2023
15.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 15-10-2018 vide dy. No. 13295/2018-DRAP specifying import of 96Kg ceftriaxone sodium sterile (USP). The invoice is cleared by AD (I&E) DRAP.
16.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
17.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their HPLC system is not 21 CFR compliant.
18.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC[3]:

Submit module 1 as per the CTD guidance document approved by Registration Board by providing all the information and documents in relevant sections / sub-sections instead of referring to annexures.	Module I is submitted as per CTD guidance document.
Submit data in section 3.2.S.4.1 and 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."	Copies of the drug substance specifications and analytical procedures used for routine testing of drug substance by both drug product and drug substance manufacturer in the relevant sections as per guidance document for Form 5F.
Provide details of the analytical method and concentrations in terms of mg/ml used to test the parameters in verification / validation studies of the drug substance. Further justify significant difference in peak areas value at same concentration during different tests like precision and accuracy/linearity.	The firm has submitted analytical method verification studies (including specificity, precision and accuracy etc) with the detail of concentrations of different dilutions used to test the parameters of required studies.
Justify why the test of specificity is not performed during the verification / validation studies of the drug substance.	The firm has submitted analytical method verification report mentioning the results of the test for specificity parameter for analytical method verification studies for dug substance performed by drug product manufacturer.
Submit COA of reference standard actually used in the analysis of drug substance in section 3.2.S.5.	Certificate of analysis of reference standard actually used in the development of the applied product is provided.
Justify how compatibility studies of IV injection can be used for ceftriaxone IM injection as well	The firm has submitted compatibility studies for 500mg IM injection with the recommended diluent. The data is presented in the relevant section (0H, 4H, 8H & 16H).

Provide details of sample solution 2 preparation i.e. exact volume of water required for initial constitution of the ceftriaxone for injection.	Detail of preparation of sample solution II is provided in the relevant section which is in-lined with USP for 500mg IM injection.
Your analytical method for drug product specifies two different sample solutions as well as two different analysis, calculation formula and acceptance criteria as per USP monograph, while your specifications does not specify two different tests and acceptance criteria for assay and you have released your batches with only 1 type of assay results. Justify why your specifications, analytical method and practices of batch release are not aligned with USP monograph recommendations.	Specifications of finished product has been revised with addition of acceptance criteria for assay as per USP monograph. Revised specifications are submitted which are in-lined with USP. The firm has stated that they have performed one test at the stage of drug substance analysis and the other test is performed at the drug product stage. "*as we are dealing with the toll manufacturing in order for better understanding on COA we opted the 90-115% assay specifications. However, we have revised the SOP along with the specifications and would update and align all the practices and documents".*
Justify how you are releasing commercial batches of ceftriaxone 500mg IM and IV as a single batch by producing two COA having exactly same results for each test.	The firm has submitted separate COAs for 500mg IM injection. Certificate of Analysis of finished products are also attached in executed BMRS of three batches enclosed in module 3 section 3.2.R.
Justify how single BMR can be used for a single batch of two separately registered products like ceftriaxone 500mg IM and 500mg IV Injection.	Separate BMRs for 500mg ceftriaxone IM injection is submitted in section 3.2.R.1.2 along with the blank template of BM. The firm has submitted that the BMR were placed in 500mg IM injection mistakenly in the dossier on 500mg IV injection.
Submit product development and stability study data of 3 batches of ceftriaxone 250mg IM injection for further evaluation.	The firm has submitted product development and stability study data of 3 batches of Ceftriaxone 500mg IM Injection along with the raw data sheets chromatograms, COAs etc.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

80.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Rogen Pharmaceuticals Plot No. 30, Street # S-4, National Industrial Zone, Rawat, Islamabad**
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	**Global pharmaceuticals:** Firm has submitted copy of GMP certificate dated 04-01-2022 issued on the basis of inspection dated 03-01-2022.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of Grant of additional section / amendment under DML No 000417 of M/s Global Pharmaceuticals Islamabad dated 18-12-2017 specifying reallocation of dry powder injection (carbapenem) section is place of withdrawn Biotech section (BSF)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29915: 09-11-2020
	Details of fee submitted	PKR 50,000/-: 02-01-2020
	The proposed proprietary name / brand name	**G-Perium Injection 500mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Meropenem trihydrate eq to meropenem……500mg
	Pharmaceutical form of applied drug	White to off white powder filled in clear glass vials with sea green color flip off seal along with 10ml WFI ampoule.
	Pharmacotherapeutic Group of (API)	Carbapenem antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Merrem Injection **(USFDA** Approved)
	For generic drugs (me-too status)	Merrem Injection of Global Pharmaceuticals
	Name and address of API manufacturer.	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture,

		manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against Merrem 500mg Injection manufactured by Boehringer Ingelheim.
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.		
API Lot No.	682107003		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	22A169	22A363	22A364
Batch Size	7418 vials	7418 vials	7418 vials
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	25-01-2022	25-01-2022	25-01-2022
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has referred to previous inspection of stability data of the same dosage form on the basis of which Registration Board in 289th meeting decided to approve registration of Promig Plus 500mg/20mg Tablet and Promig Plus 375mg/20mg Tablet. Inspection date: 14th March, 2019 The report shows that: • The HPLC software is 21 CFR compliant. • The firm has provided data loggers with stability chambers.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. HE20180065) issued by China Food and Drugs Administration dated 17-08-2018. The certificate is valid till 16-08-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 13-09-2021 specifying import of 200Kg Meropenem for Batch No. 682107002 and

		682107003. The commercial invoice is attested by AD (I&E) DRAP field office.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail record of product testing of HPLC for all test intervals.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC[3]:

- Firm has initially submitted stability data of batches manufactured using drug substance from M/s Sterile India Pvt Ltd. Plot No. 100& 118-G, Phase-IV, Sector-56, HSIIDC, Industrial Estate Kundli District Sonepat Haryana India. Later on the firm revised the stability data as well as source of API without submission of fee.
- The applied formulation to be manufactured by M/s Global Pharmaceuticals, Islamabad have already been granted approval by Registration Board in its 320th meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already considered product in 320th meeting are as follows:

Applicant firm	M/s Reliance Pharma. Plot No 8, Street No. S-8, Industrial Estate, Rawat, Islamabad
Manufacturer firm	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
Brand Name	RELEM 500mg Injection
Batch No. of drug product	22A169, 22A363, 22A364
Case No.	201
Registration Board meeting	320th meeting of Registration Board

Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for revision of source of drug substance, as per Notification No. 7-11/2012-B&A dated 07.05.2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".**
- **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**

81.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Rogen Pharmaceuticals Plot No. 30, Street # S-4, National Industrial Zone, Rawat, Islamabad**
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	**Global pharmaceuticals:** Firm has submitted copy of GMP certificate dated 04-01-2022 issued on the basis of inspection dated 03-01-2022.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of Grant of additional section / amendment under DML No

		000417 of M/s Global Pharmaceuticals Islamabad dated 18-12-2017 specifying reallocation of dry powder injection (carbapenem) section is place of withdrawn Biotech section (BSF)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29916: 09-11-2020
	Details of fee submitted	PKR 50,000/-: 02-01-2020
	The proposed proprietary name / brand name	**G-Perium Injection 1g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Meropenem trihydrate eq to meropenem……1g
	Pharmaceutical form of applied drug	White to off white powder filled in clear glass vials with brown color flip off seal along with 20ml WFI ampoule.
	Pharmacotherapeutic Group of (API)	Carbapenem antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Merrem Injection **(USFDA** Approved)
	For generic drugs (me-too status)	Merrem Injection of Global Pharmaceuticals
	Name and address of API manufacturer.	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ±

		5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against Merrem 500mg Injection manufactured by Boehringer Ingelheim.
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.		
API Lot No.	682107003		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	22A335	21M270	21M271
Batch Size	3709 vials	3709 vials	3709 vials
Manufacturing Date	01-2022	12-2021	12-2021
Date of Initiation	10-01-2022	30-12-2021	30-12-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has referred to previous inspection of stability data of the same dosage form on the basis of which Registration Board in 289th meeting decided to approve registration of Promig Plus 500mg/20mg Tablet and Promig Plus 375mg/20mg Tablet. Inspection date: 14th March, 2019 The report shows that: • The HPLC software is 21 CFR compliant. • The firm has provided data loggers with stability chambers.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. HE20180065) issued by China Food and Drugs Administration dated 17-08-2018. The certificate is valid till 16-08-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice cleared dated 13-09-2021 specifying import of 200Kg Meropenem for Batch No. 682107002 and 682107003. The commercial invoice is attested by AD (I&E) DRAP field office.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail record of product testing of HPLC for all test intervals.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC[3]:

- Firm has initially submitted stability data of batches manufactured using drug substance from M/s Sterile India Pvt Ltd. Plot No. 100& 118-G, Phase-IV, Sector-56, HSIIDC, Industrial Estate Kundli District Sonepat Haryana India. Later on the firm revised the stability data as well as source of API without submission of fee.
- The applied formulation to be manufactured by M/s Global Pharmaceuticals, Islamabad have already been granted approval by Registration Board in its 320th meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already considered product in 320th meeting are as follows:

Applicant firm	M/s Reliance Pharma. Plot No 8, Street No. S-8, Industrial Estate, Rawat, Islamabad
Manufacturer firm	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
Brand Name	RELEM 1g Injection
Batch No. of drug product	22A335, 21M270, 21M271
Case No.	202
Registration Board meeting	320th meeting of Registration Board

Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for revision of source of drug substance, as per Notification No. 7-11/2012-B&A dated 07.05.2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".**
- **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**

b. Deferred cases of local manufacturing

82.	Name, address of Applicant / Marketing Authorization Holder	M/s SAMI Pharmaceuticals (Pvt) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.
	Name, address of Manufacturing site.	M/s SAMI Pharmaceuticals (Pvt) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.

	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate of the firm issued dated 11-08-2020 based on the inspection dated 28-08-2019.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of regularization of existing facility under DML number 000072 of M/s Sami Pharma which specifies Tablet (General / General antibiotic) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 4785: 21-02-2022
	Details of fee submitted	PKR 75,000/-: 17-02-2022
	The proposed proprietary name / brand name	**PROVAS ACTIFAST 500mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Paracetamol ……500mg
	Pharmaceutical form of applied drug	White to off-white coated oblong shaped film coated tablet plain from both sides
	Pharmacotherapeutic Group of (API)	NSAID
	Reference to Finished product specifications	USP
	Proposed Pack size	10’s, 20’s, 30’s, 50’s and 100’s.
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Panadol ActiFast 500mg Tablet by GlaxoSmithKline Consumer Healthcare (**MHRA** Approved)
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	Hebei Jiheng (Group) Pharmaceutical Co. Ltd. Shenzhou Plant Southeast Xijingming Village Donganzhuang Township, Shenzhou County Henshui City, Hebei Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40ºC ± 2ºC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30ºC ± 2ºC / 75% ± 5% RH for 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the reference product i.e. PANADOL Actifast tablet of GSK Ireland. Firm has submitted results of CDP in three dissolution medium for their product against the reference product i.e. PANADOL Actifast tablet of GSK Ireland.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	Hebei Jiheng (Group) Pharmaceutical Co. Ltd. Shenzhou Plant Southeast Xijingming Village Donganzhuang Township, Shenzhou County Henshui City, Hebei Province, China.		
API Lot No.	31709016		
Description of Pack (Container closure system)	Alu-PVC blister		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Lab-01	Lab-02	Lab-03
Batch Size	1000 Tablet	1000 Tablet	1000 Tablet
Manufacturing Date	11-2020	11-2020	11-2020
Date of Initiation	21-12-2020	21-12-2020	21-12-2020
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted reference of last onsite panel inspection for instant dosage form conducted during last two years i.e. EMPOLI (Empagliflozin) 10mg & 25mg Tablets which was presented in 290th meeting of the registration board & hence approved & registered by registration board Date of inspection: 13th June 2019. The inspection report confirms following points • The HPLC software is 21CFR Compliant. • Audit trail on the testing reports is available.

		• Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. HE20180054 issued by China Food And Drug Administration valid till 08/07/2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice (Invoice# 1708ZP03 dated 19th October 2017 with received quantity i.e. 5000 kgs) for the purchase of Paracetamol from M/s Hebei Jiheng Shenzhou Pharmaceutical Co., Ltd. China with attestation of DRAP dated 01-11-2017
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete analytical record of product testing of all batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail record of product testing of HPLC for all test intervals.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC:

- Qualitative composition is different from the reference product, since reference product has not used potassium sorbate and pregelatinized starch.
- Justify the use of preservative i.e. potassium sorbate in the applied formulation as tablet.
- Dissolution acceptance in USP is NLT 80% in 30 minutes while the firm has set acceptance criteria NLT 80% in 10 minutes.
- Disintegration test acceptance criteria is NMT 30 minutes, while dissolution criteria is NLT 80% in 10 minutes.

Decision of 320th meeting of Registration Board:

Deferred for the following;

- Qualitative composition is different from the reference product, since reference product has not used potassium sorbate and pregelatinized starch.
- Justify the use of preservative i.e. potassium sorbate in the applied formulation as tablet.
- Dissolution acceptance in USP is NLT 80% in 30 minutes while the firm has set acceptance criteria NLT 80% in 10 minutes.
- Disintegration test acceptance criteria is NMT 30 minutes, while dissolution criteria is NLT 80% in 10 minutes.

Response by the firm:

Firm vide its letter dated 13-09-2022 has submitted a request as follows:
Kindly note that we applied the dossier initially with the brand name of PROVAS ACTIFAST which was later on changed to PROVAS FASTIV vide our letter dated 03-05-2022.

Sr. No	Reason for deferment	Response by the firm
1.	Qualitative composition is different from the reference product, since reference product has not used potassium sorbate and pregelatinized starch.	We have used potassium sorbate and pregelatinized starch same as of innovator formulation. Firm has also submitted PIL of Panadol Actifast Tablets manufactured by GSK Ireland. However we have already submitted API-Excipient compatibility in our dossier for difference in other excipients, API –Excipient compatibility studies attached
2.	Justify the use of preservative i.e. potassium sorbate in the applied formulation as tablet.	We have used potassium sorbate in our formulation same as of innovator formulation
3.	Dissolution acceptance in USP is NLT 80% in 30 minutes while the firm has set acceptance criteria NLT 80% in 10 minutes.	With reference to our letter dated 22nd August 2022 is attached, we have revised our specifications from USP to Innovator's. Our specifications confirms to the Innovator's

		(GSK) specifications which are more stringent than USP specifications. Revised specifications and testing method (SPTM) and Pharmaceutical Equivalence is provided by the firm
4.	Disintegration test acceptance criteria is NMT 30 minutes, while dissolution criteria is NLT 80% in 10 minutes.	We set the disintegration specification according to USP general monograph for Disintegration <701> which specifies NMT 30 minutes for film coated tablets. Our product is fast dissolving with a dissolution specs of NLT 80% (Q) in 10 minutes and disintegration time of our product is also found within 01 minute which correlates with dissolution. We have revised the specification of DT from NMT 30 minutes to NMT 10 minutes. Revised specifications and testing method (SPTM) is provided by the firm.

Decision of 321st meeting of Registration Board: Registration Board discussed that the applicant already has the registration of formulation containing Paracetamol 500mg as immediate release tablet whereas the firm has applied for the same formulation having different excipients and there is no change in strength, dosage form, salt form, drug delivery system etc. Considering the fact that different excipients are used in the applied product and already approved formulation, the Board deferred the case for clarification from applicant and then further deliberation.

Response by the firm:

Firm vide its reply Dy No. 1302 dated 16-01-2023 submitted as under:

Our applied product PROVAS ACTIFAST was deferred in Registration Board Meeting no. M-321 for which we would like to respectfully submit as under:

Keeping in line with the International developments for new & innovative drug therapies in Pain Management, and as per DRAP's Vision to ensure access to safe, quality assured and efficacious therapeutic drugs in line with the national laws and international best practices, we have developed this formulation

Paracetamol is considered as a safe and efficacious drug from the time of its first introduction in 1950. Since then, in order to improve over its limitations while providing innovative therapies to healthcare professionals as well as the patients, the innovator / Research Company, M/s. GSK introduced a new and improved formulation in 2001 under the name of PANADOL ACITIFAST. This formulation, besides Conventional Paracetamol, is available in many countries worldwide as detailed below:

Reference Regulatory Authority (RRA) /PICs Member States	**Conventional formulation**	**Actifast formulation**
EMA	PANADOL Original	PANADOL ACTIFAST
United Kingdom	PANADOL Original	PANADOL ACTIFAST
Australia	PANADOL	PANADOL RAPID
Belgium	PANADOL	PANADOL ZAPP
Ireland	PANADOL Original	PANADOL ACTIFAST
Netherland	PANADOL	PANADOL ZAPP
Denmark	PANADOL	PANADOL ZAPP
Belgium	PANADOL	PANADOL ZAPP
Lebanon	PANADOL	PANADOL ACTIFAST
Malaysia	PANADOL	PANADOL ACTIFAST
Greece	Plain not available	PANADOL ACTIFAST
Hong Kong	PANADOL	PANADOL ACTIFAST
United Arab Emirates	PANADOL	PANADOL ACTIFAST

Reference pages from respective RRA are provided by the firm

Comparison of various parameters between "Conventional Paracetamol Tablets" viz. a viz. newly applied ACTIFAST formulation is mentioned as under; our applied formulation is comparable with the Innovator brand – PANADOL ACTIFAST

Parameters	**Conventional Panadol / Provas Tablets**	**PANADOL ACTIFAST / PROVAS FASTIV**
Disintegration	Within 15 minutes	Within 10 minutes

		Gamma scintigraphic images of the stomach showed 2 times faster disintegration against Conventional Paracetamol tablets
Absorption	Paracetamol is poorly absorbed in the stomach but well absorbed in the small intestine due to the greater surface area and absorptive capacity. Conventional Paracetamol tablets have no such ingredient(s) to increase the rate of absorption	It is absorbed into the bloodstream at least twice as fast as against conventional (Conventional) Paracetamol Tablets Following administration, Paracetamol has a median time to peak plasma concentrations (t_{max}) of 25 minutes in fasted subjects and 45 minutes in the fed subjects Maximum plasma concentrations were reached at least twice as fast than Conventional Paracetamol Tablets in both the fed and fasted state
Dissolution	NLT 80% (Q) in 30 minutes	NLT 80% (Q) in 10 minutes
Gastric safety	-	It does not compromise the stomach's protective lining and can be taken even in an empty stomach or by those at risk of stomach ulcers
Onset of action	Onset of action is slow, as peak plasma concentrations occur about 30 minutes to 2 hours after ingestion	Due to a combination of faster disintegration and gastric emptying, this new formulation is responsible for the faster rate of absorption of Paracetamol than Conventional Paracetamol formulation
Other attributes	Round conventional shape Uncoated tablets and hence a bitter taste	Oblong shape makes it easy to swallow. The bitter taste of Paracetamol is masked through film coating Product specifications conform to the Innovator's Specifications, being more stringent than USP Specifications
Formulation detail	Each tablet contains Paracetamol Maize starch Povidone Potassium sorbate Soluble starch Purified talc Stearic acid	Each film coated tablet contains: Paracetamol Maize starch Povidone Potassium sorbate Pre-gelatinized starch Silicon dioxide Magnesium stearate Sodium starch glycolate Sodium Bicarbonate Microcrystalline cellulose Hydroxypropylmethyl cellulose E15 Polyethylene glycol 6000 Titanium Dioxide Talcum Powder

Above references taken from SmPC & Official website of PANADOL ACTIFAST are provided by the firm

A study comparing the rates of disintegration, gastric emptying and drug absorption of PANADOL ACTIFAST Tablet and Conventional Paracetamol Tablet was published in Pharmaceutical Research (Volume 20, issue 10, October 2003), an official journal of the American Association of Pharmaceutical Scientists. According to the study, the pharmacokinetics of PANADOL ACTIFAST showed significantly shorter time to maximum serum concentration (T_{max}) (in both fed and fasted state) and a significantly higher maximum serum concentration (C_{max}) (in the fasted state) as compared to conventional Paracetamol tablet, which is due to faster disintegration and gastric emptying; copy of article is enclosed

Conventional Paracetamol Tablet is available in Pharmacopeia, whereas under applied PROVAS FASTIV having different specifications which is more stringent than the Pharmacopeal specifications, for which we have already submitted our revised Finished Product specifications, vide our two letters dated 22-08-2022 & 31-08-2022 respectively, complying with that of the Innovator brand

While considering the difference in various parameters between the two formulations i.e. Conventional Paracetamol & PROVAS FASTIV Tablets and its availability in many RRA countries besides conventional Paracetamol Tablets, we hope you will find the above explanation in order and grant us registration of this novel formulation		
Decision of 324th meeting: Registration Board while deliberating the instant case recalled its decision of 262nd meeting, wherein while discussing the case of "Price fixation under the Drug Pricing Policy-2015", decided that "generic drug product means same molecule and its salt, same strength and dosage form, otherwise it will be considered as new drug product and same is being practiced by Registration Board. Moreover, drug product has 04 main components i.e. drug substance, dosage form, formulation and container-closure and delievery system." **In context of the above cited decision, Registration Board decided to approve instant application of "PROVAS ACTIFAST 500mg Tablet" as generic drug product.** • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
83.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat**
	Name, address of Manufacturing site.	M/s Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of grant of additional section dated 30-12-2020 for following 4 sections. • Tablet (General) • Capsule (General) • Sachet (General) • Oinment / Cream / Gel (General)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7362: 16-03-2022
	Details of fee submitted	PKR 30,000/-: 14-01-2022
	The proposed proprietary name / brand name	**DEXZEN 30mg Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Dexlansoprazole (as dual delayed release pellets)…….30mg
	Pharmaceutical form of applied drug	Small white round enteric coated pellets encapsulated in hard gelatin capsule
	Pharmacotherapeutic Group of (API)	PPI
	Reference to Finished product specifications	Manufacturer's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	Dexilant capsule **USFDA** Approved
	For generic drugs (me-too status)	Razodex Capsule by Getz Pharma
	Name and address of API manufacturer.	Vision Pharmaceuticals, Plot No. 22-23, Industrial Triangle Kahuta Road Islamabad.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and the drug product.

STABILITY STUDY DATA

Manufacturer of API	Vision Pharmaceuticals, Plot No. 22-23, Industrial Triangle Kahuta Road Islamabad.
API Lot No.	
Description of Pack (Container closure system)	Alu-alu blister
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T-01	T-02	T-01
Batch Size	1200 Capsule	1200 Capsule	1200 Capsule
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	27-02-2021	27-02-2021	27-02-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate issued by Additional Director DRAP, Islamabad dated 31-07-2019. The GMP certificate was granted based on inspection dated 11-02-2019. The GMP certificate is valid till 10-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice dated 23-02-2021 specifying purchase of 2Kg dexlansoprazole pellets 22.5%.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm submitted that their HPLC system is not 21 CFR compliant therefore the audit trail reports are not applicable.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC[3]:

- GMP certificate / inspection report of the firm conducted within a period of last three years.
- Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.
- Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."
- Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any method and procedures for preparation of each type of solution. Furthermore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.
- Provide COA of relevant batch of drug substance from both API manufacturer as well as drug product manufacturer which is used in the manufacturing of batches of drug product, since you have submitted COA of multiple irrelevant batches in this section.
- Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in section 3.2.S.1 of your application and is neither the manufacturer of these pellets or any other source of reference standard manufacturing.
- Section 3.2.S.6 specifies that the API manufacturer is using food grade double polyethylene bag for storing these pellets which are highly sensitive to moisture and light. Justification is required in this regard.
- Provide information in section 3.2.S.7.1 amd 3.2.S.7.2 as per CTD guidance document since you have only submitted stability data sheets in section 3.2.S.7 which is not in line with the Form 5-F as well as CTD guidance document.
- The stability study of dexlansoprazole pellets performed by Vision Pharmaceuticals specify that the pellets were stored in PET sealed bottles during stability studies while as per section 3.2.S.6 the packaging

material of commercially manufactured pellets is food grade double polyethylene bag. Justify how these stability studies are applicable in this case and how it represents the true shelf life of the commercially manufactured pellets.

- Registration Board in its 276th meeting held on 22-25th November, 2017 reviewed the formulation of dexlansoprazole pellets wherein the representative from the pellets manufacturer appeared before the Board and admitted that previously they were not specifying testing of pellets at 5.5 pH in the COA. The submitted stability study data of the three batches of pellets manufactured in 2014 is submitted in which testing at pH 5.5 is also specified. Clarification is required in this regard.
- Submit complete information in section 3.2.P.1 as per form 5F without skipping any section or heading.
- Submit pharmaceutical equivalence report of the applied product along with reference / innovator's product in which all tests as per specifications shall be perfomed, since you have mentioned that pharmaceutical equivaelence is not required and then you have also provided a brief report of dexlansoprazole tablet in which all tests are not performed.
- Provide complete report of comparative dissolution profile along with test parameters, analytical method and how the results are obtained and analysed, since you have only submitted tabulated and graphical representation without specifying any parameter.
- Submit information in section 3.2.P.3 as per the guidance document which specifies that "The selection and optimization of the manufacturing process described in 3.2.P.3.3, in particular its critical aspects, shall be explained. Any specific manufacturing process development shall be provided e.g., sterilization shall be explained and justified".
- Provide information in section 3.2.P.3.2 as per the CTD guidance document which specifies that "A batch formula for proposed commercial batch size shall be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards, since you have only submitted the same table which is already provided in section 3.2.P.1.
- Provide information in section 3.2.P.3.3 as per the CTD guidance document which specifies that "A flow diagram shall be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted shall be identified. Proposals for the reprocessing of materials (if any) shall be justified. Any data to support this justification shall be provided in this section. The maximum holding time for bulk product prior to final packaging shall be stated. The holding time shall be supported by the submission of stability data if longer than 30 days. For an aseptically processed drug product, sterile filtration of the bulk and filling into final containers shall preferably be continuous; any holding time shall be justified".
- Provide information in section 3.2.P.3.4 as per the CTD guidance document which specifies that "Tests and acceptance criteria shall be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled."
- Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established.
- Provide specifications of the drug product in section 3.2.P.5.1 along with submission of fee for revision of specifications since you have submitted Vision pharmaceuticals specifications of pellets in this section.
- Provide complete and analytical procedures of drug product in section 3.2.P.5.2 since you have provided analytical procedures of pellets in this section. Moreover, in assay test you have mentioned both UV and HPLC test. Clarification is required in this regard.
- Provide validation studies of the analytical method of drug product in section 3.2.P.5.3.
- Provide batch analysis certificate of three batches of drug product in section 3.2.P.5.4 where you have provided COA of dexlansoprazole pellets of Vision Pharmaceuticals with same results and your signatures after removing header containing name of Vision Pharmaceuticals.
- Provide COA of the reference standard / working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard.
- Provide information in section 3.2.P.7 as per the CTD guidance document which specifies that "A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided."
- You have mentioned white to off white pellets in section 3.2.P.1 while white and green pellets in section 3.2.P.8.1. Justification is required in this regard.
- Provide information in section 3.2.P.8.1 and 3.2.P.8.2 as per the Form 5F and CTD guidance document, since you have skipped these two sections and did not provide any information in these sections.

- Justify why only assay and dissolution test at one medium is performed in stability studies as evident from the submitted stability summary sheets.
- Your drug product specifications submitted in section 3.2.P.5.1 and specifications mentioned in COA of stability studies are different specifically in terms of dissolution test. Justify how you have performed stability studies without having any clear written specifications and analytical method.
- Justify the dissolution test in which the acceptance criteria is NLT 75% in 5 hours which is against the specificatiosn of innovator's product.
- Justify the dissolution acceptance criteria without specifying the value of Q as well as without identifying the criteria for analysis of results of dissolution test as per the criteria defined in USP general chapter <711> as well as defined by Registration Board in its 293rd meeting.
- Provide complete results of dissolution test including result of individual unit of capsule in the summary sheet or COA since results cannot be analysed without having results of individual units of the capsule.
- Provide stability study data in a proper sequence by providing stability summary sheet of individual batch along with proper separators to provide COA / raw data sheets along with HPLC chromatograms of standard and sample for the particular time point of that batch. Your submitted data is without any sequence, you have provided all COA and raw data sheets together and the rest of the data is also provided without proper sequence and sperators as per the guidelines of Registration Board. Submit your aligned data in a sequence so that further evaluation may be carried out.
- Submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following:
    - Reference of previous approval of applications with stability study data of the firm (if any)
    - Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.
    - Documents for the procurement of API with approval from DRAP (in case of import).
    - Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
    - Compliance Record of HPLC software 21CFR & audit trail reports on product testing.
    - Record of Digital data logger for temperature and humidity monitoring of both stability chambers.

Decision of 323rd meeting of Registration Board:
Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response by the firm:

Sr. No	Short coming	Annexure
01	GMP certificate /inspection report of the firm conducted within a period of last three years.	Firm has not submitted GMP certificate / inspection report.
02	Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.	Firm has **not** submitted QOS as per WHO template.
03	Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."	Firm has submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer
04	Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any procedures for preparation of each type of solution. Furtherore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.	Firm has **not** submitted report of verification studies of the analytical method of drug substance performed by drug product manufacturer.
05	Provide COA of relevant batch of drug substance from both API manufacturer as well as drug product manufacturer which is used in the manufacturing of	Firm has submitted COA of batch number DLP664.

	batches of drug product, since you have submitted COA of multiple irrelevant batches in this section.	
06	Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in section 3.2.S.1 of your application and is neither the manufacturer of hese pellets or any other source of reference standard manufacturing.	Firm has **not** sumitted COA of reference / working standard.
07	Section 3.2.S.6 specifies that the API food grade double manufacturer is using polyethylene bag for storing these which are pellets highly sensitive to moisture and light. Justification is required in this regard.	Three polyethylene bag used for packing of pellets. Two transparent and one black color bags along with silica gel.
08	Provide information in section 3.2.S.7.1 and 3.2.S.7.2 as CTD per guidance document since you have only submitted stability data sheets in section 3.2.S.7 which is not in line with the Form 5-F as well as CTD guidance document.	Firm has submitted information in section 3.2.S.7.1 and 3.2.S.7.2 as CTD per guidance document.
09	The stability study of Vision Dexlansoprazole pellets performed by Pharmaceuticals specify that the pellets were stored in PET sealed bottles during stability studies while as per section 3.2.S.6 the packaging material of commercially manufactured pellets is food grade double polyethylene bag. Justify how these stability studies are applicable in this case and how it represents the true shelf life of the commercially manufactured pellets.	Study performed at lab scale and in chamber they placed sample in pet bottle and for commercial they provide polythene bags and drum which is not possible in pet bottle.
10	Registration Board in its 276th meeting held on 22-25th November, 2017 reviewed the formulation of Dexlansoprazole pellets wherein the manufacturer appeared before the Board and admitted that previously they were not specifying testing of pellets at 5.5 pH in the COA. The submitted stability study data of the three batches of pellets manufactured in 2014 is submitted in which testing at pH 5.5 is also specified. Clarifications required in this regard.	DMF provided by vision pharma
11	Submit complete information in section 3.2.P.1 as per form 5F without skipping any section or heading.	Submitted by the firm.
12	Submit pharmaceutical equivalence report of the applied product along with reference / innovator's product in which all tests as per specifications shall be performed, since you have mentioned that pharmaceutical equivalence is not required and then you have also provided a brief report of Dexlansoprazole tablet in which all tests are not performed.	Firm has submitted pharmaceutical equivalence studies against the comparator product manufactured by Weatherfolds pharma.
13	Provide complete report of comparative dissolution profile along with test parameters, analytical method and how the results are obtained and analysed, since you have only submitted tabulated and graphical representation without specifying any parameter	Firm has submitted results of comparative dissolution profile against the brand leader.
14	submit information in section 3.2.P.3 as per the guidance document which specifies that The selection and optimization of the manufacturing process described in 3.2.P.3.3, in particular its critical aspects, shall be explained. Any specific manufacturing process development shall be provided e.g., sterilization shall be explained and justified"	Firm has submitted information in section 3.2.P.3 as per the guidance document.
15	Provide information in section 3.2.P.3.2 as per the CTD guidance document which specifies that "A batch	Firm has submitted information in section 3.2.P.3.2 as per the guidance document.

	formula for proposed commercial batch size shall be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards, since you have only submitted the same table which is already provided in section 3.2.P.1	
16	Provide information in section 3.2.P.3.3 as per the CTD guidance document which specifies that "A flow diagram shall be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted shall be identified. Proposals for the reprocessing of materials (if any) shall be justified. Any data t supports this justification shall be provided in this section. The maximum holding time for bulk product prior to final packaging shall be stated. The holding time shall be supported by the submission of stability data if longer than 30 days. For an aseptically processed drug product, sterile filtration of the bulk and filling into final containers shall preferably be continuous; any holding time shall be justified"	Firm has submitted information in section 3.2.P.3.3 as per the guidance document.
17	Provide information in section 3.2.P.3.4 as per the CTD guidance document which specifies that "Tests and acceptance criteria shall be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled."	Firm has submitted information in section 3.2.P.3.4 as per the guidance document.
18	Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established	Firm has **not** submitted process validation protocols.
19	Provide specifications of the drug product in section 3.2.P.5.1 along with submission of fee for revision of specifications since you have submitted Vision pharmaceuticals specifications of pellets in this section.	Firm has submitted specifications of the drug product in section 3.2.P.5.1.
20	provide complete and analytical procedures of drug product in section 3.2.P.5.2 since you have provided analytical procedures of pellets in this section. Moreover, in assay test you have mentioned both UV and HPLC test. Clarifications required in this regard	Firm has submitted specifications of the drug product in section 3.2.P.5.2.
21	Provide validation studies of the analytical method of drug product in section 3.2. P.5.3.	Firm has **not** submitted complete validation studies of the analytical method of drug product in section 3.2. P.5.3.
22	provide batch analysis certificate of three batches of drug product in section 3.2.P.5.4 where you have provided COA of Dexlansoprazole pellets of Vision Pharmaceuticals with same results and your signatures after removing header containing name of Vision Pharmaceuticals.	Firm has submitted Batch analysis report of 3 stability batches.
23	Provide COA of the reference standard I working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard	Firm has **not** submitted COA of reference standard / working standard.
24	Provide information in section 3.2.P.7 as per the CTD guidance document which specifies that "A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided."	Firm has submitted details of container closure system.

25	You have mentioned white to off white pellets in section 3.2.P.1 while white and green pellets in section 3.2.P.8.1. Justification is required in this regard	Written mistakenly, revised and correct submitted.
26	Provide information in section 3.2.P.8.1 and 3.2.P.8.2 as per the Form 5F and CTD guidance document, since you have skipped these two sections and did not provide any information in these sections.	Firm has submitted information in section 3.2.P.8.1 and 3.2.P.8.2.
27	justify why only assay and dissolution test at one medium is performed in stability studies as evident from the submitted stability summary sheets	Firm has now submitted dissolution test results at different medium in stability studies.
28	Your drug product specifications submitted in section 3.2.P.5.1 and specifications mentioned in COA of stability studies are different specifically in terms of dissolution test. Justify how you have performed stability studies without having any clear written specifications and analytical method.	Firm has submitted specifications and analytical method of drug product.
29	justify the dissolution test in which the acceptance criteria NLT 75% in 5 hours which is against the specifications of innovator's product	Typo mistake Revised COA attached
30	justify the dissolution acceptance criteria without specifying the value of Q as well as without identifying the criteria for analysis of results of dissolution test as per the criteria defined in USP general chapter as well as defined by Registration Board in its 293d meeting	Corrected and resubmitted by the firm
31	provide complete results of dissolution test including result of individual unit of capsule in the summary sheet or COA since results cannot be analysed without having results of individual units of the capsule	Revised COA are submitted by the firm.
32	provide stability study data in a proper se stability summary sheet of individual batch along with proper separators to provide COA / raw data sheets along with HPLC chromatograms of standard and sample for the particular time point of that batch. Your submitted data is without any sequence, you have provided all COA and raw data sheets together and the rest of the data is also provided without proper sequence and separators as per the guidelines of Registration Board. Submit your aligned data in a sequence so that further evaluation may be carried out	Firm has submitted stability data in a proper sequence.
33	submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following: • Reference of previous approval of applications with stability study data of the firm (if any) • Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin • Documents for the procurement of APl with approval from DRAP (in case of import). • Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc • Compliance Record of HPLC software 21CFR & audit trail reports on product testing • Record of Digital data logger for temperature and humidity monitoring of both stability chambers	Firm has submitted response against the 6 points checklist as per CTD guidance document.

Decision: Deferred for following observations:

- **Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.**

• **Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any procedures for preparation of each type of solution. Furtherore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.** • **Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in section 3.2.S.1 of your application and is neither the manufacturer of hese pellets or any other source of reference standard manufacturing.** • **Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established** • **Provide validation studies of the analytical method of drug product in section 3.2. P.5.3.** • **Provide COA of the reference standard I working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard**		
84.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat**
	Name, address of Manufacturing site.	M/s Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	
	Evidence of approval of manufacturing facility	has submitted copy of letter of grant of additional section dated 30-12-2020 for following 4 sections. • Tablet (General) • Capsule (General) • Sachet (General) • Oinment / Cream / Gel (General)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7363: 16-03-2022
	Details of fee submitted	PKR 30,000/-: 14-01-2022
	The proposed proprietary name / brand name	**DEXZEN 60mg Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Dexlansoprazole (as dual delayed release pellets)…….60mg
	Pharmaceutical form of applied drug	Small white round enteric coated pellets encapsulated in hard gelatin capsule
	Pharmacotherapeutic Group of (API)	PPI
	Reference to Finished product specifications	Manufacturer's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Dexilant capsule **USFDA** Approved
	For generic drugs (me-too status)	Razodex Capsule by Getz Pharma
	Name and address of API manufacturer.	Vision Pharmaceuticals, Plot No. 22-23, Industrial Triangle Kahuta Road Islamabad.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	Firm has submitted verification studies of the drug substance and the drug product.

STABILITY STUDY DATA

Manufacturer of API	Vision Pharmaceuticals, Plot No. 22-23, Industrial Triangle Kahuta Road Islamabad.		
API Lot No.			
Description of Pack (Container closure system)	Alu-alu blister		
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-04	T-05	T-06
Batch Size	1200 Capsule	1200 Capsule	1200 Capsule
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	27-02-2021	27-02-2021	27-02-2021

No. of Batches	03	
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate issued by Additional Director DRAP, Islamabad dated 31-07-2019. The GMP certificate was granted based on inspection dated 11-02-2019. The GMP certificate is valid till 10-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice dated 23-02-2021 specifying purchase of 2Kg dexlansoprazole pellets 22.5%.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm submitted that their HPLC system is not 21 CFR compliant therefore the audit trail reports are not applicable.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC[3]:

- GMP certificate / inspection report of the firm conducted within a period of last three years.
- Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.
- Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."
- Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any method and procedures for preparation of each type of solution. Furthermore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.
- Provide COA of relevant batch of drug substance from both API manufacturer as well as drug product manufacturer which is used in the manufacturing of batches of drug product, since you have submitted COA of multiple irrelevant batches in this section.
- Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in section 3.2.S.1 of your application and is neither the manufacturer of these pellets or any other source of reference standard manufacturing.
- Section 3.2.S.6 specifies that the API manufacturer is using food grade double polyethylene bag for storing these pellets which are highly sensitive to moisture and light. Justification is required in this regard.
- Provide information in section 3.2.S.7.1 amd 3.2.S.7.2 as per CTD guidance document since you have only submitted stability data sheets in section 3.2.S.7 which is not in line with the Form 5-F as well as CTD guidance document.
- The stability study of dexlansoprazole pellets performed by Vision Pharmaceuticals specify that the pellets were stored in PET sealed bottles during stability studies while as per section 3.2.S.6 the packaging material of commercially manufactured pellets is food grade double polyethylene bag. Justify how these stability studies are applicable in this case and how it represents the true shelf life of the commercially manufactured pellets.
- Registration Board in its 276th meeting held on 22-25th November, 2017 reviewed the formulation of dexlansoprazole pellets wherein the representative from the pellets manufacturer appeared before the Board and admitted that previously they were not specifying testing of pellets at 5.5 pH in the COA. The

submitted stability study data of the three batches of pellets manufactured in 2014 is submitted in which testing at pH 5.5 is also specified. Clarification is required in this regard.

- Submit complete information in section 3.2.P.1 as per form 5F without skipping any section or heading.
- Submit pharmaceutical equivalence report of the applied product along with reference / innovator's product in which all tests as per specifications shall be perfomed, since you have mentioned that pharmaceutical equivaelence is not required and then you have also provided a brief report of dexlansoprazole tablet in which all tests are not performed.
- Provide complete report of comparative dissolution profile along with test parameters, analytical method and how the results are obtained and analysed, since you have only submitted tabulated and graphical representation without specifying any parameter.
- Submit information in section 3.2.P.3 as per the guidance document which specifies that "The selection and optimization of the manufacturing process described in 3.2.P.3.3, in particular its critical aspects, shall be explained. Any specific manufacturing process development shall be provided e.g., sterilization shall be explained and justified".
- Provide information in section 3.2.P.3.2 as per the CTD guidance document which specifies that "A batch formula for proposed commercial batch size shall be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards, since you have only submitted the same table which is already provided in section 3.2.P.1.
- Provide information in section 3.2.P.3.3 as per the CTD guidance document which specifies that "A flow diagram shall be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted shall be identified. Proposals for the reprocessing of materials (if any) shall be justified. Any data to support this justification shall be provided in this section. The maximum holding time for bulk product prior to final packaging shall be stated. The holding time shall be supported by the submission of stability data if longer than 30 days. For an aseptically processed drug product, sterile filtration of the bulk and filling into final containers shall preferably be continuous; any holding time shall be justified".
- Provide information in section 3.2.P.3.4 as per the CTD guidance document which specifies that "Tests and acceptance criteria shall be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled."
- Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established.
- Provide specifications of the drug product in section 3.2.P.5.1 along with submission of fee for revision of specifications since you have submitted Vision pharmaceuticals specifications of pellets in this section.
- Provide complete and analytical procedures of drug product in section 3.2.P.5.2 since you have provided analytical procedures of pellets in this section. Moreover, in assay test you have mentioned both UV and HPLC test. Clarification is required in this regard.
- Provide validation studies of the analytical method of drug product in section 3.2.P.5.3.
- Provide batch analysis certificate of three batches of drug product in section 3.2.P.5.4 where you have provided COA of dexlansoprazole pellets of Vision Pharmaceuticals with same results and your signatures after removing header containing name of Vision Pharmaceuticals.
- Provide COA of the reference standard / working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard.
- Provide information in section 3.2.P.7 as per the CTD guidance document which specifies that "A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided."
- You have mentioned white to off white pellets in section 3.2.P.1 while white and green pellets in section 3.2.P.8.1. Justification is required in this regard.
- Provide information in section 3.2.P.8.1 and 3.2.P.8.2 as per the Form 5F and CTD guidance document, since you have skipped these two sections and did not provide any information in these sections.
- Justify why only assay and dissolution test at one medium is performed in stability studies as evident from the submitted stability summary sheets.
- Your drug product specifications submitted in section 3.2.P.5.1 and specifications mentioned in COA of stability studies are different specifically in terms of dissolution test. Justify how you have performed stability studies without having any clear written specifications and analytical method.
- Justify the dissolution test in which the acceptance criteria is NLT 75% in 5 hours which is against the specificatiosn of innovator's product.

- Justify the dissolution acceptance criteria without specifying the value of Q as well as without identifying the criteria for analysis of results of dissolution test as per the criteria defined in USP general chapter <711> as well as defined by Registration Board in its 293rd meeting.
- Provide complete results of dissolution test including result of individual unit of capsule in the summary sheet or COA since results cannot be analysed without having results of individual units of the capsule.
- Provide stability study data in a proper sequence by providing stability summary sheet of individual batch along with proper separators to provide COA / raw data sheets along with HPLC chromatograms of standard and sample for the particular time point of that batch. Your submitted data is without any sequence, you have provided all COA and raw data sheets together and the rest of the data is also provided without proper sequence and sperators as per the guidelines of Registration Board. Submit your aligned data in a sequence so that further evaluation may be carried out.
- Submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following:
    - Reference of previous approval of applications with stability study data of the firm (if any)
    - Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.
    - Documents for the procurement of API with approval from DRAP (in case of import).
    - Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
    - Compliance Record of HPLC software 21CFR & audit trail reports on product testing.
    - Record of Digital data logger for temperature and humidity monitoring of both stability chambers.

Decision of 323rd meeting of Registration Board:
Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response by the firm:

Sr. No	Short coming	Annexure
01	GMP certificate /inspection report of the firm conducted within a period of last three years.	Firm has not submitted GMP certificate / inspection report.
02	Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.	Firm has **not** submitted QOS as per WHO template.
03	Submit data in section 3.2.S.4.1 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."	Firm has submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer
04	Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any procedures for preparation of each type of solution. Furtherore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.	Firm has **not** submitted report of verification studies of the analytical method of drug substance performed by drug product manufacturer.
05	Provide COA of relevant batch of drug substance from both API manufacturer as well as drug product manufacturer which is used in the manufacturing of batches of drug product, since you have submitted COA of multiple irrelevant batches in this section.	Firm has submitted COA of batch number DLP664.
06	Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in	Firm has **not** sumitted COA of reference / working standard.

	section 3.2.S.1 of your application and is neither the manufacturer of hese pellets or any other source of reference standard manufacturing.	
07	Section 3.2.S.6 specifies that the API food grade double manufacturer is using polyethylene bag for storing these which are pellets highly sensitive to moisture and light. Justification is required in this regard.	Three polyethylene bag used for packing of pellets. Two transparent and one black color bags along with silica gel.
08	Provide information in section 3.2.S.7.1 and 3.2.S.7.2 as CTD per guidance document since you have only submitted stability data sheets in section 3.2.S.7 which is not in line with the Form 5-F as well as CTD guidance document.	Firm has submitted information in section 3.2.S.7.1 and 3.2.S.7.2 as CTD per guidance document.
09	The stability study of Vision Dexlansoprazole pellets performed by Pharmaceuticals specify that the pellets were stored in PET sealed bottles during stability studies while as per section 3.2.S.6 the packaging material of commercially manufactured pellets is food grade double polyethylene bag. Justify how these stability studies are applicable in this case and how it represents the true shelf life of the commercially manufactured pellets.	Study performed at lab scale and in chamber they placed sample in pet bottle and for commercial they provide polythene bags and drum which is not possible in pet bottle.
10	Registration Board in its 276th meeting held on 22-25th November, 2017 reviewed the formulation of Dexlansoprazole pellets wherein the manufacturer appeared before the Board and admitted that previously they were not specifying testing of pellets at 5.5 pH in the COA. The submitted stability study data of the three batches of pellets manufactured in 2014 is submitted in which testing at pH 5.5 is also specified. Clarifications required in this regard.	DMF provided by vision pharma
11	Submit complete information in section 3.2.P.1 as per form 5F without skipping any section or heading.	Submitted by the firm.
12	Submit pharmaceutical equivalence report of the applied product along with reference / innovator's product in which all tests as per specifications shall be performed, since you have mentioned that pharmaceutical equivalence is not required and then you have also provided a brief report of Dexlansoprazole tablet in which all tests are not performed.	Firm has submitted pharmaceutical equivalence studies against the comparator product manufactured by Weatherfolds pharma.
13	Provide complete report of comparative dissolution profile along with test parameters, analytical method and how the results are obtained and analysed, since you have only submitted tabulated and graphical representation without specifying any parameter	Firm has submitted results of comparative dissolution profile against the brand leader.
14	submit information in section 3.2.P.3 as per the guidance document which specifies that The selection and optimization of the manufacturing process described in 3.2.P.3.3, in particular its critical aspects, shall be explained. Any specific manufacturing process development shall be provided e.g., sterilization shall be explained and justified"	Firm has submitted information in section 3.2.P.3 as per the guidance document.
15	Provide information in section 3.2.P.3.2 as per the CTD guidance document which specifies that "A batch formula for proposed commercial batch size shall be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards, since you have only submitted the same table which is already provided in section 3.2.P.1	Firm has submitted information in section 3.2.P.3.2 as per the guidance document.
16	Provide information in section 3.2.P.3.3 as per the CTD guidance document which specifies that "A flow	Firm has submitted information in section 3.2.P.3.3 as per the guidance document.

	diagram shall be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted shall be identified. Proposals for the reprocessing of materials (if any) shall be justified. Any data t supports this justification shall be provided in this section. The maximum holding time for bulk product prior to final packaging shall be stated. The holding time shall be supported by the submission of stability data if longer than 30 days. For an aseptically processed drug product, sterile filtration of the bulk and filling into final containers shall preferably be continuous; any holding time shall be justified"	
17	Provide information in section 3.2.P.3.4 as per the CTD guidance document which specifies that "Tests and acceptance criteria shall be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled."	Firm has submitted information in section 3.2.P.3.4 as per the guidance document.
18	Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established	Firm has **not** submitted process validation protocols.
19	Provide specifications of the drug product in section 3.2.P.5.1 along with submission of fee for revision of specifications since you have submitted Vision pharmaceuticals specifications of pellets in this section.	Firm has submitted specifications of the drug product in section 3.2.P.5.1.
20	provide complete and analytical procedures of drug product in section 3.2.P.5.2 since you have provided analytical procedures of pellets in this section. Moreover, in assay test you have mentioned both UV and HPLC test. Clarifications required in this regard	Firm has submitted specifications of the drug product in section 3.2.P.5.2.
21	Provide validation studies of the analytical method of drug product in section 3.2. P.5.3.	Firm has **not** submitted complete validation studies of the analytical method of drug product in section 3.2. P.5.3.
22	provide batch analysis certificate of three batches of drug product in section 3.2.P.5.4 where you have provided COA of Dexlansoprazole pellets of Vision Pharmaceuticals with same results and your signatures after removing header containing name of Vision Pharmaceuticals.	Firm has submitted Batch analysis report of 3 stability batches.
23	Provide COA of the reference standard I working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard	Firm has **not** submitted COA of reference standard / working standard.
24	Provide information in section 3.2.P.7 as per the CTD guidance document which specifies that "A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided."	Firm has submitted details of container closure system.
25	You have mentioned white to off white pellets in section 3.2.P.1 while white and green pellets in section 3.2.P.8.1. Justification is required in this regard	Written mistakenly, revised and correct submitted.
26	Provide information in section 3.2.P.8.1 and 3.2.P.8.2 as per the Form 5F and CTD guidance document, since you have skipped these two sections and did not provide any information in these sections.	Firm has submitted information in section 3.2.P.8.1 and 3.2.P.8.2.

27	justify why only assay and dissolution test at one medium is performed in stability studies as evident from the submitted stability summary sheets	Firm has now submitted dissolution test results at different medium in stability studies.
28	Your drug product specifications submitted in section 3.2.P.5.1 and specifications mentioned in COA of stability studies are different specifically in terms of dissolution test. Justify how you have performed stability studies without having any clear written specifications and analytical method.	Firm has submitted specifications and analytical method of drug product.
29	justify the dissolution test in which the acceptance criteria NLT 75% in 5 hours which is against the specifications of innovator's product	Typo mistake Revised COA attached
30	justify the dissolution acceptance criteria without specifying the value of Q as well as without identifying the criteria for analysis of results of dissolution test as per the criteria defined in USP general chapter as well as defined by Registration Board in its 293d meeting	Corrected and resubmitted by the firm
31	provide complete results of dissolution test including result of individual unit of capsule in the summary sheet or COA since results cannot be analysed without having results of individual units of the capsule	Revised COA are submitted by the firm.
32	provide stability study data in a proper se stability summary sheet of individual batch along with proper separators to provide COA / raw data sheets along with HPLC chromatograms of standard and sample for the particular time point of that batch. Your submitted data is without any sequence, you have provided all COA and raw data sheets together and the rest of the data is also provided without proper sequence and separators as per the guidelines of Registration Board. Submit your aligned data in a sequence so that further evaluation may be carried out	Firm has submitted stability data in a proper sequence.
33	submit stability study data in section 3.2.P.8.3 as per the checklist approved by Registration Board in its 296th meeting and the CTD guidance document, which includes the following: • Reference of previous approval of applications with stability study data of the firm (if any) • Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin • Documents for the procurement of APl with approval from DRAP (in case of import). • Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc • Compliance Record of HPLC software 21CFR & audit trail reports on product testing • Record of Digital data logger for temperature and humidity monitoring of both stability chambers	Firm has submitted response against the 6 points checklist as per CTD guidance document.

Decision: Deferred for following observations:

- **Provide Quality Overall Summary in module 2 as per WHO QOS PD template or as per the template defined by Registration Board by providing summarized data in the tabulated form. You have submitted same data of module 3 in QOS as well which is not in line with the CTD guidance document.**
- **Provide complete report of verification studies of the analytical method of drug substance performed by drug product manufacturer in section 3.2.S.4.3, since you have only submitted tabulated results without any procedures for preparation of each type of solution. Furtherore, you have performed 6 replicates in specificity test which is not in line with the recommendations of ICH.**
- **Provide COA of the reference standard / working standard in section 3.2.S.5 which is actually used in the analysis of drug substance / pellets along with its standardization record with the primary**

standard, since you have submitted COA of batch No WS/RLP/01 from Integrin Life Sciences whose product description is different from that specified in section 3.2.S.1 of your application and is neither the manufacturer of hese pellets or any other source of reference standard manufacturing.

- **Justify why the process validation protocols does not include any step for validation of process of capsule filling, sealing and blistering. Moreover, no critical steps, sampling plan, and evaluation criteria has been established**
- **Provide validation studies of the analytical method of drug product in section 3.2. P.5.3.**
- **Provide COA of the reference standard I working standard in section 3.2.P.6 which is actually used in the analysis of drug product along with its standardization record with the primary standard**

85.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Nawan Laboratories (Pvt) Ltd, 136, Sector 15, Korangi Industrial Area, Karachi**
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahua Road, Islamabad
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Nawan Laboratories (Pvt) Ltd and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Nawan laboratories:** The firm is granted GMP certificate based on inspection conducted on 01-02-2020. **M/s Bio-Labs:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 6957: 02-03-2021
	Details of fee submitted	PKR 50,000/-: 15-02-2021
	The proposed proprietary name / brand name	Oltrix Injection 40mg IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoz Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajasthan, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications,

		reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajesthan, India		
API Lot No.	AOSS19032		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not submitted

3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

S.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used in stability studies procured from Rajasthan Antibiotics while provided DMF was from Metrochem. We are submitting DMF from Rajasthan antibiotics and COAs accordingly.
2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence report has been submitted.
3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validation on all manufactured batches. We performed stability study and process validation on different batches however we are submitting revised batch analysis of stability batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used market leader product (Risek 40mg Injection) of GETZ pharma which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since product is of in-house specifications and in-house validated method is applied for testing which is UV-visible spectrophotometer. Validation of analytical method is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.
- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.

- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:
Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.
Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.
Firm has also submitted record of stability data including HPLC testing.
However, firm has not submitted any fee for revision of data of stability study batches.
The details of the newly submitted stability batches are as under:

STABILITY STUDY DATA

Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India		
API Lot No.	AOSS18021		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
Batch No.	L-231	L-232	L-230
Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg &

		25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

- The firm has submitted GMP certificate for drug substance manufacturer issued on 10-03-2022 by the Drug Controller Rajhastan.

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)
- Lyophilized vial injectable (General)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

• **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.** **Registration letter will be issued upon submission of following:** • **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.** • **Fee of Rs. 75,000/- for pre-approval change in stability studies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**		
86.	Name, address of Applicant / Marketing Authorization Holder	M/s Islam Pharmaceuticals., 7 km, Pasrur Road, Sialkot.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahuta Road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Islam Pharmaceuticals and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Islam Pharmaceuticals:** The firm is granted GMP certificate based on inspection conducted on 01-02-2020. **M/s Bio-Labs Pvt Ltd:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7168: 04-03-2021
	Details of fee submitted	PKR 50,000/-: 18-01-2021
	The proposed proprietary name / brand name	**Mozole Injection 40mg IV**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoza Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajasthan, India

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.
STABILITY STUDY DATA		
Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajesthan, India	
API Lot No.	AOSS19032	

Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not submitted
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

S.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used in stability studies procured from Rajasthan Antibiotics while provided DMF was from Metrochem. We are submitting DMF from Rajasthan antibiotics and COAs accordingly.
2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence report has been submitted.

3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validation on all manufactured batches. We performed stability study and process validation on different batches however we are submitting revised batch analysis of stability batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used market leader product (Risek 40mg Injection) of GETZ pharma which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since product is of in-house specifications and in-house validated method is applied for testing which is UV-visible spectrophotometer. Validation of analytical method is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.
- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.
- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:

Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.
Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.
Firm has also submitted record of stability data including HPLC testing.
However, firm has not submitted any fee for revision of data of stability study batches.
The details of the newly submitted stability batches are as under:

STABILITY STUDY DATA

Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India		
API Lot No.	AOSS18021		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
Batch No.	L-231	L-232	L-230

Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg & 25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA

6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)
- Lyophilized vial injectable (General)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**
- **Fee of Rs. 75,000/- for pre-approval changein stabilitystudies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**

87.	Name, address of Applicant / Marketing Authorization Holder	M/s Bio-Next Pharmaceuticals., Plot No. 50, Street No. S-10, RCCI, Rawat
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahuta Road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Islam Pharmaceuticals and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Bio-Next Pharmaceuticals:** The firm is granted GMP certificate based on inspection conducted on 01-02-2020. **M/s Bio-Labs Pvt Ltd:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7097: 03-03-2021
	Details of fee submitted	PKR 50,000/-: 19-11-2020
	The proposed proprietary name / brand name	**Omepranext Injection 40mg IV**

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoza Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajasthan, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control

		of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA

Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, RICO Industrial Area Bhiwadi-301019 Rajasthan, India		
API Lot No.	AOSS19032		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	--
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate of M/s Metrochem API (Pvt) Ltd, India issued by Food & Drugs administration, Maharashtra state, India. The certificate is valid till 13 April, 2023.

3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time & accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Sr.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used i studies procured from Rajasthan Antibiot provided DMF was from Metrochem. submitting DMF from Rajasthan antibi COAs accordingly.
2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence repor submitted.
3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validatio manufactured batches. We performed stabi and process validation on different batches we are submitting revised batch analysis o batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used mark product (Risek 40mg Injection) of GET which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since produc house specifications and in-house validate is applied for testing which is U spectrophotometer. Validation of analytica is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.
- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.
- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:

Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.
Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.
Firm has also submitted record of stability data including HPLC testing.
However, firm has not submitted any fee for revision of data of stability study batches.
The details of the newly submitted stability batches are as under:

STABILITY STUDY DATA

Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India		
API Lot No.	AOSS18021		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
Batch No.	L-231	L-232	L-230
Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg & 25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION

		software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

- The firm has submitted GMP certificate for drug substance manufacturer issued on 10-03-2022 by the Drug Controller Rajhastan.

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)
- Lyophilized vial injectable (General)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**

• **Fee of Rs. 75,000/- for pre-approval changein stabilitystudies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**		
88.	Name, address of Applicant / Marketing Authorization Holder	M/s Cherwel Pharmaceuticals (Pvt) Ltd., Plot No. 20, Phase 4, Hattar Industrial Estate Hattar
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahuta Road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Islam Pharmaceuticals and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Cherwel Pharmaceuticals:** The firm is granted GMP certificate **M/s Bio-Labs Pvt Ltd:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7457: 08-03-2021
	Details of fee submitted	PKR 50,000/-: 24-02-2021
	The proposed proprietary name / brand name	**Nifzole Injection 40mg IV**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoza Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico

		Industrial Area Bhiwadi-301019 Rajasthan, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical

		procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajesthan, India		
API Lot No.	AOSS19032		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	--
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by	The firm has submitted copy of GMP certificate of M/s Metrochem API (Pvt) Ltd, India

	concerned regulatory authority of country of origin.	issued by Food & Drugs administration, Maharashtra state, India. The certificate is valid till 13 April, 2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

S.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used in stability studies procured from Rajasthan Antibiotics while provided DMF was from Metrochem. We are submitting DMF from Rajasthan antibiotics and COAs accordingly.
2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence report has been submitted.
3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validation on all manufactured batches. We performed stability study and process validation on different batches however we are submitting revised batch analysis of stability batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used market leader product (Risek 40mg Injection) of GETZ pharma which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since product is of in-house specifications and in-house validated method is applied for testing which is UV-visible spectrophotometer. Validation of analytical method is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.

- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.
- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:
Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.
Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.
Firm has also submitted record of stability data including HPLC testing.
However, firm has not submitted any fee for revision of data of stability study batches.
The details of the newly submitted stability batches are as under:

STABILITY STUDY DATA

Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India		
API Lot No.	AOSS18021		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
Batch No.	L-231	L-232	L-230
Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg & 25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

- The firm has submitted GMP certificate for drug substance manufacturer issued on 10-03-2022 by the Drug Controller Rajhastan.

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)
- Lyophilized vial injectable (General)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**
- **Fee of Rs. 75,000/- for pre-approval changein stabilitystudies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**

89.	Name, address of Applicant / Marketing Authorization Holder	M/s Alliance Pharmaceutical Pvt Ltd. 112 A, Hayatabad Industrial Estate, Peshawar.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahuta Road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer

		☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Islam Pharmaceuticals and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Alliance Pharmaceuticals:** The firm is granted GMP certificate **M/s Bio-Labs Pvt Ltd:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13167: 06-05-2021
	Details of fee submitted	PKR 50,000/-: 07-04-2021
	proposed proprietary name / brand name	**Allomep 40mg IV Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specification	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoza Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajasthan, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

		The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajesthan, India		
API Lot No.	AOSS19032		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate of M/s Metrochem API (Pvt) Ltd, India issued by Food & Drugs administration, Maharashtra state, India. The certificate is valid till 13 April, 2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

S.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used i studies procured from Rajasthan Antibiot provided DMF was from Metrochem. submitting DMF from Rajasthan antibi COAs accordingly.

2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence report has been submitted.
3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validation on all manufactured batches. We performed stability study and process validation on different batches however we are submitting revised batch analysis of stability batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used market leader product (Risek 40mg Injection) of GETZ pharma which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since product is of in-house specifications and in-house validated method is applied for testing which is UV-visible spectrophotometer. Validation of analytical method is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.
- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.
- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:

Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.
Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.
Firm has also submitted record of stability data including HPLC testing.
However, firm has not submitted any fee for revision of data of stability study batches.
The details of the newly submitted stability batches are as under:

STABILITY STUDY DATA	
Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India
API Lot No.	AOSS18021
Description of Pack (Container closure system)	Glass vial
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 24 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)

Batch No.	L-231	L-232	L-230
Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg & 25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

- The firm has submitted GMP certificate for drug substance manufacturer issued on 10-03-2022 by the Drug Controller Rajhastan.

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)

• Lyophilized vial injectable (General)		
Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.** **Registration letter will be issued upon submission of following:** • **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.** • **Fee of Rs. 75,000/- for pre-approval changein stabilitystudies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**		
90.	Name, address of Applicant / Marketing Authorization Holder	M/s Novartana Pharmaceuticals Pvt Ltd. Plot No. 87-B, Sundar Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot # 145 Industrial Triangles, kahuta Road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) The firm has submitted copy of agreement between M/s Islam Pharmaceuticals and M/s Bio-Labs (Pvt.) Ltd, Islamabad made on 21-01-2020.
	GMP status of the firm	**M/s Novartana Pharmaceuticals:** The firm is granted GMP certificate **M/s Bio-Labs Pvt Ltd:** The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	Evidence of approval of manufacturing facility	The manufacturer has provided Lyophilized vial (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13166: 18-05-2021
	Details of fee submitted	PKR 50,000/-: 07-04-2021
	proposed proprietary name / brand name	**Novarzole 40mg IV Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Omeprazole sodium eq. to Omeprazole…….40mg
	Pharmaceutical form of applied drug	Lyophilized Powder for injection
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specification	Innovator's specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	Omeprazole powder for solution for infusion of M/s Sandoza Novartis (MHRA approved)
	For generic drugs (me-too status)	Risek Injection 40mg of M/s Getz Pharma Pakistan
	Name and address of API manufacturer.	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajasthan, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	The firm has submitted stability study data of 6 months accelerated and 36 months real time data of 3 batches of API as per Zone-IV A.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or

		materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of their developed formulation Delka 40mg IV Injection (B # L 289) with comparator product Risek 40mg Injection IV (B # 788P06) of M/s GETZ Pharma, Karachi. Quality tests of both products including description, identification, pH, assay, Sterility and bacterial endotoxins were performed and compared.
	Analytical method validation/verification of product	Firm has submitted analytical method validation report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Rajasthan Antibiotics Ltd., Plot no A-619 & 630, Rico Industrial Area Bhiwadi-301019 Rajesthan, India		
API Lot No.	AOSS19032		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Delka 40mg IV Injection			
Batch No.	L-140	L-163	L-197
Batch Size	25000 vials	20,000 vials	15,000 vials
Manufacturing Date	03-2018	06-2018	11-2018
Date of Initiation	10-03-2018	15-06-2018	13-12-2018
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	--
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate of M/s Metrochem API (Pvt) Ltd, India issued by Food & Drugs administration, Maharashtra state, India. The certificate is valid till 13 April, 2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of invoice for the import of Omeprazole sodium.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.

	data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail on testing reports of product submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

S.#	Observations communicated	Response by the firm
1.	Provide results of analysis of relevant batch(es) of Drug Substance used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance manufacturer.	The firm has submitted that API lot used in stability studies procured from Rajasthan Antibiotics while provided DMF was from Metrochem. We are submitting DMF from Rajasthan antibiotics and COAs accordingly.
2.	Details of applicant batch number and comparator product batch number used for pharmaceutical equivalence studies are required.	Revised pharmaceutical equivalence report has been submitted.
3.	Data of commercial batches with different batch numbers was given in process validation reports, batch analysis of finished product and stability studies.	We do not perform process validation on all manufactured batches. We performed stability study and process validation on different batches however we are submitting revised batch analysis of stability batches.
4.	Pharmaceutical equivalence of the applied drug shall be established with the innovator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator product should be submitted and discussed as per requirements of section 3.2.P.2.	The firm has submitted we used market leader product (Risek 40mg Injection) of GETZ pharma which was approved by DRAP.
5.	Justification is required for using UV spectrophotometric method in place of HPLC method for assay testing of Delka 40mg Injection IV.	The firm has submitted that since product is of in-house specifications and in-house validated method is applied for testing which is UV-visible spectrophotometer. Validation of analytical method is provided in module 3.
6.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Response not submitted against this point.
7.	Evidence of procurement of drug substance with approval from DRAP is required.	Response not submitted against this point.

Decision of 313th meeting of Registration Board:

Deferred for following submissions:

- Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized omeprazole sodium from M/s Rajasthan Antibiotics, India.
- Justification of adopting UV-visible spectrophotometric method for assay testing of applied formulation.
- Approval of API/ DML/GMP certificate of API manufacturer (Rajasthan antibiotics) issued by concerned regulatory authority of country of origin.
- Evidence of procurement of drug substance with approval from DRAP.

Response by the firm:

Firm has submitted stability study data of newly manufactured batches in which firm has procured sterile non-lyophilized drug substance from the same source and have performed lyophilisation after vial filling in Bio-Labs. Firm has also submitted copy of BMR of three stability batches.

Firm has also revised its specifications and adopted HPLC method for assay testing of the drug product.

Firm has also submitted record of stability data including HPLC testing.

However, firm has not submitted any fee for revision of data of stability study batches.

The details of the newly submitted stability batches are as under:			
STABILITY STUDY DATA			
Manufacturer of API	M/s. Rajasthan Antibiotics Limited A 619 – 630, RIICO Industrial Area, Bhiwadi – 301019, Alwar Rajasthan, India		
API Lot No.	AOSS18021		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
Batch No.	L-231	L-232	L-230
Batch Size	1000 Vials	1000 Vials	1000 Vials
Manufacturing Date	06-2019	06-2019	06-2019
Date of Initiation	30-06-2019	30-06-2019	30-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has refered to their previous inspection of M/s Bio-Labs conducted for Empaglif 10mg Tablet (Empagliflozin) & Empaglif 25mg Tablet which was considered by the Board in its 296th meeting and the product was approved based on the inspection report. Following points were noted during the inspection: • All the stability study of EMPAGLIF (10mg & 25mg) Tablets has been conduct on Shimadzu HPLC (Model SPD-20) operated via LABSOLUTION software version 6.5 (complying FDA 21 CFR part 11) • Audit trail reports for Testing of Empaglif 10mg & 25mg Tablets are available. • Proper and continuous monitoring record for stability chamber is available, along with 5KV backup generator with ATS.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (2020/1961) issued by Drug Control Organization, Government of Rajasthan dated 09-12-2020 and was valid till 26-02-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice and clearance certificate issued by AD (I&E) specifying import of 15kg Omeprazole sodium sterile (Batch number AOSS18021) dated 01-06-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.

	sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

- The firm has submitted GMP certificate for drug substance manufacturer issued on 10-03-2022 by the Drug Controller Rajhastan.

Registration Board in its 293rd meeting on basis of capacity assessment inspection, decided to allow contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections:

- Dry Suspension (Cephalosporin)
- Capsule (Cephalosporin)
- Dry vial injectable (Cephalosporin)
- Lyophilized vial injectable (General)

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**
- **Fee of Rs. 75,000/- for pre-approval changein stabilitystudies data as per Notification No. 7-11/2012-B&A dated 07.05.2021.**

Case No. 03 Registration applications of stability cases

a. New cases

91.	Name and address of manufacturer / Applicant	M/s Hudson Pharma (Pvt) Ltd, Plot No. D-93, North Western Industrial Zone, Port Qasim, Karachi
	Brand Name +Dosage Form + Strength	SYMBIVENT 400mcg +12mcg Rotacaps
	Composition	Each Rotacap contains: Budesonide ……400mcg Formoterol fumarate …….12mcg
	Diary No. Date of R& I & fee	Diary No:42060, 07/12/2018, Rs: 20,000/-, 7/12/2018
	Pharmacological Group	Adrenergics, Inhalants (Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)
	Type of Form	Form-5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	30's/ As per SRO
	Approval status of product in Reference Regulatory Authorities	Symbicort 400/12 Inhalation Powder of M/s Astrazeneca, UK (MHRA approved)

	Me-too status	Venticort 400mcg+12mcg Rotacaps of Highnoon Labs (Reg#089365)
	GMP status	19-01-2018, Panel recommends grant of additional sections
	Remarks of the Evaluator	The submitted me-too reference could not be verified.
	Previous decision(s)	Deferred for further deliberation upon required manufacturing facility for applied formulation (M-287). Deferred for following reasons: (M-291) Confirmation of manufacturing facility for applied formulation. Scientific justification for using ambient conditions in submitted stability studies data.
	Evaluation by PEC	The firm has submitted 6 months accelerated and 6 months ambient stability studies data for three trial batches.

STABILITY STUDY DATA			
Drug	SYMBIVENT 400mcg +12mcg Rotacaps		
Name of Manufacturer	M/s Hudson Pharma (Pvt) Ltd, Plot No.D-93, North Western Industrial Zone, Port Qasim, Karachi.		
Manufacturer of API	**Budesonide micronized:** M/s Industriale Chimica s.r.l., Address: Via E. H. Grieg 13 – SARONNO (VA), Italy **Formoterol Fumarate dihydrate micronized:** M/s Industriale Chimica s.r.l., Address: Via E. H. Grieg 13 – SARONNO (VA), Italy		
API Lot No.	**Budesonide micronized:** PR160746 **Formoterol Fumarate dihydrate micronized:** PR160075		
Description of Pack (Container closure system)	Alu-Alu Blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,1,3,6 months Real Time: 0,1,3,6 months		
SYMBIVENT 400mcg +12mcg Rotacaps			
Batch No.	SB01	SB02	SB03
Batch Size	400gm (16,000 Rotacaps)	400gm (16,000 Rotacaps)	400gm (16,000 Rotacaps)
Manufacturing Date	09-2018	09-2018	09-2018
Date of Initiation	01-10-2018	01-10-2018	01-10-2018
No. of Batches	03		
Date of Submission	27-06-2019 (Dy. No. 9808)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT	
Documents To Be Provided	**Status**
Certificate of analysis of API.	Yes
Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	The firm has submitted copy of GMP Certificate for M/s Industriale Chimica s.r.l., Via E. H. Grieg 13 – SARONNO (VA), Italy issued by AIFA, Italy valid upto 20-10-2020.
Protocols followed for conduction of stability	Yes

study and details of tests.	
Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
Documents confirming import of API etc.	**Budesonide micronized**: The firm has submitted copy of invoice for the purchase of Budesonide (175gm), attested by Assistant Director (I & E) DRAP, Karachi dated 05-10-2016 has been submitted. **Formoterol Fumarate dihydrate micronized:** The firm has submitted copy of invoice for the purchase of Formoterol fumarate micronized (2.00gm), attested by Assistant Director (I & E) DRAP, Karachi dated 05-10-2016 has been submitted.
All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
Commitment to continue real time stability study till assigned shelf life of the product.	Yes
Commitment to follow Drug Specification Rules, 1978.	Yes

REMARKS OF EVALUATOR

- The firm has submitted 06 months Accelerated and 06 months Real Time Stability Data for 03 Batches.

Sr. No.	Observations	Response of the firm
•	The submitted GMP certificate mentions name of API manufacturer as M/s Industriale Chimica s.r.l., via E. H. Grieg 13 – Saronno (VA), Italy while that mentioned on COA and invoice are M/s CHEMO S.A., Lugano Branch, Via F. Pelli 17, P.O. Bo, 6901, Lugano, Switzerland. Clarification is required.	The firm has submitted that both APIs are manufactured by Industriale Chimica s.r.l., vial E.H Grieg 13- Saronno (VA), Italy and also mentioned in COA. Whereas chemo serves as the supplier of both the APIs.
•	GMP certificate submitted is issued by *Directorate General for Animal Health and Veterinary Medicinal Products* while applied formulation is for human use. Clarification needs to be submitted in this regard.	The firm has submitted copy of GMP certificate for issued by AIFA, Italy valid till 20-10-2020.
•	Details of stability studies indicate that you have not performed tests of Aerodynamic particle size and uniformity of delivered dose required for Dry Powder inhalers (DPIs) as per decision of 290th meeting of Registration Board. Clarification/ justification is required.	The firm has submitted that we had initiated stability studies for our stability batches SB01, SB02 and SB03 on 1st October 2018. Prior to the board guidance on the DPI we were performing the content uniformity test only. Once the guidance was issued in DRB 290 held in July 2019 we performed DDU on month 9, 12, 18 and 24 and APSD on month 12, 18 and 24 on stability batches placed on ambient conditions. Additionally, we are working on conducting comparative studies of our product with innovator brand "Symbicort". Since we are in process of procuring the innovator product alongwith other items necessary to conduct comparative study at the time of stability audit.

		Proof of equipment to perform DDU and APSD tests by virtue of FID report is attached.
•	Performance of the test of content uniformity in addition to the test of DDU needs to be submitted.	The firm has submitted results of content uniformity tests.
•	Submit the label claim for "Target Delivery Dose" based upon the studies with the intended delivery system under defined test conditions.	The firm submitted label claim of Target delivery dose without performance of test.
•	Description of the delivery device (inhaler) intended to be marketed along with the applied formulation shall be submitted.	The firm replied that, "The said application is for the registration of DPI capsules only. We don't market any delivery device with the product. In order to make it convenient for ailing masses of Pakistan, we make the product compatible with most of the delivery devices available in Pakistan by extensive testing before commercial release of the product. The firm has now submitted that we are using a DPI device also known as "ROBUST-H03" manufactured by Rizwan associate. Product code: *HALER-H03*
•	Submitted finished product specifications declare the assay limits as 90% - 120% of label claim for both APIs. Justification should be submitted in this regard.	The firm submitted that the stated product is not a pharmacopoeial product and therefore the assay limit (80%-120%) is set according to the other pharmacopoeial product which are mentioned in BP. The limits of Budesonide and Formoterol for APSD were computed as per the limits provided in the USP for Fluticasone + Salmeterol inhalation powder. No other guidance was available in any general chapter.
•	Analytical record for the test of Uniformity of delivered dose, Aerodynamic particle size distribution and foreign particulate matter has not been submitted.	The firm has submitted that tests for uniformity of delivered dose and aerodynamic particle size distribution has been performed and all were submitted.
•	Submitted specifications does not include test for Particle size distribution since reference product literature states that the particle size distribution is crucial to achieving the required delivered dose and lung deposition characteristics.	Performance of APSD provides details of particle size distribution as per CQA developed in house. Also, the active pharmaceutical ingredients used have particle size in the range required for DPI products. Details of particle size for the active used is given below: **Budesonide:** Particle size **Test: D99 (Indicates 99% of particle size)** Specification: Not more than 5 µm Result: 3.49 µm (indicates 99% of particles are less than 3.49 µm. **Test: D90 (Indicates 99% of particle size)** Specification: Not more than 2.8 µm Result: 2.25 µm (indicates 90% of particles are less than 2.25 µm. **Formoterol:** Particle size Test: D90 (Indicates 90% of particle size) Specification: Not more than 4.3 µm

		Result: 3.0 µm (indicates 90% of particles are less than 3.0 µm. **Test: D50 (Indicates 50% of particle size)** Specification: Not more than 2.3 µm Result: 1.6 µm (indicates 50% of particles are less than 1.6 µm). **Test: D10 (Indicates 10% of particle size)** Specification: Not more than 1.0 µm Result: 0.8 µm (indicates 10% of particles are less than 0.8 µm).

- The case was processed for panel inspection for product specific inspection, however till date no inspection report has been received.

Further submission by the firm:

The firm in its response vide Dy no. 2853 dated 05-10-2022 has submitted that they got inspection letter on 04-11-2021 and that the inspection was conducted on 01-12-2021 and the panel guided us to manufacture new batches using high shear mixer and again perform stability studies and submit to DRAP. However, no inspection report is received in PEC.

Firm has submitted stability study data of newly manufactured batches and the product specific inspection report is not yet received. The detailed summary of newly submitted data is as under:

STABILITY STUDY DATA

Manufacturer of API	**Formoterol Fumarate**:M/s Aarti Industries Limited Plot No. E-50, Unit-IV, MIDC, Tarapur Taluka & District Palghar Mahrashtra State India. **Budesonide**: M/s Industriale Chimica S.r.l.Via E. H. Grieg, 1321047 Saronno (VA) ITALY		
API Lot No.	**Formoterol Fumarate:** FF-18002(JM-01)-001**, Budesonide:** PR182023		
Description of Pack (Container closure system)	Alu-Alu Blister of 30's packed in printed unit carton		
Stability Storage Condition	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	SB-BF-DP-01	SB-BF-DP-02	SB-BF-DP-03
Batch Size	5.0 Kg	5.0 Kg	5.0 Kg
Manufacturing Date	02-2022	03-2022	03-2022
Date of Initiation	24-03-2022	24-03-2022	24-03-2022
No. of Batches	03		
Date of Submission	05-10-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Firm has referred to previous inspection report of their product Brinzoson Eye Drops which was carried out on 08-10-2020 and the report was preseted in 297th meeting of Registration Board. The report confirms following points: • HPLC system is 21 CFR compliant • Audit trail report were available.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	The firm has submitted API CoAs i.e. API manufacturer and FPP manufacturer (Hudson Pharma Pvt. Ltd.)
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	The firm has submitted both APIs method of testing i.e. API manufacturer and FPP manufacturer (Hudson Pharma Pvt. Ltd.)

<table>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td><s>The firm has already provided the both APIs stability data.</s></td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Formoterol Fumarate: Firm has submitted copy of GMP certificate (No. 92338/2020/11/32133) of M/s Aarti Industries Limited Plot No. E-50, Unit-IV, MIDC, Tarapur Taluka & District Palghar Mahrashtra State India dated 30-05-2021 by FDA Mahrashtra. The certificate is valid till 09-06-2023.
Budesonide: Firm has submitted copy of GMP certificate (No. IT-API/98/Hl2019) of M/s Industriale Chimica S.r.l.Via E. H. Grieg, 1321047 Saronno (VA) ITALY issued by AIFA Italy on the basis of inspection dated 21-09-2018.</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Formoterol Fumarate:
The firm has submitted ADC attested invoice dated 25-02-2019 with their CoAs
<table>
<tr><th colspan="4">Formoterol Fumarate</th></tr>
<tr><td>Batch No.</td><td>Date of clearance</td><td>Invoice No.</td><td>Quantity Import</td></tr>
<tr><td>FF-18002(JM-01)-001</td><td>25-02-2019</td><td>Ex/6963/18</td><td>0.020 Kg</td></tr>
</table>
Budesonide:
The firm has submitted ADC attested invoice dated 21-02-2019 with their CoAs
<table>
<tr><th colspan="4">Budesonide (Micronized)</th></tr>
<tr><td>Batch No.</td><td>Date of clearance</td><td>Invoice No.</td><td>Quantity Import</td></tr>
<tr><td>PR182023</td><td>21-02-2019</td><td>CS-19/01540</td><td>0.390Kg</td></tr>
</table></td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>The firm has submitted protocol for 03 stability batches.</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>The firm has submitted complete method of testing for FPP.</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has submitted that they have used the same excipient as used by innovator (Symbicort), therefore compatibility studies are not needed.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has manufactured 03 new stability batches for the stability studies
<table>
<tr><th>Batch No.</th><th>Mfg. date</th><th>Batch size</th></tr>
<tr><td>SB-BF-DP-01</td><td>02-2022</td><td>5.0 Kg</td></tr>
<tr><td>SB-BF-DP-02</td><td>03-2022</td><td>5.0 Kg</td></tr>
<tr><td>SB-BF-DP-03</td><td>03-2022</td><td>5.0 Kg</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>The firm has performed comparative studies with Formiget (Getz Pharma) & Venticort (Macter Pharma) DPI Rotacaps in respect of Assay for APIs, Content uniformity, Delivered dose unit & aerodynamic particle size distribution</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>The firm has submitted stability study data of three batches</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>The firm has submitted the record of HPLC software 21CFR & audit trail reports on product testing</td></tr>
</table>

14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm has submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator:

- Firm has submitted tests of delivered dose uniformity and aerodynamic particle size distribution apart from other routine tests as per specifications during stability studies.
- Firm has not submitted the details of the device used with the DPIs.
- Firm has not submitted stability data of both APIs
- The GMP certificate of budesonide is not valid.

Decision: Approved with Innovator's specifications.

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Registration Board further decided that following details of "Accompanyiing Delivery device" shall be declared on registration letter:**

  "Device Name: ROBUST-H03
  Model No: HALER-H03
  Manufacturer: Rizwan Associate".

Registration letter will be issued upon submission of following:

- **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**
- **Evidence of availability of separate dispensing booth for steroidal formulations,**

b. Deferred cases

Sr. No.	Name & Address of Manufacturer / Applicant	Brand Name (Proprietary Name + Dosage Form + Strength), Composition, Pharmacological Group, Finished Product Specification	Type of Form, Initial Diary & Date, Fee (including differential fee), Demanded Price / Pack size	International Availability / Local Availability GMP Inspection Report Date & Remarks
92.	M/s Remington Pharmaceutical Industries (Pvt) Ltd., 18 Km Multan Road, Lahore.	Nepaday Ophthalmic Suspension 0.3% Each ml contains: Nepafenac … 3.0mg Anti-inflammatory agent	Form 5-D Dy. No.Nil dated 18-09-2013 Rs.60,000/- Differential fee of 90,000/- on 20th January 2014 (1,50,000/-) plastic vial fitted with dropping nozzle and hard PVC Pilfer Proof cap containing solution in two pack sizes 5ml, 10ml	Ilevro Ophthalmic suspension by Novartis (**USFDA** Approved)
	Decision of previous meeting of Registration Board: • Deferred for expert opinion by Gen Mazhar, Head Al-Shifa Eye Trust and Head PIMS (**M-242**) • Registration Board discussed and agreed to above expert opinions for registration of drugs. However, the Board advised the firm to provide product development data alongwith stability studies as per ICH/WHO guidelines for consideration. (**M-247**).			
STABILITY STUDY DATA				

Drug	Nepaday Ophthalmic Suspension 0.3%		
Name of Manufacturer	M/s Remington Pharmaceutical Industries (Pvt) Ltd., 18 Km Multan Road, Lahore.		
Manufacturer of API	Jinan Kehui Pharmaceutical Sci & Tech Co. Ltd. 21- Huaxin Road, Jinan City China		
API Lot No.	161101		
Description of Pack (Container closure system)	5ml suspension in 10ml LDPE bottle with polypropylene nozzle and hard HDPE cap.		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, (Months)		
Batch No.	RD-17146	RD-17147	RD-17163
Batch Size	5 L	5 L	5 L
Manufacturing Date	15-8-2017	16-8-2017	18-9-2017
Date of Initiation	22-8-2017	23-8-2017	26-9-2017
No. of Batches	03		
Date of Submission	Dy.# 12075 dated 02-04-2018		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	COA of API	Firm has submitted COA of nepafenac Batch # 161101 manufactured by Jinan Kehui Pharmaceutical Sci & Tech Co. Ltd.
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	**Submitted GMP certificate is in Chinese language**
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
5.	Documents confirming import of API etc.	Firm has submitted ADC commercial invoice provided by Hangzhou Rainbow Import and Export Co. Ltd. The invoice was cleared on 14-12-2017.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

REMARKS OF EVALUATOR

After initial evaluation firm was communicated with shortcomings on 24-4-2018, the response of the firm was received, which is still deficient for following observations.

Shortcomings communicated to the firm after evaluation	Reply of the firm
• Master formulation and method of manufacturing required to be submitted for verification of stability studies.	Firm has submitted master formulation without any overage. The amount of nepafenac added is exactly as per the label claim i.e. 3mg/ml.
• GMP Certificate issued by relevant reference regulatory authority of the country / state of origin as per the decision of Registration Board in its 274th meeting, since the submitted GMP certificate is in Chinese language instead of English.	Firm has submitted that they have requested the API manufacturer to provide GMP certificate.
• The assay values above 100% at accelerated and real time conditions for all the three batches need scientific justification.	Firm has submitted that their **in-house** specification for assay has limit 90-110%, overage is added to compensate the process loss and to maintain the product quality during shelf life. **While addressing to point 1, the master formulation submitted by the firm do not contain any overage.**
• Specify the density of the product, which is also used in calculation of assay results.	Firm has submitted that the density of the product is calculated as 1.0401 g/ml.
• Justify the manufacturing of stability batches on 15-08-2017, 16-08-2017 and 18-09-2017 while the API was cleared by ADC on 14-12-2017.	Firm has submitted copy of ADC attested invoice of batch 161101 which was cleared on 3-3-2017. Firm has submitted that they have used this batch of API for manufacturing of all the three batches.
Justify the complete stability data of Batch RD-17163, since this batch was manufactured on 18-9-2017 and the stability was initiated on 26-9-2017. Justify the submission of 6th month stability data on 2nd April 2018.	Firm has submitted that the analytical work was started on 02-04-2018, although the six month interval was completed on 26-3-2018. The analytical work was delayed by one week due to work load in QC and this delay has no impact on quality of the stability testing. **As per the submission of firm, the analytical work was started on 02-04-2018 and the firm has submitted result of all analysis (including sterility test) conducted in Lahore, on the same day in DRAP office Islamabad. Furthermore Firm has specified BP specifications for sterility testing in their "finished product specification" which specify 14 days for the samples to be kept for stability testing.**

Decision of 284th meeting of Registration Board:

Registration Board deferred the case for following submission:

- Justification and scientific rational regarding the assay values above 100% in all batches at accelerated and real time conditions while the master formulation do not contains any overage.
- Submission of GMP Certificate of the API manufacturer issued by relevant (i.e. provincial or federal) reference regulatory authority of China.
- Justification of submission of complete stability study data along with analytical results (including sterility test) on 02-04-2018, since the analytical work including stability test of Batch RD-17163 was also initiated on the same day i.e. 02-04-2018 and the firm has specified BP specifications for sterility testing in their "finished product specification" which specify 14 days for the samples to be kept for stability testing.

Submission by the firm:

Firm has submitted stability study data of newly manufactured batches. The detailed summary of newly submitted data is as under:

STABILITY STUDY DATA

Manufacturer of API	M/s Pioneer Agro Industries, Plot No. 8, 6, 7, 20, MIDC Industrial Area, Post Kulgaon, Badlapur District, Thane, Maharashtra State India.		
API Lot No.	NE/002/03/21		
Description of Pack (Container closure system)	LDPE Bottles with polypropylene white cap and LDPE nozzle, further packed in unit carton with PIL		
Stability Storage Condition	**Real time:** 30˚C ± 2˚ C / 35% ± 5% RH, 30˚C ± 2˚ C / 75% ± 5% RH, 25˚C ± 2˚ C / 60% ± 5% RH, **Accelerated:** 40 °C ± 2 °C / NMT 25% ± 5% , 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6 (months)		
Batch No.	E21009	E21010	E21011
Batch Size	5 Litre	5 Litre	5 Litre
Manufacturing Date	8-11-2021	10-11-2021	15-11-2021
Date of Initiation	25-11-2021	26-11-2021	3-12-2021
No. of Batches	03		
Date of Submission	30-09-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	NA
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA (Batch# NE/002/03/21) of API (Nepafenac) from M/s Pioneer Agro Industries, Plot No. 8, 6, 7, 20, MIDC Industrial Area, Post Kulgaon, Badlapur District, Thane, Maharashtra State India are submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
4.	Stability study data of API from API manufacturer	Nepafenac: Firm has submitted stability study data of API as per zone IV-A. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 36 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 6 months at intervals 0, 3, 6, 9, 12, 18, 24 , 36 & 0, 1, 2, 3 & 6 months respectively. Batches:(RD/NF014/06/14, RD/NF015/06/14, RD/NF016/06/14)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate dated 24-08-2020 in the name of M/s Pioneer Agro Industries, Plot No. 8, 6, 7, 20, MIDC Industrial Area, Post Kulgaon, Badlapur District, Thane, Maharashtra State India issued by Food &

<table>
<tr><td></td><td></td><td>Drugs Administration (Maharashtra State). Valid till 09-08-2023.</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>The firm has submitted copy of invoice No. PAI/009/21-22 dated 03/05/2021 from exporter M/s Pioneer Agro Industries, Plot No. 8, 6, 7, 20, MIDC Industrial Area, Post Kulgaon, Badlapur District, Thane, Maharashtra State India, for import of 530gm of Nepafenac (Batch No. NE/002/03/21) in name of M/s Pioneer Agro Industries. Lahore attested by AD (I&E) DRAP Lahore dated 03-06-2021.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Firm has submitted protocols for stability studies.</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Firm has submitted method used for analysis of FPP</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Drug-excipients compatibility studies is not applicable since the qualitative composition is similar as that of the innovator’s product.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>E21009</td><td>5 Litre</td><td>8-11-2021</td></tr>
<tr><td>E21010</td><td>5 Litre</td><td>10-11-2021</td></tr>
<tr><td>E21011</td><td>5 Litre</td><td>15-11-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>Not applicable</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Firm has submitted stability data of 3 batches</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Firm has submitted certificate of compliance for CFR</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted record of digital data logger for stability studies.</td></tr>
<tr><td colspan="3">Remarks of Evaluator:</td></tr>
<tr><td colspan="3">Decision: Approved with Innovator’s specifications. The firm shall submit fee of Rs. 30,000/- for submission fnew stability studies data as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.
• Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.</td></tr>
</table>

Sr. No.	Name & Address of Manufacturer / Applicant	Brand Name (Proprietary Name + Dosage Form + Strength), Composition, Pharmacological Group, Finished Product Specification	Type of Form, Initial Diary & Date, Fee (including differential fee), Demanded Price / Pack size	International Availability / Local Availability GMP Inspection Report Date & Remarks
93.	M/s Pharmevo (Pvt) Ltd., Plot # A-29, North Western	Doxab 15mg Tablet Each film coated tablet contains:	Form 5D 09-02-2018 PKR 50,000/-	Savaysa Tablet (**USFDA** Approved)

	Industrial zone, Port Qasim, Karachi.	Edoxaban (as tosylate monohydrate)….15mg Anticoagulant	(09-02-2018) (**DUPLICATE DOSSIER)**	Last inspection dated 23-02-2018 confirms that the firm is operating at an acceptable level of GMP compliance
	Evaluation by PEC: Firm has submitted accelerated and real time stability data of 6 months as per the requirement of Registration Board.			

STABILITY STUDY DATA			
Drug	Doxab 15mg Tablet		
Name of Manufacturer	M/s Pharmevo (Pvt) Ltd., Plot # A-29, North Western Industrial zone, Port Qasim, Karachi.		
Manufacturer of API	Jiangsu Yongan Pharmaceutical Co. Ltd. No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu China.		
API Lot No.	0300-201604001		
Description of Pack (Container closure system)	Large orange to orange color round shape film coated tablet having a bisect line on one side and plain from other side		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	18PD-2206-02-T	18PD-2207-03-T	18PD-2208-04-T
Batch Size	2500 Tablet	2500 Tablet	2500 Tablet
Manufacturing Date	Jan-2018	Jan-2018	Jan-2018
Date of Initiation	26-04-2018	26-04-2018	26-04-2018
No. of Batches	03		
Date of Submission	Dy.# 6653 dated 21-05-2019		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	**Documents To Be Provided**	**Status**
1.	COA of API	Yes
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. JS20160548) issued by China Food and Drug Administration valid till 03-03-2021
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
5.	Documents confirming import of API etc.	Firm has submitted ADC attested invoice dated 23-05-2016 specifying import of 1200gm edoxaban tosylate.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes

7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

REMARKS OF EVALUATOR

Shortcoming communicated	Response received by the firm
Justify the acceptance criteria of dissolution test i.e. NLT 75% after 30 minutes without defining the value of "Q" since the value of Q at level S1 is defined between 75 to 80 in various guidance documents of EDQM, FDA guidance documents and USP and the overall acceptance criteria for level S1 is set as Q+5.	Firm has submitted that we have set the dissolution specification NLT 75% as per USFDA and USP general chapter 1092. As per the revised specifications provided by the firm the value of "Q" is 75% and the overall acceptance criteria at S1 level is NLT 80% in 30 minutes.
Justify the difference in initial testing conducted at 23-01-2018 and initiation of stability studies at 26-04-2018.	Firm has submitted that *"the initial testing of edoxaban was carried out on 23-01-2018 and then initial testing report was provided to product development department, but delayed due to delay in blistering of this product due to other priority products"* **The firm has performed initial testing on 23-01-2018 and the samples were placed in stability chambers on 26-04-2018, the impact of delay in initiation of stability studies on the outcomes of stability results needs to be determined.**
Provide the detail of quantities of API used in the development and testing of Doxab 15, 30 and 60mg strengths, since the same material (imported vide invoice No. ZY16050503G/W) has been used for the development of all strengths of Doxab.	Firm has submitted material stock record for edoxaban which specifis that 28.865gm API is still remaining. **According to the submitted stock record, the manufacturer of API is Suzhou Biotechnology Co. Ltd, while as per the rest of documents API manufacturer is Jiangsu Yongan Pharmaceutical Co. Ltd**
Justify the finished product specification without the test for content uniformity	Firm has submitted that they are not performing content uniformity test on new drug product at initial stage but after getting registration from DRAP after inspection on commercial batches we include the test of content uniformity as per guidelines.

Decision of 291st meeting of Registration Board:

Deferred for following:

- Scientific justification for initiation of stability studies 3 months after the initial testing of the applied product.
- Clarification since the manufacturer of API mentioned on submitted stock report is Suzhou Biotechnology Co. Ltd, while as per the rest of documents along with stability data the API manufacturer is Jiangsu Yongan Pharmaceutical Co. Ltd. China.

Response by the firm:

Sr. No	Reason for deferment	Response by the firm
1.	Scientific justification for initiation of stability studies 3 months after the initial testing of the applied product.	Product was manufactured on January, 2018, tested initially on January 2018 and blistered on April, 2018. Though there was a noticeable time period between the date of initial testing and date of 3rd month testing stability studies but it is important to mention here that even after considerable gap between initial testing and 3rd month testing of stability studies, product found to be compliance as per the defined specifications.

		Furthermore stability study results at both conditions i.e. long term and accelerated, are well within specification, showing that the product was properly stored and no effect was occurred due to this delay in stability testing initiation.
2.	Clarification since the manufacturer of API mentioned on submitted stock report is Suzhou Biotechnology Co. Ltd, while as per the rest of documents along with stability data the API manufacturer is Jiangsu Yongan Pharmaceutical Co. Ltd. China.	The API has been manufactured by Jiangsu Yongan Pharmaceutical Co. Ltd. may be confirmed by the submitted cGMP whereas Suzhou Biotechnology Co. Ltd. as an exporter of Edoxaban, declaration letter is also attached.

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. 04 Registration applications of Form-5 cases

a) New cases

94.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories. 41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Podo-JR 50mg/5ml Dry Suspension
	Composition	Each 5ml Contains: Cefpodoxime As Proxetil…50mg
	Diary No. Date of R& I & fee	Dy No. 39401: 30-11-2018 PKR 20,000/-: 30-11-2018 Duplicate dossier received vide Dy No. 1559 dated 17-01-2023
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Oribro suspension by Tabros Pharma
	GMP status	Last GMP inspection dated 03-03-2022 and the report concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
95.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories. 41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Ala-D XR 60/120 mg Tablets
	Composition	Each Extended Release Tablet Contains: Fexofenadine Hydrochloride…60mg Pseudoephidrine Hydrochloride…120mg
	Diary No. Date of R& I & fee	Dy No. 39396: 30-11-2018 PKR 20,000/-: 30-11-2018 Duplicate dossier received vide Dy No. 1564 dated 17-01-2023
	Pharmacological Group	Other antihistamines for systemic use - Nasal decongestant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved (Over-the-counter drug) as bilayer tablet Telfast Decongestant Tablet (TGA Approved) Bi-layer, capsule shaped, film coated tablets
	Me-too status	Telfast D Tablet by Sanofi Aventis

	GMP status	Last GMP inspection dated 03-03-2022 and the report concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator[3].	• Evidence of bilayer tablet machine. • Reference product is available as a bilayer extended release film coated tablet, revise your label claim as per the reference product along with submission of full fee as per the following: Each bilayer extended release film coated tablet Contains: Fexofenadine HCl…60mg Pseudoephedrine HCl…120mg
	Decision: Deferred for revisionof formulation to "bilayer extended release film coated tablet" as per innovator product along with submission of evidence of availability of bi-layer compression machine.	
96.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories.** **41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Tibuten 400mg Capsule
	Composition	Each Capsule Contains: Ceftibuten As Dihydrate…400mg
	Diary No. Date of R& I & fee	Dy No. 39411: 30-11-2018 PKR 20,000/-: 30-11-2018 Duplicate dossier received vide Dy No. 1559 dated 17-01-2023
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed (discontinued in USFDA)
	Me-too status	Xigris Capsule by Wilshire
	GMP status	Last GMP inspection dated 03-03-2022 and the report concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator[3].	• Evidence of required manufacturing facility / section approval letter from Licensing Division. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
97.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories.** **41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Tibuten 90mg/5ml Dry Suspension
	Composition	Each 5ml Contains: Ceftibuten As Dihydrate…90mg
	Diary No. Date of R& I & fee	Dy No. 38409: 30-11-2018 PKR 20,000/-: 30-11-2018 Duplicate dossier received vide Dy No. 1562 dated 17-01-2023
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed (discontinued in USFDA)
	Me-too status	Xigris suspension by Wilshire
	GMP status	Last GMP inspection dated 03-03-2022 and the report concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
98.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories.** **41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Tibuten 180mg/5ml Dry Suspension

	Composition	Each 5ml Contains: Ceftibuten As Dihydrate…180mg
	Diary No. Date of R& I & fee	Dy No. 39410: 30-11-2018 PKR 20,000/-: 30-11-2018 Duplicate dossier received vide Dy No. 1561 dated 17-01-2023
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed (discontinued in USFDA)
	Me-too status	Could not be confirmed
	GMP status	Last GMP inspection dated 03-03-2022 and the report concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm**	
99.	**Name and address of manufacturer / Applicant**	**M/s Winbrains Research Laboratories. Plot No. 69/1, Block B, Phase I-II, Industrial Estate, Hattar, Pakistan**
	Brand Name +Dosage Form + Strength	D-Tral 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline As HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 16682: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 12-10-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
100.	**Name and address of manufacturer / Applicant**	**M/s Winbrains Research Laboratories. Plot No. 69/1, Block B, Phase I-II, Industrial Estate, Hattar, Pakistan**
	Brand Name +Dosage Form + Strength	D-Tral 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline As HCl…100mg
	Diary No. Date of R& I & fee	Dy No. 16683: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 12-10-2022
	Remarks of the Evaluator[3].	•

	Decision: Approved.	
101.	**Name and address of manufacturer / Applicant**	**M/s Welwink Pharmaceuticals.Factory G.T. Road, Industrial Estate, Gujranwala Cantt**
	Brand Name +Dosage Form + Strength	M Zin 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…50mg
	Diary No. Date of R& I & fee	Dy No. 16967: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 28-07-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
102.	**Name and address of manufacturer / Applicant**	**M/s Welwink Pharmaceuticals.Factory G.T. Road, Industrial Estate, Gujranwala Cantt**
	Brand Name +Dosage Form + Strength	M Zin 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…100mg
	Diary No. Date of R& I & fee	Dy No. 16968: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 28-07-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
103.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Amlod V 5/80mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine As Besylate…5mg Valsartan…80mg
	Diary No. Date of R& I & fee	Dy No. 14776: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
104.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Amlod V 5/160mg Tablet

	Composition	Each Film Coated Tablet Contains: Amlodipine As Besylate…5mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 14774: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
105.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Amlod V 10/160mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine As Besylate…10mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 14775: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
106.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Ito win Tablet 50mg
	Composition	Each Film Coated Tablet Contains: Itopride HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 14800: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antiemetics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	PMDA Japan Approved
	Me-too status	Ganaton Tablet by Abbott
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
107.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Lacaso 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…50mg

	Diary No. Date of R& I & fee	Dy No. 14799: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
108.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Laksawin Tablet 100mg
	Composition	Each Film Coated Tablet Contains: Lacosamide…100mg
	Diary No. Date of R& I & fee	Dy No. 14647: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
109.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Wincetam tablet 250mg
	Composition	Each Film Coated Tablet Contains: Levetiracetam…250mg
	Diary No. Date of R& I & fee	Dy No. 14788: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
110.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Wincetam tablet 500mg
	Composition	Each Film Coated Tablet Contains: Levetiracetam…500mg
	Diary No. Date of R& I & fee	Dy No. 14789: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
111.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Wincetam oral solution 100mg/ml
	Composition	Each ml Contains: Levetiracetam…100mg
	Diary No. Date of R& I & fee	Dy No. 14787: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark oral solution by Searle
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
112.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Monty 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Montelukast As Sodium…10mg
	Diary No. Date of R& I & fee	Dy No. 14795: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Leukotriene receptor antagonists
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Montiget Tablet by Getz
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
113.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Ruvasta 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium…10mg
	Diary No. Date of R& I & fee	Dy No. 14641: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.

	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Rosuvastatin (as Calcium)…10mg
	Decision: Approved as per following label claim: **"Each Film Coated Tablet Contains:** **Rosuvastatin (as Calcium) ……10mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
114.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Serta 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 14784: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Sertraline (as HCl)…50mg
	Decision: Approved as per following label claim: **"Each Film Coated Tablet Contains:** **Sertraline (as HCl) …… 50mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
115.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Serta Tablet 100mg
	Composition	Each Film Coated Tablet Contains: Sertraline HCl…100mg
	Diary No. Date of R& I & fee	Dy No. 14785: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Sertraline (as HCl)…100mg
	Decision: Approved as per following label claim: **"Each Film Coated Tablet Contains:** **Sertraline (as HCl) …… 100mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
116.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**

	Brand Name +Dosage Form + Strength	Terbena 125mg Tablet
	Composition	Each Tablet Contains: Terbinafine HCl…125mg
	Diary No. Date of R& I & fee	Dy No. 14781: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	LAMISIL terbinafine 125mg (as hydrochloride) tablet blister pack TGA Australia Approved
	Me-too status	Terbitec Tablet by Fynk Pharma
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
117.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Terbena 250mg Tablet
	Composition	Each Tablet Contains: Terbinafine HCl…250mg
	Diary No. Date of R& I & fee	Dy No. 14782: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	LAMISIL terbinafine 125mg (as hydrochloride) tablet blister pack TGA Australia Approved
	Me-too status	Terbitec Tablet by Fynk Pharma
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
118.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Valturn Tablet 80mg
	Composition	Each Film Coated Tablet Contains: Valsartan…80mg
	Diary No. Date of R& I & fee	Dy No. 14777: 07-03-2019 PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Valtec Tablets by Tabros
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
119.	**Name and address of manufacturer / Applicant**	**M/s Winthrox Laboratories Pvt Ltd. K-219/A, S.I.T.E, Super Highway, Phase-II, Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Valturn 160mg Tablet
	Composition	Each Film Coated Tablet Contains: Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 14778: 07-03-2019

		PKR 20,000/-: 28-02-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Valtec Tablets by Tabros
	GMP status	The last inspection conducted on 31-01-2022 and report concludes that overall GMP compliance was found good.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
120.	**Name and address of manufacturer / Applicant**	**M/s Pearl Pharmaceuticals Plot No. 204, Street No.1, I-10/3, Islamabad**
	Brand Name +Dosage Form + Strength	Treclin Gel 12/0.25mg
	Composition	Each gm of Gel Contains: Clindamycin As Phospate…12mg Tretinoin …0.25mg
	Diary No. Date of R& I & fee	Dy No. 16175: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antiinfectives for treatment of acne
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Veltin Gel (USFDA Approved)
	Me-too status	Clinda-T Gel by Valor Pharma
	GMP status	The last inspection conducted on 03-11-2022, the panel recommended renewal of DML.
	Remarks of the Evaluator[3].	• Firm has cream / ointment / Gel (steroid) and cream / ointment / Gel (General) section. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each gm of Gel Contains: Clindamycin Phospate…12mg Tretinoin …0.25mg
	Decision: Approved with innovator's specifications as per following label claim: "Each gm of Gel Contains: Clindamycin Phospate…12mg Tretinoin …0.25mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
121.	**Name and address of manufacturer / Applicant**	**M/s Pearl Pharmaceuticals Plot No. 204, Street No.1, I-10/3, Islamabad**
	Brand Name +Dosage Form + Strength	Pregab 50mg Capsules
	Composition	Each Capsule Contains: Pregabalin…50mg
	Diary No. Date of R& I & fee	Dy No. 16179: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	The last inspection conducted on 03-11-2022, the panel recommended renewal of DML.
	Remarks of the Evaluator[3].	•

	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
122.	**Name and address of manufacturer / Applicant**	**M/s Pearl Pharmaceuticals Plot No. 204, Street No.1, I-10/3, Islamabad**
	Brand Name +Dosage Form + Strength	Sitamin-50/500mg Tablets
	Composition	Each Film Coated Tablet Contains: Sitagliptin Phosphate Monohydrate Eq. To Sitagliptin…50mg Metformin Hydrochloride…500mg
	Diary No. Date of R& I & fee	Dy No. 16176: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	The last inspection conducted on 03-11-2022, the panel recommended renewal of DML.
	Remarks of the Evaluator[3].	•
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
123.	**Name and address of manufacturer / Applicant**	**M/s Pearl Pharmaceuticals Plot No. 204, Street No.1, I-10/3, Islamabad**
	Brand Name +Dosage Form + Strength	Sitamin-50/1000mg Tablets
	Composition	Each Film Coated Tablet Contains: Sitagliptin Phosphate Monohydrate Eq. To Sitagliptin…50mg Metformin Hydrochloride…1000mg
	Diary No. Date of R& I & fee	Dy No. 16177: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	The last inspection conducted on 03-11-2022, the panel recommended renewal of DML.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
124.	**Name and address of manufacturer / Applicant**	**M/s Pearl Pharmaceuticals Plot No. 204, Street No.1, I-10/3, Islamabad**
	Brand Name +Dosage Form + Strength	Vildomin 50/500mg Tablets
	Composition	Each Tablet Contains: Vildagliptin…50mg Metformin Hydrochloride…500mg
	Diary No. Date of R& I & fee	Dy No. 16178: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	TGA Approved
	Me-too status	Galmet Tablet by Vision Pharma

	GMP status	The last inspection conducted on 03-11-2022, the panel recommended renewal of DML.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

The Central Licensing Board in its 280th meeting held on 26th & 27th April 2021 has cancelled the Drug Manufacturing License No. 000416 by way of (formulation) of M/s Obsons Pharmaceuticals, 209-S, Quaid-e-
Azam Industrial Estate, Kot lakhpat, Lahore, conveyed vide letter No. F.1-5/84-Lic (Vol-IV) dated 25th May 2021
by Secretary Central Licensing Board. ***Later on, the Appellate Board in its meeting No. 156th held on 31st August, 2021 decided as: The Board after hearing the arguments and pursuing record of case, decided to give final opportunity of two years' period to the firm for submission of new lay out plan for approval of the Central Licensing Board. The decision of cancellation of Drug Manufacturing License by the Central Licensing Board is set aside.***
Furthermore, the firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.

125.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Amlosartan Tablet 5/80mg
	Composition	Each Tablet Contains: Amlodipine As Bsylate…5mg Valsartan…80mg
	Diary No. Date of R& I & fee	Dy No. 16056: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim to film coated tablet as per the innovator's product as under along with submission of 7,500/- fee: Each Film Coated Tablet Contains: Amlodipine As Bsylate…5mg Valsartan…80mg
	Decision: Approved as per following label claim: "Each Film Coated Tablet Contains: Amlodipine As Bsylate…5mg Valsartan…80mg" The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product decription tofilm coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
126.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Amlosartan Tablet 10/160mg
	Composition	Each Tablet Contains: Amlodipine As Bsylate…10mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 16057: 07-03-2019 PKR 20,000/-: 07-03-2019

	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim to film coated tablet as per the innovator's product as under along with submission of 7,500/- fee: Each Film Coated Tablet Contains: Amlodipine As Bsylate…10mg Valsartan…160mg
	Decision: Approved as per following label claim: "Each Film Coated Tablet Contains: Amlodipine As Bsylate…10mg Valsartan…160mg" The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product decription tofilm coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
127.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obstatin Tablet 10mg
	Composition	Each Film Coated Tablet Contains: Atorvastatin As Calcium…10mg
	Diary No. Date of R& I & fee	Dy No. 16059: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lipiget Tablet by Getz
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Atorvastatin (as Calcium trihydrate)…10mg
	Decision: Approved as per folloiwng label claim: Each Film Coated Tablet Contains: Atorvastatin (as Calcium trihydrate) …… 10mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
128.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obstatin Tablet 20mg
	Composition	Each Film Coated Tablet Contains: Atorvastatin As Calcium…20mg
	Diary No. Date of R& I & fee	Dy No. 16060: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lipiget Tablet by Getz
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Atorvastatin (as Calcium trihydrate)…20mg
	Decision: Approved as per folloiwng label claim: Each Film Coated Tablet Contains: Atorvastatin (as Calcium trihydrate) …… 20mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
129.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obizex Tablet 8mg
	Composition	Each Tablet Contains: Betahistine Dihydrochloride…8mg
	Diary No. Date of R& I & fee	Dy No. 16079: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antivertigo preparations
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Serc Tablet by Abbott
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
130.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obizex Tablet 16mg
	Composition	Each Tablet Contains: Betahistine Dihydrochloride…16mg
	Diary No. Date of R& I & fee	Dy No. 16065: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antivertigo preparations
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Serc Tablet by Abbott
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
131.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obcoline Syrup 500mg/5ml
	Composition	Each 5ml of Syrup Contains: Citicoline As Sodium…500mg
	Diary No. Date of R& I & fee	Dy No. 16068: 07-03-2019 PKR 20,000/-: 07-03-2019

	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	SOMAZINE 100 mg/ml Oral Solution CIMA Spain Approved
	Me-too status	Citicode Syrup by Rotex Pharma
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
132.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals.** **209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obonal Tablet 50mg
	Composition	Each Tablet Contains: Eperisone HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 16073: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Muscle Relaxants, Centrally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Eperisone Hydrochloride Tablets 50mg "TCK" PMDA Japan Approved (Sugar coated tablet)
	Me-too status	Eprisa Tablet by Fynk Pharma
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim to sugar coated tablet as per the innovator's product as under along with submission of 7,500/- fee: Each Sugar coated Tablet Contains: Eperisone HCl…50mg
	Decision: Approved as per following label claim: **"Each Sugar coated Tablet Contains:** **Eperisone HCl…50mg"** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to sugar coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
133.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals.** **209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obitop Tablet 50mg
	Composition	Each Film Coated Tablet Contains: Itopride HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 16058: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiemetics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	PMDA Japan Approved
	Me-too status	Ganaton Tablet by Abbott
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•

	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
134.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Oblonid tablet 10mg
	Composition	Each Film Coated Tablet Contains: Leflunomide…10mg
	Diary No. Date of R& I & fee	Dy No. 16072: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective immunosuppressants (L04AA)
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Leflomid Tablet by Pharmatec
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
135.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obvastatin Tablet 5mg
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium…5mg
	Diary No. Date of R& I & fee	Dy No. 16061: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Rosuvastatin (as calcium)…5mg
	Decision: Approved as per following label claim: "Each Film Coated Tablet Contains: Rosuvastatin (as calcium) ..…. 5mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
136.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obvastatin Tablet 10mg
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium…10mg
	Diary No. Date of R& I & fee	Dy No. 16062: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Rosuvastatin (as calcium)…10mg
	Decision: Approved as per following label claim: "Each Film Coated Tablet Contains: Rosuvastatin (as calcium) ..…. 10mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
137.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obvastatin Tablet 20mg
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium…20mg
	Diary No. Date of R& I & fee	Dy No. 16063: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Rosuvastatin (as calcium)…20mg
	Decision: Approved as per following label claim: "Each Film Coated Tablet Contains: Rosuvastatin (as calcium) ..…. 20mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
138.	**Name and address of manufacturer / Applicant**	**M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Obfenacin Tablet 5mg
	Composition	Each Film Coated Tablet Contains: Solifenacin Succinate…5mg
	Diary No. Date of R& I & fee	Dy No. 16069: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Drugs for urinary frequency and incontinence
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Solif Tablet by Global
	GMP status	GMP certificate issued on dated 07-03-2022 based on inspection conducted on 22-02-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
139.	**Name and address of manufacturer / Applicant**	**M/s Rasco Pharma. 5.5 Km, Raiwind Road, Lahore**

	Brand Name +Dosage Form + Strength	Kinzapine 200mg Tablet
	Composition	Each Tablet Contains: Carbamazepine…200mg
	Diary No. Date of R& I & fee	Dy No. 16935: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Xepil Tablet by shaigan
	GMP status	Inspection report dated 05-10-2022, where the panel confirmed fair level of GMP compliance and recommended issuance of GMP certificate.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
140.	**Name and address of manufacturer / Applicant**	**M/s Rasco Pharma. 5.5 Km, Raiwind Road, Lahore**
	Brand Name +Dosage Form + Strength	Sitico Syrup
	Composition	Each 5ml Contains: Citicoline Sodium Eq. To Citicoline…500mg
	Diary No. Date of R& I & fee	Dy No. 16817: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	SOMAZINE 100 mg/ml Oral Solution CIMA Spain Approved
	Me-too status	Citicode Syrup by Rotex Pharma
	GMP status	Inspection report dated 05-10-2022, where the panel confirmed fair level of GMP compliance and recommended issuance of GMP certificate.
	Remarks of the Evaluator[3].	• Firm has Liquid Syrup (General) Section.
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
141.	**Name and address of manufacturer / Applicant**	**M/s Rasco Pharma. 5.5 Km, Raiwind Road, Lahore**
	Brand Name +Dosage Form + Strength	Sycline 5mg Tablet
	Composition	Each Tablet Contains: Procyclidine HCl…5mg
	Diary No. Date of R& I & fee	Dy No. 16816: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anti-Parkinson Drugs
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Kemadrin tablet by GSK
	GMP status	Inspection report dated 05-10-2022, where the panel confirmed fair level of GMP compliance and recommended issuance of GMP certificate.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
142.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Amlosar 5/80 mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine Besylate Eq. To Amlodipine…5mg Valsartan…80mg
	Diary No. Date of R& I & fee	Dy No. 17106: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
143.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Amlosar 10/160 mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine Besylate Eq. To Amlodipine…10mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 17102: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Exforge Tablet by Novartis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
144.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	AcFre 0.2gm Cream
	Composition	Each Gram Cream Contains: Azelaic acid…0.2gm
	Diary No. Date of R& I & fee	Dy No. 17096: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other anti-acne preparations for topical use
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Acnoderm cream by Pharmevo
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section.
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
145.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Bactroid N Cream

	Composition	Each Gram Cream Contains: Betamethasone as Valerate…1mg Neomycin Sulphate…5mg
	Diary No. Date of R& I & fee	Dy No. 17077: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Corticosteroids, potent, combinations with antibiotics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Betnovate N cream by GSK
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
146.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fetirizine 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Cetirizine Dihydrochloride…10mg
	Diary No. Date of R& I & fee	Dy No. 17068: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Piperazine derivatives
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Baydal Tablet by Bayer
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
147.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Clinda 2% Vaginal Cream
	Composition	Each Gram Contains: Clindamycin as Phosphate…20mg
	Diary No. Date of R& I & fee	Dy No. 17099: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Vagibact cream by Nabiqasim
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section.
	Decision: Approved.	
148.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Feslin 5mg Tablet
	Composition	Each Film Coated Tablet Contains:

		Desloratadine…..5mg
	Diary No. Date of R& I & fee	Dy No. 17112: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antihistamines for systemic use
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Destina Tablet by Hilton
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
149.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dic-Gel 1%
	Composition	Each Gram Contains: Diclofenac Diethylamine 11.6mg Corresponding to Diclofenac Sodium…10mg
	Diary No. Date of R& I & fee	Dy No. 17076: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Dicloran gel by Sami Pharma
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section.
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
150.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	D-Pain 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Diclofenac Potassium…50mg
	Diary No. Date of R& I & fee	Dy No. 17101: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Diclorep Tablet by Sami
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
151.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fticox 30mg Tablet
	Composition	Each Film Coated Tablet Contains: Etoricoxib…30mg
	Diary No. Date of R& I & fee	Dy No. 17119: 07-03-2019 PKR 20,000/-: 07-03-2019

	Pharmacological Group	Antiinflammatory and Antirheumatic Products, Non-Steroids
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Etoxib Tablet by Hiranis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.
	Decision: Deferred for submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
152.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fticox 60mg Tablet
	Composition	Each Film Coated Tablet Contains: Etoricoxib…60mg
	Diary No. Date of R& I & fee	Dy No. 17122: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiinflammatory and Antirheumatic Products, Non-Steroids
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Etoxib Tablet by Hiranis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
153.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fticox 90mg Tablet
	Composition	Each Film Coated Tablet Contains: Etoricoxib…90mg
	Diary No. Date of R& I & fee	Dy No. 17075: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiinflammatory and Antirheumatic Products, Non-Steroids
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Etoxib Tablet by Hiranis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.
	Decision: Deferred for submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
154.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Fabix 40mg Tablet
	Composition	Each Film Coated Tablet Contains: Febuxostat…40mg
	Diary No. Date of R& I & fee	Dy No. 17067: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anti-gout Preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Zurig Tablet by Getz
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
155.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Febix 80mg Tablet
	Composition	Each Film Coated Tablet Contains: Febuxostat…80mg
	Diary No. Date of R& I & fee	Dy No. 17104: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anti-gout Preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Zurig Tablet by Getz
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
156.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fusitone 2% Cream
	Composition	Each Gram Contains: Fusidic Acid…20mg
	Diary No. Date of R& I & fee	Dy No. 17100: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antibiotics for topical use
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Fudic Cream by Shaigan
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section.
	Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter.	
157.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Itrox 100mg Capsule
	Composition	Each Capsule Contains: Itraconazole…100mg
	Diary No. Date of R& I & fee	Dy No. 17093: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antimycotics For Systemic Use
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Icon Capsule by Ferozesons
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Itraconazole (as IR pellets)…100mg
	Decision: Approved as per following label claim: **"Each Capsule Contains:** **Itraconazole (as IR pellets)…100mg"** **Firm shall submit fee for pre-approval change/correction for product label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021.**	
158.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Ketozol 2% Cream
	Composition	Each Gram Contains: Ketoconazole…20mg
	Diary No. Date of R& I & fee	Dy No. 17097: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Ketacon Cream by Davis Pharma
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Firm has cream, ointment, gel section.
	Decision: Approved.	
159.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Flanso 30mg Capsule
	Composition	Each Capsule Contains: Lansoprazole (as enteric Coated Pellets)..…30mg
	Diary No. Date of R& I & fee	Dy No. 17089: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lanzol Capsule by Pharmatec
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals
	Decision: Approved.	

160.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fetrazole 2.5mg Tablet
	Composition	Each Film Coated Tablet Contains: Letrozole…2.5mg
	Diary No. Date of R& I & fee	Dy No. 17113: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Aromatase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Femara Tablet by Novartis
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
161.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Liset 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Levetiracetam …250mg
	Diary No. Date of R& I & fee	Dy No. 17111: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
162.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Liset 500mg Tablet
	Composition	Each Film Coated Tablet Contains: Levetiracetam …500mg
	Diary No. Date of R& I & fee	Dy No. 17109: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
163.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Liset 750mg Tablet

	Composition	Each Film Coated Tablet Contains: Levetiracetam …750mg
	Diary No. Date of R& I & fee	Dy No. 17114: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
164.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Bactlos 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Levofloxacin as Hemihydrate…250mg
	Diary No. Date of R& I & fee	Dy No. 17115: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Fluoroquinolones
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Leflox Tablet by Getz Pharma
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
165.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fotadine 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Loratadine…10mg
	Diary No. Date of R& I & fee	Dy No. 17069: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiallergic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Smartec Tablet by Hilton Pharma
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Revise your label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Loratadine…10mg
	Decision: Approved as per following label claim: **"Each Tablet Contains:** **Loratadine…10mg"** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoated tablet, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
166.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Risdone 2mg Tablet
	Composition	Each Film Coated Tablet Contains: Risperidone…2mg
	Diary No. Date of R& I & fee	Dy No. 17105: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antipsychotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Neo-Risp Tablet by Wilshire
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
167.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Wart Nill Lotion
	Composition	Each Gram Gel Contains: Salicylic Acid…270mg
	Diary No. Date of R& I & fee	Dy No. 17059: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Salicylic acid preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications / available in USP as Gel
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Could not be confirmed
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Your applied brand name is Wart Nil Lotion while the applied composition is of "gel". Clarification is required in this regard along with evidence of requisite manufacturing facility. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting. • Evidence of me-too status of the clarified composition.
	Decision: Deferred for following: • **applied brand name is Wart Nil Lotion while the applied composition is of "gel". Clarification is required in this regard along with evidence of requisite manufacturing facility.** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.** • **Evidence of me-too status of the clarified composition.**	
168.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Serline 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline As HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 17107: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch

	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approvved.	
169.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Falm 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin As Phosphate Monohydrate…50mg
	Diary No. Date of R& I & fee	Dy No. 17121: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Tagip tablets by Highnoon
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
170.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Falm 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin As Phosphate Monohydrate…100mg
	Diary No. Date of R& I & fee	Dy No. 17073: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Tagip tablets by Highnoon
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
171.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Falmet 50/500 mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phosphate Monohydrate…50mg Metformin HCl…500mg
	Diary No. Date of R& I & fee	Dy No. 17103: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•

	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
172.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Falmet 50/850 mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phosphate Monohydrate…50mg Metformin HCl…850mg
	Diary No. Date of R& I & fee	Dy No. 17110: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
173.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Falmet 50/1000 mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phosphate Monohydrate…50mg Metformin HCl…1000mg
	Diary No. Date of R& I & fee	Dy No. 17120: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
174.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Sol-Fer Tablet
	Composition	Each Film Coated Tablet Contains: Solifenacin Succinate…10mg
	Diary No. Date of R& I & fee	Dy No. 17116: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Drugs for urinary frequency and incontinence
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Solif Tablet by Global

	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
175.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fung Derm Cream
	Composition	Each Gram Cream Contains: Terbinafine HCl…10mg
	Diary No. Date of R& I & fee	Dy No. 17070: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications but available in JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Terbin Cream by Seatle
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved withJP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
176.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Fresmic 4mg Capsule
	Composition	Each Hard Gelatin Capsule Contains: Thiocolchicoside…4mg
	Diary No. Date of R& I & fee	Dy No. 17078: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Muscle Relaxants, Centrally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MIOREL 4 mg, capsule ANSM France Approved
	Me-too status	Thiolax Capsule by S.J&G Fazul Ellahie
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
177.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dytor 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Torsemide…10mg
	Diary No. Date of R& I & fee	Dy No. 17118: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Diuretic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Could not be confirmed

	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Evidence of applied formulation as film coated tablet in reference regulatory authorities. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.
	Decision: Deferred for following: • **Evidence of applied formulation as film coated tablet in reference regulatory authorities.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.**	
178.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dytor 20mg Tablet
	Composition	Each Film Coated Tablet Contains: Torsemide…20mg
	Diary No. Date of R& I & fee	Dy No. 17123: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Diuretic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Could not be confirmed
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML
	Remarks of the Evaluator[3].	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.
	Decision: Deferred for following: • **Evidence of applied formulation as film coated tablet in reference regulatory authorities.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.**	
179.	**Name and address of manufacturer / Applicant**	**M/s Fresh Pharmaceuticals Plot No. 7, Street No. S-6, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dytor 40mg Tablet
	Composition	Each Film Coated Tablet Contains: Torsemide…40mg
	Diary No. Date of R& I & fee	Dy No. 17117: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Diuretic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Could not be confirmed
	GMP status	Last inspection dated 31-05-2022 where the panel recommends renewal of DML

	Remarks of the Evaluator[3].	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.
	Decision: Deferred for evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
180.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Clovira Cream 5%
	Composition	Each Gram of Cream Contains: Acyclovir …5% w/w
	Diary No. Date of R& I & fee	Dy No. 15729: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved.
	Me-too status	Zovirax cream by GSK
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
181.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Atomera 25mg Capsule
	Composition	Each Capsule Contains: Atomoxetine HCl…25mg
	Diary No. Date of R& I & fee	Dy No. 15739: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Centrally acting sympathomimetics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Moxitine Capsule by CCL
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Atomoxetine (as HCl)…25mg
	Decision: Approved as per following label claim: **"Each Capsule Contains:** **Atomoxetine (as HCl)…25mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
182.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dabaflo-5mg Tablet
	Composition	Each Film Coated Tablet Contains: Dapagliflozin…5mg

	Diary No. Date of R& I & fee	Dy No. 15744: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Daploz Tablet by Highnoon
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 293rd meeting. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Dapagliflozin as Propanediol Monohydrate…5mg
	Decision: Deferred for following: • **Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 293rd meeting.** • **Revise your label claim as per the innovator's product as under along with submission of full fee of registration:** **"Each Film Coated Tablet Contains:** **Dapagliflozin as Propanediol Monohydrate…5mg"**	
183.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Dabaflo-10mg Tablet
	Composition	Each Film Coated Tablet Contains: Dapagliflozin…10mg
	Diary No. Date of R& I & fee	Dy No. 15743: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Daploz Tablet by Highnoon
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 293rd meeting. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Dapagliflozin as Propanediol Monohydrate…10mg
	Decision: Deferred for following: • **Submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 293rd meeting.** • **Revise your label claim as per the innovator's product as under along with submission of full fee of registration:** **"Each Film Coated Tablet Contains:** **Dapagliflozin as Propanediol Monohydrate…10mg"**	
184.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	E Flor 11.5% Cream
	Composition	Each Gram of Cream Contains: Eflornithine HCl…11.5% w/w
	Diary No. Date of R& I & fee	Dy No. 15732: 07-03-2019

		PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other dermatologicals
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Eniqa Cream by Seraph Pharmaceuticals
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Gram of Cream Contains: Eflornithine (as hydrochloride monohydrate)…11.5%w/w
	Decision: Approved wih innovator's specifications as per following: **Each Gram of Cream Contains:** **Eflornithine (as hydrochloride monohydrate) …... 11.5%w/w** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
185.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	E Flor 13.9% Cream
	Composition	Each Gram of Cream Contains: Eflornithine HCl…13.9% w/w
	Diary No. Date of R& I & fee	Dy No. 15733: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other dermatologicals
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Health Canada Approved
	Me-too status	Verona Cream by Rotex Pharma
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications as per following label claim: **Each Gram of Cream Contains:** **Eflornithine hydrochloride monohydrate eq.to Eflornithine hydrochloride (anhydrous) … 13.9% w/w.** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
186.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Flopine 3/25 Capsules
	Composition	Each Capsule Contains: Fluoxetine HCl…25mg Olanzapine…3mg
	Diary No. Date of R& I & fee	Dy No. 15742: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.

	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Fluoxetine (as HCl) …..… 25mg Olanzapine…3mg
	Decision: Approved as per following label claim: **"Each Capsule Contains:** **Fluoxetine (as HCl) …..… 25mg** **Olanzapine … 3mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
187.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Flopine 6/25 Capsules
	Composition	Each Capsule Contains: Fluoxetine HCl…25mg Olanzapine…6mg
	Diary No. Date of R& I & fee	Dy No. 15741: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Fluoxetine (as HCl) …25mg Olanzapine…6mg
	Decision: Approved as per following label claim: **"Each Capsule Contains:** **Fluoxetine (as HCl) …..… 25mg** **Olanzapine … 6mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
188.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Flutimed 0.05% Cream
	Composition	Each Gram of Cream Contains: Fluticasone Propionate…0.05% w/w
	Diary No. Date of R& I & fee	Dy No. 15727: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Corticosteroids
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Cutivate cream by GSK
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved.	
189.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Nystera Ointment 0.25mg/0.25%/0.1%
	Composition	Each Gram of Ointment Contains Gramicidin…0.25mg Neomycin Sulphate…0.25% Nystatin…1000000IU Triamcinolone Acetonide…0.1%
	Diary No. Date of R& I & fee	Dy No. 15734: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Corticosteroids, combinations with antibiotics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications but available in USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Could not be confirmed
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
190.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Meloride Tablet 50/5mg
	Composition	Each Film Coated Tablet Contains: Hydrochlorothiazide…50mg Amiloride HCl…5mg
	Diary No. Date of R& I & fee	Dy No. 15740: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Diuretics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Modoretic Tablet by OBS
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim to uncoated tablet as per the innovator's product as under along with submission of 7,500/- fee: Each Tablet Contains: Hydrochlorothiazide…50mg Amiloride HCl…5mg
	Decision: Approved as per followinglabel claim: **Each Tablet Contains:** **Hydrochlorothiazide…..50mg** **Amiloride HCl……5mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
191.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Cosamide 50mg Tablet
	Composition	Each Film Coated Tablet Contains:

		Lacosamide…50mg
	Diary No. Date of R& I & fee	Dy No. 15746: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
192.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Cosamide 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…100mg
	Diary No. Date of R& I & fee	Dy No. 15747: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
193.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Medvantan 0.1% Cream
	Composition	Each Gram of Cream Contains: Methylprednisolone…0.1% w/w
	Diary No. Date of R& I & fee	Dy No. 15738: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Corticosteroids
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Could not be confirmed
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
194.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**

	Brand Name +Dosage Form + Strength	Muprin 2% Cream
	Composition	Each Gram of Cream Contains: Mupirocin…2% w/w
	Diary No. Date of R& I & fee	Dy No. 15735: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antibiotics for topical use
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Bactoderm cream by GSK
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Gram of Cream Contains: Mupirocin (as calcium)…2% w/w
	Decision: Approved as per following label claim: **"Each Gram of Cream Contains:** **Mupirocin (as calcium)..…2% w/w"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
195.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Nemar Tablet 30mg
	Composition	Each Film Coated Tablet Contains: Nimodipine…30mg
	Diary No. Date of R& I & fee	Dy No. 15745: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Calcium channel blocker
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nidopin Tablet by Global
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
196.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Seroxitin 20mg Tablet
	Composition	Each Film Coated Tablet Contains: Paroxetine HCl…20mg
	Diary No. Date of R& I & fee	Dy No. 15756: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Seroxat CR Tablet by GSK
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration:

		Each Film Coated Tablet Contains: Paroxetine (as HCl)…20mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **Paroxetine (as HCl)…20mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
197.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	E Spaz Tablet 80mg
	Composition	Each Sugar Coated Tablet Contains: Phlorglucinol…80mg Trimethylphloroglucinol…80mg
	Diary No. Date of R& I & fee	Dy No. 15736: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antispasmodic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Spasfon, coated tablet by M/s Teva Sante, ANSM France Approved.
	Me-too status	Gluwix Tablet by Wnsfield
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
198.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Epigab 50mg Capsule
	Composition	Each Capsule Contains: Pregabalin…50mg
	Diary No. Date of R& I & fee	Dy No. 15728: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
199.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Epigab 75mg Capsule
	Composition	Each Capsule Contains: Pregabalin…75mg
	Diary No. Date of R& I & fee	Dy No. 15737: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
200.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Epigab 100mg Capsule
	Composition	Each Capsule Contains: Pregabalin…100mg
	Diary No. Date of R& I & fee	Dy No. 15730: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
201.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Tazera 0.1% Gel
	Composition	Each Gram of Gel Contains: Tazarotene…0.1% w/w
	Diary No. Date of R& I & fee	Dy No. 15726: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antipsoriatics for topical use
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Trazene 0.1% Gel by Pharmaevo
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
202.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	E-Trop 5mg Capsule
	Composition	Each Capsule Contains: Tropisetron As HCl…5mg
	Diary No. Date of R& I & fee	Dy No. 15731: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	Norway Approved
	Me-too status	Navoban 5mg Capsule by Sandoz
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
203.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Vanalaxine 37.5mg Tablet
	Composition	Each Film Coated Tablet Contains: Venlafaxine As HCl…37.5mg
	Diary No. Date of R& I & fee	Dy No. 15749: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antidepressants
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Velax Tablet by Schazoo Zaka
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
204.	**Name and address of manufacturer / Applicant**	**M/s Medera Pharmaceuticals Pvt Ltd. Plot #2, Street #4, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Zolip 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Zolpidem Tartrate…10mg
	Diary No. Date of R& I & fee	Dy No. 15748: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Benzodiazepine related drugs
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Stilnox Tablet by Sanofi Aventis
	GMP status	GMP certificate issued on basis of inspection conducted on 26-10-2021.
	Remarks of the Evaluator[3].	• Evidence of required manufacturing facility (i.e. psychotropic tablet section) approval letter from Licensing Division.
	Decision: Registration Board rejected the application since firm does not have approved manufacturing facility of "Tablet (psychotropic) section".	
205.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Atoprovasc 5/10 mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine as Besylate…5mg Atorvastatin…10mg
	Diary No. Date of R& I & fee	Dy No. 15832: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	USFDA Approved.
	Me-too status	Lipifal Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Amlodipine as Besylate…5mg Atorvastatin as Calcium Trihydrate…10mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **Amlodipine as Besylate ..… 5mg** **Atorvastatin as Calcium Trihydrate …… 10mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
206.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Atoprovasc 10/20 mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine as Besylate…10mg Atorvastatin…20mg
	Diary No. Date of R& I & fee	Dy No. 15874: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved.
	Me-too status	Lipifal Plus Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Amlodipine as Besylate…10mg Atorvastatin as Calcium Trihydrate…20mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **Amlodipine as Besylate ..… 10mg** **Atorvastatin as Calcium Trihydrate …… 20mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
207.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Mobrine 15mg Capsule
	Composition	Each Capsule Contains: Cyclobenzaprine HCl…15mg
	Diary No. Date of R& I & fee	Dy No. 15862: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Muscle Relaxants, Centrally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Cyclorest ER Capsule by Martin Dow
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma

		• Firm has revise the label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Cyclobenzaprine HCl (as extended release pellets)…15mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **"Each Capsule Contains:** **Cyclobenzaprine HCl (as extended release pellets) …15mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
208.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	D-Lordin 5mg Tablet
	Composition	Each Film Coated Tablet Contains: Desloratadine…5mg
	Diary No. Date of R& I & fee	Dy No. 15940: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other antihistamines for systemic use
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Destina Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
209.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Dexofen 400mg Tablet
	Composition	Each Film Coated Tablet Contains: Dexibuprofen…400mg
	Diary No. Date of R& I & fee	Dy No. 15880: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Tercica Tablet by Sami
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
210.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Duloxin 30mg Capsule
	Composition	Each Capsule Contains: Duloxetine HCl Enteric Coated Pellets Eq. To Duloxetine…30mg
	Diary No. Date of R& I & fee	Dy No. 15844: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Other antidepressant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Dulan Capsule by Hilton

	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma
	Decision: Approved.	
211.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Duloxin 60mg Capsule
	Composition	Each Capsule Contains: Duloxetine HCl Enteric Coated Pellets Eq. To Duloxetine…60mg
	Diary No. Date of R& I & fee	Dy No. 15863: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other antidepressant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Dulan Capsule by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma
	Decision: Approved.	
212.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davipram 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Escitalopram Oxalate Eq. to Escitalopram…10mg
	Diary No. Date of R& I & fee	Dy No. 15864: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Citanew Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
213.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Festat 80mg Tablet
	Composition	Each Film Coated Tablet Contains: Febuxostat…80mg
	Diary No. Date of R& I & fee	Dy No. 15871: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Anti-gout Preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Zurig Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

214.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Allegra-D 60/120 mg Tablet
	Composition	Each Film Coated Tablet Contains: Fexofenadine HCl…60mg Pseudoephedrine HCl…120mg
	Diary No. Date of R& I & fee	Dy No. 15949: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other antihistamines for systemic use - Nasal decongestant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved (Over-the-counter drug) as bilayer tablet Telfast Decongestant Tablet (TGA Approved) Bi-layer, capsule shaped, film coated tablets
	Me-too status	Telfast D Tablet by Sanofi Aventis
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Evidence of bilayer tablet machine. • Firm has revised the label claim as per the reference product along with submission of full fee as per the following: Each bilayer extended release film coated tablet Contains: Fexofenadine HCl…60mg Pseudoephedrine HCl…120mg
	Decision: Approved as per following label claim: **"Each bilayer extended release film coated tablet Contains:** **Fexofenadine HCl…60mg** **Pseudoephedrine HCl…120mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product dosage for to bilayer extended release tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.** **Registration Board further decided that registration letter will be issued upon submission of evidence of availability of bilayer tablet compression machine.**	
215.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Gemipride 1mg Tablet
	Composition	Each Film Coated Tablet Contains: Glimepiride…1mg
	Diary No. Date of R& I & fee	Dy No. 15815: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Econid Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Glimepiride…1mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Glimepiride…1mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
216.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Gemipride 2mg Tablet

	Composition	Each Film Coated Tablet Contains: Glimepiride…2mg
	Diary No. Date of R& I & fee	Dy No. 15816: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Econid Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Glimepiride…2mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Glimepiride…2mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
217.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Gemipride 3mg Tablet
	Composition	Each Film Coated Tablet Contains: Glimepiride…3mg
	Diary No. Date of R& I & fee	Dy No. 15817: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Econid Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Glimepiride…3mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Glimepiride…3mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
218.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Gemipride 4mg Tablet
	Composition	Each Film Coated Tablet Contains: Glimepiride…4mg
	Diary No. Date of R& I & fee	Dy No. 15818: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Econid Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Glimepiride…4mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Glimepiride…4mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
219.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Isotil 20mg Tablet
	Composition	Each Film Coated Tablet Contains: Isosorbide Mononitrate…20mg
	Diary No. Date of R& I & fee	Dy No. 15812: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Organic nitrates
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications / available in USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Monosorbid Tablet by Brookes
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Isosorbide Mononitrate…20mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Isosorbide Mononitrate…20mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
220.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Gastrid 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Itopride HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 15865: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antiemetics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	PMDA Japan Approved
	Me-too status	Ganaton Tablet by Abbott
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

221.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davilap 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…100mg
	Diary No. Date of R& I & fee	Dy No. 15849: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
222.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Ledra 2.5mg Tablet
	Composition	Each Film Coated Tablet Contains: Letrozole …2.5mg
	Diary No. Date of R& I & fee	Dy No. 16450: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Aromatase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Femara Tablet by Novartis
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
223.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Levecet 1000mg Tablet
	Composition	Each Film Coated Tablet Contains: Levetiracetam…1000mg
	Diary No. Date of R& I & fee	Dy No. 15866: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
224.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Levecet 500mg Tablet

	Composition	Each Film Coated Tablet Contains: Levetiracetam…500mg
	Diary No. Date of R& I & fee	Dy No. 15868: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
225.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Lornix 8mg Tablet
	Composition	Each Film Coated Tablet Contains: Lornoxicam…8mg
	Diary No. Date of R& I & fee	Dy No. 15823: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Xefo 8mg Film-Coated Tablet, Takeda Austria GmbH, Austria approved.
	Me-too status	Zafon Tablets by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
226.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davimentin 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Memantine HCl…10mg
	Diary No. Date of R& I & fee	Dy No. 16451: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Other anti-dementia drugs
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Afdol Tablet by AGP
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
227.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Nebilet 5mg Tablet
	Composition	Each Tablet Contains: Nebivolol Hcl Eq. To Nebivolol…5mg
	Diary No. Date of R& I & fee	Dy No. 15834: 07-03-2019 PKR 20,000/-: 05-03-2019

	Pharmacological Group	Beta blocking agents, selective
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nebil Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
228.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Nebilet 10mg Tablet
	Composition	Each Tablet Contains: Nebivolol HCl Eq. To Nebivolol…10mg
	Diary No. Date of R& I & fee	Dy No. 15854: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Beta blocking agents, selective
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nebil Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
229.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Fluzapine 12/25 mg Capsule
	Composition	Each Capsule Contains: Olanzapine…12mg Fluoxetine as HCl…25mg
	Diary No. Date of R& I & fee	Dy No. 15814: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
230.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Appitant 125mg Capsule
	Composition	Each Capsule Contains: Aprepitant…125mg
	Diary No. Date of R& I & fee	Dy No. 15856: 07-03-2019 PKR 20,000/-: 04-03-2019

	Pharmacological Group	Other antiemetics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	US FDA approved
	Me-too status	Apritus 125mg Capsule of M/s S.J&G Karachi (Reg.# 074887)
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
231.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Olesta 40mg Tablet
	Composition	Each Film Coated Tablet Contains: Olmesartan Medoxomil…40mg
	Diary No. Date of R& I & fee	Dy No. 15839: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs)
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Olmie Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
232.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Levecet 100mg/ml Syrup
	Composition	Each ml Contains: Levetiracetam…100mg
	Diary No. Date of R& I & fee	Dy No. 15846: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark oral solution by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
233.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Cidopex 1.08g Tablet
	Composition	Each Extended Release Tablet Contains: Potassium Citrate…..10mEq (1080mg)
	Diary No. Date of R& I & fee	Dy No. 15934: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Mineral Supplements
	Type of Form	Form 5
	Finished Product Specification	USP

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Lithocit Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
234.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Daviquet 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Quetiapine Fumarate Eq. To Quetiapine…100mg
	Diary No. Date of R& I & fee	Dy No. 15860: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Q-Par Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
235.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Daviquet 150mg Tablet
	Composition	Each Film Coated Tablet Contains: Quetiapine Fumarate Eq. To Quetiapine…150mg
	Diary No. Date of R& I & fee	Dy No. 15681: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Quitin Tablet by Werrick
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
236.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Daviquet 200mg Tablet
	Composition	Each Film Coated Tablet Contains: Quetiapine Fumarate Eq. To Quetiapine…200mg
	Diary No. Date of R& I & fee	Dy No. 15843: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Q-Par Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.

	Remarks of the Evaluator[3].	•
	Decision: Approved.	
237.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davidex 10mg Capsule
	Composition	Each Capsule Contains: Rabeprazole Sodium As Enteric Coated Pellets Eq. To Rabeprazole…10mg
	Diary No. Date of R& I & fee	Dy No. 15803: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Proton Pump Inhibitors
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Repit Capsule by Shrooq Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting. • Source of pellets: M/s Vision Pharma
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
238.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Rolid 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium Eq. To Rosuvastatin…10mg
	Diary No. Date of R& I & fee	Dy No. 15833: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
239.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Rolid 20mg Tablet
	Composition	Each Film Coated Tablet Contains: Rosuvastatin Calcium Eq. To Rosuvastatin…20mg
	Diary No. Date of R& I & fee	Dy No. 15836: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat Tablet by CCL
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•

	Decision: Approved.	
240.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Serlex 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline HCl Eq. To Sertraline…100mg
	Diary No. Date of R& I & fee	Dy No. 15869: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
241.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Sita-M 50/500 mg Tablet
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phosphate Monohydrate…50mg Metformin HCl…500mg
	Diary No. Date of R& I & fee	Dy No. 15824: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
242.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Preservex 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Aceclofenac…100mg
	Diary No. Date of R& I & fee	Dy No. 15820: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Airtal Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

243.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Solinate 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Solifenacin Succinate…10mg
	Diary No. Date of R& I & fee	Dy No. 15952: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Drugs for urinary frequency and incontinence
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Solif Tablet by Global
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifcations. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
244.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Prosurin 0.4mg Capsule
	Composition	Each Capsule Contains: Tamsulosin HCl…0.4mg
	Diary No. Date of R& I & fee	Dy No. 16455: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Alpha-adrenoreceptor antagonists
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Maxflow Capsule by CCL
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma • Firm has revised the label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Tamsulosin HCl Modified Release Pellets Eq To Tamsulosin……0.4mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Tamsulosin HCl Modified Release Pellets Eq to Tamsulosin……0.4mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
245.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Tizgesic 4mg Tablet
	Composition	Each Film Coated Tablet Contains: Tizanidine HCl Eq. To Tizanidine…4mg
	Diary No. Date of R& I & fee	Dy No. 15847: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Muscle Relaxants, Centrally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved

	Me-too status	Movax Tablet by Sami
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
246.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Monte-Day Sachet
	Composition	Each Sachet Contains: Montelukast…4mg
	Diary No. Date of R& I & fee	Dy No. 15804: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Leukotriene receptor antagonists
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Montiget Sachet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has sachet (General) section • Firm has revised the label claim as per the innovator's product as under along with submission of full fee of registration: Each Sachet Contains: Montelukast (as sodium)…….4mg
	Decision: Approved as per following label claim: **Each Sachet Contains:** **Montelukast (as sodium) ……. 4mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
247.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Topimate 200mg Tablet
	Composition	Each Film Coated Tablet Contains: Topiramate…200mg
	Diary No. Date of R& I & fee	Dy No. 15845: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Hitop Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
248.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davitradol 50mg Capsule
	Composition	Each Capsule Contains: Tramadol HCl…50mg
	Diary No. Date of R& I & fee	Dy No. 15805: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Analgesic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications but available in BP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Tramal Capsule by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
249.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Texamic 250mg Tablet
	Composition	Each Tablet Contains: Tranexamic Acid…250mg
	Diary No. Date of R& I & fee	Dy No. 15851: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Antifibrinolytics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications but available in BP an JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Traumax tablet by Siza International
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
250.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Texamic 500mg Tablet
	Composition	Each Tablet Contains: Tranexamic Acid…500mg
	Diary No. Date of R& I & fee	Dy No. 15870: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antifibrinolytics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications but available in BP an JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Traumax tablet by Siza International
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has revised the label claim to film coated tablet as per the innovator's product as under along with submission of 7,500/- fee: Each Film Coated Tablet Contains: Tranexamic Acid…500mg
	Decision: Approved with USP specifications as per following label claim: **Each Film Coated Tablet Contains:** **Tranexamic Acid…500mg** **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product description to film coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**	
251.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Destolit 250mg Capsule
	Composition	Each Capsule Contains:

		Ursodeoxycholic Acid…250mg
	Diary No. Date of R& I & fee	Dy No. 15950: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Bile acids and derivatives
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications but available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Ursodol capsule by Aspin Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approvd with USP specifcations. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
252.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Valad 160/25 mg Tablet
	Composition	Each Film Coated Tablet Contains: Valsartan…160mg Hydrochlorothiazide…25mg
	Diary No. Date of R& I & fee	Dy No. 15810: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Co-Valsan Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
253.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Davischoll 1% Cream
	Composition	Each Gram of cream Contains: Terbinafine HCl…1%
	Diary No. Date of R& I & fee	Dy No. 15802: 07-03-2019 PKR 20,000/-: 05-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications but available in JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Terbin Cream by Seatle
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	• Firm has cream / ointment / Gel section
	Decision: Approvd with JP specifcations. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
254.	**Name and address of manufacturer / Applicant**	**M/s Davis Pharmaceuticals Laboratories. Plot No. 121, Industrial Triangle, kahuta Road, Islamabad**
	Brand Name +Dosage Form + Strength	Metovild 50/1000 mg Tablet
	Composition	Each Film Coated Tablet Contains: Vildagliptin…50mg

		Metformin HCl…1000mg
	Diary No. Date of R& I & fee	Dy No. 15825: 07-03-2019 PKR 20,000/-: 04-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	TGA Approved
	Me-too status	Galmet Tablet by Vision Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted 02-02-2022.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
255.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Valzide Tablet 5/12.5/160mg
	Composition	Each Film Coated Tablet Contains: Amlodipine as Besylate…5mg Hydrochlorothiazide…12.5mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 13892: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs), other combinations
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Co-Extor Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
256.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Valzide Tablet 10/12.5/160mg
	Composition	Each Film Coated Tablet Contains: Amlodipine as Besylate…10mg Hydrochlorothiazide…12.5mg Valsartan…160mg
	Diary No. Date of R& I & fee	Dy No. 13890: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs), other combinations
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Co-Extor Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
257.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**

	Brand Name +Dosage Form + Strength	Telpine 5/40 mg Tablet
	Composition	Each Film Coated Tablet Contains: Amlodipine as Besylate…5mg Telmisartan…40mg
	Diary No. Date of R& I & fee	Dy No. 13828: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) and calcium channel blockers
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Am-Telsan Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Evidence of bilayer tablet machine since the applied product is available as bilayer tablet in reference regulatory authorities. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each bilayer tablet Contains: Amlodipine as Besylate…5mg Telmisartan…40mg
	Decision: Approved as per following label claim: "Each bilayer tablet Contains: Amlodipine as Besylate…5mg Telmisartan…40mg" Registration letter will be issued upon submission of fee of Rs. 7500/- for correction/pre-approval change in product description to bilayer tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 along with evidenceof availability of "bilayer tablet compression machine".	
258.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd. 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medirol 60ml Syrup
	Composition	Each 5ml Contains: Bambuterol…5mg
	Diary No. Date of R& I & fee	Dy No. 13829: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective beta-2-adrenoreceptor agonists
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Pulmitac Oral solution by Platinum Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
259.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	CT med 500mg Tablet
	Composition	Each Tablet Contains: Citicoline Sodium…500mg
	Diary No. Date of R& I & fee	Dy No. 13816: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5

	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Cercolin Tablet by The Schazoo Pharmaceutical
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
260.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Acneclin Vgainal 2% Cream
	Composition	Each gm of cream contains: Clindamycin Phosphate eq. to Clindamycin…2%
	Diary No. Date of R& I & fee	Dy No. 13807: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Vagibact cream by Nabiqasim
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
261.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Clopid Tablet 75mg
	Composition	Each Film Coated Tablet Contains: Clopidogrel…75mg
	Diary No. Date of R& I & fee	Dy No. 13896: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Platelet aggregation inhibitors excl. heparin
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lowplat tablet by Pharmevo
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Clopidogrel As Bisulphate…75mg
	Decision: Approved as per following claim: Each Film Coated Tablet Contains: Clopidogrel As Bisulphate…75mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim and salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
262.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Lorich-D 5mg Tablet
	Composition	Each Tablet Contains:

		Desloratadine…5mg
	Diary No. Date of R& I & fee	Dy No. 13882: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antihistamines for systemic use
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Destina Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of 7,500/- fee of registration: Each Film Coated Tablet Contains: Desloratadine…5mg
	Decision: Approved as per following claim: **Each Film Coated Tablet Contains:** **Desloratadine…5mg** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to film coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
263.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Artijesic-D 120ml Suspension
	Composition	Each 5ml Contains: Dexibuprofen…100mg
	Diary No. Date of R& I & fee	Dy No. 13844: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Tercica suspension by Sami
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Specify whether the applied product is a liquid suspension or dry powder for suspension. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred fro following: • **Specify whether the applied product is a liquid suspension or dry powder for suspension.** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
264.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Artiquin Tablet 40/320mg
	Composition	Each Film Coated Tablet Contains: Dihydroartemisinin …40mg Piperaquine Phosphate…320mg
	Diary No. Date of R& I & fee	Dy No. 13868: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anti-malarial
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	WHO Prequalified formulation

	Me-too status	Hitecxin Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Dihydroartemisinin …40mg Piperaquine tetraphosphate …320mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **Dihydroartemisinin …40mg** **Piperaquine tetraphosphate …320mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
265.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Dulmed 30mg Capsule
	Composition	Each Capsule Contains: Duloxetine HCl Enteric Coated Pellets Eq. To Duloxetine…30mg
	Diary No. Date of R& I & fee	Dy No. 13808: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antidepressant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Dulan Capsule by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals.
	Decision: Approved.	
266.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Dulmed Capsule 60mg
	Composition	Each Capsule Contains: Duloxetine as HCl…60mg
	Diary No. Date of R& I & fee	Dy No. 13883: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antidepressant
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Dulan Capsule by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Duloxetine HCl Enteric Coated Pellets Eq. To Duloxetine…60mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Duloxetine HCl Enteric Coated Pellets Eq. To Duloxetine…60mg**	

	The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
267.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	SD Nil Tablet 10mg
	Composition	Each Film Coated Tablet Contains: Ebastine…10mg
	Diary No. Date of R& I & fee	Dy No. 13768: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antihistamines for systemic use
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Netherland Approved.
	Me-too status	Kestine Tablet by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• You have applied in house specifications while the product monograph is available in JP. Revise your specifications along with submission of 7,500/- fee.
	Decision: Approved JP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
268.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medicav 0.5mg Tablet
	Composition	Each Film Coated Tablet Contains: Entecavir…0.5mg
	Diary No. Date of R& I & fee	Dy No. 13860: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Enteca Tablet by Getz Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
269.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Citamed 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Escitalopram As Oxalate…10mg
	Diary No. Date of R& I & fee	Dy No. 13821: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Citanew Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.

	Remarks of the Evaluator[3].	•
	Decision: Approved.	
270.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Fesit Tablet 40mg
	Composition	Each Film Coated Tablet Contains: Febuxostat…40mg
	Diary No. Date of R& I & fee	Dy No. 13889: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anti-gout Preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Zurig Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
271.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Fesit Tablet 80mg
	Composition	Each Film Coated Tablet Contains: Febuxostat…80mg
	Diary No. Date of R& I & fee	Dy No. 13856: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anti-gout Preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Zurig Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
272.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Flenza Capsule 25mg/3mg
	Composition	Each Capsule Contains: Fluoxetine HCl…25mg Olanzapine…3mg
	Diary No. Date of R& I & fee	Dy No. 13842: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow

	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Fluoxetine (as HCl)…25mg Olanzapine…3mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Fluoxetine (as HCl)…25mg** **Olanzapine…3mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
273.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Flenza 25/6 mg Capsule
	Composition	Each Capsule Contains: Fluoxetine HCl…25mg Olanzapine…6mg
	Diary No. Date of R& I & fee	Dy No. 13841: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Fluoxetine (as HCl)…25mg Olanzapine…6mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Fluoxetine (as HCl)…25mg** **Olanzapine…6mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
274.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Flenza 25/12 mg Capsule
	Composition	Each Capsule Contains: Fluoxetine HCl…25mg Olanzapine…12mg
	Diary No. Date of R& I & fee	Dy No. 13891: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Atypical antipsychotic and a selective serotonin reuptake inhibitor
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Byflanz capsule by martin dow

	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Fluoxetine (as HCl)…25mg Olanzapine…12mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Fluoxetine (as HCl)…25mg** **Olanzapine…12mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
275.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Fusid Plus 15gm Cream
	Composition	Each gm of cream Contains: Fusidic Acid…2% Hydrocortisone…1%
	Diary No. Date of R& I & fee	Dy No. 13835: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antibiotics for topical use and corticosteroids
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Fucidin H cream (MHRA Approved)
	Me-too status	Fusac-H cream by Sante
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each gm of cream Contains: Fusidic Acid…2% Hydrocortisone acetate…1%
	Decision: Approved as per following label claim: **Each gm of cream Contains:** **Fusidic Acid…2%** **Hydrocortisone acetate…1%** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with evidence of availability of separate dispensing booth for dispensing steroidal formulations, before issuance of registration letter.**	
276.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medigap Capsule 300mg
	Composition	Each Capsule Contains: Gabapentin…300mg
	Diary No. Date of R& I & fee	Dy No. 13880: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Gabapentinoids
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Parketin capsule by Pfizer
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•

	Decision: Approved.	
277.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Monosor 60mg Tablet
	Composition	Each Film Coated Tablet Contains: Isosorbide Mononitrate…60mg
	Diary No. Date of R& I & fee	Dy No. 13830: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Organic nitrates
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications / available in USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved (extended release tablet)
	Me-too status	Monosorbid-60 SR Tablet by Brookes
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• The reference product is available as extended release tablet while you have applied for immediate release tablet. Justification is required in this regard. • You have claimed in-house specifications while the product monograph is available in USP pharmacopoeia. Clarification is required in this regard. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Extended Release Tablet Contains: Isosorbide Mononitrate…60mg
	Decision: Approved as per following label claim: Each Film Coated Extended Release Tablet Contains: Isosorbide Mononitrate…60mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product dosage form to extended release tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
278.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Itab Tablet 50mg
	Composition	Each Film Coated Tablet Contains: Itopride Hcl…50mg
	Diary No. Date of R& I & fee	Dy No. 13814: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antiemetics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	PMDA Japan Approved
	Me-too status	Ganaton Tablet by Abbott
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
279.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Conaz Capsule 100mg
	Composition	Each Capsule Contains: Itraconazole…100mg
	Diary No. Date of R& I & fee	Dy No. 13866: 07-03-2019 PKR 20,000/-: 07-03-2019

	Pharmacological Group	Antimycotics For Systemic Use
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Icon Capsule by Ferozesons
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Itraconazole (as IR pellets)…100mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Itraconazole (as IR pellets)…100mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
280.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medicos 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Lacosamide…50mg
	Diary No. Date of R& I & fee	Dy No. 13867: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
281.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medicos Tablet 150mg
	Composition	Each Film Coated Tablet Contains: Lacosamide…150mg
	Diary No. Date of R& I & fee	Dy No. 13832: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lacolep tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
282.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Tilac Syrup 120ml
	Composition	Each 5ml Contains:

		Lactitol As Monohydrate…3.35Gm
	Diary No. Date of R& I & fee	Dy No. 13846: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Osmotically acting laxatives
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Importal solution (Lactitolum monohydricum 667mg/ml) by Zambon Schweiz **Swissmedic** approved
	Me-too status	Lacasil By CCL Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Provide evidence of availability of RI detector which is required for the drug substance and product testing. • Provide source of lactitol along with COA, stability study data of 3 batches of API, GMP certificate of API manufacturer and differential fee (in case of imported pellets).
	Decision: Deferred for submission of following: • **Evidence of availability of RI detector which is required for the drug substance and product testing.** • **Source of lactitol along with COA, stability study data of 3 batches of API, GMP certificate of API manufacturer and differential fee (in case of imported source).**	
283.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Troz Tablet 2.5mg
	Composition	Each Film Coated Tablet Contains: Letrozole…2.5mg
	Diary No. Date of R& I & fee	Dy No. 13886: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Aromatase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Femara Tablet by Novartis
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
284.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	L-Cetam 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Levetiracetam…250mg
	Diary No. Date of R& I & fee	Dy No. 13810: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	

285.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	L Cetam Tablet 500mg
	Composition	Each Film Coated Tablet Contains: Levetiracetam…500mg
	Diary No. Date of R& I & fee	Dy No. 13887: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lumark Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
286.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Leed suspension 60ml
	Composition	Each 5ml after reconstitution contains: Linezolid…100mg
	Diary No. Date of R& I & fee	Dy No. 13884: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antibacterials
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Nezkil suspension by S.J&G Fazul Ellahie
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
287.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Leed 600mg Tablet
	Composition	Each Film Coated Tablet Contains: Linezolid…600mg
	Diary No. Date of R& I & fee	Dy No. 13822: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antibacterials
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Nezkil Tablet by S.J&G Fazul Ellahie
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	

288.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Lorna tablet 4mg
	Composition	Each Film Coated Tablet Contains: Lornoxicam…4mg
	Diary No. Date of R& I & fee	Dy No. 13857: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Xefo 4mg Film-Coated Tablet, Austria approved.
	Me-too status	Zafon Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
289.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Mebesrch Capsule 200mg
	Composition	Each Capsule Contains: Mebeverine HCl….200mg
	Diary No. Date of R& I & fee	Dy No. 13879: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Synthetic anticholinergics, esters with tertiary amino group
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Sameb MR 200mg Capsule by Hilton Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharmaceuticals. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Capsule Contains: Mebeverine HCl (as modified release pellets pellets)…200mg
	Decision: Approved as per following label claim: Each Capsule Contains: Mebeverine HCl (as modified release pellets pellets)…200mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
290.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	M Zole Gel 20gm
	Composition	Each 100Gm Contains: Miconazole Nitrate…2% w/w
	Diary No. Date of R& I & fee	Dy No. 13863: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antiinfectives and antiseptics for local oral treatment
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	DAKTARINTM Oral Gel (Miconazole base), Gyno-Daktarin 20mg/g vaginal cream (miconazole nitrate) MHRA Approved

	Me-too status	
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Specify whether the applied formulation is for oral or vaginal use.
	Decision: Deferred for clarification of applied dosage form whether the applied formulation is for oral or vaginal use.	
291.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Ondra Tablet 8mg
	Composition	Each Film Coated Tablet Contains: Ondansetron HCl …8mg
	Diary No. Date of R& I & fee	Dy No. 13872: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antiemetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Danset Tablet by CCL
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Ondansetron (as hydrochloride Dihydrate)…8mg
	Decision: Approved as per following label claim: Each Film Coated Tablet Contains: Ondansetron (as hydrochloride Dihydrate)…8mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
292.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	M Rel Tablet 35/450mg
	Composition	Each Film Coated Tablet Contains: Paracetamol…450mg Orphendrine Citrate…35mg
	Diary No. Date of R& I & fee	Dy No. 13859: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Analgesic / Antipyretic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	(**TGA Australia** Approved)
	Me-too status	Nuberol Tablet by Searle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee of registration: Each Tablet Contains: Paracetamol…450mg Orphendrine Citrate…35mg
	Decision: Approved with innovator's specifications as per following label claim: Each Tablet Contains: Paracetamol…450mg Orphendrine Citrate…35mg	

	The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
293.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Glita 30mg Tablet
	Composition	Each Film Coated Tablet Contains: Pioglitazone…30mg
	Diary No. Date of R& I & fee	Dy No. 13888: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Thiazolidinediones
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Piozer Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Tablet Contains: Pioglitazone (as hydrochloride)…30mg
	Decision: Approved as per following label claim: Each Tablet Contains: Pioglitazone (as hydrochloride) … 30mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim and salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
294.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Piomed 15/850 mg Tablets
	Composition	Each Film Coated Tablet Contains: Pioglitazone…15mg Metformin…850mg
	Diary No. Date of R& I & fee	Dy No. 13808: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Piozer Plus Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Pioglitazone (as hydrochloride)…15mg Metformin hydrochloride…850mg
	Decision: Approved as per following label claim: Each Film Coated Tablet Contains: Pioglitazone (as hydrochloride)…15mg Metformin hydrochloride…850mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim and salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
295.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**

	Brand Name +Dosage Form + Strength	Racet Tablet 800mg
	Composition	Each Film Coated Tablet Contains: Piracetam…800mg
	Diary No. Date of R& I & fee	Dy No. 13811: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Nootropics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nootropil Tablet by M/s GSK
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
296.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Racet 120ml Syrup
	Composition	Each 5ml Contains: Piracetam…1gm
	Diary No. Date of R& I & fee	Dy No. 13834: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	NOOTROPYL 20%, oral solution (Piracetam 200mg/ml) ANSM France Approved.
	Me-too status	Nootropil Syrup by AGP
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
297.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Gabalin Capsule 50mg
	Composition	Each Capsule Contains: Pregabalin…50mg
	Diary No. Date of R& I & fee	Dy No. 13838: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• You have claimed in house specifications while the product monograph is available in BP. Revise the specifications along with submission of 7,500/- fee.

	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
298.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Gabalin Capsule 100mg
	Composition	Each Capsule Contains: Pregabalin…100mg
	Diary No. Date of R& I & fee	Dy No. 13840: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications while available in BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA approved
	Me-too status	Gabica Capsule by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• You have claimed in house specifications while the product monograph is available in BP. Revise the specifications along with submission of 7,500/- fee.
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
299.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Qumed Tablet 100mg
	Composition	Each Film Coated Tablet Contains: Quetiapine …100mg
	Diary No. Date of R& I & fee	Dy No. 13874: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Q-Par Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Quetiapine as Fumarate…100mg
	Decision: Approved as per following label claim: Each Film Coated Tablet Contains: Quetiapine as Fumarate…100mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim and salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
300.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Qumed Tablet 400mg
	Composition	Each Film Coated Tablet Contains: Quetiapine …400mg
	Diary No. Date of R& I & fee	Dy No. 13875: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antipsychotic

	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Q-Par Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Quetiapine as Fumarate…400mg
	Decision: Approved as per following label claim: **Each Film Coated Tablet Contains:** **Quetiapine as Fumarate…400mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim and salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
301.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Pramid Tablet 20mg
	Composition	Each Film Coated Tablet Contains: Rabeprazole Sodium…20mg
	Diary No. Date of R& I & fee	Dy No. 13823: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Proton Pump Inhibitors
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Protorib Tablet by Helix
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Reference product is available as delayed release tablet while you have applied for film coated tablet. Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Enteric Coated Tablet Contains: Rabeprazole sodium …20mg
	Decision: Approved withinnovator's specifications as per following label claim: **Each Enteric Coated Tablet Contains:** **Rabeprazole sodium …20mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product dosage form to enteric coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
302.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Redone Tablet 1mg
	Composition	Each Film Coated Tablet Contains: Risperidone…1mg
	Diary No. Date of R& I & fee	Dy No. 13853: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antipsychotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Neo-Risp Tablet by Wilshire

	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
303.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Redone Tablet 2mg
	Composition	Each Film Coated Tablet Contains: Risperidone…2mg
	Diary No. Date of R& I & fee	Dy No. 13852: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antipsychotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Neo-Risp Tablet by Wilshire
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
304.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Redone Tablet 3mg
	Composition	Each Tablet Contains: Risperidone…3mg
	Diary No. Date of R& I & fee	Dy No. 13851: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antipsychotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Neo-Risp Tablet by Wilshire
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
305.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Redone Tablet 4mg
	Composition	Each Film Coated Tablet Contains: Risperidone…4mg
	Diary No. Date of R& I & fee	Dy No. 13856: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Other antipsychotics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Neo-Risp Tablet by Wilshire
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	

306.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	T-Ser 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Sertraline HCl Eq. To Sertraline…50mg
	Diary No. Date of R& I & fee	Dy No. 13847: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
307.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	T Ser Tablet 100mg
	Composition	Each Film Coated Tablet Contains: Sertraline HCl…100mg
	Diary No. Date of R& I & fee	Dy No. 13854: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Selective serotonin reuptake inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Seralin Tablet by Bosch
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Sertraline HCl Eq. To Sertraline…100mg
	Decision:	
308.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Sitamin Tablet 50/500mg
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phospate Monohydrate…50mg Metformin HCl…500mg
	Diary No. Date of R& I & fee	Dy No. 13813: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•

	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
309.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Sitamin Tablet 50/1000mg
	Composition	Each Film Coated Tablet Contains: Sitagliptin as Phospate Monohydrate…50mg Metformin HCl…1000mg
	Diary No. Date of R& I & fee	Dy No. 13812: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Treivamet Tablet by Getz
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
310.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medicon 500mg/10ml Syrup
	Composition	Each 10ml Contains: Sodium Alginate…500mg Sodium Bicarbonate…267mg Calcium Carbonate…160mg
	Diary No. Date of R& I & fee	Dy No. 13878: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antacid
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Gaviscon Liquid Sachets (MHRA Approved)
	Me-too status	Lagita Suspension by Sami
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• The reference product approved by MHRA i.e. Gaviscon Liquid Sachets which is available as 10ml suspension in sachet form while you have applied for syrup in glass bottle. Clarification is required in this regard.
	Decision: Deferred for justification of applied dosage form since reference product approved by MHRA i.e. Gaviscon Liquid Sachets which is available as 10ml suspension in sachet form while firm has applied for syrup in glass bottle	
311.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Solinate 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Solifenacin Succinate Eq. To Solifenacin…10mg
	Diary No. Date of R& I & fee	Dy No. 13869: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Drugs for urinary frequency and incontinence
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Solif Tablet by Global
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Solifenacin Succinate …10mg
	Decision: Approved with innovator's specifications as per following label claim: **Each Film Coated Tablet Contains:** **Solifenacin Succinate …10mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
312.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Medifate Suspension 60ml
	Composition	Each 5ml Contains: Sucralfate…1gm
	Diary No. Date of R& I & fee	Dy No. 13845: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Ulsanic suspension by Highnoon
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each 10ml suspension Contains: Sucralfate…….1gm
	Decision: Approved with innovator's specifications as per following label claim: **Each 10ml suspension Contains:** **Sucralfate…….1gm** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
313.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd** **5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Tina Cream 10gm
	Composition	Each gm of Cream Contains: Terbinafine HCl…..1%
	Diary No. Date of R& I & fee	Dy No. 13870: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications but available in JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Terbin Cream by Seatle
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• You have claimed in house specification while the product monograph is available in JP pharmacopoeia. Revise your specifications along with submission of 7500/-fee.

	Decision: Decision: Approved with JP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
314.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Tina 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Terbinafine Hcl…250mg
	Diary No. Date of R& I & fee	Dy No. 13873: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	LAMISIL tablet TGA Australia Approved
	Me-too status	Terbitec Tablet by Fynk Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	• Revise your label claim to uncoated tablet as per the innovator's product as under along with submission of full fee of registration: Each Tablet Contains: Terbinafine Hcl…250mg
	Decision: Approved as per following label claim: Each Tablet Contains: Terbinafine Hcl…250mg The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
315.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Ticol Capsule 4mg
	Composition	Each Capsule Contains: Thiocolchicoside…4mg
	Diary No. Date of R& I & fee	Dy No. 13839: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Muscle Relaxants, Centrally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MIOREL 4 mg, capsule ANSM France Approved
	Me-too status	Thiolax Capsule by S.J&G Fazul Ellahie
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
316.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Ramate 25mg Tablet
	Composition	Each Film Coated Tablet Contains: Topiramate…25mg
	Diary No. Date of R& I & fee	Dy No. 13848: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5

	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Hitop Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
317.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Ramate Tablet 50mg
	Composition	Each Film Coated Tablet Contains: Toprimate…50mg
	Diary No. Date of R& I & fee	Dy No. 13849: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Hitop Tablet by Hilton
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
318.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Vilmin 50/500mg Tablet
	Composition	Each Film Coated Tablet Contains: Vildagliptin…50mg Metformin HCl…500mg
	Diary No. Date of R& I & fee	Dy No. 13837: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	TGA Approved
	Me-too status	Galmet Tablet by Vision Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
319.	**Name and address of manufacturer / Applicant**	**M/s Medisearch Pharma Pvt Ltd 5-Km, Raiwind Manga Road, Lahore**
	Brand Name +Dosage Form + Strength	Vilmin 50/850 mg Tablet
	Composition	Each Film Coated Tablet Contains: Vildagliptin…50mg Metformin HCl…850mg
	Diary No. Date of R& I & fee	Dy No. 13836: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	TGA Approved
	Me-too status	Galmet Tablet by Vision Pharma
	GMP status	The firm is granted GMP certificate based on inspection conducted on 22-02-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
320.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Acesave 150gm/3ml Injection
	Composition	Each 3ml Ampoule Contains: Aceclofenac…150mg
	Diary No. Date of R& I & fee	Dy No. 14980: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Could not be confirmed
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
321.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Acisave 25mg Capsule
	Composition	Each Capsule Contains: Acitretin…25mg
	Diary No. Date of R& I & fee	Dy No. 16586: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Retinoids for treatment of psoriasis
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved.
	Me-too status	Acetin Capsule by Genome Pharma
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	
	Decision: Approved.	
322.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Baclomed 10mg Tablet
	Composition	Each Film Coated Tablet Contains:

		Baclofen…10mg
	Diary No. Date of R& I & fee	Dy No. 14972: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Muscle relaxants, centrally acting agents
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Baclofa Tablet by Helix
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Provide evidence of applied product as film coated tablet in reference regulatory authorities or else revise your formulation to uncoated tablet along with submission of 7,500/- fee.
	Decision: Approved as per following label claim: **"Each Tablet Contains:** **Baclofen…10mg"** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
323.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals.** **Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Kalasave 250mg/5ml Oral Dry Powder for Suspension
	Composition	Each 5ml Reconstituted Suspension Contains: Clarithromycin…250mg
	Diary No. Date of R& I & fee	Dy No. 14977: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Macrolides
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Claritek suspension by Getz
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Evidence of required manufacturing facility approval letter from Licensing Division. • Specify if you are using taste masked granules or not, in case you are using taste masked granules, provide source of granules along with COA, stability study data of 3 batches of pellets, GMP certificate of pellets manufacturer and differential fee (in case of imported pellets), along with revision of label claim with submission of requisite fee.
	Decision: Deferred for source of granules along with COA, stability study data of 3 batches of pellets, GMP certificate of pellets manufacturer and differential fee (in case of imported pellets).	
324.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals.** **Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Ferimed 500mg/10ml Injection
	Composition	Each 10ml Vial Contains: Ferric Carboxymaltose…500mg
	Diary No. Date of R& I & fee	Dy No. 14978: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Iron preparations
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ferinject 50 mg iron/mL solution for injection/infusion (MHRA Approved)
	Me-too status	Ferinject 500mg/10ml by M/s RG. Pharmaceuticals

	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each 10ml Vial Contains: Ferric Carboxymaltose corresponding to elemental iron…500mg
	Decision: Approved with innovator's specifications as per following label claim: "Each 10ml Vial Contains: Ferric Carboxymaltose corresponding to elemental Iron……500mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
325.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Ronic 3mg/3ml Injection
	Composition	Each 3ml Ampoule Contains: Ibandronic Acid…3mg
	Diary No. Date of R& I & fee	Dy No. 16584: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Bisphosphonates
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ibandronic Acid 3 mg/ 3 ml solution for injection (pre-filled syringe) MHRA Approved
	Me-too status	Ibnate 3mg/3ml injection by Genix Pharma
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Evidence of required manufacturing facility approval letter from Licensing Division. • The innovator's product is available as pre-filled syringe, while you have applied for the same formulation in ampoules. Justification is required in this regard. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each 3ml ampoule Contains: Ibandronate monosodium monohydrate eq. to Ibandronic Acid …3mg
	Decision: Approved with innovator's specifications as per following label claim: "Each 3ml ampoule Contains: Ibandronate monosodium monohydrate eq. to Ibandronic Acid …3mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
326.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Ivermed 6mg Tablet
	Composition	Each Tablet Contains: Ivermectin…6mg
	Diary No. Date of R& I & fee	Dy No. 14976: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antinematodal Agents
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Stromectol 6mg Tablet **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** USFDA
	Me-too status	Ivermite Tablet by Atco
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.

	Remarks of the Evaluator[3].	
	Decision: Approved.	
327.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Neostig 2.5mg/ml Injection
	Composition	Each 1ml Ampoule Contains: Neostigmine Methylsulphate…2.5mg
	Diary No. Date of R& I & fee	Dy No. 14979: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Anticholinesterases
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Istigmine injection by Indus Pharma
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
328.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Normed 4mg/4ml Injection
	Composition	Each 4ml Ampoule Contains: Norepinephrine Bitartarate…4mg
	Diary No. Date of R& I & fee	Dy No. 16585: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Adrenergic and dopaminergic agents
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Noradrin injection by atco
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each 4ml Ampoule Contains: Norepinephrine (as bitartarate)…4mg
	Decision: Approved as per following label claim: "Each 4ml Ampoule Contains: Norepinephrine (as bitartarate)…4mg" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
329.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Rekro 50mg/5ml Injection
	Composition	Each 5ml Ampoule Contains: Rocuronium Bromide…50mg
	Diary No. Date of R& I & fee	Dy No. 16583: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Muscle Relaxants, Peripherally Acting Agents
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved (as 5ml vial)
	Me-too status	Rocurex injection by Getz Pharma

	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
330.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Rosun 20mg Tablet
	Composition	Each Film Coated Tablet Contains: Rosuvastatin As Calcium…20mg
	Diary No. Date of R& I & fee	Dy No. 14974: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	HMG CoA reductase inhibitors
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Crestat tablet by CCL
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
331.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	Fensave 200mg Tbalet
	Composition	Each Film Coated Tablet Contains: Sorafenib…200mg
	Diary No. Date of R& I & fee	Dy No. 16587: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antineoplastic Agents (L01)
	Type of Form	Form 5
	Finished Product Specification	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Sonib Tablet by Pharmasol
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Evidence of required manufacturing facility (i.e. tablet anticancer section) approval letter from Licensing Division. • Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Film Coated Tablet Contains: Sorafenib (as tosylate)..…200mg
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e, Tablet (Oncology/Cytotoxic/Anti-cancer) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
332.	**Name and address of manufacturer / Applicant**	**M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan**
	Brand Name +Dosage Form + Strength	T-Save 100mg Tablet
	Composition	Each Sustained Release Tablet Contains: Tramadol HCl Eq. To Tramadol…100mg
	Diary No. Date of R& I & fee	Dy No. 14975: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Analgesic
	Type of Form	Form 5

	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Tonoflex SR Tablet by Sami
	GMP status	GMP certificate issued on basis of inspection conducted on 18-09-2021.
	Remarks of the Evaluator[3].	• Revise your label claim as per the innovator's product as under along with submission of full fee of registration: Each Sustained Release Tablet Contains: Tramadol HCl …100mg
	Decision: Approved as per following label claim: **"Each Sustained Release Tablet Contains:** **Tramadol HCl …100mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	

333.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Acnazol 150mg Capsule
	Composition	Each Capsule contains: Fluconazole 150mg
	Diary No. Date of R& I & fee	Dy. No 14639 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form-5
	Finished product Specifications	BP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Zolanix 150mg capsule of M/s. Glaxosmithkline,Karachi
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II:	
	Decision: Approved.	
334.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Axib Tablet 60mg
	Composition	Each Film Coated Tablet Contains: Etoricoxib…….60mg
	Diary No. Date of R& I & fee	Dy.No 14633 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti-inflammatory and Antirheumatic Products, Non-Steroids
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Hetoxib Tablet by Hilton Pharma
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II:	

	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
335.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd. Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Bentovate Cream
	Composition	Each gm contains: Betamethasone Valerate ……..… 0.1% w/w Neomycin Sulfate ……. 0.5% w/w
	Diary No. Date of R& I & fee	Dy.No 14634 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Combination corticosteroid + antibiotic
	Type of Form	Form-5
	Finished product Specifications	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Betnovate – N Cream by M/s. Glaxo smithkline ,Karachi (Reg. # 000254).
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II: Innovator product contains "Betamethasone as Valerate ……. 0.1%w/w", while the firm has applied for Betamethasone Valerate ……..… 0.1% w/w "	
	Decision: Approved as per following label claim: "Each gm contains: Betamethasone as Valerate ……..… 0.1% w/w Neomycin Sulfate ……. 0.5% w/w" The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
336.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd. Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Clofderm NN Ointment
	Composition	Each Ointment gm Contains: Clobetasole Propionate …… 0.05% w/w, Neomycin Sulphate ……. 0.5% w/w Nystatin …….100,000
	Diary No. Date of R& I & fee	Dy. No 14637 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Corticosteroid+ Anti-Bacterial
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Dermovate –NN Ointment by M/s. Glaxosmithkline ,Karachi
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

337.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	E-Pol Plus Tablet
	Composition	Each Tablet Contains: Paracetamol……500mg Caffeine…..……65mg Chlorpheniramine……..…2mg
	Diary No. Date of R& I & fee	Dy.No 14636 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antipyretic/Analgesic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too status (with strength and dosage form)	Hesmol Extra tablets by Wisdom Pharmaceuticals
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II: Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
338.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Alvina cream 2%
	Composition	Each gram of cream contains : Clindamycin Phosphate eq. to …… 20.0mg
	Diary No. Date of R& I & fee	Dy.No 14638 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Gynaecological anti-infectives and antiseptics
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	CLEOCIN Vaginal Cream 2%, which contains 2% clindamycin phosphate, USP, at a concentration equivalent to 20 mg clindamycin per gm, **USFDA approved**
	Me-too status (with strength and dosage form)	Acneris V Cream 2%, M/s Global Pharmaceuticals, Reg. No. 085735
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II: Innovator product contains "Clindamycin as phosphate……. 2%w/w", while the firm has applied for Clindamycin phosphate……. 2%w/w".	
	Decision: Approved as per following label claim: **"Each gram of cream contains:** **Clindamycin as Phosphate …… 20.0mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
339.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Fucidon Cream

	Composition	Each gram of cream contains: Fusidic acid …….. 20mg
	Diary No. Date of R& I & fee	Dy.No : dated 07-03-2019 Rs.20,000 dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specifications	As per Innovator Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Axxo 2% Cream of M/s Rotex Pharmaceuticals , Registration No. 100794
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator [II]:	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 along with submission of evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter before issuance of registration letter.	
340.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd. Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Fucidon Topical H cream
	Composition	Each gram cream contains: Fusidic Acid (BP)……..….20mg Hydrocortisone Acetate……10mg
	Diary No. Date of R& I & fee	Dy.No 14635 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antibiotics & corticosteroid For Topical Use
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Fusimax-H 2%+1% Cream by M/s Maxitech Pharma (Reg# 83733)
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 along with submission of evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter before issuance of registration letter.	
341.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd. Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Legocaine Gel
	Composition	Each 100 gram contains: Lignocaine HCl ……20mg
	Diary No. Date of R& I & fee	Dy.No 14626 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antibiotics & corticosteroid For Topical Use
	Type of Form	Form-5

	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Xylocaine 2% jelly TGA(Australia) Approved.
	Me-too status (with strength and dosage form)	Lignopharm Gel 2% by M/s E-Pharm Laboratories (Reg#092768)
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II:	
	Decision: Approved.	
342.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Licomycin 500mg Capsule
	Composition	Each Capsule Contains: Lincomycin…….500mg
	Diary No. Date of R& I & fee	Dy. No 14627 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Lincocine 500 mg capsule (Lincomycin as HCl hydrate) by Pfizer Holding France. Approved by ANSM France
	Me-too status (with strength and dosage form)	Lincocin capsule 500mg by M/s Pfizer Pakistan (Reg#000602)
	GMP status	Last GMP inspection report conducted on 15-05-2018.
	Remarks of Evaluator II: Submit complete salt form of the drug substance as per innovator product.	
	Decision: Approved as per following label claim: **"Each Capsule Contains:** **Lincomycin as hydrochloride…….500mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
343.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd.** **Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	P-Fax Ointment
	Composition	Each gram contains: Polymyxin B Sulphate ……..10000IU Bacitracin Zinc …… 500IU
	Diary No. Date of R& I & fee	Dy.No 14628 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Multifax Ointment by M/s Xenon Pharmaceuticals (Reg#32328)
	GMP status	Last GMP inspection was conducted on 27-6-2018 concluded good GMP.

	Remarks of Evaluator II:	
	Decision: Approved.	
344.	**Name and address of manufacturer / Applicant**	**M/s Eros Pharmaceuticals (Pvt.) Ltd. Address: 94-95/23, Korangi Industrial Area, Karachi-Pakistan**
	Brand Name + Dosage Form + Strength	Vibcin Capsule
	Composition	Each Capsule contains: Doxycycline Hyclate as eq.to Doxycycline……..100mg
	Diary No. Date of R& I & fee	Dy. No 14625 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic (Tetracyclines)
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Dok-C-M Capsule 100mg by M/s Mediate Pharmaceuticals
	GMP status	Last GMP inspection was conducted on 27-6-2018 concluded good GMP.
	Remarks of Evaluator II:	
	Decision: Approved.	
345.	**Name and address of manufacturer / Applicant**	**M/s Briell Pharmaceutical (Pvt) Ltd. 538C Sundar Industrial Estate Multan Road, Lahore.**
	Brand Name + Dosage Form + Strength	Hazar 12.5/50mg Tablet
	Composition	Each Film Coated Tablet Contains: Hydrochlorothiazide ……. 12.5mg Losartan Potassium ……50mg
	Diary No. Date of R& I & fee	Dy.No 16045 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Angiotensin II antagonists and diuretics
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Co-Eziday Tablets of M/s Werrick Pharmaceutical
	GMP status	GMP certificate issued on basis of inspection conducted on 20-10-22
	Remarks of the Evaluator II:	
	Decision: Approved.	
346.	**Name and address of manufacturer / Applicant**	**M/s Briell Pharmaceutical (Pvt) Ltd. 538C Sundar Industrial Estate Multan Road, Lahore.**
	Brand Name + Dosage Form + Strength	Lamisil 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Terbinafine HCl…..…250mg
	Diary No. Date of R& I & fee	Dy.No 16041 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form-5
	Finished product Specifications	BP
	Pack size & Demanded Price	1 x 10's; As per PRC

	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Mycoderm 250mg Tablet by M/s Nabiqasim Karachi. (Reg.# 074882)
	GMP status	GMP certificate issued on basis of inspection conducted on 20-10-22
	Remarks of the Evaluator [II]: • Submit revised label claim as per innovator product declaring label claim in terms of Terbinafine, and dosage form as uncoated tablet along with master formulation and relevant fee as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021.	
	Decision: Approved as per following label claim and with change of brand name: **"Each uncoated Tablet Contains:** **Terbinafine as HCl……250mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
347.	**Name and address of manufacturer / Applicant**	**M/s Liven Pharmaceuticals Pvt Ltd. 49 km, Lahore Multan Road.**
	Brand Name + Dosage Form + Strength	Tromanil Plus 37.5/325mg Tablet
	Composition	Each Tablet Contains: Tramadol HCl…….37.5mg Paracetamol…325mg
	Diary No. Date of R& I & fee	Dy.No 16271 dated 07-03-2019 Rs.20,000/- dated 05-03-2019
	Pharmacological Group	Antipyretic/Analgesic
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ultraset film coated tablet by M/s Janssen Pharms, USFDA Approved.
	Me-too status (with strength and dosage form)	Tramal Plus tablet by M/s Searle Company Ltd, Reg No.77129
	GMP status	Firm has submitted copy of GMP certificate based on the inspection dated 03-07-2019.
	Remarks of Evaluator [II]: Valid GMP inspection report conducted within last three years is required.	
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
348.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Lamogen tablets 25mg
	Composition	Each Film Coated Tablet Contains: Lamotrigine … 25mg
	Diary No. Date of R& I & fee	Dy.No 13774 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Lamnet Tablet by M/s Searle pharma
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]:	
	Decision: Approved.	
349.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**

	Brand Name + Dosage Form + Strength	Lamogen tablets 50mg
	Composition	Each Tablet Contains: Lamotrigine … 50mg
	Diary No. Date of R& I & fee	Dy.No 13779 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Lamnet Tablet by M/s Searle pharma
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved.	
350.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Lamogen tablets 100mg
	Composition	Each Tablet Contains: Lamotrigine … 100mg
	Diary No. Date of R& I & fee	Dy.No 13773 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Lamnet Tablet by M/s Searle pharma
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved.	
351.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Febgen tablets 40mg
	Composition	Each Film Coated Tablet Contains: Febuxostat … 40mg
	Diary No. Date of R& I & fee	Dy. No 13791 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Xanthine oxidase inhibitors
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	GOURIC Tablet by M/s Novartis pharma
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
352.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**

	Brand Name + Dosage Form + Strength	Valogen tablets 320mg
	Composition	Each Film Coated Tablet Contains: Valsartan … 320mg
	Diary No. Date of R& I & fee	Dy.No 13793 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Angiotensin II Receptor blocker
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Diovan Tablet by M/s Novartis pharma
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved.	
353.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biolol tablets 2.5mg
	Composition	Each Film Coated Tablet Contains: Nebivolol … 2.5mg
	Diary No. Date of R& I & fee	Dy.No 13790 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Beta blocker
	Type of Form	Form-5
	Finished product Specifications	Manufcaturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Nebil Tablet by M/s Getz pharma karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
354.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biolol tablets 5mg
	Composition	Each Film Coated Tablet Contains: Nebivolol … 5mg
	Diary No. Date of R& I & fee	Dy.No 13770 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Beta blocker
	Type of Form	Form-5
	Finished product Specifications	Manufcaturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Nebil Tablet by M/s Getz pharma karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	

	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
355.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biotrax capsules 250mg
	Composition	Each Capsule Contains: Tranexamic acid …… 250mg
	Diary No. Date of R& I & fee	Dy.No 13787 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti-fibrinolytics
	Type of Form	Form-5
	Finished product Specifications	JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by PMDA of Japan
	Me-too status (with strength and dosage form)	Btrol 250mg by M/s Bosch pharma Karachi.
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved.	
356.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biotrax capsules 500mg
	Composition	Each Capsule Contains: Tranexamic acid 500mg
	Diary No. Date of R& I & fee	Dy. No 13788 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti-fibrinolytics
	Type of Form	Form-5
	Finished product Specifications	J.P
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by PMDA of Japan
	Me-too status (with strength and dosage form)	Btrol 500mg by M/s Bosch pharma Karachi.
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved.	
357.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Nimgen tablets 100mg
	Composition	Each Tablet Contains: Nimesulide … 100mg
	Diary No. Date of R& I & fee	Dy.No 13795 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Non steroidal Anti-inflammatory drugs
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's Specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by HPRA of Ireland
	Me-too status (with strength and dosage form)	Nise 100mg Tablet by M/s Pharmevo karachi
	GMP status	GMP certificate issued on 26.01.2021

	Remarks of Evaluator [II]:	
	Decision: Keeping in view the approval status of Nimesulide 100mg tablet in EMA, Registration Board approved the applied formulation of Nimesulide Tablets 100mg with innovators specifications and pack size of 15 tablets as per recommendations of EMA only for the following clinical indications as a second line choice. • **Treatment of acute pain** • **Primary dysmenorrhea** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
358.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Carbagen tablets 400mg
	Composition	Each Film Coated Tablet Contains: Carbamazepine … 400mg
	Diary No. Date of R& I & fee	Dy.No 13771 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Seizunil 400mg Tablet by M/s Platinum pharma Karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]: Firm has applied for film coated tablet whereas innovator product has been approved as uncoated tablet. Firm shall revise composition as per the innovator product along with submission of relevant fee as per notification No.F.7-11/2012- B&A/DRAP dated 13-07-2021.	
	Decision: Approved as per following label claim: **Each tablet Contains:** **Carbamazepine … 400mg"** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoarted tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
359.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biogrel tablets 10mg
	Composition	Each Film Coated Tablet Contains: Prasugrel ……. 10mg
	Diary No. Date of R& I & fee	Dy.No 13777 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti-platelets drugs
	Type of Form	Form-5
	Finished product Specifications	Innovator's Specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Prisa 10mg Tablet by M/s Getz pharma Karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]: Innovator product approved by US FDA contains Prasugrel in "hydrochloride" salt form. Firm shall revise composition as per the innovator product along with submission of relevant fee as per notification No.F.7-11/2012- B&A/DRAP dated 13-07-2021.	
	Decision: Approved as per following label claim: **"Each Film Coated Tablet Contains:**	

	Prasugrel as hydrochloride ……. 10mg" **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in drug substance salt form as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
360.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Bioment tablets 10mg
	Composition	Each Film Coated Tablet Contains: Memantine HCl ……10mg
	Diary No. Date of R& I & fee	Dy.No 13789 dated 07-03-2019 Rs.20,000 dated 07-03-2019
	Pharmacological Group	Psychoanaleptics
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Rement 10mg Tablet by M/s HIGH-Q pharma Karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
361.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Bioment tablets 20mg
	Composition	Each Film Coated Tablet Contains: Memantine HCl …… 20mg
	Diary No. Date of R& I & fee	Dy.No 13778 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Psychoanaleptics
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Rement 20mg Tablet by M/s HIGH-Q pharma Karachi
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
362.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Biofenac Injection 25mg/ml
	Composition	Each ml Contains: Aceclofenac As Sodium…25mg
	Diary No. Date of R& I & fee	Dy.No 13778 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	--

	Me-too status (with strength and dosage form)	Mediloc Injection 50mg/ml of M/s Mediate Pharma (Reg.#073594)
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]: Submit evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
363.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Cyanomin 250mcg/ml
	Composition	Each ml Contains: Cyanocobalamin…250mcg
	Diary No. Date of R& I & fee	Dy.No 13768 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Vitamin B12
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	--
	Me-too status (with strength and dosage form)	--
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]: Submit following: • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.	
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.**	
364.	**Name and address of manufacturer / Applicant**	**M/s Biogen Pharma 8km chakbeli Road Rawat Rawalpindi**
	Brand Name + Dosage Form + Strength	Predchlor Injection 4mg/10mg
	Composition	Each ml Contains: Chlorpheniramine Maleate……4mg Prednisolone……10mg
	Diary No. Date of R& I & fee	Dy.No 13754 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	--
	Me-too status (with strength and dosage form)	--
	GMP status	GMP certificate issued on 26.01.2021
	Remarks of Evaluator [II]: Submit following: • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Evidence of approval of required manufacturing facility of "Liquid Injection (steroid) section" from CLB.	

	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.** • **Submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (steroid) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.**	
365.	**Name and address of manufacturer / Applicant**	**M/s Jinnah Pharmaceuticals Pvt Ltd. 13 km, Lahore Road, Multan**
	Brand Name + Dosage Form + Strength	J-Mecta Sachet
	Composition	Each Sachet Contains: Dioctahedral Smectite …..… 3gm
	Diary No. Date of R& I & fee	Dy. No 16215 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antidiarrhoeal
	Type of Form	Form 5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Diosmectal 3g powder of Diosmectite for oral suspension, approved by Italian Medicines Agency
	Me-too status (with strength and dosage form)	Semetamed 3.0g Sachets. Reg. No. 61925
	GMP status	The panel recommended renewal of DML, inspection date 03/05/2019.
	Remarks of Evaluator[II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
366.	**Name and address of manufacturer / Applicant**	**M/s Jinnah Pharmaceuticals Pvt Ltd. 13 km, Lahore Road, Multan** contract manufactured **by M/s Aventek Pharmaceuticals 44-C, Sundar Industrial Estate, Lahore**
	Brand Name + Dosage Form + Strength	J-Cef 250mg IM Dry Powder Injection
	Composition	Each Vial Contains: Ceftriaxone As Sodium…250mg
	Diary No. Date of R& I & fee	Dy.No 16254 dated 07-03-2019 Rs.50,000/- dated 06-03-2019
	Pharmacological Group	Cephalosporin antibiotic (J01DD04)
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	CEFNIG INJECTION (CEFTRIAXONE AS SODIUM) of M/s GLOBAL PHARMACEUTICALS.
	GMP status	The panel recommended renewal of DML, inspection date 03/05/2019.
	Remarks of Evaluator [II]:	
	Decision: Approved.	
367.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Normalip Tablet 10mg**
	Composition	Each film coated tablet contains: Atorvastatin …… 10mg
	Diary No. Date of R& I & fee	Dy.No 15028 dated 07-03-2019 Rs.20,000/- dated 07-03-2019

	Pharmacological Group	HMG-CoA Reductase inhibitor
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Astatin tablet 10mg Reg. No. 035802 by Pharmacare
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: • Submit revised label claim as per innovator product declaring the strength in terms of Atorvastatin and complete salt form of drug substance along with master formulation and relevant fee as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. • Firm has submitted revised label claim as under along with fee of Rs. 7,500/- vide deposit slip# 49908957989: Each film coated tablet contains: Atorvastatin as Calcium trihydrate…… 10mg	
	Decision: Approved as per following label claim: **Each film coated tablet contains:** **Atorvastatin as Calcium trihydrate …… 10mg** **Firm shall submit differential fee of Rs. 22,500/- for pre-approval correction/change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
368.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Normalip Tablet 20mg**
	Composition	Each film coated tablet contains: Atorvastatin …… 20mg
	Diary No. Date of R& I & fee	Dy. No 15029 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	HMG-CoA Reductase inhibitor
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Astatin tablet 20mg Reg. No. 049122 by Pharmacare
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: • Submit revised label claim as per innovator product declaring the strength in terms of Atorvastatin and complete salt form of drug substance along with master formulation and relevant fee as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. • Firm has submitted revised label claim as under along with fee of Rs. 7,500/- vide deposit slip# 354967908815: Each film coated tablet contains: Atorvastatin as Calcium trihydrate…… 20mg	
	Decision: Approved as per following label claim: **Each film coated tablet contains:** **Atorvastatin as Calcium trihydrate …… 20mg** **Firm shall submit differential fee of Rs. 22,500/- for pre-approval correction/change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
369.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**

	Brand Name + Dosage Form + Strength	**Normalip Tablet 40mg**
	Composition	Each film coated tablet contains: Atorvastatin …… 40mg
	Diary No. Date of R& I & fee	Dy.No 15030 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	HMG-CoA Reductase inhibitor
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Astatin tablet 40mg Reg. No. 049123 by Pharmacare
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: • Submit revised label claim as per innovator product declaring the strength in terms of Atorvastatin and complete salt form of drug substance along with master formulation and relevant fee as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. • Firm has submitted revised label claim as under along with fee of Rs. 7,500/- vide deposit slip# 9841800234: Each film coated tablet contains: Atorvastatin as Calcium trihydrate…… 40mg	
	Decision: Approved as per following label claim: **Each film coated tablet contains:** **Atorvastatin as Calcium trihydrate …… 40mg** **Firm shall submit differential fee of Rs. 22,500/- for pre-approval correction/change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
370.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Rivaborn 10mg Tablet**
	Composition	Each film coated tablet contains: Rivaroxaban …… 10mg
	Diary No. Date of R& I & fee	Dy.No 15031 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Anticoagulant
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	XCEPT tablet 10mg Reg. No. 076157 by M/s. PharmEvo
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: Firm shall submit revised drug product specifications as per Pharmacopoeial monograph along with fee of Rs. 7,500/- as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. Firm has submitted revised specifications as per USP monograph along with submission of fee of Rs.7,500/- vide deposit slip# 74698381693.	
	Decision: Approved with USP specifications.	
371.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Rivaborn 15mg Tablet**

	Composition	Each film coated tablet contains: Rivaroxaban …… 15mg
	Diary No. Date of R& I & fee	Dy.No 15032 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Anticoagulant
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	XCEPT tablet 15mg Reg. No. 079930 by M/s. PharmEvo
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: Firm shall submit revised drug product specifications as per Pharmacopoeial monograph along with fee of Rs. 7,500/- as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. Firm has submitted revised specifications as per USP monograph along with submission of fee of Rs.7,500/- vide deposit slip# 088202242.	
	Decision: Approved with USP specifications.	
372.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Rivaborn 20mg Tablet**
	Composition	Each film coated tablet contains:- Rivaroxaban……20mg
	Diary No. Date of R& I & fee	Dy.No 15033 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Anticoagulant
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	XCEPT tablet 20mg Reg. No. 079931 by M/s. PharmEvo
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: Firm shall submit revised drug product specifications as per Pharmacopoeial monograph along with fee of Rs. 7,500/- as per Notification No. F.7-11/2012-B&A/DRAP dated 07th May, 2021. Firm has submitted revised specifications as per USP monograph along with submission of fee of Rs.7,500/- vide deposit slip# 605998529.	
	Decision: Approved with USP specifications.	
373.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Clarbact Tablet 250mg**
	Composition	Each film coated tablet contains:- Clarithromycin……250mg
	Diary No. Date of R& I & fee	Dy.No 15025 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Macrolide
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	KLARICID tablet 250mg Reg. No. 013149 by M/s. Abbott

	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
374.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Clarbact Tablet 500mg**
	Composition	Each film coated tablet contains:- Clarithromycin……500mg
	Diary No. Date of R& I & fee	Dy.No 15026 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Macrolide
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	KLARICID tablet 500mg Reg. No. 018145 by M/s. Abbott
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
375.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Sentan Tablet 62.5mg**
	Composition	Each film coated tablet contains: Bosentan (as monohydrate) …….62.5 mg
	Diary No. Date of R& I & fee	Dy.No 15964 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Endothelin receptor antagonist
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Bosmon tablet 62.5mg Reg. No. 066965 by M/s. Hilton
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
376.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd.** **Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Sentan Tablet 125mg**
	Composition	Each film coated tablet contains: Bosentan (as monohydrate) ……. 125 mg
	Diary No. Date of R& I & fee	Dy.No 15965 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Endothelin receptor antagonist
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Bosmon tablet 125mg Reg. No. 081521 by M/s. Hilton
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
377.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Vertiga Tablet 8mg**
	Composition	Each tablet contains: Betahistine dihydrochloride …… 8mg
	Diary No. Date of R& I & fee	Dy.No 15970 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Histamine analogue
	Type of Form	Form-5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Serc Tablet 8mg Reg. No. 006653 by M/s. Abbott
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved.	
378.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Vertiga Tablet 16mg**
	Composition	Each tablet contains: Betahistine dihydrochloride …… 16mg
	Diary No. Date of R& I & fee	Dy.No 15971 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Histamine analogue
	Type of Form	Form-5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Serc Tablet 16mg Reg. No. 014494 by M/s. Abbott
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved.	
379.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Vertiga Tablet 24mg**
	Composition	Each tablet contains: Betahistine dihydrochloride …… 24mg
	Diary No. Date of R& I & fee	Dy.No 15972 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Histamine analogue

	Type of Form	Form-5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Serc Tablet 24mg Reg. No. 059823 by M/s. Abbott
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved.	
380.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Serodone Tablet 2mg**
	Composition	Each tablet contains: Illoperidone ……. 2mg
	Diary No. Date of R& I & fee	Dy.No 15966 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti Pshycotic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Ilodone Tablet 2mg Reg. No. 070642 by M/s. Genix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
381.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Serodone Tablet 4mg**
	Composition	Each tablet contains: Illoperidone …….. 4mg
	Diary No. Date of R& I & fee	Dy.No 15967 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti Pshycotic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Ilodone Tablet 4mg Reg. No. 070463 by M/s. Genix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
382.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Serodone Tablet 6mg**

	Composition	Each tablet contains: Illoperidone ……. 6mg
	Diary No. Date of R& I & fee	Dy.No 15968 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti Pshycotic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Ilodone Tablet 6mg Reg. No. 070464 by M/s. Genix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
383.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Serodone Tablet 12mg**
	Composition	Each tablet contains: Illoperidone …….. 12mg
	Diary No. Date of R& I & fee	Dy.No 15969 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Anti Pshycotic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Ilodone Tablet 12mg Reg. No. 070467 by M/s. Genix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
384.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals (Pvt.) Ltd. Plot No. E-145 to E-149, North Western Industrial Zone, Port Qasim, Karachi, Pakistan**
	Brand Name + Dosage Form + Strength	**Fascort Tablet 0.5mg**
	Composition	Each tablet contains: Betamethasone (as sodium phosphate) …… 0.5mg
	Diary No. Date of R& I & fee	Dy. No dated: 07/03/2019 Rs. 20,000
	Pharmacological Group	Corticosteroid
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Betnesol Tablet 0.5mg Reg. No. 000262 by M/s. GSK
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator [II]: • Firm has applied for USP monograph, whereas monograph for applied formulation is not available in USP.	

	• Evidence of approval of required manufacturing facility of "Tablet (Steroidal)" section from CLB shall be submitted. Firm has submitted revised specifications as per BP monograph along with submission of fee of Rs. 7,500/- vide deposit slip# 91098736. Firm has also submitted letter from secretary CLB dated 07-02-014 declaring issuance of DML including Tablet (steroid) section.	
	Decision: Approved with BP specifications.	
385.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals, Karachi**
	Brand Name + Dosage Form + Strength	**Lurasid Tablet 40mg**
	Composition	Each tablet contains:- Lurasidone HCl …… 40mg
	Diary No. Date of R& I & fee	Dy.No 15962 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Benzisothiazol derivatives
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Lurisa Tablet 40mg Reg. No. 089358 by M/s. Helix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: Submit stability studies data as per checklist approved by Registration Board in its 293rd meeting.	
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
386.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals, Karachi**
	Brand Name + Dosage Form + Strength	**Lurasid Tablet 80mg**
	Composition	Each tablet contains: Lurasidone HCl …… 80mg
	Diary No. Date of R& I & fee	Dy.No 15963 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	benzisothiazol derivatives
	Type of Form	Form-5
	Finished product Specifications	Manufacturer Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Lurisa Tablet 80mg Reg. No. 089359 by M/s. Helix
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II: Submit stability studies data as per checklist approved by Registration Board in its 293rd meeting.	
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
387.	**Name and address of manufacturer / Applicant**	**M/s Hiranis Pharmaceuticals, Karachi**
	Brand Name + Dosage Form + Strength	**Baclodox 10mg Tablet**
	Composition	Each Tablet Contains: Baclofen ……. 10mg
	Diary No. Date of R& I & fee	Dy.No 15974 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Skeletal muscle relaxant
	Type of Form	Form 5
	Finished product Specifications	USP

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Beclotab Tablets by M/s Werrick Pharmaceuticals. (Reg#026758)
	GMP status	GMP inspection conducted on dated 05-11-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
388.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Legend Plus Sachet 40/1680
	Composition	"Each Sachet Contains: Omeprazole…40mg Sodium Bicarbonate……..1680"
	Diary No. Date of R& I & fee	Dy.No 14034 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Risek Insta Sachet by Getz
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Sachet (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
389.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Legend Plus Sachet 20/1680mg
	Composition	"Each Sachet Contains: Omeprazole…20mg Sodium Bicarbonate……..1680"
	Diary No. Date of R& I & fee	Dy.No 14035 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Risek Insta Sachet by Getz
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Sachet (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
390.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**

	Brand Name + Dosage Form + Strength	Wintol tablet
	Composition	Each Tablet Contains: Salbutamol Sulfate Equivalent To Sabutamol……2mg
	Diary No. Date of R& I & fee	Dy.No 14032 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Selective beta-2-adrenoreceptor agonists
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	MHRA Approved
	Me-too status (with strength and dosage form)	BRONKAL-2 TAB Reg. No. 011638 of M/s Atco
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
391.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd. L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Clotix Cream 10%
	Composition	Each Gram Of Cream Contains: Clotrimazole…..…100mg
	Diary No. Date of R& I & fee	Dy.No 14044 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Canesten 10% w/w Vaginal Cream of (MHRA approved)
	Me-too status (with strength and dosage form)	Vaginex-1 Cream of M/s Global Pharmaceuticals
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
392.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd. L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Maxime 200mg Capsule
	Composition	Each Capsule Contains: Cefixime As Trihydrate…200mg
	Diary No. Date of R& I & fee	Dy.No 14022 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Third generation cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	SUPRAX 200 mg CAPSULE by SANOFI Aventis Spain Approved
	Me-too status (with strength and dosage form)	Cefiget 200 mg Capsule by M/s GETZ Pharma
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
393.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd. L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**

	Brand Name + Dosage Form + Strength	Ceftra Dry Powder Injection 500mg
	Composition	Each Vial Of Dry Substance Contains: Ceftriaxone Sodium…500mg
	Diary No. Date of R& I & fee	Dy.No 16205 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Third generation cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Rocephin injection 500mg IV by M/s F.Hoffman-La Roche Ltd. Basel, Switzerland, Reg. No.00843
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II: Firm has applied for ceftriaxone sodium 500mg whereas reference product contains ceftriaxone as sodium 500mg. Details of route of administration required.	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Cephalosporin) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
394.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd. L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Ceftra Dry Powder Injection 250mg
	Composition	Each Vial Of Dry Substance Contains: Ceftriaxone Sodium…250mg
	Diary No. Date of R& I & fee	Dy.No 16209 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Oxidil injection 250mg of M/s Sami Pharma
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II: Firm has applied for ceftriaxone sodium 250mg whereas reference product contains ceftriaxone as sodium 250mg.	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Cephalosporin) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
395.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd. L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Anastra Tablet 1mg
	Composition	Each Film Coated Tablet Contains: Anastrazole…1mg
	Diary No. Date of R& I & fee	Dy. No 16200 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Aromatase inhibitor (L02BG).
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Arimidex Anastrozole 1mg film coated tablets, TGA approved.

	Me-too status (with strength and dosage form)	Arimisol 1mg Tablet, Swiss Pharmaceuticals, Reg. No. 091125.
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator [II]:	
	Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
396.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Suprem Injection 40mg
	Composition	Each Vial Of Dry Substance Contains: Esomeprazole Sodium…40mg
	Diary No. Date of R& I & fee	Dy.No 16207 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Proton pump inhibitors
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	Nexum IV 40mg Injection. Reg. No. 050651 M/s Getz Pharma Karachi
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator [II]: Reference product contains Esomeprazole as sodium 40mg while firm has applied for Esomeprazole sodium 40mg.	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
397.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Voltrex 75mg/3ml Injection
	Composition	Each 3ml Ampoule Contains: Diclofenac Sodium…75mg
	Diary No. Date of R& I & fee	Dy.No 16202 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	NSAIDS
	Type of Form	Form 5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status (with strength and dosage form)	V- Ren Liquid Injection of M/s Regal Pharmaceuticals (Reg#082002)
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator [II]:	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection ampoule (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
398.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Ceftra Dry Powder Injection 1gm

	Composition	Each Vial Of Dry Substance Contains: Ceftriaxone Sodium…1gm
	Diary No. Date of R& I & fee	Dy.No 16208 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Oxidil injection 1gm of M/s Sami Pharma
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II: Firm has applied for ceftriaxone sodium 1gm whereas reference product contains ceftriaxone as sodium 1gm. Details of route of administration required.	
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Cephalosporin) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
399.	**Name and address of manufacturer / Applicant**	**M/s Lisko Pakistan Pvt Ltd.** **L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi**
	Brand Name + Dosage Form + Strength	Maxime DS 100mg/5ml
	Composition	Each ml Contains: Cefixime As Trihydrate…100mg
	Diary No. Date of R& I & fee	Dy.No 14023 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status (with strength and dosage form)	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi
	GMP status	GMP certificate issued on the basis of inspection dated 17-08-2021
	Remarks of Evaluator II:	
	Decision: Approved.	
400.	**Name and address of manufacturer / Applicant**	M/s Athan Pharmaceuticals. Plot 84/1, Block B, Phase 5, Industrial Estate, Hattar, Kpk, Pakistan
	Brand Name + Dosage Form + Strength	Timo Eye Drops
	Composition	Each ml Contains: Timolol as Maleate Eq. To Timolol …… 2.5mg
	Diary No. Date of R& I & fee	Dy.No 16546 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antiglaucoma preparations
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA of UK
	Me-too status (with strength and dosage form)	Timox 0.25% Sterile Ophthalmic of M/s Medicaids (Reg.#073722)
	GMP status	Issuance of DML to M/s Athan Pharmaceuticals Hattarin 269th Meeting of CLB dated 05-03-2019.
	Remarks of Evaluator II:	

	Decision: Approved.	
401.	**Name and address of manufacturer / Applicant**	M/s Athan Pharmaceuticals. Plot 84/1, Block B, Phase 5, Industrial Estate, Hattar, Kpk, Pakistan
	Brand Name + Dosage Form + Strength	Diopin 10mg Tablets
	Composition	Each Film Coated Tablet Contains: Domperidone …… 10mg
	Diary No. Date of R& I & fee	Dy. No 16501 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Propulsives
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved by TGA of Australia
	Me-too status (with strength and dosage form)	Epodom 10mg Tablets of M/s Atlantic Pharmaceutical (Pvt.) Ltd, (Reg.# 062326)
	GMP status	Issuance of DML to M/s Athan Pharmaceuticals Hattarin 269th Meeting of CLB dated 05-03-2019.
	Remarks of Evaluator [II]:	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
402.	**Name and address of manufacturer / Applicant**	M/s Athan Pharmaceuticals. Plot 84/1, Block B, Phase 5, Industrial Estate, Hattar, Kpk, Pakistan
	Brand Name + Dosage Form + Strength	Artho 200/50mg Tablet
	Composition	Each Film Coated Tablet Contains: Diclofenac Sodium…50mg Misoprostol…200mg
	Diary No. Date of R& I & fee	Dy.No 17353 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	NSAID/Prostaglandins
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Arthrotec 50 modified-release tablets (MHRA)
	Me-too status (with strength and dosage form)	Erwin 50mg of M/s Sami Pharmaceuticals (Reg # 024492)
	GMP status	Issuance of DML to M/s Athan Pharmaceuticals Hattarin 269th Meeting of CLB dated 05-03-2019.
	Remarks of Evaluator [II]: Firm shall submit revised composition as per innovator product declaring the dosage form as enteric coated bilayer tablet.	
	Decision: Approved as per following label claim: **"Each film coated bilayer tablet contains:** **Diclofenac Sodium (Gastro-Resistant Core) .....75mg** **Misoprostol (Immediate Release Outer Mantle) ..... 200mcg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with evidence of availability of bi-layer tablet compression machine, before issuance of registration letter.**	
403.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	B-free Sachet
	Composition	Each Sachet Contains: Montelukast Sodium Equivalent To Montelukast …… 4mg

	Diary No. Date of R& I & fee	Form-5 Dy.No 13577 dated 07-03-2019 Rs.20,000 dated 07-03-2019
	Pharmacological Group	USP Specification
	Type of Form	Form-5
	Finished product Specifications	Antihistamine
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	SINGULAIR® USFDA Approved.
	Me-too status (with strength and dosage form)	080865; "Myteka 4mg Sachet" "Hilton Pharma"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
404.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	L Zine 5mg Tablet
	Composition	Each Film Coated Tablet Contains: Levocetrizine Dihydrochloride ……. 5mg
	Diary No. Date of R& I & fee	Dy.No 13530 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antihistaminic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	XYZAL® USFDA Approved.
	Me-too status (with strength and dosage form)	044424; "BELAIR 5mg Tablet" "BAYER."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
405.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Alenid 70mg tablet
	Composition	Each Tablet Contains: Alendronic Acid Eq. To 91.363mg Of Sodium Alendronate Trihydrate ….. 70mg
	Diary No. Date of R& I & fee	Dy.No 13548 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Antiosteoporosis
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	FOSAMAX® USFDA Approved.
	Me-too status (with strength and dosage form)	039195; "Bonpart 70mg Tablet" "Barrett Hodgson."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]: Declaration of strength shall be harmonized along with the innovator product	
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Alendronate sodium trihydrate …. 91.37mg eq. to Alendronnic acid ….. 70mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	

406.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ornip Sachet
	Composition	Each Sachet Contains: L-Ornithine L-Aspartate ……3000mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13575 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Hepatoprotectant
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Hepa-Merz 3gm Sachet containing ornithine aspartate (granules for solution). AGES (Austria) approved
	Me-too status (with strength and dosage form)	Lolar Sachet by M/s Hiranis Pharmaceuticals (Reg#076499)
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
407.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	ADTRIN 0.1% Cream
	Composition	Each 1Gm Cream Contains: Adapalene….. 1mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13564 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	retinoid-like compounds
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	DIFFERIN® USFDA Approved.
	Me-too status (with strength and dosage form)	050526; "ADAPCO 0.1% Cream" "Atco Pharm."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]: BP monograph is available for applied formulation.	
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
408.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Maltomax-f Tablet
	Composition	Each Chewable Tablet Contains: Iron (Iii) Hydroxide Polymaltose Equivalent To Elemental Iron ….100mg Folic Acid ….. 0.35mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13553 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Iron & Other Anti-anaemic
	Type of Form	Form-5
	Finished product Specifications	Innovator's Specification
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities	WHO approved
	Me-too status (with strength and dosage form)	034675; "MOTOZ-F Tablet" "SAIMS Pharmaceuticals."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
409.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Co-Ibtan 300mg/ 25mg Tablet
	Composition	Each Film Coated Tablet Contains: Irbesartan …..300mg Hydrochlorothiazide ……25mg
	Diary No. Date of R& I & fee	Dy.No 13522 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	AVALIDE® USFDA Approved.
	Me-too status (with strength and dosage form)	053883; "CO-APROVEL 300/25mg Tablet" "Sanofi-aventis."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
410.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	ALENID-D 70mg / 2800IU Tablet
	Composition	Each Tablet Contains: Sodium Alendronate eq. to Alendronic Acid …… 70mcg Colecalciferol Vit D3 ….. 2800IU
	Diary No. Date of R& I & fee	Form-5 Dy.No 13581 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Antiosteoporosis
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	FOSAMAX® PLUS D USFDA Approved.
	Me-too status (with strength and dosage form)	079561; "OSTEMET 70mg/2800IU Tablet" "Paramount"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
411.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	LOWAT-A 10mg / 5mg film coated Tablet
	Composition	Each Film Coated Tablet Contains: Atorvastatin ….. 10mg (As Atorvastatin Calcium Trihydrate) Amlodipine as Amlodipine Besylate ……. 5mg
	Diary No. Date of R& I & fee	Dy.No 13525 dated 07-03-2019 Rs.20,000 dated 06-03-2019

	Pharmacological Group	Antihypertensive Agent
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	CADUET® USFDA Approved.
	Me-too status (with strength and dosage form)	045339; "AM-DESCOL 5/10mg Tablet" "NABIQASIM"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	
412.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	L-Zine Oral Solution
	Composition	Each ml of Oral Solution Contains: Levocetirizine Dihydrochloride …….0.5mg
	Diary No. Date of R& I & fee	Dy.No 13521 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Anti-Histamine
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	XYZAL® USFDA Approved.
	Me-too status (with strength and dosage form)	058380; "AIVIGO 2.5mg/5ml Syrup" "PLATINUM"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
413.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	IVER 6mg Tab
	Composition	Each Tablet Contains: Ivermectin….. 6mg
	Diary No. Date of R& I & fee	Dy.No 13579 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	STROMECTOL® USFDA Approved.
	Me-too status (with strength and dosage form)	061339; "IVERMITE 6mg Tablet" "ATCO"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	
414.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	IVER 3mg Tab
	Composition	Each Tablet Contains: Ivermectin …..3mg
	Diary No. Date of R& I & fee	Dy.No 13580 dated 07-03-2019 Rs.20,000 dated 06-03-2019

	Pharmacological Group	Anthelmintic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	STROMECTOL® USFDA Approved.
	Me-too status (with strength and dosage form)	; "MACTOVIN 3mg Tablet" "VALOR/AL-HAMEED"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	
415.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Lotan-H 50mg /12.5 Tablet
	Composition	Each Film Coated Tablet Contains: Losartan Potassium ……50mg Hydrochlorothiazide ……. 12.5mg
	Diary No. Date of R& I & fee	Dy.No 13542 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	HYZAAR® USFDA Approved.
	Me-too status (with strength and dosage form)	029210; "DIU-TANSIN 50/12.5mg TABLET" "PHARMEVO."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	
416.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Lotan 25mg film coated Tablet
	Composition	Each Film Coated Tablet Contains: Losartan Potassium …..25mg
	Diary No. Date of R& I & fee	Dy.No 13544 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	COZAAR® USFDA Approved.
	Me-too status (with strength and dosage form)	027206; "BEPSAR 50mg Tablet" "NABIQASIM."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	
417.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Co-Ibtan 300mg/ 12.5mg Tablet
	Composition	Each Film Coated Tablet Contains: Irbesartan ……. 300mg Hydrochlorothiazide …….. 12.5mg
	Diary No. Date of R& I & fee	Dy.No 13541 dated 07-03-2019 Rs.20,000 dated 06-03-2019

	Pharmacological Group	Antihypertensive
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	AVALIDE® USFDA Approved.
	Me-too status (with strength and dosage form)	043096; "CO-APROVEL 300/12.5mg Tablet" "SANOFI-AVENTIS."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
418.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ontron 4mg Tablet
	Composition	Each Film Coated Tablet Contains: Ondansetron …… 4mg (As Ondansetrone Hydrochloride Dihydrate)
	Diary No. Date of R& I & fee	Form-5 Dy.No 13551 dated 07-03-2019 Rs.20,000 dated 06-03-2019
	Pharmacological Group	Antiemetic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	**Zofran Tablet®** USFDA Approved.
	Me-too status (with strength and dosage form)	093250; "VEMTIX 4mg TABLET" "BIO-LABS"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
419.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Kezon 200mg tablet
	Composition	Each Tablet Contains: Ketoconazole …… 200mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13578 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Antifungal
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Nizoral Tablet® USFDA Approved.
	Me-too status (with strength and dosage form)	028108; "MYCOLOCK TABLET" "BRYON"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator [II]:	
	Decision: Approved.	
420.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ommee Fast 40/1680mg Sachet
	Composition	Each Sachet Contains: Omeprazole…… 40mg

		Sodium Bicarbonate ……1680mg
	Diary No. Date of R& I & fee	Dy. No 13512 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Proton pump Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Zegerid® USFDA Approved.
	Me-too status (with strength and dosage form)	084738; "UZION SACHET" "MARTIN DOW"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
421.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ommee Fast 20/1680mg Sachet
	Composition	Each Sachet Contains: Omeprazole……. 20mg Sodium Bicarbonate…… 1680mg
	Diary No. Date of R& I & fee	Dy. No 13572 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Proton pump Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Maxitech Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Zegerid® USFDA Approved.
	Me-too status (with strength and dosage form)	084739; "UZION SACHET" "MARTIN DOW"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
422.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ontron Injection 8mg/4ml
	Composition	Each 4ml Ampoule Contains: Ondansetron As Ondansetron Hcl ……. 8mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13549 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Antiemetic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	ZOFRAN INJECTION® USFDA Approved.
	Me-too status (with strength and dosage form)	084587; "AMTRON INJECTION" "AMGOMED"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II: Firm shall declare complete salt form as dihydrate in the label claim.	
	Decision: Approved as per following label claim: **Each 4ml Ampoule Contains:**	

	Ondansetron As Ondansetron HCl dihydrate……. 8mg **Firm shall submit fee of Rs. 30,000/- for pre-approval correction/change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
423.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Ontron 8mg Tablet
	Composition	Each Tablet Contains: Ondansetron As Ondansetron Hcl …… 8mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 13550 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Antiemetic
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	**Zofran Tablet®** USFDA Approved.
	Me-too status (with strength and dosage form)	093251; "VEMTIX 8mg TABLET" "BIO-LABS"
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II: Firm shall declare complete salt form as dihydrate in the label claim.	
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Ondansetron As Ondansetron HCl dihydrate…… 8mg** **Firm shall submit fee of Rs. 30,000/- for pre-approval correction/change in salt form of drug substance as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
424.	**Name and address of manufacturer / Applicant**	**M/s Maxitech Pharma Pvt Ltd. Plot No. E-178, S.I.T.E. Super Highway, Phase II, Karachi**
	Brand Name + Dosage Form + Strength	Lotan H 100mg/25mg Tablet
	Composition	Each Film Coated Tablet Contains: Losartan Potassium …..100mg Hydrochlorothiazide …..25mg
	Diary No. Date of R& I & fee	Dy.No 13537 dated 07-03-2019 Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) and diuretics
	Type of Form	Form-5
	Finished product Specifications	USP Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	HYZAAR® USFDA Approved.
	Me-too status (with strength and dosage form)	035618; "ZOSTAT PLUS 100/25mg TABLET" "HIMONT."
	GMP status	GMP certificate issued on 31.08.2022
	Remarks of Evaluator II:	
	Decision: Approved.	

a) Deferred cases

425.	**Name and address of manufacturer / Applicant**	**M/s Navegal Laboratories. 41/1-A2, Phase-1, Industrial Estate, Hattar**
	Brand Name +Dosage Form + Strength	Modagil 200mg Tablet
	Composition	Each Tablet Contains: Modafinil……200mg
	Diary No. Date of R& I & fee	Dy. No.39404; 30.11.2018 PKR. 20,000/-; 30.11.2018

	Pharmacological Group	Folic acid analogs (not in ATC)
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	1x10's, 2x10's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	PROVIGIL® (modafinil) 100mg and 200mg tablets, for oral use, C-IV. TGA approved
	Me-too status	Monalert 200mg Tablet. Reg. No. 47171
	GMP status	Staisfactory GMP level on 11.03.2017
	Remarks of the Evaluator[3].	• The firm revised the formulation from film-coated tablet to uncoated tablet along with submission of Rs. 7,500/- fee (Challan 173132402) dated 20.09.2021.
	Decision of 313th meeting of Registration Board: The Board deferred the case for consideration with the other cases submitted on Form 5 for human drug products.	
	Response by the firm: Firm has request to consider their case	
	Decision: Approved.	

426.	**Name and address of manufacturer / Applicant**	**M/s Medimarker's Labortaries Pvt Ltd. A-104, S.I.T.E Area, Hyderabad**
	Brand Name +Dosage Form + Strength	Zepa-Mark 1mg Tablet
	Composition	Each Tablet Contains: Lorazepam…1mg
	Diary No. Date of R& I & fee	Dy No. 17143: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Benzodiazepine derivatives
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Lorapram tablet by Hiranis
	GMP status	Last GMP inspection of conducted on 16-10-2018 and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator[3].	• Latest GMP inspection report conducted within a period of last three years. • Evidence of approval of psychotropic tablet section from Licensing Division DRAP.
	Decision of 323rd meeting of Registration Board: Deferred for confirmation of required manufacturing facility / section from Licensing Division.	
	Response by the firm: Firm has submitted copy of letter of regularization of master layout plan of the firm dated 03-12-2018 specifying Tablet (psychotropic) section.	
	Decision: Approved.	
427.	**Name and address of manufacturer / Applicant**	**M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad**
	Brand Name +Dosage Form + Strength	Zepa-Mark 2mg Tablet
	Composition	Each Tablet Contains: Lorazepam…2mg
	Diary No. Date of R& I & fee	Dy No. 17181: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Benzodiazepine derivatives
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Lorapram tablet by Hiranis
	GMP status	Last GMP inspection of conducted on 16-10-2018 and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator[3].	• Latest GMP inspection report conducted within a period of last three years.

		• Evidence of approval of psychotropic tablet section from Licensing Division DRAP.
	Decision of 323rd meeting of Registration Board: Deferred for confirmation of required manufacturing facility / section from Licensing Division.	
	Response by the firm: Firm has submitted copy of letter of regularization of master layout plan of the firm dated 03-12-2018 specifying Tablet (psychotropic) section.	
	Decision: Approved.	
428.	**Name and address of manufacturer / Applicant**	**M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad**
	Brand Name +Dosage Form + Strength	Phenidate 10mg Tablet
	Composition	Each Tablet Contains: Methylphenidate HCl…10mg
	Diary No. Date of R& I & fee	Dy No. 17156: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Centrally acting sympathomimetics
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Ritalin Tablet by Novartis
	GMP status	Last GMP inspection of conducted on 16-10-2018 and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator[3].	• Latest GMP inspection report conducted within a period of last three years. • Evidence of approval of psychotropic tablet section from Licensing Division DRAP.
	Decision of 323rd meeting of Registration Board: Deferred for confirmation of required manufacturing facility / section from Licensing Division.	
	Response by the firm: Firm has submitted copy of letter of regularization of master layout plan of the firm dated 03-12-2018 specifying Tablet (psychotropic) section.	
	Decision: Approved.	

429.	**Name and address of manufacturer / Applicant**	**M/s Moon Pharmaceuticals Plot No. 5, SS-4 Road, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Isotret E Gel 0.5/20mg
	Composition	Each gram of gel contains: Isotretinoin…0.5mg Erythromycin…20mg
	Diary No. Date of R& I & fee	Dy No. 14442: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Retinoids for topical use in acne
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Oratraxin gel by Crystolite
	GMP status	Firm has submitted inspection report dated 11- 12-2019 conducted to verify rectification status of observations noted in previous inspection. The panel in its written statement on inspection book mentioned that the firm is operating at acceptable level of GMP as of today. The panel in its detailed report concluded that firm has rectified majority of observations and the report is being forwarded to competent authority for

		resumption of production activities in Oral Liquid Syrup section.

Remarks of the Evaluator[3].

Sr. No	Observation	Response by the firm
1.	Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	**Firm has not submitted any response**

Decision of 323 meeting:
Deferred for evidence of approval of applied formulation in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting.

Evaluation by PEC:
The applied product is approved by EMA and France. Following are the approved products.

- Isotrexin 20 mg/g + 0,5 mg/g gel by M/s GSK, EMA approved

https://www.ema.europa.eu/en/documents/psusa/erythromycin/isotretinoin-list-nationally-authorised-medicinal-products-psusa/00001796/201508_en.pdf

- Antibiotrex, Gel (Isotretinoin 0.05g/100g & Erythromycin 2g/100g) by M/s Stiefel Laboratories (Ireland) Ltd, ANSM France Approved.

http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=61402743&typedoc=R&ref=R0243241.htm

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

430.	**Name and address of manufacturer / Applicant**	**M/s Moon Pharmaceuticals Plot No. 5, SS-4 Road, National Industrial Zone, Rawat, Islamabad**
	Brand Name +Dosage Form + Strength	Citro-Mon sachet
	Composition	Each sachet Contains: Citric acid ……. 0.702gm Sodium citrate …... 0.613gm Tartaric acid …… 0.858gm Sodium bicarbonate …… 1.716gm
	Diary No. Date of R& I & fee	R&I Dy.No 1614 dated 17-10-2016 verified by R&I Incharge, Rs.20,000/- dated 17-10-2016
	Pharmacological Group	Gastric antacid and urinary alkalising agent
	Type of Form	Form-5 (Duplicate dossier)
	Finished Product Specification	Manufacturer specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	----
	Me-too status	----
	GMP status	Firm has submitted inspection report dated 11- 12-2019 conducted to verify rectification status of observations noted in previous inspection. The panel in its written statement on inspection book mentioned that the firm is operating at acceptable level of GMP as of today. The panel in its detailed report concluded that firm has rectified majority of observations and the report is being forwarded to competent authority for resumption of production activities in Oral Liquid Syrup section.
	Evaluation by PEC: • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
	Decision of 321st meeting: Deferred for following: • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.	

	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. **Evaluation by PEC:** The applied product is approved by TGA Australia as provided by the applicant. **Product name:** Ural Powder Sachet Mfg by M/s Aspen Pharma Pty Ltd. TGA Australia Approved. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=29693&agid=%28PrintDetailsPublic%29&actionid=1 However, the composition of the applied product is slight different from the initially applied composition. A comparison is provided in the following table:

Applied product (Each Sachet)	**Product approved in reference country Each Sachet)**
Citric acid ……. 0.702gm	Citric acid ……. 0.72gm
Sodium citrate ….. 0.613gm	Sodium citrate ….. 0.63gm
Tartaric acid …….. 0.858gm	Tartaric acid …….. 0.89gm
Sodium bicarbonate …… 1.716gm	Sodium bicarbonate …… 1.76gm

Me-too: Citro-mint Sachet* by M/s Axis Pharma (Reg. no. 59639)
The firm has submitted Rs. 7,500/- vide challan number 305381892312 dated 18-01-2023 for revision of formulation.

Decision: Approved as per following label claim:
Each sachet Contains:
Citric acid ……. 0.72gm
Sodium citrate ….. 0.63gm
Tartaric acid …… 0.89gm
Sodium bicarbonate …… 1.76gm
Firm shall submit differential fee of Rs. 22,500/- for pre-approval correction/change in product composition as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

431.	Name and address of manufacturer / Applicant	M/s Pliva Pakistan Pvt Ltd Plot # B-77, Hub Industrial Trading Estate, Baluchistan
	Brand Name +Dosage Form + Strength	Plitox Tablet 2.5/0.25mg
	Composition	Each Tablet Contains: Diphenoxylate HCl…2.5mg Atropine Sulphate…0.25mg
	Diary No. Date of R& I & fee	Dy No. 16487: 07-03-2019 PKR 20,000/-: 07-03-2019
	Pharmacological Group	Antipropulsives
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Lomotil Tablet by Searle
	GMP status	Last inspection report dated 15-02-2022 concludes that the overall GMP of the firm is rated as good.
	Remarks of the Evaluator[3].	• Reference of finished product specifications. • Revise your label claim along with submission of full fee as per the innovator's product as per following: Each Tablet Contains: Diphenoxylate HCl…2.5mg Atropine Sulphate…0.025mg
	Decision of 323rd meeting: Deferred for revision of formulation as per the Innovator's product along with submission of fee 30,000/- as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. **Submission by the firm:** The firm has revised the for mulation as per innovator's product with out submission of any fee. Correct label claim of the produt is as under. Each Tablet Contains: Diphenoxylate HCl…2.5mg Atropine Sulphate…0.025mg	

	Decision: Approved as per following label claim: **Each Tablet Contains:** **Diphenoxylate HCl…2.5mg** **Atropine Sulphate…0.025mg** **Firm shall submit fee of Rs. 30,000/- for pre-approval correction/change in drug product composition as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**

432.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd.** **Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Mepraxime 40mg/5ml Dry Powder Suspension
	Composition	Each 5ml Contains: Cefpodoxime As Proxetil…40mg
	Diary No. Date of R& I & fee	Dy No. 15140: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Prelox suspension by Bosch
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Firm has dry powder suspension (ceph) section.
	Decision: Approved.	
433.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd.** **Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Mepraxime 100mg Capsule
	Composition	Each Capsule Contains: Cefpodoxime…100mg
	Diary No. Date of R& I & fee	Dy No. 15127: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished Product Specification	In-house specs
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed
	Me-too status	Podox capsule by EG Pharma
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Firm has dry Capsule (ceph) section. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
434.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd.** **Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Cepaxin Tablet 250mg
	Composition	Each Film Coated Tablet Contains: Ciprofloxacin As Hcl…250mg
	Diary No. Date of R& I & fee	Dy No. 15122: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Fluoroquinolones
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO

	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Novidat Tablet by Sami
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
435.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Cepaxin 500mg tablet
	Composition	Each Film Coated Tablet Contains: Ciprofloxacin Hcl Eq To Ciprofloxacin …500mg
	Diary No. Date of R& I & fee	Dy No. 15145: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Fluoroquinolones
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Novidat Tablet by Sami
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	•
	Decision: Approved.	
436.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Diafac K 50mg Tablet
	Composition	Each Film Coated Tablet Contains: Diclofenac Potassium…50mg
	Diary No. Date of R& I & fee	Dy No. 15132: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Diclorep Tablet by Sami
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	•
	Decision:	
437.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Cyclin D Capsule 100mg
	Composition	Each Capsule Contains: Doxycycline as Hyclate…100mg
	Diary No. Date of R& I & fee	Dy No. 15144: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Vibramycin Capsule by Pfizer
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	•

	Decision:Approved.	
438.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Merzole Capsule 40mg
	Composition	Each Capsule Contains: Esomeprazole Enteric Coated Pellets…40mg
	Diary No. Date of R& I & fee	Dy No. 15131: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nexum capsule by Getz
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma • Revise your label claim as per follow along with submission of full fee of registration: Each Capsule Contains: Esomeprazole as Magnesium Trihydrate (enteric coated pellets)…40mg
	Decision: Approved as per following label claim: Each Capsule Contains: Esomeprazole as Magnesium Trihydrate (enteric coated pellets)…40mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
439.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Merzole Capsule 20mg
	Composition	Each Capsule Contains: Esomeprazole Enteric Coated Pellets…20mg
	Diary No. Date of R& I & fee	Dy No. 15130: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Nexum capsule by Getz
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma • Revise your label claim as per follow along with submission of full fee of registration: Each Capsule Contains: Esomeprazole as Magnesium Trihydrate (enteric coated pellets)…20mg
	Decision: Approved as per following label claim: Each Capsule Contains: Esomeprazole as Magnesium Trihydrate (enteric coated pellets)…20mg The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
440.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd. Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Misole Capsule 15mg

	Composition	Each Capsule Contains: Lansoprazole…15mg
	Diary No. Date of R& I & fee	Dy No. 15128: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Prozol Capsule by Platinum
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma • Revise your label claim as per follow along with submission of full fee of registration: Each Capsule Contains: • Lansoprazole (as enteric Coated Pellets)..…15mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Lansoprazole (as enteric Coated Pellets)..…15mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
441.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd.** **Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Misole Capsule 30mg
	Composition	Each Capsule Contains: Lansoprazole…30mg
	Diary No. Date of R& I & fee	Dy No. 15142: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Lanzol Capsule by Pharmatec
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Source of pellets: M/s Vision Pharma • Revise your label claim as per follow along with submission of full fee of registration: Each Capsule Contains: Lansoprazole (as enteric Coated Pellets)..…30mg
	Decision: Approved as per following label claim: **Each Capsule Contains:** **Lansoprazole (as enteric Coated Pellets)..…30mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
442.	**Name and address of manufacturer / Applicant**	**M/s Mission Pharmaceuticals Pvt Ltd.** **Plot No. A-94, SITE Super Highway Karachi, Pakistan**
	Brand Name +Dosage Form + Strength	Mislor Tablet 10mg
	Composition	Each Film Coated Tablet Contains: Loratadine…10mg
	Diary No. Date of R& I & fee	Dy No. 15125: 07-03-2019 PKR 20,000/-: 06-03-2019
	Pharmacological Group	Antiallergic
	Type of Form	Form 5
	Finished Product Specification	USP

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Smartec Tablet by Hilton Pharma
	GMP status	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 10-01-2022
	Remarks of the Evaluator[3].	• Revise your label claim to uncoated tablet as per the innovator's product as under along with submission of 7500/- fee: Each Tablet Contains: Loratadine…10mg
	Decision: Approved as per following label claim: **Each Tablet Contains:** **Loratadine…10mg** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to uncoated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	

443.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefcon IM/IV 2g Injection
	Composition	Each Vial Contains: Cefoperazone as Sodium…1000mg Sulbactam as Sodium…….1000mg
	Diary No. Date of R& I & fee	Dy.No 16323 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Cephalosporin/beta lactamase inhibitor
	Type of Form	Form 5
	Finished Product Specification	JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Approved by 3 European countries: **Czech:** http://www.sukl.eu/modules/medication/detail.php?code=0015 273&tab=info **Slovakia:** https://www.sukl.sk/hlavna-stranka/english-version/specialpages/medical-product-detail?page_id=842&lie_id=6343A **Poland:** http://pub.rejestrymedyczne.csioz.gov.pl/?AspxAutoDetectCookieSupport=1#results Links are assessed on 1st Oct 2018
	Me-too status	2Sum Injection 1g by M/s Sami Pharmaceuticals, Karachi (Reg.# 047002)
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General)

		• Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
444.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefcon IM/IV 1g Injection
	Composition	Each Vial Contains: Cefoperazone as Sodium…500mg Sulbactam as Sodium…500mg
	Diary No. Date of R& I & fee	Dy.No 16326 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Cephalosporin/beta lactamase inhibitor
	Type of Form	Form 5
	Finished Product Specification	JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Sulperazon Injection, Pfizer Inc. PMDA Approved
	Me-too status	2Sum Injection 1g by M/s Sami Pharmaceuticals, Karachi (Reg.# 047002)
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
445.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IV 500mg Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…500mg
	Diary No. Date of R& I & fee	Dy.No 16330 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA
	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available

		capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
446.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IV 250mg Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…250mg
	Diary No. Date of R& I & fee	Dy.No 16328 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA
	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
447.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IV 1gm Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…1Gm
	Diary No. Date of R& I & fee	Dy.No 16327 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA

	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
448.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IM 500mg Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…500mg
	Diary No. Date of R& I & fee	Dy.No 16329 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA
	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
449.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IM 1000mg Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…1000mg

	Diary No. Date of R& I & fee	Dy.No 16324 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA
	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
450.	Name and address of manufacturer / Applicant	Applicant: M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan MFG BY: Astellas Pharmaceuticals pvt Ltd. 15-C Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Cefmed IM 250mg Injection
	Composition	Each Vial Contains: Ceftriaxone as Sodium…250mg
	Diary No. Date of R& I & fee	Dy.No 16325 dated 07-03-2019 Rs.50,000/- dated 07-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA
	Me-too status	Oxidil injection by M/s Sami
	GMP status	Copy of last inspection report of M/s Astellas Pharmaceuticals (Pvt) Ltd. Peshawar dated 06-07-2021 (indication "Good" level of compliance) Registration Board discussed the inspection report in detail. Deliberations were made on used and available capacity keeping in view registered product, currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Astellas pharmaceutical (Pvt.) Ltd, 15-C, Hayatabad Industrial Estate, Peshawar for following sections: • Dry Powder Injectable (Cephalosporin) • Liquid Injection (Ampoule General) • Liquid Injection (Vial General) SVP, LVP
	Decision: Approved.	
451.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan

	Brand Name +Dosage Form + Strength	Dexazole 60mg Capsule
	Composition	Each Capsule Contains: Dexlansoprazole Dual Delayaed Release Pellets Eq To Dexlansoprazole…60mg
	Diary No. Date of R& I & fee	Dy.No 13464 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Razodex Capsule of Getz
	GMP status	Copy of last GMP inspection report dated 14/12/2020, Satisfactory level of GMP compliance.
	Remarks	Stability study data is required
	Decision: Deferred for submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
452.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Dexazole 30mg Capsule
	Composition	Each Capsule Contains: Dexlansoprazole Dual Delayaed Release Pellets Eq To Dexlansoprazole…30mg
	Diary No. Date of R& I & fee	Dy.No 13465 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	PPI
	Type of Form	Form 5
	Finished Product Specification	Firm has claimed in house specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved
	Me-too status	Razodex Capsule of Getz
	GMP status	Copy of last GMP inspection report dated 14/12/2020, Satisfactory level of GMP compliance.
	Remarks	Stability study data is required
	Decision: Deferred for submission of stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
453.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Flumaxi 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Fluvoxamine Maleate…100mg
	Diary No. Date of R& I & fee	Dy.No 13461 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	SSRIs
	Type of Form	Form-5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Meduxa 100mg Tablet by M/s Mediate Pharma (Reg. No. 61960)
	GMP status	Copy of last GMP inspection report dated 14/12/2020, Satisfactory level of GMP compliance.
	Decision: Approved.	
454.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Qutamax 100mg Tablet
	Composition	Each Film Coated Tablet Contains: Quetiapine as Fumarate…100mg

	Diary No. Date of R& I & fee	Dy.No 13463 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Q-Par Tablet by Helix
	GMP status	Copy of last GMP inspection report dated 14/12/2020, Satisfactory level of GMP compliance.
	Decision: Approved.	
455.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Medisol Plus Tablet
	Composition	Each Film Coated Tablet Contains: Tramadol HCl…37.5mg Paracetamol…325mg
	Diary No. Date of R& I & fee	Dy.No 13462 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Analgesic/antipyretic
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference Regulatory Authorities.	Ultraset film coated tablet by M/s Janssen Pharms, USFDA Approved
	Me-too status	Tramal Plus tablet by M/s Searle Company limited, Reg No.77129
	GMP status	Copy of last GMP inspection report dated 14/12/2020, Satisfactory level of GMP compliance.
	Decision: Approved.	
456.	Name and address of manufacturer / Applicant	M/s Medicon Pharmaceuticals Pvt Ltd. Industrial Estate, Jamrud Road, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Zolpicon 10mg Tablet
	Composition	Each Film Coated Tablet Contains: Zolpidem Tartrate…10mg
	Diary No. Date of R& I & fee	Dy.No 13466 dated 07-03-2019 Rs.20,000/- dated 07-03-2019
	Pharmacological Group	Benzodiazepine related drugs
	Type of Form	Form 5
	Finished Product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	MHRA Approved
	Me-too status	Stilnox Tablet by Sanofi Aventis
	GMP status	
	Remarks	Firm has submitted section approval letter no. F.3-7/91-Lic (Vol-II) dated 11-08-2015 for the Tablet (Psychotropic) section.
	Decision: Approved.	

Item No. 4: Agenda of Evaluator PEC-IV (Mst. Farzana Raja)

Case no. 01 Registration applications for local manufacturing of (Human) drugs Form 5F

a. New cases

457.	Name, address of Applicant / Marketing Authorization Holder	M/s W.WoodWard Pakistan(Pvt) Ltd F-275 S.I.T.E Karachi,Pakistan
	Name, address of Manufacturing site.	M/s W.WoodWard Pakistan(Pvt) Ltd F-275 S.I.T.E Karachi,Pakistan

	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 8859: 18-03-2021
	Details of fee submitted	PKR 20,000/-: 30-06-2020
	The proposed proprietary name / brand name	Dapawood 10mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated Tablet Contains: Dapagliflozin as Propanediol monohydrate……10mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Antidiabetics
	Reference to Finished product specifications	Manufacturer specifications
	Proposed Pack size	14's
	Proposed unit price	Rs:400/pack
	The status in reference regulatory authorities	FARXIGA of Bristol-MayersUSFDA approved
	For generic drugs (me-too status)	Dapa 10mg tablet of M/S Hilton Pharma (Reg # 089368)
	GMP status of the Finished product manufacturer	Last inspection conducted on 02-07-2020 and concludes that firm is found to be maintain at Good level of compliance
	Name and address of API manufacturer.	Fuxin Long Rui Pharmaceuticals Co.,Ltd Address:Fluoride Industrial Park, FumengCounty (Yi Ma Tu),Fuxin City, Liaoning Province, China
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of

		manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substances.
	Stability studies of Drug substance	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has performed comparative dissolution profile against the product i.e Dapa 10mg by M/s Hilton pharma Batch No# 132035, and the results are within acceptable limit
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, accuracy, precision, robustness, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Fuxin Long Rui Pharmaceuticals Co.,Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu),Fuxin City, Liaoning Province, China		
API Lot No.	DG-20190116-D01-DG06-01		
Description of Pack (Container closure system)	Alu-Alu		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 9 months Accelerated: 6 months		
Frequency	Accelerated: 0,3, 6 (Months) Real Time: 0, 3, 6, 9 (Months)		
Batch No.	PD-155	PD-158	PD-159
Batch Size	700 Tablets	700 Tablets	700 Tablets
Manufacturing Date	04.2019	04.2019	04.2019
Date of Initiation	17-04-2019	17-04-2019	17-04-2019
No. of Batches	03		

Administrative Portion		
19.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
20.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of Drug manufacturing license (License no. Liao 20150233) for M/s Fuxin Long Rui Pharmaceutical Co. Ltd, Fluoride Industrial park, Fuxin City, Liaoning

		Province issued by Liaoning Food and Drug Administration of the People's Republic of China is submitted, valid upto 20-12-2022
21.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.
22.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
23.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted.
24.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated
1.	1.3.4.	Valid Drug Manufacturing License (DML) of manufacturer / Applicant shall be submitted as submitted DML was valid up to 13-02-2021
2.	3.2.S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required.
3.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer of drug substance(s) shall be submitted
4.	3.2. P.2.2.1	• Pharmaceutical equivalence of the applied drug shall be established with the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed • As per relevant guidelines & structure of Form 5F, Comparative Dissolution profile shall be established with the innovator / reference / comparator product at the time of formulation development, while according to your submitted data, Comparative Dissolution profile have been performed after commencing stability studies.i.e 04-04-2020 Justification shall be submitted. • In CDP batch no of Dapawood tablet 10mg is PD145. Clarification is required in this regard.
5.	3.2.P.3.5	Submitted process validation protocol are general. Product related process validation protocol
6.	3.2.P.5.1	• Justify the dissolution acceptance criteria of value of Q = 80% in 30 min while the innovator product (Farxiga) has specified the dissolution specifications of NLT 85% in 15 min. • Submit dissolution testing data with specifications of "NLT Q within 15 minutes" at initial and one month time point at both accelerated and real time stability conditions for 2 batches.
7.	3.2.P.5.3	• As per relevant guidelines & structure of Form 5F Analytical test method validation has to be performed at the time of formulation development, while according to your submitted data, Analytical test method validation have been performed on 09-01-2020 while stability studies started on 17-04-2019. Justification shall be submitted in this regard.

		• Submit Analytical test method validation protocols
8.	3.2.P.5.4	Content uniformity not performed at initial testing of three batches
9.	3.2.P.6	Submitted COA of Reference standard shows Expiry date of 10-06-2017. Justification is required in this regard.
10.	3.2.P.8	Documents for the procurement of API with approval from DRAP (in case of import). In Dissolution testing on raw data sheets, date mentioned of 2017 and 2007 while batch No PD -155,PD -158 and PD-159 manufactured in 04.2019. Clarification is required.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

458.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals(Pvt.)Ltd Lahore
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals(Pvt.)Ltd ., 28km Ferozepur Road Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 32578 dated 30/11/2021
	Details of fee submitted	PKR 30,000/-: Deposit slip # 091274756084
	The proposed proprietary name / brand name	**Dapaflo-M 5mg/850mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: - Dapagliflozin Propanediol Monohydrate Eq to Dapagliflozin)……..…5mg Metformin Hydrochloride……850mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Biguanide with antihyperglycemic activity
	Reference to Finished product specifications	In-House
	Proposed Pack size	10’s, 14’s
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Xigduo Tablet 5/850mg AstraZeneca Pharmaceuticals (Ireland) EMA approved.
	For generic drugs (me-too status)	Dapa-Met 5/850mg by Hilton Pharma ·
	GMP status of the Finished product manufacturer	License granted on 08/04/2006 and renewed on 08/04/2021 General tablet section approved and GMP certificate on 31/08/2021.
	Name and address of API manufacturer.	**Dapagliflozin:** Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China. **Metformin HCL:**

		Aarti Drugs Ltd Address: Plot No 211 & 213, Road -2, G.I.D.C AT & Post Sarigam. City Sarigam– 396 155 Dist. Valsad Gujarat industrial estate India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, s Solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Dapagliflozin: Official monograph of Dapagliflozin is not present in any pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance Metformin HCl: Official monograph of Metformin HCl is present in BP. The firm has submitted detail of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Dapagliflozin**: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (130401, 130402, 130501) **Metformin**: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months (MEF/1510145, MEF/1510146, MEF/1510147)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Xigduo Tablet 5/850mg of Astrazeneca Farmaceutica Spain by performing quality tests (Identification, Assay, Dissolution,

		Hardness, Disintegration Time). CDP has been performed against the same brand that is Xigduo Tablet 5/850mg of Astrazeneca Farmaceutica Spain in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity, robustness and Limit of Quantification.

STABILITY STUDY DATA			
Manufacturer of API	**Dapagliflozin:** Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China. **Metformin HCL:** Aarti Drugs Ltd Address: Plot No 211 & 213, Road -2, G.I.D.C AT & Post Sarigam. City Sarigam– 396 155 Dist. Valsad Gujarat industrial estate India.		
API Lot No.	**Dapagliflozin:** 7100-202006001 **Metformin:** MEF/19123234		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**RD/PR20-012/T1/S1**	**RD/PR20-012/T1/S2**	**RD/PR20-012/T1/S3**
Batch Size	2000 tablets	2000 tablets	2000 tablets
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	06-10-2020	06-10-2020	06-10-2020
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Dapagliflozin:** Firm has submitted copy of GMP certificate No # JS2020921 of M/s Jiangsu Yongan Pharmaceutical Co. Ltd., China issued by Jiangsu Drugs Administration, China. The certificate is valid till 20-09-2025 **Metformin:** Copy of GMP certificate No. 20031933 issued by Food & Drug Control administration Gujrat state India valid till 19-03-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Dapagliflozin:** Firm has submitted copy of Commercial Invoice (Invoice #ZY20061201G/W) Dated: 12-06-2020 attested by DRAP Lahore office dated 16-06-2020 of Dapagliflozin (Batch# 7100-202006001). **Metformin:** Firm has submitted copy of Commercial Invoice (Invoice #2387/19-20-25) Dated: 25-12-2019

		attested by DRAP Lahore office dated 08-01-2020 Metformin (Batch# MEF/19123234).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.S.4.4	Certificate of analysis of dapagliflozin Propanediol Monohydrate by drug substance manufacturer and drug product manufacturer are of different batch.	Certificate of analysis of the same batch of dapagliflozin Propanediol Monohydrate from both drug substance manufacturer and drug product manufacturer are submitted.
2.	3.2.P.5.4	Specifications for dissolution testing claimed in section 3.2.P.5.1 are NLT 80% (Q) in 30 minutes while in COA's it is mentioned as NLT 75% (Q) in 30 minutes. Clarification is required	There was a typo error in the dissolution specification in COA's of which has been amended. Revised COA's are attached.
3.	3.2.P.8	Documents for the procurement of API with approval from DRAP.	Submitted.

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

459.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals(Pvt.) Ltd Lahore
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals(Pvt.)Ltd ., 28km Ferozepur Road Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 32550 dated 25/11/2021

	Details of fee submitted	PKR 30,000/-: Deposit slip # 2636948748
	The proposed proprietary name / brand name	Dapaflo-M 5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: - Dapagliflozin Propanediol Monohydrate Eq to Dapagliflozin)……..…5mg Metformin Hydrochloride……1000mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Biguanide with antihyperglycemic activity
	Reference to Finished product specifications	In-House
	Proposed Pack size	10's, 14's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Xigduo Tablet 5/1000mg AstraZeneca Pharmaceuticals (Ireland) EMA approved.
	For generic drugs (me-too status)	Dapa-Met 5/1000mg by Hilton Pharma ·
	GMP status of the Finished product manufacturer	License granted on 08/04/2006 and renewed on 08/04/2021 General tablet section approved and GMP certificate on 31/08/2021.
	Name and address of API manufacturer.	**Dapagliflozin:** Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China. **Metformin HCL:** Aarti Drugs Ltd Address: Plot No 211 & 213, Road -2, G.I.D.C AT & Post Sarigam. City Sarigam– 396 155 Dist. Valsad Gujarat industrial estate India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Dapagliflozin: Official monograph of Dapagliflozin is not present in any pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance Metformin HCl:

		Official monograph of Metformin HCl is present in BP. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Dapagliflozin**: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (130401, 130402, 130501) **Metformin**: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months (MEF/1510145, MEF/1510146, MEF/1510147)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Xigduo Tablet 5/1000mg of Astrazeneca Farmaceutica Spain by performing quality tests (Identification, Assay, Dissolution, Hardness, Disintegration Time). CDP has been performed against the same brand that is Xigduo Tablet 5/1000mg of Astrazeneca Farmaceutica Spain in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity, robustness and Limit of Quantification.

STABILITY STUDY DATA	
Manufacturer of API	**Dapagliflozin:** Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China. **Metformin HCL:** Aarti Drugs Ltd Address: Plot No 211 & 213, Road -2, G.I.D.C AT & Post Sarigam. City Sarigam– 396 155 Dist. Valsad Gujarat industrial estate India.
API Lot No.	**Dapagliflozin:** 7100-202006001/7100-202106001(drug substance) **Metformin:** MEF/19123234
Description of Pack (Container closure system)	Alu-Alu blister
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH

Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**RD/PR20-013/T1/S1**	**RD/PR20-013/T1/S2**	**RD/PR20-013/T1/S3**
Batch Size	2000 tablets	2000 tablets	2000 tablets
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	29-09-2020	29-09-2020	29-09-2020
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Dapagliflozin:** Firm has submitted copy of GMP certificate No # JS2020921 of M/s Jiangsu Yongan Pharmaceutical Co. Ltd., China issued by Jiangsu Drugs Administration, China. The certificate is valid till 20-09-2025 **Metformin:** Copy of GMP certificate No. 20031933 issued by Food & Drug Control administration Gujrat state India valid till 19-03-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Dapagliflozin:** Firm has submitted copy of Commercial Invoice (Invoice #ZY20061201G/W) Dated: 12-06-2020 attested by DRAP Lahore office dated 16-06-2020 of Dapagliflozin (Batch# 7100-202006001). **Metformin:** Firm has submitted copy of Commercial Invoice (Invoice #2387/19-20-25) Dated: 25-12-2019 attested by DRAP Lahore office dated 08-01-2020 Metformin (Batch# MEF/19123234).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.S.4.4	Certificate of analysis of dapagliflozin Propanediol Monohydrate by drug substance manufacturer and drug product manufacturer are of different batch.	Certificate of analysis of the same batch of dapagliflozin Propanediol Monohydrate from both drug substance manufacturer and drug product manufacturer are submitted.
2.	3.2.P.5.4	Specifications for dissolution testing claimed in section 3.2.P.5.1 are NLT 80% (Q) in 30 minutes while in COA's it is mentioned as NLT 75% (Q)	There was a typo error in the dissolution specification in COA's of which has been amended. Revised COA's are attached.

		in 30 minutes. Clarification is required	
3.	3.2.P.8	Documents for the procurement of API with approval from DRAP.	Submitted.

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

460.	Name, address of Applicant / Marketing Authorization Holder	M/s Martin Dow Marker Limited 7, Jail Road Quetta, Pakistan
	Name, address of Manufacturing site.	M/s Martin Dow Marker Limited 7, Jail Road Quetta, Pakistan **BULK API MANUFACTURER:** Fresenius Kabi Austria GmbH Estermannstraße 17 4020 Linz Austria, Europe
	Status of the applicant	☒ Manufacturer (Bulk import local repack) ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 6613: 01-03-2021
	Details of fee submitted	PKR 100,000/-: 11-02-2021
	The proposed proprietary name / brand name	**Laxocare Syrup**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains: Lactulose Solution USP …. 3.35g
	Pharmaceutical form of applied drug	**Syrup**
	Pharmacotherapeutic Group of (API)	LAXATIVE
	Reference to Finished product specifications	USP Specifications
	Proposed Pack size	120ml & 240ml
	Proposed unit price	AS PER DPC
	The status in reference regulatory authorities	DUPHALAC of Mylan MHRA Approved
	For generic drugs (me-too status)	DUPHALAC of M/s Abbott Laboratories (Reg. No.: 06655)
	GMP status of the Finished product manufacturer	Certificate of cGMP on the basis of inspection conducted on 15 & 16, August 2018
	Name and address of API manufacturer.	Fresenius Kabi Austria GmbH Estermannstraße 17 4020 Linz Austria, Europe
	Module-II (Quality Overall Summary)	Firm has submitted QOS details as per WHO QOS PD template.

	Remarks: Firm has performed Pharmaceutical equivalence against the product i.e DUPHALAC of M/s Abbott Laboratories and the results are within acceptable limit.	
	Module-III (Drug Product):	Firm has submitted relevant information against the Module III, including, Process validation protocol, Finished product analytical method validation report & stability studies data.
	Remarks: Firm has performed Pharmaceutical equivalence against the product i.e DUPHALAC of M/s Abbott Laboratories , and the results are within acceptable limit	

STABILITY STUDY DATA			
Manufacturer of API	Fresenius Kabi Austria GmbH Estermannstraße 17 4020 Linz Austria, Europe		
API Lot No.	17190532		
Description of Pack (Container closure system)	Amber glass bottle		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T01	T02	T03
Batch Size	5 Liter	5 Liter	5 Liter
Manufacturing Date	02.2020	02.2020	02.2020
Date of Initiation	02-2020	02-2020	02-2020
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION		
The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.		
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate (Certificate No.INS-480019-0063-011) for M/s Fresenius Kabi Austria GmbH Estermannstraße 17 4020 Linz issued by Austria on the basis of Inspection conducted on 24-09-2018 and, valid for three Year.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Evaluation:

S.No	Section	Shortcomings Communicated
1.	1.1	In covering letter label claim is 33.5 gm. Clarification is required in this regard.
2.	1.5.2.	Strength of API is 3.35mg. Clarification is required in this regard.
3.	3.2.S.4	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer of drug substance before initiation of stability studies and manufacturing however you are performing after completion of 6 month of stability studies. Clarification is required.
4.	3.2.P.3	A flow diagram shall be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted shall be identified shall be submitted by Drug product manufacturer.
5.	3.2.P.3.3	Tests and acceptance criteria shall be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled , shall be submitted by Drug product manufacturer.
6.	3.2.P.5	Provide Evidence of RI detector
7.	3.2.P.5	As per relevant guidelines & structure of Form 5F Analytical test method validation has to be performed at the time of formulation development, while according to your submitted data, Analytical test method validation protocols has been approved after commencement of stability studies as well as Analytical test method validation have been performed on 29-10-2020 while stability studies started on 02-2020. Justification shall be submitted in this regard.
8.	3.2.P.8	• Documents for the procurement of API with approval from DRAP. • Stability initiation date mentioned is 02-2020 while initial testing conducted in march

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

461.	Name, address of Applicant / Marketing Authorization Holder	Vision Pharmaceuticals (Pvt.) Ltd. Plot # 22-23, Industrial triangle, kahuta road, Islamabad-44000.
	Name, address of Manufacturing site.	Vision Pharmaceuticals (Pvt.) Ltd. Plot # 22-23, Industrial triangle, kahuta road, Islamabad-44000.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 16358 dated :14-06-2021

	Details of fee submitted	PKR 20,000/-: dated 23/09/2020
	The proposed proprietary name / brand name	**CALADOR 400mg/4ml Infusion**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each LDPE Ampoule contains: Ibuprofen……..400mg (Innovator's Specifications)
	Pharmaceutical form of applied drug	Clear liquid filled in LDPE ampoule for injection
	Pharmacotherapeutic Group of (API)	NSAIDs
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	10Amp x 4ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	CALDOLOR 400mg/4ml Infusion by M/s CUMBERLAND Pharmaceuticals, USFDA Approved. TGA approved
	For generic drugs (me-too status)	Xaleve 400mg/4ml Infusion by M/s Hudson Pharma (Pvt.) Ltd. Karachi. Registration No. 093088
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 11-02-2019 and valid till 10-02-2022.
	Name and address of API manufacturer.	M/s Hubei Granules-Biocause Pharmaceutical Company, Ltd. 122 Yangwan Road, Jingmen, Hubei, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ibuprofen is present in Ph. Eur. The firm has submitted detail of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies of Drug substance	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 60 months Batches: (C100-1507197M, C100-1507198M, C100-1507199M)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure

		system and stability studies of drug product. Water loss test	
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is XALEVE 400mg/4ml Injection by Hudson Pharma Pvt Ltd. by performing quality tests (Physical appearance, pH, Liquid particle test, BET & assay).	
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity.	
STABILITY STUDY DATA			
Manufacturer of API	M/s Hubei Granules-Biocause Pharmaceutical Company, Ltd. 122 Yangwan Road, Jingmen, Hubei, China		
API Lot No.	C-100-1904272M		
Description of Pack (Container closure system)	10 LDPE ampoule packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 06th months Accelerated: 6th months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 5, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	NDP-905 T-01	NDP-905 T-01	NDP-905 T-01
Batch Size	1250 LDPE ampoules	1250 LDPE ampoules	1250 LDPE ampoules
Manufacturing Date	25-11-2019	25-11-2019	25-11-2019
Date of Initiation	03-12-2019	03-12-2019	03-12-2019
No. of Batches	03		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product Calador 400mg/100ml Infusion which was conducted on 24-08-2021 and was presented in 312th meeting of Registration Board held on 14-16th September, 2021. According to the report following points were confirmed. • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. The firm possesses stability chambers with digital data loggers.	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP Certificate for Zhuhai Rundu Pharmaceutical Co., Ltd (Certificate#. HB20170363) issued by China Food and Drug Control Administration, valid upto 28-08-2022 is submitted	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Form 6 from & invoice (invoice# GIB19057275) cleared by DRAP Islamabad office dated 19-07-2019 specifying import 25Kg Ibuprofen (Batch# C100-190427M).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted	

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated
1.	1.1	Differential fee of Rs: 10000/-
2.	1.5.9	Evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form, with same container closure system in one of the reference regulatory authority specified by Registration Board.
3.	2.3.R.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3
4.	2.3.R.2	Analytical Procedures and Validation Information for Drug Product does not match with details provided in 3.2.P. 5.3. Clarification is required.
5.	3.2.P.2.1.2	Firm claimed that excipients were selected for the development of Calador as used by USFDA innovator product, but excipients are different. Clarify
6.	3.2.P.2.2.1	Justification is required that Pharmaceutical Equivalence was established against comparator product instead of Innovator Product.
7.	3.2.P.3.3	Terminal sterilization mentioned for vials 121˚C 15 PSI for 15 minutes while in 3.2.P.2.5 LDPE ampoules are mentioned and autoclaved at 106 ˚C for 85 minutes. Clarification is required
8.	3.2.P.3.5	• In Process validation vials and LDPE Ampoules both are mentioned Clarification is required • In Terminal sterilization LDPE Ampoules autoclaved at 121˚C 15 PSI for 15 minutes and LDPE Ampoules autoclaved at 106 ˚C for 85 minutes mentioned. Clarify which temperature is used for Terminal sterilization.
9.	3.2.P.5.4	The copies of complete analysis of at least two batches shall be provided
10.	3.2.P.7.1	Primary packaging system is LDPE Ampules . Provide evidence in reference Regulatory Authority.
11.	3.2.8	• Scientific justification is required regarding the performance of stability studies at 30°C ± 2°C / 65% ± 5%RH and 40°C ± 2°C / 75% ± 5%RH being a product packed in LDPE (semi permeable) container, while ICH guidelines recommend performing stability studies at 30°C ± 2°C / 35% ± 5%RH and 40°C ± 2°C / NMT 25% RH for products packed in semi permeable containers. • Justification is required that water loss test performed after 13 months of initiation of stability studies. • Ampoules which are kept for water loss test in incubator on 20-01-2021. What are storage conditions before this after manufacturing. • In water loss test in Accelerated condition factor used is 1.9 while according to ICH for 75% factor is 3.0. clarification is required.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

462.	Name, address of Applicant / Marketing Authorization Holder	Vision Pharmaceuticals (Pvt.) Ltd. Plot # 22-23, Industrial triangle, kahuta road, Islamabad-44000.
	Name, address of Manufacturing site.	Vision Pharmaceuticals (Pvt.) Ltd. Plot # 22-23, Industrial triangle, kahuta road, Islamabad-44000.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 17349 dated :22-06-2021
	Details of fee submitted	PKR 50,000/-: dated 05/05/2021 and PKR 25,000/-: dated 10/06/2021
	The proposed proprietary name / brand name	**CALADOR 800mg/8ml Infusion**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 8ml contains: Ibuprofen……..800mg (Innovator's Specifications)
	Pharmaceutical form of applied drug	Clear liquid filled in LDPE ampoule for injection
	Pharmacotherapeutic Group of (API)	NSAIDs
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	CALDOLOR 800mg/8ml Infusion by M/s CUMBERLAND Pharmaceuticals, USFDA Approved.
	For generic drugs (me-too status)	Xaleve 800mg/8ml Infusion by M/s Hudson Pharma (Pvt.) Ltd. Karachi. Registration No. 093088
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 11-02-2019 and valid till 10-02-2022.
	Name and address of API manufacturer.	M/s Hubei Granules-Biocause Pharmaceutical Company, Ltd. 122 Yangwan Road, Jingmen, Hubei, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ibuprofen is present in Ph. Eur. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance

	Stability studies of Drug substance	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 60 months Batches: (C100-1507197M, C100-1507198M, C100-1507199M)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the Innovator that is Caldolor 800mg/8ml Injection by Cumberland Pharmaceuticals nashville by performing quality tests (Physical appearance, pH, Liquid particle test, BET & assay).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Hubei Granules-Biocause Pharmaceutical Company, Ltd. 122 Yangwan Road, Jingmen, Hubei, China		
API Lot No.	C-100-1904272M		
Description of Pack (Container closure system)	LDPE ampoule		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 06th months Accelerated: 6th months		
Frequency	Accelerated: 0, 1, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	NDP-906 T-01	NDP-906 T-01	NDP-906 T-01
Batch Size	1042 LDPE ampoules	1042 LDPE ampoules	1042 LDPE ampoules
Manufacturing Date	25-11-2019	25-11-2019	25-11-2019
Date of Initiation	19-12-2019	19-12-2019	19-12-2019
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product Calador 400mg/100ml Infusion which was conducted on 24-08-2021 and was presented in 312th meeting of Registration Board held on 14-16th September, 2021. According to the report following points were confirmed. • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. The firm possesses stability chambers with digital data loggers.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP Certificate for Zhuhai Rundu Pharmaceutical Co., Ltd (Certificate#. HB20170363) issued by China Food and Drug Control Administration, valid upto 28-08-2022 is submitted
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Form 6 from & invoice (invoice# GIB19057275) cleared by DRAP Islamabad office dated 19-07-2019 specifying import 25Kg Ibuprofen (Batch# C100-1904272M).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated
1.	1.5.9	Evidence of approval / registration / marketing status of the applied formulation in the same container closure i.e LDPE in one of the reference regulatory authority specified by Registration Board
2.	3.2.P.1	Composition of Calador 800mg/8ml and Calador 400mg/4ml is different in terms of excipient. Clarification is required
3.	3.2.P.2.1.2	Firm claimed that excipients were selected for the development of Calador as used by USFDA innovator product Caldolor, but hydrochloric acid as pH adjusters is not used . Justify how pH is adjusted.
4.	3.2.P.3.3	In manufacturing process it is not evident that LDPE blow fill technology is used as container closure system. Clarify.
5.	3.2.P.3.5	In Process validation bottle are mentioned as container closure system. Clarification is required.
6.	3.2.P.7.1	Primary packaging system is LDPE Ampules . Provide evidence in reference Regulatory Authority.
7.	3.2.8	• Scientific justification is required regarding the performance of stability studies at 30°C ± 2°C / 65% ± 5%RH and 40°C ± 2°C / 75% ± 5%RH being a product packed in LDPE (semi permeable) container, while ICH guidelines recommend performing stability studies at 30°C ± 2°C / 35% ± 5%RH and 40°C ± 2°C / NMT 25% RH for products packed in semi permeable containers. • Justification is required that water loss test performed after 13 months of initiation of stability studies. • Ampoules which are kept for water loss test in incubator on 20-01-2021. What are storage conditions before this after manufacturing. • In water loss test in Accelerated condition factor used is 1.9 while according to ICH for 75% factor is 3.0. clarification is required.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

b. Deferred cases

463.	Name, address of Applicant / Marketing Authorization Holder	M/s Citi Pharma Private Limited
	Name, address of Manufacturing site.	M/s Citi Pharma Private Limited Factory: 3 K.M, Head Balloki Road, Phool Nagar, Distt. Kasur
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 17868 dated 20-06-2022
	Details of fee submitted	PKR 30,000/-: Deposit slip # 2746758563
	The proposed proprietary name / brand name	**Panadol Extra Tablets**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Paracetamol……. 500mg Caffeine….. 65mg
	Pharmaceutical form of applied drug	Oral (Tablet)
	Pharmacotherapeutic Group of (API)	Analgesics and Psychoactive drug.
	Reference to Finished product specifications	USP
	Proposed Pack size	10x10's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Panadol Extra by GSK (GlaxosmithKline), UK Approved in UK.
	For generic drugs (me-too status)	Panadol Extra GSK (GlaxosmithKline). Pakistan
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of evaluation conducted on 19-03-2019
	Name and address of API manufacturer.	Paracetamol: Citi Pharma Pvt Ltd 3.5-Km, Head Balloki Road, Phool Nagar Kasur-Pakistan. Caffeine: Aarti Industries Limited Plot No D-53, phase II, M.I.D.C Kalyanshil RD Dombival (East) Thane 421204 Maharashtra state, India. K-17/18/19, M.I.D.C, tararpur, Distict, Thane zone 4.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paracetamol and Caffeine is present in BP. The firm as submitted detail of

		nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, , specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Paracetamol: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (PGP14-37, PGP14-38, PGP14-39) Caffeine: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (C-3011 C-3076, C-3115)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Panadol Extra Tablets by M/s GSK (GlaxosmithKline). Pakistan performing quality tests (Identification, Weight variation, Disintegration, Assay, Dissolution). CDP has been performed against the same brand that is Panadol Extra Tablets by M/s GSK (GlaxosmithKline). Pakistan in Acid media (pH-1.2),Acetate Buffer(pH-4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	

STABILITY STUDY DATA			
Manufacturer of API	Paracetamol: M/s Citi Pharma Private Limited Lahore. Caffeine: Aarti Industries Limited		
API Lot No.	Caffeine: CF/1520147 Paracetamol: PGP21-183		
Description of Pack (Container closure system)	10X10's Blistered in ALU-PVC packed in standard unit carton provided with leaflet inside.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TRA-PE001	TRA-PE002	TRA-PE003
Batch Size	10,000 Tablets	10,000 Tablets	10,000 Tablets

Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	01-2022	01-2022	01-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Paracetamol: Copy of cGMP certificate on the basis of evaluation conducted on 17-12-2020 and valid for 2 years Caffeine: Copy of GMP certificate No. 6101335 for Aarti Industries Limited (K-17/18/19, M.I.D.C, tararpur, Distict, Thane zone 4) issued by Food and Drug Administration Mahrashtra India-valid for 12-08-2022
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Paracetamol: Purchase documents Invoice No# F20-34 Dated: 11-08-2021 of Batch No # PGP21-513. Caffeine: Form 6 for Caffeine submitted of dated: 15-07-21 by Lahore office
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Remarks of Evaluator: Firm submitted NOC as follows:

M/s GlaxoSmithKline Consumer health Pakistan Limited 35-Dockyard Road, West Whraf –Karachi-Pakistan has provided no objection certificate for utilization of Panadol brand name as under :-
"We, owners of the **"Panadol"** brand name since may decades globally and in Pakistan for last 45 years, would like to manufacture our following products at **"Citi Pharma Private Limited"** under the DRAP's Contract manufacturing policy:

S.No.	**Brand Name**
1.	Panadol Extra Tablets
2.	Panadol Migraine tablets
3.	Panadol Muscle Relaxant tablets

Further to this, Please note that we have no objection to the use of the brand Name **"Panadol"** for the aforementioned products, applied by Citi Pharma for the registration on contract manufacturing on behalf of GlaxoSmithKline consumer Healthcare Limited Pakistan."

S.No	**Section**	**Shortcomings Communicated**
1.	1.6.5	Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine)
2.	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3
3.	3.2.S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active (Caffeine)Pharmaceutical Ingredient by Drug Product manufacturer is required.
4.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine)shall be submitted.

5.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.
6.	3.2.S.5	COA of primary / secondary reference standard including source and lot number for Caffeine shall be provided.
7.	3.2.P.2.2.1	6 units are used for CDP. Clarification is required in the light of FDA guidance for industry and EMA guidelines of Comparative dissolution. F2 calculations for paracetamol and caffeine not submitted.
8.	3.2.P.3.5	Submitted Process validation protocol are general not product related. Clarification is required.
9.	3.2.P.5.1	Specification claimed are USP while in section 1.5.6 applied as B.P. Clarification is required. Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol and caffeine while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen and caffeine is dissolved.
10.	3.2.P.5.3	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.
11.	3.2.P.8	Stability studies of three (03) months submitted. Documents for the procurement of API (Caffeine) with approval from DRAP Compliance Record of HPLC software 21CFR & audit trail reports on product testing. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Previous Decision (M-321): Deferred for following:

Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine)

Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3

Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active (Caffeine) Pharmaceutical Ingredient by Drug Product manufacturer is required.

Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine) shall be submitted.

Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.

COA of primary / secondary reference standard including source and lot number for Caffeine shall be provided.

6 units are used for CDP. Clarification is required in the light of FDA guidance for industry and EMA guidelines of Comparative dissolution.

F2 calculations for paracetamol and caffeine not submitted.

Submitted Process validation protocol are general not product related. Clarification is required.

Specification claimed are USP while in section 1.5.6 applied as B.P. Clarification is required.

Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol and caffeine while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen and caffeine is dissolved.

Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.

Stability studies of three (03) months submitted.

Documents for the procurement of API (Caffeine) with approval from DRAP Compliance Record of HPLC software 21CFR & audit trail reports on product testing.

Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Reply

S.No	Section	Shortcomings Communicated	Reply

1.	1.6.5	Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine)	Firm submitted now GMP certificate # 6101335 valid upto 12-08-2022 of Aarti Industries Limited Address: K-17/18/19, M.I.D.C, tararpur, Distict, Thane zone 4.(mentioned on all documents)
2.	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3	Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3 submitted
3.	3.2.S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient (Caffeine) by Drug Product manufacturer is required.	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient (Caffeine) by Drug Product manufacturer is submitted.
4.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine)shall be submitted.	Analytical method verification of tablet (Drug Product) submitted instead of drug substance.
5.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.	COA of paracetamol submitted while, COA of drug substance for Caffeine of a different Drug substance supplier (Kores India limited submitted.
6.	3.2.S.5	COA of primary / secondary reference standard including source and lot number for Caffeine shall be provided.	Submitted.
7.	3.2.P.2.2.1	6 units are used for CDP. Clarification is required in the light of FDA guidance for industry and EMA guidelines of Comparative dissolution. F2 calculations for paracetamol and caffeine not submitted.	No reply about 6 units used by firm F2 calculations submitted but now data is different from previous submitted data.
8.	3.2.P.3.5	Submitted Process validation protocol are general not product related. Clarification is required.	Submitted.
9.	3.2.P.5.1	Specification claimed are USP while in section 1.5.6 applied as B.P. Clarification is required. Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol and caffeine while USP has specified as NLT 75% (Q) of the	Typographical error. USP specifications are applied. Rectified and correction has been made. Revised documents submitted. No reply of dissolution specifications**.**

		labelled amounts of acetaminophen and caffeine is dissolved.	
10.	3.2.P.5.3	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.	No reply
11.	3.2.P.8	Stability studies of three (03) months submitted. Documents for the procurement of API (Caffeine) with approval from DRAP Compliance Record of HPLC software 21CFR & audit trail reports on product testing. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Stability studies summary sheets of 6 months submitted. Import documents Not Submitted. Submitted Submitted

Previous Decision (M-322): Deferred for following:

Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine) shall be submitted.

Performance of CDP studies using 12 units each of sample and reference product.

Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol and caffeine while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen and caffeine is dissolved.

Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.

Documents for the procurement of API (Caffeine) with approval from DRAP.

Since the submitted dossier does not reflect any details for contract manufacturing while annexed NOC from M/s GlaxoSmithKline Consumer Health declare it by way of contract manufacturing hence firm shall submit clarity regarding the status of registration application whether it's for self-manufacturing with registration in name of M/s Citi Pharma Private Limited or for contract manufacturing with registration in name of M/s GlaxoSmithKline Consumer health Pakistan Limited. In case of contract manufacturing for M/s GlaxoSmithKline Consumer health Pakistan Limited, the application shall be re submitted as per relevant SRO of contract manufacturing policy.

Clarification for using of Panadol brand name as per Rule 20A of Drugs (L,R &A) Rules, 1976.

S.NO	Reason of deferment	Reply Evaluation
1.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine) shall be submitted.	Analytical Method Verification studies performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine) submitted.
2.	Performance of CDP studies using 12 units each of sample and reference product.	CDP studies using 12 units each of sample and reference product is submitted.
3.	Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol and caffeine while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen and caffeine is dissolved.	Revised specifications submitted
4.	Analytical Method Verification studies performed by the Drug Product	Submitted

	manufacturer for drug product shall be submitted.	
5.	Documents for the procurement of API (Caffeine) with approval from DRAP.	Form 6 for caffeine submitted of dated: 15-07-2021
6.	• Since the submitted dossier does not reflect any details for contract manufacturing while annexed NOC from M/s GlaxoSmithKline Consumer Health declare it by way of contract manufacturing hence firm shall submit clarity regarding the status of registration application whether it's for self-manufacturing with registration in name of M/s Citi Pharma Private Limited or for contract manufacturing with registration in name of M/s GlaxoSmithKline Consumer health Pakistan Limited. In case of contract manufacturing for M/s GlaxoSmithKline Consumer health Pakistan Limited, the application shall be re submitted as per relevant SRO of contract manufacturing policy. • Clarification for using of Panadol brand name as per Rule 20A of Drugs (L,R &A) Rules, 1976.	Withdrawn Our submitted NOC and request to convert the name with Askprol Extra tablet.

Decision: Approved with change of brand name.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

464.	Name, address of Applicant / Marketing Authorization Holder	M/s Citi Pharma Private Limited
	Name, address of Manufacturing site.	M/s Citi Pharma Private Limited Factory: 3 K.M, Head Balloki Road, Phool Nagar, Distt. Kasur
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 17866 dated 20-06-2022
	Details of fee submitted	PKR 30,000/-: Deposit slip # 66410331823
	The proposed proprietary name / brand name	**Panadol Migraine Tablets**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Paracetamol……. 250mg Caffeine anhydrous….. 65mg Aspirin…… 250mg

	Pharmaceutical form of applied drug	Oral (Tablet)
	Pharmacotherapeutic Group of (API)	NSAID and Psychoactive drug.
	Reference to Finished product specifications	USP
	Proposed Pack size	4 X6's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	EXCEDRIN (MIGRAINE) by M/s GSK (GlaxosmithKline) Consumer Health, USA, Approved in USA. (OTC product)
	For generic drugs (me-too status)	….
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of evaluation conductd on 19-03-2019
	Name and address of API manufacturer.	Paracetamol: Citi Pharma Pvt Ltd 3.5-Km, Head Balloki Road, Phool Nagar Kasur-Pakistan. Caffeine: Aarti Industries Limited Plot No D-53, phase II, M.I.D.C Kalyanshil RD Dombival (East) Thane 421204 Maharashtra state, India. K-17/18/19, M.I.D.C, tararpur, Distict, Thane. Aspirin: JQC HUAYIN PHARMACEUTICAL CO., LTD. Yuqan Road,Huayian City, Shanxi Province. China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paracetamol and Caffeine is present in BP and Official monograph of Aspirin is present in USP. The firm as submitted detail of nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Paracetamol: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (PGP14-37, PGP14-38, PGP14-39) Caffeine: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (C-3011 C-3076, C-3115)

		Aspirin: Real time: 30°C ± 2°C / 65% ± 5%RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months. Batches: (A201104081, A201104082, A201104083
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Panadol Migraine Tablets by M/s GSK (GlaxosmithKline) Consumer Health, USA performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Panadol Migraine Tablets by M/s GSK (GlaxosmithKline) Consumer Health, USA in Acid media (pH-1.2),Acetate Buffer(pH-4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Paracetamol: M/s Citi Pharma Private Limited Lahore. Caffeine: Aarti Industries Limited Aspirin: JQC HUAYIN PHARMACEUTICAL CO., LTD.		
API Lot No.	Caffeine: CF/1520147 Paracetamol : PGP21-183 Aspirin: A201903162		
Description of Pack (Container closure system)	Alu, PVC foil blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TRA-PM001	TRA-PE002	TRA-PE003
Batch Size	10,000 Tablets	10,000 Tablets	10,000 Tablets
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	09-2021	09-2021	09-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Paracetamol: Copy of cGMP certificate on the basis of evaluation conducted on 17-12-2020 and valid for 2 years

		Caffeine: Copy of GMP certificate No. NEW-WHO-GMP/KD/88375/2019/11/30185 issued by Food and Drug Administration Mahrashtra India-valid for 19-11-2022 Aspirin:
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Paracetamol: Purchase documents Invoice No# F20-34 Dated: 11-08-2021 of Batch No # PGP21-513
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:
Firm submitted NOC as follows:

M/s GlaxoSmithKline Consumer health Pakistan Limited 35-Dockyard Road, West Whraf –Karachi-Pakistan has provided no objection certificate for utilization of Panadol brand name as under :-
"We, owners of the **"Panadol"** brand name since may decades globally and in Pakistan for last 45 years, would like to manufacture our following products at **"Citi Pharma Private Limited"** under the DRAP's Contract manufacturing policy:

S.No.	Brand Name
1.	Panadol Extra Tablets
2.	Panadol Migraine tablets
3.	Panadol Muscle Relaxant tablets

Further to this, Please note that we have no objection to the use of the brand Name **"Panadol"** for the aforementioned products, applied by Citi Pharma for the registration on contract manufacturing on behalf of GlaxoSmithKline consumer Healthcare Limited Pakistan.

S.No	Section	Shortcomings Communicated
1.	1.6.5	Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine). Valid Drug Manufacturing License or Valid Good Manufacturing Practice (GMP) certificate of the Aspirin manufacturer issued by relevant regulatory authority of country of origin.
2.	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3
3.	3.2.S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active (Caffeine)Pharmaceutical Ingredient by Drug Product manufacturer is required.
4.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirin)shall be submitted.
5.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.
6.	3.2.S.5	COA of primary / secondary reference standard including source and lot number for Caffeine and Aspirin shall be provided.
7.	3.2.P.1	Composition of tablet is different from reference product in terms of excipients. Applied formulation is film coated however it is not evident from composition in section 3.2.P.1 and 3.2.P.3.2 as there are no excipients for coating.

8.	3.2.P.2.3	Manufacturing process Coating step is not included however applied product is film coated.
9.	3.2.P.2.2.1	Submitted CDP data for paracetamol and Caffeine is same as in Panadol Extra tablet. Clarification s is required.
10.	3.2.P.3.5	Submitted Process validation protocol are general not product related. Clarification is required.
11.	3.2.P.5.1	Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol ,caffeine and Aspirin while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen , Aspirin and caffeine is dissolved
12.	3.2.P.5.3	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.
13.	3.2.P.6	COA of primary / secondary reference standard including source and lot number for paracetamol, Aspirin and Caffeine shall be provided
14.	3.2.P.8	Manufacturing of batches was done in Dec, 2021 than how stability studies started in September 2021. Stability studies of three (03) months submitted. Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP

Previous Decision (M-321): Deferred for following:

Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine).

Valid Drug Manufacturing License or Valid Good Manufacturing Practice (GMP) certificate of the Aspirin manufacturer issued by relevant regulatory authority of country of origin.

Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3

Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active (Caffeine)Pharmaceutical Ingredient by Drug Product manufacturer is required.

Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirin)shall be submitted.

Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.

COA of primary / secondary reference standard including source and lot number for Caffeine and Aspirin shall be provided.

Composition of tablet is different from reference product in terms of excipients.

Applied formulation is film coated however it is not evident from composition in section 3.2.P.1 and 3.2.P.3.2 as there are no excipients for coating.

Manufacturing process Coating step is not included however applied product is film coated.

Submitted CDP data for paracetamol and Caffeine is same as in Panadol Extra tablet. Clarification s is required.

Submitted Process validation protocol are general not product related. Clarification is required.

Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol ,caffeine and Aspirin while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen , Aspirin and caffeine is dissolved

Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.

COA of primary / secondary reference standard including source and lot number for paracetamol, Aspirin and Caffeine shall be provided

Manufacturing of batches was done in Dec, 2021 than how stability studies started in September 2021.

Stability studies of three (03) months submitted.

Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP

Reply

S.No	Section	Shortcomings Communicated	Reply
1.	1.6.5	Submitted GMP certificate of different site than documents submitted for drug substance (Caffeine).	Caffeine: Firm submitted now GMP certificate # 6101335 valid upto 12-08-2022 of Aarti Industries Limited Address: K-17/18/19, M.I.D.C, tararpur, District, Thane zone 4.(mentioned on all documents)

		Valid Drug Manufacturing License or Valid Good Manufacturing Practice (GMP) certificate of the Aspirin manufacturer issued by relevant regulatory authority of country of origin.	In Chinese submitted which can not be read.
2.	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3	Submitted.
3.	3.2.S.4.1	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active (Caffeine)Pharmaceutical Ingredient by Drug Product manufacturer is required.	Copies of the Drug substance specifications (BP) and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient (Caffeine) by Drug Product manufacturer is submitted.
4.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirine)shall be submitted.	Analytical method verification of tablet (Drug Product) submitted instead of drug substance.
5.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / Active Pharmaceutical Ingredient (Paracetamol and Caffeine) manufacture.	COA of paracetamol and Aspirin submitted while, COA of drug substance for Caffeine of a different Drug substance supplier (Kores India limited submitted.
6.	3.2.S.5	COA of primary / secondary reference standard including source and lot number for Caffeine and Aspirin shall be provided.	Submitted.
7.	3.2.P.1	Composition of tablet is different from reference product in terms of excipients. Applied formulation is film coated however it is not evident from composition in section 3.2.P.1 and 3.2.P.3.2 as there are no excipients for coating.	Correct formulation as per reference product attached. Revised section 3.2.P.1 and 3.2.P.3 are attached.

8.	3.2.P.2.3	Manufacturing process Coating step is not included however applied product is film coated.	Correct manufacturing method submitted.
9.	3.2.P.2.2.1	Submitted CDP data for paracetamol and Caffeine is same as in Panadol Extra tablet. Clarification s is required.	Correct CDP with F2 calculations submitted.
10.	3.2.P.3.5	Submitted Process validation protocol are general not product related. Clarification is required.	Submitted.
11.	3.2.P.5.1	Justify your acceptance criteria for dissolution test as NLT 75% after 60 minutes of the labeled amount of paracetamol ,caffeine and Aspirin while USP has specified as NLT 75% (Q) of the labelled amounts of acetaminophen , Aspirin and caffeine is dissolved	Correction is done and revised specifications
12.	3.2.P.5.3	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.	Not submitted.
13.	3.2.P.6	COA of primary / secondary reference standard including source and lot number for paracetamol, Aspirin and Caffeine shall be provided	Submitted.
14.	3.2.P.8	Manufacturing of batches was done in Dec, 2021 than how stability studies started in September 2021. Stability studies of three (03) months submitted. Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP	Not submitted.

Previous Decision (M-322): Deferred for following:

Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirine) shall be submitted.

Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.

Justification for initiating stability studies in Se [ptember 2021, whereas manufacturing of batches was done in Dec, 2021.

Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP.

Stability studies of three (03) months submitted.

Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP

Clarity regarding drug substance manufacturer since COA of drug substance for Caffeine of two different Drug substance manufacturers has been submitted.

Since the submitted dossier does not reflect any details for contract manufacturing while annexed NOC from M/s GlaxoSmithKline Consumer Health declare it by way of cntract manufacturing hence firm shall submit clarity regarding the status of registration application whether it's for self-manufacturing with registration in name of M/s Citi Pharma Private Limited or for contract manufacturing with registration in name of M/s GlaxoSmithKline Consumer health Pakistan Limited. In case of contract manufacturing for M/s GlaxoSmithKline Consumer health Pakistan Limited, the application shall be re submitted as per relevant SRO of contract manufacturing policy.
Clarification for using of Panadol brand name as per Rule 20A of Drugs (L,R &A) Rules, 1976.

S.NO	Reason of deferment	Reply Evaluation
1.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirine) shall be submitted.	Analytical Method Verification studies performed by the Drug Product manufacturer for drug substance(s) (Paracetamol and Caffeine and Aspirine) submitted.
2.	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product shall be submitted.	Analytical Method Verification studies performed by the Drug Product manufacturer for drug product submitted.
3.	Justification for initiating stability studies in September 2021, whereas manufacturing of batches was done in Dec, 2021.	It was typographical error . Correct data is submitted that stability studies initiated in December 2021.
4.	Documents for the procurement of API (Caffeine and Aspirin) with approval from DRAP.	Form 6 for caffeine dated: 15-07-2021 Aspirin form 6 dated: 03-06-2021 submitted
5.	Stability studies of three (03) months submitted.	06 month stability summary sheets submitted
6.	Clarity regarding drug substance manufacturer since COA of drug substance for Caffeine of two different Drug substance manufacturers has been submitted.	COA of Caffeine by Aarti Industries Limited and by drug product manufacturer of Batch No# CF/1520147 submitted
7.	• Since the submitted dossier does not reflect any details for contract manufacturing while annexed NOC from M/s GlaxoSmithKline Consumer Health declare it by way of cntract manufacturing hence firm shall submit clarity regarding the status of registration application whether it's for self-manufacturing with registration in name of M/s Citi Pharma Private Limited or for contract manufacturing with registration in name of M/s GlaxoSmithKline Consumer health Pakistan Limited. In case of contract manufacturing for M/s GlaxoSmithKline Consumer health	Withdrawn Our submitted NOC and request to convert the name with Askprol ACF tablet

	Pakistan Limited, the application shall be re submitted as per relevant SRO of contract manufacturing policy. • Clarification for using of Panadol brand name as per Rule 20A of Drugs (L,R &A) Rules, 1976.	

Decision: Approved with change of brand name.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

465.	Name, address of Applicant / Marketing Authorization Holder	M/s Welmark pharmaceuticals Industrial estate Hattar, Kpk Pakistan
	Name, address of Manufacturing site.	M/S Welmark pharmaceuticals Plot No 122 Block-B phase-5 Industrial estate Hattar Kpk Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30576 dated 08-11-2021
	Details of fee submitted	PKR 20,000/-: Dated: 26-01-2021 Deposit slip # 1985094
	The proposed proprietary name / brand name	**Teno 25mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Tenofovir Alafenamide Fumarate eq to Tenofovir Alafenamide……25mg
	Pharmaceutical form of applied drug	Brown red color 8mm round shaped bisected one side and other plain film coated tablet.
	Pharmacotherapeutic Group of (API)	Antiviral for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors.
	Reference to Finished product specifications	Manufacturer specifications
	Proposed Pack size	30’s
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Vemlidy Tablet 25mg by Gilead Sciences Ltd. U.S.A.., USFDA Approved.
	For generic drugs (me-too status)	Tenofomide Tablet 25mg by M/s. Getz pharma ., Reg. No. 093109
	GMP status of the Finished product manufacturer	Not submitted.
	Name and address of API manufacturer.	Shandong Haiyo Freda Pharmaceutical Co Ltd Address: 666 Bianhai West Road Linshu West Industrial Zone, Shandong Province.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Tenofovir Alafenamide Fumarate is present is as per In-house (Manufacturer's) specifications. The firm as submitted detail of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Impurity A, PMPA, Unspecified impurity and Total impurities), specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (180702, 180713, 180725)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against Tenofomide 25mg Tablets (Batch No. 004FB1, Mfg date 04-2020) by Getz Pharmaceuticals Karachi. Firm has submitted results of CDP for their product against Tenofomide 25mg Tablets (Batch No. 004FB1, Mfg date 04-2020). Firm has tested CDP in three dissolutions medium ie. (0.1N Hcl pH 1.2, Acetate Buffer pH 4.5, Phosphate Buffer pH 6.8 and the results of f1, f2 factor are within the acceptable limit.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	Shandong Haiyo Freda Pharmaceutical Co Ltd Address: 666 Bianhai West Road Linshu West Industrial Zone, Shandong Province.
API Lot No.	20021701
Description of Pack (Container closure system)	30's Tablets Teno 25mg Tablets will be packed in jar and Secondary Packing in Unit Carton.
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months)

	Real Time: 0, 3, 6 (Months)		
Batch No.	T010	T011	T012
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	15-09-2020	16-09-2020	17-09-2020
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. SD20160495 issued by NMPA valid till 08-08-2021.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of form 3, form 7 , invoice (invoice# JNXKYY20030302) dated 03-03-2020 specifying import of Tenofovir Alafenamide Fumarate 2 Kg (Batch# 20021701). But Not attested.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.1	Differential fee of Rs: 10000/-	Fee of Rs: 10000/- Deposit slip #0874644724055 submitted.
2.	1.3.5.	GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Not submitted.
3.	1.6.5	• Drug substance manufacturer mentioned in this section is M/s Jinan Xinke Pharmaceuticals Sci & Tech. C0., Ltd , . While certificate of analysis an import documents are from Shandong Haiyo Freda Pharmaceutical Co Ltd . Clarification is required amongst them which one is drug substance manufacturer.	• The drug substance manufacturer is Shandong Haiyo Freda Pharmaceuticals Co Ltd. Documents submitted • Submitted GMP certificate is valid upto 08-08-2021 (Submitted again same GMP certificate which is not valid)

		• Valid Drug Manufacturing License issued by the relevant regulatory authority of country of origin. Or Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.	
4.	3.2.S.4.1	Copies of the Drug substance Specifications by Drug Product manufacturer is required.	Submitted
5.	3.2.S.4.2	Detailed analytical procedures used for routine testing of the Drug substance by drug product manufacturer shall be provided.	Submitted
6.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.	Submitted
7.	3.2.S.5	COA of primary / secondary reference standard including source and lot number shall be provided.	Submitted
8.	3.2.P.2.3	Manufacturing process by Innovator is dry granulation while your method is Wet granulation. Clarify.	We are following innovators manufacturing process and our method is dry granulation.
9.	3.2.P.5.1	US FDA review document of the Innovator product, specifies the dissolution limit as "NLT Q in 15 minutes" whereas submitted specifications declare the dissolution limits as "NLT 75% in 30 minutes" .	That was a typographic mistake, we are following innovators specification and dissolution limit is NLT Q in 15 minutes.
10.	3.2.P.5.2	Submit complete analytical method for testing of drug product.	Submitted
11.		• Documents for the procurement of API with approval from DRAP. • US FDA review document of the Innovator product, specifies the dissolution limit as "NLT Q in 15	• Not Submitted • We are following innovator specifications i.e. dissolution limit is NLT Q in 15 minutes in 50mM Sodium Acetate buffer pH 4.5. • Compliance record of HPLC software 21CFR & audit trail reports on product testing submitted.

		minutes" in 50mM Sodium Acetate buffer pH 4.5. whereas submitted specifications declare the dissolution limits as "NLT 75% in 30 minutes with Phosphate Buffer pH 6.8". • Compliance Record of HPLC software 21CFR & audit trail reports on product testing • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Previous Decision (M-322): Deferred for following:

- Valid Drug Manufacturing License issued by the relevant regulatory authority of country of origin or Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.
- Documents for the procurement of API with approval from DRAP.
- Analytical record for the dissolution test for stability studies as per Innovator product.

S.NO	Reason of deferment	Reply
1.	Valid Drug Manufacturing License issued by the relevant regulatory authority of country of origin or Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.	Copy of GMP certificate # Lu20200438 issued on 14-04-2020 and valid till 15-046-2025 Submitted.
2.	Documents for the procurement of API with approval from DRAP.	Commercial Invoice # JNXKYY20030302 Dated: 03-03-2020 Attested by DRAP Peshawar office Dated:12-03-2020 for Tenofovir Alafenamide Fumarate Batch # 20021701
3.	Analytical record for the dissolution test for stability studies as per Innovator product.	Analytical record for the dissolution test for stability studies Submitted with Acetate buffer pH 4.5 with 15 minutes.

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case no. 01 Registration applications for local manufacturing of (Human) drugs Form 5

a. New cases

466.	Name and address of manufacturer / Applicant	M/s Adamjee Pharmaceuticals Pvt Ltd. Plot 39, Sector 15, Korangi Industrial Area, Karachi By M/s Safe Pharmaceuticals Pvt Ltd.

		Plot No. C.I-20, Sector 6-B, Industrial Area, North Karachi
	Brand Name +Dosage Form + Strength	Sodium Chloride Injection 0.9%/5ml
	Composition	Each 5ml contains: Sodium chloride(B.P)……..45mg
	Diary No. Date of R& I & fee	Dy.No. 20597 dated 07-06-2018 Rs.50,000/- Dated 06-06-2018
	Pharmacological Group	Electrolyte
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	5ml : As per SRO
	Approval status of product in Reference Regulatory Authorities	WHO recommended formulation
	Me-too status	Sacro Injection of Macter Intr. Karachi. (Reg.# 079756)
	GMP status	Panel inspection for renewal of DML of the firm conducted on 02-06-2021, wherein inter-alia following remarks given: "The panel found an adequate level of GMP compliance after thorough review of their system. Based on the stated facts and observations, production facilities, QA system, QC labs, stores, utilities and people met during inspection, the panel unanimously recommended" the grant of renewal of DML for different sections, including Capsule (General/antibiotic) section. **&** The firm was inspected on 24.03.2021, wherein GMP was rated as GOOD
	Remarks of the Evaluator	• In manufacturing method Sodium Bicarbonate is mentioned. Clarify • Submit Form 5 by applicant. • Contract manufacturing agreement.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
467.	Name and address of manufacturer / Applicant	M/s Adamjee Pharmaceuticals Pvt Ltd. Plot 39, Sector 15, Korangi Industrial Area, Karachi By M/s Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6-B, Industrial Area, North Karachi
	Brand Name +Dosage Form + Strength	Sodium Bicarbonate 5% Injection
	Composition	Each 2ml contains: Sodium Bicarbonate….100mg
	Diary No. Date of R& I & fee	Dy.No. 20596 dated 07-06-2018 Rs.50,000/- Dated 06-06-2018
	Pharmacological Group	Antacids, Antiflatulent, Electrolyte
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	2ml : As per SRO
	Approval status of product in Reference Regulatory Authorities	WHO recommended formulation only for Reconstitution Of Artesunate Injection.
	Me-too status	Sodium Bicarbonate Injection 5% of M/s Genix Pharma

	GMP status	Panel inspection for renewal of DML of the firm conducted on 02-06-2021, wherein inter-alia following remarks given: "The panel found an adequate level of GMP compliance after thorough review of their system. Based on the stated facts and observations, production facilities, QA system, QC labs, stores, utilities and people met during inspection, the panel unanimously recommended" the grant of renewal of DML for different sections, including Capsule (General/antibiotic) section. **&** The firm was inspected on 24.03.2021, wherein GMP was rated as GOOD
	Remarks of the Evaluator	• Submit Form 5 by applicant. • Contract manufacturing agreement.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
468.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan By M/s English Pharmaceuticals Industries. Link Kattar Bund Road, Thokar Niaz Baig, Multan Road, Lahore
	Brand Name +Dosage Form + Strength	Ezolin 200mg/100ml Infusion
	Composition	Each 100ml Contains: Linezolid…….200mg
	Diary No. Date of R& I & fee	Dy.No. 33326 dated 08-10-2018 Rs.50,000/- Dated 08-10-2018
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specification
	Pack size & Demanded Price	100ml ; As per SRO
	Approval status of product in Reference Regulatory Authorities	ZYVOX linezolid 200mg/100mL injection infusion bag of (USFDA approved.)
	Me-too status	Linzol Infusion 200mg/100ml of M/s Regal Pharmaceuticals
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance & GMP certificate issued on the basis of inspection conducted on 17& **18-01-2019**
	Remarks of the Evaluator	• Submit Form 5 by applicant . • Composition in form 5 Each 200ml contains: Linezolid….100mg Clarify. • Number of sections of applicant approved by licensing Board. • Number of products already registered/approved on contract manufacturing in the name of applicant..
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

469.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan By M/s English Pharmaceuticals Industries. Link Kattar Bund Road, Thokar Niaz Baig, Multan Road, Lahore
	Brand Name +Dosage Form + Strength	Ezolin 400mg/200ml Infusion
	Composition	Each 200ml Contains: Linezolid…….400mg
	Diary No. Date of R& I & fee	Dy.No. 33327 dated 08-10-2018 Rs.50,000/- Dated 08-10-2018
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specification
	Pack size & Demanded Price	200ml; As per SRO
	Approval status of product in Reference Regulatory Authorities	ZYVOX linezolid 400mg/200mL injection infusion bag of (USFDA approved.)
	Me-too status	Linzol Infusion 400mg of M/s Regal Pharmaceuticals
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance & GMP certificate issued on the basis of inspection conducted on 17& **18-01-2019**
	Remarks of the Evaluator	• Submit Form 5 by applicant . • Number of sections of applicant approved by licensing Board. • Number of products already registered/approved on contract manufacturing in the name of applicant..
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
470.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan By M/s English Pharmaceuticals Industries. Link Kattar Bund Road, Thokar Niaz Baig, Multan Road, Lahore
	Brand Name +Dosage Form + Strength	Ezolin 600mg/300ml Infusion
	Composition	Each 300ml Contains: Linezolid…….600mg
	Diary No. Date of R& I & fee	Dy.No. 33328 dated 08-10-2018 Rs.50,000/- Dated 08-10-2018
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specification
	Pack size & Demanded Price	200ml ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Linezolid 400mg/200mL injection infusion bag of (USFDA approved.)
	Me-too status	Linzol Infusion 400mg of M/s Regal Pharmaceuticals
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance &

		GMP certificate issued on the basis of inspection conducted on 17& **18-01-2019**
	Remarks of the Evaluator	• Submit Form 5 by applicant . • Number of sections of applicant approved by licensing Board. • Number of products already registered/approved on contract manufacturing in the name of applicant..
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
471.	Name and address of manufacturer / Applicant	M/s Meditech Pharmaceuticals. 15-D, Industrial Estate, Hayatabad, Peshawar, Pakistan By M/s Polyfine Chempharma. 51-Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Molten 100mg/5ml IV Injection
	Composition	Each 5ml Ampoule Contains: Iron as Iron Sucrose (Iron (III) Hydroxide Sucrose Complex)…….100mg
	Diary No. Date of R& I & fee	Dy.No. 33318 dated 08-10-2018 Rs.50,000/- Dated 08-10-2018
	Pharmacological Group	Iron replacement product
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	5ml ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Venofer 100mg/5ml Injection of MHRA approved
	Me-too status	Bisleri 100mg/5ml Injection of M/S Sami Pharma
	GMP status	Last GMP inspection of Polyfine Chempharma conducted on **07-02-2018** and report concludes that Based on the area inspected the people met and document reviewed and considering the findings of inspection firm was considered to be operated at acceptable level of compliance with GMP guideline
	Remarks of the Evaluator	• Latest GMP inspection report of Meditech Pharmaceuticals. (conducted within the period of last three years). • Contract Agreement • Submit Form 5 by applicant . • Number of sections of applicant approved by licensing Board. • Number of products already registered/approved on contract manufacturing in the name of applicant.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
472.	Name and address of manufacturer / Applicant	M/s Welmark Pharmaceuticals. Plot #122 Phase 5, Block B, Industrial Hattar
	Brand Name +Dosage Form + Strength	Octre 0.05mg/ml Injection
	Composition	Each 1ml Ampoule Contains: Octreotide as Acetate…0.05mg

	Diary No. Date of R& I & fee	Dy.No. 36436 dated 05-11-2018 Rs.20,000/- Dated 01-11-2018
	Pharmacological Group	Somatostatin analogue (Cytostatics)
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	SANDOSTATIN (octreotide acetate)100mcg injection,solution of USFDA approved.
	Me-too status	Octreotide 50mcg Injection By M/SRevive Health Care, (Reg#082066)
	GMP status	Last GMP inspection conducted on **04-09-2018** & 26-09-2018 and report concludes that As per observation made, facilities of production and quality control inspected, technical staff employed and keeping in view the overall GMP compliance status of the firm, the panel unanimously recommends the renewal of DML 000614 by way of formulation granted to M/s Welmark KPK
	Remarks of the Evaluator	• Source of API whether of synthetic or biological origin. • Evidence of hormonal injection section.
	Decision: Registration Board deferred the case for following: • **Source of API whether of synthetic or biological origin.** • **Submission of evidence of approval of required manufacturing facility i.e., Liquid injection ampoule (Hormone) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.**	
473.	Name and address of manufacturer / Applicant	M/s Welmark Pharmaceuticals. Plot #122 Phase 5, Block B, Industrial Hattar
	Brand Name +Dosage Form + Strength	Octre 0.1mg/ml Injection
	Composition	Each 1ml Ampoule Contains: Octreotide as Acetate…0.1mg
	Diary No. Date of R& I & fee	Dy.No. 36437 dated 05-11-2018 Rs.20,000/- Dated 01-11-2018
	Pharmacological Group	Somatostatin analogue (Cytostatics)
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	SANDOSTATIN (octreotide acetate)100mcg injection,solution of USFDA approved.
	Me-too status	Sandostatin 0.1mg injection by Novartis (Reg. No. 013472)
	GMP status	Last GMP inspection conducted on **04-09-2018** & 26-09-2018 and report concludes that As per observation made, facilities of production and quality control inspected, technical staff employed and keeping in view the overall GMP compliance status of the firm, the panel unanimously recommends the renewal of DML 000614 by way of formulation granted to M/s Welmark KPK
	Remarks of the Evaluator	• Source of API whether of synthetic or biological origin. • Evidence of hormonal injection section.
	Decision: Registration Board deferred the case for following: • **Source of API whether of synthetic or biological origin.**	

	• **Submission of evidence of approval of required manufacturing facility i.e., Liquid injection ampoule (Hormone) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.**	
474.	Name and address of manufacturer / Applicant	M/s Winlet Pharmaceuticals. 30-km, Lahore Sargodha Road, Lahore
	Brand Name +Dosage Form + Strength	Winpride 1mg Tablet
	Composition	Each Tablet Contains: Cinitapride as Acid Tartrate…1mg
	Diary No. Date of R& I & fee	Dy.No. 39623 dated 03-12-2018 Rs.20,000/- Dated 03-12-2018
	Pharmacological Group	Propulsives
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	10's,; As per SRO
	Approval status of product in Reference Regulatory Authorities	Cidine 1 mg Tablet of Spain approved
	Me-too status	Cint 1mg Tablet M/s High-Q Pharmaceutical
	GMP status	Last GMP inspection conducted on **12-10-2017** & 12-12-2017, and the report concludes that panel are of the opinion to recoomend the grant of Drug Manufacturing License for the following Section by the way for 1. General Tablet Section 2. General Capsule Section 3. General Dry Powder Suspension Section (General) Section 4. Liquid Syrup (General)
	Remarks of the Evaluator	Coating step mentioned in manufacturing method. Justify.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications along with revised manufacturing method for uncoated tablet, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
475.	Name and address of manufacturer / Applicant	M/s Winlet Pharmaceuticals. 30-km, Lahore Sargodha Road, Lahore
	Brand Name +Dosage Form + Strength	Safet Tablet 75mg/200mcg
	Composition	Each delayed release tablet contains: Diclofenac Sodium…75mg Misoprostol…200mcg
	Diary No. Date of R& I & fee	Dy.No. 41782 dated 07-12-2018 Rs.20,000/- Dated 07-12-2018
	Pharmacological Group	NSAID along with mucoprotective
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	20's / As per SRO
	Approval status of product in Reference Regulatory Authorities	Arthrotec of USFDA Approved
	Me-too status	Dipros 50 Tablet of Helix
	GMP status	Last GMP inspection conducted on **12-10-2017** & 12-12-2017, and the report concludes that panel are of the opinion to recoomend the grant of Drug Manufacturing License for the following Section by the way for 1. General Tablet Section 2. General Capsule Section 3. General Dry Powder Suspension Section (General) Section

		4. Liquid Syrup (General)
	Remarks of the Evaluator	• Availability of Misoprostol as 1 % HPMC could not be verified from Form 5. Clarify • Method of manufacturing submitted is not in line with the innovator product. • Evidence of tablet biayered machine.& • Installation Qualification & Performance Qualification Reports of required manufacturing equipment i.e. tablet bilayered machine.
	Decision: Approved as per following label claim: **"Each film coated bilayer tablet contains:** **Diclofenac Sodium (Gastro-Resistant Core) .....75mg** **Misoprostol (Immediate Release Outer Mantle) ..... 200mcg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with evidence of availability of bi-layer tablet compression machine, before issuance of registration letter.**	
476.	Name and address of manufacturer / Applicant	M/s Winlet Pharmaceuticals. 30-km, Lahore Sargodha Road, Lahore
	Brand Name +Dosage Form + Strength	Irovit 100mg Tablet
	Composition	Each chewable tablet Contains: Iron III Hydroxide Polymaltose Complex Eq. to Elemental Iron…100mg
	Diary No. Date of R& I & fee	Dy.No. 41784 dated 07-12-2018 Rs.20,000/- Dated 07-12-2018
	Pharmacological Group	Anti-anemic
	Type of Form	Form 5
	Finished product Specification	Manufacturer,s specification
	Pack size & Demanded Price	1 x 10's, 2 x 20's, 3 x 10's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	N/A
	Me-too status	Polymalt 100mg Chewable Table Of M/s High-Q
	GMP status	Last GMP inspection conducted on **12-10-2017** & 12-12-2017, and the report concludes that panel are of the opinion to recoomend the grant of Drug manufacturing License for the following Section by the way for 1. General Tablet Section 2. General Capsule Section 3. General Dry Powder Suspension Section (General) Section 4. Liquid Syrup (General)
	Remarks of the Evaluator	On Challan form 02 different brand names are mentioned. Justify
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 30,000/- since on submitted challan forms 02 different brand names are mentioned.	
477.	Name and address of manufacturer / Applicant	M/s Winlet Pharmaceuticals. 30-km, Lahore Sargodha Road, Lahore
	Brand Name +Dosage Form + Strength	Safet Tablet 50mg/200mcg
	Composition	Each delayed release tablet contains: Diclofenac Sodium…50MG Misoprostol…200mcg
	Diary No. Date of R& I & fee	Dy.No. 41780 dated 07-12-2018 Rs.20,000/- Dated 07-12-2018
	Pharmacological Group	NSAID along with mucoprotective
	Type of Form	Form-5

	Finished product Specification	USP
	Pack size & Demanded Price	20's / As per SRO
	Approval status of product in Reference Regulatory Authorities	Arthrotec of USFDA Approved
	Me-too status	Dipros 50 Tablet of Helix
	GMP status	Last GMP inspection conducted on **12-10-2017** & 12-12-2017, and the report concludes that panel are of the opinion to recoomend the grant of Drug manufacturing License for the following Section by the way for 1. General Tablet Section 2. General Capsule Section 3. General Dry Powder Suspension Section (General) Section 4. Liquid Syrup (General)
	Remarks of the Evaluator	• Availability of Misoprostol as 1 % HPMC could not be verified from Form 5. Clarify • Method of manufacturing submitted is not in line with the innovator product. • Evidence of . tablet bilayered machine.& • Installation Qualification & Performance Qualification Reports of required manufacturing equipment i.e. tablet biayered machine.
	Decision: Approved as per following label claim: **"Each film coated bilayer tablet contains:** **Diclofenac Sodium (Gastro-Resistant Core) .....50mg** **Misoprostol (Immediate Release Outer Mantle) ..... 200mcg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with evidence of availability of bi-layer tablet compression machine, before issuance of registration letter.**	
478.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan
	Brand Name +Dosage Form + Strength	Vedagon XR 1.5mg Tablet
	Composition	Each extended release tablet contains: Paliperidone……..…1.5mg
	Diary No. Date of R& I & fee	Dy.No. 40506 dated 06-12-2018 Rs.20,000/- Dated 05-12-2018
	Pharmacological Group	Antipsychotic Drugs
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	10's, 14's, 20's, 30's, 50's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	INVEGA of USFDA approved.
	Me-too status	Paliris-XR Tablets 1.5mg of M/s Genome Pharmaceuticals
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance
	Remarks of the Evaluator	**Reference product is capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components.**

		There are two precision laser-drilled orifices on the drug-layer dome of the tablet. submit of manufacturing method of applied formulation in line with reference product which is prepared by OROS Push Pull technology.
	Decision: Deferred for confirmation of manufacturing requirements as per reference product.	
479.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan
	Brand Name +Dosage Form + Strength	Vedagon XR 3mg Tablet
	Composition	Each extended release tablet contains: Paliperidone……..…3mg
	Diary No. Date of R& I & fee	Dy.No. 40507 dated 06-12-2018 Rs.20,000/- Dated 05-12-2018
	Pharmacological Group	Antipsychotic Drugs
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	10's, 14's, 20's, 30's, 50's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	INVEGA of USFDA approved.
	Me-too status	Avega 6mg Tablets of M/s Biogen Pharma
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance
	Remarks of the Evaluator	**Reference product is capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There are two precision laser-drilled orifices on the drug-layer dome of the tablet**. Submit manufacturing method of applied formulation in line with reference product which is prepared by OROS Push Pull technology.
	Decision: Deferred for confirmation of manufacturing requirements as per reference product.	
480.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan
	Brand Name +Dosage Form + Strength	Vedagon XR 6mg Tablet
	Composition	Each extended release tablet contains: Paliperidone……..…6mg
	Diary No. Date of R& I & fee	Dy.No. 40508 dated 06-12-2018 Rs.20,000/- Dated 05-12-2018
	Pharmacological Group	Antipsychotic Drugs
	Type of Form	Form 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	10's, 14's, 20's, 30's, 50's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	INVEGA of USFDA approved.
	Me-too status	Avega 6mg Tablets of M/s Biogen Pharma
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance

	Remarks of the Evaluator	**Reference product is capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There are two precision laser-drilled orifices on the drug-layer dome of the tablet.** Submit manufacturing method of applied formulation in line with reference product which is prepared by OROS Push Pull technology.
	Decision: Deferred for confirmation of manufacturing requirements as per reference product.	
481.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals B-64, KDA, Scheme No. 1, Main Karsaz Road, Karachi, Pakistan
	Brand Name +Dosage Form + Strength	Eprion 50mg Tablet
	Composition	Each Tablet Contains: Eperisone Hcl…50mg sugar coated
	Diary No. Date of R& I & fee	Dy.No. 41492 dated 07-12-2018 Rs.20,000/- Dated 07-12-2018
	Pharmacological Group	Muscle relaxant, Centrally acting agent
	Type of Form	Form 5
	Finished product Specification	Manufacturer,s specification
	Pack size & Demanded Price	10's, 20's & 30's, 100's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Myonal 50mg Tablet of PMDA Approved
	Me-too status	Feloni 50mg Tablet of Hirani Pharmaceutical (Reg# 076583)
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance
	Remarks of the Evaluator	• The applied drug has been approved as "sugar coated" while you have applied for the drug without coating, justification/clarification is required in this required. • Submit master formulation Manufacturing method, analytical method.
	Decision: Approved as per following label claim: **"Each sugar coated tablet contains:** **Eperisone HCl…50mg"** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to sugar coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with master formulation, manufacturing method, analytical method, before issuance of registration letter.**	
482.	Name and address of manufacturer / Applicant	M/s Lowitt Pharma (pvt) Ltd. 24- Industrial Estate, Hayatabad, Peshawar
	Brand Name +Dosage Form + Strength	Fylline Syrup 125mg/5ml
	Composition	Each 5ml syrup Contains: Acefylline Piperazine…125mg
	Diary No. Date of R& I & fee	Dy.No. 603 dated 07-02-2020 Duplicate dossier of 16-04-2013
	Pharmacological Group	Xanthines (Brochodilator & anti-asthama)
	Type of Form	Form -5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	60ml, 90ml & 120ml: As per SRO

	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Broncophyline Syrup of M/s Wilson's Pharmaceutical Reg# 037947
	GMP status	
	Remarks of the Evaluator	• Latest GMP inspection report of (which should have been conducted within the period of last three year. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
483.	Name and address of manufacturer / Applicant	M/s Lowitt Pharma (pvt) Ltd. 24- Industrial Estate, Hayatabad, Peshawar
	Brand Name +Dosage Form + Strength	Fylline Syrup 125mg/5ml
	Composition	Each 5ml contains: Acefylline piperazine……45mg Diphenhydramine hydrochloride……8mg
	Diary No. Date of R& I & fee	Dy.No. 604 dated 07-02-2020 Duplicate dossier of 16-04-2013
	Pharmacological Group	Antihistamine /Xanthines (Brochodilator & anti-asthama)
	Type of Form	Form -5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	60ml, 90ml & 120ml: As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Acelyf Syrup of M/s Hicon Pharmaceuticals Reg# 077431
	GMP status	
	Remarks of the Evaluator	• Latest GMP inspection report of (which should have been conducted within the period of last three year. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
484.	Name and address of manufacturer / Applicant	M/s Searle IV Solutions Pvt Ltd. 1.5 km, Manga Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Femclo 50mg Tablet
	Composition	Each Tablet Contains: Clomiphene Citrate…50mg
	Diary No. Date of R& I & fee	Dy.No 508 dated 04-01-2019 Rs.20,000/- Dated 04-01-2019
	Pharmacological Group	Anti-Oestrogen
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	10's, 20's, 30's: As per SRO
	Approval status of product in Reference Regulatory Authorities	Clomid of (USFDA approved)
	Me-too status	Kins Tablets by Stanley Pharmaceuticals
	GMP status	

	Remarks of the Evaluator	DML renewal inspection conducted on 02.03.2021 and renewed the DML up to 2025
	Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
485.	Name and address of manufacturer / Applicant	M/s High-Q Pharmaceuticals. Plot No.224, Sector 23, Korangi Industrial Area, Karachi
	Brand Name +Dosage Form + Strength	Runlax 30/50/450mg Tablets
	Composition	Each Tablet Contains: Caffeine Anhydrous…30mg Orphenadrine citrate…50mg Paracetamol…450mg
	Diary No. Date of R& I & fee	Dy.No 1459 dated 11-01-2019 Rs.20,000/- Dated 10-01-2018
	Pharmacological Group	Analgesic
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	10's and 30's/As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	Copy of inspection report dated 10-8-2022 concludes good level of compliance
	Remarks of the Evaluator	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Decision: Defered for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.**	
486.	Name and address of manufacturer / Applicant	M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Exten 25mg Tablet
	Composition	Each Film Coated Tablet Contains: Exemestane…25mg
	Diary No. Date of R& I & fee	Dy.No 8696 dated 27-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Aromatase inhibitors (Steroidal)
	Type of Form	Form 5
	Finished product Specifications	Manufacturers specification
	Pack size & Demanded Price	15's, 30's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Aromasin 25 mg coated tablets. Of MHRA approved
	Me-too status	Ph&T Exemestane 25mg Coated Tablets by M/s Mehran International (Reg#078122)
	GMP status	Last GMP inspection conducted on 05-01-2018 and report concludes that firm had maintained conformance to cGMP.

	Remarks of the Evaluator	Approval of section/manufacturing facility (Steriodal hormonal tablet) by the Central Licensing Board.
	Decision: Deferred for deliberation regarding the classification of applied formulation whether it is a steroidal drug or otherwise.	
487.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Artisin 30mg Powder for Injection
	Composition	Each Vial Contains: Artesunate……30mg
	Diary No. Date of R& I & fee	Dy.No 8316 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Antimalarial
	Type of Form	Form- 5
	Finished product Specifications	IP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	WHO recommended formulation
	Me-too status	Gen-M Injection of M/s Genix Pharma
	GMP status	Last GMP inspection was conducted on 21-02-2019 concluded as, "Based on above observations and keeping in view the attitude of the management of the firm towards constant improvement their current GMP compliance level is rated as Good."
	Remarks of the Evaluator	Approval of section/manufacturing facility (Dry powder vial) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (general) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
488.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Artisin 60mg Powder for Injection
	Composition	Each Vial Contains: Artesunate……60mg
	Diary No. Date of R& I & fee	Dy.No 8297 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Antimalarial
	Type of Form	Form- 5
	Finished product Specifications	IP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	WHO recommended formulation
	Me-too status	Misonate 60mg Injection by M/s Tabros Pharma (Reg#057719)
	GMP status	Last GMP inspection was conducted on 21-02-2019 concluded as, "Based on above observations and keeping in view the attitude of the management of the firm towards constant improvement their current GMP compliance level is rated as Good."
	Remarks of the Evaluator	Approval of section/manufacturing facility(Dry powder vial) by the Central Licensing Board.

	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (general) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
489.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Artisin 120mg Powder for Injection
	Composition	Each Vial Contains: Artesunat…120mg
	Diary No. Date of R& I & fee	Dy.No 8298 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Antimalarial
	Type of Form	Form- 5
	Finished product Specifications	IP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	WHO recommended formulation
	Me-too status	Gen-M Injection of M/s Genix Pharma
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility(Dry powder vial) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
490.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Erapam 1gm Powder for concentrate for solution for infusion
	Composition	Each Vial Contains: Ertapenem…….1gm
	Diary No. Date of R& I & fee	Dy.No 8218 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Carbapenems
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	1's: As per SRO
	Approval status of product in Reference Regulatory Authorities	INVANZ (ertapenem for injection) for intravenous (IV) or intramuscular (IM) use by M/s Merck Sharp & Dohme USA (USFDA Approved)
	Me-too status	Ernem Injection of M/s Genix Pharma, (Reg.# 081179)
	GMP status	Same as above
	Remarks of the Evaluator	• Approval of section/manufacturing facility (carbapenem section) by the Central Licensing Board. • In reference as sodium while applied without sodium clarify, otherwise revise your formulation with submission of applicable fee
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Carbapenem) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
491.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals.

		Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Smep IV 40mg Powder for solution for injection Infusion
	Composition	Each Vial Contains: Esomeprazole Sodium eq to Esomeprazole ……40mg
	Diary No. Date of R& I & fee	Dy.No 8312 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Proton Pump Inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacture's specification
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Nexium IV injection of (USFDA approved)
	Me-too status	Esold Injection of M/s Weather Folds Pharmaceutical
	GMP status	Same as above
	Remarks of the Evaluator	• Approval of section/manufacturing facility (dry vial section) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
492.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Cinipem IV 250mg/250mg Powder for solution for infusion
	Composition	Each Vial Contains: Imipenem (as 265mg Imipenem Monohydrate)..……..250mg Cilastatin (as 265mg cilastatin sodium salt)……250mg (Sterile mixture also contains sodium bicarbonate as buffer)
	Diary No. Date of R& I & fee	Dy.No 8315 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Carbapenems
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities	PRIMAXIN® (imipenem and cilastatin) for Injection, For intravenous use. USFDA approved
	Me-too status	Cilapen 250mg Injections of M/s Bosch Pharmaceuticals,
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility (carbapenem section) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Carbapenem) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
493.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals.

		Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Cinipem IV 500mg/500mg Powder for solution for infusion
	Composition	Each Vial Contains: Imipenem (as 530mg Imipenem Monohydrate)..……..500mg Cilastatin (as 530mg cilastatin sodium salt)……500mg (Sterile mixture also contains sodium bicarbonate as buffer)
	Diary No. Date of R& I & fee	Dy.No 8302 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Carbapenems
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities	PRIMAXIN® (imipenem and cilastatin) for Injection, For intravenous use. USFDA approved
	Me-too status	Cilapen 500mg Injections of M/s Bosch Pharmaceuticals,
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility (carbapenem section) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Carbapenem) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
494.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Crystofer Injection 20MG/ML
	Composition	Each 1ml contains: Iron as iron sucrose (iron (III)-hydroxide sucrose complex…….20mg
	Diary No. Date of R& I & fee	Dy.No 8533 dated 26-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Iron replacement product
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	5ml x 5's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Venofer 100mg/5ml Injection of MHRA approved
	Me-too status	Bisleri 100mg/5ml Injection of M/S Sami Pharma
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
495.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Mecobal 500mcg Injection

	Composition	Each 1ml contains Mecobalamin…500mcg
	Diary No. Date of R& I & fee	Dy.No 8320 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Co-enzyme-type vitamin B12
	Type of Form	Form 5
	Finished product Specifications	Manufacture's specification
	Pack size & Demanded Price	1ml x 5's, 1ml x10's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	PMDA Japan approved
	Me-too status	Wycomin 500 mcg Injection by Wnsfeild Pharmaceutical,
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
496.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Merolite 500mg Powder for solution for injection or infusion
	Composition	Each Vial Contains: Meropenem (as 570.78mg Meropenem Trihydrate eq to Anhydrous Meropenem)….. ……500mg (with anhydrous Sodium Carbonate)
	Diary No. Date of R& I & fee	Dy.No 8305 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Carbapenems
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities	MERREM® IV (meropenem for injection) 500mg, for intravenous use. US-FDA approved
	Me-too status	Olver Injection of M/s Genix
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility (carbapenem section) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Carbapenem) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
497.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Merolite 1g Powder for solution for injection or infusion
	Composition `	Each Vial Contains: Meropenem (as 1141.56mg Meropenem Trihydrate eq to Anhydrous Meropenem) …… 1g (with anhydrous Sodium Carbonate)
	Diary No. Date of R& I & fee	Dy.No 8308 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Carbapenems
	Type of Form	Form-5

	Finished product Specifications	USP
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in Reference Regulatory Authorities	MERREM® IV (meropenem for injection) 1g, for intravenous use. US-FDA approved
	Me-too status	Olver Injection of M/s Genix
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility (carbapenem section) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (Carbapenem) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
498.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Oraz 40mg Powder for solution for injection
	Composition `	Each vial of powder for solution for infusion contains: Omeprazole Sodium eq. to Omeprazole Sodium…….40mg
	Diary No. Date of R& I & fee	Dy.No 8310 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Proton Pump Inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacture's specification
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Omeprazol 40mg injection of (MHRA approved)
	Me-too status	Fymezole Dry Powder Injection IV of M/s Fynk Pharmaceuticals
	GMP status	Same as above
	Remarks of the Evaluator	• Approval of section/manufacturing facility by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
499.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Trupan 40mg Powder for Solution for Injection
	Composition `	Each Vial Contains: Pantoprazole as sodium sesquihydrate……40mg
	Diary No. Date of R& I & fee	Dy.No 8296 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Proton Pump Inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacture's specification
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Protonix injection of (USFDA approved)
	Me-too status	Pazole Dry Powder Injection IV of M/s Fynk Pharmaceuticals,
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility by the Central Licensing Board.

	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
500.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Biovac 500mg Powder for solution for injection
	Composition `	Each Vial Contains: Vancomycin HCl…….500mg(eq to 500,000 IU Vanomycin)
	Diary No. Date of R& I & fee	Dy.No 8295 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Vancomycin 500mg Powder for Solution for Infusion of MHRA approved
	Me-too status	Vancotic 500mg Injection by M/s English Pharm,
	GMP status	Same as above
	Remarks of the Evaluator	Approval of section/manufacturing facility by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (General) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
501.	Name and address of manufacturer / Applicant	M/s Crystolite Pharmaceuticals. Plot # 1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Biovac 1gm Powder for solution for injection
	Composition `	Each Vial Contains: Vancomycin HCl …..1gm(eq to 1,000,000 IU Vanomycin)
	Diary No. Date of R& I & fee	Dy.No 8313 dated 25-02-2019 Rs.20,000/- Dated 25-02-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Vancomycin 1g Powder for Solution for Infusion n of MHRA approved
	Me-too status	Vancotic 1gm Injection by M/s English Pharm,
	GMP status	Same as above
	Remarks of the Evaluator	• Approval of section/manufacturing facility by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Dry powder injection (general) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
502.	Name and address of manufacturer / Applicant	M/S Meditech Pharmaceuticals 15-D, Industrial Estate, Peshawar Contract Manufactured by M/S Polyfine Chempharma, 51- Industrial Estate, Hayatabad Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Verev 500mg injection I.M
	Composition	Each vial contains:

		Ceftriaxon Sodium equivalent to ceftriaxon …….500mg
	Diary No. Date of R& I & fee	Dy.No.20165; 06-11-2017; Rs.50,000/- (06-11-2017)
	Pharmacological Group	Cephalosporin
	Type of Form	Form 5
	Finished product Specifications	USP
	Pack size & Demanded Price	1's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Rocephin I.M injection of (MHRA approved)
	Me-too status (with strength and dosage form)	Wixone 500 mg Injection IM M/s Wise Pharmaceuticals,
	GMP status	
	Remarks of the Evaluator	• Latest GMP inspection report (conducted within the period of last one year). • Contract manufacturing agreement. • Number of sections of applicant approved by Licensing Board • Number of products already registered/approved on contract manufacturing in the name of applicant
	Decision: Deferred for clarification as the DML site of M/s Meditech Pharmaceuticals has been changed to Plot No. 83-A, 83-B, Indusytrail Estate, Hayatabad, Peshawar, whereas the instant application has been applied from previous site.	
503.	Name and address of manufacturer / Applicant	M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad
	Brand Name +Dosage Form + Strength	Neodesone 0.5% Cream
	Composition	Each Gram Contains: Neomycin as Sulphate…5mg
	Diary No. Date of R& I & fee	Dy.No. 17153 dated 07-03-2019 Rs.20,000/- Dated 06-03-2019
	Pharmacological Group	Anti-bacterial
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	20gm /As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Primaneo cream of M/s Prime Laboratories
	GMP status	Last GMP inspection of conducted on **16-10-2018** and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator [IV]	• On challan and covering letter ointment mentioned. Clarify. • Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting • Approval of section/manufacturing facility (cream section) by the Central Licensing Board.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
504.	Name and address of manufacturer / Applicant	M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad
	Brand Name +Dosage Form + Strength	Oflomark 0.6% w/v Drops
	Composition	Each 5ml contains:

		Ofloxacin as Hcl…0.6% w/v
	Diary No. Date of R& I & fee	Dy.No. 12246 dated 06-03-2019 Rs.20,000/- Dated 05-03-2019
	Pharmacological Group	Fluroquinolone Antibiotic
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	5ml / As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	Last GMP inspection of conducted on **16-10-2018** and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm**	
505.	Name and address of manufacturer / Applicant	M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad
	Brand Name +Dosage Form + Strength	Ome-Mark Plus 20/1680 mg Sachet
	Composition	Each Sachet Contains: Omeprazole…20mg Sodium Bicarbonate…1680mg
	Diary No. Date of R& I & fee	Dy.No. 17176 dated 07-03-2019 Rs.20,000/- Dated 06-03-2019
	Pharmacological Group	Proton pump inhibitor, Antacid
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	1x 7's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Zegerid (USFDA Approved) Powder for oral suspension
	Me-too status	Risek Insta by Getz
	GMP status	Last GMP inspection of conducted on **16-10-2018** and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator [IV]	• **Sachet section available** • In challan form and covering letter 1680 mg while in dossier 1100mg mentioned. Clarify and justify.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in strength mentioned on challan form and covering lette, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
506.	Name and address of manufacturer / Applicant	M/s Medimarker's Labortaries Pvt Ltd A-104, S.I.T.E Area, Hyderabad

	Brand Name +Dosage Form + Strength	Ome-Mark Plus 40/1100 mg Sachet
	Composition	Each Sachet Contains: Omeprazole…40mg Sodium Bicarbonate…1100mg
	Diary No. Date of R& I & fee	Dy.No. 17180 dated 07-03-2019 Rs.20,000/- Dated 06-03-2019
	Pharmacological Group	Proton pump inhibitor, Antacid
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	10's; 20's ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	Last GMP inspection of conducted on **16-10-2018** and the report concludes that the panel unanimously recommend the grant of renewal DML
	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm
	Decision: Approved as per following label claim with USP specifications: **"Each Sachet Contains:** **Omeprazole…40mg** **Sodium Bicarbonate…1680mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
507.	Name and address of manufacturer / Applicant	M/s Swiss Pharmaceuticals Pvt Ltd. A-159, S.I.T.E Super Highway, Karachi, Pakistan
	Brand Name +Dosage Form + Strength	Locam 8mg Injection
	Composition	Each 2ml vial contains: Lornoxicam…8mg
	Diary No. Date of R& I & fee	Dy.No. 11424 dated 05-03-2019 Rs.20,000/- Dated 05-03-2019
	Pharmacological Group	NSAID
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	2ml x 1's Vial / As per SRO
	Approval status of product in Reference Regulatory Authorities	Xefo 8mg powder for solution for injection EMA approved
	Me-too status	Viltaz Injection 8mg/2ml by Wilshire (Reg. No. 077112)
	GMP status	Inspection conducted on **18-10-2018** and GMP compliance level is rated as GOOD."
	Remarks of the Evaluator [IV]	• Approval of section/manufacturing facility (Lyophilized section) by the Central Licensing Board. • Master formulation, method of manufacturing and analytical testing method not submitted
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Injectable (Lyophilisation) section from CLB or else while firm may transfer	

<table>
<tr><td></td><td colspan="2">the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.</td></tr>
<tr><td rowspan="12">508.</td><td>Name and address of manufacturer / Applicant</td><td>M/s Mediate Pharmaceutical Pvt Ltd.
Plot No. 150-151, Sector 24, Korangi Industrial Area, Karchi, Pakistan</td></tr>
<tr><td>Brand Name +Dosage Form + Strength</td><td>Tridol SR 100mg Capsule</td></tr>
<tr><td>Composition</td><td>Each Capsule Contains:
Tramadol Hcl…100mg</td></tr>
<tr><td>Diary No. Date of R& I & fee</td><td>Dy.No. 9796 dated 04-03-2019 Rs.20,000/-
Dated 04-02-2019</td></tr>
<tr><td>Pharmacological Group</td><td>Narcotic analgesic</td></tr>
<tr><td>Type of Form</td><td>Form 5</td></tr>
<tr><td>Finished product Specifications</td><td>BP</td></tr>
<tr><td>Pack size & Demanded Price</td><td>10’s,: As per SRO</td></tr>
<tr><td>Approval status of product in Reference Regulatory Authorities</td><td>CONZIP 100mg Capsules of (USFDA approved) MHRA</td></tr>
<tr><td>Me-too status</td><td>Zultra SR 100mg of M/s. Wilshire Laboratories</td></tr>
<tr><td>GMP status</td><td>Last GMP inspection conducted on 02-04-2019, and report concludes firm was considered to be operating at an acceptable level of good compliance with GMP guidelines</td></tr>
<tr><td>Remarks of the Evaluator [IV]</td><td>CIP-TRAMADOL ER (tramadol hydrochloride) extended-release) capsules are a new formulation of tramadol HCl for analgesia. The drug product consists of extended release film coated white beads and an immediate release tablet encapsulated in white opaque, size 1, 0 and 00, hard gelatin capsules. Strengths are 100 mg, containing a 25 mg immediate release tablet, the appropriate amount of film coated beads . The drug product is an extended release oral dosage form with in-vitro drug release within 1h, within 7-8h and after 24h.
<table>
<tr><th>Dosage</th><th>Immediate release Tablet strength</th><th>Extended release Beads Strength</th></tr>
<tr><td>100 mg</td><td>25 mg</td><td>75 mg</td></tr>
</table>
Justify you master formulation and method of manufacturing in line with reference product.
Source of Extended release beads (In case of imported source remaining Rs: 80000/- fee)
GMP certificate of source of pellets
Stability study of 3 batches of pellets
Certificate of analysis of pellets.</td></tr>
<tr><td colspan="2">Decision: Deferred for justification of applied formulation against the Innovator drug product as Innovator drug product capsules contain a total dose of tramadol hydrochloride 100, 200, and 300 mg in a combination of immediate-release and extended-release components, whereas no such declaration has been submitted by firm.</td></tr>
<tr><td rowspan="3">509.</td><td>Name and address of manufacturer / Applicant</td><td>M/s Aries Pharmaceuticals.
1-W, Industrial Estate, Hayatabad, Peshawar, k.p.k</td></tr>
<tr><td>Brand Name +Dosage Form + Strength</td><td>Methasol 0.5mg Tablet</td></tr>
<tr><td>Composition</td><td>Each Tablet Contains:</td></tr>
</table>

		Betamethasone as Sodium Phosphate…0.5mg
	Diary No. Date of R& I & fee	Dy.No. 14403 dated 07-03-2019 Rs.20,000/- Dated 07-03-2019
	Pharmacological Group	Corticosteroid
	Type of Form	Form 5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Betnesol 500 microgram Soluble Tablets of (MHRA Approved)
	Me-too status	Betmatab Tab of M/s Nabiqasim (Reg # 011908)
	GMP status	cGMP certificate on the basis of Evaluation conducted on 06-04-2022
	Remarks of the Evaluator [IV]	Approval of section/manufacturing facility (Steriodal tablet) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Tablet (Steroid) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
510.	Name and address of manufacturer / Applicant	M/s Aries Pharmaceuticals. 1-W, Industrial Estate, Hayatabad, Peshawar, k.p.k
	Brand Name +Dosage Form + Strength	Decadex 0.5mg Tablet
	Composition	Each Tablet Contains: Dexamethasone…0.5mg
	Diary No. Date of R& I & fee	Dy.No. 14404 dated 07-03-2019 Rs.20,000/- Dated 07-03-2019
	Pharmacological Group	Corticosteroid
	Type of Form	Form 5
	Finished product Specifications	BP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Dexamethasone Krka 0.5 mg tablets of (MHRA approved)
	Me-too status	Phesone Tab by M/s Pharmacare
	GMP status	cGMP certificate on the basis of Evaluation conducted on 06-04-2022
	Remarks of the Evaluator [IV]	Approval of section/manufacturing facility(Steriodal tablet) by the Central Licensing Board.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Tablet (Steroid) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.	
511.	Name and address of manufacturer / Applicant	M/s Aries Pharmaceuticals. 1-W, Industrial Estate, Hayatabad, Peshawar, k.p.k
	Brand Name +Dosage Form + Strength	Ibudex 100mg/5ml Suspension
	Composition	Each 5ml Contains: Dexibuprofen…100mg
	Diary No. Date of R& I & fee	Dy.No. 14397 dated 07-03-2019 Rs.20,000/- Dated 06-03-2019
	Pharmacological Group	NSIADs
	Type of Form	Form 5
	Finished product Specifications	Manufacturer's specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found

	Me-too status	Detefen Liquid Suspension of M/s Fynk Pharmaceuticals (Reg.# 074443)
	GMP status	cGMP certificate on the basis of Evaluation conducted on 06-04-2022
	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
512.	Name and address of manufacturer / Applicant	M/s Genix Pharma Pvt Ltd. 44,45-B, Korangi Creek Road, Karachi, 75190, Pakistan
	Brand Name +Dosage Form + Strength	Incat 300mcg Dry Powder Capsule for Oral Inhalation
	Composition	Each Capsule Contains: Indacaterol Maleate Eq. to Indacaterol…300mcg
	Diary No. Date of R& I & fee	Dy.No. 10004 dated 04-03-2019 Rs.50,000/- Dated: 04-03-2019
	Pharmacological Group	Ultra Long acting B-2 adrenergic agonist.
	Type of Form	Form-5D
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	6's, 10's, 15's, 20's, 30's: As per SRO
	Approval status of product in Reference Regulatory Authorities	Onbrez Breezhaler 300 microgram inhalation powder, hard capsules: of MHRA approved
	Me-too status	Onbrez Breezhaler 300mcg Inhalation Powder Hard Capsules 300mcg. Of M/S Novartis Pharma
	GMP status	New GMP granted on 07/10/2021
	Remarks of the Evaluator [IV]	• Approval of section/manufacturing facility by the Central Licensing Board. • Submit stability studies along with requisite documents
	Decision: Deferred for submission of evidence of availability of manufacturing and analytical equipments as recommended by Registration Board in its 290th meeting for the "Dry Powder Inhaler Capsule" dosage form.	
513.	Name and address of manufacturer / Applicant	M/s Genix Pharma Pvt Ltd. 44,45-B, Korangi Creek Road, Karachi, 75190, Pakistan
	Brand Name +Dosage Form + Strength	Levarol Inhalation Solution
	Composition	Each ml Contains: Levalbuterol Hcl Eq. to Levalbuterol…0.31mg
	Diary No. Date of R& I & fee	Dy.No. 9998 dated 04-03-2019 Rs.50,000/- Dated 04-03-2019
	Pharmacological Group	Relatively selective beta2- Adrenergic receptor Agonist
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	3ml, 5ml, 10ml: As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	New GMP granted on 07/10/2021

	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.** • **Evidence of approval of required manufacturing facility i.e., Respule section from CLB along with stability studies data as per checklist approved in 312th meeting of Registration Board or else while firm may transfer the registration application to by way of contract manufacturing upon submission of Form 5F, within six months.**	
514.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Beat-C Lotion 0.05/0.005 % w/v
	Composition	Each ml Contains: Betamethasone Dipropionate …500mcg Calcipotriol as Monohydrate…50mcg
	Diary No. Date of R& I & fee	Dy.No. 14068 dated 07-03-2019 Rs.20,000/- Dated 07-03-2019
	Pharmacological Group	Corticosteriod, Vitamin D analogue
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specificsation
	Pack size & Demanded Price	30ml, As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.**	
515.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Calrol 0.005% w/v Lotion
	Composition	Each ml Contains: Calcipotriol monohydrate eq to Calcipotriol…50mcg
	Diary No. Date of R& I & fee	Dy.No. 14061 dated 07-03-2019 Rs.20,000/-

		Dated 07-03-2019
	Pharmacological Group	Vitami D analogue
	Type of Form	Form-5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	30ml ; As per SRO
	Approval status of product in Reference Regulatory Authorities	Daivonex solution 50mcg/ml of TGA Austraila approved
	Me-too status	Not found
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator [IV]	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Decision: Deferred applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
516.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207 Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Stigo 100mg/ml Injection
	Composition	Each 1ml Contains: Sodium Stibogluconate…100mg
	Diary No. Date of R& I & fee	Dy.No. 14255 dated 07-03-2019, Rs. 20,000/- Dated 07-03-2019
	Pharmacological Group	Antidopaminergic
	Type of Form	Form 5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	6ml x 5'Ampoule: As per SRO
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status	Not found
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator [IV]	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm
	Decision: Deferred for following: • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm**	
517.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Novaclop Plus 75/75 mg Tablet
	Composition	Each Film Coated Tablet Contains: Clopidogrel as Bisulphate…75mg Aspirin…75mg
	Diary No. Date of R& I & fee	Dy.No. 12696 dated 06-03-2019 Rs.20,000/- Dated 05-03-2019

	Pharmacological Group	Antiplatelet and Nonsteriodal Anti-inflammatory Drug
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	10's:As per SRO
	Approval status of product in Reference Regulatory Authorities	CoPlavix Tablet Of (TGA Approved)
	Me-too status	Clodril Plus Tablet M/s Macter International
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator [IV]	• Applied formulation is film coated tablet while innovator product is bilayered film coated tablet Clarify, otherwise revise your formulation to bilayered film coated tablet with submission of requisite fee & also submit evidence of bilayered tablet machine. • Submit manufacturing method in line with reference product
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

b. Deferred cases

518.	Name and address of manufacturer / Applicant	Well care Pharmaceuticals A/7 P.S.I.E. Lahore Road Sargodha
	Brand Name +Dosage Form + Strength	Wellfer-F Syrup
	Composition	Each 5ml contains:- Iron III Hydroxide Polymaltose Complex……50mg
	Diary No. Date of R& I & fee	Dy.No 558 dated 05-06-2014
	Pharmacological Group	Haematinic
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specification
	Pack size & Demanded Price	60ml : Rs :160/ 60ml
	Approval status of product in Reference Regulatory Authorities	Not found
	Me-too status (with strength and dosage form)	Luberon 50mg/5ml Syrup of M/s Ankaz Pharmaceuticals
	GMP status	
	Previous remarks of the Evaluator.	• 1st Letter: 24th April , 2018 • Reminder Letter: 16th May , 2018 .Latest GMP inspection report (which should have been conducted within the period of last one year).
	Previous decision(s)	**Deferred for following reasons:** Registration Board deferred the case for further deliberation. **(M-284)**
	Evaluation by PEC	Last GMP inspection of conducted on 10th -09-2021 and the report concludes that the firm is operating at satisfactory level of GMP compliance as of today, suggestion for improvement have been agreed upon by management.
	Decision: Approved as per following label claim: **"Each 5ml contains:** **Iron (III) Hydroxide Polymaltose Complex eq. to elemental Iron …… 50mg"**	

	The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

Case no. 02 Registration applications of newly granted DML or New section (Human)

a. New/Additional section(s)

Deferred Case:

519.	Name, address of Applicant / Marketing Authorization Holder	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan
	Name, address of Manufacturing site.	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1197- dated 13-01/2022
	Details of fee submitted	PKR 30000/-: dated 03/12/2021
	The proposed proprietary name / brand name	Tyno 156.25mg/5ml Suspension
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Each reconstituted 5ml contains:** Amoxicillin Trihydrate eq. to Amoxicillin ……. 125mg Potassium Clavulanate Eq to Clavulanic Acid…..31.25mg
	Pharmaceutical form of applied drug	Powder for Reconstitution for Oral use (Suspension)
	Pharmacotherapeutic Group of (API)	Penicillin antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Augmentin 125/31 Suspension M/s GlaxoSmithKline UK of MHRA approved
	For generic drugs (me-too status)	Augmentin 156.25mg/5ml Suspension by M/s GSK, Reg# 009264
	GMP status of the Finished product manufacturer	GMP certificate issued on basis of inspection conducted on 18-11-2020.
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 22-12-2020, wherein approval for "Sterile dry powder for injection (Penicillin)", Capsule (Penicillin), Dry powder for suspension (Penicillin)."
	Name and address of API manufacturer.	**Amoxicillin Trihydrate:**

		Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. **Potassium Clavulanate:** Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Amoxicillin Trihydrate & Potassium Clavulanate is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Amoxicillin Trihydrate:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months **Potassium Clavulanate:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Augmentin 156.25mg/5ml suspension by GSK Pakistan by performing quality tests (Identification, Assay, pH). CDP has not been performed because it is not applicable in this case.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificty.

STABILITY STUDY DATA	
Manufacturer of API	**Amoxicillin Trihydrate:** Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. **Potassium Clavulanate:** Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.
API Lot No.	**Amoxicillin Trihydrate:**00078/522/2021 **Potassium Clavulanate:**04NB2104013
Description of Pack	Glass bottle with PP cap (1's)

(Container closure system)			
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-001	T-002	T-003
Batch Size	1000 bottles	1000 bottles	1000 bottles
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	26-02-2021	26-02-2021	26-02-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Amoxicillin Trihydrate:** Copy of GMP certificate No. 06/2019-DRAP (AD/607409-530) issued by DRAP on he basis if evaluation conducted on 08-01-2019 **Potassium Clavulanate:** Copy of GMP certificate No (SX20180229) issued by China Food and Drug Administration valid until 05-06-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Amoxicillin Trihydrate:** Copy commercial invoice (Invoice# 321) Dated: 03-02-2021 with received quantity i.e. 16 Kg) of Amoxicillin Trihydrate Batch No# 00078/522/2021 without attestation as local source. **Potassium Clavulanate:** Copy commercial invoice (Invoice# EX/3198577) Dated: 18-12-2020 with received quantity i.e. 4Kg gm) of **Potassium Clavulanate** Batch No# 04NB2104013 with attestation of DRAP Karachi dated:01-12-2020.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	We have maintained manual logs of all tests.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.5.2.	In Label Claim SiO2 mentioned. Clarify.	Innovator also used the silicon dioxide but mentioned as excipients rather than relate with Drug substance. **(but label claim not revised)**

2.	2.3.R.1.1	Submit complete calculations for Drug substance's quantity dispensed for manufacturing	Submitted.
3.	2.3.R.1.2	For applications of locally manufactured drug product(s), provide blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product	Blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product submitted.
4.	3.2.S.4.1	• Copies of the Drug substance (Amoxicillin) specifications Drug Product manufacturer is required. • Submitted specification of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required how on diluted Potassium Clavulanate USP monograph applied.	• Drug substance (Amoxicillin) specifications by Drug Product manufacturer are submitted. • Diluted Potassium Clavulanate is present in BP and the corrected specifications is attached.
5.	3.2.S.4.2	• Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active Pharmaceutical Ingredient (Amoxicillin) by Drug product manufacturer is required. • Submitted testing method of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required.	• Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active Pharmaceutical Ingredient Amoxicillin)by Drug product manufacture submitted. • Testing method of potassium Clavulanate according to BP monograph submitted**.**
6.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Amoxicillin & Potassium clavulanate) shall be submitted.	Submitted
7.	3.2.S.4.4	• COA of Amoxicillin trihydrate by Drug product manufacturer mentioned Dry powder	• Corrected COA of Amoxicillin trihydrate by Drug product manufacturer attached. • Corrected COA of Potassium Clavulanate by Drug product manufacturer attached.

		injection. Clarification is required. • COA of drug substance Potassium Clavulanate by drug product manufacturer claims USP specification while Potassium Clavulanate is diluted with Syloid 1:1. Clarification is required.	
8.	3.2.P.1	Quantity of Amoxicillin trihydrate and Potassium clavulanate is not according to label claim.	It was typographical error made the actual quantity in the formulation. Corrected quantity is attached.
9.	3.2.P.2.1.2	• Compatibility studies with excipients as excipients are different than innovator. • Innovator product does not contain preservative while you are adding Sodium benzoate as preservative. Clarification is required.	• Not submitted • No reply submitted
10.	3.2.P.2.3	Complete manufacturing method of stability batches is required.	Complete manufacturing method is submitted.
11.	3.2.P.5.1	Claimed specification is USP while Deliverable volume and • microbial enumeration tests and Tests for specified microorganism not performed mentioned in USP monograph	Testing according to USP monograph submitted.
12.	3.2.P.5.2	Detailed analytical procedures used for testing the drug product shall be provided.	Detailed analytical procedures used for testing the drug product is submitted.
13.	3.2.P.5.3	• Verification studies of Amoxicillin trihydrate is not in line with USP monograph Assay method. Clarification is required. • Verification studies of Clavulanic acid not submitted.	Submitted.
14.	3.2.P.5.4	The COA of Drug product mentioned Dry Powder injection mentioned. Clarification is required.	Corrected COA of drug product are attached.
15.	3.2.P.8	• In stability summary sheets 6th month mentioned 26-08-2020 while on other months mentioned 2021. Clarification is required.	• The year was written as 2020 by typing error. The corrected stability data sheets are attached. • The supporting chromatograms are attached. • Compatibility studies with diluent not submitted.

		• Data of stability batches will be supported by attested respective documents like Raw data sheets, COA, • Submit Compatibility studies with diluent	

Previous Decision (M_317): Deferred for following:

- Revised label claim without Sio2 with submission of applicable fee.
- Compatibility studies with excipients as excipients are different than innovator.
- Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.
- Compatibility studies with diluent**.**

Reply by firm		
1.	Revised label claim without Sio2 with submission of applicable fee.	Revised label claim without SiO2 submitted with submission of fee of Rs: 7500/- Deposit slip # 5462502434 Dated: 17-05-2022
2.	Compatibility studies with excipients as excipients are different than innovator.	Submitted for Sodium CMC and Aeorsil.
3.	Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.	After reconstitution of dry powder for Oral suspension, the risk of microbial contamination and subsequent product spoilage is much increased during use y the patient. For these reason, Pharmaceutical suspensions formulations contain antimicrobial preservatives. Preservatives are required in most suspensions because the suspending agents and sweetner are good growth media for microorganism. Sodium benzoate is approved as first of all preservative by the Food and drug administration (FDA) Morever Co-amoxiclav 125/31 Oral Suspension Sugar-Free of Bristol Laboratories Limited approved in MHRA also contain sodium benzoate.
4.	Compatibility studies with diluent**.**	Compatibility studies with diluent submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

520.		
	Name, address of Applicant / Marketing Authorization Holder	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan
	Name, address of Manufacturing site.	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 401- dated 05-01-2022

	Details of fee submitted	PKR 30000/-: dated 03/12/2021
	The proposed proprietary name / brand name	Tyno 312.5mg/5ml Suspension
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each reconstituted 5ml contains: Amoxicillin Trihydrate eq. to Amoxicillin ……. 250mg Potassium Clavulanate equivalent to Clavulanic Acid …… 62.50 mg
	Pharmaceutical form of applied drug	Powder for Reconstitution for Oral use (Suspension)
	Pharmacotherapeutic Group of (API)	Penicillin antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Augmentin 312.5mg/5ml Powder for reconstitution for oral use by M/s GlaxoSmithKline UK , MHRA Approved.
	For generic drugs (me-too status)	Augmentin 312.5mg/5ml Suspension by M/s GSK Pakistan, Reg. No. 0018360
	GMP status of the Finished product manufacturer	GMP certificate issued on basis of inspection conducted on 18-11-2020.
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 22-12-2020, wherein approval for "Sterile dry powder for injection (Penicillin)", Capsule (Penicillin), Dry powder for suspension (Penicillin)."
	Name and address of API manufacturer.	Amoxicillin Trihydrate: Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. Potassium Clavulanate: Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Amoxicillin Trihydrate & Potassium Clavulanate is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Amoxicillin Trihydrate:

		Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Potassium Clavulanate: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months		
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Augmentin 312.5mg/5ml suspension by GSK Pakistan by performing quality tests (Identification, Assay, pH). CDP has not been performed because it is not applicable in this case.		
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificty.		
STABILITY STUDY DATA				
Manufacturer of API		Amoxicillin Trihydrate: Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. Potassium Clavulanate: Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.		
API Lot No.		Amoxicillin Trihydrate:00078/522/2021 Potassium Clavulanate:04NB2104013		
Description of Pack (Container closure system)		Glass bottle with PP cap (1's)		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		T-001	T-002	T-003
Batch Size		1000 bottles	1000 bottles	1000 bottles
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		26-02-2021	26-02-2021	26-02-2021
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Amoxicillin Trihydrate: Copy of GMP certificate No. 06/2019-DRAP (AD/607409-530) issued by DRAP on the basis if evaluation conducted on 08-01-2019		

		Potassium Clavulanate: Copy of GMP certificate No (SX20180229) issued by China Food and Drug Administration valid until 05-06-2023
	Documents for the procurement of API with approval from DRAP (in case of import).	Amoxicillin Trihydrate: Copy commercial invoice (Invoice# 321) Dated: 03-02-2021 with received quantity i.e. 16 Kg) of Amoxicillin Trihydrate Batch No# 00078/522/2021 without attestation as local source. Potassium Clavulanate: Copy commercial invoice (Invoice# EX/3198577) Dated: 18-12-2020 with received quantity i.e. 4Kg gm) of Potassium Clavulanate Batch No# 04NB2104013 with attestation of DRAP Karachi dated:01-12-2020.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	We have maintained manual logs of all tests.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
	1.5.2.	In Label Claim SiO2 mentioned. Clarify.	Innovator also used the silicon dioxide but mentioned as excipients rather than relate with Drug substance. (but label claim not revised)
	2.3.R.1.1	Submit complete calculations for Drug substance's quantity dispensed for manufacturing	Submitted.
	2.3.R.1.2	For applications of locally manufactured drug product(s), provide blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product	Blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product submitted.
	3.2.S.4.1	Copies of the Drug substance (Amoxicillin) specifications Drug Product manufacturer is required. Submitted specification of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required how on diluted Potassium Clavulanate USP monograph applied.	Drug substance (Amoxicillin) specifications by Drug Product manufacturer are submitted. Diluted Potassium Clavulanate is present in BP and the corrected specifications is attached.
	3.2.S.4.2	Detailed analytical procedures for the testing of	Detailed analytical procedures for the testing of drug substance used for routine testing of the

		drug substance used for routine testing of the Drug substance /Active Pharmaceutical Ingredient (Amoxicillin) by Drug product manufacturer is required. Submitted testing method of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required.	Drug substance /Active Pharmaceutical Ingredient Amoxicillin)by Drug product manufacture submitted. Testing method of potassium Clavulanate according to BP monograph submitted.
	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Amoxicillin & Potassium clavulanate) shall be submitted.	Submitted
	3.2.S.4.4	COA of Amoxicillin trihydrate by Drug product manufacturer mentioned Dry powder injection. Clarification is required. COA of drug substance Potassium Clavulanate by drug product manufacturer claims USP specification while Potassium Clavulanate is diluted with Syloid 1:1. Clarification is required.	Corrected COA of Amoxicillin trihydrate by Drug product manufacturer attached. Corrected COA of Potassium Clavulanate by Drug product manufacturer attached.
	3.2.P.1	Quantity of Amoxicillin trihydrate and Potassium clavulanate is not according to label claim.	It was typographical error made the actual quantity in the formulation. Corrected quantity is attached.
	3.2.P.2.1.2	Compatibility studies with excipients as excipients are different than innovator. Innovator product does not contain preservative while you are adding Sodium benzoate as preservative. Clarification is required.	Not submitted No reply submitted
	3.2.P.2.3	Complete manufacturing method of stability batches is required.	Complete manufacturing method is submitted.
	3.2.P.5.1	Claimed specification is USP while Deliverable volume and • microbial enumeration tests and Tests for specified microorganism not performed mentioned in USP monograph	Testing according to USP monograph submitted.
	3.2.P.5.2	Detailed analytical procedures used for testing	Detailed analytical procedures used for testing the drug product is submitted.

		the drug product shall be provided.	
	3.2.P.5.3	Verification studies of Amoxicillin trihydrate is not in line with USP monograph Assay method. Clarification is required. Verification studies of Clavulanic acid not submitted.	Submitted.
	3.2.P.5.4	The COA of Drug product mentioned Dry Powder injection mentioned. Clarification is required.	Corrected COA of drug product are attached.
	3.2.P.8	In stability summary sheets 6th month mentioned 26-08-2020 while on other months mentioned 2021. Clarification is required. Data of stability batches will be supported by attested respective documents like Raw data sheets, COA, Submit Compatibility studies with diluent	The year was written as 2020 by typing error. The corrected stability data sheets are attached. The supporting chromatograms are attached. Compatibility studies with diluent not submitted.

Previous Decision (M_317): Deferred for following:
Revised label claim without Sio2 with submission of applicable fee.
Compatibility studies with excipients as excipients are different than innovator.
Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.
Compatibility studies with diluent.

Reply by firm		
	Revised label claim without Sio2 with submission of applicable fee.	Revised label claim without SiO2 submitted with submission of fee of Rs: 7500/- Deposit slip # 4942746179 Dated: 17-05-2022
	Compatibility studies with excipients as excipients are different than innovator.	Submitted for Sodium CMC and Aeorsil.
	Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.	After reconstitution of dry powder for Oral suspension, the risk of microbial contamination and subsequent product spoilage is much increased during use y the patient. For these reason, Pharmaceutical suspensions formulations contain antimicrobial preservatives. Preservatives are required in most suspensions because the suspending agents and sweetner are good growth media for microorganism. Sodium benzoate is approved as first of all preservative by the Food and drug administration (FDA) Morever Co-amoxiclav 125/31 Oral Suspension Sugar-Free of Bristol Laboratories Limited approved in MHRA also contain sodium benzoate.
	Compatibility studies with diluent.	Compatibility studies with diluent submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case no. 03 Registration applications for local manufacturing of (veterinary) drugs

a. New Cases

521.	Name and address of manufacturer / Applicant	MYLAB Pvt. Ltd, Khankah Shariff Bahawalpur.
	Brand Name +Dosage Form + Strength	Ibamec Injection
	Composition	Each 100ml Contains: Abamectin…20gm
	Diary No. Date of R& I & fee	Dy.No 40624 dated 06-12-2018 Rs.20,000/- Dated 04-12-2018
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20ml: Decontrolled
	Me-too status	Not found
	GMP status	Panel inspection conducted on 13-09-2018 to 14-09-2018 recommends renewal of DML and grant of additional sections.
	Remarks of the Evaluator [IV]	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. Master formulation and Method of manufacturing not submitted
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

Case no. 04 Registration applications of categories to be considered on priority

a. Local manufacturing applications of priority categories defined by Registration Board in its 257th meeting

522.	Name, address of Applicant / Marketing Authorization Holder	M/s The Schazoo Pharmaceuticals Laboratories (Pvt) Ltd., Seikhupura
	Name, address of Manufacturing site.	M/s Ophth Pharma (Pvt) Ltd. Plot No. 24L,Sector-Z4, Korangi lndustrial Area, Karachi-Pakistan
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 5750 dated 02/03/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 54759534479
	The proposed proprietary name / brand name	Meso-Steride 0.01% Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Dutasteride (Mfg spec).....0.1mg

	Pharmaceutical form of applied drug	Clear, colorless aqueous solution filled in sterile glass vials and packed in unit carton along with Leaflet.
	Pharmacotherapeutic Group of (API)	**5-alpha reductase inhibitors**
	Reference to Finished product specifications	Manufacturer's specification
	Proposed Pack size	8mL
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Not found
	For generic drugs (me-too status)	Not applicable
	GMP status of the Finished product manufacturer	M/s Ophth Pharma: cGMP certificate on the basis of Evaluation conducted 0n 27 -09-2021 and valid for 2 years.

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.5.9	Evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form (injection) in any one of the reference regulatory authority specified by Registration Board in its 275th meeting for further evaluation of application.	

Decision: Deferred for evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form (injection) in any one of the reference regulatory authority specified by Registration Board in its 275th meeting for further evaluation of application.

523.	Name, address of Applicant / Marketing Authorization Holder	M/s Vision Pharmaceuticals (Pvt) Ltd Plot # 22-23, Industrial Triangle, Kahuta Road, Islamabad
	Name, address of Manufacturing site.	M/s Vision Pharmaceuticals (Pvt) Ltd Plot # 22-23, Industrial Triangle, Kahuta Road, Islamabad
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No 29747 dated 20/10/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 5994448166
	The proposed proprietary name / brand name	Ornid 500mg Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3ml Ampoules contains: Ornidazole 500mg
	Pharmaceutical form of applied drug	Parenteral (IV)

	Pharmacotherapeutic Group of (API)	Agents Against Amoebiasis And Other Protozoal Diseases AATC code:P01AB03
	Reference to Finished product specifications	Innovator specifications
	Proposed Pack size	1's, 5's, 10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Tiberal® (Concentrate for the preparation of an infusion solution for iv use) of Swissmedic approved
	For generic drugs (me-too status)	**N/A**
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of Evaluation conducted 0n 11-02-2019 and valid for 3 years.
	Name and address of API manufacturer.	M/s Hunan Jiudian Pharmaceuticals Co., Ltd. Tongguan Circular Economy Industrial Base, Wang Cheng Economic and Technological Development Zone, Hunan, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ornidazole is not present in any Pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (201803A01, 201803A02 & 201803A03)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Tiberal 500mg/3ml Injection of Orpha Swiss GmbH by performing quality tests (Appearance, pH, Liquid particle count, BET, Assay).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity, robustness.
alidation	**STABILITY STUDY DATA**	

Manufacturer of API	M/s Hunan Jiudian Pharmaceuticals Co., Ltd. Tongguan Circular Economy Industrial Base, Wang Cheng Economic and Technological Development Zone, Hunan, China		
API Lot No.	WT201808A03		
Description of Pack (Container closure system)	Type 1 transparent glass ampoule		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	NPD-920 T01	NPD-920 T02	NPD-920 T03
Batch Size	555 Vials	555 Vials	555 Vials
Manufacturing Date	02-2020	02-2020	02-2020
Date of Initiation	14-02-2020	14-02-2020	14-02-2020
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. HN20180310 issued by CFDA valid till 22/05/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice (invoice# JDD2019011802) dated: 18-01-2019 cleared by DRAP Islamabad office dated 08-02-2019 specifying import 1.5Kg Ornidazole (Batch# WT201808A03).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.P.2.1.1	Citric acid is used which not used by Innovator product moreover Compatibility studies also not conducted with citric acid.	Compatibility study with Citric acid is performed and the report is attached
2.	3.2.P.5.3	In AMV Accuracy concentration Recovered mg/ml for 80% is 0.1 while concentration Recovered	It was due to typographical error in reports but the protocol has the correct concentration mentioned. We are providing the protocol and corrected reports as well.

		mg/ml for 100% is 0.08. Clarify how this is possible as for 80%, initial concentration used is 0.08 mg/ml while recovered 0.1mg/ml.	

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

524.	Name, address of Applicant / Marketing Authorization Holder	M/s Tabros Pharma (Pvt) Ltd L-20/B, Sector-22, F.B. Industrial Area Karachi, Pakistan.
	Name, address of Manufacturing site.	M/s Tabros Pharma (Pvt) Ltd L-20/B, Sector-22, F.B. Industrial Area Karachi, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No 29845 dated 21/10/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 070938188707
	The proposed proprietary name / brand name	Nebivol-H Tablet 5/12.5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated Tablet contains: Nebivolol HCl eq to Nebivolol ……..5mg Hydrochlorothiazide…….12.5mg
	Pharmaceutical form of applied drug	Film coated Tablet
	Pharmacotherapeutic Group of (API)	Selective beta-receptor antagonist and Thiazid diuretic
	Reference to Finished product specifications	Manufacturer specification
	Proposed Pack size	1 x 14's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Germany approved **Three European countries Bulgaria, Romania, Hungary** Bulgaria:https://www.bda.bg/images/stories/documents/bdias/N-1.htm Latvia: https://dati.zva.gov.lv/zalu-registrs/?iss=1&q=Nebivololum,%20Hydrochlorothiazidum Hungry: https://ogyei.gov.hu/gyogyszeradatbazis&action=show_details&item=27357 (Marketing authorization holder

		Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare L-1611 Luxembourg Berlin-Chemie AG Glienicker Weg 125, 12489 Berlin, Germany)
	For generic drugs (me-too status)	**N/A**
	GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conducted on 28-02-2020
	Name and address of API manufacturer.	**Nebivolol HCl:** Zhejiang Huahai Pharmaceuticals Co., Ltd Address:Chuannan, Duqiao, Linhai, Zhejiang, China. **Hydrochlorothiazide:** M/s CTX Lifesciences Pvt. Ltd. Address:Block No. 251-252, Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230, Gujarat, INDIA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Nebivolol HCl is not present in any Pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Official monograph of Hydrochlorothiazide is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: **Nebivolol HCl:** Real time: 30°C ± 2°C / 75% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Batch No. D5283-15-002, D5283-15-003 & D5283-15-004) **Hydrochlorothiazide:** Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Batches: (Batch No. HZ111012, HZ111013 & HZ111014) Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Batch No. HZJ131015, HZJ131016 & HZJ131017)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls,

		impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Nebilet Plus Tablet 5/12.5mg of Menarini International Operations Luxembourg S.A by performing quality tests (Appearance, Disintegration time, Dissolution, Assay). CDP has been performed against the same brand that is Nebilet Plus Tablet 5/12.5mg of Menarini International Operations Luxembourg S.A in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, accuracy, precision, specificity, robustness.

STABILITY STUDY DATA			
Manufacturer of API	**Nebivolol HCl:** Zhejiang Huahai Pharmaceuticals Co., Ltd Address:Chuannan, Duqiao, Linhai, Zhejiang, China. **Hydrochlorothiazide:** M/s CTX Lifesciences Pvt. Ltd. Address:Block No. 251-252, Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230, Gujarat, INDIA		
API Lot No.	**Nebivolol HCl:** D5304-20-001 **Hydrochlorothiazide:** 21HZ00051		
Description of Pack (Container closure system)	Alu- Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TR001-1/NVH	TR002-1/NVH	TR003-1/NVH
Batch Size	1500 Tablet	1500 Tablet	1500 Tablet
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	14-02-2022	14-02-2022	14-02-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product Baxib 2.5mg and 5mg (Apixaban) which was conducted on 05-0-2021 and was presented in 297th meeting of Registration Board held on 12-15th January, 2021. According to the report following points were confirmed. • The firm has 21 CFR compliant HPLC software. • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Nebivolol HCl:** Copy of GMP certificate No. ZJ200047 in the name of Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China issued by Zhejiang Medical Product Administration valid till 28-06-2023 is submitted. Copy of DML No#2000031 valid till 12-01-2025 **Hydrochlorothiazide:** Copy of GMP certificate No. 22063346 issued by Food & Drugs Control Administration, Gujrat valid till 29/09/2025.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Nebivolol HCl: Firm has submitted copy of form 3, 5, 7 and invoice (invoice# HH20211623) dated: 03-08-2021 cleared by DRAP Karachi office dated 16-08-2021 specifying import of 5Kg Nebivolol HCl (Batch# D5304-20-001). Hydrochlorothiazide: Firm has submitted copy of form 3, 5, 7 and invoice (invoice# EI/3012100356) dated: 20-08-2021 cleared by DRAP Karachi office dated 02-09-2021 specifying import of 50Kg of Hydrochlorothiazide (Batch# 21HZ00051).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.S.5	Submit COA of reference standard Chlorothiazid and Benzothiazidine related compound A.	COA's of Chlorothiazide, Benzothiazidine and related compound A, reference standards are being attached along with invoice and form 6, by the signature of ADC.
2.	3.2.P.2.1	In composition Crosscarmellose Sodium . two times separately mentioned. Clarification is required.	Since this formulation was developed with wet granulation, At this point, Crosscarmellose sodium (Intra – and extra granularly used), so that the wicking and swelling ability of the disintegrate is best utilized.
3.	3.2.P.5.2	You have applied Paddle speed = 100 rpm in dissolution parameters. You are advised to justify the speed of paddle apparatus with reference to USP general chapter <1092>	• Nebivol-H tablets is not a compendia product. Its dissolution method is also not available in any pharmacopeia as well as in any reference literature, so there was no limitation of any specified fixed RPM, Initially, we have been selected the method of Hydrochlorothiazide tablets as per USP compendia, where 100 rpm given while in basket method, on the other hand we have paddle method. Primarily, we applied the method 75rpm

			on trial batch activity, on 75 rpm we have been found some challenges in dissolution results, in other ingredient that is Nabivolol which was marginally satisfactory, therefore, based on trial batches dissolution results we have been selected 100rpm.. • USP general chapter <1092> also allows 100rpm for paddle apparatus with sufficient justification, i-e, aforementioned text is self-explanatory. • USP also recommends 100rpm with apparatus II in some monographs of tablets.(Ethinyl Estradion tablets., Letrozole tablets, Methenamine Hippurate tablets)
4.	3.2.P.5.3	• In Linearity and Range for Theoretical concentration is in mcg/ml while practical concentration is in mg/ml. • In Linearity and Range for Hydrocholorothiazide concentration on page No# 553 and concentration on page No# 555 are change.	• It is a typographical error in linearity document of analytical test method validation. Corrected copy is being attached. • It is also typographical error in range document. Corrected copy is being attached.

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

525.	Name, address of Applicant / Marketing Authorization Holder	M/s Global Pharmaceuticals (Pvt) Ltd Plot # 204-205, Industrial Triangle, Kahuta Road, Islamabad.
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd Plot # 204-205, Industrial Triangle, Kahuta Road, Islamabad"
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No 13992 dated 09/06/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 997841154329
	The proposed proprietary name / brand name	Merem 2g Injection

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Meropenem trihydrate eq to meropenem……2g (blended with sodium carbonate)
	Pharmaceutical form of applied drug	Sterile powder for Injection
	Pharmacotherapeutic Group of (API)	Carbapenem
	Reference to Finished product specifications	USP Specification
	Proposed Pack size	Glass vial USP type II partially sealed by rubber stopper and fully sealed by flip off seal. Pack Size: 1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MEROPENEM Injection by Venus Pharma Germany approved And MHRA approved
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of evaluation conducted on 03-01-2022
	Name and address of API manufacturer.	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (681909001, 681909002, 681909003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.

	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product Meropenem 2000mg Injection manufactured by Venus Pharma GmBH Germany (Batch No: M34256), by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form).	
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity, robustness.	
STABILITY STUDY DATA			
Manufacturer of API	M/s CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province PR. China.		
API Lot No.	682102003		
Description of Pack (Container closure system)	Type I Glass vial		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	ST21M023	ST21M024	ST21M025
Batch Size	550 Vials	550 Vials	550 Vials
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	05-01-2022	05-01-2022	05-01-2022
No. of Batches	03		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has referred to previous inspection of stability data of the same dosage form on the basis of which Registration Board in 289 meeting of Registration Board decided to approve registration of Promig Plus 500mg/20mg Tablet and Promig Plus 375mg/20mg Tablet. Inspection date: 14th March, 2019 The report shows that: • The HPLC software is 21 CFR compliant. • The firm has provided data loggers with stability chambers.	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. HE20180065) issued by China Food and Drugs Administration dated 17-08-2018. The certificate is valid till 16-08-2023.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Clearance certificate by DRAP Islamabad office dated 11-03-2021 specifying Invoice No # 2021ZN-0008A dated: 24-02-2021, import of 5Kg of Meropenem with Sodium Carbonate Sterile USP (Batch# 2103R0073).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms,	Submitted	

	Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	2.3.A.1	Provide evidence of Atomic absorption spectrometer.	Firm submitted calibration certificate.
2.	3.2.P.2.6	Innovator product does not mentioned ringer lactate as a diluent while you have mentioned with other diluents ringer lactate as a diluent. Clarify.	We have performed compatibility study in recommended diluent as specified by Innovator e.g Water for Injection, o.9% Sodium Chloride and Dextrose 5% but additionally we added Ringer lactate in compatibility study in order to get clear picture of the product in the study
3.	3.2.P.8	Submit stability data for 6th months.	Stability data for 6th months submitted.

Decision: Regsitration Board deferred the application for further deliberation regarding pharmaceutical and clinical fetaures of the innovator product approved by the reference regulatory authorities adopted by Registration Board in its 275th meeting.

526.	Name, address of Applicant / Marketing Authorization Holder	**M/s OPHTH PHARMA (PVT.) LTD.** **Plot No. 241, Sector-24, Korangi Industrial Area, Karachi-Pakistan**
	Name, address of Manufacturing site.	M/s OPHTH PHARMA (PVT.) LTD. Plot No. 241, Sector-24, Korangi Industrial Area, Karachi-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 5750 dated 03/10/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 6692802619
	The proposed proprietary name / brand name	Trop M Plus 5% Sterile Ophthalmic Solution
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Tropicamide ……. 8mg Phenylephrine HCl….50mg.
	Pharmaceutical form of applied drug	Eye Drops
	Pharmacotherapeutic Group of (API)	Cycloplegics / Mydriatic
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	10 ml

	Proposed unit price	Rs. 350
	The status in reference regulatory authorities	**Not found**
	For generic drugs (me-too status)	**Not Applicable**
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of Evaluation conducted 0n 27 -09-2021 and valid for 2 years.

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.5.9	Evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form in any one of the reference regulatory authority specified by Registration Board in its 275th meeting for further evaluation of application.	Diophenyl-T Solution of Canada of Sandoz Canada Incorporated provided by firm but **Status is Cancelled post market.**

Decision: Deferred for evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form in any one of the reference regulatory authority specified by Registration Board in its 275th meeting for further evaluation of application.

527.	Name, address of Applicant / Marketing Authorization Holder	**M/s OPHTH PHARMA (PVT.) LTD.** **Plot No. 241, Sector-24, Korangi Industrial Area, Karachi-Pakistan**
	Name, address of Manufacturing site.	M/s OPHTH PHARMA (PVT.) LTD. Plot No. 241, Sector-24, Korangi Industrial Area, Karachi-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 7346 dated 15/03/2022
	Details of fee submitted	PKR 75,000/-: Deposit slip # 4577578069
	The proposed proprietary name / brand name	PRIMLA (Topical Cream 5%)
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each gram of cream contains: Lidocaine Base USP.....25mg Prilocaine Base USP… 25mg
	Pharmaceutical form of applied drug	Topical Cream
	Pharmacotherapeutic Group of (API)	Local Anesthetics
	Reference to Finished product specifications	USP
	Proposed Pack size	30 gm
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	LIDOCAINE AND PRILOCAINE Cream of M/s Tolmar Inc of USFDA approved
	For generic drugs (me-too status)	**N/A**
	GMP status of the Finished product manufacturer	cGMP certificate on the basis of Evaluation conducted 0n 27 -09-2021 and valid for 2 years. (Section Sterile Eye Ointment/Topical Cream mentioned)
	Name and address of API manufacturer.	**Lidocaine and Prilocaine :** Shandong Chengui Shuangda Pharmaceutical Co., ltd. Address: Economic Development zone, Pingyuan County, Dezhou City, Shandong Province253100, China Shandong Chengui Shuangda Pharmaceutical Co., ltd.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Lidocaine:** Official monograph of Lidocaine is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Prilocaine :** Official monograph of Prilocaine is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubility's,, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Lidocaine:** Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (17050301, 17061502, 17062203) **Prilocaine :** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (16091101, 16091702, 16092303)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and

		justification of specification, reference standard, container closure system and stability studies of drug product.	
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Emla Topical cream by performing quality tests (Appearance, Identification, pH, Fill volume Drug Release).	
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity, robustness.	
STABILITY STUDY DATA			
Manufacturer of API	**Lidocaine and Prilocaine :** Shandong Chengui Shuangda Pharmaceutical Co., ltd. Address: Economic Development zone, Pingyuan County, Dezhou City, Shandong Province253100, China Shandong Chengui Shuangda Pharmaceutical Co., ltd.		
API Lot No.	**Lidocaine:** 21081605 **Prilocaine :** 21091206		
Description of Pack (Container closure system)	Aluminium Tube		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 24 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	**TB-101**	**TB-102**	**TB-103**
Batch Size	3Kg (100 Tubes)	3Kg (100 Tubes)	3Kg (100 Tubes)
Manufacturing Date	01-2019	01-2019	01-2019
Date of Initiation			
No. of Batches	03		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted	
6.	Record of Digital data logger for temperature and humidity monitoring of	Submitted	

	stability chambers (real time and accelerated)	

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated
1.	1.6.5	Valid Drug Manufacturing License or Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance manufacturer issued by the relevant regulatory authority of country of origin.
2.	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3
3.	3.2.S.4.2	Copies of the Drug substance specifications and analytical procedures used for routine testing of the both Drug substance /Active Pharmaceutical Ingredient (Lidocaine and Prilocaine) by Drug Product manufacturer is required.
4.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance (Lidocaine and Prilocaine) shall be submitted.
5.	3.2.P.2.2.1	• Details , origin and procurement documents of product against which Pharmaceutical equivalence is established. • Assay was not conducted of both test product and reference product in Pharmaceutical equivalence. Clarification is required. • Provide reference of Drug release performed in Pharmaceutical equivalence.
6.	3.2.P.3.5	A brief description of process validation including the proposed protocol shall be Submitted.
7.	3.2.P.5.1	Microbial Enumeration tests and test for specified organism is not included in specification however USP monograph include these tests.
8.	3.2.P.8	• Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin Documents for the procurement of API with approval from DRAP. • Date of Initiation of stability study. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

b. Export facilitation

Export Facilitation: Applications was received through letter No.F.1-76/2019-PR-I (EFD)
"M/s Getz Pharma, Karachi have achieved benchmark OF USD 1123,074.35 as defined in the Board's decision during fiscal year 2021-2022. In this regard, please find the (1 molecule) 02 products applications submitted by the firm."

528.	Name and address of manufacturer / Applicant	Getz Pharma (Pvt.) Ltd., 29-30, Sector-27, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	VORTIGET Tablet 10 mg
	Composition	Each Film Coated Tablet Contains; Vortioxetine Hydrobromide eq. to Vortioxetine…10 mg
	Diary No. Date of R& I & fee	Dy. No 12727 dated 06-03-2019; Rs.50,000/- dated 05-03-2019.
	Pharmacological Group	Antidepressant
	Type of Form	Form 5D
	Finished product Specifications	Manufacturers specifications
	Pack size & Demanded Price	14's Rs: 1250 & 28s Rs:2500

	Approval status of product in Reference Regulator Authorities	USFDA Approved
	Me-too status	BRINTELLIX Tablets 10mg imported and marketed by M/s Lundbeck Pakistan (Pvt.) Ltd., Karachi. (Reg. No. 087080)
	GMP status	Last GMP certificate is issued on 24-02-2019 based on inspection conducted on 07-01-2019 valid for 3 years.
	Remarks of the Evaluator.	• Stability study data as per the guidelines approved in 293rd meeting of Registration Board. • GMP certificate/inspection conducted within last 3 years.
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-321)**	

STABILITY STUDY DATA			
Drug	VORTIGET Tablet 10 mg		
Name of Manufacturer	Getz Pharma (Pvt.) Ltd., 29-30, Sector-27, Korangi Industrial Area, Karachi.		
Manufacturer of API	M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou city, Zhejiang China.		
API Lot No.	20200601		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet.		
Stability Storage Condition	Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6 (months)		
Batch No.	567DS01	567DS01	567DS01
Batch Size	2,500 tablets	2,500 tablets	2,500 tablets
Manufacturing Date	24-12-2020	24-12-2020	24-12-2020
Date of Initiation	14-01-2021	14-01-2021	14-01-2021
No. of Batches	03		
Date of Submission	02-11-2021(29856)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**
15.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: • The HPLC software is 21CFR Compliant as per record available with the firm. • Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.

<table>
<tr><td></td><td></td><td>• Related manufacturing area, equipment, personnel and utilities are GMP compliant.</td></tr>
<tr><td>16.</td><td>Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.</td><td>Copies of COAs (Batch#20200601) of API from M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou City, Zhejiang China and M/s Getz Pharma (Pvt.) Limited Karachi are submitted.</td></tr>
<tr><td>17.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm</td></tr>
<tr><td>18.</td><td>Stability study data of API from API manufacturer</td><td>The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 12 Months (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches.
Batches: (20200501, 20200502, 20200503)</td></tr>
<tr><td>19.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>The firm has submitted copy of GMP certificate (ZJ20190027) of M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou City, Zhejiang China issued on dated 22-02-2019 by China Food and Drug Administration valid till 21-02-2024.</td></tr>
<tr><td>20.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of form 3, Form 7 and Commercial Invoice No:20BNGZ Dated: 30-10-2020 from M/s Zhejiang Lepu Pharmaceutical Co., Ltd. attested by AD DRAP (Karachi) dated ; 12-11-2020 for Vortioxetine Hydrobromide batch No# # 20200601</td></tr>
<tr><td>21.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>22.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>23.</td><td>Drug-excipients compatibility studies</td><td>Firm has submitted that same excipients has been used as used by innovator ‘BRINTELLIX 10mg Tablets’. However, there is only difference in film coating materials Therefore, Drug-excipients compatibility studies were not performed.</td></tr>
<tr><td>24.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">VORTIGET Tablet 10 mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>567DS01</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
<tr><td>567DS02</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
<tr><td>567DS03</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
</table></td></tr>
<tr><td>25.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Innovator’s Brand “Brintellix ”.
The details are as follows:
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr>
<tr><td>Brand name</td><td>Vortiget Tablet 10mg</td><td>BRINTELLIX 10mg Tablets</td></tr>
</table></td></tr>
</table>

		<table><tr><td>Batch No.</td><td>567DS01</td><td>2631816</td></tr></table> ● Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer
26.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
27.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
28.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator

There was a typographical error in fee mentioned in agenda in RB-321 that is Rs: 50000/- It was actually Rs: 20000/- of Challan No 0828775 dated:05-03-2019. Now firm submitted differential fee of Rs: 10000/- Deposit slip # 16642980656 Dated: 30-12-2022

S.NO	Shortcomings communicated	Reply
1.	Which polymorphic form of Vortioxetine Hydrobromide is used in stability batches as polymorphic confirmation is not done by both Drug substance manufacturer and drug product manufacturer.	This is to inform you that Vortioxetine appears in four polymorphs and the most thermodynamically stable polymorphic form is β-Form. The same polymorphic form of Vortioxetine is used in manufacturing of innovator's product "BRINTELLIX Tablets 10mg". Please Refer to for extract of Australian Public Assessment Report for Vortioxetine hydrobromide. Further, our drug substance manufacturer that is Zhejiang Lepu Pharmaceutical Co., Ltd china has confirmed that polymorphic form of Vortioxetine produced by Zhejiang Lepu Pharmaceutical Co., Ltd is β-Form. Please Refer documents provided by Zhejiang Lepu Pharmaceutical Co., Ltd for the confirmation of polymorphic form.
2.	Submit details of product against which CDP was conducted.	This is to inform you that we have conducted CDP of Vortiget tablet 10mg against innovator product BRINTELLIX Tablets 10mg. Details are as follows: Batch No.: 2631816 Mfg. Date: 08.2019 Exp. Date: 02-2022 Manufactured by: H. Lundbeck Denmark.
3.	Submit CDP data in detail.	Firm submitted CDP of Vortiget tablet 10mg Batch No # 567DS01 against innovator product BRINTELLIX Tablets 10mg Batch No# 2631816.

		Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

529.	Name and address of manufacturer / Applicant	Getz Pharma (Pvt.) Ltd., 29-30, Sector-27, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	VORTIGET Tablet 20 mg
	Composition	Each Film Coated Tablet Contains; Vortioxetine Hydrobromide eq. to Vortioxetine…20 mg
	Diary No. Date of R& I & fee	Dy. No 12729 dated 06-03-2019; Rs.50,000/- dated 05-03-2019.
	Pharmacological Group	Antidepressant
	Type of Form	Form 5D
	Finished product Specifications	Manufacturers specifications
	Pack size & Demanded Price	14's Rs: 1250 & 28s Rs:2500
	Approval status of product in Reference Regulator Authorities	USFDA Approved
	Me-too status	BRINTELLIX Tablets 20mg imported and marketed by M/s Lundbeck Pakistan (Pvt.) Ltd., Karachi. (Reg. No. 087081)
	GMP status	Last GMP certificate is issued on 24-02-2019 based on inspection conducted on 07-01-2019 valid for 3 years.
	Remarks of the Evaluator.	• Stability study data as per the guidelines approved in 293rd meeting of Registration Board. • GMP certificate/inspection conducted within last 3 years.
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-321)**	

STABILITY STUDY DATA

Drug	VORTIGET Tablet 20 mg
Name of Manufacturer	Getz Pharma (Pvt.) Ltd., 29-30, Sector-27, Korangi Industrial Area, Karachi.
Manufacturer of API	M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou city, Zhejiang China.
API Lot No.	20200601
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet.
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%
Time Period	Real time: 6 months

	Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6 (months)		
Batch No.	568DS01	568DS02	568DS03
Batch Size	2,500 tablets	2,500 tablets	2,500 tablets
Manufacturing Date	24-12-2020	24-12-2020	24-12-2020
Date of Initiation	14-01-2021	14-01-2021	14-01-2021
No. of Batches	03		
Date of Submission	02-11-2021(29855)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: • The HPLC software is 21CFR Compliant as per record available with the firm. • Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well. • Related manufacturing area, equipment, personnel and utilities are GMP compliant.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copies of COAs (Batch#20200601) of API from M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou City, Zhejiang China and M/s Getz Pharma (Pvt.) Limited Karachi are submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm
4.	Stability study data of API from API manufacturer	The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 12 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (20200501, 20200502, 20200503)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate (ZJ20190027) of M/s Zhejiang Lepu Pharmaceutical Co., Ltd. No. 29, Binhai Road, Jiaojiang District, Taizhou City, Zhejiang China issued on dated 22-02-2019 by China Food and Drug Administration valid till 21-02-2024.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of form 3, Form 7 and Commercial Invoice No:20BNGZ Dated: 30-10-2020 from M/s Zhejiang Lepu Pharmaceutical Co., Ltd. attested by AD DRAP (Karachi) dated ; 12-11-2020 for Vortioxetine Hydrobromide batch No# # 20200601
7.	Protocols followed for conduction of stability study	Yes
8.	Method used for analysis of FPP	Yes

<table>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td>Firm has submitted that same excipients has been used as used by innovator ‘BRINTELLIX 20mg Tablets’. However, there is only difference in film coating materials Therefore, Drug-excipients compatibility studies were not performed.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">VORTIGET Tablet 20 mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>568DS01</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
<tr><td>568DS02</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
<tr><td>568DS03</td><td>2,500 tablets</td><td>24-12-2020</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Innovator’s Brand “Brintellix ”.
The details are as follows:
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr>
<tr><td>Brand name</td><td>Vortiget Tablet 20mg</td><td>BRINTELLIX 20mg Tablets</td></tr>
<tr><td>Batch No.</td><td>568DS01</td><td>2633476</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
pH 1.2 HCl buffer
pH 4.5 Acetate buffer
pH 6.8 Phosphate buffer</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
<tr><td colspan="3">Remarks of Evaluator</td></tr>
<tr><td colspan="3">There was a typographical error in fee mentioned in agenda in RB-321 that is Rs: 50000/- It was actually Rs: 20000/- of Challan No 0828771 dated:05-03-2019. Now firm submitted differential fee of Rs: 10000/- Deposit slip # 572250429168 Dated: 30-12-2022</td></tr>
<tr><td colspan="3">
<table>
<tr><td>S.NO</td><td>Shortcomings communicated</td><td>Reply</td></tr>
<tr><td>1.</td><td>Which polymorphic form of Vortioxetine Hydrobromide is used in stability batches as polymorphic confirmation is not done by both Drug</td><td>This is to inform you that Vortioxetine appears in four polymorphs and the most thermodynamically stable polymorphic form is β-Form. The same polymorphic</td></tr>
</table>
</td></tr>
</table>

	substance manufacturer and drug product manufacturer.	form of Vortioxetine is used in manufacturing of innovator's product "BRINTELLIX Tablets 10mg". Please Refer to for extract of Australian Public Assessment Report for Vortioxetine hydrobromide. Further, our drug substance manufacturer that is Zhejiang Lepu Pharmaceutical Co., Ltd china has confirmed that polymorphic form of Vortioxetine produced by Zhejiang Lepu Pharmaceutical Co., Ltd is β-Form. Please Refer documents provided by Zhejiang Lepu Pharmaceutical Co., Ltd for the confirmation of polymorphic form.
2.	Submit details of product against which CDP was conducted.	This is to inform you that we have conducted CDP of Vortiget tablet 10mg against innovator product BRINTELLIX Tablets 10mg. Details are as follows: Batch No.: 2633476 Mfg. Date: 08.2019 Exp. Date: 02-2022 Manufactured by: H. Lundbeck Denmark.
3.	Submit CDP data in detail.	Firm submitted CDP of Vortiget tablet 20mg Batch No # 568DS01 against innovator product BRINTELLIX Tablets 20mg Batch No# 2633476. Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

Export Facilitation: Applications was received through letter No.F.1-76/2019-PR-I (EFD)
"M/s Seraph Pharmaceuticals, Islamabad have achieved benchmark OF USD 548,766 as defined in the Board's decision during fiscal year 2021-2022. In this regard, please find the (1 molecule) 05 products applications submitted by the firm."

530.	Name and address of manufacturer / Applicant	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	**Emphomet Tablet 5/850mg**
	Composition	Each Film Coated Tablet Contains: Empagliflozin…5mg Metformin Hcl…850mg
	Diary No. Date of R& I & fee	Dy.No. 11260 dated 05-03-2019 Rs.20,000/- Dated 01-03-2019
	Pharmacological Group	Anti-Diabetic Drug, Sodium-Glucose Co-Transporter2 (SGLT2) Inhibitor
	Type of Form	Form-5

	Finished product Specifications	Manufacturer's specification
	Pack size & Demanded Price	7's, 10's, 14's, 28's, 30's, 60's, 100's: As per SRO
	Approval status of product in Reference Regulator Authorities	Synjardy Tablets 5 mg/850 mg of EMA approved
	Me-too status	Diampa-M Tablets 5mg + 850mg, of M/s Getz Pharma
	GMP status	GMP certificate issued on 03-07-2018."
	Remarks of the Evaluator.	Submit Stability studies with requisite documents
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-296)**	

STABILITY STUDY DATA			
Drug	Emphomet Tablet 5/850mg		
Name of Manufacturer	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad		
Manufacturer of API	**Empagliflozin:** HuaiNan Shunglong Pharmaceutical co. Ltd. Address: No. 9th YongXing Road, Huaninan economic and Technological Development zone, Huaninan City, China **Metformin**: Aarti Drugs Limited (Unit-II) Plot No. 211&213, Road-2, G.I.D.C. At & Post: Sarigam, Dist: Valsad, Gujarat State, India.		
API Lot No.	**Empagliflozin:** 20201201 **Metformin HCl :** MEF/19071360		
Description of Pack (Container closure system)	Alu-Alu blister foil with unit carton		
Stability Storage Condition	Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6, 9, 12 (months)		
Batch No.	T 001	T 002	T 003
Batch Size	730 Tablets	730 Tablets	730 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	05 – 06 -2021	05 – 06 -2021	05 – 06 -2021
No. of Batches	03		
Date of Submission	13-06-2022(14275)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for **Neovel (Sevelamer Carbonate) tablets 800mg** on 27th December, 2018. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th February 2019. The case was approved and the inspection report confirms following points: • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.

2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Empagliflozin:** Copies of COAs (Batch#20201201) of API from M/s HuaiNan Shunglong Pharmaceutical co. Ltd. are submitted. Copies of COAs (Batch#20201201) of API from M/s M/s Seraph Pharmaceuticals are not submitted. **Metformin HCl** : Copies of COAs (Batch# MEF/19071360) of API from Aarti Drugs Limited (Unit-II) are submitted. Copies of COAs (Batch# MEF/19071360) of API from M/s Seraph Pharmaceuticals are not submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm
4.	Stability study data of API from API manufacturer	**Empagliflozin:** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 18 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (20190101, 20190102, 20190103) **Metformin HCl :** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 60 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (MET/10040109, MET/10040110, MET/10040111)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:**Firm has submitted copy of DML certificate (Anhui 20160342) issued by Anhui Food and Drug Administration, China. The certificate is valid till 31-12-2025. **Metformin HCl:** Firm has submitted copy of GMP certificate (20031933) issued by Food & Drugs Control Adminstration, Block No. 8, 1st floor, dr. Jivraj Mehta Bhavan, Gandhinagar, Gujarat state, India – Pin 382010. Valid till 19-03-2023
6.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Copy of Clearance certificate and Commercial Invoice No:CF20210208 Dated: 08-02-2021 from M/s Hefei Corn Field Biotechnology Co., Ltd. attested by AD DRAP (Islamabad) dated ; 02-04-2021 for Empagliflozin batch No# # 20201201 **Metformin HCl:** Copy of Clearance certificate and Commercial Invoice No:EXP/1968/19-20 Dated: 12-11-2019 from M/s Aari drugs Limited, Mahendra Industrail Estate, GR Floor India.. attested by AD DRAP (Islamabad) dated ; 04-02-2019 for Metformin HCl batch No# # MEF/19071360
7.	Protocols followed for conduction of stability study	Yes
8.	Method used for analysis of FPP	Yes
9.	Drug-excipients compatibility studies	Drug-excipients compatibility studies submitted

<table>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:<table><tr><td colspan="3">Emphomet Tablet 5/850mg</td></tr><tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr><tr><td>T001</td><td>730 tablets</td><td>25-05-2021</td></tr><tr><td>T002</td><td>730 tablets</td><td>25-05-2021</td></tr><tr><td>T003</td><td>730 tablets</td><td>25-05-2021</td></tr></table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Diampa-M 5/850mg of “Getz Pharma”
The details are as follows:<table><tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr><tr><td>Brand name</td><td>Emphomet Tablet 5/850mg</td><td>Diampa-M 5/850mg</td></tr><tr><td>Batch No.</td><td>T001</td><td>001FD7</td></tr></table>● Comparative dissolution studies have been performed in following mediums:
1. pH 1.2 HCl buffer
2. pH 4.5 Acetate buffer
3. pH 6.8 Phosphate buffer</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
<tr><td colspan="3">Remarks of Evaluator</td></tr>
<tr><td colspan="3"><table><tr><td>S.No</td><td>Shortcomings communicated</td><td>Reply</td></tr><tr><td>1.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer submitted.</td></tr><tr><td>2.</td><td>Stability study data of API (Metformin) from API manufacturer.</td><td>Stability study data of API (Metformin) from API manufacturer submitted.</td></tr><tr><td>3.</td><td>Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin.</td><td>Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin submitted.</td></tr><tr><td>4.</td><td>Drug-excipients compatibility studies.</td><td>Drug-excipients compatibility studies submitted.</td></tr></table></td></tr>
</table>

5.	Method for dissolution testing not submitted.	Firm Initally submitted dissolution testing where medium used is 0.1N HCl and time for Q :45 minutes *while Innovator product used medium Phosphate buffer pH 6.8 and time for Q: 20 minutes.* Firm submitted revised specifications with used medium Phosphate buffer pH 6.8 and time for Q: 30 minutes and also submitted one time dissolution testing according to new specifications.
6.	You have not performed uniformity of dosage unit by content uniformity, as recommended by USP General Chapter <905> throughout stability studies. Justification shall be submitted in this regard.	Submitted
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

531.	Name and address of manufacturer / Applicant	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Emphomet Tablet 5/1000mg
	Composition	Each Film Coated Tablet Contains: Empagliflozin…5mg Metformin Hcl…1000mg
	Diary No. Date of R& I & fee	Dy.No. 11261 dated 05-03-2019 Rs.20,000/- Dated 01-03-2019
	Pharmacological Group	Anti-Diabetic Drug, Sodium-Glucose Co-Transporter2 (SGLT2) Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specification
	Pack size & Demanded Price	7's, 10's, 14's, 28's, 30's, 60's, 100's: As per SRO
	Approval status of product in Reference Regulator Authorities	Synjardy Tablets 5 mg/1000 mg by Boehringer Ingelheim Pharmaceuticals, USFDA
	Me-too status	Diampa-M Tablets 5mg + 1000mg of M/s Getz Pharma, Karachi, Pakistan.
	GMP status	GMP certificate issued on 03-07-2018."
	Remarks of the Evaluator.	Submit Stability studies with requisite documents
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-296)**	

STABILITY STUDY DATA

Drug	Emphomet Tablet 5/1000mg
Name of Manufacturer	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
Manufacturer of API	**Empagliflozin:** HuaiNan Shunglong Pharmaceutical co. Ltd.

	Address: No. 9th YongXing Road, Huaninan economic and Technological Development zone, Huaninan City, China **Metformin**: Aarti Drugs Limited (Unit-II) Plot No. 211&213, Road-2, Gidc. At & Post: Sarigam, Dist: Valsad, Gujarat State, India.		
API Lot No.	**Empagliflozin:** 20201201 **Metformin HCl :** MEF/19071360		
Description of Pack (Container closure system)	Alu-Alu blister foil with unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6, 9, 12 (months)		
Batch No.	T 001	T 002	T 003
Batch Size	730 Tablets	730 Tablets	730 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	05 – 06 -2021	05 – 06 -2021	05 – 06 -2021
No. of Batches	03		
Date of Submission	13-06-2022(14276)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for **Neovel (Sevelamer Carbonate) tablets 800mg** on 27th December, 2018. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th February 2019. The case was approved and the inspection report confirms following points: • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Empagliflozin:** Copies of COAs (Batch#20201201) of API from M/s HuaiNan Shunglong Pharmaceutical co. Ltd. are submitted. Copies of COAs (Batch#20201201) of API from M/s M/s Seraph Pharmaceuticals are not submitted. **Metformin HCl** : Copies of COAs (Batch# MEF/19071360) of API from Aarti Drugs Limited (Unit-II) are submitted. Copies of COAs (Batch# MEF/19071360) of API from M/s Seraph Pharmaceuticals are not submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm
4.	Stability study data of API from API manufacturer	**Empagliflozin:** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 18 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches.

<table>
<tr><td></td><td></td><td>Batches: (20190101, 20190102, 20190103)
Metformin HCl : The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 60 Months (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches.
Batches: (MET/10040109, MET/10040110, MET/10040111)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Empagliflozin:Firm has submitted copy of DML certificate (Anhui 20160342) issued by Anhui Food and Drug Administration, China. The certificate is valid till 31-12-2025.
Metformin HCl: Firm has submitted copy of GMP certificate (20031933) issued by Food & Drugs Control Adminstration, Block No. 8, 1st floor, dr. Jivraj Mehta Bhavan, Gandhinagar, Gujarat state, India – Pin 382010. Valid till 19-03-2023</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Empagliflozin: Copy of Clearance certificate and Commercial Invoice No:CF20210208 Dated: 08-02-2021 from M/s Hefei Corn Field Biotechnology Co., Ltd. attested by AD DRAP (Islamabad) dated ; 02-04-2021 for Empagliflozin batch No# # 20201201
Metformin HCl: Copy of Clearance certificate and Commercial Invoice No:EXP/1968/19-20 Dated: 12-11-2019 from M/s Aari drugs Limited, Mahendra Industrail Estate, GR Floor India.. attested by AD DRAP (Islamabad) dated ; 04-02-2019 for Metformin HCl batch No# # MEF/19071360</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td>Drug-excipients compatibility studies submitted</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Emphomet Tablet 5/1000mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>T001</td><td>730 tablets</td><td>28-05-2021</td></tr>
<tr><td>T002</td><td>730 tablets</td><td>28-05-2021</td></tr>
<tr><td>T003</td><td>730 tablets</td><td>28-05-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Diampa-M 5/1000mg of “Getz Pharma”
The details are as follows:
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr>
<tr><td>Brand name</td><td>Emphomet Tablet 5/1000mg</td><td>Diampa-M 5/1000mg</td></tr>
<tr><td>Batch No.</td><td>T001</td><td>001FD7</td></tr>
</table></td></tr>
</table>

		● Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator

S.No	Shortcomings communicated	Reply
1.	Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer.	Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer submitted.
2.	Stability study data of API (Metformin) from API manufacturer.	Stability study data of API (Metformin) from API manufacturer submitted.
3.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin submitted.
4.	Drug-excipients compatibility studies.	Drug-excipients compatibility studies submitted.
5.	Method for dissolution testing not submitted.	Firm Initally submitted dissolution testing where medium used is 0.1N HCl and time for Q :45 minutes *while Innovator product used medium Phosphate buffer pH 6.8 and time for Q: 20 minutes.* Firm submitted revised specifications with used medium Phosphate buffer pH 6.8 and time for Q: 30 minutes and also submitted one time dissolution testing according to new specifications.
6.	You have not performed uniformity of dosage unit by content uniformity, as recommended by USP General Chapter <905> throughout stability studies. Justification shall be submitted in this regard.	Submitted
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

532.	Name and address of manufacturer / Applicant	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Emphomet Tablet 12.5/500mg
	Composition	Each Film Coated Tablet Contains: Empagliflozin…12.5mg Metformin Hcl…500mg
	Diary No. Date of R& I & fee	Dy.No. 11262 dated 05-03-2019 Rs.20,000/- Dated 01-03-2019
	Pharmacological Group	Anti-Diabetic Drug, Sodium-Glucose Co-Transporter2 (SGLT2) Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specification
	Pack size & Demanded Price	7's, 10's, 14's, 28's, 30's, 60's, 100's: As per SRO
	Approval status of product in Reference Regulator Authorities	Synjardy Tablets 12.5 mg/500 mg by Boehringer Ingelheim Pharmaceuticals, USFDA
	Me-too status	Diampa-M Tablets 12.5mg + 500mg of M/S Getz Pharma, Karachi, Pakistan
	GMP status	GMP certificate issued on 03-07-2018."
	Remarks of the Evaluator.	Submit Stability studies with requisite documents
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-296)**	

STABILITY STUDY DATA			
Drug	Emphomet Tablet 12.5/500mg		
Name of Manufacturer	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad		
Manufacturer of API	**Empagliflozin:** HuaiNan Shunglong Pharmaceutical co. Ltd. Address: No. 9th YongXing Road, Huaninan economic and Technological Development zone, Huaninan City, China **Metformin**: Aarti Drugs Limited (Unit-II) Plot No. 211&213, Road-2, Gidc. At & Post: Sarigam, Dist: Valsad, Gujarat State, India.		
API Lot No.	**Empagliflozin:** 20210204 **Metformin HCl :** MEF/19071360		
Description of Pack (Container closure system)	Alu-Alu blister foil with unit carton		
Stability Storage Condition	Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6, 9, 12 (months)		
Batch No.	T 001	T 002	T 003
Batch Size	730 Tablets	730 Tablets	730 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	05 – 06 -2021	05 – 06 -2021	05 – 06 -2021
No. of Batches	03		

Date of Submission	13-06-2022(14277)	
DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for **Neovel (Sevelamer Carbonate) tablets 800mg** on 27th December, 2018. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th February 2019. The case was approved and the inspection report confirms following points: • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Empagliflozin:** Copies of COAs (Batch#20210204) of API from M/s HuaiNan Shunglong Pharmaceutical co. Ltd. are submitted. Copies of COAs (Batch#20210204) of API from M/s M/s Seraph Pharmaceuticals are not submitted. **Metformin HCl** : Copies of COAs (Batch# MEF/19071360) of API from Aarti Drugs Limited (Unit-II) are submitted. Copies of COAs (Batch# MEF/19071360) of API from M/s Seraph Pharmaceuticals are not submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm
4.	Stability study data of API from API manufacturer	**Empagliflozin:** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 18 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (20190101, 20190102, 20190103) **Metformin HCl :** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 60 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (MET/10040109, MET/10040110, MET/10040111)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:**Firm has submitted copy of DML certificate (Anhui 20160342) issued by Anhui Food and Drug Administration, China. The certificate is valid till 31-12-2025. **Metformin HCl:** Firm has submitted copy of GMP certificate (20031933) issued by Food & Drugs Control Adminstration, Block No. 8, 1st floor, dr. Jivraj Mehta Bhavan, Gandhinagar, Gujarat state, India – Pin 382010. Valid till 19-03-2023
6.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Copy of Clearance certificate and Commercial Invoice No:CF20210329 Dated: 29-03-2021 from M/s Hefei Corn Field Biotechnology Co., Ltd. attested by AD DRAP (Islamabad) dated ; 27-05-2021 for Empagliflozin batch No# # 20210204 **Metformin HCl:** Copy of Clearance certificate and Commercial Invoice No:EXP/1968/19-20 Dated: 12-11-2019 from M/s Aari drugs Limited, Mahendra Industrail Estate, GR Floor India.. attested by AD DRAP

<table>
<tr><td></td><td></td><td>(Islamabad) dated ; 04-02-2019 for Metformin HCl batch No# # MEF/19071360</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td>Drug-excipients compatibility studies not submitted</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Emphomet Tablet 12.5/500mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>T001</td><td>730 tablets</td><td>29-05-2021</td></tr>
<tr><td>T002</td><td>730 tablets</td><td>29-05-2021</td></tr>
<tr><td>T003</td><td>730 tablets</td><td>29-05-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Diampa-M 12.5/500mg of “Getz Pharma”
The details are as follows:
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr>
<tr><td>Brand name</td><td>Emphomet Tablet 12.5/500mg</td><td>Diampa-M 12.5/500mg</td></tr>
<tr><td>Batch No.</td><td>T001</td><td>001FE9</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
pH 1.2 HCl buffer
pH 4.5 Acetate buffer
pH 6.8 Phosphate buffer</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
<tr><td colspan="3">Remarks of Evaluator</td></tr>
<tr><td colspan="3">
<table>
<tr><td>S.No</td><td>Shortcomings communicated</td><td>Reply</td></tr>
<tr><td>1.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer submitted.</td></tr>
</table>
</td></tr>
</table>

2.	Stability study data of API (Metformin) from API manufacturer.	Stability study data of API (Metformin) from API manufacturer submitted.
3.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin submitted.
4.	Drug-excipients compatibility studies.	Drug-excipients compatibility studies submitted.
5.	Method for dissolution testing not submitted.	Firm Initally submitted dissolution testing where medium used is 0.1N HCl and time for Q :45 minutes *while Innovator product used medium Phosphate buffer pH 6.8 and time for Q: 20 minutes.* Firm submitted revised specifications with used medium Phosphate buffer pH 6.8 and time for Q: 30 minutes and also submitted one time dissolution testing according to new specifications.
6.	You have not performed uniformity of dosage unit by content uniformity, as recommended by USP General Chapter <905> throughout stability studies. Justification shall be submitted in this regard.	Submitted
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

533.	Name and address of manufacturer / Applicant	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Emphomet Tablet 12.5/850mg
	Composition	Each Film Coated Tablet Contains: Empagliflozin…12.5mg Metformin HCl…850mg
	Diary No. Date of R& I & fee	Dy.No. 11263 dated 05-03-2019; Rs.20,000/- dated 01-03-2019
	Pharmacological Group	Anti-Diabetic Drug, Sodium-Glucose Co-Transporter2 (SGLT2) Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Innovator's specifications.
	Pack size & Demanded Price	7's, 10's, 14's, 28's, 30's, 60's, 100's: As per SRO
	Approval status of product in Reference Regulator Authorities	Synjardy 12.5 mg/850 mg film-coated tablets, MHRA approved.
	Me-too status	Adrance -M Tablets 12.5mg/850mg, Atco Laboratories, Reg. No. 095147.
	GMP status	GMP certificate issued on 21-07-2019 on the basis of inspection conducted on 11-07-2019
	Remarks of the Evaluator.	Submit Stability studies with requisite documents

	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-312)**		
STABILITY STUDY DATA			
Drug	Emphomet Tablet 12.5/850mg		
Name of Manufacturer	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad		
Manufacturer of API	**Empagliflozin:** HuaiNan Shunglong Pharmaceutical co. Ltd. Address: No. 9th YongXing Road, Huaninan economic and Technological Development zone, Huaninan City, China **Metformin**: Aarti Drugs Limited (Unit-II) Plot No. 211&213, Road-2, Gidc. At & Post: Sarigam, Dist: Valsad, Gujarat State, India.		
API Lot No.	**Empagliflozin:** 20210204 **Metformin HCl :** MEF/19071360		
Description of Pack (Container closure system)	Alu-Alu blister foil with unit carton		
Stability Storage Condition	Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6, 9, 12 (months)		
Batch No.	T 001	T 002	T 003
Batch Size	730 Tablets	730 Tablets	730 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	05 – 06 -2021	05 – 06 -2021	05 – 06 -2021
No. of Batches	03		
Date of Submission	13-06-2022(14278)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for **Neovel (Sevelamer Carbonate) tablets 800mg** on 27th December, 2018. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th February 2019. The case was approved and the inspection report confirms following points: • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Empagliflozin:** Copies of COAs (Batch#20210204) of API from M/s HuaiNan Shunglong Pharmaceutical co. Ltd. are submitted. Copies of COAs (Batch#20210204) of API from M/s M/s Seraph Pharmaceuticals are not submitted. **Metformin HCl** : Copies of COAs (Batch# MEF/19071360) of API from Aarti Drugs Limited (Unit-II) are submitted.

<table>
<tr><td></td><td></td><td>Copies of COAs (Batch# MEF/19071360) of API from M/s Seraph Pharmaceuticals are not submitted.</td></tr>
<tr><td>3.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm</td></tr>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td>Empagliflozin: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 18 Months (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches.
Batches: (20190101, 20190102, 20190103)
Metformin HCl : The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 60 Months (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches.
Batches: (MET/10040109, MET/10040110, MET/10040111)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Empagliflozin:Firm has submitted copy of DML certificate (Anhui 20160342) issued by Anhui Food and Drug Administration, China. The certificate is valid till 31-12-2025.
Metformin HCl: Firm has submitted copy of GMP certificate (20031933) issued by Food & Drugs Control Adminstration, Block No. 8, 1st floor, dr. Jivraj Mehta Bhavan, Gandhinagar, Gujarat state, India – Pin 382010. Valid till 19-03-2023</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Empagliflozin: Copy of Clearance certificate and Commercial Invoice No:CF20210329 Dated: 29-03-2021 from M/s Hefei Corn Field Biotechnology Co., Ltd. attested by AD DRAP (Islamabad) dated ; 27-05-2021 for Empagliflozin batch No# # 20210204
Metformin HCl: Copy of Clearance certificate and Commercial Invoice No:EXP/1968/19-20 Dated: 12-11-2019 from M/s Aari drugs Limited, Mahendra Industrail Estate, GR Floor India.. attested by AD DRAP (Islamabad) dated ; 04-02-2019 for Metformin HCl batch No# # MEF/19071360</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td>Drug-excipients compatibility studies not submitted</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Emphomet Tablet 12.5/850mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>T001</td><td>730 tablets</td><td>30-05-2021</td></tr>
<tr><td>T002</td><td>730 tablets</td><td>30-05-2021</td></tr>
<tr><td>T003</td><td>730 tablets</td><td>30-05-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Diampa-M 12.5/850mg of “Getz Pharma”
The details are as follows:</td></tr>
</table>

<table>
<tr><td></td><td></td><td>
<table>
<tr><th>Feature</th><th>Reference product</th><th>Product of Getz</th></tr>
<tr><td>Brand name</td><td>Emphomet Tablet 12.5/850mg</td><td>Diampa-M 12.5/850mg</td></tr>
<tr><td>Batch No.</td><td>T001</td><td>007FF1</td></tr>
</table>

Comparative dissolution studies have been performed in following mediums:

pH 1.2 HCl buffer
pH 4.5 Acetate buffer
pH 6.8 Phosphate buffer

</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
<tr><td colspan="3">Remarks of Evaluator</td></tr>
<tr><td colspan="3">
<table>
<tr><th>S.No</th><th>Shortcomings communicated</th><th>Reply</th></tr>
<tr><td>1.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer.</td><td>Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer submitted.</td></tr>
<tr><td>2.</td><td>Stability study data of API (Metformin) from API manufacturer.</td><td>Stability study data of API (Metformin) from API manufacturer submitted.</td></tr>
<tr><td>3.</td><td>Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin.</td><td>Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin submitted.</td></tr>
<tr><td>4.</td><td>Drug-excipients compatibility studies.</td><td>Drug-excipients compatibility studies submitted.</td></tr>
<tr><td>5.</td><td>Method for dissolution testing not submitted.</td><td>Firm Initally submitted dissolution testing where medium used is 0.1N HCl and time for Q :45 minutes while Innovator product used medium Phosphate buffer pH 6.8 and time for Q: 20 minutes.
Firm submitted revised specifications with used medium Phosphate buffer pH 6.8 and time for Q: 30 minutes and also submitted one time dissolution testing according to new specifications.</td></tr>
<tr><td>6.</td><td>You have not performed uniformity of dosage unit by content uniformity, as recommended by USP General</td><td>Submitted</td></tr>
</table>
</td></tr>
</table>

	Chapter <905> throughout stability studies. Justification shall be submitted in this regard.	
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

534.	Name and address of manufacturer / Applicant	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Emphomet Tablet 12.5/1000mg
	Composition	Each Film Coated Tablet Contains: Empagliflozin…12.5mg Metformin HCl…1000mg
	Diary No. Date of R& I & fee	Dy.No. 11264 dated 05-03-2019 Rs.20,000/- Dated 01-03-2019
	Pharmacological Group	Anti-Diabetic Drug, Sodium-Glucose Co-Transporter2 (SGLT2) Inhibitor
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specification
	Pack size & Demanded Price	7's, 10's, 14's, 28's, 30's, 60's, 100's: As per SRO
	Approval status of product in Reference Regulator Authorities	Synjardy Tablets 12.5 mg/1000 mg by Boehringer Ingelheim Pharmaceuticals, USFDA
	Me-too status	Diampa-M Tablets 12.5mg + 1000mg of M/s Getz Pharma, Karachi, Pakistan
	GMP status	GMP certificate issued on 21-07-2019 on the basis of inspection conducted on 11-07-2019
	Remarks of the Evaluator.	Submit Stability studies with requisite documents
	Previous Decision: Deferred for submission and evaluation of Stability study data as per the guidelines approved in 293rd meeting of Registration Board on their turn **. (M-296)**	

STABILITY STUDY DATA

Drug	Emphomet Tablet 12.5/1000mg
Name of Manufacturer	M/s Seraph Pharmaceuticals. Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad
Manufacturer of API	**Empagliflozin:** HuaiNan Shunglong Pharmaceutical co. Ltd. Address: No. 9th YongXing Road, Huaninan economic and Technological Development zone, Huaninan City, China **Metformin**: Aarti Drugs Limited (Unit-II) Plot No. 211&213, Road-2, Gidc. At & Post: Sarigam, Dist: Valsad, Gujarat State, India.
API Lot No.	**Empagliflozin:** 20210204 **Metformin HCl :** MEF/19071360
Description of Pack (Container closure system)	Alu-Alu blister foil with unit carton

Stability Storage Condition	Real time: 30˚C ± 2˚ C / 75% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6, 9, 12 (months)		
Batch No.	T 001	T 002	T 003
Batch Size	730 Tablets	730 Tablets	730 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	05 – 06 -2021	05 – 06 -2021	05 – 06 -2021
No. of Batches	03		
Date of Submission	13-06-2022(14278)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if available)	Firm has referred to onsite inspection report of their product for **Neovel (Sevelamer Carbonate) tablets 800mg** on 27th December, 2018. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th February 2019. The case was approved and the inspection report confirms following points: • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Empagliflozin:** Copies of COAs (Batch#20210204) of API from M/s HuaiNan Shunglong Pharmaceutical co. Ltd. are submitted. Copies of COAs (Batch#20210204) of API from M/s M/s Seraph Pharmaceuticals are not submitted. **Metformin HCl** : Copies of COAs (Batch# MEF/19071360) of API from Aarti Drugs Limited (Unit-II) are submitted. Copies of COAs (Batch# MEF/19071360) of API from M/s Seraph Pharmaceuticals are not submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Methods used for analysis of API from both API Manufacturer and Finished Product Manufacturer are provided by the firm
4.	Stability study data of API from API manufacturer	**Empagliflozin:** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 18 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (20190101, 20190102, 20190103) **Metformin HCl :** The firm has submitted copy of **accelerated, 06 Months** (40°C ± 2°C & 75±5%RH) & **long term, 60 Months** (30°C ± 2°C & 60±5%RH) stability study reports of 03 batches. Batches: (MET/10040109, MET/10040110, MET/10040111)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:**Firm has submitted copy of DML certificate (Anhui 20160342) issued by Anhui Food and Drug Administration, China. The certificate is valid till 31-12-2025.

<table>
<tr><td></td><td></td><td>Metformin HCl: Firm has submitted copy of GMP certificate (20031933) issued by Food & Drugs Control Adminstration, Block No. 8, 1st floor, dr. Jivraj Mehta Bhavan, Gandhinagar, Gujarat state, India – Pin 382010. Valid till 19-03-2023</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Empagliflozin: Copy of Clearance certificate and Commercial Invoice No:CF20210329 Dated: 29-03-2021 from M/s Hefei Corn Field Biotechnology Co., Ltd. attested by AD DRAP (Islamabad) dated ; 27-05-2021 for Empagliflozin batch No# # 20210204
Metformin HCl: Copy of Clearance certificate and Commercial Invoice No:EXP/1968/19-20 Dated: 12-11-2019 from M/s Aari drugs Limited, Mahendra Industrail Estate, GR Floor India.. attested by AD DRAP (Islamabad) dated ; 04-02-2019 for Metformin HCl batch No# # MEF/19071360</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies</td><td>Drug-excipients compatibility studies submitted</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Emphomet Tablet 12.5/1000mg</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>T001</td><td>730 tablets</td><td>31-05-2021</td></tr>
<tr><td>T002</td><td>730 tablets</td><td>31-05-2021</td></tr>
<tr><td>T003</td><td>730 tablets</td><td>31-05-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution</td><td>Firm has submitted Comparative dissolution study of their product with Diampa-M 12.5/1000mg of “Getz Pharma”
The details are as follows:
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of Getz</td></tr>
<tr><td>Brand name</td><td>Emphomet Tablet 12.5/1000mg</td><td>Diampa-M 12.5/1000mg</td></tr>
<tr><td>Batch No.</td><td>T001</td><td>228FC2</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
pH 1.2 HCl buffer
pH 4.5 Acetate buffer
pH 6.8 Phosphate buffer</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
</table>

13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator

S.No	Shortcomings communicated	Reply
1.	Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer.	Certificate of Analysis of API (Empagliflozin) from Finished Product manufacturer submitted.
2.	Stability study data of API (Metformin) from API manufacturer.	Stability study data of API (Metformin) from API manufacturer submitted.
3.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin.	Valid Approval of API/ DML/GMP certificate of API manufacturer for metformin issued by concerned regulatory authority of country of origin submitted.
4.	Drug-excipients compatibility studies.	Drug-excipients compatibility studies submitted.
5.	Method for dissolution testing not submitted.	Firm Initally submitted dissolution testing where medium used is 0.1N HCl and time for Q :45 minutes *while Innovator product used medium Phosphate buffer pH 6.8 and time for Q: 20 minutes.* Firm submitted revised specifications with used medium Phosphate buffer pH 6.8 and time for Q: 30 minutes and also submitted one time dissolution testing according to new specifications.
6.	You have not performed uniformity of dosage unit by content uniformity, as recommended by USP General Chapter <905> throughout stability studies. Justification shall be submitted in this regard.	Submitted
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

c. Import applications of priority categories defined by Registration Board in its 257th meeting

i. Human

535.	Name, address of Applicant / Importer	M/s Schazoo Pharmaceuticals Laboratories (Pvt) Ltd., Sheikhupura.
	Details of Drug Sale License of importer	License No: 05-354-0076-059245D Address: Kalawala stop 20-KM Lahore Jaranwala Road Tehsil Sharaqpur Sharif District Sheikhupura. Address of Godown: NA Validity: 25-09-2022 Status: License to sell drugs as distributor

	Name and address of marketing authorization holder (abroad)	BDR Pharmaceutical International Pvt.Ltd R.S.NO.578, NR EFFLUENT CHANNEL ROAD, VILLAGE:-LUNA, TAL: PADRA,DIST-VADODARA-391 440
	Name, address of manufacturer(s)	BDR Pharmaceutical International Pvt.Ltd R.S.NO.578, NR EFFLUENT CHANNEL ROAD, VILLAGE:-LUNA, TAL: PADRA,DIST-VADODARA-391 440
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# MFG/WHO-COPP/BDR Pharma/2021/069340) Valid up to 15-12-2022 by , Food and Drug control administration Gujrat state india **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. Section of Tablet Cytotoxic mentioned in Eudra GMP certificate
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from M/s BDR Pharmaceuticals International Private Limited 407/408, Sharda Chambers, New Marine Lines Mumbai., Maharashtra, India. The letter specifies that the manufacturer appoints M/s Schazoo Pharmaceuticals Laboratories (Pvt) Ltd., Sheikhupura to register their products in Pakistan. Issued on 23-08-2021
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10475 dated: 25-04-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 81027502940
	The proposed proprietary name / brand name	**Kapcitabine Tablet 500mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated Tablet contains: Capecitabine USP…… 500mg
	Pharmaceutical form of applied drug	Film coated Tablet
	Pharmacotherapeutic Group of (API)	Anti-Neoplastic (Colorectal) WHO ATC code: (L01BC06) (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

		• Adjuvant Colon Cancer – Patients with Dukes' C colon cancer. • Metastatic Colorectal Cancer– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer– In combination with docetaxel after failure of prior anthracyclinecontaining therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
	Reference to Finished product specifications	USP
	Proposed Pack size	12 Alu PVC blisters of 10 tablets each packed in a monocarton along with pack insert.
	Proposed unit price	30,000/Pack
	The status in reference regulatory authorities	XELODA® 500mg of USFDA approved.
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	BDR Life Sciences Private Limited Address: R.S.No.578, Near Effluent Channel At & post- Luna, Taluka-padra, City- Luna 391 440 Dist. Vadodara, Gujrat Stat, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 30°C ± 2°C / 75 ± 5% RH for 12 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (CPZO17001M, CPZO17002M, CPZO17003M)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	The firm has submitted CDP wit of XELODA (Reference Drug Product)
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	Alu-PVC blister
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 12 months. Batches:((ECKAN2117, ECKAN2217, ECKAN0418)

Remarks of Evaluator: Fee submitted on DML

S.No	Section	Shortcomings Communicated
1.	1.3.4	• Address on DSL mentioned is M/s Schazoo Pharmaceuticals (Pvt) Ltd., Sheikhupura while, address in section 1.3.1 and on letter of Authorization, M/s Schazoo Pharmaceuticals Laboratories (Pvt) Ltd mentioned. Clarification is required. • Submit Valid DSL.
2.	3.2.P.2.2.1	• Pharmaceutical equivalence of the applied drug shall be established with the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed. • Submit CDP in details with details of Reference product against which CDP was conducted and its origin.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

536.	Name, address of Applicant / Importer	M/s. Al Habib Pharmaceuticals, **Address:** Plot # 81, Block B, SMCHS, Karachi – Pakistan
	Details of Drug Sale License of importer	**License No:** 0230 **Address:** Plot # 81, Block B, SMCHS, Karachi – Pakistan **Address of Godown:** NA **Validity:** 18-05-2024 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# COPP/CERT/KD/100457/2021/11/34994/172799) Valid up to 03-04-2022 by , Food and Drug control administration Gujrat state india **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly.

		(Section of Tablet cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from NAPROD LIFE SCIENCES PVT. LTD. (304, Town Center-1 Andheri Kurla Road, Andheri , Mumbai.The letter specifies that the manufacturer appoints M/s. Al Habib Pharmaceuticals to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5226 dated: 24-02-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 47789098702
	The proposed proprietary name / brand name	NAPROCAP Tablet 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated Tablet contains: Capecitabine USP…… 500mg
	Pharmaceutical form of applied drug	Film coated Tablet
	Pharmacotherapeutic Group of (API)	Anti-Neoplastic (Colorectal) WHO ATC code: (L01BC06) (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer – Patients with Dukes' C colon cancer. • Metastatic Colorectal Cancer– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer– In combination with docetaxel after failure of prior anthracyclinecontaining therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XELODA® 500mg of USFDA approved.
	For generic drugs (me-too status)	NA

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	Mac- Chem Products (India) Pvt. Ltd. N-211/2/10. MIDC, Boisar, District- Thane, Pin - 401 506, Maharashtra, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 12 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (CAP0210002, CAP0210001, CAP0210003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against XELODA Tablet 500mg manufactured by Hoffmann-La-Roche Inc. USA by performing quality tests (Identification, Assay, Dissolution, Hardness, Disintegration Time). The firm has submitted CDP with of XELODA Tablet 500mg manufactured by Hoffmann-La-Roche Inc. USA (Reference Drug Product) in in water, Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	PVC film coated with PVDC and printed Aluminium foil
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 65% ± 5% for 24 months.

		Batches:(NT1131, NT1132, NT1133)
Remarks of Evaluator: Registration Board was apprised regarding an e. mail received to Director PE&R Division form M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.		
Decision: Deferred for the Verification of "Sole Agency Agreement" between M/s. Al Habib Pharmaceuticals, Plot # 81, Block B, SMCHS, Karachi & M/s Naprod Life Sciences Pvt. Ltd. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, India.		
537.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 16-06-2024 Status: License to sell Drugs by way of Wholesale Renewal: Yes
	Name and address of marketing authorization holder (abroad)	Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan.
	Name, address of manufacturer(s)	Lotus Pharmaceuticals Co., Ltd. Nantou Plant, No. 30, Chenggong 1st Rd., Sinsing Village, Nantou City, Nantou County 54066, Taiwan.
	Name of exporting country	Taiwan
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP**: Original legalized COPP (Certificate# 083895) dated 1/Oct/2021 issued by Food and Drug Administration, Ministry of Health and Welfare, Republic of China (Taiwan). Free sale: Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and through periodic inspection every 2 years. (Section of Tablet cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan. The letter specifies that the manufacturer appoints M/s Martin Dow Limited, to register their products in Pakistan. Issued on 16-11-2021
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)

		☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3339 dated: 03-02-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 330123856967
	The proposed proprietary name / brand name	ALVOSUNI CAPSULES 12.5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Sunitinib Malate equivalent to Sunitinib……12.5mg
	Pharmaceutical form of applied drug	Capsules
	Pharmacotherapeutic Group of (API)	Antineoplastic (Chemotherapeutic agent) ATC Code : L01EX01 kinase inhibitor indicated for: • Treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Treatment of adult patients with advanced renal cell carcinoma (RCC). • Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. • Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10’s, 28’s & 30’s
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	SUTENT 12.5mg Capsules of (FDA Approved)
	For generic drugs (me-too status)	SUTENT® of Pfizer Laboratories. Ltd. (Reg # 052225)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility’s, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	M/s Hetero Labs Limited. Unit-I, Survey No.10, I.D.A., Gaddapotharam Village, Jinnaram Mandal, Sangareddy District-502319 Telangana State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility’s, physical form, manufacturers, description of manufacturing process

		and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 48 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (SU0010715, SU0020715, SU0030715)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence not done. The firm has submitted CDP of Sunitinib 12.5mg (Batch No# 8064P1) of Lotus Pharmaceuticals Co., Ltd with Sunitinib 50mg Capsule (Biobatch No# 8055P1) of manufactured by Lotus Pharmaceuticals Co., Ltd. Nantou Plant, No. 30, Chenggong 1st Rd., Sinsing Village, Nantou City, Nantou County 54066, Taiwan (Reference Drug Product) in in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	White PVC/Aclar-Alu blisters
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches:(8063P1, 8064P1, 8065P1)

Remarks of Evaluator: Fee submitted on DML

S.No	Section	Shortcomings Communicated	Reply
1.	1.3.4	Submit Valid DSL.	Valid DSL is attached
2.	1.3.5	Evidence of approval of manufacturing facility / Approved Section of relevant dosage form	GMP Certificate issued from Icelandic Medicines Agency and GMP Certificate issued from Ministry of Health and Welfare Republic of China (Taiwan) is attached in the following pages having details of **Capsule Section** GMP certificate No# IS/GMP/5/22
3.	3.2.P.2.2.1	• Pharmaceutical equivalence of the applied drug shall be established with same strength of the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or	1) We would like to clarify that the Sunitinib Capsules 12.5mg, 25mg and 50mg developed and manufactured by Lotus Pharmaceutical Co., Ltd., have the same active substance, same dosage form, same route of administration and identical in strength

		section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed. • Comparative dissolution profile of same strength of applied formulation and innovator / reference / comparator product conducted in three BCS media across the physiological pH range along with calculation of similarity factor f2 shall be submitted and discussed, along details of Reference product against which CDP was conducted and its origin.	as reference product, Sutent 12.5mg, 25mg and 50mg capsules. Please find attached in the following pages, the Comparison Chart (Pharmaceutical Equivalence) and COA's for the Lotus Sunitinib Capsules 50mg and Sutent capsules 50mg. It is demonstrated that Sunitinib Capsules developed by Lotus Pharmaceutical Co., Ltd., have the same the quality compared to the reference product. Hence, it is considered that physical and chemical properties are similar with reference product, Sutent Capsules. Moreover, according to the EMA Guidance, CPMP/EWP/QWP/1401/98 Rev.1/Corr**, the bioequivalence study in general be conducted at the highest strength. For Sunitinib Capsules, the in-vivo and in-vitro similarities are also demonstrated through BE and CDP studies. For 12.5mg and 25mg, there is no compared to the reference products that have the same strengths; however, as Sunitinib capsules are manufactured as common blend and then split and encapsulated into the 4 strengths, which the strength 50mg is the highest and considered as representative strength. They are manufactured by the similar process as 50mg and are controlled by the equivalent specifications. 2) We would like to clarify that Sunitinib Capsules are manufactured as common blend and then split and encapsulated into the 4 strengths, the strength 50mg is considered as representative strength at the development stage. Hence, the CDP study against reference product is performed on 50mg only. Please refer to page 70 to 72 of 88 of Section 3.2.P.2 for the CDP between Lotus Sunitinib Capsules 50mg and Sutent Capsules 50mg. Moreover, as per section 4.2.2 In vitro dissolution tests in support of biowaiver of strengths of EMA guidance CPMP/EWP/QWP/1401/98 Rev.1/Corr**, the biowaiver of additional strength is performed between additional strength (12.5/25) and batches used in the bioequivalence testing. Please refer to the page 54 to 65 of 88 of Section 3.2.P.2 for the CDP between 50mg and 12.5/25mg. It is

			confirmed that 12.5/25mg show similar dissolution profile in 3 pH's. Also, please refer in the attached pages for the RLD information (Packaging insert and packaging photo), invoice for the BE RLD, and for the RLD COA from Pfizer Italia S.R.L. RLD used in the CDP study was manufactured by Pfizer Italia S.R.L.(MAH Pfizer Europe) and purchased from Latvia Batch No# T93732

Decision: Deferred for submission of Pharmaceutical equivalence & Comparative dissolution profile of the applied formulation against the same strength of innovator/reference product.

538.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 16-06-2024 Status: License to sell Drugs by way of Wholesale Renewal: Yes
	Name and address of marketing authorization holder (abroad)	Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan.
	Name, address of manufacturer(s)	Lotus Pharmaceuticals Co., Ltd. Nantou Plant, No. 30, Chenggong 1st Rd., Sinsing Village, Nantou City, Nantou County 54066, Taiwan.
	Name of exporting country	Taiwan
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP**: Original legalized COPP (Certificate# 083896) dated 1/Oct/2021 issued by Food and Drug Administration, Ministry of Health and Welfare, Republic of China (Taiwan). Free sale: Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and through periodic inspection every 2 years. (Section of Tablet cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan. The letter specifies that the manufacturer appoints M/s Martin Dow Limited, to register their products in Pakistan. Issued on 16-11-2021
	Status of the applicant	☐ Manufacturer ☒ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3340 dated: 03-02-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 3549369023
	The proposed proprietary name / brand name	ALVOSUNI CAPSULES 25mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Sunitinib Malate equivalent to Sunitinib……25mg
	Pharmaceutical form of applied drug	Capsules
	Pharmacotherapeutic Group of (API)	Antineoplastic (Chemotherapeutic agent) ATC Code : L01EX01 kinase inhibitor indicated for: • Treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Treatment of adult patients with advanced renal cell carcinoma (RCC). • Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. • Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10’s, 28’s & 30’s
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	SUTENT® (Sunitinib) 25mg Capsules (FDA Approved)
	For generic drugs (me-too status)	SUTENT® of Pfizer Laboratories. Ltd. (Reg # 052226)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility’s, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	M/s Hetero Labs Limited. Unit-I, Survey No.10, I.D.A., Gaddapotharam Village, Jinnaram Mandal, Sangareddy District-502319 Telangana State, India.

	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 48 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (SU0010715, SU0020715, SU0030715)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence not done. The firm has submitted CDP of Sunitinib 25mg (Batch No# 8060P1) of Lotus Pharmaceuticals Co., Ltd with Sunitinib 50mg Capsule (Biobatch No# 8055P1) of manufactured by Lotus Pharmaceuticals Co., Ltd. Nantou Plant, No. 30, Chenggong 1st Rd., Sinsing Village, Nantou City, Nantou County 54066, Taiwan (Reference Drug Product) in in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	White PVC/Aclar-Alu blisters
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches:(8060P1, 8061P1, 8062P1)

Remarks of Evaluator: Fee submitted on DML

S.No	Section	Shortcomings Communicated	Reply
1.	1.3.4	Submit Valid DSL.	Valid DSL is attached
2.	1.3.5	Evidence of approval of manufacturing facility / Approved Section of relevant dosage form	GMP Certificate issued from Icelandic Medicines Agency and GMP Certificate issued from Ministry of Health and Welfare Republic of China (Taiwan) is attached in the following pages having details of **Capsule Section** GMP certificate No# IS/GMP/5/22
3.	3.2.P.2.2.1	1) Pharmaceutical equivalence of the applied drug shall be established with same strength of	1) We would like to clarify that the Sunitinib Capsules 12.5mg, 25mg and 50mg developed and manufactured by

		the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed. 2) Comparative dissolution profile of same strength of applied formulation and innovator / reference / comparator product conducted in three BCS media across the physiological pH range along with calculation of similarity factor f2 shall be submitted and discussed, along details of Reference product against which CDP was conducted and its origin.	Lotus Pharmaceutical Co., Ltd., have the same active substance, same dosage form, same route of administration and identical in strength as reference product, Sutent 12.5mg, 25mg and 50mg capsules. Please find attached in the following pages, the Comparison Chart (Pharmaceutical Equivalence) and COA's for the Lotus Sunitinib Capsules 50mg and Sutent capsules 50mg. It is demonstrated that Sunitinib Capsules developed by Lotus Pharmaceutical Co., Ltd., have the same the quality compared to the reference product. Hence, it is considered that physical and chemical properties are similar with reference product, Sutent Capsules. Moreover, according to the EMA Guidance, CPMP/EWP/QWP/1401/98 Rev.1/Corr**, the bioequivalence study in general be conducted at the highest strength. For Sunitinib Capsules, the in-vivo and in-vitro similarities are also demonstrated through BE and CDP studies. For 12.5mg and 25mg, there is no compared to the reference products that have the same strengths; however, as Sunitinib capsules are manufactured as common blend and then split and encapsulated into the 4 strengths, which the strength 50mg is the highest and considered as representative strength. They are manufactured by the similar process as 50mg and are controlled by the equivalent specifications. 3) We would like to clarify that Sunitinib Capsules are manufactured as common blend and then split and encapsulated into the 4 strengths, the strength 50mg is considered as representative strength at the development stage. Hence, the CDP study against reference product is performed on 50mg only. Please refer to page 70 to 72 of 88 of Section 3.2.P.2 for the CDP between Lotus Sunitinib Capsules 50mg and Sutent Capsules 50mg. Moreover, as per section 4.2.2 In vitro dissolution tests in support of biowaiver of strengths of EMA guidance CPMP/EWP/QWP/1401/98 Rev.1/Corr**, the biowaiver of additional strength is performed between additional strength (12.5/25)

			and batches used in the bioequivalence testing. Please refer to the page 54 to 65 of 88 of Section 3.2.P.2 for the CDP between 50mg and 12.5/25mg. It is confirmed that 12.5/25mg show similar dissolution profile in 3 pH's. Also, please refer in the attached pages for the RLD information (Packaging insert and packaging photo), invoice for the BE RLD, and for the RLD COA from Pfizer Italia S.R.L. RLD used in the CDP study was manufactured by Pfizer Italia S.R.L.(MAH Pfizer Europe) and purchased from Latvia Batch No# T93732

Decision: Deferred for submission of Pharmaceutical equivalence & Comparative dissolution profile of the applied formulation against the same strength of innovator/reference product.

539.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 16-06-2024 Status: License to sell Drugs by way of Wholesale Renewal: Yes
	Name and address of marketing authorization holder (abroad)	Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan.
	Name, address of manufacturer(s)	Lotus Pharmaceuticals Co., Ltd. Nantou Plant, No. 30, Chenggong 1st Rd., Sinsing Village, Nantou City, Nantou County 54066, Taiwan.
	Name of exporting country	Taiwan
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP**: Original legalized COPP (Certificate# 083897) dated 1/Oct/2021 issued by Food and Drug Administration, Ministry of Health and Welfare, Republic of China (Taiwan). Free sale: Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and through periodic inspection every 2 years. (Section of Tablet cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from Lotus Pharmaceuticals Co., Ltd. 17th floor, No. 277, SongRen Road, Xinyi District, Taipei City 110, Taiwan. The letter specifies that the manufacturer appoints M/s Martin Dow Limited, to

		register their products in Pakistan. Issued on 16-11-2021
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3341 dated: 03-02-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 2185342290
	The proposed proprietary name / brand name	ALVOSUNI CAPSULES 50mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Sunitinib Malate equivalent to Sunitinib……50mg
	Pharmaceutical form of applied drug	Capsules
	Pharmacotherapeutic Group of (API)	Antineoplastic (Chemotherapeutic agent) ATC Code : L01EX01 kinase inhibitor indicated for: • Treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Treatment of adult patients with advanced renal cell carcinoma (RCC). • Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. • Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10's, 28's & 30's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	SUTENT® (Sunitinib) 50mg Capsules (FDA Approved)
	For generic drugs (me-too status)	SUTENT® of Pfizer Laboratories. Ltd. (Reg # 052227)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..

	Name, address of drug substance manufacturer	M/s Hetero Labs Limited. Unit-I, Survey No.10, I.D.A., Gaddapotharam Village, Jinnaram Mandal, Sangareddy District-502319 Telangana State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 48 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (SU0010715, SU0020715, SU0030715)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Sutent Capsule 50mg manufactured by Pfizer Italia S.R.L.(MAH Pfizer Europe) by performing quality tests (Description, Identification, Assay, Dissolution, Uniformity of dosage units). The firm has submitted CDP of Sunitinib 50mg (Batch No# 8055P1) of Lotus Pharmaceuticals Co., Ltd with Sutent Capsule 50mg (batch No# T93732) of manufactured by Pfizer Italia S.R.L.(MAH Pfizer Europe), (Reference Drug Product) in in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	White PVC/Aclar-Alu blisters
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches:(8054P1, 8055P1, 8056P1)
Remarks of Evaluator: Fee submitted on DML		

S.No	Section	Shortcomings Communicated	Reply
1.	1.3.4	Submit Valid DSL.	Valid DSL is attached
2.	1.3.5	Evidence of approval of manufacturing facility / Approved Section of relevant dosage form	GMP Certificate issued from Icelandic Medicines Agency and GMP Certificate issued from Ministry of Health and Welfare Republic of China (Taiwan) is attached in the following pages having details of **Capsule Section** GMP certificate No# IS/GMP/5/22
3.	3.2.P.2.2.1	2) Details of Reference product against which CDP was conducted and its origin.	Please refer in the attached pages for the RLD information (Packaging insert and packaging photo), invoice for the BE RLD, and for the RLD COA from Pfizer Italia S.R.L. RLD used in the CDP study was manufactured by Pfizer Italia S.R.L.(MAH Pfizer Europe) and purchased from Latvia Batch No# T93732

Decision: Approved as per policy of inspection of manufacturer abroad and according to Authority's (DRAP) decision regarding Import of finished drug product from Taiwan.

- **Firm shall submit full fee of registration as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter since firm had initially applied fee from the head of DML instead of DSL.**

540.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt Ltd** **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi **Address of Godown:** NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** n/a
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# COPP/CERT/KD/114093/2022/11/41431/203263) Valid up to 27-04-2025 by , Food and Drug control administration Gujrat state India. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. (Section of Liquid Injection cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from NAPROD LIFE SCIENCES PVT. LTD. (304, Town Center-1 Andheri Kurla Road, Andheri , Mumbai on the request of Facilitator M/s Miles International (2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai – 400034, Idia specifies that the Facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd to register their products in Pakistan.

		Issued on : 06-09-2022
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26940 dated: 23-09-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 29422105532
	The proposed proprietary name / brand name	**CARBOLAB 150mg/15ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Carboplatin BP……... 10 mg
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Pyrimidine analogue ATC Code : L01XA02 carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents)
	Reference to Finished product specifications	BP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PARAPLATIN of USFDA approved
	For generic drugs (me-too status)	Brand Name CARBOPLATINO 150MG INJECTION Generic Name: CARBOPLATIN 150MG Importer Name: GHAZALI BROTHERS Registration Number: 043036
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	Sun pharmaceutical industries ltd., A-7/A-8, M.I.D.C., Industrial Area, Ahmednagar – 414 111, Maharashtra, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form,

		manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 72 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (AH-8-41169, AH-8-41168, AH-3-08249, AH-3-08247) And at 30°C ± 2°C / 65 ± 5% RH for 72 months Batches: (AH-5-18252, AH-5-18253, AH-5-18254)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	20ml Amber colour Type-I Glass vial with grey bromo butyl rubber stopper with aluminium
	Stability study data of drug product, shelf life and storage conditions	
Remarks of Evaluator: On COPP 5ml, 15ml and 45 ml mentioned.		

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.P.2.2.1	• Pharmaceutical equivalence of the applied drug of same strength/fill volume shall be established with same strength of the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed. • Details and origin of Reference product against which Pharmaceutical Equivalence was established and.	We, Naprod Life Sciences Pvt Ltd hereby declare that Pharmaceutical Equivalenc of Carboplatin 150mg/15ml is same as Carboplatin Injection 450mg/45ml and the basic strength of product is 10mg/ml. the change is only in the fill volume, which is as follows. The fill volume for 150mg/15ml is 15.5ml ±0.1 ml The fill volume for 450mg/45ml is 45.5ml ±0.1 ml The product development was performed on higher strength & therefore are requested to consider the same.
2.	3.2.P.5.4	Specifications of applied filled volume as extractable volume of 45ml mentioned.	Revised specifications submitted.
3.	3.2.P.5.4	Certificate of analysis of applied fill volume is required.	Certificate of analysis of applied fill volume is submitted.
4.	3.2.P.8	Submit stability studies of applied fill volume.	We, Naprod life sciences Pvt. Ltd, hereby declare that the carboplatin injection 150mg/15ml & carboplatin injection 450mg/45ml, the bulk solution is of uniform concentration where in each ml contains 10mg of active ingredient, i.e. 10mg/ml. The change is only in the fill volume, which is as follows: The fill volume for 150mg/15ml is 15.5ml± 0.1ml The fill volume for 450mg/45ml is 45.5ml ± 0.1ml The stability studies are performed on higher strength, only filled volume is different.

Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.

Decision: Deferred for submission of following:

- **Stability studies (both accelerated and long term) as per Zone IVa conditions for the applied strength and fill volume.**
- **Pharmaceutical equivalence studies against the innovator/reference product of relevant strength and fill volume as applied.**
- **Afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter**

541.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt Ltd** **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi

		Address of Godown: NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** n/a
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# COPP/CERT/KD/114093/2022/11/41431/203267) Valid up to 27-04-2025 by , Food and Drug control administration Gujrat state India. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. (Section of Liquid Injection cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from NAPROD LIFE SCIENCES PVT. LTD. (304, Town Center-1 Andheri Kurla Road, Andheri , Mumbai on the request of Facilitator M/s Miles International (2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai – 400034, Idia specifies that the Facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd to register their products in Pakistan. Issued on : 06-09-2022
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26939 dated: 23-09-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 49755434177
	The proposed proprietary name / brand name	**CARBOLAB 450mg/45ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Carboplatin BP……... 10 mg
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Pyrimidine analogue

		ATC Code : L01XA02 carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents)
	Reference to Finished product specifications	BP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	PARAPLATIN of USFDA approved
	For generic drugs (me-too status)	Brand Name CARBOPLATINO 450MG INJECTION Generic Name: CARBOPLATIN 450MG Importer Name: GHAZALI BROTHERS Registration Number: 043037
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	Sun pharmaceutical industries ltd., A-7/A-8, M.I.D.C., Industrial Area, Ahmednagar – 414 111, Maharashtra, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 72 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (AH-8-41169, AH-8-41168, AH-3-08249, AH-3-08247) And at 30°C ± 2°C / 65 ± 5% RH for 72 months Batches: (AH-5-18252, AH-5-18253, AH-5-18254)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Platamine CS 450mg (Carboplatin

		Injection) manufactured by Pfizer Laboratories by performing quality tests (Description, Identification, pH, Assay, ,).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	50ml Amber colour Type-I Glass vial with grey bromo butyl rubber stopper with aluminium
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches: NN0276-E: 24 months, NN1325-A:,12 months NN1511-A: 09 months

Remarks of Evaluator: On COPP 5ml, 15ml and 45 ml mentioned.

S.No	Section	Shortcomings Communicated	Reply
1.	3.2.P.2.2.1	Details and origin of Reference product against which Pharmaceutical Equivalence was established.	Platamine CS 450mg (Carboplatin Injection) manufactured by Pfizer Laboratories Batch No# HA03B Manufactured by: Pfizer (Perth) Ptv Ltd Bently-Australia Registered imported and distributed by: Laboratories Pfizer Ltd. Av Pres. Tancredo de A Neves 1555 CEP 07112 070 G UAN Cnpj 46.070.868/00
2.	3.2.P.8	Submit stability studies of applied fill volume till shelf life.	Please refer to attached data for one batch till completed shelf life however stability studies for 2 batches on going. Kindly refer attached declaration letter. Declaration Letter states that "We hereby commit to submit completed Accelerated and Long term stability data for below mentioned batches with 24 months shelf life. Batches: NN1325-A:Long term stability starts on 25-09-2021 and complete in October: 2023 NN1511-A: Long term stability starts on 20-01-2022 and complete in February 2024 NN0276-E: 24 months, Batch Size (5268 Vials) NN1325-A:,12 months Batch Size (3819 Vials) NN1511-A: 09 months Batch Size (5268 Vials)

Decision: Approved as per policy of inspection of manufacturer abroad with shelf life as per available long term stability data at the time of issuance of registration letter.

- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**

• **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**		
542.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt Ltd** **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi **Address of Godown:** NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** n/a
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# COPP/CERT/KD/119004/2022/11/41795/205342) Valid up to 27-04-2025 by , Food and Drug control administration Gujrat state India. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. (Section of Lyophilised/Powder Injection cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from NAPROD LIFE SCIENCES PVT. LTD. (304, Town Center-1 Andheri Kurla Road, Andheri , Mumbai on the request of Facilitator M/s Miles International (2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai – 400034, Idia specifies that the Facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd to register their products in Pakistan. Issued on : 06-09-2022
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 27753 dated: 30-09-2022

	Details of fee submitted	PKR 150,000/- deposit Slip # 47881905443
	The proposed proprietary name / brand name	**EPICIN 10mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Epirubicin Hydrochloride …….... 10mg
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Antineoplastic Agents , Anthracycline ATC Code:L01DB03 Epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small-cell lung cancer, lymphoma (non-Hodgkin's lymphoma), advanced/metastatic soft tissue sarcoma and superficial bladder cancer (Tis, Ta). In bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers
	Reference to Finished product specifications	BP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Epirubicin Actavis 10mg Powder for Injection (type I glass vial) by M/s Medis Pharma, TGA Australia Approved.
	For generic drugs (me-too status)	Ciazil Injection 10mg vial (5ml) by M/s Rotexmedica (R#063978)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	INTAS PHARMACEUTICALS LIMITED. 2702/A, GIDC Estate,Ankleshwar 393 002, District: Bharuch, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 5°C ± 3°C for 60 months. The accelerated stability data is conducted at 25°C ± 2°C / 60 ± 5% RH for 6 months Batches: (71400611, 71400711, 71400811)

	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Innorubicin 10mg/Vial Injection) manufactured by BDR Pharmaceuticals pvt Ltd. India by performing quality tests (Description, Identification, pH, Assay, Sterility,).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	20mm neck size 5ml, Tubular, Flint vial made up of USP type-I glass.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches: NN8494: 36 months, (batch size is 11040 vials) NN9143; 36 months, (batch size is 11040 vials) NN1039-B, 12 months, (batch size is 11040 vials)

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.5.5	Pharmacological group is not mentioned.	Antineoplastic Agents , Anthracycline
2.	1.5.6	Specification claimed are B.P while in section 3.2.P.5.1 in-house mentioned/. Clarification is required	The reference product is with in-house specifications and not BP See attached pharmaceutical Equivalence. Submitted product by Naprod Epirubicin Hydrochloride for injection is lyophilized Injection where as Epirubicin Injection in Pharmacopia is Liquid injection.
3.	3.2.P.5.1	Pharmacopeial reference mentioned is in-house while Epirubicin injection is pharmacopeial product. Clarification is required.	The reference/Innovator product and Naprod's (Epicin 10mg) product has in-house specifications. See attached pharmaceutical Equivalence.

Decision: Approved as per policy of inspection of manufacturer abroad with shelf life as per long term stability studies data available at the time of issuance of registration letter.

- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**
- **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**

543.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt Ltd** **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi

	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi **Address of Godown:** NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** n/a
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# COPP/CERT/KD/119095/2022/11/41945/205432) Valid up to 27-04-2025 by , Food and Drug control administration Gujrat state India. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. (Section of Lyophilised/Powder Injection cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from NAPROD LIFE SCIENCES PVT. LTD. (304, Town Center-1 Andheri Kurla Road, Andheri , Mumbai on the request of Facilitator M/s Miles International (2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai – 400034, Idia specifies that the Facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd to register their products in Pakistan. Issued on : 06-09-2022
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 27754 dated: 30-09-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 1935425451
	The proposed proprietary name / brand name	**EPICIN 50mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Epirubicin Hydrochloride …….. 50mg
	Pharmaceutical form of applied drug	Injection

	Pharmacotherapeutic Group of (API)	Antineoplastic Agents , Anthracycline ATC Code:L01DB03 Epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small-cell lung cancer, lymphoma (non-Hodgkin's lymphoma), advanced/metastatic soft tissue sarcoma and superficial bladder cancer (Tis, Ta). In bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers
	Reference to Finished product specifications	Inhouse
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Epirubicin Actavis 10mg Powder for Injection (type I glass vial) by M/s Medis Pharma, TGA Australia Approved.
	For generic drugs (me-too status)	Ciazil Injection 10mg vial (5ml) by M/s Rotexmedica (R#063978)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	INTAS PHARMACEUTICALS LIMITED. 2702/A, GIDC Estate,Ankleshwar 393 002, District: Bharuch, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 5°C ± 3°C for 60 months. The accelerated stability data is conducted at 25°C ± 2°C / 60 ± 5% RH for 6 months Batches: (71400611, 71400711, 71400811)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of

		specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Alrubicin 50mg/Vial Injection) manufactured by Alkem Laboratories India by performing quality tests (Description, Identification, pH, Assay, Sterlity,).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	20mm neck size 5ml, Tubular, Flint vial made up of USP type-I glass.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for months. Batches: NN1362-A : 9months NN1303-E: 06 months NN0424-A: 18 months (Batch size is 10580 Vials)

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
1.	1.5.5	Pharmacological group is not mentioned.	Antineoplastic Agents , Anthracycline
2.	1.5.6	Specification claimed are B.P while in section 3.2.P.5.1 in-house mentioned/. Clarification is required	The reference product is with in-house specifications and not BP See attached pharmaceutical Equivalence. Submitted product by Naprod Epirubicin Hydrochloride for injection is lyophilized Injection where as Epirubicin Injection in Pharmacopia is Liquid injection.
3.	3.2.P.5.1	Pharmacopeial reference mentioned is in-house while Epirubicin injection is pharmacopeial product. Clarification is required.	The reference/Innovator product and Naprod's (Epicin 10mg) product has in-house specifications. See attached pharmaceutical Equivalence.

Decision: Approved as per policy of inspection of manufacturer abroad with shelf life as per long term stability studies data available at the time of issuance of registration letter.

- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**
- **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**

544.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi
	Details of Drug Sale License of importer	**License No:** 565 **Address:** Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. **Address of Godown:** (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi

		(b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi **Validity:** 16-06-2024 **Status:** License to sell Drugs by way of Wholesale **Renewal:** Yes Submitted valid till 16-06-2022
	Name and address of marketing authorization holder (abroad)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece.
	Name, address of manufacturer(s)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece.
	Name of exporting country	Greece
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP (**certificate no. 67769**) dated **27-06-2022** issued by National Organization for Medicines (EOF), 284 Mesogeion Ave. 155 62 Holargos Attica, Greece. The CoPP confirms status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every 3 years. The name of importing country on CoPP is mentioned as Pakistan. **Free sale in country of origin:** NO Manufacturing Authorization in Greece only for Export.
	Details of letter of authorization / sole agency agreement	Firm has submitted original, legalized sole agency agreement (letter of authorization) as product registration holder. The letter specifies that the manufacturer **ANFARM HELLAS S.A., located at 4 Achaias Str. & Trizinias, 14564, Kifisia Attiki Greece** (administration office as per COPP) appoints M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi to register their products in Pakistan. The authorization letter is issued on 09-05-2022
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☐ Finished Pharmaceutical product import ☒ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 27409 dated: 27-09-2022
	Details of fee submitted	PKR 150,000/- deposit Slip # 434916593
	The proposed proprietary name / brand name	DOWPENEM INJECTION 2g IV

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Each vial contains:** Meropenem trihydrate 2280mg equivalent to Meropenem…….2000mg (with sodium carbonate)
	Pharmaceutical form of applied drug	Powder for Solution for Infusion
	Pharmacotherapeutic Group of (API)	Carbapenem Antibiotic
	Reference to Finished product specifications	As per Innovator
	Proposed Pack size	1's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	Meropenem 2g Powder for Solution for Infusion of VILLERTON INVEST S.A of (MHRA Approved).
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Name, address of drug substance manufacturer	ACS DOBFAR SpA 2: Addetta Site, Viale Addetta, 2a/12-3/5 20067 Tribiano, Milano - Italy
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API. Stability study conditions: Real time: 25oC ± 2oC and 60% RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Accelerated Batches: (330772 023 0, 330772 025 0, 330772 027 0) Real time Batches: (330772 8001 8, 330772 8001 0, 330772 8038 1)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification

		of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Pharmaceutical Equivalence against the product MEROPENEM DR. EBERTH 2g by Dr. Friedrich Eberth Arzneimittel GmbH, Am Bahnhof 2, 92289 Ursensollen, Germany Batch no # 22E340
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Colourless glass Vial type III sealed with rubber stopper and aluminium cap with Plastic flip-off seal
	Stability study data of drug product, shelf life and storage conditions	Accelerated stability studies have been conducted at 40ºC ±2ºC / 75%±5% RH for 06 months. Real time stability studies conducted at 30 ºC±2ºC / 65% ± 5% RH for three batch for 24 months Batches of stability studies : [20A293 (20B158), 20A303 (20B159), 20A304 (20B160)]

Evaluation by PEC: Fee submitted on DML

S.No	Shortcomings communicated	Reply
1.	Product is available in USP pharmacopeia while applied formulation is claimed in house specifications.	Kindly refer to attachment herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life. It should be noted that based on the comparison, it is evident that: - The limit for Assay set by Anfarm is stricter to the one set by USP. - The limit for Impurities set by Anfarm is in accordance to USP monograph at shelf life and stricter at the release. - The limits for Bacterial endotoxins, Loss on drying, pH, Sterility test, Particulate contamination, and Uniformity of dosage units set by Anfarm are in accordance to the USP monograph. Anfarm Hellas S.A has set extra specifications for the finished product which include "Time of reconstitution" and "Container / closure integrity'' which shows that the overall specifications of Anfarm are stringent than U Kindly refer to attachment herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life. It should be noted that based on the comparison, it is evident that: - The limit for Assay set by Anfarm is stricter to the one set by USP. - The limit for Impurities set by Anfarm is in accordance to USP monograph at shelf life and stricter at the release. - The limits for Bacterial endotoxins, Loss on drying, pH, Sterility test, Particulate contamination, and

Uniformity of dosage units set by Anfarm are in accordance to the USP monograph.
Anfarm Hellas S.A has set extra specifications for the finished product which include "Time of reconstitution" and "Container / closure integrity'' which shows that the overall specifications of Anfarm are stringent than U
Kindly refer to attachment herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life.
It should be noted that based on the comparison, it is evident that:
- The limit for Assay set by Anfarm is stricter to the one set by USP.
- The limit for Impurities set by Anfarm is in accordance to USP monograph at shelf life and stricter at
the release.
- The limits for Bacterial endotoxins, Loss on drying, pH, Sterility test, Particulate contamination, and
Uniformity of dosage units set by Anfarm are in accordance to the USP monograph.
Anfarm Hellas S.A has set extra specifications for the finished product which include "Time of reconstitution" and "Container / closure integrity'' which shows that the overall specifications of Anfarm are stringent than U
Kindly refer to attachment herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life.
It should be noted that based on the comparison, it is evident that:
- The limit for Assay set by Anfarm is stricter to the one set by USP.
- The limit for Impurities set by Anfarm is in accordance to USP monograph at shelf life and stricter at the release.
- The limits for Bacterial endotoxins, Loss on drying, pH, Sterility test, Particulate contamination, and Uniformity of dosage units set by Anfarm are in accordance to the USP monograph.
Anfarm Hellas S.A has set extra specifications for the finished product which include "Time of reconstitution" and "Container / closure integrity'' which shows that the overall specifications of Anfarm are stringent than USP.
Firm claimed that in-house specifications are more stringent than USP specifications.

Controls	**USP monograph of Meropenem Injection**	**Anafarm's Release specification**
Assay	90%-120%	95%-105%
Content of sodium	80%-120%	…

		Sodium carbonate content	….	14.7%-16.1%
		Bacterial Endotoxin	NMT 0.12 EU/mg	NMT 0.12 EU/mg
		Loss on Drying	9.0%-12.0%	9.0%-12.0%
		pH	7.3-8.3	7.3-8.3
		Sterility test	Sterile	Sterile
		Particulate contaminants	Meets the requirements for SVP injections	Meets the requirements for SVP injections
		Uniformity of dosage unit	Meets the requirement	Meets the requirement
2.	Justification of not performing test of Sodium content test by M/s Anfarm as recommended by USP monograph.	Kindly note that Anfarm Hellas S.A. has performed test for Sodium Carbonate Content, instead of Sodium Content. However, the following should be taken into account: As per the finished product composition, the % content of sodium carbonate is calculated to be equal to 15.4%; i.e. equal to 6.7% (w/w) sodium. ➢ USP limit of Sodium content = 80-120%; i.e. 80-120% of 6.7% sodium = (5.3-8.0%) w/w ➢ Anfarm's Limit of 14.7-16.1% of Sodium carbonate corresponds to sodium (6.4-7.0%) w/w. Thus, Anfarm's limit of sodium content is 6.4-7.0%, which is stricter to USP limit 5.3-8.0%.	
3.	Submit Analytical method verification studies of drug substance performed by M/s Anfarm.	The analytical methods for Assay, Related substances, Sodium carbonate content, Sterility and Bacterial Endotoxins have been validated, confirming their suitability for its intended purpose. The validation studies were performed at the manufacturing site of Anfarm Hellas. Also, please note that the validation studies are the same for the Drug Substance (Meropenem Sterile Bulk) and the Final Product (Meropenem Sterile Vials), as the limit is the same and the final product is the active substance (Meropenem Sterile Bulk) filled in vials.	
4.	Details of Diluent is not submitted.	According to MERREM FDA approved label, the concentration of solution for IV infusion ranges from 1mg/ml to 20mg/ml and there is limited safety data available to support use of a 40mg/kg (maximum of 2g) **bolus dose.** Therefore, for 2g Meropenem, at least 100ml of solution for IV infusion (0.9% NS or 5% Dextrose) should be used and drug should be administered by IV infusion over a period of 15-30 minutes. The Summary of Product Characteristics of MHRA Approved product Meropenem 2g powder for solution for infusion (Attached herewith) also claims that "***There is limited safety data available to support the***	

		administration of a 2g dose in adults as an intravenous bolus injection." Considering that Meropenem Injection 2g is not recommended to be given as bolus dose, hence it can only be administered in In-Patient/Hospital Setups. So, the diluent is not required to be provided along with the product.
5.	Submit details and origin of product against which Pharmaceutical equivalence have been established.	The Pharmaceutical equivalence have been established against the Reference Product **MEROPENEM DR. EBERTH 2g** by **Dr. Friedrich Eberth Arzneimittel GmbH, Am Bahnhof 2, 92289 Ursensollen, Germany** (Approved by Federal Institute for Drugs and Medical Devices, Germany).

Decision: Regsitration Board deferred the application for further deliberation regarding pharmaceutical and clinical features of the innovator product approved by the reference regulatory authorities adopted byRegustration Board in its 275th meeting along with clarification of "Manufacturing Authorization in country of origin i.e., Greece" for Export only purpose..

545.	Name, address of Applicant / Importer	M/s The Schazoo Pharmaceutical Laboratories Pvt Ltd, Pakistan
	Details of Drug Sale License of importer	License No: 05-354-0076-059245D Address: Kalalwala stop 20-KM Lahore Jaranwala Road Tehsil Sharaqpur Sharif District Sheikhupura. Address of Godown: NA Validity: 25-09-2022 Status: Complete Renewal: Firm has applied for renewal on 22-09-2022.
	Name and address of marketing authorization holder (abroad)	Bdr Pharmaceutical International Pvt.Ltd R.S.No.578, Nr Effluent Channel Road, Village:-Luna, Tal: Padra,Dist-Vadodara-391 440
	Name, address of manufacturer(s)	Bdr Pharmaceutical International Pvt.Ltd R.S.No.578, Nr Effluent Channel Road, Village:-Luna, Tal: Padra,Dist-Vadodara-391 440
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP ((No. MFG/WHO-COPP/BDR PHARMA/2021/069343) by Food and Drug Control administartion Gujarat State India. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP and Periodicity of inspections is mentioned Yearly. **valid till 15-12-2022** (Section of Hard shell Capsule cytotoxic mentioned in GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from BDR Pharmaceuticals international Pvt. Ltd. The letter species that the manufacturer appoints M/s The Schazoo Pharmaceutical Laboratories Pvt Ltd. to register their products in Pakistan.

	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3891 dated: 10-02-2022
	Details of fee submitted	PKR 75,000/- deposit Slip # 067677943
	The proposed proprietary name / brand name	ENZALUTA Capsules 40mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each hard gelatin capsule contains: Enzalutamide…….....40mg
	Pharmaceutical form of applied drug	Hard Gelatin capsule
	Pharmacotherapeutic Group of (API)	Androgen receptor inhibitors
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	Enzalutamide Capsules 40 mg packed in Alu-PVC blister containing 28 capsules each as primary pack. One such blister packed in a carton along with pack insert.
	Proposed unit price	12 x 10's :As per SRO
	The status in reference regulatory authorities	Not found
	For generic drugs (me-too status)	…
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	BDR Life Sciences Private Limited R.S.No.578, Near Effluent Channel, At & Post - Luna, Taluka - Padra, City – Luna 391 440 Dist. Vadodara, Gujarat State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch

		analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 30°C ± 2°C / 75 ± 5% RH for 12 months. The accelerated stability data is conducted at 40°C±2°C and 75%±5% for 6 months Batches: (EZZN170001, EZZN170002, EZZN170003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparsion have been established against **XTANDI 40mg Soft Gelatin Capsule** by performing quality tests (Identification, Assay, Uniformity of dosage units, Dissolution, , Disintegration Time).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Alu-Pvc Blisters
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 75% ± 5% for 36months. Batches: (BENAN0217, BENAN0317, BENAN0417)

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	
4.	1.5.9	Evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form (Hard gelatin Capsule) in any one of the reference regulatory authority specified by Registration Board in its 275th meeting, for further Evaluation of application.	**Firm submitted Bioequivalence study in reply against XTANDI 40mg Soft Gelatin Capsule of Astellas Pharma US,**

Comparison

S.NO	XTANDI 40mg Soft Gelatin Capsule of Astellas Pharma US,	ENZALUTA Capsules 40mg of Bdr Pharmaceutical International Pvt.Ltd
1.	**Description:** XTANDI is provided as liquid-filled soft gelatin capsules	White to off white Granular Powder filled in Hard gelatin Capsule shell
2.	**Compostion:**	**Compostion:** Acetone

	Caprylocaproyl Polyoxylglycerides NF Butylated Hydroxyanisole NF Butylated Hydroxytoluene	Caprylocaproyl Polyoxyl- 8 glycerides (Labrasol ALF) Colloidal silicon Dioxide Microcrystalline cellulose
3.	**Analytical testing method:** **Dissolution:** USP Apparatus II Paddle speed: 50 rpm Volume/Temp: 900 ml / 37o C Tier-1: 0.1N HCl/0.3% CTAB, Tier-2: 0.1N HCl/ 0.3% CTAB/pepsin; Q= % at 15 minutes	**Dissolution:** USP Apparatus II Paddle speed: 50 rpm Volume/Temp: 900 ml / 37o C .1N HCl/0.3% CTAB, Additional test : Tier-2: 0.1N HCl/ 0.3% CTAB/pepsin; Q= % at 30 minutes
Decision: Deferred for evidence of approval / registration / marketing status of the applied formulation in the same composition, salt form and dosage form (Hard gelatin Capsule) in any one of the reference regulatory authority specified by Registration Board in its 275th meeting.		

Case no. 06 Registration applications of import cases

a. New Cases (Human)

546.	Name, address of Applicant / Importer	M/s Himmel Pharmaceuticals (Pvt.) Ltd Ground Floor,6- Judicial Colony Phase-I (Ext.) Shahrah Nazaria e Pakistan, Lahore
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174-D **Address:** Ground Floor,6- Judicial Colony Phase-I (Ext.) Shahrah Nazaria e Pakistan, Lahore **Address of Godown:** NA **Validity:** 06-02-2024 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2 Toyenbee Circular Road Motijheel Dhaka Bangladesh
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2 Toyenbee Circular Road Motijheel Dhaka Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# DA/6-110/2016/3295 issued on 01-06-2020 by Government of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration, Oushad Bhaban, Mohkhali Dhaka-1212, and Bangladesh. **Free sale:** Free sale of the product in exporting country: Yes confirms from COPP GMP certificate: Yes confirms as recommended by WHO confirms from COPP (Section for Anticancer Tablet mentioned in previous GMP certificate)
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. 793-D,

		Block 'C' , Faisal Town, Lahore to register their products in Pakistan. Issued on 02-06-2020
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 32075 dated: 23-11-2021
	Details of fee submitted	PKR 50,000/- deposit Slip # 2037740 PKR 25,000/- deposit Slip # 0297702362
	The proposed proprietary name / brand name	Nindanix 100 Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Nintedanib Esylate(micronized) INN equivalent to Nintedanib…… 100mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anti-cancer 1) (kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF). 2) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. 3) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
	Reference to Finished product specifications	In house
	Proposed Pack size	80's in HDPE bottle
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	OFEV 100MG capsule (Boehringer Ingelheim pharmaceutical USFDA approved.
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Name, address of drug substance manufacturer	Beijing Mesochem Technology Co., Ltd. Floor 23, Building 9, Lippo Plaza Economic and Technological Development Zone Beijing

	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 24 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months Batches: (150515, 150623, 150721)

Evaluation by PEC:

S.No	Section	Shortcomings Communicated
1.	1.3.1.	Address mentioned in this section is different than address mentioned on Drug Sale Licence.
2.	1.3.4	Sole agency agreement / letter of authorization between applicant and marketing authorization holder have different address of applicant
3.	1.5.9	Applied formulation is applied as hard gelatin capsule while Innovator/Reference product is available as soft gelatin capsule. Provide the Evidence in reference agency as hard gelatin capsule for further Evaluation.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

c. Deferred cases

i. Human

547.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi
	Details of Drug Sale License of importer	**License No:** 565 **Address:** Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. **Address of Godown:** (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi **Validity:** 16-06-2024 **Status:** License to sell Drugs by way of Wholesale **Renewal:** Yes Submitted valid till 16-06-2022
	Name and address of marketing authorization holder (abroad)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece.
	Name, address of manufacturer(s)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece. **Local repacking by:** Global Pharmaceuticals Private Limited. Plot No. 204 – 205, Industrial Triangle, Kahuta Road, Islamabad, Pakistan

	Name of exporting country	Greece
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP (**certificate no. 72204**) dated **11-08-2021** issued by National Organization for Medicines (EOF), 284 Mesogeion Ave. 155 62 Holargos Attica, Greece. The CoPP confirms status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every 3 years. The name of importing country on CoPP is mentioned as Pakistan. **Free sale in country of origin:** Yes
	Details of letter of authorization / sole agency agreement	Firm has submitted original, legalized sole agency agreement (letter of authorization) as product registration holder. The letter specifies that the manufacturer **ANFARM HELLAS S.A., located at 4 Achaias Str. & Trizinias, 14564, Kifisia Attiki Greece** (administration office as per COPP) appoints M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi to register their products in Pakistan. The authorization letter is issued on 28-06-2021
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☐ Finished Pharmaceutical product import ☒ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 28326 dated: 14-10-2021
	Details of fee submitted	PKR 100,000/- Deposit slip # 97617572626
	The proposed proprietary name / brand name	DOWPENEM INJECTION 500g IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Each vial of Powder contains:** Meropenem trihydrate equivalent to Meropenem…….500mg (with sodium carbonate) **Diluent:** **Each ampoule contains:** Sterilized water for injection…….10ml
	Pharmaceutical form of applied drug	Powder for Injection/ Infusion
	Pharmacotherapeutic Group of (API)	Carbapenem Antibiotic
	Reference to Finished product specifications	In House
	Proposed Pack size	1's

	Proposed unit price	As per DPC
	The status in reference regulatory authorities	Merrem (Meropenem) Injection 500mg IV **(USFDA** Approved).
	For generic drugs (me-too status)	Meroget Injection of Getz Pharma Pvt. Ltd. (Reg # 083174)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Name, address of drug substance manufacturer	ACS DOBFAR SpA 2: Addetta Site, Viale Addetta, 2a/12-3/5 20067 Tribiano, Milano - Italy
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API. Stability study conditions: Real time: 25oC ± 2oC and 60% RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Accelerated Batches: (330772 023 0, 330772 025 0, 330772 027 0) Real time Batches: (330772 8001 8, 330772 8001 0, 330772 8038 1)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Pharmaceutical Equivalence against the innovator product Meronem 500mg by AstraZeneca Batch no # 14047 C
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Colourless glass Vial type III sealed with rubber stopper and aluminium cap with Plastic flip-off seal
	Stability study data of drug product, shelf life and storage conditions	Accelerated stability studies have been conducted at 40ºC ±2ºC / 75%±5% RH for 06 months.

		Real time stability studies conducted at 30 ºC±2ºC / 65% ± 5% RH for one batch for 36 months ((24410) and two batches 24 months (36474, 33994) Batches of stability studies : (24410, 36474, 33994)

Evaluation by PEC:

<table>
<tr><th>Sr.no.</th><th>Obseravtions/Shortcoming</th><th>Reply of the Firm</th></tr>
<tr><td>1.</td><td>Letter of Authorization by ANFARM HELLAS S.A does not mentioned that label vials will be imported.</td><td>Firm replied that the letter for Authorization provided in the submitted dossier states that Martin Dow Limited has expreseed its willingness to import the products Dowpenem Injection 500mg &1g in full compliance with the relevant local and international guidelines and cGMP standards which actually corresponds to the labelled vials.
We, hereby clarify that we are importing the product in the form of labelled vials and final packaging along with diluents will be done by Global Pharmaceuticals.</td></tr>
<tr><td>2.</td><td colspan="2">Product is available in USP pharmacopeia while applied formulation is claimed in house specifications. Clarify.
Firm claimed that in-house specifications are more stringent than USP specifications.
<table>
<tr><th>Controls</th><th>USP monograph of Meropenem Injection</th><th>Anafarm's Release specification</th></tr>
<tr><td>Assay</td><td>90%-120%</td><td>95%-105%</td></tr>
<tr><td>Content of sodium</td><td>80%-120%</td><td>…</td></tr>
<tr><td>Sodium carbonate content</td><td>….</td><td>14.7%-16.1%</td></tr>
<tr><td>Bacterial Endotoxin</td><td>NMT 0.12 EU/mg</td><td>NMT 0.12 EU/mg</td></tr>
<tr><td>Loss on Drying</td><td>9.0%-12.0%</td><td>9.0%-12.0%</td></tr>
<tr><td>pH</td><td>7.3-8.3</td><td>7.3-8.3</td></tr>
<tr><td>Sterility test</td><td>Sterile</td><td>Sterile</td></tr>
<tr><td>Particulate contaminants</td><td>Meets the requirements for SVP injections</td><td>Meets the requirements for SVP injections</td></tr>
<tr><td>Uniformity of dosage unit</td><td>Meets the requirement</td><td>Meets the requirement</td></tr>
</table>
Further firm stated that Anafarm do not test sodium content ,however the percentage of sodium carbonate is calculated to be equal to 15.4% i.e. equal to 6.7% (w/w) sodium, so the limits are between 6.7-7.0%.</td></tr>
<tr><td>3.</td><td>Certificate of analysis by both drug substance manufacturer and drug product manufacturer not submitted.</td><td>Firm submitted a declaration letter from ANFARM HELLAS S.A in which it is stated that we,Anafarm S.A. receives Meropenem sterile bulk and not the API Meropenem trihydrate.Thus no analysis on the API is performed and thus no method verification is performed.</td></tr>
<tr><td>4.</td><td>Manufacturing process does not show blending of Sodium carbonate with meropenem trihydrate neither by API manufacturer nor by ANFARM HELLAS S.A</td><td>Firm submitted the reply in which it is stated that the mixing of the excipient Sodium carbonate lyophilized sterile with the API meropenem trihydrate sterile is considered as the first step of the manufacturing process of the sterile bulk.</td></tr>
<tr><td>5.</td><td>Data of compatibility studies has been submitted with ANFARM HELLAS S.A diluent while in this case diluent will be locally purchased and no compatibility studies conducted. Justify.</td><td>Firm submit commitment that they perform compatibility studies of the product with the locally purchased diluent before marketing of the product.</td></tr>
<tr><td>6.</td><td>Stability studies provided by drug product manufacturer ANFARM HELLAS S.A while product will</td><td>Firm submit commitment that stability studies for the final product packaged by Global Pharmaceuticals</td></tr>
</table>

	be imported as labelled vials and final packaging will be done by Global Pharmaceuticals. Justify.	will be performed for the first three consecutive batches of commercial scale.
7.	Please specify final quality control release site.	Firm claimed that final quality release site will be Global Pharmaceuticals and the finished product specification are according to USP.
8.	Steps of packaging not mentioned performed in the global pharmaceuticals.	Submitted

Previous Decision (M-322): Deferred for following:

- Justification of not performing test of Sodium content test by M/s Anfarm as recommended by USP monograph.
- Analytical method verification studies of drug substance performed by M/s Anfarm.
- Details regarding Packaging, Quality control analysis and batch release activities to be conducted by M/s Global pharmaceuticals**.**

S.No	Reason of deferment	Reply
1.	Justification of not performing test of Sodium content test by M/s Anfarm as recommended by USP monograph.	Kindly refer to table attached herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life. Based on the provided table, please take into account the following: Anfarm has performed test for Sodium Carbonate Content instead of Sodium Content for which equivalency is provided below: As per the finished product composition, the % content of sodium carbonate is calculated to be equal to 15.4% i.e., equal to 6.7% (w/w) sodium. • USP limit of Sodium Content = 80-120%; i.e., 80-120% of 6.7% sodium = (5.3-8.0%) w/w. • Anfarm's Limit of 14.7-16.1% of Sodium carbonate corresponds to sodium (6.4-7.0%) w/w. Thus, Anfarm's limit of sodium content is **6.4-7.0%** which is stringent than USP limit **5.3-8.0%**.
2.	Analytical method verification studies of drug substance performed by M/s Anfarm	The analytical methods for Assay, Related substances, Sodium carbonate content, Sterility and Bacterial Endotoxins have been validated, confirming their suitability for its intended purpose. The validation studies were performed at the manufacturing site of Anfarm Hellas. Also, please note that the validation studies are the same for the Drug Substance (Meropenem Sterile Bulk) and the Final Product (Meropenem Sterile Vials), as the limit is the same and the final product is the active substance (Meropenem Sterile Bulk) filled in vials. For reference, Analytical Method Validation is attached.
3.	Details regarding Packaging, Quality control analysis and batch release activities to be conducted by M/s Global pharmaceuticals.	Please note that Quality Control Analysis and Batch Release activities of products **Dowpenem Injection 500mg and 1g** will be conducted by **M/s Global Pharmaceuticals (Pvt.) Ltd.** on the basis of specifications given by the manufacturer

		"Anfarm Hellas" for which Undertaking from M/s Global Pharmaceuticals (Pvt.) Ltd. is attached herewith. Also please find attached herewith, the steps of packaging and handling performed by M/s Global Pharmaceuticals (Pvt.) Ltd.

Decision: Deferred for following:

- **Submission of stability data including performance of test for "Sodium content" as recommended by USP monograph for applied formuation .**
- **Details of the manufacturing steps (including packaging and batch release) to be conducted at the site of M/s Global Pharmaceuticals (Pvt.) Ltd. Islamabad.**

548.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi
	Details of Drug Sale License of importer	**License No:** 565 **Address:** Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. **Address of Godown:** (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi **Validity:** 16-06-2024 **Status:** License to sell Drugs by way of Wholesale **Renewal:** Yes Submitted valid till 16-06-2022
	Name and address of marketing authorization holder (abroad)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece.
	Name, address of manufacturer(s)	ANFARM HELLAS S.A. 61st km NAT.RD. ATHENS-LAMIA, Schimatari Viotias 32009, Greece. **Local repacking by:** Global Pharmaceuticals Private Limited. Plot No. 204 – 205, Industrial Triangle, Kahuta Road, Islamabad, Pakistan
	Name of exporting country	Greece
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP (**certificate no. 72204**) dated **11-08-2021** issued by National Organization for Medicines (EOF), 284 Mesogeion Ave. 155 62 Holargos Attica, Greece. The CoPP confirms status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every 3 years. The name of importing country on COPP is mentioned as Pakistan. **Free sale in country of origin:** Yes
	Details of letter of authorization / sole agency agreement	Firm has submitted original, legalized sole agency agreement (letter of authorization) as product registration holder. The letter specifies that the manufacturer **ANFARM HELLAS S.A., located at 4 Achaias Str. & Trizinias, 14564, Kifisia Attiki Greece** (administration office as per COPP) appoints M/s Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi to register their

		products in Pakistan. The authorization letter is issued on 28-06-2021
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the t hese	☐ Finished Pharmaceutical product import ☒ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 29009 dated: 25-10-2021
	Details of fee submitted	PKR 150,000/- deposit Slip # 5765002081
	The proposed proprietary name / brand name	DOWPENEM INJECTION 1g IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Each vial of Powder contains:** Meropenem trihydrate equivalent to Meropenem…….1000mg (with sodium carbonate) **Diluent:** **Each ampoule contains:** Sterilized water for injection…….20ml
	Pharmaceutical form of applied drug	Powder for Injection/ Infusion
	Pharmacotherapeutic Group of (API)	Carbapenem Antibiotic
	Reference to Finished product specifications	In House
	Proposed Pack size	1's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	Merrem (Meropenem) Injection 1000mg IV **(USFDA** Approved).
	For generic drugs (me-too status)	Meroget Injection of Getz Pharma Pvt. Ltd. (Reg # 083175)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Name, address of drug substance manufacturer	ACS DOBFAR SpA 2: Addetta Site, Viale Addetta, 2a/12-3/5 20067 Tribiano, Milano - Italy

	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API. Stability study conditions: Real time: 25oC ± 2oC and 60% RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Accelerated Batches: (330772 023 0, 330772 025 0, 330772 027 0) Real time Batches: (330772 8001 8, 330772 8001 0, 330772 8038 1)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Pharmaceutical Equivalence against the innovator product Meronem 500mg by AstraZeneca Batch no # 14047 C. Firm submitted justification "The manufacturer of Meropenem injection 500mg and 1g ha performed the pharmaceutical Equivalence on the same Powder of Merpenem trihydrate that is filled in the vials of both 500mg and 1g. Hence, Pharmaceutical equivalence of one strength (500mg) with the Innovator brand shall be considered as as pharmaceutical equivalence of the other strength (1g) That is why the manufacturer has covered the same pharmaceutical equivalence under the heading of both strengths. Moreover, the parameters covering in pharmaceutical equivalence of Meropenm injection 500mg are general and can be used for bulk powder testing. Hence confirming the point of equivalence for meropenem injection"
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Colourless glass Vial type III sealed with rubber stopper and aluminium cap with Plastic flip-off seal
	Stability study data of drug product, shelf life and storage conditions	Accelerated stability studies have been conducted at 40oC ±2oC / 75%±5% RH for 06 months. Real time stability studies conducted at 30 oC±2oC / 65% ± 5% RH for one batch for 36 months (317121) and two batches 24 months (31523, 31813) Batches of stability studies : (317121, 31523, 31813)

Evaluation by PEC:

<table>
<tr><th>Sr.no.</th><th>Obseravtions/Shortcoming</th><th>Reply of the Firm</th></tr>
<tr><td>1.</td><td>Letter of Authorization by ANFARM HELLAS S.A does not mentioned that label vials will be imported.</td><td>Firm replied that the letter for Authorization provided in the submitted dossier states that Martin Dow Limited has expreseed its willingness to import the products Dowpenem Injection 500mg &1g in full compliance with the relevant local and international guidelines and cGMP standards which actually corresponds to the labelled vials.
We, hereby clarify that we are importing the product in the form of labelled vials and final packaging along with diluents will be done by Global Pharmaceuticals.</td></tr>
<tr><td>2.</td><td colspan="2">Product is available in USP pharmacopeia while applied formulation is claimed in house specifications. Clarify.
Firm claimed that in-house specifications are more stringent than USP specifications.
<table>
<tr><th>Controls</th><th>USP monograph of Meropenem Injection</th><th>Anafarm's Release specification</th></tr>
<tr><td>Assay</td><td>90%-120%</td><td>95%-105%</td></tr>
<tr><td>Content of sodium</td><td>80%-120%</td><td>…</td></tr>
<tr><td>Sodium carbonate content</td><td>….</td><td>14.7%-16.1%</td></tr>
<tr><td>Bacterial Endotoxin</td><td>NMT 0.12 EU/mg</td><td>NMT 0.12 EU/mg</td></tr>
<tr><td>Loss on Drying</td><td>9.0%-12.0%</td><td>9.0%-12.0%</td></tr>
<tr><td>pH</td><td>7.3-8.3</td><td>7.3-8.3</td></tr>
<tr><td>Sterility test</td><td>Sterile</td><td>Sterile</td></tr>
<tr><td>Particulate contaminants</td><td>Meets the requirements for SVP injections</td><td>Meets the requirements for SVP injections</td></tr>
<tr><td>Uniformity of dosage unit</td><td>Meets the requirement</td><td>Meets the requirement</td></tr>
</table>
Further firm stated that Anafarm do not test sodium content ,however the percentage of sodium carbonate is calculated to be equal to 15.4% i.e. equal to 6.7% (w/w) sodium, so the limits are between 6.7-7.0%.</td></tr>
<tr><td>3.</td><td>Certificate of analysis by both drug substance manufacturer and drug product manufacturer not submitted.</td><td>Firm submitted a declaration letter from ANFARM HELLAS S.A in which it is stated that we,Anafarm S.A. receives Meropenem sterile bulk and not the API Meropenem trihydrate.Thus no analysis on the API is performed and thus no method verification is performed.</td></tr>
<tr><td>4.</td><td>Manufacturing process does not show blending of Sodium carbonate with meropenem trihydrate neither by API manufacturer nor by ANFARM HELLAS S.A</td><td>Firm submitted the reply in which it is stated that the mixing of the excipient Sodium carbonate lyophilized sterile with the API meropenem trihydrate sterile is considered as the first step of the manufacturing process of the sterile bulk.</td></tr>
<tr><td>5.</td><td>Data of compatibility studies has been submitted with ANFARM HELLAS S.A diluent while in this case diluent will be locally purchased and no compatibility studies conducted. Justify.</td><td>Firm submit commitment that they perform compatibility studies of the product with the locally purchased diluent before marketing of the product.</td></tr>
<tr><td>6.</td><td>Stability studies provided by drug product manufacturer ANFARM HELLAS S.A while product will be imported as labelled vials and final packaging will be done by Global Pharmaceuticals. Justify.</td><td>Firm submit commitment that stability studies for the final product packaged by Global Pharmaceuticals will be performed for the first three consecutive batches of commercial scale.</td></tr>
</table>

7.	Please specify final quality control release site.	Firm claimed that final quality release site will be Global Pharmaceuticals and the finished product specification are according to USP.
8.	Steps of packaging not mentioned performed in the global pharmaceuticals.	Submitted

Previous Decision (M-322): Deferred for following:

- Justification of not performing test of Sodium content test by M/s Anfarm as recommended by USP monograph.
- Analytical method verification studies of drug substance performed by M/s Anfarm.
- Details regarding Packaging, Quality control analysis and batch release activities to be conducted by M/s Global pharmaceuticals**.**

S.No	Reason of deferment	Reply
1.	Justification of not performing test of Sodium content test by M/s Anfarm as recommended by USP monograph.	Kindly refer to table attached herewith, where you may find the comparison between the specifications mentioned in the USP monograph and the specifications set by Anfarm, both at release and during shelf life. Based on the provided table, please take into account the following: Anfarm has performed test for Sodium Carbonate Content instead of Sodium Content for which equivalency is provided below: As per the finished product composition, the % content of sodium carbonate is calculated to be equal to 15.4% i.e., equal to 6.7% (w/w) sodium. • USP limit of Sodium Content = 80-120%; i.e., 80-120% of 6.7% sodium = (5.3-8.0%) w/w. • Anfarm's Limit of 14.7-16.1% of Sodium carbonate corresponds to sodium (6.4-7.0%) w/w. Thus, Anfarm's limit of sodium content is **6.4-7.0%** which is stringent than USP limit **5.3-8.0%.**
2.	Analytical method verification studies of drug substance performed by M/s Anfarm	The analytical methods for Assay, Related substances, Sodium carbonate content, Sterility and Bacterial Endotoxins have been validated, confirming their suitability for its intended purpose. The validation studies were performed at the manufacturing site of Anfarm Hellas. Also, please note that the validation studies are the same for the Drug Substance (Meropenem Sterile Bulk) and the Final Product (Meropenem Sterile Vials), as the limit is the same and the final product is the active substance (Meropenem Sterile Bulk) filled in vials. For reference, Analytical Method Validation is attached.
3.	Details regarding Packaging, Quality control analysis and batch release activities to be conducted by M/s Global pharmaceuticals.	Please note that Quality Control Analysis and Batch Release activities of products **Dowpenem Injection 500mg and 1g** will be conducted by **M/s Global Pharmaceuticals (Pvt.) Ltd.** on the basis of specifications given by the manufacturer "Anfarm Hellas" for which Undertaking from M/s Global Pharmaceuticals (Pvt.) Ltd. is attached herewith.

		Also please find attached herewith, the steps of packaging and handling performed by M/s Global Pharmaceuticals (Pvt.) Ltd.

Decision: Deferred for following:

- **Submission of stability data including performance of test for "Sodium content" as recommended by USP monograph for applied formuation .**
- **Details of the manufacturing steps (including packaging and batch analysis) to be conducted at the site of M/s Global Pharmaceuticals (Pvt.) Ltd. Islamabad.**

Case no. 07 Registration applications of drugs for which stability study data is submitted

a. New cases

549.	**Name and address of manufacturer / Applicant**	**M/s Pacific Pharmaceuticals Limited 30 Km, Multan road Lahore**
	Brand Name +Dosage Form + Strength	Dexlan 30mg Capsule
	Composition	Each Capsules contains: Dexlansoprazol delayed release pellets eq Dexlanzoprazol.....…30mg
	Diary No. Date of R& I & fee	Dy.No 36634 dated 06-11-2018 Rs.20,000 /- Dated 06-11-2018
	Pharmacological Group	Proton Pump inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	2 x 7's, 4 x 7's :As per SRO
	Approval status of product in Reference Regulator Authorities	Dexilant Delayed Release Capsule 30mg of USFDA approved
	Me-too status	Lansodex Capsule 30mg of M/S Getz Pharma
	GMP status	Last inspection conducted on 22/02/2018 and concludes that "In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during inspection, M/s pacific pharma ltd Multan road Lahore, was considered to be operating at good level of GMP compliance at the time of inspection. Therefore, the panel of inspectors recommends considering the firm for grant of GMP certificate for export purposes." "GMP Certificate Issued on 05-03-2018."
	Remarks of the Evaluator	

STABILITY STUDY DATA	
Drug	Dexlan 30mg Capsule
Name of Manufacturer	M/s Pacific Pharmaceuticals Limited 30 Km, multan road lahore
Manufacturer of API	M/S Vision Pharmaceuticals (Pvt)., Ltd is submitted. **M/S Al Wajar Pharmaceuticals Industry LLC**
API Lot No.	**PDLB19003, PDLB19002 & PDLB19001** DLP 376
Description of Pack (Container closure system)	PVC-PVDC blisters
Stability Storage Condition	Real time : 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH

Time Period	Real time: 6 months Accelerated:6 months		
Frequency	Accelerated:0,1,2,3,4,5,6 (month) Real Time: 0,3,6, (month)		
Batch No.	TDX00101P	TDX00201P	TDX00301P
Batch Size	5000 Capsules	5000 Capsules	5000 Capsules
Manufacturing Date	10-2019	10-2019	10-2019
Date of Initiation	05-02-2020	05-02-2020	05-02-2020
No. of Batches	03		
Date of Submission	27-08-2020 (21606)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm.	• Not submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Copy of COA of Dex-Lansoprazole DDR pellets 22.5% (Batch# PDLB19003, PDLB19002 & PDLB19001) from M/S Al Wajar Pharmaceuticals Industry LLC is submitted.** Copy of COA [Batch# DLP 376)from M/S Vision Pharmaceuticals (Pvt) Ltd is submitted. Copy of COA (Batch# DLP 376) from M/S Pacific Pharmaceuticals is submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Yes
4.	Stability study data of API from API manufacturer	Yes
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Certificate of Good manufacturing practice Based on inspection conducted on 11-02-2019
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Not valid
7.	Protocols followed for conduction of stability study	Yes
8.	Method used for analysis of FPP	No
9.	Drug-excipients compatibility studies (where applicable)	Not valid
10.	Complete batch manufacturing record of three stability batches.	No
11.	Record of comparative dissolution data.	No
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	No
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Yes

14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes

Remarks of Evaluator

S.No	Shortcomings Communicated	Reply
1.	Data has not been provided as per guidelines approved by registration board in 293rd meeting nor arranged in order.	Submitted
2.	Stability data of 30mg and 60mg shall be submitted separately.	Submitted
3.	Submit differential fee of RS: 80000/- in case of imported pellets.	**Now source mentioned is vision pharmaceuticals**
4.	Submit Certificate of Analysis of API from Finished Product manufacturer	Submitted
5.	Submit Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Submitted
6.	Submit Stability study data of API from API manufacturer	Submitted
7.	Submit Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin	Submitted
8.	Submit AD attested invoice of pellets.	Not valid
9.	Protocols followed for conduction of stability study prepared after initiation of stability studies. Clarify	Submitted
10.	Data of 03 batches will be supported by attested respective documents like, Raw data sheets, COA, summary data sheets etc.	Not Submitted
2nd letter 24th November 2021		
1.	In initial submitted data source of pellets was M/S Al Wajar Pharmaceuticals Industry LLC while in reply source of pellets is changed to vision Pharmaceuticals. Clarification is required in this regard.	
2.	Method used for analysis of FPP	
3.	Reference of previous approval of applications with stability study data of the firm.	
4.	Record of comparative dissolution data.	
5.	Complete batch manufacturing record of three stability batches.	
6.	Data of 03 batches will be supported by attested respective documents like, Raw data sheets, COA, summary data sheets etc.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

550.	**Name and address of manufacturer / Applicant**	**M/s Pacific Pharmaceuticals Limited 30 Km, multan road lahore**

	Brand Name +Dosage Form + Strength	Dexlan 60mg Capsule
	Composition	Each Capsules contains: Dexlansoprazol delayed release pellets eq Dexlanzoprazol.....…60mg
	Diary No. Date of R& I & fee	Dy.No 36635 dated 06-11-2018 Rs.20,000 /- Dated 06-11-2018
	Pharmacological Group	Proton Pump inhibitor
	Type of Form	Form 5
	Finished product Specifications	Manufacturer specifications
	Pack size & Demanded Price	2 x 7's, 4 x 7's :As per SRO
	Approval status of product in Reference Regulator Authorities	Dexilant Delayed Release Capsule 60mg of USFDA approved
	Me-too status	Lansodex Capsule 60mg of M/S Getz Pharma
	GMP status	Last inspection conducted on 22/02/2018 and concludes that "In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during inspection, M/s pacific pharma ltd Multan road Lahore, was considered to be operating at good level of GMP compliance at the time of inspection. Therefore, the panel of inspectors recommends considering the firm for grant of GMP certificate for export purposes." "GMP Certificate Issued on 05-03-2018."
	Remarks of the Evaluator	

STABILITY STUDY DATA			
Drug	Dexlan 60mg Capsule		
Name of Manufacturer	M/s Pacific Pharmaceuticals Limited 30 Km, multan road lahore		
Manufacturer of API	M/S Vision Pharmaceuticals (Pvt)., Ltd is submitted. **M/S Al Wajar Pharmaceuticals Industry LLC**		
API Lot No.	**PDLB19003, PDLB19002 & PDLB19001** DLP 376		
Description of Pack (Container closure system)	PVC-PVDC blisters		
Stability Storage Condition	Real time : 30°C ± 2° C / 65% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period	Real time: 6 months Accelerated:6 months		
Frequency	Accelerated:0,1,2,3,4,5,6(month) Real Time: 0,3,6, (month)		
Batch No.	TDL00101P	TDL00201P	TDL00301P
Batch Size	4500 Capsules	4500 Capsules	4500 Capsules
Manufacturing Date	10-2019	10-2019	10-2019
Date of Initiation	05-02-2020	05-02-2020	05-02-2020
No. of Batches	03		
Date of Submission	27-08-2020 (21606)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**

1.	Reference of previous approval of applications with stability study data of the firm	• Not submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Copy of COA of Dex-Lansoprazole DDR pellets 22.5% (Batch# PDLB19003, PDLB19002 & PDLB19001) from M/S Al Wajar Pharmaceuticals Industry LLC is submitted.** Copy of COA [Batch# DLP 376)from M/S Vision Pharmaceuticals (Pvt) Ltd is submitted. Copy of COA (Batch# DLP 376) from M/S Pacific Pharmaceuticals is submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Yes
4.	Stability study data of API from API manufacturer	Yes
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Certificate of Good manufacturing practice Based on inspection conducted on 11-02-2019
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Not valid
7.	Protocols followed for conduction of stability study	Yes
8.	Method used for analysis of FPP	No
9.	Drug-excipients compatibility studies (where applicable)	Not valid
10.	Complete batch manufacturing record of three stability batches.	No
11.	Record of comparative dissolution data (where applicable)	No
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	No
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Yes
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes

Remarks of Evaluator

S.No	Shortcomings Communicated	Reply
1.	Data has not been provided as per guidelines approved by registration board in 293rd meeting nor arranged in order.	Submitted
2.	Stability data of 30mg and 60mg shall be submitted separately.	Submitted
3.	Submit differential fee of RS: 80000/- in case of imported pellets.	**Now source mentioned is vision pharmaceuticals**

4.	Submit Certificate of Analysis of API from Finished Product manufacturer	Submitted
5.	Submit Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Submitted
6.	Submit Stability study data of API from API manufacturer	Submitted
7.	Submit Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin	Submitted
8.	Submit AD attested invoice of pellets.	Not valid
9.	Protocols followed for conduction of stability study prepared after initiation of stability studies. Clarify	Submitted
10.	Data of 03 batches will be supported by attested respective documents like, Raw data sheets, COA, summary data sheets etc.	Not Submitted
2nd letter 24th November 2021		
1.	In initial submitted data source of pellets was M/S Al Wajar Pharmaceuticals Industry LLC while in reply source of pellets is changed to vision Pharmaceuticals. Clarification is required in this regard.	
2.	Method used for analysis of FPP	
3.	Reference of previous approval of applications with stability study data of the firm.	
4.	Record of comparative dissolution data.	
5.	Complete batch manufacturing record of three stability batches.	
6.	Data of 03 batches will be supported by attested respective documents like, Raw data sheets, COA, summary data sheets etc.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

551.	Name and address of manufacturer / Applicant	M/s Medisure Laboratories Pakistan (Pvt)_ Limited. A-115, S.I.T.E, Super Highway, Karachi, Pakistan.
	Brand Name +Dosage Form + Strength	Declasure 60mg Tablet
	Composition	Each film coated tablet contains: Daclatasvir as Dihydrochloride ……60 mg
	Diary No. Date of R& I & fee	Dy.No 39933 dated 04-12-2018 Rs.20,000/- 04-12-2018(Duplicate)
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specifications	Not mentioned
	Pack size & Demanded Price	
	Approval status of product in Reference Regulator Authorities	DAKLINZA 60mg, film coated tablets USFDA Approved

	Me-too status	Daclavir 60mg tablet by M/s Dyson Research Laboratories (Reg#089964)
	GMP status	

STABILITY STUDY DATA	
Drug	Declasure 60mg Tablet
Name of Manufacturer	M/s Medisure Laboratories Pakistan (Pvt)_ Limited. A-115, S.I.T.E, Super Highway, Karachi, Pakistan.

Remarks of Evaluator
Letter dated: 15-03-2021

Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.
Method used for analysis of API from both API Manufacturer and Finished Product manufacturer.
Stability study data of API from API manufacturer.
Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.
Documents for the procurement of API with approval from DRAP
Protocols followed for conduction of stability study.
Method used for analysis of drug product.
Complete batch manufacturing record of three stability batches.
Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

552.		
	Name and address of manufacturer / Applicant	M/s Hudson Pharma (Pvt) Ltd, Plot No.D-93, North Western Industrial Zone, Port Qasim, Karachi
	Brand Name +Dosage Form + Strength	Hivair 250mcg+50mcg Rotacaps
	Composition	Each Rotacap contains: Fluticasone propionate …250mcg Salmeterol Xinafoate …50mcg
	Diary No. Date of R& I & fee	Diary No:5748, 16/02/2018, Rs: 50,000/-
	Pharmacological Group	Adrenergics, Inhalants (Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)
	Type of Form	Form 5-D
	Finished product Specifications	BP
	Pack size & Demanded Price	30‘s/ As per SRO
	Approval status of product in Reference Regulator Authorities	Seretide Accuhaler 50/250 by M/s Glaxo Wellcome S.A (MHRA Approved)
	Me-too status	SERETIDE DISKUS 50/250MCG POWDER FOR INHALATION by M/s GLAXO WELLCOME PRODUCTION (Reg#074727)
	GMP status	19-01-2018 Panel recommends grant of additional sections
	Remarks of the Evaluator.	Evidence of rotacaps is not found in Reference Regulatory Authorities. This formulation is available as, metered dose dry powder inhaler. ● Evidence of rotacaps from me-too database not confirmed. ● Firm has applied on Form 5-D without submission of stability study data

	Previous Decision	Deferred for submission of stability studies data and related documents as per decision of 278th meeting of Registration board. (M-281)

STABILITY STUDY DATA			
Drug	Hivair 250mcg+50mcg Rotacaps		
Name of Manufacturer	M/s Hudson Pharma (Pvt) Ltd, Plot No.D-93, North Western Industrial Zone, Port Qasim, Karachi		
Manufacturer of API	**Fluticasone propionate :** M/s Farmabios S.P.A, Via Pavia, 1 27027 Gropello Cairo (PV), Italy **Salmeterol Xinafoate :** M/s Vamsi Labs Ltd. A-14/15, MIDC Area, Chincholl, Solapur- 413255, Maharashtra India		
API Lot No.	**Fluticasone Propionate :** 21460M0 B0051621 **Salmeterol Xinafoate :** SX-0071116		
Description of Pack (Container closure system)	HPMC capsule		
Stability Storage Condition	Real time : 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated:0,3,6 (month) Real Time: 0,3,6, 9,12,18,24 (month)		
Batch No.	SB01	SB02	SB02
Batch Size	400 gm (16000 Rotacaps)	400 gm (16000 Rotacaps)	400 gm (16000 Rotacaps)
Manufacturing Date	27-02-2018	03-09-2018	03-09-2018
Date of Initiation	05-05-2018	10-09-2018	10-09-2018
No. of Batches	03		
Date of Submission	03-12-2020 (32140)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents To Be Provided**	**Status**
1.	Reference of previous approval of applications with stability study data of the firm	Not submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Fluticasone propionate :** Copy of COA of Fluticasone propionate (Batch# 21460M0 B0051621.) from M/s Farmabios S.P.A, Via Pavia, 1 27027 Gropello Cairoli (PV), Italy is submitted. Copy of COA (Batch# 21460M0) from M/S Hudson is submitted. **Salmeterol Xinafoate :** Copy of COA of Salmeterol Xinafoate (Batch# SX-0071116.) from M/s Vamsi Labs Ltd. A-14/15, MIDC Area, Chincholl, Solapur- 413255, Maharashtra India is submitted. Copy of COA (Batch# SX-0071116) from M/S Hudson is submitted.

<table>
<tr><td>3.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Yes</td></tr>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td>Fluticasone propionate : The firm has submitted copy accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & lor term, 60 Months (30°C ± 2°C & 75±5%RH) stability stuc reports of 03 batches
Salmeterol Xinafo: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 48 Months (30°C ± 2°C & 75±5%RH) stability study reports of 03 batches</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Fluticasone propionate : Copy of GMP certificate No# :IT-API/112/H/2020 for M/s FARMABIOS S.P.A. Via Pavia, 1, GROPELLO CAIROLI, 27027, Italy issued by AIFA Italian medicine Agency, issued on the basis of inspection conducted on 12-06-2020 and, valid for three years.
Salmeterol Xinafoate : Copy of GMP certificate for M/s Vamsi Labs Ltd. A-14/15, MIDC Area, Chincholl, Solapur- 413255, Maharashtra India issued by Food and Drug Adminstration Maharastra, issued on 14-11-2018 and, valid for three years..</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Fluticasone propionate : Copy of form 6 and Commercial Invoice No: 1342 Dated: 14-09-2016 from M/s Farmabios S.P.A, Via Pavia, 1 27027 Gropello Cairoli (PV), Italy attested by AD DRAP (Karachi) dated ; 05-10-2016 for Fluticasone propionate batch No# # 21460M0 B0051621
Salmeterol Xinafoate : Copy of form 6 and Commercial Invoice No: S-024/2017-18 Dated: 31-07-2017 from M/s Vamsi Labs Ltd. A-14/15, MIDC Area, Chincholl, Solapur- 413255, Maharashtra India attested by AD DRAP (Karachi) dated ; 08-08-2017 for Salmeterol Xinafoate batch No# SX-0071116.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record.
Details are as under:
<table>
<tr><td colspan="3">Hivair 250mcg+50mcg Rotacaps</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Started</td></tr>
<tr><td>SB01</td><td>16000 Rotacap</td><td>27-02-2018</td></tr>
<tr><td>SB02</td><td>16000 Rotacap</td><td>03-09-2018</td></tr>
<tr><td>SB03</td><td>16000 Rotacap</td><td>03-09-2018</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>Not applicable</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like</td><td>Yes</td></tr>
</table>

	chromatograms, Raw data sheets, COA, summary data sheets etc.	
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not

Remarks of Evaluator

First letter Dated: 22-10-2020

- You have conducted stability studies before approval of DPI' section as specialized manufacturing and testing are required for manufacturing of DPI . Justify.
- Two different stability data has been submitted with same batch no i.e with different manufacturing dates and analysis dates . Clarify.
- Aerodynamic Particle Size Distribution and "Uniformity of Delivered Dose has not been performed in stability data submitted for first time, hence these testes has been conducted in later submitted data. Justify

Second letter after submission of Rearranged Data
Dated:28-05-2021

S.NO	Shortcomings	Reply
1.	Stability data of Batch No# SB01 manufacturing date:05-05-2018, Stability initiation date 05-05-2018, initial testing date: 08-05-2018, Batch No# SB02 manufacturing date:03-09-2018, Stability initiation date 10-09-2018 initial testing date: 20-09-2018 and Batch No# SB03 manufacturing date:03-09-2018, Stability initiation date 10-09-2018, initial testing date: 20-09-2018 was submitted on 21-07-2020. On reply of letter dated: 22-10-2020 you have submitted data of same batches however in Batch No# SB01 manufacturing date changed as 27-02-2018 and testing dates also changed in each time point in all 03 batches.	There was just typographical error in manufacturing dates of previous data because of which we updated and recompiled the stability data . Furthermore, the reason behind the difference between the dates of all 3 batches is that Batch # SB01 was manufactured on 27-02-2018 while Batch# SB02 and SB03 were manufactured on 03-09-2018
2.	Certificate of Analysis of API from Finished Product manufacturer of Fluticasone Propionate, Salmeterol Xinafoate	Fluticasone Propionate submitted Salmeterol xinafoate with batch No# Sx-0030617 submitted by both API manufacturer and drug product manufacturer while initially submitted COA by API manufacturer and commercial invoice is of Batch No# SX-0071116.
3.	Stability study data of both API from API manufacturer	Fluticasone Propionate, Real time not according to zoneIV-A/B Salmeterol Xinafoate: Submitted
4.	Provide details of device used.	We are using device manufactured by Rizwan Associates, DPI Device (Dry Powder Inhaler Device)
5.	Provide evidence of equipment's used for Delivered dose Uniformity and Aerodynamic size distribution	Pictorial evidence is attached

6.	Scientific justifications of overage of Fluticasone Propionate ,Salmeterol Xinafoate used in manufacturing of stability batches.	As API is present in micro quantities in the product ,powder loss during manufacturing is there hence additional amount of API is added as an overage. **(50% overage is added)**
7.	Aerodynamic size distribution should be performed at each time point while you have not performed between initial and 12 months in real time stability while in accelerated only initial time point performed.. Justification is required	We performed Aerodynamic size distribution studies initially in order to assure the desired quality. DRAP advised us to perform and submit this study at every testing interval, at that time 12 months testing was due we started performing the test at every time point.

Third letter After submission of reply
Dated:18-06-2021

S.No	Shortcoming communicated	Reply
1.	The batch No mentioned on submitted COA's by both API manufacturer and drug product manufacturer (Hudson) is different from that mentioned on commercial Invoice. Clarification is required in this regard	COA of Salmeterol Xinafoate from API manufacturer and Drug product manufacturer submitted in line with invoice
2.	Storage condition for Real time stability studies of API (Fluticasone Propionate) are not according to zone IV-A/B. Clarification is required.	Stability studies of API (Fluticasone Propionate) according to zone IV-B. of 3 batches Submitted
3.	Provide performance based evidence of Loss of API's during manufacturing process as 50% overage is used.	Initially we added 25% overage due to API loss during manufacturing as the API is added in very small quantities. We performed assay of this trial batch and observed that assay results found out of specification. On the basis of this testing we manufactured another trial batch with an overage of 50% and the assay results were found within specification
4.	Performance of test of content uniformity in addition to test of Delivered dose uniformity required to be submitted.	We performed content uniformity tests at time points 0 Month, 1 Month, 3 Month, 6 Month and 9 Month while we started to perform Delivered Dose Uniformity test from time point 12 Month and onwards
5.	Description of the delivery device (inhaler) intended to be marketed along with the applied formulation.	We are using the device manufactured by Rizwan Associates
6.	Provide evidence of equipment used for Delivered dose Uniformity and Aerodynamic size distribution	As per routine cGMP inspection report of Area FID dated 13-12-2019 in which there remarks is QC lab is well equipped with all necessary equipment including Cascade impactor.

4th letter Dated: 06-12-2021

- Provide details of manufacturing Loss of API's during manufacturing process as 50% overage is used.

Decision: Deferred for submission of details of manufacturing loss of drug substance during drug product manufacturing process, as 50% overage of drug substance is included in formulation.

Item No. 5: Agenda of Evaluator PEC-XV (Mst. Saima Hussain)

(a) Import applications of priority categories defined by Registration Board in its 257th meeting

553.	Name, address of Applicant / Importer	**M/s FRESENIUS KABI PAKISTAN PVT LTD**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-019525d **Address:** Tanwir Ahmed Medical Centre (TAMC), First Floor MM Alam Road, 27-C/3, Gulberg III, District Lahore. **Address of Go down:** Agility Logistics, RLC-2 26-Km Multan Road **Validity:** 21-12-2023. **Status:** License to sell drugs as distributor **Renewal: 21-12-2021**
	Name and address of marketing authorization holder (abroad)	Fresenius Kabi AB Rapsgatan 751 74 Uppsala Sweden.
	Name, address of manufacturer(s)	Fresenius Kabi AB Rapsgatan 751 74 Uppsala Sweden.
	Name of exporting country	Sweden
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. **5.8.1-2021-58760**) dated 13-07-2021 issued by ***Swedish Medical Products Agency*** for Smofkabiven Emulsion for infusion. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned as Pakistan. Furthermore the CoPP was valid till 13-08-2022.**
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Fresenius Kabi AB. The letter species that the manufacturer appoints M/s Fresenius Kabi Pakistan Pvt Ltd. to register their products in Pakistan. The authorization letter is valid until revoke my MAH.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 1303: 14-Jan-2022
	Details of fee submitted	PKR 100,000/-: 10-08-2020
	The proposed proprietary name / brand name	SmofKabiven, emulsion for infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 03-chamber bag contains: **Composition of 1000 ml amino acid solution, Aminoven 10% with Electrolytes** **Aminoven 10% with electrolytes Content** L-Alanine ….14.0 g L-Arginine ….12.0 g

<table>
<tr><td></td><td></td><td>Glycine (Amino acetic acid) ….11.0 g
L-Histidine…. 3.0 g
L-Isoleucine ….5.0 g
L-Leucine ….7.4 g
L-Lysine acetate ….9.3 g corresponding to L-Lysine 6.6 g
L-Methionine ….4.3 g
L-Phenylalanine ……5.1 g
L-Proline ……11.2 g
L-Serine ….6.5 g
Taurine ……1.0 g
L-Threonine ……4.4 g
L-Tryptophan ……2.0 g
L-Tyrosine ……0.40g
L-Valine …….6.2 g
Calcium chloride dihydrate 0.74g
corresponding to Calcium chloride ….0.56 g
Sodium glycerophosphate, hydrated * corresponding to Sodium glycerophosphate……4.18 g
Magnesium sulfate heptahydrate 2.47 g*
corresponding to Magnesium sulfate ….1.2 g
Potassium chloride…. 4.48 g
Sodium acetate trihydrate 5.62 g* corresponding to Sodium acetate …….3.4 g
Zinc sulfate heptahydrate 0.023 g*
corresponding to Zinc sulfate …….0.0129 g
Composition of 1000 ml glucose solution, Glucose 42%
Glucose monohydrate 462 g corresponding to Glucose (anhydrous)……420 g
Composition of 1000 ml emulsion, SMOFlipid 20%
Soya-bean oil, refined ….60 g
Triglycerides, medium-chain…. 60 g
Olive oil…. 50 g
Fish oil, rich in omega-3 acids…30 g</td></tr>
<tr><td></td><td>Pharmaceutical form of applied drug</td><td>Infusion in triple chamber bags (semi-permeable)
<table>
<tr><th>Chamber bag</th><th>986 ml</th><th>1477 ml</th><th>1970 ml</th><th>2463 ml</th></tr>
<tr><td>Aminoven 10% with electrolytes (ml)</td><td>500 ml</td><td>750 ml</td><td>1000 ml</td><td>1250ml</td></tr>
<tr><td>Glucose 42%</td><td>298 ml</td><td>446 ml</td><td>595ml</td><td>744 ml</td></tr>
<tr><td>SMOFlipid</td><td>188 ml</td><td>281 ml</td><td>375 ml</td><td>469ml</td></tr>
</table></td></tr>
<tr><td></td><td>Pharmacotherapeutic Group of (API)</td><td>Nutrition’s (Carbohydrates, Proteins, Electrolytes, Fats, Amino acids)</td></tr>
<tr><td></td><td>Reference to Finished product specifications</td><td>In house</td></tr>
<tr><td></td><td>Proposed Pack size</td><td>1’s</td></tr>
<tr><td></td><td>Proposed unit price</td><td>Rs /- 493ml Triple chamber bags
Rs /- 986ml Triple chamber bags
Rs /- 1477ml Triple chamber bags
Rs /- 1970ml Triple chamber bags
Rs /- 2463ml Triple chamber bags</td></tr>
<tr><td></td><td>The status in reference regulatory authorities</td><td>Smofkabiven emulsion for infusion (All over Europe)</td></tr>
<tr><td></td><td>For generic drugs (me-too status)</td><td>NA</td></tr>
<tr><td></td><td>Module-II (Quality Overall Summary)</td><td>Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers,</td></tr>
</table>

<table>
<tr><td></td><td></td><td>description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Name, address of drug substance manufacturer</td><td>25 plus APIs from different manufacturers, All Manufacturer CEP's (Certificate of suitability from EMA) are attached.</td></tr>
<tr><td></td><td>Module-III Drug Substance:</td><td>Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Stability Studies of Drug Substance (Conditions & duration of Stability studies)</td><td>Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at multiple temperatures according to the APIs. The stability study data is till 24 months. CEPs are attached.</td></tr>
<tr><td></td><td>Module-III Drug Product:</td><td>Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.</td></tr>
<tr><td></td><td>Pharmaceutical Equivalence and Comparative Dissolution Profile</td><td>Fresenius Kabi is the Innovator/originator (Statement attached).</td></tr>
<tr><td></td><td>Analytical method validation/verification of product</td><td>Firm has submitted analytical method validation studies for the applied product.</td></tr>
<tr><td></td><td>Container closure system of the drug product</td><td>03 Chamber Bag (Semi-permeable)</td></tr>
<tr><td></td><td>Stability study data of drug product, shelf life and storage conditions</td><td>Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40ºC ±2ºC / 25% ± 5% RH for 6 months. The real time stability study data is conducted at 25ºC ±2ºC / 40% ± 5% RH. The real time stability study data of 03 batches are for 24 months. (Justification attached)
<table>
<tr><th>Batch no.</th><th>Container size (ml)</th><th>Production date</th><th>Study type (temperature)</th><th>Storage time (months)</th></tr>
<tr><td>10CC1888</td><td>986ml</td><td>09-03-2009</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
<tr><td>10CC1888</td><td>986ml</td><td>09-03-2009</td><td>accelerated (40 °C ± 2 °C)</td><td>6</td></tr>
<tr><td>10CC1892</td><td>2463ml</td><td>09-03-2009</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
<tr><td>10CC1892</td><td>2463ml</td><td>09-03-2009</td><td>accelerated (40 °C ± 2 °C)</td><td>6</td></tr>
<tr><td>10CC1896</td><td>1970ml</td><td>09-03-2009</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
</table>
</td></tr>
</table>

		10CC1896	1970ml	09-03-2009	accelerated (40 °C ± 2 °C)	6
		10FI2740	1970ml	09-05-2012	long-term (25 °C ± 2 °C)	24
		10FI2740	1970ml	09-05-2012	accelerated (40 °C ± 2 °C)	6

Evaluation by PEC:

CEP no. Certification of suitability of all above-mentioned API is as under:

Sr.no.	Sections	Observations/Deficiencies/ Short-comings	Response of the Firm
1.	Module-1	Submit the valid cGMP certificate of Manufacturer abroad, since the submitted certificate was based on inspection dated 17-04-2017, more than three years had elapsed since the date of inspection.	Firm submitted the GMP certificate of Manufacturer Abroad certificate number :6.2.1-2020-002243 based on inspection dated 15-10-2020.
2.	1.3.4	Submit valid drug sale license of M/s. Fresenius Kabi, Pakistan, since the submitted DSL was expired on 21-12-2021.	Firm submitted the copy of valid DSL valid till 21-12-2023.
3.	1.5.4	Submit separate application for each individual volume of infusion on Form-5F along with the requisite fee and all the required data/documents as per CTD guidance document, since you have applied for four different volumes of infusion in a single application.	Firm replied that "We would like to go with the following volume/pack size; **For Smofkabiven; 1477ml** **For Smofkabiven Peripheral; 1448 ml** **Later firm changed the volume/pack size as per the available stability data of drug product i.e.** **Smofkabiven: 986ml** **Smofkabiven Peripheral: 1206ml**
4.	3.2.S.4.2	Submit data in section 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "*Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required*."	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
5.	3.2.S.4.3	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".*	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
6.	3.2.S.7	Justify for not performing the microbiological testing during the stability studies of following drug substance despite the test is included in the specification of that drug substance: Alanine L-arginine	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore,

		L-histidine L-Isoleucine L-leucine L-lysine acetate L-Methionine L-valine L-Tryptophan L-threonine Potassium Chloride	being an innovator of a product, we have submitted the CEPs for all the APIs.
7.	3.2.S.7	Submit stability summary of three batches of following drug substances performed both at accelerated and long term stability conditions till claimed re-test period. Serine Calcium chloride dihydrate Magnesium Sulfate heptahydrate Potassium Chloride Zinc Sulfate heptahydrate Glucose Monohydrate Olive oil Soybean oil (6 month accelerated study of three batches require)	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
8.	3.2.P.5.4	Justify for not including the pH determination test in the release specification Mixed three chamber bag to evaluate the final pH of three chambers mixture.	Firm replied that "The justification for not including the analysis of pH in the mixed bag, is that the amino acid solution functions as a buffer. The pH limit for the amino acid solution is 5.4 - 5.8. Due to the buffering capacity of the amino acid solution, the pH of the mixture will take on the same pH as the amino acid solution. Measuring the pH in the mixed bag will therefore not give any additional information and the pH is already controlled in the amino acid solution. In Table 1 and Table 2 the pH in the amino acid solution and in the mixed bag is listed for 10 SmofKabiven batches and 10 SmofKabiven Peripheral batches, respectively.
9.	3.2.P.8	Submit stability data of drug product as per zone IV-a conditions since the submitted data is not in accordance with zone-IV-a conditions.	Firm replied that We wish to inform you that the product SmofKabiven and SmofKabiven Peripheral is three chamber bag Biofine (Semi-permeable) system and the inner bag is separated into three chambers by peelable seal. Each bag contains amino acid solution with addition of electrolytes, Glucose and Lipid emulsion (SmofLipid 20% - Soya Bean Oil, medium chain triglycerides, Olive Oil and Fish Oil). Lipid emulsion consist of triglycerides dispersed in water together with emulsifiers to stabilize the system. SmofKabiven contains 42 % Glucose while SmofKabiven Peripheral contains 13% Glucose strength. **Product has storage condition below 25°C.**

			For the product, stability studies are conducted as per ICH guidelines - Q1A(R2) at below said condition for 24 months • Long term stability conditions: 25 °C ± 2°C/40 % RH ± 5% RH • Accelerated stability conditions: 40 °C ± 2°C/25 % RH ± 5% RH • Intermediate stability conditions: 30 °C ± 2°C/25 % RH ± 5% RH In order to meet the demands from countries in Climatic Zones III and IV, the batches were tested at 30°C/25% RH in addition to 25°C real time studies. The lower relative humidity at 30°C is more critical with regard to weight loss for aqueous based products in semi permeable containers. The results after 24 months storage at 25°C/40% RH and 6 months at 40°C/NMT 25% RH respectively, were all within specification. However, all results after 24 months storage at 30°C/25% RH, were out of specification. This was expected as the amount of free fatty acids will increase as the rate of hydrolysis increases with temperature. Conclusion: At 30°C, all results are out of specification after 24 months and hence Stability studies at Zone IVB condition (30°C/75% RH) for 24 months is not applicable for SmofKabiven products. Also the Lipid Emulsion is not stable at higher temperature since The rate of the hydrolysis and amount of free fatty acids will increase with temperature. Stability studies are conducted as per the ICH guidelines - Q1A(R2) for semipermeable packaging products. The results after up to 24 months of storage at 25°C/40% RH, and 6 months at 40°C/NMT 25% RH, respectively, show that the stability of the separate chambers and the individual mixtures of SmofKabiven fulfil the specification, verifying the quality and shelf life of SmofKabiven when stored at the labelled condition, 25°C for 24 months. Product is already approved and marketed in zone IV ASEAN countries with the storage condition below 25°C.
10	3.2.P.8.1	Please elaborate the procedure of weight loss study, since you have not incorporate the data of initial weight of pack which has been measured/marked initially at the zero-time point. How you have compare the weight loss of individual pack at the	Firm replied that, they have mentioned the initial weight of each bag used in the stability studies at the start of the table i.e. 960ml, 1477ml. Secondly, we have used the same pack for the all the time intervals, and compare the weight loss accordingly.

		next time point, either the same pack was used upto 24 months.	

Decision: Approved as per policy of inspection of manufacturer abroad. Registration Board further decided to approve the storage condition as "Store below 25ºC" with shelf life of two years.

- **Firm shall select only one fill volume before issuance of registration letter.**

554.	Name, address of Applicant / Importer	**M/s FRESENIUS KABI PAKISTAN PVT LTD**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-019525d **Address:** Tanwir Ahmed Medical Centre (TAMC), First Floor MM Alam Road, 27-C/3, Gulberg III, District Lahore. **Address of Go down:** Agility Logistics, RLC-2 26-Km Multan Road **Validity:** 21-12-2023. **Status:** License to sell drugs as distributor **Renewal: 21-12-2021**
	Name and address of marketing authorization holder (abroad)	Fresenius Kabi AB Rapsgatan 751 74 Uppsala Sweden.
	Name, address of manufacturer(s)	Fresenius Kabi AB Rapsgatan 751 74 Uppsala Sweden.
	Name of exporting country	Sweden
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. **5.8.1-2019-099**) dated 13-07-2021 issued by ***Swedish Medical Products Agency*** for Smofkabiven Emulsion for infusion. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned as Pakistan. Furthermore the CoPP was valid till 13-08-2022.**
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Fresenius Kabi AB. The letter species that the manufacturer appoints M/s Fresenius Kabi Pakistan Pvt Ltd. to register their products in Pakistan. The authorization letter is valid until revoke my MAH.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 1303: 14-Jan-2022
	Details of fee submitted	PKR 100000/-: 10-08-2020
	The proposed proprietary name / brand name	SmofKabiven, emulsion for infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 03-chamber bag contains: **Composition of 1000 ml amino acid solution, Aminoven 10% with** **Electrolytes** **Aminoven 10% with electrolytes Content**

<table>
<tr><td></td><td></td><td>L-Alanine ….14.0 g
L-Arginine ….12.0 g
Glycine (Amino acetic acid) ….11.0 g
L-Histidine…. 3.0 g
L-Isoleucine ….5.0 g
L-Leucine ….7.4 g
L-Lysine acetate ….9.3 g corresponding to L-Lysine 6.6 g
L-Methionine ….4.3 g
L-Phenylalanine ……5.1 g
L-Proline ……11.2 g
L-Serine ….6.5 g
Taurine ……1.0 g
L-Threonine ……4.4 g
L-Tryptophan ……2.0 g
L-Tyrosine ……0.40g
L-Valine …….6.2 g
Calcium chloride dihydrate 0.74g
corresponding to Calcium chloride ….0.56 g
Sodium glycerophosphate, hydrated * corresponding to Sodium glycerophosphate……4.18 g
Magnesium sulfate heptahydrate 2.47 g*
corresponding to Magnesium sulfate ….1.2 g
Potassium chloride…. 4.48 g
Sodium acetate trihydrate 5.62 g* corresponding to Sodium acetate …….3.4 g
Zinc sulfate heptahydrate 0.023 g*
corresponding to Zinc sulfate …….0.0129 g
Composition of 1000 ml glucose solution, Glucose 13%
Glucose monohydrate…. 143 g
corresponding to Glucose (anhydrous)…… 130 g
Composition of 1000 ml emulsion, SMOFlipid 20%
Soya-bean oil, refined ….60 g
Triglycerides, medium-chain…. 60 g
Olive oil…. 50 g
Fish oil, rich in omega-3 acids…30 g</td></tr>
<tr><td></td><td>Pharmaceutical form of applied drug</td><td>Infusion in triple chamber bags (semi-permeable)
SmofKabiven Peripheral consists of a three chamber bag system. Each bag contains the following
partial volumes depending on the three pack sizes.
<table>
<tr><th>Chamber bag</th><th>1206 ml</th><th>1448 ml</th><th>1904 ml</th><th>1000 ml</th></tr>
<tr><td>Glucose 13%</td><td>656 ml</td><td>788 ml</td><td>1036 ml</td><td>544 ml</td></tr>
<tr><td>Amino acid solution with electrolytes</td><td>380 ml</td><td>456 ml</td><td>600 ml</td><td>315 ml</td></tr>
<tr><td>Lipid emulsion</td><td>170 ml</td><td>204ml</td><td>268 ml</td><td>141 ml</td></tr>
</table></td></tr>
<tr><td></td><td>Pharmacotherapeutic Group of (API)</td><td>Nutrition’s (Carbohydrates, Proteins, Electrolytes, Fats, Amino acids)</td></tr>
<tr><td></td><td>Reference to Finished product specifications</td><td>In house</td></tr>
<tr><td></td><td>Proposed Pack size</td><td>1’s</td></tr>
<tr><td></td><td>Proposed unit price</td><td>Rs /- 493ml Triple chamber bags
Rs /- 986ml Triple chamber bags
Rs /- 1477ml Triple chamber bags
Rs /- 1970ml Triple chamber bags
Rs /- 2463ml Triple chamber bags</td></tr>
<tr><td></td><td>The status in reference regulatory authorities</td><td>Smofkabiven emulsion for infusion (All over Europe)</td></tr>
<tr><td></td><td>For generic drugs (me-too status)</td><td>NA</td></tr>
</table>

<table>
<tr><td></td><td>Module-II (Quality Overall Summary)</td><td>Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Name, address of drug substance manufacturer</td><td>25 plus APIs from different manufacturers, All Manufacturer CEP's (Certificate of suitability from EMA) are attached.</td></tr>
<tr><td></td><td>Module-III Drug Substance:</td><td>Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Stability Studies of Drug Substance (Conditions & duration of Stability studies)</td><td>Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at multiple temperatures according to the APIs. The stability study data is till 24 months. CEPs are attached.</td></tr>
<tr><td></td><td>Module-III Drug Product:</td><td>Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.</td></tr>
<tr><td></td><td>Pharmaceutical Equivalence and Comparative Dissolution Profile</td><td>Fresenius Kabi is the Innovator/originator (Statement attached).</td></tr>
<tr><td></td><td>Analytical method validation/verification of product</td><td>Firm has submitted analytical method validation studies for the applied product.</td></tr>
<tr><td></td><td>Container closure system of the drug product</td><td>03 Chamber Bag (Semi-permeable)</td></tr>
<tr><td></td><td>Stability study data of drug product, shelf life and storage conditions</td><td>Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40ºC ±2ºC / 25% ± 5% RH for 6 months. The real time stability study data is conducted at 25ºC ±2ºC / 40% ± 5% RH. The real time stability study data of 03 batches are for 24 months.
<table>
<tr><th>Batch no.</th><th>Container size (ml)</th><th>Production date</th><th>Study type (temperature)</th><th>Storage time (months)</th></tr>
<tr><td>10HL2935</td><td>1206</td><td>16-11-2016</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
<tr><td>10HL2935</td><td>1206</td><td>16-11-2016</td><td>accelerated (40 °C ± 2 °C)</td><td>6</td></tr>
<tr><td>10HL2939</td><td>1904</td><td>16-11-2016</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
<tr><td>10HL2939</td><td>1904</td><td>16-11-2016</td><td>accelerated (40 °C ± 2 °C)</td><td>6</td></tr>
<tr><td>10HL2943</td><td>1904</td><td>17-11-2017</td><td>long-term (25 °C ± 2 °C)</td><td>24</td></tr>
<tr><td>10HL2943</td><td>1904</td><td>17-11-2017</td><td>accelerated (40 °C ± 2 °C)</td><td>6</td></tr>
</table></td></tr>
<tr><td colspan="3">Evaluation by PEC:</td></tr>
</table>

Sr.no.	Sections	Observations/Deficiencies/ Short-comings	Response of the Firm
1.	Module-1	Submit the valid cGMP certificate of Manufacturer abroad, since the submitted certificate was based on inspection dated 17-04-2017, more than three years had elapsed since the date of inspection.	Firm submitted the GMP certificate of Manufacturer Abroad certificate number :6.2.1-2020-002243 based on inspection dated 15-10-2020.
2.	1.3.4	Submit valid drug sale license of M/s. Fresenius Kabi, Pakistan, since the submitted DSL was expired on 21-12-2021.	Firm submitted the copy of valid DSL valid till 21-12-2023.
3.	1.5.4	Submit separate application for each individual volume of infusion on Form-5F along with the requisite fee and all the required data/documents as per CTD guidance document, since you have applied for four different volumes of infusion in a single application.	Firm replied that "We would like to go with the following volume/pack size; **For Smofkabiven; 1477ml** **For Smofkabiven Peripheral; 1448 ml** **Later firm changed the volume/pack size as per the available stability data of drug product i.e.** **Smofkabiven: 986ml** **Smofkabiven Peripheral: 1206ml**
4.	3.2.S.4.2	Submit data in section 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "*Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required*."	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
5.	3.2.S.4.3	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".*	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
6.	3.2.S.7	Justify for not performing the microbiological testing during the stability studies of following drug substance despite the test is included in the specification of that drug substance: Alanine L-arginine L-histidine L-Isoleucine L-leucine L-lysine acetate L-Methionine L-valine L-Tryptophan L-threonine Potassium Chloride	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
7.	3.2.S.7	Submit stability summary of three batches of following drug substances performed	Firm replied that The Certification of Suitability (CEP) is a certificate that certifies

		both at accelerated and long term stability conditions till claimed re-test period. Serine Calcium chloride dihydrate Magnesium Sulfate heptahydrate Potassium Chloride Zinc Sulfate heptahydrate Glucose Monohydrate Olive oil Soybean oil (6 month accelerated study of three batches require)	compliance of the active pharmaceutical ingredients (API) or pharmaceutical ingredients with that of the rules laid down in the monograph of the European Pharmacopoeia (EP). Therefore, being an innovator of a product, we have submitted the CEPs for all the APIs.
8.	3.2.P.5.4	Justify for not including the pH determination test in the release specification Mixed three chamber bag to evaluate the final pH of three chambers mixture.	Firm replied that "The justification for not including the analysis of pH in the mixed bag, is that the amino acid solution functions as a buffer. The pH limit for the amino acid solution is 5.4 - 5.8. Due to the buffering capacity of the amino acid solution, the pH of the mixture will take on the same pH as the amino acid solution. Measuring the pH in the mixed bag will therefore not give any additional information and the pH is already controlled in the amino acid solution. In Table 1 and Table 2 the pH in the amino acid solution and in the mixed bag is listed for 10 SmofKabiven batches and 10 SmofKabiven Peripheral batches, respectively.
9.	3.2.P.8	Submit stability data of drug product as per zone IV-a conditions since the submitted data is not in accordance with zone-IV-a conditions.	Firm replied that We wish to inform you that the product SmofKabiven and SmofKabiven Peripheral is three chamber bag Biofine (Semi-permeable) system and the inner bag is separated into three chambers by peelable seal. Each bag contains amino acid solution with addition of electrolytes, Glucose and Lipid emulsion (SmofLipid 20% - Soya Bean Oil, medium chain triglycerides, Olive Oil and Fish Oil). Lipid emulsion consist of triglycerides dispersed in water together with emulsifiers to stabilize the system. SmofKabiven contains 42 % Glucose while SmofKabiven Peripheral contains 13% Glucose strength. **Product has storage condition below 25°C.** For the product, stability studies are conducted as per ICH guidelines - Q1A(R2) at below said condition for 24 months • Long term stability conditions: 25 °C ± 2°C/40 % RH ± 5% RH • Accelerated stability conditions: 40 °C ± 2°C/25 % RH ± 5% RH • Intermediate stability conditions: 30 °C ± 2°C/25 % RH ± 5% RH In order to meet the demands from countries in Climatic Zones III and IV, the batches were tested at 30°C/25% RH in addition to 25°C real time studies. The lower relative humidity at 30°C is more critical with regard to weight loss for aqueous based products in semi permeable containers.

			The results after 24 months storage at 25°C/40% RH and 6 months at 40°C/NMT 25% RH respectively, were all within specification. However, all results after 24 months storage at 30°C/25% RH, were out of specification. This was expected as the amount of free fatty acids will increase as the rate of hydrolysis increases with temperature. Conclusion: At 30°C, all results are out of specification after 24 months and hence Stability studies at Zone IVB condition (30°C/75% RH) for 24 months is not applicable for SmofKabiven products. Also the Lipid Emulsion is not stable at higher temperature since The rate of the hydrolysis and amount of free fatty acids will increase with temperature. Stability studies are conducted as per the ICH guidelines - Q1A(R2) for semipermeable packaging products. The results after up to 24 months of storage at 25°C/40% RH, and 6 months at 40°C/NMT 25% RH, respectively, show that the stability of the separate chambers and the individual mixtures of SmofKabiven fulfil the specification, verifying the quality and shelf life of SmofKabiven when stored at the labelled condition, 25°C for 24 months. Product is already approved and marketed in zone IV ASEAN countries with the storage condition below 25°C.
10	3.2.P.8.1	Please elaborate the procedure of weight loss study, since you have not incorporate the data of initial weight of pack which has been measured/marked initially at the zero-time point. How you have compare the weight loss of individual pack at the next time point, either the same pack was used uptill 24 months.	Firm replied that, they have mentioned the initial weight of each bag used in the stability studies at the start of the table i.e. 960ml, 1477ml. Secondly, we have used the same pack for the all the time intervals, and compare the weight loss accordingly.

Decision: Approved as per policy of inspection of manufacturer abroad. Registration Board further decided to approve the storage condition as "Store below 25°C" with shelf life of two years.

- **Firm shall select only one fill volume before issuance of registration letter.**

555.	**Name, address of Applicant / Importer**	**M/s Al Habib Pharmaceuticals**
	Details of Drug Sale License of importer	**License No:** 0230 **Address:** 81-B Block B, S.M.C.H.S., Karachi **Address of Godown:** 393/7,393/8 Sector 7-A KIA Karachi **Validity:** 19/05/2022 till 18/05/2024 **Status:** License to sell drugs as distributor **Renewal:** Valid
	Name and address of marketing authorization holder (abroad)	Naprod Life Sciences Pvt. Ltd. Plot no. G-17/1,MIDC,Tarapur,Boisar,Thane 401506 Maharashtra State, India
	Name, address of manufacturer(s)	Naprod Life Sciences Pvt. Ltd. Plot no. G-17/1,MIDC,Tarapur,Boisar,Thane 401506 Maharashtra State, India

	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. COPP/CERT/KD/104901/2021/11/1799901) dated 16 August, 2021 (valid till 03-April,2022) issued by Food & Drug Administration Maharashtra State, Mumbai for Macabi (Bicalutamide Tablets USP 50mg). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. Certificate of renewal of Licence to Manufacture of M/s. NAPROD LIFE SCIENCES PVT. LTD valid from 01-01-2017 to 31-12-2021. Certificate of Good Manufacturing Practices of M/s. Naprod Life Sciences Pvt. Ltd. Maharashtra State, India certificate no. NEW-WHO-GMP/CERT/KD/80691/2019/11/27530 DATED 04-April,2019 valid till 03-April,2022.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of Authorization from M/s. Naprod Life Sciences Pvt. Ltd. authorize to M/s. Al Habib Pharmaceuticals, Karachi as a sole agent and distributor of Macabi (Bicalutamide) Tablet 50mg.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5227 dated 24-02-2022
	Details of fee submitted	PKR 150,000/-: dated 26-01-2022
	The proposed proprietary name / brand name	**MACABI Tablets 50mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film coated tablet contains: Bicalutamide……50mg ATC Code L02BB03
	Pharmaceutical form of applied drug	1 × 10's in Alu-Alu Blister
	Pharmacotherapeutic Group of (API)	ATC Code L02BB03 (Anti Androgens)
	Reference to Finished product specifications	USP
	Proposed Pack size	As per policy
	Proposed unit price	As per policy
	The status in reference regulatory authorities	USFDA (Casodex 50mg Tablet)
	For generic drugs (me-too status)	Casodex 50mg Tablet of M/s. ICI Pakistan Ltd., Hattar (Reg.no. 027380)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to

		nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s. Mac Chem Products (India) Pvt. Ltd. N-211/2/10.Tarapur MIDC,Biosar,District Thane, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 30ºC ± 2ºC,60%±5% RH (60 months) and accelerated time stability study conducted at 40°C±2°C,75%±5% RH (6 months) of following batches: BCL0211001,BCL0211002,BCL0211003
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has established against the innovator product casodex 50mg Tablet (M/s. AstraZeneca Pvt. Ltd.) Batch no. 60022647. Comparative dissolution has performed in all three recommended physiological medium against the innovator brand.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Alu foil & PVC film coated with PVDC Blister foil.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of 10,000 tablets batch size. The accelerated stability study is conducted at 40°C/75%RH and data of 6 months has submitted. The real time stability study is conducted at 30°C±2°C/75%±5%RH. The real time stability study data of 24 months has been submitted. Batch no. NT1160,NT1161,NT1162

Evaluation by PEC:

S.no.	Observations/Deficiencies/ Short-comings	Reply of the Firm
1.	Drug substance Bicalutamide is a racemate mixture, please provide the detail along with quantitative results, that which enantiomeric	Bicalutamide is racemic mixture i.e. a mixture of equal quantities (50:50) of two enantiomers.as single enantiomeric form is not used, enantiomeric purity is not applicable.

	form of API has been used in the manufacturing of drug product.	*CASODEX is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive.*
2.	Justify for keeping the water content limit NMT 7.0% comparing the water content of active ingredient NMT 0.2%.	Firm replied that our product complies with the current USP monograph of bicalutamide tablet 50mg ,drug product monograph in USP does not contain water content test ,hence the limit of water content was given in-house based on the water content of API ,excipients and manufacturing process.
3.	justify, for submitting the validation report of 150mg strength instead of applied 50mg strength.	Submitted
Registration Board was apprised regarding an e. mail received to Director PE&R Division form M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.		

Decision: Deferred for following:

- **Verification of "Sole Agency Agreement" between M/s. Al Habib Pharmaceuticals, Plot # 81, Block B, SMCHS, Karachi & M/s Naprod Life Sciences Pvt. Ltd. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, India.**
- **Scientific justification regarding declaration of Bicalutamide as racemic mixture i.e. a mixture of equal quantities (50:50) of two enantiomers**

556.	**Name, address of Applicant / Importer**	**M/s SA Pharmaceuticals, Pakistan**
	Details of Drug Sale License of importer	**License No:** 01-373-0020-019224D **Address:** Tehsil Road, Opposite Masjid Afghanan, Tehsil & District Jhelum **Address of Godown:** NA **Validity:** 02-Nov-2023. **Status:** License to sell drugs as distributor **Renewal:** Valid
	Name and address of marketing authorization holder (abroad)	ESKAYEF PHARMACEUTICALS LIMITED 400 SQUIBB ROAD, TONGI INDUSTRIAL AREA TONGI GAZIPUR, BD-1711, BANGLADESH .
	Name, address of manufacturer(s)	ESKAYEF PHARMACEUTICALS LIMITED 400 SQUIBB ROAD, TONGI INDUSTRIAL AREA TONGI GAZIPUR, BD-1711, BANGLADESH .
	Name of exporting country	BANGLADESH
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. DA/6-39/05/23679) dated 30-Nov 2021 issued by Government of the People's Republic of Bangladesh Ministry of Health & family Welfare Directorate General of Drug Administration Oushad Bhaban, Mohakhali Dhaka-1212, Bangladesh for MONUVIR 200 Capsule (Molnupiravir INN 200mg) . The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned as Pakistan.** **Furthermore the CoPP (EUA) was valid up to the COVID-19 Pandemic Situation and the submitted**

		CoPP bears all the conditions of Emergency use Authorization.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from M/s Eskayef Pharmaceuticals Limited. The letter specifies that the manufacturer appoints M/s Eastgate Biotech Pakistan to register their products in Pakistan. M/s Eastgate Biotech Pakistan further authorize to M/s SA Pharmaceuticals to register the product on behalf of Eastgate Biotech Pakistan. The authorization letter is valid till 17-11-2023.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 8916: 07-04-2022
	Details of fee submitted	PKR 75,000/-: 05-04-2022
	The proposed proprietary name / brand name	**MONUVIR 200 Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains Molnupiravir INN 200 mg.
	Pharmaceutical form of applied drug	1 × 10's in Alu-Alu Blister
	Pharmacotherapeutic Group of (API)	Anti Viral
	Reference to Finished product specifications	In house
	Proposed Pack size	Box containing 1 strip of 10 capsules.
	Proposed unit price	Rs 6000/- per pack (Calculated on dollar exchange rate PKR 178)
	The status in reference regulatory authorities	Molnupiravir 200mg USFDA approved for EUA
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Name, address of drug substance manufacturer	Henan JinHuaitang Biological Engineering., Co., Ltd Address:5329, Hesuodadao Road Street Avenue, Wuzhi Country, Jiazuo City, Henan Province China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC,60%±5% RH (24 months) and accelerated time stability study conducted at 40°C±2°C,75%±5% RH (6 months) of following batches: 20200901,20200919,20201009
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Alu-Alu Bottom Foil- 234 mm
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of 100,000 capsules batch size. The accelerated stability study data is conducted at 40°C/75%RH and data of 54 days has submitted. The real time stability study data is conducted at 25°C±2°C/60%±5%RH. The real time stability study data of only 2 points has been submitted includes initial and 54 days' time points.

Evaluation by PEC:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.	**1.5.9**	Submit regulatory status of approval of applied formulation by reference regulatory authority by way of routine procedure of market authorisation.
2.	**3.2.S.4.2**	Submit data in section 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "*Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required*."Since you have only submitted the requisite information provided by drug substance manufacturer.
3.	**3.2.S.4.3**	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".* Since you have only submitted the requisite information provided by drug substance manufacturer.

4.	**3.2.P.2.2.1**	• Submit the comparative dissolution profile data as per the guidance document approved by Registration Board which specifies that "*Where applicable the results of comparative dissolution profile conducted in three BCS media against the reference product across the physiological pH range along with calculation of similarity factor f2 should be submitted and discussed."* Since you have only submitted the data of test product, which did not fulfill the requirement of comparative dissolution profiling. • Submit data in section 3.2.P.2.2.1 as per the guidance document approved by Registration Board which specifies that "*Pharmaceutical equivalence of the applied drug shall be established with the innovator / reference / comparator product and results of all the quality tests (mentioned in any official pharmacopoe ia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed*."
5.	**3.2.P.5.2**	• According to the assay method given in respective section, for preparation of sample solution weight of powder taken should be equivalent to 250mg of molnupiravir, justify, for taking powder eq. to 250 mg of molnupiravir for the assay of capsule of 200mg strength. • Scientifc justification for including the sample of intermediate blend in the assay of finished drug product along with the supported reference from the international literature,pharmacoepias and international regulatory guidelines.
6.	**3.2.P.5.4**	• Justify for adapting the broader dissolution criteria i.e. NLT 75% (Q) within 45 minutes when the drug dissolved more than 90% at 45 minutes, further the dissolution profiling submitted in section 3.2.P.2.2.1 also revealed that drug shows more than 95% dissolution at 45 minutes. • Justify for selecting 0.1N HCL as a dissolution medium ,when the drug dissolution behavior was similar in all three dissolution mediums after 30 minutes as per the dissolution profiling submit in section 3.2.P.2.2.1.
7.	**3.2.P.6**	Submit COA of reference standard / working standard used for the testing of the stability batches in section 3.2.P.6.
8.	**3.2.P.8**	Submit stability study data of drug product conducted as per zone IV-a conditions till the claimed shelf life, since the stability data of only 1 month has been submitted in the concerned section which was also not conducted at zone IV-a condition.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

557.	**Name, address of Applicant / Importer**	**M/s. Medical Equipment & Systems**
	Details of Drug Sale License of importer	**Address:** 60/61 F.C.C. Syed Maratib Ali Road, Gulberg IV, Lahore **Validity:** **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s. GUERBET BP-57400 F-95943 ROISSY CdG CEDEX
	Name, address of manufacturer(s)	M/s. GUERBET 16-24 rue Jean Chaptal 93600 Aulnay-sous-Bois
	Name of exporting country	France
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of legalized CoPP certificate (No.034154) dated October,2015 issued by chamber and Commerce Industrial Region Paris, France for Xenetix 350, Solution for injection (350mg Iodine/ml). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. Copy of Certificate of Good Manufacturing Practices of M/s. GUERBET 16-24 rue Jean Chaptal, AULNAY SOUS BOIS,93600, France certificate no. 2019/HPF/FR/111 DATED 10-04-2019.

	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of Authorization from M/s. GUERBET 15 rue des Vanesses, VILLEPINTE,93420, France authorize to M/s. Medical Equipment a sole agent and distributor of Xenetix 300mg Pack size 50ml. The releasing site of contrast media drugs for Pakistan is M/s. Guerbet and contrast media will be exported to Pakistan from Hong Kong.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 30261 dated 25-10-2022
	Details of fee submitted	PKR 75,000/-: dated 25-07-2022 slip no.3678562376
	The proposed proprietary name / brand name	**Xenetix 300mg/50ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Xenetix is a 300/ml aqueous injectable solution of Iobitridol. Xenetix 300 in 50ml vial contains 32.905g of Iobitridol.
	Pharmaceutical form of applied drug	Contrast Media (Solution for Injection)
	Pharmacotherapeutic Group of (API)	ATC Code V08AB11 Iodinated contrast media
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	1's (50ml)
	Proposed unit price	As per policy
	The status in reference regulatory authorities	MHRA Approved, ANSM France approved
	For generic drugs (me-too status)	NA (NEW DRUG ,INNOVATOR BRAND)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s.GUERBET Rue Denis PAPIN ZI Kerpont 56600 Lanester France (Manufacturing ,QC testing and Batch release)
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25°C±2°C,60%±5% RH (36 months) and accelerated time stability study conducted at 40°C±2°C,75%±5% RH (6 months) of following batches: At Accelerated storage condition: L001, L002, L003 At Real time storage condition: 97L2676,98L0987,99L0603.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	NA (innovator brand)
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	The drug product is packaged in type II clear glass vials, closed with a type I elastomeric rubber stopper and crimped with aluminium cap.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 following batches. The accelerated stability study is conducted at 40°C/75%RH and data of 6 months has submitted. The real time stability study is conducted at 30°C±2°C/65%±5%RH and data of 36month has submitted.

Batch no.	**Date of Manufacture**	**Packaging**	**Batch size (Litre)**
04WC021A	01/06/2004	Type II colourless glass bottle, closed by an elastomeric (chlorobutyl rubber) stopper	768
04WC022A	01/06/2004		1020
04WC023A	01/06/2004		2400

Evaluation by PEC:

S.no.	Observations/Deficiencies/ Short-comings
1.	Submit original legalized CoPP of Xenetix 300mg Iodine/ml (50ml),since you have submitted the copy of CoPP of product Xenetin 350mg Iodine /ml Injection.
2.	Submit original legalized letter of authorization from Guerbet, France mentioning the product alongwith the applied volume, since you have submitted the copy of letter without any details of applied product.
3.	Submit the legal agreement letter between Hong Kong site and the Guerbet, France since you have mentioned that the product will be exported from Hong Kong to Pakistan. Further,you have mentioned in Form-5F that secondary packaging of applied product will be performed in Pharmtech(HongKong Limited) for Pakistan, so, please clarify the final QC release site of applied product for Pakistan and why the secondary packaging site has not mentioned in the submitted copy of CoPP.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

558.	**Name, address of Applicant / Importer**	**M/s. Medical Equipment & Systems**
	Details of Drug Sale License of importer	**Address:** 60/61 F.C.C. Syed Maratib Ali Road, Gulberg IV, Lahore **Validity:** **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s. GUERBET BP-57400 F-95943 ROISSY CdG CEDEX
	Name, address of manufacturer(s)	M/s. GUERBET 16-24 rue Jean Chaptal 93600 Aulnay-sous-Bois
	Name of exporting country	France
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of legalized CoPP certificate (No.034529) dated 27 May,2020 issued by chamber and Commerce Industrial Region Paris, France for Xenetix 350, Solution for injection (350mg Iodine/ml). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. Copy of Certificate of Good Manufacturing Practices of M/s. GUERBET 16-24 rue Jean Chaptal, AULNAY SOUS BOIS,93600, France certificate no. 2019/HPF/FR/111 DATED 10-04-2019.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of Authorization from M/s. GUERBET 15 rue des Vanesses, VILLEPINTE,93420, France authorize to M/s. Medical Equipment a sole agent and distributor of Xenetix 300mg Pack size 50ml. The releasing site of contrast media drugs for Pakistan is M/s. Guerbet and contrast media will be exported to Pakistan from Hong Kong.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 30259 dated 25-10-2022
	Details of fee submitted	PKR 150,000/-: dated 25-07-2022 slip no.00194398
	The proposed proprietary name / brand name	**Dotarem Injection 20ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Dotarem is a 0.5mmol/mL The composition per 100ml is as follows: Gadoteric Acid…27.932g Corresponding to Dota…. 20.246g Corresponding to gadolinium oxide….9.062g Gadoteric acid: complex of gadolinium with 1,4,7,10-tetraazacyclododecane-N,N',N'',N''' tetraacetic acid

<table>
<tr><td></td><td>Pharmaceutical form of applied drug</td><td>Contrast Media (Solution for Injection)</td></tr>
<tr><td></td><td>Pharmacotherapeutic Group of (API)</td><td>Paramagnetic Contrast media for MRI ATC CODE :V08CA02</td></tr>
<tr><td></td><td>Reference to Finished product specifications</td><td>Manufacturer’s Specification</td></tr>
<tr><td></td><td>Proposed Pack size</td><td>1’s (20ML)</td></tr>
<tr><td></td><td>Proposed unit price</td><td>As per policy</td></tr>
<tr><td></td><td>The status in reference regulatory authorities</td><td>USFDA Approved</td></tr>
<tr><td></td><td>For generic drugs (me-too status)</td><td>NA (NEW DRUG ,INNOVATOR BRAND)</td></tr>
<tr><td></td><td>Module-II (Quality Overall Summary)</td><td>Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Name, address of drug substance manufacturer</td><td>M/s. SIMAFEX 16, Avenue des Fours a´Chaux 17230 MARANS France (Manufacturing, QC testing and Batch release)
M/s. PCAS Finland, O.y Messukentankatu,8 20210 TURKU,Finland ((Manufacturing, QC testing and Batch release)</td></tr>
<tr><td></td><td>Module-III Drug Substance:</td><td>Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.</td></tr>
<tr><td></td><td>Stability Studies of Drug Substance (Conditions & duration of Stability studies)</td><td>Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25°C±2°C,60%±5% RH (36 months) and accelerated time stability study conducted at 40°C±2°C,75%±5% RH (6 months) of following batches:
<table>
<tr><th>Batches</th><th>Manufacturing Date</th><th>Manufacturing site</th></tr>
<tr><td>6113</td><td>Nov 2006</td><td>SIMAFEX</td></tr>
<tr><td>7105</td><td>Oct 2007</td><td>SIMAFEX</td></tr>
<tr><td>11002E</td><td>Mar 2011</td><td>SIMAFEX</td></tr>
</table></td></tr>
<tr><td></td><td>Module-III Drug Product:</td><td>Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.</td></tr>
<tr><td></td><td>Pharmaceutical Equivalence and Comparative Dissolution Profile</td><td>NA (innovator brand)</td></tr>
<tr><td></td><td>Analytical method validation/verification of product</td><td>Firm has submitted analytical method validation studies for the applied product.</td></tr>
</table>

	Container closure system of the drug product	The drug product is packaged in type II clear glass vials, closed with a type I elastomeric rubber stopper and crimped with aluminium cap.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 following batches of DOTA 15ml. The accelerated stability study is conducted at 40°C/75%RH and data of 6 months has submitted. The real time stability study is conducted at 30°C±2°C/65%±5%RH and data of 36month has submitted.

Batch no.	Date of Manufacture	Packaging	Batch size (Litre)
Accelerated Stability study			
08GD021A	March,2008	Type I clear glass vials	400
11GD076B	September 2011		600
15GD040B	May 2015		600
Long term stability study			
15GD040B	May 2015	Type I clear glass vials	600
16GD170B	Dec 2016		900
10GD035B	April 2010		600

Evaluation by PEC:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.		Submit original legalized CoPP for 20ml volume of injection,since you have submitted the copy of CoPP, which was previously considered for 15ml injection.
2.		Submit original legalized letter of authorization from Guerbet, France mentioning the product alongwith the applied volume, since you have submitted the copy of letter without any details of applied product.
3.		Submit the legal agreement letter between Hong Kong site and the Guerbet, France since you have mentioned that the product will be exported from Hong Kong to Pakistan. Further,you have mentioned in Form-5F that secondary packaging of applied product will be performed in Pharmtech(HongKong Limited) for Pakistan, so, please clarify the final QC release site of applied product for Pakistan and why the secondary packaging site has not mentioned in the submitted copy of CoPP.
4.	**3.2.P.8**	Submit the stability data of 20ml filled volume vials as per zone-IV-a conditions till the claimed shelf life, since you have submitted the stability data of Dotarem Injection of 15ml filled volume.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

559.	**Name, address of Applicant / Importer**	**M/s AGP Limited, B-23-C, S.I.T.E., Karachi-75700, Pakistan**
	Details of Drug Sale License of importer	**License No:** DHOKW (Drugs)/-329/-**045** **Address:** AGP Limited, B-23-C, S.I.T.E., Karachi-75700, Pakistan. **Address of Godown:** AGP Limited, B-23-C, S.I.T.E., Karachi **Status:** License to sell, stock & exhibit for sale, distribute and sell drugs by way of whole sale by of manufacturer, importer or indenter **Renewed:** 22-09-2021
	Name and address of marketing authorization holder (abroad)	Mylan Laboratories Limited, Plot No. 11, 12 & 13, Indore, Special Economic Zone, Pharma zone, Phase-II, Sector-III, Pithampur 454775, Dist. Dhar, Madhya Pradesh India.
	Name, address of manufacturer(s)	Mylan Laboratories Limited, Plot No. 11, 12 & 13, Indore, Special Economic Zone, Pharma zone, Phase-II, Sector-III, Pithampur 454775, Dist. Dhar, Madhya Pradesh India.
	Name of exporting country	India

	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP (certificate 7/2014) dated 29-Nov-2021 issued by Food and Drug Administration Maharashtra State Mumbai for Acritega (Dolutegravir 50mg /Lamivudine 300mg /Tenofovir Disoproxil Fumarate 300mg) Tablet The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned as Pakistan (As per annexure). Furthermore, the CoPP was valid till 25-10-2024** **GMP:** Firm has submitted original, legalized GMP certificate (No. V/WHO-GMP/M-1/2021/5686) dated 26-10-2021 issued by Food and Drug Administration Maharashtra State Mumbai **WHO Approval:** Product is prequalified by WHO in 2018. (Reference No. HA688)
	Details of letter of authorization / sole agency agreement	Firm has submitted original and legalized copy of letter of Authorization certificate from Mylan Laboratories. The letter species that the manufacturer appoints M/s AGP Limited to register their products in Pakistan. The authorization letter is valid till June-2024
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy.no.22873 dated 12-08-2022
	Details of fee submitted	PKR 75,000/-: 20-07-2022
	The proposed proprietary name / brand name	**ACRIPTEGA**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dolutegravir (as Dolutegravir Sodium) …50mg Lamivudine …….300mg Tenofovir Disoproxil Fumarate (equivalent to 245mg Tenofovir Disoproxil)…..300mg
	Pharmaceutical form of applied drug	Film Coated Tablets.
	Pharmacotherapeutic Group of (API)	Anti-retroviral drug (J05AR27)
	Reference to Finished product specifications	In house
	Proposed Pack size	30's (Bottle of 30 Tablets)
	Proposed unit price	As per DRAP Approved Price
	The status in reference regulatory authorities	Acriptega Tablet **(WHO** Approved).
	For generic drugs (me-too status)	Not Applicable
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature,

		structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	**Dolutegravir** Mylan Laboratories Limited (Unit-9) Plot No. 5, Road No. 12, J.N. Pharma City, Tadi Village, Parawada Mandal, Visakhapatnam – 531021, Andhra Pradesh, India. **Lamivudine** Mylan Laboratories Limited (Unit-2) Survey No. 10/42, Gaddapotharam, Kazipally Industrial Area Sangareddy District-502319 Telangana, India **Tenofovir Disoproxil Fumarate** Mytan Laboratories Limited (Unit-10) Plot No. 86, Ramky Pharma City (India) Ltd, SEZ, JN Pharma City, Parawada Mandal, Visakhapatnam – 531019 Andhra Pradesh, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of all API **Dolutegravir** 3 batches (25510775, 25510776 & 25510777) 6 months Accelerated (40°C±2°C /75%RH±5%) 24 months Long Term (30°C±2°C /75%RH±5%) **Lamivudine** 3 batches (22103288, 22103289 & 22103290) 6 months Accelerated (40°C±2°C /75%RH±5%) 60 months Long Term (30°C±2°C /75%RH±5%) **Tenofovir Disoproxil Fumarate** 3 batches (25502774, 25502808, 25502828) 6 months Accelerated (30°C±2°C /65%RH±5%) 24 months Long Term (25°C±2°C /60%RH±5%)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted CDP and bioequivalence studies of Acriptega Tablet against its innovator brand ViiV's EPIVIR® Tablets, 300 mg, Gilead's

		VIREAD® Tablets, 300 mg and ViiV's TIVICAY® Tablets, 50 mg.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE bottle pack (30's)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches (2011638, 2011639, 2011640). The accelerated stability study data is conducted at 40°C ±2°C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30°C ±2°C / 75% ± 5% RH. The real time stability study data of 3 batches is for 36 months Storage condition: Do not store above 30°C, store in original container. Shelf life: 36 months

Evaluation by PEC:

Section#	Observation	Firm's response
3.2.S.4.1	Justification shall be submitted for applying in-house specifications for the "Tenofovir Disoproxil Fumarate", whereas Pharmacopoeial monograph is available for it.	In CDP study, an Incomplete release of Dolutegravir sodium in all three dissolution mediums (Without surfactant) was observed whereas all other API released completely. FDA dissolution test of Dolutegravir in 0.01M pH 6.8 phosphate buffer showing the use of surfactant 0.25% w/v sodium dodecyl sulfate (SDS) at 45min. The released enhancement was checked with different concentrations of sodium dodecyl sulfate (SDS), the optimized complete release was achieved with 1% w/v sodium dodecyl sulfate (SDS) at 15min.The results showed that the release profile of other APIs had no major impact. After dissolution development surfactant with 1% concentration is used in CDP study.
3.2.P.2.2.1	• The rationale for the choice and concentration of surfactant in dissolution mediums for performance of CDP studies should be provided as mandated by Annex 4 of WHO TRS 970, 2012. • Clarification shall be submitted for non-comparable results of in-vitro drug release for "Tenofovir Disoproxil fumarate" and "Dolutegravir" between reference and test product, although the test product has been declared bio-equivalent with reference product.	The Disintegration time of Acriptega Tablets is little higher (11 mins) compared to single relative API products. Therefore, the initial release of Tenofovir Disoproxil fumarate and Dolutegravir is little low in initial 15 mins compared with single relative reference Products (DT : 1-2 mins). The peak plasma level (Cmax) of Dolutegravir sodium reached in 1 to 3hr The peak plasma level (Cmax) of Tenofovir Disoproxil fumarate reached in 1.0 ± 0.4hr Therefore, initial slow dissolution rate of Acriptega is unlikely to affect the pharmacokinetics. However, The Acriptega is Bioequivalent against combination individual reference product and it is also a WHO Prequalified product.

Decision: Approved as per policy of inspection of manufacturer abroad.

a) <u>Local manufacturing applications of priority categories defined by Registration Board in its 257th meeting</u>

560.	Name, address of Applicant / Marketing Authorization Holder	M/s Hiranis Pharmaceuticals (Pvt.) Ltd
	Name, address of Manufacturing site.	M/s Hiranis Pharmaceuticals (Pvt.) Ltd Plot E-145-149, North Western Industrial Zone, Port Qasim, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.no. 3131 dated 01/02/2022
	Details of fee submitted	PKR 75,000/-: dated 20/01/2022
	The proposed proprietary name / brand name	Rinvok 15mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated prolong released tablet contains: Upadacitinib Hemihydrate equivalent to Upadacitinib 15mg **(L02BB03)**
	Pharmaceutical form of applied drug	Film coated prolong release tablet
	Pharmacotherapeutic Group of (API)	Oral Janus Kinase (JAK-1) Selective Inhibitor
	Reference to Finished product specifications	Innovator's Specification
	Proposed Pack size	2×7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Rinvoq 15mg Tablet M/s AbbVie S.r.l. S.R. 148 Pontina, km 52 SNC 04011 Campoverde di Aprilia (Latina) Italy EMA Approved
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	DML by way of formulation No. 000785 dated 03-02-2019
	Name and address of API manufacturer.	**Upadacitinib** M/s Zhejiang Hongyuan Pharmaceutical Co. Ltd. **Address:** Chem & API Industrial Zone, Linhai Zhejiang, China, 317016.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph is not present in any pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: **Upadacitinib:** **Real time:** 30˚C ± 2˚C / 65% ± 5%RH for 24 months **Accelerated:** 40˚C ± 2˚C / 75% ± 5%RH for 6 months **Batches:** UPDT190501, UPDT190502 & UPDT190503
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is **Rinvoq 15mg Tablet** by **M/s AbbVie S.r.l.** by performing quality tests (Identification, Assay, Dissolution, and Uniformity of dosage form). CDP has been performed against the same brand that is **Rinvoq 15mg Tablet by M/s AbbVie S.r.l.** in Acid media (0.1 N HCL) & Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8): • It was found that both reference & test product shows similar release profile in 0.1N HCl till 24 hours. Therefore, both reference & test product is comparable & the f_2 value was observed to be 83. • It was found that both reference & test product shows similar release profile in pH 4.5 Acetate Buffer till 24 hours. Therefore, both reference & test product is comparable & the f_2 value was observed to be 83. • It was found that both reference & test product shows similar release profile in pH 6.8 Phosphate Buffer till 24 hours. Therefore both reference & test product are comparable & the f_2 value was observed to be 80.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	**Upadacitinib** M/s Zhejiang Hongyuan Pharmaceutical Co. Ltd. **Address:** Chem & API Industrial Zone, Linhai Zhejiang, China, 317016.
API Lot No.	**Upadacitinib** UPDT210402
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2×7's)
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH

	Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**TF-170521A**	**TF-170521B**	**TF-170521C**
Batch Size	700 tablets	700 tablets	700 tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	21-05-2021	21-05-2021	21-05-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Etoxib 90mg Tablet Etoxib 120mg Tablet Approved in 294th minutes of meeting of DRB
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Upadacitinib:** Copy of GMP certificate No. 213300B0/008106 issued by Linhai Medical & Chemical Industry Administration valid till 31/01/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Attested invoice from ADC attached for Upadacitinib Invoice No. 0405/2021 with courier details
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Observations/Deficiencies/Short-comings	Reply
1.	Justify for setting the recommended sampling time points of dissolution till 12hours comparing the time point recommended by the innovator product i.e. 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 Hours.	Firm submitted the reply that they have chosen three time points until 12 hours (with dissolution >80%) based on the guidelines of USP general chapter <1092>, Ema guidelines and FDA guidance for Industry Extended release oral dosage forms and according to these guidelines "Minimum of three points should be included in the where at least 80% of drug has dissolved."
2.	Dissolution testing data of trial batch no. TF-170521A and TF-170521C at initial time point and 6th month time point respectively, revealed that individual value of dissolution lies outside the specification, justify for not proceeding toward level 2 as recommended by USP general chapter <711> for interpretation of results.	Firm submitted the raw data sheet of trial batch no. TF-170521A in which two units were out of specification and according to the firm difference of values from specification is insignificant, if we apply rounding rule on above values, all values will be within specification. Furthermore, above batch number also used in Pharmaceutical equivalence studies, therefore requirement of L2 stage already met.

		Further, the individual unit data at 6th month time point of trial batch TF-170521C reveals that one unit is out of specification on which firm replied that "*The difference is less than 1%, which is insignificant. As concerned for not proceeding to level 2 of dissolution test under USP <711>. We did not proceed for the L2 stage due to the reasons discussed in details in the submitted response. Furthermore, we have continued the stability studies further to 18months and found the results to be satisfactory*".
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm replied that It is respectfully submitted that Since the Courier Details /Shipment Details are not attested by DRAP therefore, we herewith attached complete Shipment Details for the import of API (Upadacitinib) in this case for your kind perusal. Firm has submitted detailsof courier as follows: • UPS Express receipt (Track# 1Z73AW280403735055). • Copy of Commercial invoice nO. 0405/2021.

Therapeutic indications:

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Atopic dermatitis RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

See full prescribing information for complete boxed warning.

• Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ.

• If a serious infection develops, interrupt RINVOQ until the infection is controlled.

• Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ.

• Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative.

• Lymphoma and other malignancies have been observed in patients treated with RINVOQ.

• Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.

DOSAGE AND ADMINISTRATION

• The recommended dose of RINVOQ is 15 mg once daily.

• RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs. • Avoid initiation or interrupt RINVOQ if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3, or haemoglobin level is less than 8 g/dL.		
Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.** **Registration Board further advised the firm to adopt formal procedure through approval from DRAP I&E for import of drug substance, in future.**		
561.	Name, address of Applicant / Marketing Authorization Holder	M/s Helix Pharma (Pvt.)., Ltd.
	Name, address of Manufacturing site.	A-56, S.I.T.E, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.No.3626 dated : 08/02/2022
	Details of fee submitted	PKR 30,000/-:dated : 23/06/2021
	The proposed proprietary name / brand name	BICLU 50mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet contains: Bicalutamide ……. 50mg
	Pharmaceutical form of applied drug	Oral (Film Coated Tablets)
	Pharmacotherapeutic Group of (API)	Nonsteroidal antiandrogens
	Reference to Finished product specifications	USP
	Proposed Pack size	10's , 20's , 28's & 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Casodex 50mg Tablets by M/s AstraZeneca Pharmaceuticals, LP approved by FDA in Dec,2008.
	For generic drugs (me-too status)	Reg.no. 027380; Casodex Tablets 50mg by ICI Reg.no. 078117; Geperprostin Tabs. 50mg by Novartis
	GMP status of the Finished product manufacturer	DML # 000030; Renewal on 24/04/2020 Tablet (General) section approved. GMP routine inspection conducted on 13/09/2022
	Name and address of API manufacturer.	M/s Jari Pharmaceutical Co., Ltd. Address: No. 18 Zhenhua Road, Lianyungang, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and

		stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Bicalutamide is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 25˚C ± 2˚C / 60% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months Batches: (100701, 100702 & 100703)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Casodex Tablets 50mg; Batch # **RE843** manufactured by Corden Pharma GmbH Germany by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Casodex Tablets 50mg manufactured by Corden Pharma GmbH Germany in Acid media (pH 1.2 HCl & pH 4.5 Acetic Acid) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm has submitted analytical method verification report.

STABILITY STUDY DATA

Manufacturer of API	M/s Jari Pharmaceutical Co., Ltd.; Address: No. 18 Zhenhua Road, Lianyungang, China. Tel: +86-518-85152301		
API Lot No.	BKL-191201		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 09 months Accelerated: 06 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6 , 9 (Months)		
Batch No.	TF-001	TF-002	TF-003
Batch Size	1000 Tablets	1000 Tablets	1000 Tablets
Manufacturing Date	06 - 2020	06 - 2020	06 - 2020
Date of Initiation	10-06-2020	10-06-2020	10-06-2020
No. of Batches	03 Batches		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has referred the DRB 312th meeting Minutes for approval of new molecule "ZALPO (VONOPRAZAN) TABLETS 10mg & 20mg which were approved on basis of onsite inspection for another product of same dosage form. The said DRB Meeting minutes has mentioned that: • The HPLC is 21CFR Compliant. • Audit trail on the testing reports of "ZALPO Tablet 10mg & 20mg" were available. • Adequate monitoring & control are available for stability chamber. The firm has installed software for recording temperature/Humidity of the chamber (for real time stability software V5.7T Thermo, India & Accelerated Stability studies, software is Logit Chrt Technoman; Pakistan) & the data can been verified for 01 year.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. JS20180878 issued by CFDA valid till 03/09/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm submitted the Form-6 & invoice dully attested by AD DRAP Karachi on 01/04/2020, confirming the import of API "Bicalutamide USP grade" Qty: 0.24 Kgs ; Batch # BKL-191201 ; Invoice # 20YX2007B ; dated: 02/03/2020.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all stability batches along with chromatograms , raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted complete compliance record of HPLC software 21CFR & audit trail reports on product testing.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	submitted

Remarks of Evaluator:

S.no.	**Observations/Deficiencies/ Short-comings**	**Reply of the Firm**
1.	Drug substance Bicalutamide is a racemate mixture, please provide the detail along with quantitative results, that which enantiomeric form of API has been imported and used in the manufacturing of drug product.	Firm replied that they imported API "Bicalutamide" USP grade and there is no enantiomeric purity test in the USP monograph of bicalutamide.
2.	Submit data for both drug substances in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that "Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted" Further specify how the testing of drug substance was carried out without performing verification studies.	Firm submitted the analytical method verification studies of drug substance by drug product manufacturer.

3.	Provide COA of valid working standard, since the submitted COA was expired on 12-2021.	Firm submitted the COA of reference standard imported from drug substance manufacturer with the retest date 09-10-2023.
4.	Submit stability data of drug substance as per zone-IV-a condition, since the submitted stability was performed at 25±2°C and 60±5%.	Firm submitted the stability data of 24 months performed both at accelerated and long stability condition: 30°C±2°C,65±5% RH & 40°C ± 2°C / 75% ± 5%RH of following batches: 2013 1004,20131005,20131006
5.	Provide COA of primary / secondary reference standard including source and lot number used for testing of drug product.	submitted
6.	Clarify the acceptance criteria of dissolution in term of time point at which NLT 80% should be achieved, as the time point has not mentioned on stability data sheet. Further set the acceptance criteria of dissolution in term of Q, since the USP monograph specify the limit with Q value i.e. NLT 80% (Q) of the labelled amount of BICALUTAMIDE dissolved.	Firm submitted the correct dissolution acceptance criteria in accordance with USP monograph i.e. NLT 80% (Q) within 45 minutes.
7.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm submitted the reference of 312th meeting of Registration Board in which their product Tranz Tablet approved with stability data.
8.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin	Firm submitted the GMP certificate of M/s. JARI Pharmaceuticals Co. Ltd. Lianyungang certificate no. JS20180878 valid till 03-09-2023.
9.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm submitted the copy of Form-6 as an evidence of import of bicalutamide USP grade.

Decision: Registration Board deliberated that since firm has performed the drug substance analysis as per USP monograph including test of related substances hence no further testing for establishing enantiomeric purity of the drug substance is required. Therefore, Registration Board approved the applied formulation.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

562.	Name, address of Applicant / Marketing Authorization Holder	Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Name, address of Manufacturing site.	Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.6974 dated 14-03-2022
	Details of fee submitted	PKR 75,000/- dated 08/12/2021
	The proposed proprietary name / brand name	Iguramod 25mg tablet

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Iguratimod …… 25mg
	Pharmaceutical form of applied drug	White colored, Round shaped, Film coated oral tablet plain on both sides
	Pharmacotherapeutic Group of (API)	Non-Steroidal Anti-Inflammatory Disease Modifying Anti-Rheumatic Drug (DMARD)
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	1x10's, 2x10's, 3x10's (as per SRO)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Careram Tablets 25mg by Eisai Co., Ltd., PMDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	New GMP Inspection granted on 09/09/2021 Tablet (General) section approved.
	Name and address of API manufacturer.	Simcere Pharmaceutical Co., Ltd (Simcere Pharm) Hongsha, Town, Sanya City, Hainan, China Valid till 03-08-2021
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 72 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (A17-100701, A17-100702, A17-100703)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Careram Tablets 25mg by Eisai Co., Ltd by performing quality tests (Identification, Assay, Dissolution, and Uniformity of dosage form). CDP has been performed against the same brand that is Careram Tablets 25mg by Eisai Co., Ltd in Acid media

		(0.1N HCl), Buffer (pH 4.5) & Buffer (pH 8.0). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Hainan Simcere Pharmaceutical Co., Ltd (Simcere Pharm) Hongsha, Town, Sanya City, Hainan, China		
API Lot No.	A17-180608		
Description of Pack (Container closure system)	Alu-PVC blister packed in unit carton (1×10's, 2×10's, 3×10's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 18 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 (Months)		
Batch No.	TF-09	TF-10	TF-11
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	04-01-2020	04-01-2020	04-01-2020
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product "Rofair 500mcg Tablet", which was conducted on 25th June, 2019, and was presented in 290th meeting of Registration Board. The report confirms: ▪ The HPLC software is 21CFR Compliant. ▪ Audit trail on testing reports is available ▪ Firm has adequate monitoring and controls for stability chambers. Chambers are controlled and monitored through software having alarm system for alerts as well
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. HI20160011 issued by HAINAN PROVINCIAL FOOD AND DRUG ADMINISTRATION valid till 03/08/2021.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Courier slip tracking number: 452563080508 delivery date: Aug 08, 2018
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:
Clinical Indication:
Rheumatoid Arthritis

Approved with the warning box:

Warning

In an overseas clinical trial, pancytopenia leading to a fatal outcome was observed in patients administered 125 mg/day. This drug should be used by physicians with sufficient knowledge of this drug and experience in treating rheumatoid arthritis at medical facilities where adequate measures can be taken in an emergency.

S.no.	**Observations/Deficiencies/ Short-comings**	**Response of the Firm**
1.	Submit copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by drug product manufacturer as per the guidance document approved by Registration Board.	Firm submit specification of drug substance and analytical procedure used for routine testing of drug substance by drug product manufacturer.
2.	Submit analytical method verification studies including specificity, accuracy and repeatability (method precision) of drug substance performed by the Drug Product manufacturer under section 3.2.S.4.3 as per the decision of 293rd meeting of Registration Board. Further justify how the analysis of drug substance was conducted without performing verification studies of the analytical method of drug substance.	Firm submit analytical method validation report of drug substance by drug product manufacturer.
3.	Justify for not performing the comparative dissolution testing at pH 6.8, since it is the recommended medium in which the dissolution studies should be conducted. Further, you have to performed the comparative dissolution testing using test and innovator /reference products under a variety of test conditions as recommended in 293rd meeting of Registration Board. The test conditions may include different dissolution media (pH 1 to 6.8), addition of surfactant, and use of apparatus 1 and 2 with varying agitation. In all cases, dissolution profiles in comparison with the innovator / reference product should be generated. Submit the data in accordance with the said guidance of Registration Board.	Firm replied that Comparative dissolution studies were performed on multiple dissolution buffers including the phosphate buffer pH 6.8 as per USFDA guidelines (mentioned in 293rd meeting of Registration Board), no results were obtained in buffer pH 6.8 as tablet remained intact in this buffer. That's why calculation was not done. Tablet showed more than 90% dissolution in another buffer pH 8.0 as shown in the CDP.For reference we can enclose calculation sheet of CDP in phosphate buffer pH 6.8.
4.	Composition of applied product submitted in respective section is not qualitatively similar to the composition of innovator product, so, in this case please submit the compatibility study of active with the excipients.	Firm submitted the compatibility study of drug substance with excipient.
5.	Justify for selecting the pH 8.0 for the dissolution medium in the light of international literature, review literature of innovator drug, Pharmacopeial recommendations and BCS classification of drug substance.	Iguratimod belong to BCS class-II drug, dissolution of these drugs are obtained in intestinal pH range. Comparative drug profile performed with the dissolution medium pH 6.8 in which tablet remain intact. That's why its result were not included in CDP.
6.	Justify for adapting the broader acceptance criteria i.e. NLT 75% within 60 minutes, since the drug shows more than 90% drug dissolution within 60 minutes as evident from the stability data. Further, justify the adapted dissolution acceptance criteria in the light of guidance "for setting dissolution release	Firm replied that the dissolution studies were performed in phosphate buffer pH 8.0 according to the Chinese Journal of Pharmaceutical Analysis that is a Professional Journal administrated by China Association for Science & Technology sponsored by China Association held by National Institute for Food and Drug control. For BCS-II drugs

	specification" approved in 293rd meeting of Registration Board.	the time points can be taken 30,45 and 60minutes for NLT 75%. But our product attains dissolution more than 85% at 45 minutes so we can take dissolution limit 75% Q at 45 minutes. We have changed the limits in Finished product specification. According to USFDA guidance document for dissolution "For slowly dissolving or poorly water soluble drugs (BCS class 2), a two-point dissolution specification, one at 15 minutes to include a dissolution range (a dissolution window) and the other at a later point (30, 45, or 60 minutes) to ensure 85% dissolution, is recommended to characterize the quality of the product".
7.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm submitted the invoice receipt, which is not attested from DRAP.
8.	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product under section 2.3.R.1.1, for which stability studies data is provided in Module 3 section 3.2. P.8.	Submitted.

Decision: Deferred for following:

- **Documents for the procurement of API with approval from DRAP.**
- **Scientific justifications for the adopted parameters and specifications for dissolution test, while referring to the guidelines from reference regulatory authorities.**

563.	Name, address of Applicant / Marketing Authorization Holder	M/s. CCL Pharmaceuticals (Pvt.) Ltd. 62-Industrial Estate, Kot Lakhpat, Lahore.
	Name, address of Manufacturing site.	M/s. CCL Pharmaceuticals (Pvt.) Ltd. 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☒ **Manufacture**r ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ **New Drug Product (NDP)** ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Dy. No. and date of submission	Dy. No.18317 dated 23/06/2022
	Details of fee submitted	PKR 75,000/-: dated 16/06/2022
	The proposed proprietary name / brand name	Molvir Capsule 200mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Molnupiravir……200mg (As per innovator Specification)
	Pharmaceutical form of applied drug	White color cap and blue color body, size # 0 having white color powder
	Pharmacotherapeutic Group of (API)	Antiviral
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	As per SRO

	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Lagevrio Capsule by Merck sharp & Dohme, UK.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP certificate granted on 13-05-2019 and valid for three years. Capsule (non-antibiotic) section is included in the GMP certificate.
	Name and address of API manufacturer.	**OPTIMUS DRUGS PRIVATE LIMITED** Survey No. 239 & 240 Dothigudem (V), Pochampally (M),Yadadri-Bhuvanagiri (Dist)-508 284.Telangana, INDIA.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Molnupiravir is non-pharmacopeial, so firm has to developed manufacturer's specification. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 6 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (OP-VICTR-A1-001/21, OP-VICTR-A1-002/21 & OP-VICTR-A1-003/21)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the reference product that is Molcovir 200mg Capsule of M/s. Optimus Pharma Pvt. Ltd., India (Batch no. MOLCD1005A) by performing quality tests (Appearance, Identification, weight, disintegration, assay & dissolution test). CDP has been performed against the same reference product in Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer (pH 6.8). The f2 value was in acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	**OPTIMUS DRUGS PRIVATE LIMITED** Dothigudem (V), Pochampally (M),Yadadri-Bhuvanagiri (Dist)-508 284.Telangana, INDIA
API Lot No.	OP-VICTR-A1-040/21

Description of Pack (Container closure system)	Alu/alu blister in bleach board with leaflet		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 3 & 6(Months) Real Time: 3, 6, 9, 12,18 & 24 (Months)		
Batch No.	T2-22	T3-22	T4-22
Batch Size	2500 Capsules	2500 Capsules	2500 Capsules
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	01-2022	01-2022	01-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm submitted a list of 22 products which were approved with stability data.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. L.Dis.No: 60996/TS/2021 valid till 24/05/2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Purchase Order No. IMP-1015 for batch no: OP-VICTR-A1-040/21,DRAP attested vide Dy.no. 18262/2021 DRAP dated 30-11-2021.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.	**1.5.9**	Submit regulatory status of approval of applied formulation by reference regulatory authority by way of routine procedure of market authorisation.
2.	**3.2.S.7**	Submit complete stability data of drug substance till the claimed retest date as per zone IV-a conditions.
3.	**3.2.P.2.2.1**	Justify for not performing the comparative study against the innovator product i.e.Lagevrio capsule 200mg.
4.	**3.2.P.5.4**	Justify for selecting 0.1N HCL as a dissolution medium ,when the drug dissolution behavior was similar in all three dissolution mediums as per the comparative dissolution profile submitted in section 3.2.P.2.2.1.
5.	**3.2.P.8**	Submit the remaining stability data of drug product ,since you have submitted only three month stability data.
6.	**2.3. R.1.1**	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product under section 2.3.R.1.1, for which stability studies data is provided in Module 3 section 3.2. P.8.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

564.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Name, address of Manufacturing site.	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Status of the applicant	☒ **Manufacture**r ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ **New Drug Product (NDP)** ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Dy. No. and date of submission	Dy. No.23278 dated 17/08/2022
	Details of fee submitted	PKR 75,000/-: dated 05/08/2022
	The proposed proprietary name / brand name	Molvir Capsule 200mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Molnupiravir……200mg (As per innovator Specification)
	Pharmaceutical form of applied drug	White color cap and blue color body, size # 0 having white color powder
	Pharmacotherapeutic Group of (API)	Antiviral
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Lagevrio Capsule by Merck sharp & Dohme, UK.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP granted on 07/10/2021 Capsule (General) approved.
	Name and address of API manufacturer.	**OPTIMUS DRUGS PRIVATE LIMITED** Survey No. 239 & 240 Dothigudem (V), Pochampally (M),Yadadri-Bhuvanagiri (Dist)-508 284.Telangana, INDIA.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Molnupiravir is non-pharmacopeial, so firm has to developed manufacturer's specification. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance

	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 72 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (OP-VICTR-A1-001/21, OP-VICTR-A1-002/21 & OP-VICTR-A1-003/21)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Lagevrio Capsule (Batch no: C0021) by Merck, Sharp & Dohme UK Limited by performing quality tests (Appearance, Identification, weight, disintegration, assay & dissolution test). CDP has been performed against the same brand that is Lagevrio Capsule (Batch no: C0021) by Merck, Sharp & Dohme in Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer (pH 6.8). The f2 value was in acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	**OPTIMUS DRUGS PRIVATE LIMITED** Dothigudem (V), Pochampally (M),Yadadri-Bhuvanagiri (Dist)-508 284.Telangana, INDIA		
API Lot No.	OP-VICTR-A1-034/21		
Description of Pack (Container closure system)	Alu/alu blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 3 & 6(Months) Real Time: 3, 6, 9, 12,18 & 24 (Months)		
Batch No.	21SB(B)-338-01	21SB(B)-339-02	21SB(B)-340-03
Batch Size	800 Capsules	800 Capsules	800 Capsules
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	18-01-2022	18-01-2022	18-01-2022
No. of Batches	03		
Administrative Portion			
25.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A	
26.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. L.Dis.No: 60996/TS/2021 valid till 24/05/2022.	

27.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Purchase Order No.PO-00010484 for batch no: OP-VICTR-A1-034/21 dated 30.10.2021 is submitted which is without DRAP attestation.
28.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
29.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
30.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Observations/Deficiencies/ Short-comings	Reply
1.	Submit regulatory status of approval of applied formulation by reference regulatory authority by way of routine procedure of market authorization.	Firm submitted the reference of EUA letter of USFDA dated 27th October, 2022 in which it was written that that revising this EUA is appropriate to protect the public health or safety under section 564(g)(2) of the Act, FDA is reissuing the August 5, 2022 letter in its entirety, to incorporate clarifying revisions to Condition BB of this letter.
2.	Submit data in section 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "*Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required*." Since you have only submitted the requisite information provided by drug substance manufacturer.	Submitted
3.	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".* Since you have only submitted the requisite information provided by drug substance manufacturer.	Submitted
4.	Submit results of batch analysis in section 3.2.S.4.4 as per the decision of 293rd meeting of Registration Board, which states that "*Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture*".	Submitted
5.	Submit complete stability data of drug substance till the claimed retest date as per zone IV-a conditions.	Firm submitted the stability data of 18 month performed at real time condition as per zone IV-a condition, while the claimed retest date is 60 month.

6.	Justify for selecting 0.1N HCL as a dissolution medium ,when the drug dissolution behavior was similar in all three dissolution mediums as per the comparative dissolution profile submitted in section 3.2.P.2.2.1.	Firm replied that solubility of molnupiravir is greater in 0.1N HCl other two buffers medium that's why we preferred 0.1N HCl as dissolution medium.
7.	Submit the remaining stability data of drug product, since you have submitted only three-month stability data. Submit documents for the procurement of API including copy of commercial invoice attested by AD (I&E) DRAP.	Submitted the stability data of 6 month time point.

Decision: Deferred for following:

- **Documents for the procurement of API including copy of commercial invoice attested by AD (I&E) DRAP.**
- **Regulatory status of approval of applied formulation by reference regulatory authority by way of routine procedure of market authorisation.**

565.	Name, address of Applicant / Marketing Authorization Holder	M/s Curexa Health (Pvt.) Ltd. Plot 517, Sundar Industrial Estate, Raiwind Road, Lahore
	Name, address of Manufacturing site.	M/s Curexa Health (Pvt.) Ltd. Plot 517, Sundar Industrial Estate, Raiwind Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22724 dated 11/08/2022
	Details of fee submitted	PKR 75,000/-: (Rs. 25,000 dated 06/07/2022 (vide Slip No. 8570310414 & Differential Fee of Rs. 50,000 dated 02/08/2022 vide Slip No. 74476073709)
	The proposed proprietary name / brand name	**Ceflaro 400mg Injection IV**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftaroline Fosamil monoacetate monohydrate eq. to Ceftaroline Fosamil……. 400mg (With Arginine)
	Pharmaceutical form of applied drug	Dry Powder for Injection
	Pharmacotherapeutic Group of (API)	Antibacterial for systemic use. Fifth-generation cephalosporin
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Teflaro 400mg Injection (US-FDA Approved) by M/s ALLERGAN Pharma
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	The firm is granted GMP certificate based on inspection conducted on 24-05-2019, was valid till 24-05-2022. Request for GMP inspection R&1 date: 30-12-2021 is provided.

	Name and address of API manufacturer.	M/s Qilu Antibiotics Pharmaceutical Co., Ltd. No.849 Dongjia Town, Licheng District, Jinan, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Ceftaroline Fosamil is not present in any Pharmacopoeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (60001EJ87Z-A, 60002EJ87Z-A, 60003EJ87Z-A)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence with Innovator Brand Teflaro Injection 400mg IV has been submitted Comparative Dissolution Profile - NA
	Analytical method validation/verification of product	Analytical Method Validation of the product is provided

STABILITY STUDY DATA

Manufacturer of API	M/s Qilu Antibiotics Pharmaceutical Co., Ltd. No.849 Dongjia Town, Licheng District, Jinan, Shandong Province, China		
API Lot No.	1003DJ87ZA		
Description of Pack (Container closure system)	1's (Blister of 1 filled vial & 1 WFI 20mL, LDPE ampoule), securely packed in carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	RD-CH-22001	RD-CH-22002	RD-CH-22003
Batch Size	200 Vials	200 Vials	200 Vials
Manufacturing Date	Feb-2022	Feb-2022	Feb-2022

Date of Initiation	08-Feb-2022	08-Feb-2022	08-Feb-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Fortez Injection 2g IV CTD Dossier approved in 317th DRB Meeting held on 16th-17th May-2022
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. SD20170569 issued by CFDA & Copy of DML certificate No. Lu 20160006 issued by CFDA valid till 03/11/2025 has been provided
3.	Documents for the procurement of API with approval from DRAP (in case of import).	DRAP Approved Commercial Invoice No. A21229J dated 14/10/2021 is enclosed (DRAP Approval Ref. No. 17934/2021-DRAP dated 24-11-2021) (Approval letter No. F.08-10/2021-I&E (QA&LT) is also provided)
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

- CAS NO. of starting material used in the applied product is 229016-73-3 i.e. sterile Ceftaroline fosamil monoacetate
- CAS no. of starting material used in the manufacturing of innovator brand is 866021-48-9 i.e. Ceftaroline Fosamil monoacetate monohydrate with the statement that Ceftaroline Fosamil is not stable in the anhydrous form

S.no.	Observations/Deficiencies/ Short-comings	Reply of the Firm
1.	According to the review literature of innovator brand salt form of drug substance is Ceftaroline fosamil acetic acid solvate monohydrate, while the drug substance used in the applied drug product is Ceftaroline fosamil monoacetate as per the information submitted in substance part. Justification is required for variation in the drug substance against the innovator product.	Firm replied that the drug substance used in the applied drug product is same as used by the innovator brand i.e. Ceftaroline fosamil monoacetate monohydrate. However, the CAS number of starting material mentioned in the documents of drug substance manufacturer is different from the CAS no. specified in the review documents of innovator brands.
2.	Please provide complete composition of drug product, specifiy the composition of ceftaroline fosamil monoacetone and L-arginine separately.	Firm replied that Ceftaroline fosamil and arginine are mixed in ratio of 1:0.66 so as per ratio quantity used for injection is Ceftaroline fosamil monoacetate monohydrate eq. to ceftaroline fosamil…400mg Arginine eq. to….264mg
3.	As per the assay results of pharmaceutical equivalence report ceftaroline is quantify instead of ceftaroline fosamil, justification is required in this regard.	Firm replied that it was a typographical error and in pharmaceutical equivalence report in assay ceftaroline fosamil was quantified.
4.	• Justify for not including the test of Constitution Time, Content Uniformity (by Assay) and extractable volume test in the release specification of drug product, since these test are included in the specification of innovator brand.	Firm replied that product is dry powder injection so extractable volume is not applicable and content uniformity test is applicable at the blending stage. However, the test of Constitution Time, Content Uniformity (by Assay) and extractable volume test is

	• Elaborate the calculation formula for determination of potency of ceftaroline fosamil.	included in the release specification of innovator product. Firm submitted the following calculation formula: Assay = 99.2% (on anhydrous,acetic acid & arginine free basis) Potency = {(100-water-arginine-acetic acid)/100}xassay
5.	Submit the remaining stability data of drug product ,since you have submitted only three month stability data.	Submitted
6.	Justify the dispensed quantity of ceftaroline fosamil injection comparing the potency of active (ceftaroline fosamil).	Filled weight = (Label claim/Potency) x 100 Ceflaro 400mg Injection= (400/56.8416)x100= 703.7mg per vial.

Decision: Deferred for scientific justification for the drug substance used for the formulation of the applied product since as evident from the submitted data drug substance used in applied formulation i.e., Ceftaroline fosamil monoacetate (229016-73-3) is different from that used in the innovator drug product i.e., Ceftaroline fosamil monoacetate monohydrate (866021-48-9).

566.	Name, address of Applicant / Marketing Authorization Holder	M/s High-Q Pharmaceuticals.
	Name, address of Manufacturing site.	M/s High-Q Pharmaceuticals. Plot No.224 & 225/1 Sector 23, Korangi Industrial Area, Karachi-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29842 dated 21-10-2022
	Details of fee submitted	PKR 30,000/-: dated 05-10-2022
	The proposed proprietary name / brand name	Daytef 400mg Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: 400mg Ceftaroline fosamil (equivalent to 466mg of ceftaroline fosamil monoacetate monohydrate) powder for intravenous infusion
	Pharmaceutical form of applied drug	Yellow white to light yellow powder for intravenous infusion
	Pharmacotherapeutic Group of (API)	Antibacterial for systemic use
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Teflaro 400mg/vial for Injection, USFDA Approved.
	For generic drugs (me-too status)	Not applicable since the product is New drug
	GMP status of the Finished product manufacturer	GMP issuance date: 21st Dec, 2021 Dry Powder Injectable (Cephalosporin) section is approved

	Name and address of API manufacturer.	M/s Qilu Antibiotics Pharmaceutical Co., Ltd. No.849 Dongjia Town, Licheng District, PC-250105 Jinan, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Ceftaroline fosamil is not present in any monograph. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, working standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 25˚C ± 2˚C / 60% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (60001EJ87Z-A, 60002EJ87Z-A, 60003EJ87Z-A)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, force degradation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator that is Teflaro 400mg/vial for Injection by performing quality tests (Identification, Assay, completeness & clarity of solution, Particulate matter, pH, Water content, Fill weight variation, Related substances, bacterial endotoxin and Sterility test.) CDP is not applicable
	Analytical method validation/verification of product	Method validation studies are submitted including linearity, accuracy, precision, LOD, LOQ, Robustness and Force degradation studies

STABILITY STUDY DATA	
Manufacturer of API	M/s Qilu Antibiotics Pharmaceutical Co., Ltd. No.849 Dongjia Town, Licheng District, PC-250105 Jinan, Shandong Province, China
API Lot No.	1002DJ87ZA
Description of Pack (Container closure system)	Clear glass vial plugged with rubber stopper and secured with Aluminium seal (1's) packed in unit carton along with Water for Injection as diluent and leaflet
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months

Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	4DTFPD01/22	4DTFPD02/22	4DTFPD03/22
Batch Size	470 vials	470 vials	470 vials
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	29-03-2022	29-03-2022	29-03-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Inspection dated 12th July, 2018 for verification of authenticity of stability data of Vesoft 400mg/100mg tablet (Approved in 284th meeting minute of Registration Board)
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. SD20170569 issued by Shandong Food & Drug Administration valid till 25/06/2023. According to the latest Drug Administration Law of the People's Republic of China, GMP certification program for all the Chinese pharmaceutical manufacturers is cancelled and won't be issued since Dec 1st, 2019
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Form 6 license No. 2556/21, DRAP/K dated 13/8/2021 is submitted wherein the permission to import for the purpose of test/analysis and stability studies is granted. Commercial Invoice No.A21176J attested by AD I&E DRAP, Karachi dated: 13th Aug, 2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms,Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

- CAS NO. of starting material used in the applied product is 229016-73-3 i.e. sterile ceftaroline fosamil monoacetate
- CAS no. of starting material used in the manufacturing of innovator brand is 866021-48-9 i.e. Ceftaroline Fosamil monoacetate monohydrate with the statement that Ceftaroline Fosamil is not stable in the anhydrous form

S.no.	Observations/Deficiencies/ Short-comings	Reply of the Firm
1.	Submit differential fee for the registration of applied new drug product as per the notification for revision of fee vide SRO No. F.7-11/2012-B&A/DRA dated 7th May 2021.	Firm submit Rs. 45,000/- differential fee vide Challan No.786519557 dated: 09-01-2023
2.	According to the review literature of innovator brand salt form of drug substance is ceftaroline fosamil acetic acid solvate monohydrate, while the drug substance used in the applied drug product is ceftaroline fosamil monoacetate as per	Firm replied that "Molecular formula and structure submitted by the manufacturer (Qilu Antibiotics Pharmaceutical Co., Ltd. China) did not reflect the solvate hydrate. The reason being that they are using USAN (synonym) chemical name of the molecule as the title of the USAN monograph for this drug

	the information submitted in substance part.Justification is required for variation in the drug substance against the innovator product.	substance is Ceftaroline fosamil according to the current USAN dictionary. The USAN monograph currently lists this as monoacetate monohydrate as the chemical name. However, the CAS number of starting material mentioned in the documents of drug substance manufacturer is different from the CAS no. specified in the review documents of innovator brands.
3.	Submit stability data of drug substance as per zone-IV-A condition **OR** In case where the real time stability data of drug substance is not conducted at zone IV-A conditions (e.g 30°C ± 2°C/65% RH ± 5% RH), the drug product manufacturer shall have to submit long term stability studies data of the product for 6 months along with degradation studies in the finished pharmaceutical product.	Firm in their reply submit the validation report of forced degradation studies while the Registration Board in its decision stated that the drug product manufacturer shall have to submit long term stability studies data of the product for 6 months along with degradation studies in the finished pharmaceutical product.
4.	• Justify for not including the test of Constitution Time and extractable volume test in the release specification of drug product, since these test are included in the specification of innovator brand. •	Firm replied that Since we do not have access to innovation's specification, therefore we have performed universal tests (related to dry powder injection) and some specific tests on the finished product. However, considering the importance of these two tests (constitution time & extractable volume), we have performed the tests on retention samples of trial batches of Daytef 400 mg Injection to know the compliance level of our product in comparison with the innovator's product. The results are attached. We have also included these tests in the following documents: Specification and Testing Methods of Daytef 400 mg Injection • Stability Protocol for Commercial batches • Certificate of Analysis format for Finished Product Copies of revised documents, as above, enclosed for your reference.
5.	Elaborate the calculation formula for determination of potency of ceftaroline fosamil.	Firm submitted the following calculation formula: Calculation formula as provided in Doc # API/STM-093 (Raw Material Specification and Control methods): **% of Ceftaroline Fosamil in the sample=(ru/rs) x (Cs/Cu) x P** Where: ru= Peak area of sample solution rs= Peak area of standard solution Cu= Concentration of sample solution in mg/ml = Weight of sample x 10 / Dilution (100 ml) 100 Cs= Concentration of working standard in mg/ml = Weight of standard (Ceftaroline fosamil) / Dilution (100 ml) P= Potency of Ceftaroline Fosamil working standard

		= Taken from the respective CoA from the supplier (ru/rs) = Peak area of Sample / Peak area of Standard
6.	Justify, how ceftaroline fosamil separately eluted using the reference standard of ceftaroline fosamil with arginine.	Firm replied that "Prior to analyzing API mix (Ceftaroline fosamil monoacetate monohydrate + L-arginine) we had run working standard of Ceftaroline fosamil and Reference standard of L-Arginine separately, following exactly the same method as to be used for API mix analysis, in order to identify the peaks and to ensure proper resolution (Certificate of Analysis of both these standards are enclosed in **Annexure 3**). As you would see from the chromatograms of API mix and the reference standard; the peak due to Ceftaroline fosamil and L-arginine are completely separate and reproducible.
7.	Submit the remaining stability data of drug product ,since you have submitted only three month stability data.	Firm submit the stability data of drug product till 6 month.
8.	Justify the dispensed quantity of ceftaroline fosamil injection with respect to the potency of active.	Firm replied that Ceftaroline fosamil with L-arginine is received as sterile powder, in ready to fill form, therefore the sealed container, of known net weight, is dispensed as such to maintain the sterility. The potency of ceftaroline fosamil is adjusted while calculating the fill weight of powder in vials. % Potency of Ceftaroline fosamil (as monoacetate, monohydrate) = _____% Factor (Ceftaroline fosamil to Ceftaroline fosamil monoacetate monohydrate) = 1.114* Label Claim = Ceftaroline fosamil 400 mg (as Ceftaroline fosamil monoacetate monohydrate) and 264 mg L-arginine per vial Target Fill Weight (Ceftaroline fosamil monoacetate monohydrate) = Label claim x F x 100 / % Potency of Ceftaroline fosamil = 400 x 1.114 x 100 / % Potency of Ceftaroline fosamil = _____ mg/vial (A) Total Fill Weight (Ceftaroline fosamil monoacetate monohydrate + L-arginine) = A + 264 mg = _____ mg / vial * calculated from the molecular weights of Ceftaroline fosamil and Ceftaroline fosamil monoacetate monohydrate: Molecular weight of ceftaroline fosamil monoacetate monohydrate =762.8 Molecular weight of ceftaroline fosamil = 684.7 or 1 mg of ceftaroline fosamil = 1.114 mg of ceftaroline fosamil monoacetate monohydrate

Decision: Deferred for scientific justification for the drug substance used for the formulation of the applied product since as evident from the submitted data drug substance used in applied formulation i.e., Ceftaroline fosamil monoacetate (229016-73-3) is different from that used in the innovator drug product i.e., Ceftaroline fosamil monoacetate monohydrate (866021-48-9).

b) Export facilitation

Export Facilitation: Applications was received through letter No.F.1-76/2019-PR-I (EFD) "M/s Pharmedic Laboratories (Pvt.) Ltd. have achieved benchmark OF USD 1576776.335 as defined in the Board's decision during fiscal year 2020-2021. In this regard, please find the (1 molecule) 05 products applications submitted by the firm."

567.	Name, address of Applicant / Marketing Authorization Holder	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Name, address of Manufacturing site.	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.no.2629 dated 27/01/2022
	Details of fee submitted	PKR 30,000/-: dated 24/11/2021
	The proposed proprietary name / brand name	Nevol 2.5mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Nebivolol HCl equivalent to Nebivolol…..2.5mg
	Pharmaceutical form of applied drug	White colored, round shaped, biconvex uncoated tablets with both sides plain.
	Pharmacotherapeutic Group of (API)	Beta blocking agent, selective
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	1×10's , 3x 10's and 2x 7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Bystolic tablets, Allergen, USA
	For generic drugs (me-too status)	Nabil 2.5mg Tablet by M/s Getz Pharma, Reg. No. 061344
	GMP status of the Finished product manufacturer	Last GMP was granted on 09/06/2020 GMP is in Renewal Process
	Name and address of API manufacturer.	**Name:** Jiangsu Weiqida Pharmaceutical Co., Ltd. **Old Name**: Shanghai Shyndec Pharmaceutical (Haimen) Co., Ltd **Address:** No.1, Linjiang Avenue, Nantong, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures

		and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Nebivolol HCl is not present in any pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Test for Impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (NBB-1711001-1M, NBB-1711002-1M, NBB-1711003-1M)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Nebil 2.5mg tablet by Getz Pharma (Pvt) Ltd. by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Nebil 2.5mg tablet by Getz Pharma (Pvt) Ltd.in Acid media (pH 1.2), pH 4.5 & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, linearity, accuracy, precision (repeatability and Intermediate), Limit of Detection, Limit of Quantification, Robustness.

STABILITY STUDY DATA

Manufacturer of API	Jiangsu Weiqida Pharmaceutical Co., Ltd.		
API Lot No.	NBB-19070031M		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×10's , 3x 10's and 2x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, 36 (Months)		
Batch No.	NEB2.5-TR002	NEB2.5-TR003	NEB2.5-TR004
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	09-2020	09-2020	09-2020

No. of Batches		03
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by DCA valid till 17/01/2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Copy of letter No.759/2020DRAP-AD (I&E) dated 13/01/2020 is submitted wherein the permission to import Nebivolol HCl for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.	**3.2.S.4.2**	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".* Since you have only submitted the requisite information provided by drug substance manufacturer.
2.	**3.2.S.4.4**	Justify how you have calculate the potency of nebivolol without HCl as mentioned in the COA of drug substance comparing the COA of drug substance by drug substance manufacturer calculated the assay on anhydrous basis only.
3.	**3.2.P.2.2.1**	• Justify for not performing the test of content uniformity by HPLC and water content test while establishing the pharmaceutical equivalence aginst the reference product, since these test are included in the specification of innovator brand of USFDA. • Justify for not performing the pharmaceutical equivalence and comparative dissolution against the innovator brand/brand leador approved in Pakistan.
4.	**3.2.P.5.1**	• Justify for not including the test of water conent in the release specification of drug product, since these test are included in the specification of innovator brand. • Clarification is required that in assay either you have quantified the nebivolol or nebivolol HCl, since the calculated % is of nebivolol HCl, while the main peak in the chromatogram represent the nebivolol without HCl. • Sample preparation for assay is more general rather than specific, without the clarity that transfer quantity of the sample equivalent to 50mg represent either the quantity of nebivolol or nebivolol HCl. • Justify for adapting the acceptance criteria of dissolution NLT 80% within 45 minutes comparing the results of CDP in 0.01N HCl medium

		which was more than 80% within 15minutes and the acceptance criteria of innovator brand approved in USFDA.
5.	**3.2.R.1.1**	Justify for taking the strength of tablet with HCl factor for calculation of dispensed quantity of powder as revealed from the batch manufacturing record since you have taken the potency of drug substance without HCl on as is basis.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

568.	Name, address of Applicant / Marketing Authorization Holder	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Name, address of Manufacturing site.	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.no.2630 dated 27/01/2022
	Details of fee submitted	PKR 30,000/-: dated 24/11/2021
	The proposed proprietary name / brand name	Nevol 5mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Nebivolol HCl equivalent to Nebivolol…..5mg
	Pharmaceutical form of applied drug	White colored, round shaped, biconvex uncoated tablets with both sides plain.
	Pharmacotherapeutic Group of (API)	Beta blocking agent, selective
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	1×10's , 3x 10's and 2x 7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Bystolic tablets, Allergen, USA
	For generic drugs (me-too status)	Nabil 5mg Tablet by M/s Getz Pharma, Reg. No. 061345
	GMP status of the Finished product manufacturer	Last GMP was granted on 09/06/2020 GMP is in Renewal Process
	Name and address of API manufacturer.	**Name:** Jiangsu Weiqida Pharmaceutical Co., Ltd. **Old Name**: Shanghai Shyndec Pharmaceutical (Haimen) Co., Ltd **Address:** No.1, Linjiang Avenue, Nantong, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	Official monograph of Nebivolol HCl is not present in Pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Test for Impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (NEB5-TR002, NEB5-TR003, NEB5-TR004)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Nebil 5mg tablet by Getz Pharma (Pvt) Ltd. by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Nebil 5mg tablet by Getz Pharma (Pvt) Ltd.in Acid media (pH 1.2), pH 4.5 & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, linearity, accuracy, precision (repeatability and Intermediate), Limit of Detection, Limit of Quantification, Robustness.

STABILITY STUDY DATA			
Manufacturer of API	Jiangsu Weiqida Pharmaceutical Co., Ltd.		
API Lot No.	NBB-19070031M		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×10's3x 10's and 2x 7's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, 36 (Months)		
Batch No.	NEB5-TR002	NEB5-TR003	NEB5-TR004
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	09-2020	09-2020	09-2020
No. of Batches	03		
Administrative Portion			

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by DCA valid till 17/01/2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Copy of letter No.759/2020DRAP-AD (I&E) dated 13/01/2020 is submitted wherein the permission to import Nebivolol HCl for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.	**3.2.S.4.2**	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".* Since you have only submitted the requisite information provided by drug substance manufacturer.
2.	**3.2.S.4.4**	Justify how you have calculate the potency of nebivolol without HCl as mentioned in the COA of drug substance comparing the COA of drug substance by drug substance manufacturer calculated the assay on anhydrous basis only.
3.	**3.2.P.2.2.1**	• Justify for not performing the test of content uniformity by HPLC and water content test while establishing the pharmaceutical equivalence aginst the reference product, since these test are included in the specification of innovator brand of USFDA. • Justify for not performing the pharmaceutical equivalence and comparative dissolution against the innovator brand/brand leador approved in Pakistan.
4.	**3.2.P.5.1**	• Justify for not including the test of water conent in the release specification of drug product, since these test are included in the specification of innovator brand. • Clarification is required that in assay either you have quantified the nebivolol or nebivolol HCl, since the calculated % is of nebivolol HCl, while the main peak in the chromatogram represent the nebivolol without HCl. • Sample preparation for assay is more general rather than specific, without the clarity that transfer quantity of the sample equivalent to 50mg represent either the quantity of nebivolol or nebivolol HCl. • Justify for adapting the acceptance criteria of dissolution NLT 80% within 45 minutes comparing the results of CDP in 0.01N HCl medium which was more than 80% within 15minutes and the acceptance criteria of innovator brand approved in USFDA.
5.	**3.2.R.1.1**	Justify for taking the strength of tablet with HCl factor for calculation of dispensed quantity of powder as revealed from the batch manufacturing record since you have taken the potency of drug substance without HCl on as is basis.

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.		
569.	Name, address of Applicant / Marketing Authorization Holder	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Name, address of Manufacturing site.	**Name:** Pharmedic Laboratories (Pvt.) Ltd. **Address:** 16km Multan Road, Lahore-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.no.9330 dated 12/04-2022
	Details of fee submitted	PKR 30,000/-: dated 17/03/2022
	The proposed proprietary name / brand name	Nevol 10mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Nebivolol HCl equivalent to Nebivolol…..10mg
	Pharmaceutical form of applied drug	White colored, round shaped, biconvex uncoated tablets with both sides plain.
	Pharmacotherapeutic Group of (API)	Beta blocking agent, selective
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	1×10's , 3x 10's and 2x 7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Bystolic tablets, Allergen, USA
	For generic drugs (me-too status)	Bynevol 10mg Tablet by Atco Laboratories, Reg. No. 081562
	GMP status of the Finished product manufacturer	Last GMP was granted on 09/06/2020 GMP is in Renewal Process
	Name and address of API manufacturer.	**Name:** Jiangsu Weiqida Pharmaceutical Co., Ltd. **Old Name**: Shanghai Shyndec Pharmaceutical (Haimen) Co., Ltd **Address:** No.1, Linjiang Avenue, Nantong, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Nebivolol HCl is not present in any Pharmacoepia. The firm has submitted detail of nomenclature, structure, general properties, solubilities,

		physical form, manufacturers, description of manufacturing process and controls, Test for Impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (NBB-1711001-1M, NBB-1711002-1M, NBB-1711003-1M)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Bynevol 10mg tablet by Atco Laboratories. by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Bynevol 10mg tablet by Atco Laboratories..…. in Acid media (pH 1.2), pH 4.5 & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, linearity, accuracy, precision (repeatability and Intermediate), Limit of Detection, Limit of Quantification, Robustness.

STABILITY STUDY DATA

Manufacturer of API	Jiangsu Weiqida Pharmaceutical Co., Ltd.		
API Lot No.	NBB-19070031M		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×10's, 3x 10's and 2x 7's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, 36 (Months)		
Batch No.	NEB10-TR002	NEB10-TR003	NEB10-TR004
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	09-2020	09-2020	09-2020
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by DCA valid till 17/01/2024.

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of letter No.759/2020DRAP-AD (I&E) dated 13/01/2020 is submitted wherein the permission to import Nebivolol HCl for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings
1.	**3.2.S.4.2**	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that *"Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".* Since you have only submitted the requisite information provided by drug substance manufacturer.
2.	**3.2.S.4.4**	Justify how you have calculate the potency of nebivolol without HCl as mentioned in the COA of drug substance comparing the COA of drug substance by drug substance manufacturer calculated the assay on anhydrous basis only.
3.	**3.2.P.2.2.1**	• Justify for not performing the test of content uniformity by HPLC and water content test while establishing the pharmaceutical equivalence aginst the reference product, since these test are included in the specification of innovator brand of USFDA. • Justify for not performing the pharmaceutical equivalence and comparative dissolution against the innovator brand/brand leador approved in Pakistan.
4.	**3.2.P.5.1**	• Justify for not including the test of water conent in the release specification of drug product, since these test are included in the specification of innovator brand. • Clarification is required that in assay either you have quantified the nebivolol or nebivolol HCl, since the calculated % is of nebivolol HCl, while the main peak in the chromatogram represent the nebivolol without HCl. • Sample preparation for assay is more general rather than specific, without the clarity that transfer quantity of the sample equivalent to 50mg represent either the quantity of nebivolol or nebivolol HCl. • Justify for adapting the acceptance criteria of dissolution NLT 80% within 45 minutes comparing the results of CDP in 0.01N HCl medium which was more than 80% within 15minutes and the acceptance criteria of innovator brand approved in USFDA.
5.	**3.2.R.1.1**	Justify for taking the strength of tablet with HCl factor for calculation of dispensed quantity of powder as revealed from the batch manufacturing record since you have taken the potency of drug substance without HCl on as is basis.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Export Facilitation: Applications was received through letter No.F.1-76/2019-PR-I (EFD)
"M/s Martin Dow Marker Limited, Quetta have achieved benchmark OF USD 306,234,54 as defined in the Board's decision during fiscal year 2021-2022. In this regard, please find the (1 molecule) 05 products applications submitted by the firm."

570.	Name, address of Applicant / Marketing Authorization Holder	M/s Martin Dow Marker Limited, 7-Jail Road, Quetta	
	Name, address of Manufacturing site.	M/s Martin Dow Marker Limited, 7-Jail Road, Quetta	
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)	
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales	
	Dy. No. and date of submission	Dy.no. 2524 dated 26-01-2022	
	Details of fee submitted	PKR 75,000/-:	dated 10/12/2021
	The proposed proprietary name / brand name	Canrec AM 8mg+2.5mg Tablet	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Candesartan Cilexetil…...8mg Amlodipine Besilate, BP eq. to Amlodipine…...2.5mg	
	Pharmaceutical form of applied drug	Off White, Round Biconvex Tablets having break line on side and other side plain.	
	Pharmacotherapeutic Group of (API)	Candesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs) Amlodipine belongs to a class of drugs called calcium channel blockers	
	Reference to Finished product specifications	Specifications as per Innovator's product.	
	Proposed Pack size	As per DPC	
	Proposed unit price	As per SRO	
	The status in reference regulatory authorities	Product Name: Unisia Combination Tablets LD 8mg+ 2.5mg RRA: Pharmaceuticals and Medical Devices Agency (PMDA) Japan	
	For generic drugs (me-too status)	Not Applicable	
	GMP status of the Finished product manufacturer	Certificate No:015/2021-DRAP (Q)/K issued on 10th September 2021 Tablet (General & Psychotropic), Capsule (General), Oral Liquid Syrup (General), Sterile Liquid Injection/Ampoule, Ointment/Cream, Dry Powder Sachet (General), Dry Powder Suspension (General) section approved.	
	Name and address of API manufacturer.	**Candesartan:** M/s Zhejiang Huahai Pharmaceutical Co., Ltd.-Xunqiao site Xuqiao, Linhai, Zhejiang 317024, China. **Amlodipine:** M/s Prudence Pharmachem, Gujarat (India)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.	

	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **(Candesartan Cilexetil)** Real time: 30˚C ± 2˚C / 75% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: 5258-12-208,5258-12-209,5258-12-210 Stability study conditions: **(Amlodipine Besylate)** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches:AMB/002/01/14,AMB/003/02/14,AMB/004/02/14
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Innovator product Unisia Tablet 8mg + 2.5mg Tablet (Innovator product) PMDA Japan by performing quality tests (Identification, Assay, Dissolution). CDP has been performed against the same brand that is Innovator product Unisia Tablet 8mg + 2.5mg Tablet (Innovator product) PMDA Japan, Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	**Candesartan:** M/s Zhejiang Huahai Pharmaceutical Co., Ltd.-Xunqiao site Xuqiao, Linhai, Zhejiang 317024, China. **Amlodipine:** M/s Prudence Pharma chem, Gujarat (India)		
API Lot No.	**Candesartan:** 5668-19-508 **Amlodipine:** AMB/111/05/20		
Description of Pack (Container closure system)	Aluminium and Cold forming foil (CFF) which are sealed together and packed in Unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-01	T-02	T-03
Batch Size	10000 Tablets	10000 Tablets	10000 Tablets
Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	12-2020	12-2020	12-2020

No. of Batches	03	
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**M/s Zhejiang Huahai Pharmaceutical Co. Ltd China:** GMP Certificate No 201907047 issued by CFDA valid till 15-1-2023. **M/s Prudence Pharmachem:** GMP Certificate No S-GMP & GLP/22053332 issued by Food & Drug Control Administration Gujrat India valid till 26-05-2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**M/s Zhejiang Huahai Pharmaceutical Co. Ltd China:** ADC Invoice No: HH20201167, 03-June-2020 is submitted wherein the permission to import API (Candesartan) for the purpose of test/analysis and stability studies is granted. **M/s Prudence Pharmachem:** ADC Invoice No: PPC/030/20-21, 30-May-2020 is submitted wherein the permission to import API (Amlodipine) for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	**Sections**	**Observations/Deficiencies/ Short-comings**	**Response of the Firm**
1.	**3.2.S.4.2 (Candesartan Cilexetil)**	Analytical procedure given in section 3.2.S.4.2 exhibited the assay method via HPLC while the assay method which has verified in section 3.2.S.4.3 performed via titration method, clarification is required in this regard.	Firm replied that, to address above mentioned query, we have revised the analytical procedure of Candesartan Cilexetil as per USP monograph and method verification has also been performed accordingly via HPLC
2.	**3.2.P.1**	Composition of applied product submitted in respective section is not qualitatively similar to the composition of innovator product, so, in this case please submit the compatibility study of active with the excipients.	Submitted
3.	**3.2.P.1**	Justify the quantity of amlodipine besylate used in the composition of applied product i.e. 7mg comparing the quantity mentioned in the composition of reference product i.e.6.93mg.	Firm replied that amlodipine besylate 6.93mg is equivalent to about 5mg of amlodipine as per innovator product. The concentration of API 7mg is used in master formulation as 6.93 values are rounded off to 7mg.
4.	**3.2.P.2.2.1**	Justify for not performing all the quality test mentioned in specification of finished product while establishing the pharmaceutical against reference product.	Firm replied that Only significant quality tests including assay and dissolution were performed for establishing pharmaceutical equivalence. Other less critical tests including

			disintegration and average weight tests were not performed at this stage.
5.	**3.2.P.5.1**	Justify for not including loss on drying/water determination test in the specification of finished product.	Firm replied that "As loss on drying/water determination is not included in USP monographs of both Candesartan Cilexetil Tablets and Amlodipine Tablets and proposed packing of product is alu-alu blister , therefore, these tests not included in the specification of finished product".
6.	**3.2.P.5.2**	Scientific justification for setting the UV detector limit at 238nm, since the USP recommended the UV detection limit at 282nm for candesartan cilexetil both in individual and in combination product.	Firm replied that "With respect to selection of 238nm wavelength, please note that combination product having candesartan and Amlodipine is not present in USP, therefore, if we followed individual monographs of Candesartan and Amlodipine product as per USP monograph, we need to perform testing for both API is using different HPLC procedures which was more time consuming. To resolve this Issue, we followed a research article to develop and validate the analytical procedure for simultaneous determination of candesartan and Amlodipine via HPLC using 238nm wavelength".
7.	**3.2.P.5.2**	Justify the selection of Buffer pH 6.8 medium for dissolution from the international literature and pharmacoepial reference, further provide the percentile quantity of polysorbate 80 used in the dissolution medium.	Firm replied that "Preparation of buffer solution for dissolution test has been taken form USP monograph of candesartan Cilexetil Tablets and polysorbate 20 is used as per USP monograph which is mentioned in provided finished product testing method. However, as this product is a non-pharmacopeial product and according to CDP study against comparator product, dissolution results found comparable with comparator product in pH 6.8 buffer, therefore, we selected pH 6.8 for release testing as well".
8.	**3.2.P.8**	Justify for using different method for preparation of sample solution as evident from the raw data sheet from that specified in analytical procedure given in section 3.2. P.5.2.	Firm replied that "Deviation from specified analytical procedure only observed in initial testing of product because at this stage method has been developed and under review if required any improvement. Once method has been finalized including method of preparation of sample solution, no deviation was observed from 3rd. month stability data".
9.	**3.2.P.8**	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Submitted
10	**3.2.P.8**	Documents for the procurement of API with approval from DRAP (in case of import).	Submitted
Decision: Deferred for submission of scientific justification for:			

• **Applying different analytical procedure for the drug substance of "Candesartan cilexetil" analysis than that recommended by the USP monograph.** • **Applied wavelength for Assay analysis of drug product in deviation to that recommended by pharmacopoeial monographs for candesartan cilexetil formulations.**		
571.	Name, address of Applicant / Marketing Authorization Holder	M/s Martin Dow Marker Limited, 7-Jail Road, Quetta
	Name, address of Manufacturing site.	M/s Martin Dow Marker Limited, 7-Jail Road, Quetta
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.no.2525 dated 26-01-2022
	Details of fee submitted	PKR 75,000/-: dated 10/12/2021
	The proposed proprietary name / brand name	**Canrec AM 8mg+5mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Candesartan Cilexetil…...8mg Amlodipine Besilate, BP eq to Amlodipine…...5mg
	Pharmaceutical form of applied drug	Off white, Round Biconvex tablets having break line on one side and other side plain
	Pharmacotherapeutic Group of (API)	Candesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs) Amlodipine belongs to a class of drugs called calcium channel blockers
	Reference to Finished product specifications	Specifications as per Innovator's product.
	Proposed Pack size	As per DPC
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Product Name: Unisia Combination Tablets LD 8mg+ 5mg RRA: Pharmaceuticals and Medical Devices Agency (PMDA) Japan Approved in Austria (Candeblo/Amlo 8mg/5mg Table)
	For generic drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer	Certificate No:015/2021-DRAP (Q)/K issued on 10th September 2021 Tablet (General & Psychotropic), Capsule (General), Oral Liquid Syrup (General), Sterile Liquid Injection/Ampoule, Ointment/Cream, Dry Powder Sachet (General), Dry Powder Suspension (General) section approved.
	Name and address of API manufacturer.	**Candesartan:** M/s Zhejiang Huahai Pharmaceutical Co., Ltd.-Xunqiao site Xuqiao, Linhai, Zhejiang 317024, China. **Amlodipine:** M/s Prudence Pharmachem, Gujarat (India)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

		specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **(Candesartan Cilexetil)** Real time: 30˚C ± 2˚C / 75% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: 5258-12-208,5258-12-209,5258-12-210 Stability study conditions: **(Amlodipine Besylate)** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: AMB/002/01/14,AMB/003/02/14,AMB/004/02/14
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Innovator product Unisia Tablet 8mg + 5mg Tablet (Innovator product) PMDA Japan by performing quality tests (Identification, Assay, Dissolution). CDP has been performed against the same brand that is Innovator product Unisia Tablet 8mg + 5mg Tablet (Innovator product) PMDA Japan, Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	**Candesartan:** M/s Zhejiang Huahai Pharmaceutical Co., Ltd.-Xunqiao site Xuqiao, Linhai, Zhejiang 317024, China. **Amlodipine:** M/s Prudence Pharmachem, Gujarat (India)		
API Lot No.	**Candesartan:** 5668-19-508 **Amlodipine:** AMB/111/05/20		
Description of Pack (Container closure system)	Aluminum and Cold forming foil (CFF) which are sealed together and packed in Unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-01	T-02	T-03
Batch Size	10000 Tablets	10000 Tablets	10000 Tablets

Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	12-2020	12-2020	12-2020
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**M/s Zhejiang Huahai Pharmaceutical Co. Ltd China:** GMP Certificate No 201907047 issued by CFDA valid till 15-1-2023 **M/s Prudence Pharmachem:** GMP Certificate No S-GMP & GLP/22053332 issued by Food & Drug Control Administration Gujrat India valid till 26-05-2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**M/s Zhejiang Huahai Pharmaceutical Co. Ltd China:** ADC Invoice No: HH20201167, 03-June-2020 is submitted wherein the permission to import API (Candesartan) for the purpose of test/analysis and stability studies is granted. **M/s Prudence Pharmachem:** ADC Invoice No: PPC/030/20-21, 30-May-2020 is submitted wherein the permission to import API (Amlodipine) for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings	Response of the Firm
1.	**3.2.S.4.2 (Candesartan Cilexetil)**	Analytical procedure given in section 3.2.S.4.2 exhibited the assay method via HPLC while the assay method which has verified in section 3.2.S.4.3 performed via titration method, clarification is required in this regard.	Firm replied that, to address above mentioned query, we have revised the analytical procedure of Candesartan Cilexetil as per USP monograph and method verification has also been performed accordingly via HPLC
2.	**3.2.P.1**	Composition of applied product submitted in respective section is not qualitatively similar to the composition of innovator product, so, in this case please submit the compatibility study of active with the excipients.	Submitted
3.	**3.2.P.1**	Justify the quantity of amlodipine besylate used in the composition of applied product i.e. 7mg comparing the quantity mentioned in the composition of reference product i.e.6.93mg.	Firm replied that amlodipine besylate 6.93mg is equivalent to about 5mg of amlodipine as per innovator product. The concentration of API 7mg is used in master formulation as 6.93 values are rounded off to 7mg.
4.	**3.2.P.2.2.1**	Justify for not performing all the quality test mentioned in specification of finished product while establishing the pharmaceutical against reference product.	Firm replied that Only significant quality tests including assay and dissolution were performed for establishing pharmaceutical equivalence.

			Other less critical tests including disintegration and average weight tests were not performed at this stage.
5.	**3.2.P.5.1**	Justify for not including loss on drying/water determination test in the specification of finished product.	Firm replied that "As loss on drying/water determination is not included in USP monographs of both Candesartan Cilexetil Tablets and Amlodipine Tablets and proposed packing of product is alu-alu blister , therefore, these tests not included in the specification of finished product".
6.	**3.2.P.5.2**	Scientific justification for setting the UV detector limit at 238nm, since the USP recommended the UV detection limit at 282nm for candesartan cilexetil both in individual and in combination product.	Firm replied that "With respect to selection of 238nm wavelength, please note that combination product having candesartan and Amlodipine is not present in USP, therefore, if we followed individual monographs of Candesartan and Amlodipine product as per USP monograph, we need to perform testing for both API is using different HPLC procedures which was more time consuming. To resolve this Issue, we followed a research article to develop and validate the analytical procedure for simultaneous determination of candesartan and Amlodipine via HPLC using 238nm wavelength".
7.	**3.2.P.5.2**	Justify the selection of Buffer pH 6.8 medium for dissolution from the international literature and pharmacoepial reference, further provide the percentile quantity of polysorbate 80 used in the dissolution medium.	Firm replied that "Preparation of buffer solution for dissolution test has been taken form USP monograph of candesartan Cilexetil Tablets and polysorbate 20 is used as per USP monograph which is mentioned in provided finished product testing method. However, as this product is a non-pharmacopeial product and according to CDP study against comparator product, dissolution results found comparable with comparator product in pH 6.8 buffer, therefore, we selected pH 6.8 for release testing as well".
8.	**3.2.P.8**	Justify for using different method for preparation of sample solution as evident from the raw data sheet from that specified in analytical procedure given in section 3.2. P.5.2.	Firm replied that "Deviation from specified analytical procedure only observed in initial testing of product because at this stage method has been developed and under review if required any improvement. Once method has been finalized including method of preparation of sample solution, no deviation was observed from 3rd. month stability data".
9.	**3.2.P.8**	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Submitted
10	**3.2.P.8**	Documents for the procurement of API with approval from DRAP (in case of import).	Submitted
Decision: Deferred for submission of scientific justification for:			

- **Applying different analytical procedure for the drug substance of "Candesartan cilexetil" analysis than that recommended by the USP monograph.**
- **Applied wavelength for Assay analysis of drug product in deviation to that recommended by pharmacopoeial monographs for Candesartan cilexetil formulations.**

Previously Deferred Cases of Form 5-F

572.	**Name, Address of Applicant / Marketing Authorization Holder**	**M/s Bio-Next Pharmaceuticals Plot No. 50, Street No. S-10, RCCI Industrial Estate, Rawat Islamabad-Pakistan**
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt). Ltd Plot No. 145industrial Triangle Kahuta road Islamabad.
	Status of the applicant	☐Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 7851 dated 10/03/2021
	Details of fee submitted	PKR 50,000/-: dated 23/04/2020
	The proposed proprietary name / brand name	**Nextcraft 1MIU Injection IV**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate Sodium….1MIU
	Pharmaceutical form of applied drug	Glass vial filled with almost white to off-white coloured Lyophilized Powder.
	Pharmacotherapeutic Group of (API)	Antibiotics
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved
	For generic drugs (me-too status)	Colistim Injection by Pharmasol (Pvt) Ltd
	GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conduct 23-4-2019, valid upto 22-4-2022.
	Name and address of API manufacturer.	Mac-Chem Products (India)Pvt.Ltd N-211/2/10, midc, Boisar District –Thane.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.

	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities°, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.		
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5% RH for 12 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches:(CLS0219006, CLS0219008, CLS0219009)		
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.		
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the comparator i.e. Colistim Injection by Pharmasol (Pvt) Ltd.		
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.		
STABILITY STUDY DATA				
Manufacturer of API		Mac-Chem Products (India) Pvt. Ltd. N-211/2/10, midc, Boisar District –Thane.		
API Lot No.		A1680997, A1681004, A1600290		
Description of Pack (Container closure system)		Glass vial		
Stability Storage Condition		Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period		Real time: 24 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 ,9,12,18,24(Months)		
Batch No.		L-159	L-182	L-199
Batch Size		18200 Vials	28000 Vials	30000vials
Manufacturing Date		05-2018	09-2018	12-2018
Date of Initiation		29-05-18	03-10-18	21-12-2018
No. of Batches		03		
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Empaglif 10mg & 25mg tablet in 296th meeting (Bio-Labs (Pvt). Ltd, Islamabad).		

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (NEW-WHO GMP/CERT/KD/74238/2018/11/24897) issued by Maharashtra food and drug administration dated 11-09-2018. The certificate is valid till 10-09-2021.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Form 6 "License to import drugs for clinical trial, examination, test or analysis" for import of Colistimethate sodium 5kg from Mac-Chem Products (India)Pvt. Ltd N-211/2/10, MIDC, Boisar District –Thane. The license was issued on 14-02-2020. • Firm has submitted copy of commercial invoice dated 14-02-2020 specifying import of Colistimethate sodium 5Kg. The invoice is signed by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches including COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The product specifications of colistimethate sodium injection based on USP and there is no application of HPLC in testing method because the assay method based on microbial assay therefore compliance record of HPLC is not applicable here.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of Evaluator:

Observations	**Firm's response**
• Provide detailed analytical procedures for the testing of drug substance by the drug product manufacturer. • Provide analytical Method Verification studies including specificity, accuracy and repeatability performed by the Drug Product manufacturer.	Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Firm submitted the analytical method verification studies. Verification has been done on assay procedure which is also not as per the USP.
Justify 90.1mg filled weight of colistimethate sodium per vial against the labelled claim of colistin activity as per the USP monograph of "colistimethate for injection".	Nominal potency of colistimethate sodium used for calculation of filled weight is not correct, according to the innovator product of Colistimethate sodium 1MIU the nominal potency of the drug substance =12,500 IU/mg. So, using of 90.1 filled weight is still not scientifically rationale.
All quality test as per USP monograph has not been performed while establishing the pharmaceutical equivalence against the reference product. Provide results of all quality test of applied and reference product as per USP to establish pharmaceutical equivalence.	Test for uniformity of dosage unit, loss on drying, and free colistin under Colistimethate Sodium are not performed while establishing pharmaceutical equivalence with the reference product, while these tests are included in the USP monograph of colistimethate sodium injection.
Details of type and quantity of diluents used for reconstitution for of applied product is required.	According to the submitted information, to reconstitute the injection, use 3ml 0.9% sodium chloride solution. While the international reference product including the innovator, use the range of 7ml-10ml of water

	for injection or 0.9% sodium chloride for reconstitution of colistimethate injection.
Provide detailed analytical procedures used to evaluate the quality of drug product by the Manufacturer M/s. Bio-Lab Pvt. Ltd.	Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Further, the test for uniformity of dosage unit, loss on drying, heavy metals, and free Colistin under Colistimethate Sodium are not included in finished product specification, since these tests are included in the USP monograph.
According to the filled BMR batch size of Batch L-159, L-199 and L-182 is 11090vials, 11,000 vials and 11050 vials respectively. While according to the stability data sheet batch size of all three batches are L-159 18,200 vials, L-199 30,000 vials and L-182 28,000 vials. Justification is required regarding the disparity observed in the batch sizes of the same batch.	Firm submitted the reply that "Batch sizes mentioned on stability was written mistakenly. Please consider BMR batch sizes (11,111 packs) as valid batch size. Correct stability data has been submitted.

Decision of 316th meeting of Registration Board:

Deferred for the submission of following:

- Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.
- Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.
- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.
- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.
- For further deliberation regarding the label claim of Colistimethate sodium in line with the product approved in reference regulatory agencies and pharmacopeia.

Response of the Firm:

Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.

Firm has submitted the revised microbial assay method which is again not in accordance with USP general chapter microbial assay <81> in terms of analysis and calculations.

Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.

Firm has submitted the calculation, according to which quantity of 87.144mg of colistimethate injection has been filled per vial after adjustment of water content and sodium factor. Further, firm set the internal fill weight ±4% i.e. 83.65mg to 90.62 mg and fill weight set at 90mg/vial.

Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.

Firm has submitted revised pharmaceutical equivalence report in which only test for uniformity of dosage unit has been added but test for loss on drying and free colistin still not been included.

Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.

Firm has submitted the revised stability data and COA of relevant stability batches, in which test for loss on drying and free colistin was still not included neither any scientific justification has been submitted.

Decision of 321st meeting of Registration Board:
Registration Board deferred the case for following points:

1. Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.
2. Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.
3. Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.
4. Performance of loss on drying test for drug product as per USP monograph of colistimethate injection**.**

Response of the Firm:

Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.

Firm submitted the Batch manufacturing record of three commercial batches of colicraft 1MIU Injection from M/s. Bio Labs Pvt. Ltd., from which it is evident that sterile colistimethate sodium has been used in the formulation of colicraft and lyophilization has done in the premises of M/s. Bio-Labs Pvt. Ltd.

Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.

Firm has submitted only the microbial assay procedure of drug product without any performance data.

Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.

Firm has submitted the Pharmaceutical equivalence report performed against the comparator product Colistim Injection of M/s. Pharmasole Pvt. Ltd. Batch.no. KC032, which includes (Identification, LOD, pH, Uniformity of dose, Particulate matter, Free colistin, Sterility, bacterial endotoxin test & assay).

Performance of loss on drying test for drug product as per USP monograph of colistimethate injection.

Firm has submitted the revised stability data sheets of batches L-159, L-199 and L-182 in which results of loss on drying test were included.

Decision: Deferred for submission of following:

- **Analytical data for the performance of microbial assay of drug substance and drug product for complete stability studies, in accordance with USP general chapter of microbial assay <81>.**
- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**

573.	Name, Address of Applicant / Marketing Authorization Holder	M/s. Benson Pharmaceuticals Plot #3 Mai Road National Industrial Zone RCCI Rawat Pakistan.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt). Ltd Plot No. 145industrial Triangle Kahuta road Islamabad.
	Status of the applicant	☐Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 9700 dated 02/04/2021
	Details of fee submitted	PKR 50,000/-: vide slip no. 1913592 dated 08/03/2021
	The proposed proprietary name / brand name	Coliben 1MIU Injection IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate Sodium……...…….1MIU
	Pharmaceutical form of applied drug	Glass vial filled with almost white to off-white colored Lyophilized Powder.
	Pharmacotherapeutic Group of (API)	Antibiotics

	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved
	For generic drugs (me-too status)	Colistim Injection by Pharmasol (Pvt) Ltd
	GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conduct 23-4-2019, valid upto 22-4-2022.
	Name and address of API manufacturer.	Mac-Chem Products (India)Pvt.Ltd N-211/2/10, midc, Boisar District –Thane.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5% RH for 12 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches:(CLS0219006, CLS0219008, CLS0219009)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the comparator i.e. Colistim Injection by Pharmasol (Pvt) Ltd.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.
STABILITY STUDY DATA		
Manufacturer of API		Mac-Chem Products (India)Pvt.Ltd N-211/2/10, midc, Boisar District –Thane.
API Lot No.		A1680997, A1681004, A1600290
Description of Pack (Container closure system)		Glass vial
Stability Storage Condition		Real time: 30˚C ± 2˚C / 65% ± 5%RH

		Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period		Real time: 24 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 ,9,12,18,24(Months)		
Batch No.		L-159	L-182	L-199
Batch Size		18200 Vials	28000 Vials	30000vials
Manufacturing Date		05-2018	09-2018	12-2018
Date of Initiation		29-05-18	03-10-18	21-12-2018
No. of Batches		03		
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Empaglif 10mg & 25mg tablet in 296th meeting (Bio-Labs (Pvt). Ltd, Islamabad).		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (NEW-WHO GMP/CERT/KD/74238/2018/11/24897) issued by Maharashtra food and drug administration dated 11-09-2018.The certificate is valid till 10-09-2021.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Form 6 "License to import drugs for clinical trial, examination, test or analysis" for import of Colistimethate sodium 5Kg from Mac-Chem Products (India)Pvt.Ltd N-211/2/10, midc, Boisar District –Thane. The license was issued on 14-02-2020. • Firm has submitted copy of commercial invoice dated 14-02-2020 specifying import of Colistimethate sodium 5Kg. The invoice is signed by AD (I&E) DRAP.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches including COA and summary data sheets.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	NA		
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.		
Remarks of Evaluator:				
• Provide detailed analytical procedures for the testing of drug substance by the drug product manufacturer. • Provide analytical Method Verification studies including specificity, accuracy and repeatability performed by the Drug Product manufacturer.		Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Firm submitted the analytical method verification studies. Verification has been done on assay procedure which is also not as per the USP.		
Justify 90.1mg filled weight of colistimethate sodium per vial against the labelled claim of colistin activity as per the USP monograph of "colistimethate for injection".		Nominal potency of colistimethate sodium used for calculation of filled weight is not correct, according to the innovator product of Colistimethate sodium 1MIU the nominal potency of the drug substance =12,500 IU/mg. So, using of 90.1 filled weight is still not scientifically rationale.		

All quality test as per USP monograph has not been performed while establishing the pharmaceutical equivalence against the reference product. Provide results of all quality test of applied and reference product as per USP to establish pharmaceutical equivalence.	Test for uniformity of dosage unit, loss on drying, and free colistin under Colistimethate Sodium are not performed while establishing pharmaceutical equivalence with the reference product, while these tests are included in the USP monograph of colistimethate sodium injection.
Details of type and quantity of diluents used for reconstitution for of applied product is required.	According to the submitted information, to reconstitute the injection, use 3ml 0.9% sodium chloride solution. While the international reference product including the innovator, use the range of 7ml-10ml of water for injection or 0.9% sodium chloride for reconstitution of colistimethate injection.
Provide detailed analytical procedures used to evaluate the quality of drug product by the Manufacturer M/s. Bio-Lab Pvt. Ltd.	Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Further, the test for uniformity of dosage unit, loss on drying, heavy metals, and free colistin under Colistimethate Sodium are not included in finished product specification, since these tests are included in the USP monograph.
According to the filled BMR batch size of Batch L-159, L-199 and L-182 is 11090 vials, 11,000 vials and 11050 vials respectively. While according to the stability data sheet batch size of all three batches are L-159 18,200 vials, L-199 30,000 vials and L-182 28,000 vials. Justification is required regarding the disparity observed in the batch sizes of the same batch.	Firm submitted the reply that "Batch sizes mentioned on stability was written mistakenly. Please consider BMR batch sizes (11,111 packs) as valid batch size. Correct stability data has been submitted.

Decision of 316th meeting of Registration Board:
Deferred for the submission of following:

- Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.
- Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.
- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.
- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.
- For further deliberation regarding the label claim of Colistimethate sodium in line with the product approved in reference regulatory agencies and pharmacopeia.

Response of the Firm:
Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.
Firm has submitted the revised microbial assay method which is again not in accordance with USP general chapter microbial assay <81> in terms of analysis and calculations.
Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.
Firm has submitted the calculation, according to which quantity of 87.144mg of colistimethate injection has been filled per vial after adjustment of water content and sodium factor. Further, firm set the internal fill weight ±4% i.e. 83.65mg to 90.62 mg and fill weight set at 90mg/vial.
Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.
Firm has submitted revised pharmaceutical equivalence report in which only test for uniformity of dosage unit has been added but test for loss on drying and free colistin still not been included.
Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.

Firm has submitted the revised stability data and COA of relevant stability batches, in which test for loss on drying and free colistin was still not included neither any scientific justification has been submitted.

Decision of 321st meeting of Registration Board:
Registration Board deferred the case for following points:

5. Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.
6. Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.
7. Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.
8. Performance of loss on drying test for drug product as per USP monograph of colistimethate injection**.**

Response of the Firm:

Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.

Firm submitted the Batch manufacturing record of three commercial batches of colicraft 1MIU Injection from M/s. Bio Labs Pvt. Ltd., from which it is evident that sterile colistimethate sodium has been used in the formulation of colicraft and lyophilization has done in the premises of M/s. Bio-Labs Pvt. Ltd.

Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.

Firm has submitted only the microbial assay procedure of drug product without any performance data.

Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.

Firm has submitted the Pharmaceutical equivalence report performed against the comparator product Colistim Injection of M/s. Pharmasole Pvt. Ltd. Batch.no. KC032, which includes (Identification, LOD, pH, Uniformity of dose, Particulate matter, Free colistin, Sterility, bacterial endotoxin test & assay).

Performance of loss on drying test for drug product as per USP monograph of colistimethate injection.

Firm has submitted the revised stability data sheets of batches L-159, L-199 and L-182 in which results of loss on drying test were included.

Decision: Deferred for submission of following:

- **Analytical data for the performance of microbial assay of drug substance and drug product for complete stability studies, in accordance with USP general chapter of microbial assay <81>.**
- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**

574.	Name, address of Applicant / Marketing Authorization Holder	M/s Novartana Pharmaceuticals (Pvt). Ltd 87-B Plot of Sundar Industrial Area, Raiwind Road, Lahore Pakistan.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt). Ltd Plot No. 145industrial Triangle Kahuta road Islamabad.
	Status of the applicant	☐Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No.10322 dated 02/04/2021
	Details of fee submitted	PKR 50,000/-: vide slip no. 1913592 dated 08/03/2021
	The proposed proprietary name / brand name	ColiNova 1MIU Injection IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate Sodium…….1MIU

	Pharmaceutical form of applied drug	Glass vial filled with almost white to off-white colored Lyophilized Powder.
	Pharmacotherapeutic Group of (API)	Antibiotics
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved
	For generic drugs (me-too status)	Colistim Injection 80mg by Pharmasol (Pvt) Ltd. Reg.no. 089922
	GMP status of the Finished product manufacturer	GMP certificate no. F.3-19/2019-Addl.Dir. (QA&LT-I) issued based upon inspection conducted on 23-04-2019, valid up to 22-04-2022.
	Section Approval Status	Firm has Lyophilized vial section as per the GMP certificate issued based upon inspection conducted on 23-04-2019, valid up to 22-04-2022.
	Name and address of API manufacturer.	DMF Holder Address: Mac Chem Products (India) Pvt. Ltd. 304, Town Centre, Andheri-Kurla Road, Andheri East Mumbai Manufacturing and Testing Facilities: Mac-Chem Products (India)Pvt.Ltd N-211/2/10, MIDC, Boisar District –Thane. Maharashtra, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5% RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches:(CLS0219006, CLS0219008, CLS0219009)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence Biological Assay for their product against the comparator i.e. Colistim Injection 80mg by Pharmasol (Pvt) Ltd.		
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.		
STABILITY STUDY DATA				
Manufacturer of API		Mac-Chem Products (India)Pvt.LtdN-211/2/10, MIDC, Boisar District –Thane.		
API Lot No.		A1680997, A1681004, A1600290		
Description of Pack (Container closure system)		Glass vial		
Stability Storage Condition		Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period		Real time: 24 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 ,9,12,18,24(Months)		
Batch No.		L-159	L-182	L-199
Batch Size		18200 Vials	28000 Vials	30000vials
Manufacturing Date		05-2018	09-2018	12-2018
Date of Initiation		29-05-18	03-10-18	21-12-2018
No. of Batches		03		
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Empaglif 10mg & 25mg tablet in 296th meeting (Bio-Labs (Pvt). Ltd, Islamabad).		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (NEW-WHO GMP/CERT/KD/74238/2018/11/24897) issued by Maharashtra food and drug administration dated 11-09-2018. The certificate is valid till 10-09-2021.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Form 6 “License to import drugs for clinical trial, examination, test or analysis” for import of Colistimethate sodium 5Kg from Mac-Chem Products (India)Pvt.Ltd N-211/2/10, midc,Boisar District –Thane. The license was issued on 14-02-2020. • Firm has submitted copy of commercial invoice dated 14-02-2020 specifying import of Colistimethate sodium 5Kg. The invoice is signed by AD (I&E) DRAP.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches including COA and summary data sheets.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	NA		
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.		

Remarks of Evaluator:

Shortcomings	Response of the Firm
• Provide detailed analytical procedures for the testing of drug substance by the drug product manufacturer. • Provide analytical Method Verification studies including specificity, accuracy and repeatability performed by the Drug Product manufacturer.	Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Firm submitted the analytical method verification studies. Verification has been done on assay procedure which is also not as per the USP.
Justify 90.1mg filled weight of colistimethate sodium per vial against the labelled claim of colistin activity as per the USP monograph of "colistimethate for injection".	Nominal potency of colistimethate sodium used for calculation of filled weight is not correct, according to the innovator product of Colistimethate sodium 1MIU the nominal potency of the drug substance =12,500 IU/mg. So, using of 90.1 filled weight is still not scientifically rationale.
All quality test as per USP monograph has not been performed while establishing the pharmaceutical equivalence against the reference product. Provide results of all quality test of applied and reference product as per USP to establish pharmaceutical equivalence.	Test for uniformity of dosage unit, loss on drying, and free colistin under Colistimethate Sodium are not performed while establishing pharmaceutical equivalence with the reference product, while these tests are included in the USP monograph of colistimethate sodium injection.
Details of type and quantity of diluents used for reconstitution for of applied product is required.	According to the submitted information, to reconstitute the injection, use 3ml 0.9% sodium chloride solution. While the international reference product including the innovator, use the range of 7ml-10ml of water for injection or 0.9% sodium chloride for reconstitution of colistimethate injection.
Provide detailed analytical procedures used to evaluate the quality of drug product by the Manufacturer M/s. Bio-Lab Pvt. Ltd.	Firm submitted the analytical procedure for the testing of drug substance but the microbial assay method is not in accordance with USP in terms of composition of media, volume of media, method of analysis, incubation temperature and potency calculation. Further, the test for uniformity of dosage unit, loss on drying, heavy metals, and free colistin under Colistimethate Sodium are not included in finished product specification, since these tests are included in the USP monograph.
According to the filled BMR batch size of Batch L-159, L-199 and L-182 is 11090 vials, 11,000 vials and 11050 vials respectively. While according to the stability data sheet batch size of all three batches are L-159 18,200 vials, L-199 30,000 vials and L-182 28,000 vials. Justification is required regarding the disparity observed in the batch sizes of the same batch.	Firm submitted the reply that "Batch sizes mentioned on stability was written mistakenly. Please consider BMR batch sizes (11,111 packs) as valid batch size. Correct stability data has been submitted.

Decision of 316th meeting of Registration Board:

Deferred for the submission of following:

- Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.
- Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.
- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.

- Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.
- For further deliberation regarding the label claim of Colistimethate sodium in line with the product approved in reference regulatory agencies and pharmacopeia.

Response of the Firm:
Scientific justification for using microbial assay procedure of drug substance and drug product different from that specified in relevant USP monograph.
Firm has submitted the revised microbial assay method which is again not in accordance with USP general chapter microbial assay <81> in terms of analysis and calculations.
Scientific justification using fill weight of 90.1 mg with respect to nominal potency of 1MIU Colistimethate sodium i.e.12,500IU/mg.
Firm has submitted the calculation, according to which quantity of 87.144mg of colistimethate injection has been filled per vial after adjustment of water content and sodium factor. Further, firm set the internal fill weight ±4% i.e. 83.65mg to 90.62 mg and fill weight set at 90mg/vial.
Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the pharmaceutical equivalence studies.
Firm has submitted revised pharmaceutical equivalence report in which only test for uniformity of dosage unit has been added but test for loss on drying and free colistin still not been included.
Scientific justification for not performing critical tests like "test for uniformity of dosage unit", "loss on drying" and "free colistin" during the stability studies.
Firm has submitted the revised stability data and COA of relevant stability batches, in which test for loss on drying and free colistin was still not included neither any scientific justification has been submitted.

Decision of 321st meeting of Registration Board:
Registration Board deferred the case for following points:

1. Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.
2. Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.
3. Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.
4. Performance of loss on drying test for drug product as per USP monograph of colistimethate injection**.**

Response of the Firm:
Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise.
Firm submitted the Batch manufacturing record of three commercial batches of colicraft 1MIU Injection from M/s. Bio Labs Pvt. Ltd., from which it is evident that sterile colistimethate sodium has been used in the formulation of colicraft and lyophilization has done in the premises of M/s. Bio-Labs Pvt. Ltd.
Performance of microbial assay of drug substance and drug product in accordance with USP general chapter of microbial assay <81>.
Firm has submitted only the microbial assay procedure of drug product without any performance data.
Submission of Pharmaceutical equivalence report in which all the quality test should be included in accordance with USP monograph of colistimethate injection.
Firm has submitted the Pharmaceutical equivalence report performed against the comparator product Colistim Injection of M/s. Pharmasole Pvt. Ltd. Batch.no. KC032, which includes (Identification, LOD, pH, Uniformity of dose, Particulate matter, Free colistin, Sterility, bacterial endotoxin test & assay).
Performance of loss on drying test for drug product as per USP monograph of colistimethate injection.
Firm has submitted the revised stability data sheets of batches L-159, L-199 and L-182 in which results of loss on drying test were included.

Decision: Deferred for submission of following:

- **Analytical data for the performance of microbial assay of drug substance and drug product for complete stability studies, in accordance with USP general chapter of microbial assay <81>.**
- **Pharmaceutical Equivalence studies against the innovator/reference product manufactured by way of lyophilisation.**

575.	Name, address of Applicant / Marketing Authorization Holder	M/s SAMI Pharmaceuticals (Pvt.) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.

	Name, address of Manufacturing site.	M/s SAMI Pharmaceuticals (Pvt.) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11127 dated 09/05/2022
	Details of fee submitted	PKR 75,000/-: dated 26/02/2022
	The proposed proprietary name / brand name	AMPISOL 5mg/2ml Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 2ml contains: Ampisulpride …….5mg Innovator's specs
	Pharmaceutical form of applied drug	IV Injection
	Pharmacotherapeutic Group of (API)	dopamine-2 (D2) antagonist
	Reference to Finished product specifications	Innovator Specs
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	BARHEMSYS (Amisulpride) Injection 5mg/2ml M/s ACACIA PHARMA Inc, 8440 Allison Pointe Blvd, Suite 100, Indianapolis, IN 46250 USA, USFDA Approved.
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	GMP certificate issued dated: 03-08-2022 Liquid Injectable (LVP/SVP) (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	M/s Sun Pharmaceutical Industries Limited, Sathammai Village, Karunkuzhi PostMadhuranthagam Taluk, Kancheepuram District Tamilnadu – 603 303, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 75% ± 5%RH for 60 months, 9 months & 12 months respectively Batches: (PDAMSFL021, CCAMRNF002, AMRNF20052) Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (PDNAMSFL017, PDNAMSFL019, PDNAMSFL018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence	Pharmaceutical Equivalence have been established against the brand leader that is BARHEMSYS (Amisulpride) Injection 5mg/2ml M/s ACACIA PHARMA Inc, by performing quality tests (Appearance, Identification, Clarity, pH, Wt./ml, Osmolarity, Particulate matter, Assay, Organic impurities, Bacterial Endotoxin Test, Packaging material)
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, accuracy, precision including repeatability & intermediate precision, robustness, specificty.

STABILITY STUDY DATA			
Manufacturer of API	M/s Sun Pharmaceutical Industries Limited, Sathammai Village, Karunkuzhi PostMadhuranthagam Taluk, Kancheepuram District Tamilnadu – 603 303, India.		
API Lot No.	AMRNF20062		
Description of Pack (Container closure system)	Glass Vial USP Type-1 (Low Borosilicate)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Lab-07	Lab-08	Lab-09
Batch Size	1700ml	1700ml	1700ml
Manufacturing Date	06-2021	06-2021	06-2021
Date of Initiation	08-07-2021	08-07-2021	08-07-2021
No. of Batches	03		
Administrative Portion			

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Reference of our last onsite panel inspection for instant dosage form conducted during last two years i.e. IBRUO (Ibuprofen) 800mg/100 ml injection which was presented in 289th meeting of the registration board & hence approved & registered by registration board Date of inspection: 28th January 2019 The inspection report confirms following points The HPLC software is 21CFR Compliant • Audit trail on the testing reports is availa • Adequate monitoring and control are ava chamber. Chambers are controlled and monitored having alarm system for alerts as well. • Related manufacturing area, equipmer utilities are GMP compliant.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate of M/s. Sun Pharmaceutical Industries Ltd., is valid until 31st December 2021and they have applied for further revalidation period from 01.01.2022to 31.12.2024 and their application is under process in this Directorate *(letter attached)*
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of Aramex Courier slip and declaration from API supplier regarding sending of Amisulpride (Quantity of 100gms) through Aramex Courier receipt No. 9155441378 dated 18-04-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Raw data sheets alongwith chromatograph of Amisulpride COA & Summary data sheet are attached
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Compliance record of HPLC software 21CFR & Audit trail testing reports are attached
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Digital data logger for temperature and humidity monitoring of stability chambers are attached

Remarks of Evaluator:

S. no.	Observations/Deficiencies/ Short-comings	Reply of the Firm
1.	Justification is required for not using sterile drug substance for manufacturing of injection, as evident from the COA of drug substance by drug substance manufacturer.	Firm in their reply stated that The API *(Amisulpride)* used for development of our product Ampisol *(Amisulpride)* 5mg/2ml Injection is of injectable grade. API manufacturer has performed test for Bacterial Endotoxin test, Aerobic bacterial test, E. Coli, Salmonella, Pseudomonas & Staphylococcus aureus test to ensure the quality of injectable grade material. Certificate of Analysis of API manufacturer is enclosed for reference. Moreover it is not essential for the drug substance to be sterile for those drug products which are terminally sterilized/aseptically filled in their manufacturing process.
2.	As per the review literature of innovator brand, the drug product is subject to photo	Firm replied that Precautionary measure for photo degradation during manufacturing process from

	degradation within 12 hours, so there are no such precautionary measures included in the manufacturing procedure to protect the filled vials from light neither the step of packaging of filled vial in unit carton preferably within 12 hours after optical checking is included in the final stage. Clarification is required in this regard.	Bulk manufacturing to secondary packaging have been taken and also mentioned in batch Manufacturing record *(BMR)* which is enclosed for reference *(Annex-C, Page no.7, 12, 17)* It is also included in CTD dossier 3.2.P.2.3 Manufacturing process development and in 3.2.P.3.4. Controls of Critical steps and intermediates as a critical parameter, Reference enclosed in *(Annex-D, Page no.4 & 9)* As far duration from optical checking to secondary packaging is concerned, your suggestion is highly valuable for us and we will include this control for commercial production i.e. secondary packaging will be done within 12 hours after optical checking
3.	Submit valid GMP certificate of drug substance manufacturer, since the submitted certificate was valid until 31-12-2021.	Firm submitted the copy of GMP certificate of API manufacturer.
4.	Submit documents for the procurement of API including copy of commercial invoice attested by AD (I&E) DRAP	Firm submit the consignment receipt of API only.

Decision of 322nd meeting of Registration Board:
Deferred for justification of using non-injectable grade drug substance for preparation of parenteral solutions, along with submission of supporting reference from the ICH guidelines or other international stringent regulatory guidance documents.

Response of the Firm:
Firm replied that they have formulation the ampisol injection by using injectable grade API. All the microbiological testing has been performed including Bacterial Endotoxin test, Aerobic bacterial test, E-coli, Salmonella, Pseudomonas & Staphylococcus aureus test in accordance with USP general test <1211> sterility assurance, which assure that our product conforms with the microbiological critical quality attributes.
Reference of USP general test <1211> sterility assurance
The preparation of sterile products encompass a wide range of materials including active pharmaceutical ingredients (small and large molecules), excipients, solvents (usually water), process gases and processing aids, all of which contribute to the microbiological quality attributes of the product. Depending upon the product being manufactured, this can require consideration of bacterial, endotoxin, and particulate contamination. Specific microbiological quality testing requirements for inactive and active ingredients testing is often specified in a relevant USP–NF monograph. Requirements for microbiological testing for total aerobic bacteria, yeast and mold counts, and specified organisms are given in Microbial Enumeration Tests and Tests for Specified Microorganisms, and the recommended but non-mandatory enumeration targets for microbiological testing are given in Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use. Some specific products may require other testing for specified organisms, including viruses, as a requirement of their regulatory approval. Requirements for bacterial endotoxin testing in injectable products are covered, which describes qualification of Limulus amebocyte lysate testing for acceptable levels of bacterial endotoxin. Raw material specifications must be appropriate to ensure that the manufacturing process consistently results, as demonstrated through process validation, in products conforming to the microbiological critical quality attributes.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration Board further advised the firm to adopt formal procedure through approval from DRAP I&E for import of drug substance, in future.

576.	Name, address of Applicant / Marketing Authorization Holder	Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Name, address of Manufacturing site.	Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. dated 20/08/2021
	Details of fee submitted	PKR 20,000/-: dated 16/12/2020
	The proposed proprietary name / brand name	**Teneglip 20mg tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: 20mg of Teneligliptin
	Pharmaceutical form of applied drug	Red round biconcave film coated tablet
	Pharmacotherapeutic Group of (API)	Antidiabetic agent (dipeptidyl peptidase 4 inhibitors or gliptins)
	Reference to Finished product specifications	As per Innovator's specifications
	Proposed Pack size	10's, 20's, 30's (as per SRO)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Tenelia tablet 20mg tablet by Daiichi Sankyo Co. limited (Japan)
	For generic drugs (me-too status)	-------
	GMP status of the Finished product manufacturer	New license granted on 16/09/2020 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Ami life sciences private limited, block no.82/B,ECP road, AT and post:karakhadi-391450,taluka:padre,district:Vadodara,gujarat,india
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of

		specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 12 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches:(TNG/RD/20170816,TNG/RD/20180816, TNG/RD/20190816)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Tenelia 20mg tablet by Daiichi Sankyo Co limited performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Tenelia 20mg tablet by Daiichi Sankyo Co limited in Acid media (pH 0.1N HCl) & Phosphate Buffer (pH 6.8, 4.5). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity,LOD,LOQ)

STABILITY STUDY DATA			
Manufacturer of API	Ami lifesciences private limited, block no.82/B,ECP road, AT and post:karakhadi-391450,taluka:padre,district:Vadodara,gujarat,india		
API Lot No.	N/A		
Description of Pack (Container closure system)	PVC/ aluminum blister pack (10's, 20's, 30's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 18 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18(Months)		
Batch No.	TF-02	TF-03	TF-04
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	24-04-2018	02-05-2018	04-05-2018
Date of Initiation	16-05-2018	16-25-2018	16-05-2018
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	S-GMP/1704043 issued by primal enterprises limited province FDA valid till 23-04-2019

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Form 6 license no. 0159 dated 12-01-2018
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr.no.	Observations/Shortcoming	Reply of the Firm
1.	Submit differential fee for the registration of applied product, since the notification for revision of fee vide SRO No. F.7-11/2012-B&A/DRA was published on 7th May 2021 while this application was received in R&I section of DRAP on 20th Aug, 2021.	Firm submitted the fee of Rs.10,000/- vide slip no. 66093415 dated30-09-2022
2.	Submit copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by drug product manufacturer in section 3.2.S.4.1 as per the guidance document approved by Registration Board.	Firm submitted the analytical verification report of drug substance by drug product manufacturer.
3.	Submit stability data of drug substance till the claimed shelf life, since, according to the submitted data, study completion date is 16-09-2021.	Submitted
4.	Justify the dissolution acceptance criteria specified in section 3.2. P.5.1 i.e. "NLT 75% of labelled claim within 60 minutes" relative to the result of dissolution testing of three trial batches of drug product which revealed that more than 90% of drug release at each time point in all three batches. Further, justify, the setting of dissolution acceptance criteria in the light of general guidance of dissolution specification approved in 293rd meeting of Registration Board.	Firm replied that Dissolution of product specification is NLT 75% at 60min. This time point is verified in CDP in which 75%+Q dissolution is achieved at 60 min in all the 3 BCS dissolution medium while more than 90% of drug is released at only one time point i.e 60min and 75%+Q drug is also released in water AT 45 min that's why water was taken as dissolution medium which is in accordance with the 293rd meeting of the Registration Board.
5.	According to the procedure of dissolution test submitted in section 3.2. P.5.2 the dissolution medium is purified water, justify the choice of medium with the international reference/literature.	Firm replied that as Teneligliptin dissolution is not described in FDA guidelines then the dissolution parameters are selected using CDP criteria. CDP criteria were conducted in the 3 BCS dissolution medium (pH 1.2-6.8) and also in water. In the 3 BCS dissolution medium dissolution 75%+Q was attained in phosphate buffer 6.8 at 45 min time point but this was at border line. When we performed in water than dissolution was attained from 88.4% to 100.72% for test product at 45 min and 92.18% to 99.73% for innovator product. That's why CDP shows dissolution of both 27% at 15 min, 50% at 30 min, 75% at 45 min and more than 90% at 60 min.
6.	According the given procedure of assay in section 3.2.P.5.2, injection volume should be 10µl and the flow rate should be set at 1.4ml/min, while the chromatogram of analytical method validation studies reveals	Firm replied that It was a typographic error which is now corrected

	that the injection volume was 20µl and the flow rate maintained at 1.0ml/min. Justification is required for changing the chromatographic conditions while performing the analytical method validation studies of drug product from that specified in section 3.2. P.5.2.	
7.	Clarify, either the assay results mentioned in stability data sheets are the content of teneligliptin or the content of hydrobromide hydrate salt form of active. Similarly, dissolution results were mentioned without the time point at which the results are obtained and the acceptance limit were also mentioned without the acceptable time frame.	Firm replied that Results are of teneligliptin on as is basis.

Decision of 322nd meeting of Registration Board:
Deferred for justification of dissolution parameter considering USP general chapter 1092 and innovator product literature.

Response of the Firm:

- Firm replied that they revised the dissolution acceptance criteria from NLT 75% to NLT 80% (Q) within 45 minutes by keeping in view the dissolution profile of drug, where mean drug release is ≥85% in 45 minutes.
- Further firm informed that the average dissolution at 45 minutes is 92.51%, so we can adopt the dissolution criteria as NLT 80%(Q) in 45 minutes.

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **For commercial batches manufacturer shall adopt specifications of NLT 80% (Q) within 45 minutes for dissolution test,**

577.	Name, address of Applicant / Marketing Authorization Holder	M/s Sami Pharmaceuticals, F-95, SITE, Karachi.
	Name, address of Manufacturing site.	Name: M/s Sami Pharmaceuticals, F-95, SITE, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11278 dated 13-04-2021
	Details of fee submitted	PKR 50,000/-: dated 09/03/2021 slip no. 2050054
	The proposed proprietary name / brand name	LISTIM 150mg Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Sterile Colistimethate sodium equivalent to Colistin base ….150mg USP Specs
	Pharmaceutical form of applied drug	Lyophilized Injection

	Pharmacotherapeutic Group of (API)	Polymixins ATC code: J01XB
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Coly-Mycin M 150mg/2ml Injection
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	GMP certificate issued dated: 11-08-2020
	Name and address of API manufacturer.	Mac-Chem Products (India) Pvt. Ltd. N-211/2/10.MIDC, Boisar, Thane-401506, Maharashtra State, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Colistimethate Sodium is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches:(CMT0219001, CMT0219002, CMT0219003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Coly-Mycin M 150mg/2ml Injection by ERFA Canada by performing quality tests (Identification, Assay, Sterility, bacterial endotoxin, pH, loss on drying, Free colistin, appearance of reconstituted solution) CDP is not applicable
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Mac-Chem Products (India) Pvt. Ltd.		
API Lot No.	CMS0217012		
Description of Pack (Container closure system)	10ml clear glass vial, USP Type-I		
Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1,2,3,4, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Lab-01	Lab-02	Lab-03
Batch Size	625 vials	625 vials	625 vials
Manufacturing Date	Nov 2019	Nov 2019	Nov 2019
Date of Initiation	Dec 2019	Dec 2019	Dec 2019
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted the relevant document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. New-WHO-GMP/CERT/KD/74238/2018/11/24897 issued by FDA valid till 10/09/2021
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of letter No. MCEX180129 /DRAP-AD-CD (I&E) dated 13/2/2018 is submitted wherein the permission to import different APIs including Colistimethate sodium for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable as not run on HPLC
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Shortcomings	Response of the Firm
The median concentration i.e. U3 of colistimethate sodium should be 1mcg/ml as per USP, while the submitted assay method indicate that the median concentration U3 was 5mcg/ml. Clarification is required in this regard. For assay of drug substance, sample has been prepared using reference standard of colistimethate sodium, so justification/clarification is required for using standard material for preparation of sample stock solution.	Firm Stated that USP allows to adjust the Median conc. To optimize the zone sizes if the data remain in the linear range (linearity has been verified), USP <81> chapter has been attached for reference. However, the method of analysis is not as per USP, For the cylinder-plate assay, each plate includes only two treatments, the reference treatment (median level standard, i.e., S3) and one of the other four concentrations of the standard (S1, S2, S4 and S5) or the sample (U3). Firm revised the method in accordance with USP.

	Firm has submitted the reply that "it is a typo error, for sample preparation we use the test sample, accordingly worksheet has been revised and attached.
Validation of analytical procedures Verification of analytical procedure has not been performed in accordance with recommended USP. How the specificity of method has been verified without comparing the results of sample with standard and placebo, as in the submitted data sample solution has not been prepared.	Firm has submitted the reply that "Specificity was done compartively with blank, standard and sample , results are compared, method found selective that was missed in the method verification report, method verification report has been revised and attached for ready reference"
Reference Standards or Materials COA of primary/secondary reference standard including source and lot no. is required.	Firm submitted the COA of working standard supplied by API Manufacturer i.e. M/s. Mac-Chem Products (India) Pvt. Limited batch no. CMS0217012.
Component of drug product: Formulation Development According to the product description, it is white to slightly yellow lyophilized cake of colistimethate sodium while the label claim of product mentioned in the pharmaceutical equivalence data is "sterile lyophilized powder of colistimethate sodium. Correction of label claim is required accordingly.	Firm clarified that it is lyophilized cake as per the innovator coly-Mycin but the label claim of product will be written as Sterile colistimethate sodium equivalent to colistin base ….150mg as per the innovator.
Provide detail of type and quantity of diluent used for reconstitution of applied product. Inform about quantity of diluent used for reconstitution when the product is used for inhalation as nebulizer solution. Compatibility Provide compatibility studies data with its diluent Provide compatibility study data of drug product with its suitable diluent, after reconstitution as per the instructions provided in individual label of the drug product	Firm submitted following reply: We have developed LISTIM 150mg/2ml Injection against the reference listed drug (RLD) i.e. Coly-Mycin M 150mg /2ml injection. Quantity and type of diluents used are as under; INTRAVENOUS OR INTRAMUSCULAR: 2ml of water for injection. Reference: Coly-Mycin M ® Parenteral (Colistimethate for Injection, USP) (Distributed by M/s. Par Pharmaceutical) - INHALATION AS NEBULIZER SOLUTION: LISTIM 150mg/2ml is Lyophilized powder for injection only and product is not used for inhalation as nebulizer solution. Compatibility Study data conducted with water for injection, 0.9% NaCl, 5% Dextrose in water, 10% inverted sugar solution, 5% Dextrose in 0.9% NaCl, 5% Dextrose in 0.45% NaCl, 5% Dextrose in 0.225% NaCl, Lactated Ringers Solution as per the instruction on individual label of drug product has been submitted by the firm.
Analytical procedure: Sample stock solution has been prepared in distilled water while as per the reference product, water for injection or 0.9% sodium chloride should be used as diluent for "colistimethate for injection". Justification is required for using distilled water for preparation of sample solution.	Firm has stated that "This is typo error and sample stock solution prepared using Water for Injection. Revised testing method has been submitted for ready reference"
The median concentration i.e. U3 colistimethate sodium should be 1mcg/ml as per USP, while the submitted assay method indicate that the median concentration U3 was 5mcg/ml. Clarification is required in this regard.	Firm Stated that USP allows to adjust the Median conc. To optimize the zone sizes if the data remain in the linear range (linearity has been verified), USP <81> chapter has been attached for reference. However, the method of analysis is not as per USP, For the cylinder-plate assay, each plate includes only two

	treatments, the reference treatment (median level standard, i.e., S3) and one of the other four concentrations of the standard (S1, S2, S4 and S5) or the sample (U3). While, according to the submitted assay procedure each plate contains three treatments (S3, STANDARD and U3) which is not in accordance to USP. Firm submitted the revised analytical method in accordance with USP.
Provide assay method for the infusion and inhalation route of administration, as the amount of diluent will be varying accordingly for the preparation of sample stock solution.	Firm has submitted that Colistimethate sodium 150mg injection will only be use for injection and same testing method will be used for the sample preparation. LISTIM 150mg/2ml is Lyophilized powder for injection only and product is not used for inhalation as nebulizer solution.
Justification is required for using ±5% acceptance criteria for weight variation, provide the calculation of acceptance value as per USP.	Firm has submitted that "Basis for the limit of weight Variation is BP General Monograph (Consistency of formulated Preparation, sub heading of Uniformity of Weight (Mass), which allows the 10% weight variation for powder for parenteral administration for more than 40mg dosage form. We set the stringent of 5% instead of 10%. For the calculation of weight variation as per USP, calculation sheet has been attached "
Analytical verification report reflects that weight of sample used for sample solution is 240mg instead of 360mg (content per vial) justification/clarification required in this regard. How the specificity of method has been verified without comparing the results of sample with standard and placebo, as in the submitted data sample solution has not been prepared.	Firm has replied that "It was typo error. For sample preparation we use the whole content of product. The revised analytical verification report has been attached for ready reference". Firm has submitted the reply that "Specificity was done comparatively with blank, standard and sample , results are compared, method found selective that was missed in the method verification report, method verification report has been revised and attached for ready reference"
Batch Analyses Appearance of lyophilized cake should be mentioned on batch analysis report rather the appearance of powder of colistimethate sodium for injection.	Firm has submitted that "appearance of lyophilized cake has been revised/amended in the batch analysis report. In the batch analysis report this is missed although available on raw data sheet. Batch analysis report amended and attached for ready reference".
Acceptance criteria of assay is not as per labelled claimed of USP monograph of "Colistimethate for Injection". It is not clear that the given percentage is of colistin or Colistimethate sodium.	Firm has stated that results obtained by our calculation is labelled amount of Colistin according to USP
Stability Appearance of lyophilized cake should be mentioned on stability data sheets rather the appearance of powder of Colistimethate sodium for injection. Provide in use stability data of reconstituted solution along with give the detail of proposed in-use storage statement and in-use shelf-life.	Firm submitted the reply that Appearance of lyophilized cake has been revised/amended in the batch analysis report. The amended stability data sheets have been attached for ready reference. Firm has submitted the in-use stability studies data at storage condition 2-8°c and 20-25°C for 7 days.

Decision of 316th meeting of Registration Board:
Deferred for further deliberation regarding the label claim of Colistimethate sodium in line with the product approved in reference regulatory agencies and pharmacopeia.

Decision of 322nd meeting of Registration Board:
Deferred for following clarification:

- Manufacturing facility (lyophilized or dry powder filling) wherein the trial batches have been manufactured along with evidence of approval of required manufacturing facility from CLB.
- Applied label claim against the recommendations of USP monograph of Colistimethate for injection.

Response of the Firm:

- Firm replied that they have developed a well-equipped R&D Laboratory for developing formulations and analytical methods of sterile and non-sterile product. The R&D Lab has an efficient HVAC system to meet clean room specification and the R&D LAB has been duly approved by the CLB vide its letter no. F.2-9/2007-Lic (Vol-I) dated 22nd June,2018. Firm submitted the inspection report dated 16,17,20,23 and 24th may,2022 in which it was evident that firm has various LAB scale and pilot scale equipment including lyophilizer.
- Further the commercial batches of applied product will be manufacture in Freeze Dried Injectable section and firm has freeze dried injection section duly approved by CLB vide letter F.2-9/2007-Lic (Vol-I) dated 22-06-2018.
- Firm has submitted revised label claim in accordance with decision of 323rd meeting of Registration Board:
- Each Lyophilized vial contains:
  Colistimethate Sodium equivalent to …..150 mg of Colistin base activity.

Decision of 324th meeting: Approved with label claim for USP specifications as decided in 323rd meeting of Registration Board.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

PREVIOUSLY DEFERRED OF FORM 5-F (FINISHED IMPORT)

578.	Name, address of Applicant / Importer	M/s INAYA TRADERS Flat no. 1, 1st floor, Plot no. A-152 Block-8, KAECHS, Karachi.
	Details of Drug Sale License of importer	**License No:** 0238 **Address:** Flat no. 1, 1st floor, Plot no. A-152 Block-8, KAECHS, Karachi. **Validity:** 21-June-2024
	Name and address of marketing authorization holder (abroad)	Shouguang Fukang Pharmaceuticals Co., Ltd Address: No.666 Donghuan Road, Shounguang City Shandong Province, P.R. China.
	Name, address of manufacturer(s)	Shouguang Fukang Pharmaceuticals Co., Ltd Address: No.999 Wensheng East road, Shouguang City Country: P.R. China.
	Name of exporting country	China
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)** • Original legalized COPP (Certificate# Shandong 20222004) issued by Shandong Provincial Drug Administration issued on May,16th , 2022 • Free Sale status: The COPP endorses the free sale status of the applied product in China GMP status: COPP Specified that certifying authority arrange Periodic inspection of manufacturing plant and facility and operations confirms to GMP requirements. Drug manufacturing License: legalized copy of DML No# Lu 20160126 submitted and valid till October ,26,2025
	Details of letter of authorization / sole agency agreement	Sole agency agreement has been submitted with M/s Shouguang Fukang Pharmaceuticals Co., Ltd Dated:30-05-2022 (Copy)
	Status of the applicant	☐ Manufacturer ☒ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26228 dated: 16-11-2022
	Details of fee submitted	PKR 150,000/- Deposit slip # 2179283144
	The proposed proprietary name / brand name	**PARACETAMOL 500MG Tablet B.P**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet Contains: Paracetamol…….500mg
	Pharmaceutical form of applied drug	Uncoated Tablet
	Pharmacotherapeutic Group of (API)	Non-steroidal anti-inflammatory drug (NSAID)
	Reference to Finished product specifications	B.P
	Proposed Pack size	20 x 10's & 1000's
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	Paracetamol 500mg Tablets of Fourrts (UK) Pharmacare Ltd MHRA Approved Actavis Paracetamol 500mg Tablets of Fourrts (UK) Pharmacare Ltd MHRA Approved
	For generic drugs (me-too status)	Panadol 500mg of M/ GSK
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Hebei Jiheng Pharmaceuticals Co., LTD Address: No. 1Weiwu Street, Hengshui Industrial Park, Hebei Province, China.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for

		48 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months. Batches: (011608001, 011608002, 011608003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Paracetamol 500mg Tablet by GSK (190312) by performing quality tests (Identification, Average weight, related substances, microbial limit, Assay, Dissolution, Uniformity of weight). CDP has been performed against the same brand by in Acid media (pH 1.2) & Acetate buffer 4.5 pH and Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies of the drug product.
	Container closure system of the drug product	PVC and Aluminium foil
	Stability study data of drug product, shelf life and storage conditions	Accelerated stability studies have been conducted at 40 °C ±2 °C and 75%±5% RH for 06 months. Real time stability studies conducted at 30 °C±2 °C and 65% ± 5% RH for 36months. Batches: (180611, 180612, 180613)

Evaluation by PEC:

S.No	Section	Shortcoming communicated	Response of the Firm
1.	1.3.1	Name and address of marketing authorization holder (abroad)	Submitted
2.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.	Firm submitted analytical verification studies of drug substance.
3.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / /Active	Firm submitted Certificate of analysis by both drug substance manufacturer and drug product manufacturer.

		Pharmaceutical Ingredient manufacture	
4.	3.2.P.2.2.1	• Submit details of manufacturer, marketing authorization including country of origin of product against which pharmaceutical equivalence and Comparative dissolution profile conducted. • F1 or F2 calculation for comparative dissolution not submitted.	Paracetamol 500mg tablet manufactured by Accord Healthcare Ireland Ltd Batch No# 190312 Mfg date: 2019/04 Exp date: 2022/04 (In initial dossier firm submitted that pharmaceutical equivalence and CDP was conducted against Product of GSK in reply they submitted that pharmaceutical equivalence and CDP was conducted against Paracetamol 500mg tablet manufactured by Accord Healthcare Ireland Ltd) • F2 calculations submitted.

Decision of M-321:
The Board deferred the case for clarification since in initial dossier firm submitted that pharmaceutical equivalence and CDP was conducted against Product of GSK in reply they submitted that pharmaceutical equivalence and CDP was conducted against Paracetamol 500mg tablet manufactured by Accord Healthcare Ireland Ltd.

Firm submitted a clarification letter from the QC manager (name of manager was not written) of M/s. Shouguang Fukang Pharmaceuticals in which it was stated that " I, on behalf of Shouguang Fukang Pharmaceuticals would like to inform you here that the pharmaceutical equivalence and comparative dissolution profile which we have submitted has initially mentioned sample of GSK Ireland as the product against which our product paracetamol 500mg tablet has been tested, but it was subsequently corrected as paracetamol 500mg tablet manufactured by Accord Healthcare Ireland ,Batch no. 190312 we would like to confirm here that GSK Ireland was a typographical error which was subsequently corrected.

Decision of 322nd meeting: Deferred for submission of evidence of procurement of innovator drug product alongwith complete details regarding manufacturer and batch no of the innovator product for performance of Pharmaceutical equivalence studies.

Firm's response: Firm has replied as under:

- As the CDP and pharmaceutical equivalence test has been conducted 3.5 years ago and the innovator drug product has also been expired 9 months ago, due to this long time passed, the only evidence we could retrieve was the manufacturer's logbook record, which was also 3.5 years old. Firm has submitted extract of the **"Log book drugs for research purpose"**, declaring the date of delivery as 10-04-2019 for Paracetamol tablets (batch# 190312) of M/s Accord Healthcare Ireland.
- Nonetheless, the manufacturer has conducted a fresh Comparative Dissolution Profile and Pharmaceutical Equivalence test of Paracetamol 500mg tablet and this time the manufacturer has conducted Comparative Dissolution Profile and Pharmaceutical Equivalence test against Calpol 500mg tablet manufactured by GlaxoSmithKline Pakistan Ltd. Firm has submitted following in this regard:

	Sample product	**Reference product**
Batch#	220503	F75L
Expiry date	05/2025	09-2027
f2 factor value in pH 1.2 HCl	88.89	
f2 factor value in pH 4.5 Acetate buffer	86.1	
f2 factor value in pH 6.8 phosphate buffer	84.7	

- Firm has also submitted following:

	i. Pharmaceutical equivalence studies between applied product (Batch# 220503) and reference product i.e., Clapol tablet of GSK Pakistan (Batch# F75L). ii. NOC (No. A-779432715793) issued by AD I&E KDRAP, Karachi, dated 18-11-2022, in the name of M/s Inaya Traders for export of Calpol tablets of M/s GSK Pakistan (Batch#F75L) to M/s Shougang fukang pharmaceutical Co.s, ltd, China vide invoice# 001. iii. DHL shipment receipt (ay bill# 1873478821). iv. Tracking receipt from DHL declaring confirmation of delivery on 14-1-2022. v. Purchase invoice and screenshots of the pack of Calpol tablets of M/s GSK (Batch#F75L) of Reg.# 001612.	
Decision: Approved as per policy of inspection of manufacturer abroad.		
579.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd. 793-D, Block ''C'', Faisal Town Lahore.**
	Details of Drug Sale License of importer	License No: 05-352-0065-016174-D Address: 793-D, Block-C, Faisal Town Lahore Address of Godown: NA Validity: 06. Feb.2022 Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s BEACON Pharmaceuticals Limited Plant address: Kathali, Bhaluka, Mymensingh Bangladesh Office address: 9/B/2, Toynbee Circular Road, Motijheel Dhaka, Bangladesh
	Name, address of manufacturer(s)	M/s BEACON Pharmaceuticals Limited Plant address: Kathali, Bhaluka, Mymensingh Bangladesh Office address: 9/B/2, Toynbee Circular Road, Motijheel Dhaka, Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Original legalized COPP (Certificate# DA/6-110/2016/3300 issued on 01-06-2020 by Government of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration, Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh. GMP: Firm has submitted Legalized GMP certificate (Certificate No. DA/6-110/06/10002) issued by M/s Beacon Pharmaceuticals limited. Also, Renewal certificate is submitted (Certificate No. DA/6-110/06/4950).
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan. The authorization letter is valid till June, 2025.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales

	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No.16561 Date:15.06.2021
	Details of fee submitted	PKR: 100,030/- Date: Dec-2020
	The proposed proprietary name / brand name	Pazonix 200mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Pazopanib Hydrochloride INN….200mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	In house
	Proposed Pack size	30's (HDPE Bottle)
	Proposed unit price	As per current pricing policy of DRAP
	The status in reference regulatory authorities	Votrient 200mg Tablet
	For generic drugs (me-too status)	Votrient (Novartis)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Ace bright (India) Pharma Private Limited Address: No. 77D &116/117, KIADB Industrial Area Jigani, Bangalore - 560 105 Karnataka, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 12 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis,

		justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Votrient 200mg (Novartis) has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE Bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40ºC±2ºC and 75%±5% RH for 6 months. Real time stability studies conducted at 30ºC±2ºC and 65% ± 5% for 24 months

Evaluation by PEC:

Sr. no.	Shortcomings/Deficiencies	Response of the Firm
1.	Submit data of analytical Method verification studies including specificity, accuracy and repeatability (method precision).	Firm has submitted analytical method validation studies of drug substance performed by drug product manufacturer.
2.	Justify acceptance criteria set for dissolution test i.e. NLT 70% (Q) in 60 minutes, which is not as per the international guidelines as well as the decision of Registration Board i.e. "*For all type of drug products, the value of "Q" should not be less than 75% in any case as per the recommendations of United States Pharmacopoeia (USP) General Chapter <711> Dissolution, Dissolution testing in BP finished products monographs for solid oral dosage forms and The International Pharmacopoeia Ninth Edition, 2019 - Dissolution testing of tablets and capsules"*. As per the submitted data percentage of drug release at 30 minutes was 55.09% in the USFDA recommended release media. Justify, how your formulation can be considered equivalent to the innovator product which shows release more than Q+5% in 30 minutes.	Firm has submitted the reply, in which it is stated that "The dissolution time for pazonix 200mg tablet has been selected 60 minutes as per the FDA dissolution database. In the database, USP apparatus Type-II and 10,20,30,45 and 50 min has been mentioned for profiling. For the immediate release tablet, we have selected 60 mins as a single time point. Firm has not given any scientific justification for selecting the extreme time point i.e. 60 minutes for dissolution of drug product, while the FDA review document of innovator product reveals that the dissolution criteria should be Q= at 30 minutes using the following conditions. Apparatus: USP Apparatus 2 Volume: 900 mL Medium: 50 mM sodium acetate buffer, pH 4.5, containing 0.75% SDS Agitation: Paddle speed of 75 rpm. Analysis: UV at 270 nm with a background correction at 400 nm. Temperature: 37°C.
3.	• Justify how the results of all quality tests for every batch in stability studies are same at all-time points. • Justification is required regarding the out of specification assay results i.e. 46.5mg content of pazopanib per tablet at 6-month time interval during the accelerated stability studies of batch no. 3860003 and 3860004.	Firm has not provided any justification regarding these queries, instead submit the stability data of commercial batches. (batch no. 3860005,3860006,3860007)
4.	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product under section 2.3.R.1.1, for which stability studies data is provided in Module 3 section 3.2. P.8.	Firm has submitted the Batch Manufacturing Record of batch no. 3860002, 3860003 and 3860004.
5.	Firm has submitted the differential fee of Rs. 50,000 vide Challan no.78134245317 dated 22-08-2022 for finished import drug product, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.	

Decision of M-321:

Deferred for Scientific justification regarding difference in dissolution limits in terms of %age released and time point from that recommended by the US FDA for innovator product.

Firm revised the Dissolution parameters as per the recommendation of USFDA approved innovator product, however the submitted document did not clarify the percentage release which should be achieved at 30 minutes.

Decision of 322nd meeting of Registration Board:
Deferred for submission of dissolution test in compliance to revised dissolution parameters as per innovator drug product.

Response of the Firm:
Firm submitted the stability data of two commercial batches of Pazonix 200 tablet of M/s. Beacon Pharmaceuticals in which the dissolution criteria is NLT 70%(Q) of the labelled amount of pazonib is dissolved within 30 minutes. Details of batches and dissolution results are as under;
Accelerated Stability Data (30 days)
Long Term Stability Data (30 days)

Batch no.	Manufacturing Date
3860019	28-Nov-2022
3860020	28-Nov-2022

Decision: Approved with Innovator's specifications as per policy of inspection of manufacturer abroad. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

PREVIOUSLY DEFERRED CASES OF FORM-5:

580.	Name and address of manufacturer / Applicant	**Bryon Pharmaceuticals (Pvt.) Ltd. 48-Hayatabad Industrial Estate, Peshawar**
	Brand Name +Dosage Form + Strength	Desolar Syrup
	Diary No. Date of R& I & fee	(Original Dossier) Dy. No.41 dated 12/03/2011 of Rs. 8,000/- (original). Differential fee (original) of Rs.12,000/- Dy. No. 152 submitted on 09/10/2015
	Composition	Each 5ml contain Desloratadine ….2.5mg
	Pharmacological Group	Antihistamine
	Type of Form	Form 5
	Finished Product Specification	Manufacturer Specification
	Pack Size & Demanded Price	As per S.R. O
	Approval Status of Product in Reference Regulatory Authorities	USFDA Approved (clarinex 0.5mg/ml syrup) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
	Me-too Status	Dictrin 2.5mg/5ml Syrup of M/s. Barrett Hodgson Pakistan, Karachi Reg.no. 061122
	GMP Status	GMP Inspection conducted on 17/10/2019 and concluded with the following remarks "The firm may be considered operating in satisfactory level of cGMP compliance".
	Remarks of the Evaluator.	• Firm applied for registration of drug on Form 5-B instead of Form-5, firm inform that it is a typographical error instead of "Form-5" word "Form 5-B" was printed and request to replace the incorrect form with the rectified copy. Correct copy has been submitted by the firm. • Internationally the available formulation is 2.5mg/5ml syrup of Desloratadine in USFDA while the applied formulation is 5mg/5ml Desloratadine which is not available in approved reference regulatory agencies.
	Decision of 308th meeting of Registration Board	Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by Registration Board in its 275th meeting.

	Response of the Firm	Firm submitted the revised formulation in line international reference and available registered Me-Too along with FORM-5, revised outline of manufacturing method and fee of Rs. 30,000/- vide slip no. 761465258122 dated 08-11-2022.
	Decision: Approved with Innovator's specifications.	
581.	Name and address of manufacturer / Applicant	**M/s. Medera Pharmaceuticals (Pvt.) Ltd. Plot no.2 Street no. N-4 National Industrial Zone Rawat**
	Brand Name +Dosage Form + Strength	Azimed 250 Capsule
	Diary No. Date of R& I & fee	(Duplicate Dossier) Dy. No.2701 dated 22/06/2011 Rs. 8,000/- (photocopy) R&I verified Differential fee (photocopy) of Rs.12,000/- submitted on 18/03/2016 Dy.No.388 R&I verified
	Composition	Each Capsule contains: Azithromycin as Dihydrate…250mg
	Pharmacological Group	Macrolide Antibiotic
	Type of Form	Form 5
	Finished Product Specification	BP Specification
	Pack Size & Demanded Price	As per S.R. O
	Approval Status of Product in Reference Regulatory Authorities	MHRA Approved
	Me-too Status	Azithromycin 250mg Capsules of M/s Unipharm (Pvt.) Ltd., Lahore Reg.no.071421
	GMP Status	CAPA inspection report (Date of inspection:19/07/2021) in line with inspection conducted on 03/11/2020 concluded with the following remarks: "The firm was inspected on 19-07-2021 and improvement has been done by the firm and is satisfactory. Further improvement is a continuous process and firm is willing to improve further."
	Remarks of the Evaluator.	
	Decision of 312th meeting of Registration Board	Deferred for evidence of availability of HPLC equipped with Amperometric electrochemical detector for the assay of Azithromycin capsule as per official monograph of USP**.**
	Response of the Firm	Firm replied in response of above decision that "due to non-availability of HPLC equipped with Amperometric electrochemical detector, they are switched to BP specification. (without fee)
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
582.	Name and address of manufacturer / Applicant	**M/s. Medera Pharmaceuticals (Pvt.) Ltd. Plot no.2 Street no. N-4 National Industrial Zone Rawat**
	Brand Name +Dosage Form + Strength	Promed 100 Tablet
	Diary No. Date of R& I & fee	(Duplicate Dossier) Dy. No.260 dated 25/05/2011 Rs.8,000/- (photocopy) R&I verified Differential fee (photocopy) of Rs.12,000/- submitted on 18/03/2016 Dy.No.397 R&I verified
	Composition	Each Film Coated tablet contains: Flurbiprofen….100mg
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished Product Specification	USP Specification
	Pack Size & Demanded Price	As per S.R. O
	Approval Status of Product in Reference Regulatory Authorities	USFDA Approved

	Me-too Status	Froben 100mg Tablet of M/s. Abbot Laboratories, Karachi (Reg.no.006904)
	GMP Status	CAPA inspection report (Date of inspection:19/07/2021) in line with inspection conducted on 03/11/2020 concluded with the following remarks: "The firm was inspected on 19-07-2021 and improvement has been done by the firm and is satisfactory. Further improvement is a continuous process and firm is willing to improve further."
	Remarks of the Evaluator.	Coating ingredients has not been mentioned in the master formulation.
	Decision of 312th meeting of Registration Board	Deferred for the clarification regarding the formulation is coated or uncoated as the same was not evident from master formulation submitted along with Form-5 but the label claim indicates that the tablet film coated. So, firm has to revise the master formulation as per reference product i.e. film coated tablet along with requisite fee, revised Form-5, master formulation and outline of method of manufacturing.
	Response of the Firm	Firm submitted revised Form-5, revised formulation and outline of method of manufacturing from which it is evident that the applied product is film coated tablet.(without fee)
	Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to film coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
583.	Name and address of manufacturer / Applicant	**M/s. Medera Pharmaceuticals (Pvt.) Ltd. Plot no.2 Street no. N-4 National Industrial Zone Rawat**
	Brand Name +Dosage Form + Strength	Zincof 20mg Tablet
	Diary No. Date of R& I & fee	(Duplicate Dossier) Dy. No. 5754 dated 20/05/2011 Rs. 8,000/- (photocopy) R&I verified Differential fee (photocopy) of Rs.12,000/- submitted on 18/03/2016 Dy.No.400 R&I verified
	Composition	Each tablet contains: Zinc Sulphate Monohydrate eq. to elemental Zinc…20mg
	Pharmacological Group	Anti-Diarrheal
	Type of Form	Form 5
	Finished Product Specification	
	Pack Size & Demanded Price	As per S.R. O
	Approval Status of Product in Reference Regulatory Authorities	WHO prequalified (Zinc Sulphate Dispersible Tablet 20mg)
	Me-too Status	Zincat Dispersible Tablet 20mg of M/s. Atco Lab., Karachi (Reg.no. 070452)
	GMP Status	CAPA inspection report (Date of inspection:19/07/2021) in line with inspection conducted on 03/11/2020 concluded with the following remarks: "The firm was inspected on 19-07-2021 and improvement has been done by the firm and is satisfactory. Further improvement is a continuous process and firm is willing to improve further."
	Remarks of the Evaluator.	• Firm applied for the uncoated tablet while the reference product is dispersible tablet so revision of formulation as per reference is required. • Firm applied with USP specification while the official monograph of applied formulation is not present in USP, BP, JP and IP.
	Decision of 312th meeting of Registration Board	Deferred for either submission of evidence of approval of reference product as uncoated tablet or otherwise revision of applied formulation in line with reference product i.e. Dispersible tablet

		along with submission of requisite fee, master formulation & manufacturing method.
	Response of the Firm	Firm submitted the revised master formulation in line with WHO prequalified product and available registered Me-Too i.e. zinc sulphate dispersible tablet instead of simple zinc sulphate tablet. (without fee) Further firm claimed USP specification while the monograph of zinc sulphate dispersible tablet is not present in USP.
	Decision: Approved with Innovator's specifications as per following label claim: **"Each dispersible tablet contains:** **Zinc Sulphate Monohydrate eq. to elemental Zinc…20mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product dosage form to dispersible tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	

Following case has been forwarded from Registration Section vide letter no.1-11/2019-Reg-II dated 28TH April,2021 with reference to the decision of 297th meeting of Registration Board regarding the registration application of following product i.e. "*Registration Board decided to refer the product to PEC for evaluation as this product has not been previously considered in any meeting of Registration Board".*
After evaluation the case is presented as follows:

584.	Name and address of manufacturer / Applicant	**M/s. Hansel Pharmaceuticals (Pvt.) Ltd. Plot no.02 Pharma city,30 km, Multan Road Sunder, Lahore**
	Brand Name +Dosage Form + Strength	Neurovit Injection (IM)
	Diary No. Date of R& I & fee	(Duplicate Dossier) Dy. No. nil dated 20/05/2011 Rs. 8,000/- (photocopy) (receipt of application has not verified from the record of R&I) Differential fee (photocopy) of Rs.12,000/- submitted on 05-08-2019 Dy.No. nil
	Composition	Each 3ml contains: - Vitamin B1 …… 100mg Vitamin B6 ……. 100mg Vitamin B12 ……. 1000mcg
	Pharmacological Group	Multivitamin Formulation
	Type of Form	Form 5
	Finished Product Specification	Manufacturer's Specification
	Pack Size & Demanded Price	As per S.R. O
	Approval Status of Product in Reference Regulatory Authorities	Product is approved in DMDI Germany neurobion Injection (intramascular use) Each 3ml contains: Thiamine Chloride HCl….100mg pyridoxine hydrochloride….100mg cyanocobalamin…….1000mcg
	Me-too Status	Neurobion Injection of M/s. Martin Dow (Reg.no. 001485) THIAMINE HCL (vitamin B1) 100MG, PYRIDOXOL HCL (Vitamin B6) 100MG, CYANOCABLAMIN (Vitamin B12) 1000MCG,
	GMP Status	Copy of last DML renewal inspection report dated 15-5-2019 alongwith GMP certificate of liquid injectable (General) dated 18-GMP certificate for liquid injectable (Hormone) is not .07-2019 granted till now due to reallocation of section from first floor to ground floor. In DML renewal inspection, penel also recommended .approval of reallocated areas
	Remarks of the Evaluator.	Registration application submitted in 2011 has send for verification in R&I Section of administration division and the section replied that the application has not been found in record of R&I section.s
	Decision: Deferred for submission of R&I receiving from DRAP for initial submission of registration application.	

Item No. 6: Agenda of Evaluator PEC-XX (Mst. Sana Kanwal)

Priority molecules:

Following firms have requested to consider their application(s) on priority as per decision of Registration Board 257th meeting:

585.	Name, address of Applicant / Importer	M/s Al-Habib Pharmaceuticals, Plot#81-B, block B, SMCHS, Karachi.
	Details of Drug Sale License of importer	DSL No.: 1245 Address: M/s Al-Habib Pharmaceuticals, Plot#81-B, block B, SMCHS, Karachi.. Godown: Plot No. 10 Sector 25, K I A Karachi HT-8, Landhi Industrial Area, Karachi. Validity: 18/05/2022 Status: Drug License by way of wholesale
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, INDIA
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Original legalized CoPP (certificate No. CoPP/CERT/KD/83894/2019/11/27844/143353) valid till 03-04-2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai for Methotrexate Tablets 2.5mg . The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. GMP: Firm has submitted GMP certificate No. NEW-WHO-GMP/CERT/KD/80691/2019/11/27530 issued by Food and Drug Administration Mahrashtra Estate Mumbai. Valid till 03.04.2022
	Details of letter of authorization / sole agency agreement	Firm has submitted Original Authorization letter from Naprod Life Sciences Pvt. Ltd. The letter species that the manufacturer appoints M/s Al-Habib Pharmaceuticals, Plot #81, block B, SMCHS, Karachi as a sole agent and distributor to register their products in Pakistan .
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale

		☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5224: 24-02-2022
	Details of fee submitted	PKR 150,000/-: 26-01-2022
	The proposed proprietary name / brand name	ALLTREX (Methotrexate) 2.5mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet contains: Methotrexate ……. 2.5 mg
	Pharmaceutical form of applied drug	Tablets
	Pharmacotherapeutic Group of (API)	Anti-Metabolite (L04AX03)
	Reference to Finished product specifications	BP
	Proposed Pack size	As per Policy
	Proposed unit price	As per Policy
	The status in reference regulatory authorities	Methotrexate Orion 2.5 mg tablets by Orion Pharma UK MHRA approved
	For generic drugs (me-too status)	Methotrexate Tablet 2.5mg by Werrick Pharmaceuticals (025084)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Mac Chem Products (India) Pvt. Ltd. N-211/2/10. MIDC, Boisar Thane 401506 MAHARASHTRA state India. GMP: Firm has submitted GMP certificate No. NEW-WHO-GMP/CERT/KD/74238/2018/11/24897 by Food and Drug Administration Mahrashtra Estate Mumbai. Valid till 10.09.2021
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 60 months

		Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: MTX0213042, MTX0213043, MTX0213044,
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has been established against the reference product (Methotrexate Tabs 2.5mg Mfg. By Orion Pharma, UK). Quality parameters such as Disintegration time, hardness, dissolution, average weight, thickness etc were compared. Firm has submitted Comparative Dissolution Profile for the applied product as follows Test Product Naprod Methotrexate tablet 2.5mg Reference product Orion methotrexate tablet 2.5mg Medium Water,Acid media (pH 1.0-1.2) in Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). On the basis of similarity factor (f2) result i.e NLT 50 of dissolution profile of API in test product and reference product, both products are similar.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Alu-Alu Blister
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches 24 months real time stability data at 30°C ± 2°C / 75% ± 5%RH of 03 batches 06 month accelerated stability data 40°C ± 2°C / 75% ± 5%RH of 03 batches NT8132. NT8133, NT8134
Remarks of AD (PECXX): USFDA approved Box warning for methotrexate tablet is as follows:		

METHOTREXATE tablets, for oral use
Initial U.S. Approval: 1953

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, and SEVERE ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

- **Methotrexate Tablets can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Tablets are contraindicated in pregnancy. For neoplastic diseases, advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. (4, 5.1, 8.1, 8.3)**
- **Methotrexate Tablets are contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis. (4, 5.2)**
- **Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys. Withhold or discontinue Methotrexate Tablets as appropriate. (5.3, 5.4, 5.5, 5.6, 5.7, 5.8)**

Sr.#	Observation	Reply	Remarks
1.	RRA approved formulations are Methotrexate sodium/disodium (eq to Methotrexate) while applied product is in base form. Clarify it or provide reference regarding applied formulation (base form) in any reference country.	Relevant reference is provided by the firm as follows: MHRA approved product Methotrexate tablet 2.5mg by Sandoz Ltd	Verified MHRA approved product Methotrexate tablet 2.5mg by Sandoz Ltd is also approved in base form. Each tablet contains methotrexate 2.5 mg
2.	Compatibility of the Drug Substance(s) with excipients (Sodium Lauryl Sulphate, sodium starch glycolate, colloidal silicon dioxide) is not provided	Excipients used in formulation do not influence physicochemical property of Drug product and are routinely used in pharmaceutical industry	Sodium starch glycolate is found in RRA (MHRA) approved formulation By Cipla (EU) Limited **However Compatibility of the Drug Substance(s) with Sodium Lauryl Sulphate and colloidal silicon dioxide is required.**
	Registration Board was apprised regarding an e. mail received to Director PE&R Division form M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.		

Decision: Deferred for verification of "Sole Agency Agreement" between M/s. Al Habib Pharmaceuticals, Plot # 81, Block B, SMCHS, Karachi & M/s Naprod Life Sciences Pvt. Ltd. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, India.

586.	Name, address of Applicant / Importer	M/s Revive Health Care, 503, 5th floor, Eden heights, 6 main Gulberg, jail road, District Lahore
	Details of Drug Sale License of importer	License No: 05-352-0065-031159D Address: 503, 5th Floor Eden heights, 6 Main Gulberg Jail Road Lahore Address of Godown: NA

		Validity: 21.05.2022 Status: License to sell drugs as distributor Renewal: NA
	Name and address of marketing authorization holder (abroad)	Biem İlaç San. ve Ticaret. A.Ş. Anittepe Mah. Turgut Reis Cad. No:21 06570 Tandoğan / Ankara
	Name, address of manufacturer(s)	Gensenta Ilac Sanayi ve Ticaret A.S Sanayi Caddesi No: 66 Yenibosna Bahcelievler Istanbul, Turkey.
	Name of exporting country	Turkey
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP is not provided. Firm has submitted original, legalized GMP certificate (No. TR/GMP/2020/36) based on inspection dated 13th-15th.03.2019 issued by Republic of Turkey Ministry of Health (Turkish Medicines and Medical Devices Agency) valid till 03 years from the date of inspection.
	Details of letter of authorization / sole agency agreement	Firm has submitted original legalized letter of authorization distribution certificate from Biem İlaç San. ve Ticaret. A.Ş. The letter specifies that the manufacturer appoints M/s Revive Healthcare to register their product BUSLERA (Busulfan 60mg/10ml) in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3332 : 03-02-2022
	Details of fee submitted	PKR 75,000/-: 31-12-2021
	The proposed proprietary name / brand name	Buslera 60 mg/10 mL vial containing concentrated solution for IV infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 10 ml vial contains: Busulfan…….60 mg
	Pharmaceutical form of applied drug	Concentrated solution for IV infusion packed in type-I transparent glass vials.
	Pharmacotherapeutic Group of (API)	Cell cycle non-specific alkylating antineoplastic agent (L01AB01)
	Reference to Finished product specifications	In house
	Proposed Pack size	1’s
	Proposed unit price	As per SRO/PRC

	The status in reference regulatory authorities	Busulfan 6 mg/ml concentrate for solution for infusion by Accord Healthcare, UK (MHRA Approved).
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Shilpa Medicare Limited, plot No 33, 33-A, 40 to 47 , Blocks C,D,E,H,I and AM Raichur Industrial Growth Center, Chicksugur-584 134, Dist Raichur, Karnataka, India Copy of GMP certificate No DCD/SPL.CL/CR-262/20-21 dated 06.07.2020 valid till 13/02/2023
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25oC ± 2oC/60%±5% RH for 24 months. The accelerated stability data is conducted at 40oC ± 2oC/75%±5% RH for 6 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against Busilvex TM 6 mg/mL vial containing concentrated solution for IV infusion By M/s Pierre Fabre, France by performing quality tests (Appearance, pH, Identification, Density & Assay).

		CDP – Not applicable
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	USP type-I glass vial, Bromobutyl rubber stopper
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 2 pilot & 5 commercial batches. The accelerated stability study data is conducted at 25oC ±2oC / 60% ± 5% RH for 6 months. The real time stability study data is conducted at 5oC ±3oC for 36 months. . The real time stability study data of 2 pilot & 5 commercial batches submitted for 36 months. In use stability report with 0.9% isotonic solution and 0.5% dextrose IV solution at 20oC ±5oC for 8 hours, at 2oC-8 oC for 12 hours and 20oC ±5oC for 3 hours.

Remarks by assessor (AD PECXX):

USFDA approved Box warning for BUSULFEX (busulfan) for injection as follows:

WARNING: MYELOSUPPRESSION

See full prescribing information for complete boxed warning.

- **Causes severe and prolonged myelosuppression.**
- **Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. (5.1)**

S. No	Observations	Reply	Remarks
1.	Fee of Rs 75,000/- is submitted. While fee for imported product is 150,000/- as per DRAP Notification No F.7-11/2012-B&A/DRAP dated 7th May 2021.	Our applied product is New molecule and required fee of Rs 75000/- has already been submitted	**Fee for imported product is 150,000/- as per DRAP Notification No F.7-11/2012-B&A/DRAP dated 7th May 2021.**
2.	Original/ legalized CoPP is not provided in dossier	Copy Legalized CoPP No 2021/405 dated 04.02.2021 valid till 04.02.2023 Issued by Turkish Medicines and Medical Devices Agency	Complied

3.	GMP certificate (No. TR/GMP/2020/36) issued by Republic of Turkey Ministry of Health (Turkish Medicines and Medical Devices Agency) is invalid	Firm again submitted copy of legalized GMP certificate (No. TR/GMP/2020/36) based on inspection dated 13-15/03/2019 valid for 3 years from the date of inspection issued by Republic of Turkey Ministry of Health (Turkish Medicines and Medical Devices Agency)	
4.	3.2.P.5.1 The finished product release specifications include appropriate tests for appearance, identification (TLC, HPLC), degradation products, extractable volume (Ph Eur), water (Ph Eur), sterility (Ph Eur), bacterial endotoxins (Ph Eur), impurities (HPLC), particulate contamination (Ph Eur), assay (HPLC), and colour absorbance (UV). https://www.ema.europa.eu/en/documents/assessment-report/busulfan-fresenius-kabi-epar-public-assessment-report_en.pdf Quality parameters such as water, degradation products, impurities and colour absorbance have not been performed.	Required quality tests i.e water, degradation products, impurities and colour absorbance have been included in release specification under section 3.2.P.5.1. Manufacturer of the product had updated specifications on Batch No 16H211411 Mfg date 31.08.2016 Updated CoA and testing procedure are provided.	Complied
5.	3.2.P.8 Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when stored at 20 °C ± 5 °C or 12 hours after dilution when stored at 2 °C-8 °C followed by 3 hours stored at 20 °C ± 5 °C (including infusion time). https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf While manufacturer performed In use stability study using diluents 0.9% isotonic solution and 0.5% dextrose IV solution	It was typographic mistake In use stability was performed as per innovator product information i.e dilution was done with glucose 5% or sodium chloride 9 mg/ml (0.9%) solution	Complied

Decision: Approved with Innovator's specifications as per policy of inspection of manufacturer abroad. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

587.	Name, address of Applicant / Importer	M/s Himmel Pharmaceuticals (Pvt.) Ltd,793 D, Block C, Faisal town district, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0065-016174-D Address: Ltd,793 D, Block C, Faisal town district, Lahore Address of Godown: NA Validity: 06-02-2022 Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	EVER Valinject GmbH Oberburgau 3 4866 Unterach am Attersee, Austria
	Name, address of manufacturer(s)	EVER Pharma Jena GmbH Otto-Schott-Str, 15 07745 Jena, Germany Secondary packaging site: EVER Pharma Jena GmbH Brusseler Str.18 07747 Jena, Germany
	Name of exporting country	Austria
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has submitted Original legalized COPP (2021/121) issued on 27.05.2021 by Bundesinstitut für Arzneimittel und Medizinprodukte Kurt-Georg-Kiesinger Allee 3 53175 Bonn Deutschland. GMP: Firm has submitted Original Legalized GMP certificate (Certificate No. DE_TH_01H_GMP_2020_0016) for EVER Pharma Jena GmbH Otto-Schott-Str, 15 07745 Jena, Germany issued by Thuringen Landesamt fur Verbraucherschutz Deutschland date of inspection 25.06.2020. valid till 3 years. GMP: Firm has submitted Original Legalized GMP certificate (Certificate No. DE_TH_01H_GMP_2020_0015) for EVER Pharma Jena GmbH Brusseler Str.18 07747 Jena, Germany issued by Thuringen Landesamt fur Verbraucherschutz Deutschland date of inspection 25.06.2020. valid till 3 years.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of Authorization certificate from EVER Valinject GmbH, Oberburgau 3 4866 Unterach am Attersee, Austria. The letter species that EVER Valinject GmbH appoints M/s Himmel Pharmaceuticals (Pvt.) Ltd. to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales

	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No.: 10484 25.04.2022
	Details of fee submitted	PKR 150,000/-: 02.07.2021
	The proposed proprietary name / brand name	Cabazitaxel EVER Pharma 45mg/4.5ml concentrate solution for infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Cabazitaxel …….10mg
	Pharmaceutical form of applied drug	concentrate solution for infusion
	Pharmacotherapeutic Group of (API)	Anticancer
	Reference to Finished product specifications	European Pharmacopeia
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Jevtana injection USFDA approved Cabazitaxel EVER Pharma 10mg/ml MHRA approved
	For generic drugs (me-too status)	Jevtana of Sanofi Aventis Reg No 078125
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	MSN Laboratories Private Limited Unit II , Sy No. 50 Kardanur Patancheru, Sangareddy District Telangana, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated study was performed at 40oC ± 2oC RH 75 ± 5% for 6 months. The real time stability data was conducted at 25oC ± 2oC RH 60 ± 5% for 72months.

	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not provided
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Glass vial (hydrolytic class type I, Ph. Eur.) Fluoropolymer coated Bromobutyl Rubber stopper Ph. Eur
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 commercial scale batches (B5FC1, B5FF2, B5FE1). The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 65% ± 5% RH for 24 months.

Remarks of Assessor (AD-PECXX):

Applied formulation has been approved in USFDA with box warning as follows:

WARNING

See full prescribing information for complete boxed warning.

- **Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. Do not give JEVTANA if neutrophil counts are ≤1,500 cells/mm^3. (2.2)(4)**
- **Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm. Discontinue JEVTANA immediately if severe reactions occur and administer appropriate therapy. (2.3)(5.2)**
- **Contraindicated if history of severe hypersensitivity reactions to JEVTANA or to drugs formulated with polysorbate 80. (4)**

Innovator product is available as follows:

JEVTANA (cabazitaxel) Injection 60 mg/1.5 mL is supplied as a kit consisting of the following:
- JEVTANA Injection 60 mg/1.5 mL: contains 60 mg cabazitaxel in 1.5 mL polysorbate 80,
- Diluent for JEVTANA Injection 60 mg/1.5 mL: contains approximately 5.7 mL of 13% (w/w) ethanol in water for injection

Each vial of JEVTANA (cabazitaxel) 60 mg/1.5 mL must first be mixed with the entire contents of supplied diluent. Once reconstituted, the resultant solution contains 10 mg/mL of JEVTANA.

Applied formulation Cabazitaxel EVER Pharma 10 mg/ml concentrate for solution for infusion is as follows:

Each vial of 6 ml of concentrate for solution for infusion contains cabazitaxel 60 mg

Each vial of 4.5 ml of concentrate for solution for infusion contains cabazitaxel 45 mg

S. No	Observations	Reply	Remarks
1.	Compatibility of the Drug Substance(s) with excipient (Macrogol 300) is not provided since said ingredient is not found in innovator product i.e Jevtana injection (USFDA approved)	Innovator drug is a two vial system where the user has to prepare an intermediate premix of the concentrate containing 60mg/1.5ml cabazetaxel together with solvent i.e Ethanol while instant formulation is ready to dilute, premixing is not required. PEG has been selected as co-solubilising agent to achieve intended drug concentration i.e 10mg/ml alongwith ethanol and polysorbate 80. Compatibility with Macrogol 300 has been shown in stability data submitted under section 3.2.P.8 wherein formulation is found stable	Justified
2.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product while instant application provided comparison regarding composition (qualitative/quantitative) against JEVTANA Injection	Micelle sizes of applied formulation was compared against innovator product using Dynamic Light Scattering method, the parameter D90 indicated that 90% of the total amount of particles are smaller or equal to this size. Critical Micelle concentration (CMC) prior to infusion, of applied formulation was compared against innovator product, which was found similar. Zeta potential of test drug product and innovator product was also assessed in 0.9% NaCl and 5% Glucose, which was found similar. Furthermore, difference in disassembly of micelles upon dilution in human plasma was studied between applied drug product and innovator product, no difference was observed.	Justified The In vitro /In vivo studies revealed that applied formulation is pharmaceutically equivalent to innovator product

3.	Provide reference of applied monograph i.e European Pharmacopeia adopted for finished product specification.	There is no monograph published for Cabazitaxel injection/infusion. the Drug Product specification was defined on the basis of QbD approach identifying CQA.	**Since proposed Finished product specification mentioned on Form5F were "European Pharmacopeia" hence correction in specification is required along with fee.**
4.	In-use stability data (after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection) has not been submitted.	Firm has submitted "In use stability data" (infusion solution stability study) at 15-25°C for 8 days and at refrigerated conditions (2-8°C) for 14 days (batch No B5TS1)	Complied

Decision: Approved with Innovator's specifications as per policy of inspection of manufacturer abroad. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

588.	Name, address of Applicant / Importer	M/s Himmel Pharmaceuticals (Pvt.) Ltd,793 D, Block C, Faisal town district, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0065-016174-D Address: Ltd,793 D, Block C, Faisal town district, Lahore Address of Godown: NA Validity: 06-02-2022 Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	EVER Valinject GmbH Oberburgau 3 4866 Unterach am Attersee, Austria
	Name, address of manufacturer(s)	EVER Pharma Jena GmbH Otto-Schott-Str, 15 07745 Jena, Germany Secondary packaging site: EVER Pharma Jena GmbH Brusseler Str.18 07747 Jena, Germany
	Name of exporting country	Austria
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted Original legalized COPP (2021/121) issued on 27.05.2021 by Bundesinstitut für Arzneimittel und Medizinprodukte Kurt-Georg-Kiesinger Allee 3 53175 Bonn Deutschland. GMP: Firm has submitted Original Legalized GMP certificate (Certificate No. DE_TH_01H_GMP_2020_0016) for EVER Pharma Jena GmbH Otto-Schott-Str, 15 07745 Jena, Germany issued by Thuringen Landesamt fur Verbraucherschutz Deutschland date of inspection 25.06.2020. valid till 3 years. GMP: Firm has submitted Original Legalized GMP certificate (Certificate No. DE_TH_01H_GMP_2020_0015) for EVER

		Pharma Jena GmbH Brusseler Str.18 07747 Jena, Germany issued by Thuringen Landesamt fur Verbraucherschutz Deutschland date of inspection 25.06.2020. valid till 3 years.
	Details of letter of authorization / sole agency agreement	Firm has submitted original letter of Authorization certificate from EVER Valinject GmbH, 4866 Unterach am Attersee, Oberburgau 3 Austria. The letter species that EVER Valinject GmbH appoints M/s Himmel Pharmaceuticals (Pvt.) Ltd. to register their product in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10483: 25.04.2022
	Details of fee submitted	PKR 150,000/-: 25.06.2021
	The proposed proprietary name / brand name	Cabazitaxel EVER Pharma 60mg/6ml concentrate solution for infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Cabazitaxel …….10mg
	Pharmaceutical form of applied drug	concentrate solution for infusion
	Pharmacotherapeutic Group of (API)	Anticancer
	Reference to Finished product specifications	European Pharmacopeia
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Jevtana injection USFDA approved Cabazitaxel EVER Pharma 10mg/ml MHRA approved
	For generic drugs (me-too status)	Jevtana of Sanofi Aventis Reg No 078125
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form,

		manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	MSN Laboratories Private Limited Unit II , Sy No. 50 Kardanur Patancheru, Sangareddy District Telangana, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated study was performed at 40oC ± 2oC RH 75 ± 5% for 6 months. The real time stability data was conducted at 25oC ± 2oC RH 60 ± 5% for 72months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not provided
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Glass vial (hydrolytic class type I, Ph. Eur.) Fluoropolymer coated Bromobutyl Rubber stopper Ph. Eur
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 commercial scale batches (B5FC2, B5FF3, B5FE2). The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 65% ± 5% RH for 24 months.
Remarks of Assessor (AD-PEC XX)		
Applied formulation has been approved in USFDA with box warning as follows:		

WARNING

See full prescribing information for complete boxed warning.

- **Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. Do not give JEVTANA if neutrophil counts are ≤1,500 cells/mm^3. (2.2)(4)**
- **Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm. Discontinue JEVTANA immediately if severe reactions occur and administer appropriate therapy. (2.3)(5.2)**
- **Contraindicated if history of severe hypersensitivity reactions to JEVTANA or to drugs formulated with polysorbate 80. (4)**

Innovator product is available as follows:

JEVTANA (cabazitaxel) Injection 60 mg/1.5 mL is supplied as a kit consisting of the following:
- JEVTANA Injection 60 mg/1.5 mL: contains 60 mg cabazitaxel in 1.5 mL polysorbate 80,
- Diluent for JEVTANA Injection 60 mg/1.5 mL: contains approximately 5.7 mL of 13% (w/w) ethanol in water for injection

Each vial of JEVTANA (cabazitaxel) 60 mg/1.5 mL must first be mixed with the entire contents of supplied diluent. Once reconstituted, the resultant solution contains 10 mg/mL of JEVTANA.

Applied formulation Cabazitaxel EVER Pharma 10 mg/ml concentrate for solution for infusion is as follows:

Each vial of 6 ml of concentrate for solution for infusion contains cabazitaxel 60 mg

Each vial of 4.5 ml of concentrate for solution for infusion contains cabazitaxel 45 mg

S. No	Observations	Reply	Remarks
1.	Compatibility of the Drug Substance(s) with excipient (Macrogol 300) is not provided since said ingredient is not found in innovator product i.e Jevtana injection (USFDA approved)	Innovator drug is a two vial system where the user has to prepare an intermediate premix of the concentrate containing 60mg/1.5ml cabazetaxel together with solvent i.e Ethanol while instant formulation is ready to dilute, premixing is not required. PEG has been selected as co-solubilising agent to achieve intended drug concentration i.e 10mg/ml alongwith ethanol and polysorbate 80. Compatibility with Macrogol 300 has been shown in stability data submitted under section 3.2.P.8 wherein formulation is found stable	Justified

2.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product while instant application provided comparison regarding composition (qualitative/quantitative) against JEVTANA Injection	Micelle sizes of applied formulation was compared against innovator product using Dynamic Light Scattering method, the parameter D90 indicated that 90% of the total amount of particles are smaller or equal to this size. Critical Micelle concentration (CMC) prior to infusion, of applied formulation was compared against innovator product, which was found similar. Zeta potential of test drug product and innovator product was also assessed in 0.9% NaCl and 5% Glucose, which was found similar. Furthermore, difference in disassembly of micelles upon dilution in human plasma was studied between applied drug product and innovator product, no difference was observed.	Justified The In vitro /In vivo studies revealed that applied formulation is pharmaceutically equivalent to innovator product
3.	Provide reference of applied monograph i.e European Pharmacopeia adopted for finished product specification.	There is no monograph published for Cabazitaxel injection/infusion. the Drug Product specification was defined on the basis of QbD approach identifying CQA.	**Since proposed Finished product specification mentioned on Form5F were "European Pharmacopeia" hence correction in specification is required along with fee.**
4.	In-use stability data (after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection) has not been submitted.	Firm has submitted "In use stability data" (infusion solution stability study) at 15-25°C for 8 days and at refrigerated conditions (2-8°C) for 14 days (batch No B5TS2)	Complied

Decision: Approved with Innovator's specifications as per policy of inspection of manufacturer abroad. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

589.	Name, address of Applicant / Marketing Authorization Holder	M/s Atco Laboratories Ltd B-18, S.I.T.E Karachi
	Name, address of Manufacturing site.	M/s Atco Laboratories Ltd B-18, S.I.T.E Karachi
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1653 (dated: 18-01-2022)
	Details of fee submitted	PKR 30,000/-: dated: 27-12-2021
	The proposed proprietary name / brand name	Letrozole Tablet 2.5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Letrozole USP……2.5mg
	Pharmaceutical form of applied drug	tablet
	Pharmacotherapeutic Group of (API)	Hormonal agent and related agents- Aromatase inhibitor
	Reference to Finished product specifications	USP specification
	Proposed Pack size	1's, 5's, 10's, 20's and 30's
	Proposed unit price	As per policy
	The status in reference regulatory authorities	MHRA approved Femara 2.5mg tablet
	For generic drugs (me-too status)	Letocor 2.5mg tablet High-Q pharmaceuticals Reg No 092793
	GMP status of the Finished product manufacturer	Tablet (General) section granted on 23.01.2019
	Name and address of API manufacturer.	M/s Jiangsu Nhwa, sede pharmaceutical Co Ltd China
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (180501, 180502, 180503)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	The firm has submitted results of pharmaceutical equivalence for all the quality tests for their product as per specification and comparative study against the comparator product i.e. Femara 2.5 mg tablet by performing quality tests (appearance, Disintegration time, identification, assay and dissolution). Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer Test product: Letrozole Tablet 2.5mg Batch No: AU282C Reference product: Femara 2.5 mg tablet Batch No: TFH38 The Average % release of both Drug substances in all three mediums is more than 85% at 15 minutes hence there is no need to calculate f2 value
	Analytical method validation/verification of product	provided

STABILITY STUDY DATA			
Manufacturer of API	M/s Jiangsu Nhwa, sede pharmaceutical Co Ltd China		
API Lot No.	Not provided		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 0, 3 (Months) Real Time: 0, 3 (Months)		
Batch No.	AU282C	AU294C	AU295C
Batch Size	5000 tab	5000 tab	5000 tab
Manufacturing Date	08 – 2021	08 – 2021	08 – 2021
Date of Initiation	31-08-2021	31-08-2021	31-08-2021

No. of Batches	03	
Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Rofl (Roflumilast) Tablets 500mcg on 10th October, 2017. Further, the said panel inspection report was discussed in 277th Drug Registration Board meeting held on 27th – 29th December 2017. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software. Related manufacturing area, equipment, personnel and utilities are GMP compliant.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by People Republic of CHINA XUZHOU, JIANGSU dated 01.12.2019 valid till 01.12.2024
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of following invoice specifying: 75g of LETROZOLE (invoice #FW/IN 21N-003) attested by AD (I&E), Karachi dated 02.07.2021, License No 2099/21 DRAP is submitted
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.

Remarks of Assessor (AD PECXX):

Sr.#	Observations	Reply	Remarks
1.	Documents for the procurement of API (invoice #FW/IN 21N-003) attested by AD (I&E), Karachi dated 02.07.2021 did not specify Batch / lot no. of API	Form 3 and Form 7 have been submitted for reference wherein Batch No 20210426 is mentioned.	Complied
2.	Elucidation of Structure and other Characteristics of Drug Substance has not been provided	Provided	Complied
3.	Analytical Method Verification studies including specificity, accuracy and repeatability (method	Provided	Complied

	precision) performed by the Drug Product manufacturer to be provided		
4.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of relevant batch (Batch No 20210426) of DS has been provided by both DS and FPP manufacturer	The Assay result mentioned in CoA from DS is 99.6% while assay result of letrozole mentioned in CoA from FPP manufacturer is 101.50%.
5.	COA of primary / secondary reference standard including source and lot number to be provided	Provided	Complied
6.	Suitability testing/quality testing of container closure system (Alu-Alu blister) is not provided	Suitability testing of Alu Alu blisters i.e protection from light and protection from moisture have been submitted	Complied
7.	Batch formula for proposed commercial batch size should be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards	Batch formula for proposed commercial batch size (60,000 tab) has been provided including list of all components of the drug product to be used in the manufacturing process	Complied
8.	Data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc to be submitted at 6th month and onward.	6th month Data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheet was already submitted on 29.03.2022	Complied

Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

590.	Name, address of Applicant / Marketing Authorization Holder	Bosch Pharmaceuticals Private Limited House, 221 – 223, Sector 23, KIA Karachi Pakistan
	Name, address of Manufacturing site.	Bosch Pharmaceuticals Private Limited House, 221 – 223, Sector 23, KIA Karachi Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12641 dated 24/05/2022
	Details of fee submitted	PKR 20,000/-: dated 18/01/2021 PKR 10,000/- dated 28/04/2022
	The proposed proprietary name / brand name	Lezol Tablets 2.5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Letrozole…….2.5mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Hormone antagonist and related agent Aromatase inhibitors
	Reference to Finished product specifications	USP
	Proposed Pack size	1×10's
	Proposed unit price	As per DPC/SRO
	The status in reference regulatory authorities	MHRA approved Femara 2.5mg tablet
	For generic drugs (me-too status)	Femara 2.5mg tablet. Novartis Pharmaceutical Pakistan 15W Wharf Rd, Karachi, Sindh
	GMP status of the Finished product manufacturer	Tablet (General) section approved dated 17.03.2015 GMP certificate based on inspection dated 07.02.2020 (valid till 06.02.2022)
	Name and address of API manufacturer.	Lianyungang Jari Pharmaceutical Co Ltd, No.18 Zhenhua road, Lianyungang city, Jiangsu province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Letrozole is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity A & unspecified impurity, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance

	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20100501, 20100502, 20100503)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	CDP has been performed against Femara 2.5mg tablet by Novartis Pharmaceuticals Karachi in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer Test product: Lezole Tablet 2.5mg Batch No: TR-LZT-01 Reference product: Femara 2.5 mg tablet Batch No: 1120609 The Average % release of Drug substance in all three mediums is more than 85% at 15 minutes hence there is no need to calculate f2 value.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Lianyungang Jari Pharmaceutical Co Ltd, No.18 Zhenhua road, Lianyungang city, Jiangsu province, China		
API Lot No.	20201101		
Description of Pack (Container closure system)	PVC/PE/PVDC/Alu blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TR-LZT-02	TR-LZT-03	TR-LZT-04
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	22-02-2021	20-02-2021	22-02-2021
No. of Batches	03		
Administrative Portion			

	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Dovir (Daclatasvir) Tablets 30mg and 60mg on 25th Jan, 2019. Further, the said panel inspection report was discussed in 288th Drug Registration Board meeting held on 14th – 15th Feb 2019. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software. Related manufacturing area, equipment.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate dated 19.08.2019 issued by People Republic of China Lianyungang, Jiangsu valid till 18.08.2024
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted documents such commercial invoice (21YX0001L)dated 20.01.2021 confirming import of 0.2Kg Letrozole USP Batch No 20201101 DRAP approval License No 0353/2021DRAP dated 29.01.2021 regarding import of 0.2Kg Letrozole.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Provided

Remarks of Assessor (AD-PECXX):

Sr.#	Observation	Reply	Remarks
1.	Updated GMP status/inspection report of FPP manufacturer to be submitted.	Updated GMP certificate (No 83/2022-DRAP(K)) dated 13.06.2022 has been submitted	Complied
2.	Analytical Method Verification studies of Drug Substance including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer to be provided	Provided	Complied
3.	Pharmaceutical equivalence to be established against innovator/reference product by	Pharmaceutical equivalence established against	Complied

	comparing the results of all quality parameters of developed formulation against reference product	innovator/reference product Test product: Lezole Tablet 2.5mg Batch No: TR-LZT-03 Reference product: Femara 2.5 mg tablet Batch No: TFH38 Quality parameters such as identification, weight variation, DT, Assay, dissolution etc were compared.	
4.	Compatibility of the Drug Substance(s) with excipient (HPMC) is not provided, since it's not found in innovator/reference product.	Hypromellose (HPMC) has been used in innovator's formulation hence drug-excipient compatibility study is not required	Verified.

Decision: Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

591.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Plot No. 122, Block-A, Phase V, Industrial Estate Hattar KPK Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122, Block-A, Phase V, Industrial Estate Hattar KPK Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11158 dated 09/05/2022
	Details of fee submitted	PKR 30,000/-: dated 31/08/2021
	The proposed proprietary name / brand name	Mygest 160mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Megestrol Acetate USP…….160mg
	Pharmaceutical form of applied drug	White to off white color, Oblong shaped, Compressed tablet.
	Pharmacotherapeutic Group of (API)	Hormone related agent.

		(L02AB01)
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Progace 160mg tablet by M/s Medinet Pharmaceuticals, Rwp
	For generic drugs (me-too status)	Megace 160mg Tablets by Bausch Health Ireland Limited MHRA approved
	GMP status of the Finished product manufacturer	GMP inspection conducted on 10/12/2020 Tablet (steroidal hormonal) section is approved dated 18.01.2019 vide letter no. F.3-2/2006-Lic (Vol-II)
	Name and address of API manufacturer.	Zhejiang Xianju Yangguang Bioproduct Co. Ltd. China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Megestrol Acetate is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (5042-1008002, 5042-132 and 5042- 133)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.

	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand that is Progace 160mg tablet by M/s Laboratorio Varifarma S.A (Batch No IH124) Neither quality parameters have been compared against reference product nor CDP profile has been submitted
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Zhejiang Xianju Yangguang Bioproduct Co. Ltd. China		
API Lot No.	Not provided		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	160mg/Tablet		
Batch No.	MG-01	MG-02	MG-03
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	12-2020	12-2020	12-2020
Date of Initiation	11-12-2020	11-12-2020	11-12-2020
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Not provided
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided

	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Assessor (AD-PEC XX):

Sr.#	Observation	Reply	Remarks
1.	Approval of Drug Substance/Drug Manufacturing License (DML)/Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin to be provided. .	Not provided	Not complied Later on firm provided copy of GMP certificate valid till 19,05.2023 issued by Zhejiang Taizhou Drug and chemical Control Administration
2.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) of Drug Substance to be performed by the Drug Product manufacturer. Already submitted verification studies are not as per USP.	Firm provided analytical Analytical Method Verification studies of finished product rather than Drug substance	Firm provided Analytical Method Verification studies of Drug Substance
3.	Detailed analytical procedures for the testing of drug substance to be provided by both Drug Substance and Drug Product manufacturer	Provided	Complied
4.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of Drug substance Batch No 5042-190801 from both Drug substance and Drug product manufacturers is submitted	Complied
5.	COA of primary / secondary reference standard including source and lot number to be provided	CoA of in house reference standard Batch No RSS2101 as per USP standard is submitted	Complied
6.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product, moreover detailed CDP report is not provided in different medium along with f1 and f2 calculation..	Pharmaceutical Equivalence have been established against the brand that is Progace 160mg tablet by M/s Laboratorio Varifarma S.A (Batch No IH124) The results of quality parameters such as Assay, DT, Dissolution, hardness, uniformity of dosage and average weight were compared	Later on firm provided CDP performed in phosphate buffer medium (pH 6.8),

		CDP profile is submitted wherein CDP was performed in 0.1NHCl and acetate buffer (pH 4.5), values of f1 and f2 were found satisfactory	
7.	Finished product specifications mentioned under section 3.2.P.5 as "In house" (instead of USP). The specifications/acceptance criteria mentioned are also different from USP. Clarify/justify it	There was typographic error under section 3.2.P.5. Finished product specifications are as per USP	The specifications of finished Drug product and its acceptance criteria are not as per USP. Later on firm revised relevant section of module 3.2.P.5. wherein finished product specifications were revised as per USP
8.	Analytical method and validation/verification studies provided are not in accordance to USP. While finished product specification claimed in Form5F as USP.	Analytical method and validation/verification studies provided are in accordance to USP	Firm submitted revised Analytical method and validation/verification studies, as per USP
9.	Documents for the procurement of API attested by DRAP, specifying Batch / lot no. of API and quantity, not provided.	Firm has submitted copies of commercial invoice No WXY1909017 dated 14.10.2019, confirming import of 3Kg API .	Firm provided DRAP (Peshawar) clearance certificate dated 08.11.2019 Batch No 5042-190801
10.	Compliance Record of HPLC software 21CFR & audit trail reports and record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated), to be provided	Provided	Complied

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

592.	Name, address of Applicant / Importer	M/s Lab Diagnostic Systems Pvt. Ltd. Plot No 36-A, PSIC,SIE, Taxila, Rawalpindi Pakistan
	Details of Drug Sale License of importer	License No: 01-374-0006-049485D Address: Plot No 36-A, PSIC,SIE, Taxila, Rwp Address of Godown: NA Validity: 19-01-2022.

		Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	Actero Middle East Address: on the corner of 8th Golestan, Sarvestan Blvd., Baharestan industrial zone, Karaj, Iran,
	Name, address of manufacturer(s)	Actero Middle East Address: on the corner of 8th Golestan, Sarvestan Blvd., Baharestan industrial zone, Karaj, Iran,
	Name of exporting country	Iran
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized copy of CoPP certificate (No. 665/13174) dated 07/06/2021 issued by Food and Drug Administration Islamic Republic of Iran, for Nilotinib (as Hydrochloride Dihydrate) 200mg tablet. GMP certificate: Firm has submitted copy of GMP certificate No 665/12252 dated 1/6/2021 Grade A has been mentioned. Issued by Food and Drug Administration Islamic Republic of Iran
	Details of letter of authorization / sole agency agreement	Firm has submitted original letter of distribution certificate from Actero Middle East. The letter specifies that the manufacturer appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd. to register their product in Pakistan,
	Status of the applicant	☐ Manufacturer ☒ Importer ☐Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 2522 dated 26.01.2022
	Details of fee submitted	PKR 150,000/-: 26-01-2022
	The proposed proprietary name / brand name	Neonib 200mg capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Nilotinib (as Hydrochloride Dihydrate) …….... 200mg
	Pharmaceutical form of applied drug	Opaque, yellow cap and yellow body, size 0, hard gelatine capsule, filled with slightly yellow to yellowish granular powder
	Pharmacotherapeutic Group of (API)	N/A

	Reference to Finished product specifications	Inhouse
	Proposed Pack size	28's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Reference Product: TASIGNA FDA approved By M/s Novartis pharmaceuticals.
	For generic drugs (me-too status)	N/A
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	HETERO labs limited. 7-2-A2 Industrial Estates Sanath Nagar, Hyderabad, Telangana, India
	Module-III Drug Substance:	Firm has submitted detailed of drug substance related to nomenclature, structure, Elucidation and characteristics, general properties, solubility , physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at Temperature 40 ± 2° Relative humidity 75 ±5% RH. The long-term stability study data at Temperature 25 ± 2° Relative humidity 60 ±5% RH. till 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability. Product development data has been submitted from HETERO labs limited. 7-2-A2 Industrial Estates Sanath Nagar, Hyderabad, Telangana, India, product has been manufactured by technology transfer from HETERO labs limited.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Comparative Dissolution Profile for the applied product as follows Test Product Neonib 200mg capsule B.No NIL-H0200-F128 Reference product Tasigna 200mg capsule B.No F0034 Medium 0.1NHCl media (pH 1.0-1.2) f2 value has been calculated which was within acceptable range CDP has been performed by HETERO labs limited.7-2-A2 Industrial Estates Sanath Nagar, Hyderabad, Telangana, India
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies from HETERO labs limited.7-2-A2 Industrial Estates Sanath Nagar, Hyderabad, Telangana, India
	Container closure system of the drug product	Container: High Density Polyethylene (HDPE) Container 60 cc Closure: Child resistant plastic caps with pulp liners 30mm
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of drug product. The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH. The real time stability study data of all 3 batches is submitted till 18 months. Batch size 50000 capsules Batch No C1905 C1906 C1903

Remarks by Assessor (AD-PECXX):
Product development data, CDP and analytical method validation studies has been performed by HETERO labs limited.7-2-A2 Industrial Estates Sanath Nagar, Hyderabad, Telangana, India, as submitted by manufacturer that product has been manufactured by technology transfer from HETERO labs limited hence all development research performed by this company.
USFDA approved box warning about Tasigna (Nilotinib) 200mg capsule as follows:

TASIGNA® (nilotinib) capsules, for oral use
Initial U.S. Approval: 2007


WARNING: QT PROLONGATION AND SUDDEN DEATHS

See full prescribing information for complete boxed warning.

- **Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2). Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments (5.2, 5.3, 5.7, 5.15).**
- **Sudden deaths have been reported in patients receiving nilotinib (5.3). Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome (4, 5.2).**
- **Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors (5.8).**
- **Avoid food 2 hours before and 1 hour after taking the dose (5.9).**

----------RECENT MAJOR CHANGES----------

S.No	Observations	Reply	Remarks

1.	Firm has submitted DSL (License No: 01-374-0006-049485D) (Validity 19-01-2022). Submit valid DSL	Firm has submitted copy of valid DSL (License No: 01-374-0006-96845D) (Validity 04-08-2024)	Complied
2.	The title of importer mentioned on sole agency agreement mentioned as M/s Lab Diagnostic Systems (SMC) Pvt. Ltd while title mentioned on DSL as M/s Lab Diagnostic Systems Pvt. Ltd. Clarify it	Title mentioned on new DSL is M/s Lab Diagnostic Systems (SMC) Pvt. Ltd, same was mentioned in sole agency agreement	Verified
3.	Formulation approved in RRA (USFDA and MHRA) is Nilotinib (as Hydrochloride monohydrate) while applied formulation is Nilotinib (as Hydrochloride dihydrate). Provide reference of applied formulation.	Firm has provided declaration from Actero Middle East, Iran as follows:  We, Actero Middle east Company hereby declare regarding the selection of API of Nilotinib Hydrochloride Dihydrate (Form-A), based on the Quality Target Product (QTPP) and formulation development study with the goal to develop a formulation that is similar to RLD (Tasigna®) with respect to dissolution profile. The attached IFDA approval of dissolution study (Attachment 1) confirms that the in-house formulation is similar to RLD. Meanwhile the IFDA approved In-vivo study (Attachment 2) proves that the quality and efficacy of Neonib® is similar to Tasigna® (RLD)	The attachments referred as 1 and 2 were approval letters from Iran Food and Drug Administration (IFDA) for conducting in vitro and in vivo studies rather than study performed.
4.	Provide Compatibility of the Drug Substance(s) with excipients (Dibasic calcium phosphate and Povidone K90) being qualitatively	Compatibility of the Drug Substance(s) with excipients (Dibasic calcium phosphate and Povidone K90) has been provided	Complied

	different from innovator product Tasigna 200mg capsule		
5.	Since applied product has been manufactured by technology transfer from HETERO labs limited hence all development research was performed by this company. Agreement to be provided between HETERO labs limited and product manufacturer i.e Actero Middle East, Iran regarding technology transfer.	Agreement has been provided regarding technology transfer between HETERO labs limited, India and Actero Middle East, Iran.	Complied

Decision: Deferred for following:

- **Submission of product development and method validation data from the manufacturer site i.e., M/s Actero Middle East on the corner of 8th Golestan, Sarvestan Blvd., Baharestan industrial zone, Karaj, Iran.**
- **Scientific justicfication of variation of salt formof drug substance form that used in the innovator drug product formulation.**

593.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 507 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) Plot No 194, (Portion A) Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 17-06-2020 to 16-06-2022 Status: License to sell Drugs by way of Wholesale

	Name and address of marketing authorization holder (abroad)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name, address of manufacturer(s)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized Original CoPP certificate (No. COPP/ CERT/ KD/ 105429/2021/11/37277/181210) valid up to 13/July/2023 issued by Food and Drug Administration, Maharashtra State, India. Legalized GMP certificate (No New-WHO-GMP/CERT/KD/91940/2020/11/325020 issued by FDA Maharashtra valid till 13-07-2023 is submitted Legalized GMP certificate No. UK GMP 41432 Insp GMP 41432 Insp GMP 41432/6618812-0005 issued by MHRA based on inspection dated 06.08.2018 valid for 3 years.
	Details of letter of authorization / sole agency agreement	Firm has submitted original sole agency agreement. The agreement specifies that the manufacturer appoints M/s Martin Dow Limited. to register their products in Pakistan as sole importer.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 7365 16-03-2022
	Details of fee submitted	PKR 150,000/- Dated: 13-10-2021
	The proposed proprietary name / brand name	TEMOREL CAPSULES 20mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Hard Gelatin Capsule contains: Temozolomide (USP)…….20mg
	Pharmaceutical form of applied drug	Capsules
	Pharmacotherapeutic Group of (API)	Anti-cancerous (Alkylating agents)

	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	5's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	TEMODAR (Temozolomide) 20mg Capsules (FDA Approved)
	For generic drugs (me-too status)	Temoside Capsules 20mg of AJM Pharma Private Limited. (Reg # 066112)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API TMCI2001, TMCI2002, TMCI2003 at accelerated (40°C/ 75% RH) as well as real time conditions. The real time stability data is conducted at 25oC ± 2oC and 60% RH The stability study data is till 48 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Comparative Dissolution Profile for the applied product as follows Test Product Temozolomide 20mg capsule B.No RLTL0112 Reference product Temodol 20mg capsule B.No 1CAPA04010 Medium

		Dearated water,Acid media (pH 1.0-1.2) in Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The Average % release of both Drug substances in all four mediums is more than 85% at 15 minutes hence there is no need to calculate f2 value
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Amber coloured USP type III glass bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of drug product. The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH. The real time stability study data of all 3 batches is submitted till 24 months. Batch size 5000 capsules Batch No RLTL 0215, RLTL 0315 and RLTL 0715

Remarks by Assessor (AD PECXX):

Firm has adopted manufacturer's specification being more stringent than USP.

S No	Test/parameter	Acceptance criteria as per USP	Acceptance criteria as adopted by the firm
1.	Assay limit	90-110	95-105%
2.	Impurity testing Total impurity Any unspecified impurity	 NMT 1.2% NMT 0.2%	 NMT 1.0% NMT 0.1%
3.	water content	N.A	NMT 2%w/w

Firm has provided BMR of all three stability batches:
RLTL 0215, RLTL 0315 and RLTL 0715

Sr.#	Observation	Reply	Remarks
1.	The active substance specification which is required to be tested by the finished product manufacturer includes tests for color index, pH, sulphate ash, chloride and sulphate (as per Public assessment report, EMA) https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf The above mentioned tests have not been performed by finished product manufacturer. Justify it	The submitted specification of Temozolomide API is as per USP. The EPAR which has been shared was published in the year 2011 & Ph. Eur. monograph for Temozolomide was not available at that time. The	Justified

		Ph. Eur. monograph became official in January 2017 & it does not have these tests.	
2.	The following parameters are required to be controlled/tested during the stability studies: identification (HPLC) and uniformity of dosage (Ph.Eur), as per Public assessment report, EMA https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf	Uniformity of the dosage Unit is not a stability-indicating parameter. Hence it is not tested during stability, however, it was performed at the time of batch release. Also, Identification test by HPLC was performed at the time of batch release. Under 3.2.P.5.4 COAs are attached.	Justified
3.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product.	Firm has submitted Comparative Dissolution Profile for the applied products against Reference product Temodal 250mg capsule by SP Euorope B.No ILTAA05001 The quality parameters compared were identification by HPLC, Assay, related substances, water content	Complied

		and dissolution.	
4.	In CDP report difference factor (f1) has not been calculated	CDP report has been submitted wherein f1 and f2 values were calculated which was within acceptable range	Complied
5.	Submit valid license to sell drugs. Details of already submitted license are as under: License to sell Drugs by way of Wholesale (License No: 507 Validity: 17-06-2020 to 16-06-2022	Firm has submitted copy of valid DSL as follows: License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: 1-1st floor, Pot No 211, sec,23 K.I.A Karachi Plot No 32 sec 16 K.I.A Karachi Validity: 17-06-2022 to 16-06-2024 Status: License to sell Drugs by way of Wholesale	Complied

Manufacturer's specifications submitted are as follows:

S No	Test/parameter	Acceptance criteria as adopted by the firm
1.	Identification	As per USP
2.	Uniformity of dosage unit	As per USP
3.	Assay limit	95-105%
4.	Dissolution	NLT 80% (Q) of labelled amount in 30 min (As per USP)
5.	Impurity testing	

	2-Azahypoxanthine. Temozolomide acid Aminoimidazolecarboxamide Total impurity Any unspecified impurity	0.8% 0.2% 1.2 % NMT 1% NMT 0.1%
6.	Water content	NMT 2%w/w

Decision: Approved with manufacturer's specifications, as per policy of inspection of manufacturer abroad.

594.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 507 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) Plot No 194, (Portion A) Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 17-06-2020 to 16-06-2022 Status: License to sell Drugs by way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name, address of manufacturer(s)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized Original CoPP certificate (No. COPP/ CERT/ KD/ 105429/2021/11/37277/180647) valid up to 13/July/2023 issued by Food and Drug Administration, Maharashtra State, India. Legalized GMP certificate (No New-WHO-GMP/CERT/KD/91940/2020/11/325020 issued by FDA Maharashtra valid till 13-07-2023 is submitted
	Details of letter of authorization / sole agency agreement	Firm has submitted original sole agency agreement dated 30.08.2021. The agreement specifies that the manufacturer appoints M/s Martin Dow Limited. to register their products in Pakistan as sole importer. Valid till 3 years from the date of issuance

	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 7366; 16-03-2022
	Details of fee submitted	PKR 150,000/- Dated: 13-10-2021
	The proposed proprietary name / brand name	TEMOREL CAPSULES 100mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Hard Gelatin Capsule contains: Temozolomide (USP)…….100mg
	Pharmaceutical form of applied drug	Capsules
	Pharmacotherapeutic Group of (API)	Anti-cancerous (Alkylating agents)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	5's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	TEMODAR (Temozolomide) 100mg Capsules (USFDA Approved)
	For generic drugs (me-too status)	Temoside Capsule 100mg of AJM Pharma Private Limited. (Reg # 066113)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API TMCI2001, TMCI2002, TMCI2003 at accelerated (40°C/ 75% RH) as well as real time conditions. The real time stability data is conducted at 25oC ± 2oC and 60% RH The stability study data is till 48 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Comparative Dissolution Profile for the applied product as follows Test Product Temozolomide 100mg capsule B.No RLTM0112 Reference product Temodol 100mg capsule B.No 1DZAA18004 Medium Dearated water,Acid media (pH 1.0-1.2) in Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The Average % release of both Drug substances in all four mediums is more than 85% at 15 minutes hence there is no need to calculate f2 value
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Amber coloured USP type III glass bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of drug product. The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH. The real time stability study data of all 3 batches is submitted till 24 months. Batch size 15000 capsules Batch No RLTM 0517C, RLTM 0617B, RLTM 0717B

Remarks by Assessor (AD PECXX):

Firm has adopted manufacturer's specification being more stringent than USP.

S No	Test/parameter	Acceptance criteria as per USP	Acceptance criteria as adopted by the firm
1.	Assay limit	90-110	95-105%
2.	Impurity testing Total impurity Any unspecified impurity	 NMT 1.2% NMT 0.2%	 NMT 1.0% NMT 0.1%
3.	water content	N.A	NMT 2%w/w

Firm has provided BMR of all three stability batches:
RLTM 0517C, RLTM 0617B, RLTM 0717B

Sr.#	Observation	Reply	Remarks
1.	The active substance specification which is required to be tested by the finished product manufacturer includes tests for color index, pH, sulphate ash, chloride and sulphate (as per Public assessment report, EMA) https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf The above mentioned tests have not been performed by finished product manufacturer. Justify it	The submitted specification of Temozolomide API is as per USP. The EPAR which has been shared was published in the year 2011 & Ph. Eur. monograph for Temozolomide was not available at that time. The Ph. Eur. monograph became official in January 2017 & it does not have these tests.	Justified
2.	The following parameters are required to be controlled/tested during the stability studies: identification (HPLC) and uniformity of dosage (Ph.Eur), as per Public assessment report, EMA https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf	Uniformity of the dosage Unit is not a stability-indicating parameter. Hence it is not tested during stability, however, it was performed at the time of batch release. Also, Identification test by HPLC was performed at the time of batch release. Under 3.2.P.5.4 COAs are attached.	Justified
3.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product.	Firm has submitted Comparative Dissolution	Complied

		Profile for the applied products against Reference product Temodal 250mg capsule by SP Euorope B.No ILTAA05001 The quality parameters compared were identification by HPLC, Assay, related substances, water content and dissolution.	
4.	In CDP report difference factor (f1) has not been calculated	CDP report has been submitted wherein f1 and f2 values were calculated which was within acceptable range	Complied
5.	Submit valid license to sell drugs. Details of already submitted license are as under: License to sell Drugs by way of Wholesale (License No: 507 Validity: 17-06-2020 to 16-06-2022	Firm has submitted copy of valid DSL as follows: License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: 1-1st floor, Pot No 211, sec,23 K.I.A Karachi	Complied

		Plot No 32 sec 16 K.I.A Karachi Validity: 17-06-2022 to 16-06-2024 Status: License to sell Drugs by way of Wholesale	

Manufacturer's specifications submitted are as follows:

S No	Test/parameter	Acceptance criteria as adopted by the firm
1.	Identification	As per USP
2.	Uniformity of dosage unit	As per USP
3.	Assay limit	95-105%
4.	Dissolution	NLT 80% (Q) of labelled amount in 30 min (As per USP)
5.	Impurity testing 2-Azahypoxanthine. Temozolomide acid Aminoimidazolecarboxamide Total impurity Any unspecified impurity	 0.8% 0.2% 1 % NMT 1% NMT 0.1%
6.	water content	NMT 2%w/w

Decision: Approved with manufacturer's specifications, as per policy of inspection of manufacturer abroad.

595.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 507 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) Plot No 194, (Portion A) Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 17-06-2020 to 16-06-2022 Status: License to sell Drugs by way of Wholesale

	Name and address of marketing authorization holder (abroad)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name, address of manufacturer(s)	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plat No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized Original CoPP certificate (No. COPP/ CERT/ KD/ 105429/2021/11/37277/181211) valid up to 13/July/2023 issued by Food and Drug Administration, Maharashtra State, India. Legalized GMP certificate (No New-WHO-GMP/CERT/KD/91940/2020/11/325020 issued by FDA Maharashtra valid till 13-07-2023 is submitted
	Details of letter of authorization / sole agency agreement	Firm has submitted original sole agency agreement dated 30.08.2021. The agreement specifies that the manufacturer appoints M/s Martin Dow Limited. to register their products in Pakistan as sole importer. Valid till 3 years from the date of issuance
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 7700; 18-03-2022
	Details of fee submitted	PKR 150,000/- Dated: 13-10-2021
	The proposed proprietary name / brand name	TEMOREL CAPSULE 250mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Hard Gelatin Capsule contains: Temozolomide USP…….250mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anti-cancerous (Alkylating agents)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	5's
	Proposed unit price	As per DPC

	The status in reference regulatory authorities	TEMODAR (Temozolomide) 250mg Capsules (USFDA Approved)
	For generic drugs (me-too status)	Temoside Capsule 250mg of AJM Pharma Private Limited. (Reg # 066114)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plant No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API TMCI2001, TMCI2002, TMCI2003 at accelerated (40°C/ 75% RH) as well as real time conditions. The real time stability data is conducted at 25oC ± 2oC and 60% RH The stability study data is till 48 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Comparative Dissolution Profile for the applied product as follows Test Product Temozolomide 250mg capsule B.No RLTH0112 Reference product Temodol 250mg capsule B.No 1LTAA05001 Medium Dearated water,Acid media (pH 1.0-1.2) in Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8).

		The Average % release of both Drug substances in all four mediums is more than 85% at 15 minutes hence there is no need to calculate f2 value
	Bioequivalence study	Firm has submitted Bioequivalence study report (protocol No RC/0111/011) Version No 1.0 date 12.04.2011 Study No 1104019 Sponsor: M/s RELIANCE LIFE SCIENCES PVT. LTD Dhirubhai Ambani Life Sciences Centre (DALC), Plant No. 3,5,6 and 9. Plot No. R-282 Thane – Belapur Road, Rabale, Thane-400701, Maharashtra State, India. Test product Temozolomide 250mg capsule Reference Product: Temodol 250mg capsule of Schering Plough Ltd,UK
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Amber coloured USP type III glass bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches of drug product. The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH. The real time stability study data of all 3 batches is submitted till 24 months. Batch size 4000 capsules Batch No RLTH 0417C RLTH0517A RLTH0617A

Remarks by Assessor (AD PECXX):

Firm has adopted manufacturer's specification being more stringent than USP.

S No	Test/parameter	Acceptance criteria as per USP	Acceptance criteria as adopted by the firm
1.	Assay limit	90-110	95-105%
2.	Impurity testing Total impurity Any unspecified impurity	 NMT 1.2% NMT 0.2%	 NMT 1.0% NMT 0.1%
3.	water content	N.A	NMT 2%w/w

Firm has provided BMR of all three stability batches:
RLTH 0417C RLTH0517A RLTH0617A

Sr.#	Observation	Reply	Remarks

1.	The active substance specification which is required to be tested by the finished product manufacturer includes tests for color index, pH, sulphate ash, chloride and sulphate (as per Public assessment report, EMA) https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf The above mentioned tests have not been performed by finished product manufacturer. Justify it	The submitted specification of Temozolomide API is as per USP. The EPAR which has been shared was published in the year 2011 & Ph. Eur. monograph for Temozolomide was not available at that time. The Ph. Eur. monograph became official in January 2017 & it does not have these tests.	Justified
2.	The following parameters are required to be controlled/tested during the stability studies: identification (HPLC) and uniformity of dosage (Ph.Eur), as per Public assessment report, EMA https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf	Uniformity of the dosage Unit is not a stability-indicating parameter. Hence it is not tested during stability, however, it was performed at the time of batch release. Also, Identification test by HPLC was performed at the time of batch release. Under 3.2.P.5.4 COAs are attached.	Justified
3.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product.	Firm has submitted Comparative Dissolution Profile for the applied products against Reference product Temodal 250mg capsule by SP Euorope B.No ILTAA05001 The quality parameters compared were identification by HPLC, Assay, related substances, water content and dissolution.	Complied
4.	In CDP report difference factor (f1) has not been calculated	CDP report has been submitted wherein f1 and f2 values were	Complied

		calculated which was within acceptable range	
5.	Submit valid license to sell drugs. Details of already submitted license are as under: License to sell Drugs by way of Wholesale (License No: 507 Validity: 17-06-2020 to 16-06-2022	Firm has submitted copy of valid DSL as follows: License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: 1-1st floor, Pot No 211, sec,23 K.I.A Karachi Plot No 32 sec 16 K.I.A Karachi Validity: 17-06-2022 to 16-06-2024 Status: License to sell Drugs by way of Wholesale	Complied

Manufacturer's specifications submitted are as follows:

S No	Test/parameter	Acceptance criteria as adopted by the firm
1.	Identification	As per USP
2.	Uniformity of dosage unit	As per USP
3.	Assay limit	95-105%
4.	Dissolution	NLT 80% (Q) of labelled amount in 30 min (As per USP)
5.	Impurity testing 2-Azahypoxanthine. Temozolomide acid Aminoimidazolecarboxamide Total impurity Any unspecified impurity	 0.8% 0.2% 1% NMT 1% NMT 0.1%
6.	water content	NMT 2%w/w

Decision: Approved with manufacturer's specifications, as per policy of inspection of manufacturer abroad.

596.	Name, address of Applicant / Marketing Authorization Holder	M/s Hiranis Pharmaceuticals (Pvt.) Ltd
	Name, address of Manufacturing site.	M/s Hiranis Pharmaceuticals (Pvt.) Ltd Plot E-145-149, North Western Industrial Zone, Port Qasim, Karachi.

	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12656 dated 24/05/2022
	Details of fee submitted	PKR 75,000/-: dated 10/05/2022
	The proposed proprietary name / brand name	Tofajak 10mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Tofacitinib (as citrate)……10mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Janus Kinase Inhibitor WHO ATC code: L04AA29
	Reference to Finished product specifications	Innovator's Specification
	Proposed Pack size	1×10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Xeljanz 10mg Tablet M/s Pfizer US-FDA Approved.
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	Updated GMP status is not provided. Evidence for section approval Tablet (General) dated 07.02.2014
	Name and address of API manufacturer.	Tofacitinib M/s Glenmark Lifesciences Ltd. Address: Plot No. 3109, GIDC, Industrial estate, Ankleshwar, 393 002. District Bharuch, Gujarat state, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph is not present in any pharmacopeia. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its validation, batch analysis and

		justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: AD11014001, AD11014002, AD11014003,
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Xeljanz 10mg Tablet by M/s Pfizer by performing quality tests (Identification, Assay, Dissolution, disintegration, microbial examination, and Assay CDP has been performed against the same brand that is Xeljanz 10mg Tablet by M/s Pfizer in Acid media (0.1 N HCL) & Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). F2value calculation is not required as reference and test products released more than 85% within 15 minutes.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Tofacitinib M/s Glenmark Lifesciences Ltd. Address: Plot No. 3109, GIDC, Industrial estate, Ankleshwar, 393 002. District Bharuch, Gujarat state, India.		
API Lot No.	Tofacitinib citrate 82190846		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×10's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TF-120220	TF-130220	TF-140220
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	02-2020	02-2020	02-2020
Date of Initiation	20-02-2020	20-02-2020	20-02-2020
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Etoxib 90mg Tablet Etoxib 120mg Tablet Approved in 294th minutes of meeting of DRB
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 19061427 issued by Food & Drug Control Administration, Gandhinagar, Gujrat state, India. valid till 17/06/2022.
	Documents for the procurement of API with approval from DRAP (in case of import).	Attested invoice (No. AAACZ5212B) from DRAP for import of 0.2Kg Tofacitinib citrate (batch no 82190846). License to import drug for clinical trials (No 382/20 DRAP dated 29.01.2020
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PEC [xx]):

USFDA approved Box warning for Xeljanz 10mg Tablet (Tofacitinib citrate) as follows:

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.

- **Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving XELJANZ. (5.1)**
- **If a serious infection develops, interrupt XELJANZ/XELJANZ XR until the infection is controlled. (5.1)**
- **Prior to starting XELJANZ/XELJANZ XR, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting XELJANZ/XELJANZ XR. (5.1)**
- **Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. (5.1)**
- **Lymphoma and other malignancies have been observed in patients treated with XELJANZ. Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with XELJANZ and concomitant immunosuppressive medications. (5.2)**

Remarks of Assesor (AD-PEC[XX])

Sr.#	Observation	Reply	Remarks
1.	Updated GMP status of finished product manufacturer is required	Updated GMP certificate of Drug product manufacturer is submitted dated 12.11.2021	complied
2.	The active substance specification includes tests for description, identification (IR, Chiral LC), particle size, assay (LC), counterion of citric acid (LC), impurities (LC), residue on ignition (USP), heavy metals (USP),	Manufacturer performed LOD rather than moisture content	Justified Tofacitinib citrate falls under BCS-

	residual solvents (GC), water content, palladium (ICP-OES). https://www.ema.europa.eu/en/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf Tests such as Heavy metals, particle size and water content have not been mentioned in CoA of Drug Substance.	However, particle size is critical attribute for poorly soluble drugs while instant drug substance is highly soluble. Heavy metals ae controlled during process validation however it is not included under specification/CoA of drug substance.	class III (highly soluble and low permeability) However, firm is required to submit performance of **Heavy metals, particle size and water content tests** of drug substance.
3.	Water content test has not been performed in finished product specifications as well as stability testing (as mentioned in public assessment report of innovator product published on EMA website)	Water content test is not included in finished product specification in assessment report of innovator product published on USFDA website We have reviewed innovator assessment report on USFDA website rather than EMA.	Justified
4.	Batch no of innovator product and test product has not been mentioned under CDP	Reference product: Xeljanz 10mg Tablet by M/s Pfizer Batch No:CR4619 Test product: Tofacitinib citrate Batch No: TF-120220	Complied
5.	CoA at each time interval is required in stability data	Stability protocol and specifications of stability batches are provided.	Not complied CoA at Each time interval is not provided Later on firm submitted CoA at each time

			interval of all 3 batches.
6.	COA of primary / secondary reference standard including source and lot number to be provided	Provided	Complied
7.	Batch formula for proposed commercial batch size should be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts on a per batch basis, and a reference to their quality standards	Provided	Complied

Decision: Approved with innovator's specifications. The firm shall submit, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submisison of following:

- **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021**
- **COA for Drug substance analysis from the drug substance manufacturer including the tests of heavy metals, particle size and water content.**

Priority consideration on account of Export Facilitation:

In pursuance of decision of 133rd meeting of the Authority held on 13th April 2022, wherein it was decided that for each 100,000 USD worth of export of medicine during a fiscal year, one molecule will be considered on priority subject to fulfilment of all prescribed requirements

Following registration application of firms may be considered on priority in light of Export Facilitation Policy as communicated vide letter No.F.1-6/2019-PR-I (EFD) dated 29.12.2022:

597.	Name, address of Applicant / Marketing Authorization Holder	M/s. Surge Laboratories (Pvt.) Ltd., 10th Km, Faisalabad road, Bikhi, District Sheikhupura - Pakistan
	Name, address of Manufacturing site.	M/s. Surge Laboratories (Pvt.) Ltd., 10th Km, Faisalabad road, Bikhi, District Sheikhupura - Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22062 dated 03 / 08 / 2022
	Details of fee submitted	PKR 30,000/-: dated 24/06/2022
	The proposed proprietary name / brand name	Carbifer Injection 500mg/10ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 10ml contains: Iron as ferric carboxymaltose ……..500mg

	Pharmaceutical form of applied drug	I.V Injection
	Pharmacotherapeutic Group of (API)	Iron trivalent, parental preparation
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Ferinject Injection 10ml (Ferric Carboxymaltose) is registered and being marketed by Vifor Pharma UK limited. France (Approved by EMA).
	For generic drugs (me-too status)	FCM Injection 500mg/10ml by M/s. Genix Pharma (Pvt.) Ltd., Reg. No. 108583
	GMP status of the Finished product manufacturer	GMP Certificate granted on 05/04/2022 based on inspection dated 05.10.2021 (valid for two years) Renewal of DML granted on 11.01.2022 wherein following sections are mentioned: Liquid Injection (Including Blow Fill Seal Area) (General) Dry Powder Injection & Sterile Dry Powder Injectable section.
	Name and address of API manufacturer.	M/s. Chongqing Carelife Pharmaceutical Co., Ltd. Address: No. 2, the Third Branch Road, Huanan Road, Yan jia, Changshou District, Chongqing 401221, People's Republic of China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Specifications of Ferric Carboxymaltose is not present in any official monograph. The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (FCM-202103001V, FCM-202103002V, FCM-202103003V)
	Module-III (Drug Product):	The firm has submitted detail of manufacturing, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Innovator Product that is Ferinject Injection

		by Vifor Pharma, UK Batch No. 0091122EA by performing quality tests (Description, Identification, Assay, Ph, Bacterial Endotoxins & Sterility Test) against Test product Batch No. FCM-10-003		
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy/recovery, specificity, precision.		
STABILITY STUDY DATA				
Manufacturer of API		M/s. Chongqing Carelife Pharmaceutical Co., Ltd. Address: No. 2, the Third Branch Road, Huanan Road, Yan jia, Changshou District, Chongqing 401221, People's Republic of China.		
API Lot No.		FCM-202104001		
Description of Pack (Container closure system)		Packed in Glass Ampoule 10cc (USP Type-I)		
Stability Storage Condition		Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time : 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time : 0, 3, 6 (Months)		
Batch No.		FCM-10-002	FCM-10-003	FCM-10-004
Batch Size		100 Ampoules	100 Ampoules	100 Ampoules
Manufacturing Date		12-2021	12-2021	01-2022
Date of Initiation		10-12-2021	01-01-2022	14-01-2022
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate no. CQ210007 issued by Chongqing Municipal Drug Administration, China valid till 12/08/2023.		
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no IN211021-12631E dated 21/10/2021 duly attested by Assistant Director, DRAP, Lahore on 12/11/2021 was provided confirming import of 1Kg Ferric Carboxymaltose (Batch No FCM-202104001)		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Applicable		
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted		
Remarks of Assessor AD-PECXX:				

Sr.#	Observation	Reply	Remarks
1.	% Potency as mentioned in CoA of Drug Substance from DS manufacturer is 28.4%, % Potency as mentioned in CoA of Drug Substance from Drug Product manufacturer is 25.41% while quantity of Drug substance calculated under Batch formula and composition in accordance to 24.08%. Justify it	The Percentage potency of Iron in Ferric Carboxymaltose in the Manufacturer's COA of Drug Substance is 28.4% as mentioned. After testing this API here at Surge Laboratories, the Percentage potency of Iron obtained is 25.41% on anhydrous basis or 24.08% on as is basis. Normally the potency of API used for trials or manufacturing is "On as is basis" so the Potency of 24.08% (which is on as is basis has been used) not anhydrous basis of the substance.	Justified
2.	Proposed container closure system (Glass ampoule USP Type 1) suitability testing/Quality testing (as per pharmacopeia) to be submitted	CoA of Packaging material is submitted comprising specifications regarding physical dimensions only.	Not complied. Quality testing of (Glass ampoule USP Type 1) to be submitted as per USP General-chapter-660-glass-containers. Either performed by supplier or Finished product manufacturer.
3.	Data of stability batches supported by attested respective documents like, Raw data sheets, COA, summary data sheets etc to be submitted at 6th month and onward.	6th month Data of stability batches supported by attested respective documents like Raw data sheets, COA, summary data sheet was already submitted on 05.10.2022	Complied

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

598.	Name, address of Applicant / Marketing Authorization Holder	M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Name, address of Manufacturing site.	M/s M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Status of the applicant	☒ Manufacturer

		☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 20544 dated 20-07-2022
	Details of fee submitted	PKR 30,000/-: dated 14-06-2022
	The proposed proprietary name / brand name	Zolincid Dry Suspension 100mg/5ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains: Linezolid ……100mg
	Pharmaceutical form of applied drug	Dry powder suspension.
	Pharmacotherapeutic Group of (API)	Antibacterial (Oxazolidinone)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Zyvox Dry Suspension 100mg/5ml by M/s Pfizer, USFDA Approved.
	For generic drugs (me-too status)	Barizold Dry Suspension 100mg/5ml by M/s Barret Hodgson Pakistan Reg. No. 076343
	GMP status of the Finished product manufacturer	GMP inspection conducted on 29.12.2020, valid till 28.12.2022 Evidence for section approval is not provided.
	Name and address of API manufacturer.	M/s Optrix Laboratories Private Limited SURVEY NO. 145/A, 145/AA & 147 Ramalingampally (V) Bommalaramaram (M) Yadadri-Bhuvangiri (D), Telangana 508126, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Linezolid is available in official monograph i.e USP. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for Linezolid N-oxide, Desfluoro linezolid & related substances

		(impurity C & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (OTD-LID-S2-002/16, OTD-LID-S2-003/16, OTD-LID-S2-004/16)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing phosphate buffer 6.8) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against comparator product that is Barizold Dry Suspension 100mg/5ml Barret Hodgson Pharma by performing quality tests (Identification, Assay, Dissolution, and Uniformity of dosage form). CDP has been performed against the same brand that is Barizold Dry Suspension 100mg/5ml by Barret Hodgson Pharma in acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Optrix Laboratories Private Limited SURVEY NO. 145/A, 145/AA & 147 Ramalingampally (V) Bommalaramaram (M) Yadadri-Bhuvangiri (D), Telangana 508126, India.		
API Lot No.	OT-LIU/05//21/005		
Description of Pack (Container closure system)	60ml Amber colored glass bottle.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	21KT08	21KT09	21KT10
Batch Size	70 Bottles	70 Bottles	70 Bottles
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	12-10-2021	12-10-2021	12-10-2021

No. of Batches	03	
Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 45207/TS/2020 issued by DCA Telangana dated 14.09.2020 valid till 14/09/2021 submitted.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice No. 2122OT074/EXP, dated 17-06-2021 for 3.0Kg linezolid imported from Optrix laboratories, Clearance from DRAP office is not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Stability studies data, supported with Chromatograms and raw data sheets for three batches i.e. 21KT08, 21KT09, 21KT10 is submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):

Sr.#	Observation	Reply	Remarks
1.	Submit valid Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted Copy of License retention certificate issued by DCA Telangana dated 29.05.2020 valid till 02/06/2025 submitted.	Complied
2.	Evidence for section approval of FPP manufacturer (by CLB) to be submitted.	Approval of "Dry powder suspension (General)" dated 26.01.2022 is provided, approved in 226th meeting of CLB	Complied
3.	Batch no of innovator product and test product has not been mentioned under	Batch no of innovator product and test product are provided as follows: Reference product:	Complied

		Barizold Dry Suspension 100mg/5ml by Barret Hodgson Pharma Batch No C5021 Test product: Zolincid Dry Suspension 100mg/5ml Batch No: 21KT08	
4.	Compatibility of the Drug Substance(s) with excipients (Avicel and Aerosil) to be provided, being different from innovator's formulation.	Avicel is also known as Microcrystalline cellulose and Aerosil is also called colloidal anhydrous silica both ingredients are used in innovator's formulation	Justified
5.	Specify type of glass bottle and provide suitability testing/quality testing (as per pharmacopeia) of container closure system	USP type III bottle, specifications including hydrolytic resistance test are provided.	Complied.
6.	Provide details regarding volume of diluent to be used for reconstitution to achieve label claim 100mg/5ml along with weight/ml calculation with reference to innovator's product	The volume of diluent to be used is 50ml for reconstitution of 18g powder filled in bottle	Complied.
7.	Sampling interval as mentioned in US FDA Dissolution database is 10,20,30 and 45 while dissolution time mentioned by finished product manufacturer is 30 min, moreover sampling interval to be clarified.	Dissolution parameters (apparatus, rpm, medium etc) are selected as per innovator product (USFDA approved) However, dissolution time of 30min are adopted from USFDA guidance document for immediate release dosage form. Aforementioned sampling interval are used for	Justified

		comparison of dissolution profile however for routine dissolution testing single time point is used.	
8.	In use stability data (reconstituted form) to be provided as per guidance document by EMA.(https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products_en.pdf)	In use stability data (reconstituted form) provided with frequency of 0, 1st week, 2nd week, 3rd week and 4th week. Batch No 21KT08 21KT09 21KT10	Complied
9.	Documents for the procurement of API with approval from DRAP is required. Only commercial invoices are provided under this section.	Clearance certificate No 2547 from DRAP office is provided Dated 16.07.2021	Complied

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

599.	Name, address of Applicant / Marketing Authorization Holder	M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Name, address of Manufacturing site.	M/s M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 20722 dated :22-07-2022
	Details of fee submitted	PKR 30,000/-: dated 05-07-2022
	The proposed proprietary name / brand name	Zolincid 600mg Tablets

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Linezolid ……600mg
	Pharmaceutical form of applied drug	White colored, oblong, biconvex, film coated tablets.
	Pharmacotherapeutic Group of (API)	Antibacterial (Oxazolidinone)
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Zyvox 600mg Tablet by M/s Pfizer, USFDA Approved.
	For generic drugs (me-too status)	Barizold 600mg Tablet by M/s Barret Hodgson Pakistan Reg. No. 076341
	GMP status of the Finished product manufacturer	GMP inspection conducted on 29.12.2020, valid till 28.12.2022 Evidence for section approval is not provided.
	Name and address of API manufacturer.	M/s Optrix Laboratories Private Limited SURVEY NO. 145/A, 145/AA & 147 Ramalingampally (V) Bommalaramaram (M) Yadadri-Bhuvangiri (D), Telangana 508126, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Linezolid is available in official monograph i.e USP. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for Linezolid N-oxide, Desfluoro linezolid & related substances (impurity C & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (OTD-LID-S2-002/16, OTD-LID-S2-003/16, OTD-LID-S2-004/16)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing

		process and controls, impurities, specifications, analytical procedure (including dissolution testing phosphate buffer 6.8) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against comparator product that is Barizold Tablets 600mg Barret Hodgson Pharma (Batch No C7229) by performing quality tests (Identification, Assay, Dissolution, DT and Uniformity of dosage form) against Test product (Batch No 21KT05) CDP has been performed against the same brand that is Barizold Tablet 600mg by Barret Hodgson Pharma in acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.		
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY STUDY DATA				
Manufacturer of API		M/s Optrix Laboratories Private Limited SURVEY NO. 145/A, 145/AA & 147 Ramalingampally (V) Bommalaramaram (M) Yadadri-Bhuvangiri (D), Telangana 508126, India.		
API Lot No.		OT-LIU/05//21/005		
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton (2×6's)		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		21KT05	21KT06	21KT07
Batch Size		1200 tab	1200 tab	1200 tab
Manufacturing Date		10-2021	10-2021	10-2021
Date of Initiation		08-10-2021	08-10-2021	08-10-2021
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 45207/TS/2020 issued by DCA Telangana dated 14.09.2020 valid till 14/09/2021 submitted.		

	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of ADC approved invoice No. 2122OT074/EXP, dated 17-06-2021 for 3.0Kg linezolid imported from Optrix laboratories, Clearance from DRAP office is not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Stability studies data, supported with Chromatograms and raw data sheets for three batches i.e. 21KT05, 21KT06, 21KT07 submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
S	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):

Sr.#	Observation	Reply	Remarks
1.	Dissolution parameters as per FDA guidance document for dissolution 2018 are as follows: **B. Paddle Method (USP apparatus 2)** • Stirring rate = 50 RPM • 500 mL of 0.1N HCl in aqueous medium • No surfactant in medium • 37±0.5°C While firm adopted dissolution parameters as follows, clarify it. RPM= 50 Medium= Phosphate buffer Ph 6.8 Volume= 900ml Time=30min	USP pending monograph was adopted (will be official from May,2023) Wherein dissolution parameters are mentioned as: RPM= 50 Medium= Phosphate buffer Ph 6.8 Volume= 900ml Time=30min	Justified
2.	Submit valid Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted Copy of License retention certificate issued by DCA Telangana dated 29.05.2020 valid till 02/06/2025 submitted.	Complied
3.	Evidence for section approval of FPP manufacturer (by CLB) to be submitted.	Approval of "Dry powder suspension (General)" dated 26.01.2022 is provided, approved in 226th meeting of CLB	Available

4.	Compatibility of the Drug Substance(s) with excipients (Avicel and Primojel) to be provided, being different from innovator's formulation.	Avicel is also known as Microcrystalline cellulose and Primojel is also called sodium starch glycolate, both ingredients are used in innovator's formulation	Justified
5.	Documents for the procurement of API with approval from DRAP is required. Only commercial invoices are provided under this section.	Clearance certificate No 2547 from DRAP office is provided Dated 16.07.2021	Complied

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

600.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 23836 dated 23/08/2022
	Details of fee submitted	PKR 30,000/-: dated 10/08/2022
	The proposed proprietary name / brand name	Raceka 10mg sachet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each sachet contains: Racecadotril,…….10mg
	Pharmaceutical form of applied drug	White to off white color free flowing powder filled in sachet
	Pharmacotherapeutic Group of (API)	Antidiarrhoeal drug ('enkephalinase inhibitor')
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	Hidrasec 10mg Sachet by M/s Abbot Laboratories (Bioprojet Europe Ltd.) MHRA approved
	For generic drugs (me-too status)	Hidrasec 10mg Sachet by M/s Abbot Laboratories (Pakistan) Ltd., Landhi, Karachi, Pakistan. DRAP Approved.
	GMP status of the Finished product manufacturer	GMP certificate based on inspection dated 27.09.2019 granted on 14.10.2019 Sachet (General) section was approved on 12.02.2013
	Name and address of API manufacturer.	Symed Labs Ltd. India, Unit II, Plot No 25/B, Phase III, I.D.A, Jeedimetla, Hyderabad, Telangana, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Racecadotril is not available. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity (A,C,E,F & unspecified), analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (RAC L-009, RAC L-010 and RAC L-011)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand that is Hidrasec 10mg Sachet by M/s SOPHARTEX, 21 rue du Pressoir, 28500 Vernouillet (France). Performing quality tests (Description and Assay).

		CDP is not applicable
	Analytical method validation/verification of product	Method verification studies have been submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Symed Labs Ltd. India, Unit II, Plot No 25/B, Phase III, I.D.A, Jeedimetla, Hyderabad, Telangana, India		
API Lot No.	Not provided		
Description of Pack (Container closure system)	1×16 sachet		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	10mg/Sachet		
Batch No.	RC-01	RC-02	RC-03
Batch Size	1200 Sachet	1200 Sachet	1200 Sachet
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	05-10-2021	05-10-2021	05-10-2021
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of	Not provided

	stability chambers (real time and accelerated)	

Remarks of Assessor (AD-PEC[XX]):

Sr.#	Observation	Remarks	Reply
1.	Approval of API/ DML/GMP certificate of API manufacturer to be provided.	Not submitted	Later on firm has submitted copy of License (No 26/RR/AP/2003/B/R) valid till 27/05/2023
2.	GMP status/inspection report of FPP manufacturer to be submitted.	GMP certificate based on inspection dated 27.09.2019 granted on 14.10.2019	GMP inspection status dated 10/12/2020 has been submitted.
3.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of Drug substance Batch No 2KA0030721 from both Drug substance and Drug product manufacturers is submitted	Not complied Document for procurement of API of same batch 2KA0030721 is required. Later on firm has submitted copy of invoice No 21-22/EXP-364 dated 30.07.2021 and DRAP clearance (Peshawar) dated 12.08.2021confirming import of 0.2 Kg Racecadotril Batch No 2KA0030721
4.	Detailed analytical procedures for the testing of drug substance to be provided by Drug Product manufacturer.	Firm provided analytical procedures for testing of finished product rather than Drug substance	Later on firm has provided Analytical procedures for the testing of drug substance
5.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed (of Drug substance) by the Drug Product manufacturer to be provided	Firm provided analytical Analytical Method Verification studies of finished product rather than Drug substance	Analytical Method Verification studies of drug substance to be provided rather than drug product.
6.	Batch no of innovator product and test product has not been mentioned under Pharmaceutical equivalence study.	Innovator product: Hidrasec 10mg Sachet by M/s SOPHARTEX, (France). Batch No: SXN734 Test product: Raceka sachet Batch No: RC-01, RC-02, RC-03	Complied

7.	Suitability testing/quality testing of container closure system/packaging material is not provided.	Quality testing /specifications of poly foil is submitted	Complied
8.	Description of manufacturing process and flow chart diagram is not relevant to applied product since manufacturing steps like "compression", "film coating" and "capsuling" have been mentioned.	Description of manufacturing process and flow chart diagram are rectified and re-submitted	Complied
9.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not provided	Submitted	Complied
10.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is not provided.	Submitted	Complied
11	Documents for the procurement of API to be submitted.	Not provided	Later on firm has submitted copy of invoice No 21-22/EXP-364 dated 30.07.2021 and DRAP clearance (Peshawar) dated 12.08.2021confirming import of 0.2 Kg Racecadotril Batch No 2KA0030721

Decision: Approved. Registration letter will be issued upon submission of analytical method verification studies of drug substance performed by drug product manufacturer.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

601.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 23837 dated 23/08/2022
	Details of fee submitted	PKR 30,000/-: dated 10/08/2022

	The proposed proprietary name / brand name	Raceka 30mg sachet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each sachet contains: Racecadotril. …….30mg
	Pharmaceutical form of applied drug	White to off white color free flowing powder filled in sachet
	Pharmacotherapeutic Group of (API)	Antidiarrheal drug ('enkephalinase inhibitor')
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Hidrasec 30mg Sachet by M/s Abbot Laboratories (Bioprojet Europe Ltd.) MHRA approved
	For generic drugs (me-too status)	Hidrasec 10mg Sachet by M/s Abbot Laboratories (Pakistan) Ltd., Landhi, Karachi, Pakistan. DRAP Approved.
	GMP status of the Finished product manufacturer	GMP certificate based on inspection dated 27.09.2019 granted on 14.10.2019 Sachet (General) section was approved on 12.02.2013
	Name and address of API manufacturer.	Symed Labs Ltd. India, Unit II, Plot No 25/B, Phase III, I.D.A, Jeedimetla, Hyderabad, Telangana, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Racecadotril is not available. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (RAC L-009, RAC L-010 and RAC L-011)

	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand that is Hidrasec 30mg Sachet by M/s SOPHARTEX, 21 rue du Pressoir, 28500 Vernouillet (France). Performing quality tests (Description and Assay). CDP is not applicable
	Analytical method validation/verification of product	Method verification studies have been submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Symed Labs Ltd. India, Unit II, Plot No 25/B, Phase III, I.D.A, Jeedimetla, Hyderabad, Telangana, India.		
API Lot No.	Not provided		
Description of Pack (Container closure system)	1×16 sachet		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	30mg/Sachet		
Batch No.	RC-04	RC-05	RC-06
Batch Size	1200 Sachet	1200 Sachet	1200 Sachet
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	05-10-2021	05-10-2021	05-10-2021
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided

	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Assessor (AD-PECXX):

Sr.#	Observation	Remarks	Reply
1.	Approval of API/ DML/GMP certificate of API manufacturer to be provided.	Not submitted	Later on firm has submitted copy of License (No 26/RR/AP/2003/B/R) valid till 27/05/2023
2.	GMP status/inspection report of FPP manufacturer to be submitted.	GMP certificate based on inspection dated 27.09.2019 granted on 14.10.2019	GMP inspection status dated 10/12/2020 has been submitted.
3.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of Drug substance Batch No 2KA0030721 from both Drug substance and Drug product manufacturers is submitted	Document for procurement of API of same batch 2KA0030721 is required. Later on firm has submitted copy of invoice No 21-22/EXP-364 dated 30.07.2021 and DRAP clearance (Peshawar) dated 12.08.2021confirming import of 0.2 Kg Racecadotril Batch No 2KA0030721
4.	Detailed analytical procedures for the testing of drug substance to be provided by Drug Product manufacturer.	Firm provided analytical procedures for testing of finished product rather than Drug substance	Analytical procedures for the testing of drug substance to be provided Later on firm has provided Analytical procedures for the testing of drug substance
5.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed (of Drug substance) by the	Firm provided analytical Analytical Method Verification studies of	Analytical Method Verification studies of drug substance to be

	Drug Product manufacturer to be provided	finished product rather than Drug substance	provided rather than drug product.
6.	Batch no of innovator product and test product has not been mentioned under Pharmaceutical equivalence study.	Innovator product: Hidrasec 10mg Sachet by M/s SOPHARTEX, (France). Batch No: SXE2664 Test product: Raceka sachet Batch No: RC-04, RC-05, RC-06	Complied
7.	Suitability testing/quality testing of container closure system/packaging material is not provided.	Quality testing /specifications of poly foil is submitted	Complied
8.	Description of manufacturing process and flow chart diagram is not relevant to applied product since manufacturing steps like "compression", "film coating" and "capsuling" have been mentioned.	Description of manufacturing process and flow chart diagram are rectified and re-submitted	Complied
9.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not provided	Submitted	Complied
10.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is not provided.	Submitted	Complied
11	Documents for the procurement of API to be submitted.	Not provided	Later on firm has submitted copy of invoice No 21-22/EXP-364 dated 30.07.2021 and DRAP clearance (Peshawar) dated 12.08.2021confirming import of 0.2 Kg Racecadotril Batch No 2KA0030721

Decision: Approved. Registration letter will be issued upon submission of analytical method verification studies of drug substance performed by drug product manufacturer.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

602.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.

	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27444 dated 28.09.2022 Dy No 27921 dated 03.10.2022 (6th month stability data submission
	Details of fee submitted	PKR 75,000/- dated 16/08/2022
	The proposed proprietary name / brand name	TRIGLEM-LIN XR 5mg/2.5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…5mg Linagliptin…….2.5mg Metformin HCl USP (as Extended Release)…….1000mg
	Pharmaceutical form of applied drug	Light yellow colored, oblong shaped, film coated tablet, both sides plain oral tablet.
	Pharmacotherapeutic Group of (API)	Antidiabetics, SGLT2
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	10's, 14's, 20's & 28's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	TRIJARDY XR Tablet 5mg/2.5mg/1000mg (Empagliflozin 5mg + Linagliptin 2.5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. (FDA approved)
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP Certificate granted on 28/05/2022. Section approval letter issued dated 27.04.2022 Tablet (General) section is approved.
	Name and address of API manufacturer.	Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride:

		Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Empagliflozin: Official Monograph of Empagliflozin is not available. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Impurity A, Impurity C, Any single unknown impurity, Total impurities, Heavy metal, Chiral purity R-isomer), Residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Linagliptin: Official Monograph of Linagliptin is not available. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Single Impurity, Total impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Metformin: USP Monograph was adopted for Metformin HCl. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Metformin Related compound, Any Other Impurity, Total Impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Empagliflozin: Stability study conditions:

		Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Z1215-170601, Z1215-170602, Z1215-170603) Linagliptin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20150901, 20150902, 20150903) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is TRIJARDY XR Tablet 5mg/2.5mg/1000mg (Empagliflozin 5mg + Linagliptin 2.5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), by performing quality tests (Description, Identification, Dissolution and Assay). CDP has been performed against the same brand that is TRIJARDY XR Tablet (Batch No 3201105) (Empagliflozin 5mg + Linagliptin 2.5mg + Metformin 1000mg) by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), in Acid media (0.1N) (pH 1.2), Acetate Buffer (4.5) & Phosphate Buffer (6.8) against test product (Batch No 534DS01). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin:	

	Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India.		
API Lot No.	Empagliflozin: EPG20211101 Linagliptin: 21102401 Metformin HCl: MEF/11030675		
Description of Pack (Container closure system)	Alu-Alu blister 10's, 14's, 20's & 28's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3,6 (Months) Real Time: 0, 3,6 (Months)		
Batch No.	534DS01	534DS02	534DS03
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	11-03-2022	11-03-2022	11-03-2022
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of License issued by Zhejiang Food and Drug Administration, China valid till 31/01/2024. License No. Zhe20090508 dated 14.01.2019 Copy of GMP issued by China Food and Drug Administration No ZJ20180032 dated 15.03.2018 valid till 14.03.2023 Linagliptin: Copy of License issued by Anhui Provincial Drug Administration, China valid till 31/12/2025. License No. 20190399 dated 01.01.2021 Metformin HCl: Copy of GMP certificate No 20031933 issued by Food & Drugs Control Administration, Gujarat State, India dated 20.03.2020 valid till 19/03/2023.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of invoice no. HHSC-211025-1 dated 08th Dec, 2021 duly attested by Assistant Director, DRAP, Karachi on 17-12-2021 was provided. Batch No EPG20211101	

		Quantity 30Kg Linagliptin: Copy of invoice no. WD202105073 dated 29-10-2021 duly attested by Assistant Director, DRAP, Karachi on 12-11-2021 was provided. Batch No 21102401 Quantity 1Kg Metformin HCl: Copy of invoice no. EXP/844/21-22 dated 11-06-2021 duly attested by Assistant Director, DRAP, Karachi on 16-07-2021 was provided. Batch No MEF/11030675 Quantity 2000 Kg
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):

Sr.#	Observation	Reply	Remarks
1.	The specification of Empagliflozin includes tests for appearance, identity (IR, HPLC), impurities (HPLC), diastereomer (chiral HPLC), assay (HPLC), residual solvents (GC), water content (KF), residue on ignition (Ph. Eur.), and particle size (laser diffraction) https://www.ema.europa.eu/en/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf Particle size (laser diffraction) has not been performed in analysis of Drug Substances. Mainly Empagliflozin and Linagliptin both Drug Substances of specific particle size (d 90) has been used in innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Both Empagliflozin and Linagliptin are highly soluble Drug Substances hence particle size is neither critical quality attribute nor affect bioavailability However firm has submitted result of particle size distribution study of both Drug substances performed on 25.02.2022 wherein particle size of Empagliflozin is 6.22µm (d 90) and	Justified Empagliflozin and Linagliptin belongs to BCS Class III i.e highly soluble

		Linagliptin is 12.1 µm (d 90)	
2.	Water content test has not been performed in analysis of finished product as mentioned in finished product specification of innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Firm has submitted results of water content test as performed on 04.01.2023 as follows: 5/2.5/1000 =1.07% 10/5/1000 =1.29% 12.5/2.5/1000 =1.37% 25/5/1000 =1.57%	Complied

Metformin (extended release) core is surrounded by seal coat, followed by coating of Empagliflozin and Linagliptin containing solution over seal coat, which is further surrounded by film coating.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

603.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27445 dated 28 /09/ 2022 Dy No 27920 dated 03.10.2022 (6th month stability data submission
	Details of fee submitted	PKR 75,000/-: dated 16/08/2022
	The proposed proprietary name / brand name	TRIGLEM-LIN XR 10mg/5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin…10mg Linagliptin…….5mg Metformin HCl USP (as Extended Release)…….1000mg
	Pharmaceutical form of applied drug	Peach colored, oblong in shape, film coated tablet, both sides plain oral tablet.
	Pharmacotherapeutic Group of (API)	Antidiabetics, SGLT2
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	10's, 14's, 20's & 28's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	TRIJARDY XR Tablet 10mg/5mg/1000mg (Empagliflozin 10mg + Linagliptin 5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. (FDA Approved)
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP Certificate granted on 28/05/2022. Section approval letter issued dated 27.04.2022 Tablet (General) section is approved.
	Name and address of API manufacturer.	Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and

		controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Empagliflozin: Official Monograph of Empagliflozin is not available. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Impurity A, Impurity C, Any single unknown impurity, Total impurities, Heavy metal, Chiral purity R-isomer), Residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Linagliptin: Official Monograph of Linagliptin is not available. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Single Impurity, Total impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Metformin: USP Monograph was adopted for Metformin HCl. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Metformin Related compound, Any Other Impurity, Total Impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance..
	Stability studies	Empagliflozin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Z1215-170601, Z1215-170602, Z1215-170603) Linagliptin: Stability study conditions:

		Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20150901, 20150902, 20150903) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is TRIJARDY XR Tablet 10mg/5mg/1000mg (Empagliflozin 10mg + Linagliptin 5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), by performing quality tests (Description, Identification, Dissolution and Assay). CDP has been performed against the same brand that is TRIJARDY XR Tablet (Batch No 3199475) (Empagliflozin 10mg + Linagliptin 5mg + Metformin 1000mg) by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), in Acid media (0.1N) (pH 1.2), Acetate Buffer (4.5) & Phosphate Buffer (6.8) against test product (Batch No 536DS01). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API		Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad,
API Lot No.		Empagliflozin: EPG20211101 Linagliptin:

	21102401 Metformin HCl: MEF/11030675		
Description of Pack (Container closure system)	Alu-Alu blister 10's, 14's, 20's & 28's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3,6 (Months) Real Time: 0, 3,6 (Months)		
Batch No.	536DS01	536DS02	536DS03
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	07-03-2022	07-03-2022	07-03-2022
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of License issued by Zhejiang Food and Drug Administration, China valid till 31/01/2024. License No. Zhe20090508 dated 14.01.2019 Copy of GMP issued by China Food and Drug Administration No ZJ20180032 dated 15.03.2018 valid till 14.03.2023 Linagliptin: Copy of License issued by Anhui Provincial Drug Administration, China valid till 31/12/2025. License No. 20190399 dated 01.01.2021 Metformin HCl: Copy of GMP certificate No 20031933 issued by Food & Drugs Control Administration, Gujarat State, India dated 20.03.2020 valid till 19/03/2023.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of invoice no. HHSC-211025-1 dated 08th Dec, 2021 duly attested by Assistant Director, DRAP, Karachi on 17-12-2021 was provided. Batch No EPG20211101 Quantity 30Kg Linagliptin: Copy of invoice no. WD202105073 dated 29-10-2021 duly attested by Assistant Director, DRAP, Karachi on 12-11-2021 was provided. Batch No 21102401 Quantity 1Kg	

		Metformin HCl: Copy of invoice no. EXP/844/21-22 dated 11-06-2021 duly attested by Assistant Director, DRAP, Karachi on 16-07-2021 was provided. Batch No MEF/11030675 Quantity 2000 Kg
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):

USFDA approved Box warning for Metformin HCl is as follows:

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL *[see WARNINGS AND PRECAUTIONS (5.1)]*.

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information *[see DOSAGE AND ADMINISTRATION (2.3), CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.1), DRUG INTERACTIONS (7), and USE IN SPECIFIC POPULATIONS (8.6, 8.7)]*.

If metformin-associated lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended *[see WARNINGS AND PRECAUTIONS (5.1)]*.

CLOSE

Sr.#	Observation	Reply	Remarks

1.	The specification of Empagliflozin includes tests for appearance, identity (IR, HPLC), impurities (HPLC), diastereomer (chiral HPLC), assay (HPLC), residual solvents (GC), water content (KF), residue on ignition (Ph. Eur.), and particle size (laser diffraction) https://www.ema.europa.eu/en/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf Particle size (laser diffraction) has not been performed in analysis of Drug Substances. Mainly Empagliflozin and Linagliptin both Drug Substances of specific particle size (d 90) has been used in innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Both Empagliflozin and Linagliptin are highly soluble Drug Substances hence particle size is neither critical quality attribute nor affect bioavailability However firm has submitted result of particle size distribution study of both Drug substances performed on 25.02.2022 wherein particle size of Empagliflozin is 6.22µm (d 90) and Linagliptin is 12.1 µm (d 90)	Justified Empagliflozin and Linagliptin belongs to BCS Class III i.e highly soluble
2.	Water content test has not been performed in analysis of finished product as mentioned in finished product specification of innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Firm has submitted results of water content test as performed on 04.01.2023 as follows: 5/2.5/1000 =1.07% 10/5/1000 =1.29% 12.5/2.5/1000 =1.37% 25/5/1000 =1.57%	Complied

Metformin (extended release) core is surrounded by seal coat, followed by coating of Empagliflozin and Linagliptin containing solution over seal coat, which is further surrounded by film coating.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

604.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.

	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27446 dated 28 / 09 / 2022 Dy No 28379 dated 06.10.2022 (6th month stability data submission
	Details of fee submitted	PKR 75,000/-: dated 16/08/2022
	The proposed proprietary name / brand name	TRIGLEM-LIN XR 12.5mg/2.5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin…12.5mg Linagliptin…….2.5mg Metformin HCl USP (as Extended Release)…….1000mg (Innovator's Specs.)
	Pharmaceutical form of applied drug	Pink colored, oblong in shape, film coated tablet, both sides plain oral tablet.
	Pharmacotherapeutic Group of (API)	Antidiabetics, SGLT2
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	10's, 14's, 20's & 28's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	TRIJARDY XR Tablet 12.5mg/2.5mg/1000mg (Empagliflozin 12.5mg + Linagliptin 2.5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. (US FDA Approved)
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP Certificate granted on 28/05/2022. Section approval letter issued dated 27.04.2022 Tablet (General) section is approved.
	Name and address of API manufacturer.	Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited.

		Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Empagliflozin: Official Monograph of Empagliflozin is not available. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Impurity A, Impurity C, Any single unknown impurity, Total impurities, Heavy metal, Chiral purity R-isomer), Residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Linagliptin: Official Monograph of Linagliptin is not available. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Single Impurity, Total impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Metformin: USP Monograph was adopted for Metformin HCl. The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Metformin Related compound, Any Other Impurity, Total Impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Empagliflozin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months

		Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Z1215-170601, Z1215-170602, Z1215-170603) Linagliptin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20150901, 20150902, 20150903) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is TRIJARDY XR Tablet 12.5mg/2.5mg/1000mg (Empagliflozin 12.5mg + Linagliptin 2.5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), by performing quality tests (Description, Identification, Dissolution and Assay). CDP has been performed against the same brand that is TRIJARDY XR Tablet 12.5mg/2.5mg/1000mg (Empagliflozin 12.5mg + Linagliptin 2.5mg + Metformin 1000mg) (Batch No 320276) by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), in Acid media (0.1N) (pH 1.2), Acetate Buffer (4.5) & Phosphate Buffer (6.8) against Test product ((Batch No 535DS01). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API		Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd.

	21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India		
API Lot No.	Empagliflozin: EPG20211101 Linagliptin: 21102401 Metformin HCl: MEF/11030675		
Description of Pack (Container closure system)	Alu-Alu blister 10's, 14's, 20's & 28's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	535DS01	535DS02	535DS03
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	09-03-2022	09-03-2022	09-03-2022
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of License issued by Zhejiang Food and Drug Administration, China valid till 31/01/2024. License No. Zhe20090508 dated 14.01.2019 Copy of GMP issued by China Food and Drug Administration No ZJ20180032 dated 15.03.2018 valid till 14.03.2023 Linagliptin: Copy of License issued by Anhui Provincial Drug Administration, China valid till 31/12/2025. License No. 20190399 dated 01.01.2021 Metformin HCl: Copy of GMP certificate No 20031933 issued by Food & Drugs Control Administration, Gujarat State, India dated 20.03.2020 valid till 19/03/2023.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of invoice no. HHSC-211025-1 dated 08th Dec, 2021 duly attested by Assistant Director, DRAP, Karachi on 17-12-2021 was provided. Batch No EPG20211101 Quantity 30Kg	

		Linagliptin: Copy of invoice no. WD202105073 dated 29-10-2021 duly attested by Assistant Director, DRAP, Karachi on 12-11-2021 was provided. Batch No 21102401 Quantity 1Kg Metformin HCl: Copy of invoice no. EXP/844/21-22 dated 11-06-2021 duly attested by Assistant Director, DRAP, Karachi on 16-07-2021 was provided. Batch No MEF/11030675 Quantity 2000 Kg
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):

USFDA approved Box warning for Metformin HCl is as follows:

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL *[see WARNINGS AND PRECAUTIONS (5.1)]*.

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information *[see DOSAGE AND ADMINISTRATION (2.3), CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.1), DRUG INTERACTIONS (7), and USE IN SPECIFIC POPULATIONS (8.6, 8.7)]*.

If metformin-associated lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended *[see WARNINGS AND PRECAUTIONS (5.1)]*.

CLOSE

Sr.#	Observation	Reply	Remarks
1.	The specification of Empagliflozin includes tests for appearance, identity (IR, HPLC), impurities (HPLC), diastereomer (chiral HPLC), assay (HPLC), residual solvents (GC), water content (KF), residue on ignition (Ph. Eur.), and particle size (laser diffraction) https://www.ema.europa.eu/en/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf Particle size (laser diffraction) has not been performed in analysis of Drug Substances. Mainly Empagliflozin and Linagliptin both Drug Substances of specific particle size (d 90) has been used in innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Both Empagliflozin and Linagliptin are highly soluble Drug Substances hence particle size is neither critical quality attribute nor affect bioavailability However firm has submitted result of particle size distribution study of both Drug substances performed on 25.02.2022 wherein particle size of Empagliflozin is 6.22µm (d 90) and Linagliptin is 12.1 µm (d 90)	Justified Empagliflozin and Linagliptin belongs to BCS Class III i.e highly soluble
2.	Water content test has not been performed in analysis of finished product as mentioned in finished product specification of innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Firm has submitted results of water content test as performed on 04.01.2023 as follows: 5/2.5/1000 =1.07% 10/5/1000 =1.29% 12.5/2.5/1000 =1.37% 25/5/1000 =1.57%	Complied

Metformin (extended release) core is surrounded by seal coat, followed by coating of Empagliflozin and Linagliptin containing solution over seal coat, which is further surrounded by film coating.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

605.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27447 dated 28 / 09 / 2022 Dy No 28380 dated 06.10.2022 (6th month stability data submission)
	Details of fee submitted	PKR 75,000/-: dated 16/08/2022
	The proposed proprietary name / brand name	TRIGLEM-LIN XR 25mg/5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin…25mg Linagliptin…….5mg Metformin HCl USP (as Extended Release)…….1000mg (Innovator's Specs.)
	Pharmaceutical form of applied drug	Orange colored, oblong in shape, film coated tablet, both sides plain oral tablet.
	Pharmacotherapeutic Group of (API)	Antidiabetics, SGLT2
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	10's, 14's, 20's & 28's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	TRIJARDY XR Tablet 25mg/5mg/1000mg (Empagliflozin 25mg + Linagliptin 5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. (US FDA Approved)
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP Certificate granted on 28/05/2022. Section approval letter issued dated 27.04.2022 Tablet (General) section is approved.
	Name and address of API manufacturer.	Empagliflozin: Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd.

		21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Empagliflozin: Official Monograph of Empagliflozin is not available. The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Impurity A, Impurity C, Any single unknown impurity, Total impurities, Heavy metal, Chiral purity R-isomer), Residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Linagliptin: Official Monograph of Linagliptin is not available. The firm as submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Single Impurity, Total impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Metformin: USP Monograph was adopted for Metformin HCl. The firm as submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Metformin Related compound, Any Other Impurity, Total Impurity), residual solvents, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability studies	Empagliflozin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (Z1215-170601, Z1215-170602, Z1215-170603) Linagliptin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20150901, 20150902, 20150903) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is TRIJARDY XR Tablet 25mg/5mg/1000mg (Empagliflozin 25mg + Linagliptin 5mg + Metformin 1000mg) is being marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), by performing quality tests (Description, Identification, Dissolution and Assay). CDP has been performed against the same brand that is TRIJARDY XR Tablet 25mg/5mg/1000mg (Empagliflozin 25mg + Linagliptin 5mg + Metformin 1000mg) (Batch No. 3204436) by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Germany), in Acid media (0.1N) (pH 1.2), Acetate Buffer (4.5) & Phosphate Buffer (6.8) against Test product (Batch No 537DS01). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	Empagliflozin:	

	Zhejiang Hongyuan Pharmaceuticals Co., Ltd. Chem & API's Industrial Zone, Linhai, Zhejiang Province, China. Linagliptin: Anhui Haikang Pharmaceutical Co., Ltd. 21 Huancheng West Road, Anqing Anhui Province 246000, China. Metformin Hydrochloride: Aarti Drugs Limited. Plot No. 211 – 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat, India		
API Lot No.	Empagliflozin: EPG20211101 Linagliptin: 21102401 Metformin HCl: MEF/11030675		
Description of Pack (Container closure system)	Alu-Alu blister 10's, 14's, 20's & 28's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	537DS01	537DS02	537DS03
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	09-03-2022	09-03-2022	09-03-2022
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of GMP certificate issued by Linhai Medical and Chemical Industry Administration, China valid till 31/01/2023. Copy of Manufacturing License Linagliptin: Copy of GMP certificate issued by Anqing Biomedical Industry Association, China valid till 19/04/2026. Copy of Manufacturing License Metformin HCl: Copy of GMP certificate issued by Food & Drugs Control Administration, Gujarat State, India valid till 19/03/2023.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of invoice no. HHSC-211025-1 dated 08, 2021 duly attested by Assistant Director, DRAP, Karachi on 24-12-2021 was provided. Linagliptin: Copy of invoice no. WD202105073 dated 29-10-2021 duly attested by Assistant Director, DRAP, Karachi on 12-11-2021 was provided.	

		Metformin HCl: Copy of invoice no. EXP/844/21-22 dated 11-06-2021 duly attested by Assistant Director, DRAP, Karachi on 16-07-2021 was provided.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor (AD-PECXX):
USFDA approved Box warning for Metformin HCl is as follows:

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL *[see WARNINGS AND PRECAUTIONS (5.1)]*.

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information *[see DOSAGE AND ADMINISTRATION (2.3), CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.1), DRUG INTERACTIONS (7), and USE IN SPECIFIC POPULATIONS (8.6, 8.7)]*.

If metformin-associated lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended *[see WARNINGS AND PRECAUTIONS (5.1)]*.

CLOSE

Sr.#	Observation	Reply	Remarks

1.	The specification of Empagliflozin includes tests for appearance, identity (IR, HPLC), impurities (HPLC), diastereomer (chiral HPLC), assay (HPLC), residual solvents (GC), water content (KF), residue on ignition (Ph. Eur.), and particle size (laser diffraction) https://www.ema.europa.eu/en/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf Particle size (laser diffraction) has not been performed in analysis of Drug Substances. Mainly Empagliflozin and Linagliptin both Drug Substances of specific particle size (d 90) has been used in innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Both Empagliflozin and Linagliptin are highly soluble Drug Substances hence particle size is neither critical quality attribute nor affect bioavailability However firm has submitted result of particle size distribution study of both Drug substances performed on 25.02.2022 wherein particle size of Empagliflozin is 6.22µm (d 90) and Linagliptin is 12.1 µm (d 90)	Justified Empagliflozin and Linagliptin belongs to BCS Class III i.e highly soluble
2.	Water content test has not been performed in analysis of finished product as mentioned in finished product specification of innovator product. file:///D:/PEC%20Working/212614Orig1s000ChemR.pdf	Firm has submitted results of water content test as performed on 04.01.2023 as follows: 5/2.5/1000 =1.07% 10/5/1000 =1.29% 12.5/2.5/1000 =1.37% 25/5/1000 =1.57%	Complied

Metformin (extended release) core is surrounded by seal coat, followed by coating of Empagliflozin and Linagliptin containing solution over seal coat, which is further surrounded by film coating.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

c) New molecule:

606.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilson's Pharmaceuticals Plot No 387-388, Sector I-9, Industrial area, Islamabad
	Name, address of Manufacturing site.	M/s Wilson's Pharmaceuticals Plot No 387-388, Sector I-9, Industrial area, Islamabad
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 3133 (dated: 01-02-2022)
	Details of fee submitted	PKR 75,000/-: dated: 14-01-2022
	The proposed proprietary name / brand name	Congestin Tablet 10mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Phenylephrine Hydrochloride……10mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Sympathomimetic used as decongestant
	Reference to Finished product specifications	USP specification
	Proposed Pack size	15's, 30's and 45's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA OTC monograph SUDAFED PE congestion
	For generic drugs (me-too status)	Not available
	GMP status of the Finished product manufacturer	DML renewal inspection conducted on 28.07.2022 wherein renewal of DML granted with all approved sections including "Tablet (General) section"
	Name and address of API manufacturer.	M/s Shenzhen Oriental Pharmaceutical Co., Ltd, 43 Dakeng Road, Tongle Village Longgang Town, Longgang District Shenzhen China
	Module-II (Quality Overall Summary)	Not provided
	Module III (Drug Substance)	Not provided
	Stability studies	Not provided
	Module-III (Drug Product):	Not provided
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer Test product: Congestin Tablet 10mg Reference product: SUDAFED PE congestion tablet

		on the basis of similarity factor (f2) result i.e NLT 50 of dissolution profile of both API in test product and reference product, both products are similar.	
	Analytical method validation/verification of product	Not provided	
STABILITY STUDY DATA			
Manufacturer of API	M/s Shenzhen Oriental Pharmaceutical Co., Ltd, 43 Dakeng Road, Tongle Village Longgang Town, Longgang District Shenzhen China		
API Lot No.	PEH-180101Y1		
Description of Pack (Container closure system)	Alu-Alu strip		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trail-01	Trail-02	Trail-03
Batch Size	1500 tab	1500 tab	1500 tab
Manufacturing Date	11 – 2019	11 – 2019	11 – 2019
Date of Initiation	16-11-2019	16-11-2019	16-11-2019
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No GD190014 issued by Guangdong Food and Drug Administration China dated 12.09.2019 valid till 11.09.2022	
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of following invoices specifying: 308.25g of Phenylephrine Hydrochloride (invoice # SZ-1803039) Batch No. PEH-180101Y1 attested by AD (I&E), Karachi dated 12-03-2018 is submitted	
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted. CoA for each time interval is not provided	
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.	

Remarks of Assessor (AD PECXX):

Sr.#	Observation	Reply	Remarks
1.	Same API Lot No PEH-180101Y1 of phenylephrine HCl has been used for your product COLDENOL COLD + FLU SEVERE TABLET, considered in 321st and 323rd meeting of Registration Bord. Please clarify and justify the quantity used for test/analysis.	Total 308.25g of Phenylephrine Hydrochloride (invoice # SZ-1803039) Batch No. PEH-180101Y1 was imported, out of which 22.5 g was consumed for analysis of 3 trial batches of COLDENOL COLD + FLU SEVERE TABLET and 46.35g was consumed for analysis of Congestin 10mg tablet so total 68.85g has been consumed so far out of 308.25g drug substance.	Justified
2.	The Quality Overall Summary (QOS) to be provided in WHO QOS-PD Template	Quality Overall Summary (QOS) has been submitted in WHO QOS-PD format	Complied
3.	Elucidation of Structure and other Characteristics of Drug Substance has not been provided	IR spectrums of Phenylephrine Hydrochloride are provided	Complied
4.	Detailed analytical procedures for the testing of drug substance to be provided by Drug Substance manufacturer	Detailed analytical procedures for the testing of drug substance by Drug Substance manufacturer has been provided	Complied
5.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer to be provided	Firm has submitted analytical method verification studies of DS including specificity, accuracy and repeatability (method precision) by the Drug Product manufacturer	Complied
6.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of DS (Batch No PEH-180101Y1) has been provided from both DS and Drug Product manufacturer	Complied
7.	COA of primary / secondary reference standard including source and lot number to be provided	COA of working standard (as per USP) Batch No WSPEH-150919 has been provided	Complied
8.	Description of the container closure system(s) for the shipment and storage of the API including materials of	Description of the container closure system (PE bag) for DS has been provided	Complied

	construction of each primary packaging component		
9.	Stability data of Drug Substance not provided. The protocols used and the results of the accelerated and long-term stability studies should be summarized.	Stability data of Drug Substance has been provided as follows: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: PEH-160404, PEH-160405, PEH-160406.	Complied
10.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product .	Pharmaceutical equivalence established against innovator/reference Test product: Congestin Tablet 10mg Reference product: SUDAFED PE congestion tablet Quality parameters compared are Assay, dissolution and DT.	Complied
11.	Suitability testing/quality testing of container closure system is not provided	Provided	Complied
12.	Batch no of innovator product and test product has not been mentioned under CDP	Batch No of test product and innovator product are as follows Test product: Congestin Tablet 10mg Batch No Trial 1 Reference product: SUDAFED PE congestion tablet Batch No SEC102	Complied
13.	Discussion of the choice of excipients, their concentrations and characteristics that can influence the Drug Product performance to be provided	Provided details regarding excipients, their concentrations and characteristics	Complied
14.	Batch formula for proposed commercial batch size should be provided that includes a list of all components of the drug product to be used in the manufacturing process, their amounts	Batch formula for proposed commercial batch size is provided that includes a list of all components of the drug product	Complied

	on a per batch basis, and a reference to their quality standards		
15.	Description of manufacturing process and process controls is required	Provided flow diagram of manufacturing process	Complied
16.	Analytical method validation/verification of product is not provided	Analytical method verification study of Drug product is provided	Complied
17.	Compatibility of the Drug Substance(s) with excipients (croscarmellose sodium. Avicel and Aerosil) is not provided	Aforementioned excipients are used in innovator product as well hence there is no need to perform compatibility study	Croscarmellose sodium and Aerosil is not found in innovator product hence compatibility of the Drug Substance(s) with these excipients is required.
18.	CoA at each time interval is required in stability data.	CoA at each time interval is submitted for all stability batches: Trail-01 Trail-02 Trail-03	Complied
19.	Record of Digital data logger for temperature and humidity monitoring of stability chambers not submitted for study period (11/2019 to 05/2020)	Provided	Complied

Decision: Approved. Firm shall submit drug excipient compatibility studies before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

d) Deferred cases:

Deferred case of 322nd meeting:

607.	Name and address of manufacturer / Applicant	M/s The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan.
	Brand Name +Dosage Form + Strength	Anzo D MR Capsule
	Diary No. Date of R& I & fee	Dy No. 2368 (PEC DRAP) Dated 17.10.2022 (duplicate) Rs: 50,000/- 22-12-2017
	Composition	Each modified release capsule contains: Diclofenac sodium…….75mg Omeprazole…….20mg
	Pharmacological Group	Anti-arthritis Anti-ulcer
	Type of Form	Form 5-D
	Finished Product Specification	Innovator's Specs.
	Pack size & Demanded Price	As per DPC

	Approval status of product in Reference Regulatory Authorities.	EMA Approved Diotop 75 mg / 20 mg modified release hard capsules
	Me-too status	Not Applicable
	GMP status	GMP inspection conduced on 07/07/2022 Capsule (General & General Antibiotic) section approved.

STABILITY STUDY DATA			
Drug	Anzo D MR Capsule		
Name of Manufacturer	M/s The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan.		
Manufacturer of API	Diclofenac Sodium MR pellets : M/s Alphamed Formulations Private Limited	Omeprazole delayed release pellets: M/s Alphamed Formulations Private Limited	
API Lot No.	RD0149-017	8000201-010	
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time : 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Real time: 0,3,6 (months) Accelerated: 0,3,6,9,12,18(months)		
Batch No.	20PD-271	20PD-272	20PD-273
Batch Size	2500 cap	2500 cap	2500 cap
Manufacturing Date	10-2020	10-2020	10-2020
Date of Initiation	26-10.2020	26-10.2020	26-10.2020
No. of Batches	03		
Date of Submission	10-01-2022 (Dy No. 57 PEC, DRAP)		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT FOR EXEMPTION			
DOCUMENTS / DATA PROVIDED BY THE APPLICANT			
S. No.	Documents To Be Provided	Status	
1.	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their product for Tapendol (Tapentadol) Tablets 75mg & 100mg on 11th March, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software. Related manufacturing area, equipment, personnel and utilities are GMP compliant.	

2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Diclofenac sodium MR pellets 35%: Firm has submitted COA of Diclofenac sodium MR pellets 35% (Batch No. RD0149-017) from M/s ALPHAMED FORMULATIONS PRIVATE LIMITED. COA (Batch No. RD0149-017)) from M/s The Searle Company Limited is also submitted. Omeprazole Delayed release pellets 20%w/w: Firm has submitted COA of Omeprazole Delayed release pellets 20%w/w (Batch No. 8000201-010.) from M/s ALPHAMED FORMULATIONS PRIVATE LIMITED. COA (Batch No. 8000201-010.)) from M/s The Searle Company Limited is also submitted
3.	Method used for analysis of API from both API Manufacturer & Finished Product manufacturer	Submitted
4.	Stability study data of API from API manufacturer	Diclofenac sodium MR pellets 35%: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 36 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches Omeprazole Delayed release pellets 20%w/w: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 36 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate No. L.Dis.No:93420/TS/2022 by M/s ALPHAMED FORMULATIONS PRIVATE LIMITED issued by Drugs Control Administration Government of Telangana. The certificate is valid till 15-08-2023. ..
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Diclofenac sodium pellets 35%: Firm has submitted import License dated 02-12-2019 confirming import of 5Kg Diclofenac sodium MR pellets 35% w/w from M/s ALPHAMED FORMULATIONS PRIVATE LIMITED for Batch # RD0149-017. Omeprazole Delayed release pellets 20%w/w Firm has submitted import License dated 02-12-2019 confirming import of 1.8Kg Omeprazole Delayed release pellets 20%w/w from M/s ALPHAMED FORMULATIONS PRIVATE LIMITED for Batch # 8000201-010.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	Since there is only encapsulation of pellets carried out at FPP mfg site, no additional excipients are required hence compatibility studies are not performed.

<table>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has manufactured three stability batches of Anzo D MR Capsule and has submitted copy of complete batch manufacturing. Details are as under:
<table>
<tr><td colspan="3">Anzo D MR Capsule (75mg+20mg)</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Date</td></tr>
<tr><td>20PD-271</td><td>2500 capsules</td><td>October 2020</td></tr>
<tr><td>20PD-272</td><td>2500 capsules</td><td>October 2020</td></tr>
<tr><td>20PD-273</td><td>2500 capsules</td><td>October 2020</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>Firm has submitted Comparative dissolution study of their product against Aristo 75/20 capsule :
<table>
<tr><td>Feature</td><td>Reference product</td><td>Product of M/s The Searle Company</td></tr>
<tr><td>Brand name</td><td>Aristo capsule 75mg + 20mg</td><td>Anzo D MR capsule</td></tr>
<tr><td>Batch No.</td><td>1394180100</td><td>20PD-271</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:

1. pH 1.2 HCl buffer (omeprazole)
2. pH 4.5 Acetate buffer (diclofenac sodium)
3. pH 6.8 Phosphate buffer (both API)
4. purified water (diclofenac sodium)

on the basis of similarity factor (f2) result i.e NLT 50 of dissolution profile of both API in test product and reference product, both products are similar.</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers.</td></tr>
<tr><td colspan="3">Remarks of Evaluator:</td></tr>
<tr><td colspan="3">Permission/approval for manufacturing omeprazole delayed release pellets from relevant DCA.
Analytical Method Validation studies to be submitted by the firm.
Justify selection of Aristo 75/20 capsule for conducting comparative dissolution profile. Give details of aforementioned brand i.e manufacturer, approval status etc
Whether omeprazole pellets are tested in acetate medium or not, its not clear in profile. Clarify the results/release profile of each API tested in different mediums and conclude results accordingly, in CDP report
Innovator (EMA approved) product is Each modified release capsule contains 75 mg diclofenac sodium (25 mg as gastro resistant pellets and 50 mg as prolonged release pellets) and 20 mg of omeprazole (gastro-resistant pellets) however MR pellets of diclofenac sodium used by the firm has to be clarified in this regard.
Method of analytical testing to be submitted from pellets manufacturer.
Drug excipient computability (carried out by pellets manufacturer) to be submitted.</td></tr>
</table>

Justification to be provided for selection of acceptance criteria of dissolution (Q value, dissolution time, sampling time and medium etc)

Firm has submitted reply against above mentioned shortcomings (dated 08.11.2022) which is found unsatisfactory.

Decision: Registration Board deferred the application for above mentioned shortcomings.

Sr.#	Observation	Reply	Remarks
	Permission/approval for manufacturing omeprazole delayed release pellets from relevant DCA.	Firm has submitted copy of GMP certificate No. L.Dis.No. 4073/stores/2020 to M/s ALPHAMED FORMULATIONS PRIVATE LIMITED dated 20.11.2020 issued by Drugs Control Administration Government of Telangana. The certificate is valid till 20-11-2023.	Complied
	Analytical Method Validation studies to be submitted by the firm.	submitted	Complied
	Justify selection of Aristo 75/20 capsule for conducting comparative dissolution profile. Give details of aforementioned brand i.e manufacturer, approval status etc	Aristo 75/20 capsule is enlisted in Nationally Authorized Medicinal Product by EMA , member state where product is authorized is Germany (DE).	Complied
	Whether omeprazole pellets are tested in acetate medium or not, its not clear in profile. Clarify the results/release profile of each API tested in different mediums and conclude results accordingly, in CDP report	We have performed CDP in guidance of WHO technical report series No 992, 2015 as follows: "for delayed-release product dissolution test in acid medium (pH 1.2) for 2 hours followed by dissolution in pH 6.8. Regarding CDP of MR diclofenac sodium pellets, firm clarified that due to enteric coated and prolonged release nature of pellets there is no significant release in Ph 1.2 therefore they used purified water instead fas per WHO technical report series No 992, 2015 as under: "Water may be considered as an additional medium, especially when the API is unstable in the buffered media to the extent that the data are unusable."	Complied

	Innovator (EMA approved) product is Each modified release capsule contains 75 mg diclofenac sodium (25 mg as gastro resistant pellets and 50 mg as prolonged release pellets) and 20 mg of omeprazole (gastro-resistant pellets) however MR pellets of diclofenac sodium used by the firm has to be clarified in this regard.	MR pellets of diclofenac sodium used by the firm are same as innovator product i.e: Each modified release capsule contains 75 mg diclofenac sodium (25 mg as gastro resistant pellets and 50 mg as prolonged release pellets)	Complied
	Method of analytical testing to be submitted from pellets manufacturer.	Submitted	Complied
	Drug excipient computability (carried out by pellets manufacturer) to be submitted.	Drug excipient computability studies submitted for both pellets (Diclofenac sodium and omeprazole) from pellets manufacturer	Complied
	Justification to be provided for selection of acceptance criteria of dissolution (Q value, dissolution time, sampling time and medium etc)	As described below	Complied

Reply:

This is in reference to query regarding "Justification to be provided for selection of acceptance criteria of dissolution (Q value, dissolution time, Sampling time and medium etc.,".

As the product is not available in any pharmacopoeia that is why We, The Searle Company Limited combine the both monographs available for different pellets i.e. Diclofenac delayed released pellets and Diclofenac Extended released pellets and design a criteria to make assure that the dissolution criteria should be able to quantify the release of delayed released pellets along with the prolong released pellets simultaneously. For further elaboration please find below the details in the table;

Time	Delayed Released Pellets (i.e., 25mg)	Extended Released Pellets (i.e., 50mg)	Total (Delayed Released Pellets + Extended Released Pellets) (i.e., 75mg)	Proposed Limit
1 Hr	75% (Q) of 25mg = 18.75mg	Minimum 10% of 50mg = 5mg	23.75 mg of 75mg = 31.6%	NLT 25%
5 Hr	75% (Q) of 25mg = 18.75mg	55% of 50mg = 27.5mg	46.25mg of 75mg = 61%	60%±10% i.e.(50 – 70)%

Time	Delayed Released Pellets (i.e., 25mg)	Extended Released Pellets (i.e., 50mg)	Total (Delayed Released Pellets + Extended Released Pellets) (i.e., 75mg)	Proposed Limit
10 Hr	75% (Q) of 25mg = 18.75mg	75% of 50mg = 37.5mg	56.25mg of 75mg = 75%	75%±10% (65 – 85)%
16 Hr	75% (Q) of 25mg = 18.75mg	85% of 50mg = 42.5mg	61.25mg of 75mg = 81%	NLT 75%
24 Hr	75% (Q) of 25mg = 18.75mg	-	-	NLT 80%

Decision: Deferred for following:

- **Review of applied formulation against the innovator product for clarification regarding the Diclofenac sodium pellets, whether both modified and delayed release pellets were used or only modified release pellets.**
- **Justification for the applied pharmacological group.**

Deferred case of 322nd meeting:

608.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale

		☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 23665 DRAP (R&I) dated 22/08/2022
	Details of fee submitted	PKR 30,000/-: dated 22/06/2022
	The proposed proprietary name / brand name	Esonyp 20/375mg DR Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each modified release tablet contains: Esomeprazole (as magnesium trihydrate) as IR ……. 20mg Naproxen as enteric coated core ……. 375mg
	Pharmaceutical form of applied drug	White to Off White color Naproxen oblong shape enteric coated tablet over film coated Esomeprazole tablets.
	Pharmacotherapeutic Group of (API)	Esomeprazole: Proton Pump Inhibitors Naproxen: Anti-inflammatory and antirheumatic products, non-steroids. Propionic acid derivatives.
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	3x10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Vimovo delayed release tablet 20/375mg USFDA
	For generic drugs (me-too status)	Glomov 20/375mg tablet by M/s Global Pharmaceutical (Pakistan) Reg No 109338
	GMP status of the Finished product manufacturer	GMP inspection conducted on 10/12/2020 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Esomeprazole: Metrochem API Private Ltd. India flat No 302, Bhanu Enclave , Sunder Nagar, Erragada, Hyderabad , India. Naproxen: Divis laboratories Limited India 1-72/23(P)/DIVIS/303, Divi towers, cyber hills, Gachibowli, Hyderabad-500 032, Telangana, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Esomeprazole The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, specifications, analytical procedures and justification of specification, reference standard, container closure system and stability studies of drug substance

		Analytical verification studies not provide by both DS and FPP manufacturer. CoA of relevant batch of DS to be provided by FPP manufacturer Naproxen The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, specifications. CoA from both DS and FPP manufacturer is not provided Analytical verification studies not provide by both DS and FPP manufacturer.
	Stability studies	Esomeprazole Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (ESM M-089, ESM M-092 and ESM-M-091.) Naproxen Not provided
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has not been performed CDP has been performed against the same brand that is Glomov 20/375mg tablet Batch No 21G111 by Global Pharmaceutical (Pakistan), Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8). Naproxen: Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API (Esomeprazole)	Metrochem API Private Ltd. India
API Lot No. (Esomeprazole)	Not provided
Manufacturer of API (Naproxen)	Divis laboratories Limited India
API Lot No. (Naproxen)	Not provided

Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	Esonyp 20/375mg DR Tablet		
Batch No.	EN-01	EN-02	EN-03
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	06-08-2021	06-08-2021	06-08-2021
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Summary data sheet to be provided
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Evaluator

Sr.#	Observation	Reply
	Approval of Drug Substance/Drug Manufacturing License (DML)/Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin to be provided (for both Esomeprazole and Naproxen)	Firm has submitted copy of GMP certificate of Metrochem API Private Ltd. India No L.Dis.No 4084/A3/2019 dated 20.05.2020 Valid till three years GMP certificate of Divis laboratories Limited India No L.Dis.No 816/DCA/AP/2018 dated 24.07.2018

		Valid till three years
2.	Characterization, Elucidation of Structure and other Characteristics of Naproxen to be provided.	As naproxen is officially recognized and available in USP hence this section is not required. Drug substance (APIs) that are described in an officially recognized pharmacopoeia it is generally sufficient to provide copies of the IR spectrum. Same to be provided by the firm.
3.	Detailed analytical procedures for the testing of drug substance to be provided by both Drug Substance and Drug Product manufacturer	Not complied Firm has submitted analytical procedure of testing finished product rather than drug substance moreover only brief assay methods for both drug substances are submitted from DS manufacturer.
4.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non compendial drug substance(s) to be provided	complied
5.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	Not complied Later on firm has submitted CoA of relevant batch by Drug Product manufacturer and Drug Substance manufacturer, also documents regarding procurement of relevant batch of Drug Substances.
6.	COA of primary / secondary reference standard for Naproxen including source and lot number to be provided.	Not complied Later on firm has submitted CoA of primary / secondary reference standard for Naproxen including source and lot number.
7.	For testing of Pharmacopeial Drug Substance, the use of primary reference standard is recommended, justify use of working standard for Esomeprazole magnesium	We have used working standard from Drug substances manufacturer which is qualified against primary standard.
8.	Stability data of Naproxen to be provided.	Firm has submitted stability data of naproxen as follows: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (2-M5L003, 2-M5L004 and 2M5L005)
9.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product	Not complied Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all

		quality parameters while firm has submitted comparison of assay only. Furthermore selection of following mediums in CDP to be justified Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8). Naproxen: Phosphate Buffer (pH 6.8).
10.	The dissolution of naproxen was evaluated in two different pH media, pH 1.2 and 6.8 and dissolution of Esomeprazole has been performed at pH medium 7.4. Justify dissolution parameters adopted by firm.	Firm has selected dissolution parameters as per USFDA dissolution method database.
11.	Uniformity of dose and microbial attributes are not provided in finished product specification	Firm has provided Uniformity of dose and microbial attributes for 3 batches EN-01, EN-02 and EN-03.
12.	Provide summary data sheets for all 3 batches. EN-01, EN-02. EN-03	Complied.
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product and Record of Digital data logger for temperature and humidity monitoring of stability chambers to be provided.	We use water HPLC (USA made) with Empower2 software which is not 21CFR compliant. Manual record of temp and humidity control maintained in log book will be presented at the time of inspection.
14.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Wnsodex 60mg and 30mg DDR capsule (dexlansoprazole) on 1st September, 2020. Further, the said panel inspection report was discussed in 297th Drug Registration Board meeting. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Related manufacturing area, equipment, personnel and Related manufacturing area, equipment, personnel and utilities are GMP compliant.
Decision of 322nd meeting : Deferred for following observations:		

• Valid GMP certificate of Drug Substance manufacturer i.e M/s Divis laboratories Limited India.
• Details of analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer including characterization for Naproxen.
• Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters. Furthermore, selection of mediums in CDP studies has be justified

Updated status:

S.No	Observation	Reply	Remarks
	Valid GMP certificate of Drug Substance manufacturer i.e M/s Divis laboratories Limited India.	Firm provided GMP certificate of Divis laboratories Limited India No L.Dis.No HMF07-14051/927/2021/ TECH/DCA Inspection dated 16.02.2021 to 17.02.2021 Valid till three years issued by DCA Andhra Pradesh	Complied
	Details of analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer including characterization for Naproxen	Detailed analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer is submitted IR spectrum of Naproxen is provided	Complied
	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters. Furthermore, selection of mediums in CDP studies has to be justified	Pharmaceutical equivalence has been performed against the same brand that is Glomov 20/375mg tablet Batch No 21G111 by Global Pharmaceutical (Pakistan), quality parameters such as description, DT, Dissolution, assay.	**Selection of following mediums in CDP yet to be justified** **Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8).** **Naproxen: Only Phosphate Buffer (pH 6.8).**
As per PAR (Vimovo) more than 80% Esomeprazole is degraded in acidic medium hence there is no need to study dissolution in acidic medium however			

Naproxen being enteric coated it does not release in pH 4.5 and below so mediums used for CDP are: pH 4.5, pH 6.8 and pH 7.4
Decision: Approved. Registration letter will be issued upon submission of CDP studies against the innovator/reference product as per guidelines applicable for applied dosage form. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

609.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24965 DRAP (R&I) dated 02/09/2022
	Details of fee submitted	PKR 30,000/-: dated 22/06/2022
	The proposed proprietary name / brand name	Esonyp 20/500mg DR Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each modified release tablet contains: Esomeprazole (as magnesium trihydrate) as IR…….20mg Naproxen as enteric coated core …….500mg
	Pharmaceutical form of applied drug	White to Off White color Naproxen oblong shape enteric coated tablet over film coated Esomeprazole tablets.
	Pharmacotherapeutic Group of (API)	Esomeprazole: Proton Pump Inhibitors Naproxen: Anti-inflammatory and antirheumatic products, non-steroids. Propionic acid derivatives.
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	3x10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Vimovo delayed release tablet 20/500mg USFDA

	For generic drugs (me-too status)	Glomov 20/500mg tablet by M/s Global Pharmaceutical (Pakistan) Reg No 109338
	GMP status of the Finished product manufacturer	GMP inspection conducted on 10/12/2020 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Esomeprazole: Metrochem API Private Ltd. India flat No 302, Bhanu Enclave , Sunder Nagar, Erragada, Hyderabad , India. Naproxen: Divis laboratories Limited India 1-72/23(P)/DIVIS/303, Divi towers, cyber hills, Gachibowli, Hyderabad-500 032, Telangana, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Esomeprazole The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form,specifications, analytical procedures and justification of specification, reference standard, container closure system and stability studies of drug substance Analytical verification studies not provide by both DS and FPP manufacturer. CoA of relevant batch of DS to be provided by FPP manufacturer Naproxen The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, specifications. CoA from both DS and FPP manufacturer is not provided Analytical verification studies not provide by both DS and FPP manufacturer.
	Stability studies	Esomeprazole Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (ESM M-089, ESM M-092 and ESM-M-091.) Naproxen Not provided
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure

		(including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has not been performed CDP has been performed against the same brand that is Glomov 20/500mg tablet Batch No 21G115 by Global Pharmaceutical (Pakistan), Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8). Naproxen: Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API (Esomeprazole)	Metrochem API Private Ltd. India		
API Lot No. (Esomeprazole)	Not provided		
Manufacturer of API (Naproxen)	Divis laboratories Limited India		
API Lot No. (Naproxen)	Not provided		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	Esonyp 20/500mg DR Tablet		
Batch No.	EN-04	EN-05	EN-06
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	11-08-2021	11-08-2021	11-08-2021
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.

	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Inadequate
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Evaluator:

Sr.#	Observations	Reply
1.	Approval of Drug Substance/Drug Manufacturing License (DML)/Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin to be provided (for both Esomeprazole and Naproxen)	Firm has submitted copy of GMP certificate of Metrochem API Private Ltd. India No L.Dis.No 4084/A3/2019 dated 20.05.2020 Valid till three years GMP certificate of Divis laboratories Limited India No L.Dis.No 816/DCA/AP/2018 dated 24.07.2018 Valid till three years
2.	Characterization, Elucidation of Structure and other Characteristics of Naproxen to be provided.	As naproxen is officially recognized and available in USP hence this section is not required. Drug substance (APIs) that are described in an officially recognized pharmacopoeia it is generally sufficient to provide copies of the IR spectrum. Same to be provided by the firm.
3.	Detailed analytical procedures for the testing of drug substance to be provided by both Drug Substance and Drug Product manufacturer	Not complied Firm has submitted analytical procedure of testing finished product rather than drug substance moreover only brief assay methods for both drug substances are submitted from DS manufacturer.
4.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product	complied

	manufacturer for both compendial as well as non compendial drug substance(s) to be provided	
5.	Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	Not complied Later on firm has submitted CoA of relevant batch by Drug Product manufacturer and Drug Substance manufacturer, also documents regarding procurement of relevant batch of Drug Substances.
6.	COA of primary / secondary reference standard for Naproxen including source and lot number to be provided.	Not complied Later on firm has submitted CoA of primary / secondary reference standard for Naproxen including source and lot number
7.	For testing of Pharmacopeial Drug Substance, the use of primary reference standard is recommended, justify use of working standard for Esomeprazole magnesium	We have used working standard from Drug substances manufacturer which is qualified against primary standard.
8.	Stability data of Naproxen to be provided.	Firm has submitted stability data of naproxen as follows: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (2-M5L003, 2-M5L004 and 2M5L005)
9.	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product	Not complied Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters while firm has submitted comparison of assay only.
10.	Similarity factor f2 has not been calculated and result has not been concluded accordingly	Not complied. Later on firm has submitted calculation of f2 (similarity factor). Furthermore, selection of following mediums in CDP to be justified Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8). Naproxen: Phosphate Buffer (pH 6.8).
10.	The dissolution of naproxen was evaluated in two different pH media, pH 1.2 and 6.8 and dissolution of Esomeprazole has been performed at pH medium 7.4. Justify dissolution parameters adopted by firm.	Firm has selected dissolution parameters as per USFDA dissolution method database.
11.	Uniformity of dose and microbial attributes are not provided in finished product specification	Firm has provided Uniformity of dose and microbial attributes for 3 batches EN-04, EN-05 and EN-06.

12.	Stability data particularly chromatograms , CoA and raw data sheets (both accelerated and real time) for batch No EN-06 is not provided for each time point	complied.
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product and Record of Digital data logger for temperature and humidity monitoring of stability chambers to be provided.	We use water HPLC (USA made) with Empower2 software which is not 21CFR compliant. Manual record of temp and humidity control maintained in log book will be presented at the time of inspection.
14.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Wnsodex 60mg and 30mg DDR capsule (dexlansoprazole) on 1st September, 2020. Further, the said panel inspection report was discussed in 297th Drug Registration Board meeting. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Related manufacturing area, equipment, personnel and utilities are GMP compliant.

Decision of 322nd meeting: Deferred for following observations:
• Valid GMP certificate of Drug Substance manufacturer i.e M/s Divis laboratories Limited India.
• Details of analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer including characterisation for Naproxen.
• Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters. Furthermore, selection of mediums in CDP shall be justified

S.No	Observation	Reply	Remarks
	Valid GMP certificate of Drug Substance manufacturer i.e M/s Divis laboratories Limited India.	Firm provided GMP certificate of Divis laboratories Limited India No L.Dis.No HMF07-14051/927/2021/ TECH/DCA Inspection dated 16.02.2021 to 17.02.2021 Valid till three years issued by DCA Andhra Pradesh	Complied
	Details of analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer including characterization for Naproxen	Detailed analytical procedures for the testing of drug substances by both Drug Substance and Drug Product manufacturer is submitted IR spectrum of Naproxen is provided	Complied
	Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters. Furthermore, selection of mediums in CDP studies has to be justified	Pharmaceutical equivalence has been performed against the same brand that is Glomov 20/375mg tablet Batch No Batch No 21G115 by Global Pharmaceutical (Pakistan), quality parameters such as description, DT, Dissolution, assay.	**Selection of following mediums in CDP yet to be justified** **Esomeprazole: In water, Acetate Buffer (pH 4.5) and Phosphate Buffer (pH 6.8).** **Naproxen: Only Phosphate Buffer (pH 6.8**).
As per PAR (Vimovo) more than 80% Esomeprazole is degraded in acidic medium hence there is no need to study dissolution in acidic medium however Naproxen being enteric coated it does not release in pH 4.5 and below so mediums used for CDP are: pH 4.5, pH 6.8 and pH 7.4			

Decision: Approved. Registration letter will be issued upon submission of CDP studies against the innovator/reference product as per guidelines applicable for applied dosage form.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Deferred case of 322nd meeting:

610.	Name, address of Applicant / Marketing Authorization Holder	M/s. SAMI Pharmaceuticals (Pvt.) Ltd. F-95, Off Hub River Road, S.I.T.E., Karachi – 75730, Pakistan
	Name, address of Manufacturing site.	M/s. SAMI Pharmaceuticals (Pvt.) Ltd. F-95, Off Hub River Road, S.I.T.E., Karachi – 75730, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 10233 dated 21/04/2022
	Details of fee submitted	PKR 75,000/-: dated 23/09/2021
	The proposed proprietary name / brand name	LAGITA DOUBLE ACTION Chewable Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Chewable Tablet contains: Sodium Alginate BP……250mg Sodium Bicarbonate BP…..106.5mg Calcium Carbonate BP…..187.5mg
	Pharmaceutical form of applied drug	One layer of the tablet is colored pink with a slightly mottled appearance, with the other layer being white, Flat, Circular, bilayer tablet with beveled edges
	Pharmacotherapeutic Group of (API)	Antacid
	Reference to Finished product specifications	Innovators Specs.
	Proposed Pack size	48's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Gaviscon Double Action Mint flavor Chewable Tablets by Reckitt Benckiser Healthcare (UK) Limited, MHRA Approved
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP Certificate issued date 28-08-2019 Tablet (General/General antibiotic) section is approved dated 22.06.2018
	Name and address of API manufacturer.	Sodium Alginate: QingDao Bright Moon Seaweed Group Co. Ltd NO.777, Mingyue Road, Huangdao District Qingdao China Sodium Bicarbonate:

		Solvay Peroxythai Limited 1, I-3A Road, Tambol Map Ta Phut, Amphur Muang, Rayong 21150, Thailand Calcium Carbonate: Sudeep Pharma Private Limited Plot No. 129/1/A, G.I.D.C., Estate, Nandesari - 391 340. Dist. Vadodara.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, characterization, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, characterization, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Sodium Alginate Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (H051708011, H051708013, H051708012) Sodium bicarbonate Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (MTP25417, MTP27317, MTP28017) Calcium Carbonate Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (17B/CP/030, 17B/CP/031, 17B/CP/032)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, pharmaceutical development, impurities, individual impurity and total impurity, specifications, analytical procedure

		and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product i.e. GAVISCON double Action Tablet by M/s. Reckitt Benckiser Healthcare (UK) Ltd. (batch no. 107801) by performing quality tests (Appearance, Average weight, Taste, Raft strength, Acid neutralizing capacity, Firability, Assay, Microbial Limit Test CDP not required here since formulation is antacid preparation which has non systemic use. .		
	Analytical method validation/verification of product	Method validation studies have been submitted including Linearity, Accuracy, and Precision including Repeatability & Intermediate Precision, Robustness and Specificity.		
STABILITY STUDY DATA				
Manufacturer of API		Sodium alginate: QingDao Bright Moon Seaweed Group Co. Ltd Sodium bicarbonate: Solvay Peroxythai Limited Calcium carbonate: Sudeep Pharma Private Limited		
API Lot No.		Sodium alginate: H052002087 Sodium bicarbonate: MTP01820 Calcium carbonate: 18C/CP/080		
Description of Pack (Container closure system)		Alu-PVC blister packed in unit carton		
Stability Storage Condition		Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 1, 2, 3, 4, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		Lab-04	Lab-05	Lab-06
Batch Size		2000 tab	2000 tab	2000 tab
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		18-02-2021	18-02-2021	18-02-2021
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted reference of last onsite panel inspection for instant dosage form conducted during last two years i.e. EMPOLI (Empagliflozin) 10mg & 25mg Tablets which was presented in 290th meeting of the registration board & hence approved & registered by registration board Date of inspection: 13th June 2019. The inspection report confirms following points • The HPLC software is 21CFR Compliant		

		• Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Sodium alginate: Copy of GMP certificate No. SD20180790 issued to Qingdao Bright moon Seaweed Group Co., Ltd valid till 23/10/2023. Sodium bicarbonate: Copy of GMP certificate No. 1-2-07-17-20-00013 issued to Solvay Peroxythai Limited valid till 25/08/2022 Calcium carbonate: Copy of GMP certificate No. 20051985 issued to Sudeep Pharma Private Limited valid till 17/05/2023
	Documents for the procurement of API with approval from DRAP (in case of import).	Sodium Alginate: Attached copy of commercial invoice (Invoice# BMM20080 dated 27th March 2020, with received quantity i.e. 5000Kgs) for the purchase of Sodium Alginate from Qingdao Bright Moon Seaweed Group Co. Ltd. with attestation of DRAP dated 19th May 2020 Sodium Bicarbonate: Attached copy of commercial invoice (with received quantity i.e. 24Kgs) for the purchase of Sodium Bicarbonate from Solvay Peroxythai Limited with courier slip dated 14th March 2020 Calcium Carbonate: Attached copy of commercial invoice (Invoice# SPPL/EX021/18-19 dated 17th April 2018, with received quantity i.e. 12 Kg for the purchase of Calcium Carbonate from Sundeep Pharma PrivateLimited with attestation of DRAP dated 30th April 2018
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with raw data sheets and summary data sheets. Chromatograms are not applicable since spectroscopic method are used for analysis of drugs.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of Assessor (AD PEC-XX):

Sr.#	Observation	Reply
	Good Manufacturing Practice (GMP) certificate of the Drug Substance / API (sodium	Copy of GMP certificate No. 1-2-07-17-20-00013 issued to Solvay Peroxythai

	bicarbonate) manufacturer with valid period of time.	Limited valid till 25/08/2022 is provided. Firm has submitted notification from Food and Drug Administration, Thailand Wherein it is stated that GMP certificate of manufacturer issued by FDA that expires before 31st Dec,2022 are considered valid till 31st Dec,2022 due to ongoing threat of COVI-19 pandemic.
	Updated GMP status of FPP manufacturer to be submitted.	Firm has submitted GMP certificate dated 03.08.2022 valid till 2 years.
	The information on tablet hardness and disintegration is not provided (as recommended by USFDA guidance document on quality attributes of chewable tablet). Justify it	Firm has submitted specification of hardness and disintegration as follows Disintegration time 35 min Hardness NLT 7Kp and NMT 15Kp While USFDA recommends that hardness for chewable tablets be kept low (<12 kp). A higher hardness value (>12 kp) may be considered if justified.
	Detailed analytical procedures used for testing the drug product should be provided.	Complied
	Documents for the procurement of API with approval from DRAP is required. Only commercial invoices are provided under this section.	Not complied. Firm has submitted commercial invoice (of sodium bicarbonate) only. Batch No/Lot No is not verifiable. Clearance from DRAP is also required for all three drug substances. Furthermore, CoA of relevant batch from DS manufacturer and FPP manufacturer is required for all three drug substances.
	CoA at each time interval is required in stability data.	Complied

Decision 322nd meeting: The Registration Board considered the case deferred the request for following observations:
Specification of hardness i.e NLT 7Kp and NMT 15Kp to be justified. Since USFDA recommends hardness for chewable tablets as <12 kp.
Commercial invoices and DRAP clearance certificate of all drug substances along with CoA of relevant batches (from both Drug Substance and Finished Product manufacturer).
Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin

S.No	Observation	Reply	Remarks
1.	Specification of hardness i.e NLT 7Kp and NMT 15Kp to be justified. Since USFDA recommends hardness for chewable tablets as <12 kp.	With reference to above FDA guideline, we comparatively analyze the hardness of SAMI product (Lagita Double Action Tablet) and Reference product (Gaviscon Double Action tablets), after exposure of 1ml with simulated salivary fluid for 30 seconds. Significant reduction observed in the Hardness of both SAMI (Lagita Double	Justified

		Action Tablet) and reference listed drug (Gaviscon Double Action Tablets, from 11.96 Kp to 8.52Kp and 11.6Kp to 8.7Kp respectively. And both products meeting the requirement of FDA guideline and higher value of Hardness (>12 Kp) is justified please see below the data of hardness before and after exposure with simulated salivary fluid for 30 seconds.	
2.	Commercial invoices and DRAP clearance certificate of all drug substances along with CoA of relevant batches (from both Drug Substance and Finished Product manufacturer).	Commercial invoices and DRAP clearance certificate of all drug substances is provided along with CoA of relevant batches: Sodium alginate: H052002087 Sodium bicarbonate: MTP01820 Calcium carbonate: 18C/CP/080 from both Drug Substance and Finished Product manufacturer	Commercial invoice of Sodium bicarbonate batch No MTP01820 (from Solvay Peroxythai Limited) is not DRAP attested. According to firm they are importing **Sodium bicarbonate,** free of cost.
3.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin	Copy of GMP certificate No. 1-2-07-17-20-00013 issued to Solvay Peroxythai Limited valid till 25/08/2022 is provided. Copy of GMP certificate No. 20051985 issued to Sudeep Pharma Private Limited valid till 17/05/2023 is provided. Copy of GMP certificate No. SD20180790 issued to Qingdao Bright Moon Seaweed Group Co. Ltd valid till 23/10/2023 is provided.	Complied

S.No.	HARDNESS OF SAMI PRODUCT LAGITA DOUBLE ACTION	HARDNESS OF SAMI PRODUCT LAGITA DOUBLE ACTION	HARDNESS OF INNOVATOR'S PRODUCT GAVISCON DOUBLE ACTION	HARDNESS OF INNOVATOR'S PRODUCT GAVISCON DOUBLE ACTION

	Chewable Tablets Before Exposure to salivary fluid (Kp)	Chewable Tablets After Exposure to salivary fluid (Kp)	Chewable Tablets Before Exposure to salivary fluid (Kp)	Chewable Tablets After Exposure to salivary fluid (Kp)
1	12.6	7.4	14.1	8.9
2	13.3	5.7	10.4	7.9
3	10.3	4.6	14.7	10.6
4	11.7	9.5	12	10.7
5	13.7	9.6	9.7	8.1
6	12.7	10	8.8	6.8
7	13.6	11.1	11.2	8.6
8	10.4	8.4	13.3	10.5
9	10.3	8.2	11.4	7.2
10	11	10.7	10.4	7.7
Average	11.96	8.52	11.6	8.7
Min	10.3	4.6	8.8	6.8
Max	13.7	11.1	14.7	10.7

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration Board further advised the firm to adopt formal procedure through approval from DRAP I&E for import of drug substance, in future.

Deferred case of 322nd meeting:

611.	Name, address of Applicant / Marketing Authorization Holder	M/s Caraway Pharmaceuticals, RCCI Rawat, Islamabad.
	Name, address of Manufacturing site.	M/s Caraway Pharmaceuticals, Plot 12, Street N-3 RCCI Rawat Islamabad
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27124 dated 20 /09/2022
	Details of fee submitted	PKR 30,000/-: dated 20/09/2022
	The proposed proprietary name / brand name	Licide Syrup 2.5mg/5mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5mL contains; Levocetirizine Dihydrochloride ……2.5mg

	Pharmaceutical form of applied drug	Syrup
	Pharmacotherapeutic Group of (API)	Anti-histaminic (Piperazine derivative)
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XYZAL oral solution 2.5/5mL USFDA Approved.
	For generic drugs (me-too status)	Concidol L Syrup by M/s Convell Laboratories Registration No. 079350
	GMP status of the Finished product manufacturer	Last inspection conducted on 22-02-2022 Syrup section approved on 04.07.2022
	Name and address of API manufacturer.	M/s Metrochem API Private Limited India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Levocetirizine Dihydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 25°C ± 2°C / 65% ± 5% RH for 60 months. Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches:(LCZ/A/200801001, LCZ/A/200801002,LCZ/A/200801003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is

		T-Day syrup by GSK Pakistan by performing quality tests (Physical Appearance, Identification pH, Volume & Assay).	
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.	
STABILITY STUDY DATA			
Manufacturer of API	M/s Metrochem API Private Limited India		
API Lot No.	LVHPC20280		
Description of Pack (Container closure system)	Amber color PET bottle (60ml) packed in unit carton (1's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-031	T-032	T-033
Batch Size	250 Bottles	250 Bottles	250 Bottles
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	04-08-2021	04-08-2021	04-08-2021
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. . L.Dis.No.HMF07-14051/305/2020-TECH-DCA Dated:18.08.2020 issued by Govt of Andhra Pradesh DCA valid up to three years	
	Documents for the procurement of API with approval from DRAP (in case of import).	Levocetirizine Dihydrochloride invoice no. DE/20/104 Dated:31.10.2020 is attached as proof of procurement of API (10Kg) Batch No LVHPC20280 from Metrochem API Pvt. Ltd India.	
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm has submitted Data of stability batches supported by attested respective documents like chromatograms, raw data sheets, COA, summary data sheets etc.	
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	

Remarks of Assessor:

Sr.#	Observation	Reply

	Formulation approved in RRA is mentioned as "oral solution" while dosage form mentioned by the firm in instant application is "syrup" hence dosage form should be standardized on line with RRA along with fee.	Firm has revised dosage form as per RRA (from syrup to oral solution) without fee.
	Stability data (real time) of Drug Substance has been submitted with 25°C ± 2°C / 65% ± 5% RH condition which is not as per WHO zone IV-A. Submit real time stability study data of drug substance as per zone IV-A or else submit the following as per the decision of 290th meeting of Registration Board: Record of data logger for the storage conditions throughout the transportation. Real term stability studies data of the product for at least 1 year along with degradation studies in the finished pharmaceutical product	Firm has submitted stability data of drug substance as per zone IV-A conditions as follows: Batch No: LVU-P/19001 LVU-P/19002 LVU-P/19003 40°C ± 2°C / 75% ± 5% RH for 36 months 30°C ± 2°C / 65% ± 5% RH for 36months
	Proposed container closure system (PET) suitability testing to be submitted as per pharmacopeia. Moreover, description is required regarding suitability of the container closure system for the storage, transportation (shipping) and use of the FPP (e.g. choice of materials, protection from moisture and light, compatibility of the materials with the FPP)	Firm has submitted suitability testing of PET bottle as per USP general monograph <661> Including thermal analysis, heavy metals testing and IR spectroscopic analysis.
	Documents for the procurement of API with approval from DRAP is required. Only commercial invoices are provided under this section.	Not complied Firm has again submitted invoice no. DE/20/104 Dated:31.10.2020 is attached as proof of procurement of API (10Kg) Batch No LVHPC20280 from Metrochem API Pvt. Ltd India. Approval from DRAP is required.
	For testing of Pharmacopeial Drug Substance, the use of primary reference standard is recommended, justify use of working standard for Levocetirizine Dihydrochloride.	Firm has submitted USP reference standard of Levocetirizine Dihydrochloride 200mg (lot No R170Q0) which is used in API testing and for batch release.
	Compatibility of the Drug Substance(s) with excipients is not provided (mainly alpha tocopherol and mannitol) which are not used in reference product.	Firm has submitted compatibility testing of alpha tocopherol and mannitol with drug substance using HPLC method. There was no significant change in % quantity of drug at storage condition 60°C ± 2°C
	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided
Decision 322nd meeting: Deferred for following observations:		

• DRAP clearance certificate of drug substance (Levocetirizine Dihydrochloride) along with commercial invoice, CoA (from both Drug Substance/Drug Product manufacturer) of relevant batch no. is required
• Submission of applicable fee that is Rs. 7,500/- for revision of dosage form (from syrup to oral solution) as per notification No.F.7-11/2021-B&A/DRAP dated 13-07- 2021

Updated status:

S. No	Observation	Reply	Remarks
1.	DRAP clearance certificate of drug substance (Levocetirizine Dihydrochloride) along with commercial invoice, CoA (from both Drug Substance/Drug Product manufacturer) of relevant batch no. is required	Firm submitted invoice no. DE/20/104 Dated:31.10.2020 is attached as proof of procurement of API (10Kg) Batch No LVHPC20280 from Metrochem API Pvt. Ltd India.and DRAP clearance dated 26.11.2020 Since applied dosage mentioned on DRAP clearance certificate was Tablet Firm clarified consumption of 10Kg Levocetirizine Dihydrochloride over the years 2021 to 2022. Out of 10Kg imported API, 8.75Kg was consumed for Licide tablet (250,000 tab) and 0.033Kg was consumed for Licide oral solution trial batches (250 bottles) in year 2021, yet 1.22 Kg quantity is left.	Justified
2.	Submission of applicable fee that is Rs. 7,500/- for revision of dosage form (from syrup to oral solution) as per notification No.F.7-11/2021-B&A/DRAP dated 13-07- 2021	Firm will submit fee of Rs 7,500/- before issuance of registration letter	

Firm will submit fee (Rs 7,500/-) for revision of dosage form (from syrup to oral solution) as per notification No.F.7-11/2021-B&A/DRAP dated 13-07- 2021before issuance of registration letter

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description to oral solution as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Deferred case of 322nd meeting:

612.	Name, address of Applicant / Marketing Authorization Holder	M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical

		Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22379 dated 05/08/2022
	Details of fee submitted	PKR 75,000/- dated 13/06/2022
	The proposed proprietary name / brand name	Venospa 10/100mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vonoprazan as Fumarate (outer immediate release layer)……..…10mg Aspirin (as enteric coated inner core) ……..…..100mg
	Pharmaceutical form of applied drug	White to off-white color Aspirin round shape enteric coated tablet surrounded by film coated Vonoprazan tablets.
	Pharmacotherapeutic Group of (API)	Vonoprazan: Potassium-Competitive Acid Blocker Aspirin: Antithrombotic Agents
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	3×10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Cabpirin 10/100mg tablet by M/s Takeda Pharmaceutical (Japan)
	For generic drugs (me-too status)	Not available
	GMP status of the Finished product manufacturer	GMP inspection conducted on 10/12/2020 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Vonoprazan: Guangdong Xianqiang Pharmaceutical Pvt Ltd, No. 6, industrial Avenue, Conghua, Economical Development zone, Guangzhou city, Guangdong province, China Aspirin JQC (HUAYIN) Pharmaceutical Co, Ltd/ Yuquan Road, Huayin city, Shanxi province, P.R of China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and

		justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted
	Module III (Drug Substance)	Vonoprazan and Aspirin: The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, batch analysis and justification of specification, container closure system and stability studies of drug substance
	Stability studies	Vonoprazan: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: TAK09R150701, TAK09R150702, TAK09R150703 Aspirin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: A201104081, A201104082 A201104083
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence not performed. CDP has been performed against Cabpirin 10/100mg tablet by Takeda Pharma (Japan), in Acid media (pH 1.0-1.2) acetate buffer (Ph 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range. Release profile of aspirin has not been compared.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	Guangdong Xianqiang Pharmaceutical China (vonoprazan) JQC (HUAYIN) Pharmaceutical Co, Ltd China (aspirin)	
API Lot No.	TAK09210101(vonoprazan) A2012041 (aspirin)	
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)	

Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Strength	10/100mg Tablet		
Batch No.	VA-01	VA-02	VA-03
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	07-01-2022	07-01-2022	07-01-2022
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Vonoprazan: Firm has submitted import License No. 00169/2021-DRAP CPS/650 dated 16-02-2021 confirming import of 200g VONOPRAZAN from M/s Guangdong Xianqiang Pharmaceutical Pvt Ltd, China for Batch No. TAK09R210101 Aspirin: Firm has submitted import License No. 00138/2021-DRAP 1PS/650 dated 10-02-2021 confirming import of 2Kg ASPIRIN from M/s JQC (HUAYIN) Pharmaceutical Co, Ltd China for Batch No. A2012041
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Inadequate
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks OF Evaluator:

Sr.#	Observation	Reply (dated 30.10.2022)
	Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance / API	Firm has submitted GMP certificate of M/s Guangdong Xianqiang Pharmaceutical Pvt Ltd, China

<table>
<tr><td></td><td>manufacturer issued by concerned regulatory authority of country of origin to be provided</td><td>(GD20150397) issued by China Food and Drug Administration valid till 06.09.2020

GMP certificate of M/s JQC (HUAYIN) Pharmaceutical Co, Ltd is not submitted</td></tr>
<tr><td></td><td>Detailed analytical procedures for the testing of drug substance Aspirin to be provided by both Drug Substance and Drug Product manufacturer</td><td>Complied</td></tr>
<tr><td></td><td>Provide results of analysis of relevant batch(es) of Drug Substance Aspirin performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture</td><td>Complied</td></tr>
<tr><td></td><td>Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non compendial drug substance(s) to be provided</td><td>Not complied

Analytical method verification studies submitted for vonoprazan fumarate only.</td></tr>
<tr><td></td><td>COA of primary / secondary reference standard for Vonoprazan Fumarate and Aspirin including source and lot number to be provided</td><td>Not complied</td></tr>
<tr><td></td><td>Dissolution medium used in USFDA approved formulation VOQUEZNA for evaluation of release profile of vonoprazan tablet was 0.05M acetate buffer (pH 4.5) with 50rpm while dissolution medium used by the firm is 0.1NHCl and 75 rpm. .Justification to be provided for selection of dissolution medium and rpm for USP type II apparatus.</td><td>To avoid dissolution of enteric coated core of aspirin 0.1NHCl is used to affect only vonoprazan in film coating and further to check the enteric coating. 75rpm is selected as per general guideline of dissolution given in BP 2022 and USP.

Not justified since release profile of aspirin has been monitored separately by using acid stage (0.1N HCl) and buffer stage (phosphate buffer) dissolution.</td></tr>
<tr><td></td><td>Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters of developed formulation against reference product</td><td>Not complied

Pharmaceutical equivalence to be established against innovator/reference product by comparing the results of all quality parameters while firm has submitted comparison of assay only.</td></tr>
<tr><td></td><td>CDP for Aspirin has not been performed. Moreover, batch no of innovator product has not been mentioned in CDP of Vonoprazan</td><td>CDP for Aspirin has been provided as per following details:
<table>
<tr><td>Feature</td><td>Reference product (Takeda pharma)</td><td>Product of M/s Wnsfeild</td></tr>
<tr><td>Brand name</td><td>Cabiprin 10/100mg tablet</td><td>Venospa 10/100mg tablet</td></tr>
<tr><td>Batch No.</td><td>521559</td><td>19PD-219</td></tr>
</table></td></tr>
</table>

		Comparative dissolution studies have been performed in following mediums: 1. pH 4.5 Acetate buffer 2. pH 6.8 Phosphate buffer The values for f1 and f2 are in the acceptable range. CDP has not been assessed in acid medium (Ph 1.2)
	Hardness, LOD and microbial attributes are not provided in finished product specification.	Hardness, LOD and microbial attributes are missed from finished product specification due to typographic error, now the firm has submitted results of aforementioned quality parameters.
	Stability data particularly chromatograms , CoA and raw data sheets (both accelerated and real time) is not provided for each time point (particularly 6th month for all 3 batches)	Complied
	There is a tendency for loss on drying to increase and hardness to decrease under high temperature and high humidity hence LOD and hardness test results to be submitted, performed during stability studies	Not complied
	Compliance Record of HPLC software 21CFR & audit trail reports on product and Record of Digital data logger for temperature and humidity monitoring of stability chambers to be	We use water HPLC (USA made) with Empower2 software which is not 21CFR compliant. Manual record of temp and humidity control maintained in log book will be presented at the time of inspection.
	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Wnsodex 60mg and 30mg DDR capsule (dexlansoprazole) on 1st September, 2020. Further, the said panel inspection report was discussed in 297th Drug Registration Board meeting. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Related manufacturing area, equipment, personnel and utilities are GMP compliant.

Decision: Deferred for submission of following:

• Pharmaceutical equivalence studies against the innovator/reference product by comparing the results of all quality parameters.

• Justification for selection of dissolution mediums in CDP studies, since CDP of Aspirin has not been performed in acidic medium of pH 1.2

• Justification for selection of dissolution medium for batch release test since already submitted justification of applying 0.1N HCl dissolution medium is not satisfactory.

• Complete method of analysis for dissolution test.
• Clarification of the formulation of innovator product, whether it is bilayer by way of compression or by way of active coating of Vonoprazan.
• Justification of the variation in chromatographic conditions mentioned in drug product analytical method and those reflected in the submitted HPLC chromatograms.
• Compliance Record of HPLC software 21CFR & audit trail reports on product and Record of Digital data logger for temperature and humidity monitoring of stability chambers.

Updated status:

S.No	Observation	Reply	Remarks
1.	Pharmaceutical equivalence studies against the innovator/reference product by comparing the results of all quality parameters	Pharmaceutical equivalence studies have been submitted as follows: Feature: Reference product (Takeda pharma) / Product of M/s Wnsfeild Brand name: Cabiprin 10/100mg tablet / Venospa 10/100mg tablet by comparing the results of all quality parameters such as description, dissolution. Assay etc	Complied
2.	Justification for selection of dissolution mediums in CDP studies, since CDP of Aspirin has not been performed in acidic medium of pH 1.2	Dissolution of Aspirin enteric coated core is performed in 0.1NHCl (pH 1.2) as routine test because in acid stage the release profile of aspirin is NMT 10%. CDP is performed in other media (acetate buffer pH 4.5 and phosphate buffer pH 6.8)	
3.	Justification for selection of dissolution medium for batch release test since already submitted justification of applying 0.1N HCl dissolution medium is not satisfactory.	Vonoprazan as immediate release dissolution is performed in 0.1N HCl. Dissolution parameters are selected as per USFDA guidance document for immediate release solid dosage form	Justified
4.	Provide complete method of analysis for dissolution test.	Complete method of analysis for dissolution test is provided for both aspirin and Vonoprazan	Complied
5.	Clarification of the formulation of innovator product, whether it is bilayer by way of compression or by way of active coating of Vonoprazan.	Formulation of Innovator product is bilayer by way of active coating of Vonoprazan on enteric coated Aspirin.	Complied
6.	Justification of the variation in chromatographic conditions mentioned in drug product analytical method and those reflected in the submitted HPLC chromatograms.	Analytical method of Drug Product applied throughout the stability is same without any variation which is reflected in chromatogram	Verified
7.	Compliance Record of HPLC software 21CFR &	Provided	Complied

	audit trail reports on product and Record of Digital data logger for temperature and humidity monitoring of stability chambers.		
Firm will submit unit carton of innovator product (Cabpirin 10/100mg tablet by Takeda pharma) against which CDP was performed.			

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Deferred case of 323rd meeting:

613.	Name, address of Applicant / Marketing Authorization Holder	M/s May and Bakers (Pvt) Ltd, 45 Km, Dina Nath Multan Road, Lahore
	Name, address of Manufacturing site.	M/s May and Bakers (Pvt) Ltd, 45 Km, Dina Nath Multan Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30774 (dated: 31-10-2022)
	Details of fee submitted	PKR 30,000/-: dated: 31-10-2022
	The proposed proprietary name / brand name	Myocin 500mg Dry Powder vial I.V
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains:

		Vancomycin Hydrochloride eq. to vancomycin …… 500 mg
	Pharmaceutical form of applied drug	Dry powder injection
	Pharmacotherapeutic Group of (API)	Antibacterial
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	Vancocin injection 500mg USFDA approved
	For generic drugs (me-too status)	Cinva 500mg IV injection by M/s CCl phamaceuticals, Lahore Reg No. 102464
	GMP status of the Finished product manufacturer	Firm has submitted approval letter for DML grant dated 29-04-2022
	Name and address of API manufacturer.	Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (HAS1507001, HAS1507002, HAS1507003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	The firm has submitted results of pharmaceutical equivalence for all the quality

		tests for their product as per specification and comparative study against the comparator product i.e. Vancomycin Dry powder vial 500mg by performing quality tests (appearance, volume after reconstitution, identification, Ph after reconstitution, filled volume color, water content, Assay on anhydrous basis, BET, sterility test).
	Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product including system suitability, specificity, accuracy, repeatability, intermediate precision, linearity, range & robustness.

STABILITY STUDY DATA			
Manufacturer of API	Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China		
API Lot No.	HAF 1912013		
Description of Pack (Container closure system)	Glass vial type I with one 10ml glass ampoule of WFI		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trail-01	Trail-02	Trail-03
Batch Size	1000 packs	1000 packs	1000 packs
Manufacturing Date	02 – 2022	02 – 2022	02 – 2022
Date of Initiation	28-02-2022	28-02-2022	28-02-2022
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Not applicable
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of commercial invoice FXIN2002021A dated 25-02-2020 wherein specifying the import of vancomycin hydrochloride (lyophilized) 30 Kg (batch no HAF 1912013) in the name of M/s Vision pharmaceuticals Islamabad, DRAP clearance certificate and license to import has also been issued in the name of M/s vision pharmaceuticals Islamabad
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has recently installed HPLC software 21CFR, in future stability studies shall be performed using HPLC software 21CFR.

	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.

Remarks of Evaluator:

Sr.#	Observation	Reply	Remarks
1.	Approval of Drug Substance/Drug Manufacturing License (DML)/Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin to be provided.	Firm has submitted GMP certificate No FJ200003 dated 22.09.2020 valid till 21.09.2022 issued by China Food and Drug Administration	Not complied Valid GMP certificate to be submitted
2.	Regulatory status of diluent (WFI) in Pakistan is required with details of manufacturer and Registration No.	Gee H20 (5ml) by M/s Gallop Water Sciences.	Not complied Registration No. not provided
3.	CoA from Drug Product manufacturer is not as per USP. The Assay limit as per USP (44) is ≥ 900ug/mg while assay limit mentioned in CoA of Drug product manufacturer is 90-115%. Clarify it	It was a drafting error updated CoA as per USP (44) is submitted.	Complied
4.	Detailed analytical procedures for the testing of drug substance to be provided by both Drug Substance and Drug Product manufacturer	Firm has submitted analytical testing method of Vancomycin HCl by Drug substance manufacturer only	Not complied
5.	In use stability data (reconstituted form) to be provided as per guidance document by EMA. (https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products en.pdf)	Not applicable as the product is immediately used after reconstitution	Not complied In use stability studies are required despite of the fact that formulation is intended to be used immediately after reconstitution
6.	Documents for the procurement of API (commercial invoice FXIN2002021A dated 25-02-2020, DRAP clearance certificate and license to import) has been issued in the name of M/s vision pharmaceuticals Islamabad. Clarify it.	We are borrowing the material from M/s Vision Pharma. The borrowing undertaking is submitted	Not complied Firm has submitted acknowledgement /loan letter from M/s Global pharma rather than M/s vision pharmaceuticals Islamabad.
7.	Proposed container closure system (Glass vial Type 1) suitability testing to be submitted as per pharmacopeia.	Product is as per innovator so suitability testing of Container closure system is not required	Not complied Quality testing of container closure system is required as per USP to

			assess whether container closure system meets proclaimed criteria i.e USP glass vial type I or not
8.	Details of manufacturer and batch no of comparator product has not been mentioned under pharmaceutical equivalence study. Also justify selection of that particular comparator product	Vancomycin 1g & 500mg By Getz pharma	Not complied Batch no of comparator products are not provided
9.	Compatibility studies of drug product with container closure system is not provided.	As the material is ready to fill hence compatibility studies with container closure has been performed by drug substance manufacturer	Not complied Compatibility of the container closure system with the FPP is required as under 2.3.P.2.4 and 3.2.P.2
10.	Calculation regarding potency adjustment (salt factor and assay result of drug substance) has not been provided in Batch formula/ master formula.	Updated batch formula/master formula wherein calculation regarding potency adjustment (salt factor and assay result of drug substance) is provided	Complied

Decision 323rd meeting: Deferred for submission of following:
Valid GMP certificate of Drug Substance manufacturer i.e Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China.
Registration status/ registration number of diluent i.e Gee H20 (5ml) water for injection by M/s Gallop Water Sciences.
Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer.
In use stability data (reconstituted form) to be provided as per guidance document by EMA.
Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad.
Suitability testing/Quality testing of Proposed container closure system (Glass vial Type 1) as per pharmacopeia
Batch no of comparator product vancomycin 500mg injection to be provided
Compatibility studies of drug product with container closure system is not provided as required under 2.3.P.2.4 and 3.2.P.2

S.No	Observation	Reply	Remarks
1	Valid GMP certificate of Drug Substance manufacturer i.e Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China	Firm has submitted copy of License No 20160089 dated valid till 21.09.2025 issued by China Food and Drug Administration	Complied
2	Registration status/ registration number of diluent i.e Gee H20 (5ml) water for injection by M/s Gallop Water Sciences.	Firm has submitted registration no. of diluent Gee H20 (5ml) water for injection by M/s Gallop Water Sciences as 076881	The provided registration status of diluent is not verifiable from available record Later on firm provided registration status of diluent as follows: Gee H20 (5ml) water for injection by M/s Gallop Water Sciences as 080476, which was verifiable from database.
3	Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer.	Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer is provided.	Complied
4	In use stability data (reconstituted form) to be provided as per guidance document by EMA.	Not applicable as the product is immediately used after reconstitution, furthermore it is a single dose vial.	Justified
5	Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad.	Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad is provided along with documents regarding import of API/DRAP clearance.	Complied
6	Suitability testing/Quality testing of Proposed container closure system (Glass vial Type 1) as per pharmacopeia	Quality testing of proposed container closure system as performed by supplier Shandong pharmaceutical Glass Co Ltd. Is provided	Complied
7.	Batch no of comparator product vancomycin 500mg injection to be provided	Vancomycin 500mg injection: Batch No: 320685XW Abbott pharma	Complied
8.	Compatibility studies of drug product with container closure system is not provided as required under 2.3.P.2.4 and 3.2.P.2	Applied formulation is as per innovator, which is found stable during stability studies hence Compatibility studies are not required	Justified
Firm will submit in use stability data (reconstituted form) before issuance of registration letter.			

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

614.	Name, address of Applicant / Marketing Authorization Holder	M/s May and Bakers (Pvt) Ltd, 45 Km, Dina Nath Multan Road, Lahore
	Name, address of Manufacturing site.	M/s May and Bakers (Pvt) Ltd, 45 Km, Dina Nath Multan Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30786 (dated: 31-10-2022)
	Details of fee submitted	PKR 30,000/-: dated: 31-10-2022
	The proposed proprietary name / brand name	Myocin 1g Dry Powder vial I.V
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Vancomycin Hydrochloride eq. to vancomycin …… 1g
	Pharmaceutical form of applied drug	Dry powder injection
	Pharmacotherapeutic Group of (API)	Antibacterial
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	Vancocin injection 1g USFDA approved
	For generic drugs (me-too status)	Cinva 1g IV injection by M/s CCl phamaceuticals, Lahore Reg No. 102465
	GMP status of the Finished product manufacturer	Firm has submitted approval letter for DML grant dated 29-04-2022
	Name and address of API manufacturer.	Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls,

		specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (HAS1507001, HAS1507002, HAS1507003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	The firm has submitted results of pharmaceutical equivalence for all the quality tests for their product as per specification and comparative study against the comparator product i.e. Vancomycin Dry powder vial 1g by performing quality tests (appearance, volume after reconstitution, identification, Ph after reconstitution, filled volume color, water content, Assay on anhydrous basis, BET, sterility test).
	Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product including system suitability, specificity, accuracy, repeatability, intermediate precision, linearity, range & robustness.

STABILITY STUDY DATA			
Manufacturer of API	Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China		
API Lot No.	HAF 1912013		
Description of Pack (Container closure system)	Glass vial type I with one 20ml glass ampoule of WFI		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trail-01	Trail-02	Trail-03
Batch Size	1000 packs	1000 packs	1000 packs
Manufacturing Date	03 – 2022	03 – 2022	03 – 2022
Date of Initiation	01-03-2022	01-03-2022	01-03-2022
No. of Batches	03		
Administrative Portion			

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not applicable
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of commercial invoice FXIN2002021A dated 25-02-2020 wherein specifying the import of vancomycin hydrochloride (lyophilized) 30 Kg (batch no HAF 1912013) in the name of M/s Vision pharmaceuticals Islamabad, DRAP clearance certificate and license to import has also been issued in the name of M/s vision pharmaceuticals Islamabad
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has recently installed HPLC software 21CFR, in future stability studies shall be performed using HPLC software 21CFR.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.

Remarks of Evaluator:

Sr.#	Observation	Reply	Remarks
1.	Approval of Drug Substance/Drug Manufacturing License (DML)/Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin to be provided.	Firm has submitted GMP certificate No FJ200003 dated 22.09.2020 valid till 21.09.2022 issued by China Food and Drug Administration	Not complied Valid GMP certificate to be submitted
2.	Regulatory status of diluent (WFI) in Pakistan is required with details of manufacturer and Registration No.	Gee H20 (5ml) by M/s Gallop Water Sciences.	Not complied Registration No. not provided
3.	CoA from Drug Product manufacturer is not as per USP. The Assay limit as per USP (44) is ≥ 900ug/mg while assay limit mentioned in CoA of Drug product manufacturer is 90-115%. Clarify it	It was a drafting error updated CoA as per USP (44) is submitted.	Complied
4.	Detailed analytical procedures for the testing of drug substance to be provided by both Drug Substance and Drug Product manufacturer	Firm has submitted analytical testing method of Vancomycin HCl by Drug substance manufacturer only	Not complied

5.	In use stability data (reconstituted form) to be provided as per guidance document by EMA. (https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products en.pdf)	Not applicable as the product is immediately used after reconstitution	Not complied In use stability studies are required despite of the fact that formulation is intended to be used immediately after reconstitution
6	Documents for the procurement of API (commercial invoice FXIN2002021A dated 25-02-2020, DRAP clearance certificate and license to import) has been issued in the name of M/s vision pharmaceuticals Islamabad. Clarify it.	We are borrowing the material from M/s Vision Pharma. The borrowing undertaking is submitted	Not complied Firm has submitted acknowledgement /loan letter from M/s Global pharma rather than M/s vision pharmaceuticals Islamabad.
7.	Proposed container closure system (Glass vial Type 1) suitability testing to be submitted as per pharmacopeia.	Product is as per innovator so suitability testing of Container closure system is not required	Not complied Quality testing of container closure system is required as per USP to assess whether container closure system meets proclaimed criteria i.e USP glass vial type I or not
8.	Details of manufacturer and batch no of comparator product has not been mentioned under pharmaceutical equivalence study. Also justify selection of that particular comparator product	Vancomycin 1g & 500mg By Getz pharma	Not complied Batch no of comparator products are not provided
9.	Compatibility studies of drug product with container closure system is not provided.	As the material is ready to fill hence compatibility studies with container closure has been performed by drug substance manufacturer	Not complied Compatibility of the container closure system with the FPP is required as under 2.3.P.2.4 and 3.2.P.2
10.	Calculation regarding potency adjustment (salt factor and assay result of drug substance) has not been provided in Batch formula/ master formula.	Updated batch formula/master formula wherein calculation regarding	Complied

		potency adjustment (salt factor and assay result of drug substance) is provided	

Decision 323rd meeting: Deferred for submission of following:
Valid GMP certificate of Drug Substance manufacturer i.e Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China.
Registration status/ registration number of diluent i.e Gee H20 (5ml) water for injection by M/s Gallop Water Sciences.
Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer.
In use stability data (reconstituted form) to be provided as per guidance document by EMA.
Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad.
Suitability testing/Quality testing of Proposed container closure system (Glass vial Type 1) as per pharmacopeia
Batch no of comparator product vancomycin 1g injection to be provided
Compatibility studies of drug product with container closure system is not provided as required under 2.3.P.2.4 and 3.2.P.2

S.No	Observation	Reply	Remarks
1	Valid GMP certificate of Drug Substance manufacturer i.e Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd China	Firm has submitted copy of License No 20160089 dated valid till 21.09.2025 issued by China Food and Drug Administration	Complied
2	Registration status/ registration number of diluent i.e Gee H20 (5ml) water for injection by M/s Gallop Water Sciences.	Firm has submitted registration no. of diluent Gee H20 (5ml) water for injection by M/s Gallop Water Sciences as 076881	Gee H20 (5ml) water for injection by M/s Gallop Water Sciences as 080476, which was verifiable from database.
3	Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer.	Detailed analytical procedures for the testing of drug substance by Drug Product manufacturer is provided.	Complied
4	In use stability data (reconstituted form) to be provided as per guidance document by EMA.	Not applicable as the product is immediately used after reconstitution, furthermore it is a single dose vial.	Justified
5	Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad.	Acknowledgement /loan letter from M/s Vision pharmaceuticals Islamabad is provided along with documents regarding import of API/DRAP clearance.	Complied
6	Suitability testing/Quality testing of Proposed container closure system (Glass vial Type 1) as per pharmacopeia	Quality testing of proposed container closure system as performed by supplier Shandong pharmaceutical Glass Co Ltd. Is provided	Complied
7.	Batch no of comparator product vancomycin 500mg injection to be provided	Vancomycin 1g injection: Batch No: 402685XV Abbott pharma	Complied

8.	Compatibility studies of drug product with container closure system is not provided as required under 2.3.P.2.4 and 3.2.P.2	Applied formulation is as per innovator, which is found stable during stability studies hence Compatibility studies are not required	Justified
Gee H20 (5ml) water for injection by M/s Gallop Water Sciences as 080476, which was verifiable from database.			

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

e) Cases evaluated by Dr. Sidra Khalid (AD PEC-VII):

Deferred case of 296th meeting:

615. Name and address of manufacturer / Applicant	M/s. Synchro Pharma, 77 Industrial Estate Kot Lakhpat, Lahore
Brand Name +Dosage Form + Strength	**Duset oral dispersible tablet 4 mg**
Diary No. Date of R& I & fee	Form-5 Dy.No 14073 dated 7-3-2019 Rs. 20,000 Dated 6-3-2019 (#0800704)
Composition	Each orodispersible Tablet Contains: Ondansetron as HCL Dihydrate…4mg
Pharmacological Group	Serotonin 5-HT3 receptor antagonist
Type of Form	Form-5
Finished Product Specification	USP
Pack Size & Demanded Price	As per SRO
Approval Status of Product in Reference Regulatory Authorities.	Zofran tablet of Novartis (MHRA)
Me-too Status	Zofran tablet of Glaxo lab (020667)
GMP status	Last GMP inspection Date: 12-6-2019 and 04-7-2019, with acceptable cGMP compliance
Remarks of the Evaluator.	The firm revised there form 5 and method of manufacturer from orodispersible Tablet Contains: Ondansetron as HCL Dihydrate…4mg to Each film coated Tablet Contains: Ondansetron as HCL Dihydrate…4mg which is according to the reference product with fee of 5000/- (#0800720) dated 11/8/2020

Decision 296th meeting: Deferred for consideration on its turn	
Now firm has requested to consider it by Registration Board.	
Full fee to be submitted for change of formulation from oro dispersible tablet to film coated tablet	
Decision of 324th meeting: Approved as per following label claim: **Each film coated Tablet Contains:** **Ondansetron as HCl dihydrate …… .4mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product description to film coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with latest GMP inspection report conducted within last three years, before issuance of registration letter.**	
616. Name and address of manufacturer / Applicant	M/s. Synchro Pharma, 77 Industrial Estate KotLakhpat, Lahore
Brand Name +Dosage Form + Strength	Duset oral dispersible tablet 8 mg
Diary No. Date of R& I & fee	Form-5 Dy. No 14073 dated 7-3-2019 Rs. 20,000 Dated 6-3-2019 (#0800705)
Composition	Each orodispersible Tablet Contains: Ondansetron as HCL Dihydrate…8mg
Pharmacological Group	Serotonin 5-HT3 receptor antagonist
Type of Form	Form-5
Finished Product Specification	USP
Pack Size & Demanded Price	As per SRO
Approval Status of Product in Reference Regulatory Authorities.	Zofran tablet of Novartis (MHRA)
Me-too Status	Zofran tablet of Glaxo lab (020668)
GMP status	Last GMP inspection Date: 12-6-2019 and 04-7-2019, with acceptable cGMP compliance
Remarks of the Evaluator.	The firm revised there form 5 and method of manufacturer from orodispersible Tablet Contains: Ondansetron as HCL Dihydrate… to Each film coated Tablet Contains: Ondansetron as HCL Dihydrate…which is according to the reference product with fee of 5000/- (#0800720) dated 11/8/2020
Decision 296th meeting: Deferred for consideration on its turn	
Now firm has requested to consider it by Registration Board.	
Full fee to be submitted for change of formulation from orodispersible tablet to film coated tablet.	
Decision of 324th meeting: Approved as per following label claim: **Each film coated Tablet Contains:** **Ondansetron as HCl dihydrate …… .8mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product description to film coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with latest GMP inspection report conducted within last three years, before issuance of registration letter.**	

ii) Following Cases were evaluated, found deficient and communicated by (AD PEC-VII), now firms have submitted replies:

617.	Name, address of Applicant / Marketing Authorization Holder	M/s Pharmasol (Pvt) Ltd., Plot No. 549, Sundar Industrial Estate, Raiwind Road, Lahore.
	Name, address of Manufacturing site.	M/s Pharmasol (Pvt) Ltd. , Plot No. 549, Sundar Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 34236 dated : 31-12-2021
	Details of fee submitted	PKR 30,000/-: dated : 19-06-2021
	The proposed proprietary name / brand name	Apixasol 2.5mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Apixaban……2.5mg
	Pharmaceutical form of applied drug	Round, white to Off-white color, film coated tablet, plain on both sides (Oral tablet)
	Pharmacotherapeutic Group of (API)	Antithrombotic agents, direct factor Xa inhibitors
	Reference to Finished product specifications	As per Innovator's Specifications
	Proposed Pack size	3×10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Eliquis 2.5mg film coated Tablet manufactured by Bristol-Myers Squibb-Pfizer UK, USFDA MHRA Approved .
	For generic drugs (me-too status)	Ixaban tablet 2.5mg by Martin Dow approved in meeting 295 Xaby 2.5mg tablet by M/S SAMI approved in meeting 296 Apixaget 2.5mg by Getz pharma
	GMP status of the Finished product manufacturer	GMP certificate granted on 26-8-20222
	Name and address of API manufacturer.	M/s Changzhou Pharmaceutical Factory No.518 Laodong East Road, Changzhou, Jiangsu Province 213018, P.R. China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Apixaban is non-compendial API. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, related

		substances, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 6 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (ZSAP171104, ZSAP171105, ZSAP171106)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, process validation protocol, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Eliquis 2.5mg tablet by Pfizer by performing CDP against Eliquis Batch No: DR5724 Exp Date: 05/2022 in three BCS media across the physiological pH range i.e. 0.1N HCl Media, 4.5 pH Buffer Media and 6.8 pH Buffer Media. The values are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have been submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Changzhou Pharmaceutical Factory No.518 Laodong East Road, Changzhou, Jiangsu Province 213018, P.R. China		
API Lot No.	ZSAP200504		
Description of Pack (Container closure system)	Alu-PVC blister packed in unit carton (3×10's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	AB-T-1	AB-T-2	AB-T-3
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	12-2020	12-2020	12-2020
Date of Initiation	20-12-2020	20-12-2020	20-12-2020
No. of Batches	03		
Administrative Portion			

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate Issued by People's Republic of China Validity August 27, 2022 is attached.
	Documents for the procurement of API with approval from DRAP (in case of import).	Following documents are attached: Commercial Invoice: GGMI20513002 AD Clearance by Lahore Office
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assessor:

S No	Observation	Reply	Remarks
	Control of drug substance	CoA from drug substance manufacturer along with analytical testing method and validation studies are Provided	The particle size of the drug substance was identified as a critical factor based on its influence on the dissolution of the tablets. https://www.ema.europa.eu/en/documents/assessment-report/eliquis-epar-public-assessment-report_en.pdf hence particle size determination (laser light scattering) has to be performed.
	Provide summarized tabulated results of verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer	Firm has submitted commitment for performing analytical validation studies of both Drug substance and Drug product before commercial manufacturing	Not complied
	Justify the dissolution specification NLT 80% (Q) after 45 minutes, since the USFDA Biopharmaceutics review document of the innovator product specifies dissolution specifications i.e.	Justified	The dissolution parameters adopted by EMA approved product i.e Apixaban by Accord were as follows: 80% dissolved in 45 minutes, 50 rpm in 0.1N HCl, pH 4.5 acetate buffer and phosphate buffer pH 6.8, and 75 rpm in phosphate buffer pH 6.8 phosphate buffer. https://www.ema.europa.eu/en/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf

	NLT (Q) in 30 minutes		
• Firm will submit analytical validation studies of both Drug substance and Drug Product before issuance of registration letter. • Firm will submit performance of particle size determination of Drug Substance (laser light scattering) before issuance of registration letter.			

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Firm shall submit following before issuance of registration letter:

- **Analytical validation studies for both drug substance and drug product manufacturer performed by the drug product manufacturer.**
- **Performance of particle size distribution of the drug substance by either drug substance manufacturer or drug product manufacturer.**

618.	Name, address of Applicant / Marketing Authorization Holder	M/s Pharmasol (Pvt) Ltd., Plot No. 549, Sundar Industrial Estate, Raiwind Road, Lahore.
	Name, address of Manufacturing site.	M/s Pharmasol (Pvt) Ltd., Plot No. 549, Sundar Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. dated:31-12-2021
	Details of fee submitted	PKR 30,000/-: dated :19-06-2021
	The proposed proprietary name / brand name	Apixasol 5mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Apixaban……5mg
	Pharmaceutical form of applied drug	Round, white to Off-white color, film coated tablet, plain on both sides (Oral tablet)
	Pharmacotherapeutic Group of (API)	Antithrombotic agents, direct factor Xa inhibitors
	Reference to Finished product specifications	As per Innovator's Specifications
	Proposed Pack size	3×10's

	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Eliquis 5mg film coated Tablet manufactured by Bristol-Myers Squibb-Pfizer UK, USFDA MHRA Approved.
	For generic drugs (me-too status)	Ixaban tablet 5mg by Martin Dow approved in meeting 295 Xaby 5mg tablet by M/S SAMI approved in meeting 296 Apixaget 5mg by Getz pharma
	GMP status of the Finished product manufacturer	GMP certificate granted on 26-8-20222
	Name and address of API manufacturer.	M/s Changzhou Pharmaceutical Factory No.518 Laodong East Road, Changzhou, Jiangsu Province 213018, P.R. China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Apixaban is non-compendial API. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, related substances, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 6 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (RT-T1, RT-T2, RT-T3)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, process validation protocol, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Eliquis 5mg tablet by Pfizer by performing

		CDP against Eliquis Batch No: DR5724 Exp Date: 02/2023 in three BCS media across the physiological pH range i.e. 0.1N HCl Media, 4.5 pH Buffer Media and 6.8 pH Buffer Media. The values are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have been submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA				
Manufacturer of API		M/s Changzhou Pharmaceutical Factory No.518 Laodong East Road, Changzhou, Jiangsu Province 213018, P.R. China		
API Lot No.		ZSAP200504		
Description of Pack (Container closure system)		Alu-PVC blister packed in unit carton (3×10's)		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		RT-T1	RT-T2	RT-T3
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		12-2020	12-2020	12-2020
Date of Initiation		20-12-2020	20-12-2020	20-12-2020
No. of Batches		03		
Administrative Portion				
1	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.		
2	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate Issued by People's Republic of China Validity August 27, 2022 is attached.		
3	Documents for the procurement of API with approval from DRAP (in case of import).	Following documents are attached: Commercial Invoice: GGMI20513002 AD Clearance by Lahore Office		
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
5	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted		
6	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted		
Remarks of Assessor:				

S No	Observation	Reply	Remarks
1	Control of drug substance	CoA from drug substance manufacturer along with analytical testing method and validation studies are Provided	The particle size of the drug substance was identified as a critical factor based on its influence on the dissolution of the tablets. https://www.ema.europa.eu/en/documents/assessment-report/eliquis-epar-public-assessment-report_en.pdf hence particle size determination (laser light scattering) has to be performed.
2	Provide summarized tabulated results of verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer	Firm has submitted commitment for performing analytical validation studies of both Drug substance and Drug product before commercial manufacturing	Not Complied
3	Justify the dissolution specification NLT 80% (Q) after 45 minutes, since the USFDA Biopharmaceutics review document of the innovator product specifies dissolution specifications i.e. NLT (Q) in 30 minutes	Justified	The dissolution parameters adopted by EMA approved product i.e Apixaban by Accord were as follows: 80% dissolved in 45 minutes, 50 rpm in 0.1N HCl, pH 4.5 acetate buffer and phosphate buffer pH 6.8, and 75 rpm in phosphate buffer pH 6.8 phosphate buffer. https://www.ema.europa.eu/en/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf

- Firm will submit analytical validation studies of both Drug substance and Drug Product before issuance of registration letter.
- Firm will submit performance of particle size determination of Drug Substance (laser light scattering) before issuance of registration letter.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Firm shall submit following before issuance of registration letter:

- **Analytical validation studies for both drug substance and drug product manufacturer performed by the drug product manufacturer.**
- **Performance of particle size distribution of the drug substance by either drug substance manufacturer or drug product manufacturer.**

619.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories (Pvt) Limited Plot # 124/1 - Industrial Estate Kot Lakhpat Lahore Pakistan.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories (Pvt) Limited Plot # 124/1 - Industrial Estate Kot Lakhpat Lahore Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 31236 dated 12/11/2021
	Details of fee submitted	PKR 30,000/- dated 21/05/2021
	The proposed proprietary name / brand name	**Oxeto 2.5mg Film Coated Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Apixaban ...……. 2.5mg
	Pharmaceutical form of applied drug	Yellow, Round, biconvex Film Coated Tablets
	Pharmacotherapeutic Group of (API)	Anti-Coagulant
	Reference to Finished product specifications	Manufacturer specification
	Proposed Pack size	2×7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Eliquis 2.5mg Tablet by M/s BRISTOL MYERS SQUIBB, USFDA Approved.
	For generic drugs (me-too status)	Apixaget 2.5 mg Tablet by M/s Getz Pharma, Karachi.
	GMP status of the Finished product manufacturer	GMP inspection dated 13-9-22 concludes good level of GMP compliance.
	Name and address of API manufacturer.	M/s Jiangxi Synergy Pharmaceutical Co., Ltd. Jiangxi Fengxin Industrial Park, Jiangxi Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30ºC ± 2ºC; 65% ± 5% RH for 24 months Accelerated: 40ºC ± 2ºC; 75% ± 5% RH for 6 months Batches:(20180201Y, 20180202Y , 20180203Y)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Eliquis 2.5mg tablet by BRISTOL MYERS SQUIBB by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Eliquis 2.5mg tablet by BRISTOL MYERS SQUIBB in 0.1N HCl, Phosphate Buffer (pH 4.5), Sod. Phosphate Buffer with 0.05% SLS (pH 6.8). The values are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	M/s Jiangxi Synergy Pharmaceutical Co., Ltd. Jiangxi Fengxin Industrial Park, Jiangxi Province, China.
API Lot No.	20200301Y
Description of Pack (Container closure system)	2x7's Alu Alu blister pack
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T001	T002	T003
Batch Size	2000 Tablets	2000 Tablets	2000 Tablets
Manufacturing Date	07-2020	07-2020	07-2020
Date of Initiation	07-07-2020	07-07-2020	07-07-2020
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has also submitted a request to DRAP that as per decision of 312 DRB Meeting, they have submitted all the required documents mentioned in minutes. So, Firm requested to please interimly extend the exemption from onsite inspection to 05 years for all dosage forms on behalf of submitted required data and inspection done on 21st May 2019 and wherein the registration of that product was accorded in 292 DRB meeting.	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate No. 2020002 is issued by Jiangxi API Engineering Technology Research Centre. Valid till 11-03-2025.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Invoice HH-900-06-221 dated 05-06-2020 is submitted wherein the permission to import different APIs including Apixaban for the purpose of test/analysis and stability studies is granted vide No. 5601/2021-DRAP dated 14-04-2021.	
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.	
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.	

Remarks OF Evaluator:
Dissolution conditions of innovator as per Biopharmaceutics Review:
Apparatus: USP II
Spindle rotation: 75 rpm
Medium volume: 900ml
Temperature: 37oC
Medium: pH 6.8 phosphate buffer, 0.05% SLS
Acceptance criteria: NLT Q at 30 min
Inactive ingredients:
anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide

S No	Observations	Reply	Remarks

	Justify the dissolution specification NLT 80% (Q) after 45 minutes, since the USFDA Biopharmaceutics review document of the innovator product specifies dissolution specifications i.e. NLT (Q) in 30 minutes	The dissolution parameters adopted by EMA approved product i.e Apixaban by Accord were as follows: 80% dissolved in 45 minutes, 50 rpm in 0.1N HCl, pH 4.5 acetate buffer and phosphate buffer pH 6.8, and 75 rpm in phosphate buffer pH 6.8 phosphate buffer. https://www.ema.europa.eu/en/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf	Justified
	Summary of batch analyses release results of the drug product manufacturer for relevant batch needs to be submitted as per 2.3.S.4.4 (b).	CoA/Batch analysis results of batch No. 20200301Y is submitted by drug product manufacturer	Complied

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Firm shall submit following before issuance of registration letter:

- **Analytical validation studies for both drug substance and drug product manufacturer performed by the drug product manufacturer.**
- **Performance of particle size distribution of the drug substance by either drug substance manufacturer or drug product manufacturer.**

620.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories (Pvt) Limited Plot # 124/1 - Industrial Estate Kot Lakhpat Lahore Pakistan.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories (Pvt) Limited Plot # 124/1 - Industrial Estate Kot Lakhpat Lahore Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Form-5F Dy.No 31237 dated 12-11-2021

	Details of fee submitted	PKR 30,000/- dated 21/05/2021
	The proposed proprietary name / brand name	Apixa 5mg Film Coated Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Apixaban ...……. 5mg
	Pharmaceutical form of applied drug	Red, Round, biconvex Film Coated Tablets
	Pharmacotherapeutic Group of (API)	Anti-Coagulant
	Reference to Finished product specifications	M.S
	Proposed Pack size	2×7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Eliquis 5mg Tablet by M/s BRISTOL MYERS SQUIBB, USFDA Approved.
	For generic drugs (me-too status)	Apixaget 5 mg Tablet by M/s Getz Pharma, Karachi.
	GMP status of the Finished product manufacturer	GMP inspection dated 13-9-22 concludes good level of GMP compliance.
	Name and address of API manufacturer.	M/s Jiangxi Synergy Pharmaceutical Co., Ltd. Jiangxi Fengxin Industrial Park, Jiangxi Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30ºC ± 2ºC; 65% ± 5% RH for 24 months Accelerated: 40ºC ± 2ºC; 75% ± 5% RH for 6 months Batches:(20180201Y, 20180202Y , 20180203Y)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.

	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Eliquis 2.5mg tablet by BRISTOL MYERS SQUIBB by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Eliquis 2.5mg tablet by BRISTOL MYERS SQUIBB in 0.1N HCl, Phosphate Buffer (pH 4.5), Sod. Phosphate Buffer with 0.05% SLS (pH 6.8). The values are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Jiangxi Synergy Pharmaceutical Co., Ltd. Jiangxi Fengxin Industrial Park, Jiangxi Province, China.		
API Lot No.	20200301Y		
Description of Pack (Container closure system)	2x7's Alu Alu blister pack		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T001	T002	T003
Batch Size	2000 Tablets	2000 Tablets	2000 Tablets
Manufacturing Date	07-2020	07-2020	07-2020
Date of Initiation	12-07-2020	12-07-2020	12-07-2020
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has also submitted a request to DRAP that as per decision of 312 DRB Meeting, they have submitted all the required documents mentioned in minutes. So, Firm requested to please interimly extend the exemption from onsite inspection to 05 years for all dosage forms on behalf of submitted required data and inspection done on 21st May 2019 and wherein the registration of that product was accorded in 292 DRB meeting.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate No. 2020002 is issued by Jiangxi API Engineering Technology Research Center. Valid till 11-03-2025.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Invoice HH-900-06-221 dated 05-06-2020 is submitted wherein the permission to import different APIs including Apixaban for the purpose of test/analysis and stability studies is

		granted vide No. 5601/2021-DRAP dated 14-04-2021
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.

Remarks of Evaluator:
Dissolution conditions of innovator as per Biopharmaceutics Review:
Apparatus: USP II
Spindle rotation: 75 rpm
Medium volume: 900ml
Temperature: 37oC
Medium: pH 6.8 phosphate buffer, 0.05% SLS
Acceptance criteria: NLT Q at 30 min
Inactive ingredients:
anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide

S No	Observations	Reply	Remarks
	Justify the dissolution specification NLT 80% (Q) after 45 minutes, since the USFDA Biopharmaceutics review document of the innovator product specifies dissolution specifications i.e. NLT (Q) in 30 minutes	The dissolution parameters adopted by EMA approved product i.e Apixaban by Accord were as follows: 80% dissolved in 45 minutes, 50 rpm in 0.1N HCl, pH 4.5 acetate buffer and phosphate buffer pH 6.8, and 75 rpm in phosphate buffer pH 6.8 phosphate buffer. https://www.ema.europa.eu/en/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf	Justified
	Summary of batch analyses release results of the drug product manufacturer for relevant batch needs to be submitted as per 2.3.S.4.4 (b).	CoA/Batch analysis results of batch No. 20200301Y is submitted by drug product manufacturer	Complied

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Firm shall submit following before issuance of registration letter:

- **Analytical validation studies for both drug substance and drug product manufacturer performed by the drug product manufacturer.**
- **Performance of particle size distribution of the drug substance by either drug substance manufacturer or drug product manufacturer.**

Item No. 7: Agenda of Evaluator PEC-VI (Mr. Ishtiaq Shafiq)

CASE NO. 1 PRIORITY AS PER 257 MEETING OF REGISTRAION BOARD: (FOR NEW MOLECULES, ANTICANCER, ANTIVIRAL AND THALESEMIA)

621.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals(Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770.
	Name, address of Manufacturing site.	Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s CCL Pharmaceuticals(Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770 has GMP certificate based on evaluation conducted on 30-04-2019. M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan has GMP certificate based on evaluation conducted on 11-01-2019.
	Evidence of approval of manufacturing facility	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan has provided approval of DML renewal of following section : 1) Tablet (General), 2) Tablet (Hormonne) Section, 3)Liquid syrup(General), 4)Oral dry powder suspension (General),5) Capsule general section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 9919: 19-04-2022
	Details of fee submitted	PKR 75000/- 07-03-2021 (9033590590)
	The proposed proprietary name / brand name	**Barib 4 mg Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…4mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Janus Kinase (JAK) inhibitor(ATC code L04AA37)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7´s, 14 ´s,28´s

	Proposed unit price	As per innovator
	The status in reference regulatory authorities	Olumiant tablet 4 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 4 mg tablet , Eli Lilly, Pakistan (R.no. 110529) (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT20181001, BRCT20181002, BRCT20181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation Barib 4 mg tablet (batch no. T01) and Olumiant 4 mg tablet(Eli lilly) (B # D385031). Quality tests of both products including Dosage form, Description, Identification, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 4 mg tablet(Eli lilly) (B # D385031in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance.

		Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA

Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
API Lot No.	BRCT201801203
Description of Pack (Container closure system)	Alu-Alu Blister (2x10s) packed in printed unit carton, further packed in a master shipper.
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T01	T02	T03
Batch Size	1000 tablets	1000 tablets	1000 tablets
Manufacturing Date	05-2019	05-2019	05-2019
Date of Initiation	02-06-2019	02-06-2019	02-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided Manufacturing license, valid till 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Assistant Director, DRAP, Lahore attested invoice specifying import of 25.0 g of Baricitinib(Batch no. BRCT 20181203),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S. No.	Section	Observation	Response of the firm
1.	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	The address of drug substance manufacturer is same, but the online address has more details. The complete details of scope of license are present in GMP certificate that is issued by local authority, and Baricitinib is mentioned under scope of Inspection. *However, provided GMP certificate is not traceable.*

2.	1.3.5	Please provide GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)
3.	1.4.3	Justification required for contract manufacturing application. Whereas M/s. CCL Pharmaceuticals (Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770 has its own tablet section in light of S.R.O. 1347(I)/2021, dated 15th October, 2021. Please provide notarized copy of Contract Manufacturing Agreement in accordance with S.R.O. 1347(I)/2021, dated 15th October, 2021	CCL is already working on the development of many Drug products which are not available in the market of Pakistan, for the best of public interest. As Baricitinib was already developed by Dyson and they don't require the developmental studies for CCL's Registration application, CCL according to its mission of providing the quality health care products to the public and business strategy, opted for the contract manufacturing application from Dyson. Notarized copy of agreement is provided
4.	3.2.S.4.1	Justification required for not including heavy metals test in specification of drug substance of M/s Dyson Research Laboratories.Whereas Drug substance manufacturer CoA depicting this test.	We have revised the CoA (added heavy metals test) as per Drug substance manufacturer. However fee for revision of specification has not submitted.
5.	3.2.P.2	In comparative dissolution profile results are not in accordance with provided chromatograms and raw data sheets. Justification required.	In CDP report of Buffer 4.5, it was a typographic error, we have revised the results as per provided chromatograms.
6.	3.2.P.4	Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese Pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided. **Excipients of Human or Animal Origin** For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE. **Novel Excipients** For excipient(s) used for the first time in a drug product or by a new route of administration, full details of specification and testing method shall be provided.	All the excipients used in formulation are pharmacopoeial except Ponchue 4R lake color and New coat White. The Ponchue 4R lake color is present in EU list of permitted food colors under code E124. Copy of Specifications & Analytical procedure of Ponchue 4R lake color and New coat White is provided. The submission against this point is exempted. The in-house standard excipients are tested as per manufacturer guidelines and both complies with established specifications. None of the excipient is of Human or Animal origin. Not applicable as the product is generic formulation.
7.	3.2.P.6	Provided working standard batch no. BRCT WRS, is Valid up to 21-11-2019. Justification	We have standardized the available raw material (Baricitinib) against the provided WRS, and used it as

		required for onward testing of the product and drug substance.	secondary WS for onward testing of the product. *COA of secondary working standard not provided.*
8.	3.2.P.8	Justification required for record of Digital data logger for temperature and humidity monitoring of stability chambers indicating relative humidity and temperature out of specification (outlier).	The outlier for relative humidity and temperature in data logger data are due to take samples, or to add samples, or to change water reservoir, or to rearrange samples, etc.

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

See full prescribing information for complete boxed warning.

- **Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving OLUMIANT. (5.1)**
- **If a serious infection develops, interrupt OLUMIANT until the infection is controlled. (5.1)**
- **Prior to starting OLUMIANT, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting OLUMIANT. (5.1)**
- **Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. (5.1)**
- **Lymphoma and other malignancies have been observed in patients treated with OLUMIANT. (5.2)**
- **Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, some fatal, have occurred in patients treated with OLUMIANT. Patients with symptoms of thrombosis should be evaluated promptly. (5.3)**

Box warning of Olumiant tablet, USFDA.

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

622.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals(Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770
	Name, address of Manufacturing site.	Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s CCL Pharmaceuticals(Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770 has GMP certificate based on evaluation conducted on 30-04-2019. M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan has GMP certificate based on evaluation conducted on 11-01-2019.
	Evidence of approval of manufacturing facility	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan The firm has provided approval of DML renewal of following section : 1) Tablet (General), 2) Tablet (Hormonne) Section, 3)Liquid syrup(General), 4)Oral dry powder suspension (General),5) Capsule general section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 9918: 19-04-2022

	Details of fee submitted	PKR 75000/- 07-03-2021 (61675155499)
	The proposed proprietary name / brand name	Barib 2 mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…2mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7´s, 14 ´s,28´s
	Proposed unit price	As per innovator
	The status in reference regulatory authorities	Olumiant tablet 2 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 2 mg tablet , Eli Lilly, Pakistan (R.no. 110528) (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT20181001, BRCT20181002, BRCT20181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation Barib 2 mg tablet (batch no. T01) and Olumiant 2 mg tablet (Eli lilly) (B # D384977) Quality tests of both products including Dosage form, Description, Identification, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 4 mg tablet (Eli lilly) (B # D385031in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA

Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
API Lot No.	BRCT201801203
Description of Pack (Container closure system)	Alu-Alu Blister (2x10s) packed in printed unit carton, further packed in a master shipper.
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T01	T02	T03
Batch Size	1000 tablets	1000 tablets	1000 tablets
Manufacturing Date	05-2019	05-2019	05-2019
Date of Initiation	02-06-2019	02-06-2019	02-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of Manufacturing license issued state food and drug administration, China, with validity of 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Assistant Director, DRAP, Lahore attested invoice specifying import of 25.0 g of Baricitinib(Batch no. BRCT 20181203),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.

6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S. No.	Section	Observation	Response of the firm
1.	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	The address of drug substance manufacturer is same, but the online address has more details. The complete details of scope of license are present in GMP certificate that is issued by local authority, and Baricitinib is mentioned under scope of Inspection. *However, provided GMP certificate is not traceable.*
2.	1.3.5	Please provide GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)
3.	1.4.3	Justification required for contract manufacturing application. Whereas M/s. CCL Pharmaceuticals (Pvt.) Ltd., 62 Industrial Estate, Kot Lakhpat Lahore 54770 has its own tablet section in light of S.R.O. 1347(I)/2021, dated 15th October, 2021. Please provide notarized copy of Contract Manufacturing Agreement in accordance with S.R.O. 1347(I)/2021, dated 15th October, 2021	CCL is already working on the development of many Drug products which are not available in the market of Pakistan, for the best of public interest. As Baricitinib was already developed by Dyson and they don't require the developmental studies for CCL's Registration application, CCL according to its mission of providing the quality health care products to the public and business strategy, opted for the contract manufacturing application from Dyson. Notarized copy of agreement is provided
4.	3.2.S.4.1	Justification required for not including heavy metals test in specification of drug substance of M/s Dyson Research Laboratories.Whereas Drug substance manufacturer CoA depicting this test.	We have revised the CoA (added heavy metals test) as per Drug substance manufacturer. However fee for revision of specification has not submitted.
5.	3.2.P.2	In comparative dissolution profile results are not in accordance with provided chromatograms and raw data sheets. Justification required.	In CDP report of Buffer 4.5, it was a typographic error, we have revised the results as per provided chromatograms.
6.	3.2.P.4	Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese Pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided.	All the excipients used in formulation are pharmacopoeial except Ponchue 4R lake color and New coat White. The Ponchue 4R lake color is present in EU list of permitted food colors under code E124. Copy of Specifications & Analytical procedure of Ponchue 4R lake color and New coat White is provided. The submission against this point is exempted. The in-house standard excipients are tested as per manufacturer guidelines and both complies with established specifications.

		Excipients of Human or Animal Origin For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE. **Novel Excipients** For excipient(s) used for the first time in a drug product or by a new route of administration, full details of specification and testing method shall be provided.	None of the excipient is of Human or Animal origin. Not applicable as the product is generic formulation.
7.	3.2.P.6	Provided working standard batch no. BRCT WRS, is Valid up to 21-11-2019. Justification required for onward testing of the product and drug substance.	We have standardized the available raw material (Baricitinib) against the provided WRS, and used it as secondary WS for onward testing of the product. *COA of secondary working standard not provided.*
8.	3.2.P.8	Justification required for record of Digital data logger for temperature and humidity monitoring of stability chambers indicating relative humidity and temperature out of specification (outlier).	The outlier for relative humidity and temperature in data logger data are due to take samples, or to add samples, or to change water reservoir, or to rearrange samples, etc.

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

623.	Name, address of Applicant / Marketing Authorization Holder	M/s Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Name, address of Manufacturing site.	M//s Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan has GMP certificate based on evaluation conducted on 11-01-2019.
	Evidence of approval of manufacturing facility	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan The firm has provided approval of DML renewal of following section : 1) Tablet (General), 2) Tablet (Hormone) Section, 3)Liquid syrup(General), 4)Oral dry powder suspension (General),5) Capsule general section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 3731: 09-02-2022
	Details of fee submitted	PKR 50,000/- 15-06-2020
	The proposed proprietary name / brand name	Dynib 4 mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…4mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)

	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7´s, 14 ´s,28´s
	Proposed unit price	As per innovator
	The status in reference regulatory authorities	Olumiant tablet 4 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 4 mg tablet , Eli Lilly, Pakistan (R.no. 110529) (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT20181001, BRCT20181002, BRCT20181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation Dynib 4 mg tablet (batch no. T01) and Olumiant 4 mg tablet(Eli lilly) (B # D385031). Quality tests of both products including Dosage form, Description, Identification, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 4 mg tablet(Eli lilly) (B # D385031)in Acid media

		(pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.		
API Lot No.	BRCT201801203		
Description of Pack (Container closure system)	Alu-Alu Blister (2x10s) packed in printed unit carton, further packed in a master shipper.		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T01	T02	T03
Batch Size	1000 tablets	1000 tablets	1000 tablets
Manufacturing Date	05-2019	05-2019	05-2019
Date of Initiation	02-06-2019	02-06-2019	02-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided Manufacturing license, valid till 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Assistant Director, DRAP, Lahore attested invoice specifying import of 25.0 g of Baricitinib(Batch no. BRCT 20181203),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S. No.	Section	Observation	Submissions
1.	1.1	An original cash deposit slip endorsed by Budget & Accounts Division, DRAP of prescribed fee as per Schedule-F of L R & A Rules, 1976, for specified category shall be attached therewith.	Firm has submitted the fee on 15th June, 2020 R.s. 50,000. However, dossier was submitted on: 09-02-2022. Firm has submitted R.s. 25000/- Additional fee (8247783942)(17928286).
2.	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)
3.	1.3.5	Please provide GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)
4.	3.2.S.4.1	Justification required for not including heavy metals test in specification of drug substance of M/s Dyson Research Laboratories. Whereas Drug substance manufacturer CoA depicting this test.	We have revised the CoA (added heavy metals test) as per Drug substance manufacturer. However fee for revision of specification has not submitted.
5.	3.2.P.2	In comparative dissolution profile results are not in accordance with provided chromatograms and raw data sheets. Justification required.	In CDP report of Buffer 4.5, it was a typographic error, we have revised the results as per provided chromatograms.
6.	3.2.P.4	Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese Pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided. **Excipients of Human or Animal Origin** For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE. **Novel Excipients** For excipient(s) used for the first time in a drug product or by a new route of administration, full	All the excipients used in formulation are pharmacopoeial except Ponchue 4R lake color and New coat White. The Ponchue 4R lake color is present in EU list of permitted food colors under code E124. Copy of Specifications & Analytical procedure of Ponchue 4R lake color and New coat White is provided. The submission against this point is exempted. The in-house standard excipients are tested as per manufacturer guidelines and both complies with established specifications. None of the excipient is of Human or Animal origin. Not applicable as the product is generic formulation.

		details of specification and testing method shall be provided.	
7.	3.2.P.6	Provided working standard batch no. BRCT WRS, is Valid up to 21-11-2019. Justification required for onward testing of the product and drug substance.	We have standardized the available raw material (Baricitinib) against the provided WRS, and used it as secondary WS for onward testing of the product. *COA of secondary working standard not provided.*
8.	3.2.P.8	Justification required for record of Digital data logger for temperature and humidity monitoring of stability chambers indicating relative humidity and temperature out of specification (outlier).	The outlier for relative humidity and temperature in data logger data are due to take samples, or to add samples, or to change water reservoir, or to rearrange samples, etc.

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

624.	Name, address of Applicant / Marketing Authorization Holder	M/s Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Name, address of Manufacturing site.	M//s Dyson Research Laboratories PVT. LTD. Address: 28 km, Ferozepur road, Lahore, Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan has GMP certificate based on evaluation conducted on 11-01-2019.
	Evidence of approval of manufacturing facility	M/s Dyson Research Laboratories PVT. LTD., 28 km, Ferozepur road, Lahore, Pakistan The firm has provided approval of DML renewal of following section : 1) Tablet (General), 2) Tablet (Hormone) Section, 3)Liquid syrup(General), 4)Oral dry powder suspension (General),5) Capsule general section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 3731: 09-02-2022
	Details of fee submitted	PKR 50,000/- 15-06-2020
	The proposed proprietary name / brand name	Dynib 2 mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…2mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7´s, 14 ´s,28´s
	Proposed unit price	As per innovator
	The status in reference regulatory authorities	Olumiant tablet 2 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 2 mg tablet , Eli Lilly, Pakistan (imported from Eli llilly,, Netherland)

	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT20181001, BRCT20181002, BRCT20181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation Dynib 2 mg tablet (batch no. T01) and Olumiant 2 mg tablet(Eli lilly). Quality tests of both products including Dosage form, Description, Identification, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 4 mg tablet(Eli lilly) in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.
STABILITY STUDY DATA		

Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
API Lot No.	BRCT201801203
Description of Pack (Container closure system)	Alu-Alu Blister (2x10s) packed in printed unit carton, further packed in a master shipper.
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T01	T02	T03
Batch Size	1000 tablets	1000 tablets	1000 tablets
Manufacturing Date	05-2019	05-2019	05-2019
Date of Initiation	02-06-2019	02-06-2019	02-06-2019
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided Manufacturing license, valid till 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted Assistant Director, DRAP, Lahore attested invoice specifying import of 25.0 g of Baricitinib(Batch no. BRCT 20181203),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S. No.	Section	Observation	Submissions
1.	1.1	An original cash deposit slip endorsed by Budget & Accounts Division, DRAP of prescribed fee as per Schedule-F of L R & A Rules, 1976, for specified category shall be attached therewith.	Firm has submitted the fee on 15th June, 2020 R.s. 50,000. However, dossier was submitted on: 09-02-2022. Firm has submitted R.s. 25000/- Additional fee (8247783942)(17928286).
2.	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)

3.	1.3.5	Please provide GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Our GMP Inspection has been conducted on 03-11-2022, and we are waiting for the signed report and GMP certificate, we will submit that ASA we will receive it. However, we are submitting our DML renewal inspection report that has been conducted within last three years(date of inspection 13-07-2020.)
4.	3.2.S.4.1	Justification required for not including heavy metals test in specification of drug substance of M/s Dyson Research Laboratories. Whereas Drug substance manufacturer CoA depicting this test.	We have revised the CoA (added heavy metals test) as per Drug substance manufacturer. However fee for revision of specification has not submitted.
5.	3.2.P.2	In comparative dissolution profile results are not in accordance with provided chromatograms and raw data sheets. Justification required.	In CDP report of Buffer 4.5, it was a typographic error, we have revised the results as per provided chromatograms.
6.	3.2.P.4	Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese Pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided. **Excipients of Human or Animal Origin** For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE. **Novel Excipients** For excipient(s) used for the first time in a drug product or by a new route of administration, full details of specification and testing method shall be provided.	All the excipients used in formulation are pharmacopoeial except Ponchue 4R lake color and New coat White. The Ponchue 4R lake color is present in EU list of permitted food colors under code E124. Copy of Specifications & Analytical procedure of Ponchue 4R lake color and New coat White is provided. The submission against this point is exempted. The in-house standard excipients are tested as per manufacturer guidelines and both complies with established specifications. None of the excipient is of Human or Animal origin. Not applicable as the product is generic formulation.
7.	3.2.P.6	Provided working standard batch no. BRCT WRS, is Valid up to 21-11-2019. Justification required for onward testing of the product and drug substance.	We have standardized the available raw material (Baricitinib) against the provided WRS, and used it as secondary WS for onward testing of the product. *COA of secondary working standard not provided.*
8.	3.2.P.8	Justification required for record of Digital data logger for temperature and humidity monitoring of stability chambers indicating relative humidity and temperature out of specification (outlier).	The outlier for relative humidity and temperature in data logger data are due to take samples, or to add samples, or to change water reservoir, or to rearrange samples, etc.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

625.	Name, address of Applicant / Marketing Authorization Holder	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)
	Name, address of Manufacturing site.	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)has GMP certificate based on evaluation conducted on 05 -11-2021.
	Evidence of approval of manufacturing facility	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785) has provided section approval letter (F.1-33/2009-Lic, dated 07-02-2014) of following section : Tablet (General), Capsule (General), Dry powder suspension (General), Liquid syrup(General), Mouth wash (General), Sachet (General), Liquid Sachet (General), Effervescent tablet (general), Toothpaste (Medicated), Cream ointment/(steroid), capsule (steroid), liquid (steroid), capsule (probiotics), sachet (probiotics).
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1199: 13-01-2022
	Details of fee submitted	PKR 75,000/- 13-12-2021(95226407)
	The proposed proprietary name / brand name	**Barijak Tablet 2.0 mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…2mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Selective immunosuppressant/ Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	As per PRC
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	**Olumiant tablet 2 mg, Eli Lilly (TGA Approved)** Olumiant tablet 2 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 2 mg tablet , Eli Lilly, Pakistan (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.

	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT181001, BRCT181002, BRCT181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation against Olumiant 2 mg tablet(Eli lilly) (B # D384977). Quality tests of both products including Dosage form, Description, Identification, Disintegration, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 2 mg tablet(Eli lilly) (B # D384977)in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.
STABILITY STUDY DATA		

Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.		
API Lot No.	BRCT210502		
Description of Pack (Container closure system)	Alu-Alu Blister (2x7s) packed in printed unit carton.		
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Baricitinib 2 mg Tablet			
Batch No.	TF-070521C	TF-070521B	TF-070521A
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	21-05-2021	21-05-2021	21-05-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided Manufacturing license, valid till 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has provided invoice specifying import of 500g g of Baricitinib(Batch no. BRCT 210502),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S.no.	Section	Observation	Responses
1	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	We have received the following response from manufacture of API M/s Zhejiang Hongyan Pharmaceutical China. **"Our DML does not show all products.** **Baricitinib is patented product in China. It cannot be sold commercially in China. So no manufacturer registered it in Chinese NMPA now.** **But GMP is one certificate which is connected with quality control. Our local organization issue us this certificate for exporting products purpose.** **It is same address. This address has more details.** **No.6, Donghai Fourth Avenue is our house number. Duqiao is town name"** Further, we herewith attached once again the GMP Certificate of above manufacturer for the ready reference. As Annexure Moreover, it is bring in your good knowledge that the following products have already been approved in the following DRB minutes using the similar source of API i.e. M/s Zhejiang Hongyan Pharmaceutical China. 1. M/s. Jenner Pharmaceuticals Pvt. Ltd. brand name "Olumijent Tablet 2mg and 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China 2. M/s. MCOLSAN brand name "Olumac 2mg & 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China
2	3.2.S.7	Submit supporting data of stability studies of drug substance manufacturer.	It is respectfully submitted that the manufacturer of API M/s Zhejiang Hongyan Pharmaceutical China have already provided the complete Drug Master File of the active ingredient "Baricitinib", and they didn't agree to share any further confidential information except the DMF with us. Further, refer to DRAP guidelines we have already submitted Manufacturer API's Stability data on Zone IVA and there is no further requirement is mentioned for submission. Moreover, it is bring in your good knowledge that the following products have already been approved in the following DRB minutes using the similar source of API i.e. M/s Zhejiang Hongyan Pharmaceutical China. 1. M/s. Jenner Pharmaceuticals Pvt. Ltd. brand name "Olumijent Tablet 2mg and 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China 2. M/s. MCOLSAN brand name "Olumac 2mg & 4mg" APPROVED in 316th DRB minutes of meeting using the

			similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China
3	3.2.P.4	3.2.P.4 Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided.	submitted
4	3.2.P.8	a. Documents for the procurement of API with approval from DRAP (in case of import). b. Submit form 3 and Form 7 (Batch certificate) under drug import and export rules, 1976. c. Justification required for different assay results (2 mg tablet) in initial testing of same batch in accelerated and real time stability studies. d. Justification required for different results (2 mg tablet) in raw data sheets and stability data in accelerated and real time stability studies.	a. It is respectfully submitted that since the Courier Details /Shipment Details are not attested by DRAP therefore Form 3 and Form 7 is not required. b. Same as above. c. Firm has stated that its typographic mistake. d. We have reviewed the stability data sheet and their respective raw data sheets and no difference of values observed. On further evaluation it was found that in tests of unspecified impurities few peak area values in HPLC chromatogram & raw data sheet are differ. Firm has submitted revised stability data sheets.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration Board further advised the firm to adopt formal procedure through approval from DRAP I&E for import of drug substance, in future.

626.	Name, address of Applicant / Marketing Authorization Holder	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)
	Name, address of Manufacturing site.	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785)has GMP certificate based on evaluation conducted on 05 -11-2021.
	Evidence of approval of manufacturing facility	M/s Hiranis Pharmaceuticals(Pvt.) Ltd. , Plot No. E-145 to 149, North Western Industrial Zone, Port qasim, Karachi(DML No. 000785) has provided section approval letter (F.1-33/2009-Lic, dated 07-02-2014) of following section : Tablet (General), Capsule (General), Dry powder suspension (General), Liquid syrup(General), Mouth wash (General), Sachet (General), Liquid Sachet (General), Effervescent tablet (general), Toothpaste (Medicated), Cream ointment/(steroid), capsule (steroid), liquid (steroid), capsule (probiotics), sachet (probiotics).
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1198: 12-01-2022
	Details of fee submitted	PKR 75,000/- 13-12-2021(25748145)
	The proposed proprietary name / brand name	Barijak Tablet 4.0 mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…4mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Selective immunosuppressant/ Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	As per PRC
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	**Olumiant tablet 4 mg, Eli Lilly (TGA Approved)** Olumiant tablet 4 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 4 mg tablet , Eli Lilly, Pakistan (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its

		validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5% RH for 24 months. Batch no. BRCT181001, BRCT181002, BRCT181003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation against Olumiant 4 mg tablet(Eli lilly)(B#D385031). Quality tests of both products including Dosage form, Description, Identification, Disintegration, Dissolution, Assay were compared. CDP has been performed against the same brand that is Olumiant 4 mg tablet(Eli lilly)in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.

STABILITY STUDY DATA	
Manufacturer of API	M/s Zhejiang Hongyuan Pharmaceutical co., ltd, Chem and industrial Zone, Linhai, Zhejiang , China.
API Lot No.	BRCT210502
Description of Pack	Alu-Alu Blister (2x7s) packed in printed unit carton.

(Container closure system)			
Stability Storage Condition	Real Time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Baricitinib 4 mg Tablet			
Batch No.	TF-080521A	TF-080521B	TF-080521C
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	21-05-2021	21-05-2021	21-05-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has provided minutes of 294th meeting of registration Board, wherein product Etoxib 90 mg and Etoxib 120 mg were approved based on report of panel for Product specific inspection(PSI)
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided Manufacturing license, valid till 13-01-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has provided invoice specifying import of 500g g of Baricitinib(Batch no. BRCT 210502),(Invoice no. HY19021401, dated 20-03-2019).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S.no.	Section	Observation	Responses
1	1.6.5	Upon online verification of manufacturing license of drug substance manufacturer, address of manufacturer is different. Furthermore, Baricitinib is not present in scope of license.	We have received the following response from manufacture of API M/s Zhejiang Hongyan Pharmaceutical China. **"Our DML does not show all products.** **Baricitinib is patented product in China. It cannot be sold commercially in China. So no manufacturer registered it in Chinese NMPA now.** **But GMP is one certificate which is connected with quality control. Our local organization issue us this certificate for exporting products purpose.** **It is same address. This address has more details.** **No.6, Donghai Fourth Avenue is our house number. Duqiao is town name"** Further, we herewith attached once again the GMP Certificate of above manufacturer for the ready reference. As Annexure Moreover, it is bring in your good knowledge that the following products have already been approved in the following DRB minutes using the similar source of API i.e. M/s Zhejiang Hongyan Pharmaceutical China. 3. M/s. Jenner Pharmaceuticals Pvt. Ltd. brand name "Olumijent Tablet 2mg and 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China 4. M/s. MCOLSAN brand name "Olumac 2mg & 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China
2	3.2.S.7	Submit supporting data of stability studies of drug substance manufacturer.	It is respectfully submitted that the manufacturer of API M/s Zhejiang Hongyan Pharmaceutical China have already provided the complete Drug Master File of the active ingredient "Baricitinib", and they didn't agree to share any further confidential information except the DMF with us. Further, refer to DRAP guidelines we have already submitted Manufacturer API's Stability data on Zone IVA and there is no further requirement is mentioned for submission. Moreover, it is bring in your good knowledge that the following products have already been approved in the following DRB minutes using the similar source of API i.e. M/s Zhejiang Hongyan Pharmaceutical China. 1. M/s. Jenner Pharmaceuticals Pvt. Ltd. brand name "Olumijent Tablet 2mg and 4mg" APPROVED in 316th DRB minutes of meeting using the similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China. 2. M/s. MCOLSAN brand name "Olumac 2mg & 4mg" APPROVED in 316th DRB minutes of meeting using the

			similar API's source i.e. M/s Zhejiang Hongyan Pharmaceutical China
3	3.2.P.4	3.2.P.4 Control of Excipients **Specifications** The specifications for excipients shall be provided. If the excipient(s) are in pharmacopoeia there is no need to provide detailed specifications or its analytical procedures. However, for excipients of non-compendial standards, specifications as well as analytical procedures shall be provided. The colors permitted for use are limited to those listed in the FDA "Inactive ingredient guide", "Japanese pharmaceutical excipients" or the European Union (EU) "List of permitted food colors". For proprietary mixtures, the composition sheet provided by the supplier shall be submitted. **Analytical procedures** Copies of analytical procedures of non-compendial excipient shall be submitted. **Validation of analytical procedures** Validation information for the analytical procedures for in-house standard excipients shall be submitted. **Justification of specifications** Justification of the specifications for the analytical procedures for in-house standard excipients shall be provided.	submitted
4	3.2.P.8	a. Documents for the procurement of API with approval from DRAP (in case of import). b. Submit form 3 and Form 7 (Batch certificate) under drug import and export rules, 1976. c. Justification required for different assay results (2 mg tablet) in initial testing of same batch in accelerated and real time stability studies. d. Justification required for different results (2 mg tablet) in raw data sheets and stability data in accelerated and real time stability studies.	a. It is respectfully submitted that since the Courier Details /Shipment Details are not attested by DRAP therefore Form 3 and Form 7 is not required. b. Same as above. c. Firm has stated that its typographic mistake. d. We have reviewed the stability data sheet and their respective raw data sheets and no difference of values observed. On further evaluation it was found that in tests of unspecified impurities few peak area values in HPLC chromatogram & raw data sheet are differ. Firm has submitted revised stability data sheets.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration Board further advised the firm to adopt formal procedure through approval from DRAP I&E for import of drug substance, in future.

627.	Name, address of Applicant / Marketing Authorization Holder	M/s Atco Laboratories Limited, B-18, S.I.T.E. Karachi (DML No. 000188)
	Name, address of Manufacturing site.	M/s Atco Laboratories Limited, B-18, S.I.T.E. Karachi (DML No. 000188)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	M/s Atco Laboratories Limited, B-18, S.I.T.E. Karachi (DML No. 000188)has GMP certificate based on evaluation conducted on 03-11-2022.
	Evidence of approval of manufacturing facility	M/s Atco Laboratories Limited, B-18, S.I.T.E. Karachi (DML No. 000188) has provided section approval letter (F.2-5/85-Lic, dated 23-01-2019) of following section : **Tablet (General),** Capsule (General), Dry powder suspension (General), Dry Powder Sachet.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 3331: 03-02-2022
	Details of fee submitted	PKR 30,000/- 27-12-2021(8689208275)
	The proposed proprietary name / brand name	Baricitinib Tablet 4 mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Baricitinib…4mg
	Pharmaceutical form of applied drug	Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Selective immunosuppressant/ Janus Kinase (JAK) inhibitor(**ATC code L04AA37**)
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	7's, 10's, 14's, 20's, 28, s, 30's, 60's, 98's
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	**Olumiant tablet 4 mg, Eli Lilly (EMA Approved)** Olumiant tablet 4 mg, Eli Lilly(USFDA Approved)
	For generic drugs (me-too status)	Olumiant 4 mg tablet , Eli Lilly, Pakistan (imported from Eli llilly,, Netherland)
	Name and address of API manufacturer.	M/S Kaifeng Pharmaceutical (group) co., ltd, no. 1, yunan street, kaifeng city China.
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and

		process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Module-III Drug Substance:	The firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2 °C / 65% ± 5 RH for 24 months. Batch no. 150522,150718,150825.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	The firm has performed pharmaceutical equivalence of the developed formulation against Olumiant 4 mg tablet (Eli lilly) (B#D351131). Quality tests of both products including Dosage form, Description, Identification, Disintegration, Dissolution, Assay were compared. CDP has been performed against the same brand that is Unamity 4 mg tablet (Eli lilly) (B#D369688) in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range
	Analytical method validation/verification of product	Firm has submitted analytical method verification report of drug substance. Firm has submitted analytical method validation report of applied product.


STABILITY STUDY DATA	
Manufacturer of API	M/S Kaifeng Pharmaceutical (group) co., ltd, no. 1, yunan street, kaifeng city China.
API Lot No.	HF20201203
Description of Pack (Container closure system)	Alu-Alu Blister (2x7s) packed in printed unit carton.
Stability Storage Condition	Real Time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months

Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Baricitinib 4 mg Tablet			
Batch No.	AU324C	AU325C	AU326C
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	08-09-2021	08-09-2021	08-09-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
#	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has provided minutes of 277th meeting of registration Board, wherein product Roflumilast 500 mcg tablet were approved based on report of panel for Product specific inspection(PSI)
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has provided GMP certificate of M/S Kaifeng Pharmaceutical (group) co., ltd, no. 1, yunan street, kaifeng city China, valid till 28-09-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has provided invoice attested by Assistant Director, DRAP, Karachi specifying import of 0.15 kgs of Baricitinib(Batch no. HF20201203, HF20201113),(Invoice no. 210111A03, dated 11-01-2021).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted audit trail on testing reports of product.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of evaluator:

S.no.	Section	Question	Response of firm.
1	**1.3.5**	GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Atco Laboratories Limited, B-18, S.I.T.E. Karachi (DML No. 000188)has GMP certificate based on evaluation conducted on 03-11-2022
2	**3.2.S.4**	**a**. Justification required for not inclusion of heavy metals, pb testing in specifications of drug substance than drug substance manufacturer.	Heavy metals and Lead (Pb) Content is not a part of release and shelf life specifications of Baricitinib Drug Substance, it was only a part of development and validation testing of drug substance Baricitinib. Declaration Letter for Heavy metals and Lead Content in Baricitinib by drug substance manufacturer is provided. (Section 3.2.S.4)
3	**3.2.S.4**	**b.** In justification of specifications, specification of Tedizolid phosphate mentioned. Justification required.	Drug substance manufacturer has regretted for inconvenience, as it was a typographical error in relevant section of DMF which has been rectified by drug substance manufacturer. Updated DMF is being submitted for your ready reference. (Section 3.2.S.4)
4	**3.2.S.4**	**c.** Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	Missing
5	**3.2.P.2**	Justification required for using USP Apparatus I in Comparative dissolution profile (CDP). While innovator has used USP Apparatus -II (Paddle)	According to "In vitro Dissolution" defined in Biopharmaceutics Classification System-Based Biowaivers, M9, Final version Adopted on 20 November 2019, both USP Apparatus I (basket apparatus) and USP Apparatus –II (paddle apparatus) are allowed. Dissolution method for Baricitinib Tablets is not available at FDA Dissolution database. Similar conditions established through "Procedure for Setting Dissolution Specifications of Baricitinib Tablets" employed in the comparative dissolution studies to characterize the dissolution profile of the test product and reference product for comparative in vitro dissolution tests. The results of Baricitinib in our product Baricitinib 4mg Tablets observed from the comparative dissolution profile in all the three media are similar to the reference profile and the product is considered to be similar. Respective section of guideline is attached here for your reference. (Section 3.2.P.2)
6	**3.2.P.5**	Justification required for using USP Apparatus I for dissolution testing in analytical method of drug product. While innovator has used USP Apparatus -II (Paddle).	Dissolution method for Baricitinib Tablets is not available at FDA Dissolution database. We have established the dissolution specification and method in line with the procedure of Setting Dissolution Release Specifications in 293rd Meeting minutes for Implementation of Common Technical

			Document (CTD) by using the dissolution Method A of Standard Dissolution Testing Conditions defined in "Guidance Document, Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry, August 2018". Baricitinib Tablet is categorized as very rapidly dissolving (>85% dissolved in 15 min) and same specifications has been adopted for routine release specifications. "Procedure for Setting Dissolution Specifications of Baricitinib Tablets" is also attached for your ready reference. Furthermore, we have also performed dissolution testing on our stability batches at current time point (15 months) using USP Apparatus - II (Paddle) and results found equivalent. Dissolution Summary Report is also attached. (Section 3.2.P.5)  QUALITY ASSESSMENT 2. In vitro dissolution method and acceptance criteria: The in vitro dissolution method proposed for this NDA is shown below in Table 2: Table 2: In vitro dissolution method for baricitinib tablets (from M.3.2.P.5) USP II (Paddles) — Apparatus 75 rpm — Rotation Speed 900 mL — Media Volume pH 4.5 Acetate Buffer — Media HPLC with UV Detection at 220 nm — Sample Analysis The proposed dissolution acceptance criterion is as follows. Not less than % (Q) in 30 minutes. Table 3 shows the representative batches of baricitinib drug product that were evaluated for the dissolution specification proposal.
7	**3.2.P.8**	**a**. Data of stability batches, supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches, supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
8	**3.2.P.8**	**b.** Justification required regarding data logger data depicting relative humidity out of limits (outliers).	We would like to inform you that when we are using climatic controlled stability chambers for placement of stability samples and collection of stability samples at each testing interval in both real time and accelerated stability conditions, there is a sudden change in set temperature and relative humidity for the time being and which recovers to its initial set value rapidly after closing the door of chamber. Furthermore, according to ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products, Storage condition tolerances, short term spikes due to opening of doors of the storage facility are accepted as unavoidable. While we have a very well controlled procedure established for Excursions that exceed the defined tolerances for more than 24 hours.

			Respective section of guideline is attached here for your reference. (Section 3.2.P.8)

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Analytical Method Verification studies for drug substance including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer.**
- **Performance of dissolution test at next time point of long term stability studies and CDP studies against the innovator/reference product using the "Dissolution apparatus II" i.e., Paddle, as recommended by the innovator product literature.**

- **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.**

628.	**Name, address of Applicant / Importer**	**M/s GRATON PHARMA, Karachi.**
	Details of Drug Sale License of importer	**License No. 160** **Address:** Office no. 501 & 502 ,5th floor Plot no 42C/2 Lane-08, Bukhari Commercial Phase-VI, D.H.A Karachi, Pakistan. **Address of Godown:** NA **Validity:** 21-10-2023 **Status:** License to sell drugs as distributor **Renewal:** Firm has submitted for renewal
	Name and address of marketing authorization holder (abroad)	**M/s Jodas Expoim Pvt. Ltd.** Plot No. 55, Phase-III, Biotech Park, Karakapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name, address of manufacturer(s)	**M/s Jodas Expoim Pvt. Ltd.** Plot No. 55, Phase-III, Biotech Park, Karakapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized **copy** of CoPP certificate (No: 1985348/TS/2021) (valid upto 22-12-2023) issued by Drug Control Administration Telangana, India for Azacitadine injection 100mg. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. **The name of importing country on CoPP is mentioned.**
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Jodas Expoim pvt ltd. The letter specifies that the manufacturer appoints M/s Graton Pharma. to register, market and sell their products in Pakistan. The authorization letter is valid till **31-12-2025**.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 23966 , dated 24-08-2022

	Details of fee submitted	PKR 50,000/-: 26 March 2021. PKR 25,000:-13 Sep, 2021.
	The proposed proprietary name / brand name	**Graza Injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Azacitadine …….100mg
	Pharmaceutical form of applied drug	Injection.
	Pharmacotherapeutic Group of (API)	Antineoplastic agents(L01BC07)
	Reference to Finished product specifications	In house Specification
	Proposed Pack size	1 VIAL
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Vidaza100MG/vial (Celgene Europe B.V. Winthontlaan 6 N3526 KV Utrecht, Netherlands
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s MSN Laboratories Private limited, Sy. No. 50, Karadanur(village) Patancheru (mandal), Sangareddy District, Telanagana, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at $5^{o}C \pm 3^{o}C$. The stability study data is till 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.

	Container closure system of the drug product	Clear molded type-I glass vial with 20 mm grey bromobutyl double slotted rubber stopper along with 20 mm aluminium flip of seal.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40ºC ±2ºC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30ºC ±2ºC / 75% ± 5% RH. The real time stability study data of batches is for 12 months. Batch No. ON-E19031, ON-E19032, ON-E19033

Evaluation by PEC:

S.no.	Section	OBSERVATION
1	1.3.3	a. Free sale Certificate is expired b. Original GMP certificate missing. Provided copy of GMP certificate expired. c. Original authorization letter is missing
2.	3.2.S.4	a. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.
4.	3.2.P.5	a. Detailed analytical procedures used for testing the drug product shall be provided.
5.	3.2.P.8	a. Firm has provided 12th Months real time stability data of finished product. Complete stability data as per claimed shelf life is required. b. Summary of additional stability studies e.g. in-use studies for drug products which are to be reconstituted before use, along with proposed in-use storage statement and in-use shelf-life shall be provided. c. GMP certificate of drug substance manufacturer is expired. Please provide valid GGMP certificate of drug substance manufacturer.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

629.	Name, address of Applicant / Marketing Authorization Holder	**M/s The Searle Company Limited** **F-319, S.I.T.E., Karachi, Pakistan.(DML No. 000016)**
	Name, address of Manufacturing site.	The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	28658 & 10/10/2022
	Details of fee submitted	PKR 75,000/- : dated 30/09/2022(983342424)
	The proposed proprietary name / brand name	Bilaxten 20mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Bilastine……20 mg (As per Innovator's Specifications)
	Pharmaceutical form of applied drug	Off white color, biconvex, round shaped tablets, plain from both sides

	Pharmacotherapeutic Group of (API)	Anti-Histamine
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**Ilaxten 20mg Tablet (**Each tablet contains 20 mg of bilastine) MHRA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Firm has submitted GMP Certificate of M/s The Searle Company Limited, F-319, S.I.T.E., Karachi, Pakistan.(DML No. 000016) based on evaluation conducted on19-07-2022 Firm has provided approval of following sections vide letter (2-6/2018-Lic(Vol-IV), dated 29-10-2020): 1) Tablet (General & General Antibiotic) 2) Capsule General, 3) Sachet (General), 4) Injection Ampoule (general), 5) Oral liquid(General).
	Name and address of API manufacturer.	**BILASTINE:** **Manufacturer:** Lee Pharma Limited **Address:** Survey No. 10/G-1, Gaddapotharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana State - 502319, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for specifications, analytical procedures and its validation, impurities & related substances, residual solvents, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **BILASTINE:** Real time: 30°C ± 2°C / 75% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: BS0219002(MN), BS0219003(MN), BS0219004(MN)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence: Formulation of Bilaxten 20mg Tablet is developed by using commonly used excipients that are being widely used for dosage forms. Most of the excipients are kept constant as that of the Innovator's formulation therefore, it is presumed that inactive ingredients are compatible with the actives (Bilastine) & also with each other and this is ensured by

		satisfactory results from formal stability studies. Each of the excipient present in formulation plays significant role for the integrity of formulation. The Comparative dissolution profile is performed against Bilaxten 20mg Tablet show equivalence. F2 value 50 or greater (50-100) reflects sameness or equivalence of two curves and this equivalence of In-vitro performance of two products
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity, robustness and system suitability

STABILITY STUDY DATA			
Manufacturer of API	**M/s. Lee Pharma Limited.** Survey No. 10/G-1, Gaddapotharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana State - 502319, India.		
API Lot No.	BIFP21001		
Description of Pack (Container closure system)	ALU-ALU Blister in Unit Carton		
Stability Storage Condition	Real time: 30±2ºC, 75±5%RH Accelerated: 40±2ºC, 75±5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0,3, 6 (Months)		
Batch No.	21PD-148	21PD-149	21PD-150
Batch Size	2500 Tablets	2500 Tablets	2500 Tablets
Manufacturing Date	Aug-2021	Aug-2021	Aug-2021
Date of Initiation	Aug-2021	Aug-2021	Aug-2021
No. of Batches	03		

Administrative Portion		
31.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted documents for Reference of Previous Approval
32.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**BILASTINE:** GMP Certificate of Lee Pharma Limited **Address:** Survey No. 10/G-1, Gaddapotharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana State - 502319, India Valid till: 08-05-2023
33.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted documents of import duly attested by Assistant Director, DRAP, Karachi, vide invoice no. 1325/LP/2020-21, dated 27.01.2021. Batch: BIFP21001
34.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

35.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
36.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Remarks of evaluator	Response of the firm
2.3.R.1.1	**Executed Production Documents** Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3	Firm has Provided the copy of Batch Manufacturing Record (BMR) for 3 batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3
3.2.P.2	Justification required for performing Pharmaceutical equivalence and CDP against 2 different brands.	Firm has stated that the Searle company limited performed the comparative dissolution profile and pharmaceutical equivalence of bilastine tablets 20 mg against Bilaxten tablets 20 mg having batch 2004015.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

CASE NO. 2: M/S AGP LIMITED, B-23-C, S.I.T.E., KARACHI

Assistant Director PR-I / EFD vide its letter No. F.1-6/2019-PR-I (EFD) dated 6th October 2022 informed that as per decision of 133rd meeting of DRAP Authority wherein it was decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicine (to a maximum of 15 such molecules) during a financial year.
In compliance to the above decision M/s AGP Limited, B-23-C, S.I.T.E., Karachi have achieved benchmark of more than 100,000 USD and submitted their applications for priority consideration including following application:

630.	Name, address of Applicant / Marketing Authorization Holder	M/s AGP Limited B-23-C, S.I.T.E., Karachi
	Name, address of Manufacturing site.	M/s AGP Limited B-23-C, S.I.T.E., Karachi
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12288 dated 20/03/2022
	Details of fee submitted	PKR 30,000/-: dated 28/03/2022(363304043)
	The proposed proprietary name / brand name	Spasler Neo MR Capsules 200mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains Mebeverine HCl SR 80% Pellets……200mg
	Pharmaceutical form of applied drug	Capsule

	Pharmacotherapeutic Group of (API)	Synthetic anticholinergics, esters with tertiary amino group (ATC code A03AA04)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	1×10's
	Proposed unit price	As per DRAP approved price
	The status in reference regulatory authorities	Duspatal 200 mg retard by M/s Orifarm GmbH (Germany)
	For generic drugs (me-too status)	Mebever MR 200mg Capsule by M/s Getz Pharma Pakistan (Pvt.) Ltd (Reg. No: 050747)
	GMP status of the Finished product manufacturer	Firm has GMP Certificate based on evaluation conducted on 03rd June 2021(valid for 3 years). Firm has provided renewal of DML of vide 2-4/2010-Lic(Vol-I), dated 30-06-2020 of following sections: Tablet General, **Capsule (General)**, Sachet (general), Oral Liquid(General), Semi-solid (Cream/ Ointment, Liquid Ampoule.
	Name and address of API manufacturer.	M/s Surge Laboratories (Pvt) Ltd, 10th Km, Faisalabad Road Bikhi, District Sheikhupura –Pakistan.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and finished product.
	Module III (Drug Substance)	Official monograph of Mebeverine HCl is not present in pharmacopeia. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 09 months Batches: (MBV-80-SR-001, MBV-80-SR-002, MBV-80-SR-003) Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (MBV-SR-028, MBV-SR-029, MBV-SR-030)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Mebever MR 200mg Capsule by M/s Getz Pharma Pakistan (Pvt.) Ltd by performing quality tests

		(Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Mebever MR 200mg Capsule by M/s Getz Pharma Pakistan (Pvt.) Ltd in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). on the basis of factor range the result of dissolution profile of both are similar.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, system suitability, specificity range, accuracy, precision, LoD, LoQ, Robustness & range.

STABILITY STUDY DATA			
Manufacturer of API	M/s Surge Laboratories (Pvt) Ltd, 10th Km, Faisalabad Road Bikhi, District Sheikhupura –Pakistan.		
API Lot No.	MBV-80-SR-006		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×10's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, (Months)		
Batch No.	TR-681	TR-682	TR-683
Batch Size	2000 capsules	2000 capsules	2000 capsules
Manufacturing Date	07-2020	07-2020	07-2020
Date of Initiation	02-04-2021	02-04-2021	02-04-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 182/2019-DRAP (AD-823166-158) issued by DRAP on 04/07/2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted documents of procurements specifying the purchase of 3 kg of Mebeverine HCL pellets 80 % vide invoice no. 21020196-SG, dated 08-02-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted
Remarks of Evaluator:		

<table>
<tr><th>S.no.</th><th>Section</th><th>Remarks of evaluator</th><th>Response of firm</th></tr>
<tr><td>1</td><td>2.3.R.1.1</td><td>Executed Production Documents
Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3</td><td>The production documents of the following batches are submitted
1. TR-681
2. TR-682
3. TR-683</td></tr>
<tr><td>2</td><td>3.2.S.4</td><td>Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.</td><td>Firm has submitted analytical Method Verification studies including specificity, accuracy and repeatability (method precision)</td></tr>
<tr><td>3</td><td>3.2.S.7</td><td>a. Firm has submitted 09-month real time stability studies data. Whereas Shelf life of drug substance is 03 years as per COA. Please submit complete stability data.
b. justification required regarding composition of pellets is not similar to innovator product.</td><td>a.Firm has submitted long-term stability study data of the drug substance up to 24 months of following Batches: (MBV-80-SR-001, MBV-80-SR-002, MBV-80-SR-003)
b.
<table>
<tr><th>Innovator composition(Colofac MR) CAPSULE</th><th>Applied formulation</th></tr>
<tr><td>Magnesium stearate</td><td>Polypyrollidone K-30</td></tr>
<tr><td>Polyacrylate dispersion 30%</td><td>Eudragit RS-100</td></tr>
<tr><td>Talc</td><td>Triethyl citrate</td></tr>
<tr><td>Hypromellose</td><td>Talcum</td></tr>
<tr><td>Methacrylic acid – ethyl acrylate copolymer (1:1) dispersion 30%</td><td></td></tr>
<tr><td>Glycerol triacetate</td><td></td></tr>
</table>
Both products are manufactured with same excipients Eudragit/methacrylic-acid ethyl acrylate copolymer which make them modified release. Others are lubricant, binder & solvents. Comparative dissolution profile performed against market product Mebever MR capsule: which is satisfactory.</td></tr>
<tr><td>4</td><td>3.2.P.2</td><td>Justification for not performing Pharmaceutical equivalence and CDP against innovator brand.</td><td>Firm has stated that : Due to non-availability of the innovator brand Colofac MR Capsules manufactured by Mylan Laboratories SAS France, we selected Mebever MR Capsules of Getz Pharma, Pakistan being the comparator product/ brand leader as per guidelines of DRAP “Guidance document for submission of application on form 5-F (CTD) (Edition 1).</td></tr>
<tr><td>5</td><td>3.2.P.8</td><td>a. Valid Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.

b. In stability study data manufacturing date is July-2020. Whereas provided invoice date is 08-02-2021. Justification required.</td><td>a. Firm has submitted valid GMP certificate of M/s Surge Laboratories (Pvt) Ltd, 10th Km, Faisalabad Road Bikhi, District Sheikhupura –Pakistan, based on evaluation conducted on 25-08-2022, and valid till 24-08-2024.

b. Manufacturing date July-2020 was given from pellets COA`s of drug substance manufacturer, while stability study was performed after encapsulation dated</td></tr>
</table>

			March-2021. (Batch Manufacturing Records are submitted
		c. Justification required regarding data accelerated stability chambers logger data depicting temperature and humidity out of limits (outliers).	c. Firm has stated that: these depicting data are during sampling withdrawal from stability chambers observed within 30min.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

CASE NO. 3: M/S MACTER INTERNATIONAL LIMITED., KARACHI

Assistant Director PR-I / EFD vide its letter No. F.1-6/2019-PR-I (EFD) dated 6th October 2022 informed that as per decision of 133rd meeting of DRAP Authority wherein it was decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicine (to a maximum of 15 such molecules) during a financial year.
In compliance to the above decision **M/s Macter International limited.**, Karachi have achieved benchmark of more than 100,000 USD and submitted their applications for priority consideration including following application:

631.	**Name, address of Applicant / Importer**	**M/s Macter International limited.**
	Details of Drug Sale License of importer	**License No: 037(No. DHOKW(Drugs)/-252/-** **Address:** F-216 S.I.T.E Karachi Pakistan. **Address of Godown: N/A**. **Validity:** 07-08-2023. **Status:** Drug license by way of wolesale. **Renewal: N/A.**
	Name and address of marketing authorization holder (abroad)	**TTY Biopharm Company Limited 3f., No. 3-1, Park St., Nangang Dist., Taipei City 11503, Taiwan, R.O.C.**
	Name, address of manufacturer(s)	**Name: TTY Biopharm Company Limited Chungli Factory.** **Address**: 838, chung Hwa Rd., Sec.1,Chungli Dist., Taoyuan City,32069,Taiwan.
	Name of exporting country	Taiwan, R.O.C
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized **copy** of CoPP certificate (No.077168) dated 17-09-2019 issued by Food and Drug Administration Ministry of Health and Welfare, Republic of China (Taiwan). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every two years.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of distribution agreement from TTY Biopharm Company Limited. The letter species that the manufacturer

		appoints M/s Macter International Limited., to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
	Dy. No. and date of submission	
	Details of fee submitted	PKR 100000/ Date: 20-04-2020 PKR 50,000/ Date: 25-04-2022(15000869732)
	The proposed proprietary name / brand name	**Mac-Doxilip Injection 2MG/ML**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Pegylated Liposomal Doxorubicin HCl…….2mg/ml
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	**Antineoplastic Agent** L01DB01
	Reference to Finished product specifications	In house
	Proposed Pack size	10ml x1's
	Proposed unit price	As per SRO & DPC
	The status in reference regulatory authorities	Caelyx pegylated liposomal **(EMA Approved).**
	For generic drugs (me-too status)	Doxopeg **(Ferozsons Lab.Pkaistan)(R.no. 52205)**
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	**DMF Holder:** Teva Pharmaceutical Industries Ltd. 5 Basel Street, P.O Box 3190 Petah Tiqva 4951033, Israel. **Manufacturing site:** Sicor S.r.l., Santhia site, Tenuta S. Alessandro 13048 Santhia(VC), Italy
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities,

		physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC and 60± 5% RH. The stability study data is till 72 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	USP type-I glass
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 25ºC ±2ºC / 60% ± 5% RH for 6 months. The real time stability study data is conducted at 5ºC ±3ºC. The real time stability study data of 3 batches is for 24 months.

Evaluation by PEC:

S.no.	Section	Observation
1.	**1.3.3.**	a. Certificate of Pharmaceutical Product (CoPP) is not legalized/notarized Countersigned by embassy. b. In CoPP **pegylated liposomal** not mentioned. c. In CoPP brand name Mac-Doxilip Injection for export purpose only. d. Provided GMP Certificate of drug product manufacturer is expired.
2.	**1.5.6**	Mention the reference specifications of the finished product (drug product) from the following list • USP • BP • Int. Ph. • JP Pharmacopoeia of any Reference Regulatory Authority • Manufacturer's specifications. • Specifications as per Innovator's product • Any other (specify exact reference) • Any other pharmacopoeia as mentioned in Drug specification rules. (Specify the exact reference).
3.	**3.2.S.4**	a. Analytical method of API of drug product manufacturer.

<table>
<tr><td></td><td></td><td>b. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial
drug substance(s) shall be submitted.
c. Provide specifications of drug substance used in the manufacturing of finished drug product.</td></tr>
<tr><td>4.</td><td>3.2.P.2</td><td>Qualitative composition of the formulation is not similar to innovator / reference product</td></tr>
<tr><td>5.</td><td>3.2.P.5</td><td>a. In analytical method of finished drug product 5.3.7 Drug/phospholipid ratio it is mentioned that read the UV absorbance at 830 nm. Justification required.
Batch analysis
b. The copies of complete analysis of at least two batches shall be provided.</td></tr>
<tr><td>6.</td><td>3.2.P.8</td><td>a. In accelerated stability studies data results of assay (total drug + drug encapsulation) and impurities are out of specifications in 6 months' time interval.
<table>
<tr><td>Batch no.</td><td>Total drug: 90.0-115.0 % of the label claim of Doxorubicin HCl.</td><td>Drug encapsulation : NLT 90.0 % of label claim of Doxorubicin HCl.</td><td>1)Any individual impurity: NMT 0.5%
2)Total impurities: NMT 2.0 %</td></tr>
<tr><td>LDPIASTW1702</td><td>83.6%</td><td>83.5 %</td><td>1) 5.2 %
2) 9.2%</td></tr>
<tr><td>LDPIASTW1703</td><td>85.1%</td><td>83.9 %</td><td>1) 4.5 %
2) 8.8%</td></tr>
<tr><td>LDPIASTW1704</td><td>83.2%</td><td>83.0 %</td><td>1) 4.7 %
2) 8.9%</td></tr>
</table>
b. Firm has provided stability studies data of product lipo-dox Liposomal injection 2.0 mg/ml. whereas applied brand name is Mac-Doxilip Injection 2MG/ML.</td></tr>
</table>

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

CASE NO. 4: M/S GENIX PHARMA PRIVATE LIMITED, 44-45B KORANGI CREEK ROAD KARACHI

Assistant Director PR-I / EFD vide its letter No. F.1-6/2019-PR-I (EFD) dated 6th October 2022 informed that as per decision of 133rd meeting of DRAP Authority wherein it was decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicine (to a maximum of 15 such molecules) during a financial year.
In compliance to the above decision M/s Genix Pharma Private Limited, 44-45B Korangi creek road Karachi**.**, Karachi have achieved benchmark of more than 100,000 USD and submitted their applications for priority consideration including following application:

632.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Tablet 10mg
	Composition	Each film-coated tablet contains: Brivaracetam……...10mg (Manufacturer's specifications)
	Diary No. Date of R& I & fee	Dy. No. dated 02-03-2017, Fee Rs: 50,000/- dated 02-03-2017 vide deposit slip No.0515333.
	Pharmacological Group	N03AX23 anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications

	Pack size & Demanded Price	10's,20's & 30's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Tablets 10mg by UCB Inc. USFDA Approved
	Me-too status	Brivace tablets 10mg by Hilton Pharma (Reg no: 110124)
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
	Remarks of the Evaluator	

STABILITY STUDY DATA

Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.		
API Lot No.	BVC-202101102F1		
Description of Pack (Container closure system)	Alu/Alu		
Stability Storage Condition	Real time: 30°C ± 2° C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(A)-063-01	21SB(A)-064-02	21SB(A)-065-03
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	24-06-2021	24-06-2021	24-06-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
15.	Reference of previous approval of applications with stability study data of the firm	• N/A
16.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Firm has submitted of COA of Brivaracetam batch no. BVC-202101102F1.
17.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
18.	Stability study data of API from API manufacturer	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)

<table>
<tr><td>19.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Copy of GMP certificate valid till 28-11-2022</td></tr>
<tr><td>20.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.</td></tr>
<tr><td>21.</td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td>22.</td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td>23.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has used same qualitative composition of product as per innovator.</td></tr>
<tr><td>24.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>21SB(A)-063-01</td><td>1500 Tablets</td><td>05-2021</td></tr>
<tr><td>21SB(A)-064-02</td><td>1500 Tablets</td><td>05-2021</td></tr>
<tr><td>21SB(A)-065-03</td><td>1500 Tablets</td><td>05-2021</td></tr>
</table></td></tr>
<tr><td>25.</td><td>Record of comparative dissolution data (where applicable)</td><td>CDP has been performed against the brand that is Brivace Tablets 10mg (B#141478) by Hilton Pharma, in Acid media (0.1N HCl), acetate buffer 4.5 & Phosphate Buffer pH (6.8). The f1 value was in acceptable range.</td></tr>
<tr><td>26.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>27.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>28.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
</table>

Remarks of Evaluator

Observation	**Response of Firm**
i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (General**)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.

iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

633.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Tablet 25mg
	Composition	Each film-coated tablet contains: Brivaracetam……...25mg (Manufacturer's specifications)

	Diary No. Date of R& I & fee	Dy. No.3214 dated 02-03-2017, Fee Rs: 50,000/- dated 02-03-2017 vide deposit slip No.0515334.
	Pharmacological Group	Anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	10's, 20's & 30's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Tablets 25mg by UCB Inc. USFDA Approved
	Me-too status	Brivace tablets 25mg by Hilton Pharma (Reg no: 110125)
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. Tablet section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA

Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.		
API Lot No.	BVC-202101102F1		
Description of Pack (Container closure system)	Alu/Alu		
Stability Storage Condition	Real time: 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40 ℃ ± 2 ℃ / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(A)-066-01	21SB(A)-067-02	21SB(A)-068-03
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	05-2021	05-2021	05-2021
Date of Initiation	25-06-2021	25-06-2021	25-06-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
4.	Stability study data of API from API manufacturer	Stability study conditions:

<table>
<tr><td></td><td></td><td>Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Copy of GMP certificate valid till 28-11-2022</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has used same qualitative composition of product as per innovator.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>21SB(A)-066-01</td><td>1500 tablets</td><td>05-2021</td></tr>
<tr><td>21SB(A)-067-02</td><td>1500 tablets</td><td>05-2021</td></tr>
<tr><td>21SB(A)-068-03</td><td>1500 tablets</td><td>05-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>CDP has been performed against the brand that is Briviact Tablets 25mg (B#286323) by UCB Pharma S.A, in Acid media (0.1N HCl), acetate buffer 4.5 & Phosphate Buffer pH (6.8). The f2 value was in acceptable range.</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
</table>

<table>
<tr><th colspan="2">Remarks of evaluator</th></tr>
<tr><th>Observation</th><th>Response of Firm</th></tr>
<tr><td>i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.</td><td>M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.</td></tr>
<tr><td>ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.</td><td>Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein Liquid Injection (Ampoule, Vial, Infusion)(General) , Oral liquid (General) sections are approved.</td></tr>
</table>

	Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (Genera**l)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

634.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited

		44-45 B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Tablet 50mg
	Composition	Each film-coated tablet contains: Brivaracetam……...50mg (Manufacturer's specifications)
	Diary No. Date of R& I & fee	Dy.3212 No. dated 02-03-2017, Fee Rs: 50,000/- dated 02-03-2017 vide deposit slip No.0515335.
	Pharmacological Group	Anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	10's,20's & 30's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Tablets 50mg by UCB Inc. USFDA Approved
	Me-too status	Brivace tablets 50mg by Hilton Pharma (Reg no: 110126)
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. Tablet section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA

Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.		
API Lot No.	BVC-202101102F1		
Description of Pack (Container closure system)	Alu/Alu		
Stability Storage Condition	Real time: 30°C ± 2° C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	20SB(B)-049-01	20SB(B)-050-02	20SB(B)-051-03
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	08-09-2021	08-09-2021	08-09-2021
No. of Batches	03		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted

<table>
<tr><td>3.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer</td><td>Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.</td></tr>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td>Stability study conditions:
Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Copy of GMP certificate valid till 28-11-2022</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has used same qualitative composition of product as per innovator.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>20SB(B)-049-01</td><td>1500 Tablets</td><td>08-2021</td></tr>
<tr><td>20SB(B)-050-02</td><td>1500 Tablets</td><td>08-2021</td></tr>
<tr><td>20SB(B)-051-03</td><td>1500 Tablets</td><td>08-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>CDP has been performed against the brand that is Brivatam Tablets (B#SUI) by CCL Pharmaceuticals, in Acid media (0.1N HCl), acetate buffer 4.5 & Phosphate Buffer pH (6.8). The f2 value was in acceptable range.</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
</table>

<table>
<tr><th colspan="2">Remarks of evaluator</th></tr>
<tr><th>Observation</th><th>Response of Firm</th></tr>
<tr><td>i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.</td><td>M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.</td></tr>
</table>

ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (General**)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

635.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Tablet 75mg
	Composition	Each film-coated tablet contains: Brivaracetam……...75mg (Manufacturer's specifications)
	Diary No. Date of R& I & fee	Dy. No.3211 dated 02-03-2017, Fee Rs: 50,000/- dated 02-03-2017 vide deposit slip No.0515336.
	Pharmacological Group	Anti-epileptic ATC Code N03AX23
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	10's,20's & 30's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Tablets 75mg by UCB Inc. USFDA Approved
	Me-too status	REG.NO.110127 Brivace Tablet 75mg Hilton pharma
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. Tablet section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA			
Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.		
API Lot No.	BVC-202101102F1		
Description of Pack (Container closure system)	Alu/Alu		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(B)-052-01	21SB(B)-053-02	21SB(B)-054-03
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	08-09-2021	08-09-2021	08-09-2021
No. of Batches	03		
Date of Submission	05-09-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	**Documents to Be Provided**	**Status**

<table>
<tr><td>1.</td><td>Reference of previous approval of applications with stability study data of the firm</td><td>• Not applicable</td></tr>
<tr><td>2.</td><td>Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.</td><td>Submitted</td></tr>
<tr><td>3.</td><td>Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer</td><td>Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.</td></tr>
<tr><td>4.</td><td>Stability study data of API from API manufacturer</td><td>Stability study conditions:
Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Copy of GMP certificate valid till 28-11-2022</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has used same qualitative composition of product as per innovator.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>21SB(B)-052-01</td><td>1500 tablets</td><td>08-2021</td></tr>
<tr><td>21SB(B)-053-02</td><td>1500 tablets</td><td>08-2021</td></tr>
<tr><td>21SB(B)-054-03</td><td>1500 tablets</td><td>08-2021</td></tr>
</table></td></tr>
<tr><td>11.</td><td>Record of comparative dissolution data (where applicable)</td><td>CDP has been performed against the brand that is Briviact Tablets (B#431582) by UCB Pharma S.A, in Acid media (0.1N HCl), acetate buffer 4.5 & Phosphate Buffer pH (6.8). The f2 value was in acceptable range.</td></tr>
<tr><td>12.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>13.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>14.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
</table>

Remarks of evaluator	
Observation	**Response of Firm**
i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (General**)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

636.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Tablet 100mg
	Composition	Each film-coated tablet contains: Brivaracetam……...100mg (Manufacturer's specifications)
	Diary No. Date of R& I & fee	Dy. No.3210 dated 02-03-2017, Fee Rs: 50,000/- dated 02-03-2017 vide deposit slip No.0515337.
	Pharmacological Group	Anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	10's,20's & 30's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Tablets 100mg by UCB Inc. USFDA Approved
	Me-too status	Brivace Tablets 100mg by Hilton Pharma (110128)
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. Tablet section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA

Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.		
API Lot No.	BVC-202101102F1		
Description of Pack (Container closure system)	Alu/Alu		
Stability Storage Condition	Real time: 30°C ± 2° C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(B)-055-01	21SB(B)-056-02	21SB(B)-057-03
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets

Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	08-09-2021	08-09-2021	08-09-2021
No. of Batches	03		
Date of Submission	05-09-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
4.	Stability study data of API from API manufacturer	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate valid till 28-11-2022
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	Firm has used same qualitative composition of product as per innovator.
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** 21SB(B)-055-01 / 1500 Tablets / 08-2021 21SB(B)-056-02 / 1500 Tablets / 08-2021 21SB(B)-057-03 / 1500 Tablets / 08-2021
11.	Record of comparative dissolution data (where applicable)	CDP has been performed against the brand that is Briviact Tablets (B#SW1) by UCB Pharma S.A, in Acid media (0.1N HCl), acetate buffer 4.5 & Phosphate Buffer pH (6.8). The f2 value was in acceptable range.
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of evaluator

Observation	**Response of Firm**
i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (Genera**l)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test

	container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.
Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**	

637.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Injection
	Composition	Each ml contains: Brivaracetam….10mg (Innovator's Specifications)
	Diary No. Date of R& I & fee	Dy. No.3539 dated 18-04-2017, Fee Rs: 50,000/- dated 17-04-2017 vide deposit slip No. 0515339.
	Pharmacological Group	Anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	(Innovator's specifications)
	Pack size & Demanded Price	5mlx1's & 5mlx10's. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Injection by UCB Inc. USFDA Approved
	Me-too status	N/A
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. Liquid injectable section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA	
Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.
API Lot No.	BVC-202101102F1
Description of Pack (Container closure system)	Clear glass vial
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%
Time Period	Real time: 6 months Accelerated: 6 months

Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(B)-031-01	21SB(B)-032-02	21SB(B)-033-03
Batch Size	2250ml (450 vials)	2250ml (450 vials)	2250ml (450 vials)
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	03-09-2021	03-09-2021	03-09-2021
No. of Batches	03		
Date of Submission	21-06-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Submitted
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
4.	Stability study data of API from API manufacturer	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate valid till 28-11-2022
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	Composition of liquid injection is not similar as per innovator.
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** 21SB(B)-031-01 / 2250ml (450 vials) / 08-2021 21SB(B)-032-02 / 2250ml (450 vials) / 08-2021 21SB(B)-033-03 / 2250ml (450 vials) / 08-2021
11.	Record of comparative dissolution data (where applicable)	N/A

12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of evaluator

Observation	**Response of Firm**
i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (Genera**l)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.
x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related

	substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

638.	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Bripsy Oral Solution
	Composition	Each ml contains: Brivaracetam……10mg (Innovator's specifications)
	Diary No. Date of R& I & fee	Dy. No. 3541 dated 18-04-2017, Fee Rs: 50,000/- dated 17-04-2017 vide deposit slip No. 0532902.
	Pharmacological Group	Anti-epileptic
	Type of Form	Form 5D
	Finished product Specifications	(Innovator's specifications)
	Pack size & Demanded Price	60ml & 120ml. As per PRC
	Approval status of product in Reference Regulator Authorities	Briviact Oral Solution by UCB Inc. USFDA Approved
	Me-too status	N/A
	GMP status	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023. section approved.
	Remarks of the Evaluator	

STABILITY STUDY DATA	
Manufacturer of API	Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China.
API Lot No.	BVC-202101102F1
Description of Pack (Container closure system)	Amber glass bottle
Stability Storage Condition	Real time: 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%
Time Period	Real time: 6 months

	Accelerated: 6 months		
Frequency	Accelerated: 0,3 & 6 (Months) Real Time: 0, 3& 6 (Months)		
Batch No.	21SB(B)-036-01	21SB(B)-037-02	21SB(B)-038-03
Batch Size	2250ml (75 bottles)	2250ml (75 bottles)	2250ml (75 bottles)
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	01-09-2021	01-09-2021	01-09-2021
No. of Batches	03		
Date of Submission	21-06-2022		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	• Not applicable
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Submitted
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
4.	Stability study data of API from API manufacturer	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches (BVC-201909103F1, BVC-201909102F1, BVC-201909101F1)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate valid till 28-11-2022
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of Purchase invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director , DRAP, Karachi.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	Firm has used same qualitative composition of product as per innovator.
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches:

Batch No.	Batch Size	Mfg. Date
21SB(B)-036-01	2250ml (75 bottles)	08-2021
21SB(B)-037-02	2250ml (75 bottles)	08-2021
21SB(B)-038-03	2250ml (75 bottles)	08-2021

11.	Record of comparative dissolution data (where applicable)	N/A
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of evaluator

Observation	**Response of Firm**
i. GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	M/s Genix Pharma Private Limited,44-45B Korangi creek road Karachi has submitted the GMP certificate based on evaluation conducted on 15th June, 2021, valid till 14-06-2023.
ii. Submit renewal of DML and section approval letter of tablet and oral liquid section.	Firm has submitted renewal letter no. 2-12/93-Lic(Vol-V), dated 20-09-2021, wherein **Liquid Injection** (Ampoule, Vial, Infusion)(General) , **Oral liquid** (General) sections are approved. Firm has provided 2-12/93(Vol-V), dated 30-09-2021, wherein **Tablet (General**)-Revised section is approved.
iii. Provided GMP certificate of Drug substance manufacturer is expired.	Firm has provided GMP certificate of Ruyuan HEC Pharm Co. Ltd, Xiaba Dvelopmetn zone, Ruyuan Country, Shaoguan city, 512721, Guangdong , China., However it is valid till 28-11-2022, issued by Germany.
iv. Justification required for not including particle size and crystal form in specification of drug substance in accordance with drug substance manufacturer.	We followed the supplier results during the product development stage.
v. Justification required for usage of different RPM (i.e. 75 rpm) whereas innovator is using 50 rpm in comparative dissolution profile of tablet dosage form.	We followed HO Guidelines to perform CDP. As per WHO guidelines technical report series, No. 937, 2006, Annex 7. A paddle apparatus at 75 rpm is used for tablets.
vi. Comparative dissolution profile is submitted against comparator's brands while the studies should be performed against the innovator's / reference product.	CDP of Bripsy tablet 10 , 25 , 50, 75, and 100mg are submitted against competitor brand because of the absence of an innovator sample.
vii. Provide calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies. In calculation of stability studies average value of standard area is not in accordance with chromatograms.	Firm has submitted calculation of system suitability i.e. RSD in raw data of accelerated and real time stability studies.
viii. Firm has provided 9 months real time stability data of drug substance manufacturer. Whereas shelf life of the drug substance is 2 years. Complete stability data as per claim shelf life required.	Firm has provided 12 months real time stability data of drug substance manufacturer
ix. Qualitative master formulation composition of liquid injection and oral solution are not similar as per innovator.	In initial dossier of form 5 D formulation of the product was different. However, in stability studies batches firm has used same qualitative composition. Requisite fee for change in formulation not submitted.

x. Finished product specifications of liquid injection are not in accordance with innovator and pharmacopoeia i.e. Osmolality, Container Closure Integrity Test and extractable volume etc.	The product Bripsy injection is tested as per developed specification including test appearance, identification, pH, Assay, particulate matter, sterility, BET and related substances. other test container closure integrity and extractable volume test are conducted at development stage
xi. Firm has submitted copy of Purchase Invoice No. WIS210021 dated 25-03-2021, specifying the import of 1 kg of Brivaracetam, duly attested by Assistant Director, DRAP, Karachi. Justification required. As total theoretical value of Brivaracetam consumed in stability batches is more than imported quantity. Furthermore, evidence is required regarding import of Injectable grade material for manufacturing of liquid injection.	Material was procured from 02 invoices (wis210021 & wis210022) duly endorsed by respective Assistant Director, DRAP, Karachi.

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

CASE NO. 5. REGISTRATION APPLICATIONS OF LOCAL MANUFACTURING OF HUMAN DRUGS SUBMITTED ON CTD FORMAT (DEFERRED CASES)

639.	Name, address of Applicant / Marketing Authorization Holder	M/s Daneen Pharma Private Limited 27-Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Name, address of Manufacturing site.	M/s Daneen Pharma Private Limited 27-Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ **Is involved in none of the above (contract giver)**
	Status of application	☐ **New Drug Product (NDP)** ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Dy. No. and date of submission	Dy. No. 34242 dated 31/12/2021
	Details of fee submitted	PKR 30,000/-: dated 24/11/2021, Slip number 34264783007
	The proposed proprietary name / brand name	Zalpaz Injection 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Cefoperazone Sodium eq. to Cefoperazone ….250mg Sulbactam Sodium eq. to Sulbactam….250mg (JP specifications)
	Pharmaceutical form of applied drug	Intravenous
	Pharmacotherapeutic Group of (API)	Antibiotic

	Reference to Finished product specifications	Japanese Pharmacopoeia
	Proposed Pack size	1's
	Proposed unit price	As per PRC
	The status in reference regulatory authorities	Cefocef Injection by M/s Sawai Pharmaceutical Japan Approved.
	For generic drugs (me-too status)	Xorbact Injection by Curexa Health Private Limited, Reg no: 082734
	GMP status of the Finished product manufacturer	New GMP granted on 03/04/2019 Cephalosporin section approved.
	Name and address of API manufacturer.	Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Cefoperazone+Sulbactam are non-pharmacopeial. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (11C0311702001, 11C0311702002 & 11C0311702003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure, its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Xorbact Injection (B#2080197) by M/s CUREXA HEALTH (PVT.) LIMITED Ltd by performing quality tests (Identification, Appearance, Reconstitution, pH) CDP N/A
	Analytical method validation/verification of product	Method validation studies have been submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		

Manufacturer of API	Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., West side of yanbin Road , Economic Development Zone , Feixian, Linyi, Shandong, China.		
API Lot No.	11C0312011001		
Description of Pack (Container closure system)	Clear glass Vial		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3 6 (Months) Real Time: 0,3, 6, (Months)		
Batch No.	001IT001	002IT001	003IT003
Batch Size	120 Vials	120 Vials	120 Vials
Manufacturing Date	10-03-2021	10-03-2021	07-04-2021
Date of Initiation	25-03-2021	25-03-2021	21-04-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not provided
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate valid till 30/08/2022
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Purchase invoice dated 05/01/2021 is submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr.#	Section#	Observation
1.	**1.3.5**	Firm has provided GMP Certificate which is valid until 07-03-2022 based on evaluation conducted on 08-03-2019.GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.
2.	**1.6.5**	Provide valid GMP Certificate of drug substance manufacturer.
3.	**3.2.S.4**	• In Analytical Method drug substance manufacturer water limit is not more than 3 %. Whereas in Japanese Pharmacopoeia it is not more than 1.0 %. Justification required. Analytical procedure of drug substance manufacturer is in complete. • Analytical Method validation studies for drug substance are missing.
4.	**3.2.S.7**	In stability studies of Drug substance manufacturer data for 2-year real time stability studies has been provided. However as per COA DS manufacturer is claiming 3 years shelf life. 3 years real time stability data is required.

5.	**2.3.P.1**	Justification of overages in the formulation(s) described in 2.3.P.1
6.	**3.2.P.2.2.1**	Justification shall be submitted for not performing Pharmaceutical equivalence studies against the innovator product.
7.	**3.2.P.7**	• In Section 3.2.P.1. Type of Container Closure System is Type 1. Whereas in Section 3.2.P.8 T Is Mentioned USP Type III vials mentioned. Justification required. • Justification required for usage of USP Type- III glass for injectable.
8.	**3.2.P.8.**	• Justification required for not including sterility and bacterial Endotoxin testing in stability studies. • Justification required regarding batch size of 120 vials in stability studies. • Submit clear/readable copies of chromatograms, Raw data sheets.
Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.		

Sr.#	Section#	Observation	Response of firm
1.	**1.3.5**	Firm has provided GMP Certificate which is valid until 07-03-2022 based on evaluation conducted on 08-03-2019.GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted.	Firm has submitted valid GMP certificate of M/s Daneen Pharma Private Limited27-Sundar Industrial Estate, Sundar Raiwind Road, Lahore, based on evaluation conducted on27-10-2021 valid till 26-10-2024.
2.	**1.6.5**	Provide valid GMP Certificate of drug substance manufacturer.	Firm has submitted manufacturing license of M/s Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., valid till 26-10-2025.
3.	**3.2.S.4**	• In Analytical Method drug substance manufacturer water limit is not more than 3 %. Whereas in Japanese Pharmacopoeia it is not more than 1.0 %. Justification required. Analytical procedure of drug substance manufacturer is in complete. • Analytical Method verification studies for drug substance are missing.	• Firm has submitted revised analytical method with water limit NMT 1 %. However fee for revision of specification has not submitted. Missing
4.	**3.2.S.7**	In stability studies of Drug substance manufacturer data for 2-year real time stability studies has been provided. However as per COA DS manufacturer is claiming 3 years shelf life. 3 years real time stability data is required.	Submitted
5.	**2.3.P.1**	Justification of overages in the formulation(s) described in 2.3.P.1	
6.	**3.2.P.2.2.1**	Justification shall be submitted for not performing Pharmaceutical equivalence studies against the innovator product.	Due to non availability of innovator brand firm has performed Pharmaceutical equivalence Xorbact Injection (B#2080197) by M/s Curexa Health (Pvt.) Limited
7.	**3.2.P.7**	• In Section 3.2.P.1. Type of Container Closure System is Type 1. Whereas in Section 3.2.P.8 T Is Mentioned USP Type III vials mentioned. Justification required. • Justification required for usage of USP Type- III glass for injectable.	Zalpaz 500mg Injection Containing Cefoperazone Sodium Eq. To Cefoperazone ….250mg Sulbactam Sodium Eq. To Sulbactam….250mg is Packed In Type-III Glass Vials as its compatibility has been practically established by accelerated stability studies for reference USP<660> container-glass "suitable stability test data indicate that type iii glass is satisfactory."
8.	**3.2.P.8.**	a. Justification required for not including sterility and bacterial Endotoxin testing in stability studies. b. Justification required regarding batch size of 120 vials in stability studies. c. Submit clear/readable copies of chromatograms, Raw data sheets.	a. Stability studies of zalpaz injection 500 mg were performed as per ICH guidelines (ICH Harmonized tripartite guidelines stability testing of new drug substances and products Q1A(R2) current step 4 version dated 06 February 2003). In section 2.15 regarding the selection of the specification for stability study it states that stability studies should include testing of those attributes of the drug substance that are susceptible to change during storage. As the used container closure system is well established for its compatibility for sterile products, hence the sterility and endotoxin are not susceptible during storage. b. submitted C. submitted

Approved with container closure as Type I glass vial for drug product.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

• **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
640.	Name, Address of Applicant / Marketing Authorization Holder	M/s Bio-Labs (Pvt.) Ltd, Plot No. 145, Industrial Triangle Kahuta Road Islamabad.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd, Plot No. 145, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.17785: Dated 25-06-2021
	Details of fee submitted	PKR 30,000/-: Dated 10-06-2021
	GMP status of the Finished product manufacturer	The firm is granted GMP certificate based on inspection conducted on 23-04-2019.
	The proposed proprietary name / brand name	Colicraft Injection I.V 2MIU
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Colistimethate Sodium……..2MIU
	Pharmaceutical form of applied drug	Glass vial filled with almost white to off-white colored Lyophilized Powder for Injection.
	Pharmacotherapeutic Group of (API)	Antibacterial agent
	Reference to Finished product specifications	USP specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Colistimethate sodium for injection of M/s Mukhtar Enterprises Lahore (Reg#094757).
	For generic drugs (me-too status)	Colistimethate sodium 2 MIU, powder for solution for injection by M/s PANMEDICA (MHRA Approved).
	Name and address of API manufacturer.	M/s Mac-Chem Products (India) Pvt. Ltd., N-211/2/10, MIDC. Boisar, District –Thane, Pin – 401 506, Maharashtra, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	The firm has submitted detailed data for drug substance related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing

		process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2 °C / /65% ± 5%RH RH for 12 months Accelerated: 40°C ± 2°C /75% ± 5%RH for 6 months Batches: (CLS0219006, CLS0219008, CLS0219009).
	Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence of trial formulation (Batch # T001) against reference product Colistimethate Sodium 2MIU Injection (Lot No. 3056579) of M/s Xellia Pharmaceuticals by performing Biological assay by zone of inhibition method.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	M/s Mac-Chem Products (India) Pvt. Ltd., N-211/2/10, MIDC. Boisar, District –Thane, Pin – 401 506, Maharashtra, India.		
API Lot No.	CLS0218009		
Description of Pack (Container closure system)	Glass vial		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 ,9,12,18,24 (Months)		
Batch No.	T001	T002	T003
Batch Size	1000 Vials	1000 Vials	1000 vials
Manufacturing Date	08-2018	08-2018	08-2018
Date of Initiation	12-08-2018	14-08-2018	16-08-2018
No. of Batches	03		

DOCUMENTS / DATA REQUIRED ALONGWITH APPLICATION

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. NEW-WHO-GMP/CERT/KD/74238/2018/11/24897 issued by Food and Drug Administration, Maharashtra State, India valid till 10-09-2021.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice (Invoice # 67533/2020 dated 27-01-2020 with received quantity of 5Kg) for the purchase of Colistimethate sodium for Injection. The invoice is cleared by Assistant director (I & E), DRAP, Islamabad.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of testing of all batches along with raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	N.A.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Remarks of Evaluator:

Sr. No.	Observations communicated	Response by the firm
1.	Analytical method verification studies including specificity, accuracy and repeatability (method precision) performed by the drug product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted Bioassay test method validation protocol and reports for the determination of colistimethate sodium by performing accuracy, precision, Linearity, range, ruggedness and specificity parameters.
2.	Valid copy of GMP certificate of drug substance manufacturer issued by country of origin.	
3.	COA of primary / secondary reference standard including source and lot number shall be provided.	The firm has submitted certificate of analysis showing working standard calibration report.
4.	Submit master formulation including theoretical fill weight per vial.	The firm has submitted master formulation showing quantity of fill weight per vial.
5.	Justify why pharmaceutical equivalence studies do not include all the tests as recommended by USP. Instead the test for microbiological has been performed only.	Firm has submitted revised pharmaceutical equivalence against reference product Colistimethate Sodium 2MIU Injection (Lot No. 3056579) of M/s Xellia Pharmaceuticals by performing identification, pH, uniformity of dosage unit, particulate matter, Biological assay, sterility and Endotoxin.
6.	Scientific justification of manufacturing of applied formulation by way of lyophilization using pre-lyophilized Colistimethate for Injection from M/s Mac-Chem Products (India) Pvt. Ltd.	The firm has submitted that the bulk and raw material of colistimethate sodium was available in lyophilized powder form. The raw material is then formulated into solution which is filled and lyophilized.
7.	Provide detailed method of analysis of the drug product instead of providing copy of USP monograph.	The firm has submitted method of analysis of the drug product.

8.	Provide detailed protocols how validation of analytical procedures of the drug product was carried out and further justify how the recovered concentration (mg/ml) was calculated in accuracy and recovery.	The firm has submitted Bioassay test method validation protocol and reports for the determination of colistimethate sodium. Accuracy is determined by standard addition method, previously analyzed sample with concentration of 0.2mg/ml were spiked with 50, 100, and 150% API and the mixtures were analyzed by the proposed method.
9.	Provide COA of reference standard actually used in the analysis of drug product.	The firm has submitted copy of USP primary reference standard with lot no. H3J047.
10.	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.	The firm has submitted copies of batch manufacturing records for all the batches of drug product for which stability studies data is provided.

Decision of 321st meeting of Registration Board: Deferred for following submissions:

- Valid GMP certificate or DML of drug substance manufacturer issued by relevant regulatory authority of the country of origin since submitted GMP certificate was valid till 10-9-2021.
- Scientific justification for using prelyophilized drug substance for formulation of the finished drug product by way of lyophilization.

S.no.	Observation	Response of the firm
1.	Valid GMP certificate or DML of drug substance manufacturer issued by relevant regulatory authority of the country of origin since submitted GMP certificate was valid till 10-9-2021.	Firm has submitted valid GMP Certificcate of M/s Mac-Chem Products (India) Pvt. Ltd., N-211/2/10, MIDC. Boisar, District –Thane, Pin – 401 506, Maharashtra, India, valid till 30-04-2023.
2.	Scientific justification for using prelyophilized drug substance for formulation of the finished drug product by way of lyophilization.	Firm has stated that we do not purchase the pre-lyophilized drug substance but the sterile only. Relevant ADC is provided. COA submitted initially was wrong which was given by supplier. We are submitting again the corrected COA for your kind review and approval of product registration.

Decision of 323rd meeting of registration Board regarding Colistimethate Sodium:

Registration Board deliberated the matter in details and after through discussion, decided as under;

1. The concerned label claim of existing registrations of Injection of Colistimethate sodium shall be updated according to approved pharmacopoeial specifications as per following details:

- For U.S.P specification the revised label claim shall be,
  Each vial/lyophilized vial Contains:
  Colistimethate sodium (equivalent to) …… (Relative strength of) mg colistin base activity

  For example for 1MIU:
  Each vial Contains:
  Colistimethate sodium equivalent to 34mg Colistin base activity

- For B.P specification the revised label claim shall be,
  Each vial/ lyophilized vial contains:
  Colistimethate sodium…… (Relative strength of) million IU

  For example, for 1MIU:
  Each vial Contains:
  Colistimethate sodium ……1MIU

2. Registration Board has further decided to advise registration holders to also mention equivalency of "Colistimetahte sodium (IU)" with "Colistin base activity" in miligrams, on unit carton and label according to relevant strength as the case may be, for examples, as under.

"Potency of Colistimethate sodium:

1 Million IU	equivalent to	34 mg Colistin base Activity (approximately)
4.5 Million IU	equivalent to	150 mg Colistin base Activity (approximately)
9 Million IU	equivalent to	300 mg Colistin Base Activity (approximately)"

Pharmaceutical firms having already registration of "Colistimethate sodium injection" shall apply to PE&R Division with requisite documents and fee for harmonization of the label claim as per point 1 of above decision.
Decision of 324th meeting: Approved with label claim for USP specifications as decided in 323rd meeting of Registration Board. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

641.	Name, address of Applicant / Marketing Authorization Holder	M/s Hansel Pharmaceuticals Private Limited, Plot No. 02, Pharma City, 30-km Multan Road, Lahore-Pakistan.
	Name, address of Manufacturing site.	M/s Hansel Pharmaceuticals Private Limited, Plot No. 02, Pharma City, 30-km Multan Road, Lahore-Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24079 Dated 01-09-2021
	Details of fee submitted	PKR 20,000/- Dated 28-08-2020 PKR 10,000/- (Bank slip #6614935760)
	The proposed proprietary name / brand name	Femipla-Ject Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1mL ampoule contains: Norethisterone Enanthate……..50mg Estradiol Valerate……..5mg
	Pharmaceutical form of applied drug	Oily solution for Injection (IM)
	Pharmacotherapeutic Group of (API)	Progestogens (Contraceptive) ATC Code: G03AC
	Reference to Finished product specifications	Hansel Specifications
	Proposed Pack size	1ml × 1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Estradiol valerate/Norethisterone enantate Solution for injection 5mg/50mg/mL (WHO prequalified product).
	For generic drugs (me-too status)	FEMI-JECT Injection by M/s Bayer pharma (Pvt.) Ltd. Lahore, (Reg # 022372).
	GMP status of the Finished product manufacturer	The firm is granted GMP certificate based on inspection conducted on 15-05-2019. The firm has provided Liquid Injectable Hormone section.
	Name and address of API manufacturer.	**Norethisterone Enanthate:** M/s Zhejiang Xianju Junye Pharmaceutical Co., Ltd., No.1 Lingxiu Road, Modern Industrial Centralization zone, Xianju, Taizhou, Zhejiang, China.

		Estradiol Valerate: M/s ASG. Biochem Pvt. Ltd., Ganganagar, 24 Parganas, West Bengal India.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted details of nomenclature, structure, general properties, solubility, physical form, manufacturers, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substances (Norethisterone Enanthate+ Estradiol Valerate).
	Stability studies	**Norethisterone Enanthate:** Stability study conditions: Real time: 30°C±2°C/65% ± 5%RH for 24 months. Accelerated: 40°C±2°C/75%±5%RH for 6 months. Batches: (30761308001, 30761308002, 30761308003). **Estradiol Valerate**: Stability study conditions: Real time: 30°C±2°C/65% ± 5%RH for 48 months. Accelerated: 40°C±2°C/75%±5%RH for 6 months. Batches: (ESVZ01A002, ESVZ01A005, ESVZ01A006).
	Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence has been established against the comparator product Femi-Ject by Bayer Pharma by performing quality tests (Identification, Assay, pH, Particulate matter, Sterility). Dissolution profile in not applicable in Femipla-Ject Injection.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	**Norethisterone Enanthate:** M/s Zhejiang Xianju Junye Pharmaceutical Co., Ltd., No.1 Lingxiu Road, Modern Industrial Centralization zone, Xianju, Taizhou, Zhejiang, China.	

	Estradiol Valerate: M/s ASG. Biochem Pvt. Ltd., Ganganagar, 24 Parganas, West Bengal India.		
API Lot No.	Norethisterone Enanthate: 3076190701M Estradiol Valeartae: ESVZ01A016		
Description of Pack (Container closure system)	1 amber color ampoule of 1mL packed in unit carton along with disposable syringe, alcohol swab and a leaflet.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	FT-001	FT-002	FT-003
Batch Size	2000 Ampoules	2000 Ampoules	2000 Ampoules
Manufacturing Date	10-2019	10-2019	10-2019
Date of Initiation	08-10-2019	10-10-2019	12-10-2019
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	It is the submission of first dossier on CTD format, thus no inspection conducted regarding stability studies of the applied product.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Norethisterone Enanthate:** The firm has submitted copy of GMP certificate for M/s Zhejiang Xianju Junye Pharmaceutical Co. issued by national medical products administration valid till 29-11-2024. **Estradiol valerate:** The firm has submitted copy of GMP certificate for M/s ASG Biochem Pvt. Ltd. issued by Director of Drugs Control, Govt. of West Bangal. The license is valid till 24-10-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Norethisterone Enanthate**: The firm has submitted copy of invoice specifying import of Norethisterone enanthate 20gm (Batch # 3076190701M) attested by Assistant Director (I & E) Lahore dated 30-09-2019. **Estradiol Valerate:** The firm has submitted copy of invoice specifying import of estradiol valerate 20gm (Batch # 190401) attested by Assistant Director (I & E) Lahore dated 01-08-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, raw data sheets, COA, summary data sheets etc.	The firm has submitted data of stability batches supported by attested respective documents like chromatograms, raw data sheets, COA, summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable.
6.	Record of digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

Remarks of Evaluator:

Sr. No.	Observations	Response by the firm
1.	Provide copies of the Drug substance specifications and analytical procedures used for	The firm has provided copies of drug substance specifications and analytical procedures.

	routine testing of the Drug substance by both Drug substance & Drug Product manufacturer.	
2.	Provide certificate of Analysis (CoA) of the drug substance (Estradiol valerate) from drug substance manufacturer.	The firm has submitted certificate of analysis of Estradiol valerate from drug substance manufacturer.
3.	Provide the details of the reference product including batch number, manufacturing date and expiry date.	The firm has submitted details of reference product: Name: FEMI-JECT Injection Batch number: MP06249 Mfg date: 09-2019 Expiry date: 09-2024
4.	Justify why you have not performed the tests of clarity of solution and bacterial endotoxin in the pharmaceutical equivalence study.	Not submitted
5.	Justify why tests of pH and ampoule sealing are included in specifications under analytical procedures (3.2.P.5.2). Moreover, provide the pharmacopoeial reference where the test of "ampoule sealing" is mentioned	Not submitted
6.	Justify the test of pH throughout stability studies for development batches of oily injection.	Not submitted
7.	Reference of previous approval of applications with stability study data of the firm (if any).	The firm has submitted previous approvals of products in this section.
8.	Submit compliance Record of HPLC software 21CFR. The submitted audit trail reports do not specify the software used in HPLC and further clarify the demo version of software.	The firm has not submitted audit trail record of HPLC software 21 CFR.

Decision of 321st meeting of registration board: Deferred for following:

- Evidence of required manufacturing facility / section from Licensing Division.
- Scientific justification for not performing the tests of clarity of solution and bacterial endotoxin in the pharmaceutical equivalence study.
- Scientific justification for the test and limits of pH and ampoule sealing test for oily injection.
- Scientific justification for performing the test of pH throughout stability studies for development batches of oily injection.

Sr. No.	Observations	Response by the firm
1.	Evidence of required manufacturing facility / section from Licensing Division.	Firm has provided approval of revised section namely Liquid Injectable (Hormone) (Reallocated from list floor to ground floor), vide letter no. F. 1-9/2001-Lic(Vol-II), dated 03-10-2019
2	Scientific justification for not performing the tests of clarity of solution and bacterial endotoxin in the pharmaceutical equivalence study.	Firm has provided Pharmaceutical equivalence study with test of clarity of solution and Bacterial endotoxin tests.
3	Scientific justification for the test and limits of pH and ampoule sealing test for oily injection.	pH & ampoule sealing are included in specifications under analytical procedure (3.2.P.5.2) Because product is non-pharmacopoeial, so in-house specifications are used for pH to control process of manufacturing. Whereas ampoules sealing test is used to verify sealing integrity of container closure to maintain sterility of product.
4	Scientific justification for performing the test of pH throughout stability studies for development batches of oily injection.	The product is non-pharmacopoeial so in-house specifications are used for pH throughout stability studies for development batches of oily injection to control process of manufacturing.

Decision of 322nd meeting of registration board: Registration Board decided to defer the case for further deliberation against the quality parameters and specifications of innovator's drug product.

Firm has submitted reply in light of 322nd meeting:

We would like to omit the parameter of pH from the FPP specifications. For this purpose, we have also submitted fee for pre-registration variation i.e. change in FPP specification(30811229193).

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

642.	Name, address of Applicant / Marketing Authorization Holder	M/s Fleming Pharmaceutical. 23- Km Lahore- Sheikhupura Road, Lahore.
	Name, address of Manufacturing site.	M/s Fleming Pharmaceutical. 23- Km Lahore- Sheikhupura Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Dy. No. and date of submission	Dy. No. 23969 dated 24/08/2022
	Details of fee submitted	PKR 30,000/-: dated 12/08/2022(69080973)
	The proposed proprietary name / brand name	Flementin Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Amoxicillin (as Amoxicillin sodium) 1000 mg and Clavulanic acid (as Potassium Clavulanate) 200 mg.
	Pharmaceutical form of applied drug	Vial
	Pharmacotherapeutic Group of (API)	Penicillin antibacterial + beta-lactamase inhibitor
	Reference to Finished product specifications	BP Specification
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Augmentin Intravenous Injection by M/s GSK, MHRA Approved.
	For generic drugs (me-too status)	Calamox Injection by M/s Bosch Pharma, Reg. No. 021507
	GMP status of the Finished product manufacturer	New license granted on 14/09/2021 Dry Powder Injectable (Penicillin)
	Name and address of API manufacturer.	SinoPharm Weiqida Pharmaceutical Co. Ltd. Economic & Technological Development Zone, First Medical Zone, Datong Shanxi.China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	The firm is submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 5˚C ± 3˚C for 48 months Accelerated: 25˚C ± 2˚C / 60% ± 5%RH for 6 months Batches: (47SA1705019, 59SA1707013, 63SA1709013)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader Stamentin Injection 1200 mg by Stallion Pharma (Batch M1003) by performing quality tests (Identification, Assay, Sterility etc.).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	SinoPharm Weiqida Pharmaceutical Co. Ltd. Economic & Technological Development Zone, First Medical Zone, Datong Shanxi.China		
API Lot No.	47SA2106040		
Description of Pack (Container closure system)	Flementin injection is filled in Glass vial further packed in unit carton along with patient leaflet insert		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-001	T-002	T-003
Batch Size	1700 Vial	1700 Vial	1700 Vial
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	26-02-2022	26-02-2022	26-02-2022
No. of Batches	03		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	New DML granted.	

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. SX20180229 issued by SFDA valid till 05/06/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Commercial Invoice with Assistant Director DRAP signatures No.538/2022/DRAP dated 12-01-22 is submitted for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Section	Observations
1.	**3.2.S.4**	• In analytical method conditions for HPLC testing are not in accordance with the conditions of Drug Substance manufacturer. • In analytical testing penicillanse are not used in sterility testing, in accordance with Pharmacopoeia and analytical method of drug substance manufacturer.
2.	**3.2.P.2.2.1**	Justification shall be submitted for not performing Pharmaceutical equivalence studies against the innovator product.
3.	**3.2.P.5.2**	In official pharmacopoeia (BP) reference standard are lithium clavulante and amoxicillin trihydrate. Whereas in analytical method of drug product manufacturer amoxicillin and clavulanic acid are used as working standard. justification required**.**
4.	**3.2.P.5.2**	In analytical method validation of drug product justification is required regarding limits of Mean recovery %age in accuracy, repeatability and intermediate precision etc. (i.e. limit of Mean recovery %age for 120 % concentration is 108-144.0%).
5.	**3.2.P.7**	• A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided. Please also provide USP type of glass vials. • In BMR it is mentioned that 20 cc glass vials have been used. However, innovator is using 25 or 50 ml vial. Furthermore, Co Amoxiclave 1000 mg/200 mg should be dissolved in 20 ml of solvent. This yields approximately 20.9 ml of solution for single-dose use. Justification required. • In BMR of Co-amoxiclave 600 mg Glass Vials Type III (10cc) are mentioned). Whereas in Section 3.2.P.1 it is Type-II Glass vials. Justification required.
6.	**3.2.P.8**	• Firm has provided stability data for only 03 months for accelerated stability studies and real time stability studies. • Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Sterility testing is not included in stability data and Pharmaceutical equivalence studies. • Stability record of T-002 Batch of Co-amoxiclave 600 mg injection missing.

		• In stability data sheets resolution has not been calculated as per the official pharmacopeia i.e. BP. • Record of Digital data logger for temperature and humidity monitoring of stability chambers and audit trail reports on product testing for complete testing periods are missing.

Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

S.no.	Section	Observations	Response of firm
1.	**3.2.S.4**	• In analytical method conditions for HPLC testing are not in accordance with the conditions of Drug Substance manufacturer. • In analytical testing penicillanse are not used in sterility testing, in accordance with Pharmacopoeia and analytical method of drug substance manufacturer.	• As drug substance is in mixture form Amoxicillin: clavulanic acid(5:1) and monograph in BP available for analyzing the drug product combination of Amoxicillin: clavulanic acid with ratio (5:1) . So we have used the same method in drug substance and method is verified. • Not submitted
2.	**3.2.P.2.2.1**	Justification shall be submitted for not performing Pharmaceutical equivalence studies against the innovator product.	Firm has submitted Pharmaceutical equivalence studies against Augmentin (GSK) injection
3.	**3.2.P.5.2**	In official pharmacopoeia (BP) reference standard are lithium clavulante and amoxicillin trihydrate. Whereas in analytical method of drug product manufacturer amoxicillin and clavulanic acid are used as working standard. justification required**.**	Firm has stated that we have used the same reference standard (working standards provided by API manufacturer)
4.	**3.2.P.5.2**	In analytical method validation of drug product justification is required regarding limits of Mean recovery %age in accuracy, repeatability and intermediate precision etc. (i.e. limit of Mean recovery %age for 120 % concentration is 108-144.0%).	It was typographic mistake. Firm has submitted revised method validation report with revised limits.
5.	**3.2.P.7**	• A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided. Please also provide USP type of glass vials. • In BMR it is mentioned that 20 cc glass vials have been used. However, innovator is using 25 or 50 ml vial. Furthermore, Co Amoxiclave 1000 mg/200 mg should be dissolved in 20 ml of solvent. This yields approximately 20.9 ml of solution for single-dose use. Justification required. • In BMR of Co-amoxiclave 600 mg Glass Vials Type III (10cc) are mentioned). Whereas in Section 3.2.P.1 it is Type-II Glass vials. Justification required.	We are using 25cc glass vials type- II.
6.	**3.2.P.8**	• Firm has provided stability data for only 03 months for accelerated stability studies and real time stability studies. • Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Sterility testing is not included in stability data and Pharmaceutical equivalence studies. • Stability record of T-002 Batch of Co-amoxiclave 600 mg injection missing.	Submitted Submitted Submitted Firm has provided revised stability data

		• In stability data sheets resolution has not been calculated as per the official pharmacopeia i.e. BP. • Record of Digital data logger for temperature and humidity monitoring of stability chambers and audit trail reports on product testing for complete testing periods are missing.	Not calculated Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

643.	Name, address of Applicant / Marketing Authorization Holder	M/s Fleming Pharmaceutical. 23- Km Lahore- Sheikhupura Road, Lahore.
	Name, address of Manufacturing site.	M/s Fleming Pharmaceutical. 23- Km Lahore- Sheikhupura Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ **Domestic and Export sales**
	Dy. No. and date of submission	Dy. No. 23968 dated 24/08/2022
	Details of fee submitted	PKR 30,000/-: dated 16/08/2022(34449438664)
	The proposed proprietary name / brand name	Flementin Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Amoxicillin (as Amoxicillin sodium) 500 mg and Clavulanic acid (as Potassium Clavulanate) 100 mg.
	Pharmaceutical form of applied drug	Vial
	Pharmacotherapeutic Group of (API)	Penicillin antibacterial + beta-lactamase inhibitor
	Reference to Finished product specifications	BP Specification
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Augmentin Intravenous Injection by M/s GSK, MHRA Approved.
	For generic drugs (me-too status)	Calamox Injection by M/s Bosch Pharma, Reg. No. 021507
	GMP status of the Finished product manufacturer	New license granted on 14/09/2021 Dry Powder Injectable (Penicillin)
	Name and address of API manufacturer.	SinoPharm Weiqida Pharmaceutical Co. Ltd. Economic & Technological Development Zone, First Medical Zone, Datong Shanxi.China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to

		nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm is submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 5˚C ± 3˚C for 48 months Accelerated: 25˚C ± 2˚C / 60% ± 5%RH for 6 months Batches: (47SA1705019, 59SA1707013, 63SA1709013)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader Stamentin Injection 1200 mg by Stallion Pharma (Batch L00001) by performing quality tests (Identification, Assay, Sterility etc.).
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	SinoPharm Weiqida Pharmaceutical Co. Ltd. Economic & Technological Development Zone, First Medical Zone, Datong Shanxi.China		
API Lot No.	47SA2106040		
Description of Pack (Container closure system)	Flementin injection is filled in Glass vial further packed in unit carton along with patient leaflet insert		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-001	T-002	T-003
Batch Size	1700 Vial	1700 Vial	1700 Vial
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	26-02-2022	26-02-2022	26-02-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	New DML granted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. SX20180229 issued by SFDA valid till 05/06/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Commercial Invoice with Assistant Director DRAP signatures No.538/2022/DRAP dated 12-01-22 is submitted for the purpose of test/analysis and stability studies is granted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Remarks of Evaluator:

S.no.	Section	Observations	Response of firm
1.	**3.2.S.4**	• In analytical method conditions for HPLC testing are not in accordance with the conditions of Drug Substance manufacturer. • In analytical testing penicillanse are not used in sterility testing, in accordance with Pharmacopoeia and analytical method of drug substance manufacturer.	• As drug substance is in mixture form Amoxicillin: clavulanic acid(5:1) and monograph in BP available for analyzing the drug product combination of Amoxicillin: clavulanic acid with ratio (5:1) . So we have used the same method in drug substance and method is verified.
2.	**3.2.P.2.2.1**	Justification shall be submitted for not performing Pharmaceutical equivalence studies against the innovator product.	Firm has submitted Pharmaceutical equivalence studies against Augmentin (GSK) injection
3.	**3.2.P.5.2**	In official pharmacopoeia (BP) reference standard are lithium clavulante and amoxicillin trihydrate. Whereas in analytical method of drug product manufacturer amoxicillin and clavulanic acid are used as working standard. justification required**.**	Firm has stated that we have used the same reference standard (working standards provided by API manufacturer)
4.	**3.2.P.5.2**	In analytical method validation of drug product justification is required regarding limits of Mean recovery %age in accuracy, repeatability and intermediate precision etc. (i.e. limit of Mean recovery %age for 120 % concentration is 108-144.0%).	It was typographic mistake. Firm has submitted revised method validation report with revised limits.
5.	**3.2.P.7**	• A detail of the container closure systems, description of the primary container closure systems, including materials of construction, unit count or fill size, container size or volume shall be provided. Please also provide USP type of glass vials. • In BMR it is mentioned that 20 cc glass vials have been used. However, innovator is using 25 or 50 ml vial. Furthermore, Co Amoxiclave 1000 mg/200 mg should be dissolved in 20 ml of solvent. This yields	We are using 25cc glass vials type- II.

		approximately 20.9 ml of solution for single-dose use. Justification required. • In BMR of Co-amoxiclave 600 mg Glass Vials Type III (10cc) are mentioned). Whereas in Section 3.2.P.1 it is Type-II Glass vials. Justification required.	
6.	**3.2.P.8**	• Firm has provided stability data for only 03 months for accelerated stability studies and real time stability studies. • Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Sterility testing is not included in stability data and Pharmaceutical equivalence studies. • Stability record of T-002 Batch of Co-amoxiclave 600 mg injection missing. • In stability data sheets resolution has not been calculated as per the official pharmacopeia i.e. BP. • Record of Digital data logger for temperature and humidity monitoring of stability chambers and audit trail reports on product testing for complete testing periods are missing.	Submitted Submitted Submitted Firm has provided revised stability data Submitted Firm has provided chromatograms depicting resolution Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

CASE NO. 5. REGISTRATION APPLICATIONS OF LOCAL MANUFACTURING OF HUMAN DRUGS SUBMITTED ON FORM 5 (DEFERRED CASES).

644.	Name and address of manufacturer / Applicant	M/s Bajwa Pharmaceuticals Pvt. Ltd. 36-Km, Lahore-Gujranwala Road Khori District Sheikhupura
	Brand Name +Dosage Form + Strength	Calcium chloride Injection
	Composition	Each 10ml contains: Calcium chloride $2H_2O$…..……..2000mg
	Diary No. Date of R& I & fee	Dy. No 28768 Dated 28-08-2018, Rs. 20,000/- 28-08-2018
	Pharmacological Group	Electrolyte
	Type of Form	Form-5
	Finished product Specifications	USP specifications
	Pack size & Demanded Price	10ml x 10 Ampoules, 10ml x 5 Ampoules & As per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too status (with strength and dosage form)	Calcium Chloride Injection of M/s LC&PW, Lahore
	GMP status	DML by way of formulation dated 02-12-2014 & GMP compliance inspection dated 21-02-2018
	Previous decision(s)	Deferred for evidence of approval of applied formulation in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting (M-292).

	Evaluation by PEC	The firm has submitted reference Baxter Healthcare corporation 15mg/100ml Calcium chloride : 1g /10ml ampoules Galenica MA (Italy)
	Remarks of the Evaluator	
	Decision of 321st meeting of Registration Board: Deferred for evidence of approval of applied formulation in 10ml fill volume in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting.	
Firm has revised the formulation Each ml contains: Calcium chloride dihydrate 100 mg/ml, elemental calcium 27.2mg/ml 10 ml ampoule Firm has provided requisite R.S. 30,000/- (66755258596). Firm has provided RRA status of the product in MHRA. **Remarks of evaluator:** Evidence Me-too status (with strength and dosage form) could not ascertained		
Decision: Deferred for evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or else application on Form 5D along with differential fee and stability study data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.		

Item No. 8: Agenda of Evaluator PEC-IX (Mr. Adil Saeed)

645.	Name and address of manufacturer/ Applicant	M/s Kaizen Pharmaceuticals (Pvt.) Ltd. Plot No. E-127, E-128 & E-129North western Industrial Zone Bin Qasim Karachi. (DML No. 000755) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Relox 60mg Tablet
	Composition	Each Film Coated Tablet Contains; Raloxifene HCl…… 60mg
	Diary No. Date of R & I & fee	Dy. No. 42467 dated 12.12.2018. Fee Paid Rs. 20,000/- vide Slip No. 0775658 Duplicate Dossier Submitted vide Dy. No. 13232 dated 31.05.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Selective estrogen receptor modulators. ATC Code: G03XC01.
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	10's, 20's, 30's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Raloxifene Stada 60 mg Film-Coated Tablets - PL 11204/0235-6; UK/H/2834-5/001/DC. MHRA Approved.
	Me-too status	Evista Tablets 60mg reg. no. 023175 (import) M/s Eli Lilly Pakistan (Pvt.) Ltd. Karachi
	GMP status	Last inspection conducted on 24.03.2022. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved.	
646.	Name and address of manufacturer/ Applicant	M/s Star Laboratories (Pvt.) Ltd. 23-KM Multan Road, Lahore. (DML 000130) Tablet (general) Section
	Brand Name + Dosage Form + Strength	Dactas 30mg Tablets
	Composition	Each Film Coated Tablet Contains;

		Daclatasvir as Hydrochloride……30mg
	Diary No. Date of R & I & fee	Dy. No. 7593 dated 10.10.2017 Fee paid Rs. 20,000/- vide slip No. 0009222 Duplicated dossier submitted vide Dy. No. 18742 dated 28.06.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	ATC Code: J05AX14
	Type of Form	Form 5.
	Finished product Specification	Manufacturers Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Could not be verified. The USFDA and authorization in EMA has been expired or discontinued.
	Me-too status	Dakvir 30mg Tablet Reg. No. 084775. M/s PharmEvo (Pvt.) Ltd. Karachi.
	GMP status	Firm has provided GMP certificate valid till 23.01.2022 issued on the basis of inspection conducted on 24.01.2022
	Remarks of the Evaluator	The product is discontinued in USFDA and EMA. Proper reference of product approval in RRA is required.
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
647.	Name and address of manufacturer/ Applicant	M/s Star Laboratories (Pvt.) Ltd. 23-KM Multan Road, Lahore. (DML 000130) Tablet (general) Section
	Brand Name + Dosage Form + Strength	Dactas 60mg Tablets
	Composition	Each Film Coated Tablet Contains; Daclatasvir as Hydrochloride……60mg
	Diary No. Date of R & I & fee	Dy. No. 17594 dated 10.10.2017 Fee paid Rs. 20,000/- vide slip No. 0009223 Duplicated dossier submitted vide Dy. No. 18748 dated 28.06.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Antivirals for treatment of HCV infections ATC Code: J05AP07
	Type of Form	Form 5.
	Finished product Specification	Manufacturers Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified. The USFDA and authorization in EMA has been expired or discontinued.
	Me-too status	Dakvir 60mg Tablet Reg. No. 082273. M/s PharmEvo (Pvt.) Ltd. Karachi.
	GMP status	Firm has provided GMP certificate valid till 23.01.2022 issued on the basis of inspection conducted on 24.01.2022
	Remarks of the Evaluator	The product is discontinued in USFDA and EMA. Proper reference of product approval in RRA is required.
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
648.	Name and address of manufacturer/ Applicant	M/s Star Laboratories (Pvt.) Ltd. 23-KM Multan Road, Lahore. (DML 000130)

		Oral Liquid (general) Section
	Brand Name + Dosage Form + Strength	Alvenol Plus Oral Liquid
	Composition	Each 5mL contains; Chlorpheneramine Maleate BP…..5mg Terpine Hydrate USP……...10mg Potassium Bicarbonate BP……..0.1mg Ammonium Chloride BP…….….25mg Menthol BP…….1mg Aminophylline Ph.Eur……..32mg Potassium guaiacol sulfonate USP..…5mg Potassium Citrate BP…….0.1mg
	Diary No. Date of R & I & fee	Dy. No. 4160 dated 02.02.2018 Fee paid Rs. 20,000/- vide slip No. 0618607 Duplicated dossier submitted vide Dy. No. 22926 dated 15.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Expectorant (Cough Syrup)
	Type of Form	Form 5.
	Finished product Specification	Star Specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Not Provided
	Me-too status	Could not be verified.
	GMP status	Firm has provided GMP certificate valid till 23.01.2022 issued on the basis of inspection conducted on 24.01.2022
	Remarks of the Evaluator	For applied formulation evidence of me-too and approval in RRA is required. The firm vide letter No. SLL/DRAP-HR-000 dated 24.12.2022 has given reference of Pulmonol Syrup(Local).
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
649.	Name and address of manufacturer/ Applicant	M/s Fedro Pharmaceutical Labs (Pvt) Ltd. 149 – Industrial Estate, Hayatabad Peshawar. (DML No.000238) Tablet Section (General/Antibiotic)
	Brand Name + Dosage Form + Strength	CELIB 200mg Capsule
	Composition	Each Capsule Contains; Celecoxib …..200mg
	Diary No. Date of R & I & fee	Dy. No. 26059 dated 27.12.2017 Fee paid Rs. 20,000/- vide slip No. 0506581 Duplicated dossier submitted vide Dy. No. 1882 dated 19.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Coxibs ATC Code: M01AH01
	Type of Form	Form 5.
	Finished product Specification	Innovator's Specifications.

	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Celecoxib 100 mg and 200 mg capsules, hard - PL 30684/0265-0266 MHRA Approved.
	Me-too status	Celstar Capsules 200mg Reg. No. 029084 M/s Pharmatec Pakistan (Pvt.) Ltd. Karachi.
	GMP status	Last inspection conducted on 03.02.2022. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved.	
650.	Name and address of manufacturer/ Applicant	M/s Pharmix Laboratories (Pvt.) Ltd. 21-KM., Ferozpure Road Lahore. (DML No.000397) Tablet Section (General)
	Brand Name + Dosage Form + Strength	Iropal 20mg Chewable Tablet
	Composition	Each Chewable Tablet Contains; Iron protein succinylate equivalent to elemental Iron……20mg
	Diary No. Date of R & I & fee	Dy. No. 2722 dated 27.06.2016 Fee paid Rs. 20,000/- vide slip No. 0530916 dated 02.05.2016, endorsed on 27.06.2016.
	Pharmacological Group	Iron Supplement.
	Type of Form	Form 5.
	Finished product Specification	Manufacturers Specifications
	Pack size & Demanded Price	30's. As per SRO
	Approval status of product in Reference Regulatory Authorities	Iron preparation.
	Me-too status	Could not be verified.
	GMP status	Latest GMP inspection report not submitted.
	Remarks of the Evaluator	i. The approximate RDA values of Iron are; a. Men: 8mg/ day b. Women: 18mg/ day c. Pregnant women: 27mg/ day d. Lactating mothers: 9mg/ day e. The approximate upper tolerable limit is 45mg/ day. ii. The product falls in category of dietary supplement. GMP certificate dated 27-07-2021 issued on the basis of evaluation conducted on 26-05-2021 & 07-07-2021
	Decision: Approved.	
651.	Name and address of manufacturer/ Applicant	M/s Basel Pharmaceuticals, 227-Phase-II, Multan Industrial Estate, Multan. (DML No.) (Contract giver) Contract with M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore. (DML No. 000339) (Contract acceptor) Dry Powder Injection vial (Ceph) Section.
	Brand Name + Dosage Form + Strength	B,Cef 500mg Injection (IM/IV)
	Composition	Each Vial Contains; Ceftriaxone as sodium……500mg

	Diary No. Date of R & I & fee	Dy. No. 116 dated 09.09.2013 Fee paid Rs. 50,000/- vide slip No. 0026043 Duplicated dossier submitted vide Dy. No. 24423 dated 19.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5.
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	CEFTRIAXONE 500 MG POWDER FOR SOLUTION FOR INJECTION - PL 41947/0018; UK/H/6066/001/DC MHRA APPROVED.
	Me-too status	Zetox 500mg Injection Reg. No. 053145 M/s Lahore Pharma.
	GMP status	GMP certificate of M/s English Pharmaceutical Industries Lahore valid till 13.07.2024 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore.**	
652.	Name and address of manufacturer/ Applicant	M/s Basel Pharmaceuticals, 227-Phase-II, Multan Industrial Estate, Multan. (DML No.000726) (Contract giver) Contract with M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore. (DML No. 000339) (Contract acceptor) Dry Powder Injection vial (Ceph) Section.
	Brand Name + Dosage Form + Strength	B,Cef 250mg Injection (IM/IV)
	Composition	Each Vial Contains; Ceftriaxone as sodium……250mg
	Diary No. Date of R & I & fee	Dy. No. 114 dated 09.09.2013 Fee paid Rs. 50,000/- vide slip No. 0026042 Duplicated dossier submitted vide Dy. No. 24424 dated 29.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5.
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Zetox 250mg Injection Reg. No. 053144 M/s Lahore Pharma.
	GMP status	GMP certificate of M/s English Pharmaceutical Industries Lahore valid till 13.07.2024 is submitted

	Remarks of the Evaluator	
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore.**	
653.	Name and address of manufacturer/ Applicant	M/s Basel Pharmaceuticals, 227-Phase-II, Multan Industrial Estate, Multan. (DML No.000726) (Contract giver) Contract with M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore. (DML No. 000339) (Contract acceptor) Dry Powder Injection vial (Ceph) Section.
	Brand Name + Dosage Form + Strength	B,Cef 1g Injection (IM/IV)
	Composition	Each Vial Contains; Ceftriaxone as sodium……1g
	Diary No. Date of R & I & fee	Dy. No. 117 dated 09.09.2013 Fee paid Rs. 50,000/- vide slip No. 0024080 Duplicated dossier submitted vide Dy. No. 24427 dated 29.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5.
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	GMP certificate of M/s English Pharmaceutical Industries Lahore valid till 13.07.2024 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore.**	
654.	Name and address of manufacturer/ Applicant	M/s Basel Pharmaceuticals, 227-Phase-II, Multan Industrial Estate, Multan. (DML No.000726) (Contract giver) Contract with M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore. (DML No. 000339) (Contract acceptor) Oral Dry Powder Suspension (Ceph) Section.
	Brand Name + Dosage Form + Strength	B.XIME 100mg/5mL Oral Suspension
	Composition	Each 5mL Contains; Cefixime……100mg

	Diary No. Date of R & I & fee	Dy. No. 113 dated 09.09.2013 Fee paid Rs. 50,000/- vide slip No. 0026040 Duplicated dossier submitted vide Dy. No. 24426 dated 29.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5.
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	GMP certificate of M/s English Pharmaceutical Industries Lahore valid till 13.07.2024 is submitted
	Remarks of the Evaluator	i. The innovator product uses hydrated cefixime. The label doesn't mention the hydrated form. Justification or correction along with full fee is required.
	Decision: Approved as per following label claim: **Each 5ml Contains:** **Cefixime as trihydrate……100mg** • **The firm shall submit fee of Rs. 75,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s English Pharmaceutical Industries, Link Kattar Bund Road, Thokar Niaz Baig Multan Road Lahore.**	
655.	Name and address of manufacturer/ Applicant	M/s Basel Pharmaceuticals, 227-Phase-II, Multan Industrial Estate, Multan. (DML No.000726) (Contract giver) Contract with M/s English Pharmaceutical Industries, Link Kattar Bund Road, thokar Niaz baig Multan Road Lahore. (DML No. 000339) (Contract acceptor) Oral Dry Powder Suspension (Ceph) Section.
	Brand Name + Dosage Form + Strength	B.XIME 400mg Capsule
	Composition	Each Capsule Contains; Cefixime……400mg
	Diary No. Date of R & I & fee	Dy. No. 112 dated 09.09.2013 Fee paid Rs. 50,000/- vide slip No. 0026040 Duplicated dossier submitted vide Dy. No. 24425 dated 29.08.2022. Old entry verified by in-charge RnI.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5.
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax (Cefixime) Capsules 400mg USFDA Approved.

	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	GMP certificate of M/s English Pharmaceutical Industries Lahore valid till 13.07.2024 is submitted
	Remarks of the Evaluator	i. The innovator product uses hydrated cefixime. The label doesn't mention the hydrated form. Justification or correction along with full fee is required.
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. as per following label claim: **Each Capsule Contains:** **Cefixime as trihydrate……400mg** • **The firm shall submit fee of Rs. 75,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s English Pharmaceutical Industries, Link Kattar Bund Road, Thokar Niaz Baig Multan Road Lahore.**	
656.	Name and address of manufacturer/ Applicant	M/s Rotex Pharma (Pvt.) Ltd. Plot No. 206, 207 Industrial Triangle Kahuta Road Islamabad. (DML No.000651) (Contract giver) Contract with M/s Swiss Pharmaceuticals (Pvt.) Ltd Plot No. 37-J, Block-6, P.E.C.H.S Karachi. (DML No. 000438) (Contract acceptor)) Section.
	Brand Name + Dosage Form + Strength	Nezo ?mg/?mL Infusion.
	Composition	Each mL contains; Linezolid 2mg
	Diary No. Date of R & I & fee	Dy. No. 14288 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901294 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Other antibacterials ATC Code: J01XX08
	Type of Form	Form 5.
	Finished product Specification	Not mentioned which one will be followed.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Linezolid 200mg/100mL and 600mg/300mL USFDA Approved.
	Me-too status	
	GMP status	Latest GMP inspection report/ Certificate of M/s Swiss pharma Karachi is required.
	Remarks of the Evaluator	i. The Form-5 is signed and submitted by M/s Swiss Pharma Karachi. The Form-5 needs to be signed and submitted by M/s Rotex Pharma Islamabad along with full fee (i.e Rs. 75000/-) ii. The strength is mentioned as 2mg/ml and 2 pack sizes are given i.e. 100ml and 300ml. The strengths of 200mg/100ml and 600mg/300ml are two different products. Label claim is required to be clarified.

		iii. The reference of specifications of finished product is not given. It needs to be clarified. iv. Section approval letter/ evidence of manufacturing facility of LVP at M/s Swiss pharma Karachi is required. v. Latest GMP inspection report/ Certificate of M/s Swiss Pharma is required.
	Decision: Deferred for following: • **The Form-5 is signed and submitted by M/s Swiss Pharma Karachi. The Form-5 needs to be signed and submitted by M/s Rotex Pharma Islamabad along with full fee (i.e., Rs. 75000/-)** • **Clarification of applied label claim in terms of strength & fill volume.** • **Evidence of availability of manufacturing facility required for the applied fill volume.** • **Latest GMP inspection report of M/s Swiss Pharma, conducted within last three years.**	
657.	Name and address of manufacturer/ Applicant	M/s Rotex Pharma (Pvt.) Ltd. Plot No. 206, 207 Industrial Triangle Kahuta Road Islamabad. (DML No.000651) (Contract giver) Contract with M/s Swiss Pharmaceuticals (Pvt.) Ltd Plot No. 37-J, Block-6, P.E.C.H.S Karachi. (DML No. 000438) (Contract acceptor)) Section.
	Brand Name + Dosage Form + Strength	Curemox 400mg/250mL Infusion
	Composition	Each 250mL vial contains; Moxifloxacin as HCl…..400mg
	Diary No. Date of R & I & fee	Dy. No. 16787 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1900395 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Fluoroquinolones. ATC Code: J01MA14
	Type of Form	Form 5.
	Finished product Specification	Not mentioned which one will be followed.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Moxifloxacin 400 mg/250 ml Solution for Infusion - PL 24598/0022; UK/H/4829/001/DC MHRA
	Me-too status	Avelox Infusion Reg. No. 030851 M/s Bayer Pakistan (Pvt.) Ltd. Kot Lakhpat.
	GMP status	Latest GMP inspection report/ Certificate of M/s Swiss pharma Karachi is required.
	Remarks of the Evaluator	i. The form-5 is signed and submitted by M/s Swiss Pharma Karachi. The Form-5 needs to be signed and submitted by M/s Rotex Pharma Islamabad along with full fee (i.e Rs. 75000/-) ii. The reference of specifications of finished product is not given. It needs to be clarified. iii. Section approval letter/ evidence of manufacturing facility of LVP at M/s Swiss pharma Karachi is required. iv. Latest GMP inspection report/ Certificate of M/s Swiss Pharma is required.
	Decision: Deferred for following:	

	• **The Form-5 is signed and submitted by M/s Swiss Pharma Karachi. The Form-5 needs to be signed and submitted by M/s Rotex Pharma Islamabad along with full fee (i.e., Rs. 75000/-)** • **Evidence of availability of manufacturing facility required for the applied fill volume.** • **Latest GMP inspection report of M/s Swiss Pharma, conducted within last three years.**	
658.	Name and address of manufacturer/ Applicant	M/s Perk Pharma (Pvt.) Ltd. Plot No. 197/1-B Main Road, Industrial Estate Gadoon Pakistan. (DML No.000857) (Contract giver) Contract with M/s Bio-Labs (Pvt.) Ltd. Plot No. 145 Industrial Triangle Kahuta Road Islamabad. (DML No. 000296) (Contract acceptor) Lyophilized Vial (General) Section.
	Brand Name + Dosage Form + Strength	ESOPERK 40mg IV Injection
	Composition	Each Vail Contains Esomeprazole (as sodium) Lyophilized Powder ……..... 40mg
	Diary No. Date of R & I & fee	Dy. No. 16812 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 0840479 dated 05.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC05
	Type of Form	Form 5.
	Finished product Specification	**In-House**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ESOMEPRAZOLE 40 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION - PL 55035/0001 MHRA APPROVED.
	Me-too status	Nexum IV 40mg Injection. Reg. No. 050651 M/s Getz Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2021. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved with innovator's specification. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
659.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Rotazim 500mg Dry Powder Injection
	Composition	Each Vial Contains; Cefepime as Cefepime HCl USP…..500mg
	Diary No. Date of R & I & fee	Dy. No. 13708 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0796863 dated 06.03.2019 endorsed on 07.03.2019.

	Pharmacological Group	Fourth-generation cephalosporins ATC Code: J01DE01
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefepime hydrochloride eq to 500mg base/ vial. USFDA Approved.
	Me-too status	Avepime Injection 500mg Reg. No. 059586 M/s Aventek Pharmaceuticals Lahore.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. The innovator product contains L-arginine; it is not mentioned in the application that L-arginine will be present. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. The innovator product contains L-arginine; it is not mentioned in the application that L-arginine will be present.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
660.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Rotazim 1gm Dry Powder Injection
	Composition	Each Vial Contains; Cefepime as Cefepime HCl USP…..1000gm
	Diary No. Date of R & I & fee	Dy. No. 13709 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0796864 dated 06.03.2019 endorsed on 07.03.2019.

	Pharmacological Group	Fourth-generation cephalosporins ATC Code: J01DE01
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefepime hydrochloride eq to 1000mg base/ vial. USFDA Approved.
	Me-too status	Avepime Injection 1gm Reg. No. 059585 M/s Aventek Pharmaceuticals Lahore.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. The innovator product contains L-arginine; it is not mentioned in the application that L-arginine will be present. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. The innovator product contains L-arginine; it is not mentioned in the application that L-arginine will be present.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
661.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Mixime 200mg/5mL oral suspension
	Composition	Each 5mL Contains;
	Diary No. Date of R & I & fee	Dy. No. 13711 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0070464 dated 06.03.2019 endorsed on 07.03.2019.

	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Label claim is not mentioned in the application. Proper label claim is required. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Label claim is not mentioned in the application. Proper label claim is required.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
662.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Meflor 500mg Injection
	Composition	Each Vial Contains; Ceftriaxone Sodium…..500mg
	Diary No. Date of R & I & fee	Dy. No. 13706 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0070470 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5

	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Powder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Zetox 500mg Injection Reg. No. 053145 M/s Lahore Pharma.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Label claim submitted is 500mg ceftriaxone sodium. Innovator product has strength of Ceftriaxone 500mg as sodium. Label claim needs to be revised. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Label claim submitted is 500mg ceftriaxone sodium. Innovator product has strength of Ceftriaxone 500mg as sodium. Label claim needs to be revised.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
663.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Sterile Liquid Infusion & Injection
	Brand Name + Dosage Form + Strength	ROMIDEN 30mg/ Injection
	Composition	Each Vial Contains; Ketorolac Tromethamine as Ketorolac Tromethamine…….1gm
	Diary No. Date of R & I & fee	Dy. No. 13706 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0070470 dated 06.03.2019 endorsed on 07.03.2019.

	Pharmacological Group	Anti-inflammatory and Antirheumatic Products, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Label claim submitted is "Each vial contains Ketorolac Tromethamine as Ketorolac Tromethamine…….1gm". Correct label claim is required. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required. v. Evidence of ampoule section is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Label claim submitted is "Each vial contains Ketorolac Tromethamine as Ketorolac Tromethamine ……. 1gm". Correct label claim is required.** **iv. Evidence of ampoule section is required.** **v. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **vi. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
664.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section

	Brand Name + Dosage Form + Strength	Mixime 100mg/5mL oral suspension
	Composition	Each 5mL Contains;
	Diary No. Date of R & I & fee	Dy. No. 13710 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0070465 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Label claim is not mentioned in the application. Proper label claim is required. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Label claim is not mentioned in the application. Proper label claim is required.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
665.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Meflor 2gm Injection
	Composition	Each Vial Contains;

		Ceftriaxone as Ceftriaxone Sodium…..2gm
	Diary No. Date of R & I & fee	Dy. No. 13703 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0820542 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Powder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Traxon 2gm IM/IV Injection Reg. No. 018248 (Import) M/s Akhai Agencies Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **iv. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
666.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Meflor 1gm Injection
	Composition	Each Vial Contains; Ceftriaxone as Ceftriaxone Sodium…..1gm
	Diary No. Date of R & I & fee	Dy. No. 13705 dated 07.03.2019

		Fee paid Rs. 20,000/- vide slip No. 0070471 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Powder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV Inj. Reg. No. 008437 M/s Roche Pakistan Ltd. Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **iv. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
667.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Meflor 250mg Injection
	Composition	Each Vial Contains; Ceftriaxone as Ceftriaxone Sodium…..250mg
	Diary No. Date of R & I & fee	Dy. No. 13707 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0070469 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04

	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Powder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Zetox 250mg Injection Reg. No. 053144 M/s Lahore Pharma.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **iv. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
668.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Maroxim 20mg Tablet
	Composition	Each Tablet Contains; Piroxicam betacyclo dextrin
	Diary No. Date of R & I & fee	Dy. No. 13721 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0796866 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Oxicams ATC Code: M01AC01
	Type of Form	Form 5
	Finished product Specification	**???**

	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	BREXIN 20 MG EFFERVESCENT TABLET ANSM FRANCE APPROVED.
	Me-too status	Straza Tablet Reg. No. 096316 M/s Asian Continental Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required. iv. Label claim is not mentioned anywhere in whole dossier; it needs to be submitted. v. Reference of finished product specifications is not mentioned.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.** **iv. Label claim is not mentioned anywhere in whole dossier; it needs to be submitted.** **v. Reference of finished product specifications is not mentioned.Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **vi. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
669.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Dry Powder Injection (Cephalosporin)
	Brand Name + Dosage Form + Strength	CEFTEK 500mg Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone (as sodium) ….500mg
	Diary No. Date of R & I & fee	Dy. No. 14955 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741716 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5

	Finished product Specification	USP Specification
	Pack size & Demanded Price	01's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV Inj Reg. No. 008435 M/s Martin Dow Ltd. Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.	
670.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Dry Powder Injection (Cephalosporin)
	Brand Name + Dosage Form + Strength	CEFTEK 250mg Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone (as sodium) ….250mg
	Diary No. Date of R & I & fee	Dy. No. 14957 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741716 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specification
	Pack size & Demanded Price	01's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Zetox 250mg Injection Reg. No. 053144 M/s Lahore Pharma.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.	
671.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with

		M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Dry Powder Injection (Cephalosporin)
	Brand Name + Dosage Form + Strength	CEFTEK 1gm Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone (as sodium) ….1gm
	Diary No. Date of R & I & fee	Dy. No. 14956 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741716 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specification
	Pack size & Demanded Price	01's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV Inj. Reg. No. 008437 M/s Roche Pakistan Ltd. Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.	
672.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Dry Powder Injection (Cephalosporin)
	Brand Name + Dosage Form + Strength	PREXEN 1gm Injection (IV/IM)
	Composition	Each Vial Contains; Cefoperazone (as sodium) …..500mg Sulbactam (as sodium)……500mg
	Diary No. Date of R & I & fee	Dy. No. 14959 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741713 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	**In-House Specifications.**
	Pack size & Demanded Price	01's. As per SRO.

	Approval status of product in Reference Regulatory Authorities	SULPERAZONE FOR INTRAVENOUS INJECTION 1G PDMA JAPAN APPROVED.
	Me-too status	Q-Bact 1gm Injection Reg. No. 061169 M/s High-Q International Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved with JP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.**	
673.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Dry Powder Injection (Cephalosporin)
	Brand Name + Dosage Form + Strength	PREXEN 2gm Injection (IV/IM)
	Composition	Each Vial Contains; Cefoperazone (as sodium) …..1gm Sulbactam (as sodium)……1gm
	Diary No. Date of R & I & fee	Dy. No. 14958 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741713 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	**In-House Specifications.**
	Pack size & Demanded Price	01's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Approved in 03 European countries, i.e., Czech Republic, Poland and Slovakia
	Me-too status	Q-Bact 2gm Injection Reg. No. 061170 M/s High-Q International Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved with JP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.**	

674.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFSPOR 400mg Capsules
	Composition	Each Capsule Contains; Cefixime (as trihydrate) …..400mg
	Diary No. Date of R & I & fee	Dy. No. 14960 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741714 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**USP Specifications.**
	Pack size & Demanded Price	5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUPRAX (CEFIXIME) CAPSULES 400MG USFDA APPROVED.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.**	
675.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFSPOR 100mg/5ml Oral Suspension
	Composition	Each 5ml Contains; Cefixime trihydrate eq to Cefixime …..100mg
	Diary No. Date of R & I & fee	Dy. No. 14962 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741714 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08

	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.	
676.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore (Contract Acceptor) (DML No. 000575) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFSPOR DS 200mg/5ml Oral Suspension
	Composition	Each 5ml Contains; Cefixime trihydrate eq to Cefixime …..200mg
	Diary No. Date of R & I & fee	Dy. No. 14961 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0741714 dated 05-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Last inspection conducted on 22.01.21. GMP status is good. GMP certificate valid till 21.01.2023 is submitted
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Synchro Pharmaceuticals, 77-Industrial Estate, Kot Lakhpat, Lahore.	
677.	Name and address of manufacturer/ Applicant	M/s. Honig Pharmaceutical Laboratories, 14-KM Adyala Road Rawalpindi (contract giver) (DML No. 000550) Contract with

		M/s. Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat (Contract Acceptor) (DML No. 000670) Liquid Ampoule (general) Section
	Brand Name + Dosage Form + Strength	I-Cobal 500mcg/1mL Injection
	Composition	Each 1mL ampoule contains; Mecobalamine……..500mcg
	Diary No. Date of R & I & fee	Dy. No. 16824 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0828141 dated 02-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Vitamin B12
	Type of Form	Form-5
	Finished product Specification	**In-House**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	METHYCOBAL 500µginjection PDMA Japan Approved.
	Me-too status	Mecomed 500mcg Reg. No. 041670 M/s Global Pharma Islamabad
	GMP status	Last inspection conducted 30.01.2019.
	Remarks of the Evaluator	Latest GMP inspection report/ GMP certificate of M/s Linear Pharmaceuticals is required.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat.	
678.	Name and address of manufacturer/ Applicant	M/s. Honig Pharmaceutical Laboratories, 14-KM Adyala Road Rawalpindi (contract giver) (DML No. 000550) Contract with M/s. Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat (Contract Acceptor) (DML No. 000670) Liquid Ampoule (general) Section
	Brand Name + Dosage Form + Strength	I-D3 5mg/1ml
	Composition	Each 1mL ampoule contains; Cholecalciferol (Vitamin D3)……..5mg
	Diary No. Date of R & I & fee	Dy. No. 16824 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0828141 dated 02-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Vitamin D3
	Type of Form	Form-5
	Finished product Specification	**In-House**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.

	GMP status	Last inspection conducted 30.01.2019.
	Remarks of the Evaluator	Latest GMP inspection report/ GMP certificate of M/s Linear Pharmaceuticals is required.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat.	
679.	Name and address of manufacturer/ Applicant	M/s. Honig Pharmaceutical Laboratories, 14-KM Adyala Road Rawalpindi (contract giver) (DML No. 000550) Contract with M/s. Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat (Contract Acceptor) (DML No. 000670) Liquid Ampoule (general) Section
	Brand Name + Dosage Form + Strength	I-Ket 30mg/1ml
	Composition	Each 1mL ampoule contains; Ketorolac Tromethamine….30mg
	Diary No. Date of R & I & fee	Dy. No. 16826 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0828140 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	Last inspection conducted 30.01.2019.
	Remarks of the Evaluator	Latest GMP inspection report/ GMP certificate of M/s Linear Pharmaceuticals is required.
	Decision: Deferred for details of sterilization method for the applied formulation.	
680.	Name and address of manufacturer/ Applicant	M/s. Honig Pharmaceutical Laboratories, 14-KM Adyala Road Rawalpindi (contract giver) (DML No. 000550) Contract with M/s. Linear Pharma, Plot No. 18, St. S-4, National Industrial Zone Rawat (Contract Acceptor) (DML No. 000670) Liquid Ampoule (general) Section
	Brand Name + Dosage Form + Strength	I-fer 100mg/5ml Injection.
	Composition	Each 5mL ampoule contains;

		Elemental Iron (as Iron Sucrose) 100mg
	Diary No. Date of R & I & fee	Dy. No. 16827 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0828139 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	Last inspection conducted 30.01.2019.
	Remarks of the Evaluator	Latest GMP inspection report/ GMP certificate of M/s Linear Pharmaceuticals is required.
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.**	
681.	Name and address of manufacturer/ Applicant	M/s. Biogen Pharma, 8KM RCB Road, Rawat. (contract giver) (DML No.000639) Contract with M/s. Valor Pharmaceuticals, 124/A, Kahuta Road Industrial Triangle Islamabad. (Contract Acceptor) (DML No.000496) Softgel Capsule(general) Section
	Brand Name + Dosage Form + Strength	BONEVAL Softgel Capsules 200,000IU
	Composition	Each soft gel capsule contains; Vitamin D_3 USP……200,000IU
	Diary No. Date of R & I & fee	Dy. No. 13797 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 00832773 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Vitamin D analogue
	Type of Form	Form-5
	Finished product Specification	**USP Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified.
	Me-too status	Sunny D Softgel Capsule M/s Scottmann Pharma Islamabad.
	GMP status	Not provided.
	Remarks of the Evaluator	i. Form 5 doesn't mention name of applicant (M/s. Biogen pharma) anywhere. Correct Form 5 along with full fee is required to be submitted. ii. USP Monograph of 200,000IU vitamin D3 is required as finished product specifications are mentioned as USP.

		iii. Latest GMP inspection report/ certificate of M/s Valor Pharma is required. iv. Softgel Section approval letter of M/s Valor Pharmaceuticals is required. v. Evidence of approval of applied product in RRA is required.
	Decision: Deferred for following: **i. Form 5 doesn't mention name of applicant (M/s. Biogen pharma) anywhere. Correct Form 5 along with full fee is required to be submitted.** **ii. USP Monograph of 200,000IU vitamin D3 is required as finished product specifications are mentioned as USP.** **iii. Latest GMP inspection report/ certificate of M/s Valor Pharma is required.** **iv. Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.** **v. Evidence of approval of required manufacturing facility i.e., "Soft gel capsule" section in name of M/s Valor Pharma.**	
682.	Name and address of manufacturer/ Applicant	M/s. Arsons Pharmaceutical Industries, 2.5KM Defence Road, off Multan Road, Lahore. (contract giver) (DML No.000514) Contract with M/s. MeDPharm Research Lab, 28-KM, Ferozepur Road, Lahore. (Contract Acceptor) (DML No.000878) Dry Powder Injection (Cephalosporin) Section.
	Brand Name + Dosage Form + Strength	ARZONE IV Injection 1000mg
	Composition	Each Vial contains; Ceftriaxone as Sodium……1000mg
	Diary No. Date of R & I & fee	Dy. No. 16595 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0730984 dated 25-02-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 1g Powder for Solution for Injection or Infusion (ceftriaxone sodium) - PL 42671/0001 MHRA Approved.
	Me-too status	Rocephin IV Inj. Reg. No. 008437 M/s Roche Pakistan Ltd. Karachi.
	GMP status	Firm has submitted routine GMP inspection report dated 27.10.2022. GMP status is reported as good.
	Remarks of the Evaluator	i. Form 5 doesn't mention name of applicant (M/s. arsons Pharma) anywhere. Correct Form 5 along with full fee is required to be submitted. The firm vide letter No. MRL/DRA/024/2023 dated 06.01.2023 has stated that they have mentioned name of applicant (M/s Arson Pharma) under heading of "Manufactured for". The firm has submitted copy of annexure of application. The Form-5 submitted was from M/s MedPharm Research Lab.

	Decision: Deferred for submission of Form 5 from the applicant instead of the drug product manufacturer along with full fee of registration as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021	
683.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Dry vial Injection (general) Section.
	Brand Name + Dosage Form + Strength	TRIVANCO 500mg Injection
	Composition	Each Vial contains; Vancomycin as Hydrochloride (USP)……500mg
	Diary No. Date of R & I & fee	Dy. No. 17354 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0782089 dated 06-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Glycopeptide antibacterials. ATC Code: J01XA01
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VANCOMYCIN 500 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION MHRA Approved.
	Me-too status	Vancomycin Injection Reg. No. 015015 M/s Abbott Laboratories Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Deferred for confirmation of evidence of approval required manufacturing facility i.e., "Dry Powder Injection (General)" section in name of M/s Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar, since the submitted GMP certificate dated 28-10-2022 of M/s Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar does not include the said section.	
684.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Dry Powder General Section.
	Brand Name + Dosage Form + Strength	TRIVANCO 1000mg Inejction
	Composition	Each Vial contains; Vancomycin as Hydrochloride (USP)……1000mg
	Diary No. Date of R & I & fee	Dy. No. 17355 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0782091 dated 06-03-2019, endorsed on 07.03.2019.

	Pharmacological Group	Glycopeptide antibacterials. ATC Code: J01XA01
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VANCOMYCIN 1000 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONMHRA Approved.
	Me-too status	Vancomycin Injection Reg. No. 015016 M/s Abbott Laboratories Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Deferred for confirmation of evidence of approval required manufacturing facility i.e., "Dry Powder Injection (General)" section in name of M/s Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar, since the submitted GMP certificate dated 28-10-2022 of M/s Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar does not include the said section.	
685.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Section.
	Brand Name + Dosage Form + Strength	Fusidax 20mg Cream
	Composition	Each gram contains; Fusidic acid (BP)..,,,,20mg (2% w/w)
	Diary No. Date of R & I & fee	Dy. No. 17361 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901366 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Other antibiotics for topical use ATC Code: D06AX01
	Type of Form	Form-5
	Finished product Specification	BP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Fusidic Acid 2% Cream - PL 00289/1849; UK/H/5525/001/DC MHRA Approved.
	Me-too status	Fudic Cream Reg. No. 025938 M/s Shaigan Rawalpindi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar.	

686.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Section.
	Brand Name + Dosage Form + Strength	F-CID 20mg Cream
	Composition	Each gram contains; Fusidic acid (BP)……20mg (2% w/w) Hydrocortisone acetate (USP)…..10mg (1% w/w)
	Diary No. Date of R & I & fee	Dy. No. 17358 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901370 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Corticosteroids, weak, combinations with antibiotics. ATC Code: D07CA01
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	FUCIDIN® H Fusidic acid and Hydrocortisone acetate 2% / 1% Cream Health Canada Approved.
	Me-too status	Fusiwin-H Cream Reg. No. 062471 M/s Hoover Pharmaceuticals Lahore.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Firm shall submit evidence of availability of separate dispensing booth for steroidal formulations, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar.	
687.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Section.
	Brand Name + Dosage Form + Strength	Adapiene 1mg Topical Ointment
	Composition	Each gram Contains; Adapalene (BP)……1mg(0.1%w/w)
	Diary No. Date of R & I & fee	Dy. No. 17356 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901369 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Retinoids for topical use in acne ATC Code: D10AD03

	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	
	Me-too status	
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022. i. Evidence of approval of applied product (ointment) in RRA is required. ii. Evidence of me-too of applied product (ointment) is required.
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	
688.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Moziflox 400mg Tablet
	Composition	Each Film Coated Tablet Contains; Moxifloxacin as HCl (USP) ……400mg
	Diary No. Date of R & I & fee	Dy. No. 17362 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901355 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Fluoroquinolones ATC Code: J01MA14
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	KIMOKS 400 MG FILM-COATED TABLETS (MOXIFLOXACIN HYDROCHLORIDE) - PL 34088/0047; UK/H/6473/001/DC MHRA APPROVED.
	Me-too status	Avelox Tablets Reg. No. 024653 M/s Bayer Pakistan Ltd Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	

689.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	L-Mide 50mg Tablet
	Composition	Each Film Coated Tablet Contains; Lacosamide ……50mg
	Diary No. Date of R & I & fee	Dy. No. 17351 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901351 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Other antiepileptics ATC Code: N03AX18
	Type of Form	Form-5
	Finished product Specification	**Manufacturer's Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	LACOSAMIDE AMAROX 200 MG FILM-COATED TABLETS - PL 49445/0084 (50mg, 100mg, 150mg & 200mg) MHRA Approved.
	Me-too status	Lalap 50mg Tablets Reg. No. 070470 M/s Genix pharma Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
690.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	L-Mide 100mg Tablet
	Composition	Each Film Coated Tablet Contains; Lacosamide ……100mg
	Diary No. Date of R & I & fee	Dy. No. 17352 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901352 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Other antiepileptics ATC Code: N03AX18

	Type of Form	Form-5
	Finished product Specification	**Manufacturer's Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	LACOSAMIDE AMAROX 200 MG FILM-COATED TABLETS - PL 49445/0084 (50mg, 100mg, 150mg & 200mg) MHRA Approved.
	Me-too status	Lalap 100mg Tablets Reg. No. 070471 M/s Genix pharma Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
691.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	OLE-TAN 40mg/5mg Tablet
	Composition	Each Film Coated Tablet Contains; Amlodipine besylate eq. to Amlodipine…5mg Olmesartan medoximil……..40mg
	Diary No. Date of R & I & fee	Dy. No. 17349 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901354 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) and calcium channel blockers. ATC Code: C09DB02
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Olmesartan medoxomil and Amlodipine 20mg/5mg, 40mg/5mg & 40mg/10mg film-coated tablets PL 51718/0032-0034 MHRA AApproved.
	Me-too status	Baritec-A 50/5mg Tablet Reg. No. 081443 M/s Barrett Hodgson Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	

	Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
692.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	OLE-TAN 20mg/5mg Tablet
	Composition	Each Film Coated Tablet Contains; Amlodipine besylate eq. to Amlodipine…5mg Olmesartan medoximil……..20mg
	Diary No. Date of R & I & fee	Dy. No. 17350 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901353 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) and calcium channel blockers. ATC Code: C09DB02
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Olmesartan medoxomil and Amlodipine 20mg/5mg, 40mg/5mg & 40mg/10mg film-coated tablets PL 51718/0032-0034 MHRA AApproved.
	Me-too status	Baritec-A 50/5mg Tablet Reg. No. 081442 M/s Barrett Hodgson Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
693.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Eye Drop (General) Section.
	Brand Name + Dosage Form + Strength	NEPA Eye Drops 0.1% Suspension.
	Composition	Each 1mL contains;

		Nepafenac ……..1mg (0.1%W/V)
	Diary No. Date of R & I & fee	Dy. No. 17363 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901363 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Antiinflammatory agents, non-steroids ATC Code: S01BC10
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	NEVANAC 1 MG/ML EYE DROPS SUSPENSION MHRA Approved.
	Me-too status	Nevanac 0.1% Ophthalmic Suspension (Eye Drops) Reg. No. 047563 (Import) M/s Ali Gohar & Company Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
694.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Eye Drop (General) Section.
	Brand Name + Dosage Form + Strength	O-DINO 0.2% Eye Drops.
	Composition	Each 1mL contains; Olopatadine as Hydrochloride(USP)…..2mg
	Diary No. Date of R & I & fee	Dy. No. 17359 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901364 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Other antiallergics ATC Code: S01GX09
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Olopatadine Hydrochloride Eq 0.2% base Solution Drops Ophthalmic, Over the counter USFDA Approved.
	Me-too status	Ocudine Eye Drops Reg. No. 067448 M/s Barrett Hodgson Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing	

	facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
695.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar (Contract Acceptor) (DML No.000725) Eye Drop (General) Section.
	Brand Name + Dosage Form + Strength	M-CIN Eye Drops 0.5%
	Composition	Each 1mL contains; Moxifloxacin as Hydrochloride(USP)…..5mg
	Diary No. Date of R & I & fee	Dy. No. 17360 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1901365 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Fluoroquinolones ATC Code: S01AE07
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MOXIFLOXACIN 0.5 % W/V EYE DROPS, SOLUTION - PL 25298/0272 MHRA Approved.
	Me-too status	Moxigan 0.5% Reg. No. 042111 M/s Barrett Hodgson Karachi.
	GMP status	Not Provided
	Remarks of the Evaluator	Copy of GMP certificate issued on basis of inspection conducted on 12-10-2022.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Winbrains Research Laboratories, Plot No. 69/, Block B, Phase I-II Industrial Estate Hattar	
696.	Name and address of manufacturer/ Applicant	M/s. Gillman Pharmaceuticals, 41/2-A Phase I & II, Industrial Estate Hattar (contract giver) (DML No.000683) Contract with M/s. Aulton Pharmaceutical Plot No. 84/1, Block A, Phase V, Industrial estate Hattar (Contract Acceptor) (DML No.000828) Liquid Injection General Section.
	Brand Name + Dosage Form + Strength	Athancinol 4ml Injection 40mg/ 0.04mg
	Composition	Each 4mL ampoule contains; Phloroglucinol hydrated ….40mg Trimethylphloroglucinol…0.04mg
	Diary No. Date of R & I & fee	Dy. No. 14942 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1902264 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Other drugs for functional gastrointestinal disorders. ATC Code: A03AX12
	Type of Form	Form-5

	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Spasfon Solution for injection in ampoule ANSM France Approved.
	Me-too status	Spasfon Injection Reg. No. 018530 M/s Himont Oharma Lahore.
	GMP status	Last inspection report of M/s Aulton Pharma dated 11.12.2020 is submitted. The GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved.	
697.	Name and address of manufacturer/ Applicant	M/s. Gillman Pharmaceuticals, 41/2-A Phase I & II, Industrial Estate Hattar (contract giver) (DML No.000683) Contract with M/s. Aulton Pharmaceutical Plot No. 84/1, Block A, Phase V, Industrial estate Hattar (Contract Acceptor) (DML No.000828) Liquid Injection General Section.
	Brand Name + Dosage Form + Strength	Atra 50mg/5ml Injection
	Composition	Each 5mL ampoule contains; Atracurium besylate (USP)…….50mg
	Diary No. Date of R & I & fee	Dy. No. 14941 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1902259 dated 07-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS, Other quaternary ammonium compounds ATC Code: M03AC04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ATRACURIUM BESILATE 10MG/ML SOLUTION FOR INJECTION MHRA Approved.
	Me-too status	Tracrium Injection 50mg/5ml Reg. No. 094760 OBS Pakistan (Pvt) Ltd. Karachi.
	GMP status	Last inspection report of M/s Aulton Pharma dated 11.12.2020 is submitted. The GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved.	
698.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Road, Lahore. (contract giver) (DML No. 000875) Contract with M/s. GT Pharma (Pvt.) Ltd. Plot No. 713, Sundar Industrial Estate Raiwind Road, Lahore. (Contract Acceptor) (DML No.000829) Liquid Injectable (General) for ampoules and vials SVP
	Brand Name + Dosage Form + Strength	Rolac 30mg/1ml Injection

	Composition	Each 1mL ampoule contains; Ketorolac as Tromethamine….30mg
	Diary No. Date of R & I & fee	Dy. No. 16187 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0841697 dated 06-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	GMP certificate dated 14.12.2021 valid till 12.10.2023 is submitted.
	Remarks of the Evaluator	i. The label claim applied is Ketorolac as tromethamine, the label claim of RRA approved product is Ketorolac tromethamine 30mg. justification or correction along with full fee as per Notification No. 7-11/2012-B&A/DRAP dated 07.05.2021. The firm has submitted revised label vide letter No. RZ-DRAP-R-001 dated 09.01.2023 as under; Each 1ml Ampoule Contains; Ketorolac Tromethamine…30mg • Fee of Rs. 75000/- is paid vide slip No. 7693122747 dated 10.01.2023 for changes.
	Decision: Deferred for the details of sterilization method for applied formulation.	
699.	Name and address of manufacturer/ Applicant	M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s. GT Pharma (Pvt.) Ltd. Plot No. 713, Sundar Industrial Estate Raiwind Road, Lahore.(Contract Acceptor) (DML No.000829) Liquid Injectable (General) for ampoules and vials SVP
	Brand Name + Dosage Form + Strength	D-3 5mg/1ml injection
	Composition	Each 1mL ampoule contains; Cholecalciferol……5mg
	Diary No. Date of R & I & fee	Dy. No. 16189 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0841696 dated 06-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Vitamin D Analogue
	Type of Form	Form-5
	Finished product Specification	**BP Specifications.**

	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.
	GMP status	GMP certificate dated 14.12.2021 valid till 12.10.2023 is submitted.
	Remarks of the Evaluator	i. BP Specifications are mentioned, pharmacopoeial monograph is required. The firm vide letter No. RZ-DRAP-R-001 dated 09.01.2023 has requested to revise the specifications to "innovator's Specifications". The firm has submitted fee of Rs. 7500/- vide slip No. 429252212 dated 10.01.2023 for revision of specs.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. GT Pharma (Pvt.) Ltd. Plot No. 713, Sundar Industrial Estate Raiwind Road, Lahore.	
700.	Name and address of manufacturer/ Applicant	M/s. M/s Relizon Pharmaceuticals, Plot No. 118, Sundar Industrial Estate. Raiwind Roadd, Lahore. (contract giver) (DML No. 000875) Contract with M/s. GT Pharma (Pvt.) Ltd. Plot No. 713, Sundar Industrial Estate Raiwind Road, Lahore. (Contract Acceptor) (DML No.000829) Sachet (General Section)
	Brand Name + Dosage Form + Strength	Mont Sachet 4mg
	Composition	Each Sachet Contains; Montelukast as Sodium……..4mg
	Diary No. Date of R & I & fee	Dy. No. 16188 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0841700 dated 06-03-2019, endorsed on 07.03.2019.
	Pharmacological Group	Leukotriene receptor antagonists ATC Code: R03DC03
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MONTELUKAST 4 MG GRANULES - PL 36687/0448 MHRA Approved.
	Me-too status	Singulair 4mg Granules Reg. No. 031377 M/s OBS Health (Pvt.) Ltd. Karachi.
	GMP status	GMP certificate dated 14.12.2021 valid till 12.10.2023 is submitted.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing	

	facility of M/s. GT Pharma (Pvt.) Ltd. Plot No. 713, Sundar Industrial Estate Raiwind Road, Lahore.	
701.	Name and address of manufacturer/ Applicant	M/s Fassgen Pharmaceuticals, Plot No. 67/1-A, Phase-II, Industrial Estate Hattar. (contract giver) (DML No. 000646) Contract with M/s. Caraway Pharmaceuticals, Plot No. 12, St. No. N-3, National Industrial Zone (RCCI), Rawat. (Contract Acceptor) (DML No.000629) Liquid Ampoule Injection (General) Section.
	Brand Name + Dosage Form + Strength	D-BUILD 5mg/1ml Injection.
	Composition	Each 1ml Ampoule contains; Vitamin D3……5mg
	Diary No. Date of R & I & fee	Dy. No. 15916 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0847034 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Vitamin D analogue.
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.
	GMP status	Last inspection conducted on 17-05-2022, GMP status is good.
	Remarks of the Evaluator	i. Form-5 is submitted by M/s Caraway, its also not signed and stamped. Form-5 filled, signed and stamped by M/s Fassgen is required along with fee Rs. 75000/- for revision. The applicant vide letter No. nil, dated 10.01.2023 has submitted correct Form-5, but no fee is paid.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 75,000/- for correction/pre-approval change in Form 5 as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Caraway Pharmaceuticals, Plot No. 12, St. No. N-3, National Industrial Zone (RCCI), Rawat.	
702.	Name and address of manufacturer/ Applicant	M/s Fassgen Pharmaceuticals, Plot No. 67/1-A, Phase-II, Industrial Estate Hattar. (contract giver) (DML No. 000646) Contract with M/s. Caraway Pharmaceuticals, Plot No. 12, St. No. N-3, National Industrial Zone (RCCI), Rawat. (Contract Acceptor) (DML No.000629) Liquid Ampoule Injection (General) Section.
	Brand Name + Dosage Form + Strength	KELAC 30mg/1ml Injection.
	Composition	Each 1ml Ampoule contains; Ketorolac Tromethamine……30mg

	Diary No. Date of R & I & fee	Dy. No. 15917 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0847035 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	Last inspection conducted on 17-05-2022, GMP status is good.
	Remarks of the Evaluator	i. Form-5 is submitted by M/s Caraway, its also not signed and stamped. Form-5 filled, signed and stamped by M/s Fassgen is required along with fee Rs. 75000/- for revision. The applicant vide letter No. nil, dated 10.01.2023 has submitted correct Form-5, but no fee is paid.
	Decision: Deferred for the details of sterilization method for applied formulation.	
703.	Name and address of manufacturer/ Applicant	M/s Fassgen Pharmaceuticals, Plot No. 67/1-A, Phase-II, Industrial Estate Hattar. (contract giver) (DML No. 000646) Contract with M/s. Caraway Pharmaceuticals, Plot No. 12, St. No. N-3, National Industrial Zone (RCCI), Rawat. (Contract Acceptor) (DML No.000629) Liquid Ampoule Injection (General) Section.
	Brand Name + Dosage Form + Strength	HEM-FER 100mg/5ml Injection
	Composition	Each 5mL ampoule contains; Iron sucrose complex eq. to elemental Iron…100mg
	Diary No. Date of R & I & fee	Dy. No. 15918 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 1902586 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.

	GMP status	Last inspection conducted on 17-05-2022, GMP status is good.
	Remarks of the Evaluator	i. Form-5 is submitted by M/s Caraway, its also not signed and stamped. Form-5 filled, signed and stamped by M/s Fassgen is required along with fee Rs. 75000/- for revision. The applicant vide letter No. nil, dated 10.01.2023 has submitted correct Form-5, but no fee is paid.
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.**	
704.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858) Dry Powder Vials Injectable (Ceph) Section.
	Brand Name + Dosage Form + Strength	Brixon IV/IM Injection 1G
	Composition	Each Vial Contains; Ceftriaxone as Sodium…..1g
	Diary No. Date of R & I & fee	Dy. No. 16196 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715693 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.**	
705.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858)

		Dry Powder Vials Injectable (Ceph) Section.
	Brand Name + Dosage Form + Strength	Brixon IM Injection 250mg
	Composition	Each Vial Contains; Ceftriaxone as Sodium…..250mg
	Diary No. Date of R & I & fee	Dy. No. 16192 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715695 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	El-Cef Injection Reg. No. 075341 M/s Linear Pharma Rawat.
	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.	
706.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858) Dry Powder Vials Injectable (Ceph) Section.
	Brand Name + Dosage Form + Strength	Brixon IV Injection 500mg
	Composition	Each Vial Contains; Ceftriaxone as Sodium…..500mg
	Diary No. Date of R & I & fee	Dy. No. 16195 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715694 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Zetox 500mg Injection Reg. No. 053145 M/s Lahore Pharma.

	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.	
707.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858) Capsule (Ceph) Section.
	Brand Name + Dosage Form + Strength	IFIX Capsule 400mg
	Composition	Each Capsule Contains; Cefixime Trihydrate eq. to Cefixime…..400mg
	Diary No. Date of R & I & fee	Dy. No. 16191 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715698 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	JP Specifications.
	Pack size & Demanded Price	5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax (Cefixime) Capsules 400mg USFDA Approved.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.**	
708.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858) Capsule (Ceph) Section.

	Brand Name + Dosage Form + Strength	IFIX Oral Suspension 100mg/5mL
	Composition	Each 5mL Contains; Cefixime Trihydrate eq. to Cefixime…..100mg
	Diary No. Date of R & I & fee	Dy. No. 16193 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715696 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**Not mentioned**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	i. Reference of finished product specification is required.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.	
709.	Name and address of manufacturer/ Applicant	M/s Regent Laboratories, C-20, S.I.T.E., Super Highway Karachi (contract giver) (DML No. 000506) Contract with M/s. Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi. (Contract Acceptor) (DML No.000858) Capsule (Ceph) Section.
	Brand Name + Dosage Form + Strength	IFIX Oral Suspension 200mg/5mL
	Composition	Each 5mL Contains; Cefixime Trihydrate eq. to Cefixime…..200mg
	Diary No. Date of R & I & fee	Dy. No. 16194 dated 07.03.2019. Fee paid Rs. 50,000/- vide Slip No. 0715697 dated 04-03-2019, endorsed on 06.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**Not mentioned**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.

	GMP status	Last inspection conducted on 29.10.2020. GMP status of manufacturer is good.
	Remarks of the Evaluator	i. Reference of finished product specification is required, it is required to be submitted along with fee of Rs.7500/-.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s Palpex Pharmaceuticals (Pvt.) Ltd., FD-46-A8, ST-1, Sector 38, Korangi Creek Industrial Park Karachi.	
710.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceutical (Pvt.) Ltd. , Plot No. 45, St. No. S-5, Rawat Industrial Zone, Rawat. (Contract Giver) (DML No. 000721). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	Merowin Injection 500mg (IV)
	Composition	Each Vial Contains; Meropenem USP..…... 500mg
	Diary No. Date of R & I & fee	Dy.No.16396 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1902628 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 500mg Injection Reg. No. 096203 M/s Pfizer Pakistan.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. Label claim is without consideration of hydrated form of the API. Justification or correction of label claim is required for consideration of hydrated form of API along with submission of requisite fee (full fee) ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule General
	Decision: Approved with following label claim;	

	"Each Vial Contains: **Meropenem Trihydrate Eq. To Meropenem….1gm"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
711.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceutical (Pvt.) Ltd. , Plot No. 45, St. No. S-5, Rawat Industrial Zone, Rawat. (Contract Giver) (DML No. 000721). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	Merowin Injection 1g (IV)
	Composition	Each Vial Contains; Meropenem USP….. 1g
	Diary No. Date of R & I & fee	Dy.No.16395 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1902626 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 1g Injection Reg. No. 096204 M/s Pfizer Pakistan.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. Label claim is without consideration of hydrated form of the API. Justification or correction of label claim is required for consideration of hydrated form of API along with submission of requisite fee (full fee) ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; ○ Dry Powder Injection (Cephalosporin) ○ Dry Powder Injection (Penicillin) ○ Dry Powder Injection (Carbapenem) ○ Liquid Ampoule General
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….1gm"**	

	• **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
712.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceutical (Pvt.) Ltd. , Plot No. 45, St. No. S-5, Rawat Industrial Zone, Rawat. (Contract Giver) (DML No. 000721). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	IMIWIN 500mg IV
	Composition	Each Vial Contains; Imipenem Monohydrate eq. to Imipenem…..500mg Cilastatin Sodium eq. to Colastatin ……500mg
	Diary No. Date of R & I & fee	Dy.No.16394 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1902630 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH51
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP specifications.
	Pack size & Demanded Price	1's. As per SRO
	Approval status of product in Reference Regulatory Authorities	IMIPENEM/CILASTATIN 500/500MG POWDER FOR SOLUTION FOR INFUSION (IMIPENEM, CILASTATIN SODIUM) - UK/H/1409/001/DC; PL 14894/0665 MHRA APPROVED.
	Me-too status	Imclas Inj IV Reg. No. 048341 M/s Global Pharmaceuticals Islamabad.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; ○ Dry Powder Injection (Cephalosporin) ○ Dry Powder Injection (Penicillin) ○ Dry Powder Injection (Carbapenem) ○ Liquid Ampoule General
	Decision: Approved. • **M/s Global shall use 10ml 0.9% NaCl injection as diluent for the commercial batches and submit compatibility study with the 0.9%NaCl solution as diluent along with BMR of recently manufactured batches from M/s Global Pharmaceuticals, as evidence of use of the recommended diluent before issuance of Registration letter.** • **Firm shall use correct fill weight per vial considering the sodium content as per the drug substance manufacturer's claim for the commercial batches and submit BMR of recently manufactured batches from M/s Global Pharmaceuticals as evidence of correct fill weight before issuance of Registration letter.**	

	• **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
713.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceutical (Pvt.) Ltd. , Plot No. 45, St. No. S-5, Rawat Industrial Zone, Rawat. (Contract Giver) (DML No. 000721). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	IMIWN 1g IV
	Composition	Each Vial Contains; Imipenem Monohydrate eq. to Imipenem…..500mg Cilastatin Sodium eq. to Colastatin ……500mg
	Diary No. Date of R & I & fee	Dy.No.16393 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1902629 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH51
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP specifications.
	Pack size & Demanded Price	1's. As per SRO
	Approval status of product in Reference Regulatory Authorities	IMIPENEM/CILASTATIN 500/500MG POWDER FOR SOLUTION FOR INFUSION (IMIPENEM, CILASTATIN SODIUM) - UK/H/1409/001/DC; PL 14894/0665 MHRA APPROVED.
	Me-too status	Imclas Inj IV Reg. No. 048341 M/s Global Pharmaceuticals Islamabad.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. Duplicate formulation as IMIWIN 500mg ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; ○ Dry Powder Injection (Cephalosporin) ○ Dry Powder Injection (Penicillin) ○ Dry Powder Injection (Carbapenem) ○ Liquid Ampoule General
	Decision: Approved. • **M/s Global shall use 10ml 0.9% NaCl injection as diluent for the commercial batches and submit compatibility study with the 0.9%NaCl solution as diluent along with BMR of recently manufactured batches from M/s Global Pharmaceuticals, as evidence of use of the recommended diluent before issuance of Registration letter.** • **Firm shall use correct fill weight per vial considering the sodium content as per the drug substance manufacturer's claim for the commercial batches and submit BMR of recently manufactured batches from M/s Global Pharmaceuticals as evidence of correct fill weight before issuance of Registration letter.** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	

714.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceutical (Pvt.) Ltd. , Plot No. 45, St. No. S-5, Rawat Industrial Zone, Rawat. (Contract Giver) (DML No. 000721). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Penicillin) Section.
	Brand Name + Dosage Form + Strength	PIPRAWIN 2.25gm IV Injection
	Composition	Each Vial Contains; Sterile Piperacillin Sodium equivalent to Piperacillin……2.0gm Sterile Tazobactam Sodium equivalent to Tazobactam……...0.25gm
	Diary No. Date of R & I & fee	Dy.No.16391 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1902632 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Combinations of penicillins, incl. beta-lactamase inhibitors. ATC Code: J01CR05
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	PIPERACILLIN/TAZOBACTAM 2 G/ 0.25 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION - PL 28176/0045 MHRA APPROVED.
	Me-too status	Tanzo 2.25gm Inj Reg. No. 039593 M/s Bosch Pharmaceuticals Karachi..
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; ○ Dry Powder Injection (Cephalosporin) ○ Dry Powder Injection (Penicillin) ○ Dry Powder Injection (Carbapenem) ○ Liquid Ampoule Injectable General
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.	
715.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Dry Powder Vial (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	VELNEM 1g Injection (IV)
	Composition	Each Vial Contains; Meropenem (as mixture of sodium carbonate) eq. to Meropenem…….1g

	Diary No. Date of R & I & fee	Dy.No.15761 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825448 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 1g Injection Reg. No. 096204 M/s Pfizer Pakistan.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….1gm"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
716.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Dry Powder Vial (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	VELNEM 500mg Injection (IV)
	Composition	Each Vial Contains; Meropenem (as mixture of sodium carbonate) eq. to Meropenem…….500mg
	Diary No. Date of R & I & fee	Dy.No.15760 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825447 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Carbapenems

		ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 500mg Injection Reg. No. 096203 M/s Pfizer Pakistan.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….500mg"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
717.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Liquid Vials SVP (General) Section.
	Brand Name + Dosage Form + Strength	LINTEN 200mg/100ml IV Injection
	Composition	Each 100ml injection Contains; Linezolid……200mg
	Diary No. Date of R & I & fee	Dy.No.15759 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825446 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other antibacterials ATC Code: J01XX08
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	1's, As per SRO.

	Approval status of product in Reference Regulatory Authorities	LINEZOLID, 200MG/100ML (2MG/ML), SOLUTION; INTRAVENOUS. USFDA Approved.
	Me-too status	Nezkil 200mg Infusion Reg. No. 048802 M/s SJ&Fazul Ellahi Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 75,000/- for correction/pre-approval change in product specifications and Form 5 as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
718.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Lenovo 500mg/5ml Injection
	Composition	Each 5ml Ampoule Contains; Levetiracetam…….500mg
	Diary No. Date of R & I & fee	Dy.No.15754 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825440 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX14
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's & 10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Levetiracetam 100 mg / mL Concentrate for solution for infusion No. PL 24598/0074 (5ml ampoule) MHRA Approved.
	Me-too status	Lerace 500mg/5ml Injection Reg. No. 066949 M/s Hilton Pharma (Pvt) Ltd Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma

		(registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021 **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
719.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Monflox 500mcg/1ml Injection (IV/IM)
	Composition	Each 1ml Ampoule Contains; Mecobalamine…….500mcg
	Diary No. Date of R & I & fee	Dy.No.15753 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825439 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Vitamin B12.
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	METHYCOBAL 500µg injection PDMA Japan Approved.
	Me-too status	Reli-cobal Injection 500mcg Reg. No. 083440 M/s Reliance Pharma
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with Innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021 **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	

720.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Molan 100mg/2ml Injection (IV/IM)
	Composition	Each 2ml Ampoule Contains; Tramadol (as HCl)…….100mg
	Diary No. Date of R & I & fee	Dy.No.15756 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825443 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other opioids ATC Code: N02AX02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Tramadol 50mg/ml solution for Injection or Infusion - PL 18157/0014. MHRA Approved.
	Me-too status	Tramal Ampoules Reg. No. 010172 M/s The Searle Company Limited Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with Innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021 **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
721.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Rotanxamic Injection 250mg/5ml
	Composition	Each 5ml Ampoule Contains; Tranexamic Acid……250mg

	Diary No. Date of R & I & fee	Dy.No.15762 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825449 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Tranexamic acid injection 250/5mL "Nissin" (Plastic Ampoule) PDMA Japan Approved.
	Me-too status	Transamin Injection 250mg Reg. No. 007534
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
722.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Rotanxamic Injection 500mg/5ml
	Composition	Each 5ml Ampoule Contains; Tranexamic Acid……500mg
	Diary No. Date of R & I & fee	Dy.No.15763 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825450 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cyklokapron Injection, 500mg/5ml Solution for injection MHRA approved.
	Me-too status	Transamin –INJ Reg. No. 010452

		M/s Hilton Pharma (Pvt) Ltd. Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
723.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Colrin 5mg/1ml Injection
	Composition	Each 1ml Ampoule Contains; Cholecalciferol (Vitamin D3)…..5mg
	Diary No. Date of R & I & fee	Dy.No.15757 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825442 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Vitamin D analogue.
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	1's & 5's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.

	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
724.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Krol 30mg/1ml Injection
	Composition	Each 1ml Ampoule Contains; Ketorolac tromethamine…..30mg
	Diary No. Date of R & I & fee	Dy.No.15758 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825445 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	5's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Deferred for submission of following: • **Details of method of sterilization for applied formulation.** • **Fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021**	
725.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with

		M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Irogit 100mg/5ml Injection (IV)
	Composition	Each 5ml Ampoule Contains; Iron sucrose eq to elemental Iron …100mg
	Diary No. Date of R & I & fee	Dy.No.15755 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825444 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.** • **Fee of Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021**	
726.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Dry Powder Vial (Steroid) Section.
	Brand Name + Dosage Form + Strength	Hydron 100mg Injection (IV/IM)
	Composition	Each Vial Contains; Hydrocortisone sodium succinate eq. to Hydrocortisone……100mg
	Diary No. Date of R & I & fee	Dy.No.15752 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825436 dated 06.03.2019, endorsed on 06.03.2019

	Pharmacological Group	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN, Glucocorticoids. ATC Code: H02AB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SOLU-CORTEF 100MG, HYDROCORTISONE 100 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION. MHRA APPROVED.
	Me-too status	Hyzonate Injection 100mg Reg. No. 019228 M/s Amson Vaccines & Pharma (Pvt.) Ltd. Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
727.	Name and address of manufacturer/ Applicant	M/s, Biogen Pharma, 8KM RCB Road Rawat. (Contract Giver) (DML No. 000639). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Dry Powder Vial (Steroid) Section.
	Brand Name + Dosage Form + Strength	Hydron 250mg Injection (IV/IM)
	Composition	Each Vial Contains; Hydrocortisone sodium succinate eq. to Hydrocortisone……250mg
	Diary No. Date of R & I & fee	Dy.No.15751 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825438 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN, Glucocorticoids. ATC Code: H02AB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	1's. As per SRO.

	Approval status of product in Reference Regulatory Authorities	SOLU-CORTEF ACT-O-VIAL 250MG POWDER FOR INJECTION AND DILUENT TGA Australia Approved
	Me-too status	Hyzonate Injection 250mg Reg. No. 019226 M/s Amson Vaccines & Pharma (Pvt.) Ltd. Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Biogen Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Biogen Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
728.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s. Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Dry Powder Vial (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	VELFORT 1g Injection (IV)
	Composition	Each Vial Contains; Meropenem (as mixture of sodium carbonate) eq. to Meropenem…….1g
	Diary No. Date of R & I & fee	Dy.No.15175 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825435 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 1g Injection Reg. No. 096204 M/s Pfizer Pakistan.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.

	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….1gm"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
729.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Dry Powder Vial (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	Velfort 500mg Injection (IV)
	Composition	Each Vial Contains; Meropenem (as mixture of sodium carbonate) eq. to Meropenem…….500mg
	Diary No. Date of R & I & fee	Dy.No.15174 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825434 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 500mg Injection Reg. No. 096203 M/s Pfizer Pakistan.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma

		(registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….500mg"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
730.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Liquid Vials SVP (General) Section.
	Brand Name + Dosage Form + Strength	Arloss 200mg/100ml IV Injection
	Composition	Each 100ml injection Contains; Linezolid…..….200mg
	Diary No. Date of R & I & fee	Dy.No.15173 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825432 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other antibacterials ATC Code: J01XX08
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	1's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	LINEZOLID, 200MG/100ML (2MG/ML), SOLUTION; INTRAVENOUS. USFDA Approved.
	Me-too status	Nezkil 200mg Infusion Reg. No. 048802 M/s SJ&Fazul Ellahi Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.

	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
731.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	UTRIN 500mg/5ml Injection
	Composition	Each 5ml Ampoule Contains; Levetiracetam…….500mg
	Diary No. Date of R & I & fee	Dy.No.15168 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825426 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX14
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's & 10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Levetiracetam 100 mg / mL Concentrate for solution for infusion No. PL 24598/0074 (5ml ampoule) MHRA Approved.
	Me-too status	Lerace 500mg/5ml Injection Reg. No. 066949 M/s Hilton Pharma (Pvt) Ltd Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
732.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with

		M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Mecron 500mcg/1ml Injection (IV/IM)
	Composition	Each 1ml Ampoule Contains; Mecobalamine…….500mcg
	Diary No. Date of R & I & fee	Dy.No.15167 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825425 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Vitamin B12.
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	METHYCOBAL 500µg injection PDMA Japan Approved.
	Me-too status	Reli-cobal Injection 500mcg Reg. No. 083440 M/s Reliance Pharma
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
733.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	TRANSFIT 100mg/2ml Injection (IV/IM)
	Composition	Each 2ml Ampoule Contains; Tramadol (as HCl)…….100mg
	Diary No. Date of R & I & fee	Dy.No.15170 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825429 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other opioids

		ATC Code: N02AX02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Tramadol 50mg/ml solution for Injection or Infusion - PL 18157/0014. MHRA Approved.
	Me-too status	Tramal Ampoules Reg. No. 010172 M/s The Searle Company Limited Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
734.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Tromax Injection 250mg/5ml
	Composition	Each 5ml Ampoule Contains; Tranexamic Acid……250mg
	Diary No. Date of R & I & fee	Dy.No.13740 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825449 dated 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Tranexamic acid injection 250/5mL "Nissin" (Plastic Ampoule) PDMA Japan Approved.
	Me-too status	Transamin Injection 250mg Reg. No. 007534
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.

	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. ii. Latest GMP inspection report/certificate of M/s Rotex Pharma is required. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
735.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	TROMAX Injection 500mg/5ml
	Composition	Each 5ml Ampoule Contains; Tranexamic Acid……500mg
	Diary No. Date of R & I & fee	Dy.No.13739 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0845284 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	10's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cyklokapron Injection, 500mg/5ml Solution for injection MHRA approved.
	Me-too status	Transamin –INJ Reg. No. 010452 M/s Hilton Pharma (Pvt) Ltd. Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/- The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.

	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
736.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Calrolic 5mg/1ml Injection
	Composition	Each 1ml Ampoule Contains; Cholecalciferol (Vitamin D3)…..5mg
	Diary No. Date of R & I & fee	Dy.No.15171 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825430 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Vitamin D analogue.
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	**Rotex Specifications**
	Pack size & Demanded Price	1's & 5's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
737.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with

		M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Lectol 30mg/1ml Injection
	Composition	Each 1ml Ampoule Contains; Ketorolac tromethamine…..30mg
	Diary No. Date of R & I & fee	Dy.No.15172 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 082531 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	5's , As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Deferred for submission of following: • **Details of method of sterilization for applied formulation.** • **Fee Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021**	
738.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Liquid Ampoule SVP (General) Section.
	Brand Name + Dosage Form + Strength	Irlet 100mg/5ml Injection (IV)
	Composition	Each 5ml Ampoule Contains; Iron sucrose eq to elemental Iron …100mg
	Diary No. Date of R & I & fee	Dy.No.15159 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825427 dated 06.03.2019, endorsed on 06.03.2019

	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.** • **Fee of Rs. 75,000/- for pre-approval change/correction in Form 5 and label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021**	
739.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Dry Powder Vial (Steroid) Section.
	Brand Name + Dosage Form + Strength	LIMSED 100mg Injection (IV/IM)
	Composition	Each Vial Contains; Hydrocortisone sodium succinate eq. to Hydrocortisone……100mg
	Diary No. Date of R & I & fee	Dy.No.15166 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825424 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN, Glucocorticoids. ATC Code: H02AB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SOLU-CORTEF 100MG, HYDROCORTISONE 100 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION. MHRA APPROVED.

	Me-too status	Hyzonate Injection 100mg Reg. No. 019228 M/s Amson Vaccines & Pharma (Pvt.) Ltd. Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma (registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
740.	Name and address of manufacturer/ Applicant	M/s. Valor Pharmaceuticals, 124/A, Triangle Industrial estate, Kahuta Road, Islamabad. (Contract Giver) (DML No. 000496). Contract with M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000651) Sterile Dry Powder Vial (Steroid) Section.
	Brand Name + Dosage Form + Strength	LIMSED 250mg Injection (IV/IM)
	Composition	Each Vial Contains; Hydrocortisone sodium succinate eq. to Hydrocortisone……250mg
	Diary No. Date of R & I & fee	Dy.No.15165 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0825423 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN, Glucocorticoids. ATC Code: H02AB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SOLU-CORTEF ACT-O-VIAL 250MG POWDER FOR INJECTION AND DILUENT TGA Australia Approved
	Me-too status	Hyzonate Injection 250mg Reg. No. 019226 M/s Amson Vaccines & Pharma (Pvt.) Ltd. Islamabad.
	GMP status	As per GMP certificate Last inspection conducted on 12.08.2020.
	Remarks of the Evaluator	i. Form 5 is being filled and signed by M/s Rotex Pharmaceutical (Contract Acceptor). Form 5 filled and signed by M/s Valor Pharma

		(registration applicant) is required along with fee of Rs. 75000/-. The firm M/s Valor Pharma vide letter No. nil dated 13.01.2023 has submitted correct Form-5. No fee is paid. Latest GMP inspection report/certificate is also not submitted.
	Decision: Approved. Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in Form 5 as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road Islamabad.**	
741.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Liquid Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	IROMAL 100mg/5ml Injection (IV)
	Composition	Each 5ml Ampoule Contains; Iron Sucrose complex equivalent to elemental iron …..100mg
	Diary No. Date of R & I & fee	Dy.No.13909 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820536 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.** • **Fee of Rs. 75,000/- for pre-approval change/correction in label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021**	
742.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with

		M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Liquid Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	CEKOFEN 75mg/3ml Injection (IV/IM)
	Composition	Each 3ml Ampoule Contains; Diclofenac sodium…..75mg
	Diary No. Date of R & I & fee	Dy.No.13908 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820528 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Acetic acid derivatives and related substances. ATC Code: M01AB05
	Type of Form	Form-5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified
	Me-too status	Dicloran 75mg Injection Reg. No. 009748 M/s Sami Pharma Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. Valid evidence of approval of product in RRA is required. ii. Reference of product specifications is required.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
743.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Liquid Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	BRAWN-D 5mg/1ml Injection (IM)
	Composition	Each 1ml Ampoule Contains; Cholecalciferol (Vitamin D3)…5mg
	Diary No. Date of R & I & fee	Dy.No.13900 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820525 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Vitamin D analogue
	Type of Form	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.

	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. Reference of product specifications is required.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 7,500/- for pre-approval change/correction in product specifications as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
744.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Liquid Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	CEKOBAL 500mcg/1ml Injection (IM/IV)
	Composition	Each 1ml Ampoule Contains; Methylcobalamine…500mcg
	Diary No. Date of R & I & fee	Dy.No.13904 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820541 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Vitamin D analogue
	Type of Form	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	METHYCOBAL 500µginjection PDMA Japan Approved.
	Me-too status	Mecomed 500mcg Reg. No. 041670 M/s Global Pharma Islamabad
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	ii. Reference of product specifications is required.
	Decision: Approved with innovator's specifications. Registration letter shall be issued after submission of fee Rs. 7,500/- for pre-approval change/correction in product specifications as per Notification No. 7-11/2012-B&A dated 07.05.2021. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
745.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167)

		Dry Powder (General) Injection Section.
	Brand Name + Dosage Form + Strength	OMEL 40mg Infusion (IV)
	Composition	Each vial Contains; Omeprazole…40mg
	Diary No. Date of R & I & fee	Dy.No.13898 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820538 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC01
	Type of Form	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Omeprazole 40mg Powder for Solution for Infusion (omeprazole sodium) - PL 10622/0232 MHRA APPROVED.
	Me-too status	Risek 40mg Infusion Reg. No. 024170 M/s Getz Pharma Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. The salt/hydrate of API is not considered in label. Revision of label claim is required as per innovator product along with submission of full fee i.e. Rs. 75000/- ii. Reference of product specifications is required.
	Decision: Approved as per following label claim with innovator's specifications: **Each vial Contains;** **Omeprazole as sodium……40mg** **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in product label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021.** **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
746.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder (General) Injection Section.
	Brand Name + Dosage Form + Strength	ESOFES 40mg Infusion (IV)
	Composition	Each vial Contains; Esomeprazole…40mg
	Diary No. Date of R & I & fee	Dy.No.13902 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820529 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Proton pump inhibitors, ATC Code: A02BC05
	Type of Form	Form-5

	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ESOMEPRAZOLE 40 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION - PL 55035/0001 MHRA APPROVED.
	Me-too status	Nexum IV 40mg Injection Reg. No. 050651 M/s Getz Pharma Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. The salt/hydrate of API is not considered in label. Revision of label claim is required as per innovator product along with submission of full fee i.e. Rs. 75000/- ii. Reference of product specifications is required.
	Decision: Approved as per following label claim with innovator's specifications: **Each vial Contains;** **Esomeprazole as sodium……40mg** **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in product label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021.** **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
747.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	CEFTAM 1gm Injection (IV)
	Composition	Each Vail Contains; Cefoperazone Sodium….500mg Sulbactam Sodium……..500mg
	Diary No. Date of R & I & fee	Dy.No.13907 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820525 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SULPERAZONE FOR INTRAVENOUS INJECTION 1G PDMA JAPAN APPROVED.
	Me-too status	Q-Bact 1gm Injection Reg. No. 061169 M/s High-Q International Karachi.

	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. The salt/hydrate of API is mentioned as is in label. Revision of label claim is required as per innovator product along with submission of full fee i.e. Rs. 75000/- ii. Reference of product specifications is required.
	Decision: Approved as per following label claim with JP specifications: **Each vial Contains;** **Cefoperazone as Sodium….500mg** **Sulbactam as Sodium…….500mg** **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in product label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021.** **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
748.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	CEFTAM 2gm Injection (IV)
	Composition	Each Vail Contains; Cefoperazone Sodium….1000mg Sulbactam Sodium……..1000mg
	Diary No. Date of R & I & fee	Dy.No.13912 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820527 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Approved in 03 European countries, i.e., Czech Republic, Poland and Slovakia
	Me-too status	Q-Bact 2gm Injection Reg. No. 061170 M/s High-Q International Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. Reference of product specifications is required. ii. The salt/hydrate of API mentioned as is in label. Revision of label claim is required as per innovator product along with submission of full fee i.e. Rs. 75000/- iii. Reference of product specifications is required.

	Decision: Approved as per following label claim with JP specifications: **Each vial Contains;** **Cefoperazone as Sodium….1000mg** **Sulbactam as Sodium…….1000mg** **Registration letter shall be issued after submission of fee Rs. 75,000/- for pre-approval change/correction in product label claim as per Notification No. 7-11/2012-B&A dated 07.05.2021.** **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
749.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FOTAX 250mg Injection (IV)
	Composition	Each Vail Contains; Cefotaxime as Cefotaxime sodium…250mg
	Diary No. Date of R & I & fee	Dy.No.13899 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820531 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified.
	Me-too status	Cefotax Inj 250mg Reg. No. 015130 M/s Bosch Pharmaceuticals Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	i. The salt/hydrate of API is mentioned as is in label. Revision of label claim is required as per innovator product along with submission of full fee i.e. Rs. 75000/- ii. Evidence of approval of applied formulation in RRA is required.
	Decision: Deferred evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
750.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167)

		Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FOTAX 500mg Injection (IV)
	Composition	Each Vial Contains; Cefotaxime as Cefotaxime sodium…500mg
	Diary No. Date of R & I & fee	Dy.No.13910 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820532 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefotaxime 500mg and 1000mg Powder for Solution for Injection or Infusion - PL 25975/0043-4; UK/H/1401/001-2/DC MHRA Approved.
	Me-too status	Cefotaxime 500mg Injection Reg. No. 011452 M/s United Agencies Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.	
751.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FOTAX 1gm Injection (IV)
	Composition	Each Vial Contains; Cefotaxime as Cefotaxime sodium…1gm
	Diary No. Date of R & I & fee	Dy.No.13905 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820530 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefotaxime 500mg and 1000mg Powder for Solution for Injection or Infusion - PL 25975/0043-4; UK/H/1401/001-2/DC MHRA Approved.

	Me-too status	Cefotax 1000mg Injection Reg. No. 015131 M/s Bosch Pharmaceuticals Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.	
752.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	TRIX 250mg Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone Sodium equivalent to Ceftriaxone……250mg
	Diary No. Date of R & I & fee	Dy.No.13914 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820540 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	El-Cef Injection Reg. No. 075341 M/s Linear Pharma Rawat.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.	
753.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167)

		Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	TRIX 500mg Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone Sodium equivalent to Ceftriaxone ……500mg
	Diary No. Date of R & I & fee	Dy.No.13903 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820537 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV Inj Reg. No. 008435 M/s Martin Dow Ltd. Karachi.
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.	
754.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	TRIX 1gm Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone Sodium equivalent to Ceftriaxone ……1gm
	Diary No. Date of R & I & fee	Dy.No.13906 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820539 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5

		MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.	
755.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FRAD 250mg (IV)
	Composition	Each Vial Contains; Cephradine……250mg
	Diary No. Date of R & I & fee	Dy.No.13901 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820535 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	First-generation cephalosporins ATC Code: J01DB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Not required as per decision of 323rd meeting.
	Me-too status	Velosef Injection 250mg Reg. No. 001870 M/s GSK Pakistan
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	Label claim requires to be revised as per reference product and decision of 323rd meeting of registration board along with submission of full fee i.e. Rs. 75000/-
	Decision: Approved as per label claim approved in 323rd meeting of Registration Board for the "Cephradine for Injection" along along with submission of fee for any change if applicable as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
756.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with

		M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FRAD 500mg (IV)
	Composition	Each Vial Contains; Cephradine……500mg
	Diary No. Date of R & I & fee	Dy.No.13913 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820534 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	First-generation cephalosporins ATC Code: J01DB09
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Not required as per decision of 323rd meeting.
	Me-too status	Velosef Injection 500mg Reg. No. 001866 M/s GSK Pakistan
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	Label claim requires to be revised as per reference product and decision of 323rd meeting of registration board along with submission of full fee i.e. Rs. 75000/-
	Decision: Approved as per label claim approved in 323rd meeting of Registration Board for the "Cephradine for Injection" along along with submission of fee for any change if applicable as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
757.	Name and address of manufacturer/ Applicant	M/s. C.K.D Pharmaceuticals Pakistan (Pvt.) Ltd. 50/28, Korangi Industrial Area, Karachi. (Contract Giver) (DML No. 000144). Contract with M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi. (Contract acceptor) (DML No. 000167) Dry Powder Injection (Cephalosporin) Injection Section.
	Brand Name + Dosage Form + Strength	FRAD 1gm (IV)
	Composition	Each Vial Contains; Cephradine……1gm
	Diary No. Date of R & I & fee	Dy.No.13911 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0820533 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	First-generation cephalosporins ATC Code: J01DB09
	Type of Form	Form-5

	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Not required as per decision of 323rd meeting.
	Me-too status	Velosef Injection 1gm Reg. No. 001869 M/s GSK Pakistan
	GMP status	Last inspection of M/s Mediate Pharma conducted on 09.10.2020. GMP status is good.
	Remarks of the Evaluator	Label claim requires to be revised as per reference product and decision of 323rd meeting of registration board along with submission of full fee i.e. Rs. 75000/-
	Decision: Approved as per label claim approved in 323rd meeting of Registration Board for the "Cephradine for Injection" along along with submission of fee for any change if applicable as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Mediate Pharmaceutical (Pvt.) Ltd. 150-151, Sector 24, Korangi Industrial Area, Karachi.**	
758.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	HELAMIN 500mcg/1ml Injection (IV/IM)
	Composition	Each 1ml Ampoule Contains; Mecobalamine…….500mcg
	Diary No. Date of R & I & fee	Dy.No.13618 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791932 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Vitamin B12
	Type of Form	Form-5
	Finished product Specification	**EG Specs**
	Pack size & Demanded Price	5x5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	METHYCOBAL 500µginjection PDMA Japan Approved.
	Me-too status	Mecomed 500mcg Reg. No. 041670 M/s Global Pharma Islamabad
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.

	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
759.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	Sucron 100mg/5ml Injection (IV)
	Composition	Each 5ml Ampoule Contains; Iron as Sucrose equivalent to elemental Iron…100mg
	Diary No. Date of R & I & fee	Dy.No.13620 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791928 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	5x5's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
760.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	Helac 30mg/1ml Injection
	Composition	Each 1ml Ampoule Contains;

		Ketorolac Tromethamine….30mg
	Diary No. Date of R & I & fee	Dy.No.13619 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791929 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS, Acetic acid derivatives and related substances. ATC Code: M01AB15
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
761.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Ampoule (General) Section.
	Brand Name + Dosage Form + Strength	Eptam 500mg/5ml Injection
	Composition	Each 5ml Ampoule Contains; Levetiracetam….500mg
	Diary No. Date of R & I & fee	Dy.No.13621 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791930 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX14
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.

	Approval status of product in Reference Regulatory Authorities	Levetiracetam 100 mg / mL Concentrate for solution for infusion No. PL 24598/0074 (5ml ampoule) MHRA Approved.
	Me-too status	Lerace 500mg/5ml Injection Reg. No. 066949 M/s Hilton Pharma (Pvt) Ltd Karachi.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
762.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Dry Powder Injection(Cephalosporin) Section.
	Brand Name + Dosage Form + Strength	Nexep 1g Injection
	Composition	Each Vial Contains; Ceftriaxone as Sodium equivalent to ceftriaxone….1g
	Diary No. Date of R & I & fee	Dy.No.13624 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791931 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form 5.
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-.

		ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
763.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Dry Powder Injection(Cephalosporin) Section.
	Brand Name + Dosage Form + Strength	Hotaxim 250mg Injection
	Composition	Each Vial Contains; Cefotaxime as sodium equivalent to cefotaxime….250mg
	Diary No. Date of R & I & fee	Dy.No.13625 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791926 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified.
	Me-too status	Cefotax Inj 250mg Reg. No. 015130 M/s Bosch Pharmaceuticals Karachi.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required. iii. Evidence of product approval in RRA is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
764.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752)

		Dry Powder Injection(Cephalosporin) Section.
	Brand Name + Dosage Form + Strength	Hotaxim 500mg Injection
	Composition	Each Vial Contains; Cefotaxime as sodium equivalent to cefotaxime….500mg
	Diary No. Date of R & I & fee	Dy.No.13622 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791925 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefotaxime 500mg and 1000mg Powder for Solution for Injection or Infusion - PL 25975/0043-4; UK/H/1401/001-2/DC MHRA Approved.
	Me-too status	Cefotaxime 500mg Injection Reg. No. 011452 M/s United Agencies Karachi.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
765.	Name and address of manufacturer/ Applicant	M/s. Heal Pharmaceuticals (Pvt.) Ltd. W-33, Industrial Estate, Hayatabad, Peshawar (Contract Giver) (DML No. 000000612). Contract with M/s. EG pharmaceuticals 13-A, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000752) Dry Powder Injection(Cephalosporin) Section.
	Brand Name + Dosage Form + Strength	Hotaxim 1g Injection
	Composition	Each Vial Contains; Cefotaxime as sodium equivalent to cefotaxime….1g
	Diary No. Date of R & I & fee	Dy.No.13623 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0791927 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.

	Approval status of product in Reference Regulatory Authorities	Cefotaxime 500mg and 1000mg Powder for Solution for Injection or Infusion - PL 25975/0043-4; UK/H/1401/001-2/DC MHRA Approved.
	Me-too status	Cefotax 1000mg Injection Reg. No. 015131 M/s Bosch Pharmaceuticals Karachi.
	GMP status	Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s EG Pharma, Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Last inspection conducted in 2019. Latest GMP inspection report/Certificate of M/s EG Pharma is required.
	Decision: Deferred for submission of Form-5 filled and signed by M/s Heal Pharma (Applicant for registration) along with full fee i.e. Rs.75000/-. as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
766.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559). Contract with M/s.DeMont Research Laboratories (Pvt.) Ltd. 20-KM, Lahore-Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Sachet (General) Section.
	Brand Name + Dosage Form + Strength	Omnic Plus 20mg/1680mg Sachet
	Composition	Each Sachet Contains; Omeprazole……...20mg Sodium Bicarbonate …1680mg
	Diary No. Date of R & I & fee	Dy.No.15678 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844226 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form-5
	Finished product Specification	**USP Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ZEGERID (20mg/packet ; 1.68gm/packet, 40mg/packet ; 1.68gm/packet) for Oral Suspension USFDA Approved
	Me-too status	Risek Insta Sachet 20mg + 1680mg by M/s Getz Pharma (Reg# 58547)
	GMP status	Not submitted
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Latest GMP inspection report/Certificate of DeMont Research Lab is required.

		iii. Reference of product specifications is mentioned as USP, USP monograph of applied formulation is required.
	Decision: Deferred for following: **i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-.** **ii. Latest GMP inspection report of DeMont Research Lab conducted within last three years.**	
767.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559). Contract with M/s.DeMont Research Laboratories (Pvt.) Ltd. 20-KM, Lahore-Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Sachet (General) Section.
	Brand Name + Dosage Form + Strength	MONCIT 4mg Sachet
	Composition	Each Sachet Contains; Montelukast (as sodium)……4mg
	Diary No. Date of R & I & fee	Dy.No.15679 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844227 dated 07.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SINGULAIR PAEDIATRIC 4MG GRANULES. MHRA Approved.
	Me-too status	Singulair 4mg granules, Reg. No. 031377 M/s OBS Healthcare Karachi
	GMP status	Not submitted
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Latest GMP inspection report/Certificate of DeMont Research Lab is required.
	Decision: Deferred for following: **i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-.** **ii. Latest GMP inspection report of DeMont Research Lab conducted within last three years.**	
768.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, thoker Raiwind Road, Lahore (Contract Giver) (DML No. 000342). Contract with M/s.DeMont Research Laboratories (Pvt.) Ltd. 20-KM, Lahore-Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844)

		Sachet (General) Section.
	Brand Name + Dosage Form + Strength	OMEPRAGON 20mg/1680mg Sachet
	Composition	Each Sachet Contains; Omeprazole……...20mg Sodium Bicarbonate …1680mg
	Diary No. Date of R & I & fee	Dy.No. 16125 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900478 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form-5
	Finished product Specification	**USP Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ZEGERID (20mg/packet ; 1.68gm/packet, 40mg/packet ; 1.68gm/packet) for Oral Suspension USFDA Approved
	Me-too status	Risek Insta Sachet 20mg + 1680mg by M/s Getz Pharma (Reg# 58547)
	GMP status	Not submitted
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Trigon (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Latest GMP inspection report/Certificate of DeMont Research Lab is required. iii. Reference of product specifications is mentioned as USP, USP monograph of applied formulation is required.
	Decision: Deferred for following: **i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-.** **ii. Latest GMP inspection report of DeMont Research Lab conducted within last three years.**	
769.	Name and address of manufacturer/ Applicant	M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract Giver) (DML No. 000664). Contract with M/s.DeMont Research Laboratories (Pvt.) Ltd. 20-KM, Lahore-Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Sachet (General) Section.
	Brand Name + Dosage Form + Strength	Ringet 20mg/1680mg Sachet
	Composition	Each Sachet Contains; Omeprazole……...20mg Sodium Bicarbonate …1680mg
	Diary No. Date of R & I & fee	Dy.No. 16149 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900476 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01

	Type of Form	Form-5
	Finished product Specification	**USP Specifications**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ZEGERID (20mg/packet ; 1.68gm/packet, 40mg/packet ; 1.68gm/packet) for Oral Suspension USFDA Approved
	Me-too status	Risek Insta Sachet 20mg + 1680mg by M/s Getz Pharma (Reg# 58547)
	GMP status	Not submitted
	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s McOlson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Latest GMP inspection report/Certificate of DeMont Research Lab is required. iii. Reference of product specifications is mentioned as USP, USP monograph of applied formulation is required.
	Decision: Deferred for following: **iii. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-.** **iv. Latest GMP inspection report of DeMont Research Lab conducted within last three years.**	
770.	Name and address of manufacturer/ Applicant	M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract Giver) (DML No. 000664). Contract with M/s.DeMont Research Laboratories (Pvt.) Ltd. 20-KM, Lahore-Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Sachet (General) Section.
	Brand Name + Dosage Form + Strength	NOWEEZ 4mg Sachet
	Composition	Each Sachet Contains; Montelukast (as sodium)……4mg
	Diary No. Date of R & I & fee	Dy.No.16148 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900475 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SINGULAIR PAEDIATRIC 4MG GRANULES. MHRA Approved.
	Me-too status	Singulair 4mg granules, Reg. No. 031377 M/s OBS Healthcare Karachi
	GMP status	Not submitted

	Remarks of the Evaluator	i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s McOlson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-. ii. Latest GMP inspection report/Certificate of DeMont Research Lab is required.
	Decision: Deferred for following: **i. Form-5 is filled and signed by M/s DeMont, Form-5 filled and signed by M/s Dyson Research Laboratories (Applicant for registration) is required along with full fee i.e. Rs.75000/-.** **ii. Latest GMP inspection report of DeMont Research Lab conducted within last three years.**	
771.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFTALEX 500mg Injection
	Composition	Each vial contains; Sterile powder of ceftriaxone sodium equivalent to ceftriaxone …500mg
	Diary No. Date of R & I & fee	Dy.No.15686 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900486 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV Inj Reg. No. 008435 M/s Martin Dow Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..**	
772.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with

		M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFTALEX 250mg Injection
	Composition	Each vial contains; Sterile powder of ceftriaxone sodium equivalent to ceftriaxone …250mg
	Diary No. Date of R & I & fee	Dy.No.15687 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900487 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	El-Cef Injection Reg. No. 075341 M/s Linear Pharma Rawat.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	ii. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..**	
773.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFTALEX 1g Injection
	Composition	Each vial contains; Sterile powder of ceftriaxone sodium equivalent to ceftriaxone …1g
	Diary No. Date of R & I & fee	Dy.No.15685 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900485 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.

	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Firm shall select only one route of administration i.e., either I/M or I/V at the time issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..**	
774.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	BERCEF 1g Injection
	Composition	Each vial contains; Sterile Cefoperazone Sodium equivalent to Cefoperazone USP…500mg Sulbactam Sodium equivalent to Sulbactam USP…..500mg
	Diary No. Date of R & I & fee	Dy.No.15681 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900481 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	JP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SULPERAZONE FOR INTRAVENOUS INJECTION 1G PDMA JAPAN APPROVED.
	Me-too status	Q-Bact 1gm Injection Reg. No. 061169 M/s High-Q International Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..	

775.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	BERCEF 2g Injection
	Composition	Each vial contains; Sterile Cefoperazone Sodium equivalent to Cefoperazone USP…1000mg Sulbactam Sodium equivalent to Sulbactam USP…..1000mg
	Diary No. Date of R & I & fee	Dy.No.15682 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900482 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Approved in 03 European countries, i.e., Czech Republic, Poland and Slovakia
	Me-too status	Q-Bact 2gm Injection Reg. No. 061170 M/s High-Q International Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..	
776.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFBER 500mg Injection
	Composition	Each vial contains; Sterile powder of Cefepime HCl with L-Arginine equivalent to Cefepime …500mg
	Diary No. Date of R & I & fee	Dy.No.15684 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900484 dated 06.03.2019, endorsed on 06.03.2019

	Pharmacological Group	Fourth-generation cephalosporins ATC Code: J01DE01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefepime hydrochloride eq to 500mg base/ vial. USFDA Approved.
	Me-too status	Avepime Injection 500mg Reg. No. 059586 M/s Aventek Pharmaceuticals Lahore.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura..	
777.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFBER 1gm Injection
	Composition	Each vial contains; Sterile powder of Cefepime HCl with L-Arginine equivalent to Cefepime …1gm
	Diary No. Date of R & I & fee	Dy.No.15683 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900483 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Fourth-generation cephalosporins ATC Code: J01DE01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefepime hydrochloride eq to 1000mg base/ vial. USFDA Approved.
	Me-too status	Avepime Injection 1gm Reg. No. 059585 M/s Aventek Pharmaceuticals Lahore.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	ii. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
778.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678).

		Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	BERCEF 400mg Capsule
	Composition	Each Capsule contains; Cefixime trihydrate eq to Cefixime 400mg
	Diary No. Date of R & I & fee	Dy.No.15690 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900489 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax (Cefixime) Capsules 400mg USFDA Approved.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
779.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Oral dry suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	BERCEF 100mg/5ml Oral suspension
	Composition	Each 5ml contains; Cefixime trihydrate eq to Cefixime 100mg
	Diary No. Date of R & I & fee	Dy.No.15688 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900488 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**

	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	ii. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
780.	Name and address of manufacturer/ Applicant	M/s. Berlex Lab International, 10-KM Nagshah Chowk, Karachi Road, Multan. (Contract Giver) (DML No. 000678). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Oral dry suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	BERCEF 200mg/5ml Oral suspension
	Composition	Each 5ml contains; Cefixime trihydrate eq to Cefixime …… 200mg
	Diary No. Date of R & I & fee	Dy.No.15689 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 1900480 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
781.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559).

		Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Tricef 2.0gm Injection
	Composition	Each vial contains; Sterile Cefoperazone Sodium equivalent to Cefoperazone USP…1000mg Sulbactam Sodium equivalent to Sulbactam USP…..1000mg
	Diary No. Date of R & I & fee	Dy.No.15676 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844250 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor. ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Approved in 03 European countries, i.e., Czech Republic, Poland and Slovakia
	Me-too status	Q-Bact 2gm Injection Reg. No. 061170 M/s High-Q International Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	ii. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
782.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Tricef 1.0gm Injection
	Composition	Each vial contains; Sterile Cefoperazone Sodium equivalent to Cefoperazone USP…500mg Sulbactam Sodium equivalent to Sulbactam USP…..500mg
	Diary No. Date of R & I & fee	Dy.No.15675 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844249 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins, cefoperazone and beta-lactamase inhibitor.

		ATC Code: J01DD62
	Type of Form	Form-5
	Finished product Specification	JP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SULPERAZONE FOR INTRAVENOUS INJECTION 1G PDMA JAPAN APPROVED.
	Me-too status	Q-Bact 1gm Injection Reg. No. 061169 M/s High-Q International Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	iii. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
783.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	OD-Cef 2gm Injection
	Composition	Each vial contains; Ceftriaxone sodium equivalent to ceftriaxone USP…..2 gm
	Diary No. Date of R & I & fee	Dy.No.2442 dated 15.04.2013; Copy of Fee Slip not submitted, Duplicate dossier submitted vide Dy. No. 33009 dated 17.11.2022, Diary verified from RnI.
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Cefxone 2gm Injection Reg. No. 055913 M/s Bosch Pharmaceuticals (Pvt) Ltd Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Copy of endorsed deposit slip is required.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
784.	Name and address of manufacturer/ Applicant	M/s. Dyson Research Laboratories, 28-KM, Ferozpur Road, Lahore (Contract Giver) (DML No. 000559).

		Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Ampoule (General) Section
	Brand Name + Dosage Form + Strength	Ondsave 8mg/4ml Injection
	Composition	Each 4ml Ampoule contains; Ondansetron hydrochloride dihydrate….8mg
	Diary No. Date of R & I & fee	Dy.No.40251 dated 05.12.2018; Fee Rs. 50,000/- paid vide slip No. 0821306 dated 05.12.18, Fee slip is not endorsed. Duplicate dossier submitted vide Dy. No. 33010 dated 17.11.2022, Diary verified from RnI.
	Pharmacological Group	ANTIEMETICS AND ANTINAUSEANTS, Serotonin (5HT3) antagonists ATC Code: A04AA01
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ONDANSETRON 8MG/4ML INJECTION (ONDANSETRON HYDROCHLORIDE) PL 04543/0508 MHRA APPROVED.
	Me-too status	Periset 4ml injection Reg. No. 090250 M/s Linear Pharma Islamabad.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Copy of fee slip does not have endorsement stamp. Copy of endorsed deposit slip is required. iii. The label claim applied includes amount of salt and hydrate, reference products mention strength of base. Correction along with submission of full fee i.e. Rs.75000/- is required.
	Decision: Approved as per following label claim: **"Each 4ml Ampoule contains;** **Ondansetron as hydrochloride dihydrate….8mg"** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura along with verification of fee challan as per decision of 285th meeting of Registration Board.**	
785.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with

		M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Cefigon 400mg Capsule
	Composition	Each Capsule contains; Cefixime trihydrate eq to Cefixime 400mg
	Diary No. Date of R & I & fee	Dy.No.16124 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844247 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax (Cefixime) Capsules 400mg USFDA Approved.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura	
786.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Oral dry suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFIGON 100mg/5ml Oral suspension
	Composition	Each 5ml contains; Cefixime trihydrate eq to Cefixime 100mg
	Diary No. Date of R & I & fee	Dy.No.16122 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844245 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.

	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura**	
787.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Oral dry suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	CEFIGON 200mg/5ml Oral suspension
	Composition	Each 5ml contains; Cefixime trihydrate eq to Cefixime 200mg
	Diary No. Date of R & I & fee	Dy.No.16123 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844246 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**JP Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.**	
788.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342).

		Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	Esomepragon 40mg Capsules
	Composition	Each capsule contains; Esomperaon….40mg
	Diary No. Date of R & I & fee	Dy.No.16117 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844240 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton Pump inhibitors. ATC Code: A02BC05
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ESOMEPRAZOLE 40 MG GASTRO-RESISTANT CAPSULES HARD. MHRA Approved.
	Me-too status	Nexum 40mg Capsule Reg. No. 033891 M/s Getz Pharma (Pvt.) Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Label claim is unclear. It is required to be submitted along with full fee i.e. Rs. 75000/- iii. Source of pellets is required to be defined along with submission of requisite fee.
	Decision: Deferred for clarification of label claim for applied formulation along with fee of Rs. 75,000/- as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
789.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	Esomepragon 20mg Capsules
	Composition	Each capsule contains; Esomperagon….20mg
	Diary No. Date of R & I & fee	Dy.No.16116 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844239 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton Pump inhibitors. ATC Code: A02BC05
	Type of Form	Form-5
	Finished product Specification	USP Specifications.

	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Esomeprazole 20mg Gastro-resistant Capsules (esomeprazole magnesium dihydrate) - PL 16028/0166. MHRA Approved.
	Me-too status	Nexum 20mg Capsule Reg. No. 033890 M/s Getz Pharma (Pvt.) Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Label claim is unclear. It is required to be submitted along with full fee i.e. Rs. 75000/- iii. Source of pellets is required to be defined along with submission of requisite fee.
	Decision: Deferred for clarification of label claim for applied formulation along with fee of Rs. 75,000/- as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
790.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	**E-GAB 50mg Capsule**
	Composition	Each capsule contains; Pregabalin ……75mg
	Diary No. Date of R & I & fee	Dy.No.16118 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844241 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other anti-epileptics ATC Code: N03AX16
	Type of Form	Form-5
	Finished product Specification	Manufacturers Specifications.
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Lyrica® 50 mg hard capsules MHRA Approved.
	Me-too status	Gabica 50 mg Capsule Reg. No. 048725 M/s Getz Pharma (Pvt) Ltd Karachi
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Label claim is of 75mg, needs correction along with full fee i.e. Rs.75000/-
	Decision: Approved with BP specifications as per following label claim: **Each capsule contains:** **Pregabalin ……75mg** **The firm shall submit fee of Rs. 75,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	

	Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
791.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	E-GAB 75mg Capsule
	Composition	Each capsule contains; Pregabalin……75mg
	Diary No. Date of R & I & fee	Dy.No.16119 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844242 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX16
	Type of Form	Form-5
	Finished product Specification	Manufacturers Specifications.
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Pregabalin Noumed 25, 50, 75, 100, 150, 200, 225 and 300mg Capsules, hard (pregabalin) - PL 44041/0065-0072 MHRA Approved.
	Me-too status	Gabica 75 mg Capsule Reg. No. 047365 M/s Getz Pharma (Pvt) Ltd Karachi
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved with BP specifications. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
792.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	**Itragon 100mg Capsule**
	Composition	Each Capsule Contains; Itraconazole (as immediate release pellets)…..100mg
	Diary No. Date of R & I & fee	Dy.No.16121 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844244 dated 05.03.2019, endorsed on 06.03.2019

	Pharmacological Group	Triazole and tetrazole derivatives. ATC Code: J02AC02
	Type of Form	Form-5
	Finished product Specification	Manufacturers Specifications.
	Pack size & Demanded Price	4's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Itraconazole 100mg Capsules, hard MHRA Approved.
	Me-too status	Sporanox Capsule Reg. No. 012647 M/s Aspin Pharma (pvt.) Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Source of pellets is not defined. It is required to be defined along with submission of requisite fee.
	Decision: Approved with USP specifications. Registration letter will be issued upon submission of following: • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Source of pellets along with stability studies data, GMP certificate of supplier and differential fee in case of import of pellets.** **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.**	
793.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	FLUCAGON 150mg Capsule
	Composition	Each Capsule Contains; Fluconazole……..150mg
	Diary No. Date of R & I & fee	Dy.No.16120 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844243 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Triazole and tetrazole derivatives ATC Code: J02AC01
	Type of Form	Form-5
	Finished product Specification	BP Specifications.
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Fluconazole 150mg Capsules - PL 08137/0120 MHRA Approved.
	Me-too status	Alfumet 150mg Capsule Reg. No. 069263 M/s Wilshire Laboratories Lahore.
	GMP status	Inspection report dated 2018 is submitted.

	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required.
	Decision: Approved Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 Km, Lahore Sharikpur Road, Sheikhupura.	
794.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	Omepragon 20mg Capsule
	Composition	Each Capsule Contains; Omepragon…20mg
	Diary No. Date of R & I & fee	Dy.No.16113 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844236 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton Pump inhibitors. ATC Code: A02BC05
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Esomeprazole 20mg Gastro-resistant Capsules (esomeprazole magnesium dihydrate) - PL 16028/0166. MHRA Approved.
	Me-too status	Nexum 20mg Capsule Reg. No. 033890 M/s Getz Pharma (Pvt.) Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Label claim needs to be corrected as per innovator product along with submission of full fee i.e. Rs. 75000/-. iii. Source of pellets is required to be defined along with submission of required fee.
	Decision: Deferred for clarification of label claim for applied formulation along with fee of Rs. 75,000/- as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
795.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section

	Brand Name + Dosage Form + Strength	Omepragon 40mg Capsule
	Composition	Each Capsule Contains; Omepragon…40mg
	Diary No. Date of R & I & fee	Dy.No.16112 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844235 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton Pump inhibitors. ATC Code: A02BC05
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	ESOMEPRAZOLE 40 MG GASTRO-RESISTANT CAPSULES HARD. MHRA Approved.
	Me-too status	Nexum 40mg Capsule Reg. No. 033891 M/s Getz Pharma (Pvt.) Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Label claim needs to be corrected as per innovator product, along with submission of full fee i.e. Rs. 75000/-. iii. Source of pellets is required to be defined along with submission of required fee.
	Decision: Deferred for clarification of label claim for applied formulation along with fee of Rs. 75,000/- as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
796.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	Dexlagon 30mg Capsule
	Composition	Each Capsule Contains; Dexlansoprazole as Dual Delayed Release pellets…30mg
	Diary No. Date of R & I & fee	Dy.No.16114 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844237 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC06
	Type of Form	Form-5
	Finished product Specification	**Manufacturers Specifications**
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	DEXILANT (dexlansoprazole) delayed-release capsules, for oral use Delayed-release capsules: 30 mg and 60 mg MHRA Approved.

	Me-too status	Daplazole DDR Capsule 30 mg Reg. No. 104251 M/s AGP Ltd. Karachi.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Source of pellets is required to be defined along with submission of required fee. iii. Stability study data as per guidelines provided in 293rd meeting of Registration Board is required.
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
797.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342). Contract with M/s. McOlson Research Laboratories (Pvt.) Ltd. Plot No. 2, M2-Pharma zone, 26 KM, Lahore Sharikpur Road, Sheikhupura. (Contract acceptor) (DML No. 000844) Capsule (General) Section
	Brand Name + Dosage Form + Strength	Dexlagon 60mg Capsule
	Composition	Each Capsule Contains; Dexlansoprazole as Dual Delayed Release pellets…60mg
	Diary No. Date of R & I & fee	Dy.No.16115 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844238 dated 05.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC06
	Type of Form	Form-5
	Finished product Specification	**Manufacturers Specifications**
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	DEXILANT (dexlansoprazole) delayed-release capsules, for oral use Delayed-release capsules: 30 mg and 60 mg MHRA Approved.
	Me-too status	Remit DR Capsules 60 mg Reg. No. 090301 M/s Scotmann Pharmaceuticals Plot No. 5-D, Sector I-10/3 Islamabad.
	GMP status	Inspection report dated 2018 is submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/Certificate of M/s McOlson Research Lab is required. ii. Source of pellets is required to be defined along with submission of required fee. iii. Stability study data as per guidelines provided in 293rd meeting of Registration Board is required.
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
798.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil

		Sharaqpur. District Sheikhupura (contract giver) (DML No.000880). Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Capsule (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	FAMICEF 400mg Capsule
	Composition	Each Capsule Contains; Cefixime trihydrate eq. to Cefixime USP…..400mg
	Diary No. Date of R & I & fee	Dy.No.14463 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763736 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	**In-House**
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	SUPRAX (CEFIXIME) CAPSULES 400MG USFDA APPROVED.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th meeting of Registration Board wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved with manufacturer specifications as approved by Registration Board in its 313th meeting and notified vide letter No. F.14-I/2022-PEC dated 14th March 2022. • **Registration letter shall be issued after submission of fee Rs. 75,00/- as per Notification No. 7-11/2012-B&A dated 07.05.2021 for correction/pre-approval change of the composition of product.** • **As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.**	
799.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil Sharaqpur. District Sheikhupura (contract giver) (DML No.000880).

		Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Dry Powder Suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	FAMICEF 100mg/5ml Oral Suspension
	Composition	Each 5ml Contains; Cefixime trihydrate eq. to Cefixime USP…..100mg
	Diary No. Date of R & I & fee	Dy.No.14464 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763734 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Cefixime 100 mg/5 mL Powder for Oral Suspension - PL 04569/1118; UK/H/2828/001/DC MHRA Approved.
	Me-too status	Fixicef Powder for oral suspension Reg. No. 080273 M/s Atco Laboratories Karachi.
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th meeting of Registration Board wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved. As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.	
800.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil Sharaqpur. District Sheikhupura (contract giver) (DML No.000880). Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Dry Powder Suspension (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	FAMICEF 200mg/5ml Oral Suspension

	Composition	Each 5ml Contains; Cefixime trihydrate eq. to cefixime USP…..200mg
	Diary No. Date of R & I & fee	Dy.No.14465 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763735 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Suprax 200mg/5ml USFDA Approved.
	Me-too status	Cefspan D.S Suspension Reg. No. 024634 M/s Barret Hodgson Pakistan Karachi.
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th meeting of Registration Board Wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved. As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.	
801.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil Sharaqpur. District Sheikhupura (contract giver) (DML No.000880). Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Famitrix 250mg Injection (IM)
	Composition	Each Vial Contains; Ceftriaxone sodium USP eq. to Ceftriaxone…250mg
	Diary No. Date of R & I & fee	Dy.No.14466 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763739 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04

	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	El-Cef Injection Reg. No. 075341 M/s Linear Pharma Rawat.
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th meeting of Registration Board Wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved. As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.	
802.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil Sharaqpur. District Sheikhupura (contract giver) (DML No.000880). Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Famitrix 500mg Injection (IM)
	Composition	Each Vial Contains; Ceftriaxone sodium USP eq to Ceftriaxone…500mg
	Diary No. Date of R & I & fee	Dy.No.14467 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763738 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5

		MHRA Approved.
	Me-too status	Zetox 500mg Injection Reg. No. 053145 M/s Lahore Pharma.
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th meeting of Registration Board Wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved. As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.	
803.	Name and address of manufacturer/ Applicant	M/s. Fahmir Pharma (Pvt.) ltd. 26-KM Lahore Jaranwala Road, Main Stop Mandianwala, tehsil Sharaqpur. District Sheikhupura (contract giver) (DML No.000880). Contract with M/s. Medisave Pharmaceuticals, Plot No. 578-579, Sundar Industrial Estate Lahore. (Contract acceptor) (DML No. 000681) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	Famitrix 1g Injection (IV)
	Composition	Each Vial Contains; Ceftriaxone sodium USP eq to Ceftriaxone…1g
	Diary No. Date of R & I & fee	Dy.No.14468 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0763737 dated 05.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Third-generation cephalosporins. ATC Code: J01DD04
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ceftriaxone 250mg, 500mg and 1g Powder for Solution for Injection and 2g Pwder for Solution for Injection or Infusion - PL 22805/0001, 3-5 MHRA Approved.
	Me-too status	Rocephin IV/IM Injection 1gm Reg. No. 007014 M/s Martin Dow Karachi
	GMP status	GMP Inspection report provided is of 2018.
	Remarks of the Evaluator	The Capacity assessment inspection report of M/s. Medisave pharmaceuticals, Lahore presented in 317th

		meeting of Registration Board Wherein Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections: • General Tablet Section (General), • Capsule Section (Cephalosporin) • Dry Powder Suspension Section (Cephalosporin) • Dry Powder Injection Section (Cephalosporin) • Liquid Injection • Infusion (LVP) Section • Liquid Syrup Section
	Decision: Approved. As decided in 317th meeting of Registration Board, M/s Medisave Pharmaceuticals shall submit compliance report from the contract manufacturer i.e., for further increase in testing capacity especially HPLC, microbiological testing etc. before issuance of registration letter.	
804.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	MIXIME 200mg Capsule
	Composition	Each Capsule Contains; Cefixime…..200mg
	Diary No. Date of R & I & fee	Dy. No. 13724 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0844377 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	10's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Cefixima Normon 200 mg cápsulas duras EFG CIMA Spain Approved.
	Me-too status	Cefspan 200mg Capsule Reg. No. 013859. M/s Barrett Hodgson Karachi..
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is

		required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. The hydrate form is not mentioned in label claim, label claim needs to be revised accordingly. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. The hydrate form is not mentioned in label claim; label claim needs to be revised accordingly.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
805.	Name and address of manufacturer/ Applicant	M/s Marvi Pharmaceuticals Plot No. 70, Sector 24 Korangi Industrial area, Karachi. (DML No.000148) (Contract giver) Contract with M/s Uni-tiech Pharmaceutical Plot No. 4/116 Sector 21, Korangi Industrial Area, Karachi (DML No. 000356) (Contract acceptor) Dry Powder Injection (Cephalosporin) Section
	Brand Name + Dosage Form + Strength	MIXIME 400mg Capsule
	Composition	Each Capsule Contains; Cefixime…..400mg
	Diary No. Date of R & I & fee	Dy. No. 13723 dated 07.03.2019 Fee paid Rs. 20,000/- vide slip No. 0844375 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Third-generation cephalosporins ATC Code: J01DD08
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	10's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Suprax (Cefixime) Capsules 400mg USFDA Approved.
	Me-too status	Cefspan 400mg Capsules Reg. No. 013860 M/s Barret Hodgson Pakistan Karachi.
	GMP status	Could not be confirmed.
	Remarks of the Evaluator	i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid. ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is

		required along with fee of Rs. 75,000/- for revision of Form 5 in current date. iii. The hydrate form is not mentioned in label claim, label claim needs to be revised accordingly. iv. Latest GMP inspection report/certificate of M/s Uni-tiech pharma is required.
	Decision: Deferred for following: **i. Fee paid is Rs. 20,000/-. At time when application was submitted, fee for contract manufacturing was Rs. 50,000/- per application. Differential fee of Rs. 30,000/- is required to be paid.** **ii. Form-5 is filled and signed on behalf of M/s Uni-tiech pharma. Applicant is M/s Marvi pharma. Application form i.e. Form-5 filled and signed by M/s Marvi Pharmaceuticals is required along with fee of Rs. 75,000/- for revision of Form 5 in current date.** **iii. The hydrate form is not mentioned in label claim; label claim needs to be revised accordingly.** **iv. Verification of validity status of DML of M/s Marvi Pharmaceuticals.** **v. Updated GMP status of M/s Uni-tiech Pharmaceutical.**	
806.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342) Contract with M/s. Welmark Pharmaceuticals, Plot No. 122, Block-B, Phase V, Industrial Estate Hattar (Contract Acceptor) (DML No.000614) Dry Powder Injection(Penicillin) Section.
	Brand Name + Dosage Form + Strength	Piprabact 4g/500mg Injection (IV)
	Composition	Each Vial Contains; Piperacillin sodium….4g Tazobactam sodium….500mg
	Diary No. Date of R & I & fee	Dy. No. 16367 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 0797010 dated 04.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Combinations of penicillins, incl. beta-lactamase inhibitors. ATC Code: J01CR05
	Type of Form	Form 5
	Finished product Specification	**Innovator's Specifications**
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	PIPERACILLIN/TAZOBACTAM 4 G/ 0.50 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION - PL 28176/0046 MHRA APPROVED.
	Me-too status	Tanzo 4.5gm Inj Reg. No. 039439 M/s Bosch Pharmaceuticals Karachi..
	GMP status	Not provided.
	Remarks of the Evaluator	i. The salt is included in strength of API, it requires revision as per products approved in RRA and me-too products along with submission of full fee i.e. Rs. 75000/-

		ii. The monograph of applied product is available in pharmacopoeia and innovator specs are applied. Clarification or correction is required. iii. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm). iv. Latest GMp inspection report/ certificate of M/s Wellmark Pharma is required. v. Section approval letter of M/s Wellmark pharma is required.
	Decision: Deferred for following: **i. The salt is included in strength of API, it requires revision as per products approved in RRA and me-too products along with submission of full fee i.e. Rs. 75000/-** **ii. The monograph of applied product is available in pharmacopoeia and innovator specs are applied. Clarification or correction is required.** **iii. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm).** **iv. Latest GMP inspection report/ certificate of M/s Welmark Pharma is required.** **v. Section approval letter of M/s Welmark pharma is required.**	
807.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342) Contract with M/s. Welmark Pharmaceuticals, Plot No. 122, Block-B, Phase V, Industrial Estate Hattar (Contract Acceptor) (DML No.000614) Dry Powder Injection(Carbapenem) Section.
	Brand Name + Dosage Form + Strength	Iminom 250mg/250mg Injection (IV)
	Composition	Each Vial Contains; Imipenem monohydrate……250mg Cilastatin sodium…....250mg
	Diary No. Date of R & I & fee	Dy. No. 16364 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 0797008 dated 04.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Carbapenems ATC Code: J01DH51
	Type of Form	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	IMIPENEM/CILASTATIN 250MG/250MG AND 500MG/500MG POWDER FOR SOLUTION FOR INFUSION - UK/H/1704/001-002/DC; PL 30306/0112-3 MHRA APPROVED.
	Me-too status	Cilnem 250mg Injection IV Reg. No. 094314 M/s Nicholas Pharma Rawat.
	GMP status	Not provided.
	Remarks of the Evaluator	i. The salt and hydrate is included in strength of API, it requires revision as per products approved in RRA and me-too products along with submission of full fee i.e. Rs. 75000/- ii. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm).

		iii. Latest GMP inspection report/ certificate of M/s Wellmark Pharma is required. iv. Section approval letter of M/s Wellmark pharma is required.
	Decision: Deferred for following: **i. The salt and hydrate is included in strength of API, it requires revision as per products approved in RRA and me-too products along with submission of full fee i.e. Rs. 75000/-** **ii. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm).** **iii. Latest GMP inspection report/ certificate of M/s Wellmark Pharma is required.** **iv. Section approval letter of M/s Wellmark pharma is required.**	
808.	Name and address of manufacturer/ Applicant	M/s. Trigon Pharmaceuticals (Pvt.) Ltd. 8-KM, Thoker Raiwind Road, Lahore. (contract giver) (DML No.000342) Contract with M/s. Welmark Pharmaceuticals, Plot No. 122, Block-B, Phase V, Industrial Estate Hattar (Contract Acceptor) (DML No.000614) Dry Powder Injection(Carbapenem) Section.
	Brand Name + Dosage Form + Strength	MERAG 500mg Injection (IV)
	Composition	Each Vial Contains; Meropenem as trihydrate (USP) ….500mg
	Diary No. Date of R & I & fee	Dy. No. 16362 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 0797004 dated 04.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Type of Form	Form 5
	Finished product Specification	**Innovator's Specification.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 500mg Injection Reg. No. 096203 M/s Pfizer Pakistan.
	GMP status	Not provided.
	Remarks of the Evaluator	i. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm) along with submission of full fee i.e. Rs. 75000/- ii. Latest GMP inspection report/ certificate of M/s Welmark Pharma is required. iii. Section approval letter of M/s Welmark pharma is required. iv. The monograph of applied product is available in Pharmacopoeia, yet innovator's specifications are applied. Clarification or correction is required.
	Decision: Deferred for following: **i. Fomr-5 is filled and signed by contact giver. It is required to be filled and signed by product registration applicant (M/s Trigon Pharm) along with submission of full fee i.e. Rs. 75000/-** **ii. Latest GMP inspection report/ certificate of M/s Wellmark Pharma is required.**	

	iii. Section approval letter of M/s Welmark pharma is required. **iv. The monograph of applied product is available in Pharmacopoeia, yet innovator's specifications are applied. Clarification or correction is required.**	
809.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Capsule (general) Section.
	Brand Name + Dosage Form + Strength	OZOLE 40mg Capsule
	Composition	Each Capsule Contains; Omeprazole as enteric coated pellets (USP)…40mg
	Diary No. Date of R & I & fee	Dy. No. 17366 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901368 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form 5.
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	OMEPRAZOLE/AYLOME/OMEANG 10MG, 20MG AND 40 MG GASTRO-RESISTANT CAPSULES, HARD PL 23218/0170-78 MHRA Approved.
	Me-too status	Risek 40mg Capsule Reg. no. 022109 M/s Getz Pharma Karach.
	GMP status	Not submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate is required. ii. Source of pellets is also required. The firm vide letter No. nil dated 20.01.2023 has stated the following; " It is to inform you that our product is already registered and we mistakenly applied for toll manufacturing from welwink pharma, kindly reject our application."
	Decision: Registration Board rejected the instant application since applied formulation has already been registered in the name of M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat	
810.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Capsule (general) Section.
	Brand Name + Dosage Form + Strength	OZOLE 20mg Capsule
	Composition	Each Capsule Contains; Omeprazole as enteric coated pellets (USP)…20mg

	Diary No. Date of R & I & fee	Dy. No. 17367 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901367 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Proton pump inhibitors ATC Code: A02BC01
	Type of Form	Form 5.
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	OMEPRAZOLE/AYLOME/OMEANG 10MG, 20MG AND 40 MG GASTRO-RESISTANT CAPSULES, HARD PL 23218/0170-78 MHRA Approved.
	Me-too status	Risek 20mg Capsule Reg. no. 019364 M/s Getz Pharma Karach.
	GMP status	Not submitted.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate is required. ii. Source of pellets is required. The firm vide letter No. nil dated 20.01.2023 has stated the following; " It is to inform you that our product is already registered and we mistakenly applied for toll manufacturing from welwink pharma, kindly reject our application."
	Decision: Registration Board rejected the instant application since applied formulation has already been registered in the name of M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat	
811.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Sachet (general) Section.
	Brand Name + Dosage Form + Strength	RALE 40mg Sachet
	Composition	Each Sachet Contains; Esomeprazole as enteric coated pellets (USP)…40mg
	Diary No. Date of R & I & fee	Dy. No. 17369 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901358 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC05
	Type of Form	Form 5.
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Nexium, Esomeprazole Magnesium eq 20mg, 40mg, 2.5mg,5mg base/packet. For suspension, delayed release, oral. USFDA Approved.
	Me-too status	Could not be verified.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted.

	Remarks of the Evaluator	i. The formulation and label claim is different from innovator product. It needs correction along with fee of Rs. 75000/-. ii. Evidence of me-too product registered locally is required. iii. Source of pellets is required. The firm vide letter No. nil dated 20.01.2023 has rectified label as under; Each sachet contains; Esomeprazole magnesium enteri coated pellets 22.5% equivalent to esomeprazole ….40mg. Source of pellets: M/s Winbrains Research Laboratories. Fee Rs. 75000/- vide Slip No. 499671313 dated 20.01.2023 is submitted. The firm has submitted copy of registration letter of Navix 40mg Sachet Reg. No. 090726 issued to M/s Wnsfield pharma Hattar.
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	
812.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Sachet (general) Section.
	Brand Name + Dosage Form + Strength	MASTE 4mg Sachet
	Composition	Each Sachet Contains; Montelukast sodium eq to Montelukast free base (USP)…….4mg
	Diary No. Date of R & I & fee	Dy. No. 17370 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901360 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Leukotriene receptor antagonists ATC Code: R03DC03
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MONTELUKAST 4 MG GRANULES - PL 36687/0448 MHRA Approved.
	Me-too status	Singulair 4mg Granules Reg. No. 031377 M/s OBS Health (Pvt.) Ltd. Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	

813.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Sachet (general) Section.
	Brand Name + Dosage Form + Strength	S-HALE 2g Sachet
	Composition	Each Sachet Contains; Strontium ranelate …..2g
	Diary No. Date of R & I & fee	Dy. No. 17357 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901359 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Other drugs affecting bone structure and mineralization. ATC Code: M05BX03
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	STRONTIUM RANELATE ARISTO 2 G GRANULES FOR ORAL SUSPENSION. MHRA Approved.
	Me-too status	Osstium 2gm Sachet Reg. no. 058698 M/s Atco Laboratories Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	
814.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Sachet (general) Section.
	Brand Name + Dosage Form + Strength	DICTITE 2gm Sachet
	Composition	Each Sachet Contains; Dioctahedral smectite ……3gm
	Diary No. Date of R & I & fee	Dy. No. 17379 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901361 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Other intestinal adsorbents ATC Code: A07BC05
	Type of Form	Form-5
	Finished product Specification	**In-house**
	Pack size & Demanded Price	As per SRO.

	Approval status of product in Reference Regulatory Authorities	SMECTA 3 g FRAISE, powder for oral suspension in sachet. ANSM France Approved.
	Me-too status	SMECTA PDRA Reg. No. 010905 M/s ATCO Labs Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. **Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.**	
815.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Liquid Ampoule (general) Section.
	Brand Name + Dosage Form + Strength	CHOLZ 5mg/ml Injection (IM)
	Composition	Each 1ml Ampoule Contains; Vitamin D3 (USP)……..5mg (Cholecalciferol 200,000IU)
	Diary No. Date of R & I & fee	Dy. No. 17310 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1902599 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Vitamin D analogue.
	Type of Form	Form-5
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	VITAMIN D3 BON 200,000 IU/1 ml solution for injection IM ampoule ANSM France Approved.
	Me-too status	Sunny D Insta Ampoule Reg. No. 063450 M/s Scotmann Pharmaceuticals Islamabad.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	
816.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Liquid Ampoule (general) Section.

	Brand Name + Dosage Form + Strength	IROZEN 100mg/ml Injection
	Composition	Each 5ml Ampoule Contains; Iron sucrose complex eq to elemental iron ….100mg
	Diary No. Date of R & I & fee	Dy. No. 16311 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1902540 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	SUCROFER 20 MG IRON/ML, SOLUTION FOR INJECTION /INFUSION (IRON SUCROSE) - UK/H/6369/001/DC; PL 20568/0083 MHRA APPROVED.
	Me-too status	Venofer IV Injection Reg. No. 085031 M/s OBS Pakistan Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Deferred for submission of following: • **Label claim as per innovator product declaring complete salt form of the drug substance.** • **Evidence of availability of Atomic absorption spectrophotometer, required as per USP monograph for applied formulation.**	
817.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Liquid Ampoule (general) Section.
	Brand Name + Dosage Form + Strength	Ketozen 30mg/1mL Injection
	Composition	Each 1ml Ampoule Contains; Ketorolac Tromethamine (USP)…..30mg
	Diary No. Date of R & I & fee	Dy. No. 16312 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901600 dated 06.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Type of Form	Form-5
	Finished product Specification	**Innovator's Specifications.**
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ketorolac trometamol 30mg/ml Solution for Injection MHRA Approved.
	Me-too status	Ketometa 30mg Injection Reg. No. 108436 M/s Lahore Chemical & Pharmaceutical Works Lahore.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023

	Remarks of the Evaluator	i. Innovator specifications are applied when monograph in pharmacopoeia is available. Revision of spec along with fee of Rs. 7500/- is required. The firm has revised specs of the product vide letter No. Nil dated 20.01.2023 and have paid fee of Rs. 7500/- vide slip No. 072566430939 dated 20.01.2023
	Decision: Deferred for details for sterilization method for applied formulation.	
818.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Dry Powder Injection (general) Section.
	Brand Name + Dosage Form + Strength	OZOLE 40mg Injection
	Composition	Each Vial Contains; Omeprazole as Sodium (BP)…..40mg
	Diary No. Date of R & I & fee	Dy. No. 17365 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901357 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC01
	Form-5	Form-5
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Omeprazole 40mg Powder for Solution for Infusion (omeprazole sodium) - PL 10622/0232 MHRA APPROVED.
	Me-too status	Risek 40mg Infusion Reg. No. 024170 M/s Getz Pharma Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	
819.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Dry Powder Injection (general) Section.
	Brand Name + Dosage Form + Strength	RALE 40mg Injection
	Composition	Each Vial Contains; Esomeprazole as Sodium (BP)…..40mg
	Diary No. Date of R & I & fee	Dy. No. 17364 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901362 dated 07.03.2019 endorsed on 07.03.2019.

	Pharmacological Group	Proton pump inhibitors. ATC Code: A02BC05
	Form-5	Form 5.
	Finished product Specification	Innovator's Specifications
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	ESOMEPRAZOLE 40 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION - PL 55035/0001 MHRA APPROVED.
	Me-too status	Nexum IV 40mg Injection. Reg. No. 050651 M/s Getz Pharma Karachi.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon satisfactory capacity assessment of manufacturing and testing facility of M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala.	
820.	Name and address of manufacturer/ Applicant	M/s. Wezen Pharmaceuticals, Plot No. 23 & 24, S-1, RCCI Industrial Estate, Rawat (contract giver) (DML No.000882) Contract with M/s. Welwink Pharmaceuticals GT Road Industrial Estate Gujranwala (Contract Acceptor) (DML No.000751) Liquid Vial LVP (general) Section.
	Brand Name + Dosage Form + Strength	M-CIN 400mg/250mL Injection
	Composition	Each 250mL Vial Contains; Moxifloxacin as HCl (USP)…400mg
	Diary No. Date of R & I & fee	Dy. No. 17360 dated 07.03.2019 Fee paid Rs. 50,000/- vide slip No. 1901356 dated 07.03.2019 endorsed on 07.03.2019.
	Pharmacological Group	Fluoroquinolones. ATC Code: J01MA14
	Form-5	Form 5.
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	Moxifloxacin 400 mg/250 ml Solution for Infusion - PL 24598/0022; UK/H/4829/001/DC MHRA Approved.
	Me-too status	Avelox Infusion Reg. No. 030851 M/s Bayer Pakistan (Pvt.) Ltd. Kot Lakhpat.
	GMP status	GMP certificate dated 25.08.2022 valid till 26.07.2025 is submitted, vide letter dated 20.01.2023
	Remarks of the Evaluator	i. Section approval letter/ evidence of large vial filling facility is required.
	Decision: Deferred for evidence of approval of required manufacturing facility for applied fill volume.	
821.	Name and address of manufacturer/ Applicant	M/s Winilton Pharmaceuticals (Pvt.) Ltd. Plot No. 45 St. No. S-5, National Industrial Zone RCCI Rawat. (Contract Giver) (DML No. 000721). Contract with

		M/s Vision Pharmaceuticals, Plot No. 22-23, Industrial Triangle, Kahuta Road Islamabad. (Contract acceptor) (DML No. 000517) Sterile Dry Powder Vial (General) Section.
	Brand Name + Dosage Form + Strength	WINMETHATE 1M IU Injection
	Composition	Each Vial Contains; Colistimethate sodium dry powder …1Million IU
	Diary No. Date of R & I & fee	Dy.No. 16397 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0713445 dated 06.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Polymyxins ATC Code: J01XB01
	Form-5	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	COLISTIMETHATE SODIUM 1 MIU POWDER FOR SOLUTION FOR INJECTION/INFUSION - PL 24598/0091 MHRA Approved.
	Me-too status	Stacolmi 1MIU Injection Reg. No. 106475 M/s Stallion Pharmaceuticals Lahore.
	GMP status	Last inspection conducted on 28.10.2020. GMP Status is good.
	Remarks of the Evaluator	i. Capacity assessment inspection of M/s Vision Pharmaceutical (DML No. 000517) was conducted on 15.06.2022 for following sections; a. Sterile Dry Powder Vial (General) b. Sterile Dry Powder Injection Vial (Steroid)
	Decision: Approved as per label claim approved in 323rd meeting of Registration Board for the "Colistimethate for Injection" along with submission of fee for any change if applicable as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.	
822.	Name and address of manufacturer/ Applicant	M/s Fresh Pharmaceuticals Plot No. 7 St. no. S-6, National Industrial Zone RCCI Rawat. (Contract Giver) (DML No. 000827). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	**Mepnam 1gm Injection**
	Composition	Each Vial Contains; Imipenem monohydrate eq. to Imipenem …500mg Cilastatin Sodium eq. to Cilastatin……500mg
	Diary No. Date of R & I & fee	Dy.No. 16451 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0844416 dated 04.03.2019, endorsed on 06.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH51
	Form-5	Form- 5 (Contract Application)
	Finished product Specification	USP specifications.

	Pack size & Demanded Price	1's. As per SRO
	Approval status of product in Reference Regulatory Authorities	IMIPENEM/CILASTATIN 500/500MG POWDER FOR SOLUTION FOR INFUSION (IMIPENEM, CILASTATIN SODIUM) - UK/H/1409/001/DC; PL 14894/0665 MHRA APPROVED.
	Me-too status	Imclas Inj IV Reg. No. 048341 M/s Global Pharmaceuticals Islamabad.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule Injectable General
	Decision: Approved. • **M/s Global shall use 10ml 0.9% NaCl injection as diluent for the commercial batches and submit compatibility study with the 0.9%NaCl solution as diluent along with BMR of recently manufactured batches from M/s Global Pharmaceuticals, as evidence of use of the recommended diluent before issuance of Registration letter.** • **Firm shall use correct fill weight per vial considering the sodium content as per the drug substance manufacturer's claim for the commercial batches and submit BMR of recently manufactured batches from M/s Global Pharmaceuticals as evidence of correct fill weight before issuance of Registration letter.** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
823.	Name and address of manufacturer/ Applicant	M/s Treat Pharmaceutical Industry (Pvt.) Ltd. A-37 Small Industrial Estate Township, Kohat Road Bannu. (Contract Giver) (DML No. 000352). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	TREATBACT 2.25gm Injection
	Composition	Each Vial Contains; Sterile Piperacillin Sodium equivalent to Piperacillin……4.0gm Sterile Tazobactam Sodium equivalent to Tazobactam……...0.5gm
	Diary No. Date of R & I & fee	Dy.No.16417 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0622503, endorsed on 07.03.2019
	Pharmacological Group	Combinations of penicillins, incl. beta-lactamase inhibitors. ATC Code: J01CR05
	Form-5	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's. As per SRO.

	Approval status of product in Reference Regulatory Authorities	PIPERACILLIN/TAZOBACTAM 2 G/ 0.25 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION - PL 28176/0045 MHRA APPROVED.
	Me-too status	Tanzo 2.25gm Inj Reg. No. 039593 M/s Bosch Pharmaceuticals Karachi..
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. Covering letter is of strength 2.25gm whereas Form-5 and whole dossier of 4.5gm strength is submitted. ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule Injectable General
	Decision: Approved as per following label claim: **"Treatbact 4.5gm Injection** **Each Vial Contains;** **Sterile Piperacillin Sodium equivalent to Piperacillin……4.0gm** **Sterile Tazobactam Sodium equivalent to Tazobactam……...0.5gm"** **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
824.	Name and address of manufacturer/ Applicant	M/s Webros Pharmaceuticals. Plot No.1 St. 10, National Industrial Zone, Rawat (Contract Giver) (DML No. 000538). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	ONUM 500mg Injection (IV)
	Composition	Each Vial Contains; Meropenem USP…..500mg
	Diary No. Date of R & I & fee	Dy.No.16416 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0807242, paid on 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Form-5	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 500mg Injection Reg. No. 096203 M/s Pfizer Pakistan.

	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.
	Remarks of the Evaluator	i. Hydrate/ salt is not considered in label claim; it needs to be revised as per innovator product along with submission of full fee i.e. Rs75000/- ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule Injectable General
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….500mg"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
825.	Name and address of manufacturer/ Applicant	M/s Webros Pharmaceuticals. Plot No.1 St. 10, National Industrial Zone, Rawat (Contract Giver) (DML No. 000538). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Carbapenem) Section.
	Brand Name + Dosage Form + Strength	ONUM 1gm Injection (IV)
	Composition	Each Vial Contains; Meropenem USP…..1gm
	Diary No. Date of R & I & fee	Dy.No.16415 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0807240, paid on 06.03.2019, endorsed on 07.03.2019
	Pharmacological Group	Carbapenems ATC Code: J01DH02
	Form-5	Form 5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	MEROPENEM 500 MG AND 1 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION (MEROPENEM) - UK/H/4098/001-2/DC; PL 34985/0003-4 MHRA APPROVED.
	Me-too status	Meronem IV 1g Injection Reg. No. 096204 M/s Pfizer Pakistan.
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.

	Remarks of the Evaluator	i. Hydrate/ salt is not considered in label claim; it needs to be revised as per innovator product along with submission of full fee i.e. Rs75000/- ii. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule Injectable General
	Decision: Approved with following label claim; **"Each Vial Contains:** **Meropenem Trihydrate Eq. To Meropenem….1gm"** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".** • **Registration letter shall be issued after submission of fee Rs. 75,000/- as per Notification No. 7-11/2012-B&A dated 07.05.2021** • **Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.**	
826.	Name and address of manufacturer/ Applicant	M/s Webros Pharmaceuticals. Plot No.1 St. 10, National Industrial Zone, Rawat (Contract Giver) (DML No. 000538). Contract with M/s Global Pharmaceuticals (Pvt.) Ltd., Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad. (Contract acceptor) (DML No. 000417) Dry Powder Injection (Penicillin) Section.
	Brand Name + Dosage Form + Strength	Z-LIN 4.5gm Injection (IV)
	Composition	Each Vial Contains; Sterile Piperacillin Sodium equivalent to Piperacillin……4.0gm Sterile Tazobactam Sodium equivalent to Tazobactam……...0.5gm
	Diary No. Date of R & I & fee	Dy.No.16414 dated 07-03-2019; Fee Rs.50,000 paid vide slip No. 0807243, endorsed on 07.03.2019
	Pharmacological Group	Combinations of penicillins, incl. beta-lactamase inhibitors. ATC Code: J01CR05
	Form-5	Form- 5 (Contract Application)
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	PIPERACILLIN/TAZOBACTAM 2 G/ 0.25 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION - PL 28176/0045 MHRA APPROVED.
	Me-too status	Tanzo 2.25gm Inj Reg. No. 039593 M/s Bosch Pharmaceuticals Karachi..
	GMP status	Last inspection conducted on 19.11.2021. GMP Status is good.

	Remarks of the Evaluator	i. The capacity verification of the firm M/s Global Pharmaceuticals was carried out on 21.10.2022 for following sections; o Dry Powder Injection (Cephalosporin) o Dry Powder Injection (Penicillin) o Dry Powder Injection (Carbapenem) o Liquid Ampoule Injectable General
	Decision: Approved. Registration Board further authorized its Chairman for issuance of registration letter upon consideration of satisfactory capacity assessment of manufacturing and testing facility of M/s Global Pharmaceuticals.	
827.	Name and address of manufacturer/ Applicant	M/s Genome Pharmaceuticals (Pvt.) Ltd. 16/1, Phase IV Industrial estate Hattar (DML No. 000454). Contract with M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road Islamabad. (Contract acceptor) (DML No. 000752) Liquid Ampoule Injection (General) Section.
	Brand Name + Dosage Form + Strength	Gennifer 100mg/5ml Injection
	Composition	Each 5mL Ampoule Contains; Iron as III hydroxide polymaltose Complex eq to Iron……100mg
	Diary No. Date of R & I & fee	Dy.No. 12663dated 06-03-2019; Fee Rs.50,000 paid vide slip No. 0847082, dated 06.03.2019 endorsed on 06.03.2019 Duplicate dossier. Old diary verified from RnI.
	Pharmacological Group	Iron, parenteral preparations ATC Code: B03AC
	Form-5	Form-5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ferrosig Injection Iron 100mg/2ml (As Polymaltose) Injection Ampoule TGA Australia Approved.
	Me-too status	The firm has given reference of Intrafer Injection Reg. No. 075039 mfg by M/s Akson Pharma. It is not verifiable from data.
	GMP status	Last inspection of M/s EG Pharma conducted on 25.08.2022. GMP status is reported as OK.
	Remarks of the Evaluator	i. The applied formulation is 100mg/5ml ampoule whereas Innovator product is 100mg/2ml ampoule. ii. Me-too of the product is not verifiable. iii. The firm vide letter No. nil, dated 21.11.2022 has submitted fee of Rs. 7500/- vide slip No. 700619185983 dated 18.11.2022 for revision of specifications from USP to innovator specs.(in response to this office letter dated 04.04.2022)
	Decision: Deferred for following: • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm** • **Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.**	

828.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Valmin Tablet 50mg/1000mg
	Composition	Each Tablet Contains; Vildagliptin……...50mg Metformin HCl….1000mg
	Diary No. Date of R & I & fee	Dy.No. 14705dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550991, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Combinations of oral blood glucose lowering drugs. ATC Code: A10BD08
	Form-5	Form-5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	14's & 30's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Vildagliptin/Metformin 50 mg/1000 mg Film-coated Tablets. MHRA Approved.
	Me-too status	VildoMET 50mg/1000mg Tablet Reg. No. 073612 M/s High-Q Pharmaceuticals Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Innovator product is film coated. Applied product is uncoated. Needs clarification or revision along with requisite fee i.e. Rs.7500/-. iii. Reference of finished product specification is not mentioned.
	Decision: Approved with innovator's specifications, as per following label claim: **Each film coated Tablet Contains;** **Vildagliptin……...50mg** **Metformin HCl….1000mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
829.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Valmin Tablet 50mg/850mg
	Composition	Each Tablet Contains; Vildagliptin……...50mg Metformin HCl….850mg
	Diary No. Date of R & I & fee	Dy.No. 14704 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550990, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Combinations of oral blood glucose lowering drugs. ATC Code: A10BD08
	Form-5	Form-5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	14's & 30's. As per SRO.

	Approval status of product in Reference Regulatory Authorities	Galvumet Film Coated Tablets (50 mg vildagliptin and 850 mg metformin hydrochloride) Swissmedic Approved
	Me-too status	Vilfor 50/850mg tablet Reg. No. 106507 M/s Hi-Medic Pharmaceuticals (Pvt) Ltd Lahore
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Innovator product is film coated. Applied product is uncoated. Needs clarification or revision along with requisite fee i.e. Rs.7500/-. iii. Reference of finished product specification is not mentioned.
	Decision: Approved with innovator's specifications, as per following label claim: **Each film coated Tablet Contains;** **Vildagliptin……...50mg** **Metformin HCl….850mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
830.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Itorown 150mg Tablets
	Composition	Each Tablet Contains; Itopride HCl…….150mg
	Diary No. Date of R & I & fee	Dy.No. 14703 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550980, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Propulsives ATC Code: A03FA07
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	20's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified.
	Me-too status	Ganaton OD Tablet Reg No. 058549 M/s Abbott Laboratories Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Evidence of product approval in RRA is required.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
831.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Itorown 50mg Tablets

	Composition	Each Tablet Contains; Itopride HCl…….50mg
	Diary No. Date of R & I & fee	Dy.No. 14702 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550979, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Propulsives ATC Code: A03FA07
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	20's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ganaton Tablets 50mg (Film Coated) PMDA Japan Approved.
	Me-too status	Inviton 50mg Tablets Reg. No. 096543 M/s Invictus Pharma Rawat.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Innovator product is film coated. Applied product is uncoated. Needs clarification or revision along with requisite fee i.e. Rs.7500/-.
	Decision: Approved with innovator's specifications, as per following label claim: **Each film coated Tablet Contains;** **Itopride HCl…….50mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
832.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Letron 2.5mg Tablets
	Composition	Each Tablet Contains; Letrozole……2.5mg
	Diary No. Date of R & I & fee	Dy.No. 14720 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550985, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Aromatase inhibitors ATC Code: L02BG04
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	10's, 30's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Letrozole 2.5 mg Film-coated tablets - PL 25258/0198 MHRA Approved.
	Me-too status	Femara 2.5mg Tablets Reg. No. 021129 M/s Novartis Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required.

		ii. Innovator product is film coated. Applied product is uncoated. Needs clarification or revision along with requisite fee i.e. Rs.7500/-. iii. Reference of finished product specification is not mentioned.
	Decision: Approved with innovator's specifications, as per following label claim: **Each film coated Tablet Contains;** **Letrozole……2.5mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.** **Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.**	
833.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Everon 0.25mg Tablets
	Composition	Each Tablet Contains; Everolimus…..0.25mg
	Diary No. Date of R & I & fee	Dy.No. 14712 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550983, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Selective immunosuppressants ATC Code: L04AA18
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	60's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Certican® 0.25 mg tablets & 0.75mg Tablets MHRA Approved.
	Me-too status	Certican 0.25mg Tablets Reg. No. 044829 (imported) M/s Novartis Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The same active has ATC code L01EG02 as protein kinase inhibitor (anti-cancer). Section approval for such products is required.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Tablet (Oncology) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5F, within six months.	
834.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Everon 0.75mg Tablets
	Composition	Each Tablet Contains; Everolimus…..0.75mg

	Diary No. Date of R & I & fee	Dy.No. 14713 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550984, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Selective immunosuppressants ATC Code: L04AA18
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	60's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Certican® 0.25 mg tablets & 0.75mg Tablets MHRA Approved.
	Me-too status	Certican 0.75mg Tablets Reg. No. 044830 (imported) M/s Novartis Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The same active has ATC code L01EG02 as protein kinase inhibitor (anti-cancer). Section approval for such products is required.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Tablet (Oncology) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5F, within six months.	
835.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Capsule (General) Section.
	Brand Name + Dosage Form + Strength	Tacrown 1mg Capsules
	Composition	Each Capsule Contains; Tacrolimus…..1mg
	Diary No. Date of R & I & fee	Dy.No. 14711 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550982, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	IMMUNOSUPPRESSANTS ATC Code: L04AD02
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	30's, 50's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Vivadex 0.5mg, 1mg, 5mg hard capsules (tacrolimus) - PL 23022/0018-20; UK/H/2179/01-03/DC MHRA Approved.
	Me-too status	Tacrosan 1mg Capsule Reg. No. 078164 (import) M/s Novartis Karachi
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with USP specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	

	Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.	
836.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Capsule (General) Section.
	Brand Name + Dosage Form + Strength	Tacrown 0.5mg Capsules
	Composition	Each Capsule Contains; Tacrolimus…..0.5mg
	Diary No. Date of R & I & fee	Dy.No. 14710 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0551000, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	IMMUNOSUPPRESSANTS ATC Code: L04AD02
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	30's, 50's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Vivadex 0.5mg, 1mg, 5mg hard capsules (tacrolimus) - PL 23022/0018-20; UK/H/2179/01-03/DC MHRA Approved.
	Me-too status	Tacrosan 0.5mg Capsule Reg. No. 078163 (import) M/s Novartis Karachi
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with USP specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.** **Registration Board approved registration of product in general manufacturing areas with condition that manufacturer shall provide safety and protective measures for workers and personnel which remain in direct contact or are involved in close handling of these drugs.**	
837.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Dictol 50mg/0.2mg Tablet
	Composition	Each Tablet Contains; Diclofenac sodium…..50mg Misoprostol…….0.2mg
	Diary No. Date of R & I & fee	Dy.No. 14706 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550981, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	diclofenac, combinations ATC Code: M01AB55
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	14's. As per SRO.

	Approval status of product in Reference Regulatory Authorities	Diclofenac sodium and misoprostol 50 mg/200 micrograms and 75 mg/200 micrograms modified release tablets (diclofenac sodium and misoprostol) - UK/H/4657/001-2/DC;PL 18909/0417-18 MHRA Approved.
	Me-too status	Arthrotec 50 Tablets Reg. no. 023362 M/s Pfizer Pakistan.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The innovator product is a delayed release product, applied product is uncoated tablet. Clarification or correction along with prescribed fee is required.
	Decision: Deferred for revision of applied formulation as per innovator product along woth submission of evidence of availability of bilayer tablet compression machine.	
838.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Dictol 75mg/0.2mg Tablet
	Composition	Each Tablet Contains; Diclofenac sodium…..75mg Misoprostol…….0.2mg
	Diary No. Date of R & I & fee	Dy.No. 14707 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550992, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	diclofenac, combinations ATC Code: M01AB55
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Diclofenac sodium and misoprostol 50 mg/200 micrograms and 75 mg/200 micrograms modified release tablets (diclofenac sodium and misoprostol) - UK/H/4657/001-2/DC;PL 18909/0417-18 MHRA Approved.
	Me-too status	Cytopan-75 Tables Reg. No. 024014 M/s Getz Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The innovator product is a delayed release product, applied product is uncoated tablet. Clarification or correction along with prescribed fee is required.
	Decision: Deferred for revision of applied formulation as per innovator product along woth submission of evidence of availability of bilayer tablet compression machine.	
839.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.

	Brand Name + Dosage Form + Strength	Riron 200mg Tablet
	Composition	Each Tablet Contains; Rifaximin…..200mg
	Diary No. Date of R & I & fee	Dy.No. 14708 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550986, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	INTESTINAL ANTIINFECTIVES, Antibiotics ATC Code: A07AA11
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	10's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Abimix/Normicron 200 mg film-coated tablets (rifaximin - PL 19364/0030 & 033) MHRA Approved.
	Me-too status	Fifaxa 200mg Tablets Reg. No. 068205 M/s Ferozsons Labs Nowshehra.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The innovator product is film coated, applied product is uncoated tablet. Clarification or correction along with prescribed fee is required.
	Decision: Approved with BP specifications, as per following label claim: **Each film coated Tablet Contains;** **Rifaximin. ….. 200mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
840.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Riron 550mg Tablet
	Composition	Each Tablet Contains; Rifaximin…..550mg
	Diary No. Date of R & I & fee	Dy.No. 14709 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550987, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	INTESTINAL ANTIINFECTIVES, Antibiotics ATC Code: A07AA11
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	10's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	XIFAXAN Tablets by SALIX PHARMA (USFDA Approved)
	Me-too status	Nixaf 550mg tablet Reg. No. 073700. M/s Sami Pharmaceuticals Karachi
	GMP status	Last inspection conducted on 03.08.2016.

	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. The innovator product is film coated, applied product is uncoated tablet. Clarification or correction along with prescribed fee is required.
	Decision: Approved with BP specifications, as per following label claim: **Each film coated Tablet Contains;** **Rifaximin. ….. 550mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.**	
841.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	FEBRO 80mg Tablet
	Composition	Each tablet Contains; Febuxostat……80mg
	Diary No. Date of R & I & fee	Dy.No. 14701 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550978, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Preparations inhibiting uric acid production ATC Code: M04AA03
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	20's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Uloric tablets 80 mg. FDA Approved.
	Me-too status	Adenuric Tablet 80mg Reg. No. 067034 M/s S.J & G. Fazul Ellahie (Pvt) Ltd., E/46 S.I.T.E Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with Innovator's specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifcations as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
842.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	FEBRO 40mg Tablet
	Composition	Each tablet Contains; Febuxostat……40mg

	Diary No. Date of R & I & fee	Dy.No. 14700 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550977, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Preparations inhibiting uric acid production ATC Code: M04AA03
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	20's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Uloric tablets 40 mg. USFDA Approved.
	Me-too status	Adenuric Tablet 40mg Reg. No. 067033 M/s S.J & G. Fazul Ellahie (Pvt) Ltd., E/46 S.I.T.E Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with Innovator's specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
843.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Ivertin 6mg Tablet
	Composition	Each tablet Contains; Ivermectin…….6mg
	Diary No. Date of R & I & fee	Dy.No. 14715 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550994, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	ANTINEMATODAL AGENTS. ATC Code: P02CF01
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	20's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Approved by US FDA
	Me-too status	Ivermite 6mg Tablet Reg. No. 061339 M/s ATCO Laboratories Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with Innovator's specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	

844.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Ivertin 3mg Tablet
	Composition	Each tablet Contains; Ivermectin…….3mg
	Diary No. Date of R & I & fee	Dy.No. 14714 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550993, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	ANTINEMATODAL AGENTS. ATC Code: P02CF01
	Form-5	Form-5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	14's. As per SRO.
	Approval status of product in Reference Regulatory Authorities	Ivermectin Tablets 3mg USFDA Approved.
	Me-too status	Mactovin 3mg Tablet Reg. No. 065224 M/s Valor Pharma Islamabad.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with Innovator's specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product specification as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
845.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Sita-Min 50mg/500mg Tablets
	Composition	Each tablet Contains; Sitagliptin……..50mg Metformin HCl…500mg
	Diary No. Date of R & I & fee	Dy.No. 14718 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550988, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Combinations of oral blood glucose lowering drugs ATC Code: A10BD07
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	10's, 14's. As per SRO
	Approval status of product in Reference Regulatory Authorities	Janumet Tablets MHRA Approved.
	Me-too status	Treviamet 50mg 500mg Tablet Reg. No. 055443 M/s Getz Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.

	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Innovator product is film coated, whereas applied product is uncoated. Clarification or correction along with requisite fee is required. iv. The innovator product is using phosphate salt of sitagliptin, in applied product salt is not mentioned. Clarification or correction along with full fee i.e. Rs.30,000/- is required.
	Decision: Approved with Innovator's specifications as per following label claim: **Each tablet Contains;** **Sitagliptin as phosphate monohydrate…….50mg** **Metformin HCl……500mg** **Registration letter will be issued upon submission of following:** • **Fee of Rs. 30,000/- label claim description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
846.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Sita-Min 50mg/1000mg Tablets
	Composition	Each tablet Contains; Sitagliptin……..50mg Metformin HCl…1000mg
	Diary No. Date of R & I & fee	Dy.No. 14719 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550989, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Combinations of oral blood glucose lowering drugs ATC Code: A10BD07
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	10's, 14's. As per SRO
	Approval status of product in Reference Regulatory Authorities	Janumet Tablets MHRA Approved.
	Me-too status	Treviamet 50mg 1000mg Tablet Reg. No. 055444 M/s Getz Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Innovator product is film coated, whereas applied product is uncoated. Clarification or correction along with requisite fee is required. iv. The innovator product is using phosphate salt of sitagliptin, in applied product salt is not mentioned. Clarification or correction along with full fee i.e. Rs. 30,000/- is required.
	Decision: Approved with Innovator's specifications as per following label claim: **Each tablet Contains;** **Sitagliptin as phosphate monohydrate…….50mg** **Metformin HCl……1000mg** **Registration letter will be issued upon submission of following:**	

	• **Fee of Rs. 30,000/- label claim description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
847.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Lacorown 100mg Tablet
	Composition	Each Film Coated Tablet Contains; Lacosamide…….100mg
	Diary No. Date of R & I & fee	Dy.No. 14699 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550976, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX18
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	14's. As per SRO
	Approval status of product in Reference Regulatory Authorities	LACOSAMIDE TORRENT 100 MG FILM-COATED - PL 36687/0442 MHRA Approved.
	Me-too status	Lalap 100mg Tablet Reg. No. 070471 M/s Genix Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with BP specifications, as per following label claim: **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
848.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Tablet (General) Section.
	Brand Name + Dosage Form + Strength	Lacorown 50mg Tablet
	Composition	Each Tablet Contains; Lacosamide…….50mg
	Diary No. Date of R & I & fee	Dy.No. 14698 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550975, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	Other antiepileptics ATC Code: N03AX18
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	14's. As per SRO
	Approval status of product in Reference Regulatory Authorities	LACOSAMIDE TORRENT 50 MG FILM-COATED TABLETS - PL 36687/0441 MHRA Approved.
	Me-too status	Lalap 50mg Tablet Reg. No. 070470 M/s Genix Pharma Karachi.

	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Innovator product is film coated, whereas applied product is uncoated. Clarification or correction along with requisite fee is required.
	Decision: Approved with BP specifications, as per following label claim: **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
849.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Capsule (General) Section.
	Brand Name + Dosage Form + Strength	Tebi 250mg Capsule
	Composition	Each Capsule Contains; Tranexamic acid….250mg
	Diary No. Date of R & I & fee	Dy.No. 14716 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550995, dated 07.03.2019 endorsed on 07.03.2019
	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Hexatron capsule 250mg PDMA Japan Approved.
	Me-too status	Haemic Capsule 250mg Reg. No. 039014 M/s Genix Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned.
	Decision: Approved with JP specifications. **Registration letter will be issued upon submission of following:** • **Fee of Rs. 7,500/- for correction/pre-approval change in product description to fim coated tablet as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Latest GMP inspection report conducted within last three years.**	
850.	Name and address of manufacturer/ Applicant	M/s Crown Pharmaceuticals, Plot No. 286 kahuta Industrial Triangle Kahuta Road Islamabad. (DML No. 000456) Capsule (General) Section.
	Brand Name + Dosage Form + Strength	Tebi 500mg Capsule
	Composition	Each Capsule Contains; Tranexamic acid….500mg
	Diary No. Date of R & I & fee	Dy.No. 14717 dated 07-03-2019; Fee Rs.20,000 paid vide slip No. 0550996, dated 07.03.2019 endorsed on 07.03.2019

	Pharmacological Group	ANTIFIBRINOLYTICS, Amino acids ATC Code: B02AA02
	Form-5	Form 5
	Finished product Specification	Not mentioned.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Could not be confirmed for capsule dosage form.
	Me-too status	Haemic Capsule 500mg Reg. No. 039016 M/s Genix Pharma Karachi.
	GMP status	Last inspection conducted on 03.08.2016.
	Remarks of the Evaluator	i. Latest GMP inspection report/ certificate required. ii. Reference of finished product specification is not mentioned. iii. Evidence of product approval in RRA is required.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
851.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Acmenoin 0.05% w/w Gel
	Composition	Each gram contains: Isotretinoin…….0.5mg (0.05% w/w)
	Dairy No. date of R &I fee	Dy. No. 44273 dated 28-12-2018 Rs. 20,000 vide Slip No. 0822238 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1153 dated 13.01.2023
	Pharmacological Group	Retinoids for topical use in acne. ATC Code: D10AD04
	Type of form	Form 5
	Finished product specifications	BP Specificaitons
	Pack size and Demand Price	10g, 15g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Isotrex Gel MHRA Approved.
	Me-too-status	Isotin Gel 0.05% Reg. No. 041923 M/s Shaigan Pharmaceuticals
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	
Decision: Approved		
852.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Acmenoin-E Gel
	Composition	Each gram contains; Isotretinoin…0.5mg (0.05% w/w) Erythromycin…20mg (2% w/w)

	Dairy No. date of R &I fee	Dy. No.44274 dated 28-12-2018 Rs. 20,000 vide slip No. 0822239 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1154 dated 13.01.2023
	Pharmacological Group	Retinoids for topical use in acne, isotretinoin, combinations. ATC Code: D10AD54
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	10g, 15g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Could not be verified.
	Me-too-status	Esotek Gel Reg. No. 070175 M/s Biogen Pharma Rawat.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	i. Evidence of approval of product in RRA is required. The firm vide letter dated 19.01.2023 has submitted SmPC of isotrexin 20mg/g +0.5mg/g gel of Irish Medicines Board. The product could not be searched on MHRA and Irish medicine board website. As per EMA this product is authorized for marketing in UK and Ireland.
Decision: Approved		
853.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Benzit 4%w/w Cream
	Composition	Each gm of Cream contains: Benzoyl Peroxide……..40mg (4% w/w)
	Dairy No. date of R &I fee	Dy. No. 44288 dated 28-12-2018 Rs. 20,000 paid vide slip No. 0822247 Dated 27-12-2018 Duplicate dossier submitted vide Dy. No. 1156 dated 13.01.2023
	Pharmacological Group	ANTI-ACNE PREPARATIONS FOR TOPICAL USE, Peroxides. ATC Code: D10AE01
	Type of form	Form 5
	Finished product specifications	BP Specifications.
	Pack size and Demand Price	20g, 40g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Could not be verified for cream.
	Me-too-status	Brevoxyl Cream Reg. No. 103152 M/s GSK jamshoro.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023

	Remark of the Evaluator	i. Evidence of approval of product in RRA is required. Firm has given RRA evidence of Gel whereas applied product is a cream. The firm vide letter dated 19.01.2023 has submitted evidence of Brevoxyl 4% cream approved by MHRA. The evidence in verifiable online.
Decision: Approved		
854.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	**Clobimit NN ointment**
	Composition	Each gram contains: Clobetasol propionate…0.5mg (0.05% w/w) Neomycin Sulphate…5mg (0.5% w/w) Nystatin …….. 100,000 IU
	Dairy No. date of R &I fee	Dy. No.44286 dated 28-12-2018 Rs. 20,000 vide slip No. 0822254 Dated 27-12-2018 Duplicate Dossier Submitted vide Dy. No. 1158 dated 13.01.2023. RnI verified.
	Pharmacological Group	Corticosteroid+ Antibiotic+ Antifungal
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	15g, 20g, 30g; as per SRO
	Approval status of product in Reference Regulatory Authorities	DERMOVATE-NN OINTMENT, CLOBETASOL PROPIONATE/NEOMYCIN SULPHATE/NYSTATIN 0.5MG/5MG/100 000 IU/G OINTMENT MHRA Approved.
	Me-too-status	Clobederm NN Ointment Reg. No. 021669 M/s Atco Laboratories Karachi.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	
Decision: Approved		
855.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Clobimit 0.05% w/w Ointment
	Composition	Each Gram Contains: Clobetasol Propionate… 0.05mg (0.05% w/w)
	Dairy No. date of R &I fee	Dy. No. 44287 dated 28-12-2018 Rs. 20,000 vide slip No. 0822246 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1157 dated 13.01.2023. RnI verified.
	Pharmacological Group	Corticosteroids, very potent (group IV). ATC Code: D07AD01
	Type of form	Form 5
	Finished product specifications	USP Specifications
	Pack size and Demand Price	15g, 20g, 30g; as per SRO

	Approval status of product in Reference Regulatory Authorities	Clobetasol Propionate 0.05% w/w Ointment (PL17507/00236) MHRA Approved.
	Me-too-status	Clobetol ointment 0.05% Reg. No. 065177 M/s Valor Pharmaceuticals Islamabad
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	
Decision: Approved		
856.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Coxwit 0.5% w/w Gel
	Composition	Each 25gm Gel contains:- Piroxicam …. 0.125gm (0.5%)
	Dairy No. date of R &I fee	Dy. No. 44284 dated 28-12-2018 Rs. 20,000 vide slip No. 0822274 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1155 dated 13.01.2023. RnI verified.
	Pharmacological Group	Antiinflammatory preparations, non-steroids for topical use. ATC Code: M02AA07
	Type of form	Form 5
	Finished product specifications	BP Specifications.
	Pack size and Demand Price	25g, 15g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Piroxicam 0.5% Gel MHRA Approved.
	Me-too-status	Pcam Gel 0.5% Reg. No.018718 M/s Martin Dow Karachi.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	i. The label claim is for 25gm of gel, innovator product has label claim of 5mg APi per gram of gel. Needs revision along with submission of full fee i.e. Rs. 30,000/- The firm vide letter dated 19.01.2023 has revised the label as under; Each gram contains; Piroxicam…….5mg (0.5%) Fee of Rs. 30,000/- vide slip No. 2038707222 dated 19.01.2023 is submitted for revision. The revised label is as RRA approved product.
Decision: Approved as per following label claim: **Each gram contains;** **Piroxicam…….5mg (0.5%)**		
857.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789)

		Capsule section (general) not present in renewal letter dated 07.06.2022.
	Brand Name + Dosage Form and Strength	Ferrium 150mg Capsule
	Composition	Each capsule contains: Polysaccharide Iron Complex equivalent to elemental iron…….150mg
	Dairy No. date of R &I fee	Dy. No. 44258 dated 28-12-2018 Rs. 20,000 vide Slip No. 0822269 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1164 dated 13.01.2023.
	Pharmacological Group	Iron Preparation.
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	30's /10's/100's; As per SRO
	Approval status of product in Reference Regulatory Authorities	NA
	Me-too-status	Elezo 150mg Capsule Reg. no. 076669 M/s Sami Pharmaceuticals Karachi.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluatr	The sections were verified from Licensing Division and it was confirmed that sections mentioned in letter dated 07.02.2014 were renewed by the Central Licensing Board
Decision: Approved with Innovator's specifications. **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**		
858.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Firm does not have section.
	Brand Name + Dosage Form and Strength	Ferrium 100mg/5ml Syrup
	Composition	Each 5ml contains: Polysaccharide Iron Complex equivalent to Elemental Iron……..100mg
	Dairy No. date of R &I fee	Dy. No. 44257dated 28-12-2018 Rs. 20,000 vide Slip No. 0822266 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1162 dated 13.01.2023.
	Pharmacological Group	Iron preparation.
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	60ml, 90ml,120ml; As per SRO
	Approval status of product in Reference Regulatory Authorities	NA
	Me-too-status	Elezo Syp 100mg/5ml Reg. No. 088234 M/s Sami Pharmaceuticals Karachi.

	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	The sections were verified from Licensing Division and it was confirmed that sections mentioned in letter dated 07.02.2014 were renewed by the Central Licensing Board
Decision: Approved with Innovator's specifications. **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**		
859.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Fluno N Cream
	Composition	Each Gram Contains: Fluocinolone acetonide……0.025% w/w Neomycin Sulphate……0.5% w/w
	Dairy No. date of R &I fee	Dy. No. 44270 dated 28-12-2018 Rs. 20,000 paid vide Slip No. 0822245Dated 27-12-2018 Duplicate dossier submitted vide Dy. No. 1152 dated 13.01.2023. RnI verified.
	Pharmacological Group	Corticosteroids, potent, combinations with antibiotics. ATC Code: D07CC02
	Type of form	Form 5
	Finished product specifications	USP Specifications.
	Pack size and Demand Price	15g, 20g, 30g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Synalar N Cream MHRA Approved.
	Me-too-status	Fucino-N cream, from M/s Jaens pharma (Reg.#091858)
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	i. The label claim of reference product of RRA mentions 3250 IU/g of neomycin sulfate. Applied label claim is of percentage. Correction along with full fee i.e. Rs. 30,000/- is required. The firm vide letter dated 19.01.2023 has submitted a page of 21 CFR Ch.1 (4-1-00 edition) wherein specifications of Fluocinolone acetonide, neomycin sulfate cream are given. The specifications are in percentages.
Decision: Approved.		
860.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Fusidim H Cream 2%/1%
	Composition	Each gram contains:

		Fusidic acid… 20 mg (2% w/w) Hydrocortisone acetate…10 mg (1% w/w)
	Dairy No. date of R &I fee	Dy. No. 44293 dated 28-12-2018 Rs. 20,000 vide slip No. 0822249 Dated 27-12-2018. Duplicate dossier submitted Vide dy. No. 1159 dated 13.01.2023. Old RnI verified
	Pharmacological Group	Corticosteroids, weak, combinations with antibiotics ATC Code: D07CA01
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	15g, 30g; As per SRO
	Approval status of product in Reference Regulatory Authorities	FUCIDIN® H Fusidic acid and Hydrocortisone acetate 2% / 1% Cream Health Canada Approved.
	Me-too-status	Fusiwin-H Cream Reg. No. 062471 M/s Hoover Pharmaceuticals Lahore.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	
Decision: Approved with Innovator's specifications. **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 along with evidence of availability of separate dispensing booth for steroidal formulatons, before issuance of registration letter.**		
861.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Oral Liquid general section. Not mentioned in renewal letter dated 07.06.2022.
	Brand Name + Dosage Form and Strength	Menixa 10mg/5ml Syrup
	Composition	Each 5ml contains: Memantine HCl…….10mg
	Dairy No. date of R &I fee	Dy. No. 44263 dated 28-12-2018 Rs. 20,000 vide Slip No. 0822209 Dated 27-12-2018 Duplicate Dossier submitted vide Dy. No. 1163 dated 13.01.2023
	Pharmacological Group	Other anti-dementia drugs ATC Code: N06DX01
	Type of form	Form 5
	Finished product specifications	In-House
	Pack size and Demand Price	60ml, 90ml, 120ml; As per SRO
	Approval status of product in Reference Regulatory Authorities	Memantine Hydrochloride 2mg/ml oral solution USFDA Approved.
	Me-too-status	Zexa Syrup Reg. No. 071544 M/s English Pharma Lahore.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	The sections were verified from Licensing Division and it was confirmed that sections mentioned in letter

		dated 07.02.2014 were renewed by the Central Licensing Board
Decision: Approved		
862.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Micol 2%w/w Cream
	Composition	Each gram contains: Miconazole Nitrate……..20mg (2%w/w)
	Dairy No. date of R &I fee	Dy. No.44264 dated 28-12-2018 Rs. 20,000 paid vide slip No. 0822213 Dated 27-12-2018. Duplicate dossier submitted vide Dy. No. 1160 dated 13.01.2023
	Pharmacological Group	ANTIFUNGALS FOR TOPICAL USE, Imidazole and triazole derivatives. ATC Code: D01AC02
	Type of form	Form 5
	Finished product specifications	BP Specifications.
	Pack size and Demand Price	10g, 20g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Daktarin 2% Cream MHRA Approved
	Me-too-status	Myconit Cream Reg. No. 009936 M/s EPLA Laboratories (Pvt) Ltd. Karachi.
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023
	Remark of the Evaluator	
Decision: Approved.		
863.	Name and address of manufacture / Applicant	M/s. Wimits Pharmaceuticals (Pvt.) Ltd., Plot No. 129, Sunder Industrial Estate, Raiwind Road, Lahore (DML No. 000789) Cream/Ointment/Lotion/Gel (General) Section.
	Brand Name + Dosage Form and Strength	Myrozole 1%w/w +1%w/w Cream
	Composition	Each gram contains: Hydrocortisone…10mg (1% w/w) Clotrimazole ……10mg (1% w/w)
	Dairy No. date of R &I fee	Form-5 Dy. No. dated 28-12-2018 Rs. 20,000 Dated 27-12-2018
	Pharmacological Group	Corticosteroids, weak, combinations with antibiotics
	Type of form	Form 5
	Finished product specifications	BP
	Pack size and Demand Price	35g, 15g; As per SRO
	Approval status of product in Reference Regulatory Authorities	Canesten HC Cream of UK-MHRA
	Me-too-status	Hydrozole Cream of GSK Health
	GMP Status	GMP certificate dated 08.09.2021 valid till 07.09.2023 is submitted vide letter dated 19.01.2023

	Remark of the Evaluator	
Decision: Approved. **The firm shall submit evidence of availability of separate dispensing booth for steroidal formulatons, before issuance of registration letter.**		

Deferred Cases

864.	Name and address of manufacturer/ Applicant	M/s Efroze Chemical Industries Pvt Ltd. 146/23, Korangi Industrial Area, Karachi.
	Brand Name + Dosage Form + Strength	Efnor 0.75mg Tablet
	Composition	Each Tablet Contains: Levonorgestrel…0.75mg
	Diary No. Date of R & I & fee	Form-5 Dy.No 11399 dated 05-03-2019 Rs.20,000/- (# 082817) Dated 05-03-2019
	Pharmacological Group	Hormonal contraceptives for systemic use
	Type of Form	Form-5
	Finished product Specification	BP
	Pack size & Demanded Price	As per SRO.
	Approval status of product in Reference Regulatory Authorities	PLAN B (LEVONORGESTREL) by Duramed (USFDA)
	Me-too status	Emkit (LEVONORGESTREL) by Zafa Pharmaceutical
	GMP status	Last inspection report 19-3-2018, panel recommends the grant of renewal of the DML by way of formulation
	Remarks of the Evaluator	Firm request change in brand name to "Gynacept tablet 0.75"
	Decision of 296:	Deferred for confirmation of segregated facility from Licensing Division DRAP Remarks of Evaluator VII: Evidence of steroidal hormone section the firm stated that we have already communicated to CLB that we are ready for this inspection and approval via letter dated sep 21 2020 on the subject of renewal of DML.
	Decision of 297:	**Deferred for confirmation of manufacturing facility by CLB.**
	Remarks of the Evaluator	Firm has provided Tablet Section (Hormone) approval letter vide No. 2-11/2000-Lic(Vol-V) dated 22.11.2021
	Decision: Approved	
865.	Name and address of manufacturer/ Applicant	M/S Wahaabsons Pharma (Pvt) Ltd. 4 KM Buner Road Barikot, Swat.
	Brand Name + Dosage Form + Strength	Wasthmol 2mg/ 5ml Syrup
	Composition	Each 5ml contains Salbutamol sulphate……2mg

	Diary No. Date of R & I & fee	Dy.No.2290; 22-02-2017; Rs.20,000/- (22-02-2017)
	Pharmacological Group	Beta 2selective adrenergic blocker/bronchodilator
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	120ml ;As Rs: 52/
	Approval status of product in Reference Regulatory Authorities	Ventolin Syrup of (MHRA approved)
	Me-too status	Ezibreath Syrup of M/s Rock Pharmaceuticals
	GMP status	Last GMP inspection conducted on 15-02-2016, the report concludes that firm is advised for purchase of stability chamber and done by firm as per their submitted compliance letter.
	Remarks of the Evaluator	Official monograph is available in BP
	Decision of 279th RB meeting:	**Registration Board referred the case to QA & LT Division to conduct GMP inspection of Firm on priority. The Board also directed the firm to change the brand name.**
	Remarks of Evaluator.	Firm vide letter No. nil, dated 24.10.2022 has submitted following; i. Inspection report dated 04.03.2022 wherein conclusion is not mentioned. ii. Suggestion of brand name "Wylax"
	Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.	
866.	Name and address of manufacturer/ Applicant	M /s Mafins Pharma. Plot No. A-5, S.I.T.E, Super Highway Industrial Area, Karachi
	Brand Name + Dosage Form + Strength	Azi-M 500mg Tablet
	Composition	Each Film Coated Tablet Contains: Azithromycin Dihydrate Eq. to Azithromycin …500mg
	Diary No. Date of R & I & fee	Dy.No 14298 dated 22-06-2020 Rs.20,000/- Dated 22-06-2020
	Pharmacological Group	Macrolides ATC Code: J01FA10
	Type of Form	Form-5
	Finished product Specification	**Not mentioned**.
	Pack size & Demanded Price	1x6's; As per SRO
	Approval status of product in Reference Regulatory Authorities	Azithromycin 250 mg and 500 mg film-coated tablets (azithromycin dihydrate) - PL 20416/0482-0483 MHRA Approved.
	Me-too status	Azomax 500mg Tablet Reg. No. 045415. M/s Novartis Pharma Karachi.
	GMP status	The firm was inspected on 05-10-2017 representing good level of GMP.
	Remarks of the Evaluator	You have applied for film coated tablets but Master formulation and manufacturing outline doesn't show coating composition and coating procedure respectively, clarify?

	Decision of 296th RB:	**Deferred for clarification of manufacturing outline for Applied formulation.**
	Remarks of Evaluator.	The firm vide letter No. M-296 dated 10.11.2022 has submitted the corrected master formulation and Manufacturing method outline.
	Decision: Approved with USP specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.	
867.	Name and address of manufacturer/ Applicant	Pakheim International Pharma (Pvt) Ltd., 28 Km Feroze Pur Road Lahore
	Brand Name + Dosage Form + Strength	Clinda-Benz Gel
	Composition	Each gram contains: Anhydrous Benzoyl peroxide…..50mg Clindamycin as phosphate….10mg
	Diary No. Date of R & I & fee	Dy No. 13637: 07.03.2019 Rs. 20,000/-: 06.03.2019
	Pharmacological Group	Benzoyl peroxide, combinations
	Type of Form	Form-5
	Finished product Specification	The firm has claimed manufacturer‘s specifications.
	Pack size & Demanded Price	10g, 25g; as per PRC
	Approval status of product in Reference Regulatory Authorities	Duac Once Daily 10 mg/g + 50 mg/g Gel
	Me-too status	Benclin Gel (Clindamycin as Phosphate…1%, Hydrous Benzoyl Peroxide eq. to Anhydrous Benzoyl Peroxide…5 %). Reg No. 61908
	GMP status	New Section
	Remarks of the Evaluator	The reference and me-too product Hydrous Benzoyl Peroxide eq. to Anhydrous Benzoyl Peroxide. Clarification was asked from the firm. The firm did not clarify
	Decision of 290th RB:	**Deferred for clarification about the hydrate state of API.**
	Remarks of Evaluator.	The firm vide letter No. PH/Reg/DPC-007 dated 07.11.2022 has submitted following corrected label claim; Each gm Contains; Clindamycin as Phosphate….10mg Hydrous Benzoyl peroxide eq to Anhydrous Benzoyl peroxide……..50mg • Fee is not paid for correction/change.
	Decision: Approved as per following label claim: Each gm Contains; Clindamycin as Phosphate….10mg Hydrous Benzoyl peroxide eq to Anhydrous Benzoyl peroxide……..50mg Decision: Approved with Innovator’s specifications. The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 along with evidence of availability of separate dispensing booth for steroidal formulatons, before issuance of registration letter.	
868.	Name and address of manufacturer/ Applicant	Pakheim International Pharma (Pvt) Ltd., 28 Km Feroze Pur Road Lahore
	Brand Name + Dosage Form + Strength	Cetum Syrup
	Composition	Each 5ml Contains:

		Piracetam…1g
	Diary No. Date of R & I & fee	Dy.No. 13653: 07.03.2018 Rs. 20,000/-: 07.03.2018
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form-5
	Finished product Specification	The firm has claimed manufacturer's specifications.
	Pack size & Demanded Price	120ml; As per PRC
	Approval status of product in Reference Regulatory Authorities	Could not be confirmed
	Me-too status	Medipil Syrup. Reg. No. 49548
	GMP status	New Section
	Remarks of the Evaluator	• Proof of International availability of same dosage form with same strength and same salt forms in reference regulatory authority as defined in 275th meeting of the Registration Board. • Name of signatory is missing on Form 5. • Undertaking at the end of Form had not been signed by the concerned persons. The firm provided signed undertaking.
	Decision of 290th RB:	**Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275thmeeting.**
	Remarks of Evaluator.	The firm vide letter No. PH/REG/DPC-006 dated 07.11.2022 has submitted reference of Nootropil 200mg/ml Oral Solution authorized on CIMA Spain. The reference is verifiable.
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.	
869.	Name and address of manufacturer/ Applicant	M/s Lisko Pakistan Private limited, L-10-D, Block-21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi.
	Brand Name + Dosage Form + Strength	D-Vit syrup 120ml
	Composition	Each 10ml contains: Cholecalciferol……1000 IU
	Diary No. Date of R & I & fee	Dy. No.678; 25-04-2016; Rs.20,000/- (18-04-2016)
	Pharmacological Group	Vitamin D3
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	10ml, 30ml, 60ml, 120ml; as per PRC
	Approval status of product in Reference Regulatory Authorities	Not provided
	Me-too status	Sunny D syrup of M/s Scottman Pharma
	GMP status	Last inspection was conducted on 23-01-017 and the report concludes good GMP compliance.
	Remarks of the Evaluator	The proposed drug couldn't be searched in any reference regulatory authority.
	Decision of 274th RB:	**Deferred for confirmation of approval status of product in reference regfulatory authorities.**
	Remarks of Evaluator.	• For Single ingredient vitamin formulation evidence of approval of applied formulation in reference

		regulatory authorities/agencies as adopted by Registration Board in its 275th meeting is required. • Firm provide the evidence of Sapvit-D3 approved in EMA which has different composition as it contains 14,400 IU Cholecalciferol in 1 ml.
	Decision of 296th RB meeting.	**Deferred for the evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in 277th meeting.**
	Remarks of Evaluator.	The firm vide letter No. Nil dated 06.04.2020 has submitted that they are changing the formulation of product from D-vit Syrup to D-vit Oral Drops having following strength; One mL (36 drops) contain 14,400 IU Cholecalciferol (Vitamin D3), One drop= 400IU cholecalciferol (Vitamin D3) The firm has paid Rs. 5000/ fee vide slip No. 0849163. • The product falls in category of dietary supplement/ nutraceuticals. • The firm has revised the product as per reference of HPRA Ireland approved product Sapvit-D3 400 IU/drop oral drops, solution
	Decision: Deferred for the evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in 275th meeting.	
870.	Name and address of manufacturer/ Applicant	M/s Dyson Research Laboratories Pvt Ltd. 28 km Ferozepur Road Lahore
	Brand Name + Dosage Form + Strength	Dykote Oral Solution 500mg/5ml
	Composition	Each 5ml contains: Valproate Sodium…500mg
	Diary No. Date of R & I & fee	Dy. No. 10541; 05.03.2019 PKR. 20,000/-; 04.03.2019
	Pharmacological Group	Antiepileptics
	Type of Form	Form-5
	Finished product Specification	BP
	Pack size & Demanded Price	60ml; as per SRO
	Approval status of product in Reference Regulatory Authorities	Epilim Syrup by Aventis Pharma Limited. Approved by MHRA
	Me-too status	Velpril Liquid by Munawar Pharma, (Pvt) Ltd, Lahore. Reg. No. 27768
	GMP status	The firm was inspected on 11.01.2019 with the following recommendations: Panel inspected the unit and evaluated documents are connection with production, quality control and quality assurance. After thorough inspection of the manufacturing facility and evaluation of documents panel concluded that on the day of inspection firm has satisfactory level of GMP compliance, hence panel recommended issuance of GMP certificate to the firm. Some advises were also given in the report to the firm for further up gradations. Copy of report handed over to the firm**.**
	Remarks of the Evaluator	• Form 5 has not been signed by Mr. Mehmood Ahmed Virk.

		• Provide proof of reference product (500mg/5ml) in reference regulatory agencies as defined in 275th meeting of the registration Board. Otherwise, revise the strength (label claim and composition) to 200mg/5ml, along with submission of applicable fee. • Mention vehicle and its quantity in the master formula
	Decision of 296th RB:	**Deferred for:** • **Signature on Form 5.** • **Revision of the strength (label claim and composition) in line with the reference product, along with submission of applicable fee.** • **Mentioning of vehicle and its quantity in the master formula**
	Remarks of Evaluator.	The firm vide letter No. DRL/RA/0720-341 dated 12.10.2022 has submitted the following; • Signed Form 5 • Revised Label Claim according to RRA reference product as under; Each 5mL contains; Valproate sodium….200mg • Revised master formula along with vehicle and its quantity. • Fee Receipt of Rs. **7500/-** for revision of label claim (Slip No. 673856263) • **Firm needs to pay differential fee of Rs. 22500/-**
	Decision: Approved as per following label claim: **Each 5mL contains;** **Valproate sodium….200mg** **The firm shall submit differential fee of Rs. 22,500/- for correction/pre-approval change in product compsoition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**	
871.	Name and address of manufacturer/ Applicant	**M/s Nabiqasim 17/24, Korangi Industrial Area, Korangi, Karachi**
	Brand Name + Dosage Form + Strength	Onuril 500mg Capsule
	Composition	Each capsule contains: Fosfomycin calcium eq. to Fosfomycin…….500 mg
	Diary No. Date of R & I & fee	Dy. No. 418, 30-12-2014, Rs.20000/- (30-12-2014)
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specification	As per Innovator‘s Specs.
	Pack size & Demanded Price	12‘s, As per PRC
	Approval status of product in Reference Regulatory Authorities	The firm couldn‘t not submit the reference of approval by the reference agencies, however it had submitted the reference of approval of Fosfocina by ERN Labs in Spain
	Me-too status	Focin by Tabros pharma
	GMP status	Last inspection conducted on 23.11.16 concludes that firm is operating at Acceptable level of GMP compliance.
	Remarks of the Evaluator	• Firm has submitted to comply with Innovator‘s Specifications.
	Decision of 269th RB:	**Deferred for evidence of approval, of applied formulation, by reference regulatory authorities as approved by Registration Board in its 249th meeting and for observations related to GMP made by panel of**

		inspection for the product SOVIR-C 400mg tablet and as recorded in inspection report (dated: 01-04-2017).
	Remarks of Evaluator.	The firm vide letter No. NQIL/DRAP/11-22/2019 dated 21.11.2022 has submitted reference of Calcium Fosfomycin Solufos 500mg hard capsule CIMA Spain Approved. The reference is verifiable. The firm has also submitted copies of inspection reports indicating that previous observations have been rectified. The last GMP inspection report dated 27.05.2022 is submitted wherein overall GMP are rated as good.
	Decision: Approved.	
872.	Name and address of manufacturer/ Applicant	M/s Benson Pharmaceuticals, Plot No. 119, Street # 8, I-10/3, Industrial Area, Islamabad.
	Brand Name + Dosage Form + Strength	Benpride tablet 50mg
	Composition	Each film-coated tablet contains: - Itopride Hydrochloride …….....50mg
	Diary No. Date of R & I & fee	Dy.No.19403;28-05-2018; Rs.20,000 (28-05-2018)
	Pharmacological Group	Propulsive/ Drugs for GIT disorders
	Type of Form	Form-5
	Finished product Specification	As per Innovator's Specs.
	Pack size & Demanded Price	10's, 30's & As per SRO
	Approval status of product in Reference Regulatory Authorities	Ganaton of M/s Abbott Laboratories (PMDA) Japan Approved
	Me-too status	Ganaton Tablets 50mg of M/s Abbott Laboratories (Reg. # 028429)
	GMP status	Last GMP inspection was conducted on 13-11-2018 and the report concludes grant of DML.
	Remarks of the Evaluator	• Tablet section (General) is available in the firm as mentioned in the submitted inspection report. • Firm's previous address was M/s Benson Pharmaceuticals, Plot No. 119, Street # 8, I-10/3, Industrial Area, Islamabad. • Now, the address has been changed as M/s Benson Pharmaceuticals, Plot # 3, Main Road, National Industrial Zone, RCCI, Rawat which is verified by submitted DML issued by CLB.
	Decision of 291st RB:	**Deferred for clarification as DML of the firm at Plot No. 119, Street # 8, I-10/3, Industrial Area, Islamabad is not valid.**
	Remarks of Evaluator.	The firm vide letter No. Nil dated 15.11.2022 has submitted revised Form-5 having new addres of the firm i.e. Plot # 3, Main Road, National Industrial Zone, RCCI, Rawat. The firm has not submitted fee for revision of Form 5.
	Decision: Approved. Firm shall submit full fee of registration for pre-approval change/correction in DML address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021	
873.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi

	Brand Name + Dosage Form + Strength	Expro 20mg Tablet
	Composition	Each film coated tablet contains: Esomeprazole …20mg
	Diary No. Date of R & I & fee	Form-5 Dy.No 13506 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Proton pump inhibitors
	Type of Form	Form-5
	Finished product Specification	Manufacturers Specifications.
	Pack size & Demanded Price	10‘s, 20‘s, 30‘s / As per SRO
	Approval status of product in Reference Regulatory Authorities	Nexium 20mg gastro-resistant tablets by Lexon (UK) Limited. Approved by MHRA
	Me-too status	Exzium 20mg Tablet by Medisure Laboratories Pakistan (Pvt.) Ltd, Karachi. Reg. No. 66773
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance.
	Remarks of the Evaluator	• Master formulation not submitted by the firm. • Firm has applied as film coated tablet whereas approved formulation in USFDA is enteric coated tablet. • Firm has applied as Esomeprazole …20mg whereas MHRA approved formulation is Esomeprazole (as magnesium trihydrate) …20mg
	Decision of 290th RB:	**Deferred for revision of formulation along with submission of requisite fee.**
	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has revised the label claim as under; Each enteric coated tablet contains; Esomeprazole Magnesium trihydrate equivalent to Esomeprazole ….20mg • Revised formulation is submitted. • Fee of Rs. 5000/- vide slip No. 1933744 dated 01.09.2020 is submitted.
	Decision: Approved as per following labl claim: **Each enteric coated tablet contains;** **Esomeprazole Magnesium trihydrate equivalent to Esomeprazole ….. 20mg** **The firm shall submit differentil fee of Rs. 25,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**	
874.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi
	Brand Name + Dosage Form + Strength	Velmark 80/5 mg Tablets
	Composition	Each Film Coated Tablet Contains: Amlodipine …5mg Valsartan…80mg
	Diary No. Date of R & I & fee	Form-5 Dy.No 13507 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Angiotensin II antagonists and calcium channel blockers
	Type of Form	Form-5
	Finished product Specification	USP.
	Pack size & Demanded Price	10‘s, 20‘s, 30‘s / As per SRO

	Approval status of product in Reference Regulatory Authorities	Amlodipine/Valsartan 5 mg/80 mg film-coated tablets by M/s Genus Pharmaceuticals Ltd (MHRA Approved)
	Me-too status	Exforge 5/80mg film coated tablets by M/s Novartis Pharma (Pakistan) Limited (Reg#047569)
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance
	Remarks of the Evaluator	• Master formulation not submitted by the firm • Firm has applied as Amlodipine …5mg whereas MHRA approved formulation is Amlodipine (as Besylate)…5mg
	Decision of 290th RB:	**Deferred for revision of formulation along with submission of requisite fee.**
	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has revised the label claim as under; Each Film Coated tablet contains; Amlodipine (as besylate)…5mg Valsartan……80mg • Revised formulation is submitted. • Fee for revisions is not paid.
	Decision: Approved as per following labl claim: **Each Film Coated tablet contains;** **Amlodipine (as besylate)…5mg** **Valsartan…….80mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**	
875.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi
	Brand Name + Dosage Form + Strength	Horcit 50mg Tablets
	Composition	Each film coated Tablet Contains: Clomiphene Citrate…50mg
	Diary No. Date of R & I & fee	Form-5 Dy.No 13508 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Slective Estrogen receptor Modulator, Ovulator Stimulant
	Type of Form	Form-5
	Finished product Specification	USP.
	Pack size & Demanded Price	10‘s, 20‘s, 30‘s / As per SRO
	Approval status of product in Reference Regulatory Authorities	Clomid 50mg Tablets by M/s Sanofi , (MHRA approved)
	Me-too status	Ovafin 50 mg tablet by M/s OBS (Reg#019173)
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance
	Remarks of the Evaluator	• Master formulation not submitted by the firm. • Firm has applied as film coated tablet whereas approved formulation in MHRA is uncoated tablet.
	Decision of 290th RB:	**Deferred for revision of formulation along with submission of requisite fee.**

	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has revised the label claim as under; Each tablet contains; Clomiphene…50mg • Revised formulation is submitted. • Fee for revisions is not paid.
	Decision: Approved as per following labl claim: **Each tablet contains;** **Clomiphene…50mg** **The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product description as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**	
876.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi
	Brand Name + Dosage Form + Strength	Libera 5mg Tablets
	Composition	Each film coated tablet contains: Desloratadine …5mg
	Diary No. Date of R & I & fee	Dy.No 13502 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Other antihistamines for systemic use
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	10‘s, 20‘s, 30‘s / As per SRO
	Approval status of product in Reference Regulatory Authorities	Desloratadine 5 mg film-coated tablets by M/s Bristol Laboratories Ltd (MHRA Approved)
	Me-too status	Aerius Film Coated Tablets 5mg by M/s ICI Pakistan Ltd. (Reg#031370)
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance
	Remarks of the Evaluator	• Master formulation not submitted by the firm.
	Decision of 290th RB:	**Deferred for submission of formulation.**
	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has submitted formulation of the applied product.
	Decision: Approved.	
877.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi
	Brand Name + Dosage Form + Strength	Naupride 50mg Tablets
	Composition	Each film coated tablet contains: Itopride hydrochloride….50mg
	Diary No. Date of R & I & fee	Dy.No 13504 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Propulsives
	Type of Form	Form-5
	Finished product Specification	Manufacturer‘s specifications
	Pack size & Demanded Price	10‘s, 20‘s, 30‘s / As per SRO

	Approval status of product in Reference Regulatory Authorities	Itopride hydrochloride tablet 50 mg by Shiseido Pharmaceutical Co., Ltd. PMDA approved
	Me-too status	Ganaton 50mg Tablet by M/s Abbott. (Reg. # 028429)
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance
	Remarks of the Evaluator	• Master formulation not submitted by the firm.
	Decision of 290th RB:	**Deferred for submission of formulation.**
	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has submitted formulation of the applied product.
	Decision: Approved with Innovator's specifications. **The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.**	
878.	Name and address of manufacturer/ Applicant	M/s Espoir Pharmaceuticals.PCSIR KLC TBIC-II PCSIR Laboratory Complex, Shahrah-e-Dr. Salim Uz Zaman Siddiqui Off University Road, Karachi
	Brand Name + Dosage Form + Strength	Glimate 1/500 mg Tablets
	Composition	Each film coated tablet contains: Glimepiride ...1mg Metformin …500mg
	Diary No. Date of R & I & fee	Dy.No 13505 dated 11-04-2018 Rs.20,000/- Dated 11-04-2018
	Pharmacological Group	Sulfonylureas / Biguanides (Antidiabetic)
	Type of Form	Form-5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10's, 20's, 30's / As per SRO
	Approval status of product in Reference Regulatory Authorities	Not confirmed.
	Me-too status	Pamaryl Plus 1 Tablets of M/s Himont Pharma (Pvt.) Ltd., (Reg.# 057223)
	GMP status	Last inspection conducted on 28-09-2017 and report concludes that firm is found at good level of GMP compliance
	Remarks of the Evaluator	• Approval status of product in Reference Regulatory Authorities not confirmed. • Master formulation not submitted by the firm.
	Decision of 290th RB:	**Deferred for evidence of approval of applied formulation in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting.**
	Remarks of Evaluator.	• The firm vide letter No. Nil dated 01.09.2020 has submitted formulation of the applied product. • The firm has not provide RRA reference of the applied product.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting.	
879.	Name and address of manufacturer/ Applicant	M/s Wellborne Pharmachem and Biologicals, Plot No.51/1 – 52/1, Phase-II, Industrial Estate, Hattar.

	Brand Name + Dosage Form + Strength	Bromep 40mg capsules
	Composition	Each capsule contains: Omeprazole (as 22.5%w/w enteric coated pellets) …….. 40mg Source of pellets: M/s Spansules Formulations, India
	Diary No. Date of R & I & fee	Dy. No. 359; 23-12-2015; Rs.20,000/- (23-12-2015)
	Pharmacological Group	Antacid
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	As fixed by government
	Approval status of product in Reference Regulatory Authorities	Approved by MHRA
	Me-too status	Acizole Capsule 40mg by M/s Cirin Pharmaceuticals, (Reg# 034369)
	GMP status	Last GMP inspection was conducted on 27-6-2018 concluded good GMP.
	Remarks of the Evaluator	Fee of Rs. 80,000/- for import of pellets shall be submitted.
	Decision of 285th RB:	**Deferred for submission of fee of Rs. 80,000/- for import of pellets.**
	Remarks of Evaluator.	• The firm vide letter No. nil dated 05.12.2022 has stated that they intend to purchase pellets from M/s Vision Pharmaceuticals. The firm has stated that they have submitted fee of Rs. 30,000/- vide challan No. 845065420513. The copy of challan is not attached with the application. The challan No. is verifiable from DRAP online fee dashboard, the said amount was paid on 02.09.2022.
	Decision: Approved.	
880.	Name and address of manufacturer/ Applicant	M/s Next Pharmaceutical Products (pvt) Limited, Plot No. 44, A-B, Sundar Industrial Estate, Lahore
	Brand Name + Dosage Form + Strength	TELDAY-PLUS 80/5 mg Film Coated Tablet
	Composition	Each film coated tablet contains: Telmisartan ……80mg Amlodipine as besylate……5mg
	Diary No. Date of R & I & fee	26627, 29-12-2017, 20,000/-, 26-12-2017
	Pharmacological Group	Anti-Hypertensive
	Type of Form	Form-5
	Finished product Specification	In-House
	Pack size & Demanded Price	14's Tablets in ALU/PVC Blisters; 28's Tablets in ALU/PVC Blisters As per price review committee of DRAP.
	Approval status of product in Reference Regulatory Authorities	Telmisartan and amlodipine tablet 5mg/80mg by M/s Mylan Pharmaceuticals Inc. (USFDAA approved)
	Me-too status	Amtas 5mg +80mg Tablet by M/s Getz Pharma (Pvt) Ltd
	GMP status	Panel inspection dated 22-02-2018 concluded that the firm was operating under satisfactory compliance of cGMP on the day of inspection.

	Remarks of the Evaluator	In reference regulatory authorities like in EMA and USFDA the applied drug is multi-layered tablet, while the applied drug is single layered tablet. Clarification is required. Finished product specification does not mention limits of dissolution test. Clarification is required.
	Decision of 285th RB:	**Deferred for submission of fee of Rs. 80,000/- for import of pellets.**
	Remarks of Evaluator.	• The firm vide letter No. NP/REG/TAB/036-C dated 22.06.2022 has; • Revised formulation as per innovator product along with submission of Rs.30,000/- fee vide deposit slip No. 56179154343 dated 21.06.2022 • added limits of dissolution in finished product specifications. • revised specifications from in-house to USP.
	Decision: Approved with USP specifications as per following label claim: **Each film coated bilayer tablet contains:** **Telmisartan ……80mg** **Amlodipine as besylate……5mg** **The firm shall submit evidence of availability of bi-layer compression machine before issuance of registration letter.**	
881.	Name and address of manufacturer/ Applicant	M/s Glitz Pharma, Plot No. 265, Industrial Triangle Kahota Road Islamabad
	Brand Name + Dosage Form + Strength	Imipra 75mg Tablets
	Composition	Each tablet contains:- Imipramine HCl ……. 75mg
	Diary No. Date of R & I & fee	12-08-2014 Dy.No.3268 Rs.8000/= Rs.12,000/= 11-10-2010
	Pharmacological Group	Non-selective monoamine reuptake inhibitors ATC Code: N06AA02
	Type of Form	Form-5
	Finished product Specification	USP Specifications.
	Pack size & Demanded Price	1x10's 2x10's 3x10's 5x10's 10x10's 25x10's 10x20's 50x10's, As Per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too status	Tofranil by M/s Novartis Pharma, Pakistan
	GMP status	Last inspection report of 10-02-2016 submitted with ompliance remarks
	Remarks of the Evaluator	
	Decision of 263rd RB:	**Deferred for evidence of approval of applied formulation & strength in reference regulatory authorities.**
	Remarks of Evaluator.	The firm vide letter dated 10.06.2022 has stated that they intend to change their product strength and name as under; Imipra 10mg Tablet Each tablet contains Imipramine Hydrochloride USP…10mg (USP Spec)

		The firm has submitted fee of Rs.7500/- vide slip No. 9750728723 dated 14.02.2022. • The product approved in MHRA (Imipramine 10 mg and 25 mg Tablets (imipramine hydrochloride) - PL 20416/0195-0196) is a film coated tablet. • Me too availability of 10mg Imipramine tablet could not be verified.
	Decision: Deferred for submission of stability studies data of three batches as per the guidelines and checklist approved by Registration Board in its 312th meeting.	
882.	Name and address of manufacturer/ Applicant	M/s Glitz Pharma, Plot No. 265, Industrial Triangle Kahota Road Islamabad
	Brand Name + Dosage Form + Strength	Palidone XR 9mg Tablets
	Composition	Each extended release tablet contains:- Paliperidone …… 9mg (Psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Recemic mixture of (+)-and (-)-paliperidone)
	Diary No. Date of R & I & fee	13-02-2015 Dy.No.937 Rs.8000/= Rs.12,000/= 19-06-2012
	Pharmacological Group	Other antipsychotics ATC Code: N05AX13
	Type of Form	Form-5
	Finished product Specification	Manufacturer's Specifications.
	Pack size & Demanded Price	1x10's, 2x10's, 3x10's, 5x10's, 10x10's, 20x10's, 50x10's, 100x10's, As Per SRO
	Approval status of product in Reference Regulatory Authorities	Invega prolong release tablets-MHRA
	Me-too status	Invega 9mg Tablrts by M/s Johnson & Johnson Pharma, Pakistan
	GMP status	Last inspection report of 10-02-2016 submitted with compliance remarks
	Remarks of the Evaluator	
	Decision of 263rd RB:	**Deferred for evidence of me-too status**
	Remarks of Evaluator.	The firm vide letter dated 10.06.2022 has stated that they intend to change their product strength and name as under; Palidone XR 1.5mg Tablet Each extended release tablet contains; Paliperidone….1.5mg (Glitz Specs) The firm has submitted fee of Rs.7500/- vide slip No. 4805777154 dated 14.02.2022. • Similar product Invega 1.5mg Extended release tablet is USFDA Approved. • Similar product Paliris-XR Tables 1.5mg is registered vide Reg. No.079270 in name of M/s Genome Pharma.
	Decision: Deferred for evidence of required manufacturing technology (OROS Push-Pull Technology) as per reference product.	
883.	Name and address of manufacturer/ Applicant	M/s Skims Pharmaceuticals, 10/B Value Addition City, Khurrianwala, Faisalabad.

	Brand Name + Dosage Form + Strength	SKIMETHER DS DRY POWDER SUSPENSION
	Composition	Each 5ml contains: Artemether….30mg Lumefantrine….180mg
	Diary No. Date of R & I & fee	Dy.No; 6345 Date:20-02-18 , Rs.20,000/-
	Pharmacological Group	Anti-malarial
	Type of Form	Form-5
	Finished product Specification	International Pharmacopoeia
	Pack size & Demanded Price	60 ml & As per SRO
	Approval status of product in Reference Regulatory Authorities	Not verifiable
	Me-too status	Mala Plus Suspension by M/s. Werrick Pharmaceuticals
	GMP status	Grant of Additional Section Approved dated:21-02-18
	Remarks of the Evaluator	Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.
	Decision of 281st RB:	Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies as adopted by the Registration Board in its 275thmeeting.
	Remarks of Evaluator.	• The firm vide letter No. SKM/022/022 dated 12.11.2022 has quoted minutes of 293rd meeting of Registration Board wherein similar case of product Lumethar –DS 30/180mg/5ml dry powder for suspension was approved (S. No.1941, applicant M/s Health Care Pharmaceuticals Lahore.) • The Evidence of product approval in RRA and in WHO model list of essential medicine could not be verified.
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	

Item No. 9: Agenda of Evaluator PEC-XVIII (Mr. Muneeb Ahmed)

i. Deferred Cases

884.	**Name, address of Applicant / Importer**	**M/s. Glisten Pharma,** **Plot No. 520 Sector 7/A Korangi Industrial Area Karachi.**
	Details of Drug Sale License of importer	**License No:** 10930 dated 15.04.2019 **Address:** Plot No. 520 Sector 7/A Korangi Industrial Area Karachi. **Address of Godown:** NA **Validity:** 19.02.2021 **Status:** Drug License by way of Whole Sale
	Name and address of marketing authorization holder (abroad)	M/s Pierrel Pharma S.R.L., Strada Statale Appia 46/48-& Bis 46/48 81043Capua Italy
	Name, address of manufacturer(s)	M/s Pierrel S.p.A Strada Statale Appia 46/48-& Bis 46/48 81043Capua Italy
	Name of exporting country	Italy
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Firm has submitted legalized CoPP Bo. No CPP /2019/1312 dated 18.06.2019

	Details of letter of authorization / sole agency agreement	The firm has submitted original sole agency agreement dated 11.09.2019 by marketing authorization holder i.e. M/s Pierrel Pharma S.R.L., Strada Statale Appia 46/48-& Bis 46/48 81043Capua Italy
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 27812 dated 07.10.2021
	Details of fee submitted	PKR 100,000/- dated 06.01.2021
	The proposed proprietary name / brand name	ORABLOC 1:200,000
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1ml solution for injection contains: Articaine HCl….40mg Adrenaline (Epinephrine) as tartrate….0.005mg
	Pharmaceutical form of applied drug	Solution for Injection for dental use
	Pharmacotherapeutic Group of (API)	Local Anaesthetic
	Reference to Finished product specifications	Ph. Eur
	Proposed Pack size	Rs. 7000/- for 50 Cartridges of 1.8ml
	Proposed unit price	Price will be communicated at time of pricing.
	The status in reference regulatory authorities	USFDA approved
	For generic drugs (me-too status)	Articaine 4% with Epinephrine 1:200000 of continental Chemical Company Islamabad. Reg. No: 052239
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	**ARTICAINE HCL:** i. **Name of Holder**: Moehs Iberica S.L Cesar MArtinell Brunet No., 12 A Poligono Industrial rubi Sur Apain 08191 Rubi Barcelona **Sites of Production**: Benechim S.P.R.L Rue Rene Magritte, 163 Begium 7860 Lessines ii. **Name of Holder:** SIEGFRIED EVIONNAZ SA, Route du Simplon 1, 36 Switzerlan-1902 Evuibbaz

		Sites of Production:SIEGFRIED ST. VULBAS SAS Parc Industrial de la plaine de I'Ain France-01150 Saint-Vulbas **Siegfried Evionnaz SA** Route du Simplon 1, 36 Switzerlan-1902 Evuibbaz **ADERNALINE TARTRATE:** **Name of Holder**: CAMBREX PROFARMACO MILANO S.R.L. Via Curiel, 34 Italy-20067 Paullo, Milano **Site of Production:-** CAMBREX PROFARMACO MILANO S.R.L. Via Curiel, 34 Italy-20067 Paullo, Milano
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC. The stability study data is provided till 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	The firm has submitted the Pharmaceutical equivalence with reference products.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	The Primary container consists of a 1.8ml glass cartridge made of neutral glass type closed with bromobutyl rubber plunger and bromobutyl rubber seal with an aluminium cap.
	Stability study data of drug product, shelf life and storage conditions	Stability testing results of 3 batches of formulation are reported at 25ºC RH 60% for 24 months, **30ºC / 65%RH for 12 months** and 40ºC RH 75% for 6 months. The only impurity detected whose concentration varies with time and temperature is Articaine acid (Hydrolysis products of Articaine) which although reaches maximum concentration of 0.35% after 6 months at 40ºC (stressed condition) still remains within the set specification of NMT 0.4% in area with respect to Articaine. Articaine Acid is the main metabolite of Articaine and the concentrations found in the drug product, even at the end of shelf life does not pose any potential heal concern. The formulation is quite stable and remains within specifications after 24 months at 25ºC, consequently a shelf life storage condition of 24 months at 25ºC is proposed for the drug product stored in its commercial packaging.
Query		**Reply**

i. Valid Drug Sale License because the submitted copy indicates validity till 19.02.2022.	The firm has submitted new drug sale license issued vide No. 0129 No. DHO (East) Drug-786 dated 18.06.2021 valid till 10.06.2023. having address Office No. 403 4th Floor Al Reef Tower, Plot No. 391/3 BYCHS Alamgir Road Karachi. The address mentioned on the aforesaid new DSL is different from the address of the DSL submitted initially with the application.
Differential fee of 50,000/- is required w.r.t. revised fee SRO because registration application was submitted on 07.10.2021.	The firm has now submitted the differential fee of 50000/- vide Slip No. 17375740 dated 03.08.2022.
Proposed Price needs to be submitted being requirement of application i.e. Form-5F.	The firm submitted price of Rs. 7000/- for 50 Cartridges of 1.8ml.
Reference of other similar approved medicines with information pertaining to Manufacturer name, brand name, strength, composition, registration number & dosage form, Pack size and Price as required under 1.5.8.	Articaine 4% with Epinephrine 1:200000 of continental Chemical Company Islamabad. Reg. No: 052239.
Long term stability study data need to be submitted as per Zone IV-A i.e. (30ºC/65%RH).	The firm has attached intermediate study of 30ºC / 65%RH for 12 months of three batches which has already been provided.
Evaluation by PEC: Registration Board in 321st meeting deferred for following and accordingly the reply is tabulated against each:	
Clarification whether the sole agency agreement is with M/s. Glisten Pharma, Plot No. 520 Sector 7/A Korangi Industrial Area Karachi or with M/s Glisten Pharma Office No. 403 4th Floor Al Reef Tower, Plot No. 391/3 BYCHS Alamgir Road Karachi.	The firm has submitted the new agency agreement indicating DSL: M/s Glisten Pharma Office No. 403 4th Floor Al Reef Tower, Plot No. 391/3 BYCHS Alamgir Road Karachi as warehouse of the firm and head office as M/s. Glisten Pharma, Plot No. 520 Sector 7/A Korangi Industrial Area Karachi
Clarification of the address of DSL since two DSL with different address have been submitted	The firm informed that we have change wareghouse due to safety reasons, hence DSL M/s Glisten Pharma Office No. 403 4th Floor Al Reef Tower, Plot No. 391/3 BYCHS Alamgir Road Karachi will be the ware house of the firm.
Submission of long term stability studies data as per Zone IV a conditions till claimed shelf life.	The storage conditions of the product is below 25C therefore stability studies for the Zone IV A are not conducted. Intermediate studies at 30C/65% RH have been performed.
Remarks: Registration Board in its 323rd meeting approved ORABLOC 1:100,000 as per following details: *"Approved with Innovators specifications as per policy of inspections of manufacturer abroad with shelf life as per available data of long term stability studies on Zone IV conditions. The firm shall also submit following before issuance of registration letter:* ***i.*** *New agency agreement in name of address as mentioned on the DSL because the earlier letter indicates DSL address as warehouse.* **ii.** *Full fee as address of Importer is changed as per submitted new DSL".*	
Decision: Approved with Innovators specifications as per policy of inspections of manufacturer abroad with shelf life as per available data of long term stability studies on Zone IV conditions. The firm shall also submit full fee of registration as address of Importer is changed as per submitted new DSL.	

885.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd. 793-D, Block C, Faisal Town Lahore.**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174D **Address:** 793-D, Block -C, Faisal Town Lahore **Address of Godown:** NA **Validity:** 06-02-2026 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized COPP (DA/6-110/2016/3302) issued on 28.07.2020 by Government of the People's Republic of Bangladesh, Ministry of Health & Family Welfare, Directorate General of Drug Administration Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3567 dated 01.02.2021
	Details of fee submitted	PKR /-: 50,030/- dated 14.12.2020
	The proposed proprietary name / brand name	Ponatinix 15 Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Ponatinib Hydrochloride equivalent to Ponatinib…...15mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-Cancer Drug
	Reference to Finished product specifications	In house

	Proposed Pack size	Pack of 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Iclusig Tablets USFDA
	For generic drugs (me-too status)	N/A
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Lianyungang Jari Pharmaceutical Co., ltd No. 18 Zhenhua Road, Lianyungang China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 24 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Iclusig 45mg tablet , Incyte Biosciences UK limited has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE Bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 65% ± 5% for 24 months

Background of the case:

Decision in 321st meeting of Registration Board:

Deferred for following points:

i. Justification for conducting Comparative Dissolution studies at "M/s Alpha laboratories India", instead of M/s Beacon Pharmaceuticals Bangladesh.

ii. Regulatory status of Alpha Laboratories India, whether it is licensed entity or otherwise.

In response to the above decision of the Board the firm has submitted the reply on 04.011.2022 which is as under:

The firm has again submitted copy of business agreement dated 04.06.2018 b/w M/s Beacon Pharmaceuticals Bangladesh and M/s Alpha Laboratories India wherein the M/s Alpha Laboratories India shall provide the services being expert in Bioequivalence studies of generic molecules to M/s Beacon Pharmaceuticals Bangladesh.

Decision in 323rd meeting of Registration Board:

Deferred for submission of evidence of License/Approval of M/s Alpha Laboratories India, from the relevant regulatory authority of India.

Remarks:

The firm has now submitted letter from manufacturer i.e. M/s Beacon Pharmaceuticals Limited indicating a website link of M/s Alpha laboratories India (www.alphalaboratories.in). The website states that **Alpha Laboratories** is a unique and leading **Contract Research Organization (CRO)** in India with its own in-house laboratory facilities for undertaking **Bioequivalence / Bioavailability Studies, Clinical Trial Studies (Phase I, Phase II, Phase III and Phase IV), Animal Toxicity Study, Dossier and DMF preparation, PSUR (Periodic Safety Update Reports), Medical Writing, Stability Studies, Analytical Method Development and Validation**

Decision: Deferred for the evidence of approval for conducting Bioequivalence / Bioavailability Studies in name of M/s Alpha Laboratories India from the relevant regulatory authority of India.

886.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd. 793-D, Block C, Faisal Town Lahore.**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174D **Address:** 793-D, Block -C, Faisal Town Lahore **Address of Godown:** NA **Validity:** 06-02-2026 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized COPP (DA/6-110/2016/3302) issued on 28.07.2020 by Government of the People's Republic of Bangladesh, Ministry of Health & Family Welfare, Directorate General of Drug Administration Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)

	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3567 dated 01.02.2021
	Details of fee submitted	PKR /-: 50,030/- dated 14.12.2020
	The proposed proprietary name / brand name	Ponatinix 45 Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Ponatinib Hydrochloride equivalent to Ponatinib…...45mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-Cancer Drug
	Reference to Finished product specifications	In house
	Proposed Pack size	Pack of 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Iclusig Tablets USFDA
	For generic drugs (me-too status)	N/A
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Lianyungang Jari Pharmaceutical Co., ltd No. 18 Zhenhua Road, Lianyungang China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 24 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of

		specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Iclusig 45mg tablet , Incyte Biosciences UK limited has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE Bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40ºC±2ºC and 75%±5% RH for 6 months. Real time stability studies conducted at 30ºC±2ºC and 65% ± 5% for 24 months

Background of the case:

Decision in 321st meeting of Registration Board:

Deferred for following points:

iii. Justification for conducting Comparative Dissolution studies at "M/s Alpha laboratories India", instead of M/s Beacon Pharmaceuticals Bangladesh.

iv. Regulatory status of Alpha Laboratories India, whether it is licensed entity or otherwise.

In response to the above decision of the Board the firm has submitted the reply on 04.011.2022 which is as under:

The firm has again submitted copy of business agreement dated 04.06.2018 b/w M/s Beacon Pharmaceuticals Bangladesh and M/s Alpha Laboratories India wherein the M/s Alpha Laboratories India shall provide the services being expert in Bioequivalence studies of generic molecules to M/s /s Beacon Pharmaceuticals Bangladesh.

Decision in 323rd meeting of Registration Board:

Deferred for submission of evidence of License/Approval of M/s Alpha Laboratories India, from the relevant regulatory authority of India.

Remarks:

The firm has now submitted letter from manufacturer i.e. M/s Beacon Pharmaceuticals Limited indicating a website link of M/s Alpha laboratories India (www.alphalaboratories.in). The website states that **Alpha Laboratories** is a unique and leading **Contract Research Organization (CRO)** in India with its own in-house laboratory facilities for undertaking **Bioequivalence / Bioavailability Studies, Clinical Trial Studies (Phase I, Phase II, Phase III and Phase IV), Animal Toxicity Study, Dossier and DMF preparation, PSUR (Periodic Safety Update Reports), Medical Writing, Stability Studies, Analytical Method Development and Validation**

Decision: Deferred for the evidence of approval for conducting Bioequivalence / Bioavailability Studies in name of M/s Alpha Laboratories India from the relevant regulatory authority of India.

887.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd. 793-D, Block C, Faisal Town Lahore.**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174D **Address:** 793-D, Block -C, Faisal Town Lahore **Address of Godown:** NA **Validity:** 06-02-2026 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh

		Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized COPP (DA/6-110/2016/3298) issued on 01-June-2020 Government of the People's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 4309 dated 08.02.2021
	Details of fee submitted	PKR /-: 50,030/- dated 14.12.2020
	The proposed proprietary name / brand name	Olaparix 50 Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Olaparib INN …..50mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anti-Cancer Drug
	Reference to Finished product specifications	In house
	Proposed Pack size	1x112's in HDPE Bottle
	Proposed unit price	As per current pricing policy of DRAP
	The status in reference regulatory authorities	Lynparza Capsules USFDA
	For generic drugs (me-too status)	N/A
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Name, address of drug substance manufacturer	M/s Shanghai Qingsong Pharmaceutical co., Ltd Suite No. 505 Building No. 2 No. 3377 Kangxin Rd, Pudong New Area Shanghai China 201318
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 24 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Iclusig 45mg tablet , Incyte Biosciences UK limited has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE Bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 65% ± 5% for 24 months
Background of the case: Deferred for clarification/ submission of following documents in 321st meeting of Registration Board		
You have submitted that drug substance is white to off white powder and no polymorphic form exists, however the as per innovator data the Olaparib exists as crystalline powder in four polymorphic forms.		Copy of letter from API manufacturer stating that Polymorphic form of Olaparib is Form-A and is synthesized at their site.
API is characterized by HNMR study only, characterization of the active substance, polymorphic forms/ impurities are required to be performed as per innovator product.		The firm submitted again the HNMR study only.
Particle size (being critical quality attribute) and residual solvents are not specified.		The CoA has been submitted by the manufacturer of API indicating particle size being specified and along with data of residual solvents.
The firm was requested to clarify that drug substance specifications by drug product manufacturer are required (3.2.S.4)) along with results of analysis of relevant batch(es) of drug substance performed by drug product manufacturer used during product		CoA of the FPP manufacturer is submitted

developmentand stability studies, along with Certificate of Analysis (CoA).		
Comparative dissolution profile is conducted by Alpha Laboratories Mumbai India, as the submitted justification is not relevant.		The firm has submitted copy of agreement between Alpha Laboratories Mumbai India and Beacon Pharmaceuticals Bangladesh. The firm has now submitted letter from manufacturer i.e. M/s Beacon Pharmaceuticals Limited indicating a website link of M/s Alpha laboratories India (www.alphalaboratories.in). The website states that **Alpha Laboratories** is a unique and leading **Contract Research Organization (CRO)** in India with its own in-house laboratory facilities for undertaking **Bioequivalence / Bioavailability Studies, Clinical Trial Studies (Phase I, Phase II, Phase III and Phase IV), Animal Toxicity Study, Dossier and DMF preparation, PSUR (Periodic Safety Update Reports), Medical Writing, Stability Studies, Analytical Method Development and Validation**
Stability data of Drug Product indicates same test results/ value for the parameters like moisture content, dissolution and assay, hence raw data needs to be submitted for verification		The firm has submitted the previous stability data.
Decision: Deferred for the evidence of approval for conducting Bioequivalence / Bioavailability Studies in name of M/s Alpha Laboratories India from the relevant regulatory authority of India.		
888.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd.** **793-D, Block C, Faisal Town Lahore.**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-016174D **Address:** 793-D, Block -C, Faisal Town Lahore **Address of Godown:** NA **Validity:** 06-02-2026 **Status:** License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/B/2, Toyenbee Circular Road, Motijheel, Dhaka, Bangladesh.
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized COPP (DA/6-110/2016/3302) issued on 01-June-2020 Government of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh. **GMP:** Firm has submitted Legalized GMP certificate (Certificate No. DA/6-110/06/5027) issued by M/s Beacon Pharmaceuticals limited.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s

		Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3566 dated 01.02.2021
	Details of fee submitted	PKR /-: 50,030/- dated 29.09.2020
	The proposed proprietary name / brand name	Olaparix 150 Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Olaparib INN …..150mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-Cancer Drug
	Reference to Finished product specifications	In house
	Proposed Pack size	120's in HDPE Bottle
	Proposed unit price	As per current pricing policy of DRAP
	The status in reference regulatory authorities	Lynparza Tablets USFDA
	For generic drugs (me-too status)	N/A
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Shanghai Qingsong Pharmaceutical co., Ltd Suite No. 505 Building No. 2 No. 3377 Kangxin Rd, Pudong New Area Shanghai China 201318
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5%

		RH for 24 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Iclusig 45mg tablet , Incyte Biosciences UK limited has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	HDPE Bottle
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 30°C±2°C and 65% ± 5% for 24 months
Background of the case: Deferred for clarification/ submission of following documents in 321st meeting of Registration Board		
You have submitted that drug substance is white to off white powder and no polymorphic form exists, however the as per innovator data the Olaparib exists as crystalline powder in four polymorphic forms.		Copy of letter from API manufacturer stating that Polymorphic form of Olaparib is Form-A and is synthesized at their site.
API is characterized by HNMR study only, characterization of the active substance, polymorphic forms/ impurities are required to be performed as per innovator product.		The firm submitted again the HNMR study only.
Particle size (being critical quality attribute) and residual solvents are not specified.		The CoA has been submitted by the manufacturer of API indicating particle size being specified along with data of residual solvents
The firm was requested to clarify that drug substance specifications by drug product manufacturer are required (3.2.S.4)) along with results of analysis of relevant batch(es) of drug substance performed by drug product manufacturer used during product developmentand stability studies, along with Certificate of Analysis (CoA).		CoA of the FPP manufacturer is submitted
Comparative dissolution profile is conducted by Alpha Laboratories Mumbai India, as the submitted justification is not relevant.		The firm has submitted copy of agreement between Alpha Laboratories Mumbai India and Beacon Pharmaceuticals Bangladesh. The firm has now submitted letter from manufacturer i.e. M/s Beacon Pharmaceuticals Limited indicating a website link of M/s Alpha laboratories India (www.alphalaboratories.in). The website states that **Alpha Laboratories** is a unique and leading **Contract Research Organization (CRO)** in India with its own in-house laboratory facilities for undertaking **Bioequivalence / Bioavailability Studies, Clinical Trial Studies (Phase I, Phase II,**

		Phase III and Phase IV), Animal Toxicity Study, Dossier and DMF preparation, PSUR (Periodic Safety Update Reports), Medical Writing, Stability Studies, Analytical Method Development and Validation
Stability data of Drug Product indicates same test results/ value for the parameters like moisture content, dissolution and assay, hence raw data needs to be submitted for verification		The firm has submitted the previous stability data.
Decision: Deferred for the evidence of approval for conducting Bioequivalence / Bioavailability Studies in name of M/s Alpha Laboratories India from the relevant regulatory authority of India.		
889.	**Name, address of Applicant / Importer**	**M/s Sohail Corporation Plot No. 474 Siraj Colony Moosa Lane Karachi.**
	Details of Drug Sale License of importer	Drug License by the way of wholesale vide No. DHODSK(Drug)/-433/- dated 01.012.2020 valid till 19-11-2022
	Name and address of marketing authorization holder (abroad)	M/s Anhui Chengsi Pharmaceuticals Co., Ltd, No. 5068 Huaishang Road Bengbu Anhui China.
	Name, address of manufacturer(s)	M/s Anhui Chengsi Pharmaceuticals Co., Ltd, No. 5068 Huaishang Road Bengbu Anhui China.
	Name of exporting country	China
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**GMP:** Copy of GMP certificate issued by CFDA vide No. CN20160035 valid till 08.03.2021.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of agency agreement.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 30796 dated 10.11.2021
	Details of fee submitted	PKR 100000/- dated 07.04.2021 and 50000/- dated 07.06.2021.
	The proposed proprietary name / brand name	**LINCOMYCIN HYDROCHLORIDE INJECTION 600MG/2ML**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ampoule of 2ml contains: Lincomycin HCl USP equivalent to Lincomycin …..600mg
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Antibiotic (Lincosamide antibacterial)
	Reference to Finished product specifications	BP 2013

	Proposed Pack size	Not submitted
	Proposed unit price	Not submitted
	The status in reference regulatory authorities	Lincomycin SXP manufactured by Southern XP IP Pty Ltd Australia (TGA Approved)
	For generic drugs (me-too status)	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Xinyu Pharmaceutical Co., Ltd No. 158 Jintai 5th Road Economic development Zone Suzhou Anhui Province China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API (17081041, 17081042, 17081043) conducted at accelerated conditions 40ºC ±2ºC / 75% ± 5% RH for 6 months as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC / 60 ± 5% RH & 30ºC ± 2ºC / 75 ± 5% RH. The stability study data is for 9 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence with 5 chines manufactured products is submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Low Borosilicate glass
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches (W170513, W170422 & W170722). The accelerated stability study data is conducted at 40ºC ±2ºC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30ºC ±2ºC / 75% ± 5% RH. The real time stability study data of 3 batches is for 34 months

Remarks: The product was deferred in 321st meeting of registration Board for submission of valid legalized CoPP issued by the regulatory authority of country of origin. The firm has now submitted Legalized CoPP vide No. Anuhi 20210023 issued by Anhui Medical Products Administration China dated 28.01.2021 valid till 23.01.2023.
Decision: Approved as per policy of inspection of manufacturer abroad.

ii. Priority consideration based on Export.

a. Form-5F Cases

Below mentioned products have been referred by PR section vide letter No. 1-6/2019-PR (EFD) dated 06.10.2022 for consideration on priority as per direction of Authority in its 133rd meeting for the firms who have achieved benchmark f export of more than 100000USD. Accordingly, the details are as under:

890.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Getz Pharma (Pvt.) Limited 29-30/27, Korangi Industrial Area, Karachi.**
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited 29-30/27, Korangi Industrial Area, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13936 dated 08.07.2022
	Details of fee submitted	PKR 75,000/-: dated 11/05/2022
	The proposed proprietary name / brand name	**Diampa LM XR 10mg+5mg+1000mg Tablets**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin… 10mg Linagliptin… 5mg Metformin HCl USP… 1000mg (as extended release)
	Pharmaceutical form of applied drug	Green colored, oblong shaped, film-coated tablet plain on both sides.
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering agent.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	14's (2×7's)
	Proposed unit price	Rs. 2,500/- (14's)
	The status in reference regulatory authorities	Trijardy XR Tablets 10mg+5mg+1000mg by M/s Boehringer Ingelheim Pharmaceuticals, USA. USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Last GMP Inspection dated 03-12-2021 concludes that M/s Getz Pharma Pvt. Ltd. is considered to be operating at an acceptable level of compliance of GMP requirements. Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd.

		Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Official monograph of Empagliflozin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Official monograph of Linagliptin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Official monograph of Metformin HCl is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: **Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 18 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04)

		Linagliptin: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-2017049-D01-L9-01, L-2017049-D01-L9-02, L-2017049-D01-L9-03) **Metformin HCl:** Real time: 30˚C ± 2˚C / 75% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-72611405016, A-72611405017, A-72611405018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product that is **Trijardy XR Tablets 10mg + 5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**. by performing quality tests (Appearance, Assay, Dissolution). CDP has been performed against the same innovator product that is **Trijardy XR Tablets 10mg + 5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**., in Acidic media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have been submitted including system suitability, specificity, linearity, accuracy, precision repeatability, intermediate precision, robustness, stability of solution and range.

STABILITY STUDY DATA	
Manufacturer of API	**Empagliflozin:** <u>Fuxin Long Rui Pharmaceutical Co., Ltd.</u> Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** <u>Fuxin Long Rui Pharmaceutical Co., Ltd.</u> Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Metformin HCl:** <u>Shouguang Fukang Pharmaceutical Co., Ltd.</u> North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
API Lot No.	**Empagliflozin:** Vendor Batch No.: H-E-20210125-D04-E06-01 Getz Pharma Batch No.: 0000189314 **Linagliptin:** Vendor Batch No.: L-20200219-D01-L09-01 Getz Pharma Batch No.: 19D01L091 **Metformin HCl:**

	Vendor Batch No.: A-22612102040-0150 Getz Pharma Batch No.: 0000189144		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet. Pack size: 14 Tablets		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**597DS01**		**597DS02**
Batch Size	5000 Tablets		5000 Tablets
Manufacturing Date	23.08.2021		23.08.2021
Date of Initiation	08.09.2021		08.09.2021
No. of Batches	02		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: • The HPLC software is 21CFR Compliant as per record available with the firm. • Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well. • Related manufacturing area, equipment, personnel and utilities are GMP compliant.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17-01-2022. **Linagliptin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17-01-2022. **Metformin HCl:** Copy of GMP Certificate No. SD20190888 issued by CFDA, China valid till 12-03-2024.

<table>
<tr><td>3.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of invoice attested by AD I&E DRAP, Karachi, has been submitted.
Empagliflozin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>H-E-20210125-D04-E06-01</td><td>HN20210402-E</td><td>60kg</td><td>29.04.2021</td></tr>
</table>
Linagliptin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>L-20200219-D01-L09-01</td><td>SY20052501-F</td><td>550g</td><td>10.06.2020</td></tr>
</table>
Metformin HCl:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>A-22612102040-0150</td><td>JC202010044-1</td><td>2000kg</td><td>02.04.2021</td></tr>
</table></td></tr>
<tr><td>4.</td><td>Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Firm has submitted data of stability batches along with batch manufacturing record, analytical record and attested documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td></tr>
<tr><td>5.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing</td><td>Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.</td></tr>
<tr><td>6.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated).</td></tr>
<tr><td colspan="2">Shortcomings</td><td>Response</td></tr>
<tr><td colspan="2">As Linagliptin is R-enantiomer, clarification is required for performing identification test by HPLC rather chiral HPLC by API manufacturer and FPP manufacturer. Further, clarification is also required for not including enantiomeric impurity test (S-isomer) in specification by the API manufacturer and by FPP manufacturer.
Justification for not performing test for water content by the API manufacturer and FPP manufacturer.</td><td>This is to inform you that the identification by HPLC has the advantages of high accuracy, high automation, simple sample pretreatment etc. It is usually completed under the item of content determination by HPLC, which is the preferred method for identification in many official pharmacopoeias.
Further, test for Enantiomeric Purity can ensure that the content of S-enantiomer in the product which should be less than 0.15%.
Further, it is evident from literature that interconversion of Linagliptin to S-Linagliptin does not showed meaningful amounts of S-enantiomer in the drug substance (Please refer to Annex-1). Hence, there is no need to perform Identification by chiral HPLC.
Moreover, both API manufacturer and FPP manufacturer has performed Identification by 02 different methods i.e., HPLC and IR as per ICH Q6A recommendations.
This is to bring to your kind information that both API manufacturer and FPP manufacturer has incorporated test for ‘Loss on Drying’ in the Testing Specification of</td></tr>
</table>

<table>
<tr><td></td><td>Linagliptin API in accordance with USP General Chapter Loss on Drying ⟨731⟩ which states:
Test for "Loss on Drying" determines the amount of volatile matter of any kind that is present in any specimen under consideration.
It is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter "Loss on Drying" has been incorporated.
Please refer to Annex-2 for the revised Raw Material Specification of Linagliptin including test for Enantiomeric Purity.</td></tr>
<tr><td>Detailed analytical method needs to be submitted for comparative dissolution profile.</td><td>Please refer to Annex-3 for the detailed analytical method for conducting comparative dissolution profile.</td></tr>
<tr><td>Justification of setting Q value NLT 75% in 30 minutes for Empagliflozin and Linagliptin but as per dissolution data of pharmaceutical development more than 80% of both aforesaid API released at 20 minutes.
Clarification required regarding the difference in dissolution criteria proposed by you and innovator.

Justification for not proposing specification for water content, arginine content and microbial purity as the aforesaid specification are proposed by innovator.</td><td>This is to bring to your information that the innovator "Trijardy XR" is targeting 45 minutes time point for Empagliflozin and 30 minutes for Linagliptin Dissolution Sampling (Please refer to Annex-4).
However, we have taken 30 minutes Dissolution Time Point for both Empagliflozin and Linagliptin which is more stringent than the Innovator.
Further, innovator has not provided acceptance criteria for dissolution, therefore we have used generalized criteria for immediate release dosage form i.e., NLT 75.0%(Q) (NLT 80%) in 30 minutes for both APIs.
This is to bring to your kind attention Microbial Parameters and Loss on Drying are part of our Finished Product Specifications.
Microbial Parameters:
In Microbial Parameters, we are testing following:
<table>
<tr><td><u>TAMC</u></td><td>NMT 10^3 cfu/g</td></tr>
<tr><td><u>TYMC</u></td><td>NMT 10^2 cfu/g</td></tr>
<tr><td><u>E. coli</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Salmonella specie</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Pseudomonas aeruginosa</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Staphylococcus aureus</u></td><td>Must be absent/10g</td></tr>
</table>
Loss on Drying:
As per USP general chapter Loss on Drying ⟨731⟩, Test for "Loss on Drying" determines the amount of volatile matter of any kind that is present in any specimen under consideration. As it is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter "Loss on Drying" has been incorporated in Finished Product Specification by FPP manufacturer.
Arginine Content:
Please refer to Annex-5 for the revised Finished Product Specification including test for Arginine Content. We hereby commit that said test will be part of our next Stability Study Testing Interval as well as said test will be part of our QC Release Specifications before commercialization.</td></tr>
<tr><td colspan="2">Remarks of Evaluator:</td></tr>
<tr><td colspan="2">Decision: Approved.</td></tr>
</table>

• **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
891.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Getz Pharma (Pvt.) Limited 29-30/27, Korangi Industrial Area, Karachi.**
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited 29-30/27, Korangi Industrial Area, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13937 dated 09.06.2022
	Details of fee submitted	PKR 75,000/-: dated 11/05/2022
	The proposed proprietary name / brand name	Diampa LM XR 12.5mg+2.5mg+1000mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin… 12.5mg Linagliptin… 2.5mg Metformin HCl USP… 1000mg (as extended release)
	Pharmaceutical form of applied drug	Yellow colored, oblong shaped, film-coated tablet plain on both sides.
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering agent.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	14's (2×7's)
	Proposed unit price	Rs. 3,000/- (14's)
	The status in reference regulatory authorities	Trijardy XR Tablets 12.5mg+2.5mg+1000mg by M/s Boehringer Ingelheim Pharmaceuticals, USA. USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Last GMP Inspection dated 03-12-2021 concludes that M/s Getz Pharma Pvt. Ltd. is considered to be operating at an acceptable level of compliance of GMP requirements. Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China

		Metformin HCl: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Official monograph of Empagliflozin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Linagliptin:** Official monograph of Linagliptin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Metformin HCl:** Official monograph of Metformin HCl is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 18 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04) **Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-2017049-D01-L9-01, L-2017049-D01-L9-02, L-2017049-D01-L9-03) **Metformin HCl:** Real time: 30˚C ± 2˚C / 75% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months

		Batches: (A-72611405016, A-72611405017, A-72611405018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product that is **Trijardy XR Tablets 12.5mg + 2.5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**. by performing quality tests (Appearance, Assay, Dissolution). CDP has been performed against the same innovator product that is **Trijardy XR Tablets 12.5mg + 2.5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**., in Acidic media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have been submitted including system suitability, specificity, linearity, accuracy, precision repeatability, intermediate precision, robustness, stability of solution and range.

STABILITY STUDY DATA	
Manufacturer of API	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
API Lot No.	**Empagliflozin:** Vendor Batch No.: H-E-20210125-D04-E06-01 Getz Pharma Batch No.: 0000189314 **Linagliptin:** Vendor Batch No.: L-20200219-D01-L09-01 Getz Pharma Batch No.: 19D01L091 **Metformin HCl:** Vendor Batch No.: A-22612101039-0150 Getz Pharma Batch No.: 0000191080
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet. Pack size: 14 Tablets
Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months

Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**598DS01**		**598DS02**
Batch Size	5000 Tablets		5000 Tablets
Manufacturing Date	26.08.2021		26.08.2021
Date of Initiation	07.09.2021		07.09.2021
No. of Batches	02		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: • The HPLC software is 21CFR Compliant as per record available with the firm. • Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well. • Related manufacturing area, equipment, personnel and utilities are GMP compliant.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027. **Linagliptin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027. **Metformin HCl:** Copy of GMP Certificate No. SD20190888 issued by CFDA, China valid till 12-03-2024.

<table>
<tr><td>3.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of invoice attested by AD I&E DRAP, Karachi, has been submitted.

Empagliflozin:<table><tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr><tr><td>H-E-20210125-D04-E06-01</td><td>HN20210402-E</td><td>60kg</td><td>29.04.2021</td></tr></table>Linagliptin:<table><tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr><tr><td>L-20200219-D01-L09-01</td><td>SY20052501-F</td><td>550g</td><td>10.06.2020</td></tr></table>Metformin HCl:<table><tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr><tr><td>A-22612101039-0150</td><td>JC202011025-1</td><td>2000kg</td><td>06.05.2021</td></tr></table></td></tr>
<tr><td>4.</td><td>Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Firm has submitted data of stability batches along with batch manufacturing record, analytical record and attested documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td></tr>
<tr><td>5.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing</td><td>Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.</td></tr>
<tr><td>6.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated).</td></tr>
<tr><td colspan="2">Shortcomings</td><td>Response</td></tr>
<tr><td colspan="2">As Linagliptin is R-enantiomer, clarification is required for performing identification test by HPLC rather chiral HPLC by API manufacturer and FPP manufacturer. Further, clarification is also required for not including enantiomeric impurity test (S-isomer) in specification by the API manufacturer and by FPP manufacturer.
Justification for not performing test for water content by the API manufacturer and FPP manufacturer.</td><td>This is to inform you that the identification by HPLC has the advantages of high accuracy, high automation, simple sample pretreatment etc. It is usually completed under the item of content determination by HPLC, which is the preferred method for identification in many official pharmacopoeias.
Further, test for Enantiomeric Purity can ensure that the content of S-enantiomer in the product which should be less than 0.15%.
Further, it is evident from literature that interconversion of Linagliptin to S-Linagliptin does not showed meaningful amounts of S-enantiomer in the drug substance (Please refer to Annex-1). Hence, there is no need to perform Identification by chiral HPLC.
Moreover, both API manufacturer and FPP manufacturer has performed Identification by 02 different methods i.e., HPLC and IR as per ICH Q6A recommendations.
This is to bring to your kind information that both API manufacturer and FPP manufacturer has incorporated test for</td></tr>
</table>

<table>
<tr><td></td><td>‘Loss on Drying’ in the Testing Specification of Linagliptin API in accordance with USP General Chapter Loss on Drying ⟨731⟩ which states:
Test for “Loss on Drying” determines the amount of volatile matter of any kind that is present in any specimen under consideration.
It is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter “Loss on Drying” has been incorporated.
Please refer to Annex-2 for the revised Raw Material Specification of Linagliptin including test for Enantiomeric Purity.</td></tr>
<tr><td>Detailed analytical method needs to be submitted for comparative dissolution profile.</td><td>Please refer to Annex-3 for the detailed analytical method for conducting comparative dissolution profile.</td></tr>
<tr><td>Justification of setting Q value NLT 75% in 30 minutes for Empagliflozin and Linagliptin but as per dissolution data of pharmaceutical development more than 80% of both aforesaid API released at 20 minutes.
Clarification required regarding the difference in dissolution criteria proposed by you and innovator.

Justification for not proposing specification for water content, arginine content and microbial purity as the aforesaid specification are proposed by innovator.</td><td>This is to bring to your information that the innovator “Trijardy XR” is targeting 45 minutes time point for Empagliflozin and 30 minutes for Linagliptin Dissolution Sampling (Please refer to Annex-4).
However, we have taken 30 minutes Dissolution Time Point for both Empagliflozin and Linagliptin which is more stringent than the Innovator.
Further, innovator has not provided acceptance criteria for dissolution, therefore we have used generalized criteria for immediate release dosage form i.e., NLT 75.0%(Q) (NLT 80%) in 30 minutes for both APIs.
This is to bring to your kind attention Microbial Parameters and Loss on Drying are part of our Finished Product Specifications.
Microbial Parameters:
In Microbial Parameters, we are testing following:
<table>
<tr><td><u>TAMC</u></td><td>NMT 10^3 cfu/g</td></tr>
<tr><td><u>TYMC</u></td><td>NMT 10^2 cfu/g</td></tr>
<tr><td><u>E. coli</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Salmonella specie</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Pseudomonas aeruginosa</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Staphylococcus aureus</u></td><td>Must be absent/10g</td></tr>
</table>
Loss on Drying:
As per USP general chapter Loss on Drying ⟨731⟩, Test for “Loss on Drying” determines the amount of volatile matter of any kind that is present in any specimen under consideration. As it is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter “Loss on Drying” has been incorporated in Finished Product Specification by FPP manufacturer.
Arginine Content:
Please refer to Annex-5 for the revised Finished Product Specification including test for Arginine Content. We hereby commit that said test will be part of our next Stability Study Testing Interval as well as said test will be part of our QC Release Specifications before commercialization.</td></tr>
<tr><td colspan="2">Remarks of Evaluator:</td></tr>
<tr><td colspan="2">Decision: Approved.</td></tr>
</table>

• **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application**		
892.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Getz Pharma (Pvt.) Limited, 29-30/27, Korangi Industrial Area, Karachi.**
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited 29-30/27, Korangi Industrial Area, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13935 dated 08.06.2022
	Details of fee submitted	PKR 75,000/-: dated 11/05/2022
	The proposed proprietary name / brand name	Diampa LM XR 5mg+2.5mg+1000mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin… 5mg Linagliptin… 2.5mg Metformin HCl USP… 1000mg (as extended release)
	Pharmaceutical form of applied drug	Blue colored, oblong shaped, film-coated tablet plain on both sides.
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering agent.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	14's (2×7's)
	Proposed unit price	Rs. 2,000/- (14's)
	The status in reference regulatory authorities	Trijardy XR Tablets 5mg+2.5mg+1000mg by M/s Boehringer Ingelheim Pharmaceuticals, USA. USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Last GMP Inspection dated 03-12-2021 concludes that M/s Getz Pharma Pvt. Ltd. is considered to be operating at an acceptable level of compliance of GMP requirements. Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China

		Metformin HCl: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Official monograph of Empagliflozin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Official monograph of Linagliptin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Official monograph of Metformin HCl is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: **Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04) **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-2017049-D01-L9-01, L-2017049-D01-L9-02, L-2017049-D01-L9-03) **Metformin HCl:** Real time: 30°C ± 2°C / 75% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months

		Batches: (A-72611405016, A-72611405017, A-72611405018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product that is **Trijardy XR Tablets 5mg + 2.5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**. by performing quality tests (Appearance, Assay, Dissolution). CDP has been performed against the same innovator product that is **Trijardy XR Tablets 5mg + 2.5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**., in Acidic media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have been submitted including system suitability, specificity, linearity, accuracy, precision repeatability, intermediate precision, robustness, stability of solution and range.

STABILITY STUDY DATA

Manufacturer of API	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
API Lot No.	**Empagliflozin:** Vendor Batch No.: H-E-20210125-D04-E06-01 Getz Pharma Batch No.: 0000189314 **Linagliptin:** Vendor Batch No.: L-20200219-D01-L09-01 Getz Pharma Batch No.: 19D01L091 **Metformin HCl:** Vendor Batch No.: A-22612102040-0150 Getz Pharma Batch No.: 0000189144
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet. Pack size: 14 Tablets
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months)

	Real Time: 0, 3, 6 (Months)		
Batch No.	**596DS01**		**596DS02**
Batch Size	5000 Tablets		5000 Tablets
Manufacturing Date	20.08.2021		20.08.2021
Date of Initiation	08.09.2021		08.09.2021
No. of Batches	02		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points: • The HPLC software is 21CFR Compliant as per record available with the firm. • Audit trail on the testing reports is available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well. • Related manufacturing area, equipment, personnel and utilities are GMP compliant.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027. **Linagliptin:** Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027. **Metformin HCl:** Copy of GMP Certificate No. SD20190888 issued by CFDA, China valid till 12-03-2024.

<table>
<tr><td>3.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of nvoice attested by AD I&E DRAP, Karachi, has been submitted.
Empagliflozin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>H-E-20210125-D04-E06-01</td><td>HN20210402-E</td><td>60kg</td><td>29.04.2021</td></tr>
</table>
Linagliptin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>L-20200219-D01-L09-01</td><td>SY20052501-F</td><td>550g</td><td>10.06.2020</td></tr>
</table>
Metformin HCl:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>A-22612102040-0150</td><td>JC202010044-1</td><td>2000kg</td><td>02.04.2021</td></tr>
</table></td></tr>
<tr><td>4.</td><td>Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Firm has submitted data of stability batches along with batch manufacturing record, analytical record and attested documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td></tr>
<tr><td>5.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing</td><td>Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.</td></tr>
<tr><td>6.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated).</td></tr>
<tr><td colspan="2">Shortcomings</td><td>Response</td></tr>
<tr><td colspan="2">As Linagliptin is R-enantiomer, clarification is required for performing identification test by HPLC rather chiral HPLC by API manufacturer and FPP manufacturer. Further, clarification is also required for not including enantiomeric impurity test (S-isomer) in specification by the API manufacturer and by FPP manufacturer.
Justification for not performing test for water content by the API manufacturer and FPP manufacturer.</td><td>This is to inform you that the identification by HPLC has the advantages of high accuracy, high automation, simple sample pretreatment etc. It is usually completed under the item of content determination by HPLC, which is the preferred method for identification in many official pharmacopoeias.
Further, test for Enantiomeric Purity can ensure that the content of S-enantiomer in the product which should be less than 0.15%.
Further, it is evident from literature that interconversion of Linagliptin to S-Linagliptin does not showed meaningful amounts of S-enantiomer in the drug substance (Please refer to Annex-1). Hence, there is no need to perform Identification by chiral HPLC.
Moreover, both API manufacturer and FPP manufacturer has performed Identification by 02 different methods i.e., HPLC and IR as per ICH Q6A recommendations.
This is to bring to your kind information that both API manufacturer and FPP manufacturer has incorporated test for</td></tr>
</table>

<table>
<tr><td></td><td>‘Loss on Drying’ in the Testing Specification of Linagliptin API in accordance with USP General Chapter Loss on Drying ⟨731⟩ which states:
Test for “Loss on Drying” determines the amount of volatile matter of any kind that is present in any specimen under consideration.
It is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter “Loss on Drying” has been incorporated.
Please refer to Annex-2 for the revised Raw Material Specification of Linagliptin including test for Enantiomeric Purity.</td></tr>
<tr><td>Detailed analytical method needs to be submitted for comparative dissolution profile.</td><td>Detailed analytical method for conducting comparative dissolution profile.</td></tr>
<tr><td>Justification of setting Q value NLT 75% in 30 minutes for Empagliflozin and Linagliptin but as per dissolution data of pharmaceutical development more than 80% of both aforesaid API released at 20 minutes.
Clarification required regarding the difference in dissolution criteria proposed by you and innovator.

Justification for not proposing specification for water content, arginine content and microbial purity as the aforesaid specification are proposed by innovator.</td><td>This is to bring to your information that the innovator “Trijardy XR” is targeting 45 minutes time point for Empagliflozin and 30 minutes for Linagliptin Dissolution Sampling (Please refer to Annex-4).
However, we have taken 30 minutes Dissolution Time Point for both Empagliflozin and Linagliptin which is more stringent than the Innovator.
Further, innovator has not provided acceptance criteria for dissolution, therefore we have used generalized criteria for immediate release dosage form i.e., NLT 75.0%(Q) (NLT 80%) in 30 minutes for both APIs.
This is to bring to your kind attention Microbial Parameters and Loss on Drying are part of our Finished Product Specifications.
Microbial Parameters:
In Microbial Parameters, we are testing following:
<table>
<tr><td><u>TAMC</u></td><td>NMT 10^3 cfu/g</td></tr>
<tr><td><u>TYMC</u></td><td>NMT 10^2 cfu/g</td></tr>
<tr><td><u>E. coli</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Salmonella specie</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Pseudomonas aeruginosa</u></td><td>Must be absent/10g</td></tr>
<tr><td><u>Staphylococcus aureus</u></td><td>Must be absent/10g</td></tr>
</table>
Loss on Drying:
As per USP general chapter Loss on Drying ⟨731⟩, Test for “Loss on Drying” determines the amount of volatile matter of any kind that is present in any specimen under consideration. As it is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter “Loss on Drying” has been incorporated in Finished Product Specification by FPP manufacturer.
Arginine Content:
Please refer to Annex-5 for the revised Finished Product Specification including test for Arginine Content. We hereby commit that said test will be part of our next Stability Study Testing Interval as well as said test will be part of our QC Release Specifications before commercialization.</td></tr>
<tr><td colspan="2">Remarks of Evaluator:</td></tr>
<tr><td colspan="2">Decision: Approved.</td></tr>
</table>

• **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
893.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Getz Pharma (Pvt.) Limited, 29-30/27, Korangi Industrial Area, Karachi.**
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited, 29-30/27, Korangi Industrial Area, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13935 dated 08.06.2022
	Details of fee submitted	PKR 75,000/-: dated 11/05/2022
	The proposed proprietary name / brand name	Diampa LM XR 25mg+5mg+1000mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Empagliflozin… 25mg Linagliptin… 5mg Metformin HCl USP… 1000mg (as extended release)
	Pharmaceutical form of applied drug	Pink colored, oblong shaped, film-coated tablet plain on both sides.
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering agent.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	14's (2×7's)
	Proposed unit price	Rs. 3,500/- (14's)
	The status in reference regulatory authorities	Trijardy XR Tablets 25mg+5mg+1000mg by M/s Boehringer Ingelheim Pharmaceuticals, USA. USFDA Approved.
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	Last GMP Inspection dated 03-12-2021 concludes that M/s Getz Pharma Pvt. Ltd. is considered to be operating at an acceptable level of compliance of GMP requirements. Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China

		Metformin HCl: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Official monograph of Empagliflozin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Linagliptin:** Official monograph of Linagliptin is not present in any pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Metformin HCl:** Official monograph of Metformin HCl is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: **Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04) **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-2017049-D01-L9-01, L-2017049-D01-L9-02, L-2017049-D01-L9-03) **Metformin HCl:** Real time: 30°C ± 2°C / 75% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months

		Batches: (A-72611405016, A-72611405017, A-72611405018)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator product that is **Trijardy XR Tablets 25mg + 5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**. by performing quality tests (Appearance, Assay, Dissolution). CDP has been performed against the same innovator product that is **Trijardy XR Tablets 25mg + 5mg + 1000mg** by **M/s Boehringer Ingelheim Pharmaceuticals, USA**., in Acidic media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have been submitted including system suitability, specificity, linearity, accuracy, precision repeatability, intermediate precision, robustness, stability of solution and range.

STABILITY STUDY DATA

Manufacturer of API	**Empagliflozin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Linagliptin:** Fuxin Long Rui Pharmaceutical Co., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang, Shandong, China.	
API Lot No.	**Empagliflozin:** Vendor Batch No.: H-E-20210125-D04-E06-01 Getz Pharma Batch No.: 0000189314 **Linagliptin:** Vendor Batch No.: L-20200219-D01-L09-01 Getz Pharma Batch No.: 19D01L091 **Metformin HCl:** Vendor Batch No.: A-22612101039-0150 Getz Pharma Batch No.: 0000191080	
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton along with leaflet. Pack size: 14 Tablets	
Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH	
Time Period	Real time: 6 months Accelerated: 6 months	
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)	
Batch No.	**599DS01**	**599DS02**

<table>
<tr><td colspan="2">Batch Size</td><td>5000 Tablets</td><td></td><td>5000 Tablets</td></tr>
<tr><td colspan="2">Manufacturing Date</td><td>27.08.2021</td><td></td><td>30.08.2021</td></tr>
<tr><td colspan="2">Date of Initiation</td><td>07.09.2021</td><td></td><td>07.09.2021</td></tr>
<tr><td colspan="2">No. of Batches</td><td colspan="3">02</td></tr>
<tr><td colspan="5">Administrative Portion</td></tr>
<tr><td>1.</td><td>Reference of previous approval of applications with stability study data of the firm (if any)</td><td colspan="3">Firm has referred to onsite inspection report of their product for Estine (Ebastine) Tablets 10mg & 20mg on 6th May, 2019. Further, the said panel inspection report was discussed in 289th Drug Registration Board meeting held on 14th – 16th May 2019. The case was approved and the inspection report confirms following points:
The HPLC software is 21CFR Compliant as per record available with the firm.
Audit trail on the testing reports is available.
Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.
Related manufacturing area, equipment, personnel and utilities are GMP compliant.</td></tr>
<tr><td>2.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td colspan="3"><u>Empagliflozin:</u> Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027.

<u>Linagliptin:</u> Copy of Drug Manufacturing License no. LIAO 20150233 issued by Liaoning Medical Products Administration valid till 17.01.2027.

<u>Metformin HCl:</u> Copy of GMP Certificate No. SD20190888 issued by CFDA, China valid till 12-03-2024.</td></tr>
<tr><td>3.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td colspan="3">Copy of invoice attested by AD I&E DRAP, Karachi, has been submitted.

Empagliflozin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>H-E-20210125-D04-E06-01</td><td>HN20210402-E</td><td>60kg</td><td>29.04.2021</td></tr>
</table>
Linagliptin:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>L-20200219-D01-L09-01</td><td>SY20052501-F</td><td>550g</td><td>10.06.2020</td></tr>
</table>
Metformin HCl:
<table>
<tr><th>Batch No.</th><th>Invoice No.</th><th>Quantity Imported</th><th>Date of approval by DRAP</th></tr>
<tr><td>A-22612101039-0150</td><td>JC202011025-1</td><td>2000kg</td><td>06.05.2021</td></tr>
</table></td></tr>
</table>

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with batch manufacturing record, analytical record and attested documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated).
Shortcomings		**Response**
As Linagliptin is R-enantiomer, clarification is required for performing identification test by HPLC rather chiral HPLC by API manufacturer and FPP manufacturer. Further, clarification is also required for not including enantiomeric impurity test (S-isomer) in specification by the API manufacturer and by FPP manufacturer. Justification for not performing test for water content by the API manufacturer and FPP manufacturer.		This is to inform you that the identification by HPLC has the advantages of high accuracy, high automation, simple sample pretreatment etc. It is usually completed under the item of content determination by HPLC, which is the preferred method for identification in many official pharmacopoeias. Further, test for Enantiomeric Purity can ensure that the content of S-enantiomer in the product which should be less than 0.15%. Further, it is evident from literature that interconversion of Linagliptin to S-Linagliptin does not showed meaningful amounts of S-enantiomer in the drug substance (Please refer to Annex-1). Hence, there is no need to perform Identification by chiral HPLC. Moreover, both API manufacturer and FPP manufacturer has performed Identification by 02 different methods i.e., HPLC and IR as per ICH Q6A recommendations. This is to bring to your kind information that both API manufacturer and FPP manufacturer has incorporated test for 'Loss on Drying' in the Testing Specification of Linagliptin API in accordance with USP General Chapter Loss on Drying ⟨731⟩ which states: *Test for "Loss on Drying" determines the amount of volatile matter of any kind that is present in any specimen under consideration.* It is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter "Loss on Drying" has been incorporated. Please refer to Annex-2 for the revised Raw Material Specification of Linagliptin including test for Enantiomeric Purity.
Detailed analytical method needs to be submitted for comparative dissolution profile.		Please refer to Annex-3 for the detailed analytical method for conducting comparative dissolution profile.
Justification of setting Q value NLT 75% in 30 minutes for Empagliflozin and Linagliptin but as per dissolution data of pharmaceutical development more than 80% of both aforesaid API released at 20 minutes. Clarification required regarding the difference in dissolution criteria proposed by you and innovator. Justification for not proposing specification for water content, arginine content and microbial purity as the aforesaid specification are proposed by innovator.		This is to bring to your information that the innovator "Trijardy XR" is targeting 45 minutes time point for Empagliflozin and 30 minutes for Linagliptin Dissolution Sampling (Please refer to Annex-4). However, we have taken 30 minutes Dissolution Time Point for both Empagliflozin and Linagliptin which is more stringent than the Innovator. Further, innovator has not provided acceptance criteria for dissolution, therefore we have used generalized criteria for immediate release dosage form i.e., NLT 75.0%(Q) (NLT 80%) in 30 minutes for both APIs. This is to bring to your kind attention Microbial Parameters and Loss on Drying are part of our Finished Product Specifications. ***Microbial Parameters:***

	In Microbial Parameters, we are testing following: **TAMC** NMT 10^3 cfu/g **TYMC** NMT 10^2 cfu/g ***E. coli*** Must be absent/10g ***Salmonella specie*** Must be absent/10g ***Pseudomonas aeruginosa*** Must be absent/10g **Staphylococcus aureus** Must be absent/10g ***Loss on Drying:*** As per USP general chapter Loss on Drying ⟨731⟩, Test for "Loss on Drying" determines the amount of volatile matter of any kind that is present in any specimen under consideration. As it is obvious from the above statement, determining Loss on Drying also encompasses the amount of water present. Therefore, test parameter "Loss on Drying" has been incorporated in Finished Product Specification by FPP manufacturer. ***Arginine Content:*** Please refer to Annex-5 for the revised Finished Product Specification including test for Arginine Content. We hereby commit that said test will be part of our next Stability Study Testing Interval as well as said test will be part of our QC Release Specifications before commercialization.
Remarks of Evaluator:	
Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**	
894.	**Name, address of Applicant / Marketing Authorization Holder** — **M/s MTI Medical (Pvt) Ltd. Plot # 586,587 Sundar Industrial Estate, Raiwind Road, Lahore.**
	Name, address of Manufacturing site. — M/s MTI Medical (Pvt.)Ltd. Plot # 586,587 Sundar Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant — ☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application — ☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product — ☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission — Dy. No. 19660 dated 05/07/2022
	Details of fee submitted — PKR 30,000/-: dated 13/06/2022
	The proposed proprietary name / brand name — Colimate Injection 150mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit — Each lyophilized vial contains; Colistimethate sodium equivalent to 150mg colistin base activity

	Pharmaceutical form of applied drug	Lyophilized Injection.
	Pharmacotherapeutic Group of (API)	Polypeptide antibiotic (active against Gram-negative bacteria)
	Reference to Finished product specifications	USP
	Proposed Pack size	1×1's vial
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Colistin-Link, Approved by TGA
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	License Renewal granted on 06/06/2022
	Name and address of API manufacturer.	**Name:** Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. **Address:** No.50 Shengxue Road, Luancheng District, Shijiazhuang, Hebei Province, 051430 P.R.China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Colistimethate Sodium is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, characterization studies, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 30 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (HN190202, HN190203, HN190301)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is CBA 150 of Biocare Pharmaceutica by performing quality tests (Description, Identification, Assay, pH, Endotoxin and Sterility).
	Analytical method validation/verification of product	Method verification studies have submitted including accuracy, precision, specificity, system suitability
STABILITY STUDY DATA		

Manufacturer of API	Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. **Address:** No.50 Shengxue Road, Luancheng District, Shijiazhuang, Hebei Province, 051430 P.R.China		
API Lot No.	HN190202		
Description of Pack (Container closure system)	Glass vial with rubber stopper and flip off seal packed in unit carton (1×1's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 30 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, expiry plus 6 months (Months)		
Batch No.	CK-001	CK-002	CK-003
Batch Size	150 vials	150 vials	150 vials
Manufacturing Date	12-2019	12-2019	12-2019
Date of Initiation	11-12-2019	14-12-2019	17-12-2019
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of manufacturing License vide No. 20150056 issued in name of M/s. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. No.50 Shengxue Road, Luancheng District, Shijiazhuang, Hebei Province, China by Hebei Drug Administration on 30.09.2020 and is valid till 29.09.2025.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy od DRAP attested invoice vide No. 13114/2019 dated 14.10.2019 for import 2Kg of API of Batch No. HN190202 Mfg. date: 23.02.2019 Exp. Date: 22.02.2022
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable as analysis performed by Bioassay
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted
Shortcomings		**Reply**
3.2.S.4.1 Clarification is required for following: i. The USP monograph and specifications proposed by you for identification test is by IR however you have performed it through Zone of Inhibition. ii. Free colistin specifications are proposed as per USP monograph but not performed as per CoA submitted for API batch.		The firm has submitted CoA wherein the identification is being conducted by FTIR and test for free colistin. The firm has submitted respective spectras
3.2. P.5.1		The firm has submitted the certificate of analysis indicating ID test by IR, test for LOD Free Colistin and

Clarification required as identification test is proposed through zone of inhibition rather IR being requirement of USP monograph. Justification required for not proposing specifications/tests for LOD, free colistin and tests for uniformity of dosage units.	uniformity of dosage unit by weight variation. The respective raw data and spectra are also submitted.
3.2. P.5.2 Analytical procedures need to be submitted as per USP monograph for specifications proposed in 3.2. P.5.1.	The firm has submitted the Analytical procedures as per USP monograph.
3.2.P.5.4 Batch analysis data needs to be submitted	The firm has submitted CoAs of three trial batches along with respective manufacturing and testing data.
3.2.P.5.7 CoA of reference standard is required	The firm has submitted they are using USP reference standard vide lot No. R07870 for standardization.
Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**	

b. Stability Case

895.	**Name and address of manufacturer / Applicant**	**M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi**
	Brand Name +Dosage Form + Strength	**DAPAMET-XR 5/500MG TABLET**
	Composition	Each Film Coated Tablet contain: 6.15mg Dapagliflozin Propanediol Monohydrate (equivalent to 5mg Dapagliflozin) + 500mg Metformin HCL as extended release
	Diary No. Date of R& I & fee	Dy. No. 12298 dated 06/03/2019; PKR 50,000/- dated 21/2/2019
	Pharmacological Group	Dapagliflozin: SGLT2 inhibitors Metformin HCl: Biguanides (Anti-diabetic)
	Type of Form	Form-5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC
	Approval status of product in Reference Regulatory Authorities	Xigduo XR 5 mg/500 mg film-coated tablets by M/s AstraZeneca UK Limited, MHRA Approved.
	Me-too status (with strength and dosage form)	Dapa-Met XR 5 mg / 500 mg tablets by M/s, Hilton Pharma
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.
	Remarks of the Evaluator :	
	Now the firm has submitted stability data detailed as under:	

STABILITY STUDY DATA	
Drug	**DAPAMET-XR 5/500MG TABLET**
Name of Manufacturer	M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.
Manufacturer of API	**Dapagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China.

		Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China.		
API Lot No.		Dapagliflozin: 7100-201905001 Metformin HCl: A-35212011121		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated:0,1,2,3,4,6 (month) Real Time: 0,3,6, (month)		
Batch No.		**21PD-3552-07-T**	**21PD-3553-08-T**	**20PD-3554-09-T**
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		12-03-2021	12-03-2021	12-03-2021
No. of Batches		03		
Date of Submission		31-3-2022		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
Documents To Be Provided		**Status**		
1	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020.		
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Dapagliflozin:** Copy of COA of Dapagliflozin: (Batch# 7100-201905001) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. Copy of COA (Batch#5918) from M/s PharmEvo (private) Limited is submitted. **Metformin HCl:** Copy of COA of Metformin HCl (Batch# A-35212011121) from M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China. Copy of COA (Batch#14781) from M/s PharmEvo (private) Limited is submitted.		
3	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Yes		
4	Stability study data of API from API manufacturer	Stability study conditions: **Dapagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (130401, 130402, 130501) **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (A-72611405016, A-72611405017, A-72611405018)		
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Dapagliflozin: Copy of GMP certificate issued by Huai'an Pharmaceutical Industrial Association valid till 14/01/2024. Metformin HCl: Copy of GMP certificate No. SD20190888 issued by Shandong Food & Drug Administration valid till 03/12/2024		
6	Documents for the procurement of API with approval from DRAP (in case of import).	Dapagliflozin:		

<table>
<tr><td></td><td></td><td>• Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
• Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.</td></tr>
<tr><td>7</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record. Details are as under:
<table>
<tr><th>Batch no.</th><th>Batch Size</th><th>Mfg. Started</th></tr>
<tr><td>21PD-3552-07-T</td><td>2500</td><td>02-2021</td></tr>
<tr><td>21PD-3553-08-T</td><td>2500</td><td>02-2021</td></tr>
<tr><td>21PD-3554-09-T</td><td>2500</td><td>02-2021</td></tr>
</table></td></tr>
<tr><td>11</td><td>Record of comparative dissolution data (where applicable)</td><td>Firm has submitted Comparative dissolution study of their product with Innovator Brand “Xigduo XR 5+500mg Tablet” The details are as follows:
<table>
<tr><th>Feature</th><th>Reference Product</th><th>Product of PharmEvo</th></tr>
<tr><td>Brand Name</td><td>Xigduo XR 5+500mg Tablet</td><td>DAPAMET 5+500MG TABLET</td></tr>
<tr><td>Batch No.</td><td>MAO476</td><td>21PD-3552-07-T</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
1. pH 1.2 HCl buffer
2. pH 4.5 Acetate buffer
3. pH 6.8 Phosphate buffer
For metformin, the firm calculated f1 and f2 values, which are within limits.</td></tr>
<tr><td>12</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Yes</td></tr>
<tr><td>13</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Firm has submitted audit trail reports of stability studies of applied formulation.</td></tr>
<tr><td>14</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Yes</td></tr>
<tr><td colspan="3">Remarks:
i) Stability data of commercial batches needs has been submitted for Dapagliflozin (API) which includes tests of optical rotation and related substances..
ii) Copy of DMLno. Su 20160324 in respect of Dapagliflozin issued by Jiangsu Medical Product administration has been submitted.</td></tr>
</table>

Decision: Approved with Innovator's specifications. Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**				
896.	**Name and address of manufacturer / Applicant**	**M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi**		
	Brand Name +Dosage Form + Strength	**DAPAMET-XR 10/500MG TABLET**		
	Composition	Each Film Coated Tablet contain: 12.3mg Dapagliflozin Propanediol Monohydrate (equivalent to 10mg Dapagliflozin) + 500mg Metformin HCL as extended release		
	Diary No. Date of R& I & fee	Dy. No. 12300 dated 06/03/2019; PKR 50,000/- dated 21/2/2019		
	Pharmacological Group	Dapagliflozin: SGLT2 inhibitors Metformin HCl: Biguanides (Anti-diabetic)		
	Type of Form	Form-5D		
	Finished product Specifications	Manufacturer's specifications		
	Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC		
	Approval status of product in Reference Regulatory Authorities	Xigduo XR 10 mg/500 mg film-coated tablets by M/s AstraZeneca UK Limited, MHRA Approved.		
	Me-too status (with strength and dosage form)	Dapa-Met XR 10 mg / 500 mg tablets by M/s, Hilton Pharma		
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.		
	Remarks of the Evaluator :			
	Now the firm has submitted stability data detailed as under:			
STABILITY STUDY DATA				
Drug		**DAPAMET-XR 10/500MG TABLET**		
Name of Manufacturer		M/s Pharmevo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.		
Manufacturer of API		**Dapagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China. **Metformin HCl:** M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China.		
API Lot No.		Dapagliflozin: 7100-201905001 Metformin HCl: A-35212011121		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time : 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated:0,1,2,3,4,6 (month) Real Time: 0,3,6, (month)		
Batch No.		**21PD-3559-05-T**	**21PD-3560-06-T**	**21PD-3561-07-T**
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		12-03-2021	12-03-2021	12-03-2021
No. of Batches		03		
Date of Submission		11-3-2022		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
Documents To Be Provided		**Status**		

<table>
<tr><td>1</td><td>Reference of previous approval of applications with stability study data of the firm</td><td>Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020. According to the report following points were confirmed.
Firm has 21 CFR compliant HPLC software.
Firm has audit trail reports available.
Firm possesses stability chambers with digital data loggers.</td></tr>
<tr><td>2</td><td>Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.</td><td>Dapagliflozin:
Copy of COA of Dapagliflozin: (Batch# 7100-201905001) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. Copy of COA (Batch#5918) from M/s PharmEvo (private) Limited is submitted.
Metformin HCl:
Copy of COA of Metformin HCl (Batch# A-35212011121) from M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China. Copy of COA (Batch#14781) from M/s PharmEvo (private) Limited is submitted.</td></tr>
<tr><td>3</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Yes</td></tr>
<tr><td>4</td><td>Stability study data of API from API manufacturer</td><td>Stability study conditions:
Dapagliflozin:
Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (130401, 130402, 130501)
Metformin HCl:
Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (A-72611405016, A-72611405017, A-72611405018)</td></tr>
<tr><td>5</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Dapagliflozin: Copy of GMP certificate issued by Huai’an Pharmaceutical Industrial Association valid till 14/01/2024.
Metformin HCl: Copy of GMP certificate No. SD20190888 issued by Shandong Food & Drug Administration valid till 03/12/2024</td></tr>
<tr><td>6</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Dapagliflozin:
• Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
• Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.</td></tr>
<tr><td>7</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record. Details are as under:
<table>
<tr><th>Batch no.</th><th>Batch Size</th><th>Mfg. Started</th></tr>
<tr><td>21PD-3559-05-T</td><td>2500</td><td>02-2021</td></tr>
</table>
</td></tr>
</table>

		21PD-3560-06-T	2500	02-2021	
		21PD-3561-07-T	2500	02-2021	
11	Record of comparative dissolution data (where applicable)	Firm has submitted Comparative dissolution study of their product with Innovator Brand "Xigduo XR 10+500mg Tablet" The details are as follows: **Feature** / **Reference Product** / **Product of PharmEvo** Brand Name / Xigduo XR 10+500mg Tablet / **DAPAMET 10+500MG TABLET** Batch No. / NF0249 / 21PD-3559-05-T Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer 2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer For metformin, the firm calculated f1 and f2 values, which are within limits.			
12	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Yes			
13	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted audit trail reports of stability studies of applied formulation.			
14	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes			
Remarks: i) Stability data of commercial batches needs has been submitted for Dapagliflozin (API) which includes tests of optical rotation and related substances.. ii) Copy of DMLno. Su 20160324 in respect of Dapagliflozin issued by Jiangsu Medical Product administration has been submitted.					
Decision: Approved with Innovator's specifications. Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**					
897.	**Name and address of manufacturer / Applicant**	**M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi**			
	Brand Name +Dosage Form + Strength	**DAPAMET-XR 10/1000MG TABLET**			
	Composition	Each Film Coated Tablet contain: 12.3mg Dapagliflozin Propanediol Monohydrate (equivalent to 10mg Dapagliflozin) + 1000mg Metformin HCl as extended release.			
	Diary No. Date of R& I & fee	PKR 50,000/- dated 21/2/2019			
	Pharmacological Group	Dapagliflozin: SGLT2 inhibitors Metformin HCl: Biguanides (Anti-diabetic)			
	Type of Form	Form-5D			
	Finished product Specifications	Manufacturer's specifications			
	Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC			

	Approval status of product in Reference Regulatory Authorities	Xigduo XR 10mg/1000 mg film-coated tablets by M/s AstraZeneca UK Limited, MHRA Approved.		
	Me-too status (with strength and dosage form)	Dapa-Met XR 10mg / 1000 mg tablets by M/s, Hilton Pharma		
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.		
	Remarks of the Evaluator :			
	Now the firm has submitted stability data detailed as under:			
STABILITY STUDY DATA				
Drug		**DAPAMET-XR 10/1000MG TABLET**		
Name of Manufacturer		M/s Pharmevo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.		
Manufacturer of API		**Dapagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China. **Metformin HCl:** M/s Smruthi Organics Limited A-27, MIDC-Chincholi, Solapur, India.		
API Lot No.		Dapagliflozin: 7100-202106001 Metformin HCl: MET-0782/21		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time : 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated:0,1,2,3,4,6 (month) Real Time: 0,3,6, (month)		
Batch No.		**21PD-4031-16-T**	**21PD-4032-17-T**	**21PD-4033-18-T**
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		12-2021	12-2021	12-2021
Date of Initiation		01-2022	01-2022	01-2022
No. of Batches		03		
Date of Submission		04-11-2022 (Dy. No 31777)		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
Documents To Be Provided		**Status**		
1	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020. According to the report following points were confirmed. • Firm has 21 CFR compliant HPLC software. • Firm has audit trail reports available. • Firm possesses stability chambers with digital data loggers.		
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Dapagliflozin:** Copy of COA of Dapagliflozin: (Batch# 7100-202106001) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. Copy of COA (Batch#17749) from M/s PharmEvo (private) Limited is submitted. **Metformin HCl:** Copy of COA of Metformin HCl (Batch# MET-0782/21) from M/s Smruthi Organics Limited A-27, MIDC-Chincholi, Solapur, India. Copy of COA (Batch#18490) from M/s PharmEvo (private) Limited is submitted.		

<table>
<tr><td>3</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Yes</td></tr>
<tr><td>4</td><td>Stability study data of API from API manufacturer</td><td>Stability study conditions:
Dapagliflozin:
Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (130401, 130402, 130501)
Metformin HCl:
Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (DMFH-026/10, DMFH-027/10, DMFH-028/10)</td></tr>
<tr><td>5</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Dapagliflozin: Copy of GMP certificate issued by Huai’an Pharmaceutical Industrial Association valid till 14/01/2024.
Metformin HCl: Copy of GMP certificate No. NEW-WHO-GMP/CERT/PD/86368/2019/11/30111issued by Food & Drug Administration India.</td></tr>
<tr><td>6</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Dapagliflozin:
• Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
• Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.</td></tr>
<tr><td>7</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record. Details are as under:
<table>
<tr><td>tch no.</td><td>Batch Size</td><td>Mfg. Started</td></tr>
<tr><td>PD-4031-16-T</td><td>2500</td><td>12-2021</td></tr>
<tr><td>PD-4032-17-T</td><td>2500</td><td>12-2021</td></tr>
<tr><td>PD-4033-18-T</td><td>2500</td><td>12-2021</td></tr>
</table></td></tr>
<tr><td>11</td><td>Record of comparative dissolution data (where applicable)</td><td>Firm has submitted Comparative dissolution study of their product with Innovator Brand “Xigduo XR 10+1000mg Tablet” The details are as follows:
<table>
<tr><td>ature</td><td>Reference Product</td><td>Product of PharmEvo</td></tr>
<tr><td>and Name</td><td>Xigduo XR 10+1000mg Tablet</td><td>DAPAMET-XR 10+1000MG TABLET</td></tr>
<tr><td>tch No.</td><td>NC0015</td><td>21PD-4031-16-T</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
1. pH 1.2 HCl buffer
2. pH 4.5 Acetate buffer
3. pH 6.8 Phosphate buffer
For metformin, the firm calculated f1 and f2 values, which are within limits.</td></tr>
<tr><td>12</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Yes</td></tr>
</table>

13	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted audit trail reports of stability studies of applied formulation.
14	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes

REMARKS OF THE EVALUATOR

Deferred in minutes of 321st meeting of registration board, held on 20-22nd September, 2022

GMP certificate/inspection conducted within last 3 years.	Firm submitted latest GMP inspection report conducted on 22-June-2022, GMP certificate grant on 22-August 2022.
Label Claim does not mention extended release dosage form which needs clarification.	The subject product has been developed in accordance with the formulation of innovator product i.e. extended release, however we are submitting the revised Form 5-D and requisite fees along with this letter for your perusal (Slip Number: 5666653995)
Submission of Stability study data as per the guidelines approved in 293rd meeting of Registration Board.	Firm submitted the Stability study data as per the guidelines approved in 293rd meeting of Registration Board on 04-Nov-2022.

Remarks:

i) Stability data of commercial batches needs has been submitted for Dapagliflozin (API) which includes tests of optical rotation and related substances.

ii) Copy of DMLno. Su 20160324 in respect of Dapagliflozin issued by Jiangsu Medical Product administration has been submitted.

Decision: Approved with Innovator's specifications. Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

898.	**Name and address of manufacturer / Applicant**	**M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi**
	Brand Name +Dosage Form + Strength	**DAPAMET 5+1000MG TABLET**
	Composition	Each film coated tablet contains: Dapagliflozin …….5mg Metformin HCl……1000mg
	Diary No. Date of R& I & fee	Dy. No. 14/07/2015; PKR 50,000/- dated 24/6/2015
	Pharmacological Group	Dapagliflozin: SGLT2 inhibitors Metformin HCl: Biguanides (Anti-diabetic)
	Type of Form	Form-5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC
	Approval status of product in Reference Regulatory Authorities	Xigduo 5 mg/1,000 mg film-coated tablets by M/s AstraZeneca UK Limited, MHRA Approved.
	Me-too status (with strength and dosage form)	Dapa-Met 5 mg / 1000 mg tablets by M/s, Hilton Pharma
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.
	Remarks of the Evaluator :	
	Now the firm has submitted stability data detailed as under:	

STABILITY STUDY DATA

Drug	**DAPAMET 5+1000MG TABLET**
Name of Manufacturer	M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.

Manufacturer of API		**Dapagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China. **Metformin HCl:** M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China.		
API Lot No.		Dapagliflozin: 7100-201905001 Metformin HCl: A-15212005074		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time : 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated:0,1,2,3,4,6 (month) Real Time: 0,3,6, (month)		
Batch No.		**20PD-3409-03-T**	**20PD-3410-04-T**	**20PD-3411-05-T**
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		11-2020	11-2020	11-2020
Date of Initiation		12-12-2020	12-12-2020	12-12-2020
No. of Batches		03		
Date of Submission		24-1-2022 (Dy. No 2160)		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
Documents To Be Provided		**Status**		
1	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020. According to the report following points were confirmed. • Firm has 21 CFR compliant HPLC software. • Firm has audit trail reports available. • Firm possesses stability chambers with digital data loggers.		
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Dapagliflozin:** Copy of COA of Dapagliflozin: (Batch# 7100-201905001) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. Copy of COA (Batch#5918) from M/s PharmEvo (private) Limited is submitted. **Metformin HCl:** Copy of COA of Metformin HCl (Batch# A-15212005074) from M/s Shouguang Fukang Pharmaceutical Co., Ltd, North-East of Dongwaihuan Road Dongcheng Industrial Area, Shouguang City, Shandong Province China. Copy of COA (Batch#12432) from M/s PharmEvo (private) Limited is submitted.		
3	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Yes		
4	Stability study data of API from API manufacturer	Stability study conditions: **Dapagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (130401, 130402, 130501) **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (A-72611405016, A-72611405017, A-72611405018)		

<table>
<tr><td>5</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Dapagliflozin: Copy of GMP certificate issued by Huai’an Pharmaceutical Industrial Association valid till 14/01/2024.
Metformin HCl: Copy of GMP certificate No. SD20190888 issued by Shandong Food & Drug Administration valid till 03/12/2024</td></tr>
<tr><td>6</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Dapagliflozin:
• Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
• Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.</td></tr>
<tr><td>7</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record. Details are as under:
<table>
<tr><th>tch no.</th><th>Batch Size</th><th>Mfg. Started</th></tr>
<tr><td>PD-3409-03-T</td><td>2500</td><td>11-2020</td></tr>
<tr><td>PD-3410-04-T</td><td>2500</td><td>11-2020</td></tr>
<tr><td>PD-3411-05-T</td><td>2500</td><td>11-2020</td></tr>
</table></td></tr>
<tr><td>11</td><td>Record of comparative dissolution data (where applicable)</td><td>Firm has submitted Comparative dissolution study of their product with Reference Brand “Dapa-Met 5+1000mg Tablet” The details are as follows:
<table>
<tr><th>ature</th><th>Reference Product</th><th>Product of PharmEvo</th></tr>
<tr><td>and Name</td><td>Dapa-Met 5+1000mg Tablet</td><td>DAPAMET 5+1000MG TABLET</td></tr>
<tr><td>tch No.</td><td>138475</td><td>20PD-3409-03-T</td></tr>
</table>
Comparative dissolution studies have been performed in following mediums:
1. pH 1.2 HCl buffer
2. pH 4.5 Acetate buffer
3. pH 6.8 Phosphate buffer</td></tr>
<tr><td>12</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Yes</td></tr>
<tr><td>13</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Firm has submitted audit trail reports of stability studies of applied formulation.</td></tr>
<tr><td>14</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Yes</td></tr>
<tr><td colspan="3">Remarks:
i) Stability data of commercial batches needs has been submitted for Dapagliflozin (API) which includes tests of optical rotation and related substances..
ii) Copy of DMLno. Su 20160324 in respect of Dapagliflozin issued by Jiangsu Medical Product administration has been submitted.</td></tr>
</table>

Decision: Approved with Innovator's specifications. Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**				
899.	**Name and address of manufacturer / Applicant**	**M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi**		
	Brand Name +Dosage Form + Strength	**DAPAMET-XR 5/1000MG TABLET**		
	Composition	Each Film Coated Tablet contain: 6.15mg Dapagliflozin Propanediol Monohydrate (equivalent to 5mg Dapagliflozin) + 1000mg Metformin HCl as extended release.		
	Diary No. Date of R& I & fee	PKR 50,000/- dated 21/2/2019		
	Pharmacological Group	Dapagliflozin: SGLT2 inhibitors Metformin HCl: Biguanides (Anti-diabetic)		
	Type of Form	Form-5D		
	Finished product Specifications	Manufacturer's specifications		
	Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC		
	Approval status of product in Reference Regulatory Authorities	Xigduo XR 5 mg/1000 mg film-coated tablets by M/s AstraZeneca UK Limited, MHRA Approved.		
	Me-too status (with strength and dosage form)	Dapa-Met XR 5 mg / 1000 mg tablets by M/s, Hilton Pharma		
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.		
	Remarks of the Evaluator :			
	Now the firm has submitted stability data detailed as under:			
STABILITY STUDY DATA				
Drug		**DAPAMET-XR 5/1000MG TABLET**		
Name of Manufacturer		M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.		
Manufacturer of API		**Dapagliflozin:** M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China. **Metformin HCl:** M/s Smruthi Organics Limited A-27, MIDC-Chincholi, Solapur, India.		
API Lot No.		Dapagliflozin: 7100-202106001 Metformin HCl: MET-0782/21		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time : 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated:0,1,2,3,4,6 (month) Real Time: 0,3,6, (month)		
Batch No.		**21PD-4028-07-T**	**21PD-4029-08-T**	**21PD-4030-09-T**
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		12-2021	12-2021	12-2021
Date of Initiation		01-2022	01-2022	01-2022
No. of Batches		03		
Date of Submission		08-11-2022 (Dy. No 32123)		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT				
Documents To Be Provided		**Status**		

<table>
<tr><td>1</td><td>Reference of previous approval of applications with stability study data of the firm</td><td>Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020. According to the report following points were confirmed.
Firm has 21 CFR compliant HPLC software.
Firm has audit trail reports available.
Firm possesses stability chambers with digital data loggers.</td></tr>
<tr><td>2</td><td>Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.</td><td>Dapagliflozin:
Copy of COA of Dapagliflozin: (Batch# 7100-202106001) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. Copy of COA (Batch#17749) from M/s PharmEvo (private) Limited is submitted.
Metformin HCl:
Copy of COA of Metformin HCl (Batch# MET-0782/21) from M/s Smruthi Organics Limited A-27, MIDC-Chincholi, Solapur, India. Copy of COA (Batch#18490) from M/s PharmEvo (private) Limited is submitted.</td></tr>
<tr><td>3</td><td>Method used for analysis of API from both API Manufacturer and Finished Product manufacturer</td><td>Yes</td></tr>
<tr><td>4</td><td>Stability study data of API from API manufacturer</td><td>Stability study conditions:
Dapagliflozin:
Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (130401, 130402, 130501)
Metformin HCl:
Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months
Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months
Batches: (DMFH-026/10, DMFH-027/10, DMFH-028/10)</td></tr>
<tr><td>5</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Dapagliflozin: Copy of GMP certificate issued by Huai’an Pharmaceutical Industrial Association valid till 14/01/2024.
Metformin HCl: Copy of GMP certificate No. NEW-WHO-GMP/CERT/PD/86368/2019/11/30111issued by Food & Drug Administration India.</td></tr>
<tr><td>6</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Dapagliflozin:
• Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
• Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.</td></tr>
<tr><td>7</td><td>Protocols followed for conduction of stability study</td><td>Yes</td></tr>
<tr><td>8</td><td>Method used for analysis of FPP</td><td>Yes</td></tr>
<tr><td>9</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Same excipients used as used by innovator.</td></tr>
<tr><td>10</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted copy of Trial batch manufacturing record. Details are as under:<table><tr><th>tch no.</th><th>Batch Size</th><th>Mfg. Started</th></tr><tr><td>PD-4028-07-T</td><td>2500</td><td>12-2021</td></tr><tr><td>PD-4029-08-T</td><td>2500</td><td>12-2021</td></tr><tr><td>PD-4030-09-T</td><td>2500</td><td>12-2021</td></tr></table></td></tr>
<tr><td>11</td><td>Record of comparative dissolution data (where applicable)</td><td>Firm has submitted Comparative dissolution study of</td></tr>
</table>

<table>
<tr><td></td><td></td><td colspan="3">their product with Innovator Brand “Xigduo XR 5+500mg Tablet” The details are as follows:</td></tr>
<tr><td></td><td></td><td>ature</td><td>Reference Product</td><td>Product of PharmEvo</td></tr>
<tr><td></td><td></td><td>and Name</td><td>Xigduo XR 5+1000mg Tablet</td><td>DAPAMET-XR 5+1000MG TABLET</td></tr>
<tr><td></td><td></td><td>tch No.</td><td>NA0046</td><td>21PD-4028-07-T</td></tr>
<tr><td></td><td></td><td colspan="3">Comparative dissolution studies have been performed in following mediums:
1. pH 1.2 HCl buffer
2. pH 4.5 Acetate buffer
3. pH 6.8 Phosphate buffer
For metformin, the firm calculated f1 and f2 values, which are within limits.</td></tr>
<tr><td>12</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td colspan="3">Yes</td></tr>
<tr><td>13</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td colspan="3">Firm has submitted audit trail reports of stability studies of applied formulation.</td></tr>
<tr><td>14</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td colspan="3">Yes</td></tr>
<tr><td colspan="5">REMARKS OF THE EVALUATOR
Deferred in minutes of 321st meeting of registration board, held on 20-22nd September, 2022</td></tr>
<tr><td colspan="2">GMP certificate/inspection conducted within last 3 years.</td><td colspan="3">Firm submitted latest GMP inspection report conducted on 22-June-2022, GMP certificate grant on 22-August 2022.</td></tr>
<tr><td colspan="2">Label Claim does not mention extended release dosage form which needs clarification.</td><td colspan="3">The subject product has been developed in accordance with the formulation of innovator product i.e. extended release, however we are submitting the revised Form 5-D and requisite fees along with this letter for your perusal
(Slip Number: 04110889697)</td></tr>
<tr><td colspan="2">Submission of Stability study data as per the guidelines approved in 293rd meeting of Registration Board.</td><td colspan="3">Firm submitted the Stability study data as per the guidelines approved in 293rd meeting of Registration Board on 08-Nov-2022.</td></tr>
<tr><td colspan="5">Decision: Approved with Innovator’s specifications. Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.</td></tr>
</table>

i. Routine Cases

900.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore**
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)

	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30775 dated 10.11.2021
	Details of fee submitted	PKR 30000/- dated 20.05.2021
	The proposed proprietary name / brand name	Oxeto Tablet 10mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vortioxetine HBr eq. to Vortioxetine….10mg
	Pharmaceutical form of applied drug	Yellow Round Biconvex Film coated Tablet
	Pharmacotherapeutic Group of (API)	Anti-Depressant
	Reference to Finished product specifications	In-House
	Proposed Pack size	3×10's Alu Alu
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Brintillex Tablets EMA Approved
	For generic drugs (me-too status)	Brintillex Tablets of Lundbeck Pakistan
	GMP status of the Finished product manufacturer	GMP certificate issued to the firm by DRAP Lahore dated 05.09.2019.
	Name and address of API manufacturer.	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paroxetine Hydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, , specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 72 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (5320-09-001, 5320-09-002, 5320-09-003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer

		medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is ABC 37.5mg tablet by … Pharma by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is ABC 37.5mg tablet Tablet by ….. Pharma in Acid media (pH 1.0-1.2) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificty.

STABILITY STUDY DATA			
Manufacturer of API	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China		
API Lot No.	20191101		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0,1,2,3,4,5,6 (Months) Real Time: 0, 3, 6, 9, 12, 24 (Months)		
Batch No.	T-001	T-002	T-003
Batch Size	2000 Tablets	2000 Tablets	2000 Tablets
Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	13.08.2022	13.08.2022	13.08.2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP Lahore attested invoice vide No. HH-991-02-725. As per aforesaid invoice 0.3386Kg of API is imported (value of 5USD). Mfg Date: 13.12.2019 Exp Date: 12.12.2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Remarks of Evaluator:

MODULE I	
1.6.5	Certificate of GMP compliance of API manufacturing site./ Valid manufacturing authorization issued by regulatory authority of country of origin as the submitted evidence is not satisfactory.
MODULE II & III	
2.3.S.1.3	Quantitative aqueous pH solubility profile (e.g. pH 1.2–6.8, dose/solubility volume) is required as submitted information is incomplete.
3.2..S.1.3	You have submitted that no polymorphic form exists, however as per innovator/ literature, the API exhibits polymorphisms. This requires clarification.
2.3.S.3.1	List has been submitted regarding the studies performed however conclusion needs to be submitted that whether whether the results support the proposed structure Polymorphic & Particle size distribution studies are required.
3.2.S.3.1	QA certified copies of spectra, peak assignments and detailed interpretation of the data in from the studies performed to elucidate and/or confirm the structure of the API are required because submitted data in insufficient for confirmation of API. Further aforesaid data needs to be submitted in English language. As API exhibits polymorphism hence polymorphic characterization details needs to be submitted with confirmation studies of preferred polymorphic form. Particle size distribution studies are not performed. This requires clarification.
2.3.S.4.1	Justification for not including test for polymorphic confirmation and particle size distribution in API specifications being critical quality attributes by the API manufacturer. API specifications (tests, acceptance criteria and type of analytical procedure) by the finished product manufacturer are required .
3.2.S.4.1	Copies of the API specifications, dated and signed by authorized personnel by the API manufacturer (e.g. the person in charge of the quality control or quality assurance department). API specifications, dated and signed by authorized personnel by the drug product manufacturer (e.g. the person in charge of the quality control or quality assurance department).
2.3.S.4.3	Justification for not performing specificity under validation studies.
3.2.S.4.3	Detailed validation studies/ reports need to be submitted as same is not provided in the dossier. Details needs to be submitted regarding size of batch for commercial scale.
3.2.S.4.4	Copies of certificate of analysis of batches by API manufacturer do not indicate the batch size. Details regarding scale of commercial batch is required.
2.3.S.5 & 3.2.S.5	Certificate of analysis of reference standard is required.
2.3.S.7	Batch size needs to ne mentioned in stability summary
3.2.S.7	The stability summary indicates that the study is performed at lab scale batches. Data of commercial scale batches needs to be submitted indicating batch size and date of manufacturing.
3.2.P.1	Description of the tablet is mentioned as film coated however composition is submitted is of plain tablet.
3.2.P.2.1.2	Justification of not using magnesium stearate being used in innovator product. Further quantities of excipients need to be justified with suitable references.
3.2.P.2.2	Under manufacturing process development, you have used mag stearate however the same is not reflected in the composition. This needs clarification.
3.2.P.4	Specification of Tab coat TC 117-2200001 Yellow/Red/ needs to be submitted.
3.2.P.5.1	Under finished product specification you have proposed identification by HPLC and IR. The method of IR needs to be submitted. Justification of proposing weight variation rather than content uniformity test. Justification of performing dissolution by UV rather than HPLC.

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

901	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore**

	Name, address of Manufacturing site.	M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 31769 dated 18.11.2021
	Details of fee submitted	PKR 30000/- dated 20.05.2021
	The proposed proprietary name / brand name	Oxeto Tablet 5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vortioxetine HBr eq. to Vortioxetine….5mg
	Pharmaceutical form of applied drug	Pink Almond Shaped Biconvex Film coated Tablet
	Pharmacotherapeutic Group of (API)	Anti-Depressant
	Reference to Finished product specifications	In-House
	Proposed Pack size	3x10's Alu Alu
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Brintillex Tablets EMA Approved
	For generic drugs (me-too status)	Brintillex Tablets of Lundbeck Pakistan
	GMP status of the Finished product manufacturer	GMP certificate issued to the firm by DRAP Lahore dated 05.09.2019.
	Name and address of API manufacturer.	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paroxetine Hydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, , specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 72 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (5320-09-001, 5320-09-002, 5320-09-003)

	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is ABC 37.5mg tablet by … Pharma by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is ABC 37.5mg tablet Tablet by ….. Pharma in Acid media (pH 1.0-1.2) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.		
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificty.		
	STABILITY STUDY DATA			
	Manufacturer of API	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China		
	API Lot No.	20191101		
	Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
	Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
	Time Period	Real time: 24 months Accelerated: 6 months		
	Frequency	Accelerated: 0,1,2,3,4,5,6 (Months) Real Time: 0, 3, 6, 9, 12, 24 (Months)		
	Batch No.	T-001	T-002	T-003
	Batch Size	2000 Tablets	2000 Tablets	2000 Tablets
	Manufacturing Date	08-2020	08-2020	08-2020
	Date of Initiation	13.08.2022	13.08.2022	13.08.2022
	No. of Batches	03		
	Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)			
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.			
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP Lahore attested invoice vide No. HH-991-02-725. As per aforesaid invoice 0.3386Kg of API is imported (value of 5USD). Mfg Date: 13.12.2019 Exp Date: 12.12.2021		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			

	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	
	Remarks of Evaluator:	

MODULE I	
1.6.5	Certificate of GMP compliance of API manufacturing site./ Valid manufacturing authorization issued by regulatory authority of country of origin as the submitted evidence is not satisfactory.
MODULE II & III	
2.3.S.1.3	Quantitative aqueous pH solubility profile (e.g. pH 1.2–6.8, dose/solubility volume) is required as submitted information is incomplete.
3.2..S.1.3	You have submitted that no polymorphic form exists, however as per innovator/ literature, the API exhibits polymorphisms. This requires clarification.
2.3.S.3.1	List has been submitted regarding the studies performed however conclusion needs to be submitted that whether whether the results support the proposed structure Polymorphic & Particle size distribution studies are required.
3.2.S.3.1	QA certified copies of spectra, peak assignments and detailed interpretation of the data in from the studies performed to elucidate and/or confirm the structure of the API are required because submitted data in insufficient for confirmation of API. Further aforesaid data needs to be submitted in English language. As API exhibits polymorphism hence polymorphic characterization details needs to be submitted with confirmation studies of preferred polymorphic form. Particle size distribution studies are not performed. This requires clarification.
2.3.S.4.1	Justification for not including test for polymorphic confirmation and particle size distribution in API specifications being critical quality attributes by the API manufacturer. API specifications (tests, acceptance criteria and type of analytical procedure) by the finished product manufacturer are required .
3.2.S.4.1	Copies of the API specifications, dated and signed by authorized personnel by the API manufacturer (e.g. the person in charge of the quality control or quality assurance department). API specifications, dated and signed by authorized personnel by the drug product manufacturer (e.g. the person in charge of the quality control or quality assurance department).
2.3.S.4.3	Justification for not performing specificity under validation studies.
3.2.S.4.3	Detailed validation studies/ reports need to be submitted as same is not provided in the dossier. Details needs to be submitted regarding size of batch for commercial scale.
3.2.S.4.4	Copies of certificate of analysis of batches by API manufacturer do not indicate the batch size. Details regarding scale of commercial batch is required.
2.3.S.5 & 3.2.S.5	Certificate of analysis of reference standard is required.
2.3.S.7	Batch size needs to ne mentioned in stability summary
3.2.S.7	The stability summary indicates that the study is performed at lab scale batches. Data of commercial scale batches needs to be submitted indicating batch size and date of manufacturing.
3.2.P.1	Description of the tablet is mentioned as film coated however composition is submitted is of plain tablet.
3.2.P.2.1.2	Justification of not using magnesium stearate being used in innovator product. Further quantities of excipients need to be justified with suitable references.
3.2.P.2.2	Under manufacturing process development, you have used mag stearate however the same is not reflected in the composition. This needs clarification.
3.2.P.4	Specification of Tab coat TC 117-2200001 Yellow/Red/ needs to be submitted.
3.2.P.5.1	Under finished product specification you have proposed identification by HPLC and IR. The method of IR needs to be submitted. Justification of proposing weight variation rather than content uniformity test. Justification of performing dissolution by UV rather than HPLC.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

902.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore**
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Pvt Limited, 124/1-Quiad-eAzam Industrial Estate Kot Lakhpat Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 30774 dated 10.11.2021
	Details of fee submitted	PKR 30000/- dated 20.05.2021
	The proposed proprietary name / brand name	Oxeto Tablet 20mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Vortioxetine HBr eq. to Vorteoxetine….20mg
	Pharmaceutical form of applied drug	Red Color, almond shaped, without any score, enteric, Film coated controlled tablet
	Pharmacotherapeutic Group of (API)	Anti-Depressant
	Reference to Finished product specifications	In-House
	Proposed Pack size	Bottle of 30 Tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Brintillex Tablets EMA Approved
	For generic drugs (me-too status)	Brintillex Tablets of Lundbeck Pakistan
	GMP status of the Finished product manufacturer	GMP certificate issued to the firm by DRAP Lahore dated 05.09.2019.
	Name and address of API manufacturer.	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paroxetine Hydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions:

		Real time: 30˚C ± 2˚C / 65% ± 5%RH for 72 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (5320-09-001, 5320-09-002, 5320-09-003)		
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile			
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.		
	STABILITY STUDY DATA			
	Manufacturer of API	M/s Lianyungang Jari Pharmaceuticals Co., Ltd Room No. 1216 Shimao Plaza Xinbei District Changzhou China		
	API Lot No.	20191101		
	Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
	Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
	Time Period	Real time: 24 months Accelerated: 6 months		
	Frequency	Accelerated: 0,1,2,3,4,5,6 (Months) Real Time: 0, 3, 6, 9, 12, 24 (Months)		
	Batch No.	T-001	T-002	T-003
	Batch Size	2000 Tablets	2000 Tablets	2000 Tablets
	Manufacturing Date	08-2020	08-2020	08-2020
	Date of Initiation	13.08.2022	13.08.2022	13.08.2022
	No. of Batches	03		
	Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)			
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.			
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP Lahore attested invoice vide No. HH-991-02-725. As per aforesaid invoice 0.3386Kg of API is imported (value of 5USD). Mfg Date: 13.12.2019 Exp Date: 12.12.2021		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			

	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	
	Remarks OF Evaluator:	

MODULE I	
1.6.5	Certificate of GMP compliance of API manufacturing site./ Valid manufacturing authorization issued by regulatory authority of country of origin as the submitted evidence is not satisfactory.
MODULE II & III	
2.3.S.1.3	Quantitative aqueous pH solubility profile (e.g. pH 1.2–6.8, dose/solubility volume) is required as submitted information is incomplete.
3.2..S.1.3	You have submitted that no polymorphic form exists, however as per innovator/ literature, the API exhibits polymorphisms. This requires clarification.
2.3.S.3.1	List has been submitted regarding the studies performed however conclusion needs to be submitted that whether whether the results support the proposed structure Polymorphic & Particle size distribution studies are required.
3.2.S.3.1	QA certified copies of spectra, peak assignments and detailed interpretation of the data in from the studies performed to elucidate and/or confirm the structure of the API are required because submitted data in insufficient for confirmation of API. Further aforesaid data needs to be submitted in English language. As API exhibits polymorphism hence polymorphic characterization details needs to be submitted with confirmation studies of preferred polymorphic form. Particle size distribution studies are not performed. This requires clarification.
2.3.S.4.1	Justification for not including test for polymorphic confirmation and particle size distribution in API specifications being critical quality attributes by the API manufacturer. API specifications (tests, acceptance criteria and type of analytical procedure) by the finished product manufacturer are required .
3.2.S.4.1	Copies of the API specifications, dated and signed by authorized personnel by the API manufacturer (e.g. the person in charge of the quality control or quality assurance department). API specifications, dated and signed by authorized personnel by the drug product manufacturer (e.g. the person in charge of the quality control or quality assurance department).
2.3.S.4.3	Justification for not performing specificity under validation studies.
3.2.S.4.3	Detailed validation studies/ reports need to be submitted as same is not provided in the dossier. Details needs to be submitted regarding size of batch for commercial scale.
3.2.S.4.4	Copies of certificate of analysis of batches by API manufacturer do not indicate the batch size. Details regarding scale of commercial batch is required.
2.3.S.5 & 3.2.S.5	Certificate of analysis of reference standard is required.
2.3.S.7	Batch size needs to ne mentioned in stability summary
3.2.S.7	The stability summary indicates that the study is performed at lab scale batches. Data of commercial scale batches needs to be submitted indicating batch size and date of manufacturing.
3.2.P.1	Description of the tablet is mentioned as film coated however composition is submitted is of plain tablet.
3.2.P.2.1.2	Justification of not using magnesium stearate being used in innovator product. Further quantities of excipients need to be justified with suitable references.
3.2.P.2.2	Under manufacturing process development, you have used mag stearate however the same is not reflected in the composition. This needs clarification.
3.2.P.4	Specification of Tab coat TC 117-2200001 Yellow/Red/ needs to be submitted.
3.2.P.5.1	Under finished product specification you have proposed identification by HPLC and IR. The method of IR needs to be submitted. Justification of proposing weight variation rather than content uniformity test. Justification of performing dissolution by UV rather than HPLC.
Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

903.	Name, address of Applicant / Marketing Authorization Holder	**Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.**
	Name, address of Manufacturing site.	Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No: 27277 dated :01.10.2021
	Details of fee submitted	Rs. 25,000/- dated 15/09/2021 Rs. 50000/- dated 04.05.2021
	The proposed proprietary name / brand name	Tornil Mouthwash 0.25%
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: 2.5mg of Flurbiprofen
	Pharmaceutical form of applied drug	Clear pale bluish colored, methanol flavored liquid
	Pharmacotherapeutic Group of (API)	NSAIDs (Non-steroidal anti-inflammatory drugs)
	Reference to Finished product specifications	Innovator's specs
	Proposed Pack size	100ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Froben Gola 0.25% by Abbot
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	GMP certificate granted on 16.09.2020 valid till 27.08.2021
	Name and address of API manufacturer.	Hy-Gro Chemicals Pharmtek Pvt. Ltd Plot No. 174 Progressive Industrial Society IDA Bollaram Jinnaram Mandal Sanga Reddy District Telangana India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	Official monograph of Flurbiprofen is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (FB-2016/04/39, FB-2016/04/40 , FB-2016/04/41)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Froben Gola 0.25% by Mylan products Limited by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form)..
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Hy-Gro Chemicals Pharmtek Pvt. Ltd		
API Lot No.			
Description of Pack (Container closure system)	Pet bottle		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 18 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6,9,12,18(Months)		
Batch No.	TF-03	TF-04	TF-05
Batch Size	1L	1L	1L
Manufacturing Date	Aug/2018	Aug/2018	Aug/2018
Date of Initiation	01.09.2018	01.09.2018	01.09.2018
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product "Rofair 500mcg Tablet", which was conducted on 25th June, 2019, and was presented in 290th meeting of Registration Board. The report confirms: □ The HPLC software is 21CFR Compliant.

		☐ Audit trail on testing reports is available ☐ Firm has adequate monitoring and controls for stability chambers. Chambers are controlled and monitored through software having alarm system for alerts as well
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. L.Dis.No:54409/TS/2021 issued by Drug Control Administration Telangana India valid till 16/02/2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	DHL No.XMLPI6.2/90-1604 dated 21/03/2017
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks:

3.2. S.4.4 Batch analysis of API by the FPP manufacturer for the batch used for manufacturing of finished product for stability testing.

3.2.S.4.5 CoA of reference standard.

3.2. P.2 Pharmaceutical equivalence studies needs to be submitted with reference product having details of brand name, batch No, manufacturer.

3.2. P.3 Batch size does not reflect the Pack size/ filled volume per pack. This needs to be clarified as the same is not mentioned in manufacturing process and not on the CoA of three batches placed on stability.

3.2. P.7 The quantity of the units produced needs to be justified w.r.t stability testing.

There CoAs submitted for API (Flurbiprofen) which indicates Mfg date of November 2018 however stability testing was initiated in Sep. 2018. This needs clarification.

Justification for not importing API with permission of DRAP. Further Copy of DHL does not reflect the date of import of API. Complete import documentation of API needs to be submitted.

Evidence of Approval of formulation in RRA.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

904.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s WnsFeild Pharmaceutical Industrial Estate Hattar Haripur Kpk Pakistan.**
	Name, address of Manufacturing site.	M/s WnsFeild Pharmaceutical Plot No. 122 Phase 5, Industrial Estate Hattar Haripur Kpk Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)

	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 33298 dated 09.12.2021
	Details of fee submitted	PKR 30000/-: dated 12.08.2021
	The proposed proprietary name / brand name	PREFEN 200MG TABLET
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Pirfenidone…….200mg
	Pharmaceutical form of applied drug	Yellow Oval Biconvex Film Coated Tablet
	Pharmacotherapeutic Group of (API)	Pyridones (Anti-inflammatory)
	Reference to Finished product specifications	As per Innovators Specifications
	Proposed Pack size	3×10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Pirfenox 200mg tablet by M/s Highnoon Pharmaceutical, DRAP Approved.
	For generic drugs (me-too status)	Pirfenox 200mg tablet by M/s Highnoon Pharmaceutical, DRAP Approved. Reg. No.
	GMP status of the Finished product manufacturer	New license granted on 14/10/2019 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	M/s Optimus Drugs Pvt Limited, Sy. No. 239 & 240 Dothigudem Village Pochampally Mandal Yadari Bhuvanagiri District 5080284 Telangana India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Pirfenidone is present in BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (OP-PIR-S3-001/17, OP-PIR-S3-002/17 and OP-PIR-S3-003/17

	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the local brand Pirfenox 200mg tablet by Highnoon Pharma Lahore. CDP has been performed against the aforesaid brand in three media.
	Analytical method validation/verification of product	Studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Optimus Drugs Pvt Limited, Sy. No. 239 & 240 Dothigudem Village Pochampally Mandal Yadari Bhuvanagiri District 5080284 Telangana India		
API Lot No.	OP-PIF-A1-001/20		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (3×10's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	PF-010	PF-011	PF-012
Batch Size	1200 tab	1200 tab	1200 tab
Manufacturing Date	01-2021	01-2021	01-2021
Date of Initiation	18-01-2021	18-01-2021	18-01-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate issued by Drugs Control Administration Govt. of Telangana India dated 03.03.2020 valid for three years from date of issuance
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of DRAP Peshawar attested invoice vide No. IEC No. 0908003404 dated 05.11.2020 is submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm has submitted stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.
Remarks of Evaluator:		
Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		

Agenda of Evaluator PEC-XVII

Export Facilitation cases:

The following applications were received vide letter No.F.1-6/2019-PR-I (EFD) dated 06th October, 2022 from Assistant Director (PR-I/EFD), PE & R, Division for evaluation on priority basis in pursuance of decision in 133rd meeting of DRAP Authority held on 13th April 2022, regarding export facilitation (Grant of registration on priority basis to the *pharmaceutical* i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year).

Case No.I Registration applications of locally manufactured (Human) drugs on Form 5F.

The firm M/s. Hilton Pharma (Pvt.) Ltd. Plot No. 13-14 & 43, Sector-15, Korangi, Industrial Area, Karachi applied for registration of their following products vide **R & I Diary No.16315 dated 03-05-2018 on Form-5 D with fee of Rs: 50,000/- (Challan No.0719472) for Erithril 5mg tablet** and **Vide R & I Diary No. 16314 dated 03-05-2018 with fee of Rs: 50,000/- (Challan No. 0719467) for Erithril 15mg tablet** and subsequently submitted 06-months stability studies data vide R & I Diary No.31861 dated 19-11-2021. However, the firm also submitted registration applications for the same products on Form 5F on 06-05-2022. The firm then vide letter dated 30-12-2022, addressed to In-Charge PEC requested to consider the registration applications submitted on Form 5F and withdrawn those submitted on Form 5D. Accordingly, the following applications submitted on Form 5F are placed for consideration of the Registration Board.

Decision: Registration Board acceded the request of withdrawal of frim and decided to dispose the application submitted on Form 5D as per following details:

Erithril 5mg tablet: R & I Diary No.16315 dated 03-05-2018 on Form-5 D with fee of Rs: 50,000/- (Challan No.0719472)

Erithril 15mg tablet: Vide R & I Diary No. 16314 dated 03-05-2018 with fee of Rs: 50,000/- (Challan No. 0719467)

905.	Name, address of Applicant / Marketing Authorization Holder	M/s. Hilton Pharma (Pvt.) Ltd. 8th & 9th floor, progressive plaza, Beaumont Road, Karachi, Pakistan.
	Name, address of Manufacturing site.	M/s. Hilton Pharma (Pvt.) Ltd. Plot No. 13-14 & 43, Sector-15, Korangi, Industrial Area, Karachi. (DML No. 000136)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11036 dated 06-05-2022
	Details of fee submitted	PKR: 30,000/- vide online deposit slip No.0730898759 dated 17-03-2022.
	The proposed proprietary name / brand name	Ertihil Tablets 5mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film-Coated Tablet Contains: Ertugliflozin L-Pyroglutamic acid equivalent to Ertugliflozin ……5 mg
	Pharmaceutical form of applied drug	Film coated tablets
	Pharmacotherapeutic Group of (API)	Antidiabetic
	Reference to Finished product specifications	Innovator's Specifications

	Proposed Pack size	7's, 10's, 14's, 28's & 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	STEGLATRO® 5 mg film-coated tablets by M/s Merck Sharp & Dohme Corp. (FDA Approved).
	For generic drugs (me-too status)	Tab. Ertuvia 5mg of M/s Ferozson's Laboratories, Nowshera. Registration No.110362
	GMP status of the Finished product manufacturer	Tablet Section (General) mentioned in DML renewal letter No.F. 2-14/85-Lic (Vol-V), Dated 30/06/2020
	Name and address of API manufacturer.	**Ertugliflozin L-Pyroglutamic acid** M/s. Chifeng Arker Pharmaceutical Technology Co., Ltd. No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Ertugliflozin L-Pyroglutamic acid:** Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 06 months Batches: (D84-161201, D84-161202, D84-170101)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence studies for higher strength that is Erithril 15mg tablet submitted. Comparative dissolution was performed against Steglatro 5mg tablet, Batch No. V019753 in HCl buffer (pH 1.2), Acetate buffer (pH 4.5) &

		Phosphate buffer (pH 6.8). The dissolution profile similarity factor, F2 found greater than 50 and the product is comparable with innovator.	
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.	
STABILITY STUDY DATA			
Manufacturer of API	Ertugliflozin L-Pyroglutamic acid M/s. Chifeng Arker Pharmaceutical Technology Co., Ltd. No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China.		
API Lot No.	As per invoice attested by DRAP, Karachi for Ertugliflozin L-Pyroglutamic acid, Batch no. D84-201101.		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	ERT-050-02/21	ERT-051-03/21	ERT-052-04/21
Batch Size	9000 Tablets	9000 Tablets	9000 Tablets
Manufacturing Date	02.2021	02.2021	02.2021
Date of Initiation	05.03.2021	05.03.2021	05.03.2021
No. of Batches	03		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product **"HILVEL 400mg + 100mg** (Sofosbuvir +Velpatasvir)", which was conducted on 14th December, 2017 and was presented in 277th meeting of Registration Board held on 27-29th December, 2017. Registration Board decided to approve registration of "HILVEL 400mg / 100mg (Sofosbuvir + Velpatasvir" by M/s. Hilton Pharma (Pvt.) Ltd., Karachi. Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months. Following two observations were reported in the report: i. The HPLC software is 21 CFR compliant. ii. Audit trail on the testing reports of Hilvel Tablets 400mg+100mg is available. Adequate monitoring and control are available for stability chamber. Chamber are controlled and monitored through software having alarm system for alerts as well.	

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of Drug Production License No. 20160053 & 91150400720172660N issued by Inner Mongolia Drug Administration valid till 28.12.2025. The firm has also submitted US FDA letter dated 12-03-2019, wherein compliance of the firm to current good manufacturing practices is communicated to the firm.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has imported Ertugliflozin L-PGA, Batch No. D84-201101, quantity 01kg vide invoice No. PSPW-201113 dated 13-11-2020, attested by Assistant Director (I & E), DRAP Karachi.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator: (PEC-XVII)

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.5	Revision of pharmacological group from antidiabetic to Sodium-glucose co-transporter 2 (SGLT2) inhibitors as per WHO ATC/DDD index along with submission of fee of Rs. 7,500 for variation in registration application i.e., correction/change of pharmacological group, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.	Firm revised pharmacological group from antidiabetic to Sodium-glucose co-transporter 2 (SGLT2) inhibitors as per WHO ATC/DDD index and submitted fee of Rs: 7,500/- vide online deposit slip No.259665987395 for revision of pharmacological group.
2.		The API Ertugliflozin L-PGA is not mentioned in Production Scope of Drug Production License of API manufacturer.	Firm re-submit same Drug Production License of API manufacturer.
3.	3.2.P.8.3	The peak areas and chromatograms of initial and 3rd month points for all the three batches are significantly different than that submitted for 06-month time point of all the three batches. Although the dissolution results are consistent. Clarification is required from the firm.	The difference in peak areas is due to two separate HPLCs system used in different days and note that standards were applied before samples and therefore no impact on results. Initial and 3rd month dissolution samples were tested on Shimadzu HPLC LC20 DB having lab solution software and 6th month dissolution samples were tested on Agilent HPLC 1260 infinity II, having open lab CDF software.
4.		Pharmaceutical equivalence studies submitted for Steglatro tablets 15mg instead of Steglatro tablet 5mg.	Pharmaceutical equivalence has been carried out for the highest strength i.e., Erithril tablet 15mg as both strengths Erithril Tablets 15mg and 5mg have same excipients and qualitative formulation, enclosed for your ready reference.
5.		As per submitted drug substance CoA, the content of L-PGA has been declared between a range of 22% – 25%, by the drug substance manufacturer. Hence it could be inferred that for achieving the desired	Ertugliflozin quantity per tablet is calculated based on actual content of L-PGA as is basis 5 × 1.3 = 6.5. Ertugliflozin quantity per tablet is calculated based on molecular weight that is 5 × 1.29 = 6.45.

		label claim of "Ertugliflozin", the amount of Ertugliflozin L-PGA dispensed must be calculated on the basis of actual %age content of L-PGA declared in the COA of the drug substance rather than the applying the theoretical factor of 1.295 on the basis of molecular weight. The submitted batch records reflect that the to achieve the desired label claim of "Ertugliflozin", the amount of Ertugliflozin L-PGA was dispensed by applying the theoretical factor of 1.295 on the basis of molecular weight instead of actual %age content of L-PGA. Clarification is required in this regard as to how the dispensed quantity of Ertugliflozin L-PGA for formulation development and trail batch manufacturing without considering the actual %age content of L-PGA declared in the COA of the drug substance corresponds/meets the desired label claim.	The difference is insignificant and no impact on the label claim. However, for commercial batches, Ertugliflozin quantity per mg tablet will be calculated on actual L-PGA content as is basis.

Approved. Firm shall submit Pharmaceutical equivalence studies against the relevant strength of innovator/reference product before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Registration letter will be issued with following additive condition of registration:**
  "During production of commercial batches, for achieving the desired label claim of "Ertugliflozin", instead of applying the theoretical factor on the basis of molecular weight, the amount of Ertugliflozin L-PGA dispensed must be calculated on the basis of actual %age content of L-PGA declared in the COA of the drug substance"

906.	Name, address of Applicant / Marketing Authorization Holder	M/s. Hilton Pharma (Pvt.) Ltd. 8th & 9th floor, progressive plaza, Beaumont road, Karachi, Pakistan.
	Name, address of Manufacturing site.	M/s. Hilton Pharma (Pvt.) Ltd. Plot No. 13-14 & 43, Sector-15, Korangi, Industrial Area, Karachi. (DML No. 000136)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11035 dated 06-05-2022.
	Details of fee submitted	PKR: 30,000/- vide online deposit slip No.490647870765 dated 17-03-2022.

	The proposed proprietary name / brand name	Ertihil Tablets 15mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film-Coated Tablet Contains: Ertugliflozin L-Pyroglutamic acid equivalent to Ertugliflozin ……15 mg
	Pharmaceutical form of applied drug	Film coated tablets
	Pharmacotherapeutic Group of (API)	Antidiabetic
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	7's, 10's, 14's, 28's & 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	STEGLATRO® 15 mg film-coated tablets by M/s Merck Sharp & Dohme Corp. (FDA Approved).
	For generic drugs (me-too status)	Tab. Ertuvia 15mg of M/s Ferozson's Laboratories, Nowshera. Registration No.110363
	GMP status of the Finished product manufacturer	Tablet Section (General) mentioned in DML renewal letter No.F. 2-14/85-Lic (Vol-V), Dated 30/06/2020
	Name and address of API manufacturer.	**Ertugliflozin L-Pyroglutamic acid** M/s. Chifeng Arker Pharmaceutical Technology Co., Ltd. No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data on CTD format related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications and analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Ertugliflozin L-Pyroglutamic acid:** Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months Batches: (D84-161201, D84-161202, D84-170101)

	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence studies performed with reference product that is Steglatro tablets 15mg (Batch No. U0197768). The firm has submitted the comparative dissolution with innovator product and dissolution profile similarity factor, F2 found greater than 50 and the product is comparable with innovator.
	Analytical method validation/verification of product	Method validation studies have submitted including, Specificity, linearity, range, accuracy, precision Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA			
Manufacturer of API	**<u>Ertugliflozin L-Pyroglutamic acid</u>** M/s. Chifeng Arker Pharmaceutical Technology Co., Ltd. No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China		
API Lot No.	As per invoice attested by DRAP for Ertugliflozin L-Pyroglutamic acid, batch no. D84-201101.		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	ERT-007-03/21	ERT-008-04/21	ERT-009-05/21
Batch Size	3000 Tablets	3000 Tablets	3000 Tablets
Manufacturing Date	01.2021	01.2021	01.2021
Date of Initiation	13.02.2021	13.02.2021	13.02.2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product **"HILVEL 400mg + 100mg** (Sofosbuvir +Velpatasvir)", which was conducted on 14th December, 2017 and was presented in 277th meeting of Registration Board held on 27-29th December, 2017. Registration Board decided to approve registration of "HILVEL 400mg / 100mg (Sofosbuvir + Velpatasvir" by M/s. Hilton Pharma (Pvt.) Ltd., Karachi. Manufacturer will place first three production batches on long term stability studies

		throughout proposed shelf life and on accelerated studies for six months. Following two observations were reported in the report: iii. The HPLC software is 21 CFR compliant. iv. Audit trail on the testing reports of Hilvel Tablets 400mg+100mg is available. Adequate monitoring and control are available for stability chamber. Chamber are controlled and monitored through software having alarm system for alerts as well.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of Drug Production License No. 20160053 & 91150400720172660N issued by Inner Mongolia Drug Administration valid till 28.12.2025. The firm has also submitted US FDA letter dated 12-03-2019, wherein compliance of the firm to current good manufacturing practices is communicated to the firm.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has imported Ertugliflozin L-PGA, Batch No. D84-201101, quantity 01kg vide invoice No. PSPW-201113 dated 13-11-2020, attested by Assistant Director (I & E), DRAP Karachi.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator: **(PEC-XVII)**

Sr. No.	Section	Observation	Reply by the firm
1.	2.3	The firm has not provided details about available literature references for the Drug Substance and Drug Product.	Literature references for the drug substance and drug product submitted (Australian Public Assessment Report on Ertugliflozin (Steglatro tablet).
2.	1.5.5	Revision of pharmacological group from antidiabetic to Sodium-glucose co-transporter 2 (SGLT2) inhibitors as per WHO ATC/DDD index along with submission of fee of Rs. 7,500 for variation in registration application i.e., correction/change of pharmacological group, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.	Firm revised pharmacological group from antidiabetic to Sodium-glucose co-transporter 2 (SGLT2) inhibitors as per WHO ATC/DDD index and submitted fee of Rs: 7,500/- vide online deposit slip No.68558470289 for revision of pharmacological group.
3.		The API Ertugliflozin L-PGA is not mentioned in Production Scope of Drug Production License of API manufacturer.	Firm re-submit same Drug Production License of API manufacturer.
4.	3.2.P.8.3	The peak areas and chromatograms of initial testing for all the three batches are significantly different than that submitted for 03-months & 06-month time point of all the three batches. Although the	The difference in peak areas is due to two separate HPLCs system used in different days and note that standards were applied before samples and therefore no impact on results. Initial dissolution samples were

		dissolution results are consistent. Clarification is required from the firm.	tested on Shimadzu HPLC LC20 DB having lab solution software while 3rd & 6th month dissolution samples were tested on Agilent HPLC 1260 infinity II, having open lab CDF software.
5.		As per submitted drug substance CoA, the content of L-PGA has been declared between a range of 22% – 25%, by the drug substance manufacturer. Hence it could be inferred that for achieving the desired label claim of "Ertugliflozin", the amount of Ertugliflozin L-PGA dispensed must be calculated on the basis of actual %age content of L-PGA declared in the COA of the drug substance rather than the applying the theoretical factor of 1.295 on the basis of molecular weight. The submitted batch records reflect that the to achieve the desired label claim of "Ertugliflozin", the amount of Ertugliflozin L-PGA was dispensed by applying the theoretical factor of 1.295 on the basis of molecular weight instead of actual %age content of L-PGA. Clarification is required in this regard as to how the dispensed quantity of Ertugliflozin L-PGA for formulation development and trail batch manufacturing without considering the actual %age content of L-PGA declared in the COA of the drug substance corresponds/meets the desired label claim.	Ertugliflozin quantity per tablet is calculated based on actual content of L-PGA as is basis 15 × 1.3 = 19.5. Ertugliflozin quantity per tablet is calculated based on molecular weight that is 15 × 1.29 = 19.35. The difference is insignificant and no impact on the label claim. However, for commercial batches, Ertugliflozin quantity per mg tablet will be calculated on actual L-PGA content as is basis.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Registration letter will be issued with following additive condition of registration:**

"During production of commercial batches, for achieving the desired label claim of "Ertugliflozin", instead of applying the theoretical factor on the basis of molecular weight, the amount of Ertugliflozin L-PGA dispensed must be calculated on the basis of actual %age content of L-PGA declared in the COA of the drug substance".

907.	Name, address of Applicant / Marketing Authorization Holder	M/S Herbion Pakistan Pvt Ltd Islamabad.
	Name, address of Manufacturing site.	M/s Herbion Pakistan Pvt Ltd Industrial Triangle Kahuta road, Islamabad. (DML No. 000795)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1305-R & I, Dated 14/01/2022
	Details of fee submitted	PKR 30,000/- vide online deposit slip No.206764738781 Dated 27/12/2021
	The proposed proprietary name / brand name	Estresto 50 mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Sacubitril ---------- 24.3 mg Valsartan ----------25.7 mg
	Pharmaceutical form of applied drug	Violet color, Oblong shape, plain on both side, film coated tablet
	Pharmacotherapeutic Group of (API)	Sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection frac
	Reference to Finished product specifications	As per Innovator's specifications
	Proposed Pack size	1* 14's (14's) 2*14's (28's)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Entresto tablets 50 mg Novartis Pharmaceuticals (FDA Approved)
	For generic drugs (me-too status)	Savesto 24.3/25.7mg tablet of M/s Getz Parma, Karachi. Registration No.093110
	GMP status of the Finished product manufacturer	Most recent GMP inspection report conducted within last three years required.
	Name and address of API manufacturer.	**Sacubitril & Valsartan:** Zhejiang Tianyu Pharmaceutical Co., Ltd. Address No.15, Donghai 5th Avenue, Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone, Taizhou City, Zhejiang Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Sacubitril sodium:** Official monograph of sacubitril sodium does not exist so firm has followed in house specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity SCB-4-

		Imp-1, SCB-5-Imp-2, SCB-5-I Sodium (chiral isomer, SCB-5-II Sodium (chiral isomer SCB-5-III Sodium (chiral isomer) specifications, analytical procedures and its validation , batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Valsartan:** Official monograph of valsartan exists in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity Valsartan Related Compound A: Not more than (NMT) 1.0% Valsartan Related Compound B: Not more than (NMT) 0.2% Valsartan Related Compound C: Not more than (NMT) 0.1% Any other individual impurity: Not more than (NMT) 0.1% Total impurities: Not more than (NMT) 0.3%, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Sacubitril Sodium:** Stability study conditions (Zone IVb). Real time: 30°C ± 2°C / 75% ± 5%RH for 24 months 0, 3, 6, 9, 12, 18, 24 months. Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months at 0, 1, 2, 3, 6 months Batches: (13700-181001, 13700 -181002, 13700-181003) **Valsartan:** Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months 0, 3, 6, 9, 12, 18, 24, 36 months. Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months. Batches: (201207301, 201207302, 201207303)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Savesto 50mg tablet of Getz Pharma, Karachi by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Savesto 50 mg tablet, batch No. 007FB2 by Getz Pharma in Acid media (pH 1.0-1.2), Acetate buffer (PH 4.5) & Phosphate Buffer (pH

		6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	**Sacubitril Sodium:** Method validation studies including linearity, range, accuracy, precision, intermediate precision, repeatability, robustness, specificity, LOD and LOQ. **Valsartan:** Verification studies for valsartan including Linearity, range, accuracy, precision (repeatability) and specificity along with chromatograms and raw data sheets submitted.

STABILITY STUDY DATA			
Manufacturer of API	Zhejiang Tianyu Pharmaceutical Co., Ltd. China.		
API Lot No.	Sacubitril Sodium (222920-210103) & Valsartan (10252-210201)		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×14's) (2×14's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	EST-50-ST-001	EST-50-ST-002	EST-50-ST-003
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	07-2021	07-2021	07-2021
Date of Initiation	3-08-2021	3-08-2021	3-8-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 201904044 issued by Zhejiang Medicine Center for Economic Development valid till 02/06/2022. Scope of inspection include (Sacubitril Sodium Valsartan).
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. TY121266 dated 19-03-2021 for import of 1.6kg Sacubitril Sodium and 1.7kg Valsartan USP from Zhejiang Tianyu Pharmaceutical Co., Ltd. Jiangkou Development Zone Huangyan Taizhou, Zhejiang, China, attested by AD (I & E), DRAP Islamabad.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted

6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Submitted

Remarks of Evaluator:-(PEC-XVII)

Sr. No.	Section	Observation	Reply by the firm
1.	3.2.S.4.4	Peak areas given for replicates 2-5 of standard injections for assay determination of Sacubitril sodium are different than those mentioned in corresponding chromatograms (sample information).	
2.		The assay calculation formula as given in the analytical procedure by the drug product manufacturer is different than that given in analytical method validation protocol/data of the drug product manufacturer. Moreover, the assay calculation formula as mentioned in the analytical method of the drug substance manufacturer and that given in the analytical method of the drug product manufacture are not the same.	
3.	3.2.P.2.2.1	In the procedure for CDP, the time point for sample withdrawal mentioned as 45 minutes, while in dissolution parameters for CDP and raw data sheets, the time points mentioned as 10, 15, 20, 30, 45 and 60 minutes.	
4.	3.2.P.5.2	Wavelength mentioned as 267nm under chromatographic conditions, however, as per reference/innovator's product dissolution method/parameters, the detection wavelength (HPLC/UV) given as 255 nm.	
5.		The flow rate in analytical method of drug product given as 1ml/min however, in method validation protocol for the drug product the flow rate given as 0.8ml/min.	
6.		As per various documents such as CoA of APIs from substance manufacturer and drug product manufacturer, import invoice, AD (I & E) clearance certificate, product development data, trial batch manufacturing record and separate stability summary data sheets for Sacubitril sodium and Valsartan by the drug substance manufacturer reflect that Sacubitril sodium and Valsartan used as separate materials, while the innovator product is designed as a combination of sacubitril and valsartan in a co-crystal, is a salt complex comprising LCZ696 (Sacubitril/Valsartan anionic moieties), sodium cations, and water molecules. Please justify how the applied formulation is in line with innovator's product.	
7.		Most recent GMP compliance inspection report conducted within last three years.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.		
908.	Name, address of Applicant / Marketing Authorization Holder	M/S Herbion Pakistan Pvt Ltd Islamabad.
	Name, address of Manufacturing site.	M/s Herbion Pakistan Pvt Ltd Industrial Triangle Kahuta road, Islamabad. (DML No. 000795)
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1306-R & I, Dated 14/01/2022
	Details of fee submitted	PKR 30,000/- vide online deposit slip No.6954377589 Dated 27/12/2021
	The proposed proprietary name / brand name	Estresto 100 mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Sacubitril ---------- 48.6 mg Valsartan ----------51.4 mg
	Pharmaceutical form of applied drug	Oval shaped, pale-yellow colored, film coated tablet, plain on both sides.
	Pharmacotherapeutic Group of (API)	Sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection frac
	Reference to Finished product specifications	As per Innovator's specifications
	Proposed Pack size	1* 14's (14's) 2*14's (28's)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Entresto tablets 100 mg Novartis Pharmaceuticals (FDA Approved)
	For generic drugs (me-too status)	Savesto 49/51mg tablet of M/s Getz Parma, Karachi. Registration No.093111
	GMP status of the Finished product manufacturer	Most recent GMP inspection report conducted within last three years required.
	Name and address of API manufacturer.	**Sacubitril Sodium & Valsartan:** Zhejiang Tianyu Pharmaceutical Co., Ltd. Address No.15, Donghai 5th Avenue, Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone, Taizhou City, Zhejiang Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to

		nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Sacubitril sodium:** Official monograph of sacubitril sodium does not exist so firm has followed in house specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity SCB-4-Imp-1, SCB-5-Imp-2, SCB-5-I Sodium (chiral isomer, SCB-5-II Sodium (chiral isomer SCB-5-III Sodium (chiral isomer) specifications, analytical procedures and its validation , batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Valsartan:** Official monograph of valsartan exists in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity Valsartan Related Compound A: Not more than (NMT) 1.0% Valsartan Related Compound B: Not more than (NMT) 0.2% Valsartan Related Compound C: Not more than (NMT) 0.1% Any other individual impurity: Not more than (NMT) 0.1% Total impurities: Not more than (NMT) 0.3%, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Sacubitril Sodium:** Stability study conditions (Zone IVb). Real time: 30˚C ± 2˚C / 75% ± 5%RH for 24 months 0, 3, 6, 9, 12, 18, 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months at 0, 1, 2, 3, 6 months Batches: (13700-181001, 13700 -181002, 13700-181003) **Valsartan:** Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months 0, 3, 6, 9, 12, 18, 24, 36 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (201207301, 201207302, 201207303)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure

		(including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Uperio 100mg tablet (Batch No. TAY84) of Novartis Pharma (Pakistan), Karachi by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand in Acid media (pH 1.0-1.2), Acetate buffer (PH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	**Sacubitril Sodium:** Method validation studies including linearity, range, accuracy, precision, intermediate precision, repeatability, robustness, specificity, LOD and LOQ. **Valsartan:** Verification studies for valsartan including Linearity, range, accuracy, precision (repeatability) and specificity along with chromatograms and raw data sheets submitted.

STABILITY STUDY DATA			
Manufacturer of API	Zhejiang Tianyu Pharmaceutical Co., Ltd. China.		
API Lot No.	Sacubitril Sodium (222920-210103) & Valsartan (10252-210201)		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×14's) (2×14's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	EST-100-ST-001	EST-100-ST-002	EST-100-ST-003
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	07-2021	07-2021	07-2021
Date of Initiation	3-08-2021	3-08-2021	3-8-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 201904044 issued by Zhejiang Medicine Center for Economic Development valid till 02/06/2022. Scope of inspection include (Sacubitril Sodium Valsartan).

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. TY121266 dated 19-03-2021 for import of 1.6kg Sacubitril Sodium and 1.7kg Valsartan USP from Zhejiang Tianyu Pharmaceutical Co., Ltd. Jiangkou Development Zone Huangyan Taizhou, Zhejiang, China, attested by AD (I & E), DRAP Islamabad.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:-(PEC-XVII)

Sr. No.	Section	Observation	Reply by the firm
1.	3.2.S.4.4	Peak areas given for replicates 2-5 of standard injections for assay determination of Sacubitril sodium are different than those mentioned in corresponding chromatograms (sample information).	
2.		The assay calculation formula as given in the analytical procedure by the drug product manufacturer is different than that given in analytical method validation protocol/data of the drug product manufacturer. Moreover, the assay calculation formula as mentioned in the analytical method of the drug substance manufacturer and that given in the analytical method of the drug product manufacture are not the same.	
3.	3.2.P.2.2.1	In the procedure for CDP, the time point for sample withdrawal mentioned as 45 minutes, while in dissolution parameters for CDP and raw data sheets, the time points mentioned as 10, 15, 20, 30, 45 and 60 minutes.	
4.	3.2.P.5.2	Wavelength mentioned as 267nm under chromatographic conditions, however, as per reference/innovator's product dissolution method/parameters, the detection wavelength (HPLC/UV) given as 255 nm.	
5.		The flow rate in analytical method of drug product given as 1ml/min however, in method validation protocol for the drug product the flow rate given as 0.8ml/min.	
6.		As per various documents such as CoA of APIs from substance manufacturer and drug product manufacturer, import invoice, AD (I & E) clearance certificate, product development data, trial batch manufacturing record and separate stability summary data sheets for Sacubitril sodium and Valsartan by the	

		drug substance manufacturer reflect that Sacubitril sodium and Valsartan used as separate materials, while the innovator product is designed as a combination of sacubitril and valsartan in a co-crystal, is a salt complex comprising LCZ696 (Sacubitril/Valsartan anionic moieties), sodium cations, and water molecules. Please justify how the applied formulation is in line with innovator's product.	
7.		Most recent GMP compliance inspection report conducted within last three years.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

909.	Name, address of Applicant / Marketing Authorization Holder	M/S Herbion Pakistan Pvt Ltd Islamabad.
	Name, address of Manufacturing site.	M/s Herbion Pakistan Pvt Ltd Industrial Triangle Kahuta road, Islamabad. (DML No. 000795)
	Status of the applicant	☒ Manufacturer l ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1307-R & I, Dated 14/01/2022
	Details of fee submitted	PKR 30,000/- vide online deposit slip No.718801025572 Dated 27/12/2021
	The proposed proprietary name / brand name	Estresto 200 mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Sacubitril ---------- 97 mg Valsartan ----------103 mg
	Pharmaceutical form of applied drug	Oblong shaped, light-pink colored, film coated tablet, break-line on one side, other side plain, no irregularity.
	Pharmacotherapeutic Group of (API)	Sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection frac
	Reference to Finished product specifications	As per Innovator's specifications
	Proposed Pack size	1* 14's (14's) 2*14's (28's)
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Entresto tablets 200 mg Novartis Pharmaceuticals (FDA Approved)

	For generic drugs (me-too status)	Savesto 97/103mg tablet of M/s Getz Parma, Karachi. Registration No.093112
	GMP status of the Finished product manufacturer	Most recent GMP inspection report conducted within last three years required.
	Name and address of API manufacturer.	**Sacubitril Sodium & Valsartan:** Zhejiang Tianyu Pharmaceutical Co., Ltd. Address No.15, Donghai 5th Avenue, Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone, Taizhou City, Zhejiang Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Sacubitril sodium:** Official monograph of sacubitril sodium does not exist so firm has followed in house specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity SCB-4-Imp-1, SCB-5-Imp-2, SCB-5-I Sodium (chiral isomer, SCB-5-II Sodium (chiral isomer SCB-5-III Sodium (chiral isomer) specifications, analytical procedures and its validation , batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance **Valsartan:** Official monograph of valsartan exists in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity Valsartan Related Compound A: Not more than (NMT) 1.0% Valsartan Related Compound B: Not more than (NMT) 0.2% Valsartan Related Compound C: Not more than (NMT) 0.1% Any other individual impurity: Not more than (NMT) 0.1% Total impurities: Not more than (NMT) 0.3%, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Sacubitril Sodium:** Stability study conditions (Zone IVb). Real time: 30˚C ± 2˚C / 75% ± 5%RH for 24 months 0, 3, 6, 9, 12, 18, 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months at 0, 1, 2, 3, 6 months

		Batches: (13700-181001, 13700 -181002, 13700-181003) **Valsartan:** Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months 0, 3, 6, 9, 12, 18, 24, 36 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (201207301, 201207302, 201207303)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Uperio 200mg tablet (Batch No. THU47) of Novartis Pharma (Pakistan), Karachi by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand in Acid media (pH 1.0-1.2), Acetate buffer (PH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	**Sacubitril Sodium:** Method validation studies including linearity, range, accuracy, precision, intermediate precision, repeatability, robustness, specificity, LOD and LOQ. **Valsartan:** Verification studies for valsartan including Linearity, range, accuracy, precision (repeatability) and specificity along with chromatograms and raw data sheets submitted.

STABILITY STUDY DATA			
Manufacturer of API	Zhejiang Tianyu Pharmaceutical Co., Ltd. China.		
API Lot No.	Sacubitril Sodium (222920-210103) & Valsartan (10252-210201)		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×14's) (2×14's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	EST-100-ST-001	EST-100-ST-002	EST-100-ST-003
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	07-2021	07-2021	07-2021
Date of Initiation	3-08-2021	3-08-2021	3-8-2021

No. of Batches		03
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	NA.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 201904044 issued by Zhejiang Medicine Center for Economic Development valid till 02/06/2022. Scope of inspection include (Sacubitril Sodium Valsartan).
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. TY121266 dated 19-03-2021 for import of 1.6kg Sacubitril Sodium and 1.7kg Valsartan USP from Zhejiang Tianyu Pharmaceutical Co., Ltd. Jiangkou Development Zone Huangyan Taizhou, Zhejiang, China, attested by AD (I & E), DRAP Islamabad.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:-(PEC-XVII)

Sr. No.	Section	Observation	Reply by the firm
1.	3.2.S.4.4	Peak areas given for replicates 2-5 of standard injections for assay determination of Sacubitril sodium are different than those mentioned in corresponding chromatograms (sample information).	
2.		The assay calculation formula as given in the analytical procedure by the drug product manufacturer is different than that given in analytical method validation protocol/data of the drug product manufacturer. Moreover, the assay calculation formula as mentioned in the analytical method of the drug substance manufacturer and that given in the analytical method of the drug product manufacture are not the same.	
3.		The run time for Valsartan USP given as 40 minutes in analytical method by the drug substance manufacturer, while the chromatograms for method verification data showed run time around 15-20 minutes. Moreover, retention time of valsartan in method verification chromatograms/data is about 5.5 minutes while the chromatograms for assay determination of valsartan (Batch No.10252-210201) has Retention time of 13.1 minutes.	

4.	3.2.P.2.2.1	In the procedure for CDP, the time point for sample withdrawal mentioned as 45 minutes, while in dissolution parameters for CDP and raw data sheets, the time points mentioned as 10, 15, 20, 30, 45 and 60 minutes.	
4.	3.2.P.5.2	Wavelength mentioned as 267nm under chromatographic conditions, however, as per reference/innovator's product dissolution method/parameters, the detection wavelength (HPLC/UV) given as 255 nm.	
5.		The flow rate in analytical method of drug product given as 1ml/min however, in method validation protocol for the drug product the flow rate given as 0.8ml/min.	
6.		As per various documents such as CoA of APIs from substance manufacturer and drug product manufacturer, import invoice, AD (I & E) clearance certificate, product development data, trial batch manufacturing record and separate stability summary data sheets for Sacubitril sodium and Valsartan by the drug substance manufacturer reflect that Sacubitril sodium and Valsartan used as separate materials, while the innovator product is designed as a combination of sacubitril and valsartan in a co-crystal, is a salt complex comprising LCZ696 (Sacubitril/Valsartan anionic moieties), sodium cations, and water molecules. Please justify how the applied formulation is in line with innovator's product.	
7.		Most recent GMP compliance inspection report conducted within last three years.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Case No. II Registration applications of locally manufactured (Human) drugs requiring stability studies data.

The following application was received vide letter No.F.1-6/2019-PR-I (EFD) dated 12th January, 2023 from Assistant Director (PR-I/EFD), PE & R, Division for evaluation on priority basis in pursuance of decision in 133rd meeting of DRAP Authority held on 13th April 2022, regarding export facilitation (Grant of registration on priority basis to the *pharmaceutical* i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year).

910.	Name and address of manufacturer / Applicant	M/s Werrick pharmaceuticals, plot No. 216-217, I-10/3, Industrial area, Islamabad.
	Brand Name +Dosage Form + Strength	Flueze Extra Day tablets
	Composition	Each film coated tablet contains: Acetaminophen·····500mg Phenylephrine hydrochloride·····5mg
	Diary No. Date of R& I & fee	Form-5, Dy. No. 17521; 09-10-2017; Rs. 20,000/- (09-10-2017) Dy. No. 34264 dated 28-11-2022, Differential Fee Rs: 10,000/- vide online deposit slip No.617672888 dated 23-11-2022.
	Pharmacological Group	Analgesic/ Decongestant

	Type of Form	Form 5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	10×10's); As per SRO
	Approval status of product in Reference Regulator Authorities	International reference has been verified as Demazin Cold + Flu Relief tablet of iNova Pharmaceuticals (Australia) Pty Ltd TGA; Australia Approved.
	Me-too status	Panadol CF Day Caplet (Paracetamol 500mg and Phenylephrine HCl 5mg of M/s GSK, Karachi 094797.
	GMP status	Most recent GMP compliance inspection report conducted within last three years required.
	Remarks of the Evaluator (PEC-XVII)	**Decision of 296th meeting of Registration Board:** *"Registration Board deferred the case for submission of stability study data as per the guidelines provided in 293rd meeting of Registration Board".*

STABILITY STUDY DATA

Manufacturer of API	(Paracetamol): Zenith Chemical Industries (Pvt.) Ltd. 16 Km off Ferozepur Road behind Wapda Grid Station, 1 Kilometer of Chandra Road, Lahore. (Phenylephrine Hydrochloride): Shenzhen Oriental Pharmaceutical Co., Ltd. No.43, Dakeng Road, Tongla village, Longgang District, Shenzhen, China.		
API Lot No.	Paracetamol: ZPAR17-337 Phenylephrine Hydrochloride: PEH-180101Y1		
Description of Pack (Container closure system)	Alu-PVC blister pack		
Stability Storage Condition	Real time: 30°C ± 2° C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6 (months)		
Batch No.	T # 01	T # 02	T # 03
Batch Size	1500 tablets	1500 tablets	1500 tablets
Manufacturing Date	02-2019	02-2019	02-2019
Date of Initiation	28-02-2019	04-03-2019	08-03-2019
No. of Batches	03		
Date of Submission	28-11-2022 (34264)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	The firm has referred to previous inspection for authenticity of stability data of their products conducted by the panel, on the basis of which Registration Board in its 294th meeting dated 04th April,2020, decided to approve registration of Xetine (Vortioxetine as hydrobromide) 10mg and Xetine 20mg tablet. Inspection date: 03-03-2020.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	1. Copies of COAs (ZPAR17-337) of API (Paracetamol) from M/s Zenith Chemical Industries (Pvt.) Ltd. 16 Km off Ferozepur

		Road behind Wapda Grid Station, 1 Kilometer of Chandra Road, Lahore and M/s Werrick pharmaceuticals, Islamabad are submitted. 2. Copies of COAs (PEH-180101Y1) of API (Phenylephrine HCl) from M/s Shenzhen Oriental Pharmaceutical Co., Ltd. No.43, Dakeng Road, Tongla village, Longgang District, Shenzhen, China and M/s Werrick pharmaceuticals, Islamabad are submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm. For Paracetamol as per BP monograph and for Phenylephrine as per USP monograph.
4.	Stability study data of API from API manufacturer	**Paracetamol:** Firm has submitted stability study data of API as per zone IV-A. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 48 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 6 months at intervals 0, 3, 6, 12, 18, 24, 30, 36, 42, 48 & 0, 1, 2, 3 & 6 months respectively. Batches:(P11-001, P11-002, P11-003) Phenylephrine hydrochloride: Firm has submitted stability study data of API as per zone IV-A. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 48 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 6 months at intervals 0, 3, 6, 9, 12, 18, 24, 36, 48 & 0, 1, 2, 3 & 6 months respectively. Batches:(PEH-160404, PEH-160405, PEH-160406)
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**For Paracetamol:** Firm has submitted copy of GMP certificate dated 24-09-2021 in the name of M/s Zenith Chemical Industries (Pvt.) Ltd. Moza Dondey, Jia Baga, Raiwind Road, Lahore issued by DRAP Lahore, on the basis of evaluation conducted on 14-07-2021. The certificate is valid for two years from the date of inspection. **For Phenylephrine hydrochloride:** The firm has submitted copy of Drug Manufacturing Certificate No.Y20160118 valid till 23-12-2025 of M/s Shenzhen Oriental Pharmaceutical Co., Ltd. No.43, Dakeng road, Tongle village, Longgang District Shenzhen, China.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	**For Paracetamol:** The firm has submitted copy of invoice No. 00023/1117 dated 13-11-2017 for purchase of Paracetamol 8000kgs (Batch No's. ZPAR17-333, ZPAR17-336 & ZPAR17-337 from M/s Zenith Pharmaceuticals, 16-Km Ferozepur Road, Lahore. **For Phenylephrine Hydrochloride:** The firm has submitted copy of invoice No. SZ-PH-1803040 dated 12-04-2018 from exporter M/s Shenzhen Oriental Pharmaceutical Co., Ltd. No.43, Dakeng road, Tongle village, Longgang District Shenzhen, China., for import of 0.5kg of

		Phenylephrine HCl USP (Batch No. PEH-180101Y1) in name of M/s Werrick Pharmaceuticals, Indusrial area, Islamabad attested by AD (I&E) DRAP Islamabad dated 28-05-2018.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	Not provided. However, the formulation is qualitatively similar to Demazin Cold + Flu relief tablet of iNova pharmaceuticals (Australia) Pvt. Ltd. (TGA approved)
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** T-01 / 1500 tablets / 02-2019 T-02 / 1500 tablets / 02-2019 T-03 / 1500 tablets / 02-2019
11.	Record of comparative dissolution data (where applicable)	Comparative dissolution studies performed against Panadol CF day caplet (Batch No. KU8B) of M/s GSK (Pakistan) Karachi in Acid media (0.1N HCl pH 1.0-1.2), Acetate buffer (PH 4.5) & Phosphate Buffer (pH 6.8) at 05, 15 & 30 minutes time points.
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

REMARKS OF EVALUATOR (**PEC**-XVII)

Deficiency/Observation	**Response by Pharma.**
In stability protocols, test parameters are mentioned for Werinta tablet 60mg.	Firm re-submit stability protocols and rectified the typo error.
Submit Raw data sheets/analysis reports of chromatograms for the comparative dissolution profile/studies, along with F2 value calculation. Also provide dissolution media preparations methods/procedures.	Firm submit raw data sheets/analysis reports for comparative dissolution data at pH 1.2, pH 4.5 and pH 6.8, along with calculation of f2 values for the same.
Justify the applied product finished drug product specifications comply innovator's product specifications (dissolution parameters, dissolution limits etc).	Firm submitted as follow: 1. The dissolution method of innovator/reference product is not available in any official pharmacopoeia or reference regulatory authority. The firm has established it dissolution method and parameters as per USP Chapter <1092> THE DISSOLUTION PROCEDURE. 2. The firm has established its pharmaceutical equivalence against Panadol CF Day Caplet, Batch No.

	KU8B, manufactured by GSK, Karachi. The determined f2 values are more than 50, which showed similarity between two profiles. The drug substances are found to be highly soluble in all physiological p H range i.e., it shows more than 85% release within 15 minutes in all three media. Furthermore, all the results observed during stability studies are within limits.
In the stability study summary data sheets for all the three trial batches, physical description of the drug product given as "film-coated tablet", while the applied formulation is "un-coated" tablet.	Firm re-submit stability study summary data sheets, with physical description as "compressed tablet" and terms it as typo error.
Submit most recent GMP compliance inspection report conducted within last three years.	Firm submitted GMP certificate issued on 22-08-2022, based on inspection and evaluation conducted on 12-08-2022.
Submit fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.	Firm submitted fee of Rs: 7500/- vide online deposit slip No.538489911 for pre-registration variations in application.

Decision: Approved with Innovator's specification.
Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.

Deferred cases:

Registration applications for local manufacturing of (Human) drugs submitted on Form 5: (Differential Fee cases)

911.	Name and address of manufacturer/ Applicant	M/s Dyson Research Laboratories (Pvt.) Ltd., 28-Km, Ferozepur Road, Lahore.
	Brand Name + Dosage Form + Strength	DICLOSTOL tablet (75mg/200mcg)
	Composition	Each modified-release tablet contains: Diclofenac Sodium…….75 mg Misoprostol…….200mcg
	Diary No. Date of R & I & fee	Dy. No. 230 dated 25-05-2011, Rs. 8,000/- dated 25-05-2011. Dy. No. dated 21-06-2016 Differential fee Rs. 12,000/- dated 21-06-2016 vide challan No. dated. "Duplicate dossier, R & I verified".
	Pharmacological Group	Anti-rheumatic, NSAID
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	2 × 10's, As per SRO
	Approval status of product in Reference Regulatory Authorities	(MHRA approved) Arthrotec 75 modified-release tablets (Each tablet consists of a gastro-resistant core containing 75 mg diclofenac sodium surrounded by an outer mantle containing 200 micrograms misoprostol).
	Me-too status	Dolact Tablet 75mg/200mcg of M/s Hiranis Pharmaceuticals, Karachi. Registration No. 103169
	GMP status	Updated GMP compliance status required
	Remarks of the Evaluator (PEC-XVII)	• As per master formulation submitted, the tablet consists of an enteric inner core of Diclofenac Sodium and a film-coated outer core of Misoprostol 1% dispersion. • Provide most recent/last GMP inspection report conducted within last 03 years.

		• Revise label claim as: Each delayed release tablet contains: Diclofenac Sodium (as gastro-resistant inner core) …...75mg Misoprostol 1% dispersion (as outer core) ……...200mcg • Provide evidence of double layer/core tablet (tablet within tablet) manufacturing facility. • For above revision, submit applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07-05-2021 & 13-07-2021.
	Decision of 323rd RB meeting:	• Deferred for: • Revision of label claim as per reference product as: Each delayed release tablet contains: Diclofenac Sodium (as gastro-resistant inner core) …...75mg Misoprostol 1% dispersion (as outer core) ……...200mcg • Confirmation of required manufacturing equipment i.e. tablet biayered machine for tablet within tablet manufacturing. • Most recent GMP audit report from QA & LT Division, valid within last three years. • Firm shall submit the fee of Rs. 30,000 for correction/pre-approval change in composition (correction/change of formulation), as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021. • Registration Board further decided to verify fee challans as per decision of 285th meeting.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised label as: Each delayed release tablet contains: Diclofenac Sodium (as gastro-resistant inner core) …...75mg Misoprostol 1% dispersion (as outer core) ……...200mcg • Firm submitted panel inspection report for renewal of DML conducted on 14-10-2015 & 03-11-2015 as evidence of availability of required manufacturing equipment i.e, tablet bilayered machine for tablet within tablet manufacturing. In the submitted report, installation of double core compression machine in tablet general section has been mentioned. However, the report is unsigned. • Firm submitted fee of Rs: 7500/- vide online deposit slip No.748905593 for label claim revision/change in composition. • The firm shall submit remaining fee of Rs: 22,500/- for change in composition/label claim as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021. • Firm shall submit most recent GMP audit report conducted within last three years.
Decision: Approved as per following label claim: **Each delayed release tablet contains:** **Diclofenac Sodium (as gastro-resistant inner core) …...75mg** **Misoprostol 1% dispersion (as outer core) ……...200mcg**		

Item No. 11: Agenda of Evaluator PEC-XIII (Mr. Shahid Nawaz)

a. Priority Registration applications of Imported Human Drugs on form 5F as per decision of 257th meeting of Registration Board.

Registration Board in its 257th meeting held on 24-25th March, 2016 deliberated that drugs for treatment of chronic ailments and drugs which are in short availability should have priority review process and consideration by the Board to ensure their free availability. The Board decided that drugs for treatment of cancer, viral diseases, thalassemia, immunosuppressant's, vaccine and sera, new molecules / formulations, blood factors and bags will be given priority consideration.
Following applications are placed before the Board for consideration in light of decision of 257th meeting of the registration Board.

912.	Name, address of Applicant / Importer	Biocare Pharmaceutica, 807-Shadman 1, Lahore-Pakistan.
	Details of Drug Sale License of importer	DSL NO. 05-352-0063-032069D. Address: M/s Biocare Pharmaceutica, 807-Shadman 1, District Lahore. Go-down address: 8-C, Street No.3, Near LGS School, Shah Jamal, District Lahore. Valid up to 17-04-2022.
	Name and address of marketing authorization holder (abroad)	Dexa Medica, Jalan Jenderal Bambang Utoyo No. 138,Palembang 30115, Indonesia.
	Name, address of manufacturer(s)	PT Ferron Par Pharmaceuticals, (Dexa Group) - Dexa Medica manufacturer Jababeka Industrial Estate I, Jl. Jababeka VI Blok J-3 Cikarang Bekasi 17520, INDONESIA.
	Name of exporting country	Indonesia.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Detail of certificates attached (CoPP, GMP certificate) **CoPP:** Legalized copy of CoPP (certificate No. RG.01.05.32.321.05.21.2865) dated 26-05-2021 issued by National Agency of Drug and Food Control, Indonesia is submitted. Certificate confirms that the product is actually on the market of the exporting country. Certificate has also mentioned the name of product license holder and manufacturer of the product. Name of the importing country mentioned on the certificate is Pakistan. **GMP:** Legalized copy of GMP certificate No. ST.03.05.33.0331.03.21.000513 dated 08-03-2021 issued by the Indonesian Food and Drug Authority is submitted. Certificate has mentioned that PT Ferron Par Pharmaceuticals, located at Jababeka Industrial Estate I, Jl. Jababeka VI Blok J-3 Cikarang Bekasi 17520, Indonesia manufactures pharmaceutical product under the establishment license No. FP.01.03/IV/0044-e/2020 issued in Jakarta on 26-06-2020 and manufacturing activities are subject to periodic inspections. The standards used for inspection is Indonesian GMP Code which is equivalent to PIC/S and WHO standards. Certificate has validity of 04-03-2023.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of supply and distribution agreement between PT Dexa Medica, Jalan Jenderal Bambang Utoyo No. 138, Palembang 30115, Indonesia (Product license holder) wherein the product license holder Dexa Medica grants an exclusive right to (Biocare

		Pharmaceutica) for market, sell, distribute the product in the territory using the trade mark including the rights to use the registration documents of the product provided by Dexa for the sole purpose of registering the products in the territory.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 2944: dated 31-01-2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 951976140721 dated 05-01-2022.
	The proposed proprietary name / brand name	Nicardex 10mg/10ml Solution for Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 10ml ampoule contains: Nicardipine hydrochloride …… 10mg.
	Pharmaceutical form of applied drug	Solution for Injection.
	Pharmacotherapeutic Group of (API)	Selective Calcium Channel Blockers with mainly Vascular effects. ATC Code: C08C
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	1's and box of 05 ampoules.
	Proposed unit price	PKR 508/ampoule and 2540/box of 05 ampoules.
	The status in reference regulatory authorities	Nicardipine 10 mg/10 ml solution for injection, Laboratoire Aguettant 1 rue Alexander Fleming 69007 LYON FRANCE, MHRA approved.
	For generic drugs (me-too status)	Could not be confirmed.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template.
	Name, address of drug substance manufacturer	Name: Lusochimica S.p.A. Address: Via Giotto, 9 - 23871 Lomagna (LC), Italy.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data regarding nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification studies, batch analysis (NIC2114, NIC1717 & NIC619) and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	• 48 months' real time stability data at 25°± 2°C / 60% RH ± 5% RH of 03 batches (2705, 2805 & 2905). • 06 month accelerated stability data 40°C ± 2°C / 70% RH ± 5% RH of 03 batches (2705, 2805 & 2905).
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacturer, batch formula, manufacturing process and process control, process validation protocols/report, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis (4210382, 5201583 & 5201584), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against Perdipine injection 10mg/10ml manufactured by Astellas Pharma Japan, Batch No. NY68Y011 by performing quality tests including identification, pH, Osmolarity, Particulate matter, Related substances, Assay, sterility, content of Sorbitol & bacterial endotoxin.
	Analytical method validation/verification of product	Submitted.
	Container closure system of the drug product	10ml type I amber glass ampoule.
	Stability study data of drug product, shelf life and storage conditions	• 36-months real time stability data at 30°C ± 2°C / 65% ± 5% RH of 03 batches (K-10290-01-F-PSC-1, K-10290-01-F-PSC-2 & K-10290-01-F-PSC-3). • 06-month accelerated stability data 40°C ± 2°C / 75% ± 5% RH of 03 batches (K-10290-01-F-PSC-1, K-10290-01-F-PSC-2 & K-10290-01-F-PSC-3).
	Therapeutic indications in MHRA.	Nicardipine 10 mg/10 ml solution for injection is indicated for the treatment of acute life-threatening hypertension, particularly in the event of: • Malignant arterial hypertension/Hypertensive encephalopathy. • Aortic dissection, when short acting beta-blocker therapy is not suitable, or in combination with a beta-blocker when beta-blockade alone is not effective. • Severe pre-eclampsia, when other intravenous antihypertensive agents are not recommended or are contra-indicated. • Nicardipine is also indicated for the treatment of post-operative hypertension

Evaluation by PEC:

Sr. No.	Section	Observations	Reply by the firm.
72.	1.1	Submitted fee is in the head of Biological drug division and for biological drug. Clarification shall be submitted.	
73.		Notarized supply and distribution agreement shall be submitted.	
74.	1.4.3	Valid copy of Drug Sale License of the applicant shall be submitted as the submitted DSL is valid up to 17-04-2022.	
75.	1.6.5	Valid copy of GMP certificate of Drug Substance shall be submitted.	

76.	3.2.S.4.1	Specifications of the drug substance by the drug substance manufacturer shall be submitted.	
77.	3.2.S.4.2	Analytical procedures used for the drug substance by the drug substance manufacturer shall be submitted.	
78.	3.2.S.4.4	• COA of the drug substance manufacturer has loss on drying of NMT 0.5% while the COA of the drug product manufacturer has Loss on drying limit of less than or equal to 1%. Justify. • COAs of the drug product manufacturer has assay test performed by the titration method while the analytical procedure has mentioned USP specification by HPLC method for assay test. Justify.	
79.	3.2.P.8	Accelerated stability data of batch No. K-10290-01-F-PSC-1 & K-10290-01-F-PSC-2 at six-month time point has total impurities out of specifications. Justification shall be submitted.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

913.	**Name, address of Applicant / Importer**	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi.
	Details of Drug Sale License of importer	**License No**: 521 **Address**: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi **Validity**: 16-06-2022 **Status**: License to sell Drugs by way of Wholesale.
	Name and address of marketing authorization holder (abroad)	Nano Daru Pajuhan Pardis Address: No. 4&8, Northern Tak Ave., Attar St., Vanak Sq., Tehran, Iran.
	Name, address of manufacturer(s)	**Nano Daru Pajuhan Pardis** Address: Behnood Pharmed Incubation Center, No. 110, Bahman St., Karafarinan Blvd., Sepehr Industrial Zone, Nazarabad City, Alborz Province, Iran.
	Name of exporting country	Iran
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. 665/68759) dated 28-02-2022 issued by the Division of Pharmaceutical and Narcotic Affairs of Ministry of Health Food and Drug Adm. MOH. Name and dosage form on the CoPP certificate mentioned is "Exopio 380mg (Naltrexone extended release powder and diluent for suspension for injection)" and name of the product license holder is Nano Daru Pajuhan Pardis, No. 4&8, Northern Tak Ave., Attar St., Vanak Sq., Tehran, Iran. The certificate also confirms that the applied formulation is actually on the market in the exporting country.

		The name of importing country on CoPP is mentioned in Annexures as Pakistan. Furthermore, the CoPP is valid till 28-02-2023. **GMP:** Applicant has submitted legalized copy of GMP certificate No. 665/60857 dated 19-01-2022 issued by Iran Food and Drug Administration the name of M/s Nano Daru Pajuhan Pardis, No. 4&8, Northern Tak Ave., Attar St., Vanak Sq., Tehran, Iran having its manufacturing site at Behnood Pharmed Incubation Center, No. 110, Bahman St., Karafarinan Blvd., Sepehr Industrial Zone, Nazarabad City, Alborz Province, Iran and the certificate confirms that Hazardous aseptic injectable vials of the firm is in compliance with the cGMP/GMP standards and relevant principals and regulation and complies with the Good Manufacturing Practices requirements of the PIC/S Guidelines.
	Details of letter of authorization / sole agency agreement	Firm has submitted original and legalized sole agency agreement. The agreement specifies that product license holder i.e. M/s Nano Daru Pajuhan Pardis, No. 4&8, Northern Tak Ave., Attar St., Vanak Sq., Tehran, Iran appoints M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi to import below mentioned product. The document also emphasized that M/s Martin Dow Limited is the sole authorized importer of the below mentioned products in Pakistan; *Exopio 380mg (Powder and diluent for suspension for injection) Naltrexone extended-release 380mg.*
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26860 dated 22-09-2022.
	Details of fee submitted	PKR 150,000/- vide slip No. 592742515 Dated: 31-12-2021
	The proposed proprietary name / brand name	EXOPIO 380 mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Each vial contains:** Naltrexone extended-release powder for suspension for injection ……..…380 mg **Each vial of Diluent contains:** Carboxy methylcellulose Sodium ……150mg Sodium Chloride……36mg Polysorbate……...……4mg Water for Injections……..…up to 4ml

	Pharmaceutical form of applied drug	Powder for suspension for injection.
	Pharmacotherapeutic Group of (API)	Drugs used in alcohol dependence.
	Reference to Finished product specifications	Innovator's Specifications.
	Proposed Pack size	1's.
	Proposed unit price	As per DPC.
	The status in reference regulatory authorities	VIVITROL (naltrexone for extended-release injectable suspension), USFDA Approved.
	For generic drugs (me-too status)	Not Available
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Temad Co. Active Pharmaceutical Ingredients Address: 28th km of Karaj Makhsous Road, Tehran, Iran.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, appearance, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches for drug substance at accelerated as well as real time conditions. The real time stability data is conducted at 30°C ± 2°C & 65% RH The stability study data is till 24 months and accelerated stability study data is conducted at 40°C ± 2°C & 75% ± 5% RH for six months. Batch No. NAB5058001, NAB5058002 & NAB5058003.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis (21002, 21003, 20003), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted Pharmaceutical Equivalence for the applied product against the reference product i.e. Vivitrol manufactured by Alkermes, Inc. by performing following tests; Appearance before preparation of suspension, Dispersion time, Appearance after preparation of

		suspension, pH, Osmolarity, Water content, Identification, Assay and In-vitro release.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Type – I clear colourless glass vial with lyophilized bromobutyl rubber stopper.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 4 batches of drug product. The real time stability study data is conducted at 5°C ±3° C for 24 months. Batch No. 19003 24 months, 20001 18 months, 20002 18 months & 20003 12 months.
	Therapeutic indications in USFDA.	VIVITROL contains naltrexone, an opioid antagonist, and is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration (1.1). • VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification (1.2). • VIVITROL should be part of a comprehensive management program that includes psychosocial support (1).

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
1.	**1.3.4**	Valid copy of Drug Sale License of the applicant shall be submitted.	Firm has submitted copy of DSL No. 565 dated 13-06-2022 in the name of M/s Martin Dow limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi valid till 16-06-2024.
2.	**1.6.5**	Valid copy of GMP certificate of drug substance manufacturer shall be submitted.	Firm has submitted copy of GMP certificate No. 665/18253 dated 17-05-2020 issued by Iran Food and Drug Administration in the name of Temad Co. Active Pharmaceutical Ingredients, 28th km of Karaj Makhsous Road, Tehran, Iran valid for three years.
3.	**1.5.5**	Pharmacotherapeutic Group of (API) shall be revised.	Firm has submitted that Pharmacotherapeutic group of Naltrexone is Narcotic/Opiate antagonist.
4.	**3.2.S.4.1**	Specification provided by the drug substance manufacturer has water content of NMT 2.0% while FPP has mentioned NMT 6.0%. Clarification shall be submitted.	Firm has submitted revised/corrected specification of the drug substance by providing a new COA for the drug substance from drug substance manufacturer. They also provided COA of the drug substance from both the drug substance and drug product manufacturer and both the COA's are having NMT 6% limit of water content.
5.	**3.2.S.4.3**	Analytical method verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Submitted.
6.	**3.2.S.5**	The submitted COA of the working standard used for analysis is of Naltrexone Hydrochloride. However, USP describes the reference standard for Naltrexone base (Cat. No. 1453504) only. Clarify.	Firm has submitted that same material was reported in section 3.2.S.5 as USP codes in drug substance and drug product. However, method of analysis which was reported in USP was for Naltrexone HCl. The method analysis of Naltrexone base was also the same. Because in the sample solution media & mobile phase, both forms become base form because of the pH conditions

7.	**3.2.P.2.2**	Justification of 12.9% of overage of naltrexone in the formulation shall be submitted.	Firm has submitted that Exopio has been prepared according to the data from originator product, Vivitrol, which applies 12.9% excess Naltrexone. Firm has also submitted a document confirming 12.9% of an excess quantity of naltrexone. ***However, the authenticity of the document could not be confirmed.*** ***Furthermore, the review of the reference product in USFDA has also not mentioned any overage of the active substance.***
8.	**3.2.P.8**	• Complete real time stability data of the product shall be submitted. • In use stability studies for the applied drug product shall be submitted. • Accelerated stability data for the applied drug product shall be submitted.	Firm has submitted complete real time stability data for all the three batches i.e. 20001, 20002 & 20003 for which initially 18 months and 12-month data was submitted. Firm has submitted that the drug product should be used immediately after reconstitution process, and it should not remain unused after reconstitution. Also, it was mentioned in the booklet and guide card too. Firm has referred to the ICH Topic Q1A (R2) wherein for drug products intended for storage in a refrigerator, accelerated stability condition is 25ºC ± 2º C / 60% ± 5% RH. Failure to meet the acceptance criteria for appearance, physical attributes, and functionality test (e.g. colour, phase separation, suspensibility, caking, hardness, dose delivery per actuation) If significant change occurs between 3 and 6 months' testing at the accelerated storage condition, the proposed re-test period should be based on the real time data available at the long term storage condition. If significant change occurs within the first 3 months' testing at the accelerated storage condition, a discussion should be provided to address the effect of short term excursions outside the label storage condition, e.g., during shipping or handling. Firm has further submitted that both Exopio and RLD samples had colour change and phenotype change after one in 25ºC ± 2º C / 60% ± 5% RH. The accelerated studies were stopped and the storage condition (2 ºC - 8 ºC) noted on vial packaging of drug product.

Decision: Deferred for submission of following;

- **Scientific justification of using 12.9% overage of drug substance i.e., Naltrexone in the applied formulation.**
- **Justification for use of Naltrexone Hydrochloride as working standard in the analysis while USP monograph recommends Naltrexone base as reference standard.**

914.	Name, address of Applicant / Importer	M/s Bayer Pakistan (Private) Limited, Plot No.23, Sector 22, Korangi Industrial Area, Karachi, Pakistan.
	Details of Drug Sale License of importer	License No: 01 Address: Plot No.23, Sector 22, Korangi Industrial Area, Karachi. Address of Godown: Plot No. l -D-22 & 1-D-23, Sector 30, Korangi Industrial Area, Karachi. Validity: 05-07-2022. Status: License to sell, stock & exhibit for sale, distribute and sell drugs by way of wholesale by of manufacturer, importer or indenter.

	Name and address of marketing authorization holder (abroad)	M/s Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany.
	Name, address of manufacturer(s)	M/s Bayer AG, Kaiser-Wilhelm-Allee 1, Wiesdorf, Leverkusen North Rhine-Westphalia, Germany.
	Name of exporting country	Germany.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized copy of CoPP certificate (No. 07/22/169217) dated 28-03-2022 issued by European Medicines Agency for Firialta 10mg (28 tablets) Tablet. The CoPP certificate confirms that the product is actually on the market in the exporting region. The CoPP certificate also confirms the GMP status of the manufacturing site through periodic inspection. **GMP:** Firm has also submitted copy of Eudra GMP certificate No. DE-NW-03-GMP-2022-0022 dated 02-05-2022 issued on the basis of inspection conducted on 23-01-2022. The certificate confirms that the manufacturer M/s Bayer AG, Kaiser-Wilhelm-Allee 1, Wiesdorf, Leverkusen North Rhine-Westphalia, Germany complies with the principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of Letter of Authorization (Sole Agency Declaration) from Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany dated 22-06-2022. The letter species that the marketing authorization / license holder abroad (Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany) authorize/appoints M/s Bayer Pakistan (Private) Limited as a sole importer of the Firialta 10 mg Tablets. The product license holder also M/s Bayer Pakistan (Private) Limited to be the marketing authorization holder and will be responsible for all matters pertaining to the registration and life cycle management of Firialta 10 mg Tablets.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 19385 dated 01-07-2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 0433295466 dated 18-05-2022.
	The proposed proprietary name / brand name	Firialta 10mg Tablet

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Finerenone ……..…. 10mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Nonsteroidal Mineralocorticoid Receptor (MR) Antagonist (C03D) Aldosterone Antagonists and other Potassium-Sparing Agents.
	Reference to Finished product specifications	Bayer's specification (Innovator).
	Proposed Pack size	14's and 28's.
	Proposed unit price	MRP will be submitted later.
	The status in reference regulatory authorities	Kerendia 10mg & 20mg tablets by Bayer Healthcare, USFDA Approved.
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Bayer AG, Friedrich-Ebert-Str. 217-333 42117 Wuppertal, Germany (Synthesis of Finerenone). & Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany (Micronization, Packaging & Quality control testing).
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis (UN80490, UN8048Z & UN8049R) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance for accelerated as well as real time conditions. The real time stability data is conducted at 30 ^{o}C / 75% RH while accelerated stability is conducted at 40 ^{o}C / 75% RH. The stability study data is till 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, batch formula, manufacturing process and process control, process validation, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability data.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equillance is not submitted by the applicant as it is an innovator product.

	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Foil 250 µm PVC with 40 g/m² PVDC colourless transparent (0107) sealed with Foil 20 µm Al sealable to PVC/PVDC (0201)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 6 batches. The accelerated stability study data is conducted at 40ºC / 75% RH for 6 months. The real time stability study data is conducted at 30ºC / 75% RH for 36 months. Batch No. BXHRUE1, 10704004, BXRHUE2, 10704004, BXRHUE3 & 10704006.
	Indications and Usage USFDA. MHRA/EMA. TGA.	Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. KERENDIA is indicated to delay progressive decline of kidney function in adults with chronic kidney disease associated with Type 2 diabetes (with albuminuria), in addition to standard of care.

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
1.	1.3.4	Valid copy of Drug Sale License shall be submitted.	Firm has submitted notarized copy of DSL No. 575 dated 12-09-2022 in the name of M/s Bayer Pakistan (Pvt.) Ltd., Plot No.23, Sector 22, Korangi Industrial Area, Karachi valid till 05-07-2024.
2.		Original/notarized agency agreement shall be submitted.	Firm has submitted notarized copy of the sole agency declaration.
3.	3.2.S.4.4	COAs of the drug substance by the drug product manufacturer shall be submitted.	Firm has submitted that the drug substance Finerenone is synthesized in house in Bayer's long time drug substance facility i.e. Bayer AG Wuppertal. As the manufacturing sites work under the same quality system and use one corporate IT system for quality data, in which the analytical results of active substances batches are uploaded for release, there are no COAs of the drug substance by the drug product manufacturer for commercial batches. Instead, the results are visible in the system and taken from the drug substance site. Bayer AG's drug product unit for finished goods i.e. the supply centre Leverkusen, as the drug product manufacturer performs identity test for the drug substance if micronized at other site of Bayer AG as it arrives from a different location in Germany per Truck, even as of the same legal entity. We confirm each batch of Finerenone drug substance is tested against the specifications and by analytical methods as presented in this

			Marketing Authorization Application, independently which site is performing he test.
4.	3.2.P.8.3	Shelf life specifications for assay test are 95% - 105% while in stability study data specifications for assay test are 93% - 105%. Clarification shall be submitted.	Firm has submitted that Firialta tablets were developed by Bayer more than 10 years agoand formulations made for clinical studies were put on stability. At that time, at that time shelf life specifications limit for assay were wide, to take into consideration the possibility that tablets, which could have been released close to the release limit (95% - 105%) might decompose slightly during the time of stability testing. A wider limit therefore is common for shelf life specifications in all projects and was submitted for clinical studies of Finerenone. Stability studies at 25ºC / 60% RH or 30 ºC / 75% RH have shown stability for 60-months real time. After that, for the planned marketing authorization, NDA stability studies were conducted. The studies used batches manufactured in 2017 already and the stability limits for the study were at this time 93% - 1055 as depicted in the stability reports. After submission in different countries prior to Pakistan, a few Health authorities requested for tightening of limits, because of excellent stability and low amounts of decomposition products found. Furthermore they have also provided reports of ongoing stability studies on commercial batches that confirm the updated limits of shelf life specifications i.e. for assay test 95% - 105%.

Decision: Approved as per policy of inspection of manufacturer abroad.

915.	Name, address of Applicant / Importer	M/s Bayer Pakistan (Private) Limited, Plot No.23, Sector 22, Korangi Industrial Area, Karachi, Pakistan.
	Details of Drug Sale License of importer	License No: 01 Address: Plot No.23, Sector 22, Korangi Industrial Area, Karachi. Address of Godown: Plot No. l -D-22 & 1-D-23, Sector 30, Korangi Industrial Area, Karachi. Validity: 05-07-2022. Status: License to sell, stock & exhibit for sale, distribute and sell drugs by way of wholesale by of manufacturer, importer or indenter.
	Name and address of marketing authorization holder (abroad)	M/s Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany.
	Name, address of manufacturer(s)	M/s Bayer AG, Kaiser-Wilhelm-Allee 1, Wiesdorf, Leverkusen North Rhine-Westphalia, Germany.
	Name of exporting country	Germany.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized copy of CoPP certificate (No. 07/22/169222) dated 28-03-2022 issued by European Medicines Agency for Firialta 10mg (28 tablets). The CoPP certificate confirms that the product is actually on the market in the exporting region. The CoPP certificate also confirms the GMP status of the manufacturing site through periodic inspection. **GMP:**

		Firm has also submitted copy of Eudra GMP certificate No. DE-NW-03-GMP-2022-0022 dated 02-05-2022 issued on the basis of inspection conducted on 23-01-2022. The certificate confirms that the manufacturer M/s Bayer AG, Kaiser-Wilhelm-Allee 1, Wiesdorf, Leverkusen North Rhine-Westphalia, Germany complies with the principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of Letter of Authorization (Sole Agency Declaration) from Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany dated 22-06-2022. The letter species that the marketing authorization / license holder abroad (Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany) authorize/appoints M/s Bayer Pakistan (Private) Limited as a sole importer of the Firialta 20 mg Tablets. The product license holder also M/s Bayer Pakistan (Private) Limited to be the marketing authorization holder and will be responsible for all matters pertaining to the registration and life cycle management of Firialta 10 mg Tablets.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 19356 dated 01-07-2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 6032727502 dated 18-05-2022.
	The proposed proprietary name / brand name	Firialta 20mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Finerenone ……..…. 20mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Nonsteroidal Mineralocorticoid Receptor (MR) Antagonist (C03D) Aldosterone Antagonists and other Potassium-Sparing Agents.
	Reference to Finished product specifications	Bayer's specification (Innovator).
	Proposed Pack size	14's and 28's.
	Proposed unit price	MRP will be submitted later.

	The status in reference regulatory authorities	Kerendia 10mg & 20mg tablets by Bayer Healthcare, USFDA Approved.
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Bayer AG, Friedrich-Ebert-Str. 217-333 42117 Wuppertal, Germany. & Bayer AG, Kaiser-Wilhelm-Allee 51368 Leverkusen, Germany.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis (UN80490, UN8048Z & UN8049R) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance for accelerated as well as real time conditions. The real time stability data is conducted at 30 ^{o}C / 75% RH while accelerated stability is conducted at 40 ^{o}C / 75% RH. The stability study data is till 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, batch formula, manufacturing process and process control, process validation, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability data.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equillance is not submitted by the applicant as it is an innovator product.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Foil 250 µm PVC with 40 g/m² PVDC colourless transparent (0107) sealed with Foil 20 µm Al sealable to PVC/PVDC (0201)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 6 batches. The accelerated stability study data is conducted at 40^{o}C / 75% 6 months. The real time stability study data is conducted at 30^{o}C / 75% RH for 36 months. Batch No. BXHRUG1, 10704007, BXRHUG2, 10704008, BXRHUG3 & 10704009.
	Indications and Usage USFDA.	Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for

		heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
	MHRA/EMA.	Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
	TGA.	KERENDIA is indicated to delay progressive decline of kidney function in adults with chronic kidney disease associated with Type 2 diabetes (with albuminuria), in addition to standard of care.

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
1.	1.3.4	Valid copy of Drug Sale License shall be submitted.	Firm has submitted notarized copy of DSL No. 575 dated 12-09-2022 in the name of M/s Bayer Pakistan (Pvt.) Ltd., Plot No.23, Sector 22, Korangi Industrial Area, Karachi valid till 05-07-2024.
2.		Original/notarized agency agreement shall be submitted.	Firm has submitted notarized copy of the sole agency declaration.
3.	3.2.S.4.4	COAs of the drug substance by the drug product manufacturer shall be submitted.	Firm has submitted that the drug substance Finerenone is synthesized in house in Bayer's long time drug substance facility i.e. Bayer AG Wuppertal. As the manufacturing sites work under the same quality system and use one corporate IT system for quality data, in which the analytical results of active substances batches are uploaded for release, there are no COAs of the drug substance by the drug product manufacturer for commercial batches. Instead, the results are visible in the system and taken from the drug substance site. Bayer AG's drug product unit for finished goods i.e. the supply centre Leverkusen, as the drug product manufacturer performs identity test for the drug substance if micronized at other site of Bayer AG as it arrives from a different location in Germany per Truck, even as of the same legal entity. We confirm each batch of Finerenone drug substance is tested against the specifications and by analytical methods as presented in this Marketing Authorization Application, independently which site is performing he test.
4.	3.2.P.8.3	Shelf life specifications for assay test are 95% - 105% while in stability study data specifications for assay test are 93% - 105%. Clarification shall be submitted.	Firm has submitted that Firialta tablets were developed by Bayer more than 10 years agoand formulations made for clinical studies were put on stability. At that time, at that time shelf life specifications limit for assay were wide, to take into consideration the possibility that tablets, which could have been released close to the release limit (95% - 105%) might decompose slightly during the time of stability testing. A wider limit therefore is common for shelf life specifications in all projects and was submitted for clinical studies of Finerenone. Stability studies at 25ºC / 60% RH or 30 ºC / 75% RH have shown stability for 60-months real time. After that, for the planned marketing authorization, NDA stability studies were conducted. The studies used batches

			manufactured in 2017 already and the stability limits for the study were at this time 93% - 1055 as depicted in the stability reports. After submission in different countries prior to Pakistan, a few Health authorities requested for tightening of limits, because of excellent stability and low amounts of decomposition products found. Furthermore they have also provided reports of ongoing stability studies on commercial batches that confirm the updated limits of shelf life specifications i.e. for assay test 95% - 105%.

Decision: Approved as per policy of inspection of manufacturer abroad.

916.	Name, address of Applicant / Importer	M/s Pfizer Pakistan Limited, B-2, S.I.T.E. Karachi.
	Details of Drug Sale License of importer	License No: 030. Address: M/s Pfizer Pakistan Limited, B-2, S.I.T.E. Karachi. Address of Godown: (a) 12-Dockyard Road, West Wharf, Karachi. (b) C-II-D S.I.T.E. Karachi. Validity: 25-02-2023. Status: Drug License by way of Wholesale.
	Name and address of marketing authorization holder (abroad)	M/s Hospira UK Limited, Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom
	Name, address of manufacturer(s)	M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.
	Name of exporting country	United Kingdom.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted legalized & Notarized copy of CoPP certificate (No. PP10170759) dated 17-03-2021 issued by MHRA. Name of the product mentioned for Pakistan is Oxaliplatin 50mg/10ml Concentrate for Solution for Infusion. Certificate has mentioned M/s Hospira UK Limited, Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom as product License/marketing authorization holder with product license No. PL 04515/0215. Status of the product License/marketing authorization is "C" which means not involved in manufacturing, packaging or labelling the dosage form but is responsible for the quality and release of the product. Certificate has also mentioned the name of the manufacturer as M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India. **GMP:** Applicant has submitted copy of GMP certificate No. 2062066 dated 06-06-2020 issued by Food & Drug Control Administration, Gandhinagar, Gujrat State of India in the name of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, N.H. No. 8A Sarkhej-Bavla Road, Matoda, Tal- Sanand, District Ahmadabad, Gujrat, India having

		manufacturing License No. G/28/1267. The certificate is issued on the basis of inspection conducted on 03-04/10/2019 & 06/02/2020 and is valid till 05/06/2023.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization from M/s Hospira UK Limited having its principal place of business at Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom wherein Hospira UK Limited authorizes M/s Pfizer Pakistan Limited, located at B-2, S.I.T.E. Karachi to be the marketing authorization holder in Pakistan for Oxaliplatin Hospira 50mg/10ml & 100mg/20ml concentrate for solution for infusion and be responsible for all matters pertaining to the regulation of this product in Pakistan. Authorization letter also confirms that these products are manufactured and released by Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10393 dated 23-04-2022.
	Details of fee submitted	PKR 150,000/- vide slip No. 60745999 Dated: 07-06-2021.
	The proposed proprietary name / brand name	Oxaliplatin 50mg/10ml, Concentrate for Solution for Infusion.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 10ml contains; Oxaliplatin ……. 50mg (5mg/ml)
	Pharmaceutical form of applied drug	Concentrate for Solution for Infusion.
	Pharmacotherapeutic Group of (API)	Antineoplastic Agents (L01)
	Reference to Finished product specifications	Not submitted.
	Proposed Pack size	1’s.
	Proposed unit price	No information provided.
	The status in reference regulatory authorities	Eloxatin (Oxaliplatin 50mg/10ml (5mg/ml) USFDA Approved.
	For generic drugs (me-too status)	Oxitan 50/10ml, Reg. No. 110554, Atco pharma.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has also summarized information related to the drug substance and drug product both.

	Name, address of drug substance manufacturer	Heraeus Deutschland GmbH & Co. Address: Heraeusstr. 12-14. 63450 Hanau, Germany. UMICORE Argentina S.A. Address: 14 Street, Building # 229 - B1629MXA Pilar Industrial Park, Buenos Aires Province, Argentina.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, appearance, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of more than 03 batches for drug substance at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC & 60% ± 05% RH. The stability study data is till 60 months and accelerated stability study data is conducted at 40ºC ± 2ºC & 75% ± 5% RH for six months. **Heraeus Deutschland GmbH & Co.** Batch No. 10902, 11002 & 11102. **UMICORE Argentina S.A.** Batch No. OX12011, OX12012 & OX12013.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, batch formula, pharmaceutical development, manufacturer, manufacturing process and process control, process validation report, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis (OX11202, OX11203, OX11605, OX21202), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Type – I clear glass vial, with elastomeric closure, and aluminum seal with plastic flip-off top.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches of drug product. Accelerated stability study data is conducted at 40ºC ±2ºC & 75% ± 5% RH for 06 months. The real time stability study data is conducted at 30ºC ±2ºC & 75% ± 5% RH for 24 months. Batch No. OX11202, OX11203 & OX11605.

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
1.		• Original, legalized copy of GMP certificate of the manufacturer shall be submitted. • Original/notarized authorization letter shall be submitted.	Firm has once again submitted coloured copy of GMP certificate. ***Legalized and notarized GMP certificate shall be submitted.*** Firm has submitted notarized letter of authorization.

2.	1.4.1.1	Authorization letter has mentioned the territory of Pakistan only, while in module one section 1.4.1.1 has mentioned domestic and export sales. Clarification shall be submitted.	Firm has submitted revised Form 5F wherein they have made change in section 1.4.1.1 from **domestic and export sales** to **domestic sales.** ***Fee required for pre-registration variation is not submitted.***
3.	1.5.6	Finished product specification for the finished product shall be mentioned.	***No specification is submitted for the finished drug product by the applicant.***
4.	3.2.S.4.1	Specification of the drug substance by the drug product manufacturer shall be submitted.	Firm has submitted two tables of specifications for both the drug substance manufacturers and stated that each lot of Oxaliplatin is tested and must meet the specifications listed in the provided table.
5.	3.2.S.4.2	Analytical method for drug substance by the finished product manufacturer shall be submitted.	Submitted.
6.	3.2.S.4.3	Analytical method verification studies for the drug substance performed by the drug product manufacturer shall be submitted.	Firm has provided validation report completed at Mulgrave, Victoria, Australia (Mulgrave) site. They further submitted that they have provided the method transfer report demonstrating successful transfer of the determination of Identification and Assay by HPLC, Impurity B, Impurity E, Impurity C, Unspecified Impurities, residual solvents (for Heraeus API only) and silver contents of Oxaliplatin method from the Mulgrave to Zydus Hospira Oncology Private Limited (ZHOPL) manufacturing sites.
7.	3.2.P.2.2	The comparison of the developed formulation with innovator product with applied strength including the results of all the quality tests (pharmaceutical equivalence) shall be submitted and discussed.	Firm has submitted pharmaceutical equivalence of their product against the innovator product i.e Sanofi Synthelabo's Eloxatin™ Injection marketed in UK, Germany and Sweden for Appearance of Solution, pH, Assay and Related substance. Results provided has shown that Mayne Pharma's Oxaliplatin Injection and the competitor product, Sanofi Synthelabo's Eloxatin™ Injection marketed in UK(50mg/10mL;100mg/20mL), Germany (50mg/10mL; 100mg/20mL) and Sweden (50mg/10mL) were similar with respect to Appearance of solution, pH, potency and related substances. Therefore, Mayne Pharma's Oxaliplatin Injection is considered equivalent to Sanofi Synthelabo's Eloxatin™ Injection marketed in UK, Germany and Sweden. ***Pharmaceutical equivalence provided by the applicant is Mayne Pharma Limited Australia instead of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.***
8.	3.2.P.5.1	This section has mentioned In-house specifications for the Assay test of the drug product while official monograph is available in USP. Justify.	Firm has submitted that the specifications and acceptance criteria for Oxaliplatin Injection 5 mg/mL comply with the USP monograph for Oxaliplatin Injection requirements. The compendial analytical procedures have been verified suitable for their intended use and comply with compendia. Assay and Related Substances tests are performed according to validated in-house analytical procedures. Validation reports are provided in dossier section 3.2.P.5.3. Justification of specifications is provided in dossier section 3.2.P.5.6.

9.	3.2.P.5.3	Submitted Validation of analytical procedure is by Hospira Australia since the drug product manufacturer responsible for manufacture & quality control of drug product is in India. Clarification is required.	Firm has submitted that Validation of the in-house analytical procedures was performed by the Hospira Australia development site. As the product was subsequently transferred for commercial manufacture to the ZHOPL facility located in India, the method transfer study from Hospira Australia to ZHOPL was completed demonstrating the ability of the receiving site to perform testing. They also refer to Report QCC-008-TMR-005 submitted previously.

Decision: Deferred for following;

- **Valid, legalized and original GMP certificate of the finished product manufacturer shall be submitted.**
- **Justification shall be submitted for providing pharmaceutical equivalence of the product from M/s Mayne Pharma Limited Australia instead of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.**
- **Current regulatory status with respect to the market authorization and manufacturing sites for the applied formulation of both the firms i.e. M/s Mayne Pharma Limited Australia and M/s Hospira Australia shall be submitted from where the Pharmaceutical equivalence and Validation of analytical procedures are provided respectively.**

917.	Name, address of Applicant / Importer	M/s Pfizer Pakistan Limited, B-2, S.I.T.E. Karachi.
	Details of Drug Sale License of importer	**License No**: 030. **Address**: M/s Pfizer Pakistan Limited, B-2, S.I.T.E. Karachi. Address of Godown: (a) 12-Dockyard Road, West Wharf, Karachi. (b) C-II-D S.I.T.E. Karachi. **Validity**: 25-02-2023. **Status**: Drug License by way of Wholesale.
	Name and address of marketing authorization holder (abroad)	M/s Hospira UK Limited, Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom
	Name, address of manufacturer(s)	M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.
	Name of exporting country	United Kingdom.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted legalized & Notarized copy of CoPP certificate (No. PP10170758) dated 17-03-2021 issued by MHRA. Name of the product mentioned for Pakistan is Oxaliplatin 100mg/20ml Concentrate for Solution for Infusion. Certificate has mentioned M/s Hospira UK Limited, Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom as product License/marketing authorization holder with product license No. PL 04515/0215. Status of the product License/marketing authorization is "C" which means not involved in manufacturing, packaging or labelling the dosage form but is responsible for the quality and release of the product. Certificate has also mentioned the name of the manufacturer as M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone,

		Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India. **GMP:** Applicant has submitted copy of GMP certificate No. 2062066 dated 06-06-2020 issued by Food & Drug Control Administration, Gandhinagar, Gujrat State of India in the name of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, N.H. No. 8A Sarkhej-Bavla Road, Matoda, Tal- Sanand, District Ahmadabad, Gujrat, India having manufacturing License No. G/28/1267. The certificate is issued on the basis of inspection conducted on 03-04/10/2019 & 06/02/2020 and is valid till 05/06/2023.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization from M/s Hospira UK Limited having its principal place of business at Horizon, Honey Lane Hurley Maidenhead SL6 6RJ United Kingdom wherein Hospira UK Limited authorizes M/s Pfizer Pakistan Limited, located at B-2, S.I.T.E. Karachi to be the marketing authorization holder in Pakistan for Oxaliplatin Hospira 50mg/10ml & 100mg/20ml concentrate for solution for infusion and be responsible for all matters pertaining to the regulation of this product in Pakistan. Authorization letter also confirms that these products are manufactured and released by Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10394 dated 23-04-2022.
	Details of fee submitted	PKR 150,000/- vide slip No. 52026247959 Dated: 07-06-2021.
	The proposed proprietary name / brand name	Oxaliplatin 100mg/20ml, Concentrate for Solution for Infusion.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 20ml contains; Oxaliplatin ……. 100mg (5mg/ml)
	Pharmaceutical form of applied drug	Concentrate for Solution for Infusion.
	Pharmacotherapeutic Group of (API)	Antineoplastic Agents (L01)
	Reference to Finished product specifications	Not submitted.

	Proposed Pack size	1's.
	Proposed unit price	No information provided.
	The status in reference regulatory authorities	Eloxatin (Oxaliplatin 100mg/20ml (5mg/ml) USFDA Approved.
	For generic drugs (me-too status)	Oxitan 100/20ml, Reg. No. 110555, Atco pharma.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has also summarized information related to the drug substance and drug product both.
	Name, address of drug substance manufacturer	**Heraeus Deutschland GmbH & Co.** Address: Heraeusstr. 12-14. 63450 Hanau, Germany. **UMICORE Argentina S.A.** Address: 14 Street, Building # 229 - B1629MXA Pilar Industrial Park, Buenos Aires Province, Argentina.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, appearance, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of more than 03 batches for drug substance at accelerated as well as real time conditions. The real time stability data is conducted at 25ºC ± 2ºC & 60% ± 05% RH. The stability study data is till 60 months and accelerated stability study data is conducted at 40ºC ± 2ºC & 75% ± 5% RH for six months. **Heraeus Deutschland GmbH & Co.** Batch No. 10902, 11002 & 11102. **UMICORE Argentina S.A.** Batch No. OX12011, OX12012 & OX12013.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, batch formula, pharmaceutical development, manufacturer, manufacturing process and process control, process validation report, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis (OX21202, OX21203, OX21605), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Type – I clear glass vial, with elastomeric closure, and aluminum seal with plastic flip-off top.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches of drug product. Accelerated stability study data is conducted at 40ºC ±2ºC & 75% ± 5% RH for 06 months.

		The real time stability study data is conducted at 30ºC ±2º C & 75% ± 5% RH for 24 months. Batch No. OX21202, OX21203 & OX21605.

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
1.		• Original, legalized copy of GMP certificate of the manufacturer shall be submitted. • Original/notarized authorization letter shall be submitted.	Firm has once again submitted coloured copy of GMP certificate. ***Legalized and notarized GMP certificate shall be submitted.*** Firm has submitted notarized letter of authorization.
2.	1.4.1.1	Authorization letter has mentioned the territory of Pakistan only, while in module one section 1.4.1.1 has mentioned domestic and export sales. Clarification shall be submitted.	Firm has submitted revised Form 5F wherein they have made change in section 1.4.1.1 from **domestic and export sales** to **domestic sales.** ***Fee required for pre-registration variation is not submitted.***
3.	1.5.6	Finished product specification for the finished product shall be mentioned.	***No specification is submitted for the finished drug product by the applicant.***
4.	3.2.S.4.1	Specification of the drug substance by the drug product manufacturer shall be submitted.	Firm has submitted two tables of specifications for both the drug substance manufacturers and stated that each lot of Oxaliplatin is tested and must meet the specifications listed in the provided table.
5.	3.2.S.4.2	Analytical method for drug substance by the finished product manufacturer shall be submitted.	Submitted.
6.	3.2.S.4.3	Analytical method verification studies for the drug substance performed by the drug product manufacturer shall be submitted.	Firm has provided validation report completed at Mulgrave, Victoria, Australia (Mulgrave) site. They further submitted that they have provided the method transfer report demonstrating successful transfer of the determination of Identification and Assay by HPLC, Impurity B, Impurity E, Impurity C, Unspecified Impurities, residual solvents (for Heraeus API only) and silver contents of Oxaliplatin method from the Mulgrave to Zydus Hospira Oncology Private Limited (ZHOPL) manufacturing sites.
7.	3.2.P.2.2	The comparison of the developed formulation with innovator product with applied strength including the results of all the quality tests (pharmaceutical equivalence) shall be submitted and discussed.	Firm has submitted pharmaceutical equivalence of their product against the innovator product i.e Sanofi Synthelabo's Eloxatin™ Injection marketed in UK, Germany and Sweden for Appearance of Solution, pH, Assay and Results provided has shown that Mayne Pharma's Oxaliplatin Injection and the competitor product, Sanofi Synthelabo's Eloxatin™ Injection marketed in UK(50mg/10mL;100mg/20mL), Germany (50mg/10mL; 100mg/20mL) and Sweden (50mg/10mL) were similar with respect to Appearance of solution, pH, potency and related substances. Therefore, Mayne Pharma's Oxaliplatin Injection is considered equivalent to Sanofi Synthelabo's Eloxatin™ Injection marketed in UK, Germany and Sweden. ***Pharmaceutical equivalence provided by the applicant is Mayne Pharma Limited Australia instead of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.***
8.	3.2.P.5.1	This section has mentioned In-house specifications for the Assay test of the drug product while official monograph is available in USP. Justify.	Firm has submitted that the specifications and acceptance criteria for Oxaliplatin Injection 5 mg/mL comply with the USP monograph for Oxaliplatin Injection requirements. The

			compendial analytical procedures have been verified suitable for their intended use and comply with compendia. Assay and Related Substances tests are performed according to validated in-house analytical procedures. Validation reports are provided in dossier section 3.2.P.5.3. Justification of specifications is provided in dossier section 3.2.P.5.6.
9.	3.2.P.5.3	Submitted Validation of analytical procedure is by Hospira Australia since the drug product manufacturer responsible for manufacture & quality control of drug product is in India. Clarification is required.	Firm has submitted that Validation of the in-house analytical procedures was performed by the Hospira Australia development site. As the product was subsequently transferred for commercial manufacture to the ZHOPL facility located in India, the method transfer study from Hospira Australia to ZHOPL was completed demonstrating the ability of the receiving site to perform testing. They also refer to Report QCC-008-TMR-005 submitted previously.

Decision: Deferred for following;

- **Valid, legalized and original GMP certificate of the finished product manufacturer shall be submitted.**
- **Justification shall be submitted for providing pharmaceutical equivalence of the product from M/s Mayne Pharma Limited Australia instead of M/s Zydus Hospira Oncology Pvt., Ltd., Plot No. 3, Pharmez-Special Economic Zone, Sarkhej Bavla Highway, N.H. No. 8A Matoda, Taluka Sanand, District Ahmadabad, Gujrat, India.**
- **Current regulatory status with respect to the market authorization and manufacturing sites for the applied formulation of both the firms i.e. M/s Mayne Pharma Limited Australia and M/s Hospira Australia shall be submitted from where the Pharmaceutical equivalence and Validation of analytical procedures are provided respectively.**

918.	Name, address of Applicant / Importer	M/s Merixil Pharma, Office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan.
	Details of Drug Sale License of importer	License No: DSL-445-ICT/2013 Address: Office 28, 2nd Floor, Rose-I Plaza, Plot No. 13, I-8 Markaz, Islamabad. Address of Godown: Nil Validity: 02-02-2022. Status: License to sell drugs by way of wholesale/distribution.
	Name and address of marketing authorization holder (abroad)	M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada.
	Name, address of manufacturer(s)	M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada.
	Name of exporting country	Canada.
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** (Copy and without notarization). Firm has submitted copy of CoPP certificate (No. 78588) dated 23-11-2021 issued by Health Canada for Docetaxel 20mg/ml with brand name in Pakistan as Biodoce 20mg/ml. The CoPP confirms that the product is licensed to be placed on the market for use in the exporting country as well as is actually on the market in the exporting country. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO. The name of importing country on CoPP is mentioned as Pakistan. Certificate is valid till 22-11-2022. **GMP:** (Copy and without notarization).

		Firm has submitted copy of GMP certificate (No. 78589) in the name of M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada dated 23-11-2021 issued by Health Canada valid till 22-11-2022. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO.
	Details of letter of authorization / sole agency agreement	Letter of Authorization: (Copy and without notarization). Firm has submitted copy of product specific letter of Authorization dated 16-03-2022 from M/s Biolyse Pharma with principal place of business 59 Welland Vale Rd., St. Catharine's, Ontario, Canada wherein the owner of M/s Biolyse Pharma (Brighitte Kiecken) authorizes M/s Merixil Pharma with its principal place of business at office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan to be the regulatory representative, importer & master distributor and get registration of below mentioned products in Pakistan manufactured by Biolyse Pharma; a. Biodoce 20mg injection. b. Biodoce 80mg injection. c. Biodoce 160mg injection.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10574: 27-04-2022.
	Details of fee submitted	PKR 150,000/- vide slip No. 51067609966 dated 07-03-2022.
	The proposed proprietary name / brand name	Biodoce injection 20mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contain; Docetaxel 20 mg / ml
	Pharmaceutical form of applied drug	Concentrate for injection for the infusion in vial.
	Pharmacotherapeutic Group of (API)	Antineoplastic Agents. ATC code: L01CD02.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	Pack of one injection.
	Proposed unit price	As per current pricing policy of DRAP.
	The status in reference regulatory authorities	TAXOTERE (docetaxel) injection 20mg/ml, USFDA Approved.
	For generic drugs (me-too status)	Taxotere 80mg, Sanofi Aventis, Reg. No. 066089.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Fresenius Kabi Oncology Limited, D-35, Industrial Area, Kalyani, District Nadia, West Bengal India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data including nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 02 batches of API at accelerated for 06 months, real time conditions for 24 months and intermediate studies for 12 months. The real time stability data is conducted at 25^{o}C ± 2^{o}C, RH 60% ± 5%, accelerated stability data is conducted at 40^{o}C ± 2^{o}C, RH 75% ± 5% and intermediate at 30^{o}C ± 2^{o}C, RH 65% ± 5%. (Batch No. 896EPU001, 896EPU002) and (897EPU002, 897EPU003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, Packing, pharmaceutical development, manufacture, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has not submitted pharmaceutical equivalence with the innovator product by comparing the results of all the quality tests. However, they have provided blood bioavailability comparison of Docetaxel of Biolyse 20mg/ml (12J7D10) with innovator product Texotere 20mg of Sanofi Aventis (D9A429). Biolyse Docetaxel gave an AUC ratio of 103.17% when compared to Taxotere AUC.
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	5ml type I tubular clear glass vial with Teflon coated grey bromobutyl rubber closures having Aluminium flip off over seal.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40^{o}C ±2^{o}C / 75% ± 5% RH for 6 months (Batch No. 17C01D, 17C02D & 19F10D/1). The real time stability study data is conducted at 30^{o}C ±2^{o}C / 75% ± 5% RH for 24 months (Batch No. 17C01D, 17C02D & 19F10D/1).

Evaluation by PEC:

Sr. No.	Observations	Reply by the firm
1	• Original, Valid and legalized CoPP certificate shall be submitted. • Original, Valid and legalized GMP certificate of the finished product manufacturer shall be submitted. • Notarized copy of the Authorization letter shall be submitted.	**<u>CoPP:</u>** Firm has submitted legalized and notarized CoPP certificate (No. 78588) dated 23-11-2021 issued by Health Canada for Docetaxel 20mg/ml with brand name in Pakistan as Biodoce 20mg/80mg & 160mg. The CoPP confirms that the product is licensed to be placed on the market for use in the exporting country as well as is actually on the market in the exporting country. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO. The name of importing country on CoPP is mentioned as Pakistan. Certificate is valid till 22-11-2022. ***Certificate is not valid as validity is till 22-11-2022.*** **GMP:** Firm has submitted legalized and notarized GMP certificate (No. 78589) in the name of M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada dated 23-11-2021 issued by Health Canada valid till 22-11-2022. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO. ***Certificate is not valid as validity is till 22-11-2022.*** Firm has submitted legalized and notarized product specific letter of Authorization dated 01-12-2021 from M/s Biolyse Pharma with principal place of business 59 Welland Vale Rd., St. Catharine's, Ontario, Canada wherein the owner of M/s Biolyse Pharma (Brighitte Kiecken) authorizes M/s Merixil Pharma with its principal place of business at office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan to be the regulatory representative, importer & master distributor and get registration of below mentioned products in Pakistan manufactured by Biolyse Pharma; a. Biodoce 20mg injection. b. Biodoce 80mg injection. c. Biodoce 160mg injection.
2	• Valid copy of Drug Sale License of the applicant shall be submitted.	Firm has submitted copy of DSL No. 445-ICT/2013 in the name of M/s Merixil Pharma, Office 28, 2nd Floor, Rose-I Plaza, Plot No.13, I-8 Markaz, Islamabad valid till 02-02-2024.
3	• Valid copy of GMP certificate of the drug substance manufacturer shall be submitted.	Firm has submitted copy of GMP certificate No. DCWB/Sch M/Certificate/2019/1935 dated 22-02-2019 issued by Directorate of Drugs Control, Government of West Bengal in the name of Fresenius Kabi Oncology Limited, D-35, Industrial Area, Kalyani, District Nadia, India valid till 05-02-2022. ***Certificate is not valid as validity is till 05-02-2022.***
4	• Table for literature references has only mentioned USP pharmacopoeia for both the drug substance and drug product while no other information is provided. Clarification shall be submitted.	Firm has submitted revised table for literature references with submission of 7500/- fee vide slip No. 665408473829 dated 03-01-2023.
5	• Analytical methods for the drug substance by the drug product manufacturer shall be submitted.	Submitted.
6	• Batch analysis i.e. COAs of the drug substance by the drug product manufacturer shall be submitted.	Firm has COA of the drug substance from finished product manufacturer.

7	• Analytical method verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Submitted.
8	• The comparison of the developed formulation with innovator product with applied strength including the results of all the quality tests (pharmaceutical equivalence) shall be submitted and discussed.	Firm has submitted Pharmaceutical equivalence of Biolyse Docetaxel for injection 20mg/ml with lot No. 14MA21DT013 & 14MA21DT014 against innovator product i.e. Taxotere having Lot No. D2C966 by performing quality test including Appearance, Assay, Impurities, pH, Density, Surface tension, Osmolarity, Particulate matter & Sterility. Specifications of both the applied and reference product are within the limit.

Decision: Approved as per policy of inspection of manufacturer abroad.
Firm shall submit following before issuance of registration letter:

- **Valid legalized and original COPP certificate**
- **Valid copy of GMP certificate of the drug substance manufacturer.**

919.	Name, address of Applicant / Importer	M/s Merixil Pharma, Office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan.
	Details of Drug Sale License of importer	License No: DSL-445-ICT/2013 Address: Office 28, 2nd Floor, Rose-I Plaza, Plot No. 13, I-8 Markaz, Islamabad. Address of Godown: Nil Validity: 02-02-2022. Status: License to sell drugs by way of wholesale/distribution.
	Name and address of marketing authorization holder (abroad)	M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada.
	Name, address of manufacturer(s)	M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada.
	Name of exporting country	Canada.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** (Copy and without notarization). Firm has submitted copy of CoPP certificate (No. 78588) dated 23-11-2021 issued by Health Canada for Docetaxel 20mg/ml with brand name in Pakistan as Biodoce 20mg/ml. The CoPP confirms that the product is licensed to be placed on the market for use in the exporting country as well as is actually on the market in the exporting country. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO. The name of importing country on CoPP is mentioned as Pakistan. Certificate is valid till 22-11-2022. **GMP:** (Copy and without notarization). Firm has submitted copy of CoPP certificate (No. 78589) in the name of M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada dated 23-11-2021 issued by Health Canada valid till 22-11-2022. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO.
	Details of letter of authorization / sole agency agreement	**Letter of Authorization:** (Copy and without notarization). Firm has submitted copy of product specific letter of Authorization dated 16-03-2022 from M/s Biolyse Pharma with principal place of business 59 Welland

		Vale Rd., St. Catharine's, Ontario, Canada wherein the owner of M/s Biolyse Pharma (Brighitte Kiecken) authorizes M/s Merixil Pharma with its principal place of business at office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan to be the regulatory representative, importer & master distributor and get registration of below mentioned products in Pakistan manufactured by Biolyse Pharma; d. Biodoce 20mg injection. e. Biodoce 80mg injection. f. Biodoce 160mg injection.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 10575: 27-04-2022.
	Details of fee submitted	PKR 150,000/- vide slip No. 959902462468 dated 07-03-2022.
	The proposed proprietary name / brand name	Biodoce injection 80mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contain; Docetaxel 80 mg / ml
	Pharmaceutical form of applied drug	Concentrate for injection for the infusion in vial.
	Pharmacotherapeutic Group of (API)	Antineoplastic Agents. ATC code: L01CD02.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	Pack of one injection.
	Proposed unit price	As per current pricing policy of DRAP.
	The status in reference regulatory authorities	TAXOTERE (docetaxel) injection 80mg/4ml, USFDA Approved.
	For generic drugs (me-too status)	Taxotere 80mg, Sanofi Aventis, Reg. No. 066090.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Fresenius Kabi Oncology Limited, D-35, Industrial Area, Kalyani, District Nadia, West Bengal India.

	Module-III Drug Substance:	Firm has submitted detailed drug substance data including nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 02 batches of API at accelerated for 06 months, real time conditions for 24 months and intermediate studies for 12 months. The real time stability data is conducted at 25°C ± 2°C, RH 60% ± 5%, accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% and intermediate at 30°C ± 2°C, RH 65% ± 5%. (Batch No. 896EPU001, 896EPU002) and (897EPU002, 897EPU003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, Packing, pharmaceutical development, manufacture, manufacturing process and process control, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has not submitted pharmaceutical equivalence with the innovator product by comparing the results of all the quality tests. However, they have provided blood bioavailability comparison of Docetaxel of Biolyse 20mg/ml (12J7D10) with innovator product Texotere 20mg of Sanofi Aventis (D9A429). Biolyse Docetaxel gave an AUC ratio of 103.17% when compared to Taxotere AUC.
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	5ml type I tubular clear glass vial with Teflon coated grey bromobutyl rubber closures having Aluminium flip off over seal.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40°C ±2°C / 75% ± 5% RH for 6 months (Batch No. 17C01E, 17C02E & 19F10E/1). The real time stability study data is conducted at 30°C ±2°C / 75% ± 5% RH for 24 months (Batch No. 17C01D, 17C02D & 19F10D/1).

Evaluation by PEC:

Sr. No.	Observations	Reply by the firm
1	• Original, Valid and legalized CoPP certificate shall be submitted.	**CoPP:** Firm has submitted legalized and notarized CoPP certificate (No. 78588) dated 23-11-2021 issued by Health Canada for Docetaxel 20mg/ml with brand name in Pakistan as Biodoce 20mg/80mg & 160mg. The CoPP confirms that the product is licensed to be placed on the market for use in the exporting

		country as well as is actually on the market in the exporting country. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO. The name of importing country on CoPP is mentioned as Pakistan. Certificate is valid till 22-11-2022. ***Certificate is not valid as validity is till 22-11-2022.***
	• Original, Valid and legalized GMP certificate of the finished product manufacturer shall be submitted.	**GMP:** Firm has submitted legalized and notarized GMP certificate (No. 78589) in the name of M/s Biolyse Pharma Corporation 59 Welland Vale Rd., St. Catharine's, Ontario, Canada dated 23-11-2021 issued by Health Canada valid till 22-11-2022. Certificate also mentioned that facilities and operations conforms to GMP as recommended by WHO.
	• Notarized copy of the Authorization letter shall be submitted.	***Certificate is not valid as validity is till 22-11-2022.*** Firm has submitted legalized and notarized product specific letter of Authorization dated 01-12-2021 from M/s Biolyse Pharma with principal place of business 59 Welland Vale Rd., St. Catharine's, Ontario, Canada wherein the owner of M/s Biolyse Pharma (Brighitte Kiecken) authorizes M/s Merixil Pharma with its principal place of business at office 28, 2nd Floor, Rose Plaza, I-8 Markaz, Islamabad Pakistan to be the regulatory representative, importer & master distributor and get registration of below mentioned products in Pakistan manufactured by Biolyse Pharma; a. Biodoce 20mg injection. b. Biodoce 80mg injection. c. Biodoce 160mg injection.
2	Valid copy of Drug Sale License of the applicant shall be submitted.	Firm has submitted copy of DSL No. 445-ICT/2013 in the name of M/s Merixil Pharma, Office 28, 2nd Floor, Rose-I Plaza, Plot No.13, I-8 Markaz, Islamabad valid till 02-02-2024.
3	Valid copy of GMP certificate of the drug substance manufacturer shall be submitted.	Firm has submitted copy of GMP certificate No. DCWB/Sch M/Certificate/2019/1935 dated 22-02-2019 issued by Directorate of Drugs Control, Government of West Bengal in the name of Fresenius Kabi Oncology Limited, D-35, Industrial Area, Kalyani, District Nadia, India valid till 05-02-2022. ***Certificate is not valid as validity is till 05-02-2022.***
4	Section 1.5.2 has mentioned 80mg/ml strength. Correction of the label claim with requisite fee is required.	Firm has submitted new form 5F wherein they have corrected section 1.5.2 with submission of 150000/- fee vide slip No. 874698204 dated 18-01-2023. ***They have changed the strength /concentration of drug of active pharmaceutical ingredient (API) per unit from;*** ***Each Vial contain; Docetaxel 80 mg / ml*** ***To*** ***Each Vial contain; Docetaxel 80 mg / 4ml Full fee is submitted.***
5	Table for literature references has only mentioned USP pharmacopoeia for both the drug substance and	Firm has submitted revised table for literature references.

	drug product while no other information is provided. Clarification shall be submitted.	
6	Analytical methods for the drug substance by the drug product manufacturer shall be submitted.	Submitted.
7	Batch analysis i.e. COAs of the drug substance by the drug product manufacturer shall be submitted.	Firm has COA of the drug substance from finished product manufacturer.
8	Analytical method verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Submitted.
9	The comparison of the developed formulation with innovator product with applied strength including the results of all the quality tests (pharmaceutical equivalence) shall be submitted and discussed.	Firm has submitted Pharmaceutical equivalence of Biolyse Docetaxel for injection 20mg/ml (80mg/4ml) with lot No. 17C01E & 17C02E against innovator product i.e. Taxotere having Lot No. D3A208 by performing quality test including Appearance, Assay, Impurities, pH, Density, Surface tension, Osmolarity, Particulate matter & Sterility. Specifications of both the applied and reference product are within the limit.

Decision: Approved as per policy of inspection of manufacturer abroad.
Firm shall submit following before issuance of registration letter:

- **Valid legalized and original COPP certificate**
- **Valid copy of GMP certificate of the drug substance manufacturer.**

b. Priority Registration applications of locally manufactured Human Drugs on form 5F as per decision of 257th meeting of Registration Board.

920.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Name, address of Manufacturing site.	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24210 dated 26/08/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 8407333782 dated: 15/08/2022.
	The proposed proprietary name / brand name	Caripz 1.5mg capsules.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Cariprazine HCL eq.to Cariprazine……1.5mg.
	Pharmaceutical form of applied drug	White coloured powder filled in blue colour capsule & white colour body of Hard Gelatin capsule size # 03.
	Pharmacotherapeutic Group of (API)	Anti-Convulsant. Antipsychotics. ATC code N05A
	Reference to Finished product specifications	Innovator Specification
	Proposed Pack size	7's, 30's, 90's & 100's.
	Proposed unit price	As per SRO.

	The status in reference regulatory authorities	VRAYLAR (Cariprazine as HCl) Capsule 1.5mg, 3mg, 4.5mg & 6mg by Actavis Pharma, USFDA approved.
	For generic drugs (me-too status)	Not available.
	GMP status of the Finished product manufacturer	GMP certificate No. 46/2021-DRAP (K) dated 07-10-2021 issued on the basis of inspection conducted on 15-06-2021 is submitted.
	Evidence of approval of manufacturing facility.	Capsule (general section) approved vide letter No. F.2-12/93-Lic(Vol-V) dated 20-09-2021.
	Name and address of API manufacturer.	**Name and address of the DMF holder:** M/s Biophore India Pharmaceuticals Private Limited. Plot No. 92, Kavuri Hills, Phase II, Jubilee Hills, Hyderabad-500033, Telangana, INDIA. **Name and address of the manufacturing site:** M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detail of the drug substance regarding its nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis (2052/PDL001/3/001/21) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance)	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5% RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5% RH for 6 months. Batches:(2052/3/001/19, 2052/3/002/19 & 2052/3/003/19)
	Module-III (Drug Product):	The firm has submitted detail of the drug product regarding its description, composition, manufacturer, pharmaceutical development, manufacturing process and controls, process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the reference product that is Vraylar Capsule 1.5mg (Batch no: 1152230) manufactured by Forest Laboratories, Ireland Limited by performing quality tests (Identification, Disintegration Time, Assay, Dissolution)

		CDP is also performed against the same brand that is Vraylar Capsule 1.5mg **(**Batch no: 1152230) manufactured by Forest Laboratories, Ireland Limited in three different mediums i.e. 0.1N HCl, Acetate Buffer (pH 4.5) & Buffer 6.8. Both 0.1N HCl and acetate buffer shows more than 85% release within 15 minutes and F2 is not calculated while the Phosphate buffer has F2 value in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including Validation protocol, Validation report, Justification of system suitability, Specificity, Linearity, Accuracy, Precision Repeatability, Intermediate Precision, Robustness.

STABILITY STUDY DATA			
Manufacturer of API	M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.		
API Lot No.	6242 **(2052/PDL001/3/001/21)**		
Description of Pack (Container closure system)	Alu/Alu blister (2 x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C /65%± 5%RH Accelerated: 40˚C ± 2˚C / 75%± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3 & 6 (Months)		
Batch No.	21SB(B)-225-01	21SB(B)-226-02	21SB(B)-227-03
Batch Size	1500 capsules	1500 capsules	1500 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	18-11-2021	18-11-2021	18-11-2021
No. of Batches	03		

Administrative Portion		
7.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
8.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate dated 22-03-2022 issued by Drugs Control Administration Government of Andhra Pradesh in the name of M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India on the basis of inspection conducted on 30-12-2021 & 31-12-2021. The certificate is valid for three years from the date of issue and is meant for export of drugs only.
9.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.
10.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

11.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted
12.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.5	Revise pharmacological group for the applied formulation as per WHO ATC with submission of applicable fee.	Firm has initially submitted Anti Convulsant as pharmacological group. However, they have revised it to Anti-psychotic. ***Fee required for pre-registration variation is not submitted.***
2.	1.6.5	This section has mentioned Biophore India Pharmaceuticals Private Limited as drug substance manufacturer while module 2 has mentioned Sonic Pharmaceuticals Pvt. Ltd., as drug substance manufacturer. Clarification shall be submitted.	Firm has submitted that it was typographic error. M/s Sonic pharmaceuticals is manufacturer while Biophore India Pharmaceuticals Private Limited is supplier.
3.	3.2.S.4.1	Specifications of the drug substance by the drug substance manufacturer shall be submitted.	Firm has submitted specifications for the drug substance as well as the analytical procedures from drug substance manufacturer.
4.	3.2.S.4.3	Method verification studies of drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted method verification studies for the drug substance including Specificity, linearity and accuracy. ***However, the date on the submitted chromatograms is January, 2023.***
5.	3.2.S.4.4	Specifications for the drug substance provided by the drug product manufacturer has assay limits (ODB) of 98.5% - 101% while submitted COA of the drug product manufacturer has assay limit (ODB) of 98% - 102%. Clarification shall be submitted.	Firm has submitted revised specification for the drug substance wherein they have changed assay limits for Cariprazine from 98.5% - 101% to 98% - 102%. ***However, fee required for pre-registration variation is not submitted.***
6.	3.2.S.7.3	Chloride content and residue on ignition tests are not performed in the stability studies of the drug substance. Clarify.	Firm has submitted that Chloride content and residue on ignition tests are not stability indicating test parameters. Hence, these tests are not conducted in stability.
7.	3.2.P.1.1	Applied formulation has SLS & Syloid 244FP while the reference product has no SLS& Syloid 244FP in the formulation. Justification shall be submitted.	Firm has submitted that in Cariprazine capsule range, the drug substance particle size distribution is non-micronized. The Cariprazine belongs to BCS II (Low solubility and high permeability). In order to improve the solubility and dissolution of Cariprazine, Sodium Lauryl Sulphate (SLS) used in the formulation. Secondly, in order to improve the flowability as well as bioavailability, Syloid 244FP was incorporated in the formulation. Firm further submitted that Cariprazine capsules were kept on stability and no changes observed in chemical and physical parameters throughout the shelf life. Stability studies demonstrated the compatibility of the formulation excipients Sodium Lauryl Sulphate (SLS) & Syloid 244FP with Cariprazine drug substance. Because stability studies is one of the technique for drug-excipients compatibility studies.
8.	3.2.P.2.2	Content uniformity test is not performed in the PE. Justification shall be submitted.	Firm has submitted results for pharmaceutical equivalence wherein they have included content uniformity test.
9.	3.2.P.5.4	Batch analysis of all the three trial batches shall be submitted.	Firm has submitted COA's for all the three trial batches.

10.	3.2.P.8	• Justification shall be submitted for not performing Content uniformity test in the stability summary sheets. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted. • Documents for the procurement of API with approval from DRAP shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted revised stability summary sheets wherein they have added content uniformity test. Firm has submitted that this point is not applicable. Firm has submitted copy of commercial invoice No. BP/CI/21-22/07E dated 23-07-2021 mentioning 160gm quantity of Cariprazine HCl, B# 2052/PDL001/3/001/21 attested by Assistant Director, I&E, DRAP, Karachi dated 13-08-2021. Submitted.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

921.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Name, address of Manufacturing site.	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24211 dated 26/08/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 032680069 dated: 15/08/2022.
	The proposed proprietary name / brand name	Caripz 3mg capsules.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Cariprazine HCL eq.to Cariprazine……3mg.
	Pharmaceutical form of applied drug	White coloured powder filled in blue colour capsule & white colour body of Hard Gelatin capsule size # 03.
	Pharmacotherapeutic Group of (API)	Anti-Convulsant. Antipsychotics. ATC code N05A
	Reference to Finished product specifications	Innovator Specification.
	Proposed Pack size	7's, 30's, 90's & 100's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	VRAYLAR (Cariprazine as HCl) Capsule 1.5mg, 3mg, 4.5mg & 6mg by Actavis Pharma, USFDA approved.

	For generic drugs (me-too status)	Not available.
	GMP status of the Finished product manufacturer	GMP certificate No. 46/2021-DRAP (K) dated 07-10-2021 issued on the basis of inspection conducted on 15-06-2021 is submitted.
	Evidence of approval of manufacturing facility.	Capsule (general section) approved vide letter No. F.2-12/93-Lic(Vol-V) dated 20-09-2021.
	Name and address of API manufacturer.	**Name and address of the DMF holder:** M/s Biophore India Pharmaceuticals Private Limited. Plot No. 92, Kavuri Hills, Phase II, Jubilee Hills, Hyderabad-500033, Telangana, INDIA. **Name and address of the manufacturing site:** M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detail of the drug substance regarding its nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis (2052/PDL001/3/001/21) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance)	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5% RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5% RH for 6 months. Batches:(2052/3/001/19, 2052/3/002/19 & 2052/3/003/19)
	Module-III (Drug Product):	The firm has submitted detail of the drug product regarding its description, composition, manufacturer, pharmaceutical development, manufacturing process and controls, process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the reference product that is Vraylar Capsule 3mg (Batch no: 1154342) manufactured by Forest Laboratories, Ireland Limited by performing quality tests (Identification, Disintegration Time, Assay, Dissolution) CDP is also performed against the same brand that is Vraylar Capsule 1.5mg **(**Batch no: 1154342) manufactured by Forest Laboratories, Ireland Limited in three different mediums i.e. 0.1N HCl, Acetate Buffer

		(pH 4.5) & Buffer 6.8. Both 0.1N HCl and acetate buffer shows more than 85% release within 15 minutes and F2 is not calculated while the Phosphate buffer has F2 value in the acceptable range.		
	Analytical method validation/verification of product	Method validation studies have submitted including Validation protocol, Validation report, Justification of system suitability, Specificity, Linearity, Accuracy, Precision Repeatability, Intermediate Precision, Robustness.		
STABILITY STUDY DATA				
Manufacturer of API		M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.		
API Lot No.		6242 **(2052/PDL001/3/001/21)**		
Description of Pack (Container closure system)		Alu/Alu blister		
Stability Storage Condition		Real time: 30°C ± 2°C /65%± 5%RH Accelerated: 40°C ± 2°C / 75%± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3 & 6 (Months)		
Batch No.		21SB(B)-228-01	21SB(B)-229-02	21SB(B)-230-03
Batch Size		1500 capsules	1500 capsules	1500 capsules
Manufacturing Date		10-2021	10-2021	10-2021
Date of Initiation		18-11-2021	18-11-2021	18-11-2021
No. of Batches		03		
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate dated 22-03-2022 issued by Drugs Control Administration Government of Andhra Pradesh in the name of M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India on the basis of inspection conducted on 30-12-2021 & 31-12-2021. The certificate is valid for three years from the date of issue and is meant for export of drugs only.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted		

6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.5	Revise pharmacological group for the applied formulation as per WHO ATC with submission of applicable fee.	Firm has initially submitted Anti Convulsant as pharmacological group. However, they have revised it to Anti-psychotic. ***Fee required for pre-registration variation is not submitted.***
2.	1.6.5	This section has mentioned Biophore India Pharmaceuticals Private Limited as drug substance manufacturer while module 2 has mentioned Sonic Pharmaceuticals Pvt. Ltd., as drug substance manufacturer. Clarification shall be submitted.	Firm has submitted that it was typographic error. M/s Sonic pharmaceuticals is manufacturer while Biophore India Pharmaceuticals Private Limited is supplier.
3.	3.2.S.4.1	Specifications of the drug substance by the drug substance manufacturer shall be submitted.	Firm has submitted specifications for the drug substance as well as the analytical procedures from drug substance manufacturer.
4.	3.2.S.4.3	Method verification studies of drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted method verification studies for the drug substance including Specificity, linearity and accuracy. ***However, the date on the submitted chromatograms is January, 2023.***
5.	3.2.S.4.4	Specifications for the drug substance provided by the drug product manufacturer has assay limits (ODB) of 98.5% - 101% while submitted COA of the drug product manufacturer has assay limit (ODB) of 98% - 102%. Clarification shall be submitted.	Firm has submitted revised specification for the drug substance wherein they have changed assay limits for Cariprazine from 98.5% - 101% to 98% - 102%. ***However, fee required for pre-registration variation is not submitted.***
6.	3.2.S.7.3	Chloride content and residue on ignition tests are not performed in the stability studies of the drug substance. Clarify.	Firm has submitted that Chloride content and residue on ignition tests are not stability indicating test parameters. Hence, these tests are not conducted in stability.
7.	3.2.P.1.1	Applied formulation has SLS & Syloid 244FP while the reference product has no SLS& Syloid 244FP in the formulation. Justification shall be submitted.	Firm has submitted that in Cariprazine capsule range, the drug substance particle size distribution is non-micronized. The Cariprazine belongs to BCS II (Low solubility and high permeability). In order to improve the solubility and dissolution of Cariprazine, Sodium Lauryl Sulphate (SLS) used in the formulation. Secondly, in order to improve the flowability as well as bioavailability, Syloid 244FP was incorporated in the formulation. Firm further submitted that Cariprazine capsules were kept on stability and no changes observed in chemical and physical parameters throughout the shelf life. Stability studies demonstrated the compatibility of the formulation excipients Sodium Lauryl Sulphate (SLS) & Syloid 244FP with Cariprazine drug substance. Because stability studies is one of the technique for drug-excipients compatibility studies.
8.	3.2.P.2.2	Content uniformity test is not performed in the PE. Justification shall be submitted.	Firm has submitted results for pharmaceutical equivalence wherein they have included content uniformity test.
9.	3.2.P.5.4	Batch analysis of all the three trial batches shall be submitted.	Firm has submitted COA's for all the three trial batches.
10.	3.2.P.8	• Justification shall be submitted for not performing Content uniformity test in the stability summary sheets.	Firm has submitted revised stability summary sheets wherein they have added content uniformity test. Firm has submitted that this point is not applicable.

		• Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted. • Documents for the procurement of API with approval from DRAP shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted copy of commercial invoice No. BP/CI/21-22/07E dated 23-07-2021 mentioning 160gm quantity of Cariprazine HCl, B# 2052/PDL001/3/001/21 attested by Assistant Director, I&E, DRAP, Karachi dated 13-08-2021. Submitted.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

922.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Name, address of Manufacturing site.	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24212 dated 26/08/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 976761657 dated: 15/08/2022.
	The proposed proprietary name / brand name	Caripz 4.5mg capsules.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Cariprazine HCL eq.to Cariprazine……4.5mg.
	Pharmaceutical form of applied drug	White coloured powder filled in blue colour capsule & white colour body of Hard Gelatin capsule size # 03.
	Pharmacotherapeutic Group of (API)	Anti-Convulsant. Antipsychotics. ATC code N05A
	Reference to Finished product specifications	Innovator Specification.
	Proposed Pack size	7's, 30's, 90's & 100's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	VRAYLAR (Cariprazine as HCl) Capsule 1.5mg, 3mg, 4.5mg & 6mg by Actavis Pharma, USFDA approved.
	For generic drugs (me-too status)	Not available.

	GMP status of the Finished product manufacturer	GMP certificate No. 46/2021-DRAP (K) dated 07-10-2021 issued on the basis of inspection conducted on 15-06-2021 is submitted.
	Evidence of approval of manufacturing facility.	Capsule (general section) approved vide letter No. F.2-12/93-Lic(Vol-V) dated 20-09-2021.
	Name and address of API manufacturer.	**Name and address of the DMF holder:** M/s Biophore India Pharmaceuticals Private Limited. Plot No. 92, Kavuri Hills, Phase II, Jubilee Hills, Hyderabad-500033, Telangana, INDIA. **Name and address of the manufacturing site:** M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detail of the drug substance regarding its nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis (2052/PDL001/3/001/21) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5% RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5% RH for 6 months. Batches:(2052/3/001/19, 2052/3/002/19 & 2052/3/003/19)
	Module-III (Drug Product):	The firm has submitted detail of the drug product regarding its description, composition, manufacturer, pharmaceutical development, manufacturing process and controls, process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the reference product that is Vraylar Capsule 4.5mg (Batch no: 1157421) manufactured by Forest Laboratories, Ireland Limited by performing quality tests (Identification, Disintegration Time, Assay, Dissolution) CDP is also performed against the same brand that is Vraylar Capsule 1.5mg **(**Batch no: 1157421) manufactured by Forest Laboratories, Ireland Limited in three different mediums i.e. 0.1N HCl, Acetate Buffer (pH 4.5) & Buffer 6.8. Both 0.1N HCl and acetate buffer

		shows more than 85% release within 15 minutes and F2 is not calculated while the Phosphate buffer has F2 value in the acceptable range.		
	Analytical method validation/verification of product	Method validation studies have submitted including Validation protocol, Validation report, Justification of system suitability, Specificity, Linearity, Accuracy, Precision Repeatability, Intermediate Precision, Robustness.		
STABILITY STUDY DATA				
Manufacturer of API		M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.		
API Lot No.		6242 **(2052/PDL001/3/001/21)**		
Description of Pack (Container closure system)		Alu/Alu blister		
Stability Storage Condition		Real time: 30˚C ± 2˚C /65%± 5%RH Accelerated: 40˚C ± 2˚C / 75%± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3 & 6 (Months)		
Batch No.		21SB(B)-231-01	21SB(B)-232-02	21SB(B)-233-03
Batch Size		1500 capsules	1500 capsules	1500 capsules
Manufacturing Date		10-2021	10-2021	10-2021
Date of Initiation		24-11-2021	24-11-2021	24-11-2021
No. of Batches		03		
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate dated 22-03-2022 issued by Drugs Control Administration Government of Andhra Pradesh in the name of M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India on the basis of inspection conducted on 30-12-2021 & 31-12-2021. The certificate is valid for three years from the date of issue and is meant for export of drugs only.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted		
6.	Record of Digital data logger for temperature and humidity monitoring of	Submitted		

	stability chambers (real time and accelerated)	

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.5	Revise pharmacological group for the applied formulation as per WHO ATC with submission of applicable fee.	Firm has initially submitted Anti Convulsant as pharmacological group. However, they have revised it to Anti-psychotic. ***Fee required for pre-registration variation is not submitted.***
2.	1.6.5	This section has mentioned Biophore India Pharmaceuticals Private Limited as drug substance manufacturer while module 2 has mentioned Sonic Pharmaceuticals Pvt. Ltd., as drug substance manufacturer. Clarification shall be submitted.	Firm has submitted that it was typographic error. M/s Sonic pharmaceuticals is manufacturer while Biophore India Pharmaceuticals Private Limited is supplier.
3.	3.2.S.4.1	Specifications of the drug substance by the drug substance manufacturer shall be submitted.	Firm has submitted specifications for the drug substance as well as the analytical procedures from drug substance manufacturer.
4.	3.2.S.4.3	Method verification studies of drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted method verification studies for the drug substance including Specificity, linearity and accuracy. ***However, the date on the submitted chromatograms is January, 2023.***
5.	3.2.S.4.4	Specifications for the drug substance provided by the drug product manufacturer has assay limits (ODB) of 98.5% - 101% while submitted COA of the drug product manufacturer has assay limit (ODB) of 98% - 102%. Clarification shall be submitted.	Firm has submitted revised specification for the drug substance wherein they have changed assay limits for Cariprazine from 98.5% - 101% to 98% - 102%. ***However, fee required for pre-registration variation is not submitted.***
6.	3.2.S.7.3	Chloride content and residue on ignition tests are not performed in the stability studies of the drug substance. Clarify.	Firm has submitted that Chloride content and residue on ignition tests are not stability indicating test parameters. Hence, these tests are not conducted in stability.
7.	3.2.P.1.1	Applied formulation has SLS & Syloid 244FP while the reference product has no SLS& Syloid 244FP in the formulation. Justification shall be submitted.	Firm has submitted that in Cariprazine capsule range, the drug substance particle size distribution is non-micronized. The Cariprazine belongs to BCS II (Low solubility and high permeability). In order to improve the solubility and dissolution of Cariprazine, Sodium Lauryl Sulphate (SLS) used in the formulation. Secondly, in order to improve the flowability as well as bioavailability, Syloid 244FP was incorporated in the formulation. Firm further submitted that Cariprazine capsules were kept on stability and no changes observed in chemical and physical parameters throughout the shelf life. Stability studies demonstrated the compatibility of the formulation excipients Sodium Lauryl Sulphate (SLS) & Syloid 244FP with Cariprazine drug substance. Because stability studies is one of the technique for drug-excipients compatibility studies.
8.	3.2.P.2.2	Content uniformity test is not performed in the PE. Justification shall be submitted.	Firm has submitted results for pharmaceutical equivalence wherein they have included content uniformity test.
9.	3.2.P.5.4	Batch analysis of all the three trial batches shall be submitted.	Firm has submitted COA's for all the three trial batches.
10.	3.2.P.8	• Justification shall be submitted for not performing Content uniformity test in the stability summary sheets.	Firm has submitted revised stability summary sheets wherein they have added content uniformity test. Firm has submitted that this point is not applicable.

		• Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted. • Documents for the procurement of API with approval from DRAP shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted copy of commercial invoice No. BP/CI/21-22/07E dated 23-07-2021 mentioning 160gm quantity of Cariprazine HCl, B# 2052/PDL001/3/001/21 attested by Assistant Director, I&E, DRAP, Karachi dated 13-08-2021. Submitted.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

923.	Name, address of Applicant / Marketing Authorization Holder	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Name, address of Manufacturing site.	M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24213 dated 26/08/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 61069772 dated: 15/08/2022.
	The proposed proprietary name / brand name	Caripz 6mg capsules.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Cariprazine HCL eq.to Cariprazine……6mg.
	Pharmaceutical form of applied drug	White coloured powder filled in blue colour capsule & white colour body of Hard Gelatin capsule size # 03.
	Pharmacotherapeutic Group of (API)	Anti-Convulsant. Antipsychotics. ATC code N05A
	Reference to Finished product specifications	Innovator Specification.
	Proposed Pack size	7's, 30's, 90's & 100's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	VRAYLAR (Cariprazine as HCl) Capsule 1.5mg, 3mg, 4.5mg & 6mg by Actavis Pharma, USFDA approved.
	For generic drugs (me-too status)	Not available.

	GMP status of the Finished product manufacturer	GMP certificate No. 46/2021-DRAP (K) dated 07-10-2021 issued on the basis of inspection conducted on 15-06-2021 is submitted.
	Evidence of approval of manufacturing facility.	Capsule (general section) approved vide letter No. F.2-12/93-Lic(Vol-V) dated 20-09-2021.
	Name and address of API manufacturer.	**Name and address of the DMF holder:** M/s Biophore India Pharmaceuticals Private Limited. Plot No. 92, Kavuri Hills, Phase II, Jubilee Hills, Hyderabad-500033, Telangana, INDIA. **Name and address of the manufacturing site:** M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detail of the drug substance regarding its nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its validation, batch analysis (2052/PDL001/3/001/21) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5% RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5% RH for 6 months. Batches:(2052/3/001/19, 2052/3/002/19 & 2052/3/003/19)
	Module-III (Drug Product):	The firm has submitted detail of the drug product regarding its description, composition, manufacturer, pharmaceutical development, manufacturing process and controls, process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the reference product that is Vraylar Capsule 4.5mg (Batch no: 1159608) manufactured by Forest Laboratories, Ireland Limited by performing quality tests (Identification, Disintegration Time, Assay, Dissolution) CDP is also performed against the same brand that is Vraylar Capsule 1.5mg **(**Batch no: 1159608) manufactured by Forest Laboratories, Ireland Limited in three different mediums i.e. 0.1N HCl, Acetate Buffer (pH 4.5) & Buffer 6.8. Both 0.1N HCl and acetate buffer

		shows more than 85% release within 15 minutes and F2 is not calculated while the Phosphate buffer has F2 value in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including Validation protocol, Validation report, Justification of system suitability, Specificity, Linearity, Accuracy, Precision Repeatability, Intermediate Precision, Robustness.

STABILITY STUDY DATA			
Manufacturer of API	M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India.		
API Lot No.	6242 **(2052/PDL001/3/001/21)**		
Description of Pack (Container closure system)	Alu/Alu blister		
Stability Storage Condition	Real time: 30˚C ± 2˚C /65%± 5%RH Accelerated: 40˚C ± 2˚C / 75%± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3 & 6 (Months)		
Batch No.	21SB(B)-234-01	21SB(B)-235-02	21SB(B)-236-03
Batch Size	1500 capsules	1500 capsules	1500 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	24-11-2021	24-11-2021	24-11-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate dated 22-03-2022 issued by Drugs Control Administration Government of Andhra Pradesh in the name of M/s. Sionc Pharmaceuticals (Pvt.) Ltd., Plot.No:34A, Road No.1, JN Pharma City, IDA, Parawada, Visakhapatnam -531021, Andhra Pradesh, India on the basis of inspection conducted on 30-12-2021 & 31-12-2021. The certificate is valid for three years from the date of issue and is meant for export of drugs only.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of	Submitted

	stability chambers (real time and accelerated)	

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.5	Revise pharmacological group for the applied formulation as per WHO ATC with submission of applicable fee.	Firm has initially submitted Anti Convulsant as pharmacological group. However, they have revised it to Anti-psychotic. ***Fee required for pre-registration variation is not submitted.***
2.	1.6.5	This section has mentioned Biophore India Pharmaceuticals Private Limited as drug substance manufacturer while module 2 has mentioned Sonic Pharmaceuticals Pvt. Ltd., as drug substance manufacturer. Clarification shall be submitted.	Firm has submitted that it was typographic error. M/s Sonic pharmaceuticals is manufacturer while Biophore India Pharmaceuticals Private Limited is supplier.
3.	3.2.S.4.1	Specifications of the drug substance by the drug substance manufacturer shall be submitted.	Firm has submitted specifications for the drug substance as well as the analytical procedures from drug substance manufacturer.
4.	3.2.S.4.3	Method verification studies of drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted method verification studies for the drug substance including Specificity, linearity and accuracy. ***However, the date on the submitted chromatograms is January, 2023.***
5.	3.2.S.4.4	Specifications for the drug substance provided by the drug product manufacturer has assay limits (ODB) of 98.5% - 101% while submitted COA of the drug product manufacturer has assay limit (ODB) of 98% - 102%. Clarification shall be submitted.	Firm has submitted revised specification for the drug substance wherein they have changed assay limits for Cariprazine from 98.5% - 101% to 98% - 102%. ***However, fee required for pre-registration variation is not submitted.***
6.	3.2.S.7.3	Chloride content and residue on ignition tests are not performed in the stability studies of the drug substance. Clarify.	Firm has submitted that Chloride content and residue on ignition tests are not stability indicating test parameters. Hence, these tests are not conducted in stability.
7.	3.2.P.1.1	Applied formulation has SLS & Syloid 244FP while the reference product has no SLS& Syloid 244FP in the formulation. Justification shall be submitted.	Firm has submitted that in Cariprazine capsule range, the drug substance particle size distribution is non-micronized. The Cariprazine belongs to BCS II (Low solubility and high permeability). In order to improve the solubility and dissolution of Cariprazine, Sodium Lauryl Sulphate (SLS) used in the formulation. Secondly, in order to improve the flowability as well as bioavailability, Syloid 244FP was incorporated in the formulation. Firm further submitted that Cariprazine capsules were kept on stability and no changes observed in chemical and physical parameters throughout the shelf life. Stability studies demonstrated the compatibility of the formulation excipients Sodium Lauryl Sulphate (SLS) & Syloid 244FP with Cariprazine drug substance. Because stability studies is one of the technique for drug-excipients compatibility studies.
8.	3.2.P.2.2	Content uniformity test is not performed in the PE. Justification shall be submitted.	Firm has submitted results for pharmaceutical equivalence wherein they have included content uniformity test.
9.	3.2.P.5.4	Batch analysis of all the three trial batches shall be submitted.	Firm has submitted COA's for all the three trial batches.
10.	3.2.P.8	• Justification shall be submitted for not performing Content uniformity test in the stability summary sheets. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted revised stability summary sheets wherein they have added content uniformity test. Firm has submitted that this point is not applicable.

		• Documents for the procurement of API with approval from DRAP shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted copy of commercial invoice No. BP/CI/21-22/07E dated 23-07-2021 mentioning 160gm quantity of Cariprazine HCl, B# 2052/PDL001/3/001/21 attested by Assistant Director, I&E, DRAP, Karachi dated 13-08-2021. Submitted.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

924.	Name, address of Applicant / Marketing Authorization Holder	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi.
	Name, address of Manufacturing site.	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29855 dated 21.10.2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 4790097193 dated 06-10-2022.
	The proposed proprietary name / brand name	Synflex Tablet 220mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Naproxen Sodium…….220mg
	Pharmaceutical form of applied drug	Film-coated Tablet
	Pharmacotherapeutic Group of (API)	Non-Steroidal Anti-Inflammatory Drug (NSAID)
	Reference to Finished product specifications	USP
	Proposed Pack size	10’s, 12’s , 20’s & 30’s.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Aleve 220mg Tablets (Naproxen Sodium) USFDA approved **(marketing status is over the counter).**
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	GMP certificate issued 15.09.2022 on the basis of Inspection conducted on 09.09.2022.
	Evidence of section approval.	Tablet (general) section approved vide letter No. F. 2-6/86-Lic (Vol-V) dated 30-07-2018.
	Name and address of API manufacturer.	Dr. Reddy's Laboratories Limited,

		D. No. 8-2-337, Road No. 3 Banjara Hills, Telangana State India. **Manufacturing Site.** Industrias Quimicas Falcon de Mexico, S.A. de C.V Km. 4.5 Carretera Federal Cuernavaca-Cuautla 62578 Jiutepec, Morelos, México.
	Module-II (Quality Overall Summary)	Firm has submitted QOS details as per WHO-QOS PD template.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis (ANOA00653A) and justification of specification, reference standard, container closure system and stability studies of drug substances.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 75% ± 5% RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5% RH for 6 months. Batch No. ANKA00240A, ANKA00258A & ANKA00259A.
	Module-III (Drug Product):	The firm has submitted detail of the drug product including its description, composition, formulation development, manufacturer, of manufacturing process and controls, process validation protocol, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the Innovator product that is Aleve 220mg Tablet Batch No. NAABRC manufactured by Bayer Healthcare LLC Whippany by performing quality tests (Identification, weight variation, Disintegration, Assay, Dissolution & impurities). CDP has been performed against the same brand that is Aleve 220mg Tablet Batch No. NAABRC manufactured by Bayer Healthcare LLC Whippany in Acid media (pH 1.2), Acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method Verification studies are submitted.

STABILITY STUDY DATA	
Manufacturer of API	Dr. Reddy's Laboratories Limited, D. No. 8-2-337, Road No. 3 Banjara Hills, Telangana State India. **Manufacturing Site.** Industrias Quimicas Falcon de Mexico, S.A. de C.V Km. 4.5 Carretera Federal Cuernavaca-Cuautla 62578 Jiutepec, Morelos, México.
API Lot No.	2112000088 (ANOA00653A)
Description of Pack (Container closure system)	Alu-PVC blisters packed in unit carton (Pack of 30's)
Stability Storage Condition	Real time: 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH
Time Period	Real time: 03 months Accelerated: 03 months

Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	NPD-T-1971-S	NPD-T-1973-S	NPD-T-1974-S
Batch Size	5000 tablets	5000 tablets	5000 tablets
Manufacturing Date	30-05-2022	08-06-2022	08-06-2022
Date of Initiation	20-06-2022	20-06-2022	20-06-2022
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to their product Pirfedow Tablets 267mg which was approved in 297th Meeting of Registration Board held on 12th – 15th January 2021 Inspection was conducted on 04th January, 2020. According to the report following points were confirmed. • The firm has 21 CFR compliant HPLC software • The firm has audit trail reports available. • The firm possesses stability chambers with digital data loggers.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 203300CT110178 in the name of Industrias Quimicas Falcon de Mexico, S.A. de C.V Km. 4.5 Carretera Federal Cuernavaca-Cuautla 62578 Jiutepec, Morelos, México issued by Federal commission for the protection against Sanitary Risks (COFEPRIS); PIC/S member since 2018 is provided by the applicant & Valid up to 09-April-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice # OS3612273491 Dated: 13.09.2021 from Dr. Reddy's Laboratories Limited, 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana, India mentioning 1000kgs of Naproxen sodium with batch number of ANOA00653A cleared by DRAP Karachi office dated 15.11.2021 is submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observations	Reply by the firm
1	1.5.2	Reference product has label claim of Naproxen sodium 220mg (Naproxen 200mg) while the applied formulation has label claim of Naproxen sodium 220mg only.	Firm has submitted that 220mg Naproxen sodium is the required dose which is used in the formulation as per innovator. Firm has further clarified that 220mg Naproxen sodium contains (equivalent to) 200 mg Naproxen.

2	2.3	• Table for literature references has mentioned that drug product is not available in any pharmacopoeia while the official monograph is available in USP. Clarification shall be submitted. • QOS has other introductory information for Synflex PM tablets. Clarification shall be submitted.	Firm has submitted revised table for literature references without submission of applicable fee. Firm has submitted that they have submitted Synflex PM 220 mg + 25mg tablets which was submitted prior to DRAP dated 07-04-2022 contains Naproxen sodium from same manufacturer/supplier as current dossier. Therefore, we have submitted the introductory information for Synflex PM tablets.
3	3.2.S.7.3	Stability studies of the drug substance has mentioned assay test by HPLC while the specification and analytical procedure has mentioned titration method. Clarification shall be submitted.	Firm has submitted that the drug substance manufacturer performed Assay test by Titration Method in the DMF but the provided stability data in DMF was on Zone-II i.e. 25°C ± 2°C, 60% ± 5% RH (attached herewith as reference) and tested according to Method No. CV0484. However, on our request the drug substance manufacturer provided the stability data on Zone-IV -B wherein the Assay is performed via HPLC method according to Method No. CV0694 which is more reliable and stringent than Titration. Also, we have requested the drug substance manufacturer to provide the Analytical Method with HPLC method No. CV0694 which will be subsequently submitted to your esteemed authority.
4	3.2.P.8.3	• Only 03-months stability data is submitted for the applied formulation. Complete six-months stability studies for all the three trial batches shall be submitted. • Clarification regarding the condition (30°C ± 2°C / 75% ± 5%RH) of real time stability data shall be submitted as conditions are not as per zone Iva.	Firm has submitted 06-month time point stability data for the applied product. Firm has submitted that ICH Q1 F explanatory note covers the scope for selection of storage condition of product as "Regulatory authorities in the ICH regions have agreed the use of more stringent humidity conditions such as 30°C/75% RH will be acceptable in place of 30°C/65% RH and it's up to the applicant who should decide to use them "

Decision: Approved with following label claim;

Each film coated tablet contains:

Naproxen Sodium 220mg eq. to Naproxen …… 200mg.

Registration letter will be issued after submission of full fee of Rs. 30,000/- for correction/pre-approval changes in label claim, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

c. Priority Registration applications on the basis of Export Facilitation of locally manufactured Human Drugs on form 5F.

Assistant Director PR-I/EFD vide letter No.F.1-6/2019-PR-I (EFD dated 06-10-2022 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the pharmaceutical i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision of the authority, the following firm i.e **M/s Indus Pharma** have achieved the benchmark of more than 100,000 USD during the fiscal Year 2021-2022 and submitted their applications for priority consideration in lieu of export facilitation for Registration Board please.,

925.	Name, address of Applicant / Marketing Authorization Holder	M/s Indus Pharma (Pvt.) Ltd., Plot No. 26-27, 63-67, Sector – 27, Korangi Industrial Area, Karachi.
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd., Plot No. 710, Sundar Industrial Estate, Lahore
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13313 dated 01/06/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 007169722952 dated 24/05/2022.
	The proposed proprietary name / brand name	Empazin Met XR 5/2.5/1000mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated extended-release tablet contains: Empagliflozin ……..…….5mg Linagliptin ……2.5mg Metformin HCl ……..1000mg
	Pharmaceutical form of applied drug	Brown colored oblong shaped biconvex, extended-release film coated tablets plain on both sides.
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	7's, 10's, 14's, 20's, 28's, 30's, 50's and 90's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Trijardy XR 5/2.5/1000mg Tablet, Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved.
	For generic drugs (me-too status)	Trixen XR 5/2.5/1000mg Tablet by M/s Hilton Pharma (Pvt.) Ltd. Could not be confirmed.
	GMP status of the Finished product manufacturer	**M/s Indus Pharma:** Copy of GMP certificate No. 53/2021-DRAP (K)/54 dated 24-12-2021 issued on the basis of inspection conducted on 17-12-2021 is submitted. **M/s Dynatis Pharma:** Copy of GMP certificate No. 29/2021-DRAP (FID-2065251-174) dated 01-07-2021 issued on the basis of inspection conducted on 26-03-2021 is submitted.
	Evidence of approval of manufacturing facility.	Tablet section (general) is approved vide letter No. F. 1-22/2013-Lic dated 08-01-2019 of M/s Dynatis pharma.
	Name and address of API manufacturer.	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Linagliptin:**

		M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20060201, Mfg. date 02-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20062701, Mfg. date 27-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#A-81411906039, Mfg. date 13-06-2019) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20160301, 20160302, 20160303) **Linagliptin:**

		Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20150901, 20150902, 20150903) **Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-71411106004, A-71411106005, A-71411106006)
	Module-III (Drug Product):	Firm has submitted detail of drug product regarding its description, composition, formulation development, manufacturers, description of manufacturing process and controls, Process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand leader that is Trijardy XR 5/2.5/1000mg Tablet (B#3188239) manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA by performing quality tests (Appearance, Assay, Dissolution, Average weight). CDP has been performed against the same brand that is Trijardy XR 5/2.5/1000mg (B#3118239) Tablet manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved, in three different mediums i.e. 0.1N HCl pH 1.2, Acetate Buffer pH 4.5 and Phosphate buffer pH 6.8. The values of F2 are more than 50 and are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity & range, accuracy (recovery), specificity, precision (repeatability & intermediate precision), robustness, solution stability and system suitability.

STABILITY STUDY DATA			
Manufacturer of API	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China.		
API Lot No.	Empagliflozin: 20060201 Linagliptin: 20062701 Metformin HCl: A-81411906039		
Description of Pack (Container closure system)	The product is filled in Alu-Alu blister. Each blister contains seven tablets and each unit carton contains two blisters along with leaflet (2x7 tablets/pack).		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 and 6 (Months) Real Time: 0, 3 and 6 (Months)		
Batch No.	TDG008	TDG009	-

Batch Size	5000 Tablets	5000 Tablets	-
Manufacturing Date	08-2021	09-2021	-
Date of Initiation	08-09-2021	05-10-2021	-
No. of Batches	02		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin & Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin & Linagliptin:** Firm has submitted copy of Invoice No. WD202003005 dated 28-06-2020 mentioning 03Kg quantity of Empagliflozin (B# 20060201) and 500gm of Linagliptin (20062701) attested by the Assistant Director I&E, DRAP, Lahore dated 13-08-2020. Firm has also submitted attested copy of form-6 dated 13-08-2020. **Metformin HCl:** Firm has submitted copy of commercial Invoice No. 419FK07Z057 dated 05-08-2019 mentioning 2000Kg, (B# A-81411906039) attested by the Assistant Director I&E, DRAP, Lahore dated 22-08-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.8	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm shall be submitted.	Firm has once again submitted Trixen XR by M/s Hilton pharma as evidence of approval of registered by DRAP. ***However, the submitted evidence is not registered with DRAP.***

2.	3.2.S.4.1	Clarification shall be submitted for Assay limits of Linagliptin (98% to 101%) whether the limits are on dried basis or as is basis.	Firm has submitted that assay of Linagliptin is calculated on anhydrous basis. They also submitted revised specification for the drug substance from both drug substance manufacturer and finished product manufacturer wherein they have mentioned assay on anhydrous basis.
3.	3.2.S.4.1	• Limits of the single impurity in Linagliptin drug substance provided by drug product manufacturer is NMT 0.8% while that of the drug substance manufacturer is NMT 0.5%. justification shall be submitted. • Specifications provided by the drug substance manufacturer for Linagliptin has mentioned single impurity limits of NMT 0.5% while the drug substance stability data has single impurity limits of NMT 0.8%. justification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein they have changed the limit of single impurity from NMT 0.5% to NMT 0.8%. They have also provided COA of the drug substance from drug substance manufacturer with revised specifications. ***However, fee required for pre-registration variation is not submitted.***
4.	3.2.S.4.2	Analytical procedures provided by the FPP for Linagliptin drug substance has mentioned Assay limits of 98% to 102% while the specification provided by both the DS and FPP has assay limits of 98% to 101%. Clarification shall be submitted.	Firm has submitted that it was a typographic error and they also provided revised analytical procedure with assay limit of 98% to 101%.
5.	3.2.P.2.1	Scientific justifications for 10% overage of 2 actives shall be submitted.	Firm has submitted that both the actives i.e. Empagliflozin and Linagliptin are part of the coating formulation which is applied to the tablet by coating process. Due to process wastage during the coating of both actives 10% overage has been considered to achieve desired label claim. However, this overage is not indicated in the finished product, and it will be further reduced after data from commercial batches is obtained.
6.	3.2.P.2.2	Batch number of the reference product in the CDP and PE are not same. Clarify.	Firm has submitted that it was a typo error. Correct batch No. is 3188239 and they also provided pictures of the innovator's pack.
7.		Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted data of their product approved on form 5F.
8.		Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021**

926.	Name, address of Applicant / Marketing Authorization Holder	M/s Indus Pharma (Pvt.) Ltd., Plot No. 26-27, 63-67, Sector – 27, Korangi Industrial Area, Karachi.
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd., Plot No. 710, Sundar Industrial Estate, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13243 dated 31/05/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 5728866176 dated 24/05/2022.
	The proposed proprietary name / brand name	Empazin Met XR 12.5/2.5/1000mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated extended-release tablet contains: Empagliflozin …….…….12.5mg Linagliptin ……2.5mg Metformin HCl ……..1000mg
	Pharmaceutical form of applied drug	Brown colored oblong shaped biconvex, extended-release film coated tablets plain on both sides.
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	7's, 10's, 14's, 20's, 28's, 30's, 50's and 90's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Trijardy XR 12.5/2.5/1000mg Tablet, Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved.
	For generic drugs (me-too status)	Trixen XR 12.5/2.5/1000mg Tablet by M/s Hilton Pharma (Pvt.) Ltd. Could not be confirmed.
	GMP status of the Finished product manufacturer	**M/s Indus Pharma:** Copy of GMP certificate No. 53/2021-DRAP (K)/54 dated 24-12-2021 issued on the basis of inspection conducted on 17-12-2021 is submitted. **M/s Dynatis Pharma:** Copy of GMP certificate No. 29/2021-DRAP (FID-2065251-174) dated 01-07-2021 issued on the basis of inspection conducted on 26-03-2021 is submitted.
	Evidence of approval of manufacturing facility.	Tablet section (general) is approved vide letter No. F. 1-22/2013-Lic dated 08-01-2019 of M/s Dynatis pharma.
	Name and address of API manufacturer.	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025.

		Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20060201, Mfg. date 02-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20062701, Mfg. date 27-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#A-81411906039, Mfg. date 13-06-2019) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Empagliflozin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months. Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months. Batches: (20160301, 20160302, 20160303) **Linagliptin:** Real time: 30°C ± 2°C / 65% ± 5%RH for 48 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months. Batches: (20150901, 20150902, 20150903) **Metformin HCl:** Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (A-71411106004, A-71411106005, A-71411106006)
	Module-III (Drug Product):	Firm has submitted detail of drug product regarding its description, composition, formulation development,

		manufacturers, description of manufacturing process and controls, Process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand leader that is Trijardy XR 5/2.5/1000mg Tablet (B#3188241) manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA by performing quality tests (Appearance, Assay, Dissolution, Average weight). CDP has been performed against the same brand that is Trijardy XR 12.5/2.5/1000mg (B#3188241) Tablet manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved, in three different mediums i.e. 0.1N HCl pH 1.2, Acetate Buffer pH 4.5 and Phosphate buffer pH 6.8. The values of F2 are more than 50 and are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity & range, accuracy (recovery), specificity, precision (repeatability & intermediate precision), robustness, solution stability and system suitability.

STABILITY STUDY DATA			
Manufacturer of API	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China.		
API Lot No.	Empagliflozin: 20060201 Linagliptin: 20062701 Metformin HCl: A-81411906039		
Description of Pack (Container closure system)	The product is filled in Alu-Alu blister. Each blister contains seven tablets and each unit carton contains two blisters along with leaflet (2x7 tablets/pack).		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 and 6 (Months) Real Time: 0, 3 and 6 (Months)		
Batch No.	TDI001	TDI002	-
Batch Size	5000 Tablets	5000 Tablets	-
Manufacturing Date	10-2021	09-2021	-
Date of Initiation	04-10-2021	05-10-2021	-
No. of Batches	02		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin & Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin & Linagliptin:** Firm has submitted copy of Invoice No. WD202003005 dated 28-06-2020 mentioning 03Kg quantity of Empagliflozin (B# 20060201) and 500gm of Linagliptin (20062701) attested by the Assistant Director I&E, DRAP, Lahore dated 13-08-2020. Firm has also submitted attested copy of form-6 dated 13-08-2020. **Metformin HCl:** Firm has submitted copy of commercial Invoice No. 419FK07Z057 dated 05-08-2019 mentioning 2000Kg, (B# A-81411906039) attested by the Assistant Director I&E, DRAP, Lahore dated 22-08-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.8	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm shall be submitted.	Firm has once again submitted Trixen XR by M/s Hilton pharma as evidence of approval of registered by DRAP. ***However, the submitted evidence is not registered with DRAP.***
2.	3.2.S.4.1	Clarification shall be submitted for Assay limits of Linagliptin (98% to 101%) whether the limits are on dried basis or as is basis.	Firm has submitted that assay of Linagliptin is calculated on anhydrous basis. They also submitted revised specification for the drug substance from both drug substance manufacturer and finished product manufacturer wherein they have mentioned assay on anhydrous basis.
3.	3.2.S.4.1	• Limits of the single impurity in Linagliptin drug substance provided by drug product manufacturer is NMT 0.8% while that of the drug substance	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein they have changed the limit of single impurity from NMT 0.5% to NMT 0.8%. They have also provided

		manufacturer is NMT 0.5%. justification shall be submitted. • Specifications provided by the drug substance manufacturer for Linagliptin has mentioned single impurity limits of NMT 0.5% while the drug substance stability data has single impurity limits of NMT 0.8%. justification shall be submitted.	COA of the drug substance from drug substance manufacturer with revised specifications. ***However, fee required for pre-registration variation is not submitted.***
4.	3.2.S.4.2	Analytical procedures provided by the FPP for Linagliptin drug substance has mentioned Assay limits of 98% to 102% while the specification provided by both the DS and FPP has assay limits of 98% to 101%. Clarification shall be submitted.	Firm has submitted that it was a typographic error and they also provided revised analytical procedure with assay limit of 98% to 101%.
5.	3.2.P.2.1	Scientific justifications for 10% overage of 2 actives shall be submitted.	Firm has submitted that both the actives i.e. Empagliflozin and Linagliptin are part of the coating formulation which is applied to the tablet by coating process. Due to process wastage during the coating of both actives 10% overage has been considered to achieve desired label claim. However, this overage is not indicated in the finished product, and it will be further reduced after data from commercial batches is obtained.
6.		Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted data of their product approved on form 5F.
7.		Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021**

927.	Name, address of Applicant / Marketing Authorization Holder	M/s Indus Pharma (Pvt.) Ltd., Plot No. 26-27, 63-67, Sector – 27, Korangi Industrial Area, Karachi.
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd., Plot No. 710, Sundar Industrial Estate, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13314 dated 01/06/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 6822442038 dated 24/05/2022.
	The proposed proprietary name / brand name	Empazin Met XR 10/5/1000mg Tablet.

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated extended-release tablet contains: Empagliflozin …….…….10mg Linagliptin …… 5mg Metformin HCl ……..1000mg
	Pharmaceutical form of applied drug	Brown colored oblong shaped biconvex, extended-release film coated tablets plain on both sides.
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs.
	Reference to Finished product specifications	Innovator's Specification.
	Proposed Pack size	7's, 10's, 14's, 20's, 28's, 30's, 50's and 90's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Trijardy XR 10/5/1000mg Tablet, Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved.
	For generic drugs (me-too status)	Trixen XR 10/5/1000mg Tablet by M/s Hilton Pharma (Pvt.) Ltd. Could not be confirmed.
	GMP status of the Finished product manufacturer	**M/s Indus Pharma:** Copy of GMP certificate No. 53/2021-DRAP (K)/54 dated 24-12-2021 issued on the basis of inspection conducted on 17-12-2021 is submitted. **M/s Dynatis Pharma:** Copy of GMP certificate No. 29/2021-DRAP (FID-2065251-174) dated 01-07-2021 issued on the basis of inspection conducted on 26-03-2021 is submitted.
	Evidence of approval of manufacturing facility.	Tablet section (general) is approved vide letter No. F. 1-22/2013-Lic dated 08-01-2019 of M/s Dynatis pharma.
	Name and address of API manufacturer.	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis and justification of specification, reference standard, container

		closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20060201, Mfg. date 02-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20062701, Mfg. date 27-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#A-81411906039, Mfg. date 13-06-2019) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20160301, 20160302, 20160303) **Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20150901, 20150902, 20150903) **Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-71411106004, A-71411106005, A-71411106006)
	Module-III (Drug Product):	Firm has submitted detail of drug product regarding its description, composition, formulation development, manufacturers, description of manufacturing process and controls, Process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand leader that is Trijardy XR 10/5/1000mg (B#3191446) manufactured by Boehringer Ingelheim

		Pharmaceuticals, Inc., USFDA by performing quality tests (Appearance, Assay, Dissolution, Average weight). CDP has is also performed against the same brand that is Trijardy XR 10/5/1000mg (B#3191446) Tablet manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved, in three different mediums i.e. 0.1N HCl pH 1.2, Acetate Buffer pH 4.5 and Phosphate buffer pH 6.8. The values of F2 are more than 50 and are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity & range, accuracy (recovery), specificity, precision (repeatability & intermediate precision), robustness, solution stability and system suitability.

STABILITY STUDY DATA			
Manufacturer of API	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China.		
API Lot No.	Empagliflozin: 20060201 Linagliptin: 20062701 Metformin HCl: A-81411906039		
Description of Pack (Container closure system)	The product is filled in Alu-Alu blister. Each blister contains seven tablets and each unit carton contains two blisters along with leaflet (2x7 tablets/pack).		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 and 6 (Months) Real Time: 0, 3 and 6 (Months)		
Batch No.	TDH001	TDH002	-
Batch Size	5000 Tablets	5000 Tablets	-
Manufacturing Date	08-2021	08-2021	-
Date of Initiation	20-08-2021	20-08-2021	-
No. of Batches	02		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin & Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China.

		Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin & Linagliptin:** Firm has submitted copy of Invoice No. WD202003005 dated 28-06-2020 mentioning 03Kg quantity of Empagliflozin (B# 20060201) and 500gm of Linagliptin (20062701) attested by the Assistant Director I&E, DRAP, Lahore dated 13-08-2020. Firm has also submitted attested copy of form-6 dated 13-08-2020. **Metformin HCl:** Firm has submitted copy of commercial Invoice No. 419FK07Z057 dated 05-08-2019 mentioning 2000Kg, (B# A-81411906039) attested by the Assistant Director I&E, DRAP, Lahore dated 22-08-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.8	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm shall be submitted.	Firm has once again submitted Trixen XR by M/s Hilton pharma as evidence of approval of registered by DRAP. ***However, the submitted evidence is not registered with DRAP.***
2.	3.2.S.4.1	Clarification shall be submitted for Assay limits of Linagliptin (98% to 101%) whether the limits are on dried basis or as is basis.	Firm has submitted that assay of Linagliptin is calculated on anhydrous basis. They also submitted revised specification for the drug substance from both drug substance manufacturer and finished product manufacturer wherein they have mentioned assay on anhydrous basis.
3.	3.2.S.4.1	• Limits of the single impurity in Linagliptin drug substance provided by drug product manufacturer is NMT 0.8% while that of the drug substance manufacturer is NMT 0.5%. justification shall be submitted. • Specifications provided by the drug substance manufacturer for Linagliptin has mentioned single impurity limits of NMT 0.5% while the drug substance stability data has single impurity limits of NMT 0.8%. justification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein they have changed the limit of single impurity from NMT 0.5% to NMT 0.8%. They have also provided COA of the drug substance from drug substance manufacturer with revised specifications. ***However, fee required for pre-registration variation is not submitted.***
4.	3.2.S.4.2	Analytical procedures provided by the FPP for Linagliptin drug substance has mentioned Assay limits of 98% to 102%	Firm has submitted that it was a typographic error and they also provided revised analytical procedure with assay limit of 98% to 101%.

		while the specification provided by both the DS and FPP has assay limits of 98% to 101%. Clarification shall be submitted.	
5.	3.2.P.2.1	Scientific justifications for 10% overage of two actives shall be submitted.	Firm has submitted that both the actives i.e. Empagliflozin and Linagliptin are part of the coating formulation which is applied to the tablet by coating process. Due to process wastage during the coating of both actives 10% overage has been considered to achieve desired label claim. However, this overage is not indicated in the finished product, and it will be further reduced after data from commercial batches is obtained.
6.		Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted data of their product approved on form 5F.
7.		Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021**

928.	Name, address of Applicant / Marketing Authorization Holder	M/s Indus Pharma (Pvt.) Ltd., Plot No. 26-27, 63-67, Sector – 27, Korangi Industrial Area, Karachi.
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd., Plot No. 710, Sundar Industrial Estate, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13244 dated 31/05/2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 07901996 dated 24/05/2022.
	The proposed proprietary name / brand name	Empazin Met XR 25/5/1000mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated extended-release tablet contains: Empagliflozin ……..…….25mg Linagliptin …… 5mg Metformin HCl ……..1000mg
	Pharmaceutical form of applied drug	Brown colored oblong shaped biconvex, extended-release film coated tablets plain on both sides.
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs.
	Reference to Finished product specifications	Innovator's Specification.

	Proposed Pack size	7's, 10's, 14's, 20's, 28's, 30's, 50's and 90's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Trijardy XR 25/5/1000mg Tablet, Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved.
	For generic drugs (me-too status)	Trixen XR 25/5/1000mg Tablet by M/s Hilton Pharma (Pvt.) Ltd. Could not be confirmed.
	GMP status of the Finished product manufacturer	**M/s Indus Pharma:** Copy of GMP certificate No. 53/2021-DRAP (K)/54 dated 24-12-2021 issued on the basis of inspection conducted on 17-12-2021 is submitted. **M/s Dynatis Pharma:** Copy of GMP certificate No. 29/2021-DRAP (FID-2065251-174) dated 01-07-2021 issued on the basis of inspection conducted on 26-03-2021 is submitted.
	Evidence of approval of manufacturing facility.	Tablet section (general) is approved vide letter No. F. 1-22/2013-Lic dated 08-01-2019 of M/s Dynatis pharma.
	Name and address of API manufacturer.	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	**Empagliflozin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20060201, Mfg. date 02-06-2020) and justification of specification,

		reference standard, container closure system and stability studies of drug substance. **Linagliptin:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#20062701, Mfg. date 27-06-2020) and justification of specification, reference standard, container closure system and stability studies of drug substance. **Metformin HCl:** Firm has submitted detailed drug substance data of drug substance related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and process controls, impurities, specifications, analytical procedures and its validation/verification, batch analysis (B#A-81411906039, Mfg. date 13-06-2019) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	**Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20160301, 20160302, 20160303) **Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months. Batches: (20150901, 20150902, 20150903) **Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (A-71411106004, A-71411106005, A-71411106006)
	Module-III (Drug Product):	Firm has submitted detail of drug product regarding its description, composition, formulation development, manufacturers, description of manufacturing process and controls, Process validation protocol, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand leader that is Trijardy XR 10/5/1000mg (B#3185608) manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA by performing quality tests (Appearance, Assay, Dissolution, Average weight). CDP has is also performed against the same brand that is Trijardy XR 25/5/1000mg (B#3185608) Tablet manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., USFDA Approved, in three different mediums i.e. 0.1N HCl pH 1.2, Acetate Buffer pH 4.5 and Phosphate buffer pH 6.8. The values of F2 are more than 50 and are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity & range, accuracy (recovery), specificity,

		precision (repeatability & intermediate precision), robustness, solution stability and system suitability.	
STABILITY STUDY DATA			
Manufacturer of API	**Empagliflozin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. **Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road Daguan District, Anquing, Anhui, China. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China.		
API Lot No.	Empagliflozin: 20060201 Linagliptin: 20062701 Metformin HCl: A-81411906039		
Description of Pack (Container closure system)	The product is filled in Alu-Alu blister. Each blister contains seven tablets and each unit carton contains two blisters along with leaflet (2x7 tablets/pack).		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 and 6 (Months) Real Time: 0, 3 and 6 (Months)		
Batch No.	TDJ007	TDJ008	-
Batch Size	5000 Tablets	5000 Tablets	-
Manufacturing Date	07-2021	07-2021	-
Date of Initiation	18-07-2021	18-07-2021	-
No. of Batches	02		
Administrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin & Linagliptin:** M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng West Road, Daguan District, Anquing, Anhui, China. Copy of DML No. 20190399 is submitted valid till 31-12-2025. **Metformin HCl:** Shouguang Fukang Pharmaceutical Co., Ltd., North-East of Dongwaihuan Road, Dongcheng Industrial Area, Shouguang City, Shandong Province, China. Copy of DML No. Lu20160126 is submitted by the firm valid till 26-10-2025. Copy of GMP certificate No. SD20190888 dated 13-03-2019 issued by the Shandong Food and Drug Administration valid till 12-03-2024 is also submitted.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin & Linagliptin:** Firm has submitted copy of Invoice No. WD202003005 dated 28-06-2020 mentioning 03Kg quantity of Empagliflozin (B# 20060201) and 500gm of Linagliptin (20062701) attested by the Assistant Director I&E, DRAP, Lahore dated 13-08-2020.	

		Firm has also submitted attested copy of form-6 dated 13-08-2020. **Metformin HCl:** Firm has submitted copy of commercial Invoice No. 419FK07Z057 dated 05-08-2019 mentioning 2000Kg, (B# A-81411906039) attested by the Assistant Director I&E, DRAP, Lahore dated 22-08-2019.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Reply by the firm
1.	1.5.8	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm shall be submitted.	Firm has once again submitted Trixen XR by M/s Hilton pharma as evidence of approval of registered by DRAP. ***However, the submitted evidence is not registered with DRAP.***
2.	3.2.S.4.1	Clarification shall be submitted for Assay limits of Linagliptin (98% to 101%) whether the limits are on dried basis or as is basis.	Firm has submitted that assay of Linagliptin is calculated on anhydrous basis. They also submitted revised specification for the drug substance from both drug substance manufacturer and finished product manufacturer wherein they have mentioned assay on anhydrous basis.
3.	3.2.S.4.1	• Limits of the single impurity in Linagliptin drug substance provided by drug product manufacturer is NMT 0.8% while that of the drug substance manufacturer is NMT 0.5%. justification shall be submitted. • Specifications provided by the drug substance manufacturer for Linagliptin has mentioned single impurity limits of NMT 0.5% while the drug substance stability data has single impurity limits of NMT 0.8%. justification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein they have changed the limit of single impurity from NMT 0.5% to NMT 0.8%. They have also provided COA of the drug substance from drug substance manufacturer with revised specifications. ***However, fee required for pre-registration variation is not submitted.***
4.	3.2.S.4.2	Analytical procedures provided by the FPP for Linagliptin drug substance has mentioned Assay limits of 98% to 102% while the specification provided by both the DS and FPP has assay limits of 98% to 101%. Clarification shall be submitted.	Firm has submitted that it was a typographic error and they also provided revised analytical procedure with assay limit of 98% to 101%.
5.	3.2.P.2.1	Scientific justifications for 10% overage of two actives shall be submitted.	Firm has submitted that both the actives i.e. Empagliflozin and Linagliptin are part of the coating formulation which is applied to the tablet by coating process. Due to process wastage during the coating of both actives 10% overage has been considered to achieve desired label claim. However, this overage is not indicated in the finished product, and it will be further reduced after data from commercial batches is obtained.

6.		Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted data of their product approved on form 5F.
7.		Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Submitted.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of following:

- **Fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021**

d. Priority Registration applications on the basis of Export Facilitation of locally manufactured Human Drugs applied on form 5D.

Assistant director PR-I/EFD vide letter No.F.1-6/2019-PR-I (EFD dated 06-10-2022 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision of the authority, the following firm i.e. **M/s Tabros Pharma** have achieved the benchmark of more than 100,000 USD during the fiscal Year 2021-2022 and submitted their applications for priority consideration in lieu of export facilitation for Registration Board please.

929.	Name and address of manufacturer / Applicant	M/s Tabros Pharma Pvt. Ltd. L-20/B, Sector-22, Federal B Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Pyromal 180mg/60mg Tablet.
	Diary No. Date of R& I & fee	Duplicate file bearing Dy. No. 353, R&I Dated 02.04.2014, Rs. 50,000/- dated 02.04.2014. Verified copy of receiving from R&I, DRAP, Islamabad with same Dy. No. and date is also attached. **(Duplicate file)**
	Composition	Each film coated tablet contains: Pyronaridine Tetraphosphate …..……. 180mg Artesunate …….. 60mg
	Pharmacological Group	Artemisinin and derivatives, combinations. (P01BF)
	Type of Form	Form 5D
	Finished Product Specification	Tabros Specifications
	Pack size & Demanded Price	Pack Size: 1x3's, 1x 9's, 2x10's & 9x10's MRP: As per DPC
	Approval status of product in Reference Regulatory Authorities.	Pyramax Tablet 180mg/60mg Tablets, **Supplier and manufacturer** Shin Poong Pharmaceutical Co., Ltd 70, Sandan-ro 19beon-gil Danwon-gu Ansan-si Gyeonggi-do South Korea. (EMA Approved)
	Me-too status	Could not be confirmed.
	GMP status	GMP certificate is issued based upon inspection conducted on 28-02-2020.

STABILITY STUDY DATA	
Drug	Pyromal 180/60mg Tablets.
Name of Manufacturer	M/s Tabros Pharma Pvt. Ltd. L-20/B, Sector-22, Federal B Industrial Area, Karachi.
Manufacturer of API	**Artesunate:** M/s Huvepharma Italia s.r.l Co., Ltd. Stabilimento di Garessio Via R. Lepetit, 142-I-12075 Garessio (CN) Italy.
	<u>Pyronaridine Tetraphosphate</u>:

	M/s Mangalam Drugs and Organics Ltd., Unit 2: Plot No. 1203 3rd Phase, G.I.D.C., Vapi-396195, Dist.-Valsad, Gujarat, India.		
API Lot No.	**Artesunate:** 200001	**Pyronaridine Tetraphosphate:** PTP-V/210201	
Description of Pack (Container closure system)	Alu-Alu blister pack in unit carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Real time: 0,3,6 (months) Accelerated: 0,3,6 (months)		
Batch No.	TR001-1/PYR	TR002-1/PYR	TR003-1/PYR
Batch Size	1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date	08-2021	08-2021	08-2021
Date of Initiation	14-09-2021	14-09-2021	14-09-2021
No. of Batches	03		
Date of Submission	27-12-2021 (Dy. No. 33741) for initial and 03rd months and 29-03-2022 (Dy. No. 8235) for 06th month.		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT FOR EXEMPTION

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

S. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Firm has submitted copy of minutes of 297th meeting of Registration Board wherein panel inspection report for their product BAXIB (Apixaban) 2.5mg & 5mg Tablets conducted on 5th January, 2021 by following panel is presented: 1. Prof. Dr. Rafeeq Alam Khan, Dean, Faculty of Pharmacy, Zia Uddin University, Karachi. (Member Registration Board). 2. Dr. Saif-ur-Rehman Khattak, Director / FGA, CDL, DRAP, Karachi. The inspection report also confirms that HPLC software is 21 CFR compliant and audit trials on the testing reports of Baxib tablets were available.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	**Artesunate:** Firm has submitted Copy of COA (Batch#200001, Mfg. date 20-07-2020) of drug substance Artesunate from M/s Huvepharma Italia s.r.l Co., Ltd. Stabilimento di Garessio Via R. Lepetit, 142-I-12075 Garessio (CN) Italy and copy of COA for the same drug substance with same batch No. from M/s Tabros Pharma Pvt. Ltd. L-20/B, Sector-22, Federal B Industrial Area, Karachi. **Pyronaridine Tetraphosphate** Firm has submitted Copy of COA (Batch # PTP-V/210201, Mfg. date 02-2021) of drug substance Pyronaridine tetra phosphate from M/s Mangalam Drugs and Organics Ltd., Unit 2: Plot No. 1203 3rd Phase, G.I.D.C., Vapi-396195, Dist.-Valsad, Gujarat, India and copy of COA for the same drug substance with same batch No. M/s Tabros Pharma Pvt. Ltd. L-20/B, Sector-22, Federal B Industrial Area, Karachi. are submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Firm has submitted analytical procedures for both the drug substances from drug substance manufacturer and also from the drug product manufacturer.
4.	Stability study data of API from API manufacturer	**Artesunate:** Firm has submitted stability study data of drug substance for both real time and accelerated stability. Stability study is

<table>
<tr><td></td><td></td><td>conducted at Real time conditions; 30˚C / 65% RH for 60 months and at Accelerated conditions; 40˚C / 75% RH for 6 months at intervals 0, 1, 3, 6, 9, 12, 18, 24, 36, 48 & 60 & 0, 1, 3 & 6 months respectively.
Batches:(120001,120002,120003)
<u>Pyronaridine Tetraphosphate:</u>
Firm has submitted stability study data of drug substance for both real time and accelerated stability. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 75% ± 5%RH for 24 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 6 months at intervals 0, 1, 3, 6, 9, 12, 18, 24 & 0, 1, 3 & 6 months respectively.
Batches:(PTD-PL-185001, PTD-PL-185002, PTD-PL-185003)</td></tr>
<tr><td>5.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td><u>Artesunate:</u>
Firm has submitted copy of Eudra GMP certificate No. IT-API/37/H/2020 issued by the competent authority of Italy in the name of M/s Huvepharma Italia s.r.l Co., Ltd. Via Roberto Lepetit, 142-12075 Garessio (CN) Italy on the basis of inspection conducted on 17-10-2019. The GMP certificate is valid till 17.10.2022.
<u>Pyronaridine Tetraphosphate:</u>
firm has submitted copy of GMP certificate No. 19111699 dated 18-11-2019 in the name of M/s Mangalam Drugs and Organics Ltd. Unit 2: Plot No. 1203 Phase-III, G.I.D.C., Vapi-396195, Dist-Valsad, Gujarat State, India issued by Food & Drugs Control Administration, Block No. 8, 1st Floor, Dr. Jivraj Mehtabhavan, Gandhinagar, Gujarat State, India.
This certificate is valid till 17-11-2022.</td></tr>
<tr><td>6.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td><u>Artesunate</u>:
Firm has submitted copy of invoice No. 6211000071 dated 13-04-2021 from M/s Huvepharma Italia s.r.l Co., Ltd. Via Roberto Lepetit, 142-12075 Garessio (CN) Italy, for import of 0.5kg of Artesunate in name of M/s Tabros Pharma Pvt. Ltd. L-20/B, Sector-22, Federal B Industrial Area, Karachi attested by AD DRAP Karachi dated 30-04-2021.
AD signed Form 6 is attached while Form 3 and Form 7 are also available.
<u>Pyronaridine Tetraphosphate</u>:
Firm has submitted copy of invoice No. EX/2116/20-21 dated 04.03.2021 from M/s Mangalam Drugs and Organics Ltd., India. for import of 1.3kg Pyronaridine Tetraphosphate with batch No. of PTP-V/210201 in the name of M/s Tabros Pharma Pvt. Ltd., Karachi attested by AD DRAP Karachi, dated 24-03-2021.
AD signed Form 6 is attached while Form 3 and Form 7 are also available.</td></tr>
<tr><td>7.</td><td>Protocols followed for conduction of stability study</td><td>Submitted.</td></tr>
<tr><td>8.</td><td>Method used for analysis of FPP</td><td>Submitted.</td></tr>
<tr><td>9.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has submitted that as same excipients are used for the applied formulation innovator so compatibility studies with excipients are not required.</td></tr>
<tr><td>10.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has manufactured three stability batches of Pyronaridine Tetraphosphate + Artesunate (180mg + 60mg) and has submitted copy of complete batch manufacturing. Details are as under:
<table>
<tr><td colspan="3">Pyromal 180mg/60mg Tablet.</td></tr>
<tr><td>Batch No.</td><td>Bach size</td><td>Mfg. Date</td></tr>
<tr><td>TR001-1/PYR</td><td>1500 Tablets</td><td>14-09-2021</td></tr>
<tr><td>TR002-1/PYR</td><td>1500 Tablets</td><td>14-09-2021</td></tr>
<tr><td>TR003-1/PYR</td><td>1500 Tablets</td><td>14-09-2021</td></tr>
</table></td></tr>
</table>

11.	Record of comparative dissolution data (where applicable)	Firm has submitted Comparative dissolution profile of the applied formulation against Pyramax Tablet 180/60mg (B#PYRATA008) manufactured by Shin Poong Pharm. Co., Ltd., in different mediums of pH 4.0, Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The F2 values are found satisfactory.
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers.

Remarks of the Evaluator:

Sr. No.	Observation	Reply by the firm
1.	Revise Pharmacological group as per WHO ATC shall be submitted with submission of applicable fee.	Firm has submitted revised pharmacological group as per WHO ATC code with submission of 7500/- fee vide slip No. 128450447 dated 12-01-2023.
2.	Stability summary sheets for drug substance Artesunate from the concerned drug substance manufacturer shall be submitted.	Stability summary sheets for drug substance Artesunate from the drug substance manufacturer is provided.
3.	Justification shall be submitted for not performing pH and heavy metals test during stability studies of Artesunate drug substance.	Firm has submitted that Drug manufacturer of Artesunate has already performed pH and heavy metals analysis on drug substance during disposition of material, they also provided COA from drug substance manufacturer. They further submitted that since, this material is being used for oral solid dosage form and we had procured this material tablet grade, therefore, based on tablet grade material manufacturer did not consider pH and heavy metal as a stability parameter.
4.	Valid copy of GMP certificate of drug substance manufacturer i.e. Artesunate issued by concerned/relevant regulatory authority shall be submitted.	Firm has submitted copy of GMP certificate No.IT-API/37/H/2020 in the name of M/s Huvepharma Italia s.r.l, Via R. Lepetit, 142-I-12075 Garessio (CN) Italy issued by the AIFA Italy. Certificate confirms the latest inspection which was conducted on 17-10-2019 and has also mentioned that it should not be relied upon to reflect the compliance status if more than three years have elapsed since the last inspection date. However, last page of the certificate has mentioned that "the inspectorate adopted a risk based approach for planning of inspections, therefore the validity of the GMP certificate for this manufacturing site is not more than 48 months from the last general GMP inspection, which was conducted on 17-10-2019."
+- .	Valid copy of GMP certificate of drug substance manufacturer i.e. Pyronaridine Tetraphosphate issued by concerned/relevant regulatory authority shall be submitted.	Firm has submitted copy of GMP certificate No. 23013542 dated 23-01-20239 in the name of M/s Mangalam Drugs and Organics Ltd. Unit 2: Plot No. 1203 Phase-III, G.I.D.C., Vapi-396195, Dist-Valsad, Gujarat State, India issued by Food & Drugs Control Administration, Block No. 8, 1st Floor, Dr. Jivraj Mehtabhavan, Gandhinagar, Gujarat State, India. This certificate is valid till 22-01-2026.

Product is available in the WHO pre-qualification list with Ref. No. EMA Art 58 H-W-2319-2 and the applicant mentioned is Shin Poong Pharmaceutical Co Ltd, 748-31 Yoksam-Dong, Gangnam-Gu, Seoul, 135-925, Republic of Korea.
Firm has also provided a page (Gazette Notification) No.F.8-43/2021-DD(PS) of MoNHSR&C dated 21-12-2021 "WHO Model List of Essential Medicines 2021 – 2022nd List" Wherein the same formulation is available in Granules and Tablet form.
Granules: 20mg + 60mg
Tablets: 60mg + 180mg.

Indications:
Indicated in the treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or by Plasmodium vivax in adults and children weighing 20 kg or more
Contra indications:

- Known hypersensitivity to pyronaridine or artesunate or any component of the formulation.
- Patients with clinical signs or symptoms of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage B or C).
- Severe renal impairment

Decision: Approved with innovator specifications. Firm will submit valid copy of GMP certificate of the drug substance manufacturer before issuance of the registration letter.

- **Manufacturer will place first three production batches on long term stability studiesthroughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

e. Registration applications of locally manufactured Human Drugs applied on form 5F (Routine applications).

930.	Name, address of Applicant / Marketing Authorization Holder	M/s Platinum Pharmaceuticals (Pvt.) Ltd., A-20 North Western Industrial Zone, Bin Qasim Karachi.
	Name, address of Manufacturing site.	M/s Platinum Pharmaceuticals (Pvt.) Ltd., A-20 North Western Industrial Zone, Bin Qasim Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 33038: dated 16-12-2021.
	Details of fee submitted	PKR 50,000/- vide old slip No. 1914653 dated 01-03-2021. 25,000/-: vide slip No. 760014090484 dated 25/10/2021.
	The proposed proprietary name / brand name	Dolonap EC Tablet 250mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each enteric coated tablet contains; Naproxen ……. 250mg.
	Pharmaceutical form of applied drug	Enteric coated tablet.
	Pharmacotherapeutic Group of (API)	Non-steroidal anti-inflammatory drug (NSAID)
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	1 x10's, 2 x 10's, 3 x 10's, & 5 x 10's.

	Proposed unit price	As per PRC.
	The status in reference regulatory authorities	Naprosyn EC 250 mg Gastro-Resistant Tablets, Atnahs Pharma UK Limited, MHRA approved.
	For generic drugs (me-too status)	Not provided.
	GMP status of the Finished product manufacturer	Not provided.
	Evidence of section approval.	Tablet general section is approved vide letter No. F. 2-3/94-Lic (Vol-I) dated 19-07-2016.
	Name and address of API manufacturer.	M/s Divis Laboratory, Unit-2, Chippada (V), Annavaram (Post) Bheemunipatnam (M) Visakhapatnam District, Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has nor submitted QOS as per WHO QOS-PD template.
	Module III (Drug Substance)	Firm has submitted detail of nomenclature, structure, general properties, physical form, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 60 months. Batches:(2-M5L003, 2-M5L004 & 2-M5L005).
	Module-III (Drug Product):	Firm has submitted detail of drug product including its description, composition, pharmaceutical development, manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand leader that is Naprosyn EC 250 mg Gastro-Resistant Tablets by M/s Atnahs Pharma UK by performing quality tests (Identification, disintegration, Dissolution in both acidic and alkaline medium & Assay. Uniformity of dosage form). CDP has been performed against Naprosyn tablets 250mg, batch No. NC6F12 manufactured by Ricordati Industria, Italy in Acid media (pH 1.2) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.

	Analytical method validation/verification of product.	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	M/s Divis Laboratory, Unit-2, Chippada (V), Annavaram (Post) Bheemunipatnam (M) Visakhapatnam District, Andhra Pradesh, India.		
API Lot No.	2006-5091FP013.		
Description of Pack (Container closure system)	Alu PVC blister packing in unit carton along with leaflet (1×10's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TF-01	TF-02	TF-03
Batch Size	3000 tablets	3000 tablets	3000 tablets
Manufacturing Date	06-2020	06-2020	06-2020
Date of Initiation	06-07-2020	08-07-2020	08-07-2020
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks by the Evaluator:

Sr. No.	Section	Observation	Response by the firm
1.	1.3.4	• Valid copy of DML of the drug product manufacturer shall be submitted. As submitted one is w.e.f. 07-08-2015. • Valid copy of GMP certificate/ last inspection report conducted within last three years of the finished product manufacturer shall be submitted.	Firm has submitted copy of DML No. 000415 in the name M/s Platinum Pharmaceuticals w.e.f. 07-08-2020. Firm has submitted copy of GMP certificate No. 40/2021-DRAP (K)/39 dated 09-09-2021 issued on the basis of inspection conducted on 07-09-2021.

2.	1.6.5	Valid copy of GMP certificate of the drug substance manufacturer issued by relevant regulatory authority shall be submitted.	Firm has submitted copy of document with file No.HMF07-14051/927/2021-TECH_DCA issued by Drug Control Administration Government of Andhra Pradesh wherein the DCA has forward WHO GMP certificate to M/s Divis Laboratory, Unit-2, Chippada (V), Annavaram (Post) Bheemunipatnam (M) Visakhapatnam District, Andhra Pradesh, India on the basis of inspection conducted on 16-02-2021 to 17-02-2021 valid for a period of three years.
3.	2.3	Table for literature references has mentioned only USP for the drug substance as well as drug product. However, both the drug substance and drug product are available in different pharmacopoeia. Clarification shall be submitted.	Firm has submitted revised table for literature references wherein they have mentioned different pharmacopoeias for both the drug substance and drug product.
4.	2.3.R	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3 along with blank master production document/ batch manufacturing record to be used during the commercial manufacturing of the applied product.	Firm has submitted complete batch manufacturing record for all the three trial batches.
5.	3.2.S.4.1	Specification for drug substance by the drug product manufacturer shall be submitted.	Submitted.
6.	3.2.S.4.2	• Analytical procedures for drug substance by the drug product manufacturer shall be submitted. • USP monograph has mentioned assay test by titration method while the analytical procedures and stability data sheets have mentioned HPLC procedure for assay. Clarification is required.	Submitted. Firm has submitted that Drug substance manufacturer (Divi's) has performed stability testing by using validated HPLC method for specificity, precision, linearity, accuracy, robustness, solution stability and system suitability.
7.	3.2.S.4.3	• Verification studies of the drug substance by the drug product manufacturer shall be submitted.	***Not submitted.***
8.	3.2.S.7.3	• Assay limits in the official monograph is from 98.5% to 101.5% while stability data sheets have assay limits of 98% to 102%. Clarification is required.	Firm has submitted that Drug substance manufacturer (Divi's) has performed stability testing by using HPLC which is more robust technique so supplier established the assay limits of 90% to 102%.
9.	3.2.P.2.1	• Qualitative composition is changed from the reference product. Clarify.	Firm has submitted that qualitative composition of the applied product is similar to their already approved and registered product Dolonap 500mg. Dolonap 500mg stability was also found satisfactory.
10.	3.2.P.2.2.1	• In CDP, buffer stage has mentioned 60minutes time points	Firm has submitted that as per WHO guidelines TRS#1003, 2017 Annex 6, 10.3 it is recommended to take below mentioned sampling point while performing CDP.
11.	3.2.P.6	• COA of the reference standard used or details shall be provided.	Submitted.
12.	3.2.P.8	• Stability data sheets shall be as per decision of 293rd meeting of RB with inclusion of API lot number and batch size manufactured. • Initial time point accelerated stability data shall be submitted.	Firm has submitted new stability summary data sheets as. per decision of 293rd meeting of Registration Board. Batch size of 3000 tablets in each trial batch with API lot No. 2-M-B1830619. Firm has also included initial time point results in the newly submitted stability summary data sheets.

		• Content of uniformity test is not included in the stability data while official monograph has mentioned it.	Firm has submitted that content uniformity test is not recommended in stability testing as per ICH guideline Q1A (R2), 2.2.5 which states that "Stability studies should include testing of those attributes of the drug product that are susceptible to change during "
13.		COA provided for the finished product has stability starting date of 15-02-2021 while the stability data sheets have mentioned some other date. Justification shall be submitted.	Firm as submitted new COA for the finished product wherein they have changed the starting date from 15-02-2021 to 06-07-2020.
14.		• Documents for the procurement of API with approval from DRAP (in case of import) shall be submitted. • Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin shall be submitted. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted. • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted commercial invoice No.5319500289 dated 17-07-2019 mentioning 1000kg of Naproxen B. No. 2-M-B-1830619 attested by Assistant Director I&E, DRAP, Karachi dated 2607-2019. Submitted. Not submitted. Submitted. Submitted.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021 along with analytical method verification studies of the drug substance performed by the drug product manufacturer.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

931.	Name, address of Applicant / Marketing Authorization Holder	M/s Weather Folds Pharmaceuticals, Plot # 69/2, Phase-II, Industrial Area, Hattar.
	Name, address of Manufacturing site.	M/s Weather Folds Pharmaceuticals, Plot # 69/2, Phase-II, Industrial Area, Hattar.
	Status of the applicant	☒ Manufacturer. ☐ Importer. ☐ Is involved in none of the above (contract giver).
	Status of application	☒New Drug Product (NDP). ☐Generic Drug Product (GDP).
	Intended use of pharmaceutical product	☐ Domestic sale. ☐ Export sale. ☒ Domestic and Export sales.
	Dy. No. and date of submission	Dy. No 33643 dated 24-12-2021.
	Details of fee submitted	PKR 30,000/- vide slip No. 5281307641 dated 02-11-2021
	The proposed proprietary name / brand name	Ticafold 90mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains; Ticagrelor …… 90mg.

	Pharmaceutical form of applied drug	Film coated tablets.
	Pharmacotherapeutic Group of (API)	Farnesoid X Receptor Agonists. Platelet aggregation inhibitors excl. heparin.
	Reference to Finished product specifications	Innovator's specifications.
	Proposed Pack size	2 x 10's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Brilinta 90 mg film coated tablets, USFDA approved.
	For generic drugs (me-too status)	Anplag 90mg, PharmEvo (Pvt.) Ltd., Reg. No.089382.
	GMP status of the Finished product manufacturer	Not provided.
	Evidence of section approval.	Could not be confirmed.
	Name and address of API manufacturer.	M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road, Yangkou Chemical Industrial park, Rudong Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Firm has submitted copy of GMP certificate for M/s Nantong Chanyoo Pharmatech Co., Ltd., issued by Nantong chemical and Medical industry association valid till 05-05-2022.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of the drug substance regarding nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis (RD-TG-202101041) and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies (Drug substance.)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (140901, 141001 & 141101)
	Module-III (Drug Product):	The firm has submitted detail of the drug product including its description and composition, formulation development, manufacturer, description of manufacturing process and controls, batch formula, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against Anplag 90mg tablets, Batch No. 0N118, manufactured by PharmEvo by performing quality tests (Disintegration, Assay, Dissolution).

		CDP is performed in four BCS media across the physiological pH range i.e. 0.1 N HCl, pH 4.5 Acetate buffer, pH 6.8 Phosphate buffer and Tween 80 in water. The values are in the acceptable range.
	Analytical method validation/verification of product	Method Validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	Nantong Chanyoo Pharmatech Co. Ltd., No. 2 Tonghai Si Road, Rudong Coastal Economic Development Zone, Nantong, Jiangsu Province China.		
API Lot No.	RD-TG-201911211.		
Description of Pack (Container closure system)	Alu-Alu blister of 2 x 10's further packed in a bleech card unit carton along with leaflet.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T001	T002	T003
Batch Size	1200 tablets	1200 tablets	1200 tablets
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	21-04-2021	21-04-2021	21-04-2021
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION		
The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.		
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice number CY121078 dated 04-03-2021 mentioning 0.5kg quantity of ticagrelor, Batch No. RD-TG-202101041 attested by Assistant Director DRAP, Peshawar vide No. 812/12-03-2021 dated 12-03-2021.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted
Remarks OF Evaluator:		

Sr. No.	Section	Observations.	Response by the firm.
1.	1.3.4	• Valid copy of DML of the drug product manufacturer shall be submitted. • Valid copy of GMP certificate/last inspection report of the drug product manufacturer shall be submitted.	Firm has submitted copy of receiving dating 18-09-2018 wherein they have applied for renewal of their DML. ***Submitted copy of DM: has renewal w.e.f. 27-09-2013.*** Firm has submitted copy of GMP certificate No.F.3-12/2021-DRAP-II dated 17-02-2022 issued on the basis of inspection conducted on 27-01-2022.
2.	1.3.5	Evidence of approval of manufacturing facility/approved section from licensing authority shall be submitted.	Firm has submitted copy of letter No. F. 3-8/2007-Lic dated 05-05-2010 wherein they changed their Tablet (Psychotropic) section to Tablet (General) section. GMP certificate has also mentioned Tablet (General) section.
3.	1.5.5	Revise Pharmacotherapeutic Group to Platelet aggregation inhibitors excl. heparin as per WHO ATC code with submission of applicable fee.	Firm has initially submitted Farnesoid X Receptor Agonists pharmacological group. Now they have provided that Ticagrelor is P2Y12 platelet inhibitor. ***Firm has revised pharmacological group without submission of applicable fee.***
4.	1.5.6	This section has mentioned innovator specifications while the official monograph is available in BP. Clarification is required.	Firm has submitted that ticagrelor was not added in 2021 addition of BP while they have performed stability studies in 2021.
5.	1.6.5	Valid copy of GMP certificate of the drug substance manufacturer issued by the relevant regulatory authority shall be submitted.	Firm has submitted copy of GMP certificate for M/s Nantong Chanyoo Pharmatech Co., Ltd., issued by Nantong chemical and Medical industry association valid till 22-03-2025. ***GMP certificate is not from relevant/concerned authority.***
6.	2..3	Table for literature references has not mentioned any pharmacopoeia neither for the drug substance nor for the drug product while the official monograph for both the drug substance as well as drug product is available in BP. Justification shall be submitted.	Firm has submitted that ticagrelor was not added in 2021 addition of BP while they have performed stability studies in 2021. ***However, they have not provided revised table for literature references for the applied formulation.***
7.	3.2.S.2 & 3.2.S.3	Clear and readable copy of the information related to the drug substance shall be submitted. From section 3.2.S.2.2 to 3.2.S.3 as provided one is not in readable form.	Submitted.
8.	3.2.S.4.1	• Specification of the drug substance by the finished product manufacturer shall be submitted. • Specifications provided by the drug substance manufacturer for the drug substance has assay limit of 98% - 102% while BP has mentioned 97.5% - 102%. Clarification shall be submitted.	**Not submitted.** Firm has submitted that the limits of assay test provided by the drug substance manufacturer (98% - 102%) are within the limits of pharmacopoeia (97.5% - 102%).
9.	3.2.S.4.2	Analytical procedures for the drug substance from both the drug substance manufacturer and finished product manufacturer shall be submitted.	Analytical procedures for drug substance by the drug substance manufacturer ae submitted. ***However, analytical procedures by the drug product manufacturer are not provided. Provided analytical procedures by the drug substance manufacturer has also mentioned "For Crystolite pharmaceutical only."***
10.	3.2.S.4.3	Complete validation studies of the drug substance performed by the drug product manufacturer shall be submitted.	Submitted.
11.	3.2.S.4.4	The reference product literature specifies polymorphic form II for ticagrelor tablets whereas no such declaration has been made in the COA of drug substance.	Firm has submitted that IN DMF they provided details of the isomeric form. ***However, no details are provided while the annexure G is the COA's of the finished product.***

12.	3.2.S.4.5	Justification of specifications shall be submitted drug substance.	Firm has submitted that at the time of file preparation, product was in house and not added in any pharmacopoeia, now added in pharmacopoeia.
13.	3.2.S.5	CoA of primary / secondary reference standard including source and lot number shall be submitted.	Submitted.
14.	3.2.P.2.2	• Justification for not performing CDP against the innovator product. • Details of the product including brand name, batch number manufacturing & expiry date and name of the manufacturer for the product used in CDP shall be submitted. • In pharmaceutical equivalence dissolution studies of the finished trial batch shall be submitted instead of giving the results of CDP. • Assay results of the both products shall be submitted in pharmaceutical equivalence.	Firm has submitted that they have performed CDP against the brand leader i.e Anplag 90mg, B. No. 0N118, mfg. date 12-2020. Submitted. Submitted.
15.	3.2.P.5.1	• This section has mentioned in-house specifications while the official monograph of the applied formulation is available in BP. • Dissolution limits provided by the drug product manufacturer (NLT 75% after 75 minutes) are different from official monograph (Q = 70% after 45 minutes). Justification shall be submitted.	Firm has submitted that at the time of development, this product was not included in any of the pharmacopoeia. Firm has submitted revised specifications for the drug product wherein they have revised dissolution specification from NLT 75% after 75 minutes to NLT 70% of the labeled amount of ticagrelor is dissolved in 45 minutes. ***Firm has not submitted any fee for revision of specifications.***
16.	3.2.P.5.2	Analytical method for assay test is also different from official monograph.	Firm has submitted that they have adopted manufacturer method of analysis as the product was not included in any pharmacopoeia. They also submitted revised SAP according to the pharmacopoeia.
17.		• Reference of previous approval of applications with stability study data shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted. • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	***Firm has not submitted any reference.*** ***No reply is submitted by the firm against this point.*** ***No record of digital data logger is for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted by the firm.***

Decision: Deferred for following;

- **Submission of fee of Rs. 7500/- for correction/pre-approval changes in specification (Revision of pharmacological group), as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.**
- **Valid copy of GMP certificate of the drug substance manufacturer issued by the relevant regulatory authority shall be submitted.**
- **Revised table of literature references for both drug substance and drug product shall submitted.**
- **Specification of the drug substance by the finished product manufacturer shall be submitted.**
- **Analytical procedures for the drug substance by the finished product manufacturer shall be submitted.**
- **Justification shall be submitted for submitted analytical procedures by the drug substance manufacturer as it has mentioned "For Crystolite pharmaceutical only."**
- **Justification shall be submitted regarding the polymorphic form of the drug substance as the reference product literature specifies polymorphic form II for ticagrelor tablets whereas no such declaration has been made in the COA of drug substance.**
- **Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.**

- **Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.**

f. Registration applications of locally manufactured Deferred drugs on form 5F.

Firm has submitted copy of Acknowledgment of receipt of application for grant of additional section under DML No. 000465 (Formulations) to M/s Well Care Pharmaceuticals (Pvt.) Ltd., dated 24-11-2021 from Secretary Central Licensing Board. The letter specifies that CLB in its 283rd meeting held on 28-10-2021 has approved the grant of following additional section to M/s Well Care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha:

1. Capsule (General) New.

932.	Name, address of Applicant / Marketing Authorization Holder	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12631: dated 24-03-2022.
	Details of fee submitted	PKR 30,000/-: dated 21/02/2022.
	The proposed proprietary name / brand name	**Tzole 20mg Capsule.**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Omeprazole (as enteric coated pellets) …….. 20mg
	Pharmaceutical form of applied drug	Oral capsule
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor.
	Reference to Finished product specifications	USP Specifications.
	Proposed Pack size	14’s.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Omeprazole 20mg delayed release capsule, USFDA Approved.
	For generic drugs (me-too status)	Helezol 20mg Capsule, Focus & Rulz, Reg. No. 027104.
	GMP status of the Finished product manufacturer	Not submitted.
	Evidence of section approval.	Capsule (general) - New section approved vide No.F.1-12/97-Lic (Vol-II) dated 24-11-2021.
	Name and address of API manufacturer.	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months. Batches: (OEC-8.5-001, OEC-8.5-002 & OEC-8.5-003)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for quality tests (Description, identification, Average weight, dissolution & assay) for their product against Omega 20mg Capsule. Firm has submitted CDP against the same brand i.e. Omega 20mg Capsule manufactured by the Ferozesons. However, no strength, Batch number, manufacturing date, Expiry date etc. are mentioned.
	Analytical method validation/verification of product	Not submitted.

STABILITY STUDY DATA	
Manufacturer of API	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.
API Lot No.	OEC-08-040.
Description of Pack (Container closure system)	14 capsules are packed in Alu-Alu plain in packing box.
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH
Time Period	Real time: 06 months Accelerated: 06 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	T1/21	T2/21	T3/21
Batch Size	4100 capsules	4100 capsules	4100 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	15-10-2021	15-10-2021	15-10-2021
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate No.43/2022-DRAP (AD-00196339815-153) dated 07-04-2022 on the basis of inspection conducted on 30-03-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted commercial invoice No. 0571 dated 01-10-2021 of pharma zone chemical (Pvt.) Limited with buyer's name of Well care pharmaceuticals mentioning 1kg quantity of each 8.5% Omeprazole pellets & 22.5% pellets of Omeprazole.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their system is not 21 CFR compliant.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks by the Evaluator:

Sr. No.	Section number	Observation	Submission by the firm.
1.	1.3.4	• Valid copy of DML of the manufacturer shall be submitted. • GMP certificate/last inspection report of the drug product manufacturer shall be submitted.	Copy of DML is submitted which is not in readable form. One page of inspection report is submitted conducted on 10-09-2021 signed by only one member out the three panel members wherein following is recommended; "Panel recommended resumption of production and grant of new capsule section. Detailed report was prepared on prescribed format and copy was handed over to the firm for record and reference."
2.	2.3	Table for literature references of the drug substance has mentioned drug substance in different pharmacopoeias. Clarification shall be submitted.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error. ***No revised table for literature references has been submitted by the firm.***
3.	3.2.S.1.3	General properties, solubilities and physical form related data for the drug substance shall be submitted.	Submitted.
4.	3.2.S.4.1	• Finished product manufacturer has submitted Specification as per USP for drug substance while there is no monograph for the pellets in the USP.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error. ***No revised specifications are provided/submitted by the firm.***
5.	3.2.S.4.2	Analytical procedures submitted by the drug product manufacturer are completely	Firm has submitted that drug substance analytical procedure is manufacturer specifications because

		different from drug substance manufacturer. Clarification is required.	Omeprazole EC pellets is not available in any pharmacopoeia. ***However, new* analytical procedure *for the drug substance as per manufacturer specifications are not provided by the drug product manufacturer.***
6.	3.2.S.4.3	Verification studies of the drug substance performed by the finished product manufacturer shall be submitted.	Submitted.
7.	.2.S.4.5.	Justification of specifications has declared USP specification. Clarification is required.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error.
8.	3.2.S.5	COA of the reference standard used shall be submitted.	Firm has submitted COA for the working standard for omeprazole. ***However, the drug substance source as per submitted dossier is M/s Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore while the submitted COA is for M/s Vision Pharmaceuticals, Islamabad.***
9.	3.2.P.2	• Justification shall be submitted regarding dissolution and assay of the applied formulation in the pharmaceutical equivalence studies. As the medium of the dissolution and time are not in accordance with the monograph. • Justification shall be submitted for not performing CDP against the innovator product. • Justify the condition of dissolution used in comparative dissolution studies. • Justification shall be submitted for carrying dissolution studies up to 30 minutes time point only in 0.1N HCl in Comparative Dissolution studies. • No data for the comparator product for CDP has been submitted.	Firm has submitted that test is performed according to the monograph but this time is typographical mistake. Firm has submitted new CDP results of the applied formulation with Risek 20mg capsules in three mediums and the f2 values are in acceptable range. ***However, submitted results are for Tzole 40mg capsule instead of 20mg & at acidic medium pH 1.2, results for only 45 minutes time points are submitted instead of 2 hours.*** ***Furthermore, pH of the medium is not mentioned with the submitted results.*** Firm has submitted that dissolution studies are performed according to monograph; we have 5 sampling intervals in 0.1 N HCl and phosphate buffer pH 4.5 and phosphate buffer pH 6.5. Firm has submitted that it is a typographic error while the dissolution in 0.1 N HCl is performing 120minutes. ***Initially submitted results have shown more than 10% release in 30 minutes while actually there should be NMT 10% in initial 2 hours.*** ***No details of the comparator product are submitted.***
10.	3.2.P.3.2	Justification shall be submitted for use of Omeprazole powder in the master formulation.	Firm has submitted that they have used Omeprazole 8.5% Ec pellets in the formulation. Omeprazole powder was typographical error.
11.	3.2.P.5.1	• Specification provided for the drug product has not mentioned dissolution at acidic stage. • Dissolution test shall be specified whether test I or any of the other test is followed by the drug product manufacturer or otherwise.	***No reply/justification is submitted against this point.*** ***No reply/justification is submitted against this point.***
12.	3.2.P.5.2	Analytical procedures for the drug product are completely different from the official monograph. Clarification is required.	Firm has submitted that all stability studies performed according to USP monograph. ***However, the conditions for dissolution test and conditions for assay test applied by the drug product manufacturer are completely different from that of the USP monograph. Standard solution, test soltion, wavelength applied & injection volume etc. all are different from USP.***

13.	3.2.P.5.2	Analytical method validation/verification of product shall be submitted.	Submitted.
14.	3.2.P.5.4	• Specification of dissolution test in the batch analysis are without time for buffer stage and without percentage for acid stage. • Batch analysis has only buffer stage dissolution results.	Firm has submitted that all limits are mentioned in analytical procedures but mistakenly not mentioned in batch analysis. ***No reply submitted against this point.***
15.	3.2.P.8.1	• Stability summary and conclusion has manufacturing date of Jan-2022 with batch No. of RLE-001, RLE-002 & RLE-003 while the stability data sheets have mentioned manufacturing date of 10-2021 with batch No. of T1/21, T2/21 & T3/21. Clarification is required.	Firm has submitted that manufacturing date of their batches is October, 2021 but the January 2021 is testing interval date.
16.	3.2.P.8.3	• Stability data sheets have no dissolution at acidic stage. Clarification is required. • Justification shall be submitted regarding the run time, injection volume and wavelength used for the assay of finished product as the applied run time, injection volume and wavelength are different from that of the official monograph. • Stability data sheets have mentioned weight of capsule as 295 while the raw data has mentioned 235mg. Clarification is required. • Dates in the submitted chromatograms have been over written by hand. Clarification shall be submitted.	Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.*** Firm has submitted that testing of the product is performed as per USP. The run time is about 10 minutes and injection volume are 20µl and flow rate is 1ml/min. column used is 4.6 mm x 15cm; 5µm packing L1 and detector is 302nm. ***However, in the submitted chromatograms the conditions are different from that mentioned in the official pharmacopoeia. Official monograph has mentioned wavelength of 305nm while firm has applied 302nm.*** Firm has submitted that stability raw data sheets have two different weights one is content weight of pellets and second weight is gross weight with capsule shell. ***No reply submitted against this point.***
17.	3.2.P.8.3	Justification shall be submitted regarding the retention time of the omeprazole in the provided chromatograms as two different retention time are mentioned for the same omeprazole.	Firm has submitted that during stability studies they have used two different companies HPLC column in which one of that have minimum 5000 number of theoretical plates and other have less than 5000 plates due to which retention time have some difference. ***Submitted chromatograph have shown two different retention times for the omeprazole i.e. 5minutes and 10 minutes.***
18.		• Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Complete Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated). • Provide specifications of HPLC system with its model including information whether gradient or isocratic column, 21 CFR compliance system. • Raw data sheets for dissolution and assay test of the finished product shall be submitted with calculation formula used. • Justification shall be submitted for the stability of both drug substance and finished product that the values at both	Only one-page Esomeprazole capsule 06 standard injection is provided. ***Not complete.*** Submitted. Only specifications of HPLC are provided while 21 CFR compliant certificate is not provided. Raw data sheets for dissolution and assay tests are not provided by the firm.

		accelerated and real time are exactly similar at same time points.	Firm has submitted that they have performed only drug product stability studies accelerated and real time in different intervals but we take print out at same time after completion of stability studies. ***Real time and accelerated stability studies of both the drug substance and drug product of all three batches have exact similar values.***
19.		• Justification regarding the drug substance shall be submitted with respect to the total quantity of the drug substance purchased and total quantity used in manufacturing and testing of all the three trial batches of Tzole 20mg capsule.	Firm has submitted that they purchased Omeprazole 8.5% and 22% each 1kg for three trial batches. Total material use in trial batches for testing. ***Executed BMR's have shown that in Tzole 20 mg capsules 8.5% of pellets have been used. Stability data sheets have three different batches each with 4100 capsules batch size.*** ***In this regard total number of capsules manufactured are;*** ***5600 x 3 = 12,300*** ***Each 20mg capsule will have 235mg of Omeprazole EC pellets.*** ***12300 x 235 = 2,890,500 mg of pellets*** ***2.89 kg pellets are required to fill the three trial batches while firm has purchased only 1kg.***

Previous Decision: Registration Board decided to defer the case for onsite verification and authenticity of the submitted t stability data due to following observations:

- Drug substance analytical procedure applied by the drug product manufacturer is different from that applied by the drug substance manufacturer.
- Submitted COA of working standard is from M/s Vision Pharmaceuticals whereas drug substance has been procured from M/s Pharmazone Chemicals.
- Submitted analytical record of CDP reflects that for pH 1.2, comparative dissolution studies have been conducted for 45 minutes only while the limits are NMT 10% release in pH 1.2 for two hours.
- The analytical method for dissolution test and for assay test applied by the drug product manufacturer are completely different in terms of run time, injection volume, wavelength, standard solution preparation etc.., from that of the USP monograph as also evident from the submitted HPLC chromatograms.
- Submitted HPLC chromatograms reflect two different retention time for 20mg and 40 mg Omeprazole EC pellets. i.e. 5minutes and 10 minutes.
- Quantity of Omeprazole pellets procured, as evident from submitted invoice is not justified for the manufacturing of trial batches of submitted batch size.
- Both accelerated and real time stability data sheets are having exactly similar values at same time points.
- Drug product Batch analysis has only buffer stage dissolution results.
- Stability data sheets have mentioned weight of capsule as 295 while the raw data has mentioned 235mg. Clarification is required.
- Dates in the submitted chromatograms have been over written by hand.
- Raw data sheets for dissolution and assay tests are not provided by the firm.
- Stability data sheets have mentioned weight of capsule as 295 while the raw data has mentioned 235mg.

933.	Name, address of Applicant / Marketing Authorization Holder	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12659: dated 24-05-2022.
	Details of fee submitted	PKR 30,000/-: dated 21/02/2022.
	The proposed proprietary name / brand name	**Rezole 40mg Capsule**.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Omeprazole (as enteric coated pellets) …….. 40mg
	Pharmaceutical form of applied drug	Oral capsule
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor.
	Reference to Finished product specifications	USP Specifications.
	Proposed Pack size	14's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Omeprazole 40mg delayed release capsule, USFDA Approved.
	For generic drugs (me-too status)	Omega 40mg Capsule, Ferozsons Laboratories, Reg. No. 050818.
	GMP status of the Finished product manufacturer	Not submitted.
	Evidence of section approval.	Capsule (general) - New section approved vide No.F.1-12/97-Lic (Vol-II) dated 24-11-2021.
	Name and address of API manufacturer.	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for drug substance data related to nomenclature, structure, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months. Batches: (OEC-22-001, OEC-22-002 & OEC-22-003)

	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for quality tests (Description, identification, Average weight, dissolution & assay) for their product against Omega 40mg Capsule. Firm has submitted CDP against the brand i.e. Risek 40mg Capsule manufactured by the Getz pharma. Results of the f2 values are in acceptable range.
	Analytical method validation/verification of product	Not submitted.

STABILITY STUDY DATA			
Manufacturer of API	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.		
API Lot No.	OEC-22-015.		
Description of Pack (Container closure system)	2 blisters of 7's capsules of Alu-Alu in single unit carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RLE001	RLE002	RLE001
Batch Size	5600 capsules	5600 capsules	5600 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	29-10-2021	29-10-2021	29-10-2021
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION		
The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.		
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate No.43/2022-DRAP (AD-00196339815-153) dated 07-04-2022 on the basis of inspection conducted on 30-03-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted commercial invoice No. 0571 dated 01-10-2021 of pharma zone chemical (Pvt.) Limited with buyer's name of Well care pharmaceuticals mentioning 1kg quantity of each

		8.5% Omeprazole pellets & 22.5% pellets of Omeprazole.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their system is not 21 CFR compliant.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks by the Evaluator:

Sr. No.	Section number	Observation	Submission by the firm.
1.	1.3.4	• Valid copy of DML of the manufacturer shall be submitted. • GMP certificate/last inspection report of the drug product manufacturer shall be submitted.	Copy of DML is submitted which is not in readable form. One page of inspection report is submitted conducted on 10-09-2021 signed by only one member out the three panel members wherein following is recommended; "Panel recommended resumption of production and grant of new capsule section. Detailed report was prepared on prescribed format and copy was handed over to the firm for record and reference."
2.	2.3	Table for literature references of the drug substance has mentioned drug substance in different pharmacopoeias. Clarification shall be submitted.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error. ***No revised table for literature references has been submitted by the firm.***
3.	3.2.S.1.3	General properties, solubilities and physical form related data for the drug substance shall be submitted.	Submitted.
4.	3.2.S.4.1	• Finished product manufacturer has submitted Specification as per USP for drug substance while there is no monograph for the omeprazole pellets in the USP.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error. ***No revised specifications are provided/submitted by the firm.***
5.	3.2.S.4.2	Analytical procedures submitted by the drug product manufacturer are different from drug substance manufacturer. Clarification is required.	Firm has submitted that drug substance analytical procedure is manufacturer specifications because Omeprazole EC pellets is not available in any pharmacopoeia. ***However, new* analytical procedure *for the drug substance as per manufacturer specifications are not provided by the drug product manufacturer.***
6.	3.2.S.4.3	Verification studies of the drug substance performed by the finished product manufacturer shall be submitted.	Submitted.
7.	.2.S.4.5.	Justification of specifications has declared USP specification. Clarification is required.	Firm has submitted that omeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error.
8.	3.2.S.5	COA of the reference standard used shall be submitted.	Firm has submitted COA for the working standard for omeprazole. ***However, the drug substance source as per submitted dossier is M/s Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore while the submitted COA is for M/s Vision Pharmaceuticals, Islamabad.***

9.	3.2.P.2	• Pharmaceutical equivalence studies are performed with Risek 40mg by Getz pharma while the results are given for Omega 40mg by Ferozsons laboratories. Clarification is required. • Justification shall be submitted for not performing CDP against the innovator product. • Justification shall be submitted regarding dissolution and assay of the applied formulation in the pharmaceutical equivalence studies. As the medium of the dissolution and time are not in accordance with the monograph. • Justify the condition of dissolution used in comparative dissolution studies. • Justification shall be submitted for carrying dissolution studies up to 30 minutes time point only in 0.1N HCl in Comparative Dissolution studies.	Firm has submitted that it was typographic error and pharmaceutical equivalence studies are performed with Risek. ***No reply submitted.*** Firm has submitted that test is performed according to the monograph but this time is typographical mistake. Firm has submitted that dissolution studies are performed according to monograph; we have 5 sampling intervals in 0.1 N HCl and phosphate buffer pH 4.5 and phosphate buffer pH 6.5. Firm has submitted that it is a typographic error while the dissolution in 0.1 N HCl is performing 120minutes.
10.	3.2.P.5.2	• Analytical procedures for the drug product are different from the official monograph. Clarification is required. • Assay in the official monograph is through HPLC while applicant has mentioned UV spectroscopy in its analytical procedures. Clarification shall be submitted.	***No reply/justification submitted.*** ***No reply/justification submitted.***
11.	3.2.P.5.2	Analytical method validation/verification of product shall be submitted.	
12.	3.2.P.5.4	• Specification of dissolution test in the batch analysis are without time for buffer stage and without percentage for acid stage. • Batch analysis has only buffer stage dissolution results.	***No reply/justification submitted.*** ***No reply/justification submitted.***
13.	3.2.P.8.3	• Stability data sheets have no dissolution at acidic stage. Clarification is required. • Weight/10 capsule in the stability data sheets is 268mg ± 10%. Clarification shall be submitted in this regard. • Raw data sheets for stability has mentioned label claim of 20mg. clarification shall be submitted. • Justification shall be submitted regarding the run time for the assay of finished product as the applied run time is different from that of the official monograph. • Justification regarding the drug substance shall be submitted with respect to the total quantity of the drug substance purchased and total quantity used in manufacturing and testing of all the three trial batches of Rezole 40mg capsule.	***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.***
14.	3.2.P.8.3	Justification shall be submitted regarding the retention time of the omeprazole in the provided chromatograms as two different	***No reply/justification submitted.***

		retention time are mentioned for the same omeprazole.	
15.		• Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Complete Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated). • Provide specifications of HPLC system with its model including information whether gradient or isocratic column, 21 CFR compliance system. • Raw data sheets for dissolution and assay test of the finished product shall be submitted with calculation formula used. • Justification shall be submitted for the stability of both drug substance and finished product that the values at both accelerated and real time are exactly similar at same time points.	***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.*** ***No reply/justification submitted.***

Previous Decision: Registration Board decided to defer the case for onsite verification and authenticity of the submitted stability data due to following observations:

- Drug substance analytical procedure applied by the drug product manufacturer is different from that applied by the drug substance manufacturer.
- Submitted COA of working standard is from M/s Vision Pharmaceuticals whereas drug substance has been procured from M/s Pharmazone Chemicals.
- Submitted analytical record of CDP reflects that for pH 1.2, comparative dissolution studies have been conducted for 45 minutes only while the limits are NMT 10% release in pH 1.2 for two hours.
- Assay in the official monograph is through HPLC while applicant has mentioned UV spectroscopy in its analytical procedures.
- The analytical method for dissolution test and for assay test applied by the drug product manufacturer are completely different in terms of run time, injection volume, wavelength, standard solution preparation etc.., from that of the USP monograph as also evident from the submitted HPLC chromatograms.
- Submitted HPLC chromatograms reflect two different retention time for 20mg and 40 mg Omeprazole capsule.
- Quantity of Omeprazole pellets procured, as evident from submitted invoice is not justified for the manufacturing of trial batches of submitted batch size.
- Drug product Batch analysis has only buffer stage dissolution results.
- Dates in the submitted chromatograms have been over written by hand.
- Raw data sheets for dissolution and assay tests are not provided by the firm.
- Stability data sheets have no dissolution at acidic stage. Clarification is required.
- Raw data sheets for stability has mentioned label claim of 20mg.
- In performance of Assay test the applied run time is different from that of the official monograph.

934.	Name, address of Applicant / Marketing Authorization Holder	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)

		☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 19735: dated 06-07-2022.
	Details of fee submitted	PKR 30,000/-: dated 31/05/2022.
	The proposed proprietary name / brand name	**ESOWELL 20mg Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Esomeprazole magnesium trihydrate enteric coated pellets Eq. to Esomeprazole …….. 20mg
	Pharmaceutical form of applied drug	Blue & Transparent colored Delayed Release Capsules
	Pharmacotherapeutic Group of (API)	PPI (Proton Pump Inhibitors).
	Reference to Finished product specifications	USP
	Proposed Pack size	2×7
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Nexium 40mg & 40mg delayed release capsule, USFDA Approved.
	For generic drugs (me-too status)	Nexum 20mg Capsule, Getz Pharma, Reg. No. 033890.
	GMP status of the Finished product manufacturer	Not submitted.
	Evidence of section approval.	Capsule (general) - New section approved vide No.F.1-12/97-Lic (Vol-II) dated 24-11-2021.
	Name and address of API manufacturer.	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months.

		Batches: (EEC-22-002, EEC-22-003 & EEC-22-004)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for quality tests (Description, identification, Weight variation, Loss on drying, Uniformity of dosage unit, dissolution & assay) for their product against Nexum 20mg capsules manufactured by Getz Pharma. Firm has submitted CDP against the same brand i.e. Nexum 20mg capsules (B. No. 384C12) manufactured by Getz Pharma.
	Analytical method validation/verification of product	Not submitted.

STABILITY STUDY DATA

Manufacturer of API	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.		
API Lot No.	EEC-22-222.		
Description of Pack (Container closure system)	14 capsules are blistered in Alu-Alu foil and with aluminum foil.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	EW1	EW2	EW3
Batch Size	5600 capsules	5600 capsules	5600 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	16-10-2021	21-10-2021	23-10-2021
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate No.43/2022-DRAP (AD-00196339815-153) dated 07-04-2022 on the basis of inspection conducted on 30-03-2022.

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted commercial invoice No. 0571 dated 01-10-2021 of pharma zone chemical (Pvt.) Limited with buyer's name of Well care pharmaceuticals mentioning 1kg quantity of each 8.5% Omeprazole pellets & 22.5% pellets of Esomeprazole.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their system is not 21 CFR compliant.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks by the Evaluator:

Sr. No.	Section number	Observation	Submission by the firm.
1.	1.3.4	• Valid copy of DML of the manufacturer shall be submitted. • GMP certificate/last inspection report of the drug product manufacturer shall be submitted.	Copy of DML is submitted which is not in readable form. One page of inspection report is submitted conducted on 10-09-2021 signed by only one member out the three panel members wherein following is recommended; "Panel recommended resumption of production and grant of new capsule section. Detailed report was prepared on prescribed format and copy was handed over to the firm for record and reference."
2.	1.5.15 – 1.5.19	All the commitments submitted are unsigned. Signed commitments shall be submitted.	Signed commitments are submitted by the firm.
3.	2.3	Table for literature references of the drug substance has mentioned drug substance in different pharmacopoeias. Clarification shall be submitted.	Firm has submitted that esomeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error. ***No revised table for literature references has been submitted by the firm.***
4.	3.2.S.4.1	Finished product manufacturer has submitted Specification as per USP for drug substance while there is no monograph for the pellets in the USP. Clarification is required.	Firm has submitted that it was typographical error while the specifications of the Esomeprazole pellets are manufacturer specifications. ***However, new specifications for the drug substance as per manufacturer specifications are not provided by the drug product manufacturer.***
5.	3.2.S.4.2	• Analytical procedure for drug substance provided by the finished product manufacturer is completely different from that of drug substance manufacturer. Clarification shall be submitted. • Drug substance has mentioned assay by HPLC while finished product manufacturer has mentioned UV spectroscopy. Clarification shall be submitted. • Justify the preparation of standard solution and sample solution in dissolution test of analytical procedure with respect to the drug substance manufacturer.	Firm has submitted that drug substance analytical procedure is manufacturer specifications. ***However, new* analytical procedure *for the drug substance as per manufacturer specifications are not provided by the drug product manufacturer.*** Firm has submitted that manufacturer have two testing methods one that on HPLC & other on UV and we have used HPLC method of testing for the drug substance testing. Firm has submitted that manufacturer has used omeprazole working standard against Esomeprazole test in assay and dissolution but we have used esomeprazole working standard for the testing of Esomeprazole EC pellets. ***Completely different from manufacturer of drug substance.***

6.	3.2.S.4.3	Verification studies of the drug substance performed by the finished product manufacturer shall be submitted.	Submitted.
7.	3.2.S.4.5.	Justification of specifications for the drug substance shall be submitted.	Submitted.
8.	3.2.S.5	COA of the reference standard used shall be submitted.	Submitted.
9.	3.2.P.2	• Standard Operating procedure for product design and development is for syrup and suspension dosage form. • Justification shall be submitted for not performing CDP against the innovator product. • Justify the condition of dissolution used in comparative dissolution studies. • Justify the analytical procedure for CDP as it has mentioned Phosphate buffer of pH7.3, pH 11. • Justify the results of CDP at acid stage as more than 10% of the drug is released in 30 minutes.	***No reply submitted.*** Firm has submitted new CDP results of the applied formulation with Nexum 20mg capsules in three mediums and the f2 values are in acceptable range. ***However, at acidic medium pH 1.2, results for only 45 minutes time points are submitted instead of 2 hours. Furthermore, submitted CDP results for Esowell 20mg capsules are having 100% similar results and values as that of submitted results for Esocare 40mg.*** ***No justification is submitted against this point. pH 7.3 and pH 11 are used in the method.*** ***No justification is submitted against this point.*** ***No justification is submitted against this point.***
10.	3.2.P.5.1	• Specification provided for the drug product has not mentioned dissolution at acidic stage. • Dissolution test shall be specified whether test I or any of the other test is followed by the drug product manufacturer or otherwise.	Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.*** ***No justification is submitted against this point.***
11.	3.2.P.5.2	• Calculation formula for assay test of the finished product is different from USP. Clarification is required. • Standard solution in dissolution test is different from USP. Clarification is required.	***No justification is submitted against this point.*** The manufacturer is using Omeprazole working standard against Esomeprazole test in assay and dissolution but we have used Esomeprazole working standard for the testing of Esomeprazole EC pellets. ***Official monograph has mentioned Omeprazole RS for preparation of standard solution in the assay of Esomeprazole delayed release capsule.***
12.	3.2.P.5.2	Analytical method validation/verification of product shall be submitted.	Submitted.
13.	3.2.P.5.4	• Specification of dissolution test in the batch analysis are without time for buffer stage and without percentage for acid stage. • Batch analysis has only buffer stage dissolution results.	Firm has submitted that all limits are mentioned in analytical procedures but mistakenly not mentioned in batch analysis. Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.***

14.	3.2.P.8.3	• Stability data sheets have no dissolution at acidic stage. Clarification is required. • Stability raw data sheets provided for EW1 & EW2 have two different weight for the sample. Clarification shall be submitted. • Justification shall be submitted regarding the run time and injection volume used for the assay of finished product as the applied conditions are different from that of the official monograph.	Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.*** Firm has submitted that stability raw data sheets of EC1 & EC2 have two different weights one is content weight of pellets and second weight is gross weight with capsule shell. Firm has submitted that testing of the product is performed as per USP. The run time is about 10 minutes and injection volume are 20µl and flow rate is 1ml/min. column used is 4.6 mm x 15cm; 5µmpacking L1 and detector is 302nm. ***Conditions are different from official monograph.***
15.		• Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Complete Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated). • Provide specifications of HPLC system with its model including information whether gradient or isocratic column, 21 CFR compliance system. • Raw data sheets for dissolution and assay test of the finished product shall be submitted with calculation formula used. • Justification shall be submitted for the stability of finished product that the values at both accelerated and real time are exactly similar at same time points.	Only one-page Esomeprazole capsule 06 standard injection is provided. ***Not complete.*** Submitted. Only specifications of HPLC are provided while 21 CFR compliant certificate is not provided. ***Raw data sheets for dissolution and assay tests are not provided by the firm.*** ***No reply is submitted against this point.***
16.		Justification regarding the drug substance shall be submitted with respect to the total quantity of the drug substance purchased and total quantity used in manufacturing and testing of all the three trial batches of Esowell 20mg capsule.	Firm has submitted that they purchased Esomeprazole 8.5% and 22% each 1kg for three trial batches. Total material use in trial batches for testing. ***However, firm has not provided any document for purchase of 8.5% Esomeprazole EC pellets.*** ***Executed BMR's have shown that in Esowell 20 mg capsules 22.5% of pellets have been used. Stability data sheets have three different batches each with 5600 capsules batch size.*** ***In this regard total number of capsules manufactured are;*** ***5600 x 3 = 16800*** ***Each 20mg capsule will have 88.8 mg of Esomeprazole EC pellets.*** ***16800 x 88.8 = 1,491,840 mg of pellets*** ***1.49 kg pellets are required to fill the three trial batches while firm has purchased only 1kg.***
17.		Justification shall be submitted regarding the chromatograms provided for Esowell 20mg and Esocare 40 mg capsules as chromatograms for both the products have same time and exact values in respect of everything.	Firm has submitted that the chromatograph of Esowell 20mg and Esocare 40mg are print on same date but the test is performed in different dates. ***Chromatographs of both the 20mg and 40mg Esomeprazole are complete copies in respect of time, Areas of the sample and standards, retentions time etc.***

Previous Decision: Registration Board decided to defer the case for onsite verification and authenticity of the submitted stability data due to following observations:

- Drug substance analytical procedure applied by the drug product manufacturer is different from that applied by the drug substance manufacturer.

• Submitted analytical record of CDP reflects that for pH 1.2, comparative dissolution studies have been conducted for 45 minutes only while the limits are NMT 10% release in pH 1.2 for two hours. • The results of CDP at acid stage of different samples were more than 10% of the drug is released in 30 minutes. • Firm has used Esomeprazole reference standard while Official monograph has mentioned Omeprazole RS for preparation of standard solution in the dissolution test of Esomeprazole delayed release capsule. • Firm has used Esomeprazole reference standard while Official monograph has mentioned Omeprazole RS for preparation of standard solution in the assay test of Esomeprazole delayed release capsule. • Verification of chromatographic conditions used in the dissolution and assay test of the Esomeprazole delayed release capsule from chromatograms in the HPLC software with reference to official monograph. • Quantity of Esomeprazole pellets procured, as evident from submitted invoice is not justified for the manufacturing of trial batches of submitted batch size. • Both accelerated and real time stability data sheets are having exactly similar values at same time points. • The chromatograms for both Esomeprazole 20mg and 40mg capsules have same time and exact values in respect of everything.		
935.	Name, address of Applicant / Marketing Authorization Holder	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Well care Pharmaceuticals (Pvt.) Ltd., A/7, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 19734: dated 06-07-2022.
	Details of fee submitted	PKR 30,000/-: dated 31/05/2022.
	The proposed proprietary name / brand name	**Esocare 40mg Capsule**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Esomeprazole magnesium trihydrate enteric coated pellets Eq. to Esomeprazole …….. 40mg
	Pharmaceutical form of applied drug	Delayed Release Capsules.
	Pharmacotherapeutic Group of (API)	PPI (Proton Pump Inhibitors).
	Reference to Finished product specifications	USP
	Proposed Pack size	2×7
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Nexium 40mg & 40mg delayed release capsule, USFDA Approved.
	For generic drugs (me-too status)	Nexum 20mg Capsule, Getz Pharma, Reg. No. 033891.
	GMP status of the Finished product manufacturer	Not submitted.
	Evidence of section approval.	Capsule (general) - New section approved vide No.F.1-12/97-Lic (Vol-II) dated 24-11-2021.
	Name and address of API manufacturer.	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months. Batches: (EEC-22-002, EEC-22-003 & EEC-22-004)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Firm has submitted results of pharmaceutical equivalence for quality tests (Description, identification, Weight variation, Loss on drying, Uniformity of dosage unit, dissolution & assay) for their product against Nexum 20mg capsules manufactured by Getz Pharma. Firm has submitted CDP against the same brand i.e. Nexum 40mg capsules (B. No. 382C12) manufactured by Getz Pharma.
	Analytical method validation/verification of product	Not submitted.

STABILITY STUDY DATA	
Manufacturer of API	Pharmazone Chemicals (Pvt.) Ltd., Plot No. 37, Sundar Industrial Estate, Lahore.
API Lot No.	EEC-22-222.
Description of Pack (Container closure system)	14 capsules are blistered in Alu-Alu foil and with aluminum foil.
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5% RH

	Accelerated: 40˚C ± 2˚C / 75% ± 5% RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	EC1	EC2	EC3
Batch Size	5600 capsules	5600 capsules	5600 capsules
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	15-10-2021	20-10-2021	22-10-2021
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate No.43/2022-DRAP (AD-00196339815-153) dated 07-04-2022 on the basis of inspection conducted on 30-03-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted commercial invoice No. 0571 dated 28-12-2021 of pharma zone chemical (Pvt.) Limited with buyer's name of Well care pharmaceuticals mentioning 1kg quantity of each 8.5% Omeprazole pellets & 22.5% pellets of Esomeprazole.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their system is not 21 CFR compliant.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks by the Evaluator:

Sr. No.	Section number	Observation	Submission by the firm.
1.	1.3.4	• Valid copy of DML of the manufacturer shall be submitted. • GMP certificate/last inspection report of the drug product manufacturer shall be submitted.	Copy of DML is submitted which is not in readable form. One page of inspection report is submitted conducted on 10-09-2021 signed by only one member out the three panel members wherein following is recommended; "Panel recommended resumption of production and grant of new capsule section. Detailed report was prepared on prescribed format and copy was handed over to the firm for record and reference."
2.	1.5.15 – 1.5.19	All the commitments submitted are unsigned. Signed commitments shall be submitted.	Signed commitments are submitted by the firm.
3.	2.3	Table for literature references of the drug substance has mentioned drug substance in different pharmacopoeias. Clarification shall be submitted.	Firm has submitted that esomeprazole pellets specification is manufacturer specifications and pharmacopoeial specifications were typographical error.

			No revised table for literature references has been submitted by the firm.
4.	3.2.S.4.2	• Analytical procedures for drug substance provided by the finished product manufacturer is completely different from that of drug substance manufacturer. Clarification shall be submitted. • Justify the preparation of standard solution and sample solution in dissolution test of analytical procedure with respect to the drug substance manufacturer.	Firm has submitted that drug substance analytical procedure is manufacturer specifications (In-house method). ***However, new* analytical procedure *for the drug substance as per manufacturer specifications are not provided by the drug product manufacturer.*** Firm has submitted that manufacturer has used omeprazole working standard against Esomeprazole test in assay and dissolution but we have used esomeprazole working standard for the testing of Esomeprazole EC pellets. ***Completely different from manufacturer of drug substance.***
5.	3.2.S.4.3	Verification studies of the drug substance performed by the finished product manufacturer shall be submitted.	Submitted.
6.	3.2.S.4.5.	Justification of specifications for the drug substance shall be submitted.	Submitted.
7.	3.2.P.2	• Standard Operating procedure for product design and development is for syrup and suspension dosage form. • Justification shall be submitted for not performing CDP against the innovator product. • Justify the condition of dissolution used in comparative dissolution studies. • Justify the analytical procedure for CDP as it has mentioned Phosphate buffer of pH7.3, pH 11. • Justify the results of CDP at acid stage as more than 10% of the drug is released in 30 minutes.	***No reply submitted.*** Firm has submitted new CDP results of the applied formulation with Nexum 20mg capsules in three mediums and the f2 values are in acceptable range. ***However, at acidic medium pH 1.2, results for only 45 minutes time points are submitted instead of 2 hours. Furthermore, submitted CDP results for Esocare 40mg capsules are having 100% similar results and values as that of submitted results for Esowel 20mg.*** ***No justification is submitted against this point.*** ***No justification is submitted against this point.*** ***No justification is submitted against this point***
8.	3.2.P.5.1	• Specification provided for the drug product has not mentioned dissolution at acidic stage. • Dissolution test shall be specified whether test I or any of the other test is followed by the drug product manufacturer or otherwise.	Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.*** ***No justification is submitted against this point.***
9.	3.2.P.5.2	• Calculation formula for assay test of the finished product is different from USP. Clarification is required. • Standard solution preparation in dissolution test is different from USP. Clarification is required.	***No justification is submitted against this point.*** The manufacturer is using Omeprazole working standard against Esomeprazole test in assay and dissolution but we have used Esomeprazole working standard for the testing of Esomeprazole EC pellets. ***Official monograph has mentioned Omeprazole RS for preparation of standard solution in the assay of Esomeprazole delayed release capsule.***

10.	3.2.P.5.2	Analytical method validation/verification of product shall be submitted.	Submitted.
11.	3.2.P.5.4	• Specification of dissolution test in the batch analysis are without time for buffer stage and without percentage for acid stage. • Batch analysis has only buffer stage dissolution results.	Firm has submitted that all limits are mentioned in analytical procedures but mistakenly not mentioned in batch analysis. Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.***
12.	3.2.P.8.1	Stability summary and conclusion has manufacturing date of Jan-2022 with batch No. of RLE-001, RLE-002 & RLE-003 while the stability data sheets have mentioned manufacturing date of 10-2021 with batch No. of T1/21, T2/21 & T3/21. Clarification is required.	Firm has submitted that manufacturing date of their batches is October, 2021 but the January, 2021 is a testing interval date.
13.	3.2.P.8.3	• Stability data sheets have no dissolution at acidic stage. Clarification is required. • Stability raw data sheets provided for EC1 & EC2 have two different weight for the sample. Clarification shall be submitted. • Justification shall be submitted regarding the run time and injection volume used for the assay of finished product as the applied conditions are different from that of the official monograph.	Firm has submitted that details of dissolution at acidic and buffer stage are described in stability summary data sheets. ***Stability summary sheets have only buffer stage dissolution results dissolution stage results are missing in stability summary data sheets.*** Firm has submitted that stability raw data sheets of EC1 & EC2 have two different weights one is content weight of pellets and second weight is gross weight with capsule shell. Firm has submitted that testing of the product is performed as per USP. The run time is about 10 minutes and injection volume are 20µl and flow rate is 1ml/min. column used is 4.6 mm x 15cm; 5µm packing L1 and detector is 302nm. ***Conditions are different from official monograph.***
14.		• Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Complete Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated). • Provide specifications of HPLC system with its model including information whether gradient or isocratic column, 21 CFR compliance system. • Raw data sheets for dissolution and assay test of the finished product shall be submitted with calculation formula used.	Only one-page Esomeprazole capsule 06 standard injection is provided. ***Not complete.*** Submitted. Only specifications of HPLC are provided while 21 CFR compliant certificate is not provided. ***Raw data sheets for dissolution and assay tests are not provided by the firm.***
15.		Justification regarding the drug substance shall be submitted with respect to the total quantity of the drug substance purchased and total quantity used in manufacturing and testing of all the three trial batches of Esocare 40mg capsule.	Firm has submitted that they purchased Esomeprazole 8.5% and 22% each 1kg for three trial batches. Total material use in trial batches for testing. ***However, firm has provided the documents for 22.5% esomeprazole only for 1kg quantity. Executed BMR's have shown that in Esocare 40 mg capsules 22.5% of pellets have been used. Stability data sheets have three different batches each with 5600 capsules batch size. In this regard total number of capsules manufactured are;*** ***5600 x 3 = 16800***

			Each 40mg capsule will have 177.7mg of Esomeprazole EC pellets. ***16800 x 177.7 = 2,985,360 mg of pellets*** ***2.9 kg pellets are required to fill the three trial batches while firm has purchased only 1kg.***
16.		Justification shall be submitted regarding the chromatograms provided for Esowell 20mg and Esocare 40 mg capsules as chromatograms for both the products have same time and exact values in respect of everything.	Firm has submitted that the chromatograph of Esowell 20mg and Esocare 40mg are print on same date but the test is performed in different dates. ***Chromatographs of both the 20mg and 40mg Esomeprazole are complete copies in respect of time, Areas of the sample and standards, retentions time etc.***

Previous Decision: Registration Board decided to defer the case for onsite verification and authenticity of the submitted stability data due to following observations:

- Drug substance analytical procedure applied by the drug product manufacturer is different from that applied by the drug substance manufacturer.
- Submitted analytical record of CDP reflects that for pH 1.2, comparative dissolution studies have been conducted for 45 minutes only while the limits are NMT 10% release in pH 1.2 for two hours.
- The results of CDP at acid stage of different samples were more than 10% of the drug is released in 30 minutes.
- Firm has used Esomeprazole reference standard while Official monograph has mentioned Omeprazole RS for preparation of standard solution in the dissolution test of Esomeprazole delayed release capsule.
- Firm has used Esomeprazole reference standard while Official monograph has mentioned Omeprazole RS for preparation of standard solution in the assay test of Esomeprazole delayed release capsule.
- Verification of chromatographic conditions used in the dissolution and assay test of the Esomeprazole delayed release capsule from chromatograms in the HPLC software with reference to official monograph.
- Quantity of Esomeprazole pellets procured, as evident from submitted invoice is not justified for the manufacturing of trial batches of submitted batch size.
- Both accelerated and real time stability data sheets are having exactly similar values at same time points.

The chromatograms for both Esomeprazole 20mg and 40mg capsules have same time and exact values in respect of everything.

M/s Well Care Pharmaceuticals, A/7 P.S.I.E. Sargodha vide their reference No. WC/1213/22 dated 20-12-2022 submitted an application with subject of "Withdrawal request of our applications for registration" wherein they have submitted that that would like to withdraw their below mentioned submitted applications for registrations on their own reasons;

Sr. No.	Generic with strength	Brand name	Fee date	Submission date
1.	Omeprazole 20mg capsule	Tzole 20mg capsule	21-03-2022	12-08-2022
2.	Omeprazole 40mg capsule	Tzole 40mg capsule	21-03-2022	12-08-2022
3.	Esomeprazole 20mg capsule	Esowell 20mg capsule	21-03-2022	12-08-2022
4.	Esomeprazole 40mg capsule	Esowell 40mg capsule	21-03-2022	12-08-2022

They further requested to please accommodate them and approve their withdrawal request.

Decision: Registration Board decided to acceded the request of M/s Well Care Pharmaceuticals, A/7 P.S.I.E. Sargodha regarding withdrawal of their registration applications i.e., Tzole 20mg Capsule. , Tzole 20mg Capsule. ESOWELL 20mg Capsule ESOWELL 20mg Capsule, Esocare 40mg Capsule & Tzole 40mg capsule and declared them as disposed of.

936.	Name, address of Applicant / Marketing Authorization Holder	Wilson's Pharmaceuticals, Plot No. 387-388, Sector I-9, Industrial Area, Islamabad.
	Name, address of Manufacturing site.	Wilson's Pharmaceuticals, Plot No. 387-388, Sector I-9, Industrial Area, Islamabad.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales.
	Dy. No. and date of submission	Form-5F Dy. No. 26709 dated 27-09-2021.
	Details of fee submitted	PKR 75,000/-: dated 20-09-2021.
	The proposed proprietary name / brand name	Coldenol Sinus Severe Caplets (day).
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated Caplet contains; Paracetamol …… 325mg Phenylephrine HCl …… 5mg Guaifenesin …… 200mg
	Pharmaceutical form of applied drug	Oral tablet.
	Pharmacotherapeutic Group of (API)	Paracetamol, combinations excl. Psycholeptics. (N02BE51)
	Reference to Finished product specifications	Manufacturer specifications.
	Proposed Pack size	10's, 20's & 30's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Tylenol Sinus Severe (day), USFDA is provided by the firm. However, the same could not be found in USFDA data. Daily med has the same product as OTC product with the following disclaimer: *Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.*
	For generic drugs (me-too status)	Could not be confirmed.
	GMP status of the Finished product manufacturer	Inspection report of 24-01-2018. Not valid.
	Evidence of section approval.	Tablet (general) section approved vide No. F. 1-19/92-Lic (P1) dated 27-07-2015.
	Name and address of API manufacturer.	Paracetamol: Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi. Guaifenesin: Zhejiang Haizhou Pharmaceutical Co., Ltd., linhai Industrial Zone, Linhai Zhejiang China. Phenylephrine Hydrochloride. M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzhen China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, analytical procedures and its validation, batch analyses and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paracetamol (USP/BP), Guaifenesin (USP) and Phenylephrine HCl (USP/BP) is present respectively. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description

		of manufacturing process and controls, tests impurities B,C,D, Individual Impurity I & any unspecified for Paracetamol, Impurities A,B,C and D for Guaifenesin and Impurities A,C,D,E and unspecified impurity for Phenylephrine HCl, specifications, analytical procedures and its validation, batch analyses and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of the following drug substances as per Zone IV-a for both accelerated as well as real time conditions: Paracetamol: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 12 months. (Batch No. 18GN60001, 18GN60002, and 18GN60003) Guaifenesin: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 72 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months. (Batch No. 08GF04156, 08GF04157, and 08GF04158) Phenylephrine hydrochloride. Real time: 30˚C ± 2˚C / 65% ± 5%RH for 48 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months. (Batch No. PEH-160404, PEH-160405, and PEH-160406)
	Module-III (Drug Product):	The firm has submitted detail of description, composition, pharmaceutical development, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against Tylenol Sinus Severe Caplets DAY by performing quality tests (Assay, Dissolution, Disintegration Time test). CDP has been performed against the same product that is Tylenol Sinus Severe Caplets DAY, Lot No. 485556 made in Italy, distributed by M/s Johnson & Johnson Consumer Inc., Mc Neil Consumer Healthcare Division USA in 0.1 N HCl, Acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have been submitted including: system suitability, accuracy, and precision.
STABILITY STUDY DATA		
Manufacturer of API		Paracetamol: Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi. Guaifenesin: Zhejiang Haizhou Pharmaceutical Co., Ltd., Linhai Industrial Zone, Linhai Zhejiang China. Phenylephrine Hydrochloride. M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzhen China.

API Lot No.	Paracetamol (Batch No.19GN60209, Batch No.19GN60213) Guaifenesin (Batch No.18GF03204) Phenylephrine HCl (Batch No.PEH-180101Y1)		
Description of Pack (Container closure system)	Alu-Alu blister packed in card box unit carton of 10's, 20's & 30's.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trial 01	Trial 02	Trial 03
Batch Size	1500 caplets	1500 caplets	1500 caplets
Manufacturing Date	17-12-2019	23-12-2019	23-12-2019
Date of Initiation	01-01-2020	01-01-2020	01-01-2020
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has submitted Reference of previous approval of applications with stability study data.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificates of: Paracetamol: Copy of GMP certificate No. 83/2020-DRAP(K) of M/s Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi issued by DRAP Karachi valid till 18/06/2022. Guaifenesin: Copy of GMP certificate No. ZJ20180122 of Zhejiang Haizhou Pharmaceutical Co., Ltd., Linhai Industrial Zone, Linhai city Zhejiang China issued by China food & Drug Administration valid until 09-25-2023. Phenylephrine Hydrochloride. Not provided.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Paracetamol Copy of commercial invoice No. PRT/2019/0191 dated 18/03/2019 is submitted. Copy of commercial invoice No. PRT/2019/0197 dated 25/03/2019 is submitted. • Guaifenesin Copy of clearance certificate attested by AD (I&E) DRAP, Islamabad dated 16/07/2018 along with commercial invoice No.130128 dated 22/06/2018 with quantity of 0.75Kg is submitted. • Phenylephrine HCl Copy of clearance certificate attested by AD (I&E) DRAP, Islamabad dated 10/05/2018 along with

		commercial invoice No. SZ-1803039 dated 12/04/2018 with quantity of 308.25 Gram is submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section No.	Observation	Response by the firm
1.	1.3	Valid copy of DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be provided.	Firm has not provided any renewal of DML. Firm has submitted GMP inspection report dated 24-01-2018. *Provided GMP inspection report is not within last three years.*
2.	1.5.9	Evidence of approval of applied formulation in reference regulatory authorities as decided by the registration board shall be submitted as the provided reference could not be confirmed.	Tylenol Sinus Severe (day), USFDA is provided by the firm. However, the same could not be found in USFDA data. Daily med has the same product as OTC product with the following disclaimer: *Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.*
3.	1.6.5	• Address of the API manufacturer for guaifenesin provided in section 1.6.5 is different from that of mentioned in GMP certificate. Clarification is required. • Valid GMP certificate of the drug substance manufacturer (phenylephrine HCL) issued by the concerned / relevant regulatory authority shall be submitted.	• Firm has submitted that due to typographical error, the address of the drug substance manufacturer mentioned in section 1.6.5 was written wrong. *Firm has submitted a document "Announcement of the state drug administration on matters concerning the implementation of the Drug Administration Law of the People's Republic of China" wherein under the heading of drug GMP & GSP management requirements following is stated.* *'starting from December 1, 2019 the pharmaceutical GMP and GSP certifications will be cancelled, GMP and GSP certificates will no longer be accepted and pharmaceutical GMP and GSP certificates will no longer be issued. Where current regulation require on site inspection, on-site inspection shall be continued after December 1, 2019 and the company shall be notified of the on-site inspection results. '*
4.	3.2.S.4.2	Guaifenesin: • Analytical method used for drug substance (guaifenesin) by the drug substance manufacturer shall be submitted. • Analytical method provided by the drug product manufacturer for drug substance (guaifenesin) has mentioned 40g/ml while the pharmacopoeia has mentioned 40mcg/ml in Identification test. Clarification is required.	Submitted. Firm has submitted that due typographic error 40g/ml was written instead of 40mcg/ml. However, finished product manufacturer has followed USP method for drug substance.

		Phenylephrine HCL: • Analytical method used for drug substance (phenylephrine HCL) by drug substance manufacturer shall be submitted.	Submitted.
5.	3.2.S.4.3	Verification studies of all the three drug substances performed by the drug product manufacturer shall be submitted.	Submitted.
6.	3.2.S.4.4	Batch analysis of paracetamol from Wilson pharma has not mentioned whether USP specifications or BP. Clarification is required.	Firm has submitted COA's wherein it is mentioned that the samples complies with both USP and BP.
7.	3.2.S.7.3	Both real time and accelerated stability study data for phenylephrine HCl from drug substance manufacturer shall be submitted.	Firm has submitted real time and accelerated stability study data for Phenylephrine HCl.
8.	3.2.P.2.	Qualitative composition of the applied formulation is different from reference product. Clarification is required.	• Firm has submitted that they used PVP K30 instead of HPC as binder in their formulation as both the materials are safely used in pharmaceutical industry for granulation purpose can be used interchangeably because of their excellent binding profiles, as mentioned in the hand book of pharmaceutical excipients. • Triacetin is used as plasticizer in the formulation and is used in the film coating to add plasticity to the film. Our film coating yields excellent film without use of plasticizer, so we didn't add triacetin in the formulation. • Carnauba wax is used to polish the caplet which is not necessarily required in our formulation. • Sucralose is not added in the formulation as it is used as sweetener and our formulation is neither chewable nor dispersible.
9.	3.2.P.2.2.1	Average weight of 10 tablets in pharmaceutical equivalence is 776.7gm. clarification is required.	Firm submitted that due to typographic error average weight of 10 tablets was mentioned 776.7 gm rather than 7.767gm.
10.	3.2.P.3.2	Batch formula has mentioned innovator's specification for paracetamol. clarification is required.	Firm has submitted new batch formula wherein USP specification is mentioned against paracetamol.
11.		Clearance certificate for Guaifenesin provided by the firm has mentioned 750Gm (0.75 Kg) quantity. While the firm has manufactured three trial batches of 1500 tablets each. With this respect only 900gm is required for the manufacturing of the said three trial batches. Clarification is required.	Firm has submitted that drug substance B. No. 18GF03204, quantity 750Gm was used in the manufacturing of trial 01, 02 trial batches. While B. No. 18GF03204 750gm & B. No. 18GF09667, 03 Kg respectively were used in the manufacturing of trial 03. We had submitted the clearance certificate of one batch 18GF03204 at the time of registration application submission, whereas the clearance certificate of the second batch was unintentionally overlooked. They also submitted the clearance certificate of the second batch. *However, there is no record of the second batch in the submitted application nor any verification studies of the said batch.*
12.	2.3.R	Dispensing of active materials without potency adjustment for Guaifenesin and Phenylephrine HCl. Justification is required.	Firm has submitted that potency was not adjusted for trial manufacturing batches (pilot scale) due to small batch size (1500 caplets) the adjustment amount was very low and does not affect the quality, efficacy and safety of the drug product. It is pertinent to mention here, that the finished drug product release limit is 90% - 110%. They also undertake that they will adjust the potency of drug substance at commercial batch for said drug product.

Decision of 321st meeting of Registration Board:
Deferred for further deliberation regarding regulatory status of applied formulation in reference regulatory authorities adopted by Registration Board in its 275th meeting.
Reply by the firm;
Firm has stated that that, they have applied for drug registration of our product namely Conofen 10/200mg tablet having composition (Phenylephrine HCl…..10mg, Ibuprofen…..200mg) on Form 5F (CTD) and submitted the dailymed reference i.e. Advil Congestion Relief Tablet 200mg/10mg https://dailymed.nlm.nih.gov/ dailymed/ drugInfo.cfm?setid=b1e29c19-fe03-4d2b-9660adf4eb4b4cf which was considered and no objection raised by Drug Registration Board in its 313th meeting of held on 16th -18th Nov, 2021 regarding dailymed reference.
They also submitted copy of that decision. Wherein the product is deferred for following submissions:

- *Pharmaceutical equivalence data of the applied product along with innovator / reference or comparator product.*
- *Comparative Dissolution Profile (CDP) data of the applied product along with innovator / reference or comparator product.*

Moreover, the firm M/s Vision Pharmaceuticals, Islamabad had applied for drug registration of their product namely, Mensodol Tablet 500/25mg with composition: Paracetamol 500mg and Pamabrom 25mg and provided "Proof of International availability of same formulation with same strength in RRA": https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb9a5647-b7c9-4820-b148-91060e34cb83 which was approved in 296th meeting of Drug registration Board held on 8-10th September, 2020. The product is approved.
In the light of above, it is requested to kindly registration of our aforementioned applied drug product Colynol Multi Symptom Severe Cold sachet may please be granted in the upcoming meeting of Drug Registration Board.

Decision of 322nd meeting of Registration Board: Deferred for deliberation regarding approval of applied formulation by reference regulatory authorities.

Reply by the firm;
Firm has once again submitted the link of dailymed for Tylenol sinus severe as international reference for the applied formulation.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a60184f-91a9-4b85-b243-871deca63450
They further requested to kindly grant them registration for the above mentioned formulation in the upcoming meeting of Registration Board.

Decision: Approved with innovator Specifications. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

937.	Name, address of Applicant / Marketing Authorization Holder	Wilson's Pharmaceuticals, Plot No. 387-388, Sector I-9, Industrial Area, Islamabad.
	Name, address of Manufacturing site.	Wilson's Pharmaceuticals, Plot No. 387-388, Sector I-9, Industrial Area, Islamabad.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales.
	Dy. No. and date of submission	Form-5F Dy. No. 3336 dated 03-02-2022.
	Details of fee submitted	PKR 75,000/-: dated 07-01-2022.

	The proposed proprietary name / brand name	Colynol Multi Symptom Severe Cold Sachet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Sachet contains; Paracetamol …….. 500mg Phenylephrine HCl …… 10mg Dextromethorphan HBr ……. 20mg
	Pharmaceutical form of applied drug	Sachet.
	Pharmacotherapeutic Group of (API)	Cough Suppressants and expectorants. (R05FB02)
	Reference to Finished product specifications	Manufacturer specifications.
	Proposed Pack size	10's.
	Proposed unit price	As per SRO.
	The status in reference regulatory authorities	Theraflu Multi Symptom Severe Cold Sachet. However, the same could not be found in USFDA data. Daily med has the same product as OTC product with the following disclaimer: *Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.*
	For generic drugs (me-too status)	Could not be confirmed.
	GMP status of the Finished product manufacturer	Inspection report of 24-01-2018. Not valid.
	Evidence of section approval.	Tablet (general) section approved vide No. F. 1-19/92-Lic (P1) dated 27-07-2015.
	Name and address of API manufacturer.	**Paracetamol:** Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi. Copy of GMP certificate No. 83/2020-DRAP(K) of M/s Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi issued by DRAP Karachi valid till 18/06/2022. **Dextromethorphan hydro bromide:** Onerio Chemicals (Pvt.) Limited, S. No. 475/P, At & Po Ekalbara – 391 440, Ta. Padra, Distt. Vadodara, Gujrat, India. Firm has submitted license to manufacture for sale of drugs in the name of M/s Onerio Chemicals (Pvt.) Limited, issued by the Food & Drug Administration Gujrat State India valid till 13-07-2022. **Phenylephrine Hydrochloride.** M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzhen China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, analytical procedures and its validation, batch analyses and justification of specification, reference standard, container closure system and stability studies of all the three drug substances and drug product is submitted.

	Module III (Drug Substance)	Official monograph of Paracetamol (USP/BP/EP), Dextromethorphan HBr (USP/BP/EP) and Phenylephrine HCl (USP/BP/EP) is present respectively. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests impurities, specifications, analytical procedures and its validation, batch analyses and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of the following drug substances as per Zone IV-a for both accelerated as well as real time conditions: **Paracetamol:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 12 months. (Batch No. 18GN60001, 18GN60002, and 18GN60003) **Dextromethorphan hydro bromide:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 72 months. Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months. (Batch No. DX/B/054/12, DX/B/055/12 and DX/B/056/12) **Phenylephrine hydrochloride.** Not provided.
	Module-III (Drug Product):	The firm has submitted detail of description, composition, pharmaceutical development, manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established again the innovator product that is Theraflu Multi symptom Severe Cold Sachet by performing quality tests (Assay) Assay of both the products are in acceptable range. CDP has not been performed because our applied dosage form is powder (sachet).
	Analytical method validation/verification of product	Method validation studies have been submitted including: system suitability, accuracy, and precision.

STABILITY STUDY DATA	
Manufacturer of API	**Paracetamol:** Copy of GMP certificate No. 83/2020-DRAP(K) of M/s Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi issued by DRAP Karachi valid till 18/06/2022. **Dextromethorphan hydro bromide:** Firm has submitted copy of license to manufacture for sale of drugs in the name of M/s Onerio Chemicals (Pvt.) Limited, issued by the Food & Drug Administration Gujrat State India valid till 13-07-2022. **Phenylephrine Hydrochloride.** Not provided.
API Lot No.	**Paracetamol** (Batch No.19GN60228, Batch No. 19GN60222) **Dextromethorphan HBr** (Batch No. DX/L/017/18) **Phenylephrine HCl** (Batch No.PEH-180101Y1)

Description of Pack (Container closure system)	Peach colored flavored powder packed in aluminum foil.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trial 01	Trial 02	Trial 03
Batch Size	1200 sachet	1200 sachet	1200 sachet
Manufacturing Date	04-2020	05-2020	05-2020
Date of Initiation	22-05-2020	22-05-2020	22-05-2020
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificates of: Paracetamol: Copy of GMP certificate No. 83/2020-DRAP(K) of M/s Saakh Pharma (Pvt.) Ltd., C-7/1, North Western Industrial Zone. Port Qasim, Karachi issued by DRAP Karachi valid till 18/06/2022. Guaifenesin: Copy of GMP certificate No. ZJ20180122 of Zhejiang Haizhou Pharmaceutical Co., Ltd., Linhai Industrial Zone, Linhai city Zhejiang China issued by China food & Drug Administration valid until 09-25-2023. Phenylephrine Hydrochloride. Not provided.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• **Paracetamol;** Copy of commercial invoice No. PRT/2019/0208 dated 30/03/2019 is submitted. Copy of commercial invoice No. PRT/2019/0197 dated 25/03/2019 is submitted. • **Dextromethorphan HBr;** Clearance certificate No. 794 dated 14-03-2019 mentioning 300 gm quantity of Dextromethorphan HBr EP, batch No. DX/L/017/18 attested by Assistant Director I&E is submitted by the firm. • **Phenylephrine HCl** Copy of clearance certificate attested by AD (I&E) DRAP, Islamabad dated 10/05/2018 along with commercial invoice No. SZ-1803039 dated 12/04/2018 with quantity of 308.25 Gram is submitted.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section No.	Observation	Response by the firm
1.	1.3	Valid copy of DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be provided.	
2.	1.6.5	• Valid copy of GMP certificate for drug substance manufacturer (Paracetamol) shall be submitted. • Valid copy of GMP certificate drug substance manufacturer (Phenylephrine Hydrochloride) shall be submitted. • Valid copy of manufacturing license or GMP certificate for the drug substance manufacturer (Dextromethorphan HBr) issued by concerned regulatory authority shall be submitted.	
3.	2.3.R.1	• Provide blank master production document/batch manufacturing record to be used during the commercial manufacturing of the applied product. • Provide copy of Batch manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.	
4.	3.2.S.4.2	• Analytical method used for drug substance (Paracetamol) used by the drug Product manufacturer shall be submitted. • Analytical method used for drug substance (Dextromethorphan HBr) used by the drug Product manufacturer shall be submitted. • Analytical method used for drug substance (Phenylephrine hydrochloride) used by both the drug substance manufacturer and drug Product manufacturer shall be submitted.	
5.	3.2.S.4.3	• Verification studies of the drug substance (Paracetamol) performed by the drug product manufacturer shall be submitted. • Verification studies of the drug substance (Dextromethorphan HBr) performed by the drug product manufacturer shall be submitted. • Verification studies of the drug substance (Phenylephrine hydrochloride) performed by the drug product manufacturer shall be submitted.	
6.	3.2.S.4.4	Provide results of analysis of relevant batch(es) of all the three Drug Substances (Paracetamol, Dextromethorphan HBr &	

		Phenylephrine hydrochloride) performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / /Active Pharmaceutical Ingredient manufacture.	
7.	3.2.S.8.3	Stability study data for the drug substance (Phenylephrine hydrochloride) from concerned manufacturer shall be submitted.	
8.	3.2.P.8.	Reference of previous approval of applications with stability study data of the firm shall be submitted.	

Decision of 321st meeting of Registration Board;

The Board deferred the case for the following:

- Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.
- Submission of valid copy of DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be provided.
- Submission of valid copy of GMP certificate for drug substance manufacturer (Paracetamol) shall be submitted.
- Submission of valid copy of GMP certificate drug substance manufacturer (Phenylephrine Hydrochloride) shall be submitted.
- Submission of valid copy of manufacturing license or GMP certificate for the drug substance manufacturer (Dextromethorphan HBr) issued by concerned regulatory authority shall be submitted.
- Submission of blank master production document/batch manufacturing record to be used during the commercial manufacturing of the applied product.
- Submission of copy of Batch manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.
- Submission of analytical method used for drug substance (Paracetamol) used by the drug Product manufacturer shall be submitted.
- Submission of analytical method used for drug substance (Dextromethorphan HBr) used by the drug Product manufacturer shall be submitted.
- Submission of analytical method used for drug substance (Phenylephrine hydrochloride) used by both the drug substance manufacturer and drug Product manufacturer shall be submitted.
- Verification studies of the drug substance (Paracetamol) performed by the drug product manufacturer shall be submitted.
- Verification studies of the drug substance (Dextromethorphan HBr) performed by the drug product manufacturer shall be submitted.
- Verification studies of the drug substance (Phenylephrine hydrochloride) performed by the drug product manufacturer shall be submitted.
- Submission of results of analysis of relevant batch(es) of all the three Drug Substances (Paracetamol, Dextromethorphan HBr & Phenylephrine hydrochloride) performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance /Active Pharmaceutical Ingredient manufacture.
- Submission of stability study data for the drug substance (Phenylephrine hydrochloride) from concerned manufacturer shall be submitted.
- Reference of previous approval of applications with stability study data of the firm shall be submitted.

Reply submitted by the firm;

Sr. No.	Observation	Reply by the firm
1.	Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	Firm has stated that that, they have applied for drug registration of our product namely Conofen 10/200mg tablet having composition (Phenylephrine HCl…..10mg, Ibuprofen…..200mg) on Form 5F (CTD) and submitted the dailymed reference i.e. Advil Congestion Relief Tablet 200mg/10mg https://dailymed.nlm.nih.gov/ dailymed/ drugInfo.cfm?setid=b1e29c19-fe03-4d2b-9660adf4eb4b4cf which was considered and no objection raised by Drug Registration Board in its 313th meeting of held on 16th -18th Nov, 2021 regarding dailymed reference.

		They also submitted copy of that decision. Wherein the product is deferred for following submissions: • ***Pharmaceutical equivalence data of the applied product along with innovator / reference or comparator product.*** • ***Comparative Dissolution Profile (CDP) data of the applied product along with innovator / reference or comparator product.*** Moreover, the firm M/s Vision Pharmaceuticals, Islamabad had applied for drug registration of their product namely, Mensodol Tablet 500/25mg with composition: Paracetamol 500mg and Pamabrom 25mg and provided "Proof of International availability of same formulation with same strength in RRA": https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb9a5647-b7c9-4820-b148-91060e34cb83 which was approved in 296th meeting of Drug registration Board held on 8-10th September, 2020. The product is approved. In the light of above, it is requested to kindly registration of our aforementioned applied drug product Colynol Multi Symptom Severe Cold sachet may please be granted in the upcoming meeting of Drug Registration Board.
2.	Submission of valid copy of DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be provided.	GMP certificate No.F.3-96/2022-Addl.Dir. (QA&LT-I) dated August, 2022 on the basis of inspection conducted on 28-07-2022 is submitted by the applicant.
3.	Submission of valid copy of GMP certificate for drug substance manufacturer (Paracetamol) shall be submitted.	Copy of GMP certificate No.83/2020-DRAP (K) dated 23-06-2020 issued on the basis of inspection conducted on 18-06-2020 in the name of M/s Saakh pharma is submitted.
4.	Submission of valid copy of GMP certificate drug substance manufacturer (Phenylephrine Hydrochloride) shall be submitted.	Firm has submitted copy of License No. Y.20160118 issued in the name of M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzhen China by Guangdong Food & Drug Administration valid till December, 2025.
5.	Submission of valid copy of manufacturing license or GMP certificate for the drug substance manufacturer (Dextromethorphan HBr) issued by concerned regulatory authority shall be submitted.	Firm has submitted copy of GMP certificate No. S-GMP/22023157 issued in the name of M/s Onerio Chemicals (Pvt.) Ltd., valid till 22-02-2024.
6.	Submission of blank master production document/batch manufacturing record to be used during the commercial manufacturing of the applied product.	Submitted.
7.	Submission of copy of Batch manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.	Submitted.
8.	Submission of analytical method used for drug substance (Paracetamol) used by the drug Product manufacturer shall be submitted.	Submitted.
9.	Submission of analytical method used for drug substance (Dextromethorphan HBr) used by the drug Product manufacturer shall be submitted.	Submitted.
10.	Submission of analytical method used for drug substance (Phenylephrine hydrochloride)	Submitted.

	used by both the drug substance manufacturer and drug Product manufacturer shall be submitted.	
11.	Verification studies of the drug substance (Paracetamol) performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies for the drug substance including Accuracy, Specificity and precision.
12.	Verification studies of the drug substance (Dextromethorphan HBr) performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies for the drug substance including Accuracy, Specificity and precision.
13.	Verification studies of the drug substance (Phenylephrine hydrochloride) performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies for the drug substance including Accuracy, Specificity and precision.
14.	Submission of results of analysis of relevant batch(es) of all the three Drug Substances (Paracetamol, Dextromethorphan HBr & Phenylephrine hydrochloride) performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance /Active Pharmaceutical Ingredient manufacture.	Firm has submitted COA's for all the three drug substances used in the trial batches both from the drug substance manufacturer and the finished product manufacturer with same batch numbers.
15.	Submission of stability study data for the drug substance (Phenylephrine hydrochloride) from concerned manufacturer shall be submitted.	Submitted.
16.	Reference of previous approval of applications with stability study data of the firm shall be submitted.	Firm has submitted that no application of powder for oral solution (Sachet) was submitted with stability studies to DRAP.
Decision of 322nd meeting of Registration Board: Deferred for deliberation regrading approval of applied formulation by reference regulatory authorities.		
Reply by the firm; Firm has once again submitted the link of dailymed for Theraflu Multi symptoms severe cold sachet as international reference for the applied formulation. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4c56ca0-7785-404b-996d-137cc135f270 They further requested to kindly grant them registration for the above mentioned formulation in the upcoming meeting of Registration Board.		

Decision: Approved with innovator Specifications. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

CLB in its 282nd meeting held on 31st August 2021 has considered and approved the grant of Drug Manufacturing License by way of formulation with following one (01) sections to M/s World Biz Pharmaceutical Company Plot No. 340, Multan Industrial Estate, Multan.

- Oral liquid syrup section (General).

Accordingly following two products of the firm are placed before the Board for consideration.

938.	Name, address of Applicant / Marketing Authorization Holder	World Biz Pharmaceutical Company Plot No. 340, Multan Industrial Estate, Multan.
	Name, address of Manufacturing site.	World Biz Pharmaceutical Company Plot No. 340, Multan Industrial Estate, Multan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 22535: dated 10-08-2022.
	Details of fee submitted	PKR 30,000/- vide slip No. 39078566893 dated 09-06-2022.
	The proposed proprietary name / brand name	Ibubiz 100mg/5ml suspension.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains; Ibuprofen ……. ….. 100mg.
	Pharmaceutical form of applied drug	Oral suspension.
	Pharmacotherapeutic Group of (API)	M01A Anti-inflammatory And Anti-rheumatic Products, Non-Steroids.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	As per DPC.
	Proposed unit price	As per DPC.
	The status in reference regulatory authorities	Tesco Health Ibuprofen 100 mg/5ml Oral Suspension, MHRA Approved.
	For generic drugs (me-too status)	Brufen Suspension, Abbot laboratories, Reg. No. 004595.
	GMP status of the Finished product manufacturer	New license issued dated 14-09-2021 w.e.f. 13-09-2021.
	Evidence of section approval.	Oral liquid syrup section (general) is approved vide letter No. F. 1-25/2008-Lic dated 17-09-2021.
	Name and address of API manufacturer.	Zenith Chemical Industries (Pvt.) Limited, 16 Km off Ferozpur-Road, Behind Wapda Grid Station, 1 Km of Chandrai Road, Lahore.
	Module-II (Quality Overall Summary)	Firm has nor submitted QOS as per WHO QOS-PD template.
	Module III (Drug Substance)	Firm has submitted detail of nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions.

		The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 36 months. Batches:(ZIBU11-001, ZIBU11-002, & ZIBU11-003).
	Module-III (Drug Product):	Firm has submitted detail of drug product including its description, composition, pharmaceutical development, manufacturer, manufacturing process and process control, process validation protocols, control of drug product, specifications, analytical procedures, analytical method verification studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the brand Ibuprofen manufactured by Abbott Laboratories by performing quality tests (Identification, pH and Assay). Results of both the products are similar.
	Analytical method validation/verification of product.	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Zenith Chemical Industries (Pvt.) Limited, 16 Km off Ferozpur-Road, Behind Wapda Grid Station, 1 Km of Chandrai Road, Lahore.		
API Lot No.			
Description of Pack (Container closure system)	Orange colour viscous liquid suspension filled in amber colour bottle.		
Stability Storage Condition	Long term: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Long term: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Long term: 0, 3, 6 (Months)		
Batch No.	RD-IS-001	RD-IS-002	RD-IS-003
Batch Size	2000 bottles.	2000 bottles.	2000 bottles.
Manufacturing Date	11-2021	11-2021	11-2021
Date of Initiation	11-11-2021.	11-11-2021.	11-11-2021.
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 75/2021-DRAP (AD-2027105-531) dated 24-09-2021 issued on the basis of inspection conducted on 14-07-2021 is submitted by the firm.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted.

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observation	Response by the firm
1.	1.1	Fee slip is for syrup Ibubiz while applied formulation is Ibubiz suspension. Clarification shall be submitted.	Firm has submitted that applied formulation is Ibubiz suspension. Due to typographic error, word syrup was written.
2.	1.5.2	Section 1.5.2 has mentioned BP specifications while 1.5.6 has mentioned USP specifications. Clarification shall be submitted regarding the specifications of the finished product.	Firm has submitted that we applied BP specifications so we mentioned on BP monograph. As per CTD requirements, the table is revised and document is attached. ***However, no revised document is attached. Same document is again submitted wherein USP specification are still written.***
3.	2.3	Table for literature references has mentioned only BP pharmacopoeia for both the drug substance and drug product. However, official monograph is available in other pharmacopoeias also. Clarification shall be submitted.	Firm has submitted that we applied BP specifications so we mentioned on BP monograph. As per CTD requirements, the table is revised and document is attached. Revised document is attached.
4.	3.2.S.4.3	Verification studies of drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies for the drug substance including Linearity, Precision, Accuracy, Range, Specificity etc.
5.	3.2.P.5.1	• This section has mentioned USP specification while the limits for test are of BP. Clarification shall be submitted regarding specifications of the drug product. • Dissolution test is not mentioned in the specification. However, both the USP and BP monograph has mentioned dissolution test. Clarification shall be submitted.	Firm has revised their specifications to BP. Firm has submitted that they applied BP specifications and dissolution test parameter was not available in BP 2020 monograph.
6.	3.2.P.5.2	• Analytical procedure has mentioned dissolution for the drug product while specification has no dissolution. • Assay test in the analytical procedure has no formula for calculation of the content.	Firm has submitted that as the analysis of stability samples was performed as per BP monograph so the procedure is revised and attached. Formula for calculation of the content is added in the revised analytical procedures.
7.	3.2.P.5.8	• Stability data sheets shall be as per decision of 293rd meeting of Registration Board with inclusion of API lot number. • Official monograph of the applied formulation has dissolution test while the drug product manufacturer has not performed any dissolution. Justification shall be submitted.	Revised stability data sheets as per decision of 293rd meeting of RB are provided. API lot No. ZIBU21-029 is used in stability data and COA of the same has already been submitted. Firm has submitted that applied product was developed as per BP 2020 specifications and BP 2020 was not having dissolution test. Stability studies for the applied formulation were started in November, 2021 while monograph of BP 2022 was available after January, 2022. They further submitted that after registration of their product, they will perform stability of first

		• Justification shall be submitted regarding the retention time of Ibuprofen in the submitted chromatograms as the monograph has mentioned that under the prescribed condition the retention time of ibuprofen is about 21 minutes.	three commercial batches as per new monograph and will perform dissolution studies. Firm has submitted that we are new DML, so due to limited resources and column unavailability, we used Column of 15cm x 4.6mm and 5µm, C18 that's why peak obtained earlier than prescribed retention time. ***Chromatograms submitted by the firm are revealing all the conditions mentioned in the pharmacopoeia, while the retention time in the chromatograms is 2.1 to 2.2 minutes while BP monograph has mentioned that under the prescribed condition the retention time of ibuprofen is about 21 minutes.***
8.		• Documents for the procurement of API used in the development of trial batches shall be submitted. • Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Firm has submitted Sales tax invoice No. 00014/1021 dated 29-10-2021 mentioning 12 kg quantity of Ibuprofen. ***No batch number and manufacturing date is mentioned.*** ***Not submitted.***

Decision of 322nd meeting of Registration Board: Deferred for justification regarding the retention time of Ibuprofen in the submitted chromatograms as the monograph has mentioned that under the prescribed condition the retention time of ibuprofen is about 21 minutes whereas submitted chromatograms reflect retention time of about 2 minutes.

- Firm will also submit revised 1.5.2 section and fee of Rs. 7,500/- for correction/pre-approval change in the table for literature references, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

Reply by the firm;

- Firm has submitted revised section 1.5.2 with applicable fee of 7500/- vide slip No. 09900702 dated 19-12-2022.
- Firm has submitted that because of new DML, due to limited resources, they initially used column of specs with 15cmx4.6mm, 5µm that's why peak obtained earlier than the prescribed time. They further clarified that they purchased the column as specified in product monograph and tested the product as per mentioned parameters and requirements of monograph. They also submitted testing record of 09th month interval of 3 batches.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application**
- **Firm shall adopt USP monograph for drug product specifications and analytical method for the batch release of commercial batches.**

In pursuance of decision of 133rd meeting of DRAP Authority held on 13th April 2022, wherein it was decided to grant registration on priority basis to the *pharmaceutical* i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year.

In compliance to the aforementioned decision of the Authority, Assistant Director (PR-I/EFD) vide letter No. F.1-6/2019-PR-I (EFD) dated 06th October, 2022 has informed that **M/s Pharmedic Laboratories (Pvt.) Ltd, Lahore** has achieved the benchmark of more than **100,000 USD (1576776.335 USD)** during the fiscal Year 2019-2020 and submitted their applications for priority consideration/ evaluation.

Following products are presented before the Board in light of the decision of the 133rd meeting of DRAP Authority held on 13th April 2022 for consideration.

939.	Name, address of Applicant / Marketing Authorization Holder	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Name, address of Manufacturing site.	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13722: dated 07-06-2022.
	Details of fee submitted	PKR 30,000/- vide slip No. 4235445044 dated 11-05-2022.
	The proposed proprietary name / brand name	Rovastin 5mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains; Rosuvastatin as Calcium ……..5mg
	Pharmaceutical form of applied drug	Light yellow color, round, biconvex film coated tablets.
	Pharmacotherapeutic Group of (API)	HMG CoA reductase inhibitors.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	10's.
	Proposed unit price	As per DPC.
	The status in reference regulatory authorities	CRESTOR (rosuvastatin as calcium) 5mg, 10mg, 20 mg & 40 mg coated tablets, USFDA approved.
	For generic drugs (me-too status)	Rovista tablet 5mg, Getz Pharma, Reg. No. 044043.
	GMP status of the Finished product manufacturer	GMP certificate No. 93/2020-DRAP (AD-2003099-790) dated 09-06-2020 issued on the basis of inspection conducted on 04-02-2020 is submitted.
	Evidence of section approval.	Tablet Non antibiotic, Antibiotic, Psychotropic, Cephalosporin & Anit-Cancer are mentioned in the above submitted GMP certificate.
	Name and address of API manufacturer.	Holder; M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. Manufacturer; M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.
	Module-II (Quality Overall Summary)	Firm has nor submitted QOS as per WHO QOS-PD template.

	Module III (Drug Substance)	Firm has submitted detail of nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months. Batches:(RS-190308, RS-190309 & RS-109311).
	Module-III (Drug Product):	Firm has submitted detail of drug product including its description, composition, pharmaceutical development, manufacturer, manufacturing process and process control, process validation protocols, control of drug product, specifications, analytical procedures, analytical method verification studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the competitor product i.e. Rovista 5mg tablets manufactured by M/s Getz Pharma having batch No. 293F17, Exp. Date 10-2023 by performing quality tests (Disintegration, Dissolution, and Assay). CDP has been performed against the same brand Rovista 5mg tablets manufactured by M/s Getz Pharma having batch No. 293F17, Exp. Date 10-2023 in three different mediums. F2 values for all the three mediums are in acceptable range.
	Analytical method validation/verification of product.	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.	

API Lot No.	RS-701-200603.		
Description of Pack (Container closure system)	Alu-Alu blister sealed with Aluminum foil of 1×10's.		
Stability Storage Condition	Long term: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Long term: 6 months Accelerated: 12 months		
Frequency	Accelerated: 0, 3, 6 (Months) Long term: 0, 3, 6, 9, 12 (Months)		
Batch No.	ROS5-TR005	ROS5-TR006	ROS5-TR007
Batch Size	1000 Tablets.	1000 Tablets.	1000 Tablets.
Manufacturing Date	02-2021.	02-2021.	02-2021.
Date of Initiation	10-03-2021.	15-12-2021.	15-12-2021.
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice No. CY120236 dated 10-06-2020 mentioning Rosuvastatin calcium with quantity of 625gm, Batch No. RS-701-200603 attested by Assistant Director I&E DRAP, Lahore.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observations	Reply by the firm
1.	1.3.4	Valid copy of DML of the finished product manufacturer shall be submitted. As submitted one is w.e.f. 07-04-2010.	
2.	1.6.5	Valid copy of GMP certificate for the drug substance manufacturer issued by the concerned/relevant regulatory authority shall be submitted.	
3.	2.3	Table of literature references has not mention BP for drug substance. Table of literature references has also shown JP for the finished product. Clarification shall be submitted.	
4.	3.2.S.4.1	Drug substance manufacturer has used Ph. Eur. specification for the drug substance while drug product manufacturer has used USP specifications. Justification shall be submitted.	
5.	3.2.S.4.2	Analytical procedures provided by the drug substance manufacturer are different from that of the drug product manufacturer. Justification shall be submitted.	
6.	3.2.S.4.3	Verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	
7.	3.2.S.4.4	• Clear and readable copies of COAs for the drug substance from drug substance manufacturer shall be submitted. • Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacturer shall also be submitted	
8.	3.2.S.5	Clear and readable copies of COAs for the reference/working standard shall be submitted.	
9.	3.2.P.2	Qualitative composition of the applied formulation is different from the innovator product. Justification shall be submitted.	
10.	3.2.P.2.2	Justification shall be submitted for not performing CDP and Pharmaceutical equivalence against the innovator product.	
11.	3.2.P.5.1	• Specifications has mentioned dissolution specification of NLT 75% Q while CDP has mentioned NLT 80% Q. Justification shall be submitted. • Value for weight variation in the specifications and stability data sheets are different from each other. Justify.	
12.	3.2.P.8.3	• 06th month time point accelerated stability study and real time stability study for Batch No. ROS5-006 and ROS5-007 shall be submitted. • Date of manufacture on BMR and stability data sheets are not similar. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	
13.		Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	

Decision of 322nd meeting of Registration Board;
Deferred for submission of above cited observations within six months.

Reply by the firm;

Sr. No.	Section	Observations	Reply by the firm

1.	1.3.4	Valid copy of DML of the finished product manufacturer shall be submitted. As submitted one is w.e.f. 07-04-2010.	Firm has submitted copies of receiving of dated 23-02-2015 & 29-01-2019 only. However, submitted copy of DML is w.e.f. 07-04-2010
2.	1.6.5	Valid copy of GMP certificate for the drug substance manufacturer issued by the concerned/relevant regulatory authority shall be submitted.	Firm has submitted copy of manufacturing license No. SU20160512 issued by Jiangsu Drug Administration in the name of M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China valid till 02-12-2025. Firm has also submitted a declaration wherein M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China has declare that M/s Nantong Chanyoo Pharmatech Co., Ltd., is their wholly owned subsidiary.
3.	2.3	Table of literature references has not mention BP for drug substance. Table of literature references has also shown JP for the finished product. Clarification shall be submitted.	***Neither revised document nor any justification is submitted against this point.***
4.	3.2.S.4.1	Drug substance manufacturer has used Ph. Eur. specification for the drug substance while drug product manufacturer has used USP specifications. Justification shall be submitted.	Firm has submitted that BP, USP and Ph. Eur. have same methods of testing for Rosuvastatin Calcium.
5.	3.2.S.4.2	Analytical procedures provided by the drug substance manufacturer are different from that of the drug product manufacturer. Justification shall be submitted.	Firm has submitted that drug substance manufacturer claims it's in house specifications as evident from COA & DMF but as rosuvastatin calcium monograph exist in pharmacopoeias so they have to follow the pharmacopoeial monograph.
6.	3.2.S.4.3	Verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies of the drug substance. ***However, date mentioned on the chromatograms is 23-11-2022.***
7.	3.2.S.4.4	• Clear and readable copies of COAs for the drug substance from drug substance manufacturer shall be submitted. • Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacturer shall also be submitted	Firm has submitted new COAs for the drug substance manufacturer. Firm has also submitted COA for the drug substance with same batch number used in the development of trial batches.
8.	3.2.S.5	Clear and readable copies of COAs for the reference/working standard shall be submitted.	Submitted.
9.	3.2.P.2	Qualitative composition of the applied formulation is different from the innovator product. Justification shall be submitted.	Firm has submitted that they have developed their product against the reference product of Zentiva Pharma UK limited, and their formulation is qualitatively similar to the reference product. They also provided qualitative composition of the reference product.
10.	3.2.P.2.2	Justification shall be submitted for not performing CDP and Pharmaceutical equivalence against the innovator product.	Firm has once again submitted CDP against the Rovista 5mg tablets manufactured by Getz pharma, Batch number 294F17 in three different dissolution medium and F2 values for all the three mediums are in acceptable range.
11.	3.2.P.5.1	• Specifications has mentioned dissolution specification of NLT 75% Q while CDP has mentioned NLT 80% Q. Justification shall be submitted. • • Value for weight variation in the specifications and stability data sheets are different from each other. Justify.	Firm has submitted revised document wherein they have provided dissolution specification of NLT 75% Q. Firm has submitted revised document wherein they have provided weight variation of 170mg ± 7.5%.

			Fee required for pre-registration variation is not submitted.
12.	3.2.P.8.3	• 06th month time point accelerated stability study and real time stability study for Batch No. ROS5-006 and ROS5-007 shall be submitted. • Date of manufacture on BMR and stability data sheets are not similar. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Submitted. No justification is submitted. Firm has once again submitted stability data sheets wherein manufacturing date for ROS5-TR005 is 02-2021 while manufacturing date for ROS5-TR006 is 10-2021 and date of initiation of stability data is 10-03-2021 & 15-12-2021 respectively. Not submitted.
13.		Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	No reply submitted against this point.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

940.	Name, address of Applicant / Marketing Authorization Holder	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Name, address of Manufacturing site.	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13723: dated 07-06-2022.
	Details of fee submitted	PKR 30,000/- vide slip No. 639696389234 dated 11-05-2022.
	The proposed proprietary name / brand name	Rovastin 10mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains; Rosuvastatin as Calcium ……..10mg
	Pharmaceutical form of applied drug	Pink color, round shaped biconvex film coated tablets.
	Pharmacotherapeutic Group of (API)	HMG CoA reductase inhibitors.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	10’s.
	Proposed unit price	As per DPC.

	The status in reference regulatory authorities	CRESTOR (rosuvastatin as calcium) 5mg, 10mg, 20 mg & 40 mg coated tablets, USFDA approved.
	For generic drugs (me-too status)	Rovista tablet 10mg, Getz Pharma, Reg. No. 044044.
	GMP status of the Finished product manufacturer	GMP certificate No. 93/2020-DRAP (AD-2003099-790) dated 09-06-2020 issued on the basis of inspection conducted on 04-02-2020 is submitted.
	Evidence of section approval.	Tablet Non antibiotic, Antibiotic, Psychotropic, Cephalosporin & Anit-Cancer are mentioned in the above submitted GMP certificate.
	Name and address of API manufacturer.	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.
	Module-II (Quality Overall Summary)	Firm has nor submitted QOS as per WHO QOS-PD template.
	Module III (Drug Substance)	Firm has submitted detail of nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months. Batches:(RS-190308, RS-190309 & RS-109311).

	Module-III (Drug Product):	Firm has submitted detail of drug product including its description, composition, pharmaceutical development, manufacturer, manufacturing process and process control, process validation protocols, control of drug product, specifications, analytical procedures, analytical method verification studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the competitor product i.e. Rovista 10mg tablets manufactured by M/s Getz Pharma having batch No. 359F18, Exp. Date 01-2023 by performing quality tests (Disintegration, Dissolution, and Assay). CDP has been performed against the same brand Rovista 10mg tablets manufactured by M/s Getz Pharma having batch No. 359F18, Exp. Date 01-2023 in three different mediums. F2 calculations for Acetate buffer and phosphate buffer are not performed. The values for f2 in 1.2 pH is in the acceptable range.
	Analytical method validation/verification of product.	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China.		
API Lot No.	RS-701-200603.		
Description of Pack (Container closure system)	Alu-Alu blister sealed with Aluminum foil of 1×10's.		
Stability Storage Condition	Long term: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Long term: 6 months Accelerated: 12 months		
Frequency	Accelerated: 0, 3, 6 (Months) Long term: 0, 3, 6, 9, 12 (Months)		
Batch No.	ROS10-TR005	ROS10-TR006	ROS10-TR007
Batch Size	1000 Tablets.	1000 Tablets.	1000 Tablets.
Manufacturing Date	02-2021.	10-2021.	02-2021.
Date of Initiation	10-03-2021.	15-12-2021.	15-12-2021.
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate of the Holder is submitted while GMP certificate of the manufacturer is not submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice No. CY120236 dated 10-06-2020 mentioning Rosuvastatin calcium with quantity of 625gm, Batch No. RS-701-200603 attested by Assistant Director I&E DRAP, Lahore.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Decision of 322nd meeting of Registration Board;
Deferred for submission of above cited observations within six months.
Reply by the firm;

Sr. No.	Section	Observations	Reply by the firm
1.	1.3.4	Valid copy of DML of the finished product manufacturer shall be submitted. As submitted one is w.e.f. 07-04-2010.	Firm has submitted copies of receiving of dated 23-02-2015 & 29-01-2019 only. However, submitted copy of DML is w.e.f. 07-04-2010.
2.	1.6.5	Valid copy of GMP certificate for the drug substance manufacturer issued by the concerned/relevant regulatory authority shall be submitted.	Firm has submitted copy of manufacturing license No. SU20160512 issued by Jiangsu Drug Administration in the name of M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China valid till 02-12-2025. Firm has also submitted a declaration wherein M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China has declare that M/s Nantong Chanyoo Pharmatech Co., Ltd., is their wholly owned subsidiary.
3.	2.3	Table of literature references has not mention BP for drug substance. Table of literature references has also shown JP for the finished product. Clarification shall be submitted.	***Neither revised document nor any justification is submitted against this point.***
4.	3.2.S.4.1	Drug substance manufacturer has used Ph. Eur. specification for the drug substance while drug product manufacturer has used USP specifications. Justification shall be submitted.	Firm has submitted that BP, USP and Ph. Eur. have same methods of testing for Rosuvastatin Calcium.
5.	3.2.S.4.2	Analytical procedures provided by the drug substance manufacturer are different from that of the drug product manufacturer. Justification shall be submitted.	Firm has submitted that drug substance manufacturer claims it's in house specifications as evident from COA & DMF but as rosuvastatin calcium monograph exist in

			pharmacopoeias so they have to follow the pharmacopoeial monograph.
6.	3.2.S.4.3	Verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies of the drug substance. ***However, date mentioned on the chromatograms is 23-11-2022.***
7.	3.2.S.4.4	• Clear and readable copies of COAs for the drug substance from drug substance manufacturer shall be submitted. • Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacturer shall also be submitted	Firm has submitted new COAs for the drug substance manufacturer. Firm has also submitted COA for the drug substance with same batch number used in the development of trial batches.
8.	3.2.S.5	Clear and readable copies of COAs for the reference/working standard shall be submitted.	Submitted.
9.	3.2.P.2	Qualitative composition of the applied formulation is different from the innovator product. Justification shall be submitted.	Firm has submitted that they have developed their product against the reference product of Zentiva Pharma UK limited, and their formulation is qualitatively similar to the reference product. They also provided qualitative composition of the reference product.
10.	3.2.P.2.2	• Justification shall be submitted for not performing CDP and Pharmaceutical equivalence against the innovator product. • F2 calculations for acetate buffer and phosphate buffer shall be submitted.	Firm has once again submitted CDP against the Rovista 10mg tablets manufactured by Getz pharma, Batch number 359F18 in three different dissolution medium and F2 values for all the three mediums are in acceptable range.
11.	3.2.P.5.1	• Specifications has mentioned dissolution specification of NLT 75% Q while CDP has mentioned NLT 80% Q. Justification shall be submitted. • Value for weight variation in the specifications and stability data sheets are different from each other. Justify.	Firm has submitted revised document wherein they have provided dissolution specification of NLT 75% Q. Firm has submitted revised document wherein they have provided weight variation of 154.5mg ± 7.5%. ***Fee required for pre-registration variation is not submitted.***
12.	3.2.P.8.3	• Weight variation test in the stability data is out of specification. Clarification shall be submitted. • Manufacturing date of batch No. ROS10-006 is December, 2021 and 06th month time point accelerated stability study and real time stability study shall be submitted. • 06th month time point accelerated stability study and real time stability study for Batch No. ROS10-007 shall be submitted. • Date of manufacture on BMR and stability data sheets are not similar. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted revised specifications for the drug product wherein they have changed their weight variation specification to 154.5mg ± 7.5%. Firm has submitted updated stability data sheets for B# ROS10-TR006 wherein they have mentioned manufacturing date of 10-2021 and also submitted 06th month time accelerated stability Firm has submitted 06th month time point accelerated and real time stability studies for B# ROS10-007. Firm has submitted new BMR with date of 18-10-2021. Not submitted.
13.		Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	No reply submitted against this point.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

941.	Name, address of Applicant / Marketing Authorization Holder	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Name, address of Manufacturing site.	Pharmedic Laboratories (Pvt.) Ltd., 16Km Multan Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 13724: dated 07-06-2022.
	Details of fee submitted	PKR 30,000/- vide slip No. 41094042890 dated 11-05-2022.
	The proposed proprietary name / brand name	Rovastin 20mg Tablet.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains; Rosuvastatin as Calcium ……..20mg
	Pharmaceutical form of applied drug	White color, round shaped, biconvex core tablets.
	Pharmacotherapeutic Group of (API)	HMG CoA reductase inhibitors.
	Reference to Finished product specifications	USP specifications.
	Proposed Pack size	10’s.
	Proposed unit price	As per DPC.
	The status in reference regulatory authorities	CRESTOR (rosuvastatin as calcium) 5mg, 10mg, 20 mg & 40 mg coated tablets, USFDA approved.
	For generic drugs (me-too status)	Rovista tablet 20mg, Getz Pharma, Reg. No. 044045.
	GMP status of the Finished product manufacturer	GMP certificate No. 93/2020-DRAP (AD-2003099-790) dated 09-06-2020 issued on the basis of inspection conducted on 04-02-2020 is submitted.
	Evidence of section approval.	Tablet Non antibiotic, Antibiotic, Psychotropic, Cephalosporin & Anit-Cancer are mentioned in the above submitted GMP certificate.
	Name and address of API manufacturer.	Holder; M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. Manufacturer; M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China.

		Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.
	Module-II (Quality Overall Summary)	Firm has nor submitted QOS as per WHO QOS-PD template.
	Module III (Drug Substance)	Firm has submitted detail of nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, tests for impurities & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies (Drug substance.)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65 ± 5% RH for 24 months. Batches:(RS-190308, RS-190309 & RS-109311).
	Module-III (Drug Product):	Firm has submitted detail of drug product including its description, composition, pharmaceutical development, manufacturer, manufacturing process and process control, process validation protocols, control of drug product, specifications, analytical procedures, analytical method verification studies, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence is established against the competitor product i.e. Rovista 20mg tablets manufactured by M/s Getz Pharma having batch No. 215F19, Exp. Date 01-2023 by performing quality tests (Disintegration, Dissolution, and Assay). CDP has been performed against the same brand Rovista 5mg tablets manufactured by M/s Getz Pharma having batch No. 215F19, Exp. Date 01-2023 in three different mediums. In all the three mediums more than 85% release is observer in 15minut time point and hence F2 values are not calculated.
	Analytical method validation/verification of product.	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China.	

	GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China.		
API Lot No.	RS-701-200603.		
Description of Pack (Container closure system)	Alu-Alu blister sealed with Aluminum foil of 1×10's.		
Stability Storage Condition	Long term: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Long term: 03 months Accelerated: 03 months		
Frequency	Accelerated: 0, 3 (Months) Long term: 0, 3 (Months)		
Batch No.	ROS20-TR002	ROS20-TR003	ROS20-TR004
Batch Size	1000 Tablets.	1000 Tablets.	1000 Tablets.
Manufacturing Date	02-2021.	02-2021.	02-2021.
Date of Initiation	15-12-2021.	15-12-2021.	15-12-2021.
No. of Batches	03		

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

The firm has requested for Exemption from On-site Investigation of their submitted stability data and provided the following documents in conjunction with the checklist approved by the Registration Board.

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Holder;** M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China. GMP certificate No. JS20180848 issued by the Jiangsu Food and Drug Administration valid till 09-07-2023 is provided. **Manufacturer;** M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China. Copy of License for drug production in the name of Nantong Chanyoo Pharmatech., Co., Ltd., with license No. Su20160512 issued by Jiangsu Food and Drug Administration dated 03-12-2020 is submitted.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice No. CY120236 dated 10-06-2020 mentioning Rosuvastatin calcium with quantity of 625gm, Batch No. RS-701-200603 attested by Assistant Director I&E DRAP, Lahore.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Decision of 322nd meeting of Registration Board;
Deferred for submission of above cited observations within six months.

Reply by the firm;

Sr. No.	Section	Observations	Reply by the firm
1.	1.3.4	Valid copy of DML of the finished product manufacturer shall be submitted. As submitted one is w.e.f. 07-04-2010.	Firm has submitted copies of receiving of dated 23-02-2015 & 29-01-2019 only. However, submitted copy of DML is w.e.f. 07-04-2010.
2.	1.6.5	Valid copy of GMP certificate for the drug substance manufacturer issued by the concerned/relevant regulatory authority shall be submitted.	Firm has submitted copy of manufacturing license No. SU20160512 issued by Jiangsu Drug Administration in the name of M/s Nantong Chanyoo Pharmatech Co., Ltd., No. 2 Tonghai Si Road,v Yangkou chemical industrial Park, Coastal Economic Development Zone, Nantong, Jiangsu Province 226407, China valid till 02-12-2025. Firm has also submitted a declaration wherein M/s Changzhou Pharmaceutical Factory, No. 518 East Laodong Road, Jiangsu Province China has declare that M/s Nantong Chanyoo Pharmatech Co., Ltd., is their wholly owned subsidiary.
3.	2.3	Table of literature references has not mention BP for drug substance. Table of literature references has also shown JP for the finished product. Clarification shall be submitted.	***Neither revised document nor any justification is submitted against this point.***
4.	3.2.S.4.1	Drug substance manufacturer has used Ph. Eur. specification for the drug substance while drug product manufacturer has used USP specifications. Justification shall be submitted.	Firm has submitted that BP, USP and Ph. Eur. have same methods of testing for Rosuvastatin Calcium.
5.	3.2.S.4.2	Analytical procedures provided by the drug substance manufacturer are different from that of the drug product manufacturer. Justification shall be submitted.	Firm has submitted that drug substance manufacturer claims it's in house specifications as evident from COA & DMF but as rosuvastatin calcium monograph exist in pharmacopoeias so they have to follow the pharmacopoeial monograph.
6.	3.2.S.4.3	Verification studies of the drug substance performed by the drug product manufacturer shall be submitted.	Firm has submitted verification studies of the drug substance. ***However, date mentioned on the chromatograms is 23-11-2022.***
7.	3.2.S.4.4	• Clear and readable copies of COAs for the drug substance from drug substance manufacturer shall be submitted. • Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacturer shall also be submitted	Firm has submitted new COAs for the drug substance manufacturer. Firm has also submitted COA for the drug substance with same batch number used in the development of trial batches.
8.	3.2.S.5	Clear and readable copies of COAs for the reference/working standard shall be submitted.	Submitted.
9.	3.2.P.2	Qualitative composition of the applied formulation is different from the innovator product. Justification shall be submitted.	Firm has submitted that they have developed their product against the reference product of Zentiva Pharma UK limited, and their formulation is qualitatively similar to the reference product. They also provided

			qualitative composition of the reference product.
10.	3.2.P.2.2	• Justification shall be submitted for not performing CDP and Pharmaceutical equivalence against the innovator product. • F2 calculations for acetate buffer and phosphate buffer shall be submitted.	Firm has once again submitted CDP against the Rovista 10mg tablets manufactured by Getz pharma, Batch number 215F19 in three different dissolution medium and F2 values for all the three mediums are in acceptable range.
11.	3.2.P.5.1	• Specifications has mentioned dissolution specification of NLT 75% Q while CDP has mentioned NLT 80% Q. Justification shall be submitted. • Value for weight variation in the specifications and stability data sheets are different from each other. Justify.	Firm has submitted revised document wherein they have provided dissolution specification of NLT 75% Q. Firm has submitted revised document wherein they have provided weight variation of 257.5mg ± 7.5%. ***Fee required for pre-registration variation is not submitted.***
12.	3.2.P.8.3	• 06th month time point accelerated stability study and real time stability study for all the batches shall be submitted. • Date of manufacture on BMR and stability data sheets are not similar. • Reference of previous approval of applications with stability study data of the firm (if any) shall be submitted.	Firm has submitted updated stability data sheets including 06th month time point stability study data for all the three trial batches with manufacturing date of 12-2021 and date of initiation of stability data as of 15-12-2021. Firm has submitted new BMR with date of 02-12-2021. Not submitted.
13.		Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	No reply submitted against this point.

Decision: Approved. Registration letter will be issued after submission of fee of Rs. 7,500/- for correction/pre-approval changes in specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

g. Registration applications of Imported Human Deferred drugs on form 5F.

942.	Name, address of Applicant / Importer	M/s Al Habib Pharmaceuticals, Plot No. 81-B Block B, S.M.C.H.S, Karachi.
	Details of Drug Sale License of importer	License No: 1245. Address: 81-B Block B, S.M.C.H.S, Karachi. Address of Godown: 1. Plot No. 10 sector 25 KIA, Karachi. 2. HT – 8, Landhi Industrial Area, Karachi. Validity: 18-05-2022. Status: License to sell, stock & exhibit for sale, distribute and sell drugs by way of wholesale by of manufacturer, importer or indenter.
	Name and address of marketing authorization holder (abroad)	Hebei Dawn Pharmaceuticals Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou China.
	Name, address of manufacturer(s)	Hebei Dawn Pharmaceuticals Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou China.
	Name of exporting country	China.
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized CoPP certificate No. 202103082 dated 12-08-2021 issued by Hebei

		Province Drug Administration, No. 391 Hongqi Street, Shi Jiazhuang P.R. of China for Paclitaxel for injection (albumen bound). CoPP has mentioned Hebei Dawn Pharmaceuticals Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou China as the manufacturer. The name of importing country on CoPP is mentioned as Pakistan. Furthermore, the CoPP was valid for one till 11-08-2023. *However, the certificate has mentioned that the above product is not registered in China and authorized to be placed in china. The exportation of the product is not restricted.* *The product has been reformulated with a view to improving its stability under specific conditions outside of china.* **GMP:** Firm has submitted copy of GMP certificate No. FT070/MH/001/2019 in the name of M/s Hebei Dawn Pharmaceuticals Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou China issued by the National Authority of Medicines and Health Products, Portugal. Latest inspection was conducted on 20-07-2018 and the certificate reflects that the principles and guidelines of Good Manufacturing Practice laid down in the Directive 2003/94/EC are complied. The certificate is valid for three years. Furthermore, the certificate has mentioned that this certificate only covers the manufacturing activities in the building No. 1 (Injection workshop)
	Details of letter of authorization / sole agency agreement	**Letter of Authorization:** Firm has submitted original legalized and notarized letter of Authorization dated 11-04-2022 from Hebei Dawn Pharmaceuticals Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou City, Hebei province China for Paclitaxel (Albumen bound) Injection 100mg wherein M/s Al Habib Pharmaceuticals, Plot No. 81-B Block B, S.M.C.H.S, Karachi is authorized as sole agent and distributor for the above said product.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 11265: 11-05-2022.

	Details of fee submitted	PKR 150,000/-: 13-04-2022.
	The proposed proprietary name / brand name	Albino 100 mg Lyophilized powder for injection.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains; Paclitaxel as albumen bound nanoparticles ……. 100mg
	Pharmaceutical form of applied drug	Lyophilized powder for injection.
	Pharmacotherapeutic Group of (API)	L01CD01 Antineoplastic Agents.
	Reference to Finished product specifications	In house specifications.
	Proposed Pack size	As per Policy.
	Proposed unit price	As per Policy.
	The status in reference regulatory authorities	Abraxane 100mg vial (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)), USFDA Approved.
	For generic drugs (me-too status)	Nab-Xelpac Injection 100mg (Lyophilized powder), Himmel Pharmaceuticals, Reg. No. 106640.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Fujian South Pharmaceutical Co. Ltd. No.98, Dongxin Road, Xuefeng Town, Mingxi Country, Fuijian Province, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated for 06 months as well as real time conditions for 36 months. The real time stability data is conducted at 25 ^{o}C ± 2^{o}C, RH 60% ± 5% and accelerated stability data is conducted at 40^{o}C ± 2^{o}C, RH 75% ± 5%. (Batch No. 902-1612411, 902-1701401, 902-1701402)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of

		specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has been established against the reference product Abraxane 100mg (Paclitaxel Albumin Bound) by Abraxis Biosciences for the quality test i.e. Identification, pH, Water content, Particulate matter, Particle size & particle size distribution, Related substances, Human albumen content, Paclitaxel binding rate, sterility, Bacterial endotoxin and assay.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Borosilicate glass vial 50ml. Brominated butyl rubber stopper Aluminum plastic combination caps for injection vial.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40°C ±2°C / 75% ± 5% RH for 6 months both upright and inverted orientation (Batch No. 1210101, 1210102 & 1210103). The real time stability study data is conducted at 30°C ±2°C / 75% ± 5% RH for 24 months (Batch No. 1210101, 1210102 & 1210103).

Evaluation by PEC:

Sr. No.	Section	Observation	Response by the firm
1	1.3.4	Valid and notarized copy of Drug Sale License of the applicant shall be submitted.	Attested copy of Drug Sale License No. 0230 dated 18-05-2022 in the name of Al Habib Pharmaceuticals 81-B Block B, S.M.C.H.S, Karachi is submitted by the firm. Validity is 18-05-2024. *However, the address of the Godown mentioned on the DSL is changed from the previously submitted.* *Plot no. 393/7 & 393/8 Sector 7A KIA, Karachi.*
2		Justification shall be submitted regarding the statement on the CoPP certificate that the product is not registered in China and not authorized to be placed in china.	Firm has submitted a document from M/s Hebei Dawn Pharmaceutical wherein they have declared the following; "We, Hebei Dawn Pharmaceutical Co., Ltd., hereby state that we are exporting Paclitaxel for injection (albumin bound) to following countries as our Plant is exclusively for export to Foreign Countries and EU GMP Certified. i. Austria. ii. Norway. iii. Iran. iv. South Korea. v. Vietnam *However, the firm has not produced any evidence of registration of their applied formulation in any of the Reference Regulatory Authorities as defined by the Registration Board.*
3		Valid, Notarized and legalized GMP certificate of the finished product manufacturer issued by the relevant regulatory authority shall be submitted.	Firm has submitted a copy of GMP certificate No. HE20170084 in the name of M/s Hebei Dawn Pharmaceutical Co., Ltd., Block 3 No. 51, Xingye Road, Economic Development Zone, Cangzhou China issued by the Hebei Drug Administration China dated 25-12-2017 valid till 24-12-2022.

4	3.2.P.1.1	• Innovator product has mentioned approximately 900 mg of human albumin while the applied formulation has mentioned 800 mg of Albumen. Justification shall be submitted. • Qualitative composition of the drug product is changed from the innovator product. Innovator product has used sodium caprylate and sodium acetyl tryptophanate while the applied formulation has chloroform, anhydrous ethanol and WFI. Compatibility studies shall be submitted.	Firm has submitted composition of formulation in different RRA as follows; • FDA 900 mg of Human Albumin. • NMPA 900 mg of Human Albumin. • PMDA 800mg of human albumin. • EMEA 800mg of human albumin. Firm has submitted that applied medicine is developed as per the innovator product following the PMDA and EMEA Abraxane and both are included in RRA. *However, the review report approved by Japan (Clinical Summary 2.7) has the following description;* *The dosage ratio of paclitaxel and human albumin in the original commercial batch prescription is 1:8 but due to the influence of the sterilization filtration process, the ratio of paclitaxel and human albumin become 1:9.* *While EPAR has not mentioned any ratio of paclitaxel and Albumin in the public assessment report.* Firm has submitted that other excipients used in the manufacturing of Paclitaxel albumin bound i.e. chloroform, anhydrous ethanol, WFI will be removed finally and the finished product does not contain these excipients that why the end product is same as reference product. Firm has also submitted new composition for the applied formulation wherein they have included sodium caprylate and sodium acetyl tryptophanate in the composition. *However, these excipients are not mentioned in the original submitted CoPP nor in original dossier submitted.*
5	3.2.P.1.3	Since the final product is lyophilized preparation, therefor, submit the details of reconstitution diluent along with the compatibility studies for the dry powder for injection.	Firm has submitted the following; "Aseptically, reconstitute each vial by injecting 20 mL of 0.9% Sodium Chloride Injection, USP. Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the inside wall of the Vial. The reconstituted suspension should be milky and homogenous without visible particulates. If particulates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Discard the reconstituted suspension if precipitates are observed. Discard any unused portion".
	3.2.P.2.2.1	Details of the innovator product including batch number, manufacturing date & Expiry date shall be submitted.	Firm has submitted the following; Batch No. 0F028C Exp. Date. 06-2023.
	3.2.P.8	Submit in use stability studies for drug product along with proposed in -use storage statement and in-use shelf life.	***Not submitted.*** Firm has submitted again the real time and accelerated stability studies that were submitted in the original dossier.

Decision of 320th meeting:

The Board deferred the case for clarification of the following points;

- The applied product is not present in the market of exporting country for free sale.
- The qualitative composition of the applied product is different from the innovator's product.
- In-use stability of the applied product is not submitted.

Reply by the firm;

Firm has submitted their reply vide reference no. nil dated 08-09-2022 wherein they have submitted new composition for the applied formulation which is similar to the innovator's product. They have also provided in use stability studies for the applied formulation.
Furthermore, they also provided copy of CoPP certificate for the applied formulation wherein it is confirmed that ***"this is to certify that the above product(s) is registered in china and authorized to be placed in china. The exportation of the product is not restricted."***
However, upon evaluation of the CoPP document following is revealed.

- Submitted CoPP is neither notarized nor countersigned by the embassy of Pakistan.
- CoPP certificate is not as per format of WHO CoPP.
- New CoPP certificate submitted by the firm has same certificate number and same date of issuance, as that of the previously submitted CoPP in which following was mentioned

  "That the above product is not registered in China and authorized to be placed in china. The exportation of the product is not restricted. The product has been reformulated with a view to improving its stability under specific conditions outside of china".
- However, status of the applied formulation is only changed from the previously submitted certificate.
- Online data of the newly submitted CoPP is not available on the official website of China.

Decision of 322nd meeting of Registration Board: Registration Board decided to send an email to NMPA China for confirmation of free sale status of applied formulation in China.

Submission by the Firm:
Firm vide their reference No. Nil dated 20-12-2022 submitted that their inexperienced junior regulatory personnel submitted the shortcomings on the same date 30-08-2022 without their knowledge and taking advice from senior regulatory management. Therefore, we humbly request to withdraw/discard or remove those photocopy documents as the person didn't understand the query and submit the photocopy document due to lack of understanding immediately. They further requested to kindly discard or withdraw those photocopy documents for the above mentioned drug and give us some time to submit the proper original documents and justifications for the queries raised.

Decision: Registration Board rejected the application since firm could not establish the authenticity of the submitted CoPP declaring the free sale status in the country of origin.

h. Registration applications of locally manufactured Human Deferred drugs on form 5D.

In pursuance of decision of 133rd meeting of DRAP Authority held on 13th April 2022, wherein it was decided to grant registration on priority basis to the pharmaceutical i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year.
In compliance to the aforementioned decision of the Board, Assistant Director (PR-I/EFD) vide letter No. F.1-6/2019-PR-I (EFD) dated 06th October, 2022 has informed that M/s Surge Laboratories (Pvt.) Ltd, Sheikhupura has achieved the benchmark of more than 100,000 USD (790529.78 USD) during the fiscal Year 2019-2020 and submitted their applications for priority consideration/ evaluation.
Following products are presented before the Board in light of the decision of the 133rd meeting of DRAP Authority held on 13th April 2022 for consideration.

943.	Name and address of manufacturer / Applicant	M/s Surge Laboratories (Pvt.) Ltd, 10-Km, Faisalabad Road, Sheikhupura.
	Brand Name +Dosage Form + Strength	Neofen Injection 400mg/4ml.
	Diary No. Date of R& I & fee	Form-5D, 17-06-2010, diary #_____ **Photocopy**& 15-08-2013 diary No.____ **Photocopy** Rs.35000 Only Photocopies are attached.
	Composition	Each 4ml contains: - Ibuprofen…….400mg
	Pharmacological Group	Analgesic.
	Type of Form	Form 5D.
	Finished Product Specification	Manufacturers specification
	Pack size & Demanded Price	Rs.435 per ampoule
	Approval status of product in Reference Regulatory Authorities.	Caldolor 400mg/4ml, USFDA approved.
	Me-too status	N/A
	GMP status	
	Decision of 254th meeting of Registration Board.	As per the decision of RB in its 251st meeting following is required: -

		• Certificate of Analysis of API. • Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin. • Manufacturer will follow Drug Specification Rules, 1986. • Protocols followed for conduction of stability study and details of tests. • Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc. • Documents confirming import of API etc. • All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents. • Shelf life of two years shall be granted based upon the results 06 month accelerated and real time stability study data. • Commitment to continue real time stability study till assigned shelf life of the product.

STABILITY STUDY DATA

Drug	Neofen Injection (Ibuprofen 400mg/4ml).		
Name of Manufacturer	M/s Surge Laboratories (Pvt.) Ltd, 10-Km, Faisalabad Road, Sheikhupura.		
Manufacturer of API	M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State Of America.		
API Lot No.	Initially not submitted. (C100-1607094M)		
Description of Pack (Container closure system)	Initially not submitted. (5ml clear glass ampoule USP type I)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Real time: 0,3,6 (months) Accelerated: 0,3,6 (months)		
Batch No.	IBI-4-004	IBI-4-005	IBI-4-006
Batch Size	121 ampoules	121 ampoules	121 ampoules
Manufacturing Date	01-2020	01-2020	01-2020
Date of Initiation	14-01-2020	25-01-2020	25-01-2020
No. of Batches	03		
Date of Submission	20-04-2021 (Dy. No. 11774)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT FOR EXEMPTION

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

S. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Not submitted.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Firm has submitted copy of COA from SI group with Lot No. 4050-3070 for Ibuprofen. However, COA from the finished product manufacturer is not provided.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Not submitted.
4.	Stability study data of API from API manufacturer	Not submitted.

5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate No. MI-2015-CE-03496-1 dated 31-03-2020 issued to M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America by TGA Australia. The certificate is valid till 16-04-2022.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided.
7.	Protocols followed for conduction of stability study	Submitted.
8.	Method used for analysis of FPP	Not Submitted.
9.	Drug-excipients compatibility studies (where applicable)	Not submitted.
10.	Complete batch manufacturing record of three stability batches.	Not submitted.
11.	Record of comparative dissolution data (where applicable)	N/A
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of the Evaluator:

Sr. No.	Observations	Submission by the firm.
1.	Valid copy of the DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be submitted.	**M/s Surge Laboratories;** Copy of DML No. 000484 w.e.f. 19-12-2020 is submitted. Copy of GMP certificate No. 41/202-DRAP(Ad-9978029213) dated 05-04-2022 issued on the basis of inspection conducted on 05-10-2021 is submitted.
2.	Valid copy of GMP certificate of the drug substance manufacturer issued by concerned/relevant regulatory authority shall be submitted.	Firm has submitted a document with heading of "written confirmation for active substances exported to EU" issued by Hubei Medical Products Administration wherein the issuing authority confirms that the manufacturing plant i.e. Hubei Biocause Heilen Pharmaceutical Co. Ltd., complies with the requirements of Chinese Good Manufacturing Practices (GMP of EU, WHO/ICT Q7) and this written confirmation remains valid till 27-08-2023. ***However, initially submitted dossier has mentioned M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America as drug substance manufacturer. While in reply they have changed it to Hubei Biocause Heilen Pharmaceutical Co. Ltd., China.***
3.	COA of the drug substance by the finished product manufacturer shall be submitted.	Firm has submitted copy of COA from M/s Surge Laboratories having name of supplier as Hubei Granules-Biocause Heilen Pharmaceutical Co. Ltd., Batch No. C100-1607094M.

		However, COA submitted in the initial dossier was from SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America with Lot No. 4050-3070 for Ibuprofen. ***Furthermore, COA from the drug substance manufacturer of China is also not provided.***
4.	Stability study data of the drug substance for both accelerated and real time from drug substance manufacturer shall be submitted.	Firm has submitted stability study data of 03 batches for the drug substance from M/s Hubei Granules-Biocause Heilen Pharmaceutical Co. Ltd., China. Real time: 30˚C ± 2˚C / 75% ± 5%RH for 72 months. Batches; (C100-1305307M, C100-1305308M & C100-1305309M) Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months. Batches; (C100-1812264M, C100-1812265M & C100-1812266M). ***Both real time and accelerated stability studies of the drug substance are for different batches.***
5.	Specifications of drug substance from both drug substance manufacturer and Finished Product manufacturer shall be submitted.	Submitted. ***Specifications from Hubei Biocause Heilen Pharmaceutical Co. Ltd., China is submitted instead of SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America***
6.	Analytical method used for analysis of drug substance from both drug substance manufacturer and Finished Product manufacturer shall be submitted.	Submitted. ***Analytical procedures from Hubei Biocause Heilen Pharmaceutical Co. Ltd., China is submitted instead of SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America***
7.	Analytical method along with specifications used for analysis of Finished Product shall be submitted.	Submitted.
8.	Specifications has mentioned pH from 7.3 to 8.3 while COA has pH specifications from 7.3 to 7.8. clarification shall be submitted.	Firm has submitted that pH limit of this product is from 7.3 to 7.8 while the pH mentioned on the stability data sheets was 7.3 to 8.3 by typographic mistake which has been corrected and revised stability sheets have also been submitted by the firm.
9.	Complete formulation including the inactive used in the applied formulation shall be submitted.	Submitted.
10.	Complete batch manufacturing record of three stability batches shall be submitted.	Submitted.
11.	Stability data sheets shall be as per decision of 293rd meeting of Registration Board with inclusion of API lot number, batch size etc.	Firm has submitted stability data summary sheets as per decision of 293rd meeting of Registration Board with inclusion of API lot number (C100-1607094M) and total batch size (121 ampoules). They have also included bacterial endotoxins and sterility test in the revised stability data sheets.
12.	Justification shall be submitted for not performing the sterility testing in the stability data for the applied formulation.	Firm has submitted that in routine they use to conduct the sterility testing of injectable products at each time point during stability, the reports were kept at microbiology section, and unfortunately we do not use to make them part of the final stability reports, since major focus were on potency degradation. They further submitted that they now collected the said reports from microbiology and

		make them part of the revised stability summary data sheets.
13.	Documents for the procurement of API with approval from DRAP with mentioning batch number of the drug substance shall be submitted.	Firm has submitted copy document having invoice No. W170217-035 dated 22-02-2017 mentioning 2kg of Ibuprofen, batch No. C100-1607094M attested by ADC, DRAP, Lahore dated 24-03-2017. ***In the initially submitted dossier copy of commercial invoice No. 434651 dated 29-03-2017 without any attestation from the DRAP.***
14.	Reference of previous approval of applications with stability study data of the firm shall be submitted.	Firm has submitted reference of their product Nervlok-Heavy Injection, approved in 313th meeting of the Registration Board. The applied product was on form 5F.
15.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Only compliance certificate is submitted however no audit trial is submitted.
16.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Hand written digital logger is submitted.

Decision of 322nd meeting of Registration Board: Deferred for following;

- Valid copy of GMP certificate/DML of the drug substance manufacturer issued by concerned/relevant regulatory authority.
- COA of the drug substance from drug substance manufacturer with lot number used in the development of the product shall be submitted.
- Justification for change of source of drug substance as initially drug substance source was from USA while afterward it was changed to China.
- Justification shall be submitted for the batch size as only 121 ampoules were manufactured in each trial batch while sterility is also claimed in the submitted data.
- Confirmation of submission of Form 5 application from R&I record.

Reply by the Firm:

Valid copy of GMP certificate/DML of the drug substance manufacturer issued by concerned/relevant regulatory authority.	Firm has submitted copy of license No. E20200154 in the name of M/s Hubei Biocause Helin Pharmaceutical Company Ltd., having registered address at 122 Yangwan Road, Jingmen City, Hubei Province China. Firm has also submitted copy of a certificate wherein Hubei Granules-Biocause Pharmaceutical Company Ltd., is merged into parent company M/s Hubei Biocause Helin Pharmaceutical Company Ltd., from May, 17, 2020.
COA of the drug substance from drug substance manufacturer with lot number used in the development of the product shall be submitted.	Firm has submitted COA for Ibuprofen having B3 C100-1607094M, Mfg. date 10-07-2016 from M/s Hubei Granules-Biocause Pharmaceutical Company Ltd.,
Justification for change of source of drug substance as initially drug substance source was from USA while afterward it was changed to China.	Firm has submitted that they have changed drug substance manufacturer from M/s *SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America to* M/s Hubei Biocause Helin Pharmaceutical Company Ltd., China due to very high cost and continuous supply issue from SI Group Inc. these both factors compel us to find good alternate source. Then we conducted retrials and submitted fresh stability data by using Hubei Biocause Helin Pharmaceutical Company Ltd., China and found this source satisfactory.

Justification shall be submitted for the batch size as only 121 ampoules were manufactured in each trial batch while sterility is also claimed in the submitted data.	Firm has submitted that they have conducted trial batches of Neofen injection 400mg/4ml with batch size of 500ml (121 ampoules). The quantity of ampoules for sterility testing were 10 ampoules as per USP. According to USP, the minimum number of articles to be tested for parenteral preparation are 10 container for more than 100 containers.
Confirmation of submission of Form 5 application from R&I record.	Firm has submitted that the applied product was on Form 5D.

Decision: Deferred for following;

- **Scientific justification for justification of manufactured batch size against the no. of units required to complete stability studies till claimed shelf life while considering the fact that firm has reported performance of sterility testing at each time point.**
- **Confirmation of submission of Form 5D application from R&I record.**

944.	Name and address of manufacturer / Applicant	M/s Surge Laboratories (Pvt.) Ltd, 10-Km, Faisalabad Road, Sheikhupura.
	Brand Name +Dosage Form + Strength	Neofen Injection 800mg/8ml.
	Diary No. Date of R& I & fee	Form-5D, 17-06-2010, diary #_____ **Photocopy**& 15-08-2013 diary No.____ **Photocopy** Rs.35000 Only Photocopies are attached.
	Composition	Each 8ml contains: - Ibuprofen…….…….800mg
	Pharmacological Group	Analgesic.
	Type of Form	Form 5D.
	Finished Product Specification	Manufacturers specification
	Pack size & Demanded Price	Rs.540 per ampoule
	Approval status of product in Reference Regulatory Authorities.	Caldolor 800mg/8ml, USFDA approved.
	Me-too status	N/A
	GMP status	
	Decision of 254th meeting of Registration Board.	Deferred for completion of application as under:- As per the decision of RB in its 251st meeting following is required: - • Certificate of Analysis of API. • Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin. • Manufacturer will follow Drug Specification Rules, 1986. • Protocols followed for conduction of stability study and details of tests. • Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc. • Documents confirming import of API etc. • All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents. • Shelf life of two years shall be granted based upon the results 06 month accelerated and real time stability study data. • Commitment to continue real time stability study till assigned shelf life of the product.

STABILITY STUDY DATA	
Drug	Neofen Injection (Ibuprofen 800mg/8ml).
Name of Manufacturer	M/s Surge Laboratories (Pvt.) Ltd, 10-Km, Faisalabad Road, Sheikhupura.
Manufacturer of API	M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State Of America.
API Lot No.	Initially not submitted. (C100-1607094M)
Description of Pack	Initially not submitted. (10ml clear glass ampoule USP type I)

(Container closure system)			
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Real time: 0,3,6 (months) Accelerated: 0,3,6 (months)		
Batch No.	IBI-8-004	IBI-8-005	IBI-8-006
Batch Size	60 ampoules.	60 ampoules.	60 ampoules.
Manufacturing Date	01-2020	01-2020	01-2020
Date of Initiation	08-01-2020	14-01-2020	14-01-2020
No. of Batches	03		
Date of Submission	20-04-2021 (Dy. No. 11775)		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT FOR EXEMPTION

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

S. No.	Documents To Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	Not submitted.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Firm has submitted copy of COA from SI group with Lot No. 4050-3070 for Ibuprofen. However, COA from the finished product manufacturer is not provided.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Not submitted.
4.	Stability study data of API from API manufacturer	Not submitted.
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate No. MI-2015-CE-03496-1 dated 31-03-2020 issued to M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America by TGA Australia. The certificate is valid till 16-04-2022.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided.
7.	Protocols followed for conduction of stability study	Submitted.
8.	Method used for analysis of FPP	Not Submitted.
9.	Drug-excipients compatibility studies (where applicable)	Not submitted.
10.	Complete batch manufacturing record of three stability batches.	Not submitted.
11.	Record of comparative dissolution data (where applicable)	N/A
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not Submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of the Evaluator:

Sr. No.	Observations	Submission by the firm.

1.	Valid copy of the DML and latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be submitted.	**M/s Surge Laboratories;** Copy of DML No. 000484 w.e.f. 19-12-2020 is submitted. Copy of GMP certificate No. 41/202-DRAP(Ad-9978029213) dated 05-04-2022 issued on the basis of inspection conducted on 05-10-2021 is submitted.
2.	Valid copy of GMP certificate of the drug substance manufacturer issued by concerned/relevant regulatory authority shall be submitted.	Firm has submitted a document with heading of "written confirmation for active substances exported to EU" issued by Hubei Medical Products Administration wherein the issuing authority confirms that the manufacturing plant i.e. Hubei Biocause Heilen Pharmaceutical Co. Ltd., complies with the requirements of Chinese Good Manufacturing Practices (GMP of EU, WHO/ICT Q7) and this written confirmation remains valid till 27-08-2023. ***However, initially submitted dossier has mentioned M/s SI Group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America as drug substance manufacturer. While in reply they have changed it to Hubei Biocause Heilen Pharmaceutical Co. Ltd., China.***
3.	COA of the drug substance by the finished product manufacturer shall be submitted.	Firm has submitted copy of COA from M/s Surge Laboratories having name of supplier as Hubei Granules-Biocause Heilen Pharmaceutical Co. Ltd., Batch No. C100-1607094M. ***However, COA submitted in the initial dossier was from SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America with Lot No. 4050-3070 for Ibuprofen.*** ***Furthermore, COA from the drug substance manufacturer of China is also not provided.***
4.	Stability study data of the drug substance for both accelerated and real time from drug substance manufacturer shall be submitted.	Firm has submitted stability study data of 03 batches for the drug substance from M/s Hubei Granules-Biocause Heilen Pharmaceutical Co. Ltd., China. Real time: 30˚C ± 2˚C / 75% ± 5%RH for 72 months. Batches; (C100-1305307M, C100-1305308M & C100-1305309M) Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 06 months. Batches; (C100-1812264M, C100-1812265M & C100-1812266M). ***Both real time and accelerated stability studies of the drug substance are for different batches.***
5.	Specifications of drug substance from both drug substance manufacturer and Finished Product manufacturer shall be submitted.	Submitted. ***Specifications from Hubei Biocause Heilen Pharmaceutical Co. Ltd., China is submitted instead of SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America***
6.	Analytical method used for analysis of drug substance from both drug substance manufacturer and Finished Product manufacturer shall be submitted.	Submitted. ***Analytical procedures from Hubei Biocause Heilen Pharmaceutical Co. Ltd., China is submitted instead of SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America***

7.	Analytical method along with specifications used for analysis of Finished Product shall be submitted.	Submitted.
8.	Specifications has mentioned pH from 7.3 to 8.3 while COA has pH specifications from 7.3 to 7.8. clarification shall be submitted.	Firm has submitted that pH limit of this product is from 7.3 to 7.8 while the pH mentioned on the stability data sheets was 7.3 to 8.3 by typographic mistake which has been corrected and revised stability sheets have also been submitted by the firm.
9.	Complete formulation including the inactive used in the applied formulation shall be submitted.	Submitted.
10.	Complete batch manufacturing record of three stability batches shall be submitted.	Submitted.
11.	Stability data sheets shall be as per decision of 293rd meeting of Registration Board with inclusion of API lot number, batch size etc.	Firm has submitted stability data summary sheets as per decision of 293rd meeting of Registration Board with inclusion of API lot number (C100-1607094M) and total batch size (121 ampoules). They have also included bacterial endotoxins and sterility test in the revised stability data sheets.
12.	Justification shall be submitted for not performing the sterility testing in the stability data for the applied formulation.	Firm has submitted that in routine they use to conduct the sterility testing of injectable products at each time point during stability, the reports were kept at microbiology section, and unfortunately we do not use to make them part of the final stability reports, since major focus were on potency degradation. They further submitted that they now collected the said reports from microbiology and make them part of the revised stability summary data sheets.
13.	Documents for the procurement of API with approval from DRAP with mentioning batch number of the drug substance shall be submitted.	Firm has submitted copy document having invoice No. W170217-035 dated 22-02-2017 mentioning 2kg of Ibuprofen, batch No. C100-1607094M attested by ADC, DRAP, Lahore dated 24-03-2017. ***In the initially submitted dossier copy of commercial invoice No. 434651 dated 29-03-2017 without any attestation from the DRAP.***
14.	Reference of previous approval of applications with stability study data of the firm shall be submitted.	Firm has submitted reference of their product Nervlok-Heavy Injection, approved in 313th meeting of the Registration Board. The applied product was on form 5F.
15.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing shall be submitted.	Only compliance certificate is submitted however no audit trial is submitted.
16.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) shall be submitted.	Hand written digital logger is submitted.

Decision of 322nd meeting of Registration Board: Deferred for following;

- Valid copy of GMP certificate/DML of the drug substance manufacturer issued by concerned/relevant regulatory authority.
- COA of the drug substance from drug substance manufacturer with lot number used in the development of the product shall be submitted.
- Justification for change of source of drug substance as initially drug substance Source was from USA while afterward it was changed to China.
- Justification shall be submitted for the batch size as only 60 ampoules were manufactured in each trial batch while sterility is also claimed in the submitted data.

Confirmation of submission of Form 5 application from R&I record.

Reply by the firm:

Valid copy of GMP certificate/DML of the drug substance manufacturer issued by concerned/relevant regulatory authority.	Firm has submitted copy of license No. E20200154 in the name of M/s Hubei Biocause Helin Pharmaceutical Company Ltd., having registered address at 122 Yangwan Road, Jingmen City, Hubei Province China. Firm has also submitted copy of a certificate wherein Hubei Granules-Biocause Pharmaceutical Company Ltd., is merged into parent company M/s Hubei Biocause Helin Pharmaceutical Company Ltd., from May, 17, 2020.
COA of the drug substance from drug substance manufacturer with lot number used in the development of the product shall be submitted.	Firm has submitted COA for Ibuprofen having B3 C100-1607094M, Mfg. date 10-07-2016 from M/s Hubei Granules-Biocause Pharmaceutical Company Ltd.,
Justification for change of source of drug substance as initially drug substance source was from USA while afterward it was changed to China.	Firm has submitted that they have changed drug substance manufacturer from M/s *SI group Inc. 725 Cannon Bridge Road Orangeburg SC United State of America to* M/s Hubei Biocause Helin Pharmaceutical Company Ltd., China due to very high cost and continuous supply issue from SI Group Inc. these both factors compel us to find good alternate source. Then we conducted retrials and submitted fresh stability data by using Hubei Biocause Helin Pharmaceutical Company Ltd., China and found this source satisfactory.
Justification shall be submitted for the batch size as only 121 ampoules were manufactured in each trial batch while sterility is also claimed in the submitted data.	Firm has submitted that they have conducted trial batches of Neofen injection 800mg/8ml with batch size of 500ml (60 ampoules). The quantity of ampoules for sterility testing were 06 ampoules as per USP. According to USP, the minimum number of articles to be tested for parenteral preparation are 10% or 04 containers whichever is greater for not more than 100 containers.
Confirmation of submission of Form 5 application from R&I record.	Firm has submitted that the applied product was on Form 5D.

Decision: Deferred for following;

- **Scientific justification for justification of manufactured batch size against the no. of units required to complete stability studies till claimed shelf life while considering the fact that firm has reported performance of sterility testing at each time point.**
- **Confirmation of submission of Form 5D application from R&I record.**

i. Registration applications of Deferred Imported Human drugs on form 5A.

945.	Name and address of Applicant	M/s Revive Healthcare. Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore, Pakistan.
	Detail of Drug Sale License	Name: M/s Revive Healthcare. Address: Office 503, 5th Floor, Eden Heights, 6 Main Gulberg, Jail Road, District Lahore. Validity: 21st May, 2020 Status: License to sell drugs as a distributor (Form No.11)
	Name and address of manufacturer	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name and address of marketing authorization holder	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name of exporting country	India.
	Type of Form	Form-5A

	Diary No. & Date of R& I	Dy. No 11418-B dated 05-03-2019.
	Fee including differential fee	Rs.50,000/- dated 05-03-2019.
	Brand Name +Dosage Form + Strength	Atazor-R Tablet.
	Composition	Each Tablet Contains: Atazanavir ……300mg Ritonavir ……..…100mg
	Finished Product Specification	Manufacturer specifications.
	Pharmacological Group	Antivirals for treatment of HIV infections, combinations.
	Shelf life	24 months
	Demanded Price	As per SRO.
	Pack size	30's
	International availability	WHO pre-qualified formulation (Ref. No. NDA 205508)/ USFDA approved.
	Me-too status	Could not be confirmed.
	Stability studies	
	Detail of certificates attached	**Letter of authorization: - (Copy submitted)** M/s Revive Healthcare. Office 503, 5th Floor, Eden Heights 6 Main Gulberg, Jail Road, Lahore, Pakistan Dated: 24-08-2017. Validity: not mentioned. Letter of authorization has neither product list nor it has any sole distribution details. **Certificate of Pharmaceutical Product (Copy submitted).** Certificate No: COPP/CERT/PD/79590/2018/11/25928/134892. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date**:** 24-11-2018. The certificate conforms to the format recommended by the WHO. Validity: 02-11-2021. Certificate also confirms that this product is also actually on the market in the exporting country. **GMP certificate (Copy submitted).** Certificate No: NEW-WHO-GMP/CERT/PD/74276/2018/11/25582. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Date: 03-11-2018. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 02-11-2021.
	Remark of the Evaluator [XIII]	**Deficiency letter was issued on 05-10-2021 with following observation but no reply received till to date.** • Form 5A has neither mentioned film coated tablets nor salt form of the active ingredients. Label claim in form 5 needs revision with submission of applicable fee. • Submit Original, valid & legalized COPP issued by concerned regulatory Authority • Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority • Submit Original and complete Letter of Authorization from Product License Holder

		• Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.

Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Reply by the firm:

Form 5A has neither mentioned film coated tablets nor salt form of the active ingredients. Label claim in form 5 needs revision with submission of applicable fee.	Firm has submitted revised Form 5A wherein they have revised their label claim by mentioning the film coating and salt form of Atazanavir with submission of 7500/- fee vide slip No. 28449585491 dated 18-11-2022 as follows; **Each film coated Tablet Contains:** **Atazanavir Sulphate eq. to Atazanavir…… 300mg** **Ritonavir ……..…100mg**
Submit Original, valid & legalized COPP issued by concerned regulatory Authority.	Firm has submitted copy of CoPP certificate No. COPP/CERT/PD/109188/2021/11/38484/188282 for Atazor R tablets. Certifying Authority: Food & Drug Administration, Maharashtra State Mumbai, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date: 17-12-2021. The certificate conforms to the format recommended by the WHO. Validity: 28-11-2024. Certificate also confirms that this product is also actually on the market in the exporting country. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid COPP is under consulate attestation and we will submit valid consulate attested COPP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority.	Firm has submitted copy of Certificate No: NEW-WHO-GMP/CERT/PD/108736/2021/11/38283 dated 29-11-2021. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 28-11-2024. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid GMP is under consulate attestation and we will submit valid consulate attested GMP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
Submit Original and complete Letter of Authorization from Product License Holder.	Firm has submitted notarized authorization letter from M/s Emcure Pharmaceuticals Limited, wherein they have authorized M/s Revive Healthcare, Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore for import, market, distribution and sale of the 08 products namely; Atazor-R Tablets, Tavin-EM Tablets, Instgra Tablets, Viropil Tablets, Spegra Tablets, Vonavir tablets, Inbec tablets and Vonday tablets.
Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2 °C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30°C ± 2 °C / 75% ± 5% RH for 36 months. Batch No. EM28258, EM2X088A & EM2Y131A. *Firm has also clarified regarding the condition of real time stability data that Zone IVb conditions (30°C ± 2 °C / 75% ± 5% RH) are more stringent than Zone Iva (30°C ± 2 °C / 65% ± 5% RH) and we provided stability on Zone IVb condition so it can be considered as the worst case scenario.*

		However, in Accelerated stability data dissolution limit of both the active substances mentioned is NLT 75% Q while in real time stability data it is NLT 80% Q of the labelled amount.
	Decision: Approved as per policy of inspection of manufacturer abroad with innovator's specifications and following label claim; **Each film coated Tablet Contains:** **Atazanavir Sulphate eq. to Atazanavir…… 300mg** **Ritonavir ……..…100mg** • **Registration letter will be issued after submission of full fee of for correction/pre-approval change in the label claim as per reference product, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.** • **Firm will also submit and original, valid & legalized COPP certificate for the applied formulation issued by concerned regulatory Authority before issuance of registration letter.**	
946.	Name and address of Applicant	M/s Revive Healthcare. Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore, Pakistan.
	Detail of Drug Sale License	Name: M/s Revive Healthcare. Address: Office 503, 5th Floor, Eden Heights, 6 Main Gulberg, Jail Road, District Lahore. Validity: 21st May, 2020 Status: License to sell drugs as a distributor (Form No.11)
	Name and address of manufacturer	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name and address of marketing authorization holder	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name of exporting country	India.
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy. No 11419-B dated 05-03-2019.
	Fee including differential fee	Rs.50,000/- dated 05-03-2019.
	Brand Name +Dosage Form + Strength	Viropil tablet.
	Composition	Each Tablet Contains: Dolutegravir Sodium ……50mg Tenofovir Disoproxil ……..…300mg Lamivudine ……300mg
	Finished Product Specification	Manufacturer specifications.
	Pharmacological Group	Antivirals for treatment of HIV infections, combinations.
	Shelf life	24 months
	Demanded Price	As per SRO.
	Pack size	30's
	International availability	WHO pre-qualified formulation (Ref. No. HA722-0)/ USFDA approved.
	Me-too status	Could not be confirmed.
	Stability studies	Not provided.
	Detail of certificates attached	**Letter of authorization: - (Copy submitted)** M/s Revive Healthcare. Office 503, 5th Floor, Eden Heights 6 Main Gulberg, Jail Road, Lahore, Pakistan Dated: 24-08-2017. Validity: not mentioned. Letter of authorization has neither product list nor it has any sole distribution details. **Certificate of Pharmaceutical Product (Copy submitted).** Certificate No: COPP/CERT/PD/80502/2018/11/26370/136689.

		Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date**:** 29-12-2018. The certificate conforms to the format recommended by the WHO. Validity: 02-11-2021. Certificate confirms that this product is also actually on the market in the exporting country. **GMP certificate (Copy submitted).** Certificate No: NEW-WHO-GMP/CERT/PD/74276/2018/11/25582. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Date: 03-11-2018. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 02-11-2021.
	Remark of the Evaluator [XIII]	• Form 5A has neither mentioned film coated tablets nor salt form of the active ingredients. Label claim in form 5 needs revision with submission of applicable fee. • Submit Original, valid & legalized COPP issued by concerned regulatory Authority • Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority • Submit Original and complete Letter of Authorization/Agency agreement from Product License Holder. • Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.
	cision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.	
	Reply by the firm:	
	Form 5A has neither mentioned film coated tablets nor salt form of the active ingredients. Label claim in form 5 needs revision with submission of applicable fee.	Firm has submitted revised Form 5A wherein they have revised their label claim by mentioning the film coating and salt form of Dolutegravir & Tenofovir Disoproxil with submission of 7500/- fee vide slip No. 1676685835 dated 18-11-2022 as follows; **Each film coated Tablet Contains:** **Dolutegravir Sodium eq. Dolutegravir to…50mg** **Tenofovir Disoproxil Fumarate 300mg eq. to Tenofovir Disoproxil …… 245mg** **Lamivudine ……300mg**
	Submit Original, valid & legalized COPP issued by concerned regulatory Authority.	Firm has submitted copy of CoPP certificate No. COPP/CERT/PD/109187/2021/11/38483/188495 for Viropil tablets. Certifying Authority: Food & Drug Administration, Maharashtra State Mumbai, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date: 17-12-2021. The certificate conforms to the format recommended by the WHO. Validity: 28-11-2024. Certificate also confirms that this product is also actually on the market in the exporting country. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid COPP is under consulate attestation and we will submit valid consulate attested

		COPP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority.	Firm has submitted copy of Certificate No: NEW-WHO-GMP/CERT/PD/108736/2021/11/38283 dated 29-11-2021. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 28-11-2024. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid GMP is under consulate attestation and we will submit valid consulate attested GMP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original and complete Letter of Authorization from Product License Holder.	Firm has submitted notarized authorization letter from M/s Emcure Pharmaceuticals Limited, wherein they have authorized M/s Revive Healthcare, Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore for import, market, distribution and sale of the 08 products namely; Atazor-R Tablets, Tavin-EM Tablets, Instgra Tablets, Viropil Tablets, Spegra Tablets, Vonavir tablets, Inbec tablets and Vonday tablets.
	Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2 °C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30°C ± 2 °C / 75% ± 5% RH for 36 months. Batch No. EM79012A, EM79015A & EM79042A. *Firm has also clarified regarding the condition of real time stability data that Zone IVb conditions (30°C ± 2 °C / 75% ± 5% RH) are more stringent than Zone Iva (30°C ± 2 °C / 65% ± 5% RH) and we provided stability on Zone IVb condition so it can be considered as the worst case scenario.*
	Decision: Approved as per policy of inspection of manufacturer abroad with innovator's specifications and following label claim; **"Each film coated Tablet Contains:** **Dolutegravir Sodium eq. Dolutegravir to…50mg** **Tenofovir Disoproxil Fumarate 300mg eq. to Tenofovir Disoproxil ……..… 245mg** **Lamivudine ……300mg"** • **Registration letter will be issued after submission of full fee of for correction/pre-approval change in the label claim as per reference product, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.** • **Firm will also submit and original, valid & legalized COPP certificate for the applied formulation issued by concerned regulatory Authority before issuance of registration letter.**	
947.	Name and address of Applicant	M/s Revive Healthcare. Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore, Pakistan.
	Detail of Drug Sale License	Name: M/s Revive Healthcare. Address: Office 503, 5th Floor, Eden Heights, 6 Main Gulberg, Jail Road, District Lahore. Validity: 21st May, 2020 Status: License to sell drugs as a distributor (Form No.11)
	Name and address of manufacturer	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name and address of marketing authorization holder	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name of exporting country	India.

	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy. No 11418-A dated 05-03-2019.
	Fee including differential fee	Rs.50,000/- dated 05-03-2019.
	Brand Name +Dosage Form + Strength	Tavin-Em Tablets
	Composition	Each Tablet Contains: Tenofovir Disoproxil Fumarate ……..…300mg Emtricitabine ……..…200mg
	Finished Product Specification	Manufacturer specifications.
	Pharmacological Group	Antivirals for treatment of HIV infections, combinations.
	Shelf life	24 months
	Demanded Price	As per SRO.
	Pack size	30's.
	International availability	WHO pre-qualified formulation (Ref. No. HA726-0)/ TRUVADA® (emtricitabine and tenofovir disoproxil fumarate) USFDA approved.
	Me-too status	Could not be confirmed.
	Stability studies	Not provided.
	Detail of certificates attached	**Letter of authorization: - (Copy submitted)** M/s Revive Healthcare. Office 503, 5th Floor, Eden Heights 6 Main Gulberg, Jail Road, Lahore, Pakistan Dated: 24-08-2017. Validity: not mentioned. Letter of authorization has neither product list nor it has any sole distribution details. **Certificate of Pharmaceutical Product (Copy submitted).** Certificate No: COPP/CERT/PD/79590/2018/11/25928/134886. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date**:** 24-11-2018. The certificate conforms to the format recommended by the WHO. Validity: 02-11-2021. Certificate confirms that this product is also actually on the market in the exporting country. **GMP certificate (Copy submitted).** Certificate No: NEW-WHO-GMP/CERT/PD/74276/2018/11/25582. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Date: 03-11-2018. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 02-11-2021.
	Remark of the Evaluator [XIII]	• Form 5A has not mentioned film coated tablets. Label claim in form 5 needs revision with submission of applicable fee. • Submit Original, Valid & legalized COPP issued by concerned regulatory Authority • Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority • Submit Original and complete Letter of Authorization/Agency agreement from Product License Holder. • Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.

	Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.	
	Reply by the Firm;	
	• Form 5A has not mentioned film coated tablets. Label claim in form 5 needs revision with submission of applicable fee.	Firm has submitted revised Form 5A wherein they have revised their label claim by mentioning the film coating and salt form of Tenofovir with submission of 7500/- fee vide slip No. 295052514153 dated 18-11-2022 as follows; **Each film coated Tablet Contains:** **Tenofovir Disoproxil Fumarate 300mg eq. to Tenofovir Disoproxil …… 245mg** **Emtricitabine ……..…200mg**
	Submit Original, Valid & legalized COPP issued by concerned regulatory Authority.	Firm has submitted copy of CoPP certificate No. COPP/CERT/PD/109187/2021/11/38483/188279 for Tavin-EM tablets. Certifying Authority: Food & Drug Administration, Maharashtra State Mumbai, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date: 17-12-2021. The certificate conforms to the format recommended by the WHO. Validity: 28-11-2024. Certificate also confirms that this product is also actually on the market in the exporting country. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid COPP is under consulate attestation and we will submit valid consulate attested COPP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority.	Firm has submitted copy of Certificate No: NEW-WHO-GMP/CERT/PD/108736/2021/11/38283 dated 29-11-2021. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 28-11-2024. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid GMP is under consulate attestation and we will submit valid consulate attested GMP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original and complete Letter of Authorization from Product License Holder.	Firm has submitted notarized authorization letter from M/s Emcure Pharmaceuticals Limited, wherein they have authorized M/s Revive Healthcare, Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore for import, market, distribution and sale of the 08 products namely; Atazor-R Tablets, Tavin-EM Tablets, Instgra Tablets, Viropil Tablets, Spegra Tablets, Vonavir tablets, Inbec tablets and Vonday tablets.
	Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2 °C / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30°C ± 2 °C / 75% ± 5% RH for 36 months. Batch No. EM3Z160B, EM3Z162B & EM47223B. *Firm has also clarified regarding the condition of real time stability data that Zone IVb conditions (30°C ± 2°C / 75% ± 5% RH) are more stringent than Zone Iva (30°C ± 2°C / 65%*

		± 5% RH) and we provided stability on Zone IVb condition so it can be considered as the worst case scenario.
	Decision: Approved as per policy of inspection of manufacturer abroad with innovator's specifications and following label claim; **Each film coated Tablet Contains:** **Tenofovir Disoproxil Fumarate 300mg eq. to Tenofovir Disoproxil ……. 245mg** **Emtricitabine ……..…200mg** • **Registration letter will be issued after submission of full fee of for correction/pre-approval change in the label claim as per reference product, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.** • **Firm will also submit and original, valid & legalized COPP certificate for the applied formulation issued by concerned regulatory Authority before issuance of registration letter.**	
948.	Name and address of Applicant	M/s Revive Healthcare. Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore, Pakistan.
	Detail of Drug Sale License	Name: M/s Revive Healthcare. Address: Office 503, 5th Floor, Eden Heights, 6 Main Gulberg, Jail Road, District Lahore. Validity: 21st May, 2020 Status: License to sell drugs as a distributor (Form No.11)
	Name and address of manufacturer	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name and address of marketing authorization holder	M/s Emcure Pharmaceuticals Limited, Plot No. P1 & P2 I.T.B.T Park, Phase II, M.I.D.C. Hinjawadi Pune 411057 Maharashtra State, India.
	Name of exporting country	India.
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy. No 11419-A dated 05-03-2019.
	Fee including differential fee	Rs.50,000/- dated 05-03-2019.
	Brand Name +Dosage Form + Strength	Instgra 50mg Tablet.
	Composition	Each Tablet Contains: Dolutegravir …… 50mg
	Finished Product Specification	Manufacturer specifications.
	Pharmacological Group	Direct Acting Antivirals.
	Shelf life	24 months
	Demanded Price	As per SRO.
	Pack size	30's.
	International availability	WHO pre-qualified formulation (Ref. No. HA701-0)/ TIVICAY (Dolutegravir) film coated tablets USFDA approved.
	Me-too status	Could not be confirmed.
	Stability studies	Not provided.
	Detail of certificates attached	**Letter of authorization: - (Copy submitted)** M/s Revive Healthcare. Office 503, 5th Floor, Eden Heights 6 Main Gulberg, Jail Road, Lahore, Pakistan Dated: 24-08-2017. Validity: not mentioned. Letter of authorization has neither product list nor it has any sole distribution details. **Certificate of Pharmaceutical Product (Copy submitted).** Certificate No: COPP/CERT/PD/79590/2018/11/25928/134887. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India.

		Date**:** 24-11-2018. The certificate conforms to the format recommended by the WHO. Validity: 02-11-2021. Certificate also confirms that this product is also actually on the market in the exporting country. **GMP certificate (Copy submitted).** Certificate No: NEW-WHO-GMP/CERT/PD/74276/2018/11/25582. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India. Date: 03-11-2018. Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 02-11-2021.
	Remark of the Evaluator [XIII]	• Form 5A has neither mentioned film coated tablets nor salt form of active ingredient. Label claim in form 5 needs revision with submission of applicable fee. • Submit Original, valid & legalized COPP issued by concerned regulatory Authority • Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority • Submit Original and complete Letter of Authorization/Agency agreement from Product License Holder. • Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.
	Decision of 322nd meeting of Registration Board: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.	
	Reply by the firm:	
	Form 5A has neither mentioned film coated tablets nor salt form of the active ingredients. Label claim in form 5 needs revision with submission of applicable fee.	Firm has submitted revised Form 5A wherein they have revised their label claim by mentioning the film coating and salt form of Dolutegravir with submission of 7500/- fee vide slip No. 16486573 dated 18-11-2022 as follows; **Each film coated Tablet Contains:** **Dolutegravir Sodium eq. Dolutegravir to…50mg**
	Submit Original, valid & legalized COPP issued by concerned regulatory Authority.	Firm has submitted copy of CoPP certificate No. COPP/CERT/PD/109187/2021/11/38483/188292 for Instgra tablets. Certifying Authority: Food & Drug Administration, Maharashtra State Mumbai, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400 051 Maharashtra, India. Date: 17-12-2021. The certificate conforms to the format recommended by the WHO. Validity: 28-11-2024. Certificate also confirms that this product is also actually on the market in the exporting country. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid COPP is under consulate attestation and we will submit valid consulate attested COPP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original, valid & legalized GMP certificate of manufacturer issued by concerned regulatory Authority.	Firm has submitted copy of Certificate No: NEW-WHO-GMP/CERT/PD/108736/2021/11/38283 dated 29-11-2021. Certifying Authority: Food & Drug Administration, M.S. Bandra-Kurla complex, Bandra (E), Mumbai-400051 Maharashtra, India.

		Complies with the Good Manufacturing Practice for the dosage forms categories and activities listed in Table 1. Validity: Valid until 28-11-2024. Firm further requested that please continue the registration process and approve our product in upcoming meeting of Board. They further added that Original valid GMP is under consulate attestation and we will submit valid consulate attested GMP as early as we receive from the manufacturer and will submit to DRAP before receiving of registration letter.
	Submit Original and complete Letter of Authorization from Product License Holder.	Firm has submitted notarized authorization letter from M/s Emcure Pharmaceuticals Limited, wherein they have authorized M/s Revive Healthcare, Office 503, 5th Floor, 6 Main Gulberg, Jail Road, Lahore for import, market, distribution and sale of the 08 products namely; Atazor-R Tablets, Tavin-EM Tablets, Instgra Tablets, Viropil Tablets, Spegra Tablets, Vonavir tablets, Inbec tablets and Vonday tablets.
	Submission of stability studies data of three batches as per zone IV-A as per Requirements of Registration Board decision of 293rd meeting.	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40ºC ± 2 ºC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30ºC ± 2 ºC / 75% ± 5% RH for 36 months. Batch No. EM65116, EM66071 & EM66072. *Firm has also clarified regarding the condition of real time stability data that Zone IVb conditions (30ºC ± 2 ºC / 75% ± 5% RH) are more stringent than Zone Iva (30ºC ± 2 ºC / 65% ± 5% RH) and we provided stability on Zone IVb condition so it can be considered as the worst case scenario.*
	Decision: Approved as per policy of inspection of manufacturer abroad with innovator's specifications and following label claim; **Each film coated Tablet Contains:** **Dolutegravir Sodium eq. Dolutegravir to…50mg** • **Registration letter will be issued after submission of full fee of for correction/pre-approval change in the label claim as per reference product, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.** • **Firm will also submit and original, valid & legalized COPP certificate for the applied formulation issued by concerned regulatory Authority before issuance of registration letter.**	

j. Registration applications of locally manufactured deferred veterinary drugs on form 5.

949.	Name and address of manufacturer / Applicant	M/s Selmore Pharmaceuticals Pvt Ltd. 36-Km, Multan Road Lahore.
	Brand Name +Dosage Form + Strength	Vital 4 Solution
	Composition	Each 1000ml Contains: Vitamin A……30,000,000 IU Vitamin D3……1,000,000 IU Vitamin E……..…5,000mg Vitamin K3……6,000mg
	Diary No. Date of R& I & fee	Dy. No. 12782 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Multivitamins
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	500ml, 1000ml, 5000ml; decontrolled.
	Reference / Me-too status	Adekbar Oral Liquid. Reg. No. 73950
	GMP status	The firm was inspected on 05-03-2018,17-08-2018 & 16-10-2018, where renewal of DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Justify the capacity of one-liter water to accommodate Vitamin A…30,000,000 IU, Vitamin D3…1,000,000 IU, Vitamin

		E…5,000mg and Vitamin K3…6,000mg. the firm submitted the quantity to be Vitamin A…17.64g, Vitamin D3…25mg, Vitamin E…5,000mg and Vitamin K3…6,000mg • You have applied for solution. Justify the solubility of water insoluble vitamins in water. The firm submitted that these are emulsified with tween-80. • The quantity of APIs in master formula are not in line with the label claim. The firm revised the master formula accordingly. • Submitted Rs. (challan-70559611534)
	Decision of 321st meeting of Registration Board.	Deferred for following; • Justification of applied strength of formulation considering the solubility of each drug substance in terms of mg/ml. • Justification for the proposing formulation of water insoluble vitamins in water.
	Submission by the firm.	Firm has submitted master formulation and batch formula for the applied formulation wherein they have shown that total of 1.764 Kg of Vitamin A will be used in 100 Liter. 2.5Gm of Vitamin Din 100 liter, 0.5Kg of Vitamin E and 1.85kg of Vitamin K3 in 100 liters. They further showed the inactive ingredients of the formulation which contain tween 80 as emulsifying agent, Isopropyl alcohol as solubilizing agent, Propylene glycol as solubilizing agent, sorbitol as sweetening agent and purified water as vehicle.
	Evaluation by PEC- XIII	• However, upon evaluation of the initial dossier, Inactive mentioned are benzyle alcohol as preservative, Polysorbate 80 as solubilizing agent, Sodium metabisulphate as anti-oxidant, Sorbitol and purified water as solvent. • Furthermore, initial applied formulation is solution while after submission of reply it becomes as emulsion. • Also the quantities mentioned in the initially submitted dossier and in reply for batch are different from each other.
	Decision of 322nd meeting of Registration Board.	Deferred for following clarifications: • Change of formulation from solution to emulsion. • Change of inactive in the applied formulation. • Change of quantities of the active ingredients mentioned in the initially submitted dossier and in reply.
	Submission by the firm.	• Firm has submitted that their formulation is still in solution form as Vitamin A, Vitamin E and Vitamin D3 are dissolved in isopropyl alcohol (IPA), then, Tween-80 is added and finally volume is make with water (WFI). • Firm has submitted that they have replaced benzyl alcohol and sodium metabisulfite of initial formulation with isopropyl alcohol and propylene glycol for the solubility of Vitamin A, Vitamin E and Vitamin K3. • Firm has submitted that inn place of Vitamin K3 (Menadion), its water soluble form Menadin Sodium Phosphate is used. So, the increase in

		quantity of Vitamin K3 is because of factor of sodium phosphate.
	Evaluation by PEC- XIII	Firm has also submitted full fee for change of their in actives in the applied formulation vide slip No. 01550927664 dated 13-01-2023.
	Decision: Approved.	
950.	Name and address of manufacturer/ Applicant	M/s Elko Organization Pvt Ltd, Plot No.27 & 28, Sector 12-B, North Karachi, Industrial Area, Karachi
	Brand Name + Dosage Form + Strength	X20 Injection 20IU/ml
	Composition	Each ml contains: Oxytocin ……..…20IU
	Diary No. Date of R & I & fee	Dy. No 1876 dated 15-01-2019 Rs. 20,000/- Dated 14-01-2019.
	Pharmacological Group	Peptide hormone
	Type of Form	Form-5
	Finished product Specification	Manufacturers
	Pack size & Demanded Price	250ml & Decontrolled
	Me-too status	X20 Injection 100ml of M/s Elko 085466.
	GMP status	Last GMP inspection was conducted on 06-07-2017 and the report concludes good level of GMP compliance with advice of some improvements of some minor observations.
	Remarks of the Evaluator	Firm has General vial/ ampoule liquid vet section as mentioned in the submitted GMP inspection report.
	Decision of 295th meeting of registration Board.	Deferred for confirmation of manufacturing facility.
	Submission by the firm.	Firm has submitted that they have already registrations of Hormonal drugs namely; 1. Oxytocin 5 IU injection, Reg. No. 011121 with pack size of 1ml ampoule. 2. Oxytocin 10 IU injection, Reg. No. 011122 with pack size of 1ml ampoule, 50ml, 100ml & 250ml. 3. X20 injection (Oxytocin 20 IU), Reg. No. 085466 with pack size of 100ml. Furthermore, firm has submitted copy of DML renewal report conducted on 22-08-2022 wherein the panel unanimously recommends the grant of renewal of DML (000245) (Formulation) for the next five years for following sections and also recommends the regularization of existing layout plan. Report has also mentioned liquid injection Ampoule/vial (Hormone) Veterinary.
	Evaluation by PEC- XIII	• Submitted DML renewal report has only first page and last page. • Furthermore, the me too mentioned has not the same fill volume as that of the applied formulation.
	Decision of 322nd meeting of registration Board.	Deferred for Submission of evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm with same fill volume.
	Submission by the firm.	Firm has submitted an appeal wherein they have stated that in 295th meeting it was decided to get verification of the manufacturing facility. We have submitted report of panel inspection mentioning that firm has manufacturing facility of liquid injection ampoule/vial

		(Hormone) Veterinary. And also LVP veterinary injectable (Hormone). Firm further submitted that at this stage we would like to mention that the permission of Oxytocin 10 IU in 500ml Pack was given to M/s Vitz Pharmaceuticals, Reg. No. 111471 and they are the only manufacturer in Pakistan manufacturing this pack. They further submitted that question arise that from where he has provided me too products? And with same fill volume…? Definitely not, but Board has granted this pack to vitz pharma. Considering Elko request of X20 Injection (Oxytocin ……. 20 I.U.) in 250ml pack, Board is asking to provide me too and same fill volume. In 322nd meeting, DRAP has deferred our case again. We therefore, request to please consider our case on merit basis and grant us registration of the said drug.
	Evaluation by PEC- XIII	
	Decision: Registration Board decide do defer the instant application while referring to its 313th meeting wherein Board endorsed the following recommendations of Expert Working group on Veterinary Drugs: **"*The Expert Working Group on Veterinary Drugs deliberate the case and decided to allow for granting multidose vials for Oxytocin as per following details:*** ***Oxytocin .... 10 UI upto 500ml as per Spanish authority approval or any pack size available in any other RRA.*** ***Oxytocin .... 20 UI upto 50ml as per Australian Pesticides and Veterinary medicine Authority approval or any pack size available in any other RRA.*"**	
951.	Name and address of manufacturer/ Applicant	M/s Eterna Pharma (Pvt.) Ltd., Plot # (99,100,101,198) C, Sector D1, Old Industrial Estate, Mirpur, AJ&K (Liquid Injection section (Veterinary) General).
	Brand Name + Dosage Form + Strength	Fenik Plus Injection.
	Composition	Each ml contains: Meloxicam ……. 20%
	Diary No. Date of R & I & fee	Dy. No. 121 dated: 01-01-2021 Rs.20,000/- 01-01-2021.
	Pharmacological Group	NSAID's.
	Type of Form	Form 5.
	Finished product Specification	BP Specification
	Pack size & Demanded Price	50ml / Decontrolled
	Me-too status	Could not be confirmed.
	GMP status	Same as above.
	Remarks of the Evaluator	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm. • Official monograph of the applied formulation is not available in pharmacopoeias.
	Decision of 307th meeting of Registration Board;	Deferred for Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Reply by the firm;	Firm has submitted revised formulation of their formulation and also provided me too for the new/ revised label claim. Camrold 20 liquid Injection, Harrolds Pharma AJK, Reg. No. 109006.

		Revised label claim is as under; Each ml Contains: Meloxicam ……. 20mg.
	Remarks of the Evaluator PEC XIII.	• Firm has neither submitted revised form 5 nor any fee for revision of label claim of the applied formulation. • Current GMP status of the firm could not be confirmed. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Decision of 323rd meeting of registration Board.	Deferred for following; • Submission of full fee of 30,000/- for correction/pre-approval change in the label claim, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021 along with Current GMP certificate/last inspection report conducted within last three years. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Reply by the firm;	Firm has submitted revised Form 5 with submission of fee of 30,000/- vide slip No. 76507722295 dated 18-01-2023. Firm has also submitted GMP certificate No. F. 3-88/2022-Addl. Dir. (QA&LT-I) dated 31-08-2022 issued on the basis of inspection conducted on 14-10-2021. GMP certificate is export to Nigeria.
	Remarks of the Evaluator PEC XIII.	Fee submitted by the firm is for Fenik Plus Injection. (Meloxicam 20 %) Change of Label Claim. However, the correct label claim is 20mg instead of 20%. Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Decision: Deferred for submission of evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.	
952.	Name and address of manufacturer/ Applicant	M/s Eterna Pharma (Pvt.) Ltd., Plot # (99,100,101,198) C, Sector D1, Old Industrial Estate, Mirpur, AJ&K (Liquid Injection section (Veterinary) General).
	Brand Name + Dosage Form + Strength	Melo 10 Injection.
	Composition	Each ml contains: Meloxicam ……. 10%
	Diary No. Date of R & I & fee	Dy. No. 119 dated: 01-01-2021 Rs.20,000/- 01-01-2021.
	Pharmacological Group	NSAID's.
	Type of Form	Form 5.
	Finished product Specification	BP Specification
	Pack size & Demanded Price	50ml / Decontrolled
	Me-too status	Could not be confirmed.
	GMP status	Same as above.
	Remarks of the Evaluator	• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along

		with registration number, brand name and name of firm. • Official monograph of the applied formulation is not available in pharmacopoeias.
	Decision of 307th meeting of Registration Board;	Deferred for Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Reply by the firm;	Firm has submitted revised formulation of their formulation and also provided me too for the new/ revised label claim. Camrold 10 liquid Injection, Harrolds Pharma AJK, Reg. No. 109003. **Revised label claim is as under;** **Each ml Contains:** **Meloxicam ……. 10mg.**
	Remarks of the Evaluator PEC XIII.	• Firm has neither submitted revised form 5 nor any fee for revision of label claim of the applied formulation. • Current GMP status of the firm could not be confirmed. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Decision of 323rd meeting of registration Board.	Deferred for following; • Submission of full fee of 30,000/- for correction/pre-approval change in the label claim, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021 along with Current GMP certificate/last inspection report conducted within last three years. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Reply by the firm;	Firm has submitted revised Form 5 with submission of fee of 30,000/- vide slip No. 09460875 dated 18-01-2023. Firm has also submitted GMP certificate No. F. 3-88/2022-Addl. Dir. (QA&LT-I) dated 31-08-2022 issued on the basis of inspection conducted on 14-10-2021. GMP certificate is export to Nigeria.
	Remarks of the Evaluator PEC XIII.	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.
	Decision: Deferred for submission of evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm and same fill volume.	

Item No. 12: Agenda of Evaluator PEC-XVI (Mr. Akbar Ali)

A : HUMAN (Deferred) (Form 5-F/CTD) **Evaluator PEC-XVI**

953.	Name, address of Applicant / Marketing Authorization Holder	M/s Allmed (Pvt.) Ltd

		Plot# 590 Sunder Industrial Estate Raiwind Road-Lahore
	Name, address of Manufacturing site.	M/ s Allmed (Pvt.) Ltd Plot# 590 Sunder Industrial Estate Raiwind Road-Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27423-A dated 04/10/2021
	Details of fee submitted	PKR 20,000/-: Slip No.49001593033 dated 13/04/2021 PKR 10,000/- Slip No .93361876 dated 08/07/2021
	The proposed proprietary name / brand name	Sopra-Praz D 30mg Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule Contains: Dual Delayed release pellets of Dexlansoprazole equivalent to Dexlansoprazole: ------- 30mg
	Pharmaceutical form of applied drug	Hard gelatin Capsule filled with white to off white dual delayed release pellets.
	Pharmacotherapeutic Group of (API)	PPIs (Proton Pump Inhibitors)
	Reference to Finished product specifications	Manufacturer Specifications
	Proposed Pack size	1×30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Dexilant 30mg Capsule Takeda Pharmaceuticals USA Inc (Innovator)
	For generic drugs (me-too status)	Razodex 30mg Capsule by Getz Pharma Reg. # 086976
	GMP status of the Finished product manufacturer	GMP inspection was conducted on 11/06/2021 and report satisfactory. Capsule (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Vision Pharmaceuticals Plot No. 22-23, Industrial Triangle, Kahuta Road, Islamabad- Pakistan Tel: (92-51) 4493587-88-89-90, Fax: (92-51) 4493591 Email: contact@visionpharmapk.com Web: www.visionpharmapk.com
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container

		closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Dexlansoprazole is not present in Pharmacopoeia. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities/related substances (Sulphone Impurity Sulphide Impurity Total Impurities), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (SP-T40, SP-T41, SP-T42)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against Razodex 30mg Capsule (B # 039C47) by Getz Pharma by performing quality tests (Identification, Dissolution, Disintegration, Assay, Total Impurity, Microbial contamination). CDP has been performed against the same brand that is Razodex 30mg Capsule (B # 039C47) by Getz Pharma in Acid media (pH 1.0-1.2) & (pH 5.5 & 7). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Vision Pharmaceuticals Plot No. 22-23, Industrial Triangle, Kahuta Road, Islamabad- Pakistan		
API Lot No.	DLP569		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×30's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 6 (Months) Real Time: 0, 1, 2, 3, 4, 6 (Months)		
Batch No.	SP-T40	SP-T41	SP-T42

Batch Size	2500 Capsule	2500 Capsule	2500 Capsule
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	23/09/2020	23/09/2020	23/09/2020
No. of Batches	03		

Administrative Portion

13.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
14.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate F. 3-26/20 19-Addl. Dir. (QA & LT-I) issued by DRAP valid till 10/02/2022.
15.	Documents for the procurement of API with approval from DRAP (in case of import).	• Purchase order No PO-9-20-7 is submitted. Purchased from Vision Pharmaceuticals, Islamabad- Pakistan hence DRAP approval is not required.
16.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
17.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
18.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr.#	Section#	Observation
1.	**1.3.5.**	Evidence of approval of manufacturing facility / Approved Section from Licensing Authority
2.	**3.2.S.2.3**	Firm has not mentioned sucrose as part of their master formulation for manufacturing control of inactive material however firm has mentioned sucrose in section 2.3.S.2.5, i-e Manufacturing process development. which needs clarification.
3.	**3.2.S.2.6**	The specification of dual release pellets at enteric coating stage is mentioned as soluble at 6.7 PH , whereas QA release specification for IPQC is mentioned as dissolution at P.H.7, which needs clarification.
4.	**3.2.S.4.4**	• The submitted COA of source of API, (Dexlansoprazole) M/s Everest Organics Limited, India, has mentioned Identification /Assay through Chiral HPLC, however same is not depicted through COA of API by local pellets manufacturer. i-e M/s Vision pharmaceuticals, Islamabad • Dexlansoprazole is a racemic enantiomer of Lansoprazole, Optical rotation test is performed by API manufacturer , however as per COA of Pellets , same is not performed by Pellet manufacturer , as well as finished product manufacturer which needs clarification.
5.	**3.2.S.7**	• API (Pellet) Manufacturer has not mentioned/conducted degradation product test while conducting stability study data of API(pellets) , which needs clarification.
6.	**3.2.P.2.2.1**	• Finished product manufacturer has submitted comparative dissolution Profile performance with Capsule Razodex ,Getz Pharma , However firm has not submitted non Model dependent Cohen's F2(Similarity factor) calculation to establish comparable dissolution with comparator .which needs clarification.

Previous Decision of 322nd Meeting: Registration Board has deferred the case for submission of the reply for above cited shortcomings within six (6) months.

Reply of Firm:

4.	**3.2.S.4.4**	• The submitted COA of the source of API, (Dexlansoprazole) M/s Everst Organics Limited, India, has mentioned Identification/Assay through chiral HPLC, however same is not depicted through COA of API by local pellet manufacturer i.e. M/s Vision Pharmaceuticals, Islamabad. • Dexlansoprazole is a racemic enantiomer of Lansoprazole, optical rotation test is performed by API manufacturer, however as per COA of the pellets, same is not performed by pellets manufacturer, as well as finish product manufacturer, which needs clarification.	Assay for chiral content (Lansoprazole) is performed at Dexlansoprazole API stage testing, not at Dexlansoprazole DDR Pellets yet. Now from onward API manufacturer will perform this test, updated testing method is attached.
5.	**3.2.S.7**	• API (pellets) manufacturer has not mentioned/conducted degradation product test while conducting stability study data of API (pellets), which need clarifications.	New stability study data is attached.
6.	**3.3.P.2.2.1**	Finish product manufacturer has submitted comparative dissolution profile performance with capsule Razodex, Getz Pharma, however firm has not submitted non-model dependent Cohen's F2(similarity factor) calculation to establish comparable dissolution with comparator,	Comparative dissolution profile with submitted non-model dependent Cohen's F2 (similarity factor) was already submitted with the dossier under section 3.2.P.2.2, same is again attached under here.

Sr. No	Section #	Observation	Company reply
1.	**1.3.5**	Evidence of approval of manufacturing facility/approval of section from licensing authority.	Approval letter (F.1-20/2005-Lic) of manufacturing facility/approval of section from licensing authority is attached.
2.	**3.2.S.2.3**	Firm has not mentioned sucrose as a part of their master formulation for manufacturing control of inactive material however firm has mentioned sucrose in Section 2.3.S.2.5, i.e. manufacturing process development, which need clarification.	Sucrose is not part of formulation; this is typographic error. In actual it is starch not sucrose. Corrected section is attached.
3.	**3.2.S.2.6**	The specification of dual release pellets is at enteric coating stage is mentioned as soluble at 6.7 PH, whereas QA released specification for IPQC is mentioned as dissolution at PH 7, which need clarification.	The specification of dual release pellets are at enteric coating stage is mentioned as soluble **6 to 7 PH not 6.7**, relevant section 3.2.S.2.6 (enteric coating stage) is attached for your reference.

Remarks of Evaluator :

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

954.	Name, address of Applicant / Marketing Authorization Holder	M/s Allmed (Pvt.) Ltd Plot# 590 Sunder Industrial Estate Raiwind Road-Lahore

	Name, address of Manufacturing site.	M/ s Allmed (Pvt.) Ltd Plot# 590 Sunder Industrial Estate Raiwind Road-Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27423-B dated 04/10/2021
	Details of fee submitted	PKR 30,000/-: dated 20,000/- 13/04/2021 10,000/- 08/07/2021
	The proposed proprietary name / brand name	Sopra-Praz D 60mg Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule Contains: Dual Delayed release pellets of Dexlansoprazole equivalent to Dexlansoprazole: ------- 60mg
	Pharmaceutical form of applied drug	Hard gelatin Capsule filled with white to off white dual delayed release pellets.
	Pharmacotherapeutic Group of (API)	PPIs (Proton Pump Inhibitors)
	Reference to Finished product specifications	Manufacturer Specifications
	Proposed Pack size	1×30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Dexilant 60mg Capsule Takeda Pharmaceuticals USA Inc (Innovator)
	For generic drugs (me-too status)	Razodex 60mg Capsule by Getz Pharma Reg. # 086977
	GMP status of the Finished product manufacturer	GMP inspection was conducted on 11/06/2021 and report satisfactory. Capsule (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	Vision Pharmaceuticals Plot No. 22-23, Industrial Triangle, Kahuta Road, Islamabad- Pakistan Tel: (92-51) 4493587-88-89-90, Fax: (92-51) 4493591 Email: contact@visionpharmapk.com Web: www.visionpharmapk.com
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Dexlansoprazole is not present in Pharmacopoeia. The firm has submitted detail of

		nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurities/related substances (Sulphone Impurity Sulphide Impurity Total Impurities), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (SP-T37, SP-T38, SP-T39)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Razodex 60mg Capsule (B # 038C48) by Getz Pharma by performing quality tests (Identification, Dissolution, Disintegration, Assay, Total Impurity, Microbial contamination). CDP has been performed against the same brand that is Razodex 60mg Capsule (B # 038C48) by Getz Pharma in Acid media (pH 1.0-1.2) & (pH 5.5 & 7). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	Vision Pharmaceuticals Plot No. 22-23, Industrial Triangle, Kahuta Road, Islamabad- Pakistan		
API Lot No.	DLP569		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×30's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 6 (Months) Real Time: 0, 1, 2, 3, 4, 6 (Months)		
Batch No.	SP-T37	SP-T38	SP-T39
Batch Size	2500 Capsule	2500 Capsule	2500 Capsule
Manufacturing Date	09-2020	09-2020	09-2020
Date of Initiation	21/09/2020	21/09/2020	21/09/2020

No. of Batches		03
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate F. 3-26/20 19-Addl. Dir. (QA & LT-I) issued by DRAP valid till 10/02/2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Purchase order No PO-9-20-7 is submitted. Purchased from Vision Pharmaceuticals, Islamabad- Pakistan hence DRAP approval is not required.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr.#	Section#	Observation
1.	**1.3.5.**	Evidence of approval of manufacturing facility / Approved Section from Licensing Authority
2.	**3.2.S.2.3**	Firm has not mentioned sucrose as part of their master formulation for manufacturing control of inactive material however firm has mentioned sucrose in section 2.3.S.2.5, i-e Manufacturing process development. which needs clarification.
3.	**3.2.S.2.6**	The specification of dual release pellets at enteric coating stage is mentioned as soluble at 6.7 PH , whereas QA release specification for IPQC is mentioned as dissolution at P.H.7, which needs clarification.
4.	**3.2.S.4.4**	• The submitted COA of source of API, (Dexlansoprazole) M/s Everest Organics Limited, India, has mentioned Identification /Assay through Chiral HPLC, however same is not depicted through COA of API by local pellets manufacturer. i-e M/s Vision pharmaceuticals, Islamabad. • Dexlansoprazole is a racemic enantiomer of Lansoprazole, Optical rotation test is performed by API manufacturer , however as per COA of Pellets , same is not performed by Pellet manufacturer , as well as finished product manufacturer which needs clarification.
5.	**3.2.S.7**	• API (Pellet) Manufacturer has not mentioned/conducted degradation product test while conducting stability study data of API(pellets) , which needs clarification.
6.	**3.2.P.2.2.1**	• Finished product manufacturer has submitted comparative dissolution Profile performance with Capsule Razodex ,Getz Pharma , However firm has not submitted non Model dependent Cohen's F2(Similarity factor) calculation to establish comparable dissolution with comparator .which needs clarification.

Previous Decision of 322nd Meeting: Registration Board has deferred the case for submission of the reply for above cited shortcomings within six (6) months.

4.	**3.2.S.4.4**	• The submitted COA of the source of API, (Dexlansoprazole) M/s Everst Organics Limited, India, has mentioned Identification/Assay through chiral HPLC, however same is not depicted through COA of API by local pellet manufacturer i.e. M/s Vision Pharmaceuticals, Islamabad. • Dexlansoprazole is a racemic enantiomer of Lansoprazole, optical rotation test is performed by API manufacturer, however as per COA of the pellets, same is not performed by pellets manufacturer, as well as finish product manufacturer, which needs clarification.	Assay for chiral content (Lansoprazole) is performed at Dexlansoprazole API stage testing not at Dexlansoprazole DDR Pellets yet. Now from onward API manufacturer will perform this test, updated testing method is attached.
5.	**3.2.S.7**	• API (pellets) manufacturer has not mentioned/conducted degradation product test while conducting stability study data of API (pellets), which need clarifications.	New stability study data is attached.
6.	**3.3.P.2.2.1**	Finish product manufacturer has submitted comparative dissolution profile performance with capsule Razodex, Getz Pharma, however firm has not submitted non-model dependent Cohen's F2(similarity factor) calculation to establish comparable dissolution with comparator,	Comparative dissolution profile with submitted non-model dependent Cohen's F2 (similarity factor) was already submitted with the dossier under section 3.2.P.2.2, same is again attached under here.

Reply of Firm:

Sr. No	Section	Observation	Company reply
1.	**1.3.5**	Evidence of approval of manufacturing facility/approval of section from licensing authority.	Approval letter (F.1-20/2005-Lic) of manufacturing facility/approval of section from licensing authority is attached.
2.	**3.2.S.2.3**	Firm has not mentioned sucrose as a part of their master formulation for manufacturing control of inactive material however firm has mentioned sucrose in Section 2.3.S.2.5, i.e. manufacturing process development, which need clarification.	Sucrose is not part of formulation; this is typographic error. In actual it is starch not sucrose. Corrected section is attached.
3.	**3.2.S.2.6**	The specification of dual release pellets are at enteric coating stage is mentioned as soluble at 6.7 PH, whereas QA released specification for IPQC is mentioned as dissolution at PH 7, which need clarification.	The specification of dual release pellets are at enteric coating stage is mentioned as soluble **6 to 7 PH not 6.7**, relevant section 3.2.S.2.6 (enteric coating stage) is attached for your reference.

Remarks of Evaluator :

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

955.	Name, address of Applicant / Marketing Authorization Holder	**M/s Novamed Pharmaceuticals(Pvt.) Ltd Lahore**
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals(Pvt.) Ltd ., 28km Ferozepur Road Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 28454 dated 15/10/2021
	Details of fee submitted	PKR 30,000/-: dated 08/10/2021
	The proposed proprietary name / brand name	**Empozin 10mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film coated Tablet Contains: Empagliflozin……10mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	**(1)Empagliflozin** is an inhibitor of SGLT2
	Reference to Finished product specifications	In-House
	Proposed Pack size	10's, 14's 20's, 28's.
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**Jardiance 10mg tablet** Boehringer Ingelheim Limited USA
	For generic drugs (me-too status)	**Empator 10mg** by Horizon Pharma Reg no. 098822
	GMP status of the Finished product manufacturer	License granted on 08/04/2006 and renewed on 08/04/2021 General tablet section approved and GMP certificate on 31/08/2021.
	Name and address of API manufacturer.	**(1) Empagliflozin;** **API manufacturer Name:**Jiangsu Yong'an Pharmacy CompanyLimited **Address:** No.18 ,237 Proviancial, Road ,Economic Development Zone, Huai'an Jiangsu,China,
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing

		process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Empagliflozin Batches:(130701,130702,130801)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is **Jardiance 10mg tablet** by performing quality tests (Identification, Assay, Dissolution, pH). **CDP** was applicable and has been submitted.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity, robustness and Limit of Quantification.

STABILITY STUDY DATA

Manufacturer of API	**Empagliflozin;** **Name:**Jiangsu Yong'an Pharmacy Company Limited **Address:** No.18 ,237 Proviancial, Road ,Economic Development Zone, Huai'an Jiangsu,China,		
API Lot No.	**Emphagliflozin:** 4500-202003001		
Description of Pack (Container closure system)	Alu-PVC blisters, each containing White colour, Oval shaped biconvex, film coated tablets having breaking line on upper side & lower side is plain. One side of blister is printed with labeling specification. After primary packing blister is packed in specific hard card unit carton along with Patient information leaflet		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**RD/PR21-058/T1/S1**	**RD/PR21-058/T1/S2**	**RD/PR21-058/T1/S3**
Batch Size	2000 tablets	2000 tablets	2000 tablets
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	05-05-2021	05-05-2021	05-05-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted copy of Last inspection Report conducted on 24/01/2018 (Daclatasvir), 06/03/2017 (Sofosbuvir)

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Emphagliflozin**: Copy of GMP certificate issued by CFDA,People's republic of china HUAI'AN JIANGSU valid till 14/01/2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Emphagliflozin** AD Attested invoice ZY20052001G/W Dated.09/06/2020 and
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr.#	Section#	Observation
1.	1.1.5	Legible copy of GMP certificate of manufacturing Site of API ,(Empagliflozin).
2.	3.2.S.2.1	The system suitability conditions set my API manufacturer is detection of API through HPLC with UV detector at 224 nm , same as innovator product , i-e Jardiance whereas under 3.2.S.4.3 validation /verification of analytical procedure by drug product manufacturer significantly varied , including UV detection at 205 nm, which needs clarification.
3.	3.2.S.2.1	Content Uniformity test conducted to establish pharmaceutical equivalence during comparative dissolution ,L1 value is not calculated to meet the specifications as per Pharmacopeia General chapter for content uniformity testing.
4.	3.2.P.2.2.1	• Justification for setting of Dissolution time specification while conducting Comparative dissolution with reference product was set as 30 minutes whereas the innovator product has mentioned specification for dissolution time as 15 minutes. • In comparative dissolution the RPM for USP type 2 (Paddle Apparatus) is set to be 50 RPM whereas innovator Tab Jardiance has conducted same at 75 RPM which needs clarification.
5.	3.2.P.5.3	• The specificity test for conducting validation of analytical method is conducted without the presence of other components like impurities, excipients and matrix compounds which is necessary to establish the specificity of testing method. • Intermediate precision is conducting without comparing the result of separate or different analyst on same apparatus.
6.	3.2.P.8.3	• Stability data of three batches for 6th month for both accelerated and real time stability is missing which is required. • Content uniformity test for Empagliflozin 10 mg is not mentioned in finished product specification nor it is part of stability batches data / COA, which needs clarification. • Documents for the procurement of API with approval from DRAP (in case of import).

Previous Decision of 322nd Meeting: Registration Board has deferred the case for submission of the reply for above cited shortcomings within six (6) months.

Reply of Firm:

S. No	Sections	Observations/ Short-comings	Reply
1.	**1.1.5**	Legible copy of GMP certificate of manufacturing site of API, (Empagliflozin).	Valid copy of DML/GMP certificate of API manufacturer site is **attached.**

2.	**3.2.S.2.1**	The system suitability condition set by API manufacturer is detection of API through HPLC with UV detector at 224nm, same as innovator product , i.e. Jardience whereas under 3.2.S.4.3 Validation/verification of analytical procedure by drug product manufacturer significantly varied, including UV detection at 205nm, which needs clarification.	For testing Empagliflozin API, analytical method was developed by firm with INH Specification & same method has been validated & results are complied with validate Specification. **Analytical method & Validation are attached**
3.	**3.2.P.2 .1**	Content uniformity test conducted to establish pharmaceutical equivalence during comparative dissolution, L1 value is not calculated to meet the specification as per pharmacopeia general chapter for content uniformity testing.	Content uniformity test conducted to establish pharmaceutical equivalence during comparative dissolution. L1 value is calculated to meet the specification as per pharmacopeia. **revised Content uniformity Sheets are attached**
4.	**3.2.P.2.2. 1**	• Justification for setting of dissolution time specification while conducting comparative dissolution with reference product was set as 30 minutes whereas the innovator product has mentioned specification for dissolution time as 15 minutes.	After reviewing the dissolution release trend in CDP report it is evident that more than 80% drug is released in 15min so we have already revised our current acceptance specification limit to **NLT 80% in 15 mins** instead of 30mins. **Revised Method & Specification are attached.**
		• In comparative dissolution the RPM for USP type 2 (Paddle Apparatus) is set to be 50 RPM whereas innovator tab Jardience has Conducted same at 75 RPM which needs clarification	CDP has been performed as per innovator specification. However, 50rpm is mentioned erroneously in the report. revised CDP report **is attached**
5.	**3.2.P.5.3**	• The specificity test for conducting validation of analytical method is conducted without the presence of other component like impurities, excipients and matrix compound which is necessary to establish the specificity of testing method. • Intermediate precision is conducting without comparing the result of separate or different analyst on same apparatus.	According to ICH Q2R1 Specificity is the ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Typically these might include impurities, degradants, matrix etc. We have run placebo containing matrix and there is no interference observed in Analytical method Validation of product, so the matrix is specific to analyte. Intermediate precision is conducting by using two different analyst and result are mentioned in the table **Attached.**

6.	**3.2.P.8.3**	• Stability data of three batches for 6th month for both accelerated and real time stability is missing which is required. • Content uniformity test for Empagliflozin 10mg is not mentioned in finished product specification nor it is part of stability batches data/ COA, which needs clarification. • Documents for the procurement of API with approval from DRAP (in case of import).	Stability data till 3rd Month has been submitted on 15-10-2021 and data against 6 month time point has been submitted on 13-01-2022. Copy of receiving is **attached.** Content Uniformity test for Empagliflozin has been performed and updated COAs of three stability batches **are attached** Documents for the procurements of API with approval from DRAP **are Attached**

Remarks of Evaluator :

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will adopt dissolution specifications of "NLT 80% in 15 minutes", for commercial batches.**
- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

B: HUMAN (NEW) (EXPORT FACCILITATION PERIORITY CASES)

Assistant Director (EFD) vide letter No. F.1-6/2019-PR-1(EFD) dated 06-10-2022 has informed that M/s Novamed Pharmaceuticals (Pvt) Ltd, Lahore has achieved the benchmark of **USD 217659/=** during the **fiscal Year 2021-2022** and requested for priority consideration of following molecules.

956.	Name and address of manufacturer / Applicant	M/s Novamed Pharmaceuticals(Pvt.)Ltd ., 28km Ferozepur Road Lahore
	Brand Name +Dosage Form + Strength	**Empozin 25mg Tablet**
	Composition	Each Film Coated Tablet Contains: Empagliflozin……. 25mg
	Diary No. Date of R& I & fee	Dy. No.2905 dated 12th, April 2017, Fee Rs: 50,000/- dated 27-02-2017. **Duplicate Dossier** Dy No.3270/PEC(DRAP) dated 02-0102023.
	Pharmacological Group	Antidiabetic
	Type of Form	Form 5D
	Finished product Specifications	In-House
	Pack size & Demanded Price	10's, 14's 20's,28's
	Approval status of product in Reference Regulator Authorities	**Jardiance Tablet 25mg** Boehringer Ingelheim Pharmaceutical company, Germany
	Me-too status	**Jardy 25mg Tablet** by CCL Pharma)
	GMP status	License granted on 08/04/2006 and renewed on 08/04/2021 General tablet section approved and GMP certificate on 31/08/2021.
	Remarks of the Evaluator	
STABILITY STUDY DATA		

Manufacturer of API	**Empagliflozin:** **Name:** Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China		
API Lot No.	Empagliflozin: 4500-202003001		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (months) Real Time: 0, 3, 6 (months)		
Batch No.	**RD/PR20-016/T1/S1**	**RD/PR20-016/T1/S2**	**RD/PR20-016/T1/S3**
Batch Size	2000 tablets	2000 tablets	2000 tablets
Manufacturing Date	10-2020	10-2020	10-2020
Date of Initiation	12-10-2020	12-10-2020	12-10-2020
No. of Batches	03		
Date of Submission	12th ,April 2017		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
15.	Reference of previous approval of applications with stability study data of the firm	The firm has referred to previous inspection for authenticity of stability data of their products conducted by the panel, on the basis of which Registration Board in its 278th meeting dated 20-03, 2018 & 268th dated 28- 04, 2017, decided to approve registration of (Daclatasvir), (Sofosbuvir). The report shows that: • Finished Pharmaceutical Product stability testing was conducted on HPLC R&D # 19 for Daclatasvir, Sofosbuvir tablet which were 21 CFR compliant for initial 6 months. • Adequate monitoring and control were available for stability chamber.
16.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	3. Copy of COA (**Batch#4500-202003001**) of API (Empagliflozin) from M/s Jiangsu Yongan Pharmaceutical Co., Limited Address: No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China is submitted.
17.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Methods used for analysis of APIs from both API Manufacturers and Finished Product Manufacturer are provided by the firm.
18.	Stability study data of API from API manufacturer	Empagliflozin: Firm has submitted stability study data of API as per zone IV-A. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 24 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 6 months at intervals 0, 3, 6, 9, 12, 18, 24 & 0, 1, 2, 3 & 6 months respectively. Batches :(Z130701,130702,130801)

<table>
<tr><td></td><td></td><td>10 days stress stability study at conditions 60˚C ± 2˚C, Photolysis 4500 ± 500LX and 92.5%± 5%RH at 0, 5th & 10th day</td></tr>
<tr><td>19.</td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td><u>Empagliflozin:</u> Firm has submitted copy of GMP/DML certificate dated 07-2020 in the name of M/s Jiangsu Yongan Pharmaceutical Co., Limited
No.18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China issued by Jiangsu medical products Administration</td></tr>
<tr><td>20.</td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td><u>For Empagliflozin</u>: The firm has submitted copy of invoice No. ZY20052001G/W dated 08/05/2020 from exporter M/s Suzhou ZhiYu Biotechnology Co.,Ltd Room 1119 No.2 Building Xingguangyao Square No. No 1583 Huchi Road, Gusu District, Suzhou 215008, China, for import of 490gms of Empagliflozin (Batch No. 4500-202003001) in name of M/s Novamed Pharmaceuticals(Pvt.)Ltd ., 28km Ferozepur Road Lahore. Attested by AD (I&E) DRAP Lahore dated 09-06-2020.</td></tr>
<tr><td>21.</td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td>22.</td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td>23.</td><td>Drug-excipients compatibility studies (where applicable)</td><td>Drug excipients compatibility study performed.</td></tr>
<tr><td>24.</td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><th>Batch No.</th><th>Batch Size</th><th>Mfg. Date</th></tr>
<tr><td>RD/PR20-016/T1/S1</td><td>2000 tablets</td><td>10-2020</td></tr>
<tr><td>RD/PR20-016/T1/S1</td><td>2000 tablets</td><td>10-2020</td></tr>
<tr><td>RD/PR20-016/T1/S1</td><td>2000 tablets</td><td>10-2020</td></tr>
</table></td></tr>
<tr><td>25.</td><td>Record of comparative dissolution data (where applicable)</td><td>ProvidedComparative dissolution was performed against Jardiance Tablet 25mg
in HCl buffer (pH 1.2), Acetate buffer (pH 4.5) & Phosphate buffer (pH 6.8)</td></tr>
<tr><td>26.</td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td>27.</td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td>28.</td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Submitted</td></tr>
<tr><td colspan="3">Remarks of Evaluator:
<table>
<tr><th>S. No</th><th>Observations/ Short-comings</th><th>Reply of firm vide dairy No.3647 PEC/DRAP dated 24-01-2023</th></tr>
</table></td></tr>
</table>

1.	Form-5D application label claim does not mention film coated tablet instead applied label claim is mentioned as "each tablet contains: Empagliflozin …..25mg", whereas master formulation mention film coated tablet , moreover innovator product is also film coated tablet . Revised label claim on form 5-D is required as per innovator product label claim.	Product has been developed as per innovator product i:e film coated tablet **Revised form 5-D is attached**
2.	COA of API Empagliflozin Batch no : 4500-202003001 does not mentioned testing of organic impurity through chiral HPLC as required and tested for API of innovator brand.	Manufacturer has reported process related impurity as impurity A ,B and same has been tested for Batch Release as impurity A,B separately .Single impurity and total impurity range has also established and testing results are well in the establish range. Our testing is based on manufacturer COA. For reference **COA is attached.**
3.	Content uniformity test conducted to establish pharmaceutical equivalence during comparative dissolution, L1 value is not calculated to meet the specification as per pharmacopeia general chapter for content uniformity testing.	Content uniformity test conducted to establish pharmaceutical equivalence during comparative dissolution.L1 value is calculated to meet the specification as per pharmacopeia. **Revised Content uniformity Sheets are attached**
4.	• Dissolution time batch and stability specification of finished product are set as 30minutes whereas the innovator product has mentioned specification for dissolution time as 15minutes. Clarification is required. • Dissolution specification for RPM for USP type 2 (Paddle apparatus) is set to be 50RPM whereas innovator Tab Jardiance has conducted same at 75RPM which also needs clarification .	• After reviewing the dissolution release trend in CDP report it is evident that more than 80% drug is released in 15min so we have already revised our current acceptance specification limit to **NLT 80% in 15 mins** instead of 30mins. **Revised Specification are attached.** • CDP has been performed as per innovator specification. However 50rpm is mentioned erroneously in the report. revised **CDP report is attached.**
5.	• Justification for setting of dissolution time specification while conducting comparative dissolution with reference product was set as 30 minutes whereas the innovator product has mentioned specification for dissolution time as 15 minutes. • In Comparative dissolution the RPM for USP type 2 (Paddle apparatus) is set to be 50RPM whereas innovator Tab Jardiance has conducted same at 75RPM which also needs clarification.	• After reviewing the dissolution release trend in CDP report it is evident that more than 80% drug is released in 15min so we have already revised our current acceptance specification limit to **NLT 80% in 15 mins** instead of 30mins. **Revised Specification are attached.** • CDP has been performed as per innovator specification. However 50rpm is mentioned erroneously in the report. revised **CDP report is attached.**
6.	BMR of trial batch no: RD-PR20-016/T1/S1 mentioned PVP-K 30 and Sodium lauryl sulphate as part of master formulation of core tablet which are not present in master formulation /excipient list of innovator product , moreover the master formulation submitted along with form 5-D also does not mention these two excipients Clarification is required.	Formulation has been development as per innovator reference and same has been submitted for registration and marked correction In BMR has been revised.

7.	• Content uniformity test for Empagliflozin 25mg is not mentioned in finished product specification nor it is part of stability batches data/COA, which needs clarification. • Documents for the procurement of API with approval from DRAP (in case of import)	Content uniformity test has been already performed as mentioned on Stability COAs. For reference, **Content uniformity test sheets and COAs are attached.** Documents for the procurement of API with approval from DRAP **are Attached**

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will adopt dissolution specifications of "NLT 80% in 15 minutes", for commercial batches.**
- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Assistant Director (EFD) vide letter No. F.1-6/2019-PR-1(EFD) dated 06-10-2022 has informed that M/s The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan has achieved the benchmark of USD 1966273.50/= during the fiscal Year 2020-2021 and requested for priority consideration of following molecules.

957.	Name, address of Applicant / Marketing Authorization Holder	The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan.
	Name, address of Manufacturing site.	The Searle Company Limited F-319, S.I.T.E., Karachi, Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.13727 dated 07/06/2022
	Details of fee submitted	PKR 75,000/-: dated 20/05/2022 (Slip No.6973977486)
	The proposed proprietary name / brand name	Acotide 100mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Acotiamide HCl hydrate…….100mg
	Pharmaceutical form of applied drug	Blue in color, biconvex, round shaped, film coated tablet, engraved SEARLE on one side and break line on other side.
	Pharmacotherapeutic Group of (API)	Gastroprokinetic
	Reference to Finished product specifications	Innovator's Specs
	Proposed Pack size	As per DPC
	Proposed unit price	As per DPC

	The status in reference regulatory authorities	Approved by PMDA (JAPAN) and marketed in JAPAN, with the name of Acofide Tablets 100mg
	For generic drugs (me-too status)	N.A
	GMP status of the Finished product manufacturer	New license granted on 13/08/2020 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	**Manufacturer:.** Emmennar Pharma Private Limited **Address:** Plot No. A-4, Industrial Estate, Opposite Sanath Nagar Police Station, Sanath Nagar, Hyderabad, Telangana, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paroxetine Hydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 75% ± 5%RH for 72 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (ACT2-1704002, ACT2-1704003, ACT2-1704004)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Acofide 100mg tablet, PMDA (Japan) approved by Zeria Pharmaceutical.Co., Ltd by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Acofide 100mg tablet, PMDA (Japan) approved by Zeria Pharmaceutical.Co., Ltd in

		Hydrochloric Acid Solution (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	**Manufacturer:.** Emmennar Pharma Private Limited **Address:** Plot No. A-4, Industrial Estate, Opposite Sanath Nagar Police Station, Sanath Nagar, Hyderabad, Telangana, India		
API Lot No.	ACT2M-20004		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×30's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	21PD-024	21PD-025	21PD-026
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	Feb-2021	Feb-2021	Feb-2021
Date of Initiation	March-2021	March-2021	March-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**GMP Certificate** Manufacturer: Emmennar Pharma Private Limited. Valid Till: 04-02-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Form 3:** Form of Undertaking to Accompany an Applicant for License to Import Drugs **Form 6:** License to import Raw material for manufacturing Trial Examination, test or Analysis **Form 7:** Batch Certification **Invoice** Invoice Num: 210018 Quantity: 1.5 kgs Batch: ACT2M-20004 Mfg Date: Feb-2020 Exp Date: Jan-2024 **Packing List** Invoice Num: 210018 Quantity: 1.5 kgs Batch: ACT2M-20004 Mfg Date: Feb-2020 Exp Date: Jan-2024 **COA of API** from drug substance and Drug product Manufacturer **Testing Method of API** from drug substance and Drug product Manufacturer

		Stability Data of API from API manufacturer
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr#	Section	Observations
01	**2.3.S.3.1.2**	API manufacturer has mentioned that "Acotiamide Hcl Hydrate exhibits polymorphism". However, the data of Innovator product registered with PDMA mentions that" The drug substance is a trihydrate and has a single crystal form. No crystalline polymorphism is observed." Please clarify .
02	**3.2.S.4.2**	Substance manufacturer has mentioned Identification testing of Acotiamide Hcl hydrate through Infrared Absorption spectroscopy following USP 197 K by using Kbr pellets, however the drug substance testing specifications provided by finished product manufacturer in 3.2.S.4.4.1 mentioned Identification through FTIR. Clarification is required.
03	**3.2.S.4**	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted. Please provide.
04	**2.3.P.5.1**	HPLC Retention time of Acotiamide Hcl hydrate mentioned by substance manufacturer is 11.83 whereas on same chromatographic conditions the retention time of Acotiamide Hcl hydrate in Drug product is mentioned as 8.3 minutes, please clarify. HPLC Run time of sample in drug substance assay testing specification is different from drug product run time , Clarification is required.
05	**3.2.P.8**	Legible/readable copy of DRAP attested copy if import invoice of API from source is required.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Assistant Director (EFD) vide letter No. F.1-6/2019-PR-1(EFD) dated 29-12-2022 has informed that M/s SURGE LABORATORIES (PVT.) LTD. Karachi,has achieved the benchmark of USD 1317092.75 during the fiscal Year 2020-2021 and requested for priority consideration of following molecules,

958.	Name, address of Applicant / Marketing Authorization Holder	SURGE LABORATORIES (PVT.) LTD. Head Office: 5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi. Telephone: UAN 111-742-762 E-mail address: info@surgelaboratories.com
	Name, address of Manufacturing site.	M/s Stallion Pharmaceuticals PVT, LTD. 581-Sundar Industrial Estate, Lahore Tel: +92 42 35297647-48
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.23522 dated 19 / 08 / 2022
	Details of fee submitted	PKR 75,000/-: dated 16/06/2022 Slip No.52319875889
	The proposed proprietary name / brand name	Mapnem IV 500mg Sterile dry Powder for Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Meropenem (as Trihydrate) USP….500mg
	Pharmaceutical form of applied drug	White to Off-White crystalline powder filled in filled in Glass Vial 20 ml USP Type III Clear Transparent.
	Pharmacotherapeutic Group of (API)	Antibacterials for systemic use, Carbapenems
	Reference to Finished product specifications	USP
	Proposed Pack size	1's vial with 10ml sterile water for Injection
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**MERREM IV** (Meropenem) and being marketed by Pfizer Inc., USA, USFDA Approved.
	For generic drugs (me-too status)	PENRO 500 mg Injection IV by M/s Bosch Pharmaceuticals Pvt. Ltd., Reg. No. 042106
	GMP status of the Finished product manufacturer	GMP Certificate granted on 02/10/2020. Capsule (Penicillin) (Mixing, Filling & Packaging etc.), Oral Dry Powder Suspension (Penicillin) (Mixing, Filling & Packaging etc.), Dry Powder Injectable (Penicillin, Carbapenem (Filling & Packaging etc.).
	Name and address of API manufacturer.	M/s Aurobindo Pharma Limited Sy.No 379, 385, 386, 388 to 396, (V), Hatnoora (M), Sanga Reddy District, Talenghana, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Meropenem is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Meropenemic acid, Meropenem Dimer), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (EMF0821004, EMF0821005, EMF0821006)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Meronem IV 500mg for Injection (Meropenem) is registered and being marketed by M/s Pfizer Pakistan Limited, by performing quality tests (Description, Identification, pH, Loss on drying, Reconstitution time, Endotoxin test, Sterility test and Assay.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	M/s Aurobindo Pharma Limited Sy.No 379, 385, 386, 388 to 396, (V), Hatnoora (M), Sanga Reddy District, Talenghana, India.		
API Lot No.	1705205135, 1705205096, 1705205623		
Description of Pack (Container closure system)	1's Glass Vial 20 ml USP Type III Clear Transparent containing Meropenem USP 500mg.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	T7003	T7004	T7005
Batch Size	7800 vials	7800 vials	7570 vials
Manufacturing Date	09-2017	10-2017	11-2017
Date of Initiation	25-09-2017	13-11-2017	16-11-2017
No. of Batches	03		

Administrative Portion

7.	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.

8.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 3298/E1/2019 issued by Drugs Control Administration, Government of Telangana, India valid till 11/02/2023.
9.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no U05/17-18/776 dated 10-10-2017 duly attested by Assistant Director, DRAP, Lahore on 19-10-2017 and Copy of invoice no U05/17-18/391 dated 28-08-2017 duly attested by Assistant Director, DRAP, Lahore on 12-09-2017, were provided.
10.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
11.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
12.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr#	Section	Observations/Deficiencies/ Short-comings	Reply of Firm Vide dairy No.3554 dated 18-01-2023
01	3.2.S.2.2	Drug substance manufacturer has only provided blending of drug substance, i.e. Meropenem with Sodium Carbonate which acts as an excipient, however the method of manufacturing / flow chart of manufacturing step involved in manufacturing of Meropenem are not provided.	The method of manufacturing, flow chart, along with control of materials, control of critical steps and intermediates, process validation, and manufacturing process development are all part of closed part of DMF.
02	3.2.S.4.2	The pharmacopoeial (USP) analytical method of testing Sodium contents is established by preforming tests on atomic absorption spectroscopy, whereas firm has used non pharmacopoeial method (inductive coupled plasma optical emission spectrometer), Clarification is required.	ICP-OES is the latest technique with the same principle as AAS, there is no difference in fact. ICP- OES analyze different metals in a sample simultaneously and AAS use individual lamps sequentially.
03	3.2.S.4.3	Analytical method validation of Drug substance conducted by Finished product manufacturer does not provide details of actual Assay method of analytical testing, which are required.	Details of actual assay method of analytical testing is enclosing as Standard Analytical Procedure (SAP) in **Annexure - I**
04	3.2.S.4.4	The COA of 3 batches (1705203623, 170525135, 1705205096), of drug substance conducted and performed by Finished product manufacturer does not mention tests for sterility and sub visible particles, Content of Sodium carbonate and Bacterial endotoxin test. Clarification is needed	Clarifications are enclosing in **Annexure - II**

05	3.2.P.2.2.1	Clarification and justification of taking 1.14 gm and 0.57 gm of Meropenem and sodium carbonate blended powder per vial of 1 gm and 500 gm of Finished product as mentioned in master formulation respectively.	Justification for the quantities of Meropenem and sodium carbonate blended powder is enclosing in **Annexure - III**
06	3.2.P.2.2.2	COA does not mentioned complete tests for conducting Pharmaceutical development as per tests mentioned in section 3.2.P.5.1	Clarification including Standard Analytical Procedure (SAP) are enclose in **Annexure - IV**
07	3.2.P.5.2	The claimed finished product specifications are USP, however the provided analytical method for determination of sodium contents is not in accordance with USP monograph as monograph stated Atomic Absorption spectroscopy test for determination sodium contents in finished product, and clarification is required. The complete analytical methods are not in accordance with USP monograph, clarification is required.	Justification and Standard Analytical Procedure (SAP) are enclose in **Annexure - V**

Firm has also submitted reply vide 1713 dated 18-01-2023 as under,

Cross reference regarding the approval of Meropenem Injection 500mg & 1000mg in 312 & 323 DRB Meetings respectively for the registration of our product "Mapnem Injection 500mg & Mapnem Injection 1000mg".

This is with reference to your Letter Vide No. F.1-1/2020/PEC-DRAP (DD PE&R/PEC) dated 06th January, 2023 regarding the Observations/Deficiencies/ Short-comings for our applied products **"Mapnem (Meropenem) Injection 500mg & Mapnem (Meropenem) Injection 1000mg".** The Finish products Batch Numbers of the above mentioned applied products Mapnem (Meropenem) Injection 500mg **(Batch Nos.: T7003, T7004 & T7005)** and Mapnem (Meropenem) Injection 1000mg **(Batch Nos: U7003, U7004 & U7005)** and also **API (Meropenem**) (Batch Nos. 1705205135, 1705205096 & 1705203623, manufactured by Aurobindo Phrama, India) given in the CTD dossiers are similar to the Meropnem Injections applied by **M/s Aspin Pharma (Pvt) Ltd.** (Refer attached Meeting minutes of DRB meeting 323) and **M/s Healthtek (Pvt.) Limited** (Refer attached Meeting minutes of DRB meeting 312), that is both the company got approval of the said products on the basis of similar Finish products samples / data manufactured by M/s Stallion Pharma, used in our dossiers. On the basis of the approval granted to M**/s** Aspin Pharma (Pvt) Ltd. and M/s Healthtek (Pvt.) Limited, we request you to kindly grant us registration of our said products at the earliest.

Applicant firm	M/s Aspin Pharma (Pvt) Ltd. Plot No. 10 & 25 Sector 20, Korangi Industrial Area Karachi
Manufacturer firm	M/s Stallion Pharmaceuticals (Pvt) Ltd. 581, Sundar Industrial Estate, Raiwind Road Lahore
Brand Name	ASPINEM 500 mg Injection
Batch No. of drug product	T7003,T7004,T7005
Source of API	M/s Aurobindo Pharma Ltd.India.
Case No.	747
Page number	620
Registration Board meeting	323rd meeting of DRB

Decision: Approved.

Registration Board further authorized its Chairman for issuance of registration letters upon satisfactory capacity assessment of manufacturing and testing facility of M/s Stallion Pharmaceuticals (Pvt) Ltd., 581-Sundar Industrial Estate, Lahore wherein panel shall also review the testing of drug substance and drug product of applied formulation as per pharmacopoeial requirements.

• **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.** • **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".**		
959.	Name, address of Applicant / Marketing Authorization Holder	SURGE LABORATORIES (PVT.) LTD. Head Office: 5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi. Telephone: UAN 111-742-762 E-mail address: info@surgelaboratories.com
	Name, address of Manufacturing site.	M/s Stallion Pharmaceuticals PVT, LTD. 581-Sundar Industrial Estate, Lahore Tel: +92 42 35297647-48
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.23521 dated 19/ 08 / 2022
	Details of fee submitted	PKR 75,000/-:dated 28/06/2022, Slip N0.03868734385
	The proposed proprietary name / brand name	Mapnem IV 1g Sterile dry Powder for Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Meropenem (as Trihydrate) USP……1g
	Pharmaceutical form of applied drug	White to Off-White crystalline powder filled in filled in Glass Vial 20 ml USP Type III Clear Transparent.
	Pharmacotherapeutic Group of (API)	Antibacterials for systemic use, Carbapenems
	Reference to Finished product specifications	USP
	Proposed Pack size	1's vial with 20ml sterile water for Injection
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	**MERREM IV** (Meropenem) and being marketed by Pfizer Inc., USA, USFDA Approved.
	For generic drugs (me-too status)	PENRO 1 g Injection IV by M/s Bosch Pharmaceuticals Pvt. Ltd.,Reg. No. 042107
	GMP status of the Finished product manufacturer	GMP Certificate granted on 02/10/2020. Capsule (Penicillin) (Mixing, Filling & Packaging etc.), Oral Dry Powder Suspension (Penicillin) (Mixing, Filling & Packaging etc.), Dry Powder Injectable (Penicillin, Carbapenem (Filling & Packaging etc.).
	Name and address of API manufacturer.	M/s Aurobindo Pharma Limited Sy.No 379, 385, 386, 388 to 396, (V), Hatnoora (M), Sanga Reddy District, Talenghana, India.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Meropenem is present in USP. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Meropenemic acid, Meropenem Dimer), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (EMF0821004, EMF0821005, EMF0821006)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Meronem IV 1g for Injection (Meropenem) is registered and being marketed by M/s Pfizer Pakistan Limited, by performing quality tests (Description, Identification, pH, Loss on drying, Reconstitution time, Endotoxin test, Sterility test and Assay.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	M/s Aurobindo Pharma Limited Sy.No 379, 385, 386, 388 to 396, (V), Hatnoora (M), Sanga Reddy District, Talenghana, India.		
API Lot No.	1705205135, 1705205096, 1705205623		
Description of Pack (Container closure system)	1's Glass Vial 20 ml USP Type III Clear Transparent containing Meropenem USP 1g.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 2, 4, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	U7003	U7004	U7005

Batch Size	3900 vials	7600 vials	3780 vials
Manufacturing Date	09-2017	10-2017	11-2017
Date of Initiation	25-09-2017	13-11-2017	16-11-2017
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. 3298/E1/2019 issued by Drugs Control Administration, Government of Telangana, India valid till 11/02/2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no U05/17-18/776 dated 10-10-2017 duly attested by Assistant Director, DRAP, Lahore on 19-10-2017 and Copy of invoice no U05/17-18/391 dated 28-08-2017 duly attested by Assistant Director, DRAP, Lahore on 12-09-2017, were provided.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr#	Section	Observations/Deficiencies/ Short-comings	Reply of Firm Vide dairy No.3554 dated 18-01-2023
01	3.2.S.2.2	Drug substance manufacturer has only provided blending of drug substance, i.e. Meropenem with Sodium Carbonate which acts as an excipient, however the method of manufacturing / flow chart of manufacturing step involved in manufacturing of Meropenem are not provided.	The method of manufacturing, flow chart, along with control of materials, control of critical steps and intermediates, process validation, and manufacturing process development are all part of closed part of DMF.
02	3.2.S.4.2	The pharmacopoeial (USP) analytical method of testing Sodium contents is established by preforming tests on atomic absorption spectroscopy, whereas firm has used non pharmacopoeial method (inductive coupled plasma optical emission spectrometer), Clarification is required.	ICP-OES is the latest technique with the same principle as AAS, there is no difference in fact. ICP-OES analyze different metals in a sample simultaneously and AAS use individual lamps sequentially.

03	3.2.S.4.3	Analytical method validation of Drug substance conducted by Finished product manufacturer does not provide details of actual Assay method of analytical testing, which are required.	Details of actual assay method of analytical testing is enclosing as Standard Analytical Procedure (SAP) in **Annexure - I**
04	3.2.S.4.4	The COA of 3 batches (1705203623, 170525135, 1705205096), of drug substance conducted and performed by Finished product manufacturer does not mention tests for sterility and sub visible particles, Content of Sodium carbonate and Bacterial endotoxin test. Clarification is needed	Clarifications are enclosing in **Annexure - II**
05	3.2.P.2.2.1	Clarification and justification of taking 1.14 gm and 0.57 gm of Meropenem and sodium carbonate blended powder per vial of 1 gm and 500 gm of Finished product as mentioned in master formulation respectively.	Justification for the quantities of Meropenem and sodium carbonate blended powder is enclosing in **Annexure - III**
06	3.2.P.2.2.2	COA does not mentioned complete tests for conducting Pharmaceutical development as per tests mentioned in section 3.2.P.5.1	Clarification including Standard Analytical Procedure (SAP) are enclose in **Annexure - IV**
07	3.2.P.5.2	The claimed finished product specifications are USP, however the provided analytical method for determination of sodium contents is not in accordance with USP monograph as monograph stated Atomic Absorption spectroscopy test for determination sodium contents in finished product, and clarification is required. The complete analytical methods are not in accordance with USP monograph, clarification is required.	Justification and Standard Analytical Procedure (SAP) are enclose in **Annexure - V**

Firm has also submitted reply vide 1713 dated 18-01-2023 as under,

Cross reference regarding the approval of Meropenem Injection 500mg & 1000mg in 312 & 323 DRB Meetings respectively for the registration of our product "Mapnem Injection 500mg & Mapnem Injection 1000mg".

This is with reference to your Letter Vide No. F.1-1/2020/PEC-DRAP (DD PE&R/PEC) dated 06th January, 2023 regarding the Observations/Deficiencies/ Short-comings for our applied products **"Mapnem (Meropenem) Injection 500mg & Mapnem (Meropenem) Injection 1000mg".** The Finish products Batch Numbers of the above mentioned applied products Mapnem (Meropenem) Injection 500mg **(Batch Nos.: T7003, T7004 & T7005)** and Mapnem (Meropenem) Injection 1000mg **(Batch Nos: U7003, U7004 & U7005)** and also **API (Meropenem**) (Batch Nos. 1705205135, 1705205096 & 1705203623, manufactured by Aurobindo Phrama, India) given in the CTD dossiers are similar to the Meropnem Injections applied by **M/s Aspin Pharma (Pvt) Ltd.** (Refer attached Meeting minutes of DRB meeting 323) and **M/s Healthtek (Pvt.) Limited** (Refer attached Meeting minutes of DRB meeting 312), that is both the company got approval of the said products on the basis of similar Finish products samples / data manufactured by M/s Stallion Pharma, used in our dossiers. On the basis of the approval granted to M**/s** Aspin Pharma (Pvt) Ltd. and M/s Healthtek (Pvt.) Limited, we request you to kindly grant us registration of our said products at the earliest.

Applicant firm	M/s Aspin Pharma (Pvt) Ltd. Plot No. 10 & 25 Sector 20, Korangi Industrial Area Karachi
Manufacturer firm	M/s Stallion Pharmaceuticals (Pvt) Ltd. 581, Sundar Industrial Estate, Raiwind Road Lahore

Brand Name	ASPINEM 1g Injection
Batch No. of drug product	U7003,U7004,U7005
Source of API	M/s Aurobindo Pharma Ltd.India.
Case No.	748
Page number	628
Registration Board meeting	323rd meeting of DRB

Decision: Approved.

Registration Board further authorized its Chairman for issuance of registration letters upon satisfactory capacity assessment of manufacturing and testing facility of M/s Stallion Pharmaceuticals (Pvt) Ltd., 581-Sundar Industrial Estate, Lahore wherein panel shall also review the testing of drug substance and drug product of applied formulation as per pharmacopoeial requirements.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Firm shall state the quantity, in mg, of sodium (Na) in a given dosage of Meropenem, on the label claim, as recommended by the USP monograph of "Meropenem for injection".**

Assistant Director (EFD) vide letter No. F.1-6/2019-PR-1(EFD) dated 29-12-2022 has informed that M/s Highnoon Laboratories Limited of 17.5km, Multan Road, Lahore, Pakistan has achieved the benchmark of USD 415947.2/= during the fiscal Year 2021-2022 and requested for priority consideration of following molecules,

960.	Name, address of Applicant / Marketing Authorization Holder	Highnoon Laboratories Limited, Lahore
	Name, address of Manufacturing site.	Highnoon Laboratories Limited of 17.5km, Multan Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.28652 dated 10/10/2022
	Details of fee submitted	PKR 75,000/-: dated 20/09/2022 Deposit Slip # 9560306224

	The proposed proprietary name / brand name	Empjardy XR 5mg/2.5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…… …….….5mg Linagliptin…….2.5mg Metformin HCl (extended release) …….1000mg
	Pharmaceutical form of applied drug	Film coated extended- release tablet.
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** Sodium glucose co-transporter 2 (SGLT2) inhibitors. **Linagliptin:** Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. **Metformin HCl:** Antihyperglycemic drug.
	Reference to Finished product specifications	**Manufacturer's Specs/ Innovator**
	Proposed Pack size	5's, 7's, 10's, 14's, 20's, 28's, 30's, 50's, 60's, 100's, 120's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 06/2022-DRAP (AD-334240006) issued by DRAP valid till 11/11/2023.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Metformin HCl is present in BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Whereas Empagliflozin and Linagliptin complies Manufacturer's specifications. So, firm has submitted

		detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance as per inhouse specifications.
	Stability studies	Stability study conditions: **1. Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04). **2. Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L09-02, L-20170604-D01-L09-03). **3. Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (9002ML2RMI, 9003ML2RMI, 9004ML2RMI).
	Module-III (Drug Product):	The firm has submitted detail of composition, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Trijardy XR Tablet 5/2.5/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablet 5/2.5/1000mg approved by US-FDA in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, Linearity, range, accuracy, precision, Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA

Manufacturer of API	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India

API Lot No.	**Empagliflozin:** E-20190920-D02-E06-01 **Linagliptin:** L-20210123-D01-L09-02 **Metformin HCl:** 21027ML2AJMI		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2 x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD-22063	RD-22069	RD-22070
Batch Size	900 Tablets	900 Tablets	900 Tablets
Manufacturing Date	28-02-2022	28-02-2022	28-02-2022
Date of Initiation	04-04-2022	04-04-2022	04-04-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to previous approval of Ultivair 50mcg/ 110mcg rotacaps, which was presented in 320th meeting of Registration Board.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024.Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Linagliptin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024. Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Metformin HCl:** The firm had provided Valid GMP certificate No. NEW-WHO-GMP/ CERT/AD/104179/2021/11/37725 issued by WHO valid till 27-Oct-2024 and DML No. 25-AD/070 issued by FDA Maharashtra valid till 31-March-2024 of M/s Ipca Laboratories Limited, India.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Firm has submitted copy of invoice (invoice# HN200116-F) Dated 16-01-2020 cleared by DRAP Lahore office dated 28-01-2020 specifying import 50Kg of Empagliflozin (Batch# E-20190920-D02-E06-01). **Linagliptin:**

		Firm has submitted copy of invoice (invoice# HN21052801) Dated 14-07-2021 cleared by DRAP Lahore office dated 09-08-2021 specifying import 01 Kg of Linagliptin (Batch# L-20210123-D01-L09-02). **Metformin HCl:** Firm has submitted copy of invoice (invoice# MEG2122/1630495) Dated 10-05-2021 cleared by DRAP Lahore office dated 21-05-2021 specifying import 2000 Kg of Metformin HCl (Batch# 21027ML2AJMI).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. No.	Section	Observations	Reply of Firm
1.	**1.6.5**	Valid GMP certificate of M/s IPCA laboratories Ltd. India is expired and valid copy of GMP for Metformin HCl is required.	Valid GMP is attached as **Annexure-I**
2.	**2.3. S.5**	COA of Reference standard / working standards of Drugs substances from corresponding sources.	COA of Reference standards from corresponding sources are attached as **Annexure-II**
3.	**1.5.2**	Reference products mention the formulation with extended-release core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release outer core however same is not mentioned as label claim in instant applications.	Our formulation is same as the reference product formulation with core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release and verified by the provided manufacturing process. Please consider the below label claim **Each film-coated extended-release tablet contains:** **Empagliflozin …….. 5mg** **Linagliptin …… 2.5 mg** **(as immediate release coating)** **Metformin HCl …… 1000mg** **(as extended release core)**
4.	**2.3. P.2.1.2**	Applied composition of finished product excipients are significantly different from innovator product as innovator product contains polyethylene oxide, carnauba vax, n-butyl alcohol, ammonium hydroxide which are not present in applied formulation.	All these excipients are used only for printing mark on tablets as innovator's tablets have printing marks on them while applied products are without any printing mark on tablet. Due to this reason, these excipients are absent in our formulation.

		However, finished product formulation mentions simethicone 30% (emulsion (which is registered API as drug in Pakistan) which is not present in Innovator's product. Clarification and compatibility studies is required.	In applied product, Simethicone has been used as an excipient in coating. The main use of Simethicone as an excipient is as an antifoaming agent in pharmaceutical manufacturing processes, mentioned in Handbook of Pharmaceutical Excipients. Reference & compatibility studies are attached as Annexure-III
5.	**2.3. P.2.2.2**	Scientific Justification of 5% excess of Empagliflozin & Linagliptin is required.	We have used 5% excess of Linagliptin & Empagliflozin in trial batches because these API's are present in coating of the products. And there might be loss in coating process. However, We will assure that we will validate the contents of these API's in commercial batches & will reduce to 3%.
6.	**2.3.P.5.1**	The dissolution release time specification of Empagliflozin (30 min) is not as per innovator product. (45 min). Clarification is required.	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
		The dissolution release time specification of Metformin HCl (1hr, 4hr & 12hr) is not as per innovator product (2hr, 4hr & 12hr.). Clarification is required	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
7.	**2.3.P.5.4**	Uniformity of Dosage form test (content uniformity test) for empagliflozin & Linagliptin as less than 25% of total weight of tablet is not conducted by USP method. (L1 & L2 Method). Clarification is required.	Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity, while uniformity of dosage unit of Metformin HCl is performed by weight variation. Specifications & Testing method is attached for reference. Attached as **Annexure-IV**
8.	**3.2.S.4.2**	Chromatographic condition of Empagliflozin used by finished product manufacturer for analytical assay are different from the conditions provided by substance manufacturer (mobile phase (acetonitrile concentration), flow rate & column temperature). Dilution method and ingredients of sample & reference used by finished products manufacturer is different from substance manufacturer. Clarification is needed. Formula for calculation used by finished product manufacturer is different from substance manufacturer. Clarification is required. Isomer testing (chiral) as provided and conducted by substance manufacturer is not conducted by finished product manufacturer. Clarification is required.	Updated specification & testing method of API manufacturer & Finished Product manufacturer for Empagliflozin is attached as **Annexure-V**
9.	**3.2.S.4.1**	Linagliptin is R-Enantiomer, however substance & finished has not mentioned enantiomeric impurity test (s-isomer) in specification by API & finished product manufacturer. Clarification is required.	Updated specification & testing method including enantiomeric impurity test (s-isomer) of API manufacturer & Finished Product manufacturer for Linagliptin is attached as **Annexure-VI**
10.	**3.2.P.5.3**	Specificity studies shall be submitted for the analysis method of metformin in dissolution test, where in it could be	Specificity studies are attached as **Annexure-VII**

		established that the assay results for Metformin HCl are not interfered with the presence of other 2 drug substances in the sample aliquot.	
11.	**3.2.P.8.3**	The provided DRAP cleared invoice No. HN200116-F dated 16-01-2020 for import of Empagliflozin mentions remarks of clearance officer "conditional clearance, consumption restricted." Consumption / utilization resumption order are required. Stability study data of applied product testing specification for dissolution test as per 2.3.P.5.1 are not in accordance to innovator product. Uniformity of dosage form test is conducted by weight verification method, however content of Empagliflozin & Linagliptin is less than 25mg per tablet. Clarification is required to for conducting content uniformity test through weight variation method as per USP. Stability study data (accelerated & real time) at 6-month time interval is missing which is required.	API was conditionally released subject to provision of verifiable GMP certificate of API manufacturer. Required document was submitted on 18-02-2020. GMP status was verified accordingly and there were many lots of same API from the same manufacturer have been released for use in our already registered products contains empagliflozin. Dissolution Specification limits are selected based on comparative dissolution profile results of Reference & applied products. Where release of empagliflozin in both products are more than 90% in 30 minutes. We updated the specification as per Innovator's specification and will assure the stability in commercial batches as per updated specification. Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity and Metformin HCl by weight variation. Specification & Testing method is attached for reference. 6 months stability data (accelerated & real time) was submitted vide letter No HNL/RA-271/22 dated 10-Nov-2022, Acknowledgment letter is enclosed. Acknowledgment along with 6-month stability data is attached as **Annexure-VIII**

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

961.	Name, address of Applicant / Marketing Authorization Holder	Highnoon Laboratories Limited, Lahore
	Name, address of Manufacturing site.	Highnoon Laboratories Limited of 17.5km, Multan Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.28259 dated 05/10/2022

	Details of fee submitted	PKR 75,000/-: dated 19-09-2022 Deposit Slip # 1440602894
	The proposed proprietary name / brand name	Empjardy XR 10mg/5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…… ……..….10mg Linagliptin…….5mg Metformin HCl (extended release) …….1000mg
	Pharmaceutical form of applied drug	Film coated extended- release tablet.
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** Sodium glucose co-transporter 2 (SGLT2) inhibitors. **Linagliptin:** Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. **Metformin HCl:** Antihyperglycemic drug.
	Reference to Finished product specifications	**Manufacturer's Specs/ Innovator**
	Proposed Pack size	5's, 7's, 10's, 14's, 20's, 28's, 30's, 50's, 60's, 100's, 120's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 06/2022-DRAP (AD-334240006) issued by DRAP valid till 11/11/2023.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Metformin HCl is present in BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

		Whereas Empagliflozin and Linagliptin complies Manufacturer's specifications. So, firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance as per inhouse specifications.
	Stability studies	Stability study conditions: **3. Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04). **4. Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L09-02, L-20170604-D01-L09-03). **3. Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (9002ML2RMI, 9003ML2RMI, 9004ML2RMI).
	Module-III (Drug Product):	The firm has submitted detail of composition, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Trijardy XR Tablet 10mg/5mg/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablet 10mg/5mg/1000mg approved by US-FDA in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, Linearity, range, accuracy, precision, Repeatability, Intermediate precision, Robustness, System Suitability.

STABILITY STUDY DATA	
Manufacturer of API	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:**

	Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India		
API Lot No.	**Empagliflozin:** E-20190920-D02-E06-01 **Linagliptin:** L-20210123-D01-L09-02 **Metformin HCl:** 21027ML2AJMI		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2 x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD-22062	RD-22067	RD-22068
Batch Size	900 Tablets	900 Tablets	900 Tablets
Manufacturing Date	28-02-2022	28-02-2022	28-02-2022
Date of Initiation	04-04-2022	04-04-2022	04-04-2022
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to previous approval of Ultivair 50mcg/ 110mcg rotacaps, which was presented in 320th meeting of Registration Board.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024..Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Linagliptin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024..Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Metformin HCl:** The firm had provided Valid GMP certificate No. NEW-WHO-GMP/ CERT/AD/104179/2021/11/37725 issued by WHO valid till 27-Oct-2024 and DML No. 25-AD/070 issued by FDA Maharashtra valid till 31-March-2024 of M/s Ipca Laboratories Limited, India.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Firm has submitted copy of invoice (invoice# HN200116-F) Dated 16-01-2020 cleared by DRAP Lahore office dated

		28-01-2020 specifying import 50Kg of Empagliflozin (Batch# E-20190920-D02-E06-01). **Linagliptin:** Firm has submitted copy of invoice (invoice# HN21052801) Dated 14-07-2021 cleared by DRAP Lahore office dated 09-08-2021 specifying import 01 Kg of Linagliptin (Batch# L-20210123-D01-L09-02). **Metformin HCl:** Firm has submitted copy of invoice (invoice# MEG2122/1630495) Dated 10-05-2021 cleared by DRAP Lahore office dated 21-05-2021 specifying import 2000 Kg of Metformin HCl (Batch# 21027ML2AJMI).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr. No.	Section	Observations	Reply of firm
1.	**1.6.5**	Valid GMP certificate of M/s IPCA laboratories Ltd. India is expired and valid copy of GMP for Metformin HCl is required.	Valid GMP is attached as **Annexure-I**
2.	**2.3. S.5**	COA of Reference standard / working standards of Drugs substances from corresponding sources.	COA of Reference standards from corresponding sources are attached as **Annexure-II**
3.	**1.5.2**	Reference products mention the formulation with extended-release core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release outer core however same is not mentioned as label claim in instant applications.	Our formulation is same as the reference product formulation with core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release and verified by the provided manufacturing process. Please consider the below label claim **Each film-coated extended-release tablet contains:** **Empagliflozin …….. 10mg** **Linagliptin …… 5 mg** **(as immediate release coating)** **Metformin HCl …… 1000mg** **(as extended release core)**

4.	**2.3. P.2.1.2**	Applied composition of finished product excipients are significantly different from innovator product as innovator product contains polyethylene oxide, carnauba vax, n-butyl alcohol, ammonium hydroxide which are not present in applied formulation.	All these excipients are used only for printing mark on tablets as innovator's tablets have printing marks on them while applied products are without any printing mark on tablet. Due to this reason, these excipients are absent in our formulation.
		However, finished product formulation mentions simethicone 30% (emulsion (which is registered API as drug in Pakistan) which is not present in Innovator's product. Clarification and compatibility studies is required.	In applied product, Simethicone has been used as an excipient in coating. The main use of Simethicone as an excipient is as an antifoaming agent in pharmaceutical manufacturing processes, mentioned in Handbook of Pharmaceutical Excipients. Reference & compatibility studies are attached as Annexure-III
5.	**2.3. P.2.2.2**	Scientific Justification of 5% excess of Empagliflozin & Linagliptin is required.	We have used 5% excess of Linagliptin & Empagliflozin in trial batches because these API's are present in coating of the products. And there might be loss in coating process. However, We will assure that we will validate the contents of these API's in commercial batches & will reduce to 3%.
6.	**2.3.P.5.1**	The dissolution release time specification of Empagliflozin (30 min) is not as per innovator product. (45 min). Clarification is required.	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
		The dissolution release time specification of Metformin HCl (1hr, 4hr & 12hr) is not as per innovator product (2hr, 4hr & 12hr.). Clarification is required	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
7.	**2.3.P.5.4**	Uniformity of Dosage form test (content uniformity test) for empagliflozin & Linagliptin as less than 25% of total weight of tablet is not conducted by USP method. (L1 & L2 Method). Clarification is required.	Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity, while uniformity of dosage unit of Metformin HCl is performed by weight variation. Specifications & Testing method is attached for reference. Attached as **Annexure-IV**
8.	**3.2.S.4.2**	Chromatographic condition of Empagliflozin used by finished product manufacturer for analytical assay are different from the conditions provided by substance manufacturer (mobile phase (acetonitrile concentration), flow rate & column temperature). Dilution method and ingredients of sample & reference used by finished products manufacturer is different from substance manufacturer. Clarification is needed. Formula for calculation used by finished product manufacturer is different from substance manufacturer. Clarification is required. Isomer testing (chiral) as provided and conducted by substance manufacturer is not	Updated specification & testing method of API manufacturer & Finished Product manufacturer for Empagliflozin is attached as **Annexure-V**

		conducted by finished product manufacturer. Clarification is required.	
9.	**3.2.S.4.1**	Linagliptin is R-Enantiomer, however substance & finished has not mentioned enantiomeric impurity test (s-isomer) in specification by API & finished product manufacturer. Clarification is required.	Updated specification & testing method including enantiomeric impurity test (s-isomer) of API manufacturer & Finished Product manufacturer for Linagliptin is attached as **Annexure-VI**
10.	**3.2.P.5.3**	Specificity studies shall be submitted for the analysis method of metformin in dissolution test, where in it could be established that the assay results for Metformin HCl are not interfered with the presence of other 2 drug substances in the sample aliquot.	Specificity studies are attached as **Annexure-VII**
11.	**3.2.P.8.3**	The provided DRAP cleared invoice No. HN200116-F dated 16-01-2020 for import of Empagliflozin mentions remarks of clearance officer "conditional clearance, consumption restricted." Consumption / utilization resumption order are required. Stability study data of applied product testing specification for dissolution test as per 2.3.P.5.1 are not in accordance to innovator product. Uniformity of dosage form test is conducted by weight verification method, however content of Empagliflozin & Linagliptin is less than 25mg per tablet. Clarification is required to for conducting content uniformity test through weight variation method as per USP. Stability study data (accelerated & real time) at 6-month time interval is missing which is required.	API was conditionally released subject to provision of verifiable GMP certificate of API manufacturer. Required document was submitted on 18-02-2020.GMP status was verified accordingly and there were many lots of same API from the same manufacturer have been released for use in our already registered products contains empagliflozin. Dissolution Specification limits are selected based on comparative dissolution profile results of Reference & applied products. Where release of empagliflozin in both products are more than 90% in 30 minutes. We updated the specification as per Innovator's specification and will assure the stability in commercial batches as per updated specification. Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity and Metformin HCl by weight variation. Specification & Testing method is attached for reference. 6 months stability data (accelerated & real time) was submitted vide letter No HNL/RA-271/22 dated 10-Nov-2022, Acknowledgment letter is enclosed. Acknowledgment along with 6-month stability data is attached as **Annexure-VIII**

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

962.	Name, address of Applicant / Marketing Authorization Holder	Highnoon Laboratories Limited, Lahore
	Name, address of Manufacturing site.	Highnoon Laboratories Limited of 17.5km, Multan Road, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 28260 dated 05-10-2022
	Details of fee submitted	PKR 75,000/-: dated 19/09/2022 Deposit Slip # 1100585156
	The proposed proprietary name / brand name	Empjardy XR 12.5mg/2.5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…… ……..….12.5mg Linagliptin……..2.5mg Metformin HCl (extended release) ……1000mg
	Pharmaceutical form of applied drug	Film coated extended- release tablet.
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** Sodium glucose co-transporter 2 (SGLT2) inhibitors. **Linagliptin:** Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. **Metformin HCl:** Antihyperglycemic drug.
	Reference to Finished product specifications	**Manufacturer's Specs/ Innovator**
	Proposed Pack size	5's, 7's, 10's, 14's, 20's, 28's, 30's, 50's, 60's, 100's, 120's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 06/2022-DRAP (AD-334240006) issued by DRAP valid till 11/11/2023.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	Official monograph of Metformin HCl is present in BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Whereas Empagliflozin and Linagliptin complies Manufacturer's specifications. So, firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance as per inhouse specifications.
	Stability studies	Stability study conditions: **5. Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04). **6. Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L09-02, L-20170604-D01-L09-03). **3. Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (9002ML2RMI, 9003ML2RMI, 9004ML2RMI).
	Module-III (Drug Product):	The firm has submitted detail of composition, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Trijardy XR Tablet 12.5mg/2.5mg/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablet 12.5mg/2.5mg/1000mg approved by US-FDA in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, Linearity, range, accuracy, precision, Repeatability, Intermediate precision, Robustness, System Suitability.
STABILITY STUDY DATA		
Manufacturer of API	**Empagliflozin:**	

	Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India		
API Lot No.	**Empagliflozin:** E-20190920-D02-E06-01 **Linagliptin:** L-20210123-D01-L09-02 **Metformin HCl:** 21027ML2AJMI		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2 x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD-22064	RD-22071	RD-22072
Batch Size	900 Tablets	900 Tablets	900 Tablets
Manufacturing Date	28-02-2022	28-02-2022	28-02-2022
Date of Initiation	04-04-2022	04-04-2022	04-04-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to previous approval of Ultivair 50mcg/ 110mcg rotacaps, which was presented in 320th meeting of Registration Board.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024. Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Linagliptin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024..Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027.

		Metformin HCl: The firm had provided Valid GMP certificate No. NEW-WHO-GMP/ CERT/AD/104179/2021/11/37725 issued by WHO valid till 27-Oct-2024 and DML No. 25-AD/070 issued by FDA Maharashtra valid till 31-March-2024 of M/s Ipca Laboratories Limited, India.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Firm has submitted copy of invoice (invoice# HN200116-F) Dated 16-01-2020 cleared by DRAP Lahore office dated 28-01-2020 specifying import 50Kg of Empagliflozin (Batch# E-20190920-D02-E06-01). **Linagliptin:** Firm has submitted copy of invoice (invoice# HN21052801) Dated 14-07-2021 cleared by DRAP Lahore office dated 09-08-2021 specifying import 01 Kg of Linagliptin (Batch# L-20210123-D01-L09-02). **Metformin HCl:** Firm has submitted copy of invoice (invoice# MEG2122/1630495) Dated 10-05-2021 cleared by DRAP Lahore office dated 21-05-2021 specifying import 2000 Kg of Metformin HCl (Batch# 21027ML2AJMI).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr. No.	Section	Observations	Reply of firm
1.	**1.6.5**	Valid GMP certificate of M/s IPCA laboratories Ltd. India is expired and valid copy of GMP for Metformin HCl is required.	Valid GMP is attached as **Annexure-I**
2.	**2.3. S.5**	COA of Reference standard / working standards of Drugs substances from corresponding sources.	COA of Reference standards from corresponding sources are attached as **Annexure-II**
3.	**1.5.2**	Reference products mention the formulation with extended-release core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release outer core however same is not mentioned as label claim in instant applications.	Our formulation is same as the reference product formulation with core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release and verified by the provided manufacturing process. Please consider the below label claim **Each film-coated extended-release tablet contains:** **Empagliflozin …….. 12.5mg** **Linagliptin …… 2.5 mg** **(as immediate release coating)**

			Metformin HCl …… 1000mg **(as extended release core**)
4.	**2.3. P.2.1.2**	Applied composition of finished product excipients are significantly different from innovator product as innovator product contains polyethylene oxide, carnauba vax, n-butyl alcohol, ammonium hydroxide which are not present in applied formulation.	All these excipients are used only for printing mark on tablets as innovator's tablets have printing marks on them while applied products are without any printing mark on tablet. Due to this reason, these excipients are absent in our formulation.
		However, finished product formulation mentions simethicone 30% (emulsion (which is registered API as drug in Pakistan) which is not present in Innovator's product. Clarification and compatibility studies is required.	In applied product, Simethicone has been used as an excipient in coating. The main use of Simethicone as an excipient is as an antifoaming agent in pharmaceutical manufacturing processes, mentioned in Handbook of Pharmaceutical Excipients. Reference & compatibility studies are attached as Annexure-III
5.	**2.3. P.2.2.2**	Scientific Justification of 5% excess of Empagliflozin & Linagliptin is required.	We have used 5% excess of Linagliptin & Empagliflozin in trial batches because these API's are present in coating of the products. And there might be loss in coating process. However, We will assure that we will validate the contents of these API's in commercial batches & will reduce to 3%.
6.	**2.3.P.5.1**	The dissolution release time specification of Empagliflozin (30 min) is not as per innovator product. (45 min). Clarification is required.	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
		The dissolution release time specification of Metformin HCl (1hr, 4hr & 12hr) is not as per innovator product (2hr, 4hr & 12hr.). Clarification is required	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
7.	**2.3.P.5.4**	Uniformity of Dosage form test (content uniformity test) for empagliflozin & Linagliptin as less than 25% of total weight of tablet is not conducted by USP method. (L1 & L2 Method). Clarification is required.	Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity, while uniformity of dosage unit of Metformin HCl is performed by weight variation. Specifications & Testing method is attached for reference. Attached as **Annexure-IV**
8.	**3.2.S.4.2**	Chromatographic condition of Empagliflozin used by finished product manufacturer for analytical assay are different from the conditions provided by substance manufacturer (mobile phase (acetonitrile concentration), flow rate & column temperature). Dilution method and ingredients of sample & reference used by finished products manufacturer is different from substance manufacturer. Clarification is needed. Formula for calculation used by finished product manufacturer is different from substance manufacturer. Clarification is required.	Updated specification & testing method of API manufacturer & Finished Product manufacturer for Empagliflozin is attached as **Annexure-V**

		Isomer testing (chiral) as provided and conducted by substance manufacturer is not conducted by finished product manufacturer. Clarification is required.	
9.	**3.2.S.4.1**	Linagliptin is R-Enantiomer, however substance & finished has not mentioned enantiomeric impurity test (s-isomer) in specification by API & finished product manufacturer. Clarification is required.	Updated specification & testing method including enantiomeric impurity test (s-isomer) of API manufacturer & Finished Product manufacturer for Linagliptin is attached as **Annexure-VI**
10.	**3.2.P.5.3**	Specificity studies shall be submitted for the analysis method of metformin in dissolution test, where in it could be established that the assay results for Metformin HCl are not interfered with the presence of other 2 drug substances in the sample aliquot.	Specificity studies are attached as **Annexure-VII**
11.	**3.2.P.8.3**	The provided DRAP cleared invoice No. HN200116-F dated 16-01-2020 for import of Empagliflozin mentions remarks of clearance officer "conditional clearance, consumption restricted." Consumption / utilization resumption order are required. Stability study data of applied product testing specification for dissolution test as per 2.3.P.5.1 are not in accordance to innovator product. Uniformity of dosage form test is conducted by weight verification method, however content of Empagliflozin & Linagliptin is less than 25mg per tablet. Clarification is required to for conducting content uniformity test through weight variation method as per USP. Stability study data (accelerated & real time) at 6-month time interval is missing which is required.	API was conditionally released subject to provision of verifiable GMP certificate of API manufacturer. Required document was submitted on 18-02-2020. GMP status was verified accordingly and there were many lots of same API from the same manufacturer have been released for use in our already registered products contains empagliflozin. Dissolution Specification limits are selected based on comparative dissolution profile results of Reference & applied products. Where release of empagliflozin in both products are more than 90% in 30 minutes. We updated the specification as per Innovator's specification and will assure the stability in commercial batches as per updated specification. Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity and Metformin HCl by weight variation. Specification & Testing method is attached for reference. 6 months stability data (accelerated & real time) was submitted vide letter No HNL/RA-271/22 dated 10-Nov-2022, Acknowledgment letter is enclosed. Acknowledgment along with 6-month stability data is attached as **Annexure-VIII**

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

963.	Name, address of Applicant / Marketing Authorization Holder	Highnoon Laboratories Limited, Lahore
	Name, address of Manufacturing site.	Highnoon Laboratories Limited of 17.5km, Multan Road, Lahore
	Status of the applicant	☒ Manufacturer

		☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.29328 dated 17-10-2022
	Details of fee submitted	PKR 75,000/-: 19/09/2022 Deposit Slip # 64365189528
	The proposed proprietary name / brand name	Empjardy XR 25mg/5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…… ……..….25mg Linagliptin…….5mg Metformin HCl (extended release) …….1000mg
	Pharmaceutical form of applied drug	Film coated extended- release tablet.
	Pharmacotherapeutic Group of (API)	**Empagliflozin:** Sodium glucose co-transporter 2 (SGLT2) inhibitors. **Linagliptin:** Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. **Metformin HCl:** Antihyperglycemic drug.
	Reference to Finished product specifications	**Manufacturer's Specs/ Innovator**
	Proposed Pack size	5's, 7's, 10's, 14's, 20's, 28's, 30's, 50's, 60's, 100's, 120's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Trijardy XR Tablets by M/s Boehringer Ingelheim, FDA Approved.
	For generic drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 06/2022-DRAP (AD-334240006) issued by DRAP valid till 11/11/2023.
	Name and address of API manufacturer.	**Empagliflozin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	Official monograph of Metformin HCl is present in BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Whereas Empagliflozin and Linagliptin complies Manufacturer's specifications. So, firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance as per inhouse specifications.
	Stability studies	Stability study conditions: **7. Empagliflozin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-E-20200409-D01-E06-02, L-E-20200409-D01-E06-03, L-E-20200409-D01-E06-04). **8. Linagliptin:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L09-02, L-20170604-D01-L09-03). **3. Metformin HCl:** Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (9002ML2RMI, 9003ML2RMI, 9004ML2RMI).
	Module-III (Drug Product):	The firm has submitted detail of composition, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against the brand leader that is Trijardy XR Tablet 25mg/5mg/1000mg approved by US-FDA. CDP has been performed against the same brand that is Trijardy XR Tablet 25mg/5mg/1000mg approved by US-FDA in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8).
	Analytical method validation/verification of product	Method validation studies have submitted including Specificity, Linearity, range, accuracy, precision, Repeatability, Intermediate precision, Robustness, System Suitability.
STABILITY STUDY DATA		
Manufacturer of API	**Empagliflozin:**	

	Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Linagliptin:** Fuxin Long Rui Pharmaceutical CO., Ltd. Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China. **Metformin HCl:** Ipca Laboratories Limited H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin: 431136, India		
API Lot No.	**Empagliflozin:** E-20190920-D02-E06-01 **Linagliptin:** L-20210123-D01-L09-02 **Metformin HCl:** 21027ML2AJMI		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2 x 7's)		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	RD-22058	RD-22065	RD-22066
Batch Size	900 Tablets	900 Tablets	900 Tablets
Manufacturing Date	28-02-2022	28-02-2022	28-02-2022
Date of Initiation	04-04-2022	04-04-2022	04-04-2022
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to previous approval of Ultivair 50mcg/ 110mcg rotacaps, which was presented in 320th meeting of Registration Board.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Empagliflozin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024..Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027. **Linagliptin:** The firm has submitted copy of GMP certificate for M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Liaoning Fuxin Management Committee for Fluoride Industrial Development Zone The certificate is valid till 16-Nov-2024.Firm has also provided Drug Manufacturing License of Manufacturer M/s Fuxin Long Rui,Co Ltd,Fluride Industrial Park,Femeny County,Fuxin city,Liaoning Province, China vide DML No .LIAO20150233 valid till 17-11-2027.

		Metformin HCl: The firm had provided Valid GMP certificate No. NEW-WHO-GMP/ CERT/AD/104179/2021/11/37725 issued by WHO valid till 27-Oct-2024 and DML No. 25-AD/070 issued by FDA Maharashtra valid till 31-March-2024 of M/s Ipca Laboratories Limited, India.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Empagliflozin:** Firm has submitted copy of invoice (invoice# HN200116-F) Dated 16-01-2020 cleared by DRAP Lahore office dated 28-01-2020 specifying import 50Kg of Empagliflozin (Batch# E-20190920-D02-E06-01). **Linagliptin:** Firm has submitted copy of invoice (invoice# HN21052801) Dated 14-07-2021 cleared by DRAP Lahore office dated 09-08-2021 specifying import 01 Kg of Linagliptin (Batch# L-20210123-D01-L09-02). **Metformin HCl:** Firm has submitted copy of invoice (invoice# MEG2122/1630495) Dated 10-05-2021 cleared by DRAP Lahore office dated 21-05-2021 specifying import 2000 Kg of Metformin HCl (Batch# 21027ML2AJMI).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Sr. No.	Section	Observations	Reply of firm
1.	**1.6.5**	Valid GMP certificate of M/s IPCA laboratories Ltd. India is expired and valid copy of GMP for Metformin HCl is required.	Valid GMP is attached as **Annexure-I**
2.	**2.3. S.5**	COA of Reference standard / working standards of Drugs substances from corresponding sources.	COA of Reference standards from corresponding sources are attached as **Annexure-II**
3.	**1.5.2**	Reference products mention the formulation with extended-release core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release outer core however same is not mentioned as label claim in instant applications.	Our formulation is same as the reference product formulation with core of Metformin HCl along with application of Empagliflozin & Linagliptin as immediate release and verified by the provided manufacturing process. Please consider the below label claim **Each film-coated extended-release tablet contains:** **Empagliflozin ……. 25mg** **Linagliptin …… 5 mg** **(as immediate release coating)**

			Metformin HCl …… 1000mg (as extended release core)
4.	**2.3. P.2.1.2**	Applied composition of finished product excipients are significantly different from innovator product as innovator product contains polyethylene oxide, carnauba vax, n-butyl alcohol, ammonium hydroxide which are not present in applied formulation.	All these excipients are used only for printing mark on tablets as innovator's tablets have printing marks on them while applied products are without any printing mark on tablet. Due to this reason, these excipients are absent in our formulation.
		However, finished product formulation mentions simethicone 30% (emulsion (which is registered API as drug in Pakistan) which is not present in Innovator's product. Clarification and compatibility studies is required.	In applied product, Simethicone has been used as an excipient in coating. The main use of Simethicone as an excipient is as an antifoaming agent in pharmaceutical manufacturing processes, mentioned in Handbook of Pharmaceutical Excipients. Reference & compatibility studies are attached as Annexure-III
5.	**2.3. P.2.2.2**	Scientific Justification of 5% excess of Empagliflozin & Linagliptin is required.	We have used 5% excess of Linagliptin & Empagliflozin in trial batches because these API's are present in coating of the products. And there might be loss in coating process. However, We will assure that we will validate the contents of these API's in commercial batches & will reduce to 3%.
6.	**2.3.P.5.1**	The dissolution release time specification of Empagliflozin (30 min) is not as per innovator product. (45 min). Clarification is required.	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
		The dissolution release time specification of Metformin HCl (1hr, 4hr & 12hr) is not as per innovator product (2hr, 4hr & 12hr.). Clarification is required	Updated specifications & testing method as per Innovator Specs are attached as **Annexure-IV**.
7.	**2.3.P.5.4**	Uniformity of Dosage form test (content uniformity test) for empagliflozin & Linagliptin as less than 25% of total weight of tablet is not conducted by USP method. (L1 & L2 Method). Clarification is required.	Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity, while uniformity of dosage unit of Metformin HCl is performed by weight variation. Specifications & Testing method is attached for reference. Attached as **Annexure-IV**
8.	**3.2.S.4.2**	Chromatographic condition of Empagliflozin used by finished product manufacturer for analytical assay are different from the conditions provided by substance manufacturer (mobile phase (acetonitrile concentration), flow rate & column temperature). Dilution method and ingredients of sample & reference used by finished products manufacturer is different from substance manufacturer. Clarification is needed.	Updated specification & testing method of API manufacturer & Finished Product manufacturer for Empagliflozin is attached as **Annexure-V**

		Formula for calculation used by finished product manufacturer is different from substance manufacturer. Clarification is required. Isomer testing (chiral) as provided and conducted by substance manufacturer is not conducted by finished product manufacturer. Clarification is required.	
9.	**3.2.S.4.1**	Linagliptin is R-Enantiomer, however substance & finished has not mentioned enantiomeric impurity test (s-isomer) in specification by API & finished product manufacturer. Clarification is required.	Updated specification & testing method including enantiomeric impurity test (s-isomer) of API manufacturer & Finished Product manufacturer for Linagliptin is attached as **Annexure-VI**
10.	**3.2.P.5.3**	Specificity studies shall be submitted for the analysis method of metformin in dissolution test, where in it could be established that the assay results for Metformin HCl are not interfered with the presence of other 2 drug substances in the sample aliquot.	Specificity studies are attached as **Annexure-VII**
11.	**3.2.P.8.3**	The provided DRAP cleared invoice No. HN200116-F dated 16-01-2020 for import of Empagliflozin mentions remarks of clearance officer "conditional clearance, consumption restricted." Consumption / utilization resumption order are required.	API was conditionally released subject to provision of verifiable GMP certificate of API manufacturer. Required document was submitted on 18-02-2020. GMP status was verified accordingly and there were many lots of same API from the same manufacturer have been released for use in our already registered products contains empagliflozin.
		Stability study data of applied product testing specification for dissolution test as per 2.3.P.5.1 are not in accordance to innovator product.	Dissolution Specification limits are selected based on comparative dissolution profile results of Reference & applied products. Where release of empagliflozin in both products are more than 90% in 30 minutes. We updated the specification as per Innovator's specification and will assure the stability in commercial batches as per updated specification.
		Uniformity of dosage form test is conducted by weight verification method, however content of Empagliflozin & Linagliptin is less than 25mg per tablet. Clarification is required to for conducting content uniformity test through weight variation method as per USP. Stability study data (accelerated & real time) at 6-month time interval is missing which is required.	Uniformity of Dosage Unit of Empagliflozin & Linagliptin is performed by content uniformity and Metformin HCl by weight variation. Specification & Testing method is attached for reference. 6 months stability data (accelerated & real time) was submitted vide letter No HNL/RA-271/22 dated 10-Nov-2022, Acknowledgment letter is enclosed. Acknowledgment along with 6-month stability data is attached as **Annexure-VIII**

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

C – HUMAN (Deferred) Form-5: -

964.	Name and address of manufacturer/ Applicant	M/S Shrooq Pharmaceuticals (Pvt)Ltd, Lahore,21-Km,Ferozpur Road,Lahore.
	Brand Name + Dosage Form + Strength	Piracet Injection IM/IV
	Composition	Each ml contains: Piracetam.....1gm/5ml
	Diary No. Date of R & I & fee	Dy. No 682 dated 11-04-2014; Rs.20,000/-
	Pharmacological Group	Nootropic and psychostimulant
	Type of Form	Form-5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	12's, as per SRO.
	Approval status of product in Reference Regulatory Authorities	Not verified during previous evaluation
	Me-too status	Cibrotam Injection 1gm of M/s Vision Pharmaceutical, Islamabad.
	GMP status	GMP certificate issued to M/s Shrooq Pharma based upon evaluationconducted on 29-10-2021.
	Previous Remarks of the Evaluator	1st letter: 09th March, 2018 Reminder letter:17th April, 2018● Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting
	Previous Decision of 282nd meeting:	The case was presented in 282nd meeting of DRB and Board decided to deferred the case for Evidence of approval of applied formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.
	Latest Firm Response:	Firm has submitted reply vide dairy No. 10008 dated 20-4-2022 and submitted international reference: Nootropil 1 g Injection of UCB Pharma S.P.A, Italy
	Remarks of Evaluator	
	Previous decision of 217th meeting :	Decision: Deferred for submission of evidence of approval of applied formulation in 5ml ampoule in reference regulatory authorities/agencies which were Adopted by the Registration Board in its 275th meeting as the applied formulation is authorized by AIFA Italy as 12g/60ml solution for infusion and 3g/15ml oral and injectable solution for intravenous use.
	Reply of the Firm	Firm has submitted reply vide dairy No 33794 dated 23-11-2022 and submitted revised label claim as " Each 60 ml Vial Contains (I/V) Piracetam……12 gm (Solution for Injection)." Firm has submitted revised formulation and Form -5 , however Preregistration variation fee is missing .
	Remarks of Evaluator	
	Decision: Deferred for evidence of approval of revised formulation in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting.	
965.	Name and address of manufacturer/ Applicant	M/S Shrooq Pharmaceuticals (Pvt)Ltd, Lahore,21-Km,Ferozpur Road,Lahore.
	Brand Name + Dosage Form + Strength	BONPAC Injection
	Composition	Each 3 ml Ampoule Contains: Ibandronate Sodium Eq. to Ibandronic Acid…….3mg

	Diary No. Date of R & I & fee	Dy. No 689 dated 11-04-2014; Rs. 20,000/- **Duplicate Dossier** Dy. No 28236 dated 05-10-2022	
	Pharmacological Group	Bisphosphonate	
	Type of Form	Form-5	
	Finished product Specification	Manufacturer's specifications	
	Pack size & Demanded Price	1's, as per SRO.	
	Approval status of product in Reference Regulatory Authorities	USFDA Approved Injection Boniva 3mg/3ml (prefilled syringe)	
	Me-too status	Adronil 3mg/3ml Injection of M/s Searle (Reg. # 075870)	
	GMP status	GMP certificate issued to M/s Shrooq Pharma based upon evaluation conducted on 29-10-2021.	
	Remarks of the Evaluator		
	Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021. **Registration Board further decided to verify fee challan as per decision of 285th meeting of Registration Board.**		
966.	Name and address of manufacturer/ Applicant	Sigma Pharma International (Pvt) Ltd.E-50, NWIZ Port Qasim, Karachi. (Capsule Section)	
	Brand Name + Dosage Form + Strength	MAYBE MR Capsule 200 mg	
	Composition	Each modified release capsule contains: Mebeverine Hydrochloride as extended release pellets eq to Mebeverine Hcl…….200 mg	
	Diary No. Date of R & I & fee	Dy. No 14775 dated 20-04-2018; Rs. 20,000/- dated 20-04-2018 Dy. No 31936 dated 22-11-2021 (Duplicate Dossier)	
	Pharmacological Group	Antispasmodics	
	Type of Form	Form-5	
	Finished product Specification	Manufacturer's Specifications	
	Pack size & Demanded Price	10's, As per SRO	
	Approval status of product in Reference Regulatory Authorities	Colofac MR Modified release capsule (MHRA Approved)	
	Me-too status	Mebro-MR 200mg Capsule by M/s Regal Pharmaceuticals (Reg# 083115)	
	GMP status	Firm has provided GMP certificate based on evaluation conducted on 12th November 2020 valid for two years.	
	Remark of the Evaluator [XVI]	Deficiency letter was issued to firm and asked to provide: 1.Form 5 mentions label claim as Each modified release capsule contains: "Mebeverine Hydrochloride as extended release pellets eq to Mebeverine Hcl…….200 mg," whereas per master formulation submitted mebeverine Hcl	Reply of the firm is awaited.

		250mg/capsule. You are required to clarify this anomaly in submitted documents along with preregistration variation fee challan. 2. Source of pellets is not provided, provide source of pellets along with GMP certificate of source, stability data and COA.In case of Imported source also provide source approval fee challan.	
	Pervious Decision of 316th meeting: Deferred for Following; • Source of pellets along with stability studies data, GMP certificate of supplier and differential fee in case of import of pellets. • Form 5 mentions label claim as Each modified release capsule contains: "Mebeverine Hydrochloride as extended release pellets eq to Mebeverine Hcl…….200 mg," whereas per master formulation submitted Mebeverine Hcl 250mg/capsule. You are required to clarify this anomaly in submitted documents along with preregistration variation fee challan.		
	Reply of Firm: Firm has submitted reply vide dairy No. 39558 dated 20-12-2022 and submitted revised Form-5 along with revised formulation with label claim as under, Each Capsule Contains: Mebeverine HCl as sustain release pellets Eq. to Mebeverine HCl …… 200 mg (Innovator specifications) Firm has also submitted source of pellets as M/s Vision Laboratories (Pvt.) ltd, along with COA of pellets , copy of GMP certificate and stability study data of pellets.		
	Remarks of Evaluator:		
	Decision: Approved as per following label claim with Innovator's specifications: **Each Capsule Contains:** **Mebeverine HCl as sustain release pellets Eq. to Mebeverine HCl …… 200 mg** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product label claim as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021, before issuance of registration letter.**		

E: - Veterinary (Deferred)

967.	Name and address of manufacturer/ Applicant	My Lab (Pvt) Ltd. Khanqah sharif, Bahawalpur.
	Brand Name + Dosage Form + Strength	METABOLASE Injectable Solution
	Composition	Each 100 ml contains: L-Carnitine Hcl(613.3 mg)Equivalent to Carnitine….50 mg D.L Acetylmethionine ……200 mg Cyanocobalamin…….0.2 m A-Tocopherol Acetate(33.0mg) Equivalent to A-Tocopherol……30 mg
	Diary No. Date of R & I & fee	Dy. No 12318 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Amino Acid and vitamins
	Type of Form	Form - 5
	Finished product Specification	Not provided

	Pack size & Demanded Price	100ml, Glass vials.
	Approval status of product in Reference Regulatory Authorities	Not applicable.
	Me-too status	METABOLASE FORTE INJECTABLE SOLUTION, 043109, PRIX PHARMACEUTICA, LAHORE, imported from ITALY
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and 25-02-2021 and concluded as " In view of above inspection proceedings and facilities verified such as company profile, building ,production, in process controls, quality control testing , machinery/equipment , material management , air handling, water treatment system , personnel and documentation etc. the firm M/s Mylab (pvt) Ltd. Khanqah sharif Bahawalpur , was found to be operating at a satisfactory level of GMP compliance for the following sections only, oral Liquid (General)II and Aerosol section were under maintenance and were not functional at time of inspection": Liquid Injection Section (General) Oral Powder Premix Section (General) Oral Liquid (General)(I) Liquid Injection (penicillin) Dry Powder Injection (penicillin) Oral Powder (penicillin) Liquid Injection (hormone) Liquid Injection (Steroid)
	Remarks of the Evaluator	• Master Formulation with Complete Outline of manufacturing method is required. • Complete finished good testing specifications mentioning assay of finished products. • Pack Size, container and closure is not provided. • Form-5 cover letter dully signed by management. • Pre-registration variation fee challan.
	Previous Decision of 321th meeting: Deferred for following shortcomings: **1. Master Formulation with Complete Outline of manufacturing method is required.** **2. Complete finished good testing specifications mentioning assay of finished products.** **3. Pack Size, container and closure is not provided.** **4. Form-5 cover letter dully signed by management.** **5. Pre-registration variation fee challan**	
	Reply of Firm: Firm has submitted revised Form-5 along with preregistration fee challan of 30000/= vide slip No 97077652776 dated 07-11-2022. In revised form-5 firm has mentioned revised label claim as under: Each ml contains: L-Carnitine Hcl(61.3mg)Equivalent to L.Carnitine……...50 mg D.L Acetylmethionine ……..……200 mg Cyanocobalamin……0.2 mg Alpha-Tocopherol Acetate(33.0mg) Equivalent to Alpha-Tocopherol……30 mg Revised form-5 also mentioned innovator specifications and pack size of 100 ml in glass vial ,me too status , and revised master formulation along with outline of manufacturing method.	
	Remarks of Evaluator :	
	Previous Decision of 323rd meeting : Deferred the case for provision of evidence of testing facility along with drug analytical procedure for applied drug product.	
	Reply of Firm: Firm has submitted reply vide dairy No.3539 PEC /DRAP dated 18-01-2023 and attached pictures of HPLC and evidence of testing facility and attached assay testing method of above formulation including ,L-Carnitine Hcl ,Acetyle methionine and Alpha tocopherol through HPLC and Cyanocobalamin on UV spectrophotometer.	

	Remarks of evaluator :	
	Decision: Approved as per following label claim: **Each ml contains:** **L-Carnitine Hcl(61.3mg)Equivalent to L.Carnitine……...50 mg** **D.L Acetylmethionine ……..……200 mg** **Cyanocobalamin……0.2 mg** **Alpha-Tocopherol Acetate(33.0mg) Equivalent to Alpha-Tocopherol……30 mg**	
968.	Name and address of manufacturer/ Applicant	My lab (Pvt) Ltd. Khanqah sharif, Bahawalpur.
	Brand Name + Dosage Form + Strength	METABOLASE FORTE Injectable Solution
	Composition	Each ml Contains: DL-Acetyl methionine 200mg Eq To Cyanocobalamin……0.2mg Carnitine Hcl…61.3mg Eq To Carnitine……50mg A-Tocopherol Acetate……30mg
	Diary No. Date of R & I & fee	Dy. No12319 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Vitamins & Amino acid
	Type of Form	Form - 5
	Finished product Specification	innovator
	Pack size & Demanded Price	50 ml glass vial
	Approval status of product in Reference Regulatory Authorities	Not Applicable
	Me-too status	METABOLASE FORTE INJECTABLE SOLUTION, 043109, PRIX PHARMACEUTICA, LAHORE, imported from ITALY
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and 25-02-2021 and concluded as" In view of above inspection proceedings and facilities verified such as company profile, building ,production, in process controls, quality control testing, machinery/equipment, material management , air handling, water treatment system , personnel and documentation etc. the firm M/s Mylab (pvt) Ltd. Khanqah sharif Bahawalpur , was found to be operating at a satisfactory level of GMP compliance for the following sections only, oral Liquid (General)II and Aerosol section were under maintenance and were not functional at time of inspection" Liquid Injection Section (General) Oral Powder Premix Section (General) Oral Liquid (General)(I) Liquid Injection (penicillin) Dry Powder Injection (penicillin) Oral Powder (penicillin) Liquid Injection (hormone) Liquid Injection (Steroid)
	Remarks of the Evaluator	• Master Formulation with Complete Outline of manufacturing method is required. • Complete finished good testing specifications mentioning assay of finished products. • Pack size, container and closure are not provided. • Undertaking at ending of Form-5 • The applied composition does not resemble to me to provided, i-e Metabolase Forte Injection. Submit revised label claim composition as per applied me to.
	Decision: Deferred for following shortcomings:	

	• Master Formulation with Complete Outline of manufacturing method is required. • Complete finished good testing specifications mentioning assay of finished products. • Pack size, container and closure are not provided. • Undertaking at ending of Form-5 • The applied composition does not resemble to me to provided, i-e Metabolase Forte Injection. Submit revised label claim composition as per applied me to
	Reply of Firm: Firm has submitted revised Form-5 along with preregistration fee challan of 30000/= vide slip No 94376926835 dated 16-11-2022. In revised form-5 firm has mentioned revised label claim as under: Each ml contains: L-Carnitine Hcl (61.3mg) Equivalent to L.Carnitine……...50 mg D.L Acetylmethionine ……..……200 mg Cyanocobalamin……0.2 mg Alpha-Tocopherol Acetate(33.0mg) Equivalent to Alpha-Tocopherol……30 mg Revised form-5 also mentioned innovator specifications and pack size of 50 ml in glass vial ,me too status , and revised master formulation along with outline of manufacturing method.
	Decision: Deferred the case for provision of evidence of testing facility along with drug analytical procedure for applied drug product.
	Reply of Firm: Firm has submitted reply vide dairy No.3539 PEC /DRAP dated 18-01-2023 and attached pictures of HPLC and evidence of testing facility and attached assay testing method of above formulation including ,L-Carnitine Hcl ,Acetyle methionine and Alpha tocopherol through HPLC and Cyanocobalamin on UV spectrophotometer.
	Remarks of Evaluator :
	Decision: Approved as per following label claim: **L-Carnitine Hcl (61.3mg) Equivalent to L.Carnitine……...50 mg** **D.L Acetylmethionine ……..……200 mg** **Cyanocobalamin……0.2 mg** **Alpha-Tocopherol Acetate(33.0mg) Equivalent to Alpha-Tocopherol……30 mg**

Item No. 13: Agenda of Evaluator PEC-X (Mst. Najia Saleem)

Case No. 01 Registration applications for local manufacturing of (veterinary) drugs

a. New Cases

969.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Top-NOC Powder
	Composition	Each Kg contains: Oxytetracycline HCl…250gm Colistin Sulphate…300MIU Neomycin Sulphate …250gm
	Diary No. Date of R& I & fee	Dy.No 5404 dated 06-05-2019 Rs.20,000/- dated 06-05-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm,1Kg: Decontrolled
	Me-too status	Neochlor Powder of M/s Alina Combine Pharmaceuticals (Pvt) Karachi. (Reg. No. 058869)
	GMP status	GMP of relevant section
	Remarks of the Evaluator X	**Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
970.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Bovilex Injection 50mg/ml
	Composition	Each ml Contains: Buparvaquone…50mg
	Diary No. Date of R& I & fee	Dy.No 14644 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20ml, 50ml, 100ml: Decontrolled
	Me-too status	Bupralex Injection of M/s Star Laboratories (Pvt) Ltd., Lahore (Reg. No. 033264) 20ml, 50ml, 100ml.
	GMP status	GMP of relevant section
	Remarks of the Evaluator X	• **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. • Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 695466498366. • Initially, multiple pack sizes (20ml, 50ml, and 100ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **20ml pack size**. **Shortcomings:**

		• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
971.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Avetonic Liquid
	Composition	Each Litre contains: Carnitine…25000mg Methionine…10000mg Choline Chloride…19000mg Magnesium Sulphate…10000mg Sorbitol…200000mg
	Diary No. Date of R& I & fee	Dy.No 14643 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Liver Tonic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 250ml, 500ml, 1Liter, 5Liter: Decontrolled
	Me-too status	Hepasol Liquid of M/s Intervac (Pvt) Ltd., Sheikhupura. (Reg. No. 069657)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [x]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 00450241. • **Liquid section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings**: • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
972.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Ave silvit Liquid 2500/1500mg
	Composition	Each Litre Contains: Silymarin…2500mg Vitamin E…1500mg
	Diary No. Date of R& I & fee	Dy.No 14645 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Liver Tonic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 250ml, 500ml, 1Liter, 5Liter: Decontrolled
	Me-too status	Liversol Liquid of M/s Intervac (Pvt) Ltd., Sheikhupura. (Reg. No. 069659)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [x]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 030122649347. • **Liquid section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Registration Board referred the instant application to Committee on "Grey area molecules."	

973.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	P Closan Bolus 500mg
	Composition	Each Bolus Contains: Closantal…500mg
	Diary No. Date of R& I & fee	Dy.No 14642 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Anthelmentic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5s, 10s, 50s: Decontrolled
	Me-too status	Priclosan Bolus of M/s Prix Pharmaceutical (Pvt) Ltd., Lahore. (Reg. No. 063687)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 37904302730. • **Bolus section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
974.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Top Valosin 50 premix powder
	Composition	Each gram contains: Tylvalosin as Tartrate…50mg
	Diary No. Date of R& I & fee	Dy.No 14641 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Aivlosin 50 Premix Powder of M/s Hilton Pharma Karachi (Reg. No. 015491)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 38745503860. • **Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
975.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Hepamax Injection 100mg/ml

	Composition	Each ml Contains: Propionic Acid…100mg
	Diary No. Date of R& I & fee	Dy.No 14640 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Liver tonic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 50ml, 100ml: Decontrolled
	Me-too status	Hepasel Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 046518)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 7876409045. • Initially, multiple pack sizes (10ml, 50ml, and 100ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **50ml pack size**. • **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved with change of brand name.	
976.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Pacid P Oral Suspension
	Composition	Each ml Contains: Sulphadimidine…35mg Sulphadiazine…36mg Streptomycin Sulphate…7.6mg Neomycin Sulphate…1.8mg Sodium Chloride…11.33mg Calcium Gluconate…2.2mg Magnesium Sulphate…0.6mg Potassium Chloride…3.6mg Kaolin…103.33mg Pectin…7.1mg Glycine…20.9mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 14646 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 250ml, 500ml, 1Liter, 5Liter: Decontrolled
	Me-too status	No-Scour Oral Suspension of M/s Nawan Laboratories (Pvt) Ltd, Karachi. (Reg. No. 072673)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 566871277080 • **Liquid section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings:**

		• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
977.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Hidralyte WSP
	Composition	Each 1000Gm Contains: Copper Sulphate…12,500mg Zinc Sulphate…12,500mg Manganese Sulphate…12,500mg Potassium Chloride…88,000mg Sodium Sulphate…210,000mg Sodium Chloride…50,000mg Iron Sulphate…5000mg Citric Acid…1,21,500mg Vitamin C…5000mg Vitamin A... 15,000 IU Vitamin D3...3000 IU
	Diary No. Date of R& I & fee	Dy.No 14647 dated 08-08-2019 Rs.20,000/- dated 07-08-2019
	Pharmacological Group	Electrolyte
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Myolyte Oral Powder of Myrtle Pharma, Karachi. (Reg. No. 072604)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• Firm has revised finished product specification from in-house to "**As per innovator's specifications**" along with the fee of Rs. 7,500/- via deposit slip no 16230421794. • **Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. • The firm has submitted field service report regarding installation and handing over **Atomic absorption spectrophotometer.** • Provided conversion of Vitamin A (15000IU=30mg) and Vitamin D3 (3000IU=6mg). **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
978.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Mitadin 10% WSP
	Composition	Each 100gm Powder Contains: **Amantadine HCl**…10gm
	Diary No. Date of R& I & fee	Dy.No 14421 dated 07-08-2019 Rs.20,000/- dated 06-08-2019
	Pharmacological Group	Antiviral, antiparkinsonian and antihyperalgesic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 1Kg: Decontrolled

	Me-too status	Antamits Water Soluble Powder of M/s Wimits Pharmaceuticals, Lahore. (Reg. No. 078316)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
979.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Streptocol Powder
	Composition	Each 1000Gm Powder Contains: Tylosin Tartrate…100gm Doxycycline HCl…200gm Bromhexine HCl…5gm Colistin Sulphate…450 MIU Streptomycin Sulphate…36gm
	Diary No. Date of R& I & fee	Dy.No 14420 dated 07-08-2019 Rs.20,000/- dated 06-08-2019
	Pharmacological Group	Antibiotic/ mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 1Kg: Decontrolled
	Me-too status	Streptodox Powder of M/s Attabak Pharma, Islamabad. **Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Provide conversion of Colistin sulphate from MIU to gm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
980.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Oxyvits WSP
	Composition	Each 1Kg Powder Contains: Colistin…50,000,000 IU Oxytetracycline HCl…40gm Vitamin A…1,050,000 IU Vitamin D3…210,000 IU Vitamin K3…375mg Vitamin E…3250mg Vitamin B2…1500mg Vitamin B12…4150mcg Nicotinic Acid…7500mg Calcium Pantothenate…3000mg

	Diary No. Date of R& I & fee	Dy.No 15281 dated 21-08-2019 Rs.20,000/- dated 21-08-2019
	Pharmacological Group	Antibiotic/ vitamins
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 1Kg: Decontrolled
	Me-too status	Big-Gro Powder of M/s Leads Pharma Pvt Ltd, Islamabad. **Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Vitamin A and Vitamin D3 from IU to mg. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
981.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobiflor 20% Liquid
	Composition	Each 1000ml Contains: Florfenicol…200gm
	Diary No. Date of R& I & fee	Dy.No 14750 dated 09-08-2019 Rs.20,000/- dated 09-08-2019
	Pharmacological Group	Antibacterial/antibiotic in poultry
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml: Decontrolled
	Me-too status	Ty-Flor Oral Liquid of M/s Farm Aid Group, Haripur. (Reg. No. 088027)
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these areas. A detailed report would be submitted later on after verification of same through onsite inspection.**
	Remarks of the Evaluator [X]	Approval of **Veterinary Oral Liquid (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015.
	Decision: Approved.	
982.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Brombar Plus Oral Liquid
	Composition	Each ml Contains: Bromhexine HCl…10mg
	Diary No. Date of R& I & fee	Dy.No 15026 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Bronchodilator/Mucolytic
	Type of Form	Form 5

	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 5000ml: As per SRO
	Me-too status	Bromosol Oral Liquid 10% of M/s Intervac (Pvt) Ltd., Sheikhupura. (Reg. No. 080725)
	GMP status	**Vet Oral Liquid (General/ Antibiotics) section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.**
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
983.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Cinariq Oral Liquid
	Composition	Each ml Contains: Enrofloxacin…75mg Sulphamethoxypyridazine…75mg Sulphamethazine…50mg Trimethoprim…25mg
	Diary No. Date of R& I & fee	Dy.No 15027 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 5000ml: As per SRO
	Me-too status	Cenatin Oral Liquid of M/s Hawk Bio Pharma (Pvt) Ltd., Islamabad (Reg. No. 078379)
	GMP status	**Vet Oral Liquid (General/ Antibiotics) section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.**
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
984.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Esel Plus Oral Liquid
	Composition	Each 1000ml contains: Vitamin E…150,000mg Selenium (as Sodium Selenite) …2000mg Zinc (as Zinc Sulphate)…8000mg
	Diary No. Date of R& I & fee	Dy.No 15028 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Vitamin and Mineral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 250ml, 500ml, 1000ml, 5000ml: As per SRO
	Me-too status	Vestol-200 Oral Liquid of M/s Sanna Laboratories, Faisalabad (Reg. No. 078273)
	GMP status	**Vet Oral Liquid (General/ Antibiotics) section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.**
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).

	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
985.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Ascoriq Oral Solution
	Composition	Each 100ml contains: Vitamin C…20gm
	Diary No. Date of R& I & fee	Dy.No 15019 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Vitamin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 250ml, 500ml, 1000ml, 2500ml, 5000ml: As per SRO
	Me-too status	I-Vit-C Oral Solution of M/s International Pharma Labs, Lahore. (Reg. No. 074776)
	GMP status	**Vet Oral Liquid (General/ Antibiotics)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
986.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Toldibar Injection
	Composition	Each 100ml contains: Toldimfos Sodium…20gm Vitamin B-12…5mg
	Diary No. Date of R& I & fee	Dy.No 15018 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Vitamin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: As per SRO
	Me-too status	Tonovit Injetion (50ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd, Lahore. (Reg. No. 033253)
	GMP status	
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years). • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Veterinary) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
987.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Asper-C WS Powder
	Composition	Each 1000gm contains: Vitamin C…200gm Acetylsalicylic Acid…67gm

		Potassium Chloride…3gm Sodium Citrate…7gm
	Diary No. Date of R& I & fee	Dy.No 15022 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Vitamin, analgesic and electrolyte
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Vita Shell Water Soluble Powder of M/s Inshal Pharmaceutical Industries, Islamabad. (Reg. No. 075772)
	GMP status	**Vet Oral Powder (II)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years). • **Justification/ clarification regarding compatibility of Acetylsalicyclic Acid with Vitamin C**
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
988.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Sipariq-L Water Soluble Powder
	Composition	Each 1000gm contains: Spiramycin Adipate…75gm Lincomycin HCl…25gm
	Diary No. Date of R& I & fee	Dy.No 15021 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Co-Spira Water Soluble Powder of M/s ICI Pakistan Limited, Life Sciences, Lahore. (Reg. No. 080764)
	GMP status	**Vet Oral Powder (II)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
989.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Nemoriq-60 Water Soluble Powder
	Composition	Each 1000gm contains: Neomycin Sulphate…600gm
	Diary No. Date of R& I & fee	Dy.No 15020 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Neocin-S Water Soluble Powder of M/s Alina Combine Pharmaceuticals (Pvt) Ltd., Karachi (Reg. No. 069625)

	GMP status	**Vet Oral Powder (II)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
990.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Tilcos-250 Oral Liquid
	Composition	Each ml contains: Tilmicosin Phosphate…250mg
	Diary No. Date of R& I & fee	Dy.No 15025 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 2500ml, 5000ml: As per SRO
	Me-too status	Tilmicobak Oral Liquid of M/s Attabak Pharmaceuticals, Islamabad (Reg. No. 075706)
	GMP status	**Vet Oral Liquid (Genaral)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
991.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Tydoxline Oral Liquid
	Composition	Each 100ml contains: Doxycycline HCl…20gm Tylosin Tartrate…10gm Guaiphenesin…20gm Aminophylline…8gm
	Diary No. Date of R& I & fee	Dy.No 15024 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic/Expectorant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 5000ml: As per SRO
	Me-too status	Tylophylline (Vet) Liquid of M/s Biorific Pharma, Islamabad (Reg. No. 090668)
	GMP status	**Vet Oral Liquid (Genaral)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
992.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Fosforiq Powder
	Composition	Each 100gm contains: Fosfomycin Calcium…20gm

		Tylosin Tartrate…10gm Fructose…18gm Sodium Phosphate…15gm Magnesium Sulphate…10gm
	Diary No. Date of R& I & fee	Dy.No 15023 dated 20-08-2019 Rs.20,000/- dated 19-08-2019
	Pharmacological Group	Antibiotic, minerals and energy booster
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Fosfotyl Powder of M/s Leads Pharma (Pvt) Ltd, Islamabad (Reg. No. 078240)
	GMP status	**Vet Oral Powder (II)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
993.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Calcifas Plus Injection
	Composition	Each ml contains: Calcium Gluconate…208.30mg Magnesium Hypophosphate…53.30mg Magnesium Chloride…20mg Calcium D Saccharate…10mg Boric Acid…43.30mg Dextrose…200mg
	Diary No. Date of R& I & fee	Dy.No 16420 dated 02-09-2019 Rs.20,000 dated 30-08-2019
	Pharmacological Group	Mineral supplement
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**300ml**: Decontrolled
	Me-too status	Calpho-M Injection (300ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. no. 043146)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Veterinary) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
994.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Fevofas Injection
	Composition	Each ml Contains: Aceclofenac…25mg
	Diary No. Date of R& I & fee	Dy.No 16419 dated 02-09-2019 Rs.20,000 dated 30-08-2019
	Pharmacological Group	NSAID

	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Clofenac Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 088082)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid Injectable (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
995.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Trizole Suspension
	Composition	Each ml Contains: Triclabendazole…85mg Oxfendazole…22.65mg
	Diary No. Date of R& I & fee	Dy.No 18061 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 200ml, 450ml, 500ml, 1Liter, 2.5Liter, 5Liter, 10Liter, 20Liter: Decontrolled
	Me-too status	Vorcid Suspension of M/s Breeze Pharma (Pvt.) Ltd, Islamabad. (Reg. No. 063563)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Liquid (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • The applied formulation is non-pharmacopoeial.
	Decision: Approved.	
996.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Trifen Oral Suspension
	Composition	Each ml Contains: Triclabendazole…50mg Fenbendazole…25mg
	Diary No. Date of R& I & fee	Dy.No 18060 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 450ml, 500ml, 1Liter, 2.5Liter, 5Liter, 10Liter, 20Liter: Decontrolled
	Me-too status	Trifen Act Liquid of M/s Mallard Pharmaceutical (Pvt) Ltd. Multan. (Reg. No. 063776)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Liquid (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • The applied formulation is non-pharmacopoeial.
	Decision: Approved.	

997.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Diclostar Injection
	Composition	Each ml contains: Aceclofenac Sodium eq. to Aceclofenac…25mg
	Diary No. Date of R& I & fee	Dy.No 18062 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 20ml, 50ml, 100ml, 450ml, 500ml: Decontrolled
	Me-too status	Clofenac Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 088082)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [x]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Initially, multiple pack sizes (10ml, 20ml, 50ml, 100ml, 450ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **50ml pack size**. • Firm has mentioned salt form while the reference formulation is **Each ml contains:** **Aceclofenac.....25mg** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
998.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Trigent Injection
	Composition	Each ml Contains: Gentamycin Sulphate…30mg Trimethoprim…25mg Sulfadiazine…125mg
	Diary No. Date of R& I & fee	Dy.No 18059 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 30ml, 50ml, 100ml, 250ml, 450ml, 500ml: Decontrolled
	Me-too status	**Could** **Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.** **Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.not be confirmed**
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022

	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Initially, multiple pack sizes (10ml, 30ml, 50ml, 100ml, 250ml, 450ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **100ml pack size**. **Shortcoming;** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
999.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Clorotin LA Injection
	Composition	Each ml Contains: Ivermectin…20mg Clorsulon…100mg
	Diary No. Date of R& I & fee	Dy.No 18062-A dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Antiparasitic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 20ml, 50ml, 100ml, 450ml, 500ml, 1000ml: Decontrolled
	Me-too status	Iver-Soun Injection (100ml) of M/s Cherished Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 109793)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Initially, multiple pack sizes (10ml, 20ml, 50ml, 100ml, 450ml, 500ml, 1000ml)of injectable dosage form were demanded in a single application. Now, the firm has demanded **100ml pack size**.
	Decision: Approved with 100ml pack size only.	
1000.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	ST-Dox Oral Powder
	Composition	Each Kg contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…450 MIU Bromhexine HCl…5gm Streptomycin Sulphate…36gm
	Diary No. Date of R& I & fee	Dy.No 18065 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Antibacterial/ bronchodilator
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 20Kg, 25Kg: Decontrolled
	Me-too status	Pulmodox-S Powder of M/s Attabak Pharmaceutical

		Islamabad. (Reg. No. 071069)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Powder (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
1001.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Colon Oral Powder
	Composition	Each Kg contains: Colistin Sulphate…500MIU Oxytetracycline HCl…300gm Neomycin Sulphate…250gm
	Diary No. Date of R& I & fee	Dy.No 18064 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Antibacterial/ bronchodilator
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 20Kg, 25Kg: Decontrolled
	Me-too status	ST Neolistin Powder of M/s Leads Pharma Pvt. Ltd, Islamabad. (Reg. No. 078242)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Powder (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • Provided conversion of Colistin Sulphate from MIU to grams (19000IU = 1mg)
	Decision: Approved.	
1002.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Fast Oral Powder
	Composition	Each 100gm contains: Fosfomycin …20gm Tylosin Tartrate…5gm Fructose Diphosphate…18gm Sodium Phosphate…15gm Magnesium Phosphate…10gm Sodium Chloride q.s …100gm
	Diary No. Date of R& I & fee	Dy.No 18063 dated 19-09-2019 Rs.20,000 dated 19-09-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 20Kg, 25Kg: Decontrolled
	Me-too status	Fofact Powder of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 075626)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022

	Remarks of the Evaluator [X]	• **Oral Powder (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • The reference product contains **Calcium Fosfomycin.20gm/ 100gm** while the applied formulation contains **Fosfomycin 20gm/100gm**, and firm has revised the label claim as follows without submission of fee: **Each 100gm contains:** **Calcium Fosfomycin …20gm** **Tylosin Tartrate…5gm** **Fructose Diphosphate…18gm** **Sodium Phosphate…15gm** **Magnesium Phosphate…10gm** **Sodium Chloride q.s …100gm**
	Decision: Approved as per following label claim: **Each 100gm contains:** **Calcium Fosfomycin …20gm** **Tylosin Tartrate…5gm** **Fructose Diphosphate…18gm** **Sodium Phosphate…15gm** **Magnesium Phosphate…10gm** **Sodium Chloride q.s …100gm** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.**	
1003.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Tydovit Oral Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Vitamin A…10gm
	Diary No. Date of R& I & fee	Dy.No 17324 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotic/ Vitamin
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Stylosin Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 044915)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1004.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Combofic Oral Powder
	Composition	Each Gram contains: Doxycycline HCl…200mg Tylosin Tartrate…100mg Colistin Sulphate…20,000 IU
	Diary No. Date of R& I & fee	Dy.No 17328 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics

	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Tylo-Cd Water Soluble Powder of M/s Westmont Pharmaceutical Industries, Gujarkhan. (Reg. No. 048192)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016. • Provided conversion of Colistin Sulphate from IU to miligrams. (19000IU of Colistin Sulphate = 1mg)
	Decision: Approved.	
1005.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Mucodox Oral Powder
	Composition	Each gram contains: Doxycycline HCl…200mg Tylosin Tartrate…100mg Bromhexine HCl…2.5mg
	Diary No. Date of R& I & fee	Dy.No 17327 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Resbro-300 W/S Oral Powder of M/s Sanna Laboratories, Faisalabad (Reg. No. 031486)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1006.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Pneumodox Oral Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…500 MIU Bromhexine HCl…5gm Streptomycin Sulphate…20gm
	Diary No. Date of R& I & fee	Dy.No 17326 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotic/ Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Respi Dox Water Soluble Powder of M/s D-Maarson Pharmaceuticals, Islamabad. (Reg. No. 072684)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016. • Provided conversion of Colistin Sulphate from IU to miligrams. (19000IU of Colistin Sulphate = 1mg)

	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1007.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Tybrox Oral Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…450 MIU Bromhexine HCl…4gm
	Diary No. Date of R& I & fee	Dy.No 17323 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotic/ Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Doxyline Water Soluble Powder of M/s Inshal Pharmaceutical Industries, Islamabad. (Reg. No. 075776)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016. • Provided conversion of Colistin Sulphate from IU to miligrams. (19000IU of Colistin Sulphate = 1mg)
	Decision: Approved.	
1008.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Triofic Oral Powder
	Composition	Each gram contains: Doxycycline HCl…200mg Tylosin Tartrate…100mg Colistin Sulphate…500,000 IU
	Diary No. Date of R& I & fee	Dy.No 17325 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Triplex Water Soluble Powder of M/s Mylab (Pvt) Ltd. Bahawalpur (Reg. No. 073910)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016. • Provided conversion of Colistin Sulphate from IU to miligrams. (19000IU of Colistin Sulphate = 1mg)
	Decision: Approved.	
1009.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Bactibro Oral Liquid
	Composition	Each 1000ml contains: Tylosin Tartrate…50gm Sulphamethoxypyridazine Sodium…50gm Trimethoprim…10gm Bromhexine HCl…5gm

	Diary No. Date of R& I & fee	Dy.No 17330 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics/ Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 200ml, 500ml, 1000ml: Decontrolled
	Me-too status	Complimax CRD Solution of M/s Noble Pharma, Mirpur Azad Kashmir (Reg. No. 078218)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Liquid Syrup section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1010.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Brodox Oral Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…500 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 17329 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Cut CRD Water Soluble Powder of M/s D-Maarson Pharmaceuticals, Rawat, Islamabad (Reg. No.078269)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016. • Provided conversion of Colistin Sulphate from IU to miligrams. (19000IU of Colistin Sulphate = 1mg)
	Decision: Approved.	
1011.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Urific Oral Powder
	Composition	Each 1000gm contains: Methenamine…950gm Thiamine HCl…3gm Riboflavin…4gm Calcium D-Pantothenate…4gm Pyridoxine HCl…3gm Nicotinamide…3gm
	Diary No. Date of R& I & fee	Dy.No 17322 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics/ Vitamins
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Methe-Vit Powder of M/s Islamabad Pharmaceutical Products Islamabad (Reg. No. 026598)

	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1012.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Renofic Oral Powder
	Composition	Each 100gm contains: Methenamine…95gm Vitamin B1…0.8gm Vitamin B2…0.92gm Vitamin K3…0.2gm
	Diary No. Date of R& I & fee	Dy.No 17320 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics/ Vitamins
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	Toxidot Oral Powder of M/s Bio-Labs (Pvt) Ltd, Islamabad (Reg. No. 026404)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1013.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Neochlorox Powder
	Composition	Each 1000gm contains: Neomycin Sulphate…70gm Oxytetracycline HCl…80gm Colistin Sulphate…4gm
	Diary No. Date of R& I & fee	Dy.No 17319 dated 12-09-2019 Rs.20,000 dated 12-09-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 200gm, 500gm, 1000gm: Decontrolled
	Me-too status	N-Colis 19 Oral Powder of M/s Eterna Pharma (Pvt) Ltd., Mirpur, AJK. (Reg. No. 113447)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1014.	Name and address of manufacturer / Applicant	M/s Biorific Pharma, Plot No.143, Industrial Triangle, Kahuta road, Islamabad.
	Brand Name +Dosage Form + Strength	Toltrafic Oral Liquid
	Composition	Each 100ml contains: Toltrazuril…2.5gm
	Diary No. Date of R& I & fee	Dy.No 17321 dated 12-09-2019 Rs.20,000 dated 12-09-2019

	Pharmacological Group	Coccidiostat
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 200ml, 500ml, 1000ml: Decontrolled
	Me-too status	Zurox Oral Solution of M/s Eterna Pharma (Pvt) Ltd., Mirpur Azad Kashmir (Reg. No. 113517)
	GMP status	Panel inspection report based on 12-12-2022 recommends renewal of DML
	Remarks of the Evaluator [X]	• **Liquid Syrup section (Veterinary)** confirmed vide letter No. F.1-48/2003-Lic dated 25-11-2016.
	Decision: Approved.	
1015.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Enbro Solution
	Composition	Each 100ml contains: Enrofloxacin…10gm Colistin Sulphate…5MIU Bromhexine…0.50%
	Diary No. Date of R& I & fee	Dy.No 18148 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibiotic/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	BP/USP specifications
	Pack size & Demanded Price	100ml, 500ml, 1Liter: Decontrolled
	Me-too status	Enrocoli Liquid of M/s Symans Pharmaceuticals (Pvt) Ltd Lahore (Reg. No. 059167)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic dated 01-08-2012. • The applied formulation is non-pharmacopoeial.
	Decision: Approved.	
1016.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Rexin Oral Suspension
	Composition	Each ml Contains: Sulphadiazine…35.5mg Sulphadimidine…28.4mg Neomycin Sulphate…1.800mg Hyosein Methylbromide…0.04mg Kaolin…103.3mg Pectin…7.1mg Vitamin B1…0.15mg Vitamin B2…0.22mg Vitamin B6…0.15mg Vitamin K3…4mg
	Diary No. Date of R& I & fee	Dy.No 18149 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibiotic/ Vitamins
	Type of Form	Form 5
	Finished product Specification	BP/USP specifications
	Pack size & Demanded Price	100ml, 500ml, 1Liter: Decontrolled
	Me-too status	Diarex Forte Oral Suspension of M/s Zakfas Pharmaceuticals (Pvt) Ltd, Multan. (Reg. No. 063570)

	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• The applied formulation is **non-pharmacopoeial.** • **Dry powder suspension (General) section** confirmed vide letter No. F. 1-31/2010-Lic dated 25-11-2016.
	Decision: Approved.	
1017.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	E Tylon Powder
	Composition	Each gram contains: Tylosin Phosphate…100mg
	Diary No. Date of R& I & fee	Dy.No 18150 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Lincomiks 10 Powder of M/s Eterna Pharma (Pvt) Ltd Mirpur, AJK. (Reg. No.113518)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Dry powder suspension (General) section** confirmed vide letter No. F. 1-31/2010-Lic dated 25-11-2016.
	Decision: Approved.	
1018.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biogulin Liquid
	Composition	Each Litre contains: Bromhexine HCl…50gm Guaiphenesin…25gm Aminophyline…20gm Menthol…20gm
	Diary No. Date of R& I & fee	Dy.No 16631 dated 03-09-2019 Rs.20,000 dated 02-09-2019
	Pharmacological Group	Bronchodilator/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml: As recommended by the PRC
	Me-too status	Bromocot Liquid of M/s Verbena Inc. Rawat, Islamabad**. Could not be confirmed in the applied combination and strength**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

1019.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biodoxy TC Powder
	Composition	Each 1000gm contains: Doxycycline HCl…160gm Tylosin Tartrate…140gm Colistin Sulphate…1000 MIU
	Diary No. Date of R& I & fee	Dy.No 18050 dated 19-09-2019 Rs.20,000 dated 18-09-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	TDC Forte Powder of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 074003)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1020.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biotetra CB WS Powder
	Composition	Each 100gm contains: Doxycycline HCl…20gm Tylosin Tartrate…10gm Colistin Sulphate…480 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 18174 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	Betabex Water Soluble Powder of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 078281)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1021.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biobromo TD WSP
	Composition	Each Kg contains:

		Tylosin Tartrate…200gm Doxycycline HCl…250gm Bromhexine HCl…5000mg
	Diary No. Date of R& I & fee	Dy.No 16632 dated 03-09-2019 Rs.20,000 dated 02-09-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20gm, 100gm, 500gm, 1Kg, 5Kg, 25Kg: As recommended by the PRC
	Me-too status	Bromodox Water Soluble Powder of M/s Symans Pharmaceuticals (Pvt) Ltd, Lahore (Reg. No. 063846)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1022.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biobromacol WS Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…500 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 18175 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	IB Tydoc Water Soluble Powder of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 078275)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1023.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biocol CB Water Soluble Powder
	Composition	Each 1000Gm Contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…480 MIU Bromhexine HCl…3gm
	Diary No. Date of R& I & fee	Dy.No 18176 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications

	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	Brnchotil Water Soluble Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 049709)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1024.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bioneocin 70% WSP
	Composition	Each 100gm contains: Neomycin Sulphate…70gm
	Diary No. Date of R& I & fee	Dy.No 16629 dated 03-09-2019 Rs.20,000 dated 02-09-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	Neomycin 70% Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 075694)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1025.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biodoxy BT WS Powder
	Composition	Each Kg contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Bromhexine HCl…20gm
	Diary No. Date of R& I & fee	Dy.No 18172 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibiotic/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: As recommended by the PRC
	Me-too status	T-Dox Water Soluble Powder of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 078285)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	

1026.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bioflorcin 10% Liquid
	Composition	Each 100ml contains: Florfenicol…10gm Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 18173 dated 20-09-2019 Rs.20,000 dated 20-09-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml: As recommended by the PRC
	Me-too status	Florobex-C Liquid of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 078286)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1027.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bromacol Liquid
	Composition	Each 1000ml Contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…500 MIU Bromhexine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 18051 dated 19-09-2019 Rs.20,000 dated 18-09-2019
	Pharmacological Group	Antibiotic/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml: As recommended by the PRC
	Me-too status	Restidox Liquid of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 073918)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1028.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Lisbro-S Oral Powder
	Composition	Each 100gm contains:

		Lincomycin HCl…5gm Spectinomycin HCl…7.5gm Spiramycin Adipitate…2.5gm Bromhexine HCl…0.5gm
	Diary No. Date of R& I & fee	Dy.No 23368 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Linc-S Bro Oral Powder of M/s Kayans Pharmaceuticals, Rawalpindi. (Reg. No. 111370)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1029.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Furnec Oral Powder
	Composition	Each Kg contains: Chlortetracycline…50gm **Furaltadone HCl**…40gm Neomycin…12.5gm
	Diary No. Date of R& I & fee	Dy.No 23367 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Furachlor-N W/S Powder of M/s Avicenna Laboratories (Pvt) Ltd., Sheikhupura. (Reg. No. 031506)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: - Registration Board deferred the case containing salt Furaltodone. Show cause already issued to other firm containing salt Furaltodone.	
1030.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Saloc-N Oral Powder
	Composition	Each Kg contains: Neomycin Sulphate…150gm **Chloramphenicol…300gm** Oxytetracycline…300gm Salicyclic Acid…50gm Stablizer…30gm Antioxidant…20gm

	Diary No. Date of R& I & fee	Dy.No 23363 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Ne-Oxy-Chlor Powder of M/s Farm Aid Group Rawalpindi. (Reg. No.033224)
	GMP status	
	Remarks of the Evaluator [X]	• **Chloramphenicol** is not used in RRA for veterinary purpose except for its rare use in cats and dogs. • **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Deferred till the decision of other applications of "Chloramphenicol" containing formulations, for which show cause has been issued.	
1031.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Necoc-c Oral Powder
	Composition	Each Kg contains: Chlortetracycline…80gm Neomycin Sulphate…70gm Colistin Sulphate…4gm
	Diary No. Date of R& I & fee	Dy.No 23369 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Chlor Nec Oral Powder of M/s Vantage Pharmaceutical, District Faisalabad. (Reg. No. 081713)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1032.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Diacox-S Oral Powder
	Composition	Each Kg contains: Sulphaquinoxaline…100gm Diaveridine…25gm Vitamin K3…2.5gm Vitamin A…1.25 MIU
	Diary No. Date of R& I & fee	Dy.No 23365 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned

	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Coccicure Plus Powder of M/s Medicure Laboratories, Karachi. (Reg. No. 063610)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. • Provided conversion of Vitamin A from MIU to grams. (500000 IU Vitamin A= 1gm Vitamin A) **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1033.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Elicol Oral Powder
	Composition	Each 100gm contains: Colistin Sulphate…24gm
	Diary No. Date of R& I & fee	Dy.No 23366 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	El-Colis Powder of M/s Elko Organization (Pvt) Ltd., Karachi. (Reg. No. 031594)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1034.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Amsulcol Oral Powder
	Composition	Each Gram contains: Amprolium HCl…166mg Sulphaquinoxaline…166mg Colistin Sulphate…500, 000 IU Vitamin K…50mg Vitamin A…5,000 IU
	Diary No. Date of R& I & fee	Dy.No 23361 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Anticoccidial/Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Coccibak Water Soluble Powder of M/s Attabak Pharmaceutical Industries, Islamabad. (Reg. No. 034528)
	GMP status	

	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. • Provided following conversion 500000 IU Vitamin A= 1gm Vitamin A 19000 IU Colistin Sulphate= 1mg Colistin Sulphate **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1035.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Amcin-70 Oral Powder
	Composition	Each 100gm contains: Amoxicillin Trihydrate eq. to 70gm of Amoxicillin Base …80gm
	Diary No. Date of R& I & fee	Dy.No 23373 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	PRIMOX 70% Water Soluble Powder of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore. (Reg. No. 074032)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (Penicillin) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1036.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Fostar-F Oral Powder
	Composition	Each 100gm contains: Calcium Fosfomycin…20gm Tylosin Tartrate…10gm Fructose…18gm Sodium Phosphate…15gm Magnesium Phosphate…10gm
	Diary No. Date of R& I & fee	Dy.No 23372 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Fosomax Oral Powder of M/s Biogen Pharma, Rawat Chak Beli Road, Rawat (Reg. No. 063808)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:**

		• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1037.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Coldox-T Oral Powder
	Composition	Each 1000gm contains: Tylosin Tartrate…140gm Colistin Sulphate…1200 MIU Doxycycline HCl…160gm
	Diary No. Date of R& I & fee	Dy.No 23370 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Fiz-Tdc Water Soluble Powder of M/s Fizi Pharmaceuticals and Chemical Laboratories, Lahore. (Reg. No. 081348)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Powder (General Antibiotic) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. • Provided following conversion 19000 IU Colistin Sulphate= 1mg Colistin Sulphate **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1038.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Aplaliv Oral Liquid
	Composition	Each 100ml contains: DL-Methionine…5gm L-Lysine Monohydrochloride…10gm Choline Chloride…19gm Vitamin B12…1mg Sorbitol…10gm
	Diary No. Date of R& I & fee	Dy.No 23375 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Hepatoprotectant
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Hepapri Oral Solution of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore. (Reg. No. 049517)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).

	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1039.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Amdox-G Oral Liquid
	Composition	Each 100ml contains: Doxycycline HCl…20gm Tylosin Tartrate…10gm Guaifenesin…20gm Aminophylline…8gm
	Diary No. Date of R& I & fee	Dy.No 23374 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Tyco-G Oral Liquid of M/s Attabak Pharmaceuticals, Islamabad (Reg. No.075704)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1040.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Colipeg Oral Liquid
	Composition	Each Liter contains: Colistin Sulphate…120gm PEG 200…100gm
	Diary No. Date of R& I & fee	Dy.No 23360 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Colifar-SP Oral Solution of M/s Alina Combine Pakistan (Pvt) Ltd., Karachi. (Reg. No. 035095)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1041.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Leco-S Oral Liquid
	Composition	Each 100ml contains: Levamisole HCl…1.5gm Cobalt Sulphate…0.382gm Sodium Selenite…0.050gm

	Diary No. Date of R& I & fee	Dy.No 23362 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Vernil S.C. Drench of M/s Star Laboratories (Pvt) Ltd., Lahore. (Reg. No. 033261)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1042.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	TMP-S Oral Liquid
	Composition	Each 100ml contains: Trimethoprim…8gm Sulphadiazine…40gm
	Diary No. Date of R& I & fee	Dy.No 23364 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Tryton Suspension of M/s Breeze Pharma (Pvt.) Ltd., Islamabad. (Reg. No. 075665)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1043.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Hynsul Oral Liquid
	Composition	Each ml Contains: Sulphadiazine…35.50mg Sulphadimidine…28.40mg Neomycin Sulphate…1.80 Hyosein Methylbromide…0.04mg Pectin…7.10mg Kaolin…103.30mg Vitamin B1…0.15mg Vitamin B2…0.22mg
	Diary No. Date of R& I & fee	Dy.No 23359 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled

	Me-too status	Peclin-S Oral Suspension of M/s Star Laboratories (Pvt) Ltd., Lahore. (Reg. No. 035132)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1044.	Name and address of manufacturer / Applicant	M/s Aptly Pharmaceuticals, 5-km, Sargodha-Sidhar Bypass Road, Faisalabad.
	Brand Name +Dosage Form + Strength	Flormax Oral Liquid
	Composition	Each 100ml contains: Florfenicol…23gm
	Diary No. Date of R& I & fee	Dy.No 23371 dated 11-11-2019 Rs.20,000/- dated 11-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Not mentioned
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1L, 2.5L, 5L: Decontrolled
	Me-too status	Floribal Liquid of M/s Wimits Pharmaceuticals, Lahore. (Reg. No. 078331)
	GMP status	
	Remarks of the Evaluator [X]	• **Oral Liquid (General) Veterinary section** confirmed vide letter No. F. 1-25/2015-Lic dated 29-08-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1045.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Evonac Injection
	Composition	Each ml contains: Aceclofenac…25mg
	Diary No. Date of R& I & fee	Dy.No 21637 dated 23-10-2019 Rs.20,000 dated 21-10-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**10ml, 50ml**,: Decontrolled
	Me-too status	Vetafenac-Super Injection **(50ml)** of M/s S.J. & G. Fazul Ellahie (Pvt) Limited, Karachi.(Reg. No. 046569)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid Injection (General) (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic (Vol-I) dated 13-02-2020. • Initially, multiple pack sizes (10ml, and 50ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **50ml pack size**.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	

1046.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Atrovin Injection
	Composition	Each ml contains: Atropine Sulphate…1mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 21533 dated 22-10-2019 Rs.20,000/- dated 22-10-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml,: Decontrolled
	Me-too status	Atopin Injection **(50ml)** of M/s Symans Pharmaceuticals (Pvt) Ltd., 10-Km Sheikhupura Road, Lahore. (Reg. No. 062122)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid injection (General) Veterinary section** confirmed vide letter No. F. 1-45/2009-Lic dated 27-08-2012.
	Decision: Deferred for evidence of approval of for veterinary use of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
1047.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Hi-Fenac Injection
	Composition	Each ml contains: Aceclofenac as Sodium…25mg
	Diary No. Date of R& I & fee	Dy.No 21534 dated 22-10-2019 Rs.20,000/- dated 22-10-2019
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml,: Decontrolled
	Me-too status	Vetafenac-Super Injection **(50ml)** of M/s S.J. & G. Fazul Ellahie (Pvt) Limited, Karachi. (Reg. No. 046569)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid injection (General) Veterinary section** confirmed vide letter No. F. 1-45/2009-Lic dated 27-08-2012. **Shortcomings:** • Firm has mentioned salt form while the reference formulation is **Each ml contains:** **Aceclofenac.....25mg** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1048.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Emicom Injection
	Composition	Each ml contains: Arginine HCl...1.40mg L-Cysteine HCl...3.20mg L-Glutamine...3.20mg Glycine...3.20mg

		L-Histidine HCl...1.32mg L-Isoleucine...3.62mg L-Lysine HCl...5.44mg DL-Methionine...3.20mg L-Tryptophane...0.86mg L-Phenylalanine...5mg Thiamine HCl...4mg Riboflavin Sodium Phosphate...0.17mg Pyridoxine HCl...0.34mg Ascorbic Acid...4mg Glucose...33mg Calcium Chloride...0.08mg Potassium Chloride...2mg Magnesium Sulphate...2mg
	Diary No. Date of R& I & fee	Dy.No 21495 dated 21-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Minerals
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 30ml, 50ml, 100ml, 250ml, 450ml, 500ml **vials**: Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• Initially, multiple pack sizes (10ml, 30ml, 50ml, 100ml, 250ml, 450ml, 500ml**)** of injectable dosage form were demanded in a single application. Now, the firm has demanded **250ml pack size**. **Shortcoming:** • Approval of **Liquid injectable (LVP) (General) section** by CLB is required • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.: • **Evidence of availability of required manufacturing facility for the applied fill volume.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.** • **Evidence of availability of required analytical facility for the applied formulation along with drug product analyticl procedure.**	
1049.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Butavit Injection
	Composition	Each ml contains: Butaphosphan…100mg Cyanocobalamin…50mcg
	Diary No. Date of R& I & fee	Dy.No 21494 dated 21-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Phosphorus supplement/ Viatmin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Carosil Injectable Solution **(100ml)** of M/s Huzaifa International, Sargodha. (Reg. No. 074046) **Could not be confirmed in the applied fill volume/ pack size**
	GMP status	cGMP certificate dated 12-09-2022 based on inspection

		conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. **Shortcoming:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) **with the applied fill volume/pack size** alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1050.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Imicent Injection
	Composition	Each ml Contains: Imidocarb Dipropionate…120mg
	Diary No. Date of R& I & fee	Dy.No 21306 dated 18-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 20ml, 50ml, 100ml, 450ml, 500ml: Decontrolled
	Me-too status	Red Mido Injection **(10ml, 20ml, 50ml 100ml)** of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 063715)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • Initially, multiple pack sizes (10ml, 20ml, 50ml, 100ml, 450ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **50ml pack size**.
	Decision: Approved.	
1051.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Tyline WSP
	Composition	Each gram contains: Tylosin Tartrate…980mg
	Diary No. Date of R& I & fee	Dy.No 21496 dated 21-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Antibacterial and bronchodilator
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 20Kg, 25Kg: Decontrolled
	Me-too status	Tylo-Forte Water Soluble Powder of M/s Breeze Pharma (Pvt) Ltd., Islamabad. (Reg. No. 088629)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	**Oral Powder (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal.
	Decision: Approved.	

1052.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Amox-50 Water Soluble Powder
	Composition	Each Kg contains: Amoxicillin Trihydrate…500gm
	Diary No. Date of R& I & fee	Dy.No 21498 dated 21-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Antibacterial /Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Rymox-50 Water Soluble Powder of M/s Zumars Pharma Fty (Pvt) Ltd., Karachi. (Reg. No. 069665)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Powder (penicillin) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal. • Firm has applied for Amoxicillin Trihydrate 500g/Kg while the reference formulation is **Each Kg contains:** **Amoxicillin as Trihydrate…500gm** • Firm shall submit fee of Rs.30000/- for correction in formulation, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Approved as per following label claim: **Each Kg contains:** **Amoxicillin as Trihydrate…500gm** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.**	
1053.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Menta-100 Soluble Powder
	Composition	Each gram contains: **Amantadine HCl…980mg**
	Diary No. Date of R& I & fee	Dy.No 21497 dated 21-10-2019 Rs.20,000/- dated 18-10-2019
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 500gm, 1Kg, 5Kg, 10Kg, 20Kg: Decontrolled
	Me-too status	Mentafarm Powder of M/s Farm Aid Group, Haripur. (Reg. No. 113612)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Powder (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1054.	Name and address of manufacturer / Applicant	M/s Prix Pharmaceutica Pvt Ltd. Plot No 5, Pharmacity, 30-km Multan Road, Lahore.

	Brand Name +Dosage Form + Strength	Prigent 20 Injection
	Composition	Each ml Contains: Gentamycin Sulphate 340mg Eq. To Gentamycin Base…200mg
	Diary No. Date of R& I & fee	Dy.No 20417 dated 11-10-2019 Rs.20,000 dated 11-10-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Gentrax Injection **(100ml)** of M/s Eterna Pharma (Pvt) Ltd. AJK (Reg. No. 113552)
	GMP status	
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years). • Section approval letter no. F 1-9/2000 –Lic dated 29-06-2012 for the "Veterinary Liquid Injectable (General)
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1055.	Name and address of manufacturer / Applicant	M/s Selmore Pharmaceuticals Pvt Ltd., 36-Km, Multan Road Lahore.
	Brand Name +Dosage Form + Strength	Probac-N Powder
	Composition	Each Kg Powder Contains: Procaine Penicillin G…12gm Streptomycin Sulphate…36gm Zinc Bacitracin…52gm Neomycin Sulphate…10gm
	Diary No. Date of R& I & fee	Dy.No 24479 dated 20-11-2019 Rs.20,000/- dated 20-11-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Kg, 5Kg, 25Kg, 50Kg: Decontrolled
	Me-too status	PSB-Excel Powder of M/s Nawan Laboratories (Pvt.) Ltd, Karachi. (Reg. No. 082489)
	GMP status	
	Remarks of the Evaluator [X]	• **Veterinary Penicillin Oral Powder section** confirmed vide panel inspection report for renewal of DML based on inspection dated 05-03-2018, 17-08-2018 and 16-10-2018. • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1056.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Hepacid 100mg/ml Injection
	Composition	Each ml Contains: Phenoxy -2-Methyl-2 Propionic Acid…100mg
	Diary No. Date of R& I & fee	Dy.No 23553 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Hepatoprotectant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications

	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Hepaguard Injection (100ml) of M/s Star Laboratories (Pvt) Ltd., Lahore. (Reg. No. 063624)
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1057.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	GTS 100ml Injection
	Composition	Each ml Contains: Gentamycin Sulphate…30mg Sulphadimethoxine…200mg Trimethoprim…40mg
	Diary No. Date of R& I & fee	Dy.No 23554 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Gentrim-S Injection (100ml) of M/s Zakfas Pharmaceuticals (Pvt) Ltd. Multan. (Reg. No. 052326)
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1058.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	GTS 10ml Injection
	Composition	Each ml Contains: Gentamycin Sulphate…30mg Sulphadimethoxine…200mg Trimethoprim…40mg
	Diary No. Date of R& I & fee	Dy.No 23555 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Gentrim-S Injection (10ml) of M/s Zakfas Pharmaceuticals (Pvt) Ltd. Multan. (Reg. No. 052326)
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. • Latest GMP inspection report (conducted within the period of last three years).

	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1059.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Sinco 50ml Injection
	Composition	Each ml Contains: Lincomycin as HCl…75mg Spiramycin as Adipate…125mg
	Diary No. Date of R& I & fee	Dy.No 23558 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Lispiracin Injection (50ml) of M/s Leads Pharma (Pvt) Ltd., Islamabad (Reg. No. 069602)
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1060.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Sinco 10ml Injection
	Composition	Each ml contains: Lincomycin as HCl…75mg Spiramycin as Adipate…125mg
	Diary No. Date of R& I & fee	Dy.No 23557 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Lispiracin Injection (10ml) of M/s Leads Pharma (Pvt) Ltd., Islamabad (Reg. No. 069602)
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1061.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Rofox-10 Injection
	Composition	Each ml Contains: Enrofloxacin…0.1Gm
	Diary No. Date of R& I & fee	Dy.No 23556 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibacterial

	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**500ml**: Decontrolled
	Me-too status	Rofox-10 Injection (**10, 20ml, 50ml, 100ml**) of M/s A & K Pharmaceutical, Faisalabad. (Reg. No. 075799) **Could not be confirmed in the applied fill volume**
	GMP status	
	Remarks of the Evaluator [X]	• **Liquid injectable (General) LVP section** approval • Latest GMP inspection report (conducted within the period of last three years). • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) **with the applied fill volume/pack size** alongwith registration number, brand name and name of firm.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.: • **Evidence of availability of required manufacturing facility for the applied fill volume.** • **Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) with the applied fill volume/pack size alongwith registration number, brand name and name of firm.**	
1062.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Ectin 0.01gm/ml Injection
	Composition	Each ml Contains: Ivermectin…0.01Gm
	Diary No. Date of R& I & fee	Dy.No 23551 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**500ml**: Decontrolled
	Me-too status	Ivobak Injection (500ml) of M/s Attabak Pharmaceuticals Islamabad (Reg. No. 053908)
	GMP status	
	Remarks of the Evaluator [X]	**Shortcomings:** • **Liquid injectable (General) LVP section** approval • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Registration Board deferred the case for submission evidence of availability of required manufacturing facility for the applied fill volume.	
1063.	Name and address of manufacturer / Applicant	M/s A & K Pharmaceuticals, 94-A, Punjab Small Industrial Estate, Faisalabad.
	Brand Name +Dosage Form + Strength	Nixin 50mg/ml Injection
	Composition	Each ml Contains: Flunixine Meglumine…50mg
	Diary No. Date of R& I & fee	Dy.No 23552 dated 12-11-2019 Rs.20,000/- dated 12-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Maxin Injection (10ml) of M/s Alina Combine Pharmaceuticals (Pvt) Ltd., Karachi (Reg. No. 043576)
	GMP status	

	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection report for renewal of DML based on inspection dated 09-11-2018. • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
1064.	Name and address of manufacturer / Applicant	M/s D-Maarson Pharmaceuticals, Plot No. 17, St SS-2, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Ivoran Plus Injection 10ml
	Composition	Each 100ml Contains: Ivermectin…1gm Vitamin A…2500,000 IU Vitamin D3…3,75,000 IU Vitamin E…2.5gm
	Diary No. Date of R& I & fee	Dy.No 24955 dated 25-11-2019 Rs.20,000/- dated 25-11-2019
	Pharmacological Group	Anthelmintic/ Multivitamins
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Mectin Plus Injection (**10ml**) of M/s Breeze Pharma Islamabad (Reg. No. 059142)
	GMP status	
	Remarks of the Evaluator [X]	• Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility. • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Vitamin A and vitamin D3 from IU to grams.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Veterinary) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1065.	Name and address of manufacturer / Applicant	M/s D-Maarson Pharmaceuticals, Plot No. 17, St SS-2, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Ivoran Plus Injection 50ml
	Composition	Each 100ml Contains: Ivermectin…1gm Vitamin A…2500,000 IU Vitamin D3…3,75,000 IU Vitamin E…2.5gm
	Diary No. Date of R& I & fee	Dy.No 24956 dated 25-11-2019 Rs.20,000/- dated 25-11-2019
	Pharmacological Group	Anthelmintic/ Multivitamins
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Mectin Plus Injection (5**0ml**) of M/s Breeze Pharma Islamabad (Reg. No. 059142)
	GMP status	
	Remarks of the Evaluator [X]	• Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.

		• Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Vitamin A and vitamin D3 from IU to grams.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Veterinary) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1066.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Foliriq-20 Oral Solution
	Composition	Each 1000ml Contains: Florfenicol…200gm
	Diary No. Date of R& I & fee	Dy.No 22903 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 450ml, 500ml, 1000ml, 2500ml, 5000ml: As per SRO
	Me-too status	Flurotin Liquid of M/s Elegance Pharmaceuticals, Rawalpindi (Reg. No. 075751)
	GMP status	**Vet Oral Liquid (General)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [x]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1067.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Hepariq Oral Solution
	Composition	Each ml Contains: Vitamin E…20% Sorbitol…5% Choline Chloride…5% Selenium as Sodium Selenite…0.23% Zinc As Zinc Sulphate…0.40%
	Diary No. Date of R& I & fee	Dy.No 22897 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Vitamins and Minerals
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2500ml, 5000ml, 10000ml, 25000ml: As per SRO
	Me-too status	Liverose 5 Solution of M/s Noble Pharma, Mirpur Azad Kashmir. (Reg. No. 063647)
	GMP status	**Vet Oral Liquid (General)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [x]	• Latest GMP inspection report (conducted within the period of last three years).

	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1068.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Neox-C Powder
	Composition	Each 1000gm Contains: Neomycin Sulphate…250gm Colistin Sulphate…300 MIU Oxytetracycline HCl…250gm
	Diary No. Date of R& I & fee	Dy.No 22899 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	ONC Forte Powder of M/s Noble Pharma, Mirpur Azad Kashmir (Reg. No. 078217)
	GMP status	**Vet Oral Powder (II)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Provided conversion of Colistin Sulphate from MIU to grams. (1mg =19,000IU) **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1069.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Mycorid Oral Powder
	Composition	Each 1000gm contains: Tylosin Tartrate…200gm Doxycycline HCl…400gm
	Diary No. Date of R& I & fee	Dy.No 22898 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	DOT Powder of M/s Attabak Pharmaceutical, Islamabad (Reg. No. 069628)
	GMP status	**Vet Oral powder (Il)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1070.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Neoxeryth Powder

	Composition	Each 1000gm Contains: Erythromycin Thiocyanate…100gm Oxytetracycline HCl…200gm Neomycin Sulphate…100gm
	Diary No. Date of R& I & fee	Dy.No 22904 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Neo-Mix Powder of M/s Attabak Pharmaceutical, Islamabad (Reg. No. 075712)
	GMP status	**Vet Oral powder (Il)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1071.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Eco Stop Oral Powder
	Composition	Each 100gm contains: Colistin Sulphate…48 MIU
	Diary No. Date of R& I & fee	Dy.No 22900 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Freecol Oral Powder of M/s Noble Pharma, Industrial Area, Mirpur Azad Kashmir (Reg. No. 071013)
	GMP status	**Vet Oral powder (Il)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [X]	• Provided conversion of Colistin Sulphate from MIU to grams. (1mg= 19,000 IU) **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1072.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Erythro Plus Powder
	Composition	Each 100gm Contains: Erythromycin Thiocyanate…10gm Sulfadiazine Sodium…10gm Trimethoprim…2gm Bromhexine HCl…2.5gm
	Diary No. Date of R& I & fee	Dy.No 22901 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Antibiotic

	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Erythrofas Plus Powder of M/s Intervac (Pvt) Ltd., Lahore (Reg. No. 048257)
	GMP status	**Vet Oral powder (Il)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [x]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1073.	Name and address of manufacturer / Applicant	M/s Baariq Pharmaceuticals, Plot # 600, Sundar Industrial Estate, Sundar Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Gumboriq Powder
	Composition	Each 100gm contains: Vitamin C…1.10g Nicotinamide…0.32g Potassium Citrate…18g Sodium Citrate…12g Vitamin B1…0.03g Vitamin B2…0.015g Menadione Bisulfite…0.115g
	Diary No. Date of R& I & fee	Dy.No 22902 dated 06-11-2019 Rs.20,000/- dated 06-11-2019
	Pharmacological Group	Vitamins and urine alkalizing agent
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 2500gm, 5000gm, 10000gm, 25000gm: As per SRO
	Me-too status	Anti Gumbo Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad (Reg. No. 046581)
	GMP status	**Vet Oral powder (Il)** section confirmed vide report based on panel inspection conducted on 28-08-2018 for GMP compliance.
	Remarks of the Evaluator [x]	• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1074.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biopyrazin V Powder
	Composition	Each 100gm Powder Contains: Sulphachlorpyrizine Sodium…30gm Vitamin K3…0.4gm Vitamin A…1.5 MIU
	Diary No. Date of R& I & fee	Dy.No 24575 dated 21-11-2019 Rs.20,000/- dated 21-11-2019
	Pharmacological Group	Antibiotic/ Vitamin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500gm, 1Kg: Decontrolled
	Me-too status	S3 Plus Powder of M/s Elegance Pharmaceutical, Rawalpindi. (Reg. No. 073922)

	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Provide conversion of Vitamin A from MIU to gm.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1075.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Prolium Water Soluble Powder
	Composition	Each 1000gm Powder Contains: Amprolium…200gm Ethopabate…10gm Sulphaquinoxaline…120gm Pyrimethamine…10gm
	Diary No. Date of R& I & fee	Dy.No 26416 dated 09-12-2019 Rs.20,000/- dated 06-12-2019
	Pharmacological Group	Coccidiostat/ Antimalarial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500gm, 1Kg: Decontrolled
	Me-too status	Noxin Water Soluble Powder of M/s Mylab (Pvt) Ltd, Khankah Sharif, Bahawalpur. (Reg. No. 105056)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. • Firm has applied for **Amprolium 200gm /1000gm,** while the reference formulation is **Each 1000gm Powder Contains:** **Amprolium HCl…200gm** **Ethopabate…10gm** **Sulphaquinoxaline…120gm** **Pyrimethamine…10gm** • Firm shall submit fee of Rs.30000/- for correction in formulation, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Approved as per follow label claim: **Each 1000gm Powder Contains:** **Amprolium HCl…200gm** **Ethopabate…10gm** **Sulphaquinoxaline…120gm** **Pyrimethamine…10gm** **The firm shall submit fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.**	
1076.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bromacol Plus WSP
	Composition	Each 1000gm Contains: Doxycycline HCl…400gm

		Tylosin Tartrate…200gm Colistin Sulphate…500 MIU Bromhexine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 26413 dated 09-12-2019 Rs.20,000/- dated 06-12-2019
	Pharmacological Group	Antibiotic/ Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500gm, 1Kg: Decontrolled
	Me-too status	Fit Respi Water Soluble Powder of M/s D-Maarson Pharmaceuticals, Islamabad. (Reg. No. 078268)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1077.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biofoxy 30% Water Soluble Powder
	Composition	Each 100gm Contains: Florfenicol…30% Oxytetracycline HCl…30%
	Diary No. Date of R& I & fee	Dy.No 26415 dated 09-12-2019 Rs.20,000/- dated 06-12-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: Decontrolled
	Me-too status	F.T 60 Water Soluble Powder of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 088610)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1078.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Biomyrin E Liquid
	Composition	Each 100ml Contains: Vitamin E…20% Silymarin…2%
	Diary No. Date of R& I & fee	Form-5 Dy.No 24576 dated 21-11-2019 Rs.20,000/- dated 21-11-2019
	Pharmacological Group	Antioxidant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml: Decontrolled
	Me-too status	Hepatotin Liquid of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 074000)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021

	Remarks of the Evaluator [X]	• **Oral Liquid section (General)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Registration Board referred the instant application to Committee on "Grey area molecules."	
1079.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bioxol Oral Liquid
	Composition	Each ml Contains: Ambroxol HCl…20mg
	Diary No. Date of R& I & fee	Dy.No 26414 dated 09-12-2019 Rs.20,000/- dated 06-12-2019
	Pharmacological Group	Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml: Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1080.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Fenicol 25% Oral Liquid
	Composition	Each 100ml Contains: Florfenicol…25%
	Diary No. Date of R& I & fee	Form-5 Dy.No 28195 dated 26-12-2019 Rs.20,000/- dated 26-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml: Decontrolled
	Me-too status	Floskill-25% Liquid of M/s Bioskils Pharmaceuticals, Gujranwala (Reg. No. 113511)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic dated 01-08-2012.
	Decision: Approved.	
1081.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Clozafend Solution
	Composition	Each ml Contains:

		Oxfendazole…2.265% Oxyclozanide…6.25% Cobalt Sulfate…0.38%
	Diary No. Date of R& I & fee	Form-5 Dy.No 28194 dated 26-12-2019 Rs.20,000/- dated 26-12-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	150ml, 250ml, 500ml,1000ml, 5000ml; Decontrolled
	Me-too status	Oxaloid Suspension of M/s Biogen Pharma Rawat (Reg. No. 058972)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic dated 01-08-2012. **Shortcomings:** • The firm has applied for "**SOLUTION"** dosage form while the reference product exists as **"SUSPENSION",** clarify and accordingly provide evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Approved. Firm shall submit revised composition as per reference product along with fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1082.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Levox Solution
	Composition	Each ml Contains: Oxyclozanide…30mg Levamisole HCl…15mg Cobalt Sulphate…382mg
	Diary No. Date of R& I & fee	Dy.No 28196 dated 26-12-2019 Rs.20,000/- dated 26-12-2019
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	150ml, 250ml, 500ml,1000ml, 5000ml; Decontrolled
	Me-too status	Nayzan Plus Oral Suspension of M/s Symans Lahore (Reg. No. 022744)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic dated 01-08-2012. **Shortcomings:** • The firm has applied for "**SOLUTION"** dosage form while the reference product exists as **"SUSPENSION",** clarify and accordingly provide evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Approved. Firm shall submit revised composition as per reference product along with fee of Rs. 30,000/- for correction/pre-approval change in product composition as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1083.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.

	Brand Name +Dosage Form + Strength	Heparok Injection
	Composition	Each ml Contains: Phenoxy 2-methyl-2- propionic acid ……100mg eq. to 2-methyl-2-phenoxy sodium propionate…112.2mg
	Diary No. Date of R& I & fee	Dy.No 28431 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Liver tonic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml vial; Decontrolled
	Me-too status	Hepaguard Injection (50ml) of M/s Star Laboratories (Pvt) Ltd., Lahore (Reg. No. 063624).
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1084.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Isoden Suspension for Injection
	Composition	Each ml Contains: Isoflupredone Acetate…2mg
	Diary No. Date of R& I & fee	Dy.No 28432 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Synthetic corticosteroid
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml vial; Decontrolled
	Me-too status	Isopred Suspension for Injection (10ml) of M/s Alina Combine Pharmaceutical Karachi. (Reg. No. 063701)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of **Injectable (Steroid)** section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Steroid) Veterinary section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1085.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Flusol-C Oral Solution
	Composition	Each ml Contains: Flumequin…200mg Colistin Sulphate…25000 IU
	Diary No. Date of R& I & fee	Dy.No 28429 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibacterial/antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2500ml, 5000ml;Decontrolled

	Me-too status	Comeq Solution of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore (Reg. No. 043536)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral Liquid Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • Provide conversion of Colistin Sulphate from IU to milligrams.
	Decision: Approved.	
1086.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Empoxin 250 Injectable Solution
	Composition	Each gm contains: Oxytetracycline HCl…200mg Neomycin Sulphate…250mg Colistin Sulphate…0.3 MIU
	Diary No. Date of R& I & fee	Dy.No 28427 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	250ml vial; Decontrolled
	Me-too status	
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • **Oxytetracycline HCl…200mg/gm, Neomycin Sulphate…250mg/gm and Colistin Sulphate…0.3 MIU/gm** is mentioned on Form-5 while **Oxytocin 10, 00,000 IU/ 100L** is mentioned in rest of the dossier; clarification is required for which formulation you want to apply this dossier. • Provide conversion of Colistin Sulphate from MIU to milligrams.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1087.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Predison-10 Injection
	Composition	Each ml Contains: Prednisolone as Acetate…25mg
	Diary No. Date of R& I & fee	Dy.No 28436 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Corticosteroid
	Type of Form	Form 5
	Finished product Specification	BP Vet specifications
	Pack size & Demanded Price	10ml vial; Decontrolled
	Me-too status	Premsone 25 Injection (10ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 111331)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.

	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility. • The firm has applied for **Prednisolone as Acetate …25mg/ml** while both the USP and BP Vet monographs state that "*Prednisolone Acetate Injectable Suspension is a sterile suspension of Prednisolone Acetate in a suitable aqueous medium/WFI".* • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1088.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Glucolac Injection
	Composition	Each ml Contains: Calcium Gluconate…440mg
	Diary No. Date of R& I & fee	Dy.No 28430 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Calcium supplement
	Type of Form	Form 5
	Finished product Specification	BP Vet specifications
	Pack size & Demanded Price	100ml vial; Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1089.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Sinolyte Oral Solution
	Composition	Each gm contains: Enrofloxacin Base…100mg Aminophylline…100mg Guaifenesin…40mg
	Diary No. Date of R& I & fee	Dy.No 28438 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibacterial/ mucolytic agent
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2500ml, 5000ml; Decontrolled
	Me-too status	Ensol-Ag Oral Liquid of M/s Biogen Pharma, Rawat. (Reg. No. 049720)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.

	Remarks of the Evaluator [X]	**Oral Liquid Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1090.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Spiralinc-200 Oral Solution
	Composition	Each ml contains: Spiramycin Adipate…125mg Lincomycin HCl…75mg
	Diary No. Date of R& I & fee	Dy.No 28440 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml; Decontrolled
	Me-too status	Lincospira Solution of M/s Selmore Pharmaceuticals (Pvt) Ltd. Lahore. (Reg. No. 049628)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1091.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Emicosin Oral Solution
	Composition	Each ml contains: Tilmicosin (as Phosphate)…250mg
	Diary No. Date of R& I & fee	Dy.No 28425 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2500ml, 5000ml; Decontrolled
	Me-too status	Kptil Oral 25% Oral Liquid of M/s Krypton Pharma (Pvt) Ltd. Faisalabad. (Reg. No. 113415)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Liquid Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1092.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Roxilyte Oral WSP
	Composition	Each gm contains: Roxithromycine…10mg Tylosin Tartrate…10mg Guaifenesin…17.5mg
	Diary No. Date of R& I & fee	Dy.No 28437 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibacterial/ Mucolytic
	Type of Form	Form 5

	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500gm, 1Kg, 2.5Kg, 5Kg; Decontrolled
	Me-too status	Roxi-TG Oral Powder of M/s Mallard Pharmaceutical (Pvt) Ltd Multan. (Reg. No. 058931)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Jar Powder Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1093.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Bactiplus-C WS Powder
	Composition	Each Kg Contains: Vitamin A...0.8gm Vitamin D3...0.16gm Vitamin E...0.38gm Vitamin B1...1gm Vitamin B2...1.25gm Vitamin B6...4gm Vitamin B12...0.001gm Nicotinamide...6.25gm Sodium Chloride...2.5gm Magnesium Sulphate...25gm Manganese Sulphate...10gm Zinc Sulphate...400mg Copper Sulphate...50mg Cobalt Sulphate...100mg Potassium Iodide...0.5gm Sodium Selenite...0.01gm Di Calcium Phosphate...120gm
	Diary No. Date of R& I & fee	Dy.No 28422 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Vitamin and minerals
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg, 2.5Kg, 5Kg; Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral Jar Powder Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Evidence of availability of testing facility required for applied formulation along with drug product analytical procedure.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1094.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Opti-Milk Feed Premix Powder

	Composition	Each Kg contains: Vitamin A...0.8gm Vitamin D3...0.16gm Vitamin E...0.38gm Vitamin B1...1gm Vitamin B2...1.25gm Vitamin B6...4gm Vitamin B12...0.001gm Nicotinamide...6.25gm Sodium Chloride...2.5gm Magnesium Sulphate...25gm Maganese Sulphate...10gm Zinc Sulphate...2.17gm Copper Sulphate...0.25gm Cobalt Sulphate...100mg Potassium Iodide...0.5gm Sodium Selenite...0.01gm Di Calcium Phosphate...120gm
	Diary No. Date of R& I & fee	Dy.No 28435 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Vitamin and minerals
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Kg, 2.5Kg, 5Kg, 25Kg; Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [x]	**Oral Jar Powder Veterinary (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Evidence of availability of testing facility required for applied formulation along with drug product analytical procedure
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1095.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Bou-Man Solution for Injection
	Composition	Each ml Contains: Buserelin Acetate 0.0042mg Eq. To Buserelin…0.004mg
	Diary No. Date of R& I & fee	Dy.No 28423 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Gonadorelin analogue
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5ml vial; Decontrolled
	Me-too status	Buserovet Injection (5ml) of M/s VETZ Pharmaceuticals (Pvt) Limited, Kotri. (Reg. No. 109961)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.

	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of **Veterinary Liquid vials injection (Hormone)** section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Veterinary Liquid vials injection (Hormone) section **from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.**	
1096.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Emicosin Injection
	Composition	Each ml Contains: Tilmicosin as Phosphate…300mg
	Diary No. Date of R& I & fee	Dy.No 28426 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml vial; Decontrolled
	Me-too status	Tilcosin Injection (100ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 035151)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1097.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Spiralinc-200 Injection
	Composition	Each ml Contains: Spiramycin Adipate…125mg Lincomycin HCl…75mg
	Diary No. Date of R& I & fee	Dy.No 28439 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml vial; Decontrolled
	Me-too status	Lincospira Injection (100ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 046570)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1098.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Marbo Ten Injection
	Composition	Each ml Contains: Marbofloxacin…100mg
	Diary No. Date of R& I & fee	Dy.No 28434 dated 27-12-2019 Rs.20,000/- dated 27-12-2019

	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20ml vial; Decontrolled
	Me-too status	Marboflox Injection (20ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 088088)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020.
	Decision: Approved.	
1099.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Trumate Injectable Solution
	Composition	Each ml Contains: Cloprostenol Sodium 263mcg eq. to Cloprostenol …250mcg
	Diary No. Date of R& I & fee	Dy.No 28411 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Prostaglandin F-2-alpha analogue
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	2ml vial; Decontrolled
	Me-too status	Prostenol Injection (2ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 029611)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1100.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Empoxin DS Injection
	Composition	Each ml Contains: Oxytocin…20 IU
	Diary No. Date of R& I & fee	Dy.No 28428 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Uterus Stimulator
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	**250ml** vial; Decontrolled
	Me-too status	Oxytovetz Injection (100ml) of M/s Vetz Pharmaceuticals (Pvt) Limited, Kotri Sindh. (Reg. No. 111472) **Could not be confirmed in the applied fill volume/ pack size**
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of **Veterinary Liquid vials injection (Hormone) (LVP)** section/manufacturing facility by

		the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status), with the **applied fill volume/ pack size,** alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1101.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Ketocam-100 Injection
	Composition	Each ml Contains: **Ketoprofen**…100mg
	Diary No. Date of R& I & fee	Dy.No 28433 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Anti-inflammatory
	Type of Form	Form 5
	Finished product Specification	BP Vet specifications
	Pack size & Demanded Price	100ml vial; Decontrolled
	Me-too status	Ketorise Injection (100ml) of M/s Biorise Pharmaceuticals Multan. (Reg. No. 113398)
	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [x]	**Sterile Liquid Injectable (General) section** confirmed vide letter No. F. 2-2/92-Lic (Vol-II) dated 30-06-2020. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status), with the **applied fill volume/ pack size,** alongwith registration number, brand name and name of firm. • The firm has claimed **BP Vet specifications** while the official monograph of applied formulation does not exist in BP.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1102.	Name and address of manufacturer / Applicant	M/s Manhattan Pharma, 209/3-B, Sector 5, Korangi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Em-Calcium Injection
	Composition	Each ml Contains: Calcium Gluconate…208.30mg Magnesium Hypophosphite…53.30mg Calcium D Saccharate…10mg Magnesium Chloride…20mg Boric Acid…43.3mg Dextrose…200mg
	Diary No. Date of R& I & fee	Dy.No 28424 dated 27-12-2019 Rs.20,000/- dated 27-12-2019
	Pharmacological Group	Calcium and Magnesium Supplement
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	450ml vial; Decontrolled
	Me-too status	Calpho-M Injection (450ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 043146)

	GMP status	Inspection conducted on 15-12-2021 concludes good level of GMP compliance.
	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of **Veterinary Liquid vials injection (LVP)** section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1103.	Name and address of manufacturer / Applicant	M/s Elegance Pharmaceuticals, Chak Belli Pandori Road, Distt. Rawalpindi.
	Brand Name +Dosage Form + Strength	Renal Plus Powder
	Composition	Each 100gm powder contains: Hexamethylene Tetramine…95.50gm Riboflavin…1000mg Calcium Pantothenate…500mg Nicotinamide…2500mg
	Diary No. Date of R& I & fee	Dy.No 27411 dated 18-12-2019 Rs.20,000/- dated 18-12-2019
	Pharmacological Group	Supplement
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm; Decontrolled
	Me-too status	Tolorenal Water Soluble Powder of M/s Mediexcel Pharmaceuticals, Islamabad (Reg. No.035175)
	GMP status	
	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report conducted within period of 3 years. • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1104.	Name and address of manufacturer / Applicant	M/s Elegance Pharmaceuticals, Chak Belli Pandori Road, Distt. Rawalpindi.
	Brand Name +Dosage Form + Strength	Asitinil Powder
	Composition	Each 100gm contains: Frusemide…2000mg Extract Belladonna…200mg
	Diary No. Date of R& I & fee	Dy.No 27410 dated 18-12-2019 Rs.20,000/- dated 18-12-2019
	Pharmacological Group	Diuretic, Flusher
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm; Decontrolled
	Me-too status	Asciticid Powder of M/s Mediexcel Pharmaceuticals, Islamabad (Reg. No. 031402)
	GMP status	
	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report conducted within period of 3 years.

		• Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Registration Board referred the instant application to Committee on "Grey area molecules."	
1105.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Afonac Injection
	Composition	Each ml Contains: **Aceclofenac As Sodium**…25mg
	Diary No. Date of R& I & fee	Dy.No 32402 dated 31-01-2020 Rs.20,000/- dated 31-01-2020
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20ml vial,: Decontrolled
	Me-too status	Aceclovetz Injection (20ml) of M/s Vetz Pharmaceuticals (Private) Limited., Kotri Sindh. (Reg. No. 088160)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid injection (General) Veterinary section** confirmed vide letter No. F. 1-45/2009-Lic dated 27-08-2012. **Shortcomings:** • Firm has mentioned sodium salt of Aceclofenac while the reference formulation is **Each ml contains:** **Aceclofenac.....25mg** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1106.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Sulfolex Injection
	Composition	Each ml Contains: Sulphadimidine Sodium…333.3mg
	Diary No. Date of R& I & fee	Dy.No 32403 dated 31-01-2020 Rs.20,000/- dated 31-01-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	100ml vial,: Decontrolled
	Me-too status	Sulphamit Injection 33.33% (100ml) of M/s Wimits Pharmaceuticals, Lahore. (Reg. No.078304)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid injection (General) Veterinary** section confirmed vide letter No. F. 1-45/2009-Lic dated 27-08-2012.
	Decision: Approved.	
1107.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobifos-20 Oral Powder

	Composition	Each Kg contains: Fosfomycin Calcium…200gm Tylosin Tartrate…100gm Fructose…180gm Sodium Phosphate…150gm Magnesium Sulphate…100gm
	Diary No. Date of R& I & fee	Dy.No 31211 dated 22-01-2020 Rs.20,000/- dated 22-01-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm: Decontrolled
	Me-too status	Fosfo-20 Oral Powder of M/s Evergreen Pharmaceuticals, Lahore. (Reg. No. 088861)
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these areas. A detailed report would be submitted later on after verification of same through onsite inspection.**
	Remarks of the Evaluator [X]	Approval of **Veterinary Oral Powder (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015.
	Decision: Approved.	
1108.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobimint 98% Powder
	Composition	Each Kg Contains: **Amantadine HCl**…980gm
	Diary No. Date of R& I & fee	Dy.No 29812 dated 08-01-2020 Rs.20,000/- dated 08-01-2020
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm: Decontrolled
	Me-too status	Vety Amantex 98% Oral Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 094402)
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these areas. A detailed report would be submitted later on after verification of same through onsite inspection.**
	Remarks of the Evaluator [X]	Approval of **Veterinary Oral Powder (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1109.	Name and address of manufacturer / Applicant	M/s Evergreen Pharmaceuticals, 69-70/B, Main Glaxo Town, Industrial Area, 20th km Ferozepur Road, Lahore.
	Brand Name +Dosage Form + Strength	Levamycin Injection
	Composition	Each ml Contains: Spiramycin Adipate…125mg Lincomycin HCl…75mg

	Diary No. Date of R& I & fee	Dy.No 32319 dated 30-01-2020 Rs.20,000/- dated 30-01-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**50ml, 100ml**,: Decontrolled
	Me-too status	Piram Injection (50ml, 100ml) of M/s Attabak Pharmaceuticals, Islamabad (Reg. No. 062144)
	GMP status	Inspection conducted on 11-03-2022 concludes satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Liquid Injection (General) (Veterinary) section** confirmed vide letter No. F. 1-31/2010-Lic dated 01-08-2012. **Shortcomings:** • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, both **100ml and 50ml** pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved. Firm shall selecet only one fill volume before issuance of registration letter.	
1110.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Inflox-10 Liquid
	Composition	Each ml Contains: Enrofloxacin…100mg
	Diary No. Date of R& I & fee	Dy.No 30047 dated 10-01-2020 Rs.20,000/- dated 07-01-2020
	Pharmacological Group	Antibacterial, Anti-infective
	Type of Form	Form 5
	Finished product Specification	Inhouse specifications
	Pack size & Demanded Price	30ml, 50ml, 100ml, 200ml, 250ml, 500ml, 1Liter, 5Liter, 10Liter, 25Liter; Decontrolled
	Me-too status	Quinosel Solution of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No.057014)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Liquid General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1111.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Enro-20 Liquid
	Composition	Each 100ml Contains: Enrofloxacin…20gm
	Diary No. Date of R& I & fee	Dy.No 30351 dated 14-01-2020 Rs.20,000/- dated 10-01-2020
	Pharmacological Group	Antibacterial, Anti-infective
	Type of Form	Form 5
	Finished product Specification	Inhouse specifications
	Pack size & Demanded Price	30ml, 50ml, 100ml,200ml, 250ml, 500ml, 1Liter, 5Liter, 10Liter, 25Liter; Decontrolled

	Me-too status	Enro-Bax 20% Oral Solution of M/s Baxter Pharmaceuticals, Karachi (Reg. No. 072635)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Liquid General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1112.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Broment Oral Liquid
	Composition	Each ml Contains: Bromhexine HCl…50mg Menthol…40mg
	Diary No. Date of R& I & fee	Dy.No 30048 dated 10-01-2020 Rs.20,000/- dated 07-01-2020
	Pharmacological Group	Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	30ml, 60ml, 100ml, 250ml, 500ml, 1Liter, 5Liter, 10Liter, 25Liter; Decontrolled
	Me-too status	Hexthol Liquid of M/s Nawal Pharmaceuticals, Taxila, Rawalpindi (Reg. No. 097984)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Liquid General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1113.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Enrocol Liquid
	Composition	Each 100ml Contains: Enrofloxacin…25% Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 31995 dated 29-01-2020 Rs.20,000/- dated 10-01-2020
	Pharmacological Group	Antibacterial, Anti-infective
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	30ml, 60ml, 100ml, 250ml, 500ml, 1Liter, 5Liter, 10Liter, 25Liter; Decontrolled
	Me-too status	Era-27. 5% Oral Liquid of M/s Attabak Pharmaceutical Islamabad (Reg. No. 071055)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Liquid General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1114.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.

	Brand Name +Dosage Form + Strength	Floxacin Liquid
	Composition	Each 100ml Contains: Enrofloxacin…25gm
	Diary No. Date of R& I & fee	Dy.No 31994 dated 29-01-2020 Rs.20,000/- dated 10-01-2020
	Pharmacological Group	Antibacterial, Anti-infective
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	30ml, 50ml, 100ml, 200ml, 250ml, 500ml, 1Liter, 5Liter, 10Liter, 25Liter; Decontrolled
	Me-too status	Enro-Gold Liquid of M/s Medicure Laboratories Karachi (Reg. No. 058961)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Liquid General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1115.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Neocycline Powder
	Composition	Each 1000gm contains: Oxytetracycline HCl…300gm Neomycin Sulphate…250gm Colistin Sulphate…500 MIU
	Diary No. Date of R& I & fee	Dy.No 30350 dated 14-01-2020 Rs.20,000/- dated 10-01-2020
	Pharmacological Group	Antibacterial, Anti-infective
	Type of Form	Form 5
	Finished product Specification	Inhouse specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	St Neolistin Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 078242)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1116.	Name and address of manufacturer / Applicant	M/s Farm Aid Pharmaceuticals, Plot No3/2 Phase I & II, Hattar Industial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Deldox Powder
	Composition	Each 1000gm contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…480 MIU Bromhexine HCl…3gm
	Diary No. Date of R& I & fee	Dy.No 30049 dated 10-01-2020 Rs.20,000/- dated 07-01-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5

	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	Doxy-Box Powder of M/s Inshal Pharmaceutical Industries, Rawat, Islamabad. (Reg. No. 079232)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1117.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Lincospect Injection
	Composition	Each ml Contains: Lincomycin as HCl…50mg Spectinomycin…100mg
	Diary No. Date of R& I & fee	Dy.No 2559 dated 24-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml vial: Decontrolled
	Me-too status	Linco-S Injection (100ml) of M/s Jfrin Pharmaceuticals, Karachi. (Reg. No. 043248)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid Injectable (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Approved.	
1118.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Peflovac 10% Liquid
	Composition	Each 100ml Contains: Pefloxacin Methanesulfonate…13.960gm eq. to Pefloxacine Base…10gm
	Diary No. Date of R& I & fee	Dy.No 2560 dated 24-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Quinolones Carboxylic Derivatives
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5ml, 10ml, 50ml, 100ml, 200ml, 500ml, 1Liter, 2Liter, 5Liter: Decontrolled
	Me-too status	Peperoxin Solution of M/s Hassan Brothers, Faisalabad (Reg. No. 082807)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Approved.	

1119.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Fencol Liquid
	Composition	Each 100ml contains: Florfenicol…10gm Colistin Sulphate…2.50gm
	Diary No. Date of R& I & fee	Dy.No 2557 dated 24-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5ml, 10ml, 50ml, 100ml, 500ml, 1000ml, 2000ml, 2500ml, 5000ml: Decontrolled
	Me-too status	Co-Flor Liquid of M/s Wimits Pharmaceuticals, Lahore. (Reg. No. 078326)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Approved.	
1120.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Atrosol Injection
	Composition	Each ml Contains: Atropine Sulphate…1mg
	Diary No. Date of R& I & fee	Dy.No 2558 dated 24-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Anticholinergic
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Atrapin Injection (50ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 112240)
	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid Injectable (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Deferred for evidence of approval of applied formulation for veterinary used in reference regulatory authorities/agencies which were declared/approved by the Registration Board in its 275th meeting	
1121.	Name and address of manufacturer / Applicant	M/s Intervac Pvt. Limited, 18-Km, Lahore Sheikhupura Road, Sheikhupura, Pakistan
	Brand Name +Dosage Form + Strength	Enro 20 Injection
	Composition	Each ml Contains: Enrofloxacin…200mg
	Diary No. Date of R& I & fee	Dy.No 2556 dated 24-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Quinosel Injection (100ml) of M/s Selmore Pharmaceuticals, Lahore (Reg. No. 057009)

	GMP status	cGMP Inspection conducted on 08-10-2020 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Liquid Injectable (General) (Veterinary) section** confirmed vide letter No. F.1-37/2004-Lic (Vol-I) dated 04-10-2019.
	Decision: Approved.	
1122.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Gentyle 50ml Injection
	Composition	Each ml Contains: Gentamicin Sulphate…50mg Tylosin Tartrate…100mg
	Diary No. Date of R& I & fee	Dy.No 2552 dated 24-02-2020 Rs.20,000/- dated 20-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Gtrise Injection (50ml) of M/s Biorise Pharmaceuticals, Multan. (Reg. No. 112179)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1123.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Gentyle 100ml Injection
	Composition	Each ml Contains: Gentamicin Sulphate…50mg Tylosin Tartrate…100mg
	Diary No. Date of R& I & fee	Dy.No 2553 dated 24-02-2020 Rs.20,000/- dated 20-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Gtrise Injection (100ml) of M/s Biorise Pharmaceuticals, Multan. (Reg. No. 112180)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1124.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Lincospec 50ml Injection
	Composition	Each ml Contains: Lincomycin as HCl…50mg Spectinomycin…100mg

	Diary No. Date of R& I & fee	Dy.No 2554 dated 24-02-2020 Rs.20,000/- dated 20-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Linco-S Injection (50ml, 100ml) of M/s Jfrin Pharmaceuticals, Karachi. (Reg. No. 043248)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1125.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Lincospec 100ml Injection
	Composition	Each ml Contains: Lincomycin as HCl…50mg Spectinomycin…100mg
	Diary No. Date of R& I & fee	Dy.No 2555 dated 24-02-2020 Rs.20,000/- dated 20-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Linco-S Injection (50ml, 100ml) of M/s Jfrin Pharmaceuticals, Karachi. (Reg. No. 043248)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1126.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Guaphen-B Powder
	Composition	Each 1000gm contains: Bromhexine HCl…50gm Guaiphenesin…106gm
	Diary No. Date of R& I & fee	Dy.No 1093 dated 12-02-2020 Rs.20,000/- dated 11-02-2020
	Pharmacological Group	Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Kg, 5Kg: Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:**

		• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1127.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	B-Cal Plus Oral Liquid
	Composition	Each 1000ml Contains: Vitamin D3…300,000 IU Calcium Sulphate…75000mg Zinc Sulphate…5000mg Sodium Metabisulphate…5000mg
	Diary No. Date of R& I & fee	Dy.No 1095 dated 12-02-2020 Rs.20,000/- dated 11-02-2020
	Pharmacological Group	Vitamin and mineral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Liter, 5Liter: As recommended by the PRC
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1128.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Respolin Liquid
	Composition	Each 1000ml Contains: Bromhexine HCl…50gm Guaphensin…100gm Aminophyline…80gm Methnol…100gm
	Diary No. Date of R& I & fee	Dy.No 1096 dated 12-02-2020 Rs.20,000/- dated 11-02-2020
	Pharmacological Group	Mucolytic/ Expectorant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Liter: As recommended by the PRC
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:**

		• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1129.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Vitaxine Plus Liquid
	Composition	Each 1000ml Contains: **Eucalyptus Oil**…35gm Thyme Oil…5gm Lemon Oil Expressed…20gm Vitamin A…10,000 IU Vitamin E Liquid…10gm Menthol…4gm Bromhexine HCl…20gm Dl-Methionine…10gm L-Lysine…30gm Sorbitol Liquid…40gm
	Diary No. Date of R& I & fee	Dy.No 1094 dated 12-02-2020 Rs.20,000/- dated 11-02-2020
	Pharmacological Group	
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	1Liter, 5Liter: As recommended by the PRC
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (General) Veterinary** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Pharmacological group is not mentioned in the form-5.
	Decision: Registration Board referred the instant application to Committee on "Grey area molecules."	
1130.	Name and address of manufacturer / Applicant	M/s SB Pharma, Plot No.5-E, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	SB Oramox Ultimate 80% Powder
	Composition	Each 100g Contains: Amoxicillin Trihydrate…80gm
	Diary No. Date of R& I & fee	Dy.No 2205 dated 21-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm, 5Kg, 20Kg: Decontrolled
	Me-too status	Amcorox-80% Water Soluble Powder of M/S Vetrox Pharmaceutical Pvt Ltd, Toba Tek Singh. (Reg. No.112342)

	GMP status	
	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
1131.	Name and address of manufacturer / Applicant	M/s SB Pharma, Plot No.5-E, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	SB Doxy Ultimate 80% Powder
	Composition	Each 100gm Contains: Doxycycline Hyclate…80gm
	Diary No. Date of R& I & fee	Dy.No 2206 dated 21-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm, 5Kg, 20Kg: Decontrolled
	Me-too status	Dox Reena 80% Water Soluble Powder of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 111573)
	GMP status	
	Remarks of the Evaluator [X]	The firm has applied for Doxycycline Hyclate…80gm/100gm while the reference formulation is **Each 100gm Contains:** **Doxycycline as Hyclate…80gm** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
1132.	Name and address of manufacturer / Applicant	M/s SB Pharma, Plot No.5-E, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	SB Levonex Ultimate 50% Powder
	Composition	Each 100gm Contains: Levamisole HCl…50gm
	Diary No. Date of R& I & fee	Dy.No 2203 dated 21-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm, 5Kg, 20Kg: Decontrolled
	Me-too status	Anthiy Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad (Reg. No. 044964)
	GMP status	

	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1133.	Name and address of manufacturer / Applicant	M/s SB Pharma, Plot No.5-E, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	SB Colistin Ultimate 50% Powder
	Composition	Each 100gm Contains: Colistin Sulphate…50gm
	Diary No. Date of R& I & fee	Dy.No 2204 dated 21-02-2020 Rs.20,000/- dated 21-02-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm, 5Kg, 20Kg: Decontrolled
	Me-too status	Emdocolin 50% Water Soluble Powder for Oral Route of M/s Orient Animal Health (Pvt.) Limited, Karachi (Reg. No. 082503)
	GMP status	
	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Approval of section/manufacturing facility by the Central Licensing Board. However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years.	
1134.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Guafloxl 10 Liquid
	Composition	Each 100ml contains: Enrofloxacin…10gm Aminophylline…4gm Guaifenesin…10gm
	Diary No. Date of R& I & fee	Dy.No 219 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant/Bronchodilator
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Anrox Plus-10% Oral Liquid of M/s Bio-Labs (Pvt) Ltd., Islamabad. (Reg. No. 033240)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).

	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
1135.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Pulmoeaz XL Oral Solution
	Composition	Each 1000ml Contains: Tylosin Tartrate…100gm Doxycycline HCl…200gm Colistin Sulphate…450 MIU Bromhexine…4gm
	Diary No. Date of R& I & fee	Dy.No 220 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Broxy Oral Solution of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 079124)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1136.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Florexcel 10 Solution
	Composition	Each ml Contains: Florfenicol…100mg
	Diary No. Date of R& I & fee	Dy.No 210 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 5000ml; Decontrolled
	Me-too status	Fenlor Solution of M/s Selmore Pharmaceutical (Pvt) Ltd., Lahore. (Reg. No. 071080)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1137.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.

	Brand Name +Dosage Form + Strength	Florexcel-C 10 Oral Liquid
	Composition	Each 100ml Contains: Florfenicol…10gm Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 213 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Floro-C Oral Liquid of M/s D-Maarson Pharmaceuticals, Rawat, Islamabad. (Reg. No. 074079)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1138.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Florexcel-C 23 Oral Liquid
	Composition	Each 100ml Contains: Florfenicol…23% Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 214 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Flatirox Oral Solution of M/s Vetrox Pharmaceutical Pvt Ltd, Toba Tek Singh. (Reg. No. 112361)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1139.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Florexcel 20 Liquid

	Composition	Each ml Contains: Florfenicol…200mg
	Diary No. Date of R& I & fee	Dy.No 211 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Flurotin Liquid of M/s Elegance Pharmaceuticals, Rawalpindi. (Reg. No. 075751)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1140.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Florexcel Forte Solution
	Composition	Each 100ml Contains: Florfenicol…23gm
	Diary No. Date of R& I & fee	Dy.No 212 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Neflox Solution of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 049647).
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1141.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Enkol XL Forte Oral Liquid
	Composition	Each 100ml Contains: Enrofloxacin…25% Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 218 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled

	Me-too status	Era-27. 5% Oral Liquid of M/s Attabak Pharmaceutical Islamabad (Reg. No. 071055)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1142.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Enkol XL Liquid
	Composition	Each 100ml Contains: Enrofloxacin…20gm Colistin Sulphate…50,000,000 IU
	Diary No. Date of R& I & fee	Dy.No 217 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Colistacin Liquid of M/s Bio-Labs (Pvt) Ltd., Islamabad. (Reg. No. 079714)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from IU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1143.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Brenko XL Liquid
	Composition	Each 100ml Contains: Enrofloxacin…10gm Colistin Sulphate…5 MIU Bromhexine…0.50%
	Diary No. Date of R& I & fee	Dy.No 215 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Enrocoli Liquid of M/s Symans Pharmaceuticals (Pvt) Ltd Lahore. (Reg. No. 059167)

	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1144.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Brenko XL Forte Liquid
	Composition	Each 100ml Contains: Enrofloxacin…10gm Colistin Sulphate…50 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 216 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Inter Flox Liquid of M/s Symans Pharmaceuticals (Pvt) Ltd Lahore. (Reg. No. 078241)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1145.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Tylocob XL Powder
	Composition	Each 100gm Contains: Tylosin Tartrate…10gm Doxycycline…20gm Colistin Sulphate…3gm Bromhexine…1gm
	Diary No. Date of R& I & fee	Dy.No 232 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm; Decontrolled
	Me-too status	Biosin Td Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 044951) **Could not be confirmed in the applied strength**
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.

	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Deferred for evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm	
1146.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Tylocob XL Forte Powder
	Composition	Each 100gm Contains: Tylosin Tartrate…20gm Doxycycline Hyclate…40gm Colistin Sulphate…10gm Bromhexine Hcl…2gm
	Diary No. Date of R& I & fee	Dy.No 233 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 5Kg; Decontrolled
	Me-too status	DOX-TYL Powder of M/s ICI Pakistan Limited, Life Sciences, Lahore. (Reg. No. 092186)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1147.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Floron XL Water Soluble Powder
	Composition	Each gm Contains: Neomycin Sulphate…150mg Florfenicol…100mg Oxytetracycline HCl…300mg
	Diary No. Date of R& I & fee	Dy.No 234 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Antibiotic
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm; Decontrolled
	Me-too status	Noxyflor Water Soluble Powder of M/s Divine Pharmaceuticals, Lahore. (Reg. No. 087584)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:**

		• Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
1148.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Neoxtin XL Water Soluble Powder
	Composition	Each 1000gm Contains: Colistin Sulphate…240 MIU Neomycin Sulphate…200gm Oxytetracycline…200gm
	Diary No. Date of R& I & fee	Dy.No 231 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm; Decontrolled
	Me-too status	Oxcinocol Water Soluble Powder of M/s Attabak Pharmaceutical Industries, Islamabad (Reg. No. 034533)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [x]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter.	
1149.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Pulmoeaz XL Oral Powder
	Composition	Each Kg contains: Tylosin Tartrate…100gm Doxycycline HCl…200gm Colsitin Sulphate…500 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 222 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 500gm, 1000gm, 5Kg; Decontrolled
	Me-too status	Respisin Oral Powder of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No.089827)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [x]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).

		• Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1150.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bromaric XL Oral Powder
	Composition	Each 100gm contains: Bromhexine HCl…1gm Tartaric Acid…15gm
	Diary No. Date of R& I & fee	Dy.No 223 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Mucolytic/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm; Decontrolled
	Me-too status	Bromotaric Water Soluble Powder of M/s ICI Pakistan Limited Life Sciences, Lahore. (Reg. No. 089822)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1151.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Wheezocid Water Soluble Powder
	Composition	Each 1000gmContains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Dihydrostreptomycin…20gm Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 221 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 5Kg; Decontrolled
	Me-too status	Doxylo-S Water Soluble Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 075695)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1152.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.

	Brand Name +Dosage Form + Strength	Amanta XL 10 Powder
	Composition	Each 100gm Contains: Amantadine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 225 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm, 5Kg; Decontrolled
	Me-too status	Amantabak 10% Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 075697)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1153.	Name and address of manufacturer / Applicant	M/s MediExcel Pharmaceuticals, Plot No. 282, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Amantaric XL Oral Powder
	Composition	Each Kg Contains: Amantadine HCl…980gm
	Diary No. Date of R& I & fee	Dy.No 224 dated 04-02-2020 Rs.20,000/- dated 30-12-2019
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1000gm; Decontrolled
	Me-too status	Vety Amantex 98% Oral Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 094402)
	GMP status	cGMP certificate dated December 2019 based on inspection conducted on **08-10-2019**.
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-10-2019 for renewal of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1154.	Name and address of manufacturer / Applicant	M/s Star Laboratories Pvt Ltd. 23-km, Multan Road, Lahore
	Brand Name +Dosage Form + Strength	Tystar Injection 50ml
	Composition	Each ml Contains: Tylosin Tartrate…100mg Gentamicin as Sulphate…50mg
	Diary No. Date of R& I & fee	Dy.No 83 dated 03-02-2020 Rs.20,000/- dated 03-02-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Inhouse specifications

	Pack size & Demanded Price	50ml; Decontrolled
	Me-too status	Tygent Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 049636)
	GMP status	cGMP certificate dated 20-07-2020 based on inspection conducted on 24-01-2020.
	Remarks of the Evaluator [X]	• Approval of **Liquid injectable (veterinary)** section confirmed vide panel inspection dated 14-12-2015 report for renewal of DML.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years before issuance of registration letter	
1155.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Morbodec Injection
	Composition	Each ml Contains: Morbofloxacin…100mg
	Diary No. Date of R& I & fee	Dy.No 5138 dated 20-03-2020 Rs.20,000/- dated 20-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml, 20ml, 50ml, 100ml, 450ml, 500ml: Decontrolled
	Me-too status	Marbostar 10% Solution (10ml, 20ml, 50ml, 100ml, 250ml) of M/s Huzaifa International, Sargodha. (Reg. No. 074054)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved. Firm shall select one fill volume only before issuance of registration letter.	
1156.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Fenoxy Injection
	Composition	Each ml contains: Oxytetracycline HCl…200mg **Ketoprofen**…30mg
	Diary No. Date of R& I & fee	Dy.No 5140 dated 20-03-2020 Rs.20,000/- dated 20-03-2020
	Pharmacological Group	Antibiotic/NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml: Decontrolled
	Me-too status	Vetoxy-K Injection (50ml) of M/s Mallard Pharmaceutical (Pvt) Ltd., Multan. (Reg. No. 109240) Ketocin Injection (100ml) of M/s A & K Pharmaceutical, Faisalabad. (Reg. No. 102101)
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022

	Remarks of the Evaluator [X]	• **Liquid injectable (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1157.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Kloroqueen 10% Oral Liquid
	Composition	Each ml Contains: Thiamphenicol…100mg
	Diary No. Date of R& I & fee	Dy.No 5137 dated 20-03-2020 Rs.20,000/- dated 20-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 200ml, 450ml, 500ml, 1Liter, 2.5Liter, 5Liter, 10Liter, 20Liter: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength.**
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	• **Oral Liquid (General) section** confirmed vide panel inspection dated 10-03-2022, 21-04-2022 and 09-05-2022 report for approval of DML renewal • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Deferred for evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.	
1158.	Name and address of manufacturer / Applicant	M/s Decent Pharma, Plot No. 30, Street SS-3, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Clomectin Pour on Liquid
	Composition	Each ml Contains: Ivermectin…5mg Closental as Sodium…200mg
	Diary No. Date of R& I & fee	Dy.No 5139 dated 20-03-2020 Rs.20,000/- dated 20-03-2020
	Pharmacological Group	Endectocide (Anthelmintic and ectoparasitic)
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 200ml, 450ml, 500ml, 1Liter, 2.5Liter, 5Liter, 10Liter, 20Liter: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength and dosage form**
	GMP status	cGMP certificate dated 12-09-2022 based on inspection conducted on 09-05-2022
	Remarks of the Evaluator [X]	**Shortcomings:** • Evidence of approval of **Topical Liquid (General)** section. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.

	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1159.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bio-Oxicam 0.75% Injection 50ml
	Composition	Each ml Contains: Meloxicam...7.5mg
	Diary No. Date of R& I & fee	Dy.No 3196 dated 02-03-2020 Rs.20,000/- dated 27-02-2020
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Melo Grand 7.5 Injection (50ml) of M/s Grand Pharma (Pvt) Ltd., Rawat, Islamabad. (Reg. No. 111554)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1160.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Animectin 1% Injection 10ml
	Composition	Each ml Contains: Ivermectin…10mg
	Diary No. Date of R& I & fee	Dy.No 3195 dated 27-02-2020 Rs.20,000/- dated 27-02-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Ivoron Injection (10ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 112245)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1161.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bio-Flox 20 Injection 100ml
	Composition	Each ml Contains: Enrofloxacin…200mg
	Diary No. Date of R& I & fee	Dy.No 4635 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Enropro 20% Injection (100ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 112252)

	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1162.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Durectin Injection 50ml
	Composition	Each ml Contains: Furosemide…50mg
	Diary No. Date of R& I & fee	Dy.No 4638 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Diuretic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Duretic Injection (50ml) of M/s Mylab (Pvt) Ltd. Khanqah Sharif, Bahawalpur. (Reg. No. 078208)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1163.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Durectin Injection 10ml
	Composition	Each ml Contains: Furosemide…50mg
	Diary No. Date of R& I & fee	Dy.No 4637 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Diuretic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Duretic Injection (10ml) of M/s Mylab (Pvt) Ltd. Khanqah Sharif, Bahawalpur. (Reg. No. 078208)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1164.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bio-Flumin Injection 10ml
	Composition	Each ml contains: Flunixin Meglumine…50mg
	Diary No. Date of R& I & fee	Dy.No 4636 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Anti-pyretic/ Analgesic/ NSAID
	Type of Form	Form 5
	Finished product Specification	USP specifications

	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Loxin Injection (10ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd, Lahore. (Reg. No. 035098)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1165.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bio-Oxyne 5% Injection 50ml
	Composition	Each ml Contains: Oxytetracycline HCl eq. to Oxytetracycline...50mg
	Diary No. Date of R& I & fee	Dy.No 3197 dated 02-03-2020 Rs.20,000/- dated 27-02-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Levamycin-5% Injection (50ml) of M/s Biorise Pharmaceuticals, Multan. (Reg. No. 113403)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1166.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Vetpro 10% Injection 20ml
	Composition	Each ml Contains: **Ketoprofen**…100mg
	Diary No. Date of R& I & fee	Dy.No 3194 dated 02-03-2020 Rs.20,000/- dated 27-02-2020
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	As per innovator's specifications
	Pack size & Demanded Price	20ml: Decontrolled
	Me-too status	Ketoject Injection (20ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore (Reg. No. 043141)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1167.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Bio-Sulpha 33.3% Injection 100ml
	Composition	Each ml Contains: Sulphadimidine Sodium…333mg

	Diary No. Date of R& I & fee	Dy.No 4634 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Dimidin Injection (100ml) of M/s Eterna Pharma (Pvt) Ltd.,Mirpur, AJK. (Reg. No. 113559)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1168.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Probiocin 5gm Injection
	Composition	Each vial contains: Procaine Penicillin…1,500,000 IU Benzyl Penicillin…500,00 I.U Streptomycin Sulphate…5Gm
	Diary No. Date of R& I & fee	Dy.No 4633 dated 16-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5gm: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Dry Powder injection (Penicillin) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1169.	Name and address of manufacturer / Applicant	M/s Grand Pharma, Plot No. 5-A, St. No N-5, National Industrial Zone, RCCI Estate, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Amanta Grand-98 Oral Powder
	Composition	Each Kg Powder Contains: Amantadine HCl…0.98Kg
	Diary No. Date of R& I & fee	Dy.No 4632 dated 16-03-2020 Rs.20,000/- dated 16-03-2020
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Emanta-98 Oral Powder of M/s Evergreen Pharmaceuticals, Lahore. (Reg. No. 081735)
	GMP status	Last GMP inspection is conducted on 12-08-2022 and the

		report concludes that firm was considered to be operating at good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Powder section (General) Veterinary** confirmed vide letter No. 1-36/2006-Lic (Vol-I) dated 26-09-2019
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1170.	Name and address of manufacturer / Applicant	M/s Grand Pharma, Plot No. 5-A, St. No N-5, National Industrial Zone, RCCI Estate, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Amanta Grand-10 Oral Powder
	Composition	Each Kg Contains: Amantadine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 4631 dated 16-03-2020 Rs.20,000/- dated 16-03-2020
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Antamits Water Soluble Powder of M/s Wimits Pharmaceuticals, Lahore. (Reg. No. 078316)
	GMP status	Last GMP inspection is conducted on 12-08-2022 and the report concludes that firm was considered to be operating at good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Powder section (General) Veterinary** confirmed vide letter No. 1-36/2006-Lic (Vol-I) dated 26-09-2019
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1171.	Name and address of manufacturer / Applicant	M/s Grand Pharma, Plot No. 5-A, St. No N-5, National Industrial Zone, RCCI Estate, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Grand CTD Water Soluble Powder
	Composition	Each 1000gm Powder Contains: Tylosin Tartrate…200gm Doxycycline HCl…400gm Colistin Sulphate…500 MIU Bromhexine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 4630 dated 16-03-2020 Rs.20,000/- dated 16-03-2020
	Pharmacological Group	Antibacterial/Expectorant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Dox-40 Water Soluble Powder of M/s Nawal Pharmaceuticals, Taxila, Rawalpindi. (Reg. No. 074096)
	GMP status	Last GMP inspection is conducted on 12-08-2022 and the report concludes that firm was considered to be operating at good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Powder section (General) Veterinary** confirmed vide letter No. 1-36/2006-Lic (Vol-I) dated 26-09-2019
	Decision: Approved.	
1172.	Name and address of manufacturer / Applicant	M/s Grand Pharma, Plot No. 5-A, St. No N-5, National Industrial Zone, RCCI Estate, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Grand Neocin WSP

	Composition	Each 100gm Contains: Neomycin Sulphate…70gm
	Diary No. Date of R& I & fee	Dy.No 4629 dated 16-03-2020 Rs.20,000/- dated 16-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Neomycin 70% Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No.075694)
	GMP status	Last GMP inspection is conducted on 12-08-2022 and the report concludes that firm was considered to be operating at good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Powder section (General) Veterinary** confirmed vide letter No. 1-36/2006-Lic (Vol-I) dated 26-09-2019
	Decision: Approved.	
1173.	Name and address of manufacturer / Applicant	M/s Grand Pharma, Plot No. 5-A, St. No N-5, National Industrial Zone, RCCI Estate, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Para Mix Oral Powder
	Composition	Each 100gm Powder Contains: **Paracetamol**…20gm Vitamin C…5gm Potassium Carbonate…12.5gm Sodium Bicarbonate…12.5gm Vitamin E…12.5gm
	Diary No. Date of R& I & fee	Dy.No 4628 dated 16-03-2020 Rs.20,000/- dated 16-03-2020
	Pharmacological Group	NSAID/Vitamin/Electrolyte
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Para CE Oral Powder of M/s Biogen Pharma, Rawat. (Reg. No. 063812)
	GMP status	Last GMP inspection is conducted on 12-08-2022 and the report concludes that firm was considered to be operating at good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral Powder section (General) Veterinary** confirmed vide letter No. 1-36/2006-Lic (Vol-I) dated 26-09-2019
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1174.	Name and address of manufacturer / Applicant	M/s Hawk Bio Pharma Pvt Ltd. Plot # 10, Street # s-6, National Industrial Estate, RCCI, Rawat, Rawalpindi.
	Brand Name +Dosage Form + Strength	Enrohawk-10 Liquid
	Composition	Each 1000ml Contains: Enrofloxacin…100gm
	Diary No. Date of R& I & fee	Dy.No 3856 dated 09-03-2020 Rs.20,000/- dated 09-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, and 2.5Liter; Decontrolled
	Me-too status	Enroriq-10 Oral Liquid of M/S. Baariq Pharmaceuticals, Lahore. (Reg. No. 079813)

	GMP status	Last panel inspection was conducted on 19-11-2020 for the grant of renewal of DML.
	Remarks of the Evaluator [X]	Veterinary oral Liquid (antibiotic) and Veterinary oral Liquid (general) sections confirmed vide letter No. F. 1-31/2011- Lic (M-235) dated 03-07-2013.
	Decision: Approved.	
1175.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobivec Oral Liquid
	Composition	Each ml Contains: Ivermectin…10mg
	Diary No. Date of R& I & fee	Dy.No 4362 dated 12-03-2020 Rs.20,000/- dated 12-03-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml,100ml, 150ml, 500ml, 1000ml: Decontrolled
	Me-too status	Kepromec Oral of M/s Better Traders International, Faisalabad. (Reg. No. 049560)
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these areas. A detailed report would be submitted later on after verification of same through onsite inspection.**
	Remarks of the Evaluator [X]	Approval of **Veterinary Oral Liquid (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015.
	Decision: Approved.	
1176.	Name and address of manufacturer / Applicant	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Col-Link Powder
	Composition	Each gm Contains: Colistin Sulphate…800,000 IU Lincomycin HCl…100mg
	Diary No. Date of R& I & fee	Dy.No 3857 dated 09-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Polinco Oral Powder of M/s Hawk Bio Pharma (Pvt) Ltd., Rawat, Islamabad. (Reg. No. 078392)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022. **Shortcomings:** • Provide conversion of Colistin Sulphate from IU to milligrams.
	Decision: Approved.	
1177.	Name and address of manufacturer / Applicant	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.

	Brand Name +Dosage Form + Strength	Colifag Powder
	Composition	Each 100gm Contains: Colistin Sulphate…50,00,000 IU
	Diary No. Date of R& I & fee	Dy.No 3860 dated 09-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Colistin Water Soluble Powder of M/s Biogen Pharma, Rawat (Reg. No. 071022)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022. **Shortcomings:** Provide conversion of Colistin Sulphate from IU to milligrams.
	Decision: Approved.	
1178.	Name and address of manufacturer / Applicant	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Fagbro Powder
	Composition	Each 100gm contains: Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 3859 dated 09-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Expectorant
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Bromo 5 % W.S. Powder of M/s Cherished Pharmaceuticals (Private) Limited, Lahore. (Reg. No. 063512)
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1179.	Name and address of manufacturer / Applicant	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.
	Brand Name +Dosage Form + Strength	Oxy-200 Powder
	Composition	Each Kg Contains: Oxytetracycline as HCl…222gm
	Diary No. Date of R& I & fee	Dy.No 3858 dated 09-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	10gm, 50gm, 100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled

	Me-too status	Nobioxy-200 Powder of M/s Noble Pharma Mirpur Azad Kashmir (Reg. No. 058733).
	GMP status	cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Remarks of the Evaluator [X]	**Oral Powder General Veterinary** section confirmed from cGMP certificate dated 14-10-2022 based on inspection conducted on 15-04-2022.
	Decision: Approved.	
1180.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Vetzflor 25% Oral Liquid
	Composition	Each 100ml contains: Florfenicol…25gm
	Diary No. Date of R& I & fee	Dy.No 3200 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 200ml, 500ml,1000ml, 5Liter: Decontrolled
	Me-too status	Florfenicol Oral Liquid of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 075707)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Liquid (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1181.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	G-Mox Plus Injection 100ml
	Composition	Each ml Contains: Amoxicillin as Trihydrate…150mg Gentamicin As Sulphate…40mg
	Diary No. Date of R& I & fee	Dy.No 3199 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	A Gent 150/40 Injection (100ml) of M/s Eterna Pharma (Pvt) Ltd., Mirpur, AJK (Reg. No. 113606)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Shortcomings:** • **Approval of section/manufacturing facility by the Central Licensing Board.** However, you may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility i.e., Liquid Injection (Veterinary) section from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	

1182.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz 5% Injection 50ml
	Composition	Each ml contains: Oxytetracycline HCl…50mg
	Diary No. Date of R& I & fee	Dy.No 3205 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	OXYLA 5% Injection (50ml) of M/s Alina Combine Pharmaceuticals Karachi. (Reg. No. 053991)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1183.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz 5% Injection 100ml
	Composition	Each ml contains: Oxytetracycline HCl…50mg
	Diary No. Date of R& I & fee	Dy.No 3206 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	OXYLA 5% Injection (100ml) of M/s Alina Combine Pharmaceuticals Karachi. (Reg. No. 053991)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1184.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Nitrovetz Injection 100ml
	Composition	Each ml Contains: Nitroxynil…340mg
	Diary No. Date of R& I & fee	Dy.No 3198 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Nitroxy Injection (100ml) of M/s Alina Combine Pharmaceuticals Karachi. (Reg. No. 049683)

	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1185.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Enrovetz-B Injection 100ml
	Composition	Each ml contains: Enrofloxacin…100mg Bromhexine HCl…5mg
	Diary No. Date of R& I & fee	Dy.No 3204 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Bromoflox Injection (100ml) of M/s Mylab (Pvt) Ltd. Khanqah Sharif, Bahawalpur (Reg. No. 075603)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1186.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Enrovetz-B Injection 10ml
	Composition	Each ml Contains: Enrofloxacin…100mg Bromhexine HCl…5mg
	Diary No. Date of R& I & fee	Dy.No 3203 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Bromoflox Injection (10ml) of M/s Mylab (Pvt) Ltd. Khanqah Sharif, Bahawalpur (Reg. No. 075603)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1187.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Colivetz Plus Injection 100ml

	Composition	Each ml Contains: Colistin Sulphate…400,000 IU
	Diary No. Date of R& I & fee	Dy.No 3202 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Coliject Injection (100ml) of M/s Geofman Pharmaceuticals, Karachi (Reg. No. 035087)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from IU to milligrams.
	Decision: Approved.	
1188.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Colicycline-N Plus Oral Powder
	Composition	Each Kg contains: Oxytetracycline HCl…300gm Neomycin Sulphate…250gm Colistin Sulphate…500 MIU
	Diary No. Date of R& I & fee	Dy.No 3201 dated 02-03-2020 Rs.20,000/- dated 02-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	ST Neolistin Powder of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 078242)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1189.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Amoxi-20 Injection
	Composition	Each ml Contains: Amoxicillin as Trihydrate…200mg
	Diary No. Date of R& I & fee	Dy.No 3548 dated 04-03-2020 Rs.20,000/- dated 04-03-2020
	Pharmacological Group	Antibacterial

	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	**50ml, 100ml vial**: Decontrolled
	Me-too status	Amcolox LA Injection (50ml, 100ml) of M/s Breeze Pharma (Pvt.) Ltd, Islamabad. (Reg. No. 063551)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Sterile liquid Injection (Penicillin) Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML. **Shortcomings:** • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved. Firm shall selct one fill volume only before issuance of registration letter.	
1190.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Amogent Injection
	Composition	Each ml contains: Amoxicillin as Trihydrate…150mg Gentamycin as Sulphate…40mg
	Diary No. Date of R& I & fee	Dy.No 3550 dated 04-03-2020 Rs.20,000/- dated 04-03-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**50ml, 100ml vial**: Decontrolled
	Me-too status	A Gent 150/40 Injection (50ml, 100ml) of M/s Eterna Pharma (Pvt) Ltd., Mirpur, AJK (Reg. No. 113605,113606)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Sterile liquid Injection (Penicillin) Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML. **Shortcomings:** • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved. Firm shall selct one fill volume only before issuance of registration letter.	
1191.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	P-Strep Injection
	Composition	Each vial contains: Penicillin G Procaine…30,00,000 IU Penicillin G Sodium…10,00,000 IU Dihydrostreptomycin Sulphate…5gm
	Diary No. Date of R& I & fee	Dy.No 3549 dated 04-03-2020 Rs.20,000/- dated 04-03-2020

	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml vial: Decontrolled
	Me-too status	PG-VET Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore (Reg. No. 080957)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Sterile liquid Injection (Penicillin) Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1192.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Tyloject Injection (solution for injection)
	Composition	Each ml Contains: Tylosin Tartrate…100mg Gentamicin As Sulphate…50mg
	Diary No. Date of R& I & fee	Dy.No 8985 dated 27-04-2020 Rs.20,000/- dated 27-04-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml vial: Decontrolled
	Me-too status	Tygent Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore (Reg. No. 049636)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Liquid Injection Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1193.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Lintec Injection
	Composition	Each ml Contains: Lincomycin as HCl…50mg Spectinomycin as HCl…100mg
	Diary No. Date of R& I & fee	Dy.No 8986 dated 27-04-2020 Rs.20,000/- dated 27-04-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	**50ml, 100ml vial:** Decontrolled
	Me-too status	Lincopec Injection (50ml, 100ml) of M/s Leads Pharma (Pvt) Ltd., Islamabad. (Reg. No. 043581)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Liquid Injection Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML. **Shortcomings:**

		• Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved.	
1194.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Cyanowan-250 Injection
	Composition	Each ml Contains: Cyanocobalamin…250mcg
	Diary No. Date of R& I & fee	Dy.No 8987 dated 27-04-2020 Rs.20,000/- dated 27-04-2020
	Pharmacological Group	Vitamin
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	100ml vial: Decontrolled
	Me-too status	Cyanocob 250 Injection (100ml) of M/s Prix Pharmaceutica (Pvt) Ltd, Lahore. (Reg. No. 072692)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Liquid Injection Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1195.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Cyno 250 Injection 100ml
	Composition	Each 100ml Contains: Cyanocobalamin…250mcg
	Diary No. Date of R& I & fee	Dy.No 9467 dated 30-04-2020 Rs.20,000/- dated 30-04-2020
	Pharmacological Group	Vitamin
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Cyanocob 250 Injection (100ml) of M/s Prix Pharmaceutica (Pvt) Ltd, Lahore. (Reg. No. 072692)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	**Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1196.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name +Dosage Form + Strength	Trivit Injection 100ml
	Composition	Each ml Contains: Vitamin A…80,000 IU Vitamin D3…40,000 IU Vitamin E…20mg
	Diary No. Date of R& I & fee	Form-5 Dy.No 9466 dated 30-04-2020 Rs.20,000/- dated 30-04-2020

	Pharmacological Group	Vitamins
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Vital-3 Injection (100ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 049635)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	**Liquid injection (General) section** confirmed vide panel inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 report for renewal of DML.
	Decision: Approved.	
1197.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Amolin-50% Powder
	Composition	Each gram contains: Amoxicillin as Trihydrate…500mg
	Diary No. Date of R& I & fee	Dy.No 9703 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	500gm, 1Kg: Decontrolled
	Me-too status	Amosel-50 Oral Dry Powder of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 080959)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Penicillin) Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1198.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name +Dosage Form + Strength	Albacure Granules
	Composition	Each gram contains: Albendazole…200mg
	Diary No. Date of R& I & fee	Dy.No 9702 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	5gm, 30gm, 50gm, 100gm: Decontrolled
	Me-too status	Alvenax Granules of M/s Star Laboratories (Pvt) Ltd Lahore (Reg. No. 026581)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Dry Powder Sachet Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1199.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.

	Brand Name +Dosage Form + Strength	Butasin Injection
	Composition	Each ml Contains: Buparvaquone…50mg
	Diary No. Date of R& I & fee	Dy.No 9704 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	20ml Vial: Decontrolled
	Me-too status	Bupralex Injection (20ml) Of M/s Star Laboratories (Pvt) Ltd., Lahore (Reg. No. 033264)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator [X]	**Liquid Injection Vet Section** confirmed from panel inspection report conducted on 31-03-2022 for renewal of DML.
	Decision: Approved.	
1200.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Enrovetz 20% Oral Liquid
	Composition	Each ml Contains: Enrofloxacin…200mg
	Diary No. Date of R& I & fee	Dy.No 9698 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml,100ml, 150ml, 200ml, 500ml, 1000ml, 5Liter: Decontrolled
	Me-too status	Enrobak-20 Oral Solution of M/s Attabak Pharmaceutical Industries, Islamabad. (Reg. No. 034540)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Liquid (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1201.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Enrovetz 10% Oral Liquid
	Composition	Each ml Contains: Enrofloxacin…100mg
	Diary No. Date of R& I & fee	Dy.No 9697 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml,100ml, 150ml, 200ml, 500ml, 1000ml, 5Liter: Decontrolled
	Me-too status	Enrobak-10 Oral Solution of M/s Attabak Pharmaceutical Industries, Islamabad. (Reg. No. 034541)

	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Liquid (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1202.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobioxy-K Injection
	Composition	Each ml contains: Oxytetracycline HCl…20mg **Ketoprofen**……3mg
	Diary No. Date of R& I & fee	Dy.No 10157 dated 06-05-2020 Rs.20,000/- dated 06-05-2020
	Pharmacological Group	Antibacterial and anti-inflammatory
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml vial: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength**
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these areas. A detailed report would be submitted later on after verification of same through onsite inspection.**
	Remarks of the Evaluator [X]	Approval of **Veterinary Liquid Vial injection (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1203.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Ampko-Vet 90 Oral Powder
	Composition	Each Kg contains: Amprolium HCl…900gm
	Diary No. Date of R& I & fee	Dy.No 13137 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Amprobar Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore. (Reg. No. 073955)

	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1204.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz Super Injection 100ml
	Composition	Each ml Contains: Oxytetracycline HCl…200mg **Ketoprofen**…30mg
	Diary No. Date of R& I & fee	Dy.No 13140 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antibacterial/ NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Oxyfen LA Injection (100ml) of M/s Selmore Pharmaceutical (Pvt) Ltd., Lahore. (Reg. No. 071091)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1205.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Vetzuril-K Oral Liquid
	Composition	Each 1000ml contains: Toltrazuril…25gm Vitamin K3…3gm
	Diary No. Date of R& I & fee	Dy.No 13141 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Anticoccidial agent
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 200ml, 500ml,1000ml, 5Liter: Decontrolled
	Me-too status	Tetzole Oral Liquid of M/s Ras Pharmaceuticals (Pvt) Ltd., Multan. (Reg. No. 097953)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Liquid (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1206.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad

	Brand Name +Dosage Form + Strength	D-Scoure Powder
	Composition	Each 12gm Contains: Neomycin Sulphate…400mg Streptomycin Sulphate…400mg Sulpha guanidine…4gm Kaolin…4gm Pectin…400mg Bismuth Subnitrate…2gm Vitamin A Acetate…80,000 IU
	Diary No. Date of R& I & fee	Dy.No 11270 dated 18-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Antibiotics, antidiarrheal with specific action on the digestive tract
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	250gm, 500gm, 1Kg & 20 x 12gm sachet: Decontrolled
	Me-too status	Diarroban Powder of M/s Star Labs Lahore (Reg. No. 026438)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1207.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Scoure Oral Suspension
	Composition	Each ml Contains: Sulphadiazine…35.50mg Sulphadimidine…28.40mg Neomycin Sulphate…1.800 Hyoscine Methylbromide…0.04mg Pectin…7.1mg Kaolin…103.3mg Vitamin B1…0.15mg Vitamin B2…0.22mg
	Diary No. Date of R& I & fee	Dy.No 11269 dated 18-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Antidiarrheal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml: Decontrolled
	Me-too status	Scour-X Oral Suspension of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 029661)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Liquid section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1208.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Gest Powder

	Composition	Each 1000gm Contains: Propionic Calcium Acid…250gm Propionic Sodium Acid…400gm Acetanilide…150gm Magnesium Oxide…125gm Iron Sulphate…400mg Magnesium Sulphate…200mg Copper Sulphate…450mg Cobalt Sulphate…400mg Sodium Molybdate…100mg Sodium Chloride…20gm
	Diary No. Date of R& I & fee	Dy.No 12597 dated 04-06-2020 Rs.20,000/- dated 01-06-2020
	Pharmacological Group	Supplement
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg: Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1209.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Fos Injection 50ml
	Composition	Each ml Contains: Toldimfos Sodium…200mg Vitamin B12…0.05mg
	Diary No. Date of R& I & fee	Dy.No 12595 dated 04-06-2020 Rs.20,000/- dated 01-06-2020
	Pharmacological Group	Restorative
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Tonovit Injetion (50ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore (Reg. No. 033253)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Oral Dry Powder section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1210.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Hepacare Injection 50ml

	Composition	Each ml Contains: Phenoxy-2-Methyl-2-Propionic Acid…100mg
	Diary No. Date of R& I & fee	Dy.No 12594 dated 04-06-2020 Rs.20,000/- dated 01-06-2020
	Pharmacological Group	Hepatoprotectant
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Hepacid Injection (50ml) of M/s A & K Pharmaceutical, Faisalabad. (Reg. No. 081690)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1211.	Name and address of manufacturer / Applicant	M/s Bio Labs Pvt Ltd., Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bio-Lex Injection 10ml
	Composition	Each ml Contains: Buparvaquone…50mg
	Diary No. Date of R& I & fee	Dy.No 12596 dated 04-06-2020 Rs.20,000/- dated 01-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml: Decontrolled
	Me-too status	Parvon Injection (10ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 034580)
	GMP status	cGMP certificate dated 28-02-2022 based on inspection dated 03-08-2021
	Remarks of the Evaluator [X]	• **Liquid Injection (General) section (Veterinary)** confirmed vide panel inspection report based on inspection dated 08-07-2021, 15-07-2021, 30-07-2021 and 03-08-2021 for renewal of DML.
	Decision: Approved.	
1212.	Name and address of manufacturer / Applicant	M/s Inshal Pharmaceutical Industries, Plot No. 2, Street SS 2, National Industrial Zone, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Imox 15% Injection
	Composition	Each ml Contains: Amoxicillin as Trihydrate…150mg
	Diary No. Date of R& I & fee	Dy.No 10653 dated 12-05-2020 Rs.20,000/- dated 12-05-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml; Decontrolled
	Me-too status	Novamox LA Injection (100ml) Of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore (Reg. No. 043135)
	GMP status	cGMP certificate dated 30-04-2021 based on inspection conducted on 15-04-2021.
	Remarks of the Evaluator [X]	**Shortcomings:** • Approval of **Penicillin Injection** section/manufacturing facility by the Central Licensing Board. However, you

		may submit panel inspection report for renewal of DML verifying the section/manufacturing facility.
	Decision: Deferred for submission of evidence of approval of required manufacturing facility from CLB or else while firm may transfer the registration application to by way of contract manufacturing upon submission of new Form 5, within six months.	
1213.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Phylofen Liquid
	Composition	Each 100ml contains: Enrofloxacin…10gm Aminophylline…10gm Guaifenesin…4gm
	Diary No. Date of R& I & fee	Dy.No 11379 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Antibacterial/Mucolytic
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	50ml, 100ml, 250ml, 500ml, 1000ml, 2.5Liter, 5Liter, 10Liter, 25Liter; Decontrolled
	Me-too status	Ensol-AG Oral Liquid of M/s Biogen Pharma, Rawat. (Reg. No. 049720)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [X]	**Oral Liquid section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1214.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Pecticin Powder
	Composition	Each 100gm contains: Lincomycin as HCl…33.30gm Spectinomycin as Sulphate…66.70gm
	Diary No. Date of R& I & fee	Dy.No 11378 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm, 1000gm, 2.5Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	Lincotin Powder of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 049618)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1215.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Valbazol 20% Powder
	Composition	Each 100gm Contains: Albendazole…20gm

	Diary No. Date of R& I & fee	Dy.No 11377 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm, 1000gm, 2.5Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	Zoben 20 Water Soluble Powder of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore (Reg. No. 043285)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [x]	• **Oral Powder section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1216.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Esozyme Powder
	Composition	Each 100gm Contains: Lysozyme HCl…22gm Vitamin E…0.50gm
	Diary No. Date of R& I & fee	Dy.No 11375 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Nutritional Supplement
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm, 1000gm, 2.5Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	LISO 10 Powder of M/s Mallard Pharmaceutical (Pvt) Ltd., Multan (Reg. No. 049566)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [x]	• **Oral Powder section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Deferred for evidence of approval of applied formulation for veterinary use by the reference regulatory authorities adopted by the Regostrain Board in its 275th meeting.	
1217.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Nytin Powder
	Composition	Each 100gm Contains: Nystatin…10 MIU
	Diary No. Date of R& I & fee	Dy.No 11376 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Antifungal
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 500gm, 1000gm, 2.5Kg, 5Kg, 10Kg, 25Kg; Decontrolled
	Me-too status	Nysta-100 Powder of M/s Intervac (Pvt) Ltd., Lahore. (Reg. No.046594)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML

	Remarks of the Evaluator [X]	• **Oral Powder section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Deferred for evidence of approval of applied formulation for veterinary use by the reference regulatory authorities adopted by the Regostrain Board in its 275th meeting.	
1218.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Albasel Suspension
	Composition	Each 100ml Contains: Albendazole…10gm Sodium Selenite…0.035gm
	Diary No. Date of R& I & fee	Dy.No 11381 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2.5Liter, 5Liter, 10Liter, 20Liter, 25Liter; Decontrolled
	Me-too status	Alba 10 Plus Suspension of M/s Breeze Pharma (Private) Limited, Islamabad (Reg. No. 063792)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [X]	• **Oral Liquid section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1219.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Rectin-1% Solution
	Composition	Each 100ml Contains: Ivermectin…1gm
	Diary No. Date of R& I & fee	Dy.No 11382 dated 19-05-2020 Rs.20,000/- dated 18-05-2020
	Pharmacological Group	Anti-parasitic
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 2.5Liter, 5Liter, 10Liter, 20Liter, 25Liter; Decontrolled
	Me-too status	Unimec Oral Solution of M/s Hilton Pharma (Pvt) Ltd., Karachi. (Reg. No. 043219)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [X]	• **Oral Liquid section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1220.	Name and address of manufacturer / Applicant	M/s Univet Pharmaceuticals, 14-km, Adyala Road, Post Office Dahgal, Rawalpindi.
	Brand Name +Dosage Form + Strength	Vamizan Suspension
	Composition	Each 100ml Contains: Levamisole HCl…1.50gm Oxyclozanide…3gm
	Diary No. Date of R& I & fee	Dy.No 11380 dated 19-05-2020 Rs.20,000/- dated 18-05-2020

	Pharmacological Group	Anthelmintic
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2.5Liter, 5Liter, 10Liter, 20Liter, 25Liter; Decontrolled
	Me-too status	Nilzan Drench of M/s ICI Karachi. (Reg. No. 002105)
	GMP status	Panel inspection conducted on 01-12-2020 for renewal of DML
	Remarks of the Evaluator [X]	• **Oral Liquid section (Veterinary)** confirmed from panel inspection conducted on 01-12-2020 for renewal of DML
	Decision: Approved.	
1221.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Ampko-Vet Oral Liquid
	Composition	Each 100ml Contains: Amprolium HCl…25gm
	Diary No. Date of R& I & fee	Dy.No 13134 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml, 150ml, 200ml, 500ml,1000ml, 5Liter: Decontrolled
	Me-too status	Cap 25% Oral Liquid of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore. (Reg. No. 074030)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Liquid (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1222.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Ampko-Vet 60 Oral Powder
	Composition	Each Kg Contains: Amprolium HCl…600gm
	Diary No. Date of R& I & fee	Dy.No 13136 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Amporo-60 Water Soluble Powder of M/s Decent Pharma, Rawat, Islamabad (Reg. No. 079825)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	

1223.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Ampko-Vet 30 Oral Powder
	Composition	Each 100gm Contains: Amprolium HCl…30gm
	Diary No. Date of R& I & fee	Dy.No 13135 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Amprobak-30 Water Soluble Powder of M/s Attabak Pharmaceuticals Islamabad (Reg. No. 063816)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1224.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	SDV-Vet Oral Powder
	Composition	Each Kg Contains: Sulphachloropyridazine Sodium…150gm Sulphaquinoxaline Sodium…120gm Sulphadimerazine Sodium…80gm Diaveridine HCl…40gm Vitamin A…30,000 IU Vitamin K3…3gm
	Diary No. Date of R& I & fee	Dy.No 13138 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antibacterial/Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Tetra-Cox Powder of M/s Mallard Pharmaceutical (Pvt) Ltd., Multan. (Reg. No. 075628)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1225.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Eri-Prim Oral Powder
	Composition	Each Kg Contains: Erythromycin Thiocyanate…100gm Sulphadiazine…100gm

		Trimethoprim…20gm
	Diary No. Date of R& I & fee	Dy.No 13143 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 150gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg: Decontrolled
	Me-too status	Erysul-T Oral Powder of M/s Bio-Oxime Pharmaceuticals, Faisalabad (Reg. No. 080135)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Oral Powder (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1226.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Cyanovet Injection 100ml
	Composition	Each ml Contains: Cyancobalamin…1000mcg
	Diary No. Date of R& I & fee	Dy.No 13142 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Vitamin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Cyanocob 1000 Injection (100ml) of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore. (Reg. No. 074021)
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML.
	Decision: Approved.	
1227.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Vetzveta Injection 250ml
	Composition	Each ml Contains: Vitamin B1...4mg Vitamin B6...0.34mg Vitamin B2...0.17mg Vitamin C...4mg L-Arginine HCl...1.44mg L-Cystine HCl...3.2mg L-Glutamine HCl...3.2mg Glycin...3.2mg L-Histidine...1.32mg L-Isoleucine...3.6mg L-Leucine HCl...4.28mg L-Lysin HCl...5.44mg

		L-Methionine...3.2mg L-Threonine...3.2mg L-Trypton...0.86mg L-Valine...3.6mg Nicotinamide...8mg Glucose...21mg Magnesium Sulphate...0.08mg L-Phenylalanine...5mg
	Diary No. Date of R& I & fee	Dy.No 13139 dated 09-06-2020 Rs.20,000/- dated 09-06-2020
	Pharmacological Group	Amino acid/ Electrolytes/Vitamin
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	250ml: Decontrolled
	Me-too status	Vetzveta Injection **(100ml)** of M/s Vetz Pharmaceuticals (Private) Limited., Kotri Sindh. (Reg. No. 089860) **Could not be confirmed in the applied fill volume/pack size**
	GMP status	The firm was inspected on 31-5-2021 with the following conclusion: Based on the above observation their current GMP compliance level is rated as good.
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Approval of required manufacturing facility of **"Liquid Injectable (LVP)- Veterinary Section"** by the Central Licensing Board. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) **with the applied fill volume/pack size** alongwith registration number, brand name and name of firm. • Evidence of availability of required testing facility for applied formulation along with drug product analytical procedure.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1228.	Name and address of manufacturer / Applicant	M/s Noble Pharma, B-1 Old Industrial Area, Mirpur, Azad Kashmir
	Brand Name +Dosage Form + Strength	Nobivec-C Injection
	Composition	Each ml Solution Contains: Ivermectin…20mg Clorsulon…10mg
	Diary No. Date of R& I & fee	Dy.No 8323 dated 20-04-2020 Rs.20,000/- dated 22-04-2020
	Pharmacological Group	Antiparasitic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml, 100ml vial: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength**
	GMP status	Panel inspection of M/s Noble Pharma, Azad Kashmir has been carried out on 09-02-2022. **It was observed to do a lot of improvements in HVAC, Pharmaceutical Quality systems including documentation and other quality related areas. The firm submitted improvements in these**

		areas. A detailed report would be submitted later on after verification of same through onsite inspection.
	Remarks of the Evaluator [X]	Approval of **Veterinary Liquid Vial injection (General)** section confirmed vide letter No.F. 5-2/2007-Lic dated 08-07-2015. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1229.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Ventyl Water Soluble Powder
	Composition	Each 1gm Contains: Tylosin Tartrate…800mg
	Diary No. Date of R& I & fee	Dy.No 14229 dated 19-06-2020 Rs.20,000/- dated 18-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm, 1Kg,: Decontrolled
	Me-too status	Tyleeo Soluble Powder of M/s Raja Poultry Karachi (Reg. No. 022752)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	• **Oral powder General Veterinary section** confirmed from panel inspection report for renewal of DML based on inspection conducted on 13-09-2018 to 14-09-2018.
	Decision: Approved.	
1230.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Colivet 48 Water Soluble Powder
	Composition	Each gm Contains: Colistin Sulphate…48 MIU
	Diary No. Date of R& I & fee	Dy.No 14230 dated 19-06-2020 Rs.20,000/- dated 18-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 200gm, 250gm, 500gm, 1000gm,: Decontrolled
	Me-too status	Policol-48 Oral Powder of M/s Kohinoor Industries, Sahiwal (Reg. No. 081304)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral powder General Veterinary section** confirmed from panel inspection report for renewal of DML based on inspection conducted on 13-09-2018 to 14-09-2018. **Shortcomings:**

		• Provide conversion of Colistin Sulphate from MIU to grams.
	Decision: Approved.	
1231.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Evanta Water Soluble Powder
	Composition	Each 1gm Contains: Amantadine HCl…100mg
	Diary No. Date of R& I & fee	Dy.No 14232 dated 19-06-2020 Rs.20,000/- dated 18-06-2020
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg,: Decontrolled
	Me-too status	Antamits Water Soluble Powder of M/s Wimits Pharmaceuticals, Lahore. (Reg. No. 078316)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral powder General Veterinary section** confirmed from panel inspection report for renewal of DML based on inspection conducted on 13-09-2018 to 14-09-2018.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1232.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Mylanta Water Soluble Powder
	Composition	Each 100gm Contains: Amantadine HCl…98gm
	Diary No. Date of R& I & fee	Dy.No 14233 dated 19-06-2020 Rs.20,000/- dated 18-06-2020
	Pharmacological Group	Antiviral
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm, 1Kg, 5Kg, 10Kg, 25Kg,: Decontrolled
	Me-too status	Amadine-98 Oral Powder of M/s Aptly Pharmaceuticals, Faisalabad. (Reg. No. 093841)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral powder General Veterinary section** confirmed from panel inspection report for renewal of DML based on inspection conducted on 13-09-2018 to 14-09-2018.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1233.	Name and address of manufacturer / Applicant	M/s Mylab Pvt Ltd. Khankah Sharif Bahawalpur.
	Brand Name +Dosage Form + Strength	Ramox 500 Water Soluble Powder
	Composition	Each Kg Contains: Amoxicillin Trihydrate…500gm
	Diary No. Date of R& I & fee	Dy.No 14231 dated 19-06-2020 Rs.20,000/- dated 18-06-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5

	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm,150gm, 200gm, 500gm, 1Kg: Decontrolled
	Me-too status	Amoxinal 50% Water Soluble Powder of M/s Alina Combine Pharmaceuticals (Pvt) Ltd., Karachi (Reg. No. 069626)
	GMP status	Inspection conducted on 24-02-2021 to 25-02-2021 concluded satisfactory level of GMP compliance.
	Remarks of the Evaluator [X]	**Oral powder (Penicillin) Veterinary section** confirmed from panel inspection report for renewal of DML based on inspection conducted on 13-09-2018 to 14-09-2018.
	Decision: Approved.	
1234.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Isbenda Bolus-600
	Composition	Each tablet Contains: Albendazole…600mg
	Diary No. Date of R& I & fee	Dy. No 10652 dated 12-05-2020 Rs.20,000 dated 12-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	Albak 600 Bolus of M/s Attabak Pharmaceutical Industries, Islamabad (Reg. No. 111519)
	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021.
	Decision: Approved.	
1235.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Isbenda Bolus-250
	Composition	Each Bolus Contains: Albendazole…250mg
	Diary No. Date of R& I & fee	Dy.No 10651 dated 12-05-2020 Rs.20,000/- dated 12-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	Albafas 250 Bolus of M/s Intervac (Pvt) Ltd., Sheikhupura. (Reg. No. 072652)
	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021.
	Decision: Approved.	
1236.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Triclosuper Bolus
	Composition	Each Bolus Contains:

		Trimethoprim…200mg Sulphadiazine…1000mg
	Diary No. Date of R& I & fee	Dy.No 10647 dated 12-05-2020 Rs.20,000/- dated 12-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	Trimodin Bolus of M/s Epla Labs Karachi (Reg. No. 017130)
	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021.
	Decision: Approved.	
1237.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Ismedine Bolus
	Composition	Each Bolus Contains: Sulphadimidine…350mg
	Diary No. Date of R& I & fee	Dy. No 10650 dated 05-11-2020 Rs.20,000 dated 04-11-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	**Could not be confirmed in the applied strength**
	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	• **Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1238.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Levamide Bolus
	Composition	Each Bolus Contains: Oxyclozanide…2250mg Levamisole…1125mg
	Diary No. Date of R& I & fee	Dy.No 10649 dated 12-05-2020 Rs.20,000/- dated 12-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	Oxysole Bolus of M/s Attabak Pharmaceutical Industries, Islamabad. (Reg. No. 111302)

	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	**Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021. **Shortcomings:** • Firm has not mentioned salt form of Levamisole while the reference formulation is **Each Bolus Contains:** **Oxyclozanide…2250mg** **Levamisole as HCl…1125mg** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Approved as per following label claim: **Each Bolus Contains:** **Oxyclozanide…2250mg** **Levamisole as HCl…1125mg** **Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 before issuance of registration letter.**	
1239.	Name and address of manufacturer / Applicant	M/s ISIS Pharmaceuticals & Chemical Works. 25/1-3, Sector 12-C, North Karachi Industrial Area, Karachi.
	Brand Name +Dosage Form + Strength	Nowerm Bolus
	Composition	Each Bolus Contains: Oxyclozanide…2.25gm Levamisole…1.125gm Cobalt Sulphate…0.286gm Sodium Selenite…0.026gm
	Diary No. Date of R& I & fee	Dy.No 10648 dated 12-05-2020 Rs.20,000/- dated 12-05-2020
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	5x 10's blister in unit carton: Decontrolled
	Me-too status	Nawazan Plus Bolus of M/s Nawan Laboratories (Pvt) Ltd., Karachi. (Reg. No. 035064)
	GMP status	Inspection conducted on 03-02-2022 concluded good level of GMP compliance.
	Remarks of the Evaluator [X]	**Tablet Bolus (Veterinary) section** confirmed vide letter No. F. 2-11/2005-Lic (Vol-I) dated 15-06-2021. **Shortcomings:** • Firm has not mentioned salt form of Levamisole while the reference formulation is **Each Bolus Contains:** **Oxyclozanide…2.25gm** **Levamisole HCl…1.125gm** **Cobalt Sulphate…0.286gm** **Sodium Selenite…0.026gm** • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Approved as per following label claim: **Oxyclozanide…2.25gm** **Levamisole HCl…1.125gm** **Cobalt Sulphate…0.286gm** **Sodium Selenite…0.026gm**	

	Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1240.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Ampro-Le 60 Powder
	Composition	Each 1000gm Contains: Amprolium HCl…600gm
	Diary No. Date of R& I & fee	Dy.No 14860 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm,1Kg, 2.5Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Amporo-60 Water Soluble Powder of M/s Decent Pharma, Rawat, Islamabad (Reg. No. 079825)
	GMP status	
	Remarks of the Evaluator X	**Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1241.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Amprox-50% WSP
	Composition	Each 100gm Contains: Amprolium HCl…50gm
	Diary No. Date of R& I & fee	Dy.No 14856 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antiprotozoal
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm,1Kg, 2.5Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Unipro-50% Powder of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 033255)
	GMP status	
	Remarks of the Evaluator X	**Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1242.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Levam-30 Powder
	Composition	Each gm Contains: Levamisole HCl…300mg
	Diary No. Date of R& I & fee	Dy.No 14862 dated 25-06-2020 Rs.20,000/- dated 24-06-2020

	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 500gm,1Kg, 2.5Kg, 5Kg, 25Kg: Decontrolled
	Me-too status	Levamin Powder of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 069644)
	GMP status	
	Remarks of the Evaluator X	**Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1243.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Td-Max WSP
	Composition	Each 1000gm Contains: Doxycycline HCl…400gm Tylosin Tartrate…200gm Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 14863 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	TB-DOX Powder of M/s Attabak Pharmaceuticals, Islamabad. (Reg. No. 075718)
	GMP status	
	Remarks of the Evaluator X	**Oral Powder (General-Vet) section** confirmed vide panel inspection report for grant of additional section based on inspection conducted on 17-02-2022. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1244.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Profenol Injection 50ml
	Composition	Each ml Contains: **Ketoprofen**…100mg
	Diary No. Date of R& I & fee	Dy.No 14854 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Analgesic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	KETO-P Injection (50ml) of M/s Star Laboratories (Pvt) Ltd., Lahore (Reg. No. 063625)
	GMP status	GMP of relevant section

	Remarks of the Evaluator [X]	• **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I) (M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1245.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Profenol Injection 100ml
	Composition	Each ml Contains: **Ketoprofen**…100mg
	Diary No. Date of R& I & fee	Dy.No 14857 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Analgesic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	KETO-P Injection (100ml) of M/s Star Laboratories (Pvt) Ltd., Lahore (Reg. No. 063625)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I) (M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
1246.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Florofen Injection 50ml
	Composition	Each ml Contains: Florfenicol…300mg
	Diary No. Date of R& I & fee	Dy.No 14853 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Rexa-Plus Injection (50ml) of M/s S.J. & G. Fazul Ellahie (Pvt) Ltd., Karachi (Reg. No. 048295)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I) (M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1247.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.

	Brand Name +Dosage Form + Strength	Florofen Injection 500ml
	Composition	Each ml Contains: Florfenicol…300mg
	Diary No. Date of R& I & fee	Dy.No 14858 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml: Decontrolled
	Me-too status	I-Florcol Injection (500ml) of M/s International Pharma Labs. Lahore. (Reg. No. 075739)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	**Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Approval of required manufacturing facility of **"Liquid Injectable (LVP)- Veterinary Section"** by the Central Licensing Board.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1248.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Ferovit Injection 100ml
	Composition	Each ml contains: Dl-Acetylmethionine…200mg Cyanocobalamin…0.2mg L-Carnitine HCl…50mg Alpha-Tocopherol As Acetate…30mg
	Diary No. Date of R& I & fee	Dy.No 14859 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Restorative
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	Sterivit Injection (100ml) of M/s Selmore Pharmaceuticals (Pvt) Limited, Lahore. (Reg. No. 095650)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• **Injectable section** confirmed vide letter No. F.1-26/93-Lic (Vol. I) (M-205) dated 30-04-2007. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). Firm has applied for Each ml contains: DL-Acetylmethionine…200mg Cyanocobalamin…0.2mg **L-Carnitine HCl…50mg** Alpha-Tocopherol as Acetate…30mg while the reference formulation is Each ml contains: DL-Acetylmethionine…..200mg Cyanocobalamin…..……..0.2mg **L-Carnitine Hydrochloride……61.3mg**

		eq. to L-Carnitine …….50mg Alpha-Tocopherol Acetate……..……32.9mg eq. to Alpha-Tocopherol ….....30mg • Firm shall submit fee of Rs.30000/- for correction in formulation (salt form), as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Deferred for evidence of availability of testing facility along with drug product analytical procedure.	
1249.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	FC-Max Liquid
	Composition	Each ml Contains: Florfenicol…250mg Colistin Sulphate…0.5 MIU
	Diary No. Date of R& I & fee	Dy.No 14861 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1Liter, 5Liter: Decontrolled
	Me-too status	Poliflor Liquid of M/s Hawk Bio Pharma (Pvt) Ltd., Rawat, Islamabad. (Reg. No. 078383)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• **Liquid section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings**: • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from MIU to milligrams.
	Decision: Approved. Firm shall submit latest GMP inspection report conducted within last three years, before issuance of registration letter.	
1250.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Floro Fort Liquid
	Composition	Each ml Contains: Florfenicol…30gm Colistin Sulphate…5 MIU
	Diary No. Date of R& I & fee	Dy.No 14855 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1Liter, 5Liter: Decontrolled
	Me-too status	**Could not be confirmed**
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	• **Liquid section** confirmed vide letter No. F.1-26/93-Lic (Vol. I)(M-205) dated 30-04-2007. **Shortcomings**: • Latest GMP inspection report (conducted within the period of last three years). • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Provide conversion of Colistin Sulphate from MIU to grams.

	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1251.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz PVP 10% Injection 100ml
	Composition	Each ml Contains: Oxytetracycline As Oxytetracycline HCl…100mg
	Diary No. Date of R& I & fee	Dy.No 9699 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml: Decontrolled
	Me-too status	EXY-PVP10 Injection (100ml) of M/s Attabak Pharmaceutical Industries, Islamabad (Reg. No. 034548)
	GMP status	
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
1252.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz PVP 10% Injection 50ml
	Composition	Each ml Contains: Oxytetracycline As Oxytetracycline HCl…100mg
	Diary No. Date of R& I & fee	Dy.No 9700 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	EXY-PVP10 Injection (50ml) of M/s Attabak Pharmaceutical Industries, Islamabad (Reg. No. 034548)
	GMP status	
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	
1253.	Name and address of manufacturer / Applicant	M/s Vetz Pharmaceutical (Pvt) Ltd, Plot # Q-1, S.I.T.E, Kotri, Sindh.
	Brand Name +Dosage Form + Strength	Oxyvetz 20% Injection
	Composition	Each ml Contains: Oxytetracycline as Oxytetracycline HCl…200mg
	Diary No. Date of R& I & fee	Dy.No 9701 dated 04-05-2020 Rs.20,000/- dated 04-05-2020
	Pharmacological Group	Antibacterial

	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml: Decontrolled
	Me-too status	Oxyta Injectable Solution (50ml) of M/s Alina Combine Pharmaceuticals (Pvt) Ltd., Karachi. (Reg. No. 048273)
	GMP status	
	Remarks of the Evaluator [X]	**Sterile Liquid Injection (Veterinary) Section** confirmed from panel inspection report conducted on 11-04-2015 for grant of DML. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years).
	Decision: Approved.	

Case No. 02 Registration applications of categories to be considered on priority

d. Export facilitation

Assistant Director PR-I/EFD vide letter NO.1-6/2019-PR-I (EFD) dated 29-12-2022 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the pharmaceutical i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision, **M/s Leads Pharma (Pvt.) Ltd, Islamabad** has achieved the benchmark of **134105.00 USD** during the fiscal Year **2019-2020** and **329260.00 USD** during the fiscal year **2020-2021.** Following applications submitted by the firm for priority consideration/ evaluation in lieu of export facilitation are submitted before the Board for its consideration please:

1254.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Til-Dox Powder
	Composition	Each 100gm contains: Doxycycline HCl…2000mg Tilmicosin Phosphate…2000mg
	Diary No. Date of R& I & fee	Dy.No 14864 dated 25-06-2020 Rs.20,000/- dated 24-06-2020
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100gm, 250gm, 500gm,1Kg, 2.5Kg, 5Kg: Decontrolled
	Me-too status	Not provided **Could not be confirmed in the applied combination**
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	The firm has submitted reference product: **Tilmi-Dox (Vietnam).** **Powder section I & II** confirmed vide panel inspection report for renewal of DML based on inspection conducted on 25-02-2020. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

1255.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	Meco Vit-1000 Injection
	Composition	Each ml Contains: Vitamin B12…1000mcg
	Diary No. Date of R& I & fee	Dy.No 18247 dated 29-06-2021 Rs.30,000/- dated 28-06-2021
	Pharmacological Group	Vitamin B12 Supplement
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml,50ml, 100ml: Decontrolled
	Me-too status	Cyanocob 1000 Injection (10ml, 50ml, 100ml) of M/s Prix Pharmaceutica (Pvt) Ltd., Lahore. (Reg. No. 074021)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	**Liquid Injection Vet (General)** section confirmed vide panel inspection report for renewal of DML based on inspection conducted on 25-02-2020. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved. Firm shall select one fill volume only before issuance of registration letter.	
1256.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.
	Brand Name +Dosage Form + Strength	E.C Max Liquid
	Composition	Each 100ml Contains: Enrofloxacin…20gm Colistin Sulphate…50,000,000 IU
	Diary No. Date of R& I & fee	Dy.No 18242 dated 29-06-2021 Rs.30,000/- dated 28-06-2021
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml,500ml, 1000ml: Decontrolled
	Me-too status	Floxicol Oral Liquid of M/s Biogen Pharma Rawat. (Reg. No. 058966)
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	**Oral Liquid section** confirmed vide panel inspection report for renewal of DML based on inspection conducted on 25-02-2020. **Shortcomings:** • Latest GMP inspection report (conducted within the period of last three years). • Provide conversion of Colistin Sulphate from IU to grams.
	Decision:	
1257.	Name and address of manufacturer / Applicant	M/s Leads Pharma Pvt Ltd., Plot No. 81-A, Street # 6, I-10/3, Islamabad.

	Brand Name +Dosage Form + Strength	Lefenac Injection
	Composition	Each ml Contains: Aceclofenac…25mg
	Diary No. Date of R& I & fee	Dy.No 18240 dated 29-06-2021 Rs.30,000/- dated 28-06-2021
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10ml,50ml, 100ml: Decontrolled
	Me-too status	**Registered with 10ml, 20ml and 50ml fill volume/pack sizes**
	GMP status	GMP of relevant section
	Remarks of the Evaluator [X]	**Liquid Injection Vet (General)** section confirmed vide panel inspection report for renewal of DML based on inspection conducted on 25-02-2020. **Shortcomings:** • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status), **with same fill volume/ pack size as applied,** alongwith registration number, brand name and name of firm
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	

e. Import applications of priority categories defined by DRAP Authority in its 129th meeting

i. Veterinary

a. New cases:

Priority Registration Applications

Drug Regulatory Authority of Pakistan in its 129th meeting held on 17th February, 2022 discussed the case regarding **"Priority Consideration of Applications for Registration Submitted After Cancellation of Their Renewal of Registration" vide Agenda Item No.V:.** Wherein, the Authority decided as under;

"The Authority acceded to the request of firms for out-of-queue submission and consideration of registration dossiers on CTD Format (5F) in regard to cancelled products due to late submission of renewals."

Accordingly, M/s Ghani Brothers, 2nd Floor, Karimje Building, Opp. Habib Bank Limited, Napair Road, Karachi has requested for priority consideration of their following product due to invalid registration status of previously registered product **Streptocin 5gm Injection (Registration No. 039971):**

1258.	Name and address of Applicant	M/s Ghani Brothers, 2nd Floor, Karimje Building, Opp. Habib Bank Limited, Napair Road, Karachi.
	Detail of Drug Sale License	Name: M/s Ghani Brothers Address: 2nd Floor, Karimje Building, Opp. Habib Bank Limited, Napair Road, Karachi Validity: 28-04-2023. Status: Drug License by Way of Whole Sale (Form No.7).
	Name and address of manufacturer	M/s Hebei Yuanzheng Pharmaceutical Co., Ltd. China No.16 Liuyuan Road, Chang' an District, Shijiazhuang City Hebei Province.
	Name and address of marketing authorization holder	M/s Wuhan Yibao Meheco Trading Co. Ltd., room 1102 Kaimeng Building Xinhua Road, Wuhan China

Name of exporting country	Peoples Rpublic of China
Type of Form	Form-5A
Diary No. & Date of R& I	Dy.No 38208 Dated 28-12-2022
Fee including differential fee	Rs : 1,50,000 Dated 20-12-2022
Brand Name +Dosage Form + Strength	Streptocin 5gm Injection
Composition	Each vial Contains: Streptomycin Sulphate…5gm Procain Penicillin…1,500,000 IU Benzyl Penicillin…500,000 IU
Finished Product Specification	Inhouse
Pharmacological Group	Antibiotics
Shelf life	4 years
Demanded Price	As per brand leader
Pack size	10vials
International availability	**N/A**
Me-too status	Not provided
Detail of certificates attached	• Legalized original COPP issued by Ministry of Agriculture of People's Republic of China Animal husbandry and Aquatic Products Bureau of Shijiazhuang City confirms GMP status of the manufacturer but does not confirm free sale status of the product in exporting country. • Originally Legalized GMP certificate No. 03008 dated 08-02-2022 issued by Hebei Animal Husbandry and Veterinary Bureau. (Scope does not cover Penicillin production line) • Copy of agreement dated 07-11-2022 between the marketing authorization holder and applicant.

Remarks of the Evaluator [X]

Sr.	Shortcoming	Reply of firm
a.	In submitted GMP certificate, scope of inspection does not cover penicillin production line and also the same could not be reflected from site master file. Provide legalized relevant document.	Submitted GMP covers all aspects of the veterinary manufacturing scope i.e., Large Volume Injection / Small volume Injection / Powder for Injection. GMP Generally does not specify products or its generic.
b.	The submitted COPP does not reflect free sale status of the applied product in country of origin; provide original legalized valid Free sale certificate.	Veterinary CoPP submitted clearly states **YES** to the point 1: "Is this product licensed to be placed on the market for use in the exporting country?" As we have already submitted the original legalized CoPP, there is no need to request and submitted FSC.
c.	Provide legalized original valid Letter of Authorization/ Sole agency certificate since already submitted document is scanned copy.	Submitted
d.	Provide valid copy of DSL	Submitted valid till 28-04-2023
e.	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.	Firm has submitted their previously granted registration letter of same product.
f.	In the finished product label the Urdu version of the following namely; (i) dosage; and (ii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.	Firm submitted an undertaking stating that they will submit it soon
g.	The submitted 48 months real time stability study data of 03 batches is not as per zone IV-A/IV-B conditions,	Firm has now submitted 06 months accelerated and 48 months real time stability studies data as per Zone IV-A conditions.

		provide stability studies data of three batches upto claimed shelf life as per zone IV-A conditions.	
	Decision: Approved as per policy of inspection of manufacturer abroad.		

Case No. 03 Registration applications of import cases

a. New Cases (Veterinary)

1259.	Name and address of Applicant	M/s Aves Care, P-63-Umer Housing Scheme, Near Younas Town/ Satiana Road, Faisalabad, Pakistan
	Detail of Drug Sale License	M/s Aves Care Address: P-63-Umer Housing Scheme, Near Younas Town/ Satiana Road, District Faisalabad. Validity: **27-04-2020** Status: License to sell drugs as a distribution (Form 11)
	Name and address of manufacturer	M/s Al-Mutawwaj Pharmaceutical Industries. Spectra Vet, King Abdullah II, Ibn Al-Hussein Industrial Zone, Sahab, Amman, Jordan Street 16, Building 401
	Name and address of marketing authorization holder	
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 13824 Dated 01-08-2019
	Fee including differential fee	Rs : 1,00,000 Dated 01-08-2019
	Brand Name +Dosage Form + Strength	Spectra Brom D.S Oral solution
	Composition	Each ml contains: Bromhexine HCl…10mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Mucolytic
	Shelf life	2 years
	Demanded Price	7.00 USD, 13.00 USD, 62.00 USD, and 10 USD
	Pack size	500ml, 1Liter, 5Liter and 10Liter
	International availability	N/A
	Me-too status	Bromexan Oral Solution of M/s. Vigilant Veterinary Services (Pvt) Ltd. Lahore. (Reg. No. 039949)
	Detail of certificates attached	**Not provided**
	Remarks of the Evaluator [X]	Provided 06 months accelerated and 24 months real time stability study data of 03 batches according to zone IV-A conditions. **Shortcomings:** • Provide legalized original valid COPP, GMP certificate, FSC and Letter of Authorization/ Sole agency certificate. • Provide valid copy of DSL • Provide evidence of pharmacopoeial reference of finished product specification. In case, the product is non pharmacopoeial, submit product specification in the light of decision taken in 267th meeting of Registration Board.

		• Submit fee Rs. 7500/- for revision of finished product specifications.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1260.	Name and address of Applicant	M/s Aves Care, P-63-Umer Housing Scheme, Near Younas Town/ Satiana Road, Faisalabad, Pakistan
	Detail of Drug Sale License	M/s Aves Care Address: P-63-Umer Housing Scheme, Near Younas Town/ Satiana Road, District Faisalabad. Validity: **27-04-2020** Status: License to sell drugs as a distribution (Form 11)
	Name and address of manufacturer	M/s Al-Mutawwaj Pharmaceutical Industries. Spectra Vet, King Abdullah II, Ibn Al-Hussein Industrial Zone, Sahab, Amman, Jordan Street 16, Building 401
	Name and address of marketing authorization holder	M/s Al-Mutawwaj Pharmaceutical Industries. Spectra Vet, King Abdullah II, Ibn Al-Hussein Industrial Zone, Sahab, Amman, Jordan Street 16, Building 401
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 13825 Dated 01-08-2019
	Fee including differential fee	Rs : 1,00,000 Dated 01-08-2019
	Brand Name +Dosage Form + Strength	Spectra Flor Oral Solution
	Composition	Each ml contains: Florfenicol…100mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	3 years
	Demanded Price	14.67 USD, 35.17 USD, 69.70 USD, and 137.40 USD
	Pack size	1Liter, 2.5Liter, 5Liter and 10Liter
	International availability	N/A
	Me-too status	Fenmit 10% Solution of M/s Wimits Pharmaceuticals (Pvt.) Ltd, Lahore. (Reg. No. 103979)
	Detail of certificates attached	Originally legalized CoPP certificate (No. 001882) dated 27-02-2019 issued by The Ministry of Agriculture, veterinary Department, Jordan. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site. Original legalized Authorization Letter dated 14-01-2019 for **Spectra Tilcosin** is provided, provide Original legalized valid LOA/sole agency certificate for the applied product.
	Remarks of the Evaluator [X]	Provided 06 months accelerated and 36 months real time stability study data of 03 batches according to zone IV-A conditions. **Shortcomings:** • Provide legalized original valid Letter of Authorization/ Sole agency certificate for the applied product, since LOA for **Spectra Tilcosin** is provided. • Provide valid copy of DSL • Provide evidence of pharmacopoeial reference of finished product specification. In case, the product is non pharmacopoeial, submit product specification in the light of decision taken in 267th meeting of Registration Board. • Submit fee Rs. 7500/- for revision of finished product specifications.

	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1261.	Name and address of Applicant	M/s Cherry Pharmaceutica International, 14-E, Ground Floor/Basement Punjab Cooperative Housing Society, Ghazi Road, Lahore Cantt. Pakistan
	Detail of Drug Sale License	M/s Cherry Pharmaceutica International Address: 14-E, Ground Floor/Basement Punjab Cooperative Housing Society, Ghazi Road, District Lahore Validity: **20-12-2019** Status: License to sell drugs as a distribution (Form 11)
	Name and address of manufacturer	M/s Mevet S.A.U. Pol. Ind. El Segre, P.409-410, 25191 LLEIDA, Spain
	Name and address of marketing authorization holder	M/s Mevet S.A.U. Pol. Ind. El Segre, P.409-410, 25191 LLEIDA, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16834 Dated 04-09-2019
	Fee including differential fee	Rs : 1,00,000 Dated 04-09-2019
	Brand Name +Dosage Form + Strength	Colivall 2,000,000 IU/ml Solution for use in Drinking Water or Milk
	Composition	Each ml Contains: Colistin (Sulphate)…2000,000 IU
	Finished Product Specification	Inhouse
	Pharmacological Group	Intestinal antiinfectives, antibiotics
	Shelf life	36 months
	Demanded Price	N/A
	Pack size	1Liter, 5Liter
	International availability	**Approved in Spain**
	Me-too status	Mili Coli 20 Oral Liquid of M/s Mili Vet Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 112193)
	Detail of certificates attached	Originally legalized FSC certificate dated 18-06-2018 issued by Spanish Agency for Medicines and Health Products confirms free sale status of the product in exporting Scanned copy of GMP certificate No. DU9761787 dated 28-30 May, 2017 issued by the Ministry of Health, social services and equality. Scanned copy of agreement dated 11-12-2018 between the Principal and applicant.
	Remarks of the Evaluator [X]	Provided 06 months accelerated and 36 months real time stability study data of 03 batches according to zone IV-B conditions. **Shortcomings:** • Provide legalized original valid Letter of Authorization/ Sole agency certificate and GMP certificate, since already submitted documents are scanned copies. • Provide valid copy of DSL • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Deferred for submission of following: • **Valid copy of DSL.** • **Valid notarized copy of Letter of Authorisation/Sole Agency Agreement.**	

	• **Valid original legalized GMP Certificate**	
1262.	Name and address of Applicant	M/s Atzan Pharmaceuticals, 13-E, Commercial Area, Aziz Bhatti Town, Sargodha, Pakistan
	Detail of Drug Sale License	Name: M/s Atzan Pharmaceutical Address: 13-E, Commercial Area, Aziz Bhatti Town, Sargodha, Pakistan. Validity: **07-11- 2027.** Status: License to sell drugs as a Distributor (Form No.11).
	Name and address of manufacturer	M/s Vietnam Sakan Technology Development & Investment Joint Stock Company, Lot D1-D4, Dong Tho Industrial Complex, Yen Phong District, Bac Ninh Province, Vietnam
	Name and address of marketing authorization holder	M/s Vietnam Sakan Technology Development & Investment Joint Stock Company, Lot D1-D4, Dong Tho Industrial Complex, Yen Phong District, Bac Ninh Province, Vietnam
	Name of exporting country	The Socialist Republic of Vietnam
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 6798 Dated 25-11-2019
	Fee including differential fee	Rs : 1,00,000 Dated 22-11-2019
	Brand Name +Dosage Form + Strength	Zoflor 23% Oral Solution
	Composition	Each 100ml Contains: Florfenicol…23gm
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	24 months
	Demanded Price	Decontrolled
	Pack size	20gml 50ml, 100ml
	International availability	N/A
	Me-too status	Floskill-23% Liquid of M/s Bioskils Pharmaceuticals, District Gujranwala. (Reg. No. 113510)
	Detail of certificates attached	➢ Original Legalized Free Sale Certificate No. 799/2019/QLT-CFS issued by Ministry of Agriculture and Rural development department of Animal Health 15/78 GiaiPhong Street- DongDa- HaNoi- Vietnam Date of issuance: 15-08-2019 ➢ Photocopy of GMP certificate No.23/22/GCN0GMP issued on 25-07-2022 and valid for 5 years. ➢ Letter of Authorization/Sole Agency Certificate dated 01-06-2019.
	Remarks of the Evaluator [X]	• 6 months accelerated and 24 months long term stability studies data has been submitted as per zone-IV-A conditions. • Provided valid copy of DSL **Shortcomings:** • Submitted photocopy of GMP certificate provide legalized original GMP certificate.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit valid, original & legalized Free sale & GMP certificate or CoPP before issuance of registration letter.	
1263.	Name and address of Applicant	M/s Geevet International, Office No. 11/12, First Floor, Naz Medicine Market, Namak Mandi, Peshawar, Pakistan
	Detail of Drug Sale License	**Not provided**
	Name and address of manufacturer	M/s Inner Mangolia Huatian Pharmaceutical Co. Ltd. Development & Experiment Zone for Transformation of Resource Dependant City, Chifeng, Inner Mangolia, China

	Name and address of marketing authorization holder	M/s Inner Mangolia Huatian Pharmaceutical Co. Ltd. Development & Experiment Zone for Transformation of Resource Dependant City, Chifeng, Inner Mangolia, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 20169 Dated 09-10-2019
	Fee including differential fee	Rs : 1,00,000 Dated 09-10-2019
	Brand Name +Dosage Form + Strength	Florcid Gold 23% Oral Solution
	Composition	Each 100ml Contains: Florfenicol…23gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotic
	Shelf life	24 months
	Demanded Price	Decontrolled
	Pack size	100ml
	International availability	N/A
	Me-too status	Floskill-23% Liquid of M/s Bioskils Pharmaceuticals, District Gujranwala. (Reg. No. 113510)
	Detail of certificates attached	➢ CoPP and Free Sale Certificate not provided ➢ Copy of GMP certificate No. 2018 GMP 05019 valid till 02-07-2023 ➢ Letter of Authorization/Sole Agency Certificate not provided
	Remarks of the Evaluator [X]	• Submitted scanned copy of GMP certificate is expired now but valid upon submission, provide legalized original valid relevant GMP certificate. • Provide legalized original valid CoPP and FSC. • Provide valid copy of DSL • Submit long term stability studies data as per zone-IV-A conditions upto claimed shelf life. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1264.	Name and address of Applicant	M/s Vet Line International, 939-A, Block-J, Phase-1, LDA Avenue-1, Lahore, Pakistan
	Detail of Drug Sale License	Name: M/s Vet Line International Address: 939-A, Block-J, Phase-1, LDA Avenue-1, Lahore. Validity: 13-02-2023. Status: License to sell drugs as a Distributor (Form No.11).
	Name and address of manufacturer	M/s Range Pharma Sdn. Bhd. No.1, Jalan TSB 11, Taman Industri Sungai Buloh, 47000 Sungai Buloh, Selangor Darul Ehsan, Malaysia
	Name and address of marketing authorization holder	M/s Range Pharma Sdn. Bhd. No.1, Jalan TSB 11, Taman Industri Sungai Buloh, 47000 Sungai Buloh, Selangor Darul Ehsan, Malaysia
	Name of exporting country	Malaysia
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23386 Dated 11-11-2019
	Fee including differential fee	Rs : 1,00,000 Dated 11-11-2019

	Brand Name +Dosage Form + Strength	Seftiovet 5% Injection
	Composition	Each ml Contains: Ceftiofur as HCl…50mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100ml
	International availability	N/A
	Me-too status	Calicef 50mg Suspension for Injection (100ml) of M/s Orient Animal Health (Pvt) Ltd. Karachi (Reg. No. 108996)
	Detail of certificates attached	➢ Original legalized CoPP No. 0402H/2019 dated 27-07-2017 issued by Malaysia Drug Control Authority confirms free sale status in exporting country as well as GMP status of the manufacturer. ➢ The scope of original legalized GMP certificate No. 1272/19 dated 03-07-2019 issued by National Pharmaceutical Regulatory Agency Ministry of Health Malaysia covers Manufacturing operations related to Penicillin and Cephalosporin. ➢ Legalized Agency agreement dated 01-07-2019 between PLH and applicant
	Remarks of the Evaluator [X]	6 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit valid DSL before issuance of registration letter.	
1265.	Name and address of Applicant	M/s Ghazi Brothers, Ghazi House, D-35, K.D.A Scheme No.1, Miran Muhammad Shah Road, Karachi-75350, Pakistan
	Detail of Drug Sale License	Name: M/s Ghazi Brothers Address: D-35, K.D.A Scheme No.1, Miran Muhammad Shah Road, Karachi Validity: 29-06-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Richter Pharma, AG, Durisolstrabe 14, 4600 Wels, Austria
	Name and address of marketing authorization holder	M/s Richter Pharma, AG, Durisolstrabe 14, 4600 Wels, Austria.
	Name of exporting country	Austria
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23013 Dated 07-11-2019
	Fee including differential fee	**Rs : 50,000** Dated 06-11-2019
	Brand Name +Dosage Form + Strength	Butomidor 10mg/ml Solution for Injection
	Composition	Each ml contains: Butorphanol Tartrate Corresponding To 10mg Butorphanol…14.58mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Morphinan derivatives **Indications:**

		HORSE As an analgesic For the short term relief of pain such as colic of gastrointestinal tract origin. As a sedative and pre-anaesthetic In combination with α2-adrenoceptor agonists (detomidine, romifidine, xylazine): For therapeutic and diagnostic procedures such as minor standing surgery and sedation of intractable patients. DOG/CAT As an analgesic For relief of moderate visceral pain e.g. pre- and post-surgical as well as post-traumatic pain. As a sedative In combination with α2-adrenoceptor agonists (medetomidine). As a pre-anaesthetic Part of anaesthetic regime (medetomidine, ketamine).
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	Not mentioned
	International availability	Austria approved
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	➢ Original Legalized COPP Certificate No. 11991657 issued by BASG/ AGES Traisengasse 5, A-1200 Wien confirms free sale status in exporting country as well as GMP status of the manufacturer. Date of issuance: 30-04-2019 ➢ Original Legalized Power of attorney dated 09-05-2019
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Approved as per policy of inspection of manufcaturer abroad.	
1266.	Name and address of Applicant	M/s Hassan Brothers, House No. 318, Street No.6, Fatehabad Sharqi, Satiana Road, Faisalabad
	Detail of Drug Sale License	Name: M/s Hassan Brothers Address: House No. 318, Street No.6, Fatehabad Sharqi, Satiana Road, Faisalabad Validity: 29-03-2027. Status: License to sell drugs as a Distributor (Form No.11). (computer generated copy submitted)
	Name and address of manufacturer	M/s Samyang Anipharm Co. Ltd. 6-5, Tongil-Ro 83-Gil, Eupyeong-Gu, Seoul, Korea
	Name and address of marketing authorization holder	M/s Samyang Anipharm Co. Ltd. 6-5, Tongil-Ro 83-Gil, Eupyeong-Gu, Seoul, Korea
	Name of exporting country	Korea
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 13117 Dated 25-07-2019
	Fee including differential fee	Rs : 100,000 Dated 25-07-2019
	Brand Name +Dosage Form + Strength	Forcetil Oral Solution

	Composition	Each Liter Contains: Tilmicosin Phosphate…250gm (activity)
	Finished Product Specification	USP specifications
	Pharmacological Group	Antimicrobial
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	500ml, 1Liter, 2.5Liter, 5Liter
	International availability	N/A
	Me-too status	Tl-Cin Oral Liquid of M/s Eterna Pharma (Pvt) Ltd., Mirpur, Ajk. (Reg. No. 109225)
	Detail of certificates attached	➢ Original Legalized Free Sale Certificate No. M1905954 issued by Animal and Plant Quarantine Agency of the Ministry for Agriculture Food and rural Affairs of the republic of Korea declaring the free sale of applied product in country of origin Date of issuance: 23-04-2019 ➢ Original legalized GMP certificate issued by Animal and Plant Quarantine Agency of the Ministry for Agriculture Food and rural Affairs of the republic of Korea ➢ Letter of Authorization/Sole Agency Certificate between PLH and Applicant
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions.
	Decision: Approved as per policy of inspection of manufcaturer abroad.	
1267.	Name and address of Applicant	M/s Chappal Enterprises, G8, Muhammadi Trade Tower, Opposite Adam Chamber, Altaf Hussain Road, New Challi, Karachi
	Detail of Drug Sale License	Name: M/s Chappal Enterprises Address: Suit No. 4/23 Arkay Square Extension New Chali Shahra e Liaquat, Karachi Validity: 08-06-2019. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name and address of marketing authorization holder	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16078 Dated 29-08-2019
	Fee including differential fee	Rs : 100,000 Dated 29-08-2019
	Brand Name +Dosage Form + Strength	Velosin-200 Injection
	Composition	Each 100ml Contains: Tylosin Tartrate…20gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	50ml x 120vials, 100ml x 80vials
	International availability	N/A
	Me-too status	Not provided.
	Detail of certificates attached	➢ Original Legalized CoPP No.181100B0/065900 declaring the applied product **is neither licensed to be placed on**

		market nor actually in the market of exporting country country of origin. ➢ Scanned copy of GMP certificate submitted valid till 22-04-2020 ➢ Letter of Authorization dated 25-04-2018 between PLH and Applicant
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Provide original legalized valid Free sale certificate. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1268.	Name and address of Applicant	M/s Chappal Enterprises, G8, Muhammadi Trade Tower, Opposite Adam Chamber, Altaf Hussain Road, New Challi, Karachi
	Detail of Drug Sale License	Name: M/s Chappal Enterprises Address: Suit No. 4/23 Arkay Square Extension New Chali Shahra e Liaquat, Karachi Validity: 08-06-2019. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name and address of marketing authorization holder	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16080 Dated 29-08-2019
	Fee including differential fee	Rs : 100,000 Dated 29-08-2019
	Brand Name +Dosage Form + Strength	Vegentan-100 Injection
	Composition	Each 100ml Contains: Gentamycin…10gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100ml x 80vials
	International availability	N/A
	Me-too status	Not provided.
	Detail of certificates attached	➢ Original Legalized CoPP No.181100B0/065897 declaring the applied product **is neither licensed to be placed on market nor actually in the market of exporting country country of origin.** ➢ Scanned copy of GMP certificate submitted valid till 22-04-2020 ➢ Letter of Authorization dated 25-04-2018 between PLH and Applicant

	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Provide original legalized valid Free sale certificate. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1269.	Name and address of Applicant	M/s Chappal Enterprises, G8, Muhammadi Trade Tower, Opposite Adam Chamber, Altaf Hussain Road, New Challi, Karachi
	Detail of Drug Sale License	Name: M/s Chappal Enterprises Address: Suit No. 4/23 Arkay Square Extension New Chali Shahra e Liaquat, Karachi Validity: 08-06-2019. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name and address of marketing authorization holder	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16077 Dated 29-08-2019
	Fee including differential fee	Rs : 100,000 Dated 29-08-2019
	Brand Name +Dosage Form + Strength	Vetoxy-200 Injection
	Composition	Each 100ml Contains: Oxytetracycline HCl…20gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100ml x 80 vials
	International availability	N/A
	Me-too status	Not provided.
	Detail of certificates attached	➢ Original Legalized CoPP No.181100B0/065901 confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Letter of Authorization dated 25-04-2018 between PLH and Applicant
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.

		• In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1270.	Name and address of Applicant	M/s Chappal Enterprises, G8, Muhammadi Trade Tower, Opposite Adam Chamber, Altaf Hussain Road, New Challi, Karachi
	Detail of Drug Sale License	Name: M/s Chappal Enterprises Address: Suit No. 4/23 Arkay Square Extension New Chali Shahra e Liaquat, Karachi Validity: 08-06-2019. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name and address of marketing authorization holder	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16079 Dated 29-08-2019
	Fee including differential fee	Rs : 100,000 Dated 29-08-2019
	Brand Name +Dosage Form + Strength	Vevermec 2% Injection
	Composition	Each 100ml Contains: Ivermectin…2gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	50ml x 120 vials
	International availability	N/A
	Me-too status	Not provided.
	Detail of certificates attached	➢ Original Legalized CoPP No.181100B0/065899 confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Letter of Authorization dated 25-04-2018 between PLH and Applicant
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.

	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1271.	Name and address of Applicant	M/s Chappal Enterprises, G8, Muhammadi Trade Tower, Opposite Adam Chamber, Altaf Hussain Road, New Challi, Karachi
	Detail of Drug Sale License	Name: M/s Chappal Enterprises Address: Suit No. 4/23 Arkay Square Extension New Chali Shahra e Liaquat, Karachi Validity: 08-06-2019. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name and address of marketing authorization holder	M/s Hebei Veyong Animal Pharmaceutical Co., Ltd. No. 68, Ganjiang Road, Shijiazhuang, Hebei, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 16076 Dated 29-08-2019
	Fee including differential fee	Rs : 100,000 Dated 29-08-2019
	Brand Name +Dosage Form + Strength	Veflorn-200 Injection
	Composition	Each 100ml Contains: Florfenicol…20gm
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	50ml x 120 vials
	International availability	N/A
	Me-too status	Not provided.
	Detail of certificates attached	➢ Original Legalized CoPP No.181100B0/065898 confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Letter of Authorization dated 25-04-2018 between PLH and Applicant
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1272.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2024. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Kepro B.V.

		Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name and address of marketing authorization holder	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name of exporting country	Holland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 21732 Dated 23-10-2019
	Fee including differential fee	Rs : 100,000 Dated 23-10-2019
	Brand Name +Dosage Form + Strength	Doxyvet 200 WSP
	Composition	Each Gram Contains: Doxycycline Hyclate…200mg
	Finished Product Specification	
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100gm, 500gm, 1000gm
	International availability	N/A
	Me-too status	Eter Doxycycline -20 Powder of M/s Eterna Pharma (Pvt) Ltd., MIRPUR, AJK. (Reg. No.109847)
	Detail of certificates attached	➢ Original Legalized CoPP No.251242 dated 02-05-2019 issued by Ministry of Agriculture, Nature and Food Quality of the Netherlands confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 24-11-2015 between PLH and Applicant
	Remarks of the Evaluator [X]	• Provided 06 months accelerated and 36 months real time stability study data of 03 batches according to zone IV-A conditions. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL and firm has submitted revised Form-5A with correct address as on DSL **without submission of fee.** **Shortcomings:** • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Approved as per policy of inspection of manufcaturer abroad. The firm shall submit full fee of registration for correction/pre-approval change in DSL address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1273.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2024. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name and address of marketing authorization holder	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name of exporting country	Holland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 21731 Dated 23-10-2019
	Fee including differential fee	Rs : 100,000 Dated 23-10-2019

	Brand Name +Dosage Form + Strength	Penstrep 20/25 Injection
	Composition	Each ml Contains: Procaine Penicillin G……...200mg Dihydrostreptomycin Sulphate…250mg
	Finished Product Specification	
	Pharmacological Group	Antibiotics
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	50ml, 100ml, 250ml, 500ml
	International availability	N/A
	Me-too status	Di Strep Procaine 200/250 Injection of M/s Eterna Pharma (Pvt) Ltd., MIRPUR, AJK. (Reg. No. 112332)
	Detail of certificates attached	➢ Original Legalized CoPP No.251247 dated 06-05-2019 issued by Ministry of Agriculture, Nature and Food Quality of the Netherlands confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 24-11-2015 between PLH and Applicant
	Remarks of the Evaluator [X]	• The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL and firm has submitted revised Form-5A with correct address as on DSL **without submission of fee.** • Initially, multiple pack sizes (50ml, 100ml, 250ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **100ml pack size**. **Shortcomings:** • **The firm shall submit full fee of registration for correction/pre-approval change in DSL address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.** • Confirmation of dedicated manufacturing facility. • Submit both accelerated and long term stability studies data as per zone-IV-A conditions upto claimed shelf life. • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1274.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2024. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name and address of marketing authorization holder	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name of exporting country	Holland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 21735 Dated 23-10-2019

	Fee including differential fee	Rs : 100,000 Dated 23-10-2019
	Brand Name +Dosage Form + Strength	Oxy 200 WSP
	Composition	Each Gram Contains: Oxytetracycline HCl…200mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotics
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg
	International availability	N/A
	Me-too status	Hans-Cycline 20% Powder of M/s D-Haans Pharmaceuticals, Bhimber, Azad Kashmir. (Reg. No. 102220)
	Detail of certificates attached	➢ Original Legalized CoPP No.251247 dated 06-05-2019 issued by Ministry of Agriculture, Nature and Food Quality of the Netherlands confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 24-11-2015 between PLH and Applicant
	Remarks of the Evaluator [X]	• Provided 06 months accelerated and 36 months real time stability study data of 03 batches according to zone IV-A conditions. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL and firm has submitted revised Form-5A with correct address as on DSL **without submission of fee.**
	Decision: Approved as per policy of inspection of manufcaturer abroad. The firm shall submit full fee of registration for correction/pre-approval change in DSL address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1275.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2024. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name and address of marketing authorization holder	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name of exporting country	Holland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 21734 Dated 23-10-2019
	Fee including differential fee	Rs : 100,000 Dated 23-10-2019
	Brand Name +Dosage Form + Strength	Vit AD3E 300 Injection
	Composition	Each ml Contains: Vitamin A…300,000 IU Vitamin D3…100,000 IU Vitamin E…50mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Vitamins
	Shelf life	2 years
	Demanded Price	Decontrolled

	Pack size	50ml, 100ml, 250ml, 500ml
	International availability	N/A
	Me-too status	**Could not be confirmed in the applied strength.**
	Detail of certificates attached	➢ Original Legalized CoPP No.251247 dated 06-05-2019 issued by Ministry of Agriculture, Nature and Food Quality of the Netherlands confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 24-11-2015 between PLH and Applicant
	Remarks of the Evaluator [X]	• Provided 06 months accelerated and 24 months real time stability study data of 03 batches according to zone IV-A conditions. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL and firm has submitted revised Form-5A with correct address as on DSL **without submission of fee.** • Initially, multiple pack sizes (50ml, 100ml, 250ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **100ml pack size**. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Approved as per policy of inspection of manufcaturer abroad for 100ml pack size only. The firm shall submit full fee of registration for correction/pre-approval change in DSL address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1276.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2024. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name and address of marketing authorization holder	M/s Kepro B.V. Maagdenburgstraat 17, 7421 ZA Deventer, Holland
	Name of exporting country	Holland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 21733 Dated 23-10-2019
	Fee including differential fee	Rs : 100,000 Dated 23-10-2019
	Brand Name +Dosage Form + Strength	Vitaflash Injection
	Composition	Each ml Contains: Vitamin A…50,000 IU Vitamin D3…25,000 IU Vitamin E…4mg Vitamin B1 HCl…2.5mg Vitamin B2 Phosphate Sodium…2mg Vitamin B3…12.5mg Vitamin B6 HCl…1.25mg Vitamin B12…30µg Vitamin C…2mg D-Panthenol…3mg
	Finished Product Specification	Inhouse

	Pharmacological Group	Vitamins
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	50ml, 100ml, 250ml, 500ml
	International availability	N/A
	Me-too status	Pri- Becovit Injection (100ml) of M/S Prix Pharmaceutica, Lahore. (Reg. No. 099073)
	Detail of certificates attached	➢ Original Legalized CoPP No.251244 dated 06-05-2019 issued by Ministry of Agriculture, Nature and Food Quality of the Netherlands confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 24-11-2015 between PLH and Applicant
	Remarks of the Evaluator [X]	• Provided 06 months accelerated and 24 months real time stability study data of 03 batches according to zone IV-A conditions. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL and firm has submitted revised Form-5A with correct address as on DSL **without submission of fee.** • Initially, multiple pack sizes (50ml, 100ml, 250ml, 500ml) of injectable dosage form were demanded in a single application. Now, the firm has demanded **100ml pack size**.
	Decision: Approved as per policy of inspection of manufcaturer abroad for 100ml pack size only. The firm shall submit full fee of registration for correction/pre-approval change in DSL address as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021 before issuance of registration letter.	
1277.	Name and address of Applicant	M/s Samara Stores, 17 Qamar Market Unit No 7, Latifabad, Hyderabad, Pakistan
	Detail of Drug Sale License	**Not provided**
	Name and address of manufacturer	M/s The Arab Pecticides & Veterinary Drugs Mfg. Co. Factory/El-Hassan Industrial Estate-Ibrid
	Name and address of marketing authorization holder	M/s The Arab Pecticides & Veterinary Drugs Mfg. Co. Factory/El-Hassan Industrial Estate-Ibrid
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 15556 Dated 26-08-2019
	Fee including differential fee	Rs : 100,000 Dated 26-08-2019
	Brand Name +Dosage Form + Strength	Bisolvet 2% Oral Solution
	Composition	Each 1ml Contains: Bromhexine HCl…20mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Expectorant
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	500ml, 1L, 2.5L
	International availability	N/A
	Me-too status	**Could not be confirmed in the applied strength**
	Detail of certificates attached	➢ Original Legalized Free Sale Certificate No. 003473 issued by minister of Agriculture and Minister of Environment Jordan declaring the free sale of applied product in country of origin Date of issuance: 08-04-2019

		➢ Original legalized GMP certificate No. 003479 dated 08-04-2019 issued by minister of Agriculture and Minister of Environment Jordan, with validity: 3 years. ➢ Letter of Authorization/Sole Agency Certificate between PLH and Applicant **is not provided**
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Provide original legalized valid GMP certificate since the already submitted is expired now but valid upon submission. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Provide Letter of Authorization/Sole Agency Certificate between PLH and Applicant
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1278.	Name and address of Applicant	M/s Samara Stores, 17 Qamar Market Unit No 7, Latifabad, Hyderabad, Pakistan
	Detail of Drug Sale License	**Not provided**
	Name and address of manufacturer	M/s The Arab Pecticides & Veterinary Drugs Mfg. Co. Factory/El-Hassan Industrial Estate-Ibrid
	Name and address of marketing authorization holder	M/s The Arab Pecticides & Veterinary Drugs Mfg. Co. Factory/El-Hassan Industrial Estate-Ibrid
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 15555 Dated 26-08-2019
	Fee including differential fee	Rs : 100,000 Dated 26-08-2019
	Brand Name +Dosage Form + Strength	Amprosol 2% Oral Liquid
	Composition	Each 1ml Contains: Amproxol HCl…20mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Expectorant
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	500ml, 1L, 2.5L
	International availability	N/A
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	➢ Original Legalized Free Sale Certificate No. 010895 issued by minister of Agriculture and Minister of Environment Jordan declaring the free sale of applied product in country of origin Date of issuance: 13-12-2018 ➢ Original legalized GMP certificate No. 010894 dated 13-12-2018 issued by minister of Agriculture and Minister of Environment Jordan, with validity: 3 years. ➢ Letter of Authorization/Sole Agency Certificate between PLH and Applicant **is not provided**
	Remarks of the Evaluator [X]	• 06 months accelerated and 24 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:**

		• Provide valid copy of DSL • Provide original legalized valid GMP certificate since the already submitted is expired now but valid upon submission. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • Provide Letter of Authorization/Sole Agency Certificate between PLH and Applicant
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1279.	Name and address of Applicant	M/s Qualivet Pharma, No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Qualivet Pharma Address: No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi. Validity: 214-10-2024 Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Laboratories Karizoo S.A. Pol. Ind. La Borda, Mas Pujades,11-12,08140 Caldes de Montbui, Barcelona, Spain
	Name and address of marketing authorization holder	M/s Vetpharma Animal Health, S.L. Les Corts, 23 08028 Barcelona, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23546 Dated 12-11-2019
	Fee including differential fee	Rs : 100,000 Dated 12-11-2019
	Brand Name +Dosage Form + Strength	Powdox 500mg/g Water Soluble Powder
	Composition	Each gram contains: Doxycycline as Hyclate…500mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antimicrobial
	Shelf life	36 months
	Demanded Price	Decontrolled
	Pack size	200gm, 1Kg
	International availability	N/A
	Me-too status	Doxiciclina 50% Water Soluble Powder M/s BinSadiq International, Lahore. (Reg. No. 088648)
	Detail of certificates attached	➢ Scanned copy of CoPP dated 31-01-2019 issued by Spanish agency of Medicines and Medical Devices, Spain confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 26-03-2019 between PLH and Applicant, valid for 5 years
	Remarks of the Evaluator [X]	• 06 months accelerated and 36 months long term stability studies data has been submitted as per zone-IV-A conditions. **Shortcomings:** • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.

	Decision: Approved as per policy of inspection of manufcaturer abroad.	
1280.	Name and address of Applicant	M/s Qualivet Pharma, No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Qualivet Pharma Address: No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi. Validity: 214-10-2024. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Laboratories Karizoo S.A. Pol. Ind. La Borda, Mas Pujades,11-12,08140 Caldes de Montbui, Barcelona, Spain
	Name and address of marketing authorization holder	M/s Vetpharma Animal Health, S.L. Les Corts, 23 08028 Barcelona, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23547 Dated 12-11-2019
	Fee including differential fee	Rs : 100,000 Dated 12-11-2019
	Brand Name +Dosage Form + Strength	Disentin 125mg/ml Oral Solution
	Composition	Each ml Contains: Tiamulin Hydrogen Fumarate…125mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antimicrobial
	Shelf life	36 months
	Demanded Price	Decontrolled
	Pack size	100ml, 1L, 5L
	International availability	N/A
	Me-too status	Tolectin Oral Solution of M/s Mylab (Pvt) Ltd, Khankah Sharif, Bahawalpur. (Reg. No. 101460)
	Detail of certificates attached	➢ Scanned copy of CoPP dated 31-01-2019 issued by Spanish agency of Medicines and Medical Devices, Spain confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 26-03-2019 between PLH and Applicant, valid for 5 years
	Remarks of the Evaluator [X]	**Shortcomings:** • Provide 06 months accelerated and 36 months long term stability studies data as per zone-IV-A conditions.
	Decision: Approved as per policy of inspection of manufcaturer abroad. **The firm shall submit valid original legalized COPP before issuance of regisration letter.**	
1281.	Name and address of Applicant	M/s Qualivet Pharma, No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Qualivet Pharma Address: No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi. Validity: 14-10-2024. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Laboratories Karizoo S.A. Pol. Ind. La Borda, Mas Pujades,11-12,08140 Caldes de Montbui, Barcelona, Spain
	Name and address of marketing authorization holder	M/s Vetpharma Animal Health, S.L. Les Corts, 23 08028 Barcelona, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23544 Dated 12-11-2019

	Fee including differential fee	Rs : 100,000 Dated 12-11-2019
	Brand Name +Dosage Form + Strength	Maxyl 500mg/g Water Soluble Powder
	Composition	Each gram Contains: Amoxicillin Trihydrate…500mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	24 months
	Demanded Price	Decontrolled
	Pack size	400gm, 1Kg
	International availability	N/A
	Me-too status	Amcorox-50% Water Soluble Powder of M/s Vetrox Pharmaceutical Pvt Ltd, Toba Tek Singh. (Reg. No. 112341)
	Detail of certificates attached	➢ Scanned copy of CoPP dated 31-01-2019 issued by Spanish agency of Medicines and Medical Devices, Spain confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ GMP certificate No. ES/135HV/19 dated 18-10-2019 issued by Spanish agency of Medicines and Medical Devices, Spain confirms the scope of manufacturing operations of β-Lactam antibiotics (Non-sterile solid dosage forms) ➢ Agreement dated 26-03-2019 between PLH and Applicant, valid for 5 years
	Remarks of the Evaluator [X]	Provided 06 months accelerated and 36 months long term stability studies data as per zone-IV-A conditions.
	Decision: Deferred for clarification of the manufacturing facility, whether Cephalospoirn & Penicillin formulations are manufactured in same section or otherwise.	
1282.	Name and address of Applicant	M/s Qualivet Pharma, No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Qualivet Pharma Address: No. 5/15, Ground Floor, Survey No. 79, Golden Town, Karachi. Validity: 14-10-2024. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Laboratories Karizoo S.A. Pol. Ind. La Borda, Mas Pujades,11-12,08140 Caldes de Montbui, Barcelona, Spain
	Name and address of marketing authorization holder	M/s Vetpharma Animal Health, S.L. Les Corts, 23 08028 Barcelona, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 23545 Dated 12-11-2019
	Fee including differential fee	Rs : 100,000 Dated 12-11-2019
	Brand Name +Dosage Form + Strength	Nifencol 100mg/ml Oral Solution
	Composition	Each ml Contains: Florfenicol…100mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antimicrobial
	Shelf life	36 months
	Demanded Price	Decontrolled
	Pack size	100ml, 1L, 5L
	International availability	N/A

	Me-too status	Kariflor 100mg Solution For Oral Administration of M/S. Unicare Enterprises, Faisalabad. (Reg. No.111214)
	Detail of certificates attached	➢ Scanned copy of CoPP dated 31-01-2019 issued by Spanish agency of Medicines and Medical Devices, Spain confirming the free sale status in exporting country as well as GMP status of the manufacturer ➢ Agreement dated 26-03-2019 between PLH and Applicant, valid for 5 years
	Remarks of the Evaluator [X]	Provided 06 months accelerated and 36 months long term stability studies data as per zone-IV-A conditions.
	Decision: Approved as per policy of inspection of manufcaturer abroad. The firm shall submit valid original legalized COPP & valid DSL, before issuance of regisration letter.	
1283.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26140 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Trimectin Cattle Suspension
	Composition	Each ml Contains: Ivermectin…2mg Triclabendazole…120mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Anthelmintic
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml, 500ml, 1Liter
	International availability	N/A
	Me-too status	Not provided
	Detail of certificates attached	• Original Legalized COPP NO. 8343 dated 25-09-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Original Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.

	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1284.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26139 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Enterocillin Plus Powder
	Composition	Each 1gm contains: Amoxicillin Trihydrate…200mg Colistin Sulphate…600,000 IU
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	04 Years
	Demanded Price	N/A
	Pack size	100gm, 500gm, 1Kg
	International availability	N/A
	Me-too status	Kepro Amoxy-Col WSP of M/s Better Traders International, Faisalabad. (Reg. No. 049737)
	Detail of certificates attached	• Original Legalized COPP NO. 8461 dated 29-09-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Scanned copy of legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 48months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**:

		• Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board deferred the case for submission of reply to the following shortcomings within six months.	
1285.	Name and address of Applicant	M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Minaa Medicose Address: Katchi Gali No.2, Marriott Road, Denson Hall, Karachi. Date of issuance: 25-11-2019 Validity: **21-11-2023** Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name and address of marketing authorization holder	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26141 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Ivermectin 1% Injection
	Composition	Each ml Contains: Ivermectin…10mg
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Anthelmintic
	Shelf life	02 Years
	Demanded Price	N/A
	Pack size	100ml, 50ml, **20ml**
	International availability	N/A
	Me-too status	Mectiver 1% Injection (100ml, 50ml, 20ml) of M/s M&H Pharmaceuticals Lahore (Reg. No. 014537) Ivermec 1% Injection (10ml) of M/s Grand Pharma (Pvt) Ltd., Rawat, Islamabad. (Reg. No.111544)
	Detail of certificates attached	• Scanned copy of COPP No. 191100B0/023176 issued by Yuanshi County of Animal Husbandry Bureau China confirms GMP status and the applied product is licensed to be placed in the market of country of origin. • Scanned copy of FSC No. 20190203 issued by Yuanshi County of Animal Husbandry Bureau China confirms Free sale status of applied product in country of origin. • **Scanned copy** of legalized GMP certificate No**:** 010233 **Certified by:** Animal Husbandry and Veterinary Bureau of Hebei Province China. **Issued on:** 09/01/2019 **Validity**: 5 years • **Scanned copy of legalized Agency Agreement** M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China & M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan for **Ivermectin 1% Injection (10ml,** 50ml, 100ml)

		Issued on: **15-09-2017**
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Provide valid copy of DSL. • The submitted letter of Authorization (LOA) is issued for **Ivermectin 1% Injection (10ml,** 50ml, 100ml) while the firm has demanded 100ml, 50ml, **20ml** pack sizes. • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit following before issuance of registration letter: • **Selection of one fill volume only along with notarized copy of Letter of Authoirsation for it.** • **Original valid legalized CoPP.**	
1286.	Name and address of Applicant	M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Minaa Medicose Address: Katchi Gali No.2, Marriott Road, Denson Hall, Karachi. Date of issuance: 25-11-2019 Validity: **21-11-2023** Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name and address of marketing authorization holder	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26144 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Tylosin 20% Injection
	Composition	Each ml Contains: Tylosin Tartrate…200mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml, 50ml
	International availability	N/A
	Me-too status	Tyrate -20% Injection (100ml, 50ml) of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 109934, 109933)
	Detail of certificates attached	• Scanned copy of COPP No. 191100B0/023179 issued by Yuanshi County of Animal Husbandry Bureau China confirms GMP status and the applied product is licensed to be placed in the market of country of origin. • Scanned copy of FSC No. 20190203 issued by Yuanshi County of Animal Husbandry Bureau China confirms Free sale status of applied product in country of origin.

		• **Scanned copy** of legalized GMP certificate No**:** 010233 **Certified by:** Animal Husbandry and Veterinary Bureau of Hebei Province China. **Issued on:** 09/01/2019 **Validity**: 5 years • **Scanned copy of legalized Agency Agreement** M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China & M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan for **Tylosin Tartrate Injection (100ml**) Issued on: **15-09-2017**
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Provide valid copy of DSL. The submitted letter of Authorization (LOA) is issued for **Tylosin Tartrate Injection (100ml**) while the firm has demanded **100ml and 50ml** pack sizes. • Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit following before issuance of registration letter: • **Selection of one fill volume only along with notarized copy of Letter of Authoirsation for it.** • **Original valid legalized CoPP.**	
1287.	Name and address of Applicant	M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Minaa Medicose Address: Katchi Gali No.2, Marriott Road, Denson Hall, Karachi. Date of issuance: 25-11-2019 Validity: **21-11-2023** Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name and address of marketing authorization holder	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26143 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Gentamicin 10% Injection
	Composition	Each ml Contains: Gentamycin Base…100mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	03 Years

	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	Gentrax Injection (100ml) of M/s Eterna Pharma (Pvt) Ltd, AJK. (Reg. No. 113552)
	Detail of certificates attached	• Scanned copy of COPP No. 191100B0/023178 issued by Yuanshi County of Animal Husbandry Bureau China confirms GMP status and the applied product is licensed to be placed in the market of country of origin. • Scanned copy of FSC No. 20190203 issued by Yuanshi County of Animal Husbandry Bureau China confirms Free sale status of applied product in country of origin. • **Scanned copy** of legalized GMP certificate No**:** 010233 **Certified by:** Animal Husbandry and Veterinary Bureau of Hebei Province China. **Issued on:** 09/01/2019 **Validity**: 5 years • **Scanned copy of legalized Agency Agreement** M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China & M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan for **Gentamycin Sulphate Injection (100ml**) Issued on: **15-09-2017**
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Provide valid copy of DSL.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit following before issuance of registration letter: • **Original valid legalized CoPP.**	
1288.	Name and address of Applicant	M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Minaa Medicose Address: Katchi Gali No.2, Marriott Road, Denson Hall, Karachi. Date of issuance: 25-11-2019 Validity: **21-11-2023** Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name and address of marketing authorization holder	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26142 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Nitroxynil 34% Injection
	Composition	Each ml Contains: Nitroxynil…340mg
	Finished Product Specification	Inhouse

	Pharmacological Group	Anthelmintic
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	Nixil Injection (100ml) of M/s Hilton Pharma (Pvt) Ltd. Karachi. (Reg. No. 035046)
	Detail of certificates attached	• Scanned copy of COPP No. 191100B0/023177 issued by Yuanshi County of Animal Husbandry Bureau China confirms GMP status and the applied product is licensed to be placed in the market of country of origin. • Scanned copy of FSC No. 20190203 issued by Yuanshi County of Animal Husbandry Bureau China confirms Free sale status of applied product in country of origin. • **Scanned copy** of legalized GMP certificate No**:** 010233 **Certified by:** Animal Husbandry and Veterinary Bureau of Hebei Province China. **Issued on:** 09/01/2019 **Validity**: 5 years • **Scanned copy of legalized Agency Agreement** M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China & M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan for **Nitroxynil 34% Injection (100ml)** Issued on: **15-09-2017**
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Provide valid copy of DSL.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit following before issuance of registration letter: • **Selection of one fill volume only along with notarized copy of Letter of Authoirsation for it.** • **Original valid legalized CoPP.**	
1289.	Name and address of Applicant	M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan
	Detail of Drug Sale License	Name: M/s Minaa Medicose Address: Katchi Gali No.2, Marriott Road, Denson Hall, Karachi. Date of issuance: 25-11-2019 Validity: **21-11-2023** Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name and address of marketing authorization holder	M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 26145 Dated 05-12-2019
	Fee including differential fee	Rs : 1,00,000 Dated 05-12-2019
	Brand Name +Dosage Form + Strength	Enroinj 20% Injection

	Composition	Each Bottle Contains: Enrofloxacin…20gm
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	Enropro 20% Injection (100ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi (Reg. No. 112252)
	Detail of certificates attached	• Scanned copy of COPP No. 191100B0/023180 issued by Yuanshi County of Animal Husbandry Bureau China confirms GMP status and the applied product is licensed to be placed in the market of country of origin. • Scanned copy of FSC No. 20190203 issued by Yuanshi County of Animal Husbandry Bureau China confirms Free sale status of applied product in country of origin. • **Scanned copy** of legalized GMP certificate No**:** 010233 **Certified by:** Animal Husbandry and Veterinary Bureau of Hebei Province China. **Issued on:** 09/01/2019 **Validity**: 5 years • **Scanned copy of legalized Agency Agreement** M/s. Hebei Hope Harmony Pharmaceutical Co., Ltd. Industry Area, Yuanshi County, Shijiazhuang City, Hebei Province, People's Republic of China & M/s Minaa Medicose. Katchi Gali No.2, Marriott Road, Denson Hall, Karachi, Pakistan for **20% Enrofloxacin Injection (50ml, 100ml**) Issued on: **15-09-2017**
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings**: • Provide valid copy of DSL.
	Decision: Approved as per policy of inspection of manufacturer abroad. Firm shall submit following before issuance of registration letter: • **Original valid legalized CoPP.**	
1290.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 84 Dated 03-02-2020
	Fee including differential fee	Rs : 1,00,000 Dated 03-02-2020
	Brand Name +Dosage Form + Strength	Aviflox Injection
	Composition	Each 1ml Contains:

		Oxytetracycline (as dihydrate) …300mg Flunixin (as meglumine)…20mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Anti-inflammatory, antibacterial
	Shelf life	02 Years
	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	MINE INJECTION (100ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No.111571)
	Detail of certificates attached	• Original Legalized COPP NO. 9746 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1291.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 85 Dated 03-02-2020
	Fee including differential fee	Rs : 1,00,000 Dated 03-02-2020
	Brand Name +Dosage Form + Strength	Avitryl 20% Injection
	Composition	Each 1ml Contains: Enrofloxacin…200mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	Enropro 20% Injection (100ml) of M/s Kayans Pharmaceuticals, Rawat, Rawalpindi. (Reg. No. 112252)

	Detail of certificates attached	• Original Legalized COPP NO. 9747 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1292.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 31212 Dated 22-01-2020
	Fee including differential fee	Rs : 1,00,000 Dated 22-01-2020
	Brand Name +Dosage Form + Strength	Aviquone Injection
	Composition	Each 1ml Contains: Buparvaquone…50mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antitheilerial
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	20ml
	International availability	N/A
	Me-too status	Butalex Injection (20ml) of M/s ICI Pakistan Ltd Karachi (Reg. No.017968)
	Detail of certificates attached	• Original Legalized COPP NO. 9748 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary

		Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1293.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 31213 Dated 22-01-2020
	Fee including differential fee	Rs : 1,00,000 Dated 22-01-2020
	Brand Name +Dosage Form + Strength	A-Methionine 20% Injection
	Composition	Each 1ml Contains: N-Acetyl-DL-Methionine…200mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Amino acid
	Shelf life	03 Years
	Demanded Price	N/A
	Pack size	100ml
	International availability	N/A
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	• Original Legalized COPP NO. 011465 dated 19-12-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings:** • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.

	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1294.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 14289 Dated 22-06-2020
	Fee including differential fee	Rs : 1,00,000 Dated 19-06-2020
	Brand Name +Dosage Form + Strength	Avicarb 12% Injection
	Composition	Each ml Contains: Imidocarb Dipropionate…120mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antiparasitic
	Shelf life	02 Years
	Demanded Price	N/A
	Pack size	50ml
	International availability	N/A
	Me-too status	Imipro Injection (50ml) of M/s Selmore Pharmaceuticals (Pvt) Ltd., Lahore. (Reg. No. 029610)
	Detail of certificates attached	• Original Legalized COPP NO. 09743 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1295.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).

	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 14286 Dated 22-06-2020
	Fee including differential fee	Rs : 1,00,000 Dated 19-06-2020
	Brand Name +Dosage Form + Strength	Butamin Injection
	Composition	Each ml Contains: Butaphosphan…100mg Vitamin B12…0.05mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Phosphorus source/ Vitamin
	Shelf life	02 Years
	Demanded Price	N/A
	Pack size	50ml
	International availability	N/A
	Me-too status	Butafos Injection (50ml) of M/s Mallard Pharmaceutical (Pvt) Ltd.,Multan (Reg. No. 109795)
	Detail of certificates attached	• Original Legalized COPP NO. 09749 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1296.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 14287 Dated 22-06-2020
	Fee including differential fee	Rs : 1,00,000 Dated 19-06-2020

	Brand Name +Dosage Form + Strength	Iveclosa Injection
	Composition	Each 1ml Contains: Closantel as Closantel Sodium Dihydrate…125mg Ivermectin…5mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Anthelmintic
	Shelf life	18 months
	Demanded Price	N/A
	Pack size	50ml
	International availability	N/A
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	• Original Legalized COPP NO. 09750 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	**Shortcomings:** • The provided 18months real time stability studies data of three batches is **not at zone IV-A conditions**; provide real time stability studies data of three batches at zone IV-A conditions upto claimed shelf-life. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1297.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of issuance: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 14288 Dated 22-06-2020
	Fee including differential fee	Rs : 1,00,000 Dated 19-06-2020
	Brand Name +Dosage Form + Strength	Oxy-Zole Suspension
	Composition	Each ml Contains: Oxyclozanide…60mg

		Levamisole HCl…30mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Anthelmintic
	Shelf life	02 Years
	Demanded Price	N/A
	Pack size	100ml,500ml, 1Liter
	International availability	N/A
	Me-too status	Nawazan DS Suspension of M/s Nawan Laboratories (Pvt.) Ltd., Karachi. (Reg. No. 101445)
	Detail of certificates attached	• Original Legalized COPP NO. 09751 dated 03-11-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1298.	Name and address of Applicant	M/s U.M. Enterprises, Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan
	Detail of Drug Sale License	Name: M/s U.M. Enterprises, Address: Plot No. 12, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan Date of validity: 21-03-2023. Status: Drug License by way of Wholesale (Form No.7).
	Name and address of manufacturer	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name and address of marketing authorization holder	M/s Arab Veterinary Industrial Co. "AVICO" P.O.Box 150906, Amman 11115-Jordan
	Name of exporting country	Jordan
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 14285 Dated 22-06-2020
	Fee including differential fee	Rs : 1,00,000 Dated 19-06-2020
	Brand Name +Dosage Form + Strength	Avitylodox Powder
	Composition	Each gram Contains: Tylosine as Tylosine Tartrate…100mg Doxycycline as Doxycycline HCl…100mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	04 Years
	Demanded Price	N/A
	Pack size	100gm,500gm, 1Kg
	International availability	N/A
	Me-too status	Vibro Tech 10/20 Powder of M/s Neotech Pharmaceuticals (Pvt) Ltd., Chak Hinda Kamoke (Reg. No. 111411)

	Detail of certificates attached	• Original Legalized COPP NO. 0429 dated 15-01-2019 issued by the Ministry of Agriculture, The Hashemite Kingdom of Jordan confirms GMP status and Free sale status of applied product in country of origin. • Copy of Legalized GMP certificate No**:** 008342 **Certified by:** Director of Veterinary & Animal Health, Ministry of Agriculture, The Hashemite Kingdom of Jordan. **Issued on:** 25/09/2019 **Validity**: 3 years • Original legalized Power of attorney from Arab Veterinary Industrial Co. "AVICO" P.O Box 150906 Amman 11115-Jordan & U.M. Enterprises, 18 C 3rd Floor Dolmen Estate Block-7, Shaheed e Millat Road, Karachi.
	Remarks of the Evaluator [X]	• Provided 06 month accelerated and 48months real time stability studies data of three batches at zone IV-A conditions.
	Decision: Approved as per policy of inspection of manufacturer abroad.	
1299.	Name and address of Applicant	M/s Geevet International, Office No. 11/12, First Floor, Naz Medicine Market, Namak Mandi, Peshawar, Pakistan
	Detail of Drug Sale License	Not provided
	Name and address of manufacturer	M/s Inner Mangolia Huatian Pharmaceutical Co. Ltd. Development & Experiment Zone for Transformation of Resource Dependant City, Chifeng, Inner Mangolia, China
	Name and address of marketing authorization holder	M/s Inner Mangolia Huatian Pharmaceutical Co. Ltd. Development & Experiment Zone for Transformation of Resource Dependant City, Chifeng, Inner Mangolia, China
	Name of exporting country	China
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 3320 Dated 03-03-2020
	Fee including differential fee	Rs : 1,00,000 Dated 03-03-2020
	Brand Name +Dosage Form + Strength	Colimed WSP
	Composition	Each 1gm Contains: Colistin Sulphate…394.75mg eq. to 480,000,0 IU
	Finished Product Specification	Chinese Vet Pharmacopoeia
	Pharmacological Group	Antibiotic
	Shelf life	24 months
	Demanded Price	Decontrolled
	Pack size	1000gm
	International availability	N/A
	Me-too status	Coli Skill-48 Powder of M/s Bioskils Pharmaceuticals, District Gujranwala. (Reg. No. 113508)
	Detail of certificates attached	➢ CoPP and Free Sale Certificate not provided ➢ Copy of GMP certificate No. 2018 GMP 05019 is provided ➢ Letter of Authorization/Sole Agency Certificate not provided

	Remarks of the Evaluator [X]	Provided 06 month accelerated and 24months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings:** • Submitted copy of GMP certificate is expired now but valid upon submission, provide legalized original valid relevant GMP certificate. • Provide legalized original valid CoPP and FSC. • Provide valid copy of DSL • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1300.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2022. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name and address of marketing authorization holder	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name of exporting country	Vietnam
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 13770 Dated 16-06-2020
	Fee including differential fee	Rs : 100,000 Dated 16-06-2020
	Brand Name +Dosage Form + Strength	Micotil Oral-App
	Composition	Each gram Contains: Tilmicosin Phosphate…250mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antimicrobial
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg
	International availability	N/A
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	➢ Scanned copy of GMP certificate No. 01/19/GCN-GMP dated 31-10-2019 issued by Department of Animal Health Ministry of Agriculture and Rural Development Vietnam **Validity: 5 Years** ➢ Copy of FSC No. 1119/2019/QLT-CFS dated 09-10-2019 issued by Department of Animal Health Vietnam, **Validity: 2 years** ➢ Scanned copy of legalized authorization letter dated 16-08-2019 between PLH and Applicant
	Remarks of the Evaluator [X]	**Shortcomings:** • Provide valid copy of DSL

		• Provide valid legalized original FSC since already submitted copy is expired now but valid upon submission. • Submit both accelerated and long term stability studies data as per zone-IV-A conditions upto claimed shelf life. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL, clarify.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially shared with the firm hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1301.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2022. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name and address of marketing authorization holder	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name of exporting country	Vietnam
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 11040 Dated 18-05-2020
	Fee including differential fee	Rs : 100,000 Dated 18-05-2020
	Brand Name +Dosage Form + Strength	RTD-Doxy 75 WS
	Composition	Each gram contains: Doxycycline Hyclate…750mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibacterial
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	100gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg
	International availability	N/A
	Me-too status	**Could not be confirmed**
	Detail of certificates attached	➢ Scanned copy of GMP certificate No. 01/19/GCN-GMP dated 31-10-2019 issued by Department of Animal Health Ministry of Agriculture and Rural Development Vietnam **Validity: 5 Years** ➢ Copy of FSC No. 1119/2019/QLT-CFS dated 09-10-2019 issued by Department of Animal Health Vietnam, **Validity: 2 years** ➢ Scanned copy of legalized authorization letter dated 16-08-2019 between PLH and Applicant

	Remarks of the Evaluator [X]	Provided 24months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Provide valid legalized original FSC since already submitted copy is expired now but valid upon submission. • Submit 06 months accelerated stability studies data as per zone-IV-A conditions. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL, clarify.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially shared with the firm hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1302.	Name and address of Applicant	M/s Better Traders International, 23-Z, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan.
	Detail of Drug Sale License	Name: M/s Better Traders International Address: 24-Z/E, Saifullah Shaheed Road, Madina Town, Faisalabad, Pakistan. Validity: 15-02-2022. Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name and address of marketing authorization holder	M/s RTD (Rural Technology Development) Veterinary Medicine Joint Stock Company. Truong An Industrial Zone, An Khanh, Hoai Duc, Ha Noi, Vietnam
	Name of exporting country	Vietnam
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 11041 Dated 18-05-2020
	Fee including differential fee	Rs : 100,000 Dated 18-05-2020
	Brand Name +Dosage Form + Strength	RTD-Flo Oral Powder
	Composition	Each 100ml contains: Florfenicol…23mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibacterial
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	100ml, 500ml, 1L, 2.5L, 5L, 10L, 25L
	International availability	N/A
	Me-too status	**Could not be confirmed in the applied strength**
	Detail of certificates attached	➢ Original GMP certificate No. 01/19/GCN-GMP dated 31-10-2019 issued by Department of Animal Health Ministry of Agriculture and Rural Development Vietnam **Validity: 5 Years** ➢ Copy of FSC No. 1119/2019/QLT-CFS dated 09-10-2019 issued by Department of Animal Health Vietnam,

		Validity: 2 years ➢ Scanned copy of legalized authorization letter dated 16-08-2019 between PLH and Applicant
	Remarks of the Evaluator [X]	Provided 24months real time stability studies data of three batches at zone IV-A conditions. **Shortcomings:** • Provide valid copy of DSL • Provide valid legalized original FSC since already submitted copy is expired now but valid upon submission. • Submit 06 months accelerated stability studies data as per zone-IV-A conditions. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986. • Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm. • The address of the applicant mentioned on form 5A is not the same as mentioned on copy of DSL, clarify.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	
1303.	Name and address of Applicant	M/s Huzaifa International, Commercial Area, Aziz Bhatti Town, Sargodha, Pakistan.
	Detail of Drug Sale License	Name: M/s Huzaifa International Address: Commercial Area, Aziz Bhatti Town, Sargodha. Validity: **20-11-2023** Status: License to sell drugs as a distributor (Form No.11).
	Name and address of manufacturer	M/s Super's Diana S.L. CTRA C.17, km 17, 08150 Parets Del Valles, Barcelona, Spain
	Name and address of marketing authorization holder	M/s Super's Diana S.L. CTRA C.17, km 17, 08150 Parets Del Valles, Barcelona, Spain
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 1092 Dated 12-02-2020
	Fee including differential fee	Rs : 100,000 Dated 12-02-2020
	Brand Name +Dosage Form + Strength	Suidox Water Soluble Powder
	Composition	Each Gram Contains: Doxycycline (Hyclate)…500mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	3 years
	Demanded Price	Decontrolled
	Pack size	1Kg, 10Kg
	International availability	N/A
	Me-too status	Farmadox 50 Oral Powder of M/s ZS Biotech, House No.22-A, Hidayat Ullah Block, Mustafa Town, Wahdat Road, Lahore.(Reg. No.113635)
	Detail of certificates attached	➢ Originally legalized FSC certificate dated 04-09-2019 issued by Spanish Agency for Medicines and Health Products confirms free sale status of the product in exporting.

		➢ Original legalized GMP certificate No. ES/073HV/17 dated 28-30 May, 2017 issued by the issued by Spanish Agency for Medicines and Health Products. ➢ Original legalized authorization letter dated 30-10-2019 between PLH and Applicant
	Remarks of the Evaluator [X]	Provided 06months accelerated and 36months real time stability studies data of three batches at zone IV-A conditions. •
	Decision: Approved as per policy of inspection of manufcaturer abroad.	
1304.	Name and address of Applicant	M/s Orion Group, P-97, Usman Block, Muslim Town No.1, Near Lasani Pully, Sargodha Road, Faisalabad
	Detail of Drug Sale License	Not provided
	Name and address of manufacturer	M/s S.P. Veterinaria, S.A. Crta. Reus-Vinyols, Km. 4.1 P.O Box 60, 43330, RIUDOMS (Tarragona) Spain.
	Name and address of marketing authorization holder	M/s S.P. Veterinaria, S.A. Crta. Reus-Vinyols, Km. 4.1 P.O Box 60, 43330, RIUDOMS (Tarragona) Spain.
	Name of exporting country	Spain
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 30497 Dated 15-01-2020
	Fee including differential fee	Rs : 100,000 Dated 15-01-2020
	Brand Name +Dosage Form + Strength	Aquadox-S.P 500mg/g Water Soluble Powder
	Composition	Each Gram Contains: Doxycycline (Hyclate)…500mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	2 years
	Demanded Price	Decontrolled
	Pack size	200gm, 1Kg
	International availability	N/A
	Me-too status	Farmadox 50 Oral Powder of M/s ZS Biotech, House No.22-A, Hidayat Ullah Block, Mustafa Town, Wahdat Road, Lahore.(Reg. No.113635)
	Detail of certificates attached	➢ Photocopy of legalized COPP dated 05-09-2019 issued by Spanish Agency for Medicines and Health Products confirms free sale status of the product in exporting. ➢ Photocopy of legalized GMP certificate No. ES/103HV/18 dated 22-08-2018 issued by the issued by Spanish Agency for Medicines and Health Products. **Validity: 20-07-2020** ➢ Photocopy of legalized power of attorney dated 16-09-2019 between PLH and Applicant
	Remarks of the Evaluator [X]	Provided 06months accelerated and 24months real time stability studies data of three batches is **NOT** as per zone IV-A/IV-B conditions. **Shortcomings:** • Provide valid copy of DSL • Provide Original legalized valid GMP certificate since the already submitted copy of GMP certificate is expired now but valid upon submission. • Provide real time stability studies data of three batches as per zone IV-A conditions upto claimed shelf life.

		• In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.
	Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.	

b. Deferred cases

i. Veterinary

1305.	Name and address of Applicant	M/s Maacs Pharmaceuticals, 194-N, Phase 8, DHA, Lahore, Cantt.
	Detail of Drug Sale License	Not provided
	Name and address of manufacturer	M/s Biofaktor Sp. Z o.o. 96-100, UI. Czysta 4, Poland
	Name and address of marketing authorization holder	M/s Biofaktor Sp. Z o.o. 96-100, UI. Czysta 4, Poland
	Name of exporting country	Poland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 4414 Dated 24-04-2019
	Fee including differential fee	Rs : 1,00,000 Dated 24-04-2019
	Brand Name +Dosage Form + Strength	Doxyfort 500mg Powder for oral Solution
	Composition	Each gram contains: Doxycycline Hyclate…500mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	2 years
	Demanded Price	Rs. 15000/ 1000gm
	Pack size	1000gm, 500gm, and 100gm
	International availability	Not provided
	Me-too status	Doxyveto- 50 S Soluble Powder of M/s VMD Pakistan Rawalpindi. (Reg. No. 023470)
	Detail of certificates attached	Photocopy of **(not embassy attested)** Certificate of Pharmaceutical Product Certificate No. 847/18 Issued on 14/11/2018, Certified by chief Pharmaceutical Inspector, 12 Senatorska Street, 00-082 Warsaw, Poland. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through routine inspection with 3 year periodicity. • Letter of authorization not provided.
	Remarks of the Evaluator [X]	**Shortcomings:** • Provide valid copy of DSL. • Provide original legalized valid CoPP and Letter of authorization between product license holder and distributor. • Provide evidence of pharmacopoeial reference of finished product specification. In case, the product is non pharmacopoeial, submit product specification in the light of decision taken in 267th meeting of Registration Board. • Provide real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions; since the already submitted 24-months real

		time stability studies data is not as per zone IV-A/ IV-B conditions. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.

Decision of 322 meeting: Deferred for following:

- **Valid copy of DSL.**
- **Original legalized valid CoPP and Letter of authorization between product license holder and distributor.**
- **Finished product specifications in the light of decision taken in 267th meeting of Registration Board.**
- **Real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions.**
- **Label in accordance with The Drugs (Labeling and Packing) Rules, 1986.**

Updated Status:

Observation	**Firm's response**
• Valid copy of DSL.	Name: M/s Maacs Pharmaceuticals, Address: 194-N, Phase 8, DHA, Lahore, Cantt. Validity: **25-02-2023** Status: License to sell drugs as a distributor (Form No.11).
• Original legalized valid CoPP and Letter of authorization between product license holder and distributor.	• Originally Legalized **COPP** No. 847/18 dated 14-11-2018 issued by chief Pharmaceutical Inspector, 12 Senatorska Street, 00-082 Warsaw, Poland confirms GMP as well as Free sale status of the applied product in the exporting country. • Original Legalized **letter of authorization** dated 10-11-2022 submitted. Validity: Valid for 3Years.
• Finished product specifications in the light of decision taken in 267th meeting of Registration Board.	The applied product is non-pharmacopoeial, The described parameters and limits are based on general monographs.
• Real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions.	**24 months** Real time stability studies data of three batches at zone IV-A and IV-B conditions submitted
• Label in accordance with The Drugs (Labeling and Packing) Rules, 1986	Provided

Decision: Approved as per policy of inspection of manufacturer abroad.

1306.	Name and address of Applicant	M/s Maacs Pharmaceuticals, 194-N, Phase 8, DHA, Lahore, Cantt.
	Detail of Drug Sale License	Not provided
	Name and address of manufacturer	M/s Biofaktor Sp. Z o.o. 96-100, UI. Czysta 4, Poland
	Name and address of marketing authorization holder	M/s Biofaktor Sp. Z o.o. 96-100, UI. Czysta 4, Poland
	Name of exporting country	Poland
	Type of Form	Form-5A
	Diary No. & Date of R& I	Dy.No 4413 Dated 24-04-2019
	Fee including differential fee	Rs : 1,00,000 Dated 24-04-2019

	Brand Name +Dosage Form + Strength	Enrofloxan 100mg/ml Oral Solution
	Composition	Each ml contains: Enrofloxacin…100mg
	Finished Product Specification	Inhouse
	Pharmacological Group	Antibiotic
	Shelf life	2 years
	Demanded Price	Rs. 2200/ 1000ml
	Pack size	1000ml, and 100ml
	International availability	Not provided
	Me-too status	Kariflox 10% Oral Solution of M/s Unicare Enterprises, Faisalabad. (Reg. No. 081715)
	Detail of certificates attached	Photocopy **(not embassy attested)** of Certificate of Pharmaceutical Product Certificate No. 845/18 Issued on 14/11/2018, Certified by chief Pharmaceutical Inspector, 12 Senatorska Street, 00-082 Warsaw, Poland. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through routine inspection with 3 year periodicity. • Letter of authorization not provided.
	Remarks of the Evaluator [X]	**Shortcomings:** • Provide valid copy of DSL. • Provide original legalized valid CoPP and Letter of authorization between product license holder and distributor. • Provide evidence of pharmacopoeial reference of finished product specification. In case, the product is non pharmacopoeial, submit product specification in the light of decision taken in 267th meeting of Registration Board. • Provide real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions; since the already submitted 24-months real time stability studies data is not as per zone IV-A/ IV-B conditions. • In the finished product label the Urdu version of the following namely; (i) Name of drug (ii) dosage; and (iii) Instruction is missing. Submit label in accordance with The Drugs (Labeling and Packing) Rules, 1986.

Decision of 322 meeting: Deferred for following:

- Valid copy of DSL.
- Original legalized valid CoPP and Letter of authorization between product license holder and distributor.
- Finished product specifications in the light of decision taken in 267th meeting of Registration Board.
- Real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions.
- Label in accordance with The Drugs (Labeling and Packing) Rules, 1986.

Updated Status:

Observation	Firm's response
• Valid copy of DSL.	Name: M/s Maacs Pharmaceuticals, Address: 194-N, Phase 8, DHA, Lahore, Cantt. Validity: **25-02-2023** Status: License to sell drugs as a distributor (Form No.11).
• Original legalized valid CoPP and Letter of authorization between product license holder and distributor.	• Originally Legalized **COPP** No. 845/18 dated 14-11-2018 issued by chief Pharmaceutical Inspector, 12 Senatorska Street, 00-082 Warsaw, Poland confirms GMP as well as

		Free sale status of the applied product in the exporting country. • Original Legalized **letter of authorization** dated 10-11-2022 submitted with Doxyfort powder. Validity: Valid for 3Years.
	• Finished product specifications in the light of decision taken in 267th meeting of Registration Board.	The applied product is non-pharmacopoeial, The described parameters and limits are based on general monographs.
	• Real time stability studies data upto claimed shelf life of three batches at zone IV-A/ IV-B conditions.	**24 months** Real time stability studies data of three batches at zone IV-A and IV-B conditions submitted
	• Label in accordance with The Drugs (Labeling and Packing) Rules, 1986	Provided
	Decision: Approved as per policy of inspection of manufacturer abroad.	

Item No. 14: Agenda of Evaluator PEC-XI (Dr. Farhadullah)

Agenda of Evaluator PEC-XI

Case No. 01: Priority Registration application as per Decision of 257th meeting of DRB on Form 5F (Local)

Registration Board in its 257th meeting decided as; "Registration Board deliberated that drugs for treatment of chronic ailments and drugs which are in short availability should have priority review process and consideration by the Board to ensure their free availability. The Board decided that drugs for treatment of cancer, viral diseases, thalassemia, immunosuppressant, vaccine and sera, new molecules / formulations, blood factors and bags will be given priority consideration".

1307.	Name, address of Applicant / Marketing Authorization Holder	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot #129 Sunder Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot #129 Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 08-09-2021 based on inspection conducted on 08-09-2021
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 1-51/2004-Lic dated 07-02-2014 which specifies Tablet (General Human) section
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No. 22953 dated 15-08-2022
	Details of fee submitted	PKR 30,000/-: dated 06/07/2022 (Slip#26043395960)
	The proposed proprietary name / brand name	Gabal 82.5mg ER tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Extended Release tablet contains: Pregabalin……....82.5mg

	Pharmaceutical form of applied drug	Extended Release Tablet
	Pharmacotherapeutic Group of (API)	Anticonvulsant
	Reference to Finished product specifications	In-house
	Proposed Pack size	3x10's, 1x10's, 2x10's, 2x7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA CR extended-release tablets (82.5mg, 165mg, 330 mg) by USFDA Approved.
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	M/s CTX Lifesciences Pvt. Ltd., Block No. 251-252 Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230,Gujarat, INDIA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (PG120001, PG120002, PG120003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Lyrica CR 82.5mg Tablet by performing quality tests (Description, Identification, Assay, Dissolution). CDP has been performed against a comparator product ***(name not mentioned)*** in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm have submitted method validation studies including linearity, range, accuracy, precision, specificity and robustness.
STABILITY STUDY DATA		
Manufacturer of API	M/s CTX Lifesciences Pvt. Ltd., Block No. 251-252 Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230,Gujarat, INDIA	

API Lot No.	21PL000050		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TPE001	TPE002	TPE003
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	03-12-2021	05-12-2021	07-12-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted cGMP certificate No. 19061470 dated 02-07-2019 of M/s CTX Lifesciences Pvt. Ltd., Block No. 251/P, 252/P, 253 TO 255, 256/P, 258/P, 276/P, 277, 278/P, 279 TO 282, 283/P, 284/P, GIDC, City: Sachin, District; Surat – Gujarat state, INDIA issued by Commissioner, Food & Drugs Administration Gandhinaga India valid upto 01-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EI/3012100599 dated 19-11-2021 for import of 50kg of Pregabalin (Batch# 21PL000050) in name of M/s Wimits Pharmaceuticals (Pvt.) Ltd., attested by AD (I&E) DRAP Lahore dated 29-11-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator [XI]:

Section	Observations	Response
1.1	• Submit differential fee Rs. 45000/- as the applied product is a new drug molecule	Firm has submitted differential Fee Rs. 45000/- on deposit slip No. 64420120 applied product is a new drug molecule.
1.3.4	• Submit Valid copy of DML	Firm has submitted Valid copy of DML
1.4	• Clarification is required as you have applied for generic drug product while the applied product is a new drug molecule	The firm submitted that it was mistakenly done please considered as New Drug Molecule and submitted revised document
1.5.2	• Clarification is required as you have applied for extended release tablets while the reference formulation is film coated extended release tablets or revise your label claim as per reference formulation along with submission of applicable fee.	• Firm has revised the label claim as per reference formulation. The revise label claim is as under: Each Film Coated Extended Release tablet contains: Pregabalin.....82.5mg

<table>
<tr><td>1.6.5</td><td>• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin</td><td>• Firm has submitted cGMP certificate dated 30-05-2022 of M/s CTX Lifesciences Pvt. Ltd., Block No. 251/P, 252/P, 253 TO 255, 256/P, 258/P, 276/P, 277, 278/P, 279 TO 282, 283/P, 284/P, GIDC, City: Sachin, District; Surat – Gujarat state, INDIA issued by Commissioner, Food & Drugs Administration Gandhinaga India valid upto 29-05-2025.</td></tr>
<tr><td>3.2.S.4</td><td>• Justification is required for not performing test for enantiomeric purity (pregabalin related compound A) in batch analysis of drug substance by drug product manufacturer as recommended by USP</td><td>• The firm submitted that we relied upon the drug substance manufacturer for the enantiomeric purity test. The performed and result of analysis as per COA submitted.</td></tr>
<tr><td>3.2.S.7</td><td>• Submitted drug substance stability summery sheets conclude as: No significant change observed during long term stability upto 60 months when stored at 25˚C ± 2˚C / 60% ± 5%RH, clarification shall be submitted for above</td><td>Firm has submitted stability study of drug substance as per zone IV-B condition.
Real time: 30˚C ± 2˚C / 75% ± 5%RH for 72 months
• Batches: (PG163006, PG163007, PG163008)</td></tr>
<tr><td>3.2.P.2</td><td>• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.
<table>
<tr><th>Applied product</th><th>LYRICA CR tablets</th></tr>
<tr><td>Pregabalin</td><td>Pregabalin</td></tr>
<tr><td>Polyethylene oxide</td><td>Kollidon SR</td></tr>
<tr><td>Avecil PH 102</td><td>Crospovidone,</td></tr>
<tr><td>Magnesium stearate</td><td>Polyethylene Oxide</td></tr>
<tr><td>Tabcoat white</td><td>Carbomer</td></tr>
<tr><td>Isopropyl alcohol</td><td>Magnesium Stearate</td></tr>
<tr><td>Purified water</td><td>Polyvinyl Alcohol</td></tr>
<tr><td></td><td>Titanium Dioxide</td></tr>
<tr><td></td><td>Talc</td></tr>
<tr><td></td><td>Polyethylene Glycol</td></tr>
<tr><td></td><td>Colorants</td></tr>
</table>
• Submit details of comparator product including name, manufacturer, batch number, manufacturing date, expiry date etc.</td><td>• Firm has submitted compatibility studies of the drug substance with excipients.
• The firm has submitted details of comparator / innovator product
Name: Lyrica CR 82.5mg Extended Release tablets
Manufacturer: Pfizer INC, NY, NY 10017 (Made in Singapore)
Exp: 08/2023
Lot: EX7809
SN: 100001252343</td></tr>
<tr><td>3.2.P.8</td><td>• Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not submitted</td><td>• Audit trial reports on product testing is submitted</td></tr>
</table>

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 75,00/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

1308.	Name, address of Applicant / Marketing Authorization Holder	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot #129 Sunder Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Wimits Pharmaceuticals (Pvt.) Ltd., Plot #129 Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 08-09-2021 based on inspection conducted on 08-09-2021
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 1-51/2004-Lic dated 07-02-2014 which specifies Tablet (General Human) section

	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No. 22954 dated 15-08-2022
	Details of fee submitted	PKR 30,000/-: dated 06/07/2022 (Slip#581425554830)
	The proposed proprietary name / brand name	Gabal 165mg ER tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Extended Release tablet contains: Pregabalin……....165mg
	Pharmaceutical form of applied drug	Extended Release Tablet
	Pharmacotherapeutic Group of (API)	Anticonvulsant
	Reference to Finished product specifications	In-house
	Proposed Pack size	3x10's, 1x10's, 2x10's, 2x7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA CR extended-release tablets (82.5mg, 165mg, 330 mg) by USFDA Approved.
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	M/s CTX Lifesciences Pvt. Ltd., Block No. 251-252 Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230,Gujarat, INDIA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (PG120001, PG120002, PG120003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Lyrica CR 165mg Tablet by performing quality tests (Description, Identification, Assay, Dissolution).

		CDP has been performed against a comparator product ***(name not mentioned)*** in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Firm have submitted method validation studies including linearity, range, accuracy, precision, specificity and robustness.

STABILITY STUDY DATA			
Manufacturer of API	M/s CTX Lifesciences Pvt. Ltd., Block No. 251-252 Sachin- Magdalla Road GIDC, Sachin, Surat – 394 230,Gujarat, INDIA		
API Lot No.	21PL000050		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TPG001	TPG002	TPG003
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	12-12-2021	14-12-2021	16-12-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted cGMP certificate No. 19061470 dated 02-07-2019 of M/s CTX Lifesciences Pvt. Ltd., Block No. 251/P, 252/P, 253 TO 255, 256/P, 258/P, 276/P, 277, 278/P, 279 TO 282, 283/P, 284/P, GIDC, City: Sachin, District; Surat – Gujarat state, INDIA issued by Commissioner, Food & Drugs Administration Gandhinaga India valid upto 01-07-2022.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EI/3012100599 dated 19-11-2021 for import of 50kg of Pregabalin (Batch# 21PL000050) in name of M/s Wimits Pharmaceuticals (Pvt.) Ltd., attested by AD (I&E) DRAP Lahore dated 29-11-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator [XI]:

Section	Observations	Response

<table>
<tr><td>1.1</td><td>• Submit differential fee Rs. 45000/- as the applied product is a new drug molecule</td><td>Firm has submitted differential Fee Rs. 45000/- on deposit slip No. 99595123264 as applied product is a new drug molecule.</td></tr>
<tr><td>1.3.4</td><td>• Submit Valid copy of DML</td><td>Firm has submitted Valid copy of DML</td></tr>
<tr><td>1.4</td><td>• Clarification is required as you have applied for generic drug product while the applied product is a new drug molecule</td><td>The firm submitted that it was mistakenly done please considered as New Drug Molecule and submitted revised document</td></tr>
<tr><td>1.5.2</td><td>• Clarification is required as you have applied for extended release tablets while the reference formulation is film coated extended release tablets or revise your label claim as per reference formulation along with submission of applicable fee.</td><td>• Firm has revised the label claim as per reference formulation. The revise label claim is as under:
Each Film Coated Extended Release tablet contains:
Pregabalin.....165mg</td></tr>
<tr><td>1.6.5</td><td>• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin</td><td>Firm has submitted cGMP certificate dated 30-05-2022 of M/s CTX Lifesciences Pvt. Ltd., Block No. 251/P, 252/P, 253 TO 255, 256/P, 258/P, 276/P, 277, 278/P, 279 TO 282, 283/P, 284/P, GIDC, City: Sachin, District; Surat – Gujarat state, INDIA issued by Commissioner, Food & Drugs Administration Gandhinaga India valid upto 29-05-2025.</td></tr>
<tr><td>3.2.S.4</td><td>• Justification is required for not performing test for enantiomeric purity (pregabalin related compound A) in batch analysis of drug substance by drug product manufacturer as recommended by USP</td><td>• The firm submitted that we relied upon the drug substance manufacturer for the enantiomeric purity test. The performed and result of analysis as per COA submitted.</td></tr>
<tr><td>3.2.S.7</td><td>• Submitted drug substance stability summery sheets conclude as: No significant change observed during long term stability upto 60 months when stored at 25˚C ± 2˚C / 60% ± 5%RH, clarification shall be submitted for above</td><td>Firm has submitted stability study of drug substance as per zone IV-B condition.
Real time: 30˚C ± 2˚C / 75% ± 5%RH for 72 months
Batches: (PG163006, PG163007, PG163008)</td></tr>
<tr><td>3.2.P.2</td><td>• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.
<table>
<tr><th>Applied product</th><th>LYRICA CR tablets</th></tr>
<tr><td>Pregabalin</td><td>Pregabalin</td></tr>
<tr><td>Polyethylene oxide</td><td>Kollidon SR</td></tr>
<tr><td>Avecil PH 102</td><td>Crospovidone,</td></tr>
<tr><td>Magnesium stearate</td><td>Polyethylene Oxide</td></tr>
<tr><td>Tabcoat white</td><td>Carbomer</td></tr>
<tr><td>Isopropyl alcohol</td><td>Magnesium Stearate</td></tr>
<tr><td>Purified water</td><td>Polyvinyl Alcohol</td></tr>
<tr><td></td><td>Titanium Dioxide</td></tr>
<tr><td></td><td>Talc</td></tr>
<tr><td></td><td>Polyethylene Glycol</td></tr>
<tr><td></td><td>Colorants</td></tr>
</table>
• Submit details of comparator product including name, manufacturer, batch number, manufacturing date, expiry date etc.</td><td>• Firm has submitted compatibility studies of the drug substance with excipients.
• The firm has submitted details of comparator / innovator product
Name: Lyrica CR 165mg Extended Release tablets
Manufacturer: Pfizer INC, NY, NY 10017 (Made in Singapore)
Exp: 07/2022
Lot: DN5359</td></tr>
<tr><td>3.2.P.8</td><td>• Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not submitted</td><td>• Audit trial reports on product testing is submitted</td></tr>
</table>

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 75,00/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. 02: Priority Registration application as per Decision of 257th meeting of DRB on Form 5F (Import)

Registration Board in its 257th meeting decided as; "Registration Board deliberated that drugs for treatment of chronic ailments and drugs which are in short availability should have priority review process and consideration by the Board to ensure their free availability. The Board decided that drugs for treatment of cancer, viral diseases, thalassemia, immunosuppressant, vaccine and sera, new molecules / formulations, blood factors and bags will be given priority consideration".

1309.	Name, address of Applicant / Importer	M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan
	Details of Drug Sale License of importer	**License No:** 030 **Address:** B-2, S.I.T.E., Karachi - Pakistan **Address of Godown:** 12-Dockyard Road West Wharf Karachi, C-11-D, S.I.T.E Karachi **Validity:** 25-02-2023 **Status:** Drug License by Way of Wholesale
	Name and address of marketing authorization holder (abroad)	Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
	Name, address of manufacturer(s)	Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany
	Name of exporting country	United Kingdom

Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)
CoPP: Firm has submitted original, legalized CoPP certificate No. PP10174753 dated 06-12-2021 issued by The Medicine and Healthcare Products Regulatory Agency (MHRA) UK for Cibinqo 50mg film coated tablets. The CoPP confirms free sale status of the product in exporting country.
The name of importing country on CoPP is mentioned as Pakistan.
GMP: Firm has submitted original, legalized cGMP certificate No. DE_BW_01_GMP_2021_0006 dated 11-02-2021 in name of M/s Pfizer Manufacturing Deutschland GmbH-Betriebsstätte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany valid upto three years from date of inspection (date of inspection 07-10-2020). The GMP states that the manufacturer complies with the Good Manufacturing Practices requirements.
Manufacturer Authorization: Firm has submitted legalized copy of manufacturer's authorization No. DE_BW_01_MIA_2021_0025/DE_BW_01_Pfizer Manufacturing_01 dated 10/03/2021

Details of letter of authorization / sole agency agreement
Original letter of authorization is submitted whereby M/s Pfizer Europe MA EEIG having principal place of business at Boulevard de la Plaine 17, 1050 Brussels, Belgium., as the MA holder in the country of origin has authorized M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan as marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan.

Product Name with Dosage Form	Generic	Strength	Manufacturing & Packaging
CIBINQO Tablet	Abrocitinib	50mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	100mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany
CIBINQO Tablet	Abrocitinib	200mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany

Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales

	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 4388_: 16-02-2022
	Details of fee submitted	PKR 75,000/-: 13-10-2021 (Deposit Slip#319408636713)
	The proposed proprietary name / brand name	**CIBINQO Film Coated Tablets 50mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Abrocitinib …… 50mg
	Pharmaceutical form of applied drug	Film Coated Tablets
	Pharmacotherapeutic Group of (API)	Other dermatological preparations, agents for dermatitis, excluding corticosteroids) ATC Code D11AH08
	Reference to Finished product specifications	Pfizer Specs (Innovator)
	Proposed Pack size	To be provided later
	Proposed unit price	To be provided later
	The status in reference regulatory authorities	Cibinqo 50mg film-coated tablets MHRA Approved CIBINQO (50mg, 100mg, 200mg) film-coated tablets USFDA Approved Cibinqo 50mg film-coated tablets Germany Approved
	For generic drugs (me-too status)	Not Applicable
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guideline including information related to Drug Substance and Drug Product. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Firm has also summarized information related to composition, product development, manufacturing process, excipients, specifications, analytical methods, Reference standards or materials, container closure system and stability studies of Drug Product.
	Name, address of drug substance manufacturer	M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to general information nomenclature, structure, general properties, Manufacturer, description of manufacturing process and controls, critical steps, process validation, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated stability study is conducted at 40°C/75% RH for 06th months. The real time stability data is conducted at 30°C / 75% RH for 12th months. (Batches: 19-AP-00096, 19-AP-00101, 19-AP-00107)

	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, batch formula, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability studies.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Polyvinylchloride (PVC) / Polyvinylidene chloride (PVDC) foil blisters with aluminum foil lidding High-density polyethylene (HDPE) bottle and polypropylene closures with induction seal liners
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of three batches for 12 months long-term stability conditions of 30°C/75% RH and 25°C/60% RH. Stability study was also monitored at accelerated storage condition at 40 °C/75% RH for 6 months. (Batches: 19-PD-00050, 19-PD-00051, 19-PD-00052)

Remarks of Evaluator [XI]:


INDICATIONS AND USAGE:

CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

- Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test.
- Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA patients.
- Malignancies have occurred with CIBINQO. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs.TNF blockers in RA patients.
- MACE has occurred with CIBINQO. Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients.
- Thrombosis has occurred with CIBINQO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers.

Section	Observations	Response
1.5.4	• Submit the proposed pack size as well as demanded price for each pack size.	• Polyvinylidene chloride (PVDC) blisters with aluminum foil lidding film containing 7 film coated tablets. Each pack contains 14, 28 or 91 film coated tablets • Demanded price will be submitted at the time of price fixation
1.3.4	• ***Query:*** Letter of authorization is from M/s Pfizer Europe MA EEIG Boulevard de la Plaine 17, 1050 Brussels, Belgium., while marketing authorization holder is Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, clarify ***Response of firm:*** Original letter of authorization is submitted whereby M/s Pfizer Limited having principal place of business at Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom., as the MA holder in the country of origin of following product hereby authorizes M/s Pfizer Pakistan Limited., located at B-2, S.I.T.E., Karachi - 75700 Pakistan to be the marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan.	

Product Name with Dosage Form	Generic	Strength	Manufacturing & Packaging
CIBINQO Tablet	Abrocitinib	50mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	100mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	200mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany

3.2.S.4	• Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted. • Provide certificate of analysis of Drug Substance performed by Drug Product manufacturer	• The drug product manufacturer, Pfizer Manufacturing Deutschland GmbH Freiburg, Germany, uses the drug substance specifications as listed in section 3.2.S.41. Pfizer Freiburg, tests the drug substance for identity and description (appearance), all other test results are taken from Pfizer Ringaskiddy certificate of analysis. A declaration from the drug product manufacturing site is provided with this response. • The firm submitted that as indicated above, Pfizer Frieberg tests the drug substance for identity and appearance only. Appearance and identity are common industry tests. Internal procedures or pharmacopeia test methods are currently followed for this confirmation testing. As appearance and identity are common tests performed per internal or pharmacopeia test methods, method validation and method transfer to the Pfizer drug product manufacturing site are not conducted as per standard Pfizer procedure • The fir submitted that certificate of analysis of three drug substance lots (EC9895, ED8499 and EE3296) manufactured and tested by Pfizer Ringaskiddy site were previously provided. As indicated above, drug substance batch analysis data from Pfizer Frieburg site is not available. Pfizer Frieburg tests the drug substance for identity and description (appearance), all other test results are taken from Pfizer Ringkaskiddy certificate of analysis.
3.2.S.7	• **Query:** Clarification is required for submitting stability study data of drug substance from Pfizer Limited., Sandwich, United Kingdom while drug substance manufacturer as per form 5F is M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland. **Response of firm:** • Current drug substance (DS) stability data for abrocitinib API are from primary registration stability batches manufactured at Pfizer, Sandwich. The DS manufacturing process used at Pfizer, Sandwich is the same as the process used at the proposed commercial site at Pfizer Ireland Pharmaceuticals at Ringaskiddy, Ireland. Pfizer confirms that the abrocitinib DS primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. The 24 months long term (30°C/75%RH) stability data for batches 19-AP-00096, 19-AP-00101 and 19-AP-00107 are provided with this response. All lots continue to meet acceptance criteria with no trends. • Stability studies at Pfizer Ireland Pharmaceuticals (Ringaskiddy) are ongoing, and 12 months long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions are provided for batches EC9895, ED8499, EE3296. • Primary Registration Stability Data declaration is also provided in Regional section of this response.	
3.2.P.7	• Specify container closure system in which the applied product will be marketed in Pakistan	Container closure system to be marketed in Pakistan is polyvinylidene chloride (PVDC) blister with an aluminum foil lidding.
3.2.P.8	**Query:**	

	Clarification is required for submitting stability study data of drug product from M/s Pfizer, Groton, CT USA while drug product manufacturer as per form 5F / CoPP is M/s Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany. **Response of firm:** • Current drug product (DP) stability data for abrocitinib 50,100 and 200 mg tablets are from primary registration stability batches manufactured at Pfizer Inc. clinical manufacturing site at Groton, CT USA. The DP manufacturing processes used at Groton site is the same as the processes to be used at the proposed Pfizer Inc. commercial site (Freiburg, Germany). The formulations, like-for-like manufacturing equipment and specifications are the same for drug product made at Freiburg and Groton. Pfizer confirms that the abrocitinib DP primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. Drug product stability data from the primary registration batches has been completed through 36 months for 3 batches of 100 and 200 mg strength tablets and 24 months for 3 batches of 50 mg strength tablets at the long term storage conditions of 25 °C/60% RH and 30 °C/75% RH, and 6 months for all strengths at the accelerated storage condition of 40 °C/75% RH.. All lots continue to meet acceptance criteria. Current long term stability data for primary registration batches has been provided in Section 3.2.P.8.1 Stability Summary and Conclusion and Section 3.2.P.8.3 Stability Data. • Stability studies at the commercial manufacturing site of Pfizer Manufacturing Deutschland GmbH in Freiburg, Germany are ongoing, and 12 month long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions were provided for batches H000021926 EJ8432, H000021926 EJ8433, H000021926 EJ8434. • Primary Registration Stability Data declaration is also provided in Regional section of this response.

Decision: Approved as per policy of inspection of manufacturer abroad.

1310.	Name, address of Applicant / Importer	M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan
	Details of Drug Sale License of importer	**License No:** 030 **Address:** B-2, S.I.T.E., Karachi - Pakistan **Address of Godown:** 12-Dockyard Road West Wharf Karachi, C-11-D, S.I.T.E Karachi **Validity:** 25-02-2023 **Status:** Drug License by Way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
	Name, address of manufacturer(s)	M/s Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany
	Name of exporting country	United Kingdom
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate) **CoPP:** Firm has submitted original, legalized CoPP certificate No. PP10174754 dated 06-12-2021 issued by The Medicine and Healthcare Products Regulatory Agency (MHRA) UK for Cibinqo 100mg film coated tablets. The CoPP confirms free sale status of the product in exporting country. The name of importing country on CoPP is mentioned as Pakistan. **GMP:** Firm has submitted original, legalized cGMP certificate No. DE_BW_01_GMP_2021_0006 dated 11-02-2021 in name of M/s Pfizer Manufacturing Deutschland GmbH-Betriebsstätte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany valid upto three years from date of inspection (date of inspection 07-10-2020). The GMP states that the manufacturer complies with the Good Manufacturing Practices requirements. **Manufacturer Authorization:** Firm has submitted legalized copy of manufacturer's authorization No. DE_BW_01_MIA_2021_0025/DE_BW_01_Pfizer Manufacturing_01 dated 10/03/2021	
	Details of letter of authorization / sole agency agreement Original letter of authorization is submitted whereby M/s Pfizer Europe MA EEIG having principal place of business at Boulevard de la Plaine 17, 1050 Brussels, Belgium., as the MA holder in the country of origin has authorized M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan as marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan.	

Product Name with Dosage Form	Generic	Strength	Manufacturing & Packaging
CIBINQO Tablet	Abrocitinib	50mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	100mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany
CIBINQO Tablet	Abrocitinib	200mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany

Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
Dy. No. and date of submission	Dy. No. 4389_: 16-02-2022
Details of fee submitted	PKR 75,000/-: 13-10-2021 (Deposit Slip#840541385)
The proposed proprietary name / brand name	**CIBINQO Film Coated Tablets 100mg**
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Abrocitinib …… 100mg
Pharmaceutical form of applied drug	Film Coated Tablets
Pharmacotherapeutic Group of (API)	Other dermatological preparations, agents for dermatitis, excluding corticosteroids) ATC Code D11AH08
Reference to Finished product specifications	Pfizer Specs (Innovator)
Proposed Pack size	To be provided later
Proposed unit price	To be provided later
The status in reference regulatory authorities	Cibinqo 100mg film-coated tablets MHRA Approved CIBINQO (50mg, 100mg, 200mg) film-coated tablets USFDA Approved Cibinqo 100mg film-coated tablets Germany Approved
For generic drugs (me-too status)	Not Applicable
Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guideline including information related to Drug Substance and Drug Product. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

		Firm has also summarized information related to composition, product development, manufacturing process, excipients, specifications, analytical methods, Reference standards or materials, container closure system and stability studies of Drug Product.
	Name, address of drug substance manufacturer	M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to general information nomenclature, structure, general properties, Manufacturer, description of manufacturing process and controls, critical steps, process validation, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated stability study is conducted at 40°C/75% RH for 06th months. The real time stability data is conducted at 30°C / 75% RH for 12th months. (Batches: 19-AP-00096, 19-AP-00101, 19-AP-00107)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, batch formula, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability studies.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Polyvinylchloride (PVC) / Polyvinylidene chloride (PVDC) foil blisters with aluminum foil lidding High-density polyethylene (HDPE) bottle and polypropylene closures with induction seal liners
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of three batches for 18 months long-term stability conditions of 30°C/75% RH and 25°C/60% RH. Stability study was also monitored at accelerated storage condition at 40 °C/75% RH for 6 months. (Batches: 19-PD-00012, 19-PD-00013, 19-PD-00014)

Remarks of Evaluator [XI]:


INDICATIONS AND USAGE:

CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

- Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test.

- Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA patients.
- Malignancies have occurred with CIBINQO. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs.TNF blockers in RA patients.
- MACE has occurred with CIBINQO. Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients.
- Thrombosis has occurred with CIBINQO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers.

<table>
<tr><th>Section</th><th>Observations</th><th>Response</th></tr>
<tr><td>1.5.4</td><td>• Submit the proposed pack size as well as demanded price for each pack size.</td><td>• Polyvinylidene chloride (PVDC) blisters with aluminum foil lidding film containing 7 film coated tablets. Each pack contains 14, 28 or 91 film coated tablets
• Demanded price will be submitted at the time of price fixation</td></tr>
<tr><td>1.3.4</td><td colspan="2">• Query:
Letter of authorization is from M/s Pfizer Europe MA EEIG Boulevard de la Plaine 17, 1050 Brussels, Belgium., while marketing authorization holder is Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, clarify
Response of firm:
Original letter of authorization is submitted whereby M/s Pfizer Limited having principal place of business at Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom., as the MA holder in the country of origin of following product hereby authorizes M/s Pfizer Pakistan Limited., located at B-2, S.I.T.E., Karachi - 75700 Pakistan to be the marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan.

<table>
<tr><th>Product Name with Dosage Form</th><th>Generic</th><th>Strength</th><th>Manufacturing & Packaging</th></tr>
<tr><td>CIBINQO Tablet</td><td>Abrocitinib</td><td>50mg</td><td>Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany</td></tr>
<tr><td>CIBINQO Tablet</td><td>Abrocitinib</td><td>100mg</td><td>Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany</td></tr>
<tr><td>CIBINQO Tablet</td><td>Abrocitinib</td><td>200mg</td><td>Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany</td></tr>
</table></td></tr>
<tr><td>3.2.S.4</td><td>• Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required.
• Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.
• Provide certificate of analysis of Drug Substance performed by Drug Product manufacturer</td><td>• The drug product manufacturer, Pfizer Manufacturing Deutschland GmbH Freiburg, Germany, uses the drug substance specifications as listed in section 3.2.S.41. Pfizer Freiburg, tests the drug substance for identity and description (appearance), all other test results are taken from Pfizer Ringaskiddy certificate of analysis. A declaration from the drug product manufacturing site is provided with this response.
• The firm submitted that as indicated above, Pfizer Frieberg tests the drug substance for identity and appearance only. Appearance and identity are common industry tests. Internal procedures or pharmacopeia test methods are currently followed for this confirmation testing. As appearance and identity are common tests performed per internal or pharmacopeia test methods, method validation and method transfer to the Pfizer drug product manufacturing site are not conducted as per standard Pfizer procedure
• The fir submitted that certificate of analysis of three drug substance lots (EC9895, ED8499 and EE3296) manufactured and tested by Pfizer Ringaskiddy site were previously provided. As indicated above, drug substance batch analysis data from Pfizer Frieburg site is not available. Pfizer Frieburg tests the drug substance for identity and description (appearance), all other test</td></tr>
</table>

		results are taken from Pfizer Ringkaskiddy certificate of analysis.
3.2.S.7	***Query:*** Clarification is required for submitting stability study data of drug substance from Pfizer Limited., Sandwich, United Kingdom while drug substance manufacturer as per form 5F is M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland. ***Response of firm:*** • Current drug substance (DS) stability data for abrocitinib API are from primary registration stability batches manufactured at Pfizer, Sandwich. The DS manufacturing process used at Pfizer, Sandwich is the same as the process used at the proposed commercial site at Pfizer Ireland Pharmaceuticals at Ringaskiddy, Ireland. Pfizer confirms that the abrocitinib DS primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. The 24 months long term (30°C/75%RH) stability data for batches 19-AP-00096, 19-AP-00101 and 19-AP-00107 are provided with this response. All lots continue to meet acceptance criteria with no trends. • Stability studies at Pfizer Ireland Pharmaceuticals (Ringaskiddy) are ongoing, and 12 months long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions are provided for batches EC9895, ED8499, EE3296. • Primary Registration Stability Data declaration is also provided in Regional section of this response.	
3.2.P.7	• Specify container closure system in which the applied product will be marketed in Pakistan	Container closure system to be marketed in Pakistan is polyvinylidene chloride (PVDC) blister with an aluminum foil lidding.
3.2.P.8	***Query:*** Clarification is required for submitting stability study data of drug product from M/s Pfizer, Groton, CT USA while drug product manufacturer as per form 5F / CoPP is M/s Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany. ***Response of firm:*** • Current drug product (DP) stability data for abrocitinib 50,100 and 200 mg tablets are from primary registration stability batches manufactured at Pfizer Inc. clinical manufacturing site at Groton, CT USA. The DP manufacturing processes used at Groton site is the same as the processes to be used at the proposed Pfizer Inc. commercial site (Freiburg, Germany). The formulations, like-for-like manufacturing equipment and specifications are the same for drug product made at Freiburg and Groton. Pfizer confirms that the abrocitinib DP primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. Drug product stability data from the primary registration batches has been completed through 36 months for 3 batches of 100 and 200 mg strength tablets and 24 months for 3 batches of 50 mg strength tablets at the long term storage conditions of 25 °C/60% RH and 30 °C/75% RH, and 6 months for all strengths at the accelerated storage condition of 40 °C/75% RH.. All lots continue to meet acceptance criteria. Current long term stability data for primary registration batches has been provided in Section 3.2.P.8.1 Stability Summary and Conclusion and Section 3.2.P.8.3 Stability Data. • Stability studies at the commercial manufacturing site of Pfizer Manufacturing Deutschland GmbH in Freiburg, Germany are ongoing, and 12 month long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions were provided for batches H000019421 EJ4550, H000019421 EJ4552, H000019421 EJ4553. • Primary Registration Stability Data declaration is also provided in Regional section of this response.	

Decision: Approved as per policy of inspection of manufacturer abroad.

1311.	Name, address of Applicant / Importer	M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan
	Details of Drug Sale License of importer	**License No:** 030 **Address:** B-2, S.I.T.E., Karachi - Pakistan **Address of Godown:** 12-Dockyard Road West Wharf Karachi, C-11-D, S.I.T.E Karachi **Validity:** 25-02-2023 **Status:** Drug License by Way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
	Name, address of manufacturer(s)	M/s Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany
	Name of exporting country	United Kingdom

Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)

CoPP: Firm has submitted original, legalized CoPP certificate No. PP10174755 dated 06-12-2021 issued by The Medicine and Healthcare Products Regulatory Agency (MHRA) UK for Cibinqo 200mg film coated tablets. The CoPP confirms free sale status of the product in exporting country.
The name of importing country on CoPP is mentioned as Pakistan.

GMP: Firm has submitted original, legalized cGMP certificate No. DE_BW_01_GMP_2021_0006 dated 11-02-2021 in name of M/s Pfizer Manufacturing Deutschland GmbH-Betriebsstätte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany valid upto three years from date of inspection (date of inspection 07-10-2020). The GMP states that the manufacturer complies with the Good Manufacturing Practices requirements.

Manufacturer Authorization: Firm has submitted legalized copy of manufacturer's authorization No. DE_BW_01_MIA_2021_0025/DE_BW_01_Pfizer Manufacturing_01 dated 10/03/2021

Details of letter of authorization / sole agency agreement

Original letter of authorization is submitted whereby M/s Pfizer Europe MA EEIG having principal place of business at Boulevard de la Plaine 17, 1050 Brussels, Belgium., as the MA holder in the country of origin has authorized M/s Pfizer Pakistan Limited, B-2, S.I.T.E., Karachi - Pakistan as marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan.

Product Name with Dosage Form	Generic	Strength	Manufacturing & Packaging
CIBINQO Tablet	Abrocitinib	50mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	100mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany
CIBINQO Tablet	Abrocitinib	200mg	Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany

Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
Dy. No. and date of submission	Dy. No. 4390_: 16-02-2022
Details of fee submitted	PKR 75,000/-: 13-10-2021 (Deposit Slip#09829246972)
The proposed proprietary name / brand name	**CIBINQO Film Coated Tablets 200mg**
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Abrocitinib …… 200mg
Pharmaceutical form of applied drug	Film Coated Tablets
Pharmacotherapeutic Group of (API)	Other dermatological preparations, agents for dermatitis, excluding corticosteroids) ATC Code D11AH08
Reference to Finished product specifications	Pfizer Specs (Innovator)
Proposed Pack size	To be provided later

	Proposed unit price	To be provided later
	The status in reference regulatory authorities	Cibinqo 200mg film-coated tablets MHRA Approved CIBINQO (50mg, 100mg, 200mg) film-coated tablets USFDA Approved Cibinqo 200mg film-coated tablets Germany Approved
	For generic drugs (me-too status)	Not Applicable
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guideline including information related to Drug Substance and Drug Product. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Firm has also summarized information related to composition, product development, manufacturing process, excipients, specifications, analytical methods, Reference standards or materials, container closure system and stability studies of Drug Product.
	Name, address of drug substance manufacturer	M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to general information nomenclature, structure, general properties, Manufacturer, description of manufacturing process and controls, critical steps, process validation, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated stability study is conducted at 40°C/75% RH for 06th months. The real time stability data is conducted at 30°C / 75% RH for 12th months. (Batches: 19-AP-00096, 19-AP-00101, 19-AP-00107)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, batch formula, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability studies.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Not applicable.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Polyvinylchloride (PVC) / Polyvinylidene chloride (PVDC) foil blisters with aluminum foil lidding High-density polyethylene (HDPE) bottle and polypropylene closures with induction seal liners

	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of three batches for 18 months long-term stability conditions of 30°C/75% RH and 25°C/60% RH. Stability study was also monitored at accelerated storage condition at 40 °C/75% RH for 6 months. (Batches: 19-PD-00012, 19-PD-00013, 19-PD-00014)


Remarks of Evaluator [XI]:

INDICATIONS AND USAGE:

CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

- Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test.
- Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA patients.
- Malignancies have occurred with CIBINQO. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs.TNF blockers in RA patients.
- MACE has occurred with CIBINQO. Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients.
- Thrombosis has occurred with CIBINQO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers.

Section	Observations	Response
1.5.4	• Submit the proposed pack size as well as demanded price for each pack size.	• Polyvinylidene chloride (PVDC) blisters with aluminium foil lidding film containing 7 film coated tablets. Each pack contains 14, 28 or 91 film coated tablets • Demanded price will be submitted at the time of price fixation
1.3.4	***Query:*** Letter of authorization is from M/s Pfizer Europe MA EEIG Boulevard de la Plaine 17, 1050 Brussels, Belgium., while marketing authorization holder is Pfizer Limited., Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, clarify ***Response of firm:*** Original letter of authorization is submitted whereby M/s Pfizer Limited having principal place of business at Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom., as the MA holder in the country of origin of following product hereby authorizes M/s Pfizer Pakistan Limited., located at B-2, S.I.T.E., Karachi - 75700 Pakistan to be the marketing authorization holder in Pakistan and be responsible for all matters pertaining to registration of this product in Pakistan. 	
3.2.S.4	• Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product	• The drug product manufacturer, Pfizer Manufacturing Deutschland GmbH Freiburg, Germany, uses the drug substance specifications as listed in section 3.2.S.41. Pfizer Freiburg, tests the drug substance for identity and description (appearance), all other test results are taken from Pfizer Ringaskiddy certificate of analysis. A declaration from the drug product manufacturing site is provided with this response.

Product Name with Dosage Form	Generic	Strength	Manufacturing & Packaging
CIBINQO Tablet	Abrocitinib	50mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	100mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany
CIBINQO Tablet	Abrocitinib	200mg	Pfizer Manufacturing Deutschland GmbH, Betriebsstätte Freiburg, Mooswaldallee 1 79090 Freiburg, Germany

	manufacturer for drug substance(s) shall be submitted. • Provide certificate of analysis of Drug Substance performed by Drug Product manufacturer	• The firm submitted that as indicated above, Pfizer Frieberg tests the drug substance for identity and appearance only. Appearance and identity are common industry tests. Internal procedures or pharmacopeia test methods are currently followed for this confirmation testing. As appearance and identity are common tests performed per internal or pharmacopeia test methods, method validation and method transfer to the Pfizer drug product manufacturing site are not conducted as per standard Pfizer procedure • The fir submitted that certificate of analysis of three drug substance lots (EC9895, ED8499 and EE3296) manufactured and tested by Pfizer Ringaskiddy site were previously provided. As indicated above, drug substance batch analysis data from Pfizer Frieburg site is not available. Pfizer Frieburg tests the drug substance for identity and description (appearance), all other test results are taken from Pfizer Ringkaskiddy certificate of analysis.
3.2.S.7	***Query:*** Clarification is required for submitting stability study data of drug substance from Pfizer Limited., Sandwich, United Kingdom while drug substance manufacturer as per form 5F is M/s Pfizer Ireland Pharmaceuticals Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland. ***Response of firm:*** • Current drug substance (DS) stability data for abrocitinib API are from primary registration stability batches manufactured at Pfizer, Sandwich. The DS manufacturing process used at Pfizer, Sandwich is the same as the process used at the proposed commercial site at Pfizer Ireland Pharmaceuticals at Ringaskiddy, Ireland. Pfizer confirms that the abrocitinib DS primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. The 24 months long term (30°C/75%RH) stability data for batches 19-AP-00096, 19-AP-00101 and 19-AP-00107 are provided with this response. All lots continue to meet acceptance criteria with no trends. • Stability studies at Pfizer Ireland Pharmaceuticals (Ringaskiddy) are ongoing, and 12 months long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions are provided for batches EC9895, ED8499, EE3296. • Primary Registration Stability Data declaration is also provided in Regional section of this response.	
3.2.P.7	• Specify container closure system in which the applied product will be marketed in Pakistan	Container closure system to be marketed in Pakistan is polyvinylidene chloride (PVDC) blister with an aluminum foil lidding.
3.2.P.8	***Query:*** Clarification is required for submitting stability study data of drug product from M/s Pfizer, Groton, CT USA while drug product manufacturer as per form 5F / CoPP is M/s Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1, 79090 Freiburg, Germany. ***Response of firm:*** • Current drug product (DP) stability data for abrocitinib 50,100 and 200 mg tablets are from primary registration stability batches manufactured at Pfizer Inc. clinical manufacturing site at Groton, CT USA. The DP manufacturing processes used at Groton site is the same as the processes to be used at the proposed Pfizer Inc. commercial site (Freiburg, Germany). The formulations, like-for-like manufacturing equipment and specifications are the same for drug product made at Freiburg and Groton. Pfizer confirms that the abrocitinib DP primary registration stability batches meet the requirements of the ICH Q1A(R2) Guidance. • To date, data from the primary registration batches meet proposed abrocitinib specifications at release and stability. Drug product stability data from the primary registration batches has been completed through 36 months for 3 batches of 100 and 200 mg strength tablets and 24 months for 3 batches of 50 mg strength tablets at the long term storage conditions of 25 °C/60% RH and 30 °C/75% RH, and 6 months for all strengths at the accelerated storage condition of 40 °C/75% RH.. All lots continue to meet acceptance criteria. Current long term stability data for primary registration batches has been provided in Section 3.2.P.8.1 Stability Summary and Conclusion and Section 3.2.P.8.3 Stability Data. • Stability studies at the commercial manufacturing site of Pfizer Manufacturing Deutschland GmbH in Freiburg, Germany are ongoing, and 12 month long-term at 30ºC/75%RH and 6 month accelerated stability data at 40ºC/75%RH storage conditions were provided for batches H000019562 EJ4554, H000019562 EJ4555, 0019562 EJ4556.	

	• Primary Registration Stability Data declaration is also provided in Regional section of this response.

Decision: Approved as per policy of inspection of manufacturer abroad.

1312.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt. Ltd.,** Plot 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi **Address of Godown:** NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** N/A
	Name and address of marketing authorization holder (abroad)	Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Tarapur, Boisar, Distt – Palghar – 401506, Mahrashtra State India.
	Name, address of manufacturer(s)	Naprod Life Sciences Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Factory address:** Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Boisar, Distt – Palghar – 401506 India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of CoPP certificate (No. COPP/CERT/KD/114093/2022/11/41431/203573 dated 20/07/2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai India for Gemcitabine for Injection USP 1g (lyophilized). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The CoPP is valid upto 27/04/2025. The name of importing country on CoPP is mentioned as Pakistan. **GMP:** Firm has submitted copy of GMP certificate (No. NEW-WHO-GMP/CERT/KD/111021/2022/11/40081 dated 28/04/2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai India The GMP certificate is valid upto 27/04/2025.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization from Naprod Life Sciences Pvt. Ltd 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. On request of facilitator M/s Miles International (Facilitator) 2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai-400034, India. The letter species that the facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd. to apply for registration of their product. The authorization letter is valid till 31/03/2027. ***However the product mentioned on letter of authorization is Gemcitabine HCl for Injection 200mg/vial while the applied product is Gemibine 1g injection***
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 27895 : dated: 03/10/2022
	Details of fee submitted	PKR 150,000/- dated 20/09/2022 Deposit Slip#398513572972)
	The proposed proprietary name / brand name	**Gemibine 1g**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Gemcitabine Hydrochloride USP 1g
	Pharmaceutical form of applied drug	IV Infusion
	Pharmacotherapeutic Group of (API)	N/A
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Gemcitabine 1 g Powder for Solution for Infusion Ireland Approved
	For generic drugs (me-too status)	Gemcitabin Ebewe 1g Injection by M/s Novartis Pharma (Pakistan) Limited (Reg. No# 066183)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	**DMF Holder:** M/s Mac Chem Products (India) Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Manufacturing and Testing Facilities:** M/s Mac Chem Products (India) Pvt. Ltd., N-211/2/10. Tarapur M.I.D.C., Boisar, Distt – Palghar – 401506, Mahrashtra State India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated conditions (40±2°C/75± 5%RH) for 6 months as well as real time conditions. The real time stability data is conducted at 30±2°C /65±5%RH for 60 months.

		(Batches: GEM0210001, GEM0210002, GEM0210003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against the product Gemcitabine for Injection USP 200mg/vial manufactured by Hospira Inc. by performing quality tests (Description, Identification, pH, Assay, water content).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies including specificity, precision, linearity and range, accuracy, solution stability and robustness for the applied product.
	Container closure system of the drug product	13mm/ 20mm neck size 2ml/ 3ml/ 4ml/ 5ml/ 10ml/ 15ml/ 20ml/ 25ml/ 30ml/ 50ml/ 100ml, molded/ Tubular, Flint/ Titanium amber vial made up of USP type-I glass with rubber stopper and aluminium flip off seal
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40° C ± 2° C / 75% ± 5% RH and real time stability study is conducted at 30° C ± 2° C / 75% ± 5% RH. The batch numbers and time duration for which stability study is conducted is presented in table given below:

Batches	**Real time**	**Accelerated**
NN1444-E	3 months (inverted)	3 months (inverted)
NN1445-A	3 months (inverted)	3 months (upright)
NN1259-A	6 months (inverted)	6 months (inverted)

Remarks of Evaluator [XI]:

Section	**Observations**	**Response**
1.3.4	• Submit product specific sole agency agreement / letter of authorization between applicant and marketing authorization holder	The firm again submitted the same sole agency agreement / letter of authorization as submitted above
1.5.2	• Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit shall be clearly mentioned. Submit correct label claim considering salt factor along with submission of applicable fee	Each vial contains: Gemcitabine HCl Equivalent to Gemcitabine USP……1000mg.
1.5.5	• Indicate Pharmacological class of the API (drug substance) with proper reference and WHO ATC code for each distinct therapeutic indication.	Pharmacological class of API (drug substance) is Pyrimidine analogue; cytotoxic and WHO ATC code is L01BC05
1.5.10	• Dosage form of applied drug shall be mentioned clearly, with complete description	It is a Lyophilized Injection and a white to off white lyophilized mass.
1.5.15-1.5.20	• Submit Commitments as per the CTD guidance document	**Submitted**
1.6.5	• Submit Name and address of API manufacturer.,	**DMF Holder:**

		M/s Mac Chem Products (India) Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Manufacturing and Testing Facilities:** M/s Mac Chem Products (India) Pvt. Ltd., N-211/2/10. Tarapur M.I.D.C., Boisar, Distt – Palghar – 401506, Mahrashtra State India.
3.2.S.4	• Clarification is required for not including the sterility test in drug substance specification by drug substance manufacturer as recommended by USP • Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted. • Provide certificate of analysis of Drug Substance performed by Drug Product manufacturer	• We would like to inform that we are not procuring sterile material from API manufacturer, sterility test is applicable for sterile material. FPP manufacturer is performing MLT analysis for API material". • Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is submitted. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision), linearity and range, solution stability performed by the Drug Product manufacturer for drug substance(s) is submitted • Certificate of analysis of Drug Substance performed by Drug Product manufacturer is submitted
3.2.P.1	• Provide information including type of diluent, its composition, quantity or volume, specifications and regulatory status in Pakistan for the diluent which is to be provided along with the applied drug	**For product development:** Type of diluent: water for injection Quantity: Quantity sufficient Specification: USP **For reconstitution:** 5ml of sodium chloride injection (0.9% w/v)
3.2.P.2	• The submitted pharmaceutical equivalence is of gemcitabine for injection 200mg strength while the applied product is gemcitabine for injection 1g. • Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the comparator product including the tests recommended by USP (Uniformity of dosage units, sterility, bacterial endotoxin, particulate matter in injections, clarity of solution)	• Pharmaceutical Equivalence have been established against the product Gemcitabine for Injection USP 01g/vial manufactured by Eli Lilly and Company by performing quality tests (Description, Identification, pH, Assay, water content, reconstitution time, osmolality and related substance). • **No justification given**
3.2.P.5.4	• In batch analysis the manufacturing date mentioned on COA of one batch is Jun 2021 and manufacturing date of two other batches is October 2021 while batch release date is 26/04/2022, clarify the gap between manufacturing date and batch release date.	• Please note that the release date is just after the manufacturing date but revised COA prepared dated 26.04.2022 to add Description of reconstituted solution test analysis result. You can see the same comment in the foot note of the attached COA also. However COA is not submitted
3.2.P.7	• Specify the container closure system in which the product will be marketed in Pakistan	• Each labelled vial of gemcitabine for injection is packed in Vial 10ml 20mm Flint Tubular type I vial plugged with 20mm Grey Bromo Butyl slotted Rubber stopper and sealed with 20mm flip off aluminium seal
3.2.p.8	• Batch release date mentioned in COA of drug product is subsequent to date of initiation of stability study mentioned stability summary sheets • *The manufacturing date mentioned on COA of batch No. NN1259 is Jun 2021 and release date is 26/04/2022 while date of initiation of stability study is 21-08-2021, clarify?* • *The manufacturing date mentioned on COA of batch No. NN12444 and NN1445 is October 2021 and release date is 26/04/2022 while date of initiation of stability study is 13-12-2021 and 16-12-2021, clarify?*	• Please note that the release date is just after the manufacturing date for finished product & stability date of initiation is 17.07.2021 which is inline. • Please note that we are submitting the stability data up to 12 months at real time conditions. In addition, we also share the declaration that the stability study is in process for further remaining time intervals. We will share the data once the study is completed up to 24 months. • However rea time data submitted is; **Batches** | **Real time** NN1444-E | 6 months (inverted)

	• Submit stability study data of drug product at accelerated conditions for six months and real time conditions till proposed shell life	NN1445-A	6 months (inverted)	
		NN1259-A	12 months (inverted)	

Decision: Approved as per Policy for inspection of manufacturer abroad with shelf life as per submitted long term stability studies data. Registration letter will be issued upon submission of Pharmaceutical equivalence studies against the innovator/reference product of same fill volume and strength including all tests recommended by USP monograph for applied formulation.

- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**
- **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**

1313.	Name, address of Applicant / Importer	**M/s Lab Diagnostic Systems (SMC) Pvt. Ltd.,** Plot 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	**License No:** 01-374-0006-96845D **Address:** 36-A, PSIC, SIE, Taxila Rawalpindi **Address of Godown:** NA **Validity:** 04/08/2024 **Status:** License to sell drugs as distributor **Renewal:** N/A
	Name and address of marketing authorization holder (abroad)	Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Tarapur, Boisar, Distt – Palghar – 401506, Mahrashtra State India.
	Name, address of manufacturer(s)	Naprod Life Sciences Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Factory address:** Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Boisar, Distt – Palghar – 401506 India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted copy of CoPP certificate (No. COPP/CERT/KD/119081/2022/11/42272/205446 dated 29/09/2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai India for Gemcitabine for Injection USP 200mg (lyophilized). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The CoPP is valid upto 17/04/2025. The name of importing country on CoPP is mentioned as Pakistan. **GMP:** Firm has submitted copy of GMP certificate (No. NEW-WHO-GMP/CERT/KD/111021/2022/11/40081 dated 28/04/2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai India The GMP certificate is valid upto 27/04/2025.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization from M/s Naprod Life Sciences Pvt. Ltd 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India., ***on request of facilitator*** M/s Miles International (Facilitator) 2/34, Tardeo Air-Conditioned Market, Tardeo Road, Mumbai-400034, India. ***The letter species***

		that the facilitator appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd. to apply for registration of their product. The authorization letter is valid till 31/03/2027. The product mentioned on letter of authorization is Gemcitabine HCl for Injection 200mg/vial.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 29846 : dated: 21/10/2022
	Details of fee submitted	PKR 150,000/- dated 17/10/2022 (Deposit Slip#356780334)
	The proposed proprietary name / brand name	**Gemibine 200mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Gemcitabine Hydrochloride 200mg
	Pharmaceutical form of applied drug	IV Infusion
	Pharmacotherapeutic Group of (API)	N/A
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Gemcitabine 200mg Powder for Solution for Infusion Ireland Approved
	For generic drugs (me-too status)	Gemcitabin Ebewe 200mg Injection by M/s Novartis Pharma (Pakistan) Limited (Reg. No# 066182)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	**DMF Holder:** M/s Mac Chem Products (India) Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Manufacturing and Testing Facilities:** M/s Mac Chem Products (India) Pvt. Ltd., N-211/2/10. Tarapur M.I.D.C., Boisar, Distt – Palghar – 401506, Mahrashtra State India.

	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated conditions (40±2°C/75± 5%RH) for 6 months as well as real time conditions. The real time stability data is conducted at 30±2°C /65±5%RH for 60 months. (Batches: GEM0210001, GEM0210002, GEM0210003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against the product Gemcitabine for Injection USP 200mg/vial manufactured by Hospira Inc. by performing quality tests (Description, Identification, pH, Assay, water content).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies including specificity, precision, linearity and range, accuracy, solution stability and robustness for the applied product.
	Container closure system of the drug product	13mm/ 20mm neck size 2ml/ 3ml/ 4ml/ 5ml/ 10ml/ 15ml/ 20ml/ 25ml/ 30ml/ 50ml/ 100ml, molded/ Tubular, Flint/ Titanium amber vial made up of USP type-I glass with rubber stopper and aluminium flip off seal
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40° C ± 2° C / 75% ± 5% RH and real time stability study is conducted at 30° C ± 2° C / 75% ± 5% RH. The batch numbers and time duration for which stability study is conducted is presented in table given below: **Batches** | **Real time** | **Accelerated** NN1297-A | 6 months (inverted) | 6 months (inverted) NN1250-B | 6 months (inverted) | 6 months (inverted) NN1301 | 6 months (inverted) | 6 months (inverted)

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.4	• Submit product specific sole agency agreement / letter of authorization between applicant and marketing authorization holder	The firm again submitted the same sole agency agreement / letter of authorization as submitted above
1.5.2	• Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit shall be clearly mentioned. Submit correct label claim	Each vial contains: Gemcitabine HCl Equivalent to Gemcitabine USP…….200mg.


	considering salt factor along with submission of applicable fee	
1.5.5	• Indicate Pharmacological class of the API (drug substance) with proper reference and WHO ATC code for each distinct therapeutic indication.	Pharmacological class of API (drug substance) is Pyrimidine analogue; cytotoxic and WHO ATC code is L01BC05
1.5.10	• Dosage form of applied drug shall be mentioned clearly, with complete description	It is a Lyophilized Injection and a white to off white lyophilized mass.
1.5.15-1.5.20	• Submit Commitments as per the CTD guidance document	**Submitted**
1.6.5	• Submit Name and address of API manufacturer.,	**DMF Holder:** M/s Mac Chem Products (India) Pvt. Ltd., 304, Town Centre, Andheri Kurla Road, Andheri (East), Mumbai – 400 059 India. **Manufacturing and Testing Facilities:** M/s Mac Chem Products (India) Pvt. Ltd., N-211/2/10. Tarapur M.I.D.C., Boisar, Distt – Palghar – 401506, Mahrashtra State India.
3.2.S.4	• Clarification is required for not including the sterility test in drug substance specification by drug substance manufacturer as recommended by USP • Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted. • Provide certificate of analysis of Drug Substance performed by Drug Product manufacturer	• We would like to inform that we are not procuring sterile material from API manufacturer, sterility test is applicable for sterile material. FPP manufacturer is performing MLT analysis for API material". • Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is submitted. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision), linearity and range, solution stability performed by the Drug Product manufacturer for drug substance(s) is submitted • Certificate of analysis of Drug Substance performed by Drug Product manufacturer is submitted
3.2.P.1	• Provide information including type of diluent, its composition, quantity or volume, specifications and regulatory status in Pakistan for the diluent which is to be provided along with the applied drug	**For product development:** Type of diluent: water for injection Quantity: Quantity sufficient Specification: USP **For reconstitution:** 5ml of sodium chloride injection (0.9% w/v)
3.2.P.2	• Submit details of comparator product including name, manufacturing date etc. against which pharmaceutical equivalence is submitted • Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the comparator product including the tests recommended by USP (Uniformity of dosage units, sterility, bacterial endotoxin, particulate matter in injections, clarity of solution)	• The firm submitted details of reference product. Name; Gemcitabin for injection 200mg/vial, Batch No; GM11905A Mfg Date; Not available. Expiry: August 2021 Manufacturer; Hospira Inc. • **No justification given**
3.2.P.5.4	• In batch analysis the manufacturing date mentioned on COA of two batches is July 2021 and manufacturing date of one other batch is June 2021 while batch release date is 24/05/2022, clarify the gap between manufacturing date and batch release date.	Please note that the release date is just after the manufacturing date but revised COA prepared dated 24.05.2022 to add Description of reconstituted solution test analysis result. You can see the same comment in the foot note of the attached COA also.
3.2.P.7	• Specify the container closure system in which the product will be marketed in Pakistan	Each labelled vial of gemcitabine for injection is packed in Vial 10ml 20mm Flint Tubular type I vial plugged with 20mm Grey Bromo Butyl slotted Rubber stopper and sealed with 20mm flip off aluminium seal
3.2.P.8	• Batch release date mentioned in COA of drug product is subsequent to date of initiation of stability study mentioned stability summary sheets, clarify	• Please note that the release date is just after the manufacturing date for finished product & stability date of initiation is 17.07.2021 which is inline. • Please note that we are submitting the stability data up to 12 months at real time conditions. In addition,

	• *The manufacturing date mentioned on COA of batch No. NN1250 is Jun 2021 and release date is 24/05/2022 while date of initiation of stability study is 17-07-2021, clarify?* • *The manufacturing date mentioned on COA of batch No. NN1297 and NN1301 is July 2021 and release date is 24/05/2022 while date of initiation of stability study is 27-08-2021 and 15-09-2021, clarify?* • Submit stability study data of drug product at real time conditions till proposed shell life	we also share the declaration that the stability study is in process for further remaining time intervals. We will share the data once the study is completed up to 24 months.

Decision: Approved as per Policy for inspection of manufacturer abroad with shelf life as per submitted long term stability studies data. Registration letter will be issued upon submission of Pharmaceutical equivalence studies against the innovator/reference product of same fill volume and strength including all tests recommended by USP monograph for applied formulation.

- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**
- **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**

1314.	Name, address of Applicant / Importer	M/s Al-Habib Pharmaceuticals, Plot #81, block B, S.M.C.H.S., Karachi.
	Details of Drug Sale License of importer	**DSL No**.: 1245 **Address**: Al-Habib Pharmaceuticals, 81-B, block B, S.M.C.H.S., Karachi. **Godown:** 1. Plot No. 10 Sector 25 KIA Karachi 2. HT-8, Landhi Industrial Area, Karachi **Validity:** 18/05/2022 **Status:** Drug License by way of wholesale
	Name and address of marketing authorization holder (abroad)	Naprod Life Sciences Pvt. Ltd., Plot No. G-17/1, M.I.D.C. Tarapur, Boisar, Thane–401506, Mahrashtra State India.
	Name, address of manufacturer(s)	Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Tarapur, Boisar, Distt – Thane – 401506 India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. COPP/CERT/KD/83867/2019/11/27845/143336 dated 02/05/2019 issued by Food and Drug Administration Mahrashtra State Mumbai India for Doxorubicin Hydrochloride for Injection BP 10mg (lyophilszed). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The CoPP is valid upto 03/04/2022. The name of importing country mentioned on annexure attached with CoPP is mentioned as Pakistan. **GMP:** Firm has submitted notarized copy of GMP certificate (No. NEW-WHO-GMP/CERT/KD/80691/2019/11/27530 dated 04/04/2019 issued by Food and Drug Administration Mahrashtra Estate Mumbai India The GMP certificate is valid upto 03/04/2022.

	Details of letter of authorization / sole agency agreement	Firm has submitted notarized copy of letter of authorization from M/s Naprod Life Sciences Pvt. Ltd 304, Town Centre-1, Andheri Kurla Road, Andheri (East), Mumbai, India., The letter species that the manufacturer authorizes M/s Al Habib Pharmaceuticals, Plot #81, block B, SMCHS., 74400 Karachi., Pakistan as sole agent and distributor of following drugs only.  S.NO / GENERICS / BRAND NAME 1 Capecitabine 500mg TAB. NAPROCAP - 500 2 Methotrexate 2.5mg TAB. ALLTREX 3 Letrozole 2.5mg TAB. LETORIPE 4 Doxorubicin HCl for inj 50mg. NAPRODOX 50 5 Leucovorin Calcium inj. 300mg. CAFONATE 6 Fluorouracil inj. 500mg. FLUONCO 7 Bicalutamide 50mg TAB. MACABI 8 Doxorubicin HCl for inj 10mg. NAPRODOX 10 9 Paclitaxel inj. 150 mg Inj Napro-Tax 10 Paclitaxel inj. 100 mg Inj Napro-Tax 11 Paclitaxel inj. 300 mg Inj Napro-Tax
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5228: dated; 24-02-2022
	Details of fee submitted	PKR 150,000 ; Dated: 26-01-2022 (Deposit slip#976636166)
	The proposed proprietary name / brand name	**NAPRODOX 10mg lyophilized powder for injection**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Doxorubicin HCl ……. 10 mg
	Pharmaceutical form of applied drug	Lyophilized powder for Injection
	Pharmacotherapeutic Group of (API)	Antineoplastic and Immunomodulating Agents; Anthracyclines and related substances WHO ATC Code: L01DB01
	Reference to Finished product specifications	BP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Doxorubicin Hydrochloride 10mg/vial for Injection by M/s Hikma USFDA Approved
	For generic drugs (me-too status)	Astrodox Lyophilized Powder for Injection 10mg by M/s Aster Life Sciences (Reg. No# 78110)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

		specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Intas Pharmaceuticals Ltd., Plot No. 2702/A, GIDC Estate, Ankleshwar-393 002, District: Bharuch, Gujarat State India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated study is conducted at 40±2°C/75± 5%RH for 6 months and the real time stability study is conducted at 25 ± 2°C/ 60 ± 5 % RH till 24 months. (Batches: 71203715, 71204715, 71204915)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability study
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has been established against the reference product ADRIAMYCIN RD 10 mg/vial injection by performing quality tests (Description, Identification, pH, Assay, particulate matter, reconstitution time).
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies including specificity, precision, linearity and range, accuracy and solution stability for the applied product.
	Container closure system of the drug product	5ml 20mm Flint Tubular-USP Type-I Glass vial with Rubber stopper 20mm Grey Bromo Butyl Slotted Siliconised by Silicon & Alu. Seal Lacq.20mm F/O Top Red Plain
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40° C ± 2° C / 75% ± 5% RH for 06 months and real time stability study is conducted at 30° C ± 2° C / 75% ± 5% RH for 36 months.

Batches	**Mfg date**	**Batch size**
NN7196	May 2017	18160 vials
NN7232	Jun 2017	18160 vials
NN7233	Jun 2017	18160 vials

Remarks of Evaluator [XI]:


<table>
<tr><th>Section</th><th>Observations</th><th>Response</th></tr>
<tr><td>1.3.3</td><td>• Submit valid Certificate of Pharmaceutical Product (CoPP) and GMP certificate of the drug product Manufacturer issued by relevant regulatory authority in the country of origin</td><td>• The firm submitted that the COPP that we submitted with CTD dossier has a validity till April 2022, as it gets expire during its period in R&I that's why as per the rule it will be considered as valid as we received R&I attested letter on 24th-Februray-2022.</td></tr>
<tr><td>1.3.4</td><td>• Submit copy of valid Drug Sale License (DSL) issued by relevant licensing authority</td><td>Firm has submitted valid copy of DSL.
DSL No.: 0230
Address: Al Habib Pharmaceuticals, 81-B, block B, S.M.C.H.S., Karachi.
Godown:
Plot No. 393/7 & 393/8 Sector 7-A KIA Karachi
Validity: 18/05/2024
Status: Drug License by way of wholesale</td></tr>
<tr><td>1.3.5</td><td>• Submit evidence of approval of manufacturing facility / Approved Section from Licensing Authority</td><td>Firm submitted cGMP certificate in name of Naprod Life Sciences Pvt. Ltd., Plot No. G-17/1, M.I.D.C. Tarapur, Boisar, District Palghar–401506, Mahrashtra State India showing lyophilized / Powder injectable cytotoxic section</td></tr>
<tr><td>1.6.5</td><td>• Submit Name and address of API manufacturer.,
• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.</td><td>• Firm has submitted details of API Manufacturer:
M/s Intas Pharmaceuticals Ltd., Plot No. 2702/A, GIDC Estate, Ankleshwar-393 002, District: Bharuch, Gujarat State India.
• Firm has submitted cGMP certificate in name of M/s Intas Pharmaceuticals Ltd., Plot No. 2702/A, GIDC Estate, Ankleshwar-393 002, District: Bharuch, Gujarat State India issued by Commissioner Food and Drug Administration Gandhinagar India valid upto 05-09-2025</td></tr>
<tr><td>3.2.S.4</td><td>• Justification is required for selecting different limits of specification of total impurities (Not more than 2.0%) by drug product manufacturer than drug substance manufacturer (Not more than 1.0%)</td><td>• Please note that we are following the BP monograph for analysis of finished product. BP Monograph of Doxorubicin for injection mentions limit of total impurities - Not more than 2.0%. BP monograph of finished product is submitted.</td></tr>
<tr><td>3.2.P.1</td><td>• Justify the role of methyl paraben in the applied formulation
<table>
<tr><th>Applied product</th><th>Reference product</th></tr>
<tr><td>Doxorubicin HCl</td><td>Doxorubicin HCl</td></tr>
<tr><td>Lactose monohydrate</td><td>Lactose Monohydrate</td></tr>
<tr><td>Methyl paraben</td><td></td></tr>
<tr><td>HCl</td><td></td></tr>
<tr><td>NaOH</td><td></td></tr>
<tr><td>Water for injection</td><td></td></tr>
</table>
• Provide information including type of diluent, its composition, quantity or volume, specifications and regulatory status in Pakistan for the diluent which is to be provided along with the applied drug</td><td>• Methyl paraben is used as Solubilizing agent in the formulation of Doxorubicin for injection 10 mg.
• Methyl paraben occurs as colorless crystals or a white crystalline powder. It is odorless or almost odorless and has a slight burning taste. Methyl paraben is widely used as an antimicrobial preservative in cosmetics, food products, and pharmaceutical formulations. Aqueous solutions at pH 3–6 are stable The WHO has set an estimated total acceptable daily intake for methyl-, ethyl-, and propyl parabens at up to 10 mg/kg body weight and official monograph available in BP.
• However as per Innovator Literature, for Doxorubicin Hydrochloride for Injection particularly used as solubilizing agent which improved or give rapid dissolution of powder in final lyophilized product. Methyl paraben was used in formulation to improve solubilization by reducing the gel formation during reconstitution. Being generic drug of existing Innovator all excipients used as per Innovator and comply as per generic drug definition.
• No information provided</td></tr>
<tr><td>3.2.P.2</td><td>• Submit details of comparator product including name of manufacturer, Batch No#, manufacturing date, expiry date etc. against which pharmaceutical equivalence is submitted
• Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator/comparator product</td><td>• Information not provided
• Pharmaceutical equivalence was proved on the basis of enclosed comparison of important physicochemical characteristic of innovator product and drug product. Also the proposed Drug product contains same active substance and excipient in similar quantity as that of innovator product. Complete testing as per the any specific pharmacopeia is not necessary during product development as we develop product for global supply with different pharmacopeia. As the results of critical Physicochemical</td></tr>
</table>

	including the tests recommended by BP (Bacterial endotoxin, Water)	parameters are similar and comparable, therefore both the drug product and innovator product are pharmaceutically equivalent. • Moreover Naprod ensure to perform complete analysis of drug product inline with the BP pharmacopoeia during release of every batch & Submitted stability study.
3.2.P.5.4	• In batch analysis the manufacturing date mentioned on COA of one batch No. NN7233 is Jun 2017 while batch release date is October 2017, clarify the gap between manufacturing date and batch release date.	• Please Note that the batch was manufactured in the end of June 2017. Subsequently the Mother batch was released in July-2017 as per the common pharmacopoeia grades (IP/BP). • Refer enclosed COA of mother batch with common IP/BP pharmacopoeia. Then this batch was charged on the stability study in August 2017. • Later as per export requirement, we have packed and released some quantity from same mother batch as per only BP specification in October-2017. • Since we are proposing the BP grade for finished product in Pakistan registration, we have submitted the same finished product COA which was released as per BP in October-2017 as per Pakistan requirement
3.2.P.8	• Batch release date mentioned in COA of drug product is subsequent to date of initiation of stability study mentioned in stability summary sheets, clarify • The manufacturing date mentioned on COA of batch No. NN7233 is Jun 2017and batch release date is October 2017 while date of initiation of stability study is 24-08-2017, clarify?	• Naprod had manufactured and initially released batch as per common pharmacopoeia (IP/BP) & then charged for stability study to meet domestic as well as export registration requirements. • Later as per Export requirement, we have released some quantity from these batches to export market as per BP pharmacopoeia grade. Since we are proposing the BP grade for finished product in Pakistan registration, we have submitted the same finished product COA which were released subsequently. • Hence COA of these batches have subsequent release date, after stability initiation date.

Remarks of Evaluator: Registration Board was apprised regarding an e. mail received to Director PE&R Division form M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.

Decision: Deferred for the Verification of "Sole Agency Agreement" between M/s. Al Habib Pharmaceuticals, Plot # 81, Block B, SMCHS, Karachi & M/s Naprod Life Sciences Pvt. Ltd. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, India.

1315.	Name, address of Applicant / Importer	M/s Al-Habib Pharmaceuticals, Plot #81, block B, S.M.C.H.S., Karachi.
	Details of Drug Sale License of importer	**DSL No**.: 1245 **Address**: Al-Habib Pharmaceuticals, 81-B, block B, S.M.C.H.S., Karachi. **Godown:** 1. Plot No. 10 Sector 25 KIA Karachi 2. HT-8, Landhi Industrial Area, Karachi **Validity:** 18/05/2022 **Status:** Drug License by way of wholesale
	Name and address of marketing authorization holder (abroad)	Naprod Life Sciences Pvt. Ltd., Plot No. G-17/1, M.I.D.C. Tarapur, Boisar, Thane–401506, Mahrashtra State India.
	Name, address of manufacturer(s)	Naprod Life Sciences Pvt. Ltd., G-17/1, M.I.D.C. Tarapur, Boisar, Distt – Thane – 401506 India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original, legalized CoPP certificate (No. COPP/CERT/KD/104901/2021/11/37012/179916 dated 16/08/2021 issued by Food and Drug Administration

		Mahrashtra State Mumbai India for Fluonco (Fluorouracil Injection BP 50mg (5ml, 10ml). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The CoPP is valid upto 03/04/2022. The name of importing country mentioned on annexure attached with CoPP is mentioned as Pakistan. **GMP:** Firm has submitted notarized copy of GMP certificate (No. NEW-WHO-GMP/CERT/KD/80691/2019/11/27530 dated 04/04/2019 issued by Food and Drug Administration Mahrashtra Estate Mumbai India The GMP certificate is valid upto 03/04/2022.
	Details of letter of authorization / sole agency agreement	Firm has submitted notarized copy of letter of authorization from M/s Naprod Life Sciences Pvt. Ltd 304, Town Centre-1, Andheri Kurla Road, Andheri (East), Mumbai, India., The letter species that the manufacturer authorizes M/s Al Habib Pharmaceuticals, Plot #81, block B, SMCHS., 74400 Karachi., Pakistan as sole agent and distributor of following drugs only. 
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 5225: dated; 24-02-2022
	Details of fee submitted	PKR 150,000 ; Dated: 26-01-2022 (Deposit slip#24358311719)
	The proposed proprietary name / brand name	**Fluonco injection BP 500mg/10ml**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Fluorouracil injection BP……. 500mg/10ml
	Pharmaceutical form of applied drug	Solution for Injection
	Pharmacotherapeutic Group of (API)	Antimetabolites; Pyrimidine analogues WHO ATC Code: L01BC
	Reference to Finished product specifications	BP

S.NO	GENERICS	BRAND NAME
1	Capecitabine 500mg TAB.	NAPROCAP - 500
2	Methotrexate 2.5mg TAB.	ALLTREX
3	Letrozole 2.5mg TAB.	LETORIPE
4	Doxorubicin HCl for inj 50mg.	NAPRODOX 50
5	Leucovorin Calcium inj. 300mg.	CAFONATE
6	Fluorouracil inj. 500mg.	FLUONCO
7	Bicalutamide 50mg TAB.	MACABI
8	Doxorubicin HCl for inj 10mg.	NAPRODOX 10
9	Paclitaxel inj. 150 mg Inj	Napro-Tax
10	Paclitaxel inj. 100 mg Inj	Napro-Tax
11	Paclitaxel inj. 300 mg Inj	Napro-Tax

	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Fluorouracil 500mg/10ml (50mg/ml) Injection by Accord Healthcare USFDA Approved
	For generic drugs (me-too status)	Flurosol Injection 500mg/10ml by M/s Pharmasol (Pvt) Ltd (Reg. No# 107202)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Nantong Jinghua Pharmaceutical Co., Ltd., No.20, 3 Haibin Road, Yanhai Economic Development Zone, Rudong, Nantong, Jiangsu, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The accelerated study is conducted at 40±2°C/75± 5%RH for 6 months and the real time stability study is conducted at 25 ± 2°C/ 60 ± 5 % RH till 48 months. (Batches: FLU2012001-RD, FLU2012002-RD, FLU2012003-RD)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability study
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has been established against the reference product Fluorouracil Injection 50mg/ml by M/s Accord Pharmaceutical Ltd., by performing quality tests (Description, pH, Assay, particulate matter, bacterial endotoxin, test for urea, test for related substances).
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies including specificity, precision, linearity and range, accuracy for the applied product.
	Container closure system of the drug product	10ml 20mm Amber coloured Type-I vial with 20mm Grey Bromo Butyl Rubber stopper with aluminium seal
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40° C ± 2° C / 75% ± 5% RH for 06 months and real time stability

		study is conducted at 30° C ± 2° C / 75% ± 5% RH for 36 months. **Batches** / **Mfg date** / **Batch size** NN9308-B inverted…LT / Jul 2019 / 22828 vials NN9358-A upright….LT / Aug 2019 / 22828 vials NN9359-A inverted…..LT / Aug 2019 / 22828 vials Firm submitted accelerated stability study data at both orientation (inverted, upright)

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.3	• Submit valid Certificate of Pharmaceutical Product (CoPP) and GMP certificate of the drug product Manufacturer issued by relevant regulatory authority in the country of origin	• The firm submitted that the COPP that we submitted with CTD dossier has a validity till April 2022, as it gets expire during its period in R&I that's why as per the rule it will be considered as valid as we received R&I attested letter on 24th-Februray-2022. • Firm has submitted cGMP certificate of M/s Naprod Life Sciences Pvt. Ltd., Plot No. G-17/1, M.I.D.C. Tarapur, Boisar, Dist. Palghar–401506, Mahrashtra State India issued by Comissioner Food and Drug Administration Maharashtra state India valid upto 27-04-2025
1.3.4	• Submit copy of valid Drug Sale License (DSL) issued by relevant licensing authority	• Firm has submitted valid copy of DSL. **DSL No**.: 0230 **Address**: Al Habib Pharmaceuticals, 81-B, block B, S.M.C.H.S., Karachi. **Godown:** Plot No. 393/7 & 393/8 Sector 7-A KIA Karachi **Validity:** 18/05/2024 **Status:** Drug License by way of wholesale
1.3.5	• Submit evidence of approval of manufacturing facility / Approved Section from Licensing Authority	Firm submitted cGMP certificate in name of Naprod Life Sciences Pvt. Ltd., Plot No. G-17/1, M.I.D.C. Tarapur, Boisar, District Palghar–401506, Mahrashtra State India showing lyophilized / Powder injectable cytotoxic section
1.5.2	• Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit shall be clearly mentioned as per reference formulation along with submission of applicable fee	Fluorouracil injection BP 500mg/10ml (50mg/ml)
1.6.5	• Submit Name and address of API manufacturer.,	Nantong Jinghua Pharmaceutical Co., Ltd., No.20, 3 Haibin Road, Yanhai Economic Development Zone, Rudong, Nantong, Jiangsu, China.
3.2.P.1	• Justify the role of Tris Buffer (tromethamine) in the applied formulation **Applied product** / **Reference product** Fluorouracil / Fluorouracil Sodium Hydroxide / Sodium Hydroxide Tris Buffer (tromethamine) / Water for injection Water for injection /	Based on information and rationale; Tris Buffer used as buffering agent and Sodium Hydroxide as pH adjustifier along with Water for Injection. Selected excipients are very conventional and normally used in Injection manufacturing for their particular function like buffering agent and pH adjuster.
3.2.P.2	• Submit details of comparator product including name, manufacturing date, expiry date etc. against which pharmaceutical equivalence is submitted	• The firm submitted details of reference / comparator product. The details of reference product are: Name: Fluorouracil Injection 50mg/ml; B. No: N03889, Mfg Date: 16-06-2015, Expiry Date: 15-06-2017 Manufacturer by: Accord Pharmaceutical Ltd.
3.2.P.8	• Clarification is required as submitted long term stability summery sheets of drug product conclude as: the product meets the prescribed standards of quality after	• The firm submitted that 36 months stability data submitted but the proposed shelf life mentioned in Stability summary sheet is 24 months. (Stability summary sheet attached)

	completion of 18 months long term stability study as per stability indicating specifications, while stability study data upto 36 months is submitted. • The submitted long term stability summary sheets include both the conditions 40° C ± 2° C / 75% ± 5% RH and 30° C ± 2° C / 75% ± 5%, clarify?	• In the sheet three conditions and temperature are mentioned but the long term and only 30°C ± 2°C and 75% ± 5%RH is marked (✓) which clearly shows the long term stability conducted on 30°C ± 2°C and 75% ± 5%RH (Sheet attach for clarification)

Remarks of Evaluator: Registration Board was apprised regarding an e. mail received to Director PE&R Division form M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.

Decision: Decision: Deferred for the Verification of "Sole Agency Agreement" between M/s. Al Habib Pharmaceuticals, Plot # 81, Block B, SMCHS, Karachi & M/s Naprod Life Sciences Pvt. Ltd. Factory: G-17/1, M.I.D.C., Tarapur, Boisar, Dist. Thane-401 506, India.

Case No. 03; New application for registration of Human drugs with stability study data on Form 5D on export facilitation

Assistant director PR-I/EFD vide letter No.F.1-6/2019-PR-I (EFD dated 06-10-2022 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the *pharmaceutical* i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision of the authority, the following firm have achieved the benchmark of more than **100,000 USD** during the **fiscal Year 2021-2022** and submitted their applications for priority consideration in lieu of export facilitation for Registration Board please.,

1316	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited., 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Racetril sachet 10mg
	Composition	Each sachet contains: Racecadotril……..10mg
	Diary No. Date of R& I & fee	Dy. No. 1330 dated 13-01-2012, Fee Rs: 20,000/- dated 17-02-2014; Rs.30,000/- (Photocopy attached) 02-09-2015.
	Pharmacological Group	Anti-diarrheal
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	Rs.600/10's
	Approval status of product in Reference Regulator Authorities	Hidrasec Infants 10mg, Granules for oral suspension MHRA Approved

	Me-too status	Hidrasec 10mg Sachet by M/s Abbott Laboratories (Reg. No# 87082)
	GMP status	
	Remarks of the Evaluator	• Stability studies are required as per checklist of 251st meeting of DRB. • Clinical data/Justification required

Decision (268-DRB): Deferred for submission of stability study data as per guidelines of 251st DRB meeting

STABILITY STUDY DATA

Manufacturer of API	M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India		
API Lot No.	2KA0261119		
Description of Pack (Container closure system)	Printed Auminium foil sachet		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	20SB(A)-025-01	20SB(A)-026-02	20SB(A)-027-03
Batch Size	1500 Sachets	1500 Sachets	1500 Sachets
Manufacturing Date	12-2020	12-2020	12-2020
Date of Initiation	04-01-2021	04-01-2021	04-01-2021
No. of Batches	03		
Date of Submission	(13589 & 13591) 20-05-2021 & (30564) 08-11-2021		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	The firm has referred to previous inspection for authenticity of stability data of their product conducted by the panel on the basis of which Registration Board in 294th meeting dated 09th April, 2020 decided to approve registration of Movcol Paediatric Sachet. Inspection date: 07th February, 2020 The report shows that: • The HPLC software is 21 CFR compliant. • Audit Trail on the testing reports are available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software 21CFR compliance.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA (2KA0261119) of Racecadotril from M/s Symed Labs Limited., India and M/s Genix Pharma (Pvt.) Ltd is submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer is provided by the firm.
4.	Stability study data of API from API manufacturer	Firm has submitted stability study data of API as per zone IV-A conditions. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 36 months and at

		Accelerated conditions; 40°C ± 2°C / 75% ± 5%RH for 06 months. Batches: (RACL009, RACL010 & RACL011))
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate in the name of M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India., issued by Deputy Director and Certifying Authority Drugs Control Administration Telangana State India valid upto 24-04-2023.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	The firm submitted that they used the same excipient as that of innovator, hence Drug-excipients compatibility studies is not required
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** 20SB(A)-025-01 / 1500 Sachets / 12-2020 20SB(A)-026-02 / 1500 Sachets / 12-2020 20SB(A)-027-03 / 1500 Sachets / 12-2020
11.	Record of comparative dissolution data (where applicable)	Firm has submitted pharmaceutical equivalence report of applied product against the product Hidresac 10mg sachet by M/s Abbot by performing quality tests. (Appearance, Identification, average weight, assay)
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of 03 batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail reports on product testing is submitted upto 3 months.
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted upto 3 months only

Remarks of Evaluator [XI]

Deficiency/Observation	**Response by Firm**
• Submit readable copy of invoice attested by AD (I&E) DRAP field office • Submit GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years • Raw data sheets at 6th month time point of real time and accelerated stability study is not submitted • Submit Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) upto 06th months	• Firm has submitted readable copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd attested by AD (I&E) DRAP Karachi dated 17-03-2020. • Firm has submitted cGMP certificate issued on 07th October 2021 based on inspection conducted on 15th June 2021 • Raw data sheets at 6th month time point of real time and accelerated stability study is submitted

	• Firm has submitted audit trail reports on product testing • Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) upto 06th months

Decision: Approved with Innovator's specification. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.**

1317	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited., 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Racetril sachet 30mg
	Composition	Each sachet contains: Racecadotril……..30mg
	Diary No. Date of R& I & fee	Dy. No. 1330 dated 13-01-2012, Fee Rs: 20,000/- dated 17-02-2014; Rs.30,000/- (Photocopy attached) 02-09-2015.
	Pharmacological Group	Anti-diarrheal
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	Rs.800/10's, Rs.1120/14's
	Approval status of product in Reference Regulator Authorities	Hidrasec Children 30mg, Granules for oral suspension MHRA Approved
	Me-too status	Hidrasec 30mg Sachet by M/s Abbott Laboratories (Reg. No# 87517)
	GMP status	
	Remarks of the Evaluator	• Stability studies are required as per checklist of 251st meeting of DRB. • Clinical data/Justification required

Decision (268-DRB): Deferred for submission of stability study data as per guidelines of 251st DRB meeting

STABILITY STUDY DATA

Manufacturer of API	M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India		
API Lot No.	2KA0261119		
Description of Pack (Container closure system)	Printed Auminium foil sachet		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	20SB(A)-028-01	20SB(A)-029-02	20SB(A)-030-03
Batch Size	1500 Sachets	1500 Sachets	1500 Sachets
Manufacturing Date	12-2020	12-2020	12-2020
Date of Initiation	04-01-2021	04-01-2021	04-01-2021
No. of Batches	03		

Date of Submission	(13590 & 13592) 20-05-2021 & (3063) 19-11-2021

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	The firm has referred to previous inspection for authenticity of stability data of their product conducted by the panel on the basis of which Registration Board in 294th meeting dated 09th April, 2020 decided to approve registration of Movcol Paediatric Sachet. Inspection date: 07th February, 2020 The report shows that: • The HPLC software is 21 CFR compliant. • Audit Trail on the testing reports are available. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software 21CFR compliance.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA (2KA0261119) of Racecadotril from M/s Symed Labs Limited., India and M/s Genix Pharma (Pvt.) Ltd is submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer is provided by the firm.
4.	Stability study data of API from API manufacturer	Firm has submitted stability study data of API as per zone IV-A conditions. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 36 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 06 months. Batches: (RACL009, RACL010 & RACL011))
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate in the name of M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India., issued by Deputy Director and Certifying Authority Drugs Control Administration Telangana State India valid upto 24-04-2023.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	The firm submitted that they used the same excipient as that of innovator, hence Drug-excipients compatibility studies is not required
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** 20SB(A)-028-01 / 1500 Sachets / 12-2020 20SB(A)-029-02 / 1500 Sachets / 12-2020 20SB(A)-030-03 / 1500 Sachets / 12-2020
11.	Record of comparative dissolution data (where applicable)	Firm has submitted pharmaceutical equivalence report of applied product against the product Hidresac 30mg sachet

		by M/s Abbot by performing quality tests. (Appearance, Identification, average weight, assay)
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of 03 batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail reports on product testing is submitted upto 3 months.
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted upto 3 months only

REMARKS OF EVALUATOR [XI]

Deficiency/Observation	Response by Firm
• Same diary number and date of both applications • Submit readable copy of invoice attested by AD (I&E) DRAP field office • Submit GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years • Raw data sheets at 6th month time point of real time and accelerated stability study is not submitted • Submit Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) upto 06th months	• Firm has submitted readable copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd attested by AD (I&E) DRAP Karachi dated 17-03-2020. • Firm has submitted cGMP certificate issued on 07th October 2021 based on inspection conducted on 15th June 2021 • Raw data sheets at 6th month time point of real time and accelerated stability study is submitted • Firm has submitted audit trail reports on product testing • Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) upto 06th months

Decision: Approved with Innovator's specification. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.**

1318	Name and address of manufacturer / Applicant	M/s Genix Pharma Private Limited., 44-45B Korangi creek road Karachi
	Brand Name +Dosage Form + Strength	Racetril capsule 100mg
	Composition	Each capsule contains: Racecadotril……..100mg
	Diary No. Date of R& I & fee	Dy. No. 762 dated 16-05-2014, Fee Rs: 20,000/- dated 16-05-2014; Rs.30,000/- (Photocopy attached) 02-09-2015.
	Pharmacological Group	Anti-diarrheal
	Type of Form	Form 5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	Rs.300/10's, Rs.600/20's
	Approval status of product in Reference Regulator Authorities	Hidrasec 100mg hard capsules MHRA Approved
	Me-too status	Hidrasec 100mg capsule by M/s Abbott Laboratories (Reg. No# 87518)
	GMP status	

	Remarks of the Evaluator	• Stability studies are required as per checklist of 251st meeting of DRB. • Clinical data/Justification required • Fee challans are needed to be verified.

Decision (268-DRB): Deferred for submission of stability study data as per guidelines of 251st DRB meeting

STABILITY STUDY DATA

Manufacturer of API	M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India		
API Lot No.	2KA0261119		
Description of Pack (Container closure system)	Alu-Alu Blister Pack		
Stability Storage Condition	Real time: 30˚C ± 2˚ C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	20SB-133-01	20SB-134-02	20SB-135-03
Batch Size	1500 capsule	1500 capsule	1500 capsule
Manufacturing Date	08-2020	08-2020	08-2020
Date of Initiation	20-08-2020	20-08-2020	20-08-2020
No. of Batches	03		
Date of Submission	(12997) 04-05-2021		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	Documents to Be Provided	Status
1.	Reference of previous approval of applications with stability study data of the firm	No reference given
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA (2KA0261119) of Racecadotril from M/s Symed Labs Limited., India and M/s Genix Pharma (Pvt.) Ltd is submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer is provided by the firm.
4.	Stability study data of API from API manufacturer	Firm has submitted stability study data of API as per zone IV-A conditions. Stability study is conducted at Real time conditions; 30˚C ± 2˚C / 65% ± 5%RH for 36 months and at Accelerated conditions; 40˚C ± 2˚C / 75% ± 5%RH for 06 months. Batches: (RACL009, RACL010 & RACL011))
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate in the name of M/s Symed Labs Limited., Plot No. 25/B, Phase-III, IDA, Jeedimetla Village, Quthbullapur Mandal, Medchal - Malkajgiri District, Pincode 500005, Telangana State, India., issued by Deputy Director and Certifying Authority Drugs Control Administration Telangana State India valid upto 24-04-2023.

6.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd.
7.	Protocols followed for conduction of stability study	Submitted
8.	Method used for analysis of FPP	Submitted
9.	Drug-excipients compatibility studies (where applicable)	No data submitted
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted Batch Manufacturing record of following 03 Batches: **Batch No.** / **Batch Size** / **Mfg. Date** 20SB-133-01 / 1500 capsule / 08-2020 20SB-134-02 / 1500 capsule / 08-2020 20SB-135-03 / 1500 capsule / 08-2020
11.	Record of comparative dissolution data (where applicable)	Firm has submitted CDP studies of applied product against the innovator's product Hidrasec 100mg capsule by M/s Abbot Laboratories Ltd in Acid media 0.1N HCl (pH 1.2), acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of 03 batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not submitted
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

REMARKS OF EVALUATOR [XI]

Deficiency/Observation	Response by Firm
• Submit readable copy of invoice attested by AD (I&E) DRAP field office • Submit GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years • Drug excipient compatibility study is not submitted • Justification is required for not including test for water content of drug product as per reference product public assessment report • Submit Compliance Record of HPLC software 21CFR & audit trail reports on product testing. • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) • Submit latest inspection report for exemption of stability data conducted by the panel for authenticity of stability data (PSI)	• Firm has submitted readable copy of invoice No. EXP/1334 dated 19-02-2020 for import of 0.85kg of Racecadotril (Batch#2KA0261119) in name of M/s Genix Pharma (Pvt.) Ltd attested by AD (I&E) DRAP Karachi dated 17-03-2020. • Firm has submitted cGMP certificate issued on 07th October 2021 based on inspection conducted on 15th June 2021 • The firm submitted that applied product is qualitatively similar to that of innovator/reference product, which is Hidrasec capsule 100mg, therefore drug-excipient compatibility studies were not performed • The firm submitted that product has been manufactured by dry blending method and there is no water used in the proess, therefore we did not include water content test • Firm has submitted audit trail reports on product testing • Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) upto 06th months • The firm has referred to previous inspection for authenticity of stability data of their product conducted

	by the panel on the basis of which Registration Board in 281st meeting dated 11th-13th April, 2018 decided to approve registration of Lanzole-D capsule 30mg, Lanzole-D capsule 60mg. Inspection date: 09th April, 2018 The report shows that: • The HPLC software is 21 CFR compliant and having certificate of compliance by USFDA • The firm has audit trail reports on their testing. • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software 21CFR compliance.

Decision: Approved with Innovator's specification. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.**

Case No. 04; New application for registration of Human drugs on Form 5-F on export facilitation

Assistant director PR-I/EFD vide letter No.F.1-6/2019-PR-I (EFD dated 06-10-2022 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the *pharmaceutical* i.e one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision of the authority, the following firm have achieved the benchmark of more than **100,000 USD** during the **fiscal Year 2020-2021** and submitted their applications for priority consideration in lieu of export facilitation for Registration Board please.,

1319.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 13-05-2019 based on inspection conducted on 30-04-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of DML renewal letter No.F.1-8/84-Lic(Vol-V) dated 08-06-2022 which specifies Tablet section (General).
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 1308 dated 14-01-2022
	Details of fee submitted	Rs.75,000/- dated 30-12-2021 (Slip#4452496739)
	The proposed proprietary name / brand name	Gablin CR 82.5mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Pregabalin……..…82.5mg
	Pharmaceutical form of applied drug	Pink colored, oblong biconvex film coated tablet
	Pharmacotherapeutic Group of (API)	Anti-epileptics
	Reference to Finished product specifications	Innovator's specifications

	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's, 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA CR extended-release tablets (82.5mg, 165mg, 330 mg) by USFDA Approved.
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (PRG/P0904005, PRG/P0904006, PRG/P0904007)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Lyrica CR 82.5mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017, by performing quality tests (Description, Identification, Assay, Dissolution). CDP has been performed against the same brand that is Lyrica CR 82.5mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017 in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Analytical method validation report is not submitted

STABILITY STUDY DATA	
Manufacturer of API	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.
API Lot No.	PRGH/P2012004D

Description of Pack (Container closure system)	Printed Alu-Alu blister packed in bleach board unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	PGA T2-21	PGA T3-21	PGA T4-21
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	05-2021	05-2021	05-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted License retention certificate dated 29-02-2020 of M/s Kopran Research Laboratories Limited., India., issued by Food & Drugs Administration Maharashtra State India valid upto 31-03-2025. Firm has submitted cGMP certificate dated 20-10-2020 of M/s Kopran Research Laboratories Limited., India., issued by Commissioner, Food & Drugs Administration Maharashtra State India valid upto 19-10-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP-393 dated 28-12-2020 for import of 100kg of Pregabalin (Batch# PRGH/P2012004D) in name of M/s CCL Pharmaceuticals (Pvt.) Ltd., attested by AD (I&E) DRAP Lahore dated 04-01-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.5	• GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted	• Firm has submitted DML renewal Inspection report conducted on 14.09.2020, 15.09.2020 and 21.10.2020 and panel has recommended renewal of DML for following sections; Tablet (General), Capsule (General), Oral Liquid, Dry Powder Suspension, Liquid Injectable & Capsule section (Steroid). • Firm has submitted Letter No. 8194/2022-DRAP (Addl.Dire) dated 07.07.2022 from Additional Director DRAP Lahore which states that; "The Firm has applied for GMP Inspection. The application is under process at DRAP Office and inspection will be

		done as per availability of Area FID. The firm's last GMP status is Compliant / Good.
1.5.2	• Clarification is required as you have applied for film coated tablets while the reference formulation is film coated extended release tablets or revise your label claim as per reference formulation along with submission of applicable fee.	The firm submitted that applied formulation is as per reference formulation i.e., film coated extended release that is evident from dissolution results. Label claim for products is: Each film coated extended-release tablet contain: Pregabalin…….82.5mg.
3.2.S.4	• Justification is required for claiming in-house specifications for drug substance by drug substance manufacturer and drug product manufacturer as the monograph for applied drug substance is available in pharmacopeia (BP, USP) • Justification is required for using in-house analytical method for drug substance by drug substance manufacturer and drug product manufacturer as the analytical method for applied drug substance is available in pharmacopeia (BP, USP) • Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug substance as the COA of Reference Standards or Materials states that it is to be used before 19-03-2016, while manufacturing date of drug substance as per submitted COA is Dec 2020.	• The firm submitted that Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house specs. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer and drug product manufacturer are in process of shifting the specification as per USP Monograph. • The firm submitted that Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house analytical method. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer and Drug product manufacturer are in process of shifting the analytical method as per USP Monograph. • The firm submitted that provided COA of reference standard was taken from DMF. COA of working standard used for the analysis of drug substance is submitted which states that it is to be used before 11-07-2021.
3.2.P.2	• Submit evidence for storing samples prepared for compatibility study at 60°C ± 3°C / 75% ± 5%RH for 10 days	***The firm submitted record of data logger for temperature and humidity monitoring for sample prepared for compatibility study***
3.2.P.5	• Justification is required for changing wavelength during assay procedure in analytical method from 300nm to 210nm after 4.5 minutes • Submit analytical method validation report for the applied product	• The firm submitted that in product test method 300nm is used to suppress blank peak and the principal peak of pregabalin is around 5.1 that's why wavelength is changed at 210nm from 4.5min to onward. • Firm has submitted analytical method validation studies including specificity, linearity and range, accuracy, precision, LOD & LOQ, robustness and solution stability and system suitability studies.
3.2.P.6	• Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug product as the COA of Reference Standards or Materials states that it is to be used before 11-07-2021, while manufacturing date of drug product as per submitted COA is April 2021 and 3rd month time point and 6th month time stability study are due on July 2021 (07-2021) and October 2021 (10-2021).	• The firm submitted that same reference standard was used for analysis of drug product as the sequence / chromatograms against this standard was saved during trial analysis and same sequence / chromatograms of standard was used at 3rd and 6th Month stability study time point for analysis of drug product. It is to submit that the Reference Standards or Materials used for test and analysis of drug product was expired at 6th month time point (October 2021 (10-2021)) of stability study.
3.2.P.8	• The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required • Clarification is required for not including the results and calculation details for content uniformity test in raw data sheet at initial time point of stability study • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and	• The firm submitted that in product test method wavelength started from 300nm and then changed to 210nm after 4.5min. So in chromatogram starting wavelength is mentioned which is 300nm. • Firm has submitted results and calculation details for content uniformity test in raw data sheet at initial time point of stability study. • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and standard potency in calculation formula is submitted.

	standard potency in calculation formula shall be submitted • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted.

Decision: Deferred for scientific justification of following points:

- **Use of sequence / chromatograms of standard saved during initial time point analysis for the drug product analysis of 3rd and 6th Month stability study time point.**
- **Use of dual wavelengths for the analysis of single drug substance containing formulation.**
- **The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required**

1320.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 13-05-2019 based on inspection conducted on 30-04-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of DML renewal letter No.F.1-8/84-Lic(Vol-V) dated 08-06-2022 which specifies Tablet section (General).
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 1309 dated 14-01-2022
	Details of fee submitted	Rs.75,000/- dated 30-12-2021 (Slip#20328944978)
	The proposed proprietary name / brand name	Gablin CR 165mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Pregabalin……..…165mg
	Pharmaceutical form of applied drug	Light brown colored, oblong biconvex film coated tablet
	Pharmacotherapeutic Group of (API)	Anti-epileptics
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's, 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA CR extended-release tablets (82.5mg, 165mg, 330 mg) by USFDA Approved.
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description

		of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (PRG/P0904005, PRG/P0904006, PRG/P0904007)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Lyrica CR 165mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017, by performing quality tests (Description, Identification, Assay, Dissolution). CDP has been performed against the same brand that is Lyrica CR 165mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017 in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Analytical method validation report is not submitted

STABILITY STUDY DATA

Manufacturer of API	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.		
API Lot No.	PRGH/P2012004D		
Description of Pack (Container closure system)	Printed Alu-Alu blister packed in bleach board unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	PGB T2-21	PGB T3-21	PGB T4-21
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	04-2021	04-2021	04-2021

Date of Initiation	05-2021	05-2021	05-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted License retention certificate dated 29-02-2020 of M/s Kopran Research Laboratories Limited., India., issued by Food & Drugs Administration Maharashtra State India valid upto 31-03-2025. Firm has submitted cGMP certificate dated 20-10-2020 of M/s Kopran Research Laboratories Limited., India., issued by Commissioner, Food & Drugs Administration Maharashtra State India valid upto 19-10-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP-393 dated 28-12-2020 for import of 100kg of Pregabalin (Batch# PRGH/P2012004D) in name of M/s CCL Pharmaceuticals (Pvt.) Ltd., attested by AD (I&E) DRAP Lahore dated 04-01-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.5	• GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted	• Firm has submitted DML renewal Inspection report conducted on 14.09.2020, 15.09.2020 and 21.10.2020 and panel has recommended renewal of DML for following sections; Tablet (General), Capsule (General), Oral Liquid, Dry Powder Suspension, Liquid Injectable & Capsule section (Steroid). • Firm has submitted Letter No. 8194/2022-DRAP (Addl.Dire) dated 07.07.2022 from Additional Director DRAP Lahore which states that; "The Firm has applied for GMP Inspection. The application is under process at DRAP Office and inspection will be done as per availability of Area FID. The firm's last GMP status is Compliant / Good.
1.5.2	• Clarification is required as you have applied for film coated tablets while the reference formulation is film coated extended release tablets or revise your label claim as per reference formulation along with submission of applicable fee.	The firm submitted that applied formulation is as per reference formulation i.e., film coated extended release that is evident from dissolution results. Label claim for product is: Each film coated extended-release tablet contain: Pregabalin…….165mg.
3.2.S.4	• Justification is required for claiming in-house specifications for drug substance by drug substance manufacturer and drug product manufacturer as the monograph for applied drug substance is available in pharmacopeia (BP, USP)	• The firm submitted that Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house specs. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer

	• Justification is required for using in-house analytical method for drug substance by drug substance manufacturer and drug product manufacturer as the analytical method for applied drug substance is available in pharmacopeia (BP, USP) • Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug substance as the COA of Reference Standards or Materials states that it is to be used before 19-03-2016, while manufacturing date of drug substance as per submitted COA is Dec 2020.	and drug product manufacturer are in process of shifting the specification as per USP Monograph. • The firm submitted Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house analytical method. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer and Drug product manufacturer are in process of shifting the analytical method as per USP Monograph. • The firm submitted that provided COA of reference standard was taken from DMF. COA of working standard used for the analysis of drug substance is submitted which states that it is to be used before 11-07-2021.
3.2.P.2	• Submit evidence for storing samples prepared for compatibility study at 60˚C ± 3˚C / 75% ± 5%RH for 10 days	***The firm submitted record of data logger for temperature and humidity monitoring for sample prepared for compatibility study***
3.2.P.5	• Justification is required for changing wavelength during assay procedure in analytical method from 300nm to 210nm after 4.5 minutes • Submit analytical method validation report for the applied product	• The firm submitted that in product test method 300nm is used to suppress blank peak and the principal peak of pregabalin is around 5.1 that's why wavelength is changed at 210nm from 4.5min to onward. • Firm has submitted analytical method validation studies including specificity, linearity and range, accuracy, precision, LOD & LOQ, robustness and solution stability and system suitability studies.
3.2.P.6	• Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug product as the COA of Reference Standards or Materials states that it is to be used before 11-07-2021, while manufacturing date of drug product as per submitted COA is April 2021 and 3rd month time point and 6th month time stability study are due on July 2021 (07-2021) and October 2021 (10-2021).	• The firm submitted that same reference standard was used for analysis of drug product as the sequence / chromatograms against this standard was saved during trial analysis and same sequence / chromatograms of standard was used at 3rd and 6th Month stability study time point for analysis of drug product. It is to submit that the Reference Standards or Materials used for test and analysis of drug product was expired at 6th month time point (October 2021 (10-2021)) of stability study.
3.2.P.8	• The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required • Clarification is required for not including the results and calculation details for content uniformity test in raw data sheet at initial time point of stability study • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and standard potency in calculation formula shall be submitted • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• The firm submitted that in product test method wavelength started from 300nm and then changed to 210nm after 4.5min. So in chromatogram starting wavelength is mentioned which is 300nm. • Firm has submitted results and calculation details for content uniformity test in raw data sheet at initial time point of stability study. • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and standard potency in calculation formula is submitted. • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted.

Decision: Deferred for scientific justification of following points:

- **Use of sequence / chromatograms of standard saved during initial time point analysis for the drug product analysis of 3rd and 6th Month stability study time point.**
- **Use of dual wavelengths for the analysis of single drug substance containing formulation.**
- **The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required**

1321.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.

	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt.) Ltd., 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 13-05-2019 based on inspection conducted on 30-04-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of DML renewal letter No.F.1-8/84-Lic(Vol-V) dated 08-06-2022 which specifies Tablet section (General).
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 1310 dated 14-01-2022
	Details of fee submitted	Rs.75,000/- dated 30-12-2021 (Slip#683187860)
	The proposed proprietary name / brand name	Gablin CR 330mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Pregabalin……..…330mg
	Pharmaceutical form of applied drug	Orange colored, oblong biconvex film coated tablet
	Pharmacotherapeutic Group of (API)	Anti-epileptics
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's, 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA CR extended-release tablets (82.5mg, 165mg, 330 mg) by USFDA Approved.
	For generic drugs (me-too status)	NA
	Name and address of API manufacturer.	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (PRG/P0904005, PRG/P0904006, PRG/P0904007)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Lyrica CR 330mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017, by performing quality tests (Description, Identification, Assay, Dissolution). CDP has been performed against the same brand that is Lyrica CR 330mg Tablet distributed by M/s Parke-Davis Division of Pfizer Inc. NY, NY 10017 in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Analytical method validation report is not submitted

STABILITY STUDY DATA

Manufacturer of API	M/s Kopran Research Laboratories Limited., K4/4, Additional MIDC, Post Birwadi, Tal. Mahad, District: Raigad, Raigad 402302, Maharashtra India.		
API Lot No.	PRGH/P2012004D		
Description of Pack (Container closure system)	Printed Alu-Alu blister packed in bleach board unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	PGC T2-21	PGC T3-21	PGC T4-21
Batch Size	1000 tab	1000 tab	1000 tab
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	05-2021	05-2021	05-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted License retention certificate dated 29-02-2020 of M/s Kopran Research Laboratories Limited., India., issued by Food & Drugs Administration Maharashtra State India valid upto 31-03-2025. Firm has submitted cGMP certificate dated 20-10-2020 of M/s Kopran Research Laboratories Limited., India., issued by Commissioner, Food & Drugs

		Administration Maharashtra State India valid upto 19-10-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice No. EXP-393 dated 28-12-2020 for import of 100kg of Pregabalin (Batch# PRGH/P2012004D) in name of M/s CCL Pharmaceuticals (Pvt.) Ltd., attested by AD (I&E) DRAP Lahore dated 04-01-2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.5	• GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years shall be submitted	• Firm has submitted DML renewal Inspection report conducted on 14.09.2020, 15.09.2020 and 21.10.2020 and panel has recommended renewal of DML for following sections; Tablet (General), Capsule (General), Oral Liquid, Dry Powder Suspension, Liquid Injectable & Capsule section (Steroid). • Firm has submitted Letter No. 8194/2022-DRAP (Addl.Dire) dated 07.07.2022 from Additional Director DRAP Lahore which states that; "The Firm has applied for GMP Inspection. The application is under process at DRAP Office and inspection will be done as per availability of Area FID. The firm's last GMP status is Compliant / Good.
1.5.2	• Clarification is required as you have applied for film coated tablets while the reference formulation is film coated extended release tablets or revise your label claim as per reference formulation along with submission of applicable fee.	The firm submitted that applied formulation is as per reference formulation i.e., film coated extended release that is evident from dissolution results. Label claim for products is: Each film coated extended-release tablet contain: Pregabalin…….330mg.
3.2.S.4	• Justification is required for claiming in-house specifications for drug substance by drug substance manufacturer and drug product manufacturer as the monograph for applied drug substance is available in pharmacopeia (BP, USP) • Justification is required for using in-house analytical method for drug substance by drug substance manufacturer and drug product manufacturer as the analytical method for applied drug substance is available in pharmacopeia (BP, USP) • Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug substance as the COA of Reference Standards or Materials states that it is to be used before 19-03-2016, while manufacturing date of drug substance as per submitted COA is Dec 2020.	• The firm submitted that Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house specs. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer and drug product manufacturer are in process of shifting the specification as per USP Monograph. • The firm submitted that Pregabalin Monograph has become official as of 01-Nov-2020, and the substance lot being used in developmental studies, manufactured in Dec 2020, that's why API manufacturer used in house analytical method. Moreover, Pregabalin is already inducted material for CCL. Both Drug substance manufacturer and Drug product manufacturer are in process of shifting the analytical method as per USP Monograph. • The firm submitted that provided COA of reference standard was taken from DMF. COA of working standard used for the analysis of drug substance is submitted which states that it is to be used before 11-07-2021.

3.2.P.2	• Submit evidence for storing samples prepared for compatibility study at 60˚C ± 3˚C / 75% ± 5%RH for 10 days	***The firm submitted record of data logger for temperature and humidity monitoring for sample prepared for compatibility study***
3.2.P.5	• Justification is required for changing wavelength during assay procedure in analytical method from 300nm to 210nm after 4.5 minutes • Submit analytical method validation report for the applied product	• The firm submitted that in product test method 300nm is used to suppress blank peak and the principal peak of pregabalin is around 5.1 that's why wavelength is changed at 210nm from 4.5min to onward. • Firm has submitted analytical method validation studies including specificity, linearity and range, accuracy, precision, LOD & LOQ, robustness and solution stability and system suitability studies.
3.2.P.6	• Clarification is required whether the same Reference Standards or Materials was used for test and analysis of drug product as the COA of Reference Standards or Materials states that it is to be used before 11-07-2021, while manufacturing date of drug product as per submitted COA is April 2021 and 3rd month time point and 6th month time stability study are due on July 2021 (07-2021) and October 2021 (10-2021).	• The firm submitted that same reference standard was used for analysis of drug product as the sequence / chromatograms against this standard was saved during trial analysis and same sequence / chromatograms of standard was used at 3rd and 6th Month stability study time point for analysis of drug product. It is to submit that the Reference Standards or Materials used for test and analysis of drug product was expired at 6th month time point (October 2021 (10-2021)) of stability study.
3.2.P.8	• The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required • Clarification is required for not including the results and calculation details for content uniformity test in raw data sheet at initial time point of stability study • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and standard potency in calculation formula shall be submitted • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• The firm submitted that in product test method wavelength started from 300nm and then changed to 210nm after 4.5min. So in chromatogram starting wavelength is mentioned which is 300nm. • Content uniformity for Gablin CR Tablet 330mg is performed by weight variation as per <USP 905>. • Raw data sheet for assay test with real time values for average area of sample, average area of standard, conc. of standard, conc. of sample, average weight, label claim and standard potency in calculation formula is submitted. • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is submitted.

Decision: Deferred for scientific justification of following points:

- **Use of sequence / chromatograms of standard saved during initial time point analysis for the drug product analysis of 3rd and 6th Month stability study time point.**
- **Use of dual wavelengths for the analysis of single drug substance containing formulation.**
- **The wavelength mentioned in analytical procedure is 210nm for assay test while submitted chromatograms of stability study show 300nm, justification is required**

Case No. 05; Routine Registration application of Human drugs on Form 5F (Import) whose Replies are not received

1322.	Name, address of Applicant / Importer	M/s Genome Pharma, House no. 166-A St. # 9, Chaklala Scheme III, Rawalpindi-PAKISTAN.
	Details of Drug Sale License of importer	DSL No.: 01-374-0176-035673D Name & Address: M/s Genome Pharma, House no. 166-A St. # 9, Chaklala Scheme III, Rawalpindi. Godown: C-19, main commercial, access road, R RCCI Industrial estat rawat, Rawalpindi. Validity: 28/08/2020 Status: license to sell drugs as a Distributor

	Name and address of marketing authorization holder (abroad)	M/s Republican Unitary Production Enterprise "Belmedpreparaty", 220007, Minsk, 30 Fabritsius St., Belarus.
	Name, address of manufacturer(s)	M/s Republican Unitary Production Enterprise "Belmedpreparaty", 220007, Minsk, 30 Fabritsius St., Republic of Belarus.
	Name of exporting country	Republic of Belarus.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original embassy attested CoPP (certificate No. 69-2020/CPP/PK) dated 17/06/2020 issued by Ministry of Health of the Republic of Belarus to M/s Republican Unitary Production Enterprise "Belmedpreparaty", 220007, Minsk, 30 Fabritsius St., Belarus for Cybine, lyophilized powder for solution for injection 1000mg. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every three year. The name of importing country on CoPP is mentioned as Islamic Republic of Pakistan.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of Sole Agency authorization letter No.6-30/852 dated 16.10.2020 from Deputy General Director for quality M.V. Bespolova, of M/s Republican Unitary Production Enterprise "Belmedpreparaty", 30 Fabritsius St., 220007, Minsk, Republic of Belarus wherein the firm has authorized M/s Genome Pharma, Head office House no. 166-A Street # 9, Chaklala Scheme III, Rawalpindi-PAKISTAN and store office C-19, Main Commercial, Access Road, RCCI Industrial estate Rawat, Rawalpindi Pakistan to act as agent for registration, sale, marketing and tender business of their 15 products including Cybine 1000mg Injection in Islamic republic of Pakistan. The Sole agent letter will be effective for first five years from date of issuance of this letter. ***The firm submitted that original sole agency agreement is attached with Belklasta 5mg infusion***
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 11564: 16-04-2021

	Details of fee submitted	PKR 100,000/-: 24-12-2020
	The proposed proprietary name / brand name	Cybine-1000mg Lyophilized Powder for Solution for Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Cytarabine……..1000mg
	Pharmaceutical form of applied drug	Lyophilized powder for solution for injection SC/IV/IT
	Pharmacotherapeutic Group of (API)	Antimetabolite
	Reference to Finished product specifications	EP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	CYTOSAR-U 1gm/Vial Injection USFDA Approved **(Discontinued)**
	For generic drugs (me-too status)	Cytabine 1000mg injection By M/s AJM Pharma (Reg No#072596)…..*the liquid or lyophilize injection status couldn't be confirmed*
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability study of drug product
	Name, address of drug substance manufacturer	Manufacturing site: M/s Zhejiang Hisun Pharmaceutical Co., Ltd, 56 Binhai Road, Jiaojiang District Taizhou city, Zhejiang Province 318000 People's republic of China. Quality control site: M/s Zhejiang Hisun Pharmaceutical Co., Ltd, 46 Waisha Road, Jiaojiang District Taizhou city, Zhejiang Province 318000 People's republic of China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	***Firm has submitted 09 months' real time stability data at 30°C ± 2°C / 75% ± 5%RH of 03 batches*** **and** 06 month accelerated stability data 40°C ± 2°C / 75% ± 5%RH of 03 batches Batches (1036-A190101, 1036-A190102, 1036-A190103) ***Firm has submitted 36 months' real time stability data at 30°C ± 2°C / 75% ± 5%RH of 03 different batches*** ***Batches (A130206, A130207, A130208)***
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability study of drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence performed aginst Cytosar, Lyphilizate for solution for injection, 1000mg, Actavis, Italy. *However, both the product are tested against different pharmacopieas i.e. EU and USP*
	Analytical method validation/verification of product	Analytical method validation studies including specificity, linearity and range, repeatability, intermediate precision, accuracy, is submitted. ***Method validation for UV method is submitted***
	Container closure system of the drug product	Glass vial with nominal capacity of 20ml sealed with rubber stopper along with aluminum caps packed in cardboard package.
	Stability study data of drug product, shelf life and storage conditions	• The firm submitted real time stability data conducted at 25°C ± 2°C / 60% ± 5%RH of 03 batches for 36 months. Batches: (010914, 020914, 031014) • The firm submitted accelerated stability data at 40°C ± 2°C / 75% ± 5%RH of 03 batches 06 month. Batches: (010914, 020914, 030914)

Evaluation by PEC[XI]:

Section	Observations	Response
1.3	• Details of applicant is not mentioned in form 5F. Provided form 5F is from the manufacturer / Marketing authorization holder side while it should be from the applicant holding the Drug sale license. • Submit correct relevant information in subsection 1.3.1 to 1.3.4 of form 5-F as per guidance document. • Correct the Name, address and contact details of Applicant / Marketing Authorization Holder along with submission of applicable fee. (*Name of and address of product license holder is written instead of applicant, status of applicant mentioned as manufacturer instead of importer*)	
1.3.4	Submit valid readable copy of Drug Sale License (DSL) issued by relevant licensing authority	

1.5.6	You have mentioned EUP specification for the product under section 1.5.6. However, official monograph is not available in EUP. Justification is required.	
1.5.9	Provide evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.	
1.5.15–1.5.20	Submit commitments as per guidance documents	
1.6.5	• Submit valid GMP certificate of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.	
3.2.S.4	• Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance by Drug Product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.	
3.2.S.7	Real time stability data and accelerated stability data of 03 different batches are submitted at 30°C ± 2°C / 75% ± 5%RH	
3.2.P.1	• Provide information including type of diluent, its composition, quantity or volume, specifications (as applicable) and regulatory status in Pakistan for the diluent which is to be provided along with the applied drug	
3.2.P.2	• In pharmaceutical equivalence the applied product is tested as per EUP while official monograph is not available in EUP and innovator product is tested as per USP, clarify.	
3.2.P.2.6	Compatibility studies of the applied product with reconstituted diluent is not submitted	
3.2.P.5	• Clarification is required since firm claimed for EUP specification for applied drug product while the official monograph is not available in EUP. Official monograph available in BP and USP.	
3.2.P.8	• Clarification is required as Real time stability data of drug product is not performed as per zone IV-A. Real time stability data of drug product performed at 25°C ± 2°C / 60% ± 5%RH (zone II climatic conditions) of 03 batches • Real time and accelerated stability data of one different batch is submitted	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

a.

Case No. 06; Deferred Registration application of Human Drugs on form 5F (Local):

1323.	Name, address of Applicant / Marketing Authorization Holder	M/s Jawa Pharmaceuticals Private Limited., 112/10 Quaid-e-Azam Industrial Area Kot Lakhpat, Lahore,
	Name, address of Manufacturing site.	M/s Jawa Pharmaceuticals Private Limited., 112/10 Quaid-e-Azam Industrial Area Kot Lakhpat, Lahore,
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale

		☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24075 dated 01-09-2021
	Details of fee submitted	PKR 30,000/-: dated 07-06-2021
	The proposed proprietary name / brand name	Cholein Tablet USP 40mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet contains: Atorvastatin (as calcium trihydrate)…….… 40mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	HMG CoA reductase inhibitors
	Reference to Finished product specifications	USP Specifications
	Proposed Pack size	1 x 10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Atorvastatin 40 mg film coated Tablet by M/s Dexcel®-Pharma Ltd.7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire, NN11 8PB, UK, MHRA Approved
	For generic drugs (me-too status)	Truva Tablet 40mg by Sami Pharmaceuticals (Reg# 100511)
	GMP status of the Finished product manufacturer	The firm have submitted cGMP certificate issued on 06-07-2020 based on inspection conducted on 04-03-2020
	Name and address of API manufacturer.	Zhejiang Haisen Pharmaceutical Co., Ltd., Xiangtan Village, Liushi Street, Dongyang City, Zhejiang Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (5616010201, 5616010202, 5616010203)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	CDP has been performed against the Lipitor Tablet (40mg) by Pfizer Pharma in Acid media (pH 1.2), acetate Buffer (pH 4.5) & Phosphate Buffer (pH 7). The values for f2 is in the acceptable range
	Analytical method validation/verification of product	Firm have submitted method verification studies including accuracy, precision and specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zhejiang Haisen Pharmaceutical Co., Ltd., Xiangtan Village, Liushi Street, Dongyang City, Zhejiang Province, China		
API Lot No.	5620051201		
Description of Pack (Container closure system)	PVC/aluminum foil blister packs - then packed in the bleach board box.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	Trial 01	Trial 02	Trail 03
Batch Size	10,000 tablets	10,000 tablets	10,000 tablets
Manufacturing Date	22-07-2020	24-07-2020	27-07-2020
Date of Initiation	28-07-2020	28-07-2020	28-07-2020
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate for M/s Zhejiang Haisen Pharmaceutical Co., Ltd., Xiangtan Village, Liushi Street, Dongyang City, Zhejiang Province, China issued by China Food & Drug Administration. The certificate is valid till 21-08-201. Firm has submitted copy of Drug Manufacturing License (DML # ZHE20000394) of M/s Zhejiang Haisen Pharmaceutical Co., Ltd., China issued by State Food & Drug Administration, China. The certificate is valid till 24-09-2025.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm have submitted Data of stability batches supported by attested respective documents like chromatograms and summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.3	In status of applicant you have mentioned "Is involved in none of the above (contract giver)", clarify?	
2.3.R.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	
3.2.S.4	• Test for enantiomeric purity is not included in specifications although given in USP monograph of drug substance, clarify? • Copies of analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required.	
3.2.S.5	• COA of primary / secondary reference standard including source and lot number shall be provided.	
3.2.P.2.1.1	• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product. (**Composition of Applied Formulation**: Atorvastatin calcium, Microcrystalline cellulose (avicel 200), Magnesium stearate, Sodium starch glycolate (Primogel), silica dioxide) • You have not performed Pharmaceutical equivalence of the applied drug with the innovator / reference / comparator product, justify?	
3.2.P.5	• In given specification of drug product, in identification test you have mentioned "identification for cefixime" while the applied product is atorvastatin calcium, clarify? • Test for uniformity of dosage unit (content uniformity) is not included in specifications and not performed in batch analysis although given in USP monograph of drug product, clarify?	
3.2.P.8	• Stability data reflect that dissolution test has not been performed after initial time point throughout stability studies at both accelerated and real time conditions, justify? • Submit COA, Raw data sheets & analytical record of stability studies containing calculation formula for both assay & dissolution test • Submit documents for the procurement of API with approval from DRAP.	

Previous Decision (322nd-DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the firm:

Section	Observations	Response
1.3.3	In status of applicant you have mentioned "Is involved in none of the above (contract giver)", clarify?	The firm submitted that it was a typographical mistake, we have corrected the status as "Manufacturer" and revised document is submitted
2.3.R.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	Firm has submitted copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>
3.2.S.4	• Test for enantiomeric purity is not included in specifications although given in USP monograph of drug substance, clarify? • Copies of analytical procedures used for routine testing of the Drug	• The firm submitted that all testing is done as per USP specifications as enantiomeric purity is not mentioned in specifications. Firm has submitted revised specifications and SOP of drug substance

	substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required.	• Firm has submitted copies of analytical procedures used for routine testing of the Drug substance by Drug Product manufacturer
3.2.S.5	• COA of primary / secondary reference standard including source and lot number shall be provided.	Firm has submitted COA of working standard from Ind-Swift Laboratories Limited Derabassi India while drug substance manufacturer is M/s Zhejiang Haisen Pharmaceutical Co., Ltd., China
3.2.P.2.1.1	• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product. (**Composition of Applied Formulation**: Atorvastatin calcium, Microcrystalline cellulose (avicel 200), Magnesium stearate, Sodium starch glycolate (Primogel), silica dioxide) • You have not performed Pharmaceutical equivalence of the applied drug with the innovator / reference / comparator product, justify?	• Firm has submitted compatibility studies of drug substance with excipients by storing samples at 40°C ± 2°C / 75% ± 5%RH for 01 month • Firm has submitted pharmaceutical equivalence of applied product against Lipitor tablet 40mg of M/s Pfizer Pharmaceuticals (Pvt) Ltd by performing quality tests (Description, identification, weight variation, dissolution, disintegration, uniformity of dosage units, assay)
3.2.P.5	• In given specification of drug product, in identification test you have mentioned "identification for cefixime" while the applied product is atorvastatin calcium, clarify? • Test for uniformity of dosage unit (content uniformity) is not included in specifications and not performed in batch analysis although given in USP monograph of drug product, clarify?	• The firm submitted that it was a typographical mistake and submitted revised specifications. • The firm submitted that as uniformity of dosage unit test was performed but didn't mention in the specifications, please find the revised batch analysis reports of Cholein tablets as per USP monograph.
3.2.P.8	• Stability data reflect that dissolution test has not been performed after initial time point throughout stability studies at both accelerated and real time conditions, justify? • Submit COA, Raw data sheets & analytical record of stability studies containing calculation formula for both assay & dissolution test • Submit documents for the procurement of API with approval from DRAP.	• Firm submitted that dissolution test is being performed at all the stability months. The firm submitted revised stability summary sheets. ***However, it is to mention that results of disintegration test and assay test are different than the original dossier.*** • Firm has submitted Raw data sheets & analytical record of stability studies containing calculation formula for both assay & dissolution test. However, COA of stability study is not submitted • The firm submitted Letter No. 633/2020/DRAP-AD-CD(I&E) dated 13-01-2020 for "permission to Import API as per guidelines for import of pharmaceutical raw material for the purpose of test/analysis and stability studies" containing Choline Tablets "Atorvastatin Calcium Trihydrate 300gm issued by AD (I&E) DRAP Lahore. ***However, the firm has not submitted any documents confirming import of API.***

Decision: Deferred for following:

- **Performance of drug substance analysis by M/s Jawa Pharmaceuticals Private Limited as per USP monograph.**
- **Firm has submitted COA of working standard from Ind-Swift Laboratories Limited Derabassi India while drug substance manufacturer is M/s Zhejiang Haisen Pharmaceutical Co., Ltd., China.**
- **Analytical record for the performance of content uniformity test as per the revised drug product batch analysis COAs.**

• **Clarification of the fact that results for Assay & Disintegration test presented in the revised stability summary sheets are different from that presented in initial submission.** • **Documents confirming import of drug substance including approval from DRAP I&E office.** • **Verification of the submitted "Letter No. 633/2020/DRAP-AD-CD(I&E) dated 13-01-2020" for the inclusion of "Atorvastatin" from the DRAP , Lahore I&E office.**		
1324.	Name, address of Applicant / Marketing Authorization Holder	M/s Jawa Pharmaceuticals Private Limited., 112/10 Quaid-e-Azam Industrial Area Kot Lakhpat, Lahore,
	Name, address of Manufacturing site.	M/s Jawa Pharmaceuticals Private Limited., 112/10 Quaid-e-Azam Industrial Area Kot Lakhpat, Lahore,
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29538 dated 29-10-2021
	Details of fee submitted	PKR 30,000/-: dated 22-06-2021 (Deposit Slip#599036870370)
	The proposed proprietary name / brand name	Phencol ophthalmic solution 0.5% w/v
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Chloramphenicol BP…… 5mg
	Pharmaceutical form of applied drug	Eye Drops
	Pharmacotherapeutic Group of (API)	Ophthalmologicals-Antibiotics
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	10ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Chloramphenicol Eye Drops BP 0.5% w/v, MHRA Approved
	For generic drugs (me-too status)	Chlorin Eye drops by M/s NovaMed Pharmaceuticals (Reg#084887)
	GMP status of the Finished product manufacturer	The firm have submitted cGMP certificate issued on 06-07-2020 based on inspection conducted on 04-03-2020
	Name and address of API manufacturer.	Mehta API Pvt. Ltd., Gut No. 546, 571, 519 & 520, Village Kumbhavali, Taluka Palghar, District Palghar, 401506, Maharashtra India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches:(CHL/0010108, CHL/0020108, CHL/0030108)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Not submitted
	Analytical method validation/verification of product	Firm have submitted method verification studies including accuracy, precision and specificity.

STABILITY STUDY DATA			
Manufacturer of API	Mehta API Pvt. Ltd., Gut No. 546, 571, 519 & 520, Village Kumbhavali, Taluka Palghar, District Palghar, 401506, Maharashtra India.		
API Lot No.	LT-OCHL/016/20-21		
Description of Pack (Container closure system)	LDPE Plastic bottles with polypropylene nozzle and high density polyethylene (HDPE) cap. ***Pack size is 5ml in 10ml bottle***		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	Trial-01	Trial-02	Trial-03
Batch Size	03 litres (300 bottles)	03 litres (300 bottles)	03 litres (300 bottles)
Manufacturing Date	30-09-2020	05-10-2020	08-10-2020
Date of Initiation			
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate of M/s Mehta API Pvt. Ltd., Gut No. 546, 571, 519 & 520, Village Kumbhavali, Taluka Palghar, District Palghar, 401506, Maharashtra India. issued by Commissioner, Food & Drugs Administration Maharashtra State India valid till 18-09-2022.

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm have submitted Data of stability batches supported by respective documents like chromatograms and summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator [XI]:

Section	Observations	Response
1.5.4	• Pack size mentioned in module 1 is 10ml while pack size mentioned in module 3 section 3.2.P.1 & 3.2.P.7 is -5ml in 10ml bottle, clarify?	
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	
2.3.	• Submit module II as per WHO QOS-PD template	
3.2.S.4	• Specifications and analytical procedure of drug substance by drug substance manufacturer are provided as per USP monograph while specification provided by drug product manufacturer are as per BP. Clarification is required. Furthermore, Batch analysis of drug substance by drug substance manufacturer show tests as per BP monograph • BP monograph uses HPLC method for assay test while drug product manufacturer uses uv method for assay test clarify?	
3.2.P.2	• Submit Pharmaceutical equivalence of the applied product against the innovator product • Sterilization by gama radiation in microbial attributes while by filtration in manufacturing process 3.2.P.3.3, clarify?	
3.2.P.5	• In batch analysis in assay test "assay for gentamycin is written while the applied product is chloramphenicol, clarification is required	
3.2.P.8	• In stability study protocols you have mentioned stability storage conditions as Real time: 30˚C ± 2˚C / 35% ± 5%RH and Accelerated: 40˚C ± 2˚C / 25% ± 5%RH and submit stability study at Real time: 30˚C ± 2˚C / 65% ± 5%RH and Accelerated: 40˚C ± 2˚C / 75% ± 5%RH, clarification is required • Initial page of stability summary sheet containing batch No. of FPP, API, storage conditions, date of manufacturing, date of initiation of stability study is not submitted • Clarification is required since the limits for assay test mentioned in stability summary sheet for all three batches is 98-102% which is not as per pharmacopeia. • Submit documents for the procurement of API with approval from DRAP (in case of import). • Submit Compliance Record of HPLC software 21CFR & audit trail reports on product testing • COA and raw data sheets of stability batches is not submitted	

	• The submitted chromatograms at initial time point does not contain batch no of applied product. • Submit data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	

Previous Decision (322nd-DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the firm:

Section	Observations	Response
1.5.4	• Pack size mentioned in module 1 is 10ml while pack size mentioned in module 3 section 3.2.P.1 & 3.2.P.7 is 5ml in 10ml bottle, clarify?	The firm submitted that it was a typographical mistake. The pack size for drops is 10ml
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	Firm has submitted copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>
2.3.	• Submit module II as per WHO QOS-PD template	Firm has submitted module II as per WHO QOS-PD template
3.2.S.4	• Specifications and analytical procedure of drug substance by drug substance manufacturer are provided as per USP monograph while specification provided by drug product manufacturer are as per BP. Clarification is required. Furthermore, Batch analysis of drug substance by drug substance manufacturer show tests as per BP monograph • Clarification is required since the BP monograph states the use of HPLC method for assay test while drug product manufacturer uses UV method.	• Firm submitted that we have revised our method according to USP specifications. Firm has also submitted revised method as per USP specifications. ***However, it is to submit that the tests given in the specifications are according to BP analytical method of some tests are given both as per USP and BP*** • The firm submitted that it was a typographic, error and submitted revised assay method as per USP specifications.
3.2.P.2	• Submit Pharmaceutical equivalence of the applied product against the innovator product • Sterilization by gama radiation in microbial attributes while by filtration in manufacturing process 3.2.P.3.3, clarify?	• Firm has submitted pharmaceutical equivalence of applied product against chloroptic 0.5% eye drops and phenoptic 0.5% eye drops by performing quality test appearance, identification, pH, extractible volume, sterility assay. It is to clarify that tests are performed as per USP monograph while firm applied for BP specifications. Furthermore, firm has not stated the name of reference product manufacturer in pharmaceutical equivalence report. • The firm submitted that it was a typographic mistake. Sterilization is done by filtration and submitted a general SOP for filtration.
3.2.P.5	• In batch analysis in assay test "assay for gentamycin is written while the applied product is chloramphenicol, clarification is required	The firm submitted that it was a typographical mistake and submitted corrected COAs.
3.2.P.8	• In stability study protocols you have mentioned stability storage conditions as Real time: 30˚C ± 2˚C / 35% ± 5%RH and Accelerated: 40˚C ± 2˚C / 25% ± 5%RH and submit stability study at Real time: 30˚C ± 2˚C / 65% ± 5%RH and Accelerated: 40˚C ± 2˚C / 75% ± 5%RH, clarification is required	• The firm submitted that stability has been performed as per zone IV-A conditions (Real time: 30˚C ± 2˚C / 65% ± 5%RH and Accelerated: 40˚C ± 2˚C / 75% ± 5%RH). But to counter the humidity condition we have performed the potential water loss studies and results are within range. The results of water loss test is submitted.

	• You have not calculated the potential water loss during stability study as mentioned in ICH Q1A (R2) (2.2.7.3 for drug products packed in semipermeable containers). Justification is required • Initial page of stability summary sheet containing batch No. of FPP, API, storage conditions, date of manufacturing, date of initiation of stability study is not submitted • Clarification is required since the limits for assay test mentioned in stability summary sheet for all three batches is 98-102% which is not as per pharmacopeia. • Submit documents for the procurement of API with approval from DRAP (in case of import). • Submit Compliance Record of HPLC software 21CFR & audit trail reports on product testing • COA and raw data sheets of stability batches is not submitted • The submitted chromatograms at initial time point does not contain batch no of applied product. • Submit data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	• The firm submitted that we have performed potential water loss studies and results are within the range. • The firm submitted that it was typographical error, since assay limit is 90-110% and results are within range and revised summary sheet is submitted • The firm submitted Letter No. 4233/2020/DRAP-AD-CD(I&E) dated 20-03-2020 for *"permission to Import API as per guidelines for import of pharmaceutical raw material for the purpose of test/analysis and stability studies"* containing Phencol Opthalmic solution 0.5% w/v (chloramphenicol) 45gm issued AD (I&E) DRAP Lahore. *The firm has also submitted unattested copy of invoice No. ZHI-CI/5340/1020 dated 20-10-2020 in name of M/s Jawa Pharmaceuticals (Pvt.) Ltd for chloramphenicol (Batch No.LT-OCHL/016/20-21) 45gm*. ***However, the firm has not submitted any documents confirming import of API.*** • Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets etc. *Firm has not submitted summary sheets and COAs of stability studies.*

Decision: Deferred for following:

- **Clarification of performance of Pharmaceutical equivalence studies as per USP monograph whereas firm has claimed drug product specifications as per BP.**
- **Details of reference product against which pharmaceutical equivalence studies have been submitted including name of manufacturer, batch no. manufacturing and expiry date.**
- **Documents confirming import of drug substance including approval from DRAP I&E office.**
- **Verification of the submitted "Letter No. 4233/2020/DRAP-AD-CD(I&E) dated 20-03-2020" for the inclusion of "Chlormaphenicol" from the DRAP , Lahore I&E office.**

Case No. 07; Deferred Registration application of Human Drugs on form 5F (Import):

1325.	Name, address of Applicant / Importer	M/s AMB HK ENTERPRISES (PVT) LTD., 2nd Floor, Plaza 60, Commercial, Block-K, Phase 1 DHA Lahore
	Details of Drug Sale License of importer	**License No:** 05-352-0058-066904D **Address:** 2nd Floor, Plaza 60, Commercial Block-K, Phase 1 DHA Lahore **Address of Godown:** NA **Validity:** 24-02-2023. **Status:** License to sell drugs as distributor **Renewal:** NA
	Name and address of marketing authorization holder (abroad)	Reyoung Pharmaceutical Co., Ltd., No.1 Ruiyang Road, Yiyuan County, Shandong Province, China
	Name, address of manufacturer(s)	Reyoung Pharmaceutical Co., Ltd., No.1 Ruiyang Road, Yiyuan County, Shandong Province, China
	Name of exporting country	China
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized CoPP certificate (No. 201910005) issued by Yiyuan Market

		Supervision Administration of P.R China for vitamin C Injection 500mg/5ml. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The name of importing country on CoPP is mentioned as Pakistan. Furthermore, the CoPP is valid till 23-10-2021.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of Registration & Distribution agreement dated 29-08-2019 from M/s Reyoung Pharmaceutical Co., Ltd. The letter species that the manufacturer appoints **M/s AMB HK ENTERPRISES Pvt Ltd, Lahore** to register and develop pharmaceutical market of their products in Pakistan. The authorization letter remains valid for 05 years from the date of product registration certificate. The letter issued for vitamin C injection 500mg/5ml in addition to 08 other product.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26417: 23-09-2021
	Details of fee submitted	PKR 150,000/-: 26-05-2021 (Slip#1272535835)
	The proposed proprietary name / brand name	VITA-C INJECTION 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Ascorbic Acid 10.0% w/v.
	Pharmaceutical form of applied drug	Solution for Injection
	Pharmacotherapeutic Group of (API)	Ascorbic acid (vitamin C), plain ATC Code: A11GA
	Reference to Finished product specifications	BP
	Proposed Pack size	5ml type I glass ampoule; 10 ampoules/tray,10trays/boxes*12boxes/carton
	Proposed unit price	PKR 21.35/unit
	The status in reference regulatory authorities	Ascorbic Acid Injection BPC 500mg/5ml MHRA Approved.
	For generic drugs (me-too status)	Ascorbic Acid Injection 500mg by M/s Enam Ellahie Karachi (Reg# '004784)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of

		specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., No. 236 Huanghe Street High-tech Industrial Development Zone, Shijiazhuang City, Hebei Province, China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 30 ºC ± 2ºC / 65 ± 5% RH for 36 months while accelerated stability study is conducted at 40 ºC ± 2ºC / 75 ± 5% RH for 06 months. Batch No# (1150452001, 1150452002, 1150452003)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability study of drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence against the reference product acido Ascorbico labesfal injection 500mg by performing quality test (identification, Acidity, Oxalic acid, Bacterial Endotoxin, Sterility, Visible particle, content of ascorbic acid).
	Analytical method validation/verification of product	Firm has submitted analytical method verification studies for the applied product.
	Container closure system of the drug product	USP type-I glass ampoule (5ml)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 40ºC ±2ºC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30ºC ±2ºC / 75% ± 5% RH. The real time stability study data is submitted for 36 months only.

Batch No.	**Mfg. date**	**Date of initiation**
173212044	03-2017	03-2017
173212045	03-2017	03-2017
173212046	03-2017	03-2017

Remarks of Evaluator [XI]:

Section	**Observations**	**Response**
1.3.3	Submit valid CoPP certificate for the applied product	Firm has submitted original legalized CoPP certificate (No. 2021120004) issued by Yiyuan Market Supervision Administration of P.R China for vitamin C Injection 500mg/5ml. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The name of importing country on CoPP is mentioned as Pakistan. Furthermore, the CoPP is valid till 06-12-2023.

1.5.2	Strength of Active ingredient shall be stated clearly. In case API is in the form of salt / hydrate, specify the equivalent strength of the base e.g., AAA sodium 50 mg (equivalent to AAA) etc.	Each 5ml ampoule contains: Ascorbic acid …….500mg
1.5.15-1.5.20	Commitments must be submitted by applicant (marketing authorization Holder) instead of manufacturer	Firm has submitted commitments as per guidance document
1.6.5	• The drug substance manufacturer as per section 3.2.S.2 is CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., No. 236 Huanghe Street High-tech Industrial Development Zone, Shijiazhuang City, Hebei Province, China while you have written Reyoung Pharmaceutical Co., Ltd., No.1 Ruiyang Road, Yiyuan County, Shandong Province, China in this section, clarify? • Submit GMP certificate of drug substance manufacturer	• The firm submitted that drug substance manufacturer is CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., No. 236 Huanghe Street High-tech Industrial Development Zone, Shijiazhuang City, Hebei Province, China and it was a mistake at their end by writing wrong name of manufacturer • The firm has submitted copy of GMP certificate No. HE20150023 in the name of M/s CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., No. 236 Huanghe Street High-tech Industrial Development Zone, Shijiazhuang, China valid upto 14/02/2020
3.2.S.4	• The specifications and analytical procedure of the drug substance provided is according to Chinese pharmacopeia while the product is available in BP. Justify that specification of drug substance are equivalent to BP specifications (the number and limits of tests are within range of BP.) • Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.	• The firm submitted that specifications of drug substance provided according to Chinese pharmacopeia is from API manufacturer, the finished product manufacturer test the API according to BP. Now the finished product manufacturer have supplemented the standards for raw material • Firm have submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer. • The firm submitted that vitamin C produced by CSPC WEISHENG is tested in strict accordance with Chinese Pharmacopoeia, ***there is not need to verify the analytical method.***
3.2.S.5	COA of primary / secondary reference standard including source and lot number shall be provided	The firm stated that the primary reference standard is from EDQM and government sector, hence no COA is submitted.
3.2.P.2.1.1	• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to reference product. • Applied product: Ascorbic acid, Sodium bicarbonate, Sodium metabisulfite, cysteine HCl, Disodium edetate, water for injection • Reference product: Ascorbic Acid, Sodium Bicarbonate, Sodium Metabisulphite Hydrochloric acid Water for injections • Details of reference / comparator product including batch numbers, manufacturing & expiry date in pharmaceutical equivalence are required to be provided • Justify why Pharmaceutical equivalence of the applied product has not been performed against the innovator product?	• Firm have submitted Compatibility studies of the Drug Substance(s) with excipients and observe the colour change and change in ph during the study • Firm have provided details of reference / comparator product including batch numbers, expiry date in pharmaceutical equivalence • The firm submitted that at that time innovator product has been delisted

Previous Decision (321-DRB): Deferred for submission of following documents:

- Pharmaceutical equivalence against innovator drug product.
- Verification studies of analytical method of drug substance by drug product manufacturer.

Response of the firm:

• Firm has submitted Pharmaceutical Equivalence against the product vitC CARE (Vitamin c injection) 500mg /5ml by M/s Advacare International Limited by performing quality tests (Description, Identification, Assay, Dissolution). • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision), linearity and range, solution stability performed by the Drug Product manufacturer for drug substance is submitted
Decision: Approved as per policy of inspection of manufacturer abroad.

Case No. 08; Deferred Registration applications of New DML of human drugs on Form 5F
M/s Biogen Pharmaceuticals, 8-km Chakbeli Road Rawat Rawalpindi.

The Central Licensing Board in its 273rd meeting held on 15th January, 2020 has considered and approved the grant of Drug Manufacturing License by way of formulation with following sections of **M/s Biogen Pharmaceuticals, 8-km Chakbeli Road Rawat Rawalpindi** under Drug Manufacturing License No. 000911 by way of Formulation vide approval letter No. F. 1-2/2019-Lic dated 14th February 2020.

Ground Floor			
1	Dry Suspension (Cephalosporin) Section	2.	Capsule Section (Cephalosporin)
3	Dry Vial Section (Cephalosporin)	4.	Penem Injection Section
5	Ware House	*	**********
First Floor			
1	Tablet Section (General)	2	Capsule Section (General)
3	Sachet Section (General)	4	Cream Section (General)
5	Ointment Section (General)	6	Lotion Section (General)
7	Dry Vial Section (General)	*	**********
Second Floor			
1	Ampoule Section SVP (General)	2	Infusion Section (General)
3	Hydrocortisone Injection (Steroid)	4	Soft Gel Capsule General
5	Quality Control Lab	*	**********

Following applications have been submitted for registration by the firm.

1326.	Name, address of Applicant / Marketing Authorization Holder	M/s Biogen Life Sciences, 8-km Chakbeli Road Rawat Rawalpindi
	Name, address of Manufacturing site.	M/s Biogen Life Sciences, 8-km Chakbeli Road Rawat Rawalpindi
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 28774 dated 11-10-2022
	Details of fee submitted	Not submitted
	The proposed proprietary name / brand name	**Fusigen-H 15gm Cream**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each gram cream contains: Fusidic Acid (BP)……..….20mg (2% w/w) Hydrocortisone Acetate……10mg (1% w/w)
	Pharmaceutical form of applied drug	White to off white color cream.
	Pharmacotherapeutic Group of (API)	Antibiotics & corticosteroid For Topical Use

	Reference to Finished product specifications	Innovator Specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Fucidin H cream MHRA approved
	For generic drugs (me-too status)	Fusimax-H 2%+1% Cream by M/s Maxitech Pharma (Reg# 83733)
	GMP status of the Finished product manufacturer	New license granted on 13/02/2020
	Name and address of API manufacturer.	**Fusidic Acid**: Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China **Hydrocortisone Acetate:** Henan Lihua Pharmaceutical Co Ltd., Middle of Huanghe Street, Anyang Hi-Tech Industry Development Zone, Henan China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities impurities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	**Fusidic Acid:** Firm has submitted stability study data of fusidic acid. Stability study is conducted Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months and at Accelerated conditions 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (121002FA, 121003FA, 121004FA) Batches: (150501FB, 150502FB, 150503FB) **Hydrocortisone Acetate:** Firm has submitted stability study data of Hydrocortisone acetate. Stability study is conducted Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months and at Accelerated conditions 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (160801, 160802, 160803)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.

	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand Genidic-H Cream by performing quality tests (Identification, Assay, Uniformity of dosage, pH).
	Analytical method validation/verification of product	Method verification studies have submitted including specificity, repeatibility, recovery and accuracy.

STABILITY STUDY DATA

Manufacturer of API	**Fusidic Acid**: Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China **Hydrocortisone Acetate:** Henan Lihua Pharmaceutical Co Ltd., Middle of Huanghe Street, Anyang Hi-Tech Industry Development Zone, Henan China		
API Lot No.	**Fusidic Acid:** 200507 FB **Hydrocortisone Acetate:** K06M20210604		
Description of Pack (Container closure system)	Cream filled in Aluminium pre-printed tube packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-001	T-002	T-003
Batch Size	500 tubes	500 tubes	500 tubes
Manufacturing Date	10-2021	10-2020	10-2021
Date of Initiation	14-10-2021	14-10-2021	14-10-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Fusidic Acid:** Firm has submitted GMP certificate No#CQ20180013 in the name of M/s Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China issued by Chonging Food and Drug administration China valid upto 06-06-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Fusidic Acid:** Firm has submitted copy of invoice No# 00025096 dated 02-04-2020 in name of M/s Biogen Pharmaceuticals for import of 1.5kg of Fusidic Acid. ***However, the invoice is not attested by AD (I&E) DRAP Field office.***
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted

6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.1	• Fee for registration of applied product is not submitted	
1.6.5	• Details of each drug substance manufacturer should be provided in this section separately • Valid GMP certificate / DML of drug substance manufacturer for hydrocortisone acetate issued by relevant regulatory authority of country of origin is required	
1.3.2	• The name of applicant as per form 5F is Biogen Life sciences while name mentioned on DML is Biogen Pharmaceuticals. Clarification is required	
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	
3.2.S.4	• Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient fusidic acid by Drug product manufacturer is required. • Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient hydrocortisone acetate by both drug substance and Drug product manufacturer is required • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and hydrocortisone acetate shall be submitted.	
3.2.P.2	• Submit details of reference / comparator product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence • Justify why Pharmaceutical equivalence of the applied product has not been performed against the innovator product?	
3.2.P.3	• Description of manufacturing process does not include the step in which the hydrocortisone is added in the formulation in manufacturing process, clarification is required	
3.2.P.8	• Documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Previous Decision (322nd–DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the Firm:

Section	Observations	Response
1.1	• Fee for registration of applied product is not submitted	Firm has submitted challan No. 78950080271 dated 07-11-2022 for registration fee of Rs.

		30000/- submitted for applied product Fusigen H Cream
1.6.5	• Details of each drug substance manufacturer should be provided in this section separately • Valid GMP certificate / DML of drug substance manufacturer for hydrocortisone acetate issued by relevant regulatory authority of country of origin is required	• Firm has submitted details of each drug substance manufacturer in this section **Fusidic Acid**: Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China **Hydrocortisone Acetate:** Henan Lihua Pharmaceutical Co Ltd., Middle of Huanghe Street, Anyang Hi-Tech Industry Development Zone, Henan China • Firm has submitted GMP certificate No. HA20170054 of M/s Henan Lihua Pharmaceutical Co Ltd., Middle of Huanghe Street, Anyang Hi-Tech Industry Development Zone, Henan China issued by Henan Province Food and Drug Administration for hydrocortisone acetate ***valid upto 26-10-2022*** • Firm has also submitted DML No. Yu 20150014 of M/s Henan Lihua Pharmaceutical Co Ltd., Middle of Huanghe Street, Anyang Hi-Tech Industry Development Zone, Henan China valid upto 31-12-2025. •
1.3.2	• The name of applicant as per form 5F is Biogen Life sciences while name mentioned on DML is Biogen Pharmaceuticals. Clarification is required	The firm submitted letter No. 1-2/2019-Lic dated 18th March 2021 for change of title of the firm from M/s Biogen Pharmaceuticals to Biogen Lifesciences.
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	Firm has submitted copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>
3.2.S.4	• Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient fusidic acid by Drug product manufacturer is required. • Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient hydrocortisone acetate by both drug substance and Drug product manufacturer is required • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and hydrocortisone acetate shall be submitted.	• Firm has submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance fusidic acid by Drug product manufacturer • Firm has submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance hydrocortisone acetate by both drug substance and Drug product manufacturer • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and hydrocortisone acetate is submitted.

3.2.P.2	• Submit details of reference / comparator product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence • Justify why Pharmaceutical equivalence of the applied product has not been performed against the innovator product?	• The firm submitted details of reference / comparator product. The details of comparator product are: Name: Genidic-H Cream; B. No: 2204, Mfg Date: 05-21, Expiry Date: 05-23 Manufacturer by: Biogen Pharma., 8-Km chakbeli Road Rawat Rawalpindi • The firm submitted that due to Easley Access of comparator *(Genidic-H manufacturer by Biogen pharma)* that's why perform pharmaceuticals equivalence study.
3.2.P.3	• Description of manufacturing process does not include the step in which the hydrocortisone is added in the formulation in manufacturing process, clarification is required	The firm submitted that due to Typographically mistake hydrocortisone acetate was not mentioned. The firm has submitted revised manufacturing process
3.2.P.8	• Documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• The firm has submitted copy of invoice No. 2021LH-0785 dated 29-07-2021 in name of M/s Biogen Lifesciences *Plot No. 260, Industrial Triangle, Kahuta Road, Islamabad for* Hydrocortisone Acetate (Batch No. K06M20210604) 10kg. *The invoice is not attested by AD (I&E) Field office. Further the address of firm mentioned in invoice is different from the actual address of the firm* • The firm has submitted copy of invoice No. 00025096 dated Apr 02-2020 in name of M/s Biogen Pharmaceuticals 8-km Chakbeli Road Rawat Rawalpindi for Fusidic Acid (Batch No. 190713FB) 1.5kg. *The invoice is not attested by AD (I&E) Field office. The batch No. of drug substance mentioned in invoice is different from that mentioned in batch analysis* • Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Decision: Deferred for Documents for procurement of drug substance with approval from DRAP I&E office.

1327.	Name, address of Applicant / Marketing Authorization Holder	M/s Biogen Life Sciences, 8-km Chakbeli Road Rawat Rawalpindi
	Name, address of Manufacturing site.	M/s Biogen Life Sciences, 8-km Chakbeli Road Rawat Rawalpindi
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 27911 dated 03-10-2022
	Details of fee submitted	Rs.30,000/- dated 14-07-2022

		(Deposit Slip#86318672487)
	The proposed proprietary name / brand name	**Fusigen-B Cream**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tube contains: Fusidic Acid……..….20mg Betamethasone (as valerate)……1mg
	Pharmaceutical form of applied drug	Cream.
	Pharmacotherapeutic Group of (API)	Antibiotics & corticosteroid For Topical Use
	Reference to Finished product specifications	Innovator Specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Fusidic acid/Betamethasone 20 mg/g + 1 mg/g cream MHRA approved
	For generic drugs (me-too status)	Fudic-B Cream by M/s Shaigan Pharmaceutical (Reg# 83599)
	GMP status of the Finished product manufacturer	New license granted on 13/02/2020
	Name and address of API manufacturer.	**Fusidic Acid**: Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China **Betamethasone valerate:** Envee Drugs Pvt. Ltd., N. H. No. 8, Dumral-387 355, Ta. Nadiad, Dist: Kheda, Gujarat, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities impurities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	**Fusidic Acid:** Firm has submitted stability study data of fusidic acid. Stability study is conducted Real time: 30˚C ± 2˚C / 65% ± 5%RH for 24 months and at Accelerated conditions 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (121002FA, 121003FA, 121004FA) Batches: (150501FB, 150502FB, 150503FB) **Betamethasone Valerate:** Firm has submitted stability study data of Betamethasone Valerate. Stability study is conducted Real time: 30˚C ± 2˚C / 65% ± 5%RH

		for 48months and at Accelerated conditions 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (EV/00808, EV/06308, EV/10507)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand Fuciden cream Cream by performing quality tests (Identification, Assay, pH, average weight).
	Analytical method validation/verification of product	Method validation studies have been submitted including accuracy, repeatability (method precision), linearity and range, specificity, system suitability.

STABILITY STUDY DATA

Manufacturer of API	**Fusidic Acid**: Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China **Betamethasone valerate:** Envee Drugs Pvt. Ltd., N. H. No. 8, Dumral-387 355, Ta. Nadiad, Dist: Kheda, Gujarat, India		
API Lot No.	**Fusidic Acid:** ~~200507 FB~~ **Betamethasone Valerate:** EV/BV-256/20		
Description of Pack (Container closure system)	Cream filled in Aluminium pre-printed tube packed in unit carton		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	**T#2004FB**	**T#2005FB**	**T#2006FB**
Batch Size	500 tubes	500 tubes	500 tubes
Manufacturing Date	10-2021	10-2021	10-2021
Date of Initiation	12-10-2021	12-10-2021	12-10-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Fusidic Acid:** Firm has submitted GMP certificate No#CQ20180013 in the name of M/s Joyang Laboratories., Haidu North Road, Sheyang Economic Development Zone, Jiangsu, China issued by Chonging Food and Drug administration China valid upto 06-06-2023 **Betamethasone valerate:**

		Firm has submitted GMP certificate No#S-GMP & GLP / 21072790 in the name of Envee Drugs Pvt. Ltd., N. H. No. 8, Dumral-387 355, Tal. Nadiad, Dist: Kheda, Gujarat, India issued by Food and Drugs control administration Gandinagar, Gujarat State India valid upto 06-07-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Fusidic Acid:** Firm has submitted copy of invoice No# 00025096 dated 02-04-2020 in name of M/s Biogen Pharmaceuticals for import of 1.5kg of Fusidic Acid. ***However, the invoice is not attested by AD (I&E) DRAP Field office.*** **Betamethasone valerate:** Firm has submitted copy of invoice No# 93 dated 02-11-2020 in name of M/s Biogen Life sciences for import of 03kg of Betamethasone valerate. ***However, the invoice is not attested by AD (I&E) DRAP Field office.***
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not Submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.2	• The name of applicant as per form 5F is Biogen Life sciences while name mentioned on DML is Biogen Pharmaceuticals. Clarification is required	
1.5.2	• Revise label claim as per reference formulation along with submission of applicable fee	
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	
3.2.S.4	• Copies of the analytical procedures used for routine testing of the Drug substance fusidic acid by both drug substance manufacturer and Drug product manufacturer is required. • Copies of the Drug substance specifications of drug substance fusidic acid by Drug product manufacturer is required. • Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Betamethasone Valerate by Drug product manufacturer is required • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and betamethasone valerate shall be submitted. • Certificate of Analysis of the same batch of fusidic acid used during product development and stability studies from Drug Substance manufacturer is required.	

3.2.P.2	• Submit details of reference / comparator product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence	
3.2.P.6	• Submit readable copy of reference standard of fusidic acid and betamethasone valerate	
3.2.P.8	• Submit stability summary sheet of batch #2006FB at accelerated conditions • Documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Previous Decision (322nd–DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the Firm:

Section	Observations	Response
1.3.2	• The name of applicant as per form 5F is Biogen Life sciences while name mentioned on DML is Biogen Pharmaceuticals. Clarification is required	The firm submitted letter No. 1-2/2019-Lic dated 18th March 2021 for change of title of the firm from M/s Biogen Pharmaceuticals to M/s Biogen Lifesciences.
1.5.2	• Revise label claim as per reference formulation along with submission of applicable fee	The firm has submitted revised label claim as per reference formulation. The revised label claim is: Each gram Contains: Fusidic Acid…….20mg (2 % w/w) Betamethasone as valerate…1mg (0.1%w/w)
2.3.R.1	• Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>	Firm has submitted copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3>
3.2.S.4	• Copies of the analytical procedures used for routine testing of the Drug substance fusidic acid by both drug substance manufacturer and Drug product manufacturer is required. • Copies of the Drug substance specifications of drug substance fusidic acid by Drug product manufacturer is required. • Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance Betamethasone Valerate by Drug product manufacturer is required • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and betamethasone valerate shall be submitted. • Certificate of Analysis of the same batch of fusidic acid used during product development and stability studies from Drug Substance manufacturer is required.	• Copies of the analytical procedures used for routine testing of the Drug substance fusidic acid by both drug substance manufacturer and Drug product manufacturer is not submitted • Copies of the Drug substance specifications of drug substance fusidic acid by Drug product manufacturer is submitted. • Firm has submitted copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance betamethasone valerate by Drug product manufacturer. *However, the limits of LOD (1.4% to 2%) mentioned in specifiations is different than USP (NMT 0.5%).* • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) i.e. fusidic acid and betamethasone valerate is submitted. • Certificate of Analysis of the same batch of fusidic acid used during product development and stability studies from Drug Substance manufacturer is not submitted

3.2.P.2	• Submit details of reference / comparator product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence	• The firm submitted details of reference / comparator product. The details of comparator product are: Name: Genidic-G Cream; B. No: 2212, Mfg Date: 05-21, Expiry Date: 05-23 Manufacturer by: Biogen Pharma., 8-Km chakbeli Road Rawat Rawalpindi
3.2.P.6	• Submit readable copy of reference standard of fusidic acid and betamethasone valerate	• Firm has submitted readable copy of reference standard of fusidic acid and betamethasone valerate
3.2.P.8	• Submit stability summary sheet of batch #2006FB at accelerated conditions • Documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• Stability summary sheet of batch #2006FB at accelerated conditions is not submitted • The firm has submitted copy of invoice No. 00025096 dated Apr 02-2020 in name of M/s Biogen Pharmaceuticals 8-km Chakbeli Road Rawat Rawalpindi for Fusidic Acid (Batch No. 190713FB) 1.5kg. *The invoice is not attested by AD (I&E) Field office. The batch No. of drug substance mentioned in invoice is different from that mentioned in batch analysis* • The firm has submitted copy of invoice No. 10 dated 03-08-2019 in name of M/s Biogen Pharma 8-km Chakbeli Road Rawat Rawalpindi for Betamethasone valerate (Batch No. EV/BV-060/19) 03kg. *The invoice is not attested by AD (I&E) Field office. The batch No. of drug substance mentioned in invoice is different from that mentioned in batch analysis* • Firm has submitted Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)
Decision: Deferred for Documents for procurement of drug substance with approval from DRAP I&E office.		

Case No. 09: Deferred Registration applications of New Section of Human drugs on Form 5-F (Local)

1328.	Name, address of Applicant / Marketing Authorization Holder	M/s Titlis Pharma (Pvt.) Limited., 528-A, Sunder Industrial Estate, Raiwind Road, Lahore.
	Name, address of Manufacturing site.	M/s Titlis Pharma (Pvt) Limited., 528-A, Sunder Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 17528 dated 15/06/2022
	Details of fee submitted	PKR 30,000/-: dated 31/05/2022 (Slip#013889185789)

	The proposed proprietary name / brand name	Linet 2.5mg/1000mg Tablets
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Linagliptin ……. 2.5mg Metformin Hydrochloride ……. 1000mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Dipeptidyl peptidase-4 (DPP-4) inhibitor & Biguanide (antidiabetic)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	2x7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	JENTADUETO 2.5mg/500mg, 2.5mg/850mg, 2.5mg/1000mg (linagliptin/metformin hydrochloride) film coated Tablets USFDA Approved Trajentamet (linagliptin/metformin hydrochloride) 2.5mg/500mg, 2.5mg/850mg, 2.5mg/1000mg film coated Tablets TGA Approved JENTADUETO (linagliptin/metformin hydrochloride) 2.5mg/500mg, 2.5mg/850mg, 2.5mg/1000mg film coated tablets Health Canada Approved
	For generic drugs (me-too status)	N/A
	GMP status of the Finished product manufacturer	New section granted on 17th & 18th March, 2022 and letter issued on 10th May, 2022
	Name and address of API manufacturer.	**Linagliptin:** Fuxin Long Rui Pharmaceutical Co. Ltd., Fluoride Industrial park, Fuxin city, Liaoning province, 123000, China. **Metformin HCl:** Aarti Drugs Limited (Unit-II)., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat. INDIA.396155
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	**Linagliptin:** Stability study conditions:

		Real time: 30˚C ± 2˚C / 65% ± 5%RH for 36 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L9-02, L-20170604-D01-L9-03) **Metformin Hydrochloride:** Stability study conditions: Real time: 30˚C ± 2˚C / 65% ± 5%RH for 60 months Accelerated: 40˚C ± 2˚C / 75% ± 5%RH for 6 months Batches: (MEF/1510145, MEF/1510146, MEF/1510147)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Jentadueto 2.5/1000mg Tablet of M/s Boehringer Ingelheim Pharma Germany by performing quality tests (disintegration, weight variation, Dissolution and Assay).
	Analytical method validation/verification of product	Firm has submitted method validation studies including linearity, range, accuracy, precision, specificity, LOD, LOQ, solution stability and robustness.

STABILITY STUDY DATA

Manufacturer of API	**Linagliptin:** Fuxin Long Rui Pharmaceutical Co. Ltd., Fluoride Industrial park, Fuxin city, Liaoning province, 123000, China. **Metformin HCl:** Aarti Drugs Limited (Unit-II)., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat. INDIA.396155		
API Lot No.	Linagliptin L-20210123-D01-L09-02 Metformin Hydrochloride MEF/10041416		
Description of Pack (Container closure system)	ALU-ALU blister packed in cardboard unit carton.		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	LP-10	LP-11	LP-12
Batch Size	700 Tablets	700 Tablets	700 Tablets
Manufacturing Date	Nov-2021	Nov-2021	Nov-2021
Date of Initiation	31-12-2021	31-12-2021	31-12-2021

No. of Batches		03
Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Linagliptin:** The firm have submitted written confirmation for active substance exported to EU to M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China for Active substance Linagliptin by Deputy General Director confirming that the manufacturing plant complies with requirement of Chinese Good Manufacturing practices. This certificate is valid till 25-05-2024 Metformin HCl: The firm has submitted GMP certificate for M/s Aarti Drugs Limited (Unit-II) India issued by Food & Drug Control Administration Gandhinagar India. The certificate is valid till 19-03-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.1	• Submit differential fee as the applied product is new drug molecule	
1.3.2	• The name of applicant as per form 5F is M/s Titlis Pharma (Pvt.) Limited., while name mentioned on DML is M/s Titlis Pharma., Clarification is required	
1.4	• Clarification is required as the applied drug product is a New Drug Product while you have applied for generic drug product	
1.6.5	• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer for Linagliptin issued by relevant regulatory authority of country of origin	
3.2.S.4	• Justification is required for not including the test for sulphated ash in drug substance specification of drug substance metformin by drug product manufacturer as recommended by BP. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) linagliptin and Metformin HCl shall be submitted. • Clarification is required as the drug substance manufacturer has performed assay of drug substance Metformin HCl in batch analysis by potentiometric method as per BP while drug product manufacturer has performed assay of drug substance Metformin HCl by titrimetric method. • Justification is required for not performing test for appearance of solution and sulphated ash test in batch analysis of drug substance metformin by drug product manufacturer as recommended by BP.	

<table>
<tr><td>3.2.S.7</td><td>• Stability study of Linagliptin drug substance batch No. L-20170604-D01-L9-03 at accelerated conditions is not submitted</td><td></td></tr>
<tr><td>3.2.P.2</td><td>• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.
<table>
<tr><th>Applied product</th><th>JENTADUETO tablet</th></tr>
<tr><td>Linagliptin
Metformin HCl</td><td>Linagliptin
Metformin HCl</td></tr>
<tr><td>Lactose</td><td>Arginine</td></tr>
<tr><td>Avecil PH 102</td><td>Corn Starch</td></tr>
<tr><td>Starch</td><td>Copovidone</td></tr>
<tr><td>PVP K30</td><td>Colloidal Silicon Dioxide</td></tr>
<tr><td>Aerosil 200</td><td>Magnesium Stearate</td></tr>
<tr><td>Ac-di-sol</td><td></td></tr>
<tr><td>Magnesium stearate</td><td></td></tr>
<tr><td>Purified water</td><td></td></tr>
</table>
• CDP of the applied product has not been submitted.
• Only protocol for CDP is submitted</td><td></td></tr>
<tr><td>3.2.P.4</td><td>• The specifications, Analytical procedures and Validation of analytical procedures for excipients shall be provided as the firm have stated that excipient specifications follow in-house or manufacturer specifications</td><td></td></tr>
<tr><td>3.2.P.5</td><td>• Justification is required for setting dissolution specification of NLT 75% in 45 minutes while innovator product review document recommends NLT Q in 30 minutes
• Justification is required for not including test for identification test active substances and uniformity of dosage units in finished product specification as recommended by innovator product review document.
• Justification is required since composition of dissolution media and rotation (0.03M Potassium dihydrogen phosphate and 75rpm) mentioned in dissolution method for applied drug product is different than that recommended by innovator product review document (0.1N HCl and 50 rpm)</td><td></td></tr>
<tr><td>3.2.P.8</td><td>• Justification is required since composition of dissolution media (0.03M Potassium dihydrogen phosphate) mentioned in dissolution test for applied drug product in stability summary sheets is different than that recommended by innovator product review document (0.1N HCl)
• Justification is required for setting dissolution specification NLT 75% in 45minutes in stability study summary sheets instead of NLT 75% in 30minutes as recommended by innovator product review document.
• Accelerated stability study of Batch No#LP-12 at 3rd month time point is not submitted
• Submit documents for procurement of API with approval from DRAP
• Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)
• Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing</td><td></td></tr>
</table>

INDICATIONS AND USAGE

JENTADUETO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

JENTADUETO should not be used in patients with type 1 diabetes.

JENTADUETO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using JENTADUETO

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

The dosage of JENTADUETO should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin hydrochloride (HCl) twice daily. JENTADUETO should be given twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with metformin use.

Recommended starting dose:

- In patients currently not treated with metformin HCl, initiate treatment with 2.5 mg linagliptin/500 mg metformin HCl twice daily.
- In patients already treated with metformin HCl, start with 2.5 mg linagliptin and the current dose of metformin HCl taken at each of the two daily meals (e.g., a patient on metformin HCl 1000 mg twice daily would be started on 2.5 mg linagliptin/1000 mg metformin HCl twice daily with meals).
- Patients already treated with linagliptin and metformin HCl individual components may be switched to JENTADUETO containing the same doses of each component.

Previous Decision (323-DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the Firm:

Section	Observations	Response
1.1	• Submit differential fee as the applied product is new drug molecule	• Differential fee for the applied product is not submitted (as applied product is new drug molecule)
1.3.2	• The name of applicant as per form 5F is M/s Titlis Pharma (Pvt.) Limited., while name mentioned on DML is M/s Titlis Pharma., Clarification is required	The firm submitted that the title of our company has been changed in 279th meeting of Central Licensing Board held on 18th February 2021, and the new approved title is "Titlis Pharma (Private) Limited". The change of title approval letter No. F. 1-11/2009-Lic (Vol-I) from Central Licensing Board in the name of "Titlis Pharma (Private) Limited" is submitted.
1.4	• Clarification is required as the applied drug product is a New Drug Product while you have applied for generic drug product	The firm submitted that we have applied for New Drug Product but Generic Drug Product was mentioned by typographic error.
1.6.5	• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer for Linagliptin issued by relevant regulatory authority of country of origin	The firm have submitted written confirmation for active substances exported to EU to M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China for Active substance Linagliptin by Deputy General Director confirming that the manufacturing plant complies with requirement of Chinese Good Manufacturing practices. This certificate is valid till 25-05-2024
3.2.S.4	• Justification is required for not including the test for sulphated ash in drug substance specification of drug substance metformin by drug product manufacturer as recommended by BP. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) linagliptin and Metformin HCl shall be submitted. • Clarification is required as the drug substance manufacturer has performed assay of drug substance Metformin HCl in batch analysis by potentiometric method as per BP while drug product manufacturer has performed assay of drug substance Metformin HCl by titrimetric method. • Justification is required for not performing test for appearance of solution and sulphated ash test in batch analysis of drug substance metformin by drug product manufacturer as recommended by BP.	• The firm submitted that we have revised our testing method and now performing testing of Metformin HCL by HPLC method as per USP43 monograph and test for sulphated ash is not mentioned in USP monograph. • The testing and COA of most recent batch of metformin HCL (Batch no; MEF/12051645) as per USP Method is submitted. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) linagliptin and Metformin HCl is submitted. • The firm submitted that previously, we were performing the assay of Metformin HCL on titrimetric method. However, we have revised our testing method and now performing testing of Metformin HCl by HPLC method as per USP43 monograph. The testing and COA of most recent batch of metformin HCL (Batch no; MEF/12051645) as per USP Method is submitted. • The firm submitted that previously, we were performing the analysis of Metformin HCl by BP method. However, we have revised our

<table>
<tr><td></td><td></td><td>testing method and now performing testing of Metformin HCL by HPLC method as per USP43 monograph and test for appearance of solution and sulphated ash is not mentioned in USP monograph.
The testing and COA of most recent batch of metformin HCl (Batch no; MEF/12051645) as per USP Method is attached for your kind perusal.</td></tr>
<tr><td>3.2.S.7</td><td>• Stability study of Linagliptin drug substance batch No. L-20170604-D01-L9-03 at accelerated conditions is not submitted</td><td>Stability study of Linagliptin drug substance batch no. L-20170604-D01-L9-03 at accelerated condition is submitted.</td></tr>
<tr><td>3.2.P.2</td><td>• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.
<table>
<tr><th>Applied product</th><th>JENTADUETO tablet</th></tr>
<tr><td>Linagliptin
Metformin HCl</td><td>Linagliptin
Metformin HCl</td></tr>
<tr><td>Lactose</td><td>Arginine</td></tr>
<tr><td>Avecil PH 102</td><td>Corn Starch</td></tr>
<tr><td>Starch</td><td>Copovidone</td></tr>
<tr><td>PVP K30</td><td>Colloidal Silicon Dioxide</td></tr>
<tr><td>Aerosil 200</td><td>Magnesium Stearate</td></tr>
<tr><td>Ac-di-sol</td><td></td></tr>
<tr><td>Magnesium stearate</td><td></td></tr>
<tr><td>Purified water</td><td></td></tr>
</table>
• CDP of the applied product has not been submitted.
• Only protocol for CDP is submitted</td><td>• The firm submitted that as per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Linet tablet 2.5mg/1000mg. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies.
• The firm further stated that we have also performed Drug Excipients Compatibility studies. However, no compatibility studies is submitted
• CDP has been performed against the brand Jentadueto 2.5/1000mg tablet by M/s Boehringer Ingelhem Pharma Germany in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.</td></tr>
<tr><td>3.2.P.4</td><td>• The specifications, Analytical procedures and Validation of analytical procedures for excipients shall be provided as the firm have stated that excipient specifications follow in-house or manufacturer specifications</td><td>The firm submitted that all the excipients used in our formulation, follow pharmacopoeial specifications and submitted pharmacopoeial monographs of all the excipients.</td></tr>
<tr><td>3.2.P.5</td><td>• Justification is required for setting dissolution specification of NLT 75% in 45 minutes while innovator product review document recommends NLT Q in 30 minutes
• Justification is required since composition of dissolution media and rotation (0.03M Potassium dihydrogen phosphate and 75rpm) mentioned in dissolution method for applied drug product is different than that recommended by innovator product review document (0.1N HCl and 50 rpm)
• Justification is required for not including test for identification test active substances and uniformity of dosage units in finished product specification as recommended by innovator product review document.</td><td>• The firm submitted that initially we performed dissolution by using following parameters:
Media: 0.03 M Potassium Dihydrogen phosphate
RPM: 75 rpm
Apparatus: II (Paddle)
Time 45 min.
• It is notable that the data of comparative dissolution profile report for Linet 2.5mg/1000mg tablet is remarkable and recognizes that the product is highly soluble and dissolves not less than 75% after 45 minutes in all three media (0.1 N HCl pH 1.2, Acetate buffer pH 4.5 and Phosphate buffer pH 6.8) at all seven sampling points. Therefore, it is ascertained that dissolution studies of test and reference products are almost similar in all three prescribed dissolution mediums including Acetate buffer pH 4.5. Moreover, f2 values comply with the acceptance criteria.
• Stability batches were analyzed at 0 & 3 months on in house testing but after innovator's product literature review, we revised our testing method and performed 6th month stability studies (accelerated + long run) as per innovator's specifications with below parameters.
Media: 0.1M HCl
RPM: 50 rpm
Apparatus: II (Paddle)
Time 30 min.</td></tr>
</table>

		• Moreover, we manufactured 3 new batches (Batch numbers: LP-28, LP-29 and LP-30) for performance of accelerated and long run stability testing as per innovator's specifications / dissolution parameters and "0", & 3rd month testing has been completed and results are complying with innovator specification. (Reports and chromatogram are attached for kind perusal). **CONCLUSION:** Therefore, we have performed 0, 3, & 6th month stability studies as per innovator's specifications / dissolution parameters and the results are complying with innovator's specifications. • The firm submitted that we have revised the specification and included the test for identification test for active substance, uniformity of dosage units in finished product specification as recommended by innovator product review document and submitted revised specifications
3.2.P.8	• Justification is required since composition of dissolution media (0.03M Potassium dihydrogen phosphate) mentioned in dissolution test for applied drug product in stability summary sheets is different than that recommended by innovator product review document (0.1N HCl) • Justification is required for setting dissolution specification NLT 75% in 45minutes in stability study summary sheets instead of NLT 75% in 30minutes as recommended by innovator product review document. • Accelerated stability study of Batch No#LP-12 at 3rd month time point is not submitted • Submit documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) • Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing	• The firm submitted that initially we performed dissolution by using following parameters: Media: 0.03 M Potassium Dihydrogen phosphate RPM: 75 rpm Apparatus: II (Paddle) Time 45 min. • Stability batches were analyzed at 0 & 3 months on in house testing but after innovator's product literature review, we revised our testing method and performed 6th month stability studies (accelerated + long run) as per innovator's specifications with below parameters. (Revised stability study summary sheets are attached) **Media: 0.1M HCl** **RPM: 50 rpm** **Apparatus: II (Paddle)** **Time 30 min.** • Moreover, we manufactured 3 new batches (Batch numbers: LP-28, LP-29 and LP-30) for performance of accelerated and long run stability testing as per innovator's specifications / dissolution parameters and "0", & 3rd month testing has been completed and results are complying with innovator specification. • Accelerated stability study of Batch No#LP-12 at 3rd month time point is submitted • The firm has submitted copy of invoice No. EXP/321/20-21 dated 18-05-2020 in name of M/s Titli Pharma for import of Metformin HCl (Batch No. MEF/10041416) 1000kg attested by AD (I&E) DRAP Lahore. • Firm has submitted copy of Form 6 for import of 0.220kg of Linagliptin from M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China attested by AD (I&E) DRAP Lahore dated 09-08-2021. • Firm has also submitted copy invoice No. HN210713-J dated 13-07-2021 for import of 0.22kg Linagliptin in name of M/s Titlis Pharma attested AD (I&E) DRAP Lahore dated 09-08-2021. • Record of Digital data logger for temperature and humidity monitoring of stability chambers is submitted at accelerated conditions only

		• Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing is not submitted

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

1329.	Name, address of Applicant / Marketing Authorization Holder	M/s Titlis Pharma (Pvt.) Limited., 528-A, Sunder Industrial Estate, Raiwind Road, Lahore.
	Name, address of Manufacturing site.	M/s Titlis Pharma (Pvt) Limited., 528-A, Sunder Industrial Estate, Raiwind Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 12952 dated 27/05/2022
	Details of fee submitted	PKR 30,000/-: dated 28/03/2022 (Slip#4224820319)
	The proposed proprietary name / brand name	Linatit 5mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Linagliptin ……. 5mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Dipeptidyl peptidase-4 (DPP-4) inhibitor (antidiabetic)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	1x10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Tradjenta 5mg film coated tablets USFDA Approved.
	For generic drugs (me-too status)	Linvesta 5mg Tablet by M/s Wilshire Laboratories (Reg#110608)
	GMP status of the Finished product manufacturer	New section granted on 17th & 18th March, 2022 and letter issued on 10th May, 2022
	Name and address of API manufacturer.	Fuxin Long Rui Pharmaceutical Co. Ltd., Fluoride Industrial park, Fuxin city, Liaoning province, 123000, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference

		standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (L-20170429-D01-L9-01, L-20170604-D01-L9-02, L-20170604-D01-L9-03)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Trajenta 5mg tablet of West-Ward Columbus USA by performing quality tests (Disintegration time, weight variation, Dissolution, Assay) and results are within specifications and comparable with Tradjenta 5mg Tablet.
	Analytical method validation/verification of product	Firm has submitted method validation studies including linearity, range, accuracy, precision, specificity, LOD, LOQ, solution stability and robustness.

STABILITY STUDY DATA			
Manufacturer of API	Fuxin Long Rui Pharmaceutical Co. Ltd., Fluoride Industrial park, Fuxin city, Liaoning province, 123000, China.		
API Lot No.	L-20210123-D01-L09-02		
Description of Pack (Container closure system)	ALU-ALU blister packed in cardboard unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	LP-01	LP-02	LP-03
Batch Size	1000 Tablets	1000 Tablets	1000 Tablets
Manufacturing Date	Nov-2021	Nov-2021	Nov-2021
Date of Initiation	20-12-2021	20-12-2021	20-12-2021
No. of Batches	03		

Administrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm have submitted written confirmation for active substance exported to EU to M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China for Active substance Linagliptin by Deputy General Director confirming that the manufacturing plant complies with requirement of Chinese Good Manufacturing practices. This certificate is valid till 25-05-2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not submitted

Remarks of Evaluator [XI]:

Section	Observations	Response
1.3.2	• The name of applicant as per form 5F is M/s Titlis Pharma (Pvt.) Limited., while name mentioned on DML is M/s Titlis Pharma., Clarification is required	
1.6.5	• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin	
3.2.S.4	• Justification is required for not including the test for water content, melting temperature and enantiomeric purity in drug substance specification by drug substance manufacturer as recommended by innovator's product review document. • Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required. • Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.	
3.2.P.2	• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.	

Applied product	**TRADJENTA tablet**
Linagliptin	Linagliptin
Lactose	Mannitol
Avecil PH 102	Pregelatinized starch
Ac-Di-Sol	Corn Starch
Aerosil 200	Copovidone
PVP K30	Magnesium Stearate
Magnesium stearate	
Purified water	

• Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator/comparator product including the tests recommended by innovator product (identification, loss on drying, uniformity of dosage units).
• Submit details of innovator / reference product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence
• (manufacturer of tradjenta 5mg tablet is Boehringer Ingelheim Pharmaceuticals while firm stated West-Ward Columbus USA)

	• CDP of the applied product has not been submitted. • Only protocol for CDP is submitted	
3.2.P.4	• The specifications, Analytical procedures and Validation of analytical procedures for excipients shall be provided as the firm have stated that excipient specifications follow in-house or manufacturer specifications	
3.2.P.5	• Justification is required for setting dissolution specification of NLT 75% in 45 minutes while innovator product review document recommends NLT Q in 30 minutes • Justification is required for not including test for identification of active substances, loss on drying and uniformity of dosage units in finished product specification as recommended by innovator product review document. • Justification is required since dissolution apparatus, composition of dissolution media and rotation speed (rpm) (Apparatus II, 0.03M Potassium dihydrogen phosphate and 75rpm) mentioned in dissolution method for applied drug product is different than that recommended by innovator product review document (Apparatus I (Basket), 01N HCl and 50 rpm)	
3.2.P.8	• Justification is required since composition of dissolution media (0.03M Potassium dihydrogen phosphate) mentioned in dissolution test for applied drug product in stability summary sheets is different than that recommended by innovator product review document (1N HCl) • Justification is required for setting dissolution specification NLT 75% in 45minutes in stability study summary sheets instead of NLT Q in 30minutes as recommended by innovator product review document. • The submitted chromatograms show that the detection wavelength used during dissolution test of stability study of all the batches at initial time point is different than that given in analytical procedure, clarification is required (275nm used instead of 267nm) • Submit documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Previous Decision (323-DRB): Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Response of the firm:

Section	Observations	Response
1.3.2	• The name of applicant as per form 5F is M/s Titlis Pharma (Pvt.) Limited., while name mentioned on DML is M/s Titlis Pharma., Clarification is required	The firm submitted that the title of our company has been changed in 279th meeting of Central Licensing Board held on 18th February 2021, and the new approved title is "Titlis Pharma (Private) Limited". The change of title approval letter No. F. 1-11/2009-Lic (Vol-I)from Central Licensing Board in the name of "Titlis Pharma (Private) Limited" is submitted.
1.6.5	• Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin	The firm have submitted written confirmation for active substances exported to EU to M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China for Active substance Linagliptin by Deputy General Director confirming that the manufacturing plant complies with requirement of Chinese Good Manufacturing practices. This certificate is valid till 25-05-2024
3.2.S.4	• Justification is required for not including the test for water content, melting temperature and enantiomeric purity in drug substance specification by drug substance manufacturer	• The firm submitted that Test for water content, melting temperature and Enantiomeric purity in drug Substance specification by drug substance manufacturer has been added as recommended by

<table>
<tr><td></td><td>as recommended by innovator's product review document.
• Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is required.
• Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) shall be submitted.</td><td>innovator's product review document and submitted COA of drug substance.
• Copies of the specifications and analytical procedures used for routine testing of the Drug substance by Drug product manufacturer is submitted
• Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) is submitted.</td></tr>
<tr><td>3.2.P.2</td><td>• Compatibility studies of the Drug Substance(s) with excipients shall be provided as the qualitative composition of the formulation is not similar to innovator / reference product.
<table>
<tr><th>Applied product</th><th>TRADJENTA tablet</th></tr>
<tr><td>Linagliptin</td><td>Linagliptin</td></tr>
<tr><td>Lactose</td><td>Mannitol</td></tr>
<tr><td>Avecil PH 102</td><td>Pregelatinized starch</td></tr>
<tr><td>Ac-Di-Sol</td><td>Corn Starch</td></tr>
<tr><td>Aerosil 200</td><td>Copovidone</td></tr>
<tr><td>PVP K30</td><td>Magnesium Stearate</td></tr>
<tr><td>Magnesium stearate</td><td></td></tr>
<tr><td>Purified water</td><td></td></tr>
</table>
• Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator/comparator product including the tests recommended by innovator product (identification, loss on drying, uniformity of dosage units).
• Submit details of innovator / reference product including batch numbers, manufacturing & expiry date, name of manufacturer in pharmaceutical equivalence
• (manufacturer of tradjenta 5mg tablet is Boehringer Ingelheim Pharmaceuticals while firm stated West-Ward Columbus USA)
• CDP of the applied product has not been submitted.
• Only protocol for CDP is submitted</td><td>• The firm submitted that as per literature review and study of Hand Book for Pharmaceutical Excipients, it is notable that all the excipients used in our formulation are inert, and are compatible with active pharmaceutical ingredient of Linet tablet 5mg. Moreover, their safety and compatibility have also been established as no harsh / adverse effect has been observed in our stability studies.
• The firm further stated that we have also performed Drug Excipients Compatibility studies. However, no compatibility studies is submitted
• Firm has submitted pharmaceutical equivalence of applied product against innovator product Trajenta 5mg tablet by M/s West Ward Columbus USA by performing quality tests (identification, disintegration time, weight variation, content uniformity, Dissolution and assay test).
• Firm has submitted details of innovator / reference product.
Name: Trajenta 5mg tablet, Batch No; AB3469B
Mfg date; 01-2021, Expiry date; 12-2023
Manufacturer: West-Ward Columbus USA
• CDP has been performed against the brand Trajenta 5mg tablet by M/s West-Ward Columbus USA in Acid media pH 1.2, acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The values for f2 are in the acceptable range.</td></tr>
<tr><td>3.2.P.4</td><td>• The specifications, Analytical procedures and Validation of analytical procedures for excipients shall be provided as the firm have stated that excipient specifications follow in-house or manufacturer specifications</td><td>The firm submitted that all the excipients used in our formulation, follow pharmacopoeial specifications and submitted pharmacopoeial monographs of all the excipients.</td></tr>
<tr><td>3.2.P.5</td><td>• Justification is required for setting dissolution specification of NLT 75% in 45 minutes while innovator product review document recommends NLT Q in 30 minutes
• Justification is required since dissolution apparatus, composition of dissolution media and rotation speed (rpm) (Apparatus II, 0.03M Potassium dihydrogen phosphate and 75rpm) mentioned in dissolution method for applied drug product is different than that recommended by innovator product review document (Apparatus I (Basket), 01N HCl and 50 rpm)
• Justification is required for not including test for identification of active substances, loss on drying and uniformity of dosage units in finished product specification as</td><td>• Firm submitted that Initially we performed dissolution by using following parameters:

Media: 0.03 M Potassium Dihydrogen phosphate
RPM: 75 rpm
Apparatus: II (Paddle)
Time 45 min.
• It is notable that the data of comparative dissolution profile report for Linatit 5mg tablet is remarkable and recognizes that the product is highly soluble and dissolves not less than 75% after 45 minutes in all three media (0.1 N HCl pH 1.2, Acetate buffer pH 4.5 and Phosphate buffer pH 6.8) at all seven sampling points. Therefore, it is ascertained that dissolution studies of test and reference products are almost similar in all three prescribed dissolution mediums including Acetate buffer pH 4.5. Moreover, f2 values comply with the acceptance criteria.</td></tr>
</table>

	recommended by innovator product review document.	• Stability batches were analyzed at 0 & 3 months on in house testing but after innovator's product literature review, we revised our testing method and performed 6th month stability studies (accelerated + long run) as per innovator's specifications with below parameters. Media: 0.1M HCl RPM: 50 rpm Apparatus: II (Paddle) Time 30 min. • Moreover, we manufactured 3 new batches (Batch numbers: LP-19, LP-20 and LP-21) for performance of accelerated and long run stability testing as per innovator's specifications / dissolution parameters and "0", & 3rd month testing has been completed and results are complying with innovator specification. (Reports and chromatogram are attached for kind perusal). **CONCLUSION:** Therefore, we have performed 0, 3, & 6th month stability studies as per innovator's specifications / dissolution parameters and the results are complying with innovator's specifications. • The firm submitted that we have revised the specification and included the test for identification test for active substance, uniformity of dosage units in finished product specification as recommended by innovator product review document.
3.2.P.8	• Justification is required since composition of dissolution media (0.03M Potassium dihydrogen phosphate) mentioned in dissolution test for applied drug product in stability summary sheets is different than that recommended by innovator product review document (1N HCl) • Justification is required for setting dissolution specification NLT 75% in 45minutes in stability study summary sheets instead of NLT Q in 30minutes as recommended by innovator product review document. • The submitted chromatograms show that the detection wavelength used during dissolution test of stability study of all the batches at initial time point is different than that given in analytical procedure, clarification is required (275nm used instead of 267nm) • Submit documents for procurement of API with approval from DRAP • Submit Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	• The firm submitted that initially we performed dissolution by using following parameters: Media: 0.03 M Potassium Dihydrogen phosphate RPM: 75 rpm Apparatus: II (Paddle) Time 45 min. • Stability batches were analyzed at 0 & 3 months on in house testing but after innovator's product literature review, we revised our testing method and performed 6th month stability studies (accelerated + long run) as per innovator's specifications with below parameters. (Revised stability study summary sheets are attached). Media: 0.1M HCl RPM: 50 rpm Apparatus: II (Paddle) Time 30 min. • Moreover, we manufactured 3 new batches (Batch numbers: LP-19, LP-20 and LP-21) for performance of accelerated and long run stability testing as per innovator's specifications / dissolution parameters and "0", & 3rd month testing has been completed and results are complying with innovator specification. • The detection wavelength used during dissolution test of stability studies is λmax 267nm but by mistakenly it was set as λmax 275nm at initial time point (analyzed on 20-12-2021). Therefore, it was mentioned as λ275 in chromatograms. • However, we had already performed analysis on all batches (analyzed on 24-12-2021) at initial stage with proper λmax 267nm.

		• Moreover, we manufactured 3 new batches (Batch numbers: LP-19, LP-20 and LP-21) for performance of accelerated and long run stability testing as per innovator's specifications / dissolution parameters and "0", & 3rd month testing has been completed and results are complying with innovator specification. • Firm has submitted copy of Form 6 for import of 0.220kg of Linagliptin from M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China attested by AD (I&E) DRAP Lahore dated 09-08-2021. • Firm has also submitted copy invoice No. HN210713-J dated 13-07-2021 for import of 0.22kg Linagliptin in name of M/s Titlis Pharma attested AD (I&E) DRAP Lahore dated 09-08-2021. • Record of Digital data logger for temperature and humidity monitoring of stability chambers at accelerated conditions is submitted only

Decision: Approved with Innovator's specifications. The firm shall submit fee of Rs. 30,000/- for submission of revised stability studies data, as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case No. 10; Deferred Registration Application of Human Drugs on form 5:

1330.	Name and address of manufacture / Applicant	M/s Paramount Pharmaceuticals., Plot No. 36, Industrial Triangle, Kahuta Road, Islamabad ***Contract Manufactured By:*** M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name + Dosage Form and Strength	Colistacin 1 M IU Injection
	Composition	Each Vial Contains: Colistimethate Sodium eq. to Colistimethate Lyophilized Powder…….1MIU
	Dairy No. date of R &I fee	Form-5 Dy.No 13002 dated 05-03-2019 Rs.20,000/- dated 04-03-2019
	Pharmacological Group	other antibacterials (polymyxins)
	Type of form	Form 5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Colistimethate Sodium 1 Million I.U. Powder for Solution for Injection MHRA Approved
	Me-too-status	Colicraft Injection by Biolabs (Pvt) Ltd. (Reg# 082407)
	GMP Status	The firm M/s Paramount Pharmaceuticals was inspected on 08-02-2019 and conclusion of inspection was: During review of approval of above-mentioned sections/manufacturing facilities, it was assessed that following two sections needs regularization from Licensing Division: 1- Cream/Ointment 2- Tablet (General) The firm has applied for the regularization of same in Licensing Division. Keeping in view the observations noticed during inspection as narrated above, the panel is of the opinion that the firm may be allowed to start manufacturing in the light of GMP guidelines. The panel further recommended granting the GMP certificate for export purpose.

		Certificate of GMP Issued to M/s Bio Labs Pvt on 25-05-2019.
	Previous Remark of the Evaluator [XI]	• The firm have submitted differential fee Rs. 55000/- on deposit slip No# 873385180685 for contract manufacturing. • Form 5 is submitted by the applicant i.e. M/s Paramount Pharmaceuticals duly signed by the applicant • The firm submitted list of 08 approved sections of applicant. i.e. M/s Paramount Pharmaceuticals • The firm submitted list of 11 products registered/approved on contract manufacturing in name of applicant. i.e. M/s Paramount Pharmaceuticals • The firm submitted list of 14 products applied for contract manufacturing by the applicant. • The firm submitted copy of contract manufacturing agreement between M/s Paramount Pharmaceuticals and M/s Bio Labs Pvt Ltd • The firm have not revised the label claim as per reference formulation without considering the salt factor. The submitted label claim is as under: Each Vial Contains: Colistimethate Sodium eq. to Colistimethate …….1MIU Lyophilized Powder
	Previous Decision (316-DRB)	Deferred for following: • Confirmation of method of manufacturing of applied formulation whether by lyophilization or otherwise. • Further deliberation for revision of label claim as per reference formulation and pharmacopoeial specifications.
	Evaluation by PEC	• The firm have submitted revised form 5 and revised label claim as per reference formulation without submission of applicable fee. The revised label claim is as under: Each Vial Contains: Colistimethate Sodium …….1MIU (Lyophilized Powder) • Firm has submitted revised form 5 and revised manufacturing method and stated that the product is manufactured by lyophilization. • Registration Board in its 293rd meeting held on 06-08th January 2020 allowed contract manufacturing from M/s Bio-Labs (Pvt) Ltd. Plot No.145 Industrial Triangle, Kahuta Road, Islamabad for following sections: Dry Suspension (Cephalosporin) Capsule (Cephalosporin) Dry vial injectable (Cephalosporin) lyophilized vial injectable (General)
	Previous Decision (321-DRB)	Registration Board deferred for following reasons: • Submission of batch manufacturing details of most recent commercial batch from M/s Bio Labs Pvt Ltd., for applied formulation to confirm the fact whether Colistimethate injection is formulated from pre-lyophilised drug substance or otherwise. • Firm shall submit fee of Rs.7,500/- for correction/pre-approval change in the method of manufacture, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021. • Submission of GMP audit report for both M/s Paramount Pharmaceuticals and M/s Bio Labs Pvt Ltd from QA&LT Division, valid within last three years

	Evaluation by PEC	• The firm submitted batch manufacturing details (Mfg. date 09-18) for applied product demonstrating that the applied product is formulated through lyophilisation process. • The firm has submitted Rs. 7500/- on deposit slip No. 586746982449 for change in the method of manufacture of applied product.
	Decision of 324th meeting: Deferred for the submission of data by M/s Bio-Labs against the Form 5F applications of applied formulation, presented in instant meeting.	

1331.	Name and address of manufacture / Applicant	M/s Global Pharmaceuticals Pvt Ltd., Plot # 204-205, Industrial Triangle, Kahuta Road, Islamabad
	Brand Name + Dosage Form and Strength	Dulic Capsule 500mg
	Composition	Each Capsule Contains: Ursodeoxycholic Acid……500mg
	Dairy No. date of R &I fee	Form-5 Dy.No 13013 dated 05-03-2019 Rs.20,000/- dated 04-03-2019
	Pharmacological Group	Bile acids and derivatives
	Type of form	Form 5
	Finished product specifications	BP
	Pack size and Demand Price	10's; As per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too-status	Vdoxyl 500mg Capsule by M/s EG Pharmaceuticals (Reg#095838)
	GMP Status	The firm was inspected on 11 & 24-10-2018 and conclusion of inspection was: On the basis of findings, panel unanimously decided to recommend the issuance of GMP certificate.
	Previous Remark of the Evaluator [XI]	• The firm provided evidence of RRA. Ursochol 500mg capsule Swedish Medical Product Agency approved. However, the product is Deregistered or temporarily recalled drugs
	Previous Decision (307-DRB)	• Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.
	Evaluation by PEC	• The firm submitted evidence of applied formulation in Reference Regulatory Authorities. Bilheptil 500mg hard capsules MHRA Approved
	Decision: Approved.	

Item No. 15: Agenda of Evaluator PEC-VIII (Mr. Muhammad Usman)

1. Cases of Export Facilitation:

1332.	**Name, address of Applicant / Marketing Authorization Holder**	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore
	Name, address of Manufacturing site.	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the drug product manufacturer	Copy of current GMP certificate dated 08-08-2019 is provided.
	Evidence of approval of manufacturing facility	Firm has submitted copy of covering letter for renewal of DML and approval letters of licensed sections.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale

		☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11091 Date: 07/5/2022
	Details of fee submitted	PKR 30000 Slip No. 8036710392
	The proposed proprietary name / brand name	TENDOL TABLET 50mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each immediate release Film Coated tablet contains: Tepentadol as Hydrochloride… 50mg
	Pharmaceutical form of applied drug	Tablet (General)
	Pharmacotherapeutic Group of (API)	Opioid Analgesic (ATC code : N02AX06)
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10's,20's & 30's (Alu-Alu Blister)
	Proposed unit price	Rs.300 for 10's
	The status in reference regulatory authorities	USFDA Approved NUCYNTA 50mg (Tepentadol HCL) Tablet manufactured by Janssen Ortho, LLC, gurabo,
	For generic drugs (me-too status)	Plaxodol Tablet 50mg (M/s Jenner Pharma, Skeikhupura) Registration No. 109504
	Name and address of API manufacturer.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 24 months. Not Provided on relevant format and date of initiation
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures,

		validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence study is not performed against the innovator / Reference Product **CDP has been performed against the same brand that is** Plaxodol Tablet 50mg (M/s Jenner Pharma, Skeikhupura) **instead of Innovator / Reference Product of same strength**.in Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The F2 values are found satisfactory(>50%).
	Analytical method validation/verification of product	Firm has submitted report of validation studies of analytical method of drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India.		
API Lot No.	**Not Provided**		
Description of Pack (Container closure system)	The proposed pack size is 10's,20's & 30's Alu-Alu Blister.		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, (Months) Real Time: 0, 3, (Months)		
Batch No.	Not Provided	Not Provided	Not Provided
Batch Size	Not Provided	Not Provided	Not Provided
Manufacturing Date	Not Provided	Not Provided	Not Provided
Date of Initiation	Not Provided	Not Provided	Not Provided
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	• Not Provided
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The document regarding import of Tramadol HCL is **not Provided.**
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	**Submitted. However needs to be evaluated in the light of date of initiation till completion of stability**

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Submitted.**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	**Submitted. However needs to be evaluated in the light of date of initiation till completion of stability**

Evaluation by PEC:

Following Documents are found deficient:

1. Provide copy of valid DML.
2. Provide analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
3. CDP studies are performed against Plaxodol Tablet 50mg (M/s Jenner Pharma, Skeikhupura manufactured by instead of Innovator / Reference Product of same strength.
4. RSD is not calculated for Robustness , Precision in method validation test reports.
5. Test of accuracy is not performed in method validation of Product development.
6. Provide stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No and storage conditions etc.
7. Documents for the procurement of API with approval from DRAP (in case of import) along with COA of relevant batch needs to be submitted.

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months

Firm has submitted following reply/documents :

1. Firm has submitted copy of valid DML No. 000494 valid till 10-10-2023.
2. Firm has Provided analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
3. Firm has stated that the innovator Product is Nucynta film coated tablet which is a controlled drug and is only available on prescription , therefore, locally manufactured Topentadol tablet manufactured by Jenner Pharma, Sheikhupura is used for CDP studies.
4. Test reports for Robustness , Precision and accuracy in method validation are submitted.
5. Documents for the procurement of API with approval from DRAP (in case of import) along with COA of relevant batch is submitted.
6. Stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No and storage conditions etc are submitted.

Decision of 324th meeting: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

1333.	**Name, address of Applicant / Marketing Authorization Holder**	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore
	Name, address of Manufacturing site.	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the drug product manufacturer	Copy of current GMP certificate dated 08-08-2019 is provided.
	Evidence of approval of manufacturing facility	Firm has submitted copy of covering letter for renewal of DML and approval letters of licensed sections.
	Status of application	☐ New Drug Product (NDP)

		☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11090 Date: 07/5/2022
	Details of fee submitted	PKR 30000 Slip No. 1530874057
	The proposed proprietary name / brand name	TENDOL TABLET 50mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each immediate release Film Coated tablet contains: Tepentadol as Hydrochloride… 50mg
	Pharmaceutical form of applied drug	Tablet (General)
	Pharmacotherapeutic Group of (API)	Opioid Analgesic (ATC code : N02AX06)
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10's,20's & 30's (Alu-Alu Blister)
	Proposed unit price	Rs.500 for 10's Rs.1000 for 10's Rs.1500 for 30's
	The status in reference regulatory authorities	USFDA Approved NUCYNTA 50mg (Tepentadol HCL) Tablet manufactured by Janssen Ortho, LLC, gurabo,
	For generic drugs (me-too status)	Tapento Tablet 50 mg (M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi)
	Name and address of API manufacturer.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability is conducted at 40ºC ± 2ºC / 75% ± 5% RH for 6 months and data is provided for (batch no. **TPT50040513, TPT50050513, TPT50050513**).

		The real time stability data is conducted at 30ºC ± 2ºC / 65% ± 5% RH for 24 months. **(TPT50111119, TPT50121119, TPT50131119)**
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence study is not performed against the innovator / Reference Product **CDP has been performed against the same brand that is** Plaxodol Tablet 50mg (M/s Jenner Pharma, Skeikhupura) **instead of Innovator / Reference Product of same strength**.in Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer pH 6.8. The F2 values are found satisfactory(>50%).
	Analytical method validation/verification of product	Firm has submitted report of validation studies of analytical method of drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India.		
API Lot No.	Not Provided		
Description of Pack (Container closure system)	The proposed pack size is 10's,20's & 30's Alu-Alu Blister.		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, (Months) Real Time: 0, 3, (Months)		
Batch No.	Not Provided	Not Provided	Not Provided
Batch Size	Not Provided	Not Provided	Not Provided
Manufacturing Date	Not Provided	Not Provided	Not Provided
Date of Initiation	Not Provided	Not Provided	Not Provided
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	• Not Provided
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**

3.	Documents for the procurement of API with approval from DRAP (in case of import).	The document regarding import of Tramadol HCL is **Provided.**
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	**Submitted.**
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Submitted.**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	**Submitted.**

Evaluation by PEC:

Following Documents are found deficient:

1. Provide copy of valid DML.
2. Provide analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
3. Pharmaceutical equivalence study and test results are not submitted against Innovator / Reference Product of same strength For Tendol Tablets 100mg.
4. Comparative Dissolution Profile studies are performed for Tendol Tablets 75mg against Tapento Tablet 75mg manufactured by (M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi instead of Innovator / Reference Product of same strength.
5. RSD is not calculated for Robustness test as performed during analytical method validation of Drug Product.
6. Precision and accuracy test and test report in analytical method validation of Drug Product are not submitted.
7. Provide stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No etc.
8. Documents for the procurement of API with approval from DRAP (in case of import) along with COA of relevant batch needs to be submitted.
9. Batch manufacturing record for all batches prepared for stability testing needs to be provided for all strengths.

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Firm has submitted following reply/documents :

1. Firm has submitted copy of valid DML No. 000494 valid till 10-10-2023.
2. Firm has Provided analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
3. Firm has stated that the innovator Product is Nucynta film coated tablet which is a controlled drug and is only available on prescription , therefore, locally manufactured Topentadol tablet manufactured by Jenner Pharma, Sheikhupura is used for CDP studies.
4. Test reports for Robustness , Precision and accuracy in method validation are submitted.
5. Documents for the procurement of API with approval from DRAP (in case of import) along with COA of relevant batch is submitted.
6. Stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No and storage conditions etc are submitted.

Decision of 324th meeting: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

1334.	**Name, address of Applicant / Marketing Authorization Holder**	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore

	Name, address of Manufacturing site.	M/s FYNK Pharmaceuticals, 19 km, GT Road, Kalashah Kaku, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the drug product manufacturer	Copy of current GMP certificate dated 08-08-2019 is provided.
	Evidence of approval of manufacturing facility	Firm has **not submitted** copy of valid DML and approval letters of licensed sections
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 11092 Date: 07/5/2022
	Details of fee submitted	PKR 30000 Slip No. 32688433
	The proposed proprietary name / brand name	**TENDOL TABLET 100mg**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated immediate release tablet contains: Tepentadol as Hydrochloride… 100mg
	Pharmaceutical form of applied drug	Tablet (General)
	Pharmacotherapeutic Group of (API)	Opioid Analgesic (ATC code : N02AX06)
	Reference to Finished product specifications	Innovator Specifications
	Proposed Pack size	10's,20's & 30's Alu-Alu Blister
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved NUCYNTA100mg (Tepentadol HCL) Tablet manufactured by Janssen Ortho, LLC, gurabo,
	For generic drugs (me-too status)	Tapento Tablet (M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi) **The strength is different**
	Name and address of API manufacturer.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.

	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40ºC ± 2ºC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30ºC ± 2ºC / 65% ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against the **Tapento 75mg Tablets manufactured by M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi instead of Innovator / Reference Product of same strength**. **CDP has been performed against the same brand that is Tapento 75mg Tablets manufactured by M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi instead of Innovator / Reference Product of same strength**.in Acid media (0.1N HCl),
	Analytical method validation/verification of product	Firm has submitted report of validation studies of analytical method of drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA

Manufacturer of API	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India.		
API Lot No.	API lot No is mentioned generally as 40000290161 but the lot no of individual API(s) is not mentioned.		
Description of Pack (Container closure system)	The proposed pack size is 10's,20's & 30's Alu-Alu Blister.		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, (Months) Real Time: 0, 3, (Months)		
Batch No.	TL100-01	TL100-02	TL100-03
Batch Size	1000 TABLETS	1000 TABLETS	1000 TABLETS
Manufacturing Date	04-2021	04-2021	04-2021

Date of Initiation	08-2019	08-2019	08-2019
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	• **Not Provided**
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Tapentadol Hydrochloride:** M/s Ami Life Sciences Private Limited, Block No. 82/B, ECP Road, Taluka Padra, Gujrat, India. **Certificate No. 19041306 dated 25-04-2019.**
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The document regarding import of Tramadol HCL is **not Provided.**
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	**Submitted.**
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	**Submitted.**

Evaluation by PEC:

Following Documents are found deficient:

1. Fee submitted is 30,000 therefore submit remaining 45,000 fee for new drug molecule.
2. Provide copy of valid DML along with approval letter of licensed sections.
3. The strength of Proposed Product is different from Tapento Tablet 75mg (M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi)
4. Provide analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
5. Pharmaceutical equivalence and CDP studies are performed against Tapento 75mg Tablets manufactured by M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi instead of Innovator / Reference Product of same strength.
6. RSD is not calculated for Robustness , Precision in method validation test reports.
7. Test of accuracy is not performed in method validation of Product development.
8. Provide stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacaturing date, date of initiation, API lot No and storage conditions etc.
9. Documents for the procurement of API with approval from DRAP (in case of import).

Decision: Registration Board deferred the case for submission of reply to the above cited shortcomings within six months.

Firm has submitted following reply/documents :

1. **Firm has not submitted the required 30,000 fee and has stated that TENDOL TABLET 100mg is not a new drug molecule as the **Tapendol 100mg tablet is approved by the DRB in its 289th meeting of M/s The Searle Company Limited, Karachi**.
2. **Firm has submitted copy of valid DML No. 000494 valid till 10-10-2023.**
3. Firm has Provided analytical method verification Protocol and test reports for API Tepentadol Hydrochloride as performed by Drug Product manufacturer.
4. **Firm has stated that the innovator Product is Nucynta film coated tablet which is a controlled drug and is only available on prescription, therefore, locally manufactured Topentadol tablet manufactured by Jenner Pharma, Sheikhupura is used for CDP studies.**
5. **Test reports for Robustness , Precision and accuracy in method validation are submitted.**
6. Documents for the procurement of API with approval from DRAP (in case of import) along with COA of relevant batch is submitted.

7. Stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No and storage conditions etc are submitted. 8. Pharmaceutical equivalence and CDP studies **are performed against Tapento 75mg Tablets** manufactured by M/s Sami Pharmaceuticals (Pvt) Ltd, Karachi instead of Innovator / Reference Product of same strength.
Decision of 324th meeting: Deferred for following: • **Submission of differential fee of Rs. 45,000/- since applied formulation is not previously registered in Pakistan.** • **Submission of Pharmaceutical equivalence & CDP studies against the relevant strength of innovator/reference product.**

New Case:

1335	**Name, address of Applicant / Marketing Authorization Holder**	M/s PharmEvo (Pvt) Ltd, Plot No. A-29, NWIZ, Port Qasim Karachi.
	Name, address of Manufacturing site.	M/s PharmEvo (Pvt) Ltd, Plot No. A-29, NWIZ, Port Qasim Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the drug product manufacturer	Copy of current GMP certificate dated 17-09-2020 is provided.
	Evidence of approval of manufacturing facility	copy of DML No. 000504 (Formulation) is provided
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 8913 Date: 07/4/2022
	Details of fee submitted	PKR 30000 dated: 21-02-2022 .
	The proposed proprietary name / brand name	DAPWIZ PLUS 5/850 mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated XR tablet contains: Dapagliflozin as Propanediol Monohydrate … 5 mg Metformin HCL … 850 mg
	Pharmaceutical form of applied drug	Tablet (General)
	Pharmacotherapeutic Group of (API)	Anti-Diabetic
	Reference to Finished product specifications	Innovator Specs
	Proposed Pack size	7’s, 10’s, 14’s,20’s,28’s,30’s,56’s,84’s,100’s,122’s
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved (Xigduo XR 5mg/500mg) Film coated extended release tablets
	For generic drugs (me-too status)	Xiga-Met Tablet of M/s CCL Pharmaceuticals (Pvt) Ltd, Lahore.

	Name and address of API manufacturer.	**Metformin HCL (USP):** M/s Shouguang Fukang Pharmaceutical Co., Ltd, North East of Dongwaihuan Province, China. Certificate No. SD20190888 valid till 12-03-2024. **Dapagliflozin :** Jiangsu Yongan Pharmaceutical Co., Ltd, No. 18, 237 Provincial Road, Economic Development Zone, Huaian Jiangsu, China GMP Certificate valid till 14-01-2024
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, , reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	**Dapagliflozin Propanediol Monohydrate :** Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for **36 months for Batch No. 130401, 130401, & 130501.** **Metformin HCL :** Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for **60 months for Batch No. A-71411106004, A-71411106005, A-71411106006.**
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence have been established against the Daplozmat-Met XR 5mg/850mg by M/s Highnoon Laboraotires Ltd ,Lahore by performing quality tests including Identification, water content, Assay, Dissolution, Disintegration. CDP has been performed against the same brand that is Daplozmat-Met XR 5mg/850mg by M/s Highnoon

		Laboraotires Ltd ,Lahore in Acid media (0.1N HCl), acetate buffer pH 4.5 & Phosphate Buffer pH 6.8.
	Analytical method validation/verification of product	Not submitted

STABILITY STUDY DATA

Manufacturer of API	**Metformin HCL (USP):** M/s Shouguang Fukang Pharmaceutical Co., Ltd, North East of Dongwaihuan Province, China. Certificate No. SD20190888 valid till 12-03-2024. **Dapagliflozin :** Jiangsu Yongan Pharmaceutical Co., Ltd, No. 18, 237 Provincial Road, Economic Development Zone, Huaian Jiangsu, China GMP Certificate valid till 14-01-2024		
API Lot No.	Metformin HCL : API Lot No is 13097. Dapagliflozin Propane diol Monohydrate: **API Lot No. 5918**		
Description of Pack (Container closure system)	7's, 10's, 14's,20's,28's,30's,56's,84's,100's,122's		
Stability Storage Condition	Real time : 30˚C ± 2˚C / 75% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 06 months Accelerated: 06 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	20PD-3447-01-T	20PD-3447-02-T	20PD-3447-03-T
Batch Size	2500 TABLETS	2500 TABLETS	2500 TABLETS
Manufacturing Date	Nov-2022	Nov-2022	Nov-2022
Date of Initiation	24-12-2020	24-12-2020	24-12-2020
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to panel inspection report of their product for EMPAGMIN XR Tablets 5/1000 mg, 10/1000 mg, 12.5/1000 mg, 25/1000 mg (Empagliflozin 5mg & Metformin HCL 1000mg) on 6th May 2019. Further, the said panel inspection report was discussed in 293rd Drug Registration Board meeting held on 6th, 7th & 8th January 2020. The case was approved by the Drug Registration Board.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	**Metformin HCL (USP):** M/s Shouguang Fukang Pharmaceutical Co., Ltd, North East of Dongwaihuan Province, China. Certificate No. SD20190888 valid till 12-03-2024. **Dapagliflozin :** Jiangsu Yongan Pharmaceutical Co., Ltd, No. 18, 237 Provincial Road, Economic Development Zone, Huaian Jiangsu, China GMP Certificate valid till 14-01-2024
3.	Documents for the procurement of API with approval from DRAP (in case of import).	**Dapagliflozin Propanediol :** Commercial Invoice No. HN200109-F

		Dated 16-01-2020 **Metformin-HCL :** **The invoice of relevant batch** 0187504 **used in Product Development is not provided.**
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Evaluation by PEC:

Following Documents are found deficient:

1. Provide analytical method for Assay of API namely Metformin and Dapagliflozin along with analytical method verification test reports
2. Provide analytical method for Assay of Drug Product along with test reports regarding validation of analytical method.
3. Submit revised label claim as per innovator Product.
4. Submit Pharmaceutical Equivalence and Comparative Dissolution studies along with test results of Drug Product with innovator Product.
5. Submit API Lot No. of API used in stability study batch(s) production and Submit BMR of stability study batches of Drug Product.
6. Provide stability studies summary sheets on Prescribed format as recommended by the DRB in its 293rd meeting including batch No, batch size, manufacturing date, date of initiation, API lot No and storage conditions etc.
7. Submit Documents for the procurement of API with approval from DRAP (in case of import) of relevant batches of API(s) used in stability study batches.

Reply of the firm :

1. Firm has submitted analytical method for Assay of API namely Metformin and Dapagliflozin along with analytical method verification test reports
2. Firm has submitted analytical method for Assay of Drug Product along with test reports regarding validation of analytical method.
3. **Firm has submitted** Pharmaceutical Equivalence and Comparative Dissolution studies along with Daplozmet 5/850 of M/s Highnoon Laboratories , Lahore **instead of with innovator Product.**
4. Firm has submitted documents confirming import of dug substance detailed as follows

Dapagliflozin:
Copy of letter No.2042/19/DRAP/K dated 22/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.
Metformin HCl:
Copy of letter No.263/19/DRAP/K dated 02/10/2019 is submitted wherein the permission to import API for the purpose of test/analysis and stability studies is granted.

Decision of 324th meeting: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Item No. 16: Agenda of AD PE&R (Mr. Muhammad Zubair Masood)

1336.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Winbrains Research Laboratories Plot No.69/1 Block B, Phase I-II, Industrial Estate, Hattar Pakistan**
	Name, address of Manufacturing site.	M/s Winbrains Research Laboratories Plot No.69/1 Block B, Phase I-II, Industrial Estate, Hattar Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1739, 2847 & 1341 dated 02/06/2021, 08-11-2022 & 16—01-2023
	Details of fee submitted	PKR 20,000/-: dated 02/03/2021
	The proposed proprietary name / brand name	Lunaz 1% Cream
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Gm Contains: Luliconazole (In-House)…10 mg (Product complies Innovator's Specs)
	Pharmaceutical form of applied drug	Off white to light yellow cream
	Pharmacotherapeutic Group of (API)	SSRI (Anti-depressant)
	Reference to Finished product specifications	Innovator Specification
	Proposed Pack size	1 ×1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Luzu 1% Japan
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	Copy of GMP Certificate No. F. 3-20/2019-DRAP-40 dated 03-06-2019
	Name and address of API manufacturer.	FLAX LABORATORIES B-29/1, MIDC MAHAD, BIRVADI VILLAGE, DIST-RAIGAD, MAHARASHTRA, INDIA.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

		specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Paroxetine Hydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 24 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (T-09, T-10, T-11)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Not Applicable
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA

Manufacturer of API	FLAX LABORATORIES B-29/1, MIDC MAHAD, BIRVADI VILLAGE, DIST-RAIGAD, MAHARASHTRA, INDIA.
API Lot No.	5301-20-029

Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (1×1's)		
Stability storage condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 24 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 24 (Months)		
Batch No.	T-09	T-10	T-11
Batch Size	500 Tube	500 Tube	500 Tube
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	02-04-2021	02-04-2021	02-04-2021
No. of Batches	03		

Administrative Portion

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Provided
3.	Documents for the procurement of API with approval from DRAP (in case of import).	• Copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Paroxetine HCl for the purpose of test/analysis and stability studies is granted. • DHL No.XMLPI6.2/90-1504 dated 22/07/2020
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

Observations	Response
• Submit valid GMP certificate as provided is expired.	Submitte
• Clarification regarding mentioning Route of administration as oral instead of topical.	Correcte

• Approval/ GMP Certificate of API manufacturing facility issued by relevant regulatory authority.	**Submitted.**
• Reference of public assessment report is not provided while it is mandatory for non-pharmacopoeial products.	**Submitted**
• API specifications provided by drug substance manufacturer are not readable.	**Provided**
• Summary of verification of analytical procedures for drug substance is not provided.	**Provided**
• Container closure system is indicating 15 g Cream while applied product is 60g cream.	**Corrected**
• Section 1.5.10 indicates pre-printed Aluminum tube while container closure system in 3.2.P.1 (d) indicates polypropylene dispenser tube.	**Pre-printed Aluminium Tube is confirmed.**
• Cetyl Alcohol, All-rac-α-tocopherol, liquid paraffin, White soft paraffin and Potassium Sorbate are indicated as excipients while these excipients are not mentioned in 2.3.P.1(b).	**Corrected as Typo error**
• Formulation Development is not provided.	**Submitted.**
• Maximum holding time of bulk before final packing is not submitted	**Submitted.**
• **In process validation protocol, Appearance is mentioned as Off white to light yellow cream while in product specification appearance is as Clear Colourless cream.**	**Corrected in Specifications.**
• **Test to check the amount of S enantiomer is not included in drug product specifications while it is being performed by the Innovator.**	**Not Performed.**
• **Justification of non-applicability of Characterization of Impurities.**	**Not Provided.**
• **Justification of specifications is not provided.**	**Not Provided.**
• Clarification of different Drug substance manufacturer in Module-II & Module-III.	**Corrected**
• COA of drug substance from drug substance manufacturer is not provided.	**Provided report indicates results from both API manufacturer & FPP manufacturer.**
• Stability data of drug substance is not readable.	**Provided.**
• pH, Viscosity and **Particulate Matter** is not tested during Pharmaceutical Equivalence.	**pH & Viscosity tests are provided.**
• Provided data is for oral dosage form instead of topical dosage form.	**Provided**
• **Information regarding Physicochemical and Biological properties is not provided**	**Not Provided**
• Justification of critical steps of manufacturing process is not provided.	**Provided**
• Process Validation protocol indicates Sifting, Melting, Milling, Congealing & Cooling as processing steps while these steps are not indicated in description of manufacturing process & flow diagram.	**Revised flow diagram is provided**
• **Justification of not performing Identification & Particulate matter tests during stability studies.** • **Compliance record of HPLC software 21CFR & audit trail reports on product testing.** • Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated). • **Clarification of 24 months demanded shelf life while Innovator has shelf life of 18 months.**	**The firm submitted that HPLC is not 21CFR compliant. Record of digital data logger is provided. Rest are not provided.**

Decision: Deferred for submission of reply to below mentioned shortcomings within six months:

- **Test for the amount of S enantiomer is not included in drug product specifications while it is being performed by the Innovator.**
- **Justification of specifications is not provided.**
- **COA of drug substance from drug substance manufacturer is not provided.**
- **pH, Viscosity and Particulate Matter is not tested during Pharmaceutical Equivalence.**
- **Information regarding Physicochemical and Biological properties is not provided**
- **Justification of not performing Identification & Particulate matter tests during stability studies.**
- **Compliance record of HPLC software 21CFR & audit trail reports on product testing.**

Case No.01. Recommendation of Provincial Quality Control Board, Punjab Regarding Cancellation of Muscadol Tablet (R.No.067173)

Provincial Quality Control Board in its 251st meeting held on 20th October, 2022 considered the following case under section 11 of the Drugs Act, 1976 on grounds that Drug Testing Laboratory showed inability for the test/ analysis of the following sample:

S/N	DTL Letter No. & Date	Product Name & Batch No.	DTL	Manufacturer	Area DI	Memo No. & Date	Reason of FNA rom DTL
1	DPN/17350/ DTL Dated 18-03-2022	Muscadol Film Coated Tablet (Paracetamol: 450mg Orphenadrine Citrate USP: 35mg) Batch No. T-052	Lahore	Lisko	Sir Ganga Raam Hospital	0000117776 dated 03-02-2022	Due to provision of wrong method of analysis from manufacturer

In this context, it has been communicated that PQCB after deliberation and discussion decided to recommend the Drug Regulatory Authority of Pakistan (DRAP) for cancellation of registration of drug in best of public interest.

Decision: Registration Board decided to issue show cause notice to M/s Lisko Pakistan (Pvt) Ltd., L-10/D, Block 21, Federal B Industrial Area, Karachi (DML No.000110) under Section 7 (11)(c) of the Drug Act, 1976 that why the registration of their drug product 'Muscadol Tablet (Reg.No.067173)' may not be cancelled for violation of the conditions subject to which the drug product was registered. The Board also decided to provide an opportunity of personal hearing to the management of the firm under section 42 of the Drugs Act, 1976.

Case No.02. Request for Change in Registration Status of Testiva Gel from M/s Searle Pakistan Limited, (Formerly M/s OBS Pakistan Pvt Ltd.) C-14, S.I.T.E, Karachi (DML No. 000012) to M/s Aspin Pharma Pvt Ltd., Korangi Industrial Area Karachi (DML No. 000045), through contract manufacturing.

M/s. Aspin Pharma (Pvt.) Ltd., Plot No.10 & 25 Sector 20, Korangi (DML No.000045) Industrial Area Karachi has requested to change the product registration status of Testiva Gel from M/s Searle Pakistan Limited, (Formerly M/s OBS Pakistan Pvt Ltd.) C-14, S.I.T.E, Karachi (DML No.000012) to their name. However, the product will continue to be manufactured at the manufacturing site of M/s Searle Pakistan Limited, (Formerly M/s OBS Pakistan Pvt Ltd.) C-14, S.I.T.E, Karachi through contract manufacturing.

The detail of cases is as following:

	Administrative Documents Submitted in the light of SOP approved by the Registration Board in its 283rd meeting
i.	GMP certificate of M/s Searle Pakistan Ltd (Formerly OBS Pakistan (Pvt Ltd, C-14, Manghopir Road, S.I.T.E, Karachi, issued on 15-02-2022 based on an inspection conducted on 08.10.2021.
ii.	Copy of DML of M/s OBS Pakistan Pvt Ltd., (DML # 000012) renewed w.e.f. 26-10-2020 and M/s Aspin Pharma Pvt Ltd, (DML# 000045) renewed w.e.f. 31-03-2020.
iii.	Copy of Panel Inspection Report of M/s Searle Pakistan Ltd (Formerly OBS Pakistan (Pvt Ltd, C-14, Manghopir Road, S.I.T.E, Karachi confirming "Sachet (Hormones) Soft Gel" section and approval letter issued on 26-10-2020 for renewal of DML confirming "Sachet (Hormone) Section".
iv.	NOC from M/s. The Searle Company Ltd; Karachi for transfer of Testiva Gel in the name of M/s. Aspin Pharma Pvt Pharma Pvt Ltd., Korangi Industrial Area, Karachi issued on 26th September 2022.
v.	Relevant undertakings & commitments.
vi.	Contract Agreement between M/s Aspin Pharma Pvt Ltd, and M/s OBS Pharma.

The cases were referred to Pharmaceutical Evaluation Cell / QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

Evaluator: Mr. Abdul Mughees Mudassir (AD to CEO)

I	II	III	IV
S.No.	**Reg. No.**	**Product Name & Composition (As per initial Registration letter)**	**Registration Trail**
1.	097085	Testiva Gel 1% Sachet Each 5gm contains: - Testosterone…….50mg (As per Innovator's Specifications)	**Initial Reg. Date:** **15-07-2019** **Change of Brand Name:** **06-05-2020**
	Name, address of Applicant / Marketing Authorization Holder		**M/s Aspin Pharma Pvt Pharma Pvt Ltd.** **Address: Plots # 10 & 25, Sector 20 Korangi Industrial Area Karachi – 74900, Pakistan**
	Name, address of Manufacturing site.		M/s Searle Pakistan Limited, (Formerly M/s OBS Pakistan (Pvt.) Ltd.) Address: C-14, Manghopir Road, S.I.T.E, Karachi- 75700, Sindh, Pakistan. **(DML 000012)**
	Status of the applicant		☐Manufacturer ☐Importer ☒Is involved in none of the above (contract giver)
	Status of application		☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)
	Intended use of pharmaceutical product		☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission		Dy. No. 27960 dated 03 October, 2022
	Details of fee submitted		PKR.75,000/-:DS 65785523301 dated 26-09-22
	The proposed proprietary name / brand name		**Testiva Gel 1% Sachet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit		Each 5gm contains: - Testosterone…….50mg
	Pharmaceutical form of applied drug		Gel in Sachet
	Pharmacotherapeutic Group of (API)		Androgens
	Reference to Finished product specifications		Innovator's Specification
	Proposed Pack size		10's & 30's
	Proposed unit price		As per DPC
	The status in reference to regulatory authorities		AndroGel, Besin Healthcare, France
	For generic drugs (me-too status)		N/A
	GMP status of finished product Manufacturer		**For transfer of registration:** GMP certificate of M/s Searle Pakistan Ltd

		(Formerly OBS Pakistan (Pvt Ltd, C-14, Manghopir Road, S.I.T.E, Karachi- 75700, issued on 15-02-2022 based on an inspection conducted on 08.10.2021.
	Name and address of API manufacturer.	IPCA Laboratories limited. PLOT NO.23-24 G.I.D.C. ESTATE, AT & POST NANDESARI, City: NANDESARI-391 340, Dist. VADODARA. GUJRAT STATE INDIA.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Material for Testosterone Gel is formulated at the manufacturing site of M/s Ipca Laboratories, India & summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of the manufacturing process, and controls, impurities, specifications, analytical procedures, and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module-III Drug Substance:	The firm has submitted data for drug substance related to nomenclature, structure, general properties, solubility, physical form, DS and raw material specifications, manufacturers, the quantitative composition of Testosterone Gel manufacturing process & tests for impurities & residual solvents, Analytical procedures, CoAs, specifications, Standard testing procedures. Reference standard or materials & container closure system.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (4016TS1RN,4017TS1RN,4018TS1RN).
	Module-III Drug Product:	The firm has submitted detail of manufacturers, a description of the manufacturing process and controls, impurities, specifications, analytical procedure, and its validation studies, batch analysis and justification of specification, reference standard, container closure system, and stability studies of the drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence has been established against the brand leader that is AndroGel by Laboratories Bezen International CAC (Physical appearance, Identification, Assay, pH, Viscosity & weight variation. On the basis of these test comparisons, both products are said to be pharmaceutically equivalent.

	Analytical method validation/verification of product	Method validation studies have been submitted including linearity, range, accuracy, precision, specificity & robustness

STABILITY STUDY DATA			
Manufacturer of API	IPCA Laboratories limited. PLOT NO.23-24 G.I.D.C. ESTATE, AT & POST NANDESARI, City: NANDESARI-391 340, Dist. VADODARA. GUJRAT STATE INDIA.		
API Lot No.	18006TS1RN		
Description of Pack Container closure system)	Testiva (Testosterone) Gel 1% are available in pack of 10's & 30's sachet (PET/Aluminum/LDPE)		
Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 12months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9,12,24 (Months)		
Batch No.	C0001	C0002	C0003
Batch Size	12000Sachet	12000Sachet	12000Sachet
Manufacturing Date	01-2021	01-2021	01-2021
Date of Initiation	01-2021	01-2021	01-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted a copy of the GMP certificate of M/s Ipca Laboratories issued by the Food and Drug Control Administration, India Valid till 20/11/2022
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of the commercial invoice specifying the purchase of 30Kg testosterone USP dated 22-08-2018, cleared from DRAP Karachi office dated:07. Sept.2018
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm has submitted the data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets, etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted the Compliance Record of HPLC software 21CFR & audit trail reports on product testing
6	Record of Digital data logger for temperature and humidity monitoring of stability chamber (Real time & Accelerated)	The firm has submitted a Record of the Digital data logger for temperature and humidity monitoring of the stability chamber (Real-time & Accelerated)

Remarks	M/s Searle Pakistan Limited, through their letter pad, has given the NOC for the transfer of registration of Testiva Gel 1% sachet from Searle Pakistan Limited (Formerly OBS Pakistan (Pvt.) Limited) to Aspin Pharma (Pvt) Ltd. dated 26th September 2022. Testiva Gel 50mg / 5g (Testosterone) is presented as a clear colourless to translucent gel packed in an Aluminium base foil sachet.

Decision: **Registration Board decided as under:**

i. Cancelled registration of following product from the name of M/s Searle Pakistan Limited (Formerly OBS Pakistan Private Limited), C-14, Manghopir Road, S.I.T.E, Karachi (DML # 000012).

S. No.	Reg. No.	Product Name & Composition
1.	097085	**Testiva Gel 1% Sachet** **Each 5gm contains: -** **Testosterone…….50mg** **(As per Innovator's Specifications)**

ii. Approved registration of following product in the name of M/s Aspin Pharma (Pvt.) Ltd., Plot No.10 & 25 Sector 20, Korangi Industrial Area Karachi (DML No.000045) by way of contract manufacturing at M/s Searle Pakistan Limited (Formerly OBS Pakistan Private Limited), C-14, Manghopir Road, S.I.T.E, Karachi (DML # 000012).

S. No.	Product Name & Composition
1.	**Testiva Gel 1% Sachet** **Each 5gm contains: -** **Testosterone…….50mg** **(As per Innovator's Specifications)**

a) **Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**

b) **Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.**

iii. **Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP) without waiting for confirmation of minutes of 324th meeting.**

Case No.03. Request for Change in Registration Status of Tamiso MR 0.4mg Capsules from M/s Sami Pharmaceuticals Pvt Ltd, F-95, off Hub, River Road, S.I.T.E, Karachi (DML #000072) to M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi (DML#000938).

M/s. Sami Pharmaceuticals Pvt Ltd. Karachi has requested to change the manufacturing site for their product Tamiso MR 0.4mg Capsules (Reg. No 081091) from M/s Sami Pharmaceuticals Pvt Ltd, F-95, off Hub, River Road, S.I.T.E, Karachi (DML #000072) to M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi (DML#000938).

The detail of case is as under:

Administrative Documents Submitted in the light of SOP approved by the Registration Board in its 283rd meeting

i.	Copy of registration letters and last renewal status.
ii.	Copy of DML of M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi (DML#000938) issued on 13-09-2021.
iii.	Copy of approval letter (dated 13-09-2021) for issuance of DML (No.000938; by way of formulation) confirming "Spansules (General)" Section.
iv.	NOC from M/s. M/s Sami Pharmaceuticals Pvt Ltd, F-95, off Hub, River Road, S.I.T.E, Karachi (DML #000072) to the M/s Sami Pharmaceuticals Pvt Ltd., Plot No. F-140/A, S.I.T.E, Karachi (DML#000938) issued on 23-08-2022
v.	Relevant undertakings & commitments.

The cases were referred to Pharmaceutical Evaluation Cell / QMS for evaluation. Detail of submitted documents and remarks of evaluators have been mentioned as under:

Evaluator: Mr. Asadullah (AD-QMS)

I	II	III	IV
S.No.	**Reg. No.**	**Product Name & Composition (As per initial Registration letter)**	**Registration Trail**
1.	081091	Tamiso MR 0.4mg Capsules Each capsules contains: - Modified released pellets Tamsulosin Hydrochloride equivalent to Tamsulosin hydrochloride 0.4mg (USP Specification)	Initial Reg. Date: **01-07-2016** Change of Brand Name **30-09-2016** Renewal of Registration Applied on: **08-04-2021 with fee of Rs.20000/-**
	Name, address of Applicant / Marketing Authorization Holder		M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi
	Name, address of Manufacturing site.		**M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi (DML#000938)**
	Status of the applicant		☒Manufacturer ☐ Importer ☐Is involved in none of the above (contract giver)
	GMP status of the firm		New License
	Evidence of approval of manufacturing facility		DML issuance covering letter dated 13-09-2021 confirming Spansules (General) as formulation section
	Status of application		☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product		☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission		Dy.No.25559 (R&I) dated 09-09-2022
	Details of fee submitted		**For transfer of registration:** PKR 150,000/- DS# 9151457461 deposited on 17-08-2022

	The proposed proprietary name / brand name	Tamiso MR 0.4mg Capsules (Reg. No. 081091)
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Modified released pellets Tamsulosin Hydrochloride equivalent to Tamsulosin Hydrochloride 0.4mg
	Pharmaceutical form of applied drug	Hard Gelatin capsule Size No. 3 Brown Pink Opaque shell with TAMISO MR Printed on Cap and sami logo printed on body 3 time, containing white to off white coloured spherical pellets.
	Pharmacotherapeutic Group of (API)	Alpha adrenoceptor antagonist
	Reference to Finished product specifications	USP Specifications
	Proposed Pack size	10's
	Proposed unit price	Already registered product
	The status in reference regulatory authorities	Flomax 0.4mg Cap, FDA approved NDA 020579
	For generic drugs (me-too status)	Tamsolin 0.4mg Capsules, manufactured by Getz Pharma, Karachi (Reg# 050392)
	Name and address of API manufacturer.	RA Chem Pharma Limited Address: Plot No A-19/C, A-23A & A-23B, Road No, 18, IDA Nacharam, Nacharam village, Telangana, INDIA
	1.5.11-Proposed Label	Same as already registered
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Monograph of Tamsulosin hydrochloride (DS)a and capsule (FPP) is available in USP. Firm has summarized information of Tamsulosin (DS) for its nomenclature, structure, physical properties, solubility, polymorphism facts and other general properties. The DS is tamsulosin pellets was manufactured by RA Chem Phrama is GMP certified and is responsible for all steps of manufacturing, packing and quality testing. Characterization elucidation studies was conducted using IR, NMR mass spectrum, XRD and elemental analysis. Potential impurities related to API was listed with their acceptance criteria. DS manufacturers followed in-house specification and accordingly analytical methods were developed and verified. DS lot procured was analyzed by DP manufacturer. Working standards, container closure and stability studies summaries of 03 batches were provided under Zone IV-b. Similarly, information summaries for drug product related to its description, composition, formulation development, manufacturing process, pharmaceutical equivalence and comparative dissolution profile against Flomax capsules manufactured by Astellas Pharma Europe were provided. Development of manufacturing process and in-process controls, batch formula, DP

<table>
<tr><td></td><td></td><td>specification based on USP specification, analytical procedure and its verification, batch analysis, reference/working standard, container closure system and stability studies has been provided. BMR of three stability batches were also provided.</td></tr>
<tr><td></td><td>Module-III Drug Substance:</td><td>Firm has submitted data for drug substance related to nomenclature, structure, general properties, solubilities, Character elucidation using spectroscopy IR and NMR, physical form, polymorphism (Tamsulosin anhydrous crystalline form is used), structure elucidation using UV, NMR, etc. were provided. DS specifications were based on the inhouse method and accordingly analytical method were developed and its verification studies were performed. DP manufacturer also performed analytical method validation of Tamsulosin pellets. Certificate of analysis of DS lot, batch analysis, reference/working standard and its CoA, container closure system, its specification and test methods for packing materials were provided. stability studies sheets were also provided.</td></tr>
<tr><td></td><td>Stability Studies of Drug Substance (Conditions & duration of Stability studies)</td><td>Firm has submitted stability study data of 3 batches of drug substance accelerated and 3 batches at real time conditions. The accelerated stability data was conducted at 40ºC ± 2ºC / 75% ± 5% RH for 6 months and the long-term stability data was conducted at 30ºC ± 2ºC / 75% ± 5% RH for 36 months. DS was packed in a double line black coloured polyethylene bags in HDPE container. The DS, remained stable and within specified limits as tested on defined intervals.</td></tr>
<tr><td></td><td>Module-III Drug Product:</td><td>Firm has submitted data of drug product including its qualitative and quantitative composition, formulation development, manufacturing process development and in-process control, manufacturing process validation protocol and report, excipients testing methods based on pharmacopeia references with analysis reports, pharmaceutical equivalence and comparative dissolution profile, specifications and analytical procedures developed on the basis of USP monograph and its verification studies were performed, batch analysis, reference standard, container closure system and stability studies.</td></tr>
<tr><td></td><td>Pharmaceutical Equivalence and Comparative Dissolution Profile</td><td>Pharmaceutical equivalence was performed against Flomax 0.4mg Capsule manufactured by Astellas pharma Europe which shows comparable results within specified limits.
The comparative dissolution profile was performed of the stability batch against the Flomax 0.4mg Capsule (Batch 21C2341). Comparison was performed using 12 samples at pH 1.2, 7.2 and 7.5 for more than 8 hours. Calculation of value is as under:
<table>
<tr><th>Sr</th><th>Mediums</th><th>Time interval</th><th>Sample</th><th>Reference</th></tr>
<tr><td rowspan="5">i</td><td rowspan="5">Acidic buffer (pH 1.2)</td><td>30 min</td><td>0.00 %</td><td>0.00 %</td></tr>
<tr><td>60 min</td><td>0.00 %</td><td>0.00 %</td></tr>
<tr><td>120 min</td><td>5.39 %</td><td>4.80 %</td></tr>
<tr><td>180 min</td><td>10.94%</td><td>8.13 %</td></tr>
<tr><td>300 min</td><td>14.26%</td><td>13.95%</td></tr>
</table>
</td></tr>
</table>

				480 min	20.00%	20.90%
				600 min	24.97%	24.92%
				720 min	30.94%	29.38%
				1440min	44.13%	42.46%
				F2=89.79		
		ii	Phosphate Buffer (pH 7.2)	30 min	0.00 %	0.00 %
				60 min	0.00 %	0.00 %
				120 min	62.41%	66.34 %
				180 min	75.58%	72.97%
				300 min	78.72%	77.61%
				480 min	83.55%	78.86%
				600 min	80.29%	78.55%
				720 min	81.36%	80.14%
				1440min	79.46%	78.38%
				F2=79.37		
		iii	Phosphate Buffer (pH 7.5)	30 min	43.08%	43.03 %
				60 min	56.95%	57.96%
				120 min	79.52%	82.55%
				180 min	93.35%	95.64%
				300 min	101.54%	102.51%
				480 min	105.34%	103.75%
				600 min	101.61%	99.82%
				720 min	102.63%	102.00%
				1440min	105.13%	103.67%
				F2=85.62		
	Analytical method validation/verification of product	Firm has claimed USP specifications for which report of analytical method verification for the drug product has been provided.				

STABILITY STUDY DATA			
Manufacturer of API	RA Chem Pharma Limited Address: Plot No A-19/C, A-23A & A-23B, Road No, 18, IDA Nacharam, Nacharam village, Telangana, INDIA		
API Lot No.	DTMPG21025		
Description of Pack (Container closure system)	Alu-Alu blister pack (10s).		
Stability Storage Condition	Real time: 30˚C ± 2˚C / 65% ± 5%RH Accelerated: 40˚C ± 2˚C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, (Months)		
Batch No.	PL001	PL002	PL003
Batch Size	10,000 Capsules	10,000 Capsules	10,000 Capsules
Manufacturing Date	12-2021	12-2021	12-2021
Date of Initiation	12-2021	12-2021	12-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	-

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate No. 85956/TS/2022 issued by Drug Control Administration, Government of Telangana issued on 15-07-22 and valid till 13-07-2025
3.	Documents for the procurement of API with approval from DRAP (in case of import).	API was purchased from RA Chem Pharma, India, invoice dated 29-05-2018, cleared on 05-06-2018 from DRAP, Karachi.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail of stability batches.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Decision: **Registration Board decided as under:**

i. Cancelled registration of following product from the name of M/s Sami Pharmaceuticals Pvt Ltd, F-95, off Hub, River Road, S.I.T.E, Karachi (DML #000072).

S. No.	Reg. No.	Product Name & Composition
1.	**081091**	**Tamiso MR 0.4mg Capsules** **Each capsules contains: -** **Modified released pellets Tamsulosin Hydrochloride equivalent to Tamsulosin hydrochloride……0.4mg** **(USP Specification)**

ii. Approved registration of following product in the name of M/s Sami Pharmaceuticals Pvt Ltd., F -140/A, S.I.T.E, Karachi (DML#000938)

S. No.	Product Name & Composition
1.	**Tamiso MR 0.4mg Capsules** **Each capsule contains:** **Modified Released Pellets Tamsulosin Hydrochloride Equivalent to Tamsulosin Hydrochloride……..0.4mg** **(USP Specifications)**

a) Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

b) Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.

iii. Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP)

Case No.04: Conditions of Registration

Registration Board in its 322nd meeting held on 08th-10th November, 2022 considered an agenda item regarding conditions of registration, however, relevant detail and decision of Registration Board could not be included in minutes of 322nd meeting. Accordingly, the same has been reproduced as under:

Proceedings of 322nd Meeting:

Under Rule 30 of Drugs (Licensing, Registering & Advertising) Rules, 1976, conditions of registration are mentioned on all letters issued for communicating registration of drug products. Previously, Registration Board in its 273rd meeting held on 28th-29th August, 2017 decided as under:

> "Registration Board deliberated that in 251st meeting it was advised to take commitments from applicants for recommended clinical use, route of administration, dosage, shelf life, storage conditions of finished product, composition, Drug Specification Rules, 1978 and labeling & prescribing information. The Board decided that for better regulatory compliance aforementioned particulars shall be part of condition of registration instead of taking commitments."

For better compliance, PE&R Division has incorporated a few changes in registration letters as per following details and are submitted for consideration of Registration Board.

A. Registration letter/ file number has been added as watermark on each page of registration letter to avoid any misuse in cases where registration of a number of products is issued on a single letter.
B. Conditions of registration have been updated (where required).

Decision of 322nd Meeting:

Registration Board endorsed addition of following information/ conditions on the registration letters:

Information to be included:

i. **"Form-6" shall be mentioned on registration letter/certificate under rule 28 of Drugs (L, R & A) Rules, 1976.**
ii. **Registration letter/ certificate shall be issued stating following 'SUBJECT' (mentioned in 'CAPITAL' letters):**

    "REGISTRATION OF DRUGS UNDER SECTION 7 OF THE DRUGS ACT, 1976 AND RULES 27, 28, 29 AND 30 OF THE DRUGS (LICENSING, REGISTERING AND ADVERTISING) RULES, 1976."

iii. **Inclusion of file/ registration letter number in the form of watermark on each page of registration letter.**
iv. **Copies of registration letter shall be distributed as per following detail for information of all concerned:**

1. **Provincial Health Secretaries of Khyber Pakhtunkhwa, Punjab, Sindh, Balochistan, Gilgit Baltistan, Azad Jammu Kashmir & Senior Drug Inspector, Islamabad.**
2. **Master file.**
3. **Reference letter No…… Islamabad, the…Name of Month, Year.**

Through E-Office

1. **The Additional Director, DRAP, Field Office (with the request to provide copy of this letter to area FID.)**
2. **The Deputy Director (Costing & Pricing), DRAP, Islamabad.**
3. **The Deputy Director (RRR), DRAP, Islamabad.**
4. **The Additional Director (Controlled Drugs), DRP, Islamabad** (where applicable)
5. **In-charge (DMC), DRAP, Islamabad.**

Conditions:

In addition to existing conditions of registration, Registration Board also endorsed to include/ update the conditions of registration as under:

i. **One copy of the complete method of testing of the finished drug(s) (containing full details of all minor and major steps and protocols along with specifications, (lower and upper limits) shall be submitted to the following institutions within a period of one month: -**

- **Chief, Drugs Control & Research Division, National Institute of Health, Islamabad.**
- **Director, Central Drug Laboratory, Building NO.4 (WFP), SMCHS, Block –B, Karachi – 74400.**

- ➢ **Director, Drugs Testing Laboratory, Lahore, Faisalabad, Bahawalpur, Multan & Rawalpindi.**
- ➢ **Director, Drugs Testing Laboratory, Mirpur Azad Jammu Kashmir.**
- ➢ **Director, Drugs Testing Laboratory, Gilgit Baltistan.**
- ➢ **Director, Drugs Testing Laboratory, Sindh, Karachi.**
- ➢ **Director, Drugs Testing Laboratory, Khyber Pakhtunkhwa, Peshawar.**
- ➢ **Director, Drugs Testing Laboratory, Balochistan, Brewery Road, Quetta.**

ii. **One copy of the master formula (of all registered drugs) containing the names of active materials (s) and inactive material(s)/ excipient(s) along with the quantities shall be furnished to the Assistant Director (I&E) concerned within a period of one month for which a receipt shall also be obtained.**

iii. **WHO Specifications shall be followed for the drug products, where such products are not included in the official pharmacopoeia of reference countries as specified by the Registration Board.**

iv. **For products registered on contract manufacturing basis (contract manufacturer and contract giver) shall follow Rule 20-A and Schedule H of the Drugs (Licensing, Registering & Advertising) Rules, 1976 under the Drugs Act, 1976.**

v. **Since, submission of stability data is a pre-requisite of all applications submitted for registration of drug products intended to be imported in finished form, therefore, following condition will be omitted from registration letter of drug products imported in finished form:**

"Other conditions as contained under the Drugs Act 1976 and rules framed thereunder including stability studies shall be strictly adhered to."

vi. **Every drug shall be manufactured/ imported** (mention whichever is applicable) **in sufficient quantity so as to ensure its regular and adequate supply in the market**

Registration Board advised to implement above instructions without waiting for approval of minutes.

Registration-II Section

Case No.01: Transfer of Registration from M/s. Wnsfield, Hattar to M/s. Horizon Pharma Lahore.

Registration Board in its 287th meeting cancelled the registration of following 16 products from the name of M/s. WnsField Pharmaceuticals, Hattar and registered in the name of M/s. Horizon Healthcare (Pvt.) Ltd; Plot No. 33, Sundar Indusrial Estate, Lahore on contract manufacturing by M/s. WnsField Pharmaceuticals, Hattar.

S.#	Reg. No.	Brand Name with Generic
1.	083140	Ridomide 50mg Tablet Each film coated tablet contains:- Lacosamide 50mg
2.	083142	Ridomide DS 100mg Tablet Each film coated tablet contains:- Lacosamide 100mg
3.	084220	Profitam 250mg Tablet Each film coated tablet contains:- Levetiracetam ..... 250mg (USP Specification)
4.	084221	Profitam 500mg Tablet Each film coated tablet contains:- Levetiracetam ..... 500mg (USP Specification)

5.	084227	Delpoflex 4mg tablet Each tablet contains:- Tizanidine as HCl ..... 4mg (USP Specification)
6.	064337	Endtron Injection Each 4ml contains:- Ondansetron (as HCl) ..... 8mg (USP Specification)
7.	064338	Respivant 1mg Tablet Each tablet contains:- Risperidone ..... 1mg (USP Specification)
8.	064339	Respivant 2mg Tablet Each tablet contains:- Risperidone ..... 2mg (USP Specification)
9.	064340	Moxofin 400mg Tablet Each tablet contains:- Moxifloxacin (as HCL)..... 50mg
10.	080877	Moxofin 400mg Infusion Each 250ml vial contains:- MoxifloxacinHCleq to:- Moxifloxacin 400mg
11.	087031	Mytodone 4mg Tablet Each film coated tablet contains:- Risperidone ..... 4mg (USP Specification)
12.	046813	Delpoflex Tablet Each tablet contains:- Tizanidine as HCl 2mg
13.	060052	Lewdes 5mg tablet Each tablet contains:- Desloratadine 5mg
14.	075596	Endtron 8mg tablet Each tablet contains:- Ondansetron (as HCldihydrate) ..... 8mg (USP Specification)
15.	075577	Zolfenac 50mg tablet Each coated tablet contains:- Diclofenac Sodium ..... 50mg Misoprostol ..... 200µg (USP specification)
16.	080244	Olaway tablet 8mg Each film coated tablet contains:- Lornoxicam 8mg

It was observed that M/s. Horizon Healthcare (Pvt.) Ltd; Plot No. 33, Sundar Indusrial Estate, Lahore has 03 approved section and they can avail registration of 15 products as per Rule 20(a) of Drugs (Licesing, Registering & Advertising) Rules, 1976. M/s. Horizon healthcare (Pvt.) Ltd; Lahore intended to withdraw following 04 products for which registration has already been cacncelled from the name of M/s. Wnsfield, Hattar.

Sr. No.	Reg. No.	Brand Name with Generic
1.	064338	Respivant 1mg Tablet Each tablet contains:- Risperidone ..... 1mg (USP Specification)
2.	064339	Respivant 2mg Tablet Each tablet contains:- Risperidone ..... 2mg (USP Specification)

3.	080877	Moxofin 400mg Infusion Each 250ml vial contains:- MoxifloxacinHCleq to:- Moxifloxacin 400mg
4.	087031	Mytodone 4mg Tablet Each film coated tablet contains:- Risperidone ..... 4mg (USP Specification)

Furthermore, M/s. Wnsfield, Hattar has submitted a letter stating that;

"We have withdrawn 04 products (mentioned above) from transferring to Horizon Pharma. So, it is requested to your good self to please cancel the transfer of registartion of these 04 products."

Decision of 295th meeting of Registration Board

Registration Board deferred the case and decided to discuss case in the presence of Representative of Ministry of Law & Justice.

Now firm has submitted that as per SRO 1347(I)/2017 dated 15-10-2021 the policy of 5 toll products per section has been changed. So, they would like to request to please don't consider their withdrawal request and issue them the transfer of registration letter.

Decision of 316th Meeting of RB.

Registration Board deferred the case for opinion of Legal Affair's Division.

As per above decision of The Board following was referred to Legal Affair's Division for their opinion:

a. Application submitted by M/s. Winsfield Pharmaceuticals, Hattar for withdrawal of application for registration in the name of M/s Horizon Healthcare (Pvt) limited, Lahore can be withdrawn by the M/s Winsfield Pharmaceuticals, Hattar, as already considered by Registration Board.

b. If it can be considered, then whether NOC from M/s Winsfield is required or otherwise.

c. Applicability of fee in case of re-consideration by Registration Board.

Accordingly, opinion of the Legal Affair's Division is as under:

Foregoing in view, reply to first query is given in detail at para 3 of this opinion, as the Registration Board in its 287th meeting has already approved cancellation of registration of 16 products from M/s WnsField Pharmaceuticals, Hattar and granted registration of the same in favaour of M/s Horizon healthcare (pvt) Limited, Lahore. Therefore, the second query above at para (b) referred by the Registration Board became irrelevant. Moreover, as for as applicability of fee for Contract manufacturing, the scheme of law regarding contract manufacturing has been changed vide SRO 1347 (I)/2021 dated 15.10.2021. The updated provision is given here for ready reference:

5. Miscellaneous.-

5.1 Fee for grant, renewal/extension and pre and post registration variation in contract manufactured products shall be applicable as determined by Authority with the approval of Policy Board.

As discussed in the previous paras, the scheme of law has been changed, wherein the limitation on contract manufacturing i.e 5 product per section has been removed, therefore, contract manufacturing by M/s Horizon healthcare (pvt) Limited, Lahore may also be allowed under new scheme of law and the new fee is applicable for contract manufacturing which is 75000 rupees per product. It should be done after transfer of the registration of products from M/s WinsField Pharmaceuticals, Hattar and granted registration of the same in favor of M/s Horizon healthcare (pvt) Limited, Lahore. After this the request of M/s Horizon healthcare (pvt) Limited, Lahore for contract manufacturing shall become valid, and the Registration Board may process it in accordance with law.

Decision: **Registration Board after through deliberation decided to process the case as per decision of 287th meeting. Registration letter shall be issued after submission of fee as per notification No.F.7-11/2012B&A/DRAP dated 07-05-2021. The Board further decided to seek opinion from legal Affair's Division regarding fee requirement for cases in which applications have been submitted before said notification while applications are under process of evaluation.**

Case No.02: Correction in Minutes of Registration Board Meetings.

i. M/s Horizon Healthcare (Pvt) Ltd. Plot No. 33, Sundar Industrial Estate, Lahore

Registration Board in its 320th meeting approved following product of M/s Horizon Healthcare (Pvt) Ltd. Plot No. 33, Sundar Industrial Estate, Lahore. There is some typo error in strength of formulation as well as in decision of said meeting. Detail is as under;

Sr. No.	Name of Approved Drug(s) & Composition	Name of Drug(s) & Corrected Composition	Decision of 320th Meeting
1.	Elmet XR 25/25/1000mg Tablet Each film-coated extended-release tablet contains: Empagliflozin …… 25mg **Linagliptin …….. 25mg** (as immediate release coating) Metformin HCl…… 1000mg	Elmet XR 25/5/1000mg Tablet Each film-coated extended-release tablet contains: Empagliflozin …… 25mg **Linagliptin …….. 5mg** (as immediate release coating) Metformin HCl…… 1000mg	**Registration Board approved Elmet XR 25/25/1000 mg Tablet, Elmet XR 10/5/1000 mg Tablet & Elmet XR 12.5/2.5/1000 mg Tablet with Innovator's specifications.**

It is confirmed from initial registration application that applied strength of Linagliptin is 5mg instead of 25mg. Furthermore, innovator product Trijardy XR is also od 25/5/1000.

Decision: **Registration Board decided to approve the correction in composition of above product as per following details.**

"Elmet XR 25/5/1000mg Tablet
Each film-coated extended-release tablet contains:
Empagliflozin …… 25mg
Linagliptin ……. 5mg
(as immediate release coating)
Metformin HCl…… 1000mg"

Case No.03: **Transfer of Registration from M/s. Pacific Pharma 30-Km Multan Road Lahore to M/s Pacific Pharmaceuticals Ltd Ravi Lane, Plot No. 384, Sundar Industrial Estate, raiwind Lahore by way of contract manufacturing from M/s. Pacific Pharma 30-Km Multan Road Lahore.**

1.	**Name, address of Applicant / Marketing Authorization Holder**	**M/s Pacific Pharmaceuticals Ltd.** **Address: Plot No. 384, Sunder Industrial Estate, Lahore-Pakistan**
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd., Multan Raod, Lahore-Pakistan
	Status of the applicant	☒Manufacturer ☐Importer ☐Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 24545 dated 30 August 2022
	Details of fee submitted	PKR.30,000/-:DS 946581159060 dated 29-08-2022
	The proposed proprietary name / brand name	**Plasenzyme Tablet**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each sugar coated tablet contains: - Sodium dehydrocholate… 20.00 mg Pancreatin 8 NF …. 69.30 mg Metoclopramide HCl…. 6.00 mg Simethicone…. 25.00 mg Bromelain… 19.88 mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Digestive Enzymes

	Reference to Finished product specifications	Innovator's Specification
	Proposed Pack size	--
	Proposed unit price	As per DPC
	The status in reference to regulatory authorities	Plasil Enzimatico, Sanofi Aventis, Italy
	For generic drugs (me-too status)	N/A
	GMP status of finished product Manufacturer	---
	Name and address of API manufacturer.	GMP certificate of API Pancreatin manufacturer "Sichuan Biosyn Pharmaceuticals Co., Ltd. Duanjiaba, Deyang City, Sichuan Province P.R. China" has been issued with certificate no SC20190121 by China Food and Drug Administration issued date 10/12/2024. GMP certificate of API Simethicone manufacturer " Basildon Chemical Co. Ltd., Kimber Road, Abingdon, Oxfordshire, United Kingdom bearing certificate number 10336 Insp GMP/GDP 10336/1297-0011 issued by MHRA, UK on basis of inspection conducted on 18/02/2019. GMP certificate of API Sodium dehydrocholate manufacturer " ICE- Industria Chimica Emiliana S.p.A, Italy" bearing certificate number IT-API/184/H/2018 issued by Agenzia Italiana Del Farmaco, Italy based on inspection conducted on 15/06/2018. GMP certificate of claimed manufacturer of API Bromelain is not attached. The claimed manufacturer in the Substance part is 'Great Food (Bio Chem) Co. Ltd, 1168/64 Lumpini Tower Bldg Khwang Thung Maha Maek Khet Sathon Bangkok. GMP certificate of API metoclopramide Hcl manufacturer is not attached
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Material for Testosterone Gel is formulated at the manufacturing site of M/s Ipca Laboratories, India & summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of the manufacturing process, and controls, impurities, specifications, analytical procedures, and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module-III Drug Substance:	The firm has submitted data for drug substance related to nomenclature, structure, general properties, solubility, physical form, DS and raw material specifications, manufacturers, the quantitative composition of Testosterone Gel manufacturing process & tests for impurities & residual solvents, Analytical procedures, CoAs, specifications, Standard testing procedures. Reference standard or materials & container closure system.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months For APIs.
	Module-III Drug Product:	The firm has submitted detail of manufacturers, a description of the manufacturing process and controls, impurities, specifications, analytical procedure, and its validation studies, batch analysis and justification of specification, reference standard, container closure system, and stability studies of the drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence has been established against their own product.
	Analytical method validation/verification of product	Method validation studies have been submitted including linearity, range, accuracy, precision, specificity & robustness

STABILITY STUDY DATA

Manufacturer of API	GMP certificate of API metoclopramide Hcl manufacturer is not attached. GMP certificate of API Pancreatin manufacturer "Sichuan Biosyn Pharmaceuticals Co., Ltd. Duanjiaba, Deyang City, Sichuan Province P.R. China" has been issued with certificate no SC20190121 by China Food and Drug Administration issued date 10/12/2024. GMP certificate of API Simethicone manufacturer " Basildon Chemical Co. Ltd., Kimber Road, Abingdon, Oxfordshire, United Kingdom bearing certificate number 10336 Insp GMP/GDP 10336/1297-0011 issued by MHRA, UK on basis of inspection conducted on 18/02/2019. GMP certificate of API Sodium dehydrocholate manufacturer " ICE-Industria Chimica Emiliana S.p.A, Italy" bearing certificate number IT-API/184/H/2018 issued by Agenzia Italiana Del Farmaco, Italy based on inspection conducted on 15/06/2018. GMP certificate of claimed manufacturer of API Bromelain is not attached. The claimed manufacturer in the Substance part is 'Great Food (Bio Chem) Co. Ltd, 1168/64 Lumpini Tower Bldg Khwang Thung Maha Maek Khet Sathon Bangkok.
API Lot No.	----
Description of Pack Container closure system)	Shiny, dark brown round biconvex sugar coated tablets

Stability Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 12 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real-Time: 0, 3, 6, 9,12,24 (Months)		
Batch No.	BL0101P	BL0201P	BL0301P
Batch Size	250,000	250,000	250,000
Manufacturing Date	01-2020	01-2020	01-2020
Date of Initiation	21-02-2020	21-02-2020	21-02-2020
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate of API metoclopramide Hcl manufacturer is not attached. GMP certificate of API Pancreatin manufacturer "Sichuan Biosyn Pharmaceuticals Co., Ltd. Duanjiaba, Deyang City, Sichuan Province P.R. China" has been issued with certificate no SC20190121 by China Food and Drug Administration issued date 10/12/2024. GMP certificate of API Simethicone manufacturer " Basildon Chemical Co. Ltd., Kimber Road, Abingdon, Oxfordshire, United Kingdom bearing certificate number 10336 Insp GMP/GDP 10336/1297-0011 issued by MHRA, UK on basis of inspection conducted on 18/02/2019. GMP certificate of API Sodium dehydrocholate manufacturer " ICE-Industria Chimica Emiliana S.p.A, Italy" bearing certificate number IT-API/184/H/2018 issued by Agenzia Italiana Del Farmaco, Italy based on inspection conducted on 15/06/2018. GMP certificate of claimed manufacturer of API Bromelain is not attached. The claimed manufacturer in the Substance part is 'Great Food (Bio Chem) Co. Ltd, 1168/64 Lumpini Tower Bldg Khwang Thung Maha Maek Khet Sathon Bangkok.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted a copy of the commercial invoices.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm has submitted the data of stability batches supported by respective documents like chromatograms, Raw data sheets, COA, summary data sheets, etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted the Compliance Record of HPLC software 21CFR & audit trail reports on product testing
6	Record of Digital data logger for temperature and humidity monitoring of stability chamber (Real time & Accelerated)	The firm has submitted a Record of the Digital data logger for temperature and humidity monitoring of the stability chamber (Real-time & Accelerated)
Remarks	The firm has submitted a fee of 30,000/- only. COA of metoclopramide by the FPP manufacturer mentions "Deafarma Italy" as supplier where as in QOS they have claimed the manufacturer of DS metoclopramide HCl to be "Vaikunth Chemicals (Pvt.) Ltd. 408/4 &, GIDC, Nr. Fire Station Panoli-394116, Ta Ankleshwar, Dist. Bharuch." They have not mentioned the name of the country but the address indicates that it is located in Gujrat, India.	

i.		M/s. Medicraft Pharmaceuticals Pvt Limited. 26-B, Industrial Estate Hayatabad Peshawar (Page 0-0/C)			
1.	056361	Panagestic Tablets Each tablet contains: Paracetamol……..650mg Orphenadrine Citrate……..50mg (USP Specification)	Paramed Forte tablet	26.03.2009 14.03.2019	Fee Deposited Rs.30000/- Dated 08.11.2022 Dy.No.32229 dated 08.11.2022 **Justification:** As per local market demand.
Decision of PRVC 94		*The Chairman Registration Board on the recommendation of the Committee referred the case to Registration Board as the said formulation is not registered in RRAs.*			
Decision: Registration Board deferred the case for evidence of availability of formulation in Reference Regulatory Authorities.					

	The firm has provided name of manufacturer for "Bromelain Enzyme" as Great Food (Bio Chem) Co., Ltd., 1168/64 Lumpini Tower Bldg Khwang Thung Maha Maek Khet Sathon Bangkok 10120 where as GMP Certificate has been provided of "PT Bromelain enzyme, JL Raya Terbanggi Besar KM 77 Lampung Tengah". Pharmaceutical Equivalence has been established against their own product, Plasil with Enzyme Tablets batch BK2009R with expiry of Aug, 2024.

Decision: Registration Board deferred the case for following:

i. **Submission of COA of metoclopramide and Bromelain drug substance from the sources mentioned in QOS.**
ii. **Submission of Pharmaceutical equivalence study with innovator drug product.**
iii. **Submission of differential fee of Rs.45000/- as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021**

Post Registration-I Section

Case No. 01: Change of Brand Name

Case No.02: Resemblance of brand names.

i.		M/s. Webros Pharmaceuticals Plot No.1 Street No.10 National Industrial Zone Rawat, Islamabad.		
S. No	**Reg.No.**	**Name of product of** M/s. Webros Pharmaceuticals	**Name of drug(s) having similarity**	**Name of firm having similar brand name**
1.	056852	Krestor 5 mg tablets	Kestore 5mg tablet, (Reg No.066798) Kestore 10mg tablet (Reg. No.066798) & Kestore 20mg tablets (Reg.No.066799)	**M/s. Scilife Pharma (Pvt) Ltd. Plot No.FD-57/58-A2 Korangi Creek Industrial Park (KCIP) Karachi**
2.	056853	Krestor 10 mg tablets		
3.	056854	Krestor 20 mg tablets		

Remarks: Accordingly, Letter No.1288/2022-PR-I(PE&R) dated 26.10.2022 was issued to M/s. Scilife Pharma (Pvt) Ltd. Plot No.FD-57/58-A2 Korangi Creek Industrial Park (KCIP) Karachi to change the brand name.

Reply of the firm is as under:

"We have checked the similarity factor and identify that both the brand didn't have similarity in terms of factors like first three letter nor phonetic. It may also be noted that there will be no safety and efficacy concern lies at end of patient and end user since both the brands have the same active Pharmaceutical ingredients that is Rosuvastatin.

For your information and record we are marketing this brand Kestore since more than 10 Years in below mentioned strength

Please also note that the brand name Kestore was initially registered in the name of Opal Laboratories, Karachi whose marketing rights were held by Scilife Pharma Pvt Ltd,.

Later, Upon commissioning of its own state of the art manufacturing facility Scilife Pharma Purchased and get the said brands transferred on its own facility as mentioned in DRAP letter No. F-3-9/2017 Reg-II (M-272) Dated 12-02-2018

The said products has been continuously manufactured and marketing by Scilife Pharma, with it being prescribed by thousands of Physicians throughout Pakistan in both government and private hospital and at present there are millions of patients who takes Kestore as their medicine every day with confidence and trust.

It is therefore submitted that any change in the brand name of the products would cause confusion at physicians level, as well as it may cause distress to innumerable patients who are users of the brand.

Furthermore, it would be appropriate to mentioned that the brand Kestore is Protected by the Intellectual property Organization (IPO) Trade Mark Registry and carries valid Trademark Certificate.

Referring to the above point and interest of the prescribed and patients who are associated with Kestore considering a brand of Scilife with promise to provided quality medicines at affordable price, you are requested to kindly accept our response and close the case positively.

Decision of 94th PRVC:

"The Chairman Registration Board on the recommendation of the Committee referred the case to Registration Board for consideration."

Decision: Registration Board advised M/s Scilife Pharma Pvt. Ltd., Karachi to propose brand names of their products Kestore 5mg tablet, (Reg No.066798), Kestore 10mg tablet (Reg. No.066798) & Kestore 20mg tablets (Reg.No.066799) for consideration of PRVC.

Case No. 03: Change in specifications.

Sr. #	Reg. No.	Name of Product with existing composition, Specifications	Proposed Specifications	Initial Date of Registration Renewal Application	Remarks
I	**II**	**III**	**IV**	**V**	**VI**
i. M/s. Healthtek (Pvt.) Ltd., Plot No. 14, Sector 19, Korangi Industrial Area, Karachi					
1.	047013	**OTID 125mg/5ml Suspension** After reconstitution each 5ml suspension contains: Cephradine …..…125mg (USP Specification)	BP Specifications	04-09-2007 Last Renewal 03-09-2022	Fee Rs.10,000/- deposit on 18-08-2022 Dy. No. 1086 -PR-I dated 24.08.2022
Decision of 94th PRVC		*The Chairman Registration Board on the recommendation of the Committee decided as follows:* • *Referred the product to Registration Board as the said formulation is not registered in RRAs.*			
Decision: Registration Board deferred the case for evidence of availability of formulation in Reference Regulatory Authorities.					

Case No. 04: Change in Specifications of products applied by M/s Sanofi Aventis Pakistan Limited, Karachi.

i. Products available in RRAs but not in Pharmacopoeia:

M/s Sanofi Aventis Pakistan Limited, Karachi applied for Innovator/ Sanofi Specifications for their following product which is not available in any pharmacopoeia:

Haemaccel Infusion (Reg No. 003382)

TEST	SPECIFICATIONS	REMARKS
Appearance	Clear, yellowish solution.	Haemaccel Infusion is available in UK. It was acquired by Piramal from Hoechst (so basically both of these are same products with same Trademark)
Identification		
a) Test 1	A distinct Violet coloration will appear	
b) Test 2	A Yellowish precipitate should produce.	
pH	7.00 – 7.60	
Viscosity (relative)	1.70 – 1.80	
Sodium Ion	139 – 152 m. mol /L	
Potassium Ion	4.6 – 5.6 m. mol /L	
Calcium Ion	5.5 – 7.0 m. mol /L.	
Chloride	130 – 160 m. mol / L.	
Free Amino Group	0.50-0.65ml 1 N NaOH / 40 ml of Haemaccel.	
Heavy Metals	≤ 1µg/ml.	
Total Nitrogen	6.0-6.6 mg Nitrogen /ml.	
Residual solvent	Not more than 20 ppm.	
Bacterial Endotoxins	< 0.5 EU/ml	
Sterility	Must be Sterile	

Decision: Registration Board approved the Innovator's/ Sanofi Aventis Specifications for above product.

ii. Products neither available in RRAs nor in Pharmacopoeia:

M/s Sanofi Aventis Pakistan Limited, Karachi applied for Innovator/ Sanofi Specifications for their following product which are not available in any pharmacopoeia:

i. Avil 25 Tablet (Reg. No 000224)

TEST	INNOVATOR SPECIFICATIONS	REMARKS
Appearance	Flat bisected round white to off white tablets, one side coded with 11AV & other side with a break-line.	Product not available in any official pharmacopeia.
Disintegration time	NMT 15 minutes	
Identification of Pheniramine Maleate	BY HPLC: Retention time of Pheniramine Maleate peak in sample solution should corresponds to the standard solution Pheniramine Maleate peak.	
Assay content of Pheniramine Maleate	21.30– 23.80 mg/tablet (93.83 – 104.85 % of stated)	
Related Substances		
Impurity A	NMT 1.0%	
Impurity B	NMT 1.0%	
Uniformity of Content	NMT 15	
Microbiological testing		
Total aerobic microbial count	NMT 2000 CFU/G	
Total yeast & mould count	NMT 200 CFU/G	
E. Coli	Must be absent	

ii. Avil Syrup (Reg No. 005323)

TEST	SPECIFICATIONS	REMARKS
Appearance	A clear colorless to pale yellow syrup.	Withdrawn from Australia due to commercial reason (Notification issued by TGA and declaration from Sanofi Australia submitted)
Odour	Of Pharma Aroma	
pH	4.00 – 5.50 at 20ºC.	
Identification by HPLC Pheniramine Maleate Methyl 4- hydroxy benzoate Propyl 4- hydroxy benzoate	Retention time in sample preparation of assay test corresponds to the retention time in standard preparation.	
Assay of Pheniramine Maleate	13.50 – 16.50 mg/5ml 90.00 - 110.00 % of stated	

Microbial limit test		
Total Aerobic Microbial count	Less than 200 CFU/ ml	
Total Yeast & Mould Count	Less than 20 CFU/ ml	
E. Coli	Absent / ml	

iii. Avil Injection (Reg No. 000226)

TEST	SPECIFICATIONS	REMARKS
Appearance	Clear colorless solution	Product not available in any official pharmacopeia.
pH	4.50 – 5.50	
Identification of Pheniramine Maleate	The absorbance maximum at about 265nm±2nm obtained in the assay is used as a mean of identification in 0.1M HCl.	
Assay of Pheniramine Maleate	21.60 – 23.90 mg/ml 95.15 - 105.28 %	
Bacterial Endotoxins	NMT 1.57 USP EU / mg	
Sterility test	Complies test	
Liquid Particulate Matter	NMT 6000 Particles/container of 10µ or above NMT 600 Particles/container of 25µ or above	

iv. Secnidal Forte Tablets (Reg No. 016061)

TEST	SPECIFICATIONS	REMARKS
Appearance	Greenish yellow capsule shaped film coated tablet, 126AV on one side & break line on the other side. No irregularities on surfaces, no capping or lamination, not unduly colored or chipped.	This strength is not available in any official pharmacopeia.
Uniformity of dosage units - Weight Variation	NMT 15.0	
Disintegration test	NMT 30 Minutes	
Identification of Secnidazole	The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the assay	
Assay content of Secnidazole	950.00 – 1050.00 mg/tablet (95.00 – 105.00 %)	
Microbiological Testing		
Total Aerobic Microbial Count	NMT 2000 CFU/g	
Total Yeast & Mould Count	NMT 200 CFU/g	
E. Coli	Absent/g	

v. Amaryl M SR 1mg Tablet (Reg No. 050372)

TEST	SPECIFICATIONS	REMARKS
Appearance	Oval shaped uncoated biconvex bilayer tablet, plain on both sides, one thick layer is white & other thin layer is pink in color.	Product not available in any official pharmacopeia.
Uniformity of Dosage Form – Weight Variation of Metformin	NMT 15.0	
Identification		
a) Glimepiride	Retention time of the major peak in chromatogram of the assay preparation corresponds to that in the chromatogram of the standard preparation as obtained in assay of Glimepiride.	
b) Metformin HCl	Retention time of the major peak in chromatogram of the assay preparation corresponds to that in	

	the chromatogram of the standard preparation as obtained in assay of Metformin HCl.	
Assay		
a) Glimepiride (LC) (Label Claim: 1mg/tablet)	0.95 – 1.05 mg/tablet (95.00 – 105.00 %)	
b) Metformin HCL (LC) (Label Claim: 500mg/tablet)	475.0 – 525.00 mg/tablet (95.00 – 105.00 %)	
Uniformity of content Glimepiride (LC)	NMT 15.0	
Related substances		
a) Glimepiride (LC) Glimepiride sulfonamide (Impurity B)	NMT 2.5%	
Individual unknown impurity	NMT 0.5%	
Total unknown impurities (Including Impurity B)	NMT 3.5%	
b) Metformin HCl (LC)		
Individual unknown impurity	NMT 0.1%	
Dissolution		
Glimepiride (LC)	NLT 75%	
Metformin HCl (UV)		
After 01 hour	22 – 42%	
After 04 hours	54 – 74%	
After 08 hours	75 – 95%	
After 12 hours	NLT 80%	
Microbial Limit Test		
Total Aerobic Microbial Count	NMT 2000CFU/g	
Total Yeast & Mould Count	NMT 200CFU/g	
E. Coli	Must be absent	

vi. Amaryl M SR 2mg Tablet (Reg No. 050373)

TEST	SPECIFICATIONS	REMARKS
Appearance	Oval shaped uncoated biconvex bilayer tablet, plain on both sides, one thick layer is white & other thin layer is green in color.	Product not available in any official pharmacopeia.
Uniformity of Dosage Form – Weight Variation of Metformin	NMT 15.0	
Identification		
a) Glimepiride	Retention time of the major peak in chromatogram of the assay preparation corresponds to that in the chromatogram of the standard preparation as obtained in assay of Glimepiride.	
b) Metformin HCl	Retention time of the major peak in chromatogram of the assay preparation corresponds to that in the chromatogram of the standard preparation as obtained in assay of Metformin HCl.	
Assay		
a) Glimepiride (LC) *(Label Claim: 2mg/tablet)*	1.90 – 2.10 mg/tablet (95.0 – 105.0 %)	
b) Metformin HCl (LC) *(Label Claim: 500mg/tablet)*	475.00 – 525.00 mg/tablet (95.0 – 105.0 %)	
Uniformity of content Glimepiride (LC)	NMT 15.0	
Related substances		
a) Glimepiride (LC) Glimepiride sulfonamide (Impurity B)	NMT 2.5%	

Individual unknown impurity	NMT 0.5%	
Total unknown impurities (Including Impurity B)	NMT 3.5%	
b) Metformin HCl (LC)		
Individual unknown impurity	NMT 0.1%	
Dissolution		
Glimepiride (LC)	NLT 75%	
Metformin HCl (UV)		
After 01 hour	22 – 42%	
After 04 hours	54 – 74%	
After 08 hours	75 – 95%	
After 12 hours	NLT 80%	
Microbial Limit Test		
Total Aerobic Microbial Count	NMT 2000CFU/g	
Total Yeast & Mould Count	NMT 200CFU/g	
E. Coli	Must be absent	

vii. Tixylix Cough Linctus (Reg No. 001238)

TEST	**SPECIFICATIONS**	**REMARKS**
1. Appearance	A brown colored syrup.	Withdrawn from Australia due to commercial reason (Notification issued by TGA and declaration from Sanofi Australia submitted)
2. Odor	Blackcurrant	
3. pH at 20^0C	4.25 – 4.75	
4. Weight per ml at 20^0C	1.100 – 1.140	
5. Identification of Promethazine HCl and Pholcodine	The Retention times for Promethazine HCl and Pholcodine in the sample chromatogram & in the test for Assay must have similar values within ± 3% as in standard chromatogram.	
6. Assay content of Promethazine HCl	1.35 – 1.65 mg/5ml 90.0 – 110.0 %	
7. Assay content of Pholcodine	1.35 – 1.65 mg/5ml 90.0 – 110.0 %	
8. Related substances		
Promethazine sulphoxide	NMT 0.5% with reference to the nominal Promethazine HCl content (Equivalent to 0.025mg/5ml of Promethazine HCl)	
Other Impurities	No impurities present at a level greater than 0.5% expressed as a % of Promethazine HCl.	
9. Microbial limit test		
Total Aerobic Microbial count	Less than 200 CFU/ ml	
Total Yeast & Mould Count	Less than 20 CFU/ ml	
E. Coli	Absent / ml	

Decision: Registration Board deferred the case for submission of evidence of availability of product in Reference Regulatory Authorities.

Post Registration-II Section

		M/s. GT Pharma Pvt Ltd., 713 Sundar Industrial Estate, Sundar Raiwind Road, Lahore			
1.	106359	K-Lot Injection 10mg / ml IV Each ml contains:- Phytomenadione… 10mg (BP Specifications)	K-Lot Injection 10mg /ml **IV/IM/Oral** Each ml contains:- Phytomenadione… 10mg (BP Specifications)	14-12-2020	Fee Rs 10,000/- deposited dated 10-08-2022 R&I Dy. No. 23311

					dated 17-08-2022
Remarks:-		The firm has submitted evidence of approval from Germany.			
Decisions of 94PRVC:-		*The Chairman Registration Board on the recommendation of the Committee decided to refer the case to Registration Board and to ask the firm to submit differential fee of Rs. 20000/-.*			
Decision: **Registration Board deferred the case for submission of evidence of availability of same formulation with proposed routes of administrations in RRAs.**					
i.		**M/s. Shaigan Pharmaceuticals Pvt Ltd., 14km Adyala Road, Post office Dahgal, Rawalpindi**			
1.	049152	Gezlin Tablet Gemifloxacin (as Mesylate)… 320mg (Manufacturer Specifications)	Gezlin Tablet Gemifloxacin (as Mesylate)… 320mg **(USP Specifications)**	09-04-2008 **Brand name change** 01-11-2011 **Last renewal** 01-03-2018	Fee Rs 10,000/- deposited dated 12-12-2022 R&I Dy. No. 36064 dated 12-12-2022
Remarks:-		Withdrawn by EMA due to negative risk benefit ratio.			
Decisions of 94 PRVC:-		*Referred the request of the firm for product at sr. no. 61to Registration Board as the product has been withdrawn by EMA due to negative risk benefit ratio.*			
Decision: Registration Board deferred the case for clarification and further deliberation by the firm as the said formulation has been withdrawn by EMA due to negative risk-benefit ratio.					

Export Facilitation Desk

Case No.01: Registration of Drug (s) of M/s Maxitech Pharma (Pvt.) Ltd, Plot No. E-178, S.I.T.E. Phase-II, Super Highway, Karachi, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5;
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided Approval of relevant section verified from letter No. F 02-12/2012-Lic dated 25-11/2016
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from Inspection report renewal of DML dated 07-07-2021
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Lydocaine 10% Solution Each ml contains: Lignocaine HCl.....100mg	Purchase order from Myanmar	Dy. No. 8566 (06.12.2022) Rs.75,000/- (04.11.2022)

Decision:

Registration Board deferred the case for submission of evidence of availability of approve requisite manufacturing facility.

Case No.02: Registration of Drug (s) of M/s Ophth Pharma (Pvt.) Ltd Plot No. 24, Korangi Industrial Area Karachi, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5;
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided Approval of relevant section verified from letter No. F 02-4/98-Lic dated 07-06/2022
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from Inspection report renewal of DML dated 24-03-2021
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Trop-M Plus (Sterile Eye Drops) Each ml contains: Tropicamide.....8.0mg Phenylephrine HCl.....100.0mg	Purchase order from Tajikistan	Dy. No. 8633 (13.12.2022) Rs.30,000/- (11.11.2022) Rs.45,000/- (22.11.2022)

Decision:

Registration Board approved the request of the firm for registration of product for Export Purpose Only.

Case No.03: Registration of Drug (s) of M/s Glitz Pharma, Plot No. 265, Industrial Triangle, Kahuta Road, Islamabad,, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5;
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided Approval of relevant section verified from Inspection report renewal of DML dated 17-06/2022
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from Inspection report renewal of DML dated 17-06-2021
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Ginkolitz Capsule Each capsule contains: Ginkobiloba.....120mg Ginseng.....120mg	Purchase order from Cambodia	Dy. No. 8699 (29.12.2022) Rs.75,000/- (28.09.2022)

Decision:

Registration Board referred the case to H&OTC Division.

Deferred case 94th PRVC

Case No.01: Registration of Drug (s) of M/s Getz Pharma (Pvt.) Ltd, Plot No. 29-30, Sector 27 Korangi Industrial Area Karachi, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5; (Pages. 974-1008/C)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided (Page-136/C). Approval of relevant section verified from letter No. F 2-5/86 dated 30-10-2019 (Page 137/C).

GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from GMP certificate based / on inspection dated 13-01-2022 (Page 138-/C).
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided (Pages. 1001/C)

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Vilflumec 25mcg+100mcg+62.5mcg DPI Capsule Each capsule contains: Vilanterol Trifenatate equivalent to Vilanterol.....25mcg Fluticasone furoate.....100mg Umeclidinium bromide equivalent to Umeclidinium.....62.5mcg	Trelegy Ellipta, USFDA	Dy. No. 8767/22 (06.01.2023) Rs.75,000/- (22.11.2022)

Remarks:

USFDA approved product is in two separate blisters. One contains fluticasone furoate while the other blister contains blend of micronized umeclidinium bromide and micronized vilanterol trifenatate. But in product at sr. no. 1, the firm has encapsulated all the three components in single hard gelatin capsule. The firm has submitted the following:

"Nonetheless, data from stability studies have shown that all the quality indicating chemical and physical parameters including appearance, assay, disposition of emitted dose and uniformity of delivered dose are in compliance with specifications and no degradation have been reported which further proves that all the three API's (Vilanterol + Fluticasone Furoate + Umeclidinium) are compatible with each other and no physical interaction takes place."

Decision of 94th PRVC:

The Chairman Registration Board on the recommendation of the Committee considered the case and referred the case at sr. no. 1 to Registration Board for deliberation.

Decision:

Registration Board deferred the case for submission of evidence of availability of formulation in RRAs.

Export Registrations of Tramadol Containing Formulations

DRAP Authority in its 115th meeting while considering the matter of issuance of NOC to Tramadol containing formulations decided as follows:

"Authority advised to assure that following additional prerequisites are also verified before issuance of NOC for export of Tramadol containing products:

i. Registration of Tramadol containing products of exporter in importing country.
ii. Legal status of Tramadol in importing country whether controlled under INCB or otherwise.
iii. *In case of any already exported consignment, clearance documents of customs and regulatory authority of country of origin."*

Export Facilitation desk has received following applications for export registration of Tramadol containing formulations which are not registered in any RRAs:

Deferred case 94th PRVC

Case No.07: Registration of Drug (s) of M/s Winlet Pharmaceuticals (Pvt.) Ltd, 30-Km, Lahore Sargodha Road, Sargodha, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5; (Pages. 154-180/C)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided (Page-161/C). Approval of relevant section verified from letter No. F 1-28/2009 dated 26-02-2018 (Page 162/C).
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from GMP certificate based / on inspection dated 25-11-2022 (Page 163-/C).

Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided (Pages. 164/C)

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Tymol 100mg Tablet Each sustained release tablet contains: Tramadol HCl.....100mg	Allay SR tablet by M/s Tabros	Dy. No. 8658/22 (22.12.2022) Rs.30,000/- (04.08.2021)

Decision of 94th PRVC:

The Chairman Registration Board on the recommendation of the Committee considered the case and Referred the case at sr. no. 1 to Registration Board for deliberation in light of reference of QA&LT Division.

Decision:

Registration Board approved the request of the firm for registration of product for Export Purpose Only.

Deferred case 94th PRVC

Case No.18: Registration of Drug (s) of M/s Rotex Pharma (Pvt.) Ltd, Plot No. 206 & 207 Industrial Triangle Kahuta Road, Islamabad, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5; (Pages. 640-646/C)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided (Page-647/C). Approval of relevant section verified from letter No. F 1-53/2003-Lic dated 04-12-2018 (Page 6149-650/C).
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from GMP certificate based / on inspection dated 11-08-2022 (Page 650-651/C).
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided (Pages. 652/C)

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Volpan 250mg Tablets Each film coated tablet contains: Tramadol HCl.....250mg		Dy. No. 8704/22 (30.12.2022) Rs.75,000/- (01.11.2022)

Decision of 94th PRVC:

The Chairman Registration Board on the recommendation of the Committee decided to refer the case to Registration Board for deliberation in light of reference of QA&LT Division.

Decision:

Registration Board deferred the case for submission of export order and verification of registration status of applied formulation in importing country.

Deferred case 93rd PRVC

Case No.18: Registration of Drug (s) of M/s Trigon Pharmaceuticals (Pvt.) Ltd, 8-Km Thokar Raiwind Road, Lahore, for export purposes only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5; (Pages. 604-627/C)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided (Page-612/C). Approval of relevant section verified from letter No. F 1-5-/92-Lic dated 10-08-2015 (Page 618/C).

GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from GMP certificate based / on inspection dated 11-01-2021 (Page 619/C).
Undertakings that the applied product is exclusively for export purpose and the proposed names/ label/ colour do not resemble with already registered brands in importing country.	Provided (Pages. 620-631/C)

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
1.	Tramaking 250mg Tablet Each film coated tablet contains: Tramadol HCl……250mg	Export Order from West Africa	Dy. No. 8564/22 (06.12.2022) Rs.75,000/- (28.11.2022)
2.	Tamral 250mg Tablet Each film coated tablet contains: Tramadol HCl……..250mg		Dy. No. 8565/22 (06.12.2022) Rs.75,000/- (28.11.2022)

Decision of 93rd PRVC:

The Chairman Registration Board on the recommendation of the Committee deferred the cases for further deliberation.

Decision:

Registration Board deferred the case for submission of export order on importers letter head and verification of registration status of applied formulations in importing country.

Post Registration-I Section (Additional Agenda)

Case No. 01: Standardization of Formulation

Sr.#	Reg. No.	Name of Product with existing composition, Specifications	Proposed Correction in composition	Initial Date of Reg. Renewal	Remarks
i.		**M/s. Abbott Laboratories Pakistan Ltd. Opp. Radio Pakistan Transmission Center, Hyderabad Road, Landhi, Karachi (Page No.0-0/C)**			
16.	007083	Somogel Contains: Ethanol….33% v/w Cetylpyridinium Chloride….0.02% w/w Lignocaine(Base)….0.6% w/w Eucalyptol….0.1%v/w Menthol….0.06%w/w	Somogel Contains: Cetylpyridinium Chloride……0.02% w/w Lidocaine….0.6% w/w	**25.02.1984 Renewal approval 25.02.2019 to 24.02.2024**	Fee Rs.10,000/- deposited on 18.10.2020 & 03.11.2022 Dy.No.1298-PR-I dated 28.10.2022
Remarks: The firm submitted that they are applying for standardization in light of formulation of Boots Mouth Ulcer Gel which is the Innovator product and Somogel is also the research brand of M/s Boots which was acquired by M/s Knoll Pharmaceuticals and later by M/s Abbott Laboratories. The firm further submitted that the rest of the ingredients are excipients and will be included in relevant section.					
Decision of 93rd PRVC: *The Chairman Registration Board on the recommendation of the Committee referred the request to Registration Board for consideration.*					
Decision: Registration Board approved the request of the firm for standardization of formulation as proposed vide column-IV.					

CASE NO.1 REGISTRATION OF DRUGS UNDER THE DRUGS ACT, 1876/ISSUANCE OF REGISTRATION LETTERS.

Registration Board in its 312th meeting approved registration of following veterinary product in the name of M/s. Haarolds Pharmaceuticals (Pvt) Ltd., Small Industrial Estate, Bhimber, Azad Kashmir and cancellation of the same from the name of M/s. Breeze Pharma (Pvt) Ltd, Islamabad.

S. No.	Reg. No.	Name of Drug(s)/ Composition	Already Approved Pack Size(s)
1.	052371	Almoxin 15% LA Injection Each ml contains: - Amoxicillin Trihydrate eq. to Amoxicillin base…150mg	10ml 50ml 100ml
2.	063550	Amoxilist LA Injection Each ml contains:- Amoxicillin as Trihydrate..100mg Colistin Sulphate……250,000 IU	50ml 100ml
3.	059158	Strepciben 5gm Powder for Injection Each vial contains:- Benzyl Penicillin ……..0.5MIU Procaine Penicillin……1.5MIU Streptomycin Sulphate……5gm	30ml
4.	063547	Moxin Injection Each ml contains:- Amoxicillin as Trihydrate……..150mg	20ml 50ml 100ml
5.	063551	Amcolox LA Injection Each ml contains:- Amoxicillin as Trihydrate……..200mg	50ml 100ml
6.	075662	Almoxin-C Water Soluble Powder Each gm contains:- Amoxycillin Trihydrate….200mg Colistin Sulphate……..60,00,000 IU	100gm 500gm 1 Kg 5 Kg 25 Kg

Registration Board in its 312th meeting decided as follow;

(a) Approved the cancellation of registration products from the name of M/s. Breeze Pharma (Pvt.) Ltd., Islamabad.

(b) Approved the registration of above mentioned product (Sr.No.3) of above table) in the name of M/s. Haarolds Pharmaceuticals (Pvt) Ltd., Small Industrial Estate, Bhimber, Azad Kashmir.

(c) Deferred products at Sr. No.1-2 & 4-6 for confirmation of renewal status.

Manufacture submitted generic which show solid dosage form as per brand name of approved product.

During process of issuance of registration letter, it was observed that firm have liquid injectable penicillin manufacturing facility while for product at Sr.No.3 powder injectable facility is required.

Decision: Registration Board after deliberation decided to re-consider its earlier decision and decided to declare decision taken in 312th meeting regarding Strepciben 5gm Powder for Injection as *void ab initio* and deferred for confirmation of manufacturing facility viz. powder injectable (penicillin).

Case No.1:- Registration of Imported Drugs

1. M/s AGP Limited, B-23, C S.I.T.E, Karachi has submitted the applications dated 06th August 2021 of below mentioned four products on form-5F for registration to their name from M/s Galaxay Pharma (Private) Limited Karachi

Sr.#	Reg.#	Name of Product	Manufacturer & Product License Holder	Manufacturer & Product License Holder as per CoPP
1.	066122	Ostrodose Gel in Canister with Metering Pump	M/s Besins Manufacturing Belgium S.A., Belgium. Registered (Dated 28-10-2010, renewal dated 24-08-2020)	**Manufacturer: -** M/s Delpharm Drogenbos SA Address: Groot Bijgaardenstraat 128, Drogenbos, 1620, Belgium **Product License Holder: -** M/s Besins Healthcare Benelux S.A, Address: Avenue Louise 287-1050 Brussels, Belgium.
2.	066123	Ostrogel Gel in Tube		
3.	062214	Utrogestan 100mg Capsules (Initial Registered Dated 27-04-2010, renewal dated 10-03-2020)	Manufacturer:- M/s Cyndea Pharma, S.L., Poligono Industrial Emiliano Revilla Sanz, Avenida de Agreda, 31, Olvega 42110 (Soria) Spain Product License Holder: - M/s Besins Healthcare Benelux 287, Avenue Louise 1050 Bruxelles (Belgium) Change of manufacturing site dated 18-05-2020	**Manufacturer: -** M/s Cyndea Pharma S.L. Address: Poligono Industrial Emiliano Revilla Sanz Avenida de Agreda, 31 Olvega 42110 (Soria), Spain **Product License Holder: -** M/s Besins Healthcare S.A, Address: Avenue Louise 287-1050 Brussels, Belgium
4.	059079	Utrogestan 200mg Capsule (Registered Dated 16-10-2009, renewal dated 25-03-2019)		

M/s AGP Limited submit following documents:

i. Application on form-5F along with fee Rs 150,000 for each product.
ii. M/s. AGP Limited, B-23 S.I.T.E, Karachi submit **termination letter** from M/s Besins Healthcare Benelux 287, Avenue Louise 1050 Bruxelles (Belgium) Dated 25th May 2021.
iii. M/s. AGP Limited, B-23 S.I.T.E, Karachi submitted **authorization letter** from M/s Besins Healthcare Benelux 287, Avenue Louise 1050 Bruxelles (Belgium) for above mentioned product.

2. Suit No. 2707 of 2021

M/s AGP Limited & Others Versus M/s Galaxy Pharma (Private) Limited & Others
In view of above facts and circumstances, allow the application under consideration as under:

I) That the defendant No.1, its officers, employees, agents and every person working through or under it, or on his behalf from representing or claiming themselves as partners, distributors, affiliates or representatives of plaintiff No.2 and is restrained from claiming any rights in the products, i.e.,

a) Utrogestan 100 mg soft capsule
(Micronized Progesterone 100mg)
(For Oral or Vaginal use)
b) Utrogestan 200 mg soft capsule
(Micronized Progesterone 200mg)
(For Oral or Vaginal use)
c) Oestrogel Gel (in Tube)
(Estradiol 0.6 mg/g)

d) Oestrodose Gel
(in Canister with metering pump)
(Estradiol 0.6 mg/g)

or utilizing the registration certificate of these products in any manner whatsoever.

II) As far as the importing of subject goods are concerned since it is an independent issue not arising out of the arguments, as raised, if otherwise prohibited, I am not inclined to pass any such order in this regard unless argued independently.

III) That the Drug Regulatory Authority within 15 days from the date of this order shall decide about the fate of registration of the above drugs in favour of defendant No.1 under the above facts and circumstances without asking for any NOC from defendant No.1 and submit report in this regard before this Court.

IV) In case they (Drugs Regulatory Authority) reaches to a conclusion that on account of severance of the contract, defendant No.1 is no more entitled to retain the registration of the aforesaid drugs and consequently cancel all such registrations, the application of the Besins Healthcare Distribution FZ-LLC and that of its principal be taken into consideration with immediate effect and an order be passed in this regard at the earliest with report to this Court.

Remarks:
The initial registration letter does not shows about the usage form of capsule but M/a AGP submit CoPP for both Oral and Vagianl Capsule for the product Utrogestan 100mg and 200mg Capsules.

Proceedings: -

Mr. Saif-ur-Rehman Director Marketing Business Development of M/s. Galaxy Pharma Karachi appeared before the Board and submitted interim order of Honourable High Court of Sindh at Karachi in HCA No.313 of 2022 dated 21.09.2022. He also provided a copy of termination of agreement issued by M/s. BESINS Health Care Benelux, Belgium wherein M/s. BESINS Health Care, Belgium has informed that M/s Besins Healthcare (Hong Kong) Ltd has terminated the distribution agreement with M/s Galaxy Pharma (Pvt Ltd) Karachi. M/s. BESINS Health Care Benelux, Belgium further added that they have a new distribution agreement with M/s. AGP limited B-23-C SITE, Karachi.
Registration Board raised query regarding product license holder of the products in question. Mr. Saif responded that Product License Holder of said product is M/s. BESINS Health Care Belgium. However, they made a contract with M/s Besins Healthcare (Hong Kong) Ltd. So, M/s Basin Healthcare Belgium has no right to cancel the distribution agreement made between M/s Galaxy Pharma Karachi and M/s Besins Healthcare (Hong Kong). The Board further inquired about the current status of agreement between Basin Healthcare Belgium and Besins Healthcare (Hong Kong) to which Mr Saif could not responded.

Registration Board after deliberation and keeping in view the above discussion decided to send an email to M/s Basin Healthcare Belgium, Product License Holder (as per CoPP) of the below mentioned products for following clarifications:

a) Updated status of agreement between M/s Basin Healthcare, Belgium and M/s Besins Healthcare (Hong Kong) and to provide any documentary evidence if M/s Basin Heathcare Belgium has cancelled the authorization of M/s Basin Healthcare Hongkong.
b) Present authorized agent in Pakistan by the Product license holder i.e. M/s Basin Healthcare Belgium for following products:
   a) Utrogestan 100 mg soft capsule
   (Micronized Progesterone 100mg)
   (For Oral or Vaginal use)
   b) Utrogestan 200 mg soft capsule
   (Micronized Progesterone 200mg)
   (For Oral or Vaginal use)
   c) Oestrogel Gel (in Tube)
   (Estradiol 0.6 mg/g)
   d) Oestrodose Gel

(in Canister with metering pump)
(Estradiol 0.6 mg/g)

3. As per director of the Registration Board email was sent to the official email (info@besins-healthcare.be) address of M/s Basin Healthcare, Belgium but the Undelivered Mail was Returned to Sender, again email was sent to another official email (information@besins-healthcare.com) address of M/s Besin Healthcare UK, which reply is awaited.

Further M/s Galaxy appealed in the Honorable High Court of Sindh at Karachi vide H.C.A 313/22 against Suit No. 2707 of 2021 for the transfer of registration of products from their name. The Honorable High Court of Sindh at Karachi vide order dated 11-10-2022 has directed DRAP to provide the opportunity of being heard to all concerned parties. Accordingly, letters for a personal hearing were issued to concerned parties dated 01-11-2022.

Proceedings of 322nd Registration Board meeting:

Mr. Shaheer Roshan Advocate counsel of M/s. Galaxy Pharma Karachi appeared before the Board. Registration Board advised to provide any document about status of current authorization from M/s Basin Healthcare Belgium (Product License Holder) in favor of M/s. Galaxy Pharma Karachi but representative of the firm was unable to provide any sort of agreement with Product License Holder. The Board further inquired about the current status of agreement between Basin Healthcare Belgium and Besins Healthcare (Hong Kong) to which Mr.Shaheer Roshan should inability to respond.

Mr. Mamoon Ch. Advocate counsel of M/s AGP Limited, Karachi and M/s Basin Healthcare Belgium informed the Board that M/s Basin Healthcare Belgium (Product License Holder) is product licensed holder for all four products and has revoked the power of attorney earlier granted to Galaxy Pharma (PVT) Ltd and has authorized M/s AGP Limited, Karachi to represent them in Pakistan as their sole authorized agent for all four products and submitted documents for consideration of Registration Board.

MARC R. FERNANDES Legal Counsel Besins Healthcare Holding Ltd. 32/F, Unit 3202, Tower 1, Enterprise Square 5, 38 Wang Chiu Road, Kowloon Bay, Hong Kong sent an email to DRAP on 05.11.2022 as follows:

First of all, our apologies for the delay response, as your e-mail got caught by an overzealous spam filter. At any rate, please be advised with regards to the matter under consideration in the email below, I am responding on behalf of Mr. Francois Brault, as I am the Vice-Present of Legal Affair incharge of ASPAC Region. I am also a director of Besins Healthcare Holding Ltd, the ultimate holding of the group.

Firstly, we do confirm that the Distribution Agrement with Galaxy Pharma Private Limited was validly terminated by our letter dated 21May 2021, as confirmed by the evidence deposed by AGP limited.

Secondly, pursuant on an internal reorganization, Besin Healthcare (Hong Kong) Ltd. No longer exercises any trading responsibility within the company and is scheduled to be liquidated pending resolution of some outstanding issues.

We do confirm that Besins Healthcare S.A., our Belgian subsidiary which holds the regulatory authorizations for the captioned products in your email, has indeed revoked the power of attorney granted to Galaxy Pharma (PVT) Ltd. and granted a new power of attorney to AGP Limited to represent it in Pakistan who is the sole authorized agent to represent Besins Healthcare S.A. in Belgium. The full details of our authorized agent for regulatory matters and distributor are:

AGP Limited, registered under number 0088506, B-23-C,SITE, Karachi

The submissions and letters by Galaxy Pharma PVT Ltd with regards to a possible conflict around the termination of their distribution agreement are purely frivolous and aim purely at delaying the regulatory processes. The Besin Healthcare Group reserve all rights to claim compensation and seek any legal redress available against Galaxy Pharma PVT Ltd for these acts of nuisance.

Decision M-322:

Registration Board after detailed deliberation and keeping in view the above discussion decided as follows:

- To cancel the registration of below mentioned products from M/s Galaxy Pharma (Private) Limited Karachi:
  a. Ostrodose Gel in Canister with Metering Pump, Registration No. 066122.
  b. Ostrogel Gel in Tube, Registration No. 066123

c. Utrogestan 100mg Capsules, Registration No.062214
d. Utrogestan 200mg Capsule, Registration No.059079

Advised to evaluate cases of registration of above products submitted by M/s AGP Limited and present for consideration of the Board.

M/s AGP Limited, B-23, C S.I.T.E, Karachi applications are complete as per form-5F and detail mentioned in above para 1.

Decision: Keeping in view the above position, Registration Board decided as follow;

a. Approved the registration of above product in the name of M/s AGP Limited, Karachi as per policy for imported finished drug registration (in accordance with details of composition and manufacturer as per CoPP).

b. A reference shall be sent to Costing & Pricing Division for their comments regarding MRP of the said product.

Case No.2: REGISTRATION OF PRODUCT OF M/S IQBAL & COMPANY, ISLAMABAD.

Registration Board in its 291st meeting approved the following product of M/s Iqbal & Company,1st floor, Al-Falah Manzil, Opp. National Police Foundation, St. No. 26, Sector E-11/4, Islamabad as per decision mentioned alongside.

Name of Importer/Manufacturer	Product Name & Composition	Demanded Pack size & MRP
M/s Iqbal & Company,1st floor, Al-Falah Manzil, Opp. National Police Foundation, St.No. 26, Sector E-11/4, Islamabad **Marketing Authorization Holder:** M/s Gambro Lundia AB Box ,Magistratsvagen 16, Lund, SE-22643, Sweden **Manufacturer:** M/s Bieffe Medital S.P.A Via Stelvio 94, 230 35 Sondalo (SO), I-23035, Italy	HEMOSOL B0 Solution for Haemodialysis/ Haemofiltration Each ml of 2 compartment bag contains: Medimar Electrolyte solution (Small Compartment A-250ml) lactic acid ……. 5.4mg Calcium chloride dehydrate …… 5.145mg Magnesium chloride hexahydrate…. 2.033mg Buffer Solution (Large Compartment B-4750 ml) Sodium Chloride……..6.450mg Sodium hydrogen carbonate…. 3.090mg After Reconstitution Calcium (Ca+2)….. 1.75 mmol/L Magnesium (Mg+2)……0.5 mmol/L Sodium (Na+)…… 140 mmol/L Chloride (Cl-)…….. 109.5 mmol/L Lactate…….. 3 mmol/L Hydrogen carbonate (HCO3-)…….. 32mmol Hemofiltrates BP 18 months (Polyolefin bag)	(2 x 5000ml) polyolefin bags, in a box Not proposed
Decision: Approved as per policy of inspection of manufacturer abroad.		

Registration Board in its M-293rd meeting deliberated in light of Rule 24 (10) of Drugs (L, R & A) Rules, 1976 and authorized Chairman for nomination of inspector for product storage verification of local premises. Accordingly, Chairman RB nominate to Assistant Director (I&V) & Assistant Director (Reg-II) PE&R Division DRAP, Islamabad to inspect the above local storage facility. Inspection of premises M/s Iqbal & Company,1st floor, Al-Falah Manzil, Opp. National Police Foundation, St. No. 26, Sector E-11/4, Islamabad was conducted on 24th September, 2020 with status **Not Recommended** on the following points: -

Sr.No.	Observations / Shortcomings	Remarks

1.	Checklist for personal safety.	No
2.	Is there a cleaning schedule in place	No
3.	Are all the products are properly placed or arrangments are made for systematic storage	No
4.	Are the temperature logs readily available for a minimum of two years	One week record available
5.	Check the alarm system. Is it ok	No.
6.	Is there any routine and emergency maintenance plan	No
7.	Check if there is any maintenance agreement with an ourside agency	No.
8.	Is routine maintenance being perfomed correctly at the internvals stated in theagreeement	No
9.	When emergencies occur, does the maintennacne technician arrive with the maximum stipulated in the agreement	No.
10.	Does the importer have established the Re-Call system of drugs	No

Furthermore, Ten Cotton of drug HEMOSOL B0 Solution for Haemodialysis/ Haemofiltration which is under registration was found in storage premises of M/s Iqbal & Sons Company.

Accordingly, above position was conveyed to Additional Director (QA/LT) Division vide letter No.F.1-11/2020-I&V-II/Human Import dated 23rd December, 2020 for further necessary action at their end.

Decision of 291st meeting: Registration Board advised QA/LT Division to finalize the case and inform PE&R Division for further processing of case.

Updated Status: -

Area FID-IV has submitted vide letter No.F.4-5/2021-FID(IV) dated 29-07-2022 as under: -

I have honor to refer to the letter No. F- 3-312021-l & VII (M312) there dated 25ft Nov. 2021, which is in continuation to the previous letter No.F.l-lll2}20 (I & VII) Human Import dated 23'd December,2020 on the subject cited above. The detail of the matter /case after scrutiny of the documents is as under:

The Registration Board in its 312 meeting refers the case to QA < Division. The firm has submitted documents which have been reviewed in light of decision of Registration Board which indicted the following details for consideration;

i. The firm has applied for the registration of Product namely "Hemosol BO solution for Heamodialysis/Flaemofiltration in 2016. the case was first presented before Registration Board in its 279th meeting.
ii. The case has finally decided by the Registration Board in its 291't meeting as under approved as per policy by the manufacture observed " (copy attached)
iii. Accordingly, Chairman Registration Board constituted the panel for verification of local storage facility comprising of
    a) Assistant Director (I&V)
    b) Assistant Director (Reg-II)

The panel conducted inspection on 24-09-2020 and observed series of shortcoming along with the observation that 10 carton of the same product (viz under registration) was present there but didn't refer the same in the shortcoming for clarification.(copy attached/. The case was referred to QA< Division on 23'd December 2020, (copy attached) mentioning that they have forwarded the pictures of the same to the predecessor FID ,which she explain that information was received on 30-09-2020 (after a weak of inspection) & no written complaint provided with detail so action can't initiated (copy attached). The letter was again received on 25th November 2021 (after laps of almost one year).

The undersigned scrutinized the available documents and Board meetings which indicate that product is categorized as medical Devices in Italy (where actually manufacturing takes place) and referred as medicinal product in Sweden (actual maker authorization holder) (copy attached). The documents further indicate that product actually imported in the year of 2018 &2019 for Shaukat Khanum Hospital (institutional supply (copy attached/ and since its fate at that time was not decided/declare whether it is medical devices or otherwise the firm thus avails the opportunity of

category of Medical Devices (as in Italy) and Rules 52 of MEDICAL Device Rules 2018 provide exemption to these class of products which is further amended vide SRO526(1) 12021 and exemption is extended S.R.O NOC not proceeded.(copy attached)

In the light of above in is worth mentioning here that no action from QA&LT Division at this point is required and case may please be processed at the end of Registration Division in the light of provided documents.

Decision M-320:

Decision: Registration Board decided to seek legal opinion from Legal Affair Division on the matter.

Legal Opinion:

After perusal of the correspondence of the FID and QA& LT Division with PE&R Division, it has been revealed that the product ***HEMOSOL*** (hereinafter referred to as the ***product***)which is under registration before the Registration Board is categorized as medical Devices in Italy (where actually manufacturing takes place) and referred as medicinal product in Sweden (actual maket authorization holder). Furthermore, product was imported in the year of 2018 &2019 for Shaukat Khanum Hospital (institutional supply) since its fate at that time was not decided/declare whether it is medical devices or any other therapeutic goods, therefore, the firm thus avails the opportunity of category of Medical Devices (as it is a Medical Device in Italy) and took the advantage of exemption from registration under ***Rule 52*** of Medical Device Rules 2017. Therefore, details may be obtained from the importer regarding the NOC issued either by Medical Devices Division or by the I&E Section of the Head Office or regional offices. Thus the situation shall become clear before the Registration Board whether import of the product was legal or illegal. Moreover, Registration Board is a competent forum to decide fate of the product either to register it as Drug or to refer it to MD&MC division in case if it is a medical device.

QA & LT Division:

As per record received from Field office Lahore and Islamabad, no NOC was issued for the referred product to Shaukat Khanum Hospital or any other by Division of QA &LT during the period 2018-2019.

Decision: **Keeping in view position narrated above, Registration Board decided to refer the matter to the DRAP's Grey molecule committee to review the status of product and then submit its recommendations to relevant statutory forum.**

Item No. IV Division of Biological Evaluation & Research

Sr. No.	Details of application	No. of Cases
A.	Imported Human Biologicals from Reference Countries	5
B.	Imported Human Biologicals from Non-Reference Countries	5
C.	Local Human Biologicals	6
D.	Local Veterinary Biologicals	4
E.	Imported Veterinary Biologicals from Reference Countries	4
F.	Imported Veterinary Biologicals from Non-Reference Countries	20
G.	Miscellaneous/ Deferred Cases	4
Total		48

Sr. No.	Assistant Director	Designated No.	No. of Cases
1.	Mr. M. Kashif	DD	2
2.	Mr. Hafiz Ahsan	AD-I	30
3.	Mr. Saadat Ali Khan	AD-II	9
4.	Ms. Haleema Sharif	AD-III	7

Cases of DD (Mr. Muhammad Kashif)

Cases deferred in 322 & 323 Registration Board Meeting.

1. Case: Change in Expression of Titer

M/s Hilton Pharma (Pvt.) Ltd has applies for change in Expression of Titer of their already registered biological product as per following details.

Reg. No. and date	Brand Name and Composition	Existing Expression of Titer	Demanded Expression of Titer
084989 dated 30-10-2017	Medivac ND G7 Emulsion (Inactivated vaccine) Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain…at least 50 PD_{50}	Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain…at least 50 PD_{50}	Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain ……at least10^7 EID_{50}

The case was placed in 322 & 323 Registration Board meetings and after deliberation the Board decided as under:

Decision: Registration Board deferred the case for provision of any reference product with requisite expression of titer.

The Firm has submitted list of products of reference regulatory authorities i.e Hipraviar-BPL 2 by Laboratorios Hipra, S.A, (Spain) and Volvac ND KV by Boehringer Ingelheim Vetmedica, (Germany) having the same expression of titer.

Decision: Registration Board approved the change in Expression of Titer as detailed below:

Reg. No. and date	Brand Name and Composition	Existing Expression of Titer	New approved Expression of Titer
084989 dated 30-10-2017	Medivac ND G7 Emulsion (Inactivated vaccine) Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain…at least 50 PD_{50}	Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain…at least 50 PD_{50}	Each dose (0.5ml) of vaccine contains: Inactivated Newcastle disease virus, MD15 strain ……at least10^7 EID_{50}

2. Case: Change in Expression of Titer.

M/s Hilton Pharma (Pvt.) Ltd has applies for change in Expression of Titer of their already registered biological product as per following details.

Reg. No. and date	Brand Name and Composition	Existing Expression of Titer	Demanded Expression of Titer
084988 dated 30-10-2017	Medivac ND Gumboro Emulsion vaccine (Freeze Dried Live Vaccine) Each dose (0.5ml) contains: Inactivated Newcastle Disease Virus, LaSota Strain..at least …….50 PD_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least 800 serum neutralization (SN).	Each dose (0.5ml) contains: - Inactivated Newcastle Disease Virus, LaSota Strain..at least …….50 PD_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least 800 serum neutralization (SN).	Each dose (0.5ml) contains: - Inactivated Newcastle Disease Virus, LaSota Strain..at least …….10^7 EID_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least $10^{4.5}$ EID_{50}.

The case was placed in 322 &323 Registration Board meetings and after deliberation the Board decided as under:

Decision: Registration Board deferred the case for provision of any reference product with requisite expression of titer.

The Firm has submitted list of products of reference regulatory authorities i.e Hipraviar-BPL 2 by Laboratorios Hipra, S.A, (Spain) and Volvac ND KV by Boehringer Ingelheim Vetmedica, (Germany) having the same expression of titer.

Decision: Registration Board approved the change in Expression of Titer as detailed below:

Reg. No. and date	Brand Name and Composition	Existing Expression of Titer	New approved Expression of Titer
084988 dated 30-10-2017	Medivac ND Gumboro Emulsion vaccine (Freeze Dried Live Vaccine) Each dose (0.5ml) contains:	Each dose (0.5ml) contains: - Inactivated Newcastle Disease Virus, LaSota	Each dose (0.5ml) contains: - Inactivated Newcastle Disease Virus, LaSota

	Inactivated Newcastle Disease Virus, LaSota Strain..at least …….50 PD_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least 800 serum neutralization (SN).	Strain..at least …….50 PD_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least 800 serum neutralization (SN).	Strain..at least …….10^7 EID_{50} Inactivated infectious bursal disease virus, winterfield 2512 strain…at least $10^{4.5}$ EID_{50}.

Cases of AD-I (Mr. Hafiz Ahsan)

Imported Human Biological product from Non-reference countries:

3.	Name, address of Applicant / Marketing Authorization Holder / Importer	M/s Genetics Pharmaceuticals Pvt. Ltd., 522 Sundar Industrial Estate, Raiwind Road, District Lahore.
	Name, address of Manufacturing site.	M/s Lanzhou Biotechnique Development Co., Limited. Address: 888 Yanchang Road, Lanzhou, Gansu, People's Republic of China
	Details of Drug Sale License of Importer	**License No.:** 05-352-0065-03297D **Address of go-down:** 522 Sundar Industrial Estate, Lahore Pakistan **Validity:** 12-Dec-2023
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Name of exporting country	China
	Details of Certificates Submitted (Free sale certificate, CoPP, GMP Certificate)	**CoPP:** The firm has submitted valid legalized CoPP (No. Gansu 20220041) issued on 29-09-2022. The CoPP confirms free sale status of the product in the country of origin. GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy No. 26484 ; Dated: 08-10-2020
	Details of fee submitted	PKR 100,000/, deposit slip no. 2004107, dated 09-09-2020
	The proposed proprietary name / brand name	BTXA 50 Units Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Botulinum Toxin Type A…….50 Units
	Pharmaceutical form of applied drug	IM Injection
	Pharmacotherapeutic Group of (API)	Other muscle relaxants, peripherally acting agents (ATC group: M03AX01)

	Reference to Finished product specifications	Chinese Pharmacopoeia
	Proposed Pack size	1×1's
	Proposed unit price	As per SRO
	Shelf life	36 months
	The status in reference regulatory authorities	**Reference Regulatory Authority:** EMA Botox 50U **of Allergan Pharmaceuticals**
	For generic drugs (me-too status)	**MAH in Pakistan:** Sante (Pvt) Ltd. **Brand name:** BTXA **Strength:** 50 IU **Composition:** Botulinum Toxin Type A **Dosage form:** Intramuscular
	GMP status of the Finished product manufacturer	GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	Name and address of API manufacturer.	**API:** Botulinum Toxin Type A **Name**: M/s Lanzhou Biotechnique Development Co., Limited., **Address:** 888 Yanchang Road, Lanzhou, Gansu, People's Republic of China.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance (Botulinum Toxin type A).
	Stability studies of Drug Substance	Stability study conditions: This study was conducted to investigate the stability of bulk at 2 ~ 8°C on Day 0, 15, 25, 30, 35, 40 and 50. Three batches of bulk were under studied. Tests performed include toxicity, purity and A260/A280. According to the result showed in section 3.2.S.7.3, the toxicity of bulk - active ingredient of BTXA was stable for at least 45 days at 2 ~ 8°C. The shelf life of bulk is then considered for 45 days at 2 ~ 8°C. Batches: (B-20141007, B-20141001, and B-20141002)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Analytical method validation/verification of product	Method validation studies have submitted including sterility, moisture, identity, potency, endotoxin and pH.
	Description of Pack (Container closure system)	The primary packaging material in contact with product of BTXA is 2mL glass vial and butyl rubber stopper. The packaging materials, which are not in contact with the product, are Aluminum-plastic combined cap, inner label, inner plastic box, package insert and paper box.

	Stability Storage Condition	Three consecutive batches of finished product of botulinum toxin type A 50U were selected for the tests. All finished products are kept in the final packaging material. Numbers of batches under examination are: 50U: 20101202, 20110305, 20110503 **Long term test conditions:** Temperature: 2°C－8°C Testing frequency: 3, 6, 12, 18, 24, 36 months **Accelerated test conditions:** Temperature: 25°C ± 2°C Humidity: 60%RH ± 5%RH Testing frequency: Initial, 3, 6 months **High temperature test conditions:** Temperature: 35°C ± 2°C Testing frequency: 15 days **Test conditions after reconstitution:** Temperature: 2°C － 8°C Testing frequency: Initial and 4 hours after product reconstitution with normal saline
Non-Clinical and Clinical data		
Module IV		The firm has submitted the Non-Clinical Studies of BTXA (Botulinum Toxin Type A). -Toxicity test on Animal model (monkey) experiments indicated that the LD_{50} of monkey was close to 50 LD_{50} (mouse)/Kg. -Toxicity Test: 0.2 LD_{50} (mouse) Kg was effective for making an artificial antagonistic extraocular muscle in proper order and time. An amount of toxin 10 LD_{50} (mouse) Kg, was given to monkeys, they were still healthy and did not occur any systemic symptom of botulism. So, it could be concluded that the products were good in quality, if a suitable amount were applied under control, they should be very effective preparation for treating some diseases of muscular spasm in human.
Module V		Clinical study including bio-similarity, toxicity and safety in human use, bioavailability study, results of clinical trials and literature references has been submitted. **A Double-blind, Randomized, Crossover Study of Prosigne (BTXA) Versus Botox in Patients with Blepharospasm and Hemifacial Spasm.** **BTXA which has been produced since 1988 by Lanzhou Biological Products Institute, was approved in 1996 for commercial use in China, It was registered in Brazil in 2003, and is provided through the Brazilian High-Cost Drugs Dispensing Program. Treatment of CD burdens the public health system with considerable expenses, and therefore the comparison of the efficacy and safety of the drugs available is of utmost importance.** Phase I, II and III Clinical Study of Treatment of Strabismus, Entropion, Blepharospasm and Hemi-facial Spasm with BTXA (Botulinum Toxin Type A) for Injection has been performed. **Phase I Study:** Phase I Clinical Study for Treatment of Strabismus, Entropion, Blepharospasm and Hemi-facial Spasm with BTXA (Botulinum Toxin Type A) for Injection i**. Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 10 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 100%.

	Safety result No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 1 week. ii**. Entropion:** **Efficacy result** This evaluation of efficacy was performed in 2 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye lid positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No any local or general side effect was observed. iii. **Blepharospasm and Hemi-facial Spasm:** **Efficacy result** This evaluation of efficacy was performed in 21 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No serious general side effect was observed. Mild side effects occur at eyes and faces in 4 cases but spontaneously normalized within 1 to 3 weeks. **Phase II Study:** The Study of evaluation of the efficacy and safety of BTXA (Botulinum Toxin Type A) injection therapy in patients with strabismus, entropion, blepharospasm and hemifacial spasm. i. **Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 27 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 4-8 weeks. ii. **Entropion:** **Efficacy result**: This evaluation of efficacy was performed in 30 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye lid positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 1-3 weeks. iii. **Blepharospasm and Hemi-facial Spasm:** **Efficacy result** This evaluation of efficacy was performed in 112 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No serious general side effect was observed. Mild side effects occur at eyes and faces in 4 cases but spontaneously normalized within 2 to 8 weeks. **Phase III Study:** Clinical Study of Treatment of Blepharospasm, Hemi-facial Spasm and Strabismus with BTXA (Botulinum Toxin Type A) for Injection. **i. Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 35 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 97.14**%.** **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized within 2-4 weeks. **ii. Blepharospasm and Hemi-facial Spasm:** **Efficacy result** This evaluation of efficacy was performed in **465 study subjects,** who were injected the study drug, within the guideline set in

	the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No serious general side effect was observed. Mild side effects occur at eyes and faces in 314 cases but spontaneously normalized within 2 or 3 weeks.

Remarks of Evaluator:

The firm has submitted termination of distribution agreement with Sante Distribution (Pvt) Limited as Follows:

"We, Lanzhou Biotechnique Development Co., Ltd, the manufacturer of BTXA (Botulinum Toxin Type A for Injection), hereby declare to terminate any distribution agreements signed with Sante Distribution (PVT) Limited. Sante Distribution (PVT) Limited is no longer authorized to import, sell, market and follow up registration of BTXA (Botulinum Toxin Type A for Injection) in Pakistan."

The evaluation of deficiencies is as under:

Modules	Sr. No.	Deficiencies / Short-comings	Reply to Deficiencies / Short-comings
		Justify how applied product is similar to innovator product (Botox) which is Onabotulinum approved by USFDA.	• BTXA contains Clostridium Botulinum Toxin Type A. • Clostridium Botulinum Toxin Type A is manufactured by Lanzhou Institute of Technology, China. (3rd in the world after UK & USA manufacturing Therapeutic Botulinum Toxin A i.e. Onabotulinum Toxin A. • Clostridium Toxin Type A (Onabotulinum Toxin A) manufactured by Lanzhou China has similar nomenclature as of Botox manufactured by Allergen Inc, Ireland. • Different comparison of Lanzhou's Clostridium Toxin Type A and Allergen's "Botox" with respect to Similarity, Efficacy and Safety is Available Internationally *(References Attached).*
Module I	i.	Valid Legalized CoPP or Valid legalized FSC + GMP Certificate	**CoPP:** The firm has submitted valid legalized CoPP (No. Gansu 20220041) issued on 29-09-2022. The CoPP confirms free sale status of the product in the country of origin. GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	ii.	Table of Contents (From Module 1 to Module 5) with page numbering	Table of Contents (From Module 1 to Module 5) is **Enclosed.**
	iii.	Valid Drug Sale License (DSL)	**License No.:** 05-352-0065-03297D **Address of go-down:** 522 Sundar Industrial Estate, Lahore Pakistan **Validity:** 12-Dec-2023
	iv.	Incorrect information against point "Proposed label (outer(secondary) & inner (Primary) & color scheme in accordance with Drug (Labelling & Packing Rules, 1986 along with specimens" as per Section 1.5.7 of Form 5-F.	Labelling and Packing of BTXA 50IU in accordance with Drug (Labelling & Packing Rules, 1986 along with specimens" as per Section 1.5.7 of Form 5-F.
Module II	i.	Identification of potential and actual impurities arising from the synthesis, manufacture and/or degradation as per Section 2.3.S.3.2 (a) of Form 5-F	Identification of potential and actual impurities arising from the synthesis, manufacture and/or degradation as per Section 2.3.S.3.2 (a) of Form 5-F is Submitted.

	ii.	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.S.4.2 (a) of Form 5-F	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.S.4.2 (a) of Form 5-F is Submitted.
	iii.	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.S.4.3 (a) of Form 5-F	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.S.4.3 (a) of Form 5-F is submitted
	iv.	Reference Standards or Materials as per Section 2.3.S.5 of Form 5-F	Reference Standards or Materials as per Section 2.3.S.5 of Form 5-F is Submitted.
	v.	Container Closure System as per Section 2.3.S.6 of Form 5-F	Container Closure System as per Section 2.3.S.6 of Form 5-F is Submitted.
	vi.	Stability summary and conclusions as per Section 2.3.S.7.1 of Form 5-F	Stability summary and conclusions as per Section 2.3.S.7.1 of Form 5-F is Submitted.
	vii.	Description and Composition of Drug Product as per Section 2.3.P.1 of Form 5-F	Description and Composition of Drug Product as per Section 2.3.P.1 of Form 5-F F is Submitted.
	viii.	Pharmaceutical Development as per Section 2.3.P.2 of Form 5-F	Pharmaceutical Development as per Section 2.3.P.2 of Form 5-F are Submitted.
	ix.	Process Validation and / or Evaluation as per Section 2.3.P.3.5 of Form 5-F	Process Validation and / or Evaluation as per Section 2.3.P.3.5 of Form 5-F is submitted.
	x.	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing)as per Section 2.3.P.5.2 (a) of Form 5-F	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.P.5.2 (a) of Form 5-F F is submitted.
	xi.	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.P.5.3 (a) of Form 5-F	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.P.5.3 (a) of Form 5-F are Submitted.
	xii.	Characterization of Impurities as per Section 2.3.P.5.5 of Form 5-F	Characterization of Impurities as per Section 2.3.P.5.5 of Form 5-F are Submitted.
	xiii.	Stability as per Section 2.3.P.8 of Form 5-F	Stability as per Section 2.3.P.8 of Form 5-F F are Submitted.
	xiv.	Analytical Procedure and Validation Information Summaries as per Section 2.3.R.2 of Form 5-F	Analytical Procedure and Validation Information Summaries as per Section 2.3.R.2 of Form 5-F are Submitted.
Module III	i.	Complete Process Validation and / or Evaluation as per Section 3.2.S.2.5 of Form 5-F	Complete Process Validation and / or Evaluation as per Section 3.2.S.2.5 of Form 5-F is Submitted.
	ii.	Manufacturing Process Development as per section 3.2.S.2.6 of Form 5-F	Manufacturing Process Development as per section 3.2.S.2.6 of Form 5-F is Submitted.
	iii.	Characterization of Impurities as per Section 3.2.S.3.2 of Form 5-F	Characterization of Impurities as per Section 3.2.S.3.2 of Form 5-F is Submitted.
	iv.	Process Validation and / or Evaluation as per Section 3.2.P.3.5 of Form 5-F	Process Validation and / or Evaluation as per Section 3.2.P.3.5 of Form 5-F is Submitted.
	v.	Manufacturing Process Development as per section 3.2.P.2.3 of Form 5-F	Manufacturing Process Development as per section 3.2.P.2.3 of Form 5-F is Submitted.
	vi.	Characterization of Impurities as per Section 3.2.P.5.5 of Form 5-F	Characterization of Impurities as per Section 3.2.P.5.5 of Form 5-F is Submitted.

Decision: Deferred for following clarification:

- **Approval status of applied product in reference regulatory authorities as adopted by Registration Board in its 275th meeting.**

	• **Whether applied product falls in Biological or Medical Device Division in the light of DRAP Act, 2012.** • **Indications proposed for the applied product.**	
4.	Name, address of Applicant / Marketing Authorization Holder / Importer	M/s Genetics Pharmaceuticals Pvt. Ltd., 522 Sundar Industrial Estate, Raiwind Road, District Lahore.
	Name, address of Manufacturing site.	M/s Lanzhou Biotechnique Development Co., Limited. Address: 888 Yanchang Road, Lanzhou, Gansu, People's Republic of China
	Details of Drug Sale License of Importer	**License No.:** 05-352-0065-03297D **Address of go-down:** 522, Sundar Industrial Estate, District Lahore. **Validity:** 12-Dec-2023
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Name of exporting country	China
	Details of Certificates Submitted (Free sale certificate, COPP, GMP Certificate)	**CoPP:** The firm has submitted valid legalized CoPP (No. Gansu 20220041) issued on 29-09-2022. The CoPP confirms free sale status of the product in the country of origin. GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy No. 26485 ; Dated: 08-10-2020
	Details of fee submitted	PKR 100,000/, deposit slip no. 2004109, dated 09-09-2020
	The proposed proprietary name / brand name	BTXA 100 Units Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial contains: Botulinum Toxin Type A…….….100 Units
	Pharmaceutical form of applied drug	IM Injection
	Pharmacotherapeutic Group of (API)	Other muscle relaxants, peripherally acting agents (ATC group: M03AX01)
	Reference to Finished product specifications	Chinese Pharmacopoeia
	Proposed Pack size	1×1's
	Proposed unit price	As per SRO
	Shelf life	36 months
	The status in reference regulatory authorities	**Reference Regulatory Authority:** EMA Botox 100U of M/s Allergan Pharmaceuticals Ireland
	For generic drugs (me-too status)	**MAH in Pakistan:** Barret Hodgson, Pakistan **Brand name:** Botox **Strength: 100** U **Composition:** Botulinum Toxin Type A **Dosage form:** Intramuscular

	GMP status of the Finished product manufacturer	GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	Name and address of API manufacturer.	**API:** Botulinum Toxin Type A **Name**: Lanzhou Biotechnique Development Co., Limited. **Address:** 888 Yanchang Road, Lanzhou, Gansu, People's Republic of China.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted details of nomenclature, structure, general properties, solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A & unspecified), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance (Botulinum Toxin type A).
	Stability studies of Drug Substance	Stability study conditions: This study was conducted to investigate the stability of bulk at 2 ~ 8°C on Day 0, 15, 25, 30, 35, 40 and 50. Three batches of bulk were under studied. Tests performed include toxicity, purity and A260/A280. According to the result showed in section 3.2.S.7.3, the toxicity of bulk - active ingredient of BTXA was stable for at least 45 days at 2 ~ 8°C. The shelf life of bulk is then considered for 45 days at 2 ~ 8°C. Batches: (B-20141007, B-20141001, and B-20141002)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Analytical method validation/verification of product	Method validation studies have submitted including sterility, moisture, identity, potency, endotoxin and pH.
	Description of Pack (Container closure system)	The primary packaging material in contact with product of BTXA is 2mL glass vial and butyl rubber stopper. The packaging materials, which are not in contact with the product, are Aluminum-plastic combined cap, inner label, inner plastic box, package insert and paper box.
	Stability Storage Condition	Three consecutive batches of finished product of botulinum toxin type A 50U were selected for the tests. All finished products are kept in the final packaging material. Numbers of batches under examination are: 100U: 20110102, 20110103, 20110104 **Long term test conditions:** Temperature: 2°C－8°C Testing frequency: 3, 6, 12, 18, 24, 36 months **Accelerated test conditions:** Temperature: 25°C ± 2°C Humidity: 60%RH ± 5%RH Testing frequency: Initial, 3, 6 months **High temperature test conditions:**

		Temperature: 35°C ± 2°C Testing frequency: 15 days **Test conditions after reconstitution:** Temperature: 2°C ─ 8°C Testing frequency: Initial and 4 hours after product reconstitution with normal saline
Non-Clinical and Clinical Data:		
Module IV		The firm has submitted the Non-Clinical Studies of BTXA (Botulinum Toxin Type A). -Toxicity test on Animal model (monkey) experiments indicated that the LD50 of monkey was close to 50 LD50 (mouse)/Kg. -Toxicity Test: 0.2 LD50 (mouse) Kg was effective for making an artificial antagonistic extraocular muscle in proper order and time. An amount of toxin 10 LD50 (mouse) Kg, was given to monkeys, they were still healthy and did not occur any systemic symptom of botulism. So, it could be concluded that the products were good in quality, if a suitable amount were applied under control, they should be very effective preparation for treating some diseases of muscular spasm in human.
Module V		Clinical study including biosimilarity, toxicity and safety in human use, bioavailability study, results of clinical trials and literature references has submitted in CTD Dossier. A Double-blind, Randomized, Crossover Study of Prosigne (BTXA) Versus Botox in Patients with Blepharospasm and Hemifacial Spasm. BTXA which has been produced since 1988 by Lanzhou Biological Products Institute, was approved in 1996 for commercial use in China, It was registered in Brazil in 2003, and is provided through the Brazilian High-Cost Drugs Dispensing Program. Treatment of CD burdens the public health system with considerable expenses, and therefore the comparison of the efficacy and safety of the drugs available is of utmost importance. Phase I, II and III Clinical Study of Treatment of Strabismus, Entropion, Blepharospasm and Hemi-facial Spasm with BTXA (Botulinum Toxin Type A) for Injection has performed. **Phase I Study:** Phase I Clinical Study for Treatment of Strabismus, Entropion, Blepharospasm and Hemi-facial spasm with BTXA (Botulinum Toxin Type A) for Injection i**. Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 10 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 1 week. ii**. Entropion:** **Efficacy result** This evaluation of efficacy was performed in 2 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye lid positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No any local or general side effect was observed. iii. **Blepharospasm and Hemi-facial Spasm:**

	Efficacy result This evaluation of efficacy was performed in 21 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No serious general side effect was observed. Mild side effects occur at eyes and faces in 4 cases but spontaneously normalized within 1 to 3 weeks. **Phase II Study:** The Study of evaluation of the efficacy and safety of BTXA (Botulinum Toxin Type A) injection therapy in patients with strabismus, entropion, blepharospasm and hemifacial spasm. i. **Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 27 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 4-8 weeks. ii. **Entropion:** **Efficacy result**: This evaluation of efficacy was performed in 30 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye lid positions. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized after 1-3 weeks. iii. **Blepharospasm and Hemi-facial Spasm:** **Efficacy result** This evaluation of efficacy was performed in 112 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result** No serious general side effect was observed. Mild side effects occur at eyes and faces in 4 cases but spontaneously normalized within 2 to 8 weeks. **Phase III Study:** Treatment of Blepharospasm, Hemi-facial Spasm and Strabismus with BTXA (Botulinum Toxin Type A) for Injection. **i. Strabismus:** **Efficacy result** This evaluation of efficacy was performed in 35 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit correction of eye ball positions. According to efficacy assessment criteria, the total efficacy is 97.14**%.** **Safety result** No general side effect was observed. Ophthalmic side effects were spontaneously normalized within 2-4 weeks. **ii. Blepharospasm and Hemi-facial Spasm:** **Efficacy result** This evaluation of efficacy was performed in 465 study subjects, who were injected the study drug, within the guideline set in the protocol, and were observed to elicit relief of spasm. According to efficacy assessment criteria, the total efficacy is 100%. **Safety result:** No serious general side effect was observed. Mild side effects occur at eyes and faces in 314 cases but spontaneously normalized within 2 or 3 weeks.

Remarks of Evaluator:

The firm has submitted notarized Termination of Distribution agreement with Sante Distribution (Pvt) Limited as Follows:

"We, Lanzhou Biotechnique Development Co., Ltd, the manufacturer of BTXA (Botulinum Toxin Type A for Injection), hereby declare to terminate any distribution agreements signed with Sante Distribution (PVT) Limited. Sante Distribution (PVT) Limited is no longer authorized to import, sell, market and follow up registration of BTXA (Botulinum Toxin Type A for Injection) in Pakistan."

The evaluation of deficiencies is as under:

Modules	Sr. No.	Deficiencies / Short-comings	Reply to Deficiencies / Short-comings
		Justify how applied product is similar to innovator product (Botox) which is Onabotulinum approved by USFDA.	• BTXA contains Clostridium Botulinum Toxin Type A. • Clostridium Botulinum Toxin Type A is manufactured by Lanzhou Institute of Technology, China. (3rd in the world after UK & USA manufacturing Therapeutic Botulinum Toxin A i.e. Onabotulinum Toxin A. • Clostridium Toxin Type A (Onabotulinum Toxin A) manufactured by Lanzhou China has similar nomenclature as of Botox manufactured by Allergen Inc, Ireland. • Different comparison of Lanzhou's Clostridium Toxin Type A and Allergen's "Botox" with respect to Similarity, Efficacy and Safety is Available Internationally *(References Attached).*
Module I	i.	Valid Legalized CoPP or Valid legalized FSC + GMP Certificate	**CoPP:** The firm has submitted valid legalized CoPP (No. Gansu 20220041) issued on 29-09-2022. The CoPP confirms free sale status of the product in the country of origin. GMP Certificate is Valid till: 25-07-2023 DML Validity: 10-06-2023
	ii.	Table of Contents (From Module 1 to Module 5) with page numbering	Table of Contents (From Module 1 to Module 5) is **Enclosed.**
	iii.	Valid Drug Sale License (DSL)	**License No.:** 05-352-0065-03297D **Address of go-down:** 522 Sundar Industrial Estate, Lahore Pakistan **Validity:** 12-Dec-2023
	iv.	Incorrect information against point "Proposed label (outer(secondary) & inner (Primary) & color scheme in accordance with Drug (Labelling & Packing Rules, 1986 along with specimens" as per Section 1.5.7 of Form 5-F	Labelling and Packing of BTXA 50IU in accordance with Drug (Labelling & Packing Rules, 1986 along with specimens" as per Section 1.5.7 of Form 5-F.
Module II	i.	Identification of potential and actual impurities arising from the synthesis, manufacture and/or degradation as per Section 2.3.S.3.2 (a) of Form 5-F	Identification of potential and actual impurities arising from the synthesis, manufacture and/or degradation as per Section 2.3.S.3.2 (a) of Form 5-F is Submitted.
	ii.	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.S.4.2 (a) of Form 5-F	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.S.4.2 (a) of Form 5-F is Submitted.
	iii.	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.S.4.3 (a) of Form 5-F	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.S.4.3 (a) of Form 5-F is submitted

	iv.	Reference Standards or Materials as per Section 2.3.S.5 of Form 5-F	Reference Standards or Materials as per Section 2.3.S.5 of Form 5-F is Submitted.
	v.	Container Closure System as per Section 2.3.S.6 of Form 5-F	Container Closure System as per Section 2.3.S.6 of Form 5-F F is Submitted.
	vi.	Stability summary and conclusions as per Section 2.3.S.7.1 of Form 5-F	Stability summary and conclusions as per Section 2.3.S.7.1 of Form 5-F is Submitted.
	vii.	Description and Composition of Drug Product as per Section 2.3.P.1 of Form 5-F	Description and Composition of Drug Product as per Section 2.3.P.1 of Form 5-F is Submitted.
	viii.	Pharmaceutical Development as per Section 2.3.P.2 of Form 5-F	Pharmaceutical Development as per Section 2.3.P.2 of Form 5-F are Submitted.
	ix.	Process Validation and / or Evaluation as per Section 2.3.P.3.5 of Form 5-F	Process Validation and / or Evaluation as per Section 2.3.P.3.5 of Form 5-F is submitted.
	x.	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing)as per Section 2.3.P.5.2 (a) of Form 5-F	Summary of the analytical procedures (e.g. key method parameters, conditions, system suitability testing) as per Section 2.3.P.5.2 (a) of Form 5-F is submitted.
	xi.	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.P.5.3 (a) of Form 5-F	Summary of the validation information (e.g. validation parameters and results) As per Section 2.3.P.5.3 (a) of Form 5-F are Submitted.
	xii.	Characterization of Impurities as per Section 2.3.P.5.5 of Form 5-F	Characterization of Impurities as per Section 2.3.P.5.5 of Form 5-F are Submitted.
	xiii.	Stability as per Section 2.3.P.8 of Form 5-F	Stability as per Section 2.3.P.8 of Form 5-F F are Submitted.
	xiv.	Analytical Procedure and Validation Information Summaries as per Section 2.3.R.2 of Form 5-F	Analytical Procedure and Validation Information Summaries as per Section 2.3.R.2 of Form 5-F are Submitted.
Module III	i.	Complete Process Validation and / or Evaluation as per Section 3.2.S.2.5 of Form 5-F	Complete Process Validation and / or Evaluation as per Section 3.2.S.2.5 of Form 5-F is Submitted.
	ii.	Manufacturing Process Development as per section 3.2.S.2.6 of Form 5-F	Manufacturing Process Development as per section 3.2.S.2.6 of Form 5-F is Submitted.
	iii.	Characterization of Impurities as per Section 3.2.S.3.2 of Form 5-F	Characterization of Impurities as per Section 3.2.S.3.2 of Form 5-F is Submitted.
	iv.	Process Validation and / or Evaluation as per Section 3.2.P.3.5 of Form 5-F	Process Validation and / or Evaluation as per Section 3.2.P.3.5 of Form 5-F is Submitted.
	v.	Manufacturing Process Development as per section 3.2.P.2.3 of Form 5-F	Manufacturing Process Development as per section 3.2.P.2.3 of Form 5-F is Submitted.
	vi.	Characterization of Impurities as per Section 3.2.P.5.5 of Form 5-F	Characterization of Impurities as per Section 3.2.P.5.5 of Form 5-F is Submitted.

Decision: Deferred for following clarification:

- **Approval status of applied product in reference regulatory authorities as adopted by Registration Board in its 275th meeting.**
- **Whether applied product falls in Biological or Medical Device Division in the light of DRAP Act, 2012.**

• **Indications proposed for the applied product.**		
5.	Name, address of Applicant / Importer	M/s AMGOMED, Office # 4, First Floor Ghausia Plaza, Jinnah Avenue Blue arejn a Islamabad Pakistan
	Details of Drug Sale License of importer	License No: DSL-002-ICT/2013 Address: Amgomed office # 4, First floor Ghausia Plaza, Jinnah Avenue Blue area Islamabad Address of Godown: Office number 5, First floor Rose-I plaza, I-8 Markaz Islamabad. Validity: 30-01-2024 Status: Drug License by way of Wholesale
	Name and address of marketing authorization holder (abroad)	M/s Gennova Biopharmaceuticals Limited, Block No.1, Plot No. P-1 and P-2, ITBT Park, Phase II, MIDC, Hinjawadi, Pune 411057 Maharashtra state, India.
	Name, address of manufacturer(s)	M/s Gennova Biopharmaceuticals Limited, Block No.1, Plot No. P-1 and P-2, ITBT Park, Phase II, MIDC, Hinjawadi, Pune 411057 Maharashtra state, India.
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP**: Firm has submitted original CoPP certificate (CoPP/CERT/PD/110860/2022/11/39406/ 191298) dated 02-07-2015 issued by Food & Drug Administration, M.S. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051, Maharashtra, India. The applied product is available for free sale in the market of exporting country. The facilities and operations conform to WHO-GMP. The CoPP is valid till 14-07-2022.
	Details of letter of authorization / sole agency agreement	The firm submitted notarized letter of authorization whereby M/s Gennova Biopharmaceuticals Limited, India authorized M/s Amgomed to apply for registration, for marketing, distribution and sale of below mentioned product; Hamsyl 3750 IU / 5ml Injection Each 5 ml vial contains: Pegasparagase (Pegylated L-Asparaginase) HIS 3750 IU The authorization letter is valid till 06-05-2022.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 26085 Dated: 30-07-2018
	Details of fee submitted	PKR 100,000 (Slip number : 0778294)
	Proposed proprietary name / brand name	Hamsyl 3750 IU / 5ml Injection

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5 ml vial contains: Pegaspargase (Pegylated L-Asparginase)……..3750 IU
	Pharmaceutical form of applied drug	Solution for IV / IM Administration
	Pharmacotherapeutic Group of (API)	Antineoplastic agents ATC-code: L01XX24
	Finished product specifications	In-house
	Proposed Pack size	1's vial
	Proposed unit price	As per SRO
	Shelf Life	24 months
	Storage Conditions	Store at 2 °C to 8 °C
	The status in reference regulatory authorities	Oncaspar Injection 3,750 IU / 5ml vial of M/s Sigma Tau (USFDA approved).
	For generic drugs (me-too status)	Pegaspargase (Peg-L-Asparaginase of LDS (Reg#105067)
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	DMF Holder Address: M/s Chanzhou Qianhong Bio-Pharma Co, Ltd., No.192, Huanghe West Road, Xinbei District, Changzhou, Jiangsu, China. Name and Address of the manufacturer: M/s Chanzhou Qianhong Bio-Pharma Co, Ltd., No.192, Huanghe West Road, Xinbei District, Changzhou, Jiangsu, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Gennova Biopharmaceuticals limited do not intend to store the API manufactured. It is immediately transfer for fill finish activities. Hence formal stability study for Pegaspargase Bulk is not intended as there is no change in the composition of Bulk and Finished product. Its only containerization process. Hence, we have carried out hold time study for bulk and finished product stability study is reflective for API stability as well.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted data of Pharmaceutical Equivalence: Hamsyl 3750 IU /5ml Injection and reference product Oncaspar by Sigma Tau Corporation, USA.
	Analytical method validation / verification of product	The firm has submitted relevant data including analytical method validation for the drug product including the impurities.
	Container closure system of the drug product	Pegaspargase Injection is filled in USP Type I Glass vial. One such labelled vial is placed in Plastic Tray and which is packed in Monocarton along with leaflet. Primary packaging materials conform to specifications.
	Stability study data of drug product, shelf life and storage conditions	Real time stability (Long term) studies have been conducted at 5°C ± 3°C for 24 months of 3 batches. Accelerated stability studies is conducted at 25 °C ± 2 °C / 60% ± 5% RH for 6 months of 3 batches. 431401H01 431402H02 431403H03
	Non-Clinical (Module IV)	**Single dose toxicity** Acute Intravenous toxicity study in Swiss Albino mice Acute Intravenous toxicity study in Sprague Dawley rat **Multiple Dose** Subchronic intravenous toxicity study in the Swiss Albino Mouse Subchronic intra venous toxicity study in the Sprague Dawley Rat
	Module V	• A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of intramuscular pegaspargase (Hamsyl) of M/s Gennova Biopharmaceuticals Ltd versus intramuscular Oncaspar in pediatric patients with **relapsed cases** of Acute Lymphoblastic Leukemia (ALL). **Twenty-four** (24) Pediatric patients diagnosed with Acute Lymphoblastic Leukemia (ALL) in relapsed stage enrolled in 1:1 ratio in two arms randomly. • To demonstrate the pharmacokinetic comparability of Hamsyl® (Pegaspargase) compared to Oncaspar® (Pegaspargase) given intramuscularly during induction in patients with ALL therapy. • To compare the immunogenicity and toxicity of Hamsyl® (Pegaspargase) compared to Oncaspar® (Pegaspargase).

Remarks of Evaluator:
The submitted original CoPP is not legalized however, the firm has submitted undertaking that we will submit legalized original copy of CoPP after attestation. Meanwhile, we request you to please include our product in DRB meeting.

Decision: Deferred for following:

- **Submission of Phase I, II, III clinical study data for the proposed indication since already submitted study is a pharmacokinetic comparison of applied product with reference product.**
- **Details of pharmaceutical comparison with reference product Oncaspar Injection 3750 IU / 5ml.**
- **Legalization of CoPP**

Deferred cases:
Locally manufactured Enoxaparin Injections (Form-5)

6.	**Name of Manufacturer**	**M/s Nextar Pharma (Pvt) Ltd** **Plot No. E-58. North Western, Industrial Zone, Port Qasim**

		Karachi.
	DML and last GMP details	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. **Evidence of section:** Injectable Ampoule and Pre-filled Syringe (biological) section dated 3rd June, 2021 GMP: Last GMP conducted on 20th-05-2021 valid up to 19th-05-2023
	Bulk Manufacturer	DONGYING TIANDONG PHARMACEUTICAL CO., LTD. NO.1236, NAN'ER ROAD, DONGYING CITY, SHANDONG PROVINCE, CHINA
	Brand Name + Dosage Form + Strength	**Clotenox Injection 20mg PFS**
	Composition	Each Pre-Filled Syringe contains: Enoxaparin Sodium……20mg
	Finished product specifications	BP Spec
	Pharmacological Group	Antithrombotic agent
	Shelf life	24 Months (Store below 25^0C)
	International availability	Lovenox the product is available in PFS in the said strength & volume.
	Products already registered in Pakistan	Clexane 20mg/0.2ml but the product is available in PFS
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5 Dy.No. dated 13-12-2018. Fee Submitted: Rs.20,000/- dated 06-11-2018.
	Demanded Price / Pack size	ml Pre-Filled Syringe / As per DPC 1
	General Documentation	The formulation in 0.2ml PFS is available in reference country.
7.	**Name of Manufacturer**	**M/s Nextar Pharma (Pvt) Ltd** **Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.**
	DML and last GMP details	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. **Evidence of section:** Injectable Ampoule and Pre-filled Syringe (biological) section dated 3rd June, 2021 GMP: Last GMP conducted on 20th-05-2021 valid up to 19th-05-2023
	Bulk Manufacturer	DONGYING TIANDONG PHARMACEUTICAL CO., LTD. No.1236, Nan-er Road, Dongying City, Shandong Province, China (Small-Volume Injection **(Injection workshop, pre-fill production line**)
	Brand Name + Dosage Form + Strength	**Clotenox Injection 40mg PFS**
	Composition	Each Pre-Filled Syringe contains: Enoxaparin Sodium……40mg
	Finished product specifications	BP Spec
	Pharmacological Group	Antithrombotic agent
	Shelf life	24 Months (Store below 25^0C)
	International availability	Lovenox the product is available in PFS in the said strength & volume.
	Products already registered in Pakistan	Clexane 40mg/0.4ml but the product is available in PFS
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5 Dy.No. dated 13-12-2018. Fee Submitted: Rs.20,000/- dated 06-11-2018.
	Demanded Price / Pack size	ml Pre-Filled Syringe / As per DPC 1
	General Documentation	The formulation in 0.4ml PFS is available in reference country.
8.	**Name of Manufacturer**	**M/s Nextar Pharma (Pvt) Ltd** **Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.**
	DML and last GMP details	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim

		Karachi. **Evidence of section:** Injectable Ampoule and Pre-filled Syringe (biological) section dated 3rd June, 2021 GMP: Last GMP conducted on 20th-05-2021 valid up to 19th-05-2023
	Bulk Manufacturer	DONGYING TIANDONG PHARMACEUTICAL CO., LTD. No.1236, Nan-er Road, Dongying City, Shandong Province, China (Small-Volume Injection **(Injection workshop, pre-fill production line**)
	Brand Name + Dosage Form + Strength	**Clotenox Injection 60mg PFS**
	Composition	Each Pre-Filled Syringe contains: Enoxaparin Sodium……60mg
	Finished product specifications	BP Spec
	Pharmacological Group	Antithrombotic agent
	Shelf life	24 Months (Store below 25^0C)
	International availability	Lovenox the product is available in PFS in the said strength & volume.
	Products already registered in Pakistan	Clexane 60mg/0.6ml but the product is available in PFS
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5 Dy.No. dated 13-12-2018. Fee Submitted: Rs.20,000/- dated 06-11-2018.
	Demanded Price / Pack size	ml Pre-Filled Syringe / As per DPC 1
	General Documentation	The formulation in 0.6ml PFS is available in reference country.
9.	**Name of Manufacturer**	**M/s Nextar Pharma (Pvt) Ltd** **Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.**
	DML and last GMP details	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. **Evidence of section:** Injectable Ampoule and Pre-filled Syringe (biological) section dated 3rd June, 2021 GMP: Last GMP conducted on 20th-05-2021 valid up to 19th-05-2023
	Bulk Manufacturer	DONGYING TIANDONG PHARMACEUTICAL CO., LTD. No.1236, Nan-er Road, Dongying City, Shandong Province, China (Small-Volume Injection **(Injection workshop, pre-fill production line**)
	Brand Name + Dosage Form + Strength	**Clotenox Injection 80mg PFS**
	Composition	Each Pre-Filled Syringe contains: Enoxaparin Sodium……80mg
	Finished product specifications	BP Spec
	Pharmacological Group	Antithrombotic agent
	Shelf life	24 Months (Store below 25^0C)
	International availability	Lovenox the product is available in PFS in the said strength & volume.
	Products already registered in Pakistan	Clexane 80mg/0.8ml but the product is available in PFS
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5 Dy.No. dated 13-12-2018. Fee Submitted: Rs.20,000/- dated 06-11-2018.
	Demanded Price / Pack size	ml Pre-Filled Syringe / As per DPC 1
	General Documentation	The formulation in 0.8ml PFS is available in reference country.
10.	**Name of Manufacturer**	**M/s Nextar Pharma (Pvt) Ltd** **Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.**
	DML and last GMP details	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. **Evidence of section:** Injectable Ampoule and Pre-filled Syringe (biological) section dated 3rd June, 2021

		GMP: Last GMP conducted on 20th-05-2021 valid up to 19th-05-2023
	Bulk Manufacturer	DONGYING TIANDONG PHARMACEUTICAL CO., LTD. No.1236, Nan-er Road, Dongying City, Shandong Province, China (Small-Volume Injection **(Injection workshop, pre-fill production line**)
	Brand Name + Dosage Form + Strength	**Clotenox Injection 100mg PFS**
	Composition	Each Pre-Filled Syringe contains: Enoxaparin Sodium……100mg
	Finished product specifications	BP Spec
	Pharmacological Group	Antithrombotic agent
	Shelf life	24 Months (Store below 25^0C)
	International availability	Lovenox the product is available in PFS in the said strength & volume.
	Products already registered in Pakistan	Clexane 100mg/1ml but the product is available in PFS
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5 Dy.No. dated 13-12-2018. Fee Submitted: Rs.20,000/- dated 06-11-2018.
	Demanded Price / Pack size	ml Pre-Filled Syringe / As per DPC 1
	General Documentation	The formulation in 1 ml PFS is available in reference country.

Data as per guidelines of 289th meeting of Registration Board;

i) For Bulk Concentrate Import, Local formulation Filling:

i.	The firms shall provide legalized GMP certificate of biological drug substance manufacturer abroad (who will provide concentrate / ready to fill bulk of biological drug to Pakistani manufacturers for further processing) as an evidence that the manufacturer is an authorized manufacturer of biological drug in the country of origin.	Legalized GMP Certificate No.SD 20180757 dated 30-08-2018 issued by Shandong Food and Drug Administration, China valid till 29-08-2023. Manufacturer and its address: Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying City, Shandong Province, China.
ii.	The firms shall provide legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk after submission of data to the concerned regulatory authority.	Legalized FSC (Certificate No.: 2018-001) dated 01-08-2018 issued by Shandong Food and Drug Administration of People's Republic of China.
iii.	The firm shall provide the complete data as adopted for imported Enoxaparin injections in 281st meeting of Registration Board of the finished product of same source (bulk concentrate or ready to fill) manufactured either from country of origin or by any reference regulatory authority as adopted by Registration Board to demonstrate the similar efficacy and safety to innovator product covering following requirements:	
	a) The first criterion for demonstrating sameness of enoxaparin is equivalence of physicochemical properties, such as molecular weight distribution using size exclusion chromatography, chain mapping by cetyltrimethylammonium-coated strong anion exchange chromatography, matrix-assisted laser desorption ionization mass spectrometry (MALDIMS), gel permeation chromatograph—electro spray ionization mass spectroscopy (GPC-ESI-MS), or reverse phase ion pair—electro spray ionization mass spectroscopy (RPIPESI-MS).	The firm has submitted physicochemical Characterization performed by the bulk manufacturer. The comparison has not been performed with innovator. 1.Molecular mass and molecular mass distribution. 2.HPLC-MS 3.NMR • 1H NMR: • 13C NMR: 4.UV: 5.Sodium content 6. Molar ratio of sulfate ions to carboxylate ions
	b) The second criterion for demonstrating the sameness of enoxaparin is equivalence of heparin source material (i.e., heparin that is derived from porcine intestinal mucosa and that meets USP monograph standards for heparin sodium USP) and mode of depolymerization (ie, cleavage by alkaline b-elimination of the benzyl ester	**Equivalence of heparin source material:** R: The starting material of generic Enoxaparin (manufactured by Tiandong) is porcine crude heparin, and no ruminant gene is detected as per qPCR.

	derivative of heparin). The equivalent heparin source material should have at least a similar distribution of natural disaccharide building block sequences (within the context of its variability). If an equivalent mode of depolymerization is used, the generic drug products should be at least similar.	
	c) The third criterion for demonstrating the sameness of enoxaparin is equivalence in disaccharide building blocks, fragment mapping, and sequence of oligosaccharide species. This can be achieved by exhaustive digestion of enoxaparin with purified heparin digesting enzymes (heparinases I, II, and III) and nitrous acid, among other means, to yield the constituent disaccharide building blocks comprising enoxaparin. These individual disaccharide building blocks can be quantified by capillary electrophoresis (CE), reverse phase high-performance liquid chromatography (RP-HPLC), strong anion exchange HPLC (SAX-HPLC), mass spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. Chemical approaches such as analysis with modifying reagents (e.g. sodium borohydride, nitrous acid) or modifying enzymes (eg, 2-0-sulfatase, 6-0-sulfatase, and 5-glucuronidase) can be included.	**Not submitted**
	d) The fourth criterion for establishing sameness of enoxaparin is equivalence of in vitro biological and biochemical assay results using activated partial thromboplastin time (aPTT) and Heptest prolongation time. The equivalence in anti-Xa activity, anti-IIa activity, and anti-Xa/anti-IIa ratio between the generic LMWHs should be provided.	**Not submitted**
	e) The fifth criterion for establishing sameness of enoxaparin is equivalence of ex vivo pharmacodynamic (PD) profile in human volunteers. The comparison of in vivo PD profiles is based on measurements of in vivo anti-Xa and Anti-IIa profiles.	**Not submitted**
iv.	The firm shall provide the lot release certificate of the finished product manufactured by same bulk concentrate/ ready to fill from country of export (If applicable).	Not Applicable
v.	The firm shall provide the 6 months accelerated and real time stability studies for drug substance.	The stability studies performed by API manufacturer for drug substance for 24months real time stability study data at 25°C±2°C, 60%RH±5% RH & 6 months accelerated stability study at 40°C±2°C, 75%RH ±5% RH and the results found satisfactory against the specified specification limits.
vi.	The local manufacturer shall perform all the tests on Enoxaparin Sodium bulk as detailed in Pharmacopoeial monograph of Enoxaparin Sodium.	Testing of Enoxaparin sodium was performed as per pharmacopeial method and results complies with specifications and the data has been submitted. i.e. • Identification by: - Size-Exclusion Chromatography (RP-HPLC) - Ratio of anti-factor Xa activity to anti-factor IIa activity - Sodium salt Assay: - Anti-factor Xa Activity - Anti-factor IIa Activity • Clarity and colour of solution • Acidity or alkalinity • Light absorption • Related Substances by HPLC

		• Sodium • Bacterial Endotoxins
vii.	The local manufacturer shall manufacture three trial batches of the finished biological product to finalize the formulation and then perform the six months stability data on all the batches along with all the tests as detailed in Pharmacopoeial monograph of Enoxaparin Sodium Injection.	The firm has submitted three trial batches for each strength i.e. 20mg, 40mg, 60mg, 80mg, 100mg conducted at 30°C ± 2°C/65% ± 5%RH for the finished biological product. The stability studies have performed till shelf life stability (24 months) as per pharmacopoeial monograph of enoxaparin sodium injection and results found within the specified limits.
viii.	The local manufacturer shall perform suitable tests to evaluate the product and process related impurities both in their product and in Innovator product e.g. Total proteins, Individual proteins, Lipids and DNA content etc. The following techniques may be used: a. SDS-PAGE for individual proteins b. GC-MS for lipid impurities c. Threshold ® Total DNA Assay System for DNA content.	Related substances by HPLC: Purity of LMWHs have been demonstrated by using Anion Exchange chromatography based test in comparison with innovator product i.e. Clexane Injections.
ix.	The firm shall provide the agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.	Not Submitted
x.	Regular monitoring through pharmacovigilance reporting system shall be observed through proper pharmacovigilance cell of the manufacturer and report will be forwarded to the National Pharmacovigilance Centre, Division of Pharmacy Services and Biological Division of DRAP. In case of any severe adverse event, immediate mandatory reporting procedure shall be followed.	The firm has submitted undertakings as detailed in 289th meeting of Registration Board by the local manufacturer.
xi.	The firm shall inform DRAP if there shall be any adverse event or ADR reporting from the country of manufacture of concentrate/ready to fill bulk and finished product as required vide Rules 30 of Drug (LR&A) Rule.	Firm has submitted undertaking if there shall be any adverse event or ADR reporting from the country of manufacture of concentrate/ready to fill bulk and finished product as required vide Rules 30 of Drug (LR&A) Rule.
xii.	If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.	Firm has submitted undertaking If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.
xiii.	All the provisions as contained in the Drugs Act, 1976 and rules made there under including provisions of Lot Release certification from National Control Laboratory for Biologicals shall be strictly adhered to.	Firm have submitted undertakings All the provisions as contained in the Drugs Act, 1976 and rules made there under including provisions of Lot Release certification from National Control Laboratory for Biologicals shall be strictly adhered to.

Remarks of Evaluator:

Sr. No.	Decision of 321st meeting of RB	Response by the firm
1.	The first criterion for demonstrating sameness of enoxaparin is equivalence of physicochemical properties, such as molecular weight distribution using size exclusion chromatography, chain mapping by cetyltrimethyl ammonium-coated strong anion exchange chromatography, matrix-assisted laser desorption ionization mass spectrometry (MALDIMS), gel permeation chromatograph—electro spray ionization mass spectroscopy (GPC-ESI-MS), or reverse phase ion pair—electro spray ionization mass spectroscopy (RPIPESI-MS).	**Physicochemical Characterization performed with innovator product by the bulk manufacturer:** 1. **Molecular mass and molecular mass distribution**. Size exclusion chromatography is used to detect molecular mass, characterizing the distribution and proportion of enoxaparin sodium oligosaccharide chain length and data is comparable between Lovenox (Branded) and generic Enoxaparin Sodium (Manufactured by Tiandong). 2. **HPLC-MS**

		MS spectra of generic Enoxaparin and branded Lovenox are submitted. The retention time and mass to charge ratio are comparable to oligosaccharide peak and oligosaccharide sequence. 3. **NMR** • ^{1}H NMR: Spectra obtained are similar to that obtained with Enoxaparin Sodium reference standard • ^{13}C NMR: Spectra obtained are similar to that obtained with Enoxaparin Sodium reference standard 4.**UV:** The maximum UV absorption wavelength of both generic Enoxaparin and brand Lovenox is 232 nm, and specific absorption coefficient falls within specified range. 5. **Sodium content** The sodium content of generic Enoxaparin (Manufactured by Tiandong) and branded Lovenox are within 11.3% to 13.5%. 6. **Molar ratio of sulfate ions to carboxylate ions** The molar ratio of sulfate ions to carboxylate ions of generic Enoxaparin and branded Lovenox are no less than 1.8.
2.	The second criterion for demonstrating the sameness of enoxaparin is equivalence of heparin source material (ie, heparin that is derived from porcine intestinal mucosa and that meets USP monograph standards for heparin sodium USP) and mode of depolymerization (ie, cleavage by alkaline b-elimination of the benzyl ester derivative of heparin). The equivalent heparin source material should have at least a similar distribution of natural disaccharide building block sequences (within the context of its variability). If an equivalent mode of depolymerization is used, the generic drug products should be at least similar.	Enoxaparin sodium is the sodium salt of a low-molecular-mass heparin that is obtained by alkaline depolymerization of the benzyl ester derivative of heparin from porcine intestinal mucosa. Enoxaparin consists of a complex set of oligosaccharides that have not yet been completely characterised. Based on current knowledge, the majority of the components have a 4-enopyranose uronate structure at the non-reducing end of their chain. 15 per cent to 25 per cent of the components have a 1,6-anhydro structure at the reducing end of the chain. The mass-average relative molecular mass ranges between 3,800 and 5,000, with a characteristic value of about 4,500. The degree of sulfation is about 2 per disaccharide unit. The potency is not less than 90 IU and not more than 125 IU of anti-Factor Xa per milligram, calculated with reference to the dried substance. The anti-factor IIa activity is not less than 20.0 IU and not more than 35.0 IU per milligram, calculated with reference to the dried substance. First, crude heparin (i.e., the starting material) through enzymolysis, centrifugation and then, following a series of purification processes, is purified to obtain heparin sodium (i.e., Intermediate I). After that, through salification, the Intermediate I is converted to benzethonium heparinate (i.e., Intermediate II). After that, through esterification, the Intermediate II is converted to heparin benzyl ester (i.e., Intermediate III), then, Enoxaparin sodium is formed by alkaline degradation. Following a series of purification process (filtering, precipitating, decoloring, filtering, lyophilizing, milling and blending, packaging, and examining), the final product (Enoxaparin sodium API) is obtained.

		The starting material of generic Enoxaparin (manufactured by Tiandong) is porcine crude heparin, and no ruminant gene is detected as per qPCR.
3.	The third criterion for demonstrating the sameness of enoxaparin is equivalence in disaccharide building blocks, fragment mapping, and sequence of oligosaccharide species. This can be achieved by exhaustive digestion of enoxaparin with purified heparin digesting enzymes (heparinases I, II, and III) and nitrous acid, among other means, to yield the constituent disaccharide building blocks comprising enoxaparin. These individual disaccharide building blocks can be quantified by capillary electrophoresis (CE), reverse phase high-performance liquid chromatography (RP-HPLC), strong anion exchange HPLC (SAX-HPLC), mass spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. Chemical approaches such as analysis with modifying reagents (e.g. sodium borohydride, nitrous acid) or modifying enzymes (eg, 2-0-sulfatase, 6-0-sulfatase, and 5-glucuronidase) can be included.	- Size exclusion chromatography is used to detect the molecular mass, characterizing the distribution and proportion of Enoxaparin sodium oligosaccharide chain length. - Oligosaccharide sequence determined by HPLC-MS. - Sulfated disaccharide structure by ^{1}H NMR, ^{13}C NMR. - Specific absorption coefficients by UV. - Molar ratio of sulfate ions to carboxylate ions by titration. - Sodium content by Atomic Absorption. Via above provided tests, equivalence in disaccharide building blocks, fragment mapping, and sequence of oligosaccharide species have been submitted.
4.	The fourth criterion for establishing sameness of enoxaparin is equivalence of in vitro biological and biochemical assay results using activated partial thromboplastin time (aPTT) and Heptest prolongation time. The equivalence in anti-Xa activity, anti-IIa activity, and anti-Xa/anti-IIa ratio between the generic LMWHs should be provided.	**APTT test:** The APTT value is related to the Enoxaparin sodium concentration, the higher the concentration, the longer the APTT value. There is no significantly difference of the APTT value between generic Enoxaparin (manufactured by Tiandong) and brand LOVENOX. **Anti-Xa activity and Anti-IIa activity test**: The Anti-Xa activities and Anti-IIa activity of generic Enoxaparin (manufactured by Tiandong) and brand LOVENOX are within the specification range of 90 IU/mg~125 IU/ mg (dry basis) and 20 IU/mg~35 IU/mg (dry basis) respectively; Anti-Xa/ Anti-IIa value of Generic Enoxaparin (manufactured by Tiandong) and brand LOVENOX are also within the specification range of 3.3~5.3.
5.	The fifth criterion for establishing sameness of enoxaparin is equivalence of *ex-vivo* pharmacodynamic (PD) profile in human volunteers. The comparison of in vivo PD profiles is based on measurements of *in vivo* anti-Xa and Anti-IIa profiles	The firm has Submitted bioequivalence study reports Open, Randomized, Single Dose, two period crossover bioequivalence trial under fasting conditions on healthy subjects. 24 subjects enrolled in the group according to the screening number of the subjects in ascending order. The statistician provides a random allocation table and randomly allocates the subjects to one of the two dosing sequence A (T-R) group or the B (R-T) group in a 1:1 ratio, with the same number of subjects in each dosing sequence. Test preparation: Enoxaparin sodium Injection 0.6 mL: 6000 AxaIU; Reference preparation: Enoxaparin sodium Injection 0.6 mL: 6000 AxaIU. The test preparation Enoxaparin sodium injection (0.6 mL: 6000 AxaIU) developed and produced by Dongying Tiandong Pharmaceutical Co., Ltd. and the brand reference preparation Clexane® (Enoxaparin sodium injection, 0.6 mL: 6000 AxaIU) were found bioequivalent in Chinese healthy subjects under fasting subcutaneous injection.

6.	The local manufacturer shall perform suitable tests to evaluate the product and process related impurities both in their product and in Innovator product e.g. Total proteins, Individual proteins, Lipids and DNA content etc. The following techniques may be used: a. SDS-PAGE for individual proteins b. GC-MS for lipid impurities c. Threshold ® Total DNA Assay System for DNA content.	The firm has submitted that comparative impurity testing for enoxaparin has been performed as per British Pharmacopoeia. Tests of related substances by HPLC has been submitted in comparison with innovator product i.e. Clexane Injections.
7.	Agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.	The firm has submitted process change declaration from source (Dongying Tiandong Pharmaceutical Co. Ltd) stating that we would inform for the critical process changes related to the product and implement only after approval.
8.	Commitment that "If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.	Submitted.
9.	Commitment that "All the provisions as contained in the Drugs Act, 1976 and rules made thereunder including provisions of Lot Release certification from National Control Laboratory for Biologicals shall be strictly adhered to".	Submitted.

Remarks of Evaluator:
The firm has provided Pre-filled syringe Biological Section. Already registered products are as under:
1. Nexfil 300 (Filgrastim)
2. Pegaron Inj. (Pagylated Interferon alpha 2a)
3. NP-POETIN (Erythropoietin)

Previous Decision: Registration Board deferred the case for submission of section wise details of products of M/s Nextar Pharma (Pvt) Ltd., Karachi in the biological facility **(M-323)**.
Evaluation by BE&R: The firm submitted details of registered products section wise in Biological Premises of M/s Nextar Pharma Pvt. Ltd as stated below:

Sr#	Name of Section	Sr#	Name of Section
1.	Pre-Filled Syringes (Biological)	2.	Injectable Ampoule Section (Biological)

PFS Biological Section:

S/#	Reg. No.	Product Name (Local)	Composition	Pack Size	Date of Registration	Shelf Life
1	095293	NP-Poetin 10000 Pre-filled Syringe (Epoein alpha)	Each Prefilled syringe contains: - Erythropoietin……..…10000I (BP Specifications)	1's PFS	28-02-2019	2 Years (2-8°C)
2	077536	NP-Poetin 2000 Inj	Each Prefilled syringe contains: - Erythropoietin……2000IU (BP Specifications)	1's PFS	30-08-2019	2 Years (2-8°C)
3	077537	NP-Poetin 4000 Inj	Each Prefilled syringe contains: - Erythropoietin……4000IU (BP Specifications)	1's PFS	30-08-2019	2 Years (2-8°C)
4	077534	Nexfil Injection 300 mcg	Solution for injection in prefilled syringe (0.5mL) contains: Filgrastim……..…300mcg (Ph.Eur.Specifications)	1's PFS	30-08-2019	24 months (2-8°C)
5	077535	Pegaron Inj	Each Prefilled Syringe Contains; Pegylated Interferon alpha 2a…….. 180mcg/ml	1's PFS	08-12-2014	24 months (2-8°C)

Injectable Ampoule section:
N/A

Furthermore, we would also like to communicate, As per Annex-2 of WHO good manufacturing practices for biological products Replacement of Annex 1 of WHO Technical Report Series, No. 822 Section 9.3 i.e. *''Killed vaccines, antisera and other biological products – including those made by rDNA techniques, toxoids and bacterial extracts – may, following inactivation, be manufactured on the same premises provided that adequate decontamination and cleaning measures are implemented on the basis of QRM''.* (Reference Attached Page 20 of WHO good manufacturing practices for biological products Replacement of Annex 1 of WHO Technical Report Series, No. 822 Section 9.3).
Decision: Keeping in view the data submitted by the firm in light of guidelines of 289th meeting, Registration Board approved the registrations of Clotenox Injection 20mg PFS, 40mg PFS, 60mg PFS & 80mg PFS (Enoxaparin 20mg PFS, 40mg PFS, 60mg PFS, 80mg PFS and 100mg PFS).

Imported Veterinary Biologicals from Non-Reference Countries:

11.	**Name and address of Importer**	**M/s Al-Asar Enterprises,** Gulshan-e- Ghulab Colony Behind, Abdullah Heart Care Pul wasll Suraj Miani Road, Multan.
	Detail of DSL	License to sell drugs as distributor License No: 04-361-0159-96972D valid upto: 05-08-2027.
	Name and address of Manufacturer	M/s BIOCAMP LABORATORIES LTDA, Rua Rui IIdefonso Martins Lisboa, nº 601 Campo dos Amarais Campanies, Sao Paulo, Brazil, Zip Code: 13082-020.
	Name of exporting country	Brazil
	Brand Name +Dosage Form + Strength	**CAMPVAC MG-F** Lyophilized, live vaccine
	Diary No. Date of R& I & fee	Dy. No. 20526 R&I Dated 28-07-2021 Rs. 150,000/- (Slip No. 50757616929)
	Composition	Each ml of vaccine contains: Mycoplasma gallisepticum with a minimum title of $10^{5.0}$ CCU…….0.5ml Stabilizer……..0.5 ml Each ml of diluent contains: Sodium chloride……..…8.5mg Monobasic potassium phosphate……0.16mg Tribasic sodium phosphate dodecahydrate……1.36mg Blue aniline dye……....8 µL Deionized water qs……...……1 mL
	Pharmacological Group	Immunological
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specifications
	Shelf Life	24 months (2°C - 8°C)
	Pack size & Price	1000 doses: Decontrolled
	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	N/A
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at 2°C to 8°C for three commercial batches as below: 001/20 002/20 003/20
	Document Details	**<u>Free Sale Certificate (Original Legalized):</u>** Legalized free sale certificate indicates that the product CampVac MG-F is legally registered with the Ministry of Agriculture,

		Livestock and Supply (MAPA) of Brazil valid until 27-05-2024 for marketing and Export purposes. The certificate was issued by Ministry of Agriculture, livestock and Food Supply, Federative Republic of Brazil. **Legalized GMP Certificate:** Legalized GMP certificate issued by Ministry of Agriculture, Livestock and Supply (MAPA) of Brazil dated 02-September, 2020. **Sole Agency Agreement:** Legalized sole agency agreement indicates Al-ASAR enterprises to be his sole agent in Pakistan to register, import and commercialize the products.

Remarks of Evaluator:

Sr. No.	Observations	Response by the firm
1.	Valid copy of DSL	License to sell drugs as distributor License No: 04-361-0159-96972D valid upto: 05-08-2027.
2.	Finished product specifications in the light of 267th Registration Board meeting.	The firm has submitted certificate of analysis.
3.	Original or notarized copy of Sole agency agreement.	The firm has submitted original sole agency agreement.
4.	Provide original legalized FSC issued by concerned regulatory authority.	Original legalized free sale certificate issued by Federative republic of Brazil, Ministry of Agriculture, Livestock and Supply (MAPA) of Brazil. The certificate is valid until 27-05-2024.
5.	Provide original legalized GMP certificate, issued by concerned regulatory authority.	Legalized GMP certificate issued by Ministry of Agriculture, Livestock and Supply (MAPA) of Brazil dated 02-September, 2020.
6.	Evidence of locally registered product for applied products.	Not submitted
7.	Submit stability data of three batches in line with ICH guidelines on all stability indicating parameters as recommended by guidelines.	The firm has submitted stability study data of 24 months conducted at 2°C to 8°C for three commercial batches as below: 001/20 002/20 003/20
8.	Large Scale Clinical Data/Field Trial Data.	Submitted
9.	Mention name of exporting country on Form 5A.	Brazil
10.	Clarification is required regarding applied formulation would it be imported in combo pack & clarification for not performing the terminal sterilization of diluent.	• 500 doses is accompanied by 15ml of sterile diluent • 1000 doses is accompanied by 1 vial of 30ml of sterile diluent • 2000 doses is accompanied by 2 vials of 30ml of sterile diluent The sterilization of diluent solution is performed in the filter cartridge with membrane of 0.20 µm (microns) before the potting as described in production method and manufacturing process flow chart.
11.	Mention unit of virus dose as it is CCU in packaging & labelling and CFU on Form 5A.	Not specified.
12.	Mention desired pack size of applied formulation.	Not specified .

- Clarification of composition on free sale certificate in terms of dose / ml of vaccine is required.
- Evidence of locally registered product for applied product could not be verified.
- Clarification of virus dose as it is CCU in packaging & labelling and CFU on Form 5A.
- Desired pack size for applied formulation is required since multiple pack sizes are mentioned on FSC.

Decision: Deferred for following:

	• **Clarification of composition on free sale certificate in terms of dose / ml of vaccine** • **Evidence of locally registered product for applied product.** • **Clarification of virus dose as it is CCU in packaging & labelling and CFU on Form 5A.** • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.**	
12.	Name of Importer	"M/s Hilton Pharma (Pvt.) Ltd., Plot No. 13-14, Sector-15, Korangi, Industrial Area, Karachi."
	DSL details	License to sell, stock & exhibit for sale, distribute and sell drugs by way of whole sale by of manufacturer, importer or indenter. No.DHOKK(Drugs)/-114/22 License No. 559, valid till 19-06-2024
	Marketing authorization holder	"M/s PT MEDION FARMA JAYA, JI Babakan Ciparay No 282, Babakan Ciparay, Bandung-Indonesia Plant: JI. Raya Batujajar No 29, Cimareme, Ngamprah, Bandung Barat-Indonesia."
	Name of Manufacturer	"M/s PT MEDION FARMA JAYA, JI Babakan Ciparay No 282, Babakan Ciparay, Bandung-Indonesia Plant: JI. Raya Batujajar No 29, Cimareme, Ngamprah, Bandung Barat-Indonesia."
	Name of exporting country	Indonesia
	Brand Name +Dosage Form + Strength	**Medivac ND G7-IB Emulsion**
	Diary No. Date of R& I & fee	Dy. No. 15311 (R&I); Dated 02-06-2021 Rs. 75,000/- (Slip No.5649136242 Dated: 26-05-2021) Pink Slip Adjustment: Rs75,000/- (Slip No 82146585491) Dated 03-08-2022.
	Composition	Each dose of vaccine contains: Inactivated Newcastle Disease Virus MD15 strain, at least $10^{7.0}$ EID_{50} Inactivated Infectious Bronchitis virus, Massachussetts 41 strain, at least $10^{4.5}$ EID_{50}
	Pharmacological Group	Veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Innovator's specification
	Shelf Life	18 months (2°C-8°C) After first opening, vaccine must be used immediately and consumed completely within 24 hours.
	Pack size and demanded price	500ml (1000 doses); De-controlled
	International availability	Not Available
	Products already registered in Pakistan	Not Available
	Stability data of finished product	The firm has submitted stability study data of 21 months conducted at 2°C to 8°C for three consecutive batches as below: 11L05 11L06 11L07
	Document Details	• Valid Legalized GMP Certificate No. 193-GMP-2021, dated 08-09-2021 for M/s PT Medion Farma Jaya., Directorate general of livestock and animal health services Ministry of Agriculture republic of Indonesia valid till 08-09-2026. • Legalized FSC issued on Aug-2018 issued by Ministry of agriculture directorate general of livestock and animal health services, Indonesia.

	Remarks of Evaluator: Evidence of locally registered product for applied strains (MD15 of ND) could not be verified.	
	Decision: Registration Board referred the case to Animal Husbandry Commissioner for comments regarding immunological relevance and need of applied strain in Pakistan.	
13.	**Name of Importer**	"M/s Hilton Pharma (Pvt.) Ltd. Plot No. 13-14, Sector-15, Korangi, Industrial Area, Karachi."
	DSL details	License to sell, stock & exhibit for sale, distribute and sell drugs by way of whole sale by of manufacturer, importer or indenter. No.DHOKK(Drugs)/-114/22 License No. 559, valid till 19-06-2024
	Marketing authorization holder	"M/s PT MEDION FARMA JAYA, JI Babakan Ciparay No 282, Babakan Ciparay, Bandung-Indonesia Plant: JI. Raya Batujajar No 29, Cimareme, Ngamprah, Bandung Barat-Indonesia."
	Name of Manufacturer	"M/s PT MEDION FARMA JAYA, JI Babakan Ciparay No 282, Babakan Ciparay, Bandung-Indonesia Plant: JI. Raya Batujajar No 29, Cimareme, Ngamprah, Bandung Barat-Indonesia."
	Name of exporting country	Indonesia
	Brand Name +Dosage Form + Strength	**Medivac ND G7-IB Variant Emulsion**
	Diary No. Date of R& I & fee	Dy. No. 4218 (R&I); Dated 08-02-2021 Rs. 50,000/- (Slip No. 2059380 Dated: 02-02-2021)
	Composition	Each dose contains: Inactivated Newcastle Disease Virus MD15 Strain, at Least $10^{7.0}$ EID_{50} Inactivated Infectious Bronchitis Virus Massachusetts 41 strain, at least $10^{4.5}$ EID_{50} Inactivated Infectious Bronchitis Virus M01 strain, at least $10^{4.5}$ EID_{50} Inactivated Infectious Bronchitis Virus M02 strain, at least $10^{4.5}$ EID_{50}
	Pharmacological Group	Veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Innovator's specification
	Shelf Life	18 months (2°C - 8°C) After first opening, vaccine must be used immediately and consumed completely within 24 hours.
	Pack size and demanded price	500ml (1000 doses); De-controlled
	International availability	Not Available
	Products already registered in Pakistan	Not Available
	Stability data of finished product	The firm has submitted stability study data of 21 months conducted at 2°C to 8°C for three consecutive batches as below: 78B076 78B077 78B078
	Document Details	• Valid Legalized GMP Certificate No. 193-GMP-2021, dated 08-09-2021 for M/s PT Medion Farma Jaya., Directorate general of livestock and animal health services Ministry of Agriculture republic of Indonesia valid till 08.09.2026 • Legalized FSC issued on May-2020 issued by Ministry of agriculture directorate general of livestock

		and animal health services, Indonesia.
	Remarks of Evaluator: Evidence of locally registered product for applied strains (MD15 of ND, M02 and M03 of IBV) could not be verified.	
	Decision: Registration Board referred the case to Animal Husbandry Commissioner for comments regarding immunological relevance and need of applied strain in Pakistan.	
14.	Name of Importer	M/s Decent Pharma, Shop No. 14, Aallishan Plaza, Shamas Abad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D valid till 26-08-2023 .
	Marketing authorization holder	M/s Middle East for Veterinary Vaccines (MEVAC), Second Industrial Zone-Extension part No. 21, 22, 24, 25 El Salhya El Gadeda, Elsharkya Governate, Egypt.
	Name of Manufacturer	M/s Huapai Bioengineering Group Co., Ltd Shipan Food and Drug Industrial Park, Jianyang Economic development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI-VACC LS** Newcastle Disease Vaccine, Live (Strain LaSota)
	Diary No. Date of R& I & fee	Dy. No. 19778 (R&I); Dated 14-07-2021 Rs.75,000 (Slip No.59516398354)
	Composition	Each dose of vaccine contains: New Castle Disease virus (Strain LaSota) ……...at least $10^{6.0}$ EID_{50}
	Pharmacological Group	Immunological for avian
	Type of Form	Form-5A
	Finished Product Specification	Chinese Veterinary pharmacopoeia
	Shelf Life	24 months (-15°C)
	Pack size and demanded price	10's × 1000 dose / vial, Decontrolled
	Products already registered in Pakistan	BIO-VAC La Sota (1000 and 2500 doses) manufactured by FATRO Italy, Local agent is Forward Solutions (Reg. No. 084167).
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at -15°C for three batches as below: 2017001 2017002 2017003
	Document Details	• Valid Legalized GMP Certificate dated 29-11-2021 for M/s Huapai Biotechnology Group Co. Ltd. China valid till 04-08-2024. • Legalized FSC issued on 18-03-2021 issued by Sichuan Provincial Agricultural Department of the People's Republic of China confirms that product is registered in China for manufacture, distribution and use. • Notarized copy of product specific sole agency agreement.
	Remarks of Evaluator: Differential fee of Rs. 75,000 shall be submitted for registration of import drug. The monograph of applied product is available in European Pharmacopoeia. The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	
	Decision: Deferred for following: • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.** • **Stability study data for applied pack size**	

	• **Differential fee of Rs. 75,000/- for registration of imported biological Drug.** • **Clarification of name of manufacturer on GMP certificate and free sale certificate**	
15.	Name of Importer	M/s Decent Pharma 14-Aalishan Plaza, Shamsabad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D Valid till 26-08-2023.
	Marketing authorization holder	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of Manufacturer	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI VACC LS-H120** Live Vaccine
	Diary No. Date of R& I & fee	Dy. No. 19781 (R&I); Dated: 14-07-2021 Rs.75,000 (Slip No.7086571007)
	Composition	Lyophilized cake Each dose contains: Live attenuated Newcastle Disease Virus, LaSota strain……..…..…≥ $10^{6.0}EID_{50}$ Live attenuated Classic Infectious Bronchitis Virus, H120 strain……..≥ $10^{3.5}EID_{50}$
	Pharmacological Group	Live viral veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months at -15°C
	Pack size and demanded price	1000 dose / vial, Decontrolled
	International availability	N/A
	Products already registered in Pakistan	BIO-VAC LS-H120 (1000 and 2500 doses) manufactured by FATRO Italy, Local agent is Forward Solutions (Reg # 077560).
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at -15°C for three consecutive batches as below: 2018001 2018002 2018003
	Document Details	• Valid Legalized GMP Certificate dated 9-04-2019 for Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China. valid till 08-04- 2024. • Legalized FSC No. 221012038 issued on 12-06-2020 issued by Jianyang Agriculture and Rural Bureau of Sichuan Province, People's Republic of China confirms that product is on free sales in the market of China. • Copy of product specific sole agency agreement.
	Remarks of Evaluator The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	
	Decision: Deferred for following: • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.** • **Stability study data for applied pack size.** • **Status of applied strain in reference regulatory authorities in combination.**	

	• Clarification of name of manufacturer on GMP certificate and free sale certificate.	
16.	Name of Importer	M/s Decent Pharma, Shop No. 14, Aallishan Plaza, Shamas Abad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D valid till 26-08-2023 .
	Name of Manufacturer	M/s Huapai Bioengineering Group Co., Ltd Shipan Food and Drug Industrial Park, Jianyang Economic development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI-NBEA** Newcastle Disease, Infectious Bronchitis, Egg Drop Syndrome and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain LaSota + Strain M41+ Strain HSH23 + Strain WD).
	Diary No. Date of R& I & fee	Dy. No. 19787 (R&I); Dated 14-07-2021 Rs.75,000 (Slip No.987604675).
	Composition	Each dose (0.5ml) of the vaccine contains at least $10^{8.5}$ EID_{50} inactivated Newcastle Disease Virus (Strain LaSota), $10^{6.5}EID_{50}$ inactivated infectious Bronchitis Virus (Strain M41), 1000HA inactivated Egg Drop Syndrome disease virus (Strain HSH23) and $10^{7.5}EID_{50}$ Inactivated Avian Influenza Virus H9 Subtype (Strain WD).
	Pharmacological Group	Inactivated virus veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	1000 dose / vial, Decontrolled
	International availability	N/A
	Products already registered in Pakistan	Pro-Vac ABNE (1000 and 2500 doses) manufactured by Komipharm South Korea, Local agent is Huzaifa International Sargodha (Reg V1-1/001).
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at 2°C to 8°C for three consecutive batches as below: 2017001 2017002 2017003
	Document Details	• Valid Legalized GMP Certificate dated 9-04-2019 for Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China. valid till 08-04- 2024. • Legalized FSC (2016)221012208 issued on 05-11-2020 issued by Jianyang Agriculture and Rural Bureau of Sichuan Province, People's Republic of China confirms that product is on free sales in the market of China. • Copy of product specific sole agency agreement.
	Remarks of Evaluator: Evidence of already registered product in applied strain (Strain HSH23 of Egg Drop syndrome). The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	
	Decision: Deferred for following: **• Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.** **• Stability study data for applied pack size.** **• Status of applied strain in reference regulatory authorities in combination.**	

	• **Clarification of name of manufacturer on GMP certificate and free sale certificate.**	
17.	Name of Importer	M/s Decent Pharma, 14-Aalishan Plaza, Shamsabad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D Valid till 26-08-2023.
	Marketing authorization holder	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of Manufacturer	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI-NBE** Inactivated Vaccine
	Diary No. Date of R& I & fee	Dy. No. 19777 (R&I); Dated 14-07-2021 Rs.75,000 (Slip No.9614290990)
	Composition	Vaccine contains Newcastle Disease Inactivated Virus (strain La Sota $\geq 3*10^{8.0}EID_{50}$/0.1ml before inactivated), Infectious Bronchitis Virus strain M41 (Virus $\geq 3*10^{6.0}EID_{50}$/0.1ml before inactivated) and Egg Drop Syndrome disease virus, Strain HE02 (virus $\geq 3*10^{6.0}TCID_{50}$/ml before inactivated).
	Pharmacological Group	Inactivated virus veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	1000 dose / vial, Decontrolled
	International availability	N/A
	Products already registered in Pakistan	Gallimune (1000 and 2500 doses) manufactured by Merial Select France, Local agent is Saadat International Lahore (Reg No. 049594)
	Stability data of finished product	The firm has submitted stability study data of 27 months conducted at 2°C to 8°C for three consecutive batches as below: 20170401 20170402 20170403
	Document Details	• Valid Legalized GMP Certificate dated 09-04-2019 for Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China. valid till 08-04- 2024. • Legalized FSC No. 221012170 issued on 27-03-2020 issued by Jianyang Agriculture and Rural Bureau of Sichuan Province, People's Republic of China confirms that product is on free sales in the market of China. • Copy of product specific sole agency agreement.
	Remarks of Evaluator: Evidence of already registered product in applied strain (Strain HE02 of Egg Drop syndrome). The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	
	Decision: Deferred for following: • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.** • **Stability study data for applied pack size.**	

	• **Status of applied strain in reference regulatory authorities in combination.** • **Clarification of name of manufacturer on GMP certificate and free sale certificate.**	
18.	Name of Importer	M/s Decent Pharma 14-Aalishan Plaza, Shamsabad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D Valid till 26-08-2023.
	Marketing authorization holder	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of Manufacturer	M/S Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI-NBA** Inactivated Vaccine
	Diary No. Date of R& I & fee	Dy. No. 19779, (R&I); Dated: 14-07-2021 Rs.75,000 (Slip No.5581046423)
	Composition	Each dose (0.5ml) of the inactivated vaccine contains at least Newcastle Disease Inactivated Virus strain LaSota ≥ $3*10^{8.0}EID_{50}$/ 0.1ml before inactivated), Infectious Bronchitis Virus strain M41 (Virus ≥ $3*10^{6.0}EID_{50}$/0.1ml before inactivated) and Avian Influenza H9 Subtype Strain (WD) (virus ≥ $3*10^{7.0}TCID_{50}$/ml before inactivated).
	Pharmacological Group	Inactivated virus veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	1000 dose /vial , Decontrolled
	International availability	N/A
	Products already registered in Pakistan	Pro-Vac ABBN (1000 and 2500) manufactured by Komipharm South Korea, Local agent is Huzaifa International Sargodha (Reg. No. 088167)
	Stability data of finished product	The firm has submitted stability study data of 27 months conducted at 2°C to 8°C for three consecutive batches as below: 2017001 2017002 2017003
	Document Details	• Valid Legalized GMP Certificate dated 9-04-2019 for M/s Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China. valid till 08-04- 2024. • Legalized FSC No. 221012166 issued on 05-11-2020 issued by Jianyang Agriculture and Rural Bureau of Sichuan Province, People's Republic of China confirms that product is on free sales in the market of China. • Copy of product specific sole agency agreement.
	Remarks of Evaluator: Evidence of already registered product in applied strain (WD Strain of Avian Influenza, M41 strain of IBV). The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	
	Decision: Deferred for following: • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.**	

	• **Stability study data for applied pack size.** • **Status of applied strain in reference regulatory authorities in combination.** • **Clarification of name of manufacturer on GMP certificate and free sale certificate.**	
19.	Name of Importer	M/s Decent Pharma, 14-Aalishan Plaza, Shamsabad, Murree Road, Rawalpindi.
	DSL details	License to sell drugs as a distributor No.01-374-0177-064204D Valid till 26-08-2023.
	Marketing authorization holder	M/s Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of Manufacturer	M/s Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	**HUAPAI-NAI** Inactivated Vaccine
	Diary No. Date of R& I & fee	Dy. No. 19780 (R&I); Dated 14-07-2021 Rs.75,000 (Slip No.3413831394)
	Composition	Each dose (0.5ml) of the inactivated vaccine contains at least Newcastle Disease Inactivated Virus strain LaSota $\geq 2\times10^{8.0}EID_{50}$/ 0.1ml before inactivated), Avian Influenza (H9 Subtype) HN106 virus Strain HE02 (virus $\geq 2\times10^{7.0}$ EID_{50} / 0.1 ml before inactivated).
	Pharmacological Group	Inactivated virus veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	1000 dose bottle / Decontrolled
	International availability	N/A
	Products already registered in Pakistan	AI-OLVAC H9 (1000 and 2500 doses) manufactured by FATRO Italy, Local agent is Forward Solutions (Reg. No. 077561).
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at 2°C to 8°C for three consecutive batches as below: 2017001 2017002 2017003
	Document Details	• Valid Legalized GMP Certificate dated 9-04-2019 for Huapai Bioengineering Group Co., Ltd. Shipan Food and Drug Industrial Park, Jianyang Economic Development Zone, Sichuan, China. valid till 08-04- 2024. • Legalized FSC No. 221012269 issued on 21-08-2017 issued by Jianyang Agriculture and Rural Bureau of Sichuan Province, People's Republic of China confirms that product is on free sales in the market of China. • Copy of product specific sole agency agreement.
	Remarks of Evaluator Evidence of already registered product in applied strain (HN 106 strain HE02 of Avian influenza virus) could not be verified. The name of manufacturer on GMP certificate is different from that mentioned on Free sale certificate. Pack size is not mentioned in stability study data while on free sale certificate, two pack sizes are mentioned.	

	Decision: Deferred for following: • **Desired pack size for applied formulation since multiple pack sizes are mentioned on FSC.** • **Stability study data for applied pack size.** • **Status of applied strain in reference regulatory authorities in combination.** • **Clarification of name of manufacturer on GMP certificate and free sale certificate.**	
20.	Name of Importer	M/s Hivet Animal Health Business, 1st Floor, 667-P, M.A. Johar town, District Lahore.
	DSL details	License to sell drugs as a distributor No. 05-352-0066-040985D valid till 23-02-2023.
	Marketing authorization holder	M/s Sanfer Salud Animal S.A de C.V., Boulevard Adolfo Lopez Mateos 314-PB Colonia Tlacopac, Alvaro Obregon C.P.01049 Cludad de Mexico.
	Name of Manufacturer	M/s Sanfer Salud Animal S.A de C.V., Paseo de los Frailes, No. 22. Col. Parque Industrial. Santiago Tianguistenco, State of Mexico, P.C. 52600.
	Name of exporting country	Mexico
	Brand Name +Dosage Form + Strength	Emulmax AI Injectable Emulsion
	Diary No. Date of R& I & fee	Dy. No. 18488 (R&I); Dated 01-07-2021 Rs.150,000 (Slip # 95316543995)
	Composition	Each dose (0.5ml) contains: Avian Influenza Virus Type A, Subtype H5N2, strain A/Chicken/Mexico/232/94/CPA, inactivated……..……0.078ml (15.6%). Excipients: Sterile distilled water……..…. 0.072 ml (14.4%) Mineral oil……0.310 ml (62.0%) Tween 80……..0.01 ml (2.0%) Span 80…….0.030 ml (6.0%) Total volume……0.500 ml (100%)
	Pharmacological Group	Inactivated Emulsified veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C - 8°C)
	Pack size and demanded price	1000 dose vial (500ml) / Decontrolled
	Products already registered in Pakistan	Gallimune Flu. H5N9 of Merial Italia spa Italy, Local agent, Sadaat International Lahore (Reg # 043501).
	Stability data of finished product	The firm has submitted stability study data of 27 months conducted at 2°C to 8°C for three consecutive batches as below: 021FV001 021MW001 021HW001
	Document Details	• Legalized FSC issued on 19-10-2020 by Directorate of Animal Health, Directorate of Livestock Services and Certification, Deputy Directorate for regulation of veterinary Establishments and Veterinary Products, Mexico. • Legalized GMP certificate issued by Secretariat of Agriculture and Rural Development, National Service of Agri-Food Health, Safety and Quality, General Directorate of Animal Health dated 22-07-2021. • Copy of product specific sole agency agreement.
	Remarks of Evaluator:	
	Decision: Keeping in view the legalized free sale certificate (FSC) indicating product availability in the country of origin and legalized GMP certificate, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	

21.	**Name of Importer**	M/s Hivet Animal Health Business, 1st Floor, 667-P, M.A. Johar town, District Lahore.
	DSL details	License to sell drugs as a distributor No.05-352-0066-040985D valid till 23-02-2023 .
	Marketing authorization holder	M/s Sanfer Salud Animal S.A de C.V., Boulevard Adolfo Lopez Mateos 314-PB Colonia Tlacopac, Alvaro Obregon C.P.01049 Cludad de Mexico.
	Name of Manufacturer	M/s Sanfer Salud Animal S.A de C.V., Paseo de los Frailes, No. 22. Col. Parque Industrial. Santiago Tianguistenco, State of Mexico, P.C. 52600.
	Name of exporting country	Mexico
	Brand Name +Dosage Form + Strength	Emulmax AI H7 Injectable Emulsion
	Diary No. Date of R& I & fee	Dy. No. 18489 (R&I); Dated 01-07-2021 Rs.150,000 (Slip # 534408256)
	Composition	Each dose (0.5ml) contains: Avian Influenza Virus type A, Subtype H7N3, strain (CPA) A/duck/2817/2006/H7N3 …….. 0.150 ml (30%) Excipients: Marcol 52 Oil……0.310 ml (62.0%) Tween 80……..0.01 ml (2.0%) Span 80…….0.030 ml (6.0%) Total volume……0.500 ml (100%)
	Pharmacological Group	Inactivated Emulsified veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specification
	Shelf Life	24 months (2°C - 8°C)
	Pack size and demanded price	1000 dose vial (500ml) / Decontrolled
	International availability	N/A
	Products already registered in Pakistan	Fluvac H7 of Sadaat International Lahore (Reg # 018495)
	Stability data of finished product	The firm has submitted stability study data of 24months conducted at 2°C to 8°C for three consecutive batches as below: 022LV003 022LV002 022KV002
	Document Details	• Legalized FSC issued on 19-10-2020 by Directorate of Animal Health, Directorate of Livestock Services and Certification, Deputy Directorate for regulation of veterinary Establishments and Veterinary Products, Mexico. • Legalized GMP certificate issued by Secretariat of Agriculture and Rural Development, National Service of Agri-Food Health, Safety and Quality, General Directorate of Animal Health dated 22-07-2021. • Copy of product specific sole agency agreement.
	Remarks of Evaluator	
	Decision: Keeping in view the legalized free sale certificate (FSC) indicating product availability in the country of origin and legalized GMP certificate, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	
22.	Name of Importer	M/s Huzaifa International, Commercial area, Aziz Bhatti Town, Sargodha
	DSL details	License to sell drugs as a distributor, DSL No. 08-384-0120-022405D,valid till . 20 –November 2023
	Marketing authorization holder	M/s Komipharm International Co. Ltd. 17,Gyeongje-ro, Siheung-Si, Gyeonggi-do, South Korea

	Name of Manufacturer	M/s Komipharm International Co. Ltd. 17, Gyeongje-ro, Siheung-Si, Gyeonggi-do, South Korea
	Name of exporting country	South Korea
	Brand Name +Dosage Form + Strength	PRO-VAC SORES (Inactivated vaccine for cattle pneumonia)
	Diary No. Date of R& I & fee	Dy no. 1456 (R&I); Dated 03-06-2021 Rs.100,000 (Slip No.0735197)
	Composition	Composition (per 1mL): Pasteurella multocida type A whole bacterial body……...7 × 10^9 CFU/mL Pasteurella multocida type A OMP (Outer membrane protein) .....200 µg/mL Mannheimia haemolytica type B whole bacterial body……7 × 10^9 CFU/mL Mannheimia haemolytica leucotoxoid ……..10 µg/mL
	Pharmacological Group	Inactivated bacterial veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	Innovator's specification
	Shelf Life	18 months (2°C-8°C)
	Pack size and demanded price	6 ml vial / Decontrolled
	International availability	N/A
	Products already registered in Pakistan	JOVAPAST Vaccine , manufactured by M/S Jordan Bio Industries center, Jordan, Local agent is M/S Eros Pharmaceuticals Karachi
	Stability data of finished product	The firm has submitted stability study data of 18 months conducted at 2°C to 8°C for three consecutive batches as below: 54 SORES 01 55 SORES 01 56 SORES 01
	Document Details	• Legalized GMP Certificate issued by Animal and Plant Quarantine Agency of the Ministry for Agriculture Food and Rural Affairs of the Republic of Korea on 06-04-2020. • Legalized FSC issued by Animal and plant quarantine agency, Ministry of Agriculture, Food and Rural affairs of Republic of Korea, confirms that product is on free sale in the market of Republic of Korea. • Copy of product specific sole agency agreement.
	Remarks of Evaluator: Differential fee of 50,000/- is required to be submitted. Evidence of already registered product in applied strains could not be verified.	
	Decision: Registration Board referred the case to Animal Husbandry Commissioner for comments regarding immunological relevance and need of the applied strain in Pakistan.	
23.	Name of Importer	M/s Huzaifa International, Commercial area, Aziz Bhatti Town, Sargodha
	DSL details	License to sell drugs as a distributor, DSL No. 08-384-0120-022405D,valid till . 20 –November 2023
	Marketing authorization holder/Manufacturer	Vetal Hayvan Sagligi Urunleri A.S (Vetal Animal Health Products S.A), Petrolosb Mah.14 Cad. No.1/1, Adiyaman /, TURKEY.
	Name of exporting country	Turkey
	Brand Name +Dosage Form + Strength	BASILAX Vaccine (live spore culture vaccine for Anthrax disease)
	Diary No. Date of R& I & fee	1455 (R&I); Dated 04-06-2021 Rs.100,000 (Slip No.0735199)

	Composition	Bacillus anthracis (Sterne Strain $34F_2$) Spores…….$1x10^7$ CFU Excipients: Physiological saline –Glycerin…… 50% Saponin……0,1 %
	Pharmacological Group	live spore culture veterinary vaccine
	Type of Form	Form-5A
	Finished Product Specification	European Pharmacopoeia specifications
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	50 ml per vial / Decontrolled
	International availability	Anthrax spore vaccine, Live culture, Manufactured by Colorado Serum Company USA (USDA Reg # 188, 1011.00).
	Products already registered in Pakistan	N/A
	Stability data of finished product	The firm has submitted stability study data of 24 months conducted at 2°C to 8°C for three consecutive batches as below: 04/BS/02 05/BS/02 06/BS/02
	Document Details	• Original Legalized Free sale certificate issued by General Directorate of food and control, Ministry of Agriculture and Forestry, Turkey confirms that product is on free sales in the market of Turkey. • Legalized GMP certificate issued by The Ministry of Food and Agriculture livestock of Turkey. Certificate no. GMP/TR/V/YI/ S0092/2018. • Original product specific sole agency agreement
	Remarks of Evaluator: The claimed shelf life and stability study data are of 24 months however, on Free sale certificate it is stated that the valid shelf life is 12 months from date of manufacturing.	
	Decision: Registration Board deferred the case for following: • **Referred the case to Animal Husbandry Commissioner for comments regarding immunological relevance and need of applied strain in Pakistan.** • **Manufacturing requirements and handling of live spore culture vaccine due to its use as dangerous biological agents.**	
24.	**Name of Importer**	**ICI Pakistan Limited** **ICI House, 5, West Wharf, Karachi-Pakistan**
	DSL details	License to sell drug as distributor No.020 valid till11-07-2023
	Name of Manufacturer	**Manufactured by:** Brugwedel Biotech GmbH Im Langen Felde 5 30938 Burgwedel, Germany.
	Brand Name + Dosage Form + Strength	ROTAVEC® CORONA Emulsion for injection for cattle 50 Doses 100ml
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5-A Dy No. 18554 Dated: 28-07-2020 Fee Submitted: Rs. 100, 000/- dated 27-07-2020
	Composition	Each 2ml Dose contain: Bovine rotavirus strain UK-Compton, Serotype G6 P5…….$10^{7.6}$-$10^{7.9}$ $TCID_{50}$ Bovine coronavirus, Strain Mebus (Inactivated)…...150-230ELISA units. E.Coli F5 (K99) adhesion…….100-200 Units.
	Finished product specifications	Innovator's Specifications

	Pharmacological Group	Veterinary Vaccine
	Shelf life	24 Months (Store at +2°C -+8°C), Do not freeze
	Demanded Price / Pack size	50 Doses 100ml
	Products already registered in Pakistan	N/A
	General Documentation	• Legalized Certificate of Pharmaceutical Product (CoPP) No 008/BBG/2019 issued by Lower Sexony State Office for Consumer Protection and Food Safety, Wadenburg, Germany dated: 03-07-2019. The submitted CoPP confirms free sale status in the country of origin as well as conformance of facilities and operations to GMP as recommended by WHO.

Remarks of Evaluator:

Sr. No.	Observations	Response by the firm
1.	Separate Registration fee along with application with relevant data for each pack size	Pack Size: 50 Doses vial, 100ml
2.	Clarification is required why the Product license holder is different in CoPP & Form 5-A.	This is to clarify that the product license holder as per CoPP **"**M/s. Intervet Deutschland GmbH. Feldstr. 1a, D-85716, Unterschleissheim" The firm revised FORM 5-A as per CoPP alongwith submission of fee Rs: 7,500/-. Fee Challan No. 8055251203 Date. 13.10.2022
3.	Original product specific sole authorization letter.	Original Submitted
4.	lnformation against point "Persons under whose direct supervision and control the drug applied for registration shall be manufactured." of Form 5A. lnformation against point "Name of equipment that will be used in the manufacture of the applied drug." of Form 5-A Information against point "Production capacity of the manufacturer per shift for the drug applied." of Form 5-A Information against point "Name, qualification and designation of the persons who will be responsible for the quality control of the drug" of Form lnformation against point "Description of the equipment to be used for the quality control of the active raw material and the finished products." of Form lnformation against point "Facility of the water processing, with specifications" of Form 5-A lnformation against point "Environment control processing with details" of Form 5-A	Submitted

Remarks of Evaluator:
The claimed shelf life and stability study data are of 24 months however, on Free sale certificate it is stated that the valid shelf life is 12 months from date of manufacturing.

Decision: Keeping in view the legalized CoPP indicating product availability in the country of origin, Registration Board approved the product with shelf life of 12 months subject to compliance of current Import Policy for finished drugs.

25.	**Name of Importer**	ICI Pakistan Limited, ICI House, 5 West Wharf Karachi-Pakistan
	DSL details	License to sell drug as distributor No.020 valid till11-07-2023
	Name of Manufacturer	Manufactured by: Schering-Plough Animal Health Limited

		33Whakatiki Street Upper Hutt, NewZealand	
	Brand Name + Dosage Form + Strength	COVEXIN™ 8 Clostridial vaccine (40ml)	
	Type of Form Dy. No. Date of Application, Fee submitted	Form 5-A Dated: Fee Submitted: Rs. 100,000/- dated 27-07-2020	
	Composition	Each ml contains: C. chauvoei whole culture ……sufficient to provide the required immunogenic activity per recommended animal dose C. haemolyticum toxoid and cells……. ≥10U/mL C. novyi toxoid and cells……≥3.5 IU/mL C. perfringens type B toxoid and cells and Type C toxoid……≥10IU/mL β C. perfringens type D toxoid…….. ≥5IU/mL Ɛ C. septicum toxoid ……≥2.5IU/mL C. tetani toxoid…….. ≥2.5IU/mL	
	Finished product specifications	Innovator's Specifications	
	Pharmacological Group	Veterinary Vaccine	
	Shelf life	24 Months (Store at +2°C -+8°C) Do not freeze	
	Demanded Price / Pack size	40ml, Decontrolled	
	Products already registered in Pakistan	N/A	
	General Documentation	• Legalized Certificate of Pharmaceutical Product (CoPP) dated 17th February 2022 issued by Ministry of Primary Industries NewZealand.	
	Evaluation by DBE&R	Observation	Response
		Separate Registration fee along with application with relevant data for each pack size.	Pack size = 40ml Proposed Label (Submitted)
		Valid legalized Free Sale Certificate (FSC)/CoPP with complete composition and pack size of the product. wherein the free sale status of the product in the country of origin has been clearly mentioned.	Original Submitted
		Original product specific sole authorization letter	Original Submitted
		Complete Stability study data on three commercial scale batches as per ICH guidelines for each pack size of the product	Submitted
	Decision: Keeping in view the legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.		

Miscellaneous cases:

The following products of M/s Hipra Pakistan were approved in 307th meeting of Registration Board. Now the firm has submitted that EMA has decided to change the titer specifications of the composition from $10^{1.48}$ – $10^{2.80}$ PU to $10^{1.18}$ – $10^{2.80}$ PU. Accordingly, the firm has applied fresh dossiers with revised specifications as below:

26.	Name of Importer	M/s Hipra Pakistan (Private) Limited, 3rd floor, plot no 8, block CCA, Phase 6-C, DHA, Lahore Go Down: 2nd Warehouse on Left side, Street no 5, Gajjumata Nadir Chowk, Hazara Chowk, Industrial Area Ferozpur Road, Distt Lahore
	DSL details	License to sell drug as distributor No. 05-352-0058-050528D valid till 19-Feb-2024.

	Marketing authorization holder	M/s Laboratorios HIPRA, S.A., Avda. la Selva, 135, 17170 Amer (Girona) Spain.
	Name of Manufacturer	Laboratorios HIPRA, S.A., Carretera C-63, Km 48, 300, Poligono Industrial El Rieral, 17170 Amer (Girona), Spain (Responsible for primary packaging). Laboratorios HIPRA, S.A., Avda. la Selva, 135, 17170 Amer (Girona) Spain. (Responsible for batch release in the EU, quality control and Secondary packaging).
	Name of exporting country	Spain
	Brand Name +Dosage Form + Strength	GUMBOHATCH, Lyophilisate and solvent for suspension for injection 2000 dose
	Diary No. Date of R& I & fee	Dy. No. 1333 (R&I); Dated 16-01-2023 Rs. 75,000 (Slip No.275750752891) Rs.75,000 (Slip No. 127496746)
	Composition	Each dose of reconstituted vaccine contains Live attenuated infectious bursal disease virus, strain 1052…….....$10^{1.18}$-$10^{2.80}$ *PU PU: Potency Units* Solvent: Phosphate buffer solution
	Pharmacological Group	Live attenuated vaccine against Infectious Bursal Disease
	Type of Form	Form-5A
	Finished Product Specification	Innovator's Specifications
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	2000 dose vial, Decontrolled
	International availability	Spain
	Products already registered in Pakistan	Gumbohatch 5000 dose
	Stability data of finished product	The firm has submitted stability study data of 3 batches conducted at 2°C - 8°C for 24 months: P.4D62 P.4S19 P.4T71
	Document Details	The firm has submitted copy of certificate of veterinary medicinal product (Certificate No. 05/21/160295) issued by European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands on 19-07-2021. The certificate confirms fee sale status of the product in the country of origin as well as GMP status of the manufacturer.
	Remarks of Evaluator:	
	Decision: Keeping in view the legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	
27.	**Name of Importer**	M/s Hipra Pakistan (Private) Limited, 3rd floor, plot no 8, block CCA, Phase 6-C, DHA, Lahore. Go Down: 2nd Warehouse on Left side, Street no 5, Gajjumata Nadir Chowk, Hazara Chowk, Industrial Area Ferozpur Road, Distt Lahore
	DSL details	License to sell drug as distributor No. 05-352-0058-050528D valid till 19-Feb-2024.
	Marketing authorization holder	M/s Laboratorios HIPRA, S.A., Avda. la Selva, 135, 17170 Amer (Girona) Spain.
	Name of Manufacturer	Laboratorios HIPRA, S.A., Carretera C-63, Km 48, 300, Poligono Industrial El Rieral, 17170 Amer (Girona), Spain (Responsible for primary packaging). Laboratorios HIPRA, S.A., Avda. la Selva,

		135, 17170 Amer (Girona) Spain. (Responsible for batch release in the EU, quality control and Secondary packaging).
	Name of exporting country	Spain
	Brand Name +Dosage Form + Strength	GUMBOHATCH, Lyophilisate and solvent for suspension for injection 4000 dose
	Diary No. Date of R& I & fee	Dy. No. 1332 (R&I); Dated 16-01-2023 Rs. 75,000 (Slip No.07250608280) Rs.75,000 (Slip No. 35318226)
	Composition	Each dose of reconstituted vaccine contains Live attenuated infectious bursal disease virus, strain 1052 ….....$10^{1.18}$ -$10^{2.80}$ *PU PU: Potency Units* Solvent: Phosphate buffer solution
	Pharmacological Group	Live attenuated vaccine against Infectious Bursal Disease
	Type of Form	Form-5A
	Finished Product Specification	Innovator's Specifications
	Shelf Life	24 months (2°C-8°C)
	Pack size and demanded price	4000 dose vial / Decontrolled
	International availability	Yes
	Products already registered in Pakistan	Gumbohatch 5000 dose
	Stability data of finished product	Now the firm has submitted stability study data of 3 batches conducted at 2°C - 8°C for 24 months: P.4D62 P.4S19 P.4T71
	Document Details	The firm has submitted copy of certificate of veterinary medicinal product (Certificate No. 05/21/160295) issued by European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands on 19-07-2021. The certificate confirms fee sale status of the product in the country of origin as well as GMP status of the manufacturer.
	Remarks of Evaluator:	
	Decision: Keeping in view the legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	

Locally manufactured veterinary vaccines:

28.	Name and address of product manufacturer (Applicant)	M/s Intervac Pvt. Ltd., 18 Km Lahore Sheikhupura Road , Sheikhupura Pakistan
	Brand Name +Dosage Form + Strength	INTERVAC 2 COMBO VACCINE
	Composition	Each Dose Contains: Inactivated Newcastle Disease (ND)-Virus $\geq 10^{9.0}EID_{50}$ Inactivated Avian Infectious Bronchitis (IB)- Virus$\geq 10^{6.5}EID_{50}$
	Pharmacological Group	Veterinary vaccine
	Finished Product Specification	Manufacturer's Specs
	Type of Form, Diary No. Date of R& I & fee	Dy no. 25861 Dated: 17-09-2021 Rs. 30,000/- (Slip # 20154971088)
	Shelf Life	Shelf-life: 12 months (2-8^{0}C)
	Document Details	Copy of GMP certificate on 26-01-2021 wherein the panel rated the facility good and GMP

		Copy of Panel inspection for DML renewal on 19-06-2019 & 28-05-2019 wherein the panel rated the facility good and GMP has been recommended for following Biological sections: Vaccine Section
	Pack size & Demanded Price	500, 1000, 2000, 5000, Dose each vial Decontrolled
	Products already registered in Pakistan	GALLIMMUNE 204 ND+IB SAADAT INTRNATIONAL
	Remarks of Evaluator: The virus strains are not specified in applied vaccine composition.	
	Decision: Deferred for confirmation of viral strain in applied vaccine composition.	
29.	Name and address of product manufacturer (Applicant)	M/S Intervac Pvt. Ltd 18 Km Lahore Sheikhupura Road , Sheikhupura Pakistan
	Brand Name +Dosage Form + Strength	INTERVAC 3 COMBO OIL BASED VACCINE
	Composition	Each 0.3ml Contains: Inactivated Newcastle disease virus, strain Lasota, at least….$10^{7.0}$ EID_{50} (Embryo infectious dose 50%). Inactivated Infectious Bronchitis virus, strain H 120, at least.$10^{5.0}$ EID_{50} (Embryo infectious dose 50%). Inactivated Egg Drop Syndrome (EDS) at Least.$10^{9.0}$ EID_{50} (Embryo infectious dose 50%).
	Pharmacological Group	Veterinary vaccine
	Finished Product Specification	Manufacturer's Specs
	Type of Form, Diary No. Date of R& I & fee	Dy no. 25860 Dated: 17-09-2021 Rs. 30,000/- (Slip # 3566017876)
	Shelf Life	Shelf-life: 12 months (2°C-8°C)
	Document Details	Copy of GMP certificate on 26-01-2021 wherein the panel rated the facility good and GMP Copy of Panel inspection for DML renewal on 19-06-2019 & 28-05-2019 wherein the panel rated the facility good and GMP has been recommended for following Biological sections: Vaccine Section
	Pack size & Demanded Price	300 ml Bottle, Decontrolled
	Products already registered in Pakistan	GALLIMUNE 302 ND+IB+EDS SAADAT INTRNATIONAL
	Remarks of Evaluator: Evidence of already registered product for applied product could not be confirmed. The strain of Egg Drop syndrome is not mentioned.	
	Decision: Deferred for following: • **Evidence of already registered product for applied product.** • **Confirmation of strain of Egg Drop Syndrome in applied vaccine composition.**	
30.	Name and address of product manufacturer (Applicant)	M/S Intervac Pvt. Ltd 18 Km Lahore Sheikhupura Road , Sheikhupura Pakistan
	Brand Name +Dosage Form + Strength	INTERVAC ND+IB+IBD OIL BASED VACCINE
	Composition	Each 0.3ml Contains: Inactivated Newcastle disease virus, strain LaSota, at least….$10^{7.0}$ EID_{50} (Embryo infectious dose 50%). Inactivated Infectious Bronchitis virus, strain H 120, at least...$10^{5.0}$ EID_{50} (Embryo infectious dose 50%). Inactivated Infectious Bursal Disease (IBD)- Virus$\geq 10^{4.0}EID_{50}$ (Embryo infectious dose 50%).
	Pharmacological Group	Veterinary vaccine
	Finished Product Specification	Manufacturer's Specs
	Type of Form, Diary No. Date of R& I & fee	Dy no. 25859 Dated: 17-09-2021 Rs. 30,000/- (Slip # 8893423)

	Shelf Life	Shelf-life: 12 months (2°C-8°C)
	Document Details	Copy of GMP certificate on 26-01-2021 wherein the panel rated the facility good and GMP Copy of Panel inspection for DML renewal on 19-06-2019 & 28-05-2019 wherein the panel rated the facility good and GMP has been recommended for following Biological sections: Vaccine Section
	Pack size & Demanded Price	300 ml Bottle, Decontrolled
	Products already registered in Pakistan	BIGOPEST ND+IB+IBD of SAADAT INTRNATIONAL
	Remarks of Evaluator: Evidence of already registered product for applied product could not be confirmed. The strain of Avian Infectious Bursal Disease is not mentioned.	
	Decision: Deferred for following: • **Evidence of already registered product for applied product.** • **Confirmation of strain of Avian Infectious Bursal Disease in applied vaccine composition.**	
31.	Name and address of product manufacturer (Applicant)	M/S Intervac Pvt. Ltd 18 Km Lahore Sheikhupura Road , Sheikhupura Pakistan
	Brand Name +Dosage Form + Strength	INTERVAC SHEEP POX VACCINE
	Composition	Each Dose Contains: Freeze-dried attenuated sheep pox virus strain RM/65……. not less than $10^{2.5}$ $TCID_{50}$ The contents of the vials are lyophilized and vacuum packed.
	Pharmacological Group	Veterinary vaccine
	Finished Product Specification	Manufacturer's Specs
	Type of Form, Diary No. Date of R& I & fee	Dy no. 25858 Dated: 17-09-2021 Rs. 30,000/- (Slip #5102768612)
	Shelf Life	Shelf-life: 2 years (2°C-8°C)
	Document Details	Copy of GMP certificate on 26-01-2021 wherein the panel rated the facility good and GMP Copy of Panel inspection for DML renewal on 19-06-2019 & 28-05-2019 wherein the panel rated the facility good and GMP has been recommended for following Biological sections: Vaccine Section
	Pack size & Demanded Price	50, 100, 200, 500, 1000 doses per vial Decontrolled
	Products already registered in Pakistan	JOVIVAC JOVAC (Jordan Bio Industry Centre)
	Remarks of Evaluator: Evidence of already registered product for applied product could not be confirmed.	
	Decision: Deferred for following: • **Evidence of already registered product for applied product.** • **Confirmation of lyophilized facility for manufacturing of applied vaccine.**	

Cases of AD-II (Mr. Saadat Ali Khan)

B: Imported Human Biologicals from Reference countries/WHO PQ.

32.	**Name, address of Applicant / Importer**	**M/s Pfizer Pakistan Limited,** **12 Dockard Road West Wharf Karachi.**
	Details of Drug Sale License of importer	**License No:** 029 **Address:**

		12 Dockard Road West Wharf Karachi. **Validity: 25-02-2023** Status: License to sell drugs by way of Whole sale.
	Name and address of marketing authorization holder (abroad)	M/s Pfizer Canada ULC, 17300 Trans-Canada Highway Kirkland, QC Canada, H9J 2M5.
	Name, address of manufacturer(s)	M/s Catalent Indiana, LLC 1300 South Patterson Drive Bloomington, Indiana (IN) 47403, USA
	Name of exporting country	Canada
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted original, legalized CoPP (No. 78703) dated 21-12-2021 issued by Health Canada. The CoPP specifies that the product is licensed for sale in country of origin but actually not available.
	Details of letter of authorization / sole agency agreement	Firm has submitted notarized copy of Letter of product specific authorization from Manager Regulatory Affairs Canada of *M/s Pfizer Canada ULC, Canada*. According to the letter, the firm *M/s Pfizer Canada ULC, Canada* authorizes "Pfizer Pakistan Limited" to be Market Authorization Holder in Pakistan and to be responsible for all matters pertaining to the regulation of this product in Pakistan. The letter was issued on 25-02-2022.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 766 (R&I) Dated 16-05-2022
	Details of fee submitted	PKR 150,000/-: 25-03-2022
	The proposed proprietary name / brand name	Abrilada 20mg/0.4mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS (0.4mL) contains: Adalimumab ……20mg
	Dosage form of applied drug	Solution for Injection in Pre-filled Syringe
	Pharmacotherapeutic Group of (API)	TNF Blocker
	Reference to Finished product specifications	As per Innovator.
	Proposed Pack size	1's PFS

	Proposed unit price	Not Provided.
	Shelf Life	36 months
	Storage Conditions	2^0C-8^0C
	The status in reference regulatory authorities	HUMIRA® (adalimumab) injection 20 mg/0.4 mL in a single-use prefilled glass syringe.
	For generic drugs (me-too status)	The product in **40mg/0.8ml PFS** is already approved by the RB & under process for price fixation.
	Module-II (Quality Overall Summary)	Firm has submitted QOS on WHO Template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
	Name, address of drug substance manufacturer	M/s Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC. One Burtt Road, Andover, MA 01810, USA
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 7 batches of Drug Substance at accelerated and real time conditions. The real time stability data conducted at --20^0C±5^0C is for 60 months for 4 batches and for 36 months for 03 batches. The accelerated stability data conducted at 5^0C±3^0C is for 6 months for 4 batches and for 9 months for 03 batches.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted that Validation of test methods performed to ensure the quality, identity, potency, purity, and safety of PF-06410293 drug product have been performed. The suitability of methods for their intended use was performed by assessment of all relevant validation elements described in International Conference on Harmonization (ICH) Guidelines on Validation of Analytical Procedures: Text and Methodology Q2 and the current USP <1225> Validation of Compendial Methods.
	Container closure system of the drug product	• 1 mL BD Hypak Type I Borosilicate glass with 29 gauge, ½ inch, thin-walled stainless steel staked needle, and

		thermoplastic elastomer (TPE) elastomeric needle shield that is not manufactured from natural rubber (latex) within a non-product contact rigid polypropylene cover. • 1mL West Pharmaceutical chlorobutyl elastomeric closure Plunger stopper
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 process validation batches. The accelerated stability study data is conducted at 30 ± 2^0C /60±5%RH for 6 months. The real time stability study data is conducted at 5 ± 3^0C for 36 months. The batches are not stable at accelerated conditions.
	Module-IV Non-Clinical	Summarized in Biosimilarity data.
	Module-V Clinical	Summarized in Biosimilarity data.

Bio similarity data as per WHO guidelines submitted by the firm is as follows:

WHO Biosimilarity Guidelines	**Data Submitted by the firm**
Quality Comparison • Physicochemical Characterization	• <u>Primary Structure and Posttranslational Modifications</u> a. Establishment and Verification of Adalimumab Amino Acid Sequence b. Characterization of Molecular Mass, Primary Structure and Posttranslational Modifications c. HILIC/MS - N-Linked Glycan Mapping d. N-LINKED GLYCAN STRUCTURE - SIALIC ACID ANALYSIS • <u>Charge Heterogeneity</u> a. Heightened Characterization of Charge Isoforms b. LC/MS Characterization of Charge Isoforms c. Characterization by Carboxypeptidase B Treatment d. Biological Activity of Charge Isoforms • **Disulfide Bonds** a. Characterization of Disulfide Bonds b. Sulfhydryl Analysis • **Higher order structure** a. Secondary Structure Characterization – Far-UV CD Spectroscopy b. Secondary Structure Characterization – FTIR Spectroscopy c. Tertiary Structure by Near-UV CD Spectroscopy d. Tertiary Structure Characterization – Intrinsic Fluorescence Emission Spectroscopy e. Thermal Stability Characterization – DSC f. Higher Order Structure - X-ray crystallography
Biological Activity & Immunochemical properties	• **Functional Characterization of the Fc domain** i. Characterization of Antibody-Dependent Cellular Cytotoxicity (ADCC) Function a. Primary NK Cell ADCC Assay

	b. PBMC ADCC Assay (FcγRIIIa 158 V/F donor genotype) c. PBMC ADCC Assay (Fc□RIIIa 158 F/F donor genotype) d. FcγRIIIa Reporter Gene Assay (FcγRIIIa RGA) e. Binding to FcγRIIIa by SPR Analysis ii. Characterization of Complement Dependent Cytotoxicity (CDC) Function a. CDC Assay b. C1q Binding ELISA c. CDC Effector Function Conclusion d. Mixed Lymphocyte Reaction (MLR) Assay e. Additional Fcγ Receptor Binding SPR Assays f. FcRn Binding SPR Assay • **Functional Characterization of the Fab Domain** i. Functional Assays Demonstrating Blockade of sTNF a. Inhibition of Apoptosis Assay b. Inhibition of ELAM-1 Expression Assay c. Binding to sTNF Target Antigen by ELISA ii. Functional Assays Demonstrating mTNF Binding Activity a. Binding to mTNF Target Antigen on NS0 Cells b. Reverse Signaling iii. Lymphotoxin alpha (LT-a) Binding Activity
Impurities	• <u>Product Purity</u> a. HMMS and Monomer – Size Exclusion HPLC b. Fragments and Heavy Chain + Light Chain - Capillary Gel Electrophoresis (Reducing) c. Intact IgG - Capillary Gel Electrophoresis (Non-Reducing)
Stability Studies	**Forced Degradation** Confirmation of similar degradation profiles forced degradation conditions of Elevated temperature, Light exposure, Forced deamidation and Forced oxidation with peracetic acid.
Non-clinical Comparison	**Primary Pharmacodynamic Studies** Already recorded in Biological Activity **Pharmacokinetic Studies** a. Quantitation of PF-06410293 and Adalimumab-EU in Cynomolgus Monkey Serum. b. Detection of Anti-PF-06410293 and Adalimumab-EU Antibodies in Cynomolgus Monkey Serum. c. Repeat-Dose Toxicokinetics
Clinical Comparison	i. A double-blind (Sponsor-open), randomized (1:1:1), parallel-group, 3-arm, single-dose, PK similarity study of PF-06410293 and adalimumab sourced from the US and EU administered SC in the lower abdomen by a PFS to healthy adult. ii. A double-blind (Sponsor-open), randomized (1:1:1), parallel-group, 3-arm, single-dose, definitive PK similarity study of PF-06410293 and adalimumab sourced from the US and EU administered SC in the lower abdomen by a PFS to healthy adult subjects.

	iii. An open-label, randomized (1:1), parallel-group, 2-arm, single-dose PK comparability study to assess the PK of PF-06410293 following SC administration in the lower abdomen or upper anterior thigh (alternative assignment in each device weight group) using a PFS or a PFP in healthy adult subjects iv. A multi-national, 2-arm, randomised (1:1), double-blind, parallel-group study designed to evaluate the safety, efficacy, population PK, and immunogenicity of PF-06410293 versus adalimumab-EU administered SC in the abdomen or thigh by a PFS, both in combination with methotrexate (MTX) to treat subjects with moderately to severely active RA who had an inadequate response to MTX therapy.

Remarks:
The CoPP submitted by the firm indicates that the product is licensed but not available in country of origin. The firm has submitted that Pfizer is currently preparing to launch **Abrilada** 20mg PFS in Canada & they will submit a marketed CoPP to DRAP as soon as possible following the launch in Canada. The firm has also submitted the **Abrilada** 20mg PFS product has not yet been launched in any country.

Decision: Registration Board deferred the case for submission of valid legalized CoPP / Free Sale Certificate from country of origin or any other reference regulatory authority wherein the product marketed/on free sale.

33.	**Name, address of Applicant / Importer**	M/s Novo Nordisk Pharma (Private) Limited, 113, Shahra-e-Iran, Clifton, Karachi.
	Details of Drug Sale License of importer	113, Shahra-e-Iran, Clifton, Karachi. Address of go-down: 208/1, Sector 23, KIA, Karachi Validity: 09-04-2023 Status: License to sell drugs by way of Wholesale.
	Name and address of marketing authorization holder (abroad)	M/s Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, **Denmark**.
	Name, address of manufacturer(s)	Novo Nordisk Producão Farmacêutica do Brasil Ltda. AvenidaC, 1413 Distrito Industrial Minas Gerais, 39404-004 Montes Claros **Brasil.**
	Name of exporting country	**Denmark**
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** • Firm has submitted legalized copy of CoPP (No. 2022063130) dated 22-06-2022 issued by Danish Medicine Agency. The CoPP specifies free sale status of the product in EU with its availability. The CoPP also confirms the GMP status of the firm. • Periodicity of routine inspections: Every two years, but not exceeding three years.
	Details of letter of authorization / sole agency agreement	Firm has submitted attested and legalized letter of product specific authorization from Senior Vice President (Submissions and Life Cycle Management) of Novo Nordisk A/S, Denmark. According to the letter, the firm Novo Nordisk A/S, Denmark authorizes "M/s Novo Nordisk Pharma (Private) Limited" to be their wholly owned subsidiary and sole importer in Pakistan

		and to import, distribute & sale the product. The letter was issued on 21-06-2022.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒Domestic sale ☐ Export sale ☐Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 21524 dated 29 July-2022
	Details of fee submitted	PKR 75,000/-: dated 20/07/2022 Deposit Slip No. 28708777526
	The proposed proprietary name / brand name	**NovoMix® 30 Penfill® 100 U/ml** 3 ml Cartridge Suspension for injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Active Ingredient(s) Insulin aspart Biphasic (recombinant DNA) Each ml of suspension contains: 100 units soluble aspart*/protamine-crystallized insulin aspart* in the ratio 30/70 (equivalent to 3.5mg) 1 cartridge contains 3ml equivalent to 300 units. *Insulin aspart is produced in *Saccharomyces cerevisiae* by recombinant DNA technology
	Dosage form of applied drug	Suspension for injection (in Cartridge)
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes. Insulins and analogues for injection, intermediate or long acting combined with fast acting. ATC code: A10AD05
	Reference to Finished product specifications	In-House/Innovator Specifications
	Proposed Pack size	Pack size of 5 and 10 cartridges
	Proposed unit price	To be submitted later
	Shelf Life	2 years
	Storage Conditions	Store in refrigerator (2°C – 8°C).
	The status in reference regulatory authorities	The product is registered in EMA.
	For generic drugs (me-too status)	The same product in Pre-filled pen is already registered.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries
	Name, address of drug substance manufacturer	M/s Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, **Denmark**. (Preparation of master cell banks & working cell banks. M/s Novo Nordisk A/S, Novo Allé, 4400 Kalundborg, Denmark.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at long term and accelerated time conditions. The long term stability data is conducted at -20°C±5°C for 60 months with 3 batches as per claim shelf life of 60 months.
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation /verification of product	Firm has submitted specification, analytical methods along with method validation.
	Container closure system of the drug product	The container closure system consists of four parts: 1. The closure system, consisting of a rubber closure with a cap. 2. The glass container, cartridge 3ml 3. The rubber plunger 4. The glass bead Both the cartridge and glass bead are produced from glass type I, colourless. The plunger is made of bromobutyl rubber. The rubber closure is sealed with a cap made of aluminium.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted 3 production scale batches stability study data biphasic insulin aspart 30, cartridge 3ml, 100 U/ml. The accelerated stability study data is conducted at 25°C±2°C for 6 months. The real time stability study data is conducted at 5°C±3°C for 24 months. Based on the stability results evaluated in this report, a shelf life

		of 24 months at 5°C ± 3°C is supported for biphasic insulin aspart 30 cartridge 3 ml, 100 U/ml.
	Module-IV Non-Clinical	The Firm has submitted following non-clinical studies: • Pharmacokinetics of BIAsp 30 and BHI 30 after s.c. Injection – Pigs. • Pharmacodynamics Studies of BIAsp 30 injected SC in the Pig. • Single Dose Toxicity Test in the Rat. • Immunogenicity of Fresh and Aged BIAsp 30 and Other Insulins in the Rabbit.. • Local Toxicity Tests in the Pig.
	Module-V Clinical	The Firm has submitted following clinical studies: • Long-term, multi-centre, multi-national, randomised (1:1) double blind, placebo controlled, two arm, parallel group • Randomised, multi centre, open label, two arm parallel group treat to target trial • Randomised, multi centre, open label, three arm parallel group treat to target trial • Non-randomised, multi-centre, one arm, three-period, observational, treat to-target trial • Randomised, multi-centre, open label two arm parallel group trial • Randomised, single centre, open-label 4 period cross over trial • A randomised, four period crossover trial in healthy subjects investigating the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and soluble insulin aspart. • Amended extension trial to: A randomised, four period crossover trial in healthy subjects investigating the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and soluble insulin aspart. A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart in Subjects with Type 1 or Type 2 Diabetes. • An International, Randomised, Open-labelled Parallel Group Four Months Comparison of Basal Bolus treatment with Insulin Aspart Including NPH and Biphasic Insulin Aspart Formulations in Subjects with type 2 Diabetes • A Single-centre, Randomised, Open-labelled, Four-period Crossover Trial to Compare the Effect of Different Injection Times of s.c. Biphasic Insulin Aspart 30 and s.c. Biphasic Human Insulin 30 on Glucose Excursions after a Standard Mixed Meal in Subjects with Type 2 Diabetes • A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Investigating the

		Pharmacokinetics and Pharmacodynamics of NN-X14Mix30 and NN-X14Mix50 in Type 2 Diabetic Patients • Randomised, multi-centre, open-label, two arm, parallel, group treat to target trial • Randomised, multi-centre, open-label, three-arm, parallel group treat to target trial • Non-randomised, multi-centre, one arm, three period, observational, treat to target trial • Randomised, multi centre, two-arm, parallel group treat to target trail
Remarks of Evaluator:		
Decision: Keeping in view legalized CoPP issued by Danish Medicine Agency (reference regulatory authority); Registration Board approved the products subject to compliance of current Import Policy for finished drugs.		
34.	**Name, address of Applicant / Importer**	M/s Novo Nordisk Pharma (Private) Limited, 113, Shahra-e-Iran, Clifton, Karachi.
	Details of Drug Sale License of importer	113, Shahra-e-Iran, Clifton, Karachi. Address of go-down: 208/1, Sector 23, KIA, Karachi Validity: 09-04-2023 Status: License to sell drugs by way of Wholesale.
	Name and address of marketing authorization holder (abroad)	M/s Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, **Denmark**.
	Name, address of manufacturer(s)	**Formulation and Filling** Novo Nordisk (China) Pharmaceuticals Co., Ltd. No. 99 Nanhai Road, TEDA, Tianjin, 300457 – People's Republic of China **Labelling & Packaging of Drug Product:** M/s Novo Nordisk A/S, Hallas Allé, 4400 Kalundborg, Denmark. **Batch Release** M/s Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark
	Name of exporting country	**Denmark**
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	**CoPP:** • Firm has submitted legalized copy of CoPP (No. 2022090824) dated 09-09-2022 issued by Danish Medicine Agency. The CoPP specifies free sale status of the product in EU with its availability. The CoPP also confirms the GMP status of the firm. Periodicity of routine inspections: Every two years, but not exceeding three years.
	Details of letter of authorization / sole agency agreement	Firm has submitted attested and legalized letter of product specific authorization from Senior Vice President (Submissions and Life Cycle Management) of Novo Nordisk A/S, Denmark. According to the letter, the firm Novo Nordisk A/S, Denmark authorizes "M/s Novo Nordisk Pharma (Private) Limited" to be

		their wholly owned subsidiary and sole importer in Pakistan and to import, distribute & sale the product. The letter was issued on 21-06-2022.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒Domestic sale ☐ Export sale ☐Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 21525 dated 29 July-2022, Dy. No. 1058 dated 12 Jan.2023
	Details of fee submitted	PKR 75,000/-: dated 20/07/2022 Deposit Slip No. 23237510
	The proposed proprietary name / brand name	**NovoMix® 50 Penfill® 100 U/ml** 3 ml Cartridge Suspension for injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Active Ingredient(s) Insulin aspart Biphasic (recombinant DNA) Each ml of suspension contains: 100 units soluble aspart*/protamine-crystallized insulin aspart* in the ratio 50/50 (equivalent to 3.5mg) 1 cartridge contains 3ml equivalent to 300 units. *Insulin aspart is produced in *Saccharomyces cerevisiae* by recombinant DNA technology
	Dosage form of applied drug	Suspension for injection (in Cartridge)
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes. Insulins and analogues for injection, intermediate or long acting combined with fast acting. ATC code: A10AD05
	Reference to Finished product specifications	In-House/Innovator Specifications
	Proposed Pack size	Pack sizes of 1, 5 and 10 cartridges
	Proposed unit price	To be submitted later
	Shelf Life	2 years
	Storage Conditions	Store in refrigerator (2°C – 8°C).

	The status in reference regulatory authorities	The product is registered in EMA.
	For generic drugs (me-too status)	The same product in Pre-filled pen is already registered.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries
	Name, address of drug substance manufacturer	M/s Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, **Denmark**. (Preparation of master cell banks & working cell banks. M/s Novo Nordisk A/S, Novo Allé, 4400 Kalundborg, Denmark.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at long term and accelerated time conditions. The long term stability data is conducted at -20°C±5°C for 60 months with 3 batches as per claim shelf life of 60 months.
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation /verification of product	Firm has submitted specification, analytical methods along with method validation.

	Container closure system of the drug product	The container closure system consists of four parts: 5. The closure system, consisting of a rubber closure with a cap. 6. The glass container, cartridge 3ml 7. The rubber plunger 8. The glass bead Both the cartridge and glass bead are produced from glass type I, colourless. The plunger is made of bromobutyl rubber. The rubber closure is sealed with a cap made of aluminium.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data for three process performance qualification (PPQ) batches of Biphasic insulin aspart 50, 100 U/ml, 3 ml cartridge manufactured at Site Tianjin, China have been stored for 9 months at long term storage conditions (5°C ± 3°C) and for 6 months at accelerated storage conditions (25°C $\pm 2^0$C). The long-term stability study stored at 5°C ± 3°C will continue until end of shelf life, 24 months. The accelerated stability study stored at 25°C ± 2°C has been completed.
	Module-IV Non-Clinical	The firm has submitted that BIAsp 50 and 70 are from a safety point of view an extension of BIAsp 30 (NovoMix 30: EMEA/H/C/308 and NovoLog Mix 70/30: NDA 21-172), which can be regarded as based on two mixing ratios of a soluble formulation of IAsp (50 and 70% respectively) and an NPH precipitation of IAsp (50 and 30% respectively). Based on these previous assessments, no further nonclinical studies for the BIAsp 50 and BIAsp 70 products have been conducted and the nonclinical evaluation shall refer to the previously conducted studies provided in prior applications. • Pharmacokinetics of BIAsp 30 and BHI 30 after s.c. Injection – Pigs. • Pharmacodynamics Studies of BIAsp 30 injected SC in the Pig. • Single Dose Toxicity Test in the Rat. • Immunogenicity of Fresh and Aged BIAsp 30 and Other Insulins in the Rabbit.. • Local Toxicity Tests in the Pig.
	Module-V Clinical	The Firm has submitted following clinical studies: • A Randomised, Double Blind, Single Centre, Three Period Crossover Trial Testing the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 and Characterising the Pharmacokinetics of Biphasic Insulin Aspart 50 in Healthy Male • A single-centre, randomised, balanced, double-blind, cross-over trial investigating the

		bioequivalence of two formulations of Biphasic Insulin Aspart 50 in healthy male subjects • Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Formulation 2 and Formulation 4 of Biphasic Insulin Aspart 50 in Healthy Male subjects • A randomised, four period crossover trial in healthy subjects investigating the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and soluble insulin aspart. • Amended extension trial to: A randomised, four period crossover trial in healthy subjects investigating the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and soluble insulin aspart • Amended extension trial to: A randomised, four period crossover trial in healthy subjects investigating the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and soluble insulin aspart • A Stratified, Randomised, Double-Blind, Two-Period Crossover Trial Comparing the Pharmacodynamics and Pharmacokinetics of BIAsp 50 and BIAsp 70 in Non-obese and Obese Subjects with Type 2 Diabetes. • A Randomised, Double-blind, 4-week, Crossover Trial on two Treatment Regimens with Biphasic Insulin Aspart 70 and 50 in Patients with Type 2 Diabetes. • A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Characterizing the Pharmacokinetics and Pharmacodynamics of NN-X14Mix50 and NN-X14Mix70 in Healthy Male Subjects • An open-labelled, randomised, parallel group, multicentre, safety and efficacy study of NNX14Mix50 (BIAsp50) in a twice daily regimen in Type 2 diabetic subjects • A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Investigating the Pharmacokinetics and Pharmacodynamics of NN-X14Mix30 and NN-X14Mix50 in Type 2 Diabetic Patients • A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects

Remarks of Evaluator:		
Decision: Keeping in view legalized CoPP issued by Danish Medicine Agency (reference regulatory authority); Registration Board approved the products subject to compliance of current Import Policy for finished drugs.		
35.	**Name, address of Applicant / Importer**	**M/s Novartis Pharma (Pakistan) Limited, 15 West Wharf, Karachi, Pakistan.**
	Details of Drug Sale License of importer	**License No:** 007 **Address:** 15 West Wharf, Dockyard Road, Karachi, Pakistan. **Address of Godown:** C-21, SITE, Karachi. **Validity:** 12-03-2023. **Status:** License to sell drugs by way of wholesale
	Name and address of marketing authorization holder (abroad)	M/s Novartis Pharma Schweiz AG, 6343 Risch, Switzerland.
	Name, address of manufacturer(s)	M/s Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland
	Name of exporting country	Switzerland
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• **CoPP:** Firm has submitted original & legalized CoPP certificate (No. 22001018) dated 25-Mar-2022 issued by Swissmedic Switzerland for product with brand name of Cosentyx (brand name in requesting country is Fraizeron) Solution for Injection 300mg/2ml. The CoPP confirms product is on market in exporting country. • **GMP Certificate:** Firm has submitted original & legalized GMP Certificate No GMP-CH-1002561 of said manufacturer.
	Details of letter of authorization / sole agency agreement	Firm has submitted Original & Legalized Letter of Authorization. According to letter the firm Novartis Pharma authorizes "M/s Novartis Pharma (Pakistan) Limited" to register and market product in Pakistan and to be responsible for all matters pertaining to the regulation of this product in Pakistan. The letter was issued on 11-May-2022.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales

	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No:17425 Date of submission: 14-06-2022
	Details of fee submitted	PKR 75,000/-: 23-04-2022
	The proposed proprietary name / brand name	**Fraizeron** Solution for Injection 300mg/2ml in Pre-filled Pen
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled Pen contains: Secukinumab.....300mg
	Dosage form of applied drug	Solution for Injection in Pre-filled Pen
	Pharmacotherapeutic Group of (API)	Interleukin Inhibitors
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	1's Pre-filled Pen
	Proposed unit price	Proposed MRP per pack shall be furnished later
	Shelf Life	24 Months
	Storage Conditions	2-8°C
	The status in reference regulatory authorities	Product is approved in EU, Switzerland & Australia
	For generic drugs (me-too status)	Product in 150mg Pre-filled Pen with brand name of **Cosentyx** is already registered.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Secukinumab: M/s Novartis Pharma S.A.S., Centre de Biotechnologie 8 rue de I'Industrie 68330 Huningue, France.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API on accelerated conditions conducted on 5 ± 3°C for 6 months duration and long-term conditions conducted on ≤ -60°C for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	To support development and establish the shelf-life of Fraizeron 300 mg/2 mL Solution for injection in auto-injector, a comparability assessment was performed between the 2 mL prefilled syringe assembled in auto-injector (Process A) and the 2 mL pre-filled syringe assembled in needle safety device along with marketed Cosentyx (Fraizeron) 150 mg/1 mL pre-filled syringe assembled in needle safety device and auto-injector.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	The container closure system for Fraizeron 300 mg/2 mL Solution for injection in pre-filled autoinjector consists of a sterile, single use, pre-filled syringe (PFS) as the primary packaging component and auto-injector; a device constituent that is used in combination with the PFS for drug delivery.
	Stability study data of drug product, shelf life and storage conditions.	Firm has submitted the long-term stability study data at 5 ± 3°C for the duration of 24 months. The accelerated stability study is conducted at 25 ± 2°C / 60 ± 5 % RH and intermediate (30°C/75%RH) storage conditions. Additionally, stress storage (40°C/75%RH) conditions are tested to support comparability studies during development.
	Module – IV Non-Clinical	Characterize the primary pharmacological properties of secukinumab and a mouse anti-mouse IL-17A surrogate antibody BZN035. Characterize the comparative pharmacology and biology of secukinumab and BZN035 Establish a pharmacological basis for the intended clinical use. Develop a suite of bioanalytical, pharmacodynamic, and immunogenicity assays in order to understand drug disposition and exposure effect relationships in in vivo studies.

		Characterize the nonclinical disposition properties of secukinumab and BNZ035. Conduct a series of safety pharmacology and toxicology studies adhering to international guidelines, and establish a thorough understanding of the potential toxicities of secukinumab for the intended clinical use. Establish the comparability of the drug product produced during the course of the development program through repeated testing. Ensure compliance to globally accepted GLP regulations where applicable.
	Module-V Clinical	The clinical development program supporting the registration of the new dosage forms for secukinumab 300 mg/2 mL s.c. injection included three studies: A Phase I pharmacokinetics (PK)/tolerability study of six different injection methods including the approved 1 mL PFS and 1 mL AI in healthy subjects. A Phase III efficacy, PK, safety and tolerability study of 2 mL PFS in moderate to severe plaque psoriasis patients. A Phase III efficacy, PK, safety and tolerability study of 2 mL AI in moderate to severe plaque psoriasis patients.
	Remarks:	
	Decision: Keeping in view legalized CoPP issued by Swissmedic Switzerland (reference regulatory authority); Registration Board approved the products subject to compliance of current Import Policy for finished drugs.	
36.	**Name, address of Applicant / Importer**	M/s Immuno Well Pvt Ltd, No. 473, Street No.7, Block J-2, Johar Town, Lahore, Pakistan
	Details of Drug Sale License of importer	**License No**: 05-352-0066-100098D **Address**: 473, Street No.07, Block J-2, Johar Town, Lahore **Validity**: 17-Nov-2027 **Status**: License to sell, stock & exhibit for sale, distribute registered products on behalf of licensed pharmaceutical manufacturer as his authorized agent on the premises.
	Name and address of marketing authorization holder/Product License Holder (abroad)	M/s Sinovac (Dalian) Vaccine Technology Co., Ltd., Address: 36, 2nd Life road, DD Port, Economic & Technical Development Zone, Dalian, China
	Name, address of manufacturer(s)	Same
	Name of exporting country	China
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	The Firm has submitted Legalized copy of CoPP (No. Liaoning 20220012) issued on 18-12-2019 valid upto 25-05-2024 issued by Liaoning Medical Products Administration, China. Legalized GMP Certificate (ROM-201-201-09-01) dated 14-05-2021. Legalized GMP Notification (No. Liao22020010) dated 20-01-2022 issued by Liaoning Medical Products Administration, China.
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific letter of Authorization Letter dated 16-Aug-2022 from M/s Sinovac (Dalian) Vaccine Technologyc co., Ltd. According to the letter, M/s Sinovac (Dalian) Vaccine Technologyc co., Ltd appoints "Immuno Well Pvt Ltd" with

		address "No. 473, Street No.7, Block J-2, Johar Town, Lahore, Pakistan" it's truthful representative for sole purpose of registration of the said product.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	R&I Dy No.35599 Date: 08-12-2022.
	Details of fee submitted	Rs. 150,000/- via e-deposit slip No. **65286973821** dated 02-01-2023.
	The proposed proprietary name / brand name	**Sinovac Varicella Vaccine** Lyophilized Vaccine
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial of 0.5mL (after reconstitution) contains: Live varicella-herpes zoster virus…..not less than 3.3 lg PFU
	Dosage form of applied drug	Lyophilized Vaccine
	Pharmacotherapeutic Group of (API)	Varicella Vaccine
	Finished product specifications	WHO Spec
	Proposed Pack size	5.0 mL/ dose/ vial/ Pack + diluent
	Proposed unit price	**Rs.5,013.00/ dose/ Pack**
	Shelf Life	24 months
	Storage Conditions	2°C to 8°C
	The status in reference regulatory authorities	**WHO Prequalified**
	For generic drugs (me-too status)	**SKY Varicell Inj. 0.5mL/ dose/ vial** **Each dose of 0.5mL of reconstituted vaccine contains:** Live attenuated varicella-zoster virus (virus strain: Oka/SK, Cell line: MRC_5) ≥2400 PFU Pack size: 5's, Price: 5,8880/dose, Reg. No.111109
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO Format. Firm has summarized information related to nomenclature, structure, general properties, manufacture, characterization, control of the API, Justification of specifications, Reference standard or materials, Container Closure System, Stability of drug substance. The firm has also summarized information of drug product including description and composition, pharmaceutical development, manufacture, control of excipients, control of Finished Pharmaceutical Product, reference standard or materials, container closure system and stability.
	Name, address of drug substance manufacturer	Sinovac (Dalian) Vaccine Technology Co., Ltd. No. 36, 2nd Life Road, DD Port, Economic and Technical Development Zone, Dalian, Liaoning Province, P.R. China
	Module-III Drug Substance:	Firm has submitted drug substance related data containing: General Information, Manufacture, Characterization, Control of Drug Substance, Reference Standards or Materials, Container Closure System, Stability
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of three batches. The stability of single virus harvest of Varicella Vaccine, Live stored in stainless-steel bottles below -60°C for 35 days, and the shelf life of the single virus harvest is 30 days. And the stability of bulk of Varicella Vaccine, Live stored in stainless-steel bottles below -60°C for 13 months.

	Module-III Drug Product	Firm has submitted drug product related date including Description and Composition, Pharmaceutical Development, Manufacture, Control of Excipients, Control of Drug Product, Reference Standard or Materials, Container Closure System and Stability.
	Analytical method validation/verification of product	Firm has submitted analytical procedures along with validation.
	Container closure system of the drug product	Primary packaging is Injection Vial (2mL tubing made of neutral borosilicate glass) with Stopper for Injection Vial (Brominated butyl rubber stopper) Cap (Cap made of aluminum-plastics combinations)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability studies performed on the product for real time storage conditions +5˚C ± 3˚C for 24 months, accelerated condition 25˚C ± 2˚C for 6 months.
	Module-IV	• Single-dose toxicity was studied through Acute Toxicity Test of Subcutaneous Injection of Varicella Vaccine, Live in Mice. • Repeat-dose toxicity was carried out by Toxicity Test of Repeated Subcutaneous Injection of Varicella Vaccine, Live in Macaca fascicularis for 6 Weeks Followed by a 6-week Recovery Period.
	Module-V	• Randomized, double blind, controlled design to emonstrate the safety of varicella vaccine in population of different age groups. (**Phase-I**) • Randomized, double blind, placebo- controlled design to Evaluate the efficacy, immunogenicity and safety of Varicella Vaccine in healthy children (**Phase-III**) • Randomized, double blind, bridging design, Evaluate the lot consistency of the three consecutive lots of vaccine in commercial scale among healthy children. (**Phase-III**)
	Remarks	
	Decision: Keeping in view legalized CoPP and WHO Prequalification (Reference Regulatory Authority); Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	

B. Human Biological from Non-Reference

37.	**Name, address of Applicant / Importer**	M/s Himmel Pharmaceuticals (Pvt.) Ltd. 793-D, Block ‘’C’’, Faisal Town Lahore.
	Details of Drug Sale License of importer	License No: 05-352-0065-016174-D Address: 793-D, Block-C, Faisal Town Lahore Address of Godown: NA Validity: 06.Feb.2024 Status: License to sell drugs as distributor
	Name and address of marketing authorization holder (abroad)	M/s BEACON Pharmaceuticals Limited Plant address: Kathali ,Bhaluka, Mymensingh Bangladesh Office address: 9/B/2, Toynbee Circular Road, Motijheel Dhaka, Bangladesh
	Name, address of manufacturer(s)	M/s BEACON Pharmaceuticals Limited Plant address: Kathali ,Bhaluka, Mymensingh Bangladesh Office address: 9/B/2, Toynbee Circular Road, Motijheel Dhaka, Bangladesh
	Name of exporting country	Bangladesh

	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Original legalized COPP (Certificate# DA/6-110/2016/3353 issued on 04-06-2020 by Government of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorate General of Drug Administration, Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh. **GMP:** Firm has submitted Legalized GMP certificate (Certificate No. DA/6-110/06/10002) issued by M/s Beacon Pharmaceuticals limited. Also Renewal certificate is submitted (Certificate No. DA/6-110/06/4950).
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan. The authorization letter is valid till June, 2025.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No32920 Dated 10.12.2020 Dy. No.8733 Dated 05.04.2022, Dy. No 1531 Dated 17.01.2023
	Details of fee submitted	PKR: 50,030/- Date: 10-12-2021
	The proposed proprietary name / brand name	Pembroxim Injection 100mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 4 ml contains Pembrolizumab INN….100mg
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Anti-cancer
	Reference to Finished product specifications	In house
	Proposed Pack size	1 s
	Proposed unit price	As per current pricing policy of DRAP
	The status in reference regulatory authorities	Keytruda 100mg
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and

		controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Geneway Bio-Technology co., Ltd Address: No. 6 Anmin Road, Huangdai Town, Xiangcheng, Suzhou, Jiangsu China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted long term stability study data of 3 batches of drug substance at 25°C ± 2°C / 60 ± 5% RH for 12 months. The accelerated stability data is conducted at 40°C ± 2°C / 75 ± 5% RH for 6 months
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative analysis Studies against the reference product Keytruda (Merck sharp & Dohme, B.V Netherlands) has been submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Type 1 Glass Vial
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months. Real time stability studies conducted at 2 °C -8 °C and 65% ± 5% for 24 months

Bio-similarity studies:

WHO Bio-similarity guidelines	**Data submitted by the firm**
Quality Comparison Physicochemical characterization	**a) Primary Structure:** i. Amino acid sequence by LC-MS & MS/MS ii. N-terminal sequence by LC-MS. iii. C-terminal lysine by LC-MS. iv. N-glycosylation site by Liquid Chromatography with tandem mass spectrometry (LC-MS-MS) **b) Secondary Structure & high order Structure** i. Intact mass by LC-MS ii. Disulfide bond by LC-MS iii. Free thiol (Ellman's) iv. Circular Dichroism (Secondary Structure) by Far spectrogram.

	v. Thermostability by differential fluorimetry (DSF) **c) Heterogenicity** i. Glycan by LC-MS ii. Heterogenicity of glycosylation by FLD-HPLC iii. Isoelectric point by CIEF iv. Charge variant (CEX-HPLC
Biological Activity	Biological activity by: • PD-I binding activity by ELISA
Impurities	• Purity by SEC-HPLC • Purity by CE-SDS • Protein A by ELISA • DNA residual by qPCR • Host cell protein by ELISA
Stability Studies	Stability studies are provided.
Non-clinical Studies	Primary pharmacodynamics by: • Binding to PD-I • Inhibitory effect against binding of PD-I to PD-L1 or PD-L2 • One month repeated doses toxicity study in monkeys • Six months repeated doses toxicity study in monkeys
Clinical Studies	Comparative clinical study has not been submitted.

Evaluation:
The firm has not submitted non-clinical & clinical study data from its finish product manufacturer (Exporter M/s Beacon Pharmaceuticals Limited Bangladesh) instead all non-clinical & clinical study conducted by the bulk manufacturer (Geneway Bio-Technology co., Ltd China) have been submitted. Comparative clinical trial data has not been submitted.

The firm has submitted guidelines of the country of origin (Bangladesh) wherein it has been mentioned in Annexure 1 that clinical trial report from bulk manufacturer may also be submitted instead of clinical trial report conducted in Bangladesh. For the regulatory (free sale) status of the finished product the has submitted a statement/declaration wherein it has been mentioned that
"Nivolumab drugs are covered under the patent rules in China, that's why these generic products Cannot be registered in NMPA (National Medical Product Administration) China, till the expiry of patent. As per China drug regulation we can perform clinical trials of Nivolumab and Pembrolizumab which are not registered in China."

Decision: Registration Board deferred the case for the following clarification /data/information:

a) Regulatory status of products in various countries where the bulk of the product is exported.
b) Publication of clinical trial in any peer reviewed journal.
c) Data of Periodic Safety Updated report of applied formulation marketed in Bangladesh.

Case: Deferred case of Nivolunix 40mg Injection applied by M/s Himmel Pharmaceuticals (Pvt) Ltd Lahore.

The following products of M/s Himmel Pharmaceuticals (pvt) Ltd Lahore was deferred in 32^{3rd} meeting of Registration Board as per following details.

38.	**Name, address of Applicant / Importer**	**M/s Himmel Pharmaceuticals (Pvt.) Ltd, 793-D, Block 'C', Faisal Town, Lahore-54000, Pakistan**
	Details of Drug Sale License of importer	**License No:** 05-352-0065-0016174D **Address:** 793-D, Block 'C', Faisal Town, Lahore-54000, Pakistan **Address of go-down: N/A** **Validity: 06-02-2022** **Status:** License to sell drugs by way of Distributor

	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited **Plant address**: Kathali Bhaluka Mymensingh **Bangladesh.** **Office Address**: 9/B/2 Toyenbee Circular Road Motijheel, Dhaka 1223 Bangladesh
	Name, address of manufacturer(s)	-do-
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	**CoPP:** Firm has submitted original legalized COPP (DA/6-110/2016/3355) issued on 4-June-2020 **by** Directorate General of Drug Administration Ministry of Health & Family welfare Government of the people's republic of Bangladesh. The CoPP specifies free sale status of the product in country of origin along with its availability. The CoPP also confirms the GMP status of the firm. (Periodicity of routine inspection:2years)
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific letter of authorization dated 02-06-2020 from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register & sell their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No32920 Dated 10.12.2020, Dy. No.8733 Dated 05.04.2022, Dy. No.13612 Dated 06.06.2022
	Details of fee submitted	Rs. /- 50000 Dated 19.11.2020
	The proposed proprietary name / brand name	Nivolunix 40 Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each dose contains Nivolumab INN….40mg
	Dosage form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Antineoplastic agents (Anti-cancer), Monoclonal Antibodies
	Reference to Finished product specifications	In house
	Proposed Pack size	Pack Size: 1's
	Proposed unit price	Retail price As per SRO

	Shelf Life	24 months
	Storage Conditions	2 ^{O}C -8^{O}C
	The status in reference regulatory authorities	OPDIVO (NIVOLUMAB 40mg/4mL single dose vial) | BLA #125554 | BRISTOL MYERS SQUIBB in USFDA
	For generic drugs (me-too status)	Not available in Pakistan
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO. Firm has summarized information related to nomenclature, structure, general properties, manufacturers, description of manufacturing process and controls, Characterization (Elucidation of Structure and Other Characteristics), impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Geneway Bio-Technology co., Ltd Address: No. 6 Anmin Road, Huangdai Town, Xiangcheng, Suzhou, Jiangsu China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at 25±2°C for 10 days, at 5 ±3 °C for 6months & ≤-30 °C for 12 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted specification & in-house analytical method along with Analytical method validation studies for the applied product.
	Container closure system of the drug product	Nivolunix 40mg injection is provided in 5mL clear glass vial (USP type-I glass) 20 mm rubber stopper, type -1 and 20 mm Flip off seal with red color top.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 commercial batches. The accelerated stability study data is conducted at 40° C ± 2° C & 75% ± 5% RH for 6 months. The real time stability study data is conducted at 2 ^{O}C -8^{O}C for 24 months.
	Module-IV	**Pharmacology studies:** The binding of product to human CD279 (programmed cell death 1, PD-1): • Effects on interaction between PD-1 and PD-1 ligands using the PD-1/CHO cell line and biotin-labeled

		recombinant human PD-L1- Fc and PD-L2-Fc fusion proteins. • Effect on immunoreactivity (on alloantigen-induced T-cell activation, antigen-specific T cell reactivity using Cynomolgus monkeys) • Activity against malignant tumors in mice with malignant melanoma B16F10 cells. • Secondary pharmacodynamics (antibody-dependent cell-mediated cytotoxicity) • Safety pharmacology (Effects on the central nervous system, Effects on the cardiovascular system, Effects on the respiratory system) **Pharmacokinetic studies:** (Analytical procedures-assay, antibody assay, Single-dose administration, Repeated-dose administration) **Toxicology studies:** Single-dose toxicity using cynomolgus monkeys, Repeated-dose toxicity in cynomolgus monkeys, Extended study of pre- and postnatal development in cynomolgus monkeys, Cross-reactivity studies, Four-week repeated intravenous dose toxicity study with ipilimumab coadministration in cynomolgus monkeys) **Note:** The submitted clinical trial data is from bulk manufacture not from the finish product manufacter.
	Module-V	**Phase I study:** • An open-label study to investigate the pharmacokinetics (PK) in 17 patients with advanced solid tumors resistant to conventional therapies. **Phase II study:** An open-label study to investigate the PK and other endpoints in 35 patients. **Phase III study:** A Phase III trial to compare the efficacy & safety of FX02 and Opidivo (Nivolumab) injection in patients with advance NSCLC who had received prior platinum-based chemotherapy. **Note:** The submitted clinical trial data is from bulk manufacture not from the finish product manufacturer.
39.	Name, address of Applicant / Importer	**M/s Himmel Pharmaceuticals (Pvt.) Ltd, 793-D, Block 'C', Faisal Town, Lahore-54000, Pakistan**
	Details of Drug Sale License of importer	License No: 05-352-0065-0016174D Address: 793-D, Block 'C', Faisal Town, Lahore-54000, Pakistan Address of go-down: N/A Validity: 06-02-2022 Status: License to sell drugs by way of Distributor
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh. Office Address: 9/B/2 Toyenbee Circular Road Motijheel, Dhaka 1223 Bangladesh
	Name, address of manufacturer(s)	-do-
	Name of exporting country	Bangladesh

	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original legalized COPP (DA/6-110/2016/3355) issued on 4-June-2020 by Directorate General of Drug Administration Ministry of Health & Family welfare Government of the people's republic of Bangladesh. The CoPP specifies free sale status of the product in country of origin along with its availability. The CoPP also confirms the GMP status of the firm. (Periodicity of routine inspection:2years)
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific letter of authorization dated 02-06-2020 from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register & sell their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No32921 Dated 10.12.2020, Dy. No.8733 Dated 05.04.2022, Dy. No.13612 Dated 06.06.2022
	Details of fee submitted	Rs. /- 50000 Dated 19.11.2020
	The proposed proprietary name / brand name	Nivolunix 100 Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each dose contains Nivolumab INN….100mg
	Dosage form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	Antineoplastic agents (Anti-cancer), Monoclonal Antibodies
	Reference to Finished product specifications	In house
	Proposed Pack size	Pack Size: 1's
	Proposed unit price	Retail price As per SRO
	Shelf Life	24 months
	Storage Conditions	2^0C -8^0C
	The status in reference regulatory authorities	OPDIVO (NIVOLUMAB 100mg single dose vial) | BLA #125554 | BRISTOL MYERS SQUIBB in USFDA
	For generic drugs (me-too status)	Not available in Pakistan

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO. Firm has summarized information related to nomenclature, structure, general properties, manufacturers, description of manufacturing process and controls, Characterization (Elucidation of Structure and Other Characteristics), impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Name, address of drug substance manufacturer	Geneway Bio-Technology co., Ltd Address: No. 6 Anmin Road, Huangdai Town, Xiangcheng, Suzhou, Jiangsu China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at 25±2 °C for 10 days, at 5 ±3 °C for 6months & ≤-30 °C for 12 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted specification & in-house analytical method along with Analytical method validation studies for the applied product.
	Container closure system of the drug product	Nivolunix 40mg injection is provided in 5mL clear glass vial (USP type-I glass) 20 mm rubber stopper, type -1 and 20 mm Flip off seal with red color top.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 commercial batches. The accelerated stability study data is conducted at 40° C ± 2° C & 75% ± 5% RH for 6 months. The real time stability study data is conducted at 2 OC -8OC for 24 months.
	Module-IV	Pharmacology studies: The binding of product to human CD279 (programmed cell death 1, PD-1): • Effects on interaction between PD-1 and PD-1 ligands using the PD-1/CHO cell line and biotin-labeled recombinant human PD-L1- Fc and PD-L2-Fc fusion proteins. • Effect on immunoreactivity (on alloantigen-induced T-cell activation, antigen-specific T cell reactivity using Cynomolgus monkeys) • Activity against malignant tumors in mice with malignant melanoma B16F10 cells. • Secondary pharmacodynamics (antibody-dependent cell-mediated cytotoxicity)

		• Safety pharmacology (Effects on the central nervous system, Effects on the cardiovascular system, Effects on the respiratory system) Pharmacokinetic studies: (Analytical procedures-assay, antibody assay, Single-dose administration, Repeated-dose administration) Toxicology studies: Single-dose toxicity using cynomolgus monkeys, Repeated-dose toxicity in cynomolgus monkeys, Extended study of pre- and postnatal development in cynomolgus monkeys, Cross-reactivity studies, Four-week repeated intravenous dose toxicity study with ipilimumab coadministration in cynomolgus monkeys) Note: The submitted clinical trial data is from bulk manufacture not from the finish product manufacter.
	Module-V	Phase I study: • An open-label study to investigate the pharmacokinetics (PK) in 17 patients with advanced solid tumors resistant to conventional therapies. Phase II study: An open-label study to investigate the PK and other endpoints in 35 patients. Phase III study: A Phase III trial to compare the efficacy & safety of FX02 and Opidivo (Nivolumab) injection in patients with advance NSCLC who had received prior platinum-based chemotherapy. Note: **The submitted clinical trial data is from bulk manufacture not from the finish product manufacturer.**

Bio-similarity studies:	
WHO Bio-similarity guidelines	**Data submitted by the firm**
Quality Comparison Physicochemical characterization	**a) Primary Structure:** i. Amino acid sequence by LC-MS & MS/MS ii. N-terminal sequence by LC-MS. iii. C-terminal lysine by LC-MS. iv. N-glycosylation site by Liquid Chromatography with tandem mass spectrometry (LC-MS-MS) **b) Secondary Structure & high order Structure** i. Intact mass by LC-MS ii. Disulfide bond by LC-MS iii. Free thiol (Ellman's) iv. Circular Dichroism (Secondary Structure) by Far spectrogram. v. Thermostability by differential fluorimetry (DSF) **c) Heterogenicity** i. Glycan by LC-MS ii. Heterogenicity of glycosylation by FLD-HPLC iii. Isoelectric point by CIEF iv. Charge variant (CEX-HPLC
Biological Activity	Biological activity by: • PD-I binding activity by ELISA
Impurities	• Purity by SEC-HPLC • Purity by CE-SDS • Protein A by ELISA • DNA residual by qPCR • Host cell protein by ELISA

Stability Studies	Stability studies are provided.
Non-clinical Studies	Primary pharmacodynamics by: • Binding to PD-I • Inhibitory effect against binding of PD-I to PD-L1 or PD-L2 • One month repeated doses toxicity study in monkeys • Six months repeated doses toxicity study in monkeys
Clinical Studies	Comparative clinical study has not been submitted.

Registration board in it 323rd meeting deferred the case as per following details.
Registration Board deferred the case to confirm the relevant guidelines and regulatory (free sale) status of the finished product manufactured by the same bulk in China.

The firm has submitted guidelines of the country of origin (Bangladesh) wherein it has been mentioned in Annexure 1 that clinical trial report from bulk manufacturer may also be submitted instead of clinical trial report conducted in Bangladesh. For the regulatory (free sale) status of the finished product the has submitted a statement/declaration wherein it has been mentioned that
"Nivolumab drugs are covered under the patent rules in China, that's why these generic products Cannot be registered in NMPA (National Medical Product Administration) China, till the expiry of patent. As per China drug regulation we can perform clinical trials of Nivolumab and Pembrolizumab which are not registered in China."

Decision: Registration Board deferred the case for the following clarification /data/information:

a) **Regulatory status of products in various countries where the bulk of the product is exported.**
b) **Publication of clinical trial in any peer reviewed journal.**
c) **Data of Periodic Safety Updated report of applied formulation marketed in Bangladesh.**

40. Case No. Local human Biological applied for registration by M/s Hilton Pharma Karachi deferred in 320th meeting of RB.

The following product for the local manufacturing biological drug was considered in 262nd Meeting of Registration Board held on 20-21stOctober, 2016 and the Board decided as under;

Central Licensing Board has approved the manufacturing facility for rDNA products, As product is also of rDNA origin, which is evident from the provided certificate of analysis and other documents, thus Registration Bard approved Gluwell- Base 3ml Cartridge (Insulin Glargine 100IU). Insulin glargine will be imported in crystalline form from M/s Biocon India and will be formulated locally at M/s Hilton Pharma Karachi.

But later on the Registration Board in its 270th meeting advise the division of Biological drugs to come up with working paper in the next meeting. The final guidelines regulatory requirements of Biological drugs using rDNA technology was approved in 278th meeting of Registration Board and it was mentioned in the Guidelines that "***For the already registered drugs for local manufacturing the current guidelines shall apply".***
And the firm was advised to submit Biosmilarity data in light of decision of 278th meeting of Registration Board. The data submitted by the firm was taken up in 296th meeting of Registration board wherein the Board deferred by deciding as under;

Registration Board referred the case to Committee on Biological Drugs constituted in 273rd meeting of Registration Board for its recommendations on the requirements of toxicity studies and abnormal toxicity studies. Moreover, Registration Board nominated Lt. Gen. (R) Prof. Dr. Karamat Ahmed Karamat (HI-M, SI-M) as Chairman of said committee. However, following documents need to be submitted by the firm:

i. Legalized GMP certificate of drug substance manufacturer abroad.
ii. Legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as evidence that the final product has been manufactured by same concentrate/ready to fill bulk.
iii. Data of sterility test performed locally on finished drug.

iv. An agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.

The detail of the product as under;

41.	Name of Manufacturer	M/s Hilton Pharma (Pvt.) Ltd. 13, sector 15, Korangi Industrial Area, Karachi.
	Manufacturing site of Bulk.	M/s Biocon Biologics Limited, Block No. M1, M2 and M6, Q1 (QC3 and QC10) & W3, 20th km Hosur Road, Electronics City, Bengaluru, 560100, India
	Brand Name +Dosage Form + Strength	Gluwell-Base 3ml Cartridge Insulin glargine (100IU/ml)
	Composition	Each ml cartridge contains: Insulin glargine ……100IU
	Finished product specifications	USP Specification
	Pharmacological Group	Therapeutic Protein
	Shelf life	2 years when stored at 2-8 ^{O}C
	Products already registered in Pakistan	Lantus by Sanofi
	Type of Form Dy No & Date of application, Fee submitted	Form-5, Dy No & Date of initial Application. Dy No.2924/2016(R&I) dated 27-06-2016, Dy No.4814(R&I) dated 21-02-2022, Dy No.5672(R&I) dated 01-03-2022, Dy No.19367(R&I) dated 01-07-2022, Dy No.22963(R&I) dated 15-08-2022 Rs. 20,000 dated 27-06-2016
	Demanded Price / Pack size	Price: As per DPC 3ml Cartridge Pack of 1's ,3's & 5's

The *Committee on Biological Drugs* revised the Biosmilarity guidelines which was approved in 297th meeting of Registration board. And the firm submitted data as per above mentioned decision of the Board which was evaluated tabulated below;

Documents required as per 297th RB decision for Biological Drugs (Concentrated Form/Ready to fill Form)	**Documents submitted by firm**
The firms shall provide legalized GMP certificate (issued by relevant regulatory authority) of biological drug substance manufacturer abroad (who will provide concentrate / ready to fill bulk of biological drug to Pakistani manufacturers for further processing) as an evidence that the manufacturer is an authorized manufacturer of biological drug in the country of origin. Submission of valid GMP is exempted, if valid GMP status is evident from official website of regulatory authority of country of origin.	The firm has submitted legalized copy of GMP issued by Drug Control Department, Govt of Karnataka. The same site also indicated on Eudra GMP for Active Substance (Drug substance) of INSULIN GLARGINE along with others APIs.
The firms shall provide legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority (or its website) as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk.	The firm has submitted that the bulk manufacturing site of the firm is "*Block No. M1, M2 and M6, Q1 (QC3 and QC10) & W3, 20th km Hosur Road, Electronics City, Bengaluru*" while finished products are manufactured from the same bulk on other site of the company i.e. "*M/s Biocon Biologics Limited, Block B1,B2,B3,B4 Q13 of Q1 And W20, & Unit S18, 1st Floor, Block B4, Special Economic*

	Zone, Plot No 2,3,4 And 5 Phase IV Bommasandra Jigani Link Road, Bengaluru, 560099, India." Instead of Free Sale Certificate of finish product manufactured from the same bulk the firm has submitted DML. The firm has submitted legalized copy of Drug Manufacturing License (DML) of the M/s Biocon Biologics Limited India with list of products attached wherein Insulin Glargine 3ml,5ml,10ml vials, 3ml Cartridge & 3ml Prefilled Pen are mentioned in permitted to manufacture for domestic purpose & in the same list the export purpose only list is separately mentioned.
The firm shall provide the complete Bio-similarity studies of the finished product of same source (bulk concentrate or ready to fill) manufactured either from country of origin or by any reference regulatory authority as adopted by Registration Board to demonstrate the biosimilarity. However, it will not be required if the finished drug product was approved before implementation of biosimilarity in the said country and finished drug product is still freely available and the firm shall provide the safety, efficacy data of finished drug product as per applicable regulatory requirements at that time.	Provided & Evaluated below
The firm shall provide the lot release certificate of the finished product manufactured by same bulk concentrate/ ready to fill from country of export (If applicable).	The firm informed that no Lot release certificate is required for such types of product in India. (The letter is from the importer side)
The firm shall provide the 6 months accelerated and real time stability studies for drug substance & drug product manufactured locally.	Provided
The local manufacturer shall manufacture three trial batches (quantity sufficient to meet the complete testing up to the assigned shelf life both for real time and accelerated stability studies) of the finished biological product to finalize the formulation and then perform tests as per following order: i. Latest Pharmacopoeia ii. Innovator Product iii. Reference Biotherapeutic Product iv. In case aforementioned tests are not available then tests as adopted by drug substance manufacturer shall be followed.	Provided results for the following tests: Appearance, Identification, PH, Product related substances and impurities, Limit of High Molecular weight proteins, m-cresol Content, Assay (Insulin Glargin), Zinc determination, Bacterial Endotoxin test & sterility test. Test result of Abnormal toxicity study conducted from HEJ Research institute is also submitted.
The manufacturer shall perform all tests locally as mentioned on Certificate of analysis of finished product of drug substance supplier in case of non-pharmacopoeial product.	Submitted as mentioned above
The firm shall also provide the list of finished products being manufactured from same bulk concentrate or ready to fill form in any country of the world (if available).	Provided
The firm shall provide the agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.	Submitted.

Regular monitoring through pharmacovigilance reporting system shall be observed through proper pharmacovigilance cell of the manufacturer and report will be forwarded to the National Pharmacovigilance Centre, Division of Pharmacy Services and Biological Division of DRAP. In case of any severe adverse event, immediate mandatory reporting procedure shall be followed.	The firm has provided SOP for Pharmacovigilance Surveillance. The firm has also provided Commitment on its letter head mentioning the said statement.
The firm shall inform DRAP if there shall be any adverse event or ADR reporting from the country of manufacture of concentrate/ready to fill bulk and finished product as required vide Rules 30 of Drug (LR&A) Rule.	Commitment provided on the letter head
If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.	Commitment provided on the letter head
All the provisions as contained in the Drugs Act, 1976 and rules made there under including provisions of Lot Release certification from National Control Laboratory for Biologicals shall be strictly adhered to.	Commitment provided on the letter head
For the already registered drugs for local manufacturing, the current guidelines shall apply at the time of renewal of product.	

Bio-similarity studies of the finished product of same source (bulk concentrate or ready to fill) manufactured from country of origin.	
WHO Bio-similarity guidelines	**Data submitted by the firm**
Quality Comparison Physicochemical characterization	**d)** Protein Content at UV 280 (by RP-HPLC method) **e) Primary Structure:** v. Intact Mass determination by Liquid Chromatography-mass spectrometry (LC-MS) vi. Molecular Mass (Reduced mass) determination by LC-MS vii. Peptide Mapping (Reduced) by LC-MS viii. Peptide sequencing by Liquid Chromatography with tandem mass spectrometry (LC-MS-MS) **f) Secondary Structure & high order Structure** vi. Peptide mass fingerprinting under non –reducing conditions for confirmation of disulfide linkage by LC-MS vii. Disulfide linkage by 2D NMR viii. Secondary Structure by FT-IR spectroscopy ix. Circular Dichroism (Secondary Structure) by Far spectroscopy. x. Circular Dichroism (Tertiary Structure) by Near spectroscopy. xi. Determination of thermal stability by mean of Differential scanning calorimetry DSC xii. Determination of Isoelectric point (pI) by means of capillary isoelectric focusing (cIEF)
Biological Activity	Biological activity was carried out for insulin glargine injections by means of four different methods:. • Cell bases metabolic assay, • Cell bases proliferation assay (Mitogenic assay) • Insulin receptor binding assay • IGF-1 receptor binding assay. Additionally in vivo bioassay /Insulin assay (USP 121 & USP 111) : Rabbit blood sugar method
Impurities	Determination of product related substances (Glycosylated species precursor, Sequence species Deamidation/Acetylation by mean of RS method
Stability Studies	Stability studies are provided.

Non-clinical Studies	**Repeat dose toxicity study:** A comparative 90-day toxicity study with recombinant Insulin Glargine (Biocon Ltd) and Lantus (Aventis Pharma) in Wistar Rats by subcutaneous route (Study no. G4668)
Clinical Studies	Phase-I study: A Single dose, randomized, double-blind, 3- way crossover, euglycemic clamp study to measure relative PK & PD of Biocon's insulin glargine (vials) with Lantus-EURP (cartrdges) and Lantus-USRLD (disposable Pens). Clinical Pharmacology Study of FFP-112 in Healthy Male Adults by Glucose Clamp Procedure-Pharmacokinetic and Pharmacodynamic Analyses. (Comparative with Lantus) Open Label, Randomized, Multicentric Study to Establish Safety and Efficacy of Recombinant Insulin Glargine Manufactured by Biocon Ltd Compared to Lantus TM in Type 1 Diabetes Mellitus Patients. **(Total 226 evaluable patients)**

The case was deferred in 320th meeting Registration Board as per following:

i. Valid legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority (or its website) as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk.
ii. Justification of performing open label safety and efficacy study instead of double-blind study.

The firm has submitted copy of Free Sale Certificate (FSC) along with under taking that they will submit the legalized Free Sale Certificate once received. For justification of open label safety and efficacy study instead of double-blind study the firm has submitted the following which is reproduced as under;
"According to FDA Guideline "Clinical Immunogenicity consideration for biosimilar and interchangeable insulin products" and updated recommendation from the European medicines' agency, which published revised guideline in 2015, A comparative clinical study immunogenicity study generally would be unnecessary to support a demonstration of bio similarity or interchangeability. Guideline attached as Annex-I.
Furthermore, European Medicine Agency (EMA) no longer recommends a clinical immunogenicity study to support a bio-similar marketing application.

As per Minutes of 323rd Meeting of Drug Registration Board the same product of "Recombinant Insulin Glargine" (of M/s Getz Pharma) has been approved on the basis Clinical Studies "Open label, comparative, randomized, multicenter clinical study", Minutes of 323rd Meeting of Drug Registration Board attached as Annex-II**."**

Decision: Keeping in view the Biosmilarity data submitted by the firm in light of guidelines approved in 297th meeting of Registration Board, the Board approved the product subject to submission of valid legalized free sale certificate/CoPP either from country of origin as evidence that the final product has been manufactured by same concentrate/ready to fill bulk.

Cases of AD-III (Ms. Haleema Sharif)

Case No. 1: Imported Veterinary Biologicals from Non-Reference Countries:

42.	**Name and address of Importer**	**M/s Orient traders international,** CM-10, Block A, Kazimabad, Model Colony, Karachi.
	Detail of DSL	**M/s Orient traders international** Address: CM-10 Block -A, Kazimabad, Model Colony, Karachi. Valid till: 25-07-2022
	Name and address of Manufacturer	**Manufacturer of Drug:** **/Marketing Authorization Holder:** Pharmagal-Bio, spol. s.r.o. Murgasova 5, 949 Nitra Slovak Republic.
	Name of exporting country	EU-Slovak Republic
	Brand Name +Dosage Form + Strength	Avipharm ND
	Diary No. Date of R& I & fee	Dy. No. 22598 R&I Dated 17-08-2021 Rs. 150,000/- (Slip No. 9176574968)

	Composition	Lyophilizate for suspension Each dose contains: Newcastle disease Virus, live strain Lasota min. 10^6 EID_{50} – 10^7 EID_{50}
	Pharmacological Group	Veterinary Vaccine
	Type of Form	Form-5A
	Finished Product Specification	Ph. Eur. specifications
	Shelf Life	24months----(2-8ºC)
	Document Details	**i. <u>Certificate of Pharmaceutical Products (Original Legalized):</u>** Certificate of Pharmaceutical Product confirming Free sale Status and GMP is submitted by firm. Certificate No.3057/I/2021 Manufacturer/Product License Holder: Pharmagal-Bio, spol. s.r.o. Murgasova 5, 949 Nitra Slovak Republic. Issued by: Institute for State Control of Veterinary Biologicals and Medicaments. **ii. Original legalized Product Specific Sole Agency Agreement made on March 01, 2022 is submitted by the firm.**
	Pack size & Price	5000doses per Vial: Decontrolled
	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	Avipharm ND (1000 doses) is already registered Reg No. 107934. Pestikal LaSota® (Lyophilisate for suspension) Reg No. 088663 Each single dose vaccine contains: Lentogenic live Newcastle disease virus, LaSota strain…..≥106.0EID50)
	Remarks of Evaluator	
	Decision: Keeping in view the legalized COPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.	
43.	**Name and address of Importer**	**M/s Orion Group, Faisalabad,** 97 Commercial Area, Usman Block, Muslim Town No. 1 Sargodha Road, Faisalabad
	Detail of DSL	**M/s Orion Group, Faisalabad,** Address: 97 Commercial Area, Usman Block, Muslim Town No. 1 Sargodha Road, Faisalabad Valid till: 22-Jan-2023
	Name and address of Manufacturer	**Manufacturer of Drug:** M/s. DOLLVET VETERINER ASI Ilac Madde Uretim Sanayi Ve Ticaret A.S. Address: Oragnize Sanayi Bolgesi Kocoren OSB Mahallesi. 106. Cad. No:6 Eyyubiye / SANLIURFA/TURKY
	Name of exporting country	Republic of Turky
	Brand Name +Dosage Form + Strength	TAYLEDOLL INJECTABLE
	Diary No. Date of R& I & fee	Dy. No. 17000 R&I Dated 14-07-2020 Rs. 100,000/- 14-07-2020
	Composition	Each dose contains: Lymphoid cell infected by living attenuated Theileria annulata macroschizoids… at least 1×10^7 lymphoid cells.

	Pharmacological Group	Vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's Specifications
	Shelf Life	3years
	Document Details	**Original Legalized Free Sale Certificate:** Manufacturer: M/s. DOLLVET BIYOTTNOLOGI A.S. **Original Legalized Free Sale Certificate:** Issued to: M/s. DOLLVET BIYOTTNOLOGI A.S. Valid till 23 May 2023. **Original Legalized Free Sale Certificate:** Product specific Sole agency agreement dated 15th June, 2021 is submitted by the firm.
	Pack size & Price	10ml
	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	
	Remarks of Evaluator	In response to this division's letter dated13th July 2021 firm has submitted following: i. Copy of valid DSL ii. Original Legalized GMP certificate and Original Legalzed Free sale certificate indicating diluent. iii. Stability studies for diluent. iv. For already registered product firm has referred to the decision of Registration Board taken in its 313th meeting wherein the Board approved ***Teylovac Vaccine of M/s. Huzaifa International*** from Turkey with following composition: Brand Name:Teylovac Vaccine Composition: Live Attenuated Freez Dried Theileria Annulata Cells Based Vaccine with Diluent Each Dose of Vaccine Contains: Theileria Annulata…. 1×10^7 Cells. *Following documents are still required by firm.* *i. Stability studies of lyophilized part of product at appropriate time intervals 0,3,6,9, … for three batches is required.* *ii. Title of firm on Submitted GMP and FSC are different then Form 5A so firm may be advised to apply for change in title of manufacturer.*
	Decision: Registration Board deferred the case for the following: **i. Submit Stability studies of lyophilized part of product at appropriate time intervals 0,3,6,9, … for three batches.** **ii. Apply for change in title of manufacturer as Title of firm on Submitted GMP and FSC are different then Form 5A.** **iii. Submit evidence of required manufacturing facility i.e. protozoal vaccine section of manufacturer.**	

Case No. 2: Imported Human Biological applied by M/s Dow Institute of Life sciences deferred in 323rd meeting of Registration Board.

44.	**Name, address of Applicant / Importer**	**M/s Dow Institute of Life sciences,** **Ojha Campus, Suparco Road, off main University road, Gulza-e-Hijri, Scheme 33, Karachi**
	Details of Drug Manufacturing License	**License No: 000915** **Address:** Ojha Campus, Suparco Road, off main University road, Gulza-e-Hijri, Scheme 33, Karachi

		Status: License to manufacture by way of formulation.
	Name and address of marketing authorization holder (abroad)	Bulk manufacture: M/s. Changchun Zhuoyi Biological Co., Ltd Address: No.2 Yongxin Road, Economic Development Zone, Shuangyang district, Changchun City Jilin Province, China.
	Name, address of manufacturer(s)	(Bulk Import Local Repack) M/s Dow Institute of Life sciences, Ojha Campus, Suparco Road, off main University road, Gulza-e-Hijri, Scheme 33, Karachi
	Name of exporting country	China (bulk import local repack)
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	Original Legalized CoPP No. 20220002 is submitted by the firm.
	Details of letter of authorization / sole agency agreement	N/A Bulk import local repack
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☐ Finished Pharmaceutical product import ☒ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No.24366 (R&I) Dated 22.09.2020
	Details of fee submitted	Rs. 100,000/-
	The proposed proprietary name / brand name	**Dow-RAB Lyophilized Powder for Injection** **Rabies Vaccine(Vero Cell) for Human Use**
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	**Lyophilized Part:** Each dose of lyophilized vaccine for immunizing dose(0.5ml) contains: Purified, Inactivated Rabies Virus ….2.5IU (Prepared on Vero cells CTN IV strain of Rabies virus) **Diluent Part:** Each ampule contains: Sterile water for injection…. 0.5ml
	Dosage form of applied drug	Powder for Injection
	Pharmacotherapeutic Group of (API)	Viral Vaccines
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	USP type I clear transparent glass vial, 1's vial with 0.5ml diluent
	Proposed unit price	As per SRO/DPC

	Shelf Life	24 months
	Storage Conditions	2-8 ºC
	The status in reference regulatory authorities	WHO Prequalified Product VERORAB (Inactivated Rabies Virus, Wistar Rabies PM/WI38 1503-3M strain)
	For generic drugs (me-too status)	**VaxiRan-N Rabies Vaccine of Hakimsons (Impex) (Private) Limited,** Each vial of lyophilized powder contains: Inactivated rabies virus (Pitman Moore Strain) Potency: ≥ 2.5 IU; Sterilized water for Injection for VaxiRab-N: one ampoule of 1ml sterilized water for Injections **Chirorab of StratHealth Pharma Pvt Ltd** Each dose of 1ml contains: Inactivated rabies virus (Flury LEP strain), (inactivated by ß-propiolactone), potency: ≥ 2.5 I.U (propagated in primary chick fibrolast cell cultures); Sterile water for injection (as solvent): 1ml (ampoule) **Rabies Vaccine (Vero Cell) Human Use of National Institute of Health (NIH).** Each single 0.5ml dose of vaccine contains: Protective activity of Rabies Antigen: ≥2.5IU (Inactivated Rabies Virus PV2061 strain)
	Module-II (Quality Overall Summary)	Firm has submitted QOS. Firm has summarized information related to general properties, manufacturers, description of manufacturing process, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
	Name, address of drug substance manufacturer	M/s Changchun Zhouyi Biological Co., Ltd. No.2 Yongxin Road, Shuangyang economic Development Area, Changchun, Jilin Province, China.
	Module-III Drug Substance:	Firm has submitted drug substance data related to nomenclature, structure, manufacturers, description of manufacturing process, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and real time stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Stability studies at 2-8ºC of three batches of drug substance for six months is submitted.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted validation of Analytical methods of Rabies Virus Assay.
	Container closure system of the drug product	USP Type I
	Stability study data of drug product	Stability Studies of three batches both Real time (2-8ºC) and Accelerated (25 ºC±2/60%RH±5) for 3 months is submitted by the firm

	Module-IV Non-Clinical	The firm has also submitted the non-clinical overviews.
	Module-V Clinical	The firm has also submitted the clinical overviews and summaries.
	Remarks of Evaluator	i. Stability data is only for three months. ii. Applied vaccine strain is CTN 1V as per documents and clarification submitted by the firm and it has not been confirmed from Reference Regulatory Authorities and also from locally registered product and name of strain is also not mentioned on CoPP.
	Decision of 323rd Registration Board meeting	Registration Board advised to seek following information before approval of minutes: • Seek information from CDC, NIH regarding circulating strains of Rabies virus in Pakistan and need of Inactivated Rabies virus CTN 1V strain vaccine in Pakistan. • Seek information from NIH regarding strain of their registered rabies virus vaccine. • Advised Dow Institute to submit 6 months' real time and accelerated stability studies for consideration by Registration Board. The Board further advised to process case for consideration of registration Board after submission of 6 months stability data.
	Evaluation by BE&R Division: Following is submitted for consideration of the Board: • CDC, NIH vide their letter dated 2nd January 2023 informed that NIH Rabies vaccine is manufactured from PV2061 of fixed rabies virus. The virus strain was isolated by Pasteur in 1882. It has been continuously passaged in rabbit brain until 1983 and named as PV2061. The PV2061 of Rabies virus was adapted in Vero cell for 14 passages and then cryopreserved as the primary seed lot of rabies virus. • In a meeting with senior scientific officer at CDC NIH it was discussed that Rabies virus is quite stable virus as its genome is non-segmented, and Origin of CTN 1V strain is old Louis Pasteur strain of rabies virus which was isolated in 1880s and since then this virus shows little mutations, different countries name this virus based on passages. and CTN 1V strain vaccine due to its origin in old Louis Pasteur strain is equally effective in preventing disease like other vaccines strains of rabies virus e.g. PM, PV2061, etc. • Firm has submitted six month accelerated (25 °C±2/60%RH±5) and real time (2-8°C) stability studies of three batches of product "**Dow-RAB Lyophilized Powder for Injection Rabies Vaccine (Vero Cell) for Human Use".**	
	Decision: Keeping in view the approval status of product in country of origin and clarifying remarks of CDC NIH Registration Board approved the product. The Board further advised BE&R division to process letter for cold storage facility verification of firm without waiting for formal approval of minutes.	

Case No. 3: Imported Human Biological applied by M/s Calory Pharma deferred in 320th meeting of Registration Board.

45.	**Name, address of Applicant / Importer**	**M/s Calory Pharma,** **75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi.**
	Details of Drug Sale License of importer	License No: 110 Address:

		75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi. Validity: 06-07-2023 Status: License to sell drugs by way of whole sale.
	Name and address of marketing authorization holder (abroad)	M/s 8161429 Venipharm, 422, Bureaux de la Colline F-92213 Saint-Cloud, France.
	Name, address of manufacturer(s)	M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France.
	Name of exporting country	Germany
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted legalized CoPP (No. VEN/270521/10) dated 23-06-2021 issued by Authority for Justice and Consumer Protection of the Free and Hanseatic City of Hamburg. The certificate specifies the GMP status of the manufacturer. The certificate specifies the Free Sale status of the product in country of origin.
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific Letter of Authorization from Qualified Person of M/s Venipharm. According to the letter, the firm M/s Venopharm authorizes "Calory Pharma Private Limited" to register, renew and to get the registration certificate for the product. The letter was issued on 17-12-2021 and valid for five years.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3894 (R&I) Dated 10-02-2022
	Details of fee submitted	Rs. 150,000/- dated 04-01-2022
	The proposed proprietary name / brand name	Enoxaparin Ledraxen 4000IU (40mg)/0.4mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS (0.4ml) contains: Enoxaparin Sodium……4000IU (equivalent to 40mg)
	Dosage form of applied drug	Solution for Injection in PFS
	Pharmacotherapeutic Group of (API)	Anticoagulant
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	10's PFS

	Proposed unit price	As per SRO/DPC
	Shelf Life	24 Months
	Storage Conditions	$\leq 25^0$C
	The status in reference regulatory authorities	The product is itself approved in Germany.
	For generic drugs (me-too status)	Noxane of M/s BF Biosciences (Reg. No. 107948).
	Module-II (Quality Overall Summary)	Firm has submitted ICH QOS. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
	Name, address of drug substance manufacturer	M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 7 batches of Drug Substance at real time conditions for 36 months, 01 batch for 12 months, 01 batch for 09 months & 01 batch for 03 months. The real time stability data conducted at 25^0C$\pm 2^0$C/60±5%RH is for 18 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted validation of Analytical methods of Anti-factor Xa activity, Anti-factor IIa Activity, Free sulfate content, Protein content, Bacterial Endotoxin, Sterility.
	Container closure system of the drug product	• A pre-filled syringe consisting of a 1-mL long barrel of type I glass with a fixed 27-gauge ½ inch stainless steel needle and a needle shield made of bromobutyl rubber • A 1-mL plunger rod made of polypropylene (which does not come directly in contact with the finished product) • A plunger stopper consisting of bromobutyl rubber
	Stability study data of drug product	Firm has submitted stability study data of 03 batches of 2000IU & 02 batches of 10000IU at real time, intermediate (Zone IVB) & conditions. The accelerated stability study data is conducted

		at 40±2^{0}C/75%RH±5% for 6 months. The real time stability study data is conducted at 25±2^{0}C/60%±5RH. The intermediate stability study data is conducted at 30±2^{0}C/65%±5RH.
46.	**Name, address of Applicant / Importer**	**M/s Calory Pharma,** **75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi.**
	Details of Drug Sale License of importer	License No: 110 Address: 75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi. Validity: 06-07-2023 Status: License to sell drugs by way of whole sale.
	Name and address of marketing authorization holder (abroad)	M/s 8161429 Venipharm, 422, Bureaux de la Colline F-92213 Saint-Cloud, France.
	Name, address of manufacturer(s)	M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France.
	Name of exporting country	Germany
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted legalized CoPP (No. VEN/270521/11) dated 23-06-2021 issued by Authority for Justice and Consumer Protection of the Free and Hanseatic City of Hamburg. The certificate specifies the GMP status of the manufacturer. The certificate specifies the Free Sale status of the product in country of origin.
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific Letter of Authorization from Qualified Person of M/s Venipharm. According to the letter, the firm M/s Venopharm authorizes "Calory Pharma Private Limited" to register, renew and to get the registration certificate for the product. The letter was issued on 17-12-2021 and valid for five years.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3895 (R&I) Dated 10-02-2022
	Details of fee submitted	Rs. 150,000/- dated 04-01-2022
	The proposed proprietary name / brand name	Enoxaparin Ledraxen 6000IU (60mg)/0.6mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS (0.6ml) contains: Enoxaparin Sodium……6000IU (equivalent to 60mg)
	Dosage form of applied drug	Solution for Injection in PFS

	Pharmacotherapeutic Group of (API)	Anticoagulant
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	10's PFS
	Proposed unit price	As per SRO/DPC
	Shelf Life	24 Months
	Storage Conditions	$\leq 25^0$C
	The status in reference regulatory authorities	The product is itself approved in Germany.
	For generic drugs (me-too status)	Noxane of M/s BF Biosciences (Reg. No. 107949).
	Module-II (Quality Overall Summary)	Firm has submitted ICH QOS. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
	Name, address of drug substance manufacturer	M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 7 batches of Drug Substance at real time conditions for 36 months, 01 batch for 12 months, 01 batch for 09 months & 01 batch for 03 months. The real time stability data conducted at 25^0C$\pm 2^0$C/60±5%RH is for 18 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has submitted validation of Analytical methods of Anti-factor Xa activity, Anti-factor IIa Activity, Free sulfate content, Protein content, Bacterial Endotoxin, Sterility.
	Container closure system of the drug product	• A pre-filled syringe consisting of a 1-mL long barrel of type I glass with a fixed 27-gauge ½ inch stainless steel needle and a needle shield made of bromobutyl rubber

		• A 1-mL plunger rod made of polypropylene (which does not come directly in contact with the finished product) • A plunger stopper consisting of bromobutyl rubber
	Stability study data of drug product	Firm has submitted stability study data of 03 batches of 2000IU & 02 batches of 10000IU at real time, intermediate (Zone IVB) & conditions. The accelerated stability study data is conducted at 40±2^{0}C/75%RH±5% for 6 months. The real time stability study data is conducted at 25±2^{0}C/60%±5RH. The intermediate stability study data is conducted at 30±2^{0}C/65%±5RH.
47.	**Name, address of Applicant / Importer**	**M/s Calory Pharma,** **75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi.**
	Details of Drug Sale License of importer	License No: 110 Address: 75-B, Circular Street No. 13, Central Lane, Phase-II, DHA, Karachi. Validity: 06-07-2023 Status: License to sell drugs by way of whole sale.
	Name and address of marketing authorization holder (abroad)	M/s 8161429 Venipharm, 422, Bureaux de la Colline F-92213 Saint-Cloud, France.
	Name, address of manufacturer(s)	M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France.
	Name of exporting country	Germany
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted legalized CoPP (No. VEN/270521/12) dated 23-06-2021 issued by Authority for Justice and Consumer Protection of the Free and Hanseatic City of Hamburg. The certificate specifies the GMP status of the manufacturer. The certificate specifies the Free Sale status of the product in country of origin.
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific Letter of Authorization from Qualified Person of M/s Venipharm. According to the letter, the firm M/s Venopharm authorizes "Calory Pharma Private Limited" to register, renew and to get the registration certificate for the product. The letter was issued on 17-12-2021 and valid for five years.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 3896 (R&I) Dated 10-02-2022
	Details of fee submitted	Rs. 150,000/- dated 04-01-2022

	The proposed proprietary name / brand name	Enoxaparin Ledraxen 8000IU (80mg)/0.8mL
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS (0.8ml) contains: Enoxaparin Sodium……8000IU (equivalent to 80mg)
	Dosage form of applied drug	Solution for Injection in PFS
	Pharmacotherapeutic Group of (API)	Anticoagulant
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	10's PFS
	Proposed unit price	As per SRO/DPC
	Shelf Life	24 Months
	Storage Conditions	$\leq 25^0$C
	The status in reference regulatory authorities	The product is itself approved in Germany.
	For generic drugs (me-too status)	Noxane of M/s BF Biosciences (Reg. No. 107950).
	Module-II (Quality Overall Summary)	Firm has submitted ICH QOS. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
	Name, address of drug substance manufacturer	M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), China
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process, Characterization, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 7 batches of Drug Substance at real time conditions for 36 months, 01 batch for 12 months, 01 batch for 09 months & 01 batch for 03 months. The real time stability data conducted at $25^0C \pm 2^0C/60 \pm 5\%RH$ is for 18 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Analytical method validation/verification of product	Firm has submitted validation of Analytical methods of Anti-factor Xa activity, Anti-factor IIa Activity, Free sulfate content, Protein content, Bacterial Endotoxin, Sterility.
	Container closure system of the drug product	• A pre-filled syringe consisting of a 1-mL long barrel of type I glass with a fixed 27-gauge ½ inch stainless steel needle and a needle shield made of bromobutyl rubber • A 1-mL plunger rod made of polypropylene (which does not come directly in contact with the finished product) • A plunger stopper consisting of bromobutyl rubber
	Stability study data of drug product	Firm has submitted stability study data of 03 batches of 2000IU & 02 batches of 10000IU at real time, intermediate (Zone IVB) & conditions. The accelerated stability study data is conducted at 40 ± 2^0C/75%RH±5% for 6 months. The real time stability study data is conducted at 25 ± 2^0C/60%±5RH. The intermediate stability study data is conducted at 30 ± 2^0C/65%±5RH.

The firm has submitted the following data as per requirements of 289th meeting of Registration Board:

Sr. No.	Required Documents	Documents Provided by the Firm
1.	Equivalence of physicochemical properties, such as:	
	a. Molecular weight distribution using size exclusion chromatography	i. Molecular mass distribution and proportion ii. %1, 6-anhydro derivatives iii. Free sulphate content iv. Ratio of sulfate ions to carboxylate ions v. UV Absorption and specific absorbance at 231 nm
	b. Chain mapping by cetyltrimethylammonium-coated strong anion exchange chromatography matrix-assisted laser desorption ionization mass spectrometry (MALDIMS), gel permeation chromatograph—electro spray ionization mass spectroscopy (GPC-ESI-MS), or reverse phase ion pair—electro spray ionization mass spectroscopy (RPIPESI-MS).	i. Chain mapping by Gel Filtration Chromatography (GFC) ii. Chain mapping by strong anion exchange HPLC (SAX-HPLC) iii. Proton nuclear magnetic resonance (1H-NMR) iv. Heteronuclear single quantum coherence (HSQC) v. Intact chain mapping by LCMS
2.	Equivalence of heparin source material (i.e. heparin that is derived from porcine intestinal mucosa and that meets USP monograph standards for heparin sodium USP) and mode of depolymerization (i.e. cleavage by alkaline b-elimination of the benzyl ester derivative of heparin). The equivalent heparin source material should have at least a similar distribution of natural disaccharide building block sequences (within the context of itsvariability). If an equivalent mode of depolymerization is used, the generic drug products should be at least similar.	• Fresh pig's small intestine is collected and squeezed to get porcine intestinal mucosa. Porcine intestinal mucosa is then digested and heparin is adsorbed on an ion exchange resin (Intermediate A). • After the washing and elution of the resin, further steps of precipitation and drying lead to crude heparin (Intermediate B). • Crude heparin (Intermediate B) is dissolved in water, submitted to enzymolysis and then purified on resins. Heparin sodium (Intermediate C) is obtained after several steps including oxidation, ultra-filtration, fractionation and a final precipitation in ethanol. • Enoxaparin sodium is manufactured in three stages, starting from the heparin sodium which undergoes a step of salification to get the quaternary ammonium salt of heparin (Intermediate I). The salification step is followed by an esterification step to form the ester salt of heparin (Intermediate II). Enoxaparin sodium is

		finally isolated after depolymerization and purification steps.
3.	Equivalence in disaccharide building blocks, fragment mapping, and sequence of oligosaccharide species. This can be achieved by exhaustive digestion of enoxaparin with purified heparin digesting enzymes (heparinases I, II, and III) and nitrous acid, among other means, to yield the constituent disaccharide building blocks comprising enoxaparin. These individual disaccharide building blocks can be quantified by following: a. Capillary Electrophoresis (CE) b. Reverse phase high-performance liquid chromatography (RP-HPLC) c. Strong anion exchange HPLC (SAX-HPLC) d. Mass spectroscopy e. Nuclear magnetic resonance (NMR) spectroscopy. f. Chemical approaches such as analysis with modifying reagents (e.g. sodium borohydride, nitrous acid) or modifying enzymes (eg, 2-0-sulfatase, 6-0-sulfatase, and 5-glucuronidase) can be included.	i. Disaccharide building block by strong anion exchange HPLC (SAX-HPLC) ii. Fragment mapping (Heparinase I/II/III) by strong anion exchange HPLC (SAX-HPLC) iii. Fragment mapping (heparinase I/II/III) by liquid chromatography – mass spectrometry (LC-MS) iv. Dp6 mapping (heparinase I/II/III) by liquid chromatography – mass spectrometry (LC-MS) v. Dp8 mapping (heparinase I/II/III) by liquid chromatography – mass spectrometry (LC-MS) vi. Dp10 mapping (heparinase I/II/III) by liquid chromatography – mass spectrometry (LC-MS) vii. Nitrous acid (HONO) depolymerisation disaccharide mapping by liquid chromatography – mass spectrometry (LC-MS) iii. Tetrasaccharides (dp4) analysis by strong anion exchange HPLC (SAX-HPLC) ix. Tetrasaccharides (dp4) sequences by reversed-phase ion-pair liquid chromatography- electrospray ionization - mass spectrometry (RPIP-ESI-MS and RPIP-ESI-MS/MS) x. Oligosaccharide mapping by liquid chromatography – mass spectrometry (LC-MS) (dp6/8/10)
4.	Equivalence of in vitro biological and biochemical assay results using activated partial thromboplastin time (aPTT) and Heptest prolongation time. The equivalence in anti-Xa activity, anti-IIa activity, and anti-Xa/anti-IIa ratio between the generic LMWHs should be provided.	i. Anti-factor Xa & Anti-factor IIa activity by using Biophen Heparin Anti-Xa (2 Stages) and Biophen Heparin Anti-IIa (2 Stages) commercial kits. ii. The anticoagulant activity of the biosimilar enoxaparin drug product is analyzed and compared with Lovenox®/Clexane® based on aPTT (Activated Partial Thromboplastin Time) and Heptest prolongation time iii.
5.	Equivalence of ex vivo pharmacodynamic (PD) profile in human volunteers. The comparison of in vivo PD profiles is based on measurements of in vivo anti-Xa and anti-IIa profiles.	A monocentric, randomized, open-label, single-dose, two-period, crossover study to assess the pharmacokinetic and pharmacodynamic equivalence of Reference Product Lovenox® 10000 IU/1 mL solution for injection in prefilled syringe and test formulation of Enoxaparin Ledraxen 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze following subcutaneous administration in healthy subjects in fasting conditions

Remarks of Evaluator	• The address of product license holder is different on CoPP from SmPC available on official website of Germany & letter of authorization. • The batch release site is different in dossier from Public Assessment Report available on official website of Germany & from Form-5F. • The manufacturer as per submitted CoPP is **M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France** while as per submitted dossier manufacturer is **M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), No. 16 Xuefu Road, Nanjing High & New Technology Development Zone, Nanjing, China**. • Firm has not submitted the verification of compendial analytical methods of drug product. • Firm has not submitted the real time and accelerated stability data of applied strengths. However, stability data of lower (2000IU) & higher strengths (10000IU) is provided.

	• Stability study data of only 02 batches of higher strength i.e. 10000IU is provided. • Related substances are not tested in real time, intermediate & accelerated stability data while 1,6-anhydro derivatives, Average Mass & Sodium content are only tested for 01 batch of each strength. • **The provided intermediate/ Zone IVB stability data is for 36 months for two batches of lower strength & one batch of higher strength and 12 months of one batch each of lower & higher strength**. • **All the batches of both strengths get out of specifications after 12 months at intermediate/ Zone IVB conditions.**

Decision: Registration Board deferred the products at S.No. 2,3 & 4 for submission of following by the firm:

i. Difference in address of product license holder on CoPP from SmPC available on official website of Germany & letter of authorization.
ii. Difference in batch release site in dossier from Public Assessment Report available on official website of Germany & from Form-5F.
iii. Any legalized evidence issued by regulatory authority of country of origin indicating that the manufacturer of product registered in Germany is M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), No. 16 Xuefu Road, Nanjing High & New Technology Development Zone, Nanjing, China while M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France is only batch release site.
iv. Verification reports of compendial analytical methods of drug product.
v. Real time & Accelerated stability data of three commercial batches of 2000IU & 10000IU upto the shelf life including all parameters as per finished product specification.
vi. Clarification is required as all the batches of both strengths get out of specification after 12 months of storage at $30\pm2^0C/65\%\pm5RH$.

Evaluation by DBE&R:

Reply of firm against each query is summarized in table below for consideration of the Board.

Queries	**Response by the firm**
Difference in address of product license holder on CoPP from SmPC available on official website of Germany & letter of authorization.	The address for Venipharm (product License Holder) mentioned in CoPP is ***422 Bureaux de la Colline F-92213 Saint-Cloud France*** and address mentioned in LoA & SmPC is ***4 Bureaux de la Colline 92210 Saint-Cloud France*.** We confirmed that these both addresses are well correct for Venipharm's (Product License Holder) office. The address on CoPP (***422 Bureaux de la Colline F-92213 Saint-Cloud France*** is more detailed version)
Difference in batch release site in dossier from Public Assessment Report available on official website of Germany & from Form-5F.	In PAR available on MHRA website, no information regarding batch release site is available. Also we would like to inform one change that was approved by BfARM, Germany. At time of our registration in EU first, the batch release site was **Melbourn Scientific Limited (United Kingdom)**. *Due to Brexit, we had to change the batch release site from* ***Melbourn Scientific Limited (United Kingdom)*** *to* ***Centre Specialites Pharmaceutiques (France)*** *via a dedicated variation submission.* May be the website you are checking may still not be updated and you may still see Melbourn Scientific Limited (United Kingdom). We confirm that there is only one batch release site for our products which is Centre Specialites Pharmaceutiques (France). For your reference we have attached cop of variation approval letter received from Bfarm.
Any legalized evidence issued by regulatory authority of country of origin indicating that the manufacturer of product registered in Germany is M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), No. 16	Firm has submitted a copy of CoPP issued to Israel showing manufacturer responsible for manufacturing and packaging M/s Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (NKF), No. 16 Xuefu Road, Nanjing High & New Technology Development Zone, Nanjing, China

Xuefu Road, Nanjing High & New Technology Development Zone, Nanjing, China while M/s Centre Specialites Pharmaceutiques ZAC des Suzots 35 rue de la Chapelle F-63450 Saint-Ament Tallende, France is only batch release site.	
Verification reports of compendial analytical methods of drug product.	We confirm that validation study for Compendial Analytical methods (Appearance, Clarity, Coloration, UV absorption, Identification, assay of sodium, molecular mass distribution and mass-average relative molecular mass, determination of the pH, related substances, extractable volume, particulate matter and Specific absorbance) were NOT performed as the principal of these analytical methods are Exactly same as described in the Ph. Eur. General monographs. Moreover, if any adjustment done according to Ph.Eur. 2.2.46, No Analytical validation study is required.
Real time & Accelerated stability data of three commercial batches of 2000IU & 10000IU up to the shelf life including all parameters as per finished product specification.	Firm has referred to bracketing design of ICH guidelines and submitted stability studies of three batches of 2000IU two batches of 10000 IU both real time and accelerated at 25±2^{0}C/60%±5RH & 40±2^{0}C/75%±5RH.
Clarification is required as all the batches of both strengths get out of specification after 12 months of storage at 30±2^{0}C/65%±5RH.	After storage of the finished product at 30^{0}C/65% RH, **the major change is for the Color which is out of specification after 12 months**. *If we consider the results of the forced degradation study in heat conditions (after one day or after 10 days at 80^{0}C). Change of color of solution was considered as Stability Indicator. So result of ICH stability at intermediate temperature (30^{0}C) are confirming the results obtained during the forced degradation study in heat conditions.* *The conclusion is that Enoxaparin sodium, solution for injection is NOT stable at 30^{0}C/65% RH. All the available results got at 25^{0}C/60% RH after 36 months are compliant with the specifications. Hence, a shelf life of 36 months is claimed with a temperature restriction for the finished product packaged in prefilled syringes Do not store above 25^{0}C.* *A commitment is also attached defining the temperature restriction.*

For stability studies firm has referred to bracketing design as per ICH guidelines which is as follow:

2.3 Bracketing

Bracketing is the design of a stability schedule such that only samples on the extremes of certain design factors (e.g., strength, container size and/or fill) are tested at all-time points as in a full design. The design assumes that the stability of any intermediate levels is represented by the stability of the extremes tested.

The use of a bracketing design would not be considered appropriate if it cannot be demonstrated that the strengths or container sizes and/or fills selected for testing are indeed the extremes.

2.3.1 Design Factors

Design factors are variables (e.g., strength, container size and/or fill) to be evaluated in a study design for their effect on product stability.

2.3.1.1 Strength

Bracketing can be applied to studies with multiple strengths of identical or closely related formulations. Examples include but are not limited to (1) capsules of different strengths made with different fill plug sizes from the same powder blend, (2) tablets of different strengths manufactured by compressing varying amounts of the same granulation, and (3) oral solutions of different strengths with formulations that differ only in

minor excipients (e.g., colorants, flavorings). With justification, bracketing can be applied to studies with multiple strengths where the relative amounts of drug substance and excipients change in a formulation. Such justification can include a demonstration of comparable stability profiles among the different strengths of clinical or development batches. In cases where different excipients are used among strengths, bracketing generally should not be applied.

2.3.1.2 Container Closure Sizes and/or Fills

Bracketing can be applied to studies of the same container closure system where either container size or fill varies while the other remains constant. However, if a bracketing design is considered where both container size and fill vary, it should not be assumed that the largest and smallest containers represent the extremes of all packaging configurations. Care should be taken to select the extremes by comparing the various characteristics of the container closure system that may affect product stability. These characteristics include container wall thickness, closure geometry, surface area to volume ratio, headspace to volume ratio, water vapor permeation rate or oxygen permeation rate per dosage unit or unit fill volume, as appropriate. With justification, bracketing can be applied to studies for the same container when the closure varies. Justification could include a discussion of the relative permeation rates of the bracketed container closure systems.

2.3.2 Design Considerations and Potential Risks

If, after starting the studies, one of the extremes is no longer expected to be marketed, the study design can be maintained to support the bracketed intermediates. A commitment should be provided to carry out stability studies on the marketed extremes post-approval. Before a bracketing design is applied, its effect on the retest period or shelf life estimation should be assessed. If the stability of the extremes is shown to be different, the intermediates should be considered no more stable than the least stable extreme (i.e., the shelf life for the intermediates should not exceed that for the least stable extreme).

Example of bracketing design as per ICH is as under:

This example is based on a product available in three strengths and three container sizes. In this example, it should be demonstrated that the 15 ml and 500 ml high-density polyethylene container sizes truly represent the extremes. The batches for each selected combination should be tested at each time point as in a full design.

Strength		**50mg**			**75mg**			**100mg**		
Batch		1	2	3	1	2	3	1	2	3
Container size	**15ml**	T	T	T				T	T	T
	100ml									
	500ml	T	T	T				T	T	T

In case of firm submitted stability studies is as follow:

Strength		**20mg/0.2ml (2000IU/ml)**			**40mg/0.4ml (4000IU/ml)**			**60mg/0.6ml (6000IU/ml)**			**80mg/0.8ml (8000IU/ml)**			**10mg/1ml (10,000IU/ml)**		
Batch		1	2	3	1	2	3	1	2	3	1	2	3	1	2	3
Container size	**1ml(0.2ml)**	T	T	T										T	T	---
	1ml(0.4ml)															
	1ml(0.6ml)															
	1ml(0.8ml)															
	1ml (1ml)	T	T	T										T	T	---

Firm has further submitted data of following commercial batches as per following details:

Strength	**Data**	**Conditions**
4000IU	36 months Real time/6 month Accelerated	25 ± 2^0C/60%±5RH. 40 ± 2^0C/75%±5RH.
2000IU	18 months Real time/6 month Accelerated	25 ± 2^0C/60%±5RH. 40 ± 2^0C/75%±5RH.
10000IU	18 months Real time/6 month Accelerated	25 ± 2^0C/60%±5RH.

Decision of RB in its 321st meeting.

i. Submission of real time stability data of three commercial batches up to the demanded shelf life as per ICH guidelines.
ii. Submission of valid legalized CoPP indicating actual product License Holder, manufacturer and batch release site.

Evaluation by DBE&R: Now the firm has submitted following: i. Real time stability studies data of three commercial batches of 2000IU and 10,000IU at 25±2^{0}C/60%±5RH. Stability data of two batches of both strengths is for 36 months and one batch of both strengths for 24 months. ii. Legalized CoPP for Enoxaparin Ledraxen 4000IU, 6000IU, 8000IU indicating actual product License Holder, manufacturer and batch release site. **Product License Holder**: *M/s Venipharm, 422, Bureaux de la Colline F-92213 Saint-Cloud, France.* **Manufacturer:** *M/s. Nanjing King-Friend Biochemical Pharmaceutical Co, Ltd, No. 16 Xuefu Road, Nanjing High & New Technology Development Zone, 210061 Nanjing, China.* **Batch Release Site:** M/s. Centre Specialities Pharmaceutiques ZAC Suzots 35 rue de la chapelle F-63450 Saint-Amant Tallende France.
Decision: Keeping in view the legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance of current Import Policy for finished drugs.

Case No. 4: Imported Veterinary Biological applied by M/s Pharmakon International Enterprises Shamsabad deferred in 320th meeting of Registration Board.

48.	**Name and address of Importer**	**M/s Pharmakon International Enterprises,** Office No. 26, 2nd Floor, Aries Plaza, Murree Road, Shamsabad.
	Detail of DSL	**M/s Pharmakon International Enterprises,** Address: Valid till:
	Name and address of Manufacturer	**Manufacturer of Drug:** M/s JinyuBaoling Bio-Pharmaceutical Co., Ltd. No. 1 Jinyu street, Shaerqin Industrial park, Economic and tecnological Development zone, Hohhot, inner Mongolia, China.
	Name of exporting country	Peoples Republic of China.
	Brand Name +Dosage Form + Strength	Goat Pox Vaccine, Live
	Diary No. Date of R& I & fee	Dy. No. 25395 R&I Dated 13-09-2021 Rs. 150,000/- (Slip No. 33810920261)
	Composition	Each inoculation dose of vaccine contains: Attenuated Goat Pox Virus (Strain CVCC AV41) … $10^{3.5}$ $TCID_{50}$
	Pharmacological Group	Biological
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's Specifications
	Shelf Life	24months----(-15^{o}C)
	Document Details	**<u>Free Sale Certificate (Original Legalized):</u>** Manufacturer: M/s Jinyu Baoling Bio-Pharmaceutical Co., Ltd Issued by: Department Of Agriculture and Animal Husbandry Of Inner Mongolia Autonomous Region, P.R.China Issue date: 09/03/2020 **<u>GMP Certificate (Original Legalized):</u>** Issued to: M/s JinyuBaoling Bio-Pharmaceutical Co., Ltd. Issued by: Administrative unit: Department Of Agriculture And Animal Husbandry Of Inner Mongolia Autonomous Region, P.R.China Validity: 05-03-2021-04-03-2026 **<u>Sole Agency Agreement:</u>** Product specific Sole agency agreement dated 15th June, 2021 is submitted by the firm
	Pack size & Price	25doses per Vial: Decontrolled

	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	Could not be confirmed (no any registered product)
	Remarks of Evaluator	Currently there is no any registered Goat pox vaccine. Firm has submitted application for renewal of DSL.
	Decision in 320th Registration Board meeting	Registration Board referred the case to Animal Husbandry Commissioner for comments regarding immunological relevance and need of applied strain in Pakistan.
	Evaluation of DBE&R Division	• *Assistant Animal Husbandry Commissioner vide their letter dated 11th January 2023 submitted following response:* *I am directed to refer to the Drug Regulatory Authority of Pakistan (DRAP) letter No. F.l-15/2018-AD(BD) Vol-I dated 22nd December, 2022 regarding the subject noted above and to say that this Ministry recommends import of Goat Pox Vaccine (Strain CVCC AV41 $10^{3.5}$ $TCID_{50}$) by M/s Pharmakon International Enterprises from china to cater the national needs subject to fulfillment of all codal formalities.* • *Firm has also applied for change in DSL address from office No.23 and 26, second floor, Aries Tower, Shamsabad Murree road, Rawalpindi, Previous DSL No.01-374-0177-0486990 to the new address at:* *First floor Hum Height service road, East near Sohan Interchange, Islamabad and submitted a Fee challan of rupees 7500/-*
Decision: Registration Board referred the case to Animal Husbandry Commissioner for comments regarding need of applied vaccine/strain in Pakistan.		

Item No. V Division of Quality Assurance & Laboratory Testing

S. NO.	CASE TITLE
AGENDA ITEM NO. 01 - PERSONAL HEARING CASES	
1	**SUBSTANDARD 25% DEXTROSE INFUSION B. NO. A042C21 MANUFACTURED BY M/S. OTSUKA PAKISTAN LTD., HUB, BALOCHISTAN**
2	**SUBSTANDARD NYLOZ CAPSULE MANUFACTURED BY M/S. ZEPHYR PHARMATEC (PVT) LTD. KARACHI**
3	**SUBSTANDARD DELMOL SUSPENSION MANUFACTURED BY M/S. DELTA PHARMA (PVT.) LTD., NOWSHERA**
4	**MANUFACTURE AND SALE OF SUBSTANDARD REM-D 100MG/20ML IV INFUSION MANUFACTURED BY M/S. LIVEN PHARMACEUTICALS, KASUR**
5	**CANCELLATION/SUSPENSION OF REGISTRATION OF WATER FOR INJECTION 2ml (REGISTRATION NO. Q24873) MANUFACTURED BY M/S AMSON VACCINES PHARMA (PVT) LTD, PLOT #154, INDUSTRIAL TRIANGLE KAHUTA ROAD, ISLAMABAD**
6	**CASE REFERED BY PQCB, PUNJAB REGARDING REGULATORY METHOD OF ANALYSIS OF HEMOROSE-F TABLETS SUBMITTED BY M/S NEOMEDIX PHARMA**
	AGENDA ITEM NO. 02 - ROUTINE CASES
7	**MANUFACTURE & SALE OF SUB-STANDARD TEMPRIN TABLETS, BATCH NO. 055, MANUFACTURED BY M/S KOHS PHARMACEUTICAL (PVT.) LTD., HYDERABAD.**
8	**NOT TO DISPOSE OF UNDER SECTION 18(1)(I) OF DRUGS ACT, 1976 – M/S. HAWK BIO PHARMACEUTICALS PVT LTD, PLOT NO.10, STREET NO. S-6, NATIONAL INDUSTRIAL ESTATE, RCCI RAWAT.**

9	**IMPORT OF REGISTERED PRODUCTS THROUGH FAKE/FORGED INVOICES BY M/S. BIOCURE PHARMACEUTICALS, LAHORE.**
10	**MANUFACTURE & SALE OF SUB-STANDARD BLOMOX FORTE SUSPENSION, REG. NO. 026072, BATCH NO. PF-045, MANUFACTURED BY M/S. BLOOM PHARMACEUTICALS (PVT) LTD., HATTAR**
	AGENDA ITEM NO. 03 APPELLATE TESTING CASES REPORTS FROM NIH
11	**SUBSTANDARD MECONOR INJECTION MANUFACTURED BY M/S. NORTECH PHARMACEUTICALS (PVT.) LTD., ISLAMABAD**

Case No. 1: SUBSTANDARD 25% DEXTROSE INFUSION B. NO. A042C21 MANUFACTURED BY M/S. OTSUKA PAKISTAN LTD., HUB, BALOCHISTAN.

Federal Government Analyst CDL Karachi vide test report No. F. 5-3(K)/2021-CDL/S-1468 dated 03-12-2021 informed that sample of product "25% Dextrose Infusion" Batch No. A042C21 (Mfg. date 31-03-2021, Exp date 30-03-2024) sent to CDL Karachi by FID-II Karachi has been declared as of substandard quality on the basis on non-compliance of pH specifications. Details of the test report are given as under:

S. No.	Test	Acceptance Criteria	Result	Reference
1.	Identification	The identification test must identify Glucose (Dextrose)	Complies	BP 2020
2.	pH	3.5 to 6.5	**2.73 – Does not comply**	BP 2020
3.	Bacterial Sterility	Must be sterile	Complies	BP 2020
4.	Endotoxin	The Endotoxin limit concentration is 0.25 IU/ml	Complies	BP 2020
5.	Assay Glucose (Dextrose), (Label claim 250mg/ml)	95.0% to 105.0%	96.80% Complies	BP 2020

02. FID-III Karachi vide letter No. F. ARS-19-25/2021-FID-III (K) dated 28-12-2021 forwarded the request of M/s. Otsuka Pakistan, Hub dated 23-12-2021 for appellate testing of their product namely "25% Dextrsoe Infusion" batch No. A042C21 declared substandard by CDL Karachi on 03-12-2021.

03. Registration Board in its 313th meeting decided to fulfill the codal formalities. Therefore, in the light of decision of Registration Board, a vide letter No. F. 03-48/2021-QC dated 27-01-2021 issued to M/s. Otsuka Pakistan, and to FGA CDL Karachi for submission of OOS investigation and complete testing record of report vide No. F. 5-3(K)/2021-CDL-S-1486 dated 03-12-2021.

Technical evaluation of OOS report by QC section:

05. M/s. Otsuka Pakistan Limited, Hub vide letter dated 15-02-2022 and CDL Karachi vide letter No.1-1/2013-SRK/CDL/-1069 dated 15-03-2022 provided OOS investigation. Comparison is given as under:

S.	**Laboratory**	**Test Performed**	**Results**	**Standard Value**	**Remarks**
01	CDL Karachi	pH (BP 2020)	2.73	3.5 – 6.5	-
02	M/s Otsuka	pH (BP)	At the time of batch release: 5.38 **Retesting:** Sample 1: - 3.58 Sample 2: - 3.54 Sample 3:- 3.58	-do-	The results of retesting performed by the firm show a decline in pH value from 5.38 to 3.58 over a period on 10 months. Moreover, the value 3.58 is also very close to the lower acceptance criteria i.e. 3.5

06. The case has been deferred due to paucity of time in 320th meeting

In view of decision of 320th meeting, they have been called for personal hearing.

07. Decision of 321st meeting Keeping in view position narrated above, the Board did not accede the firm's request of appellate testing and decided to issue show cause notice and called them for personal hearing before Registration Board.

08. In compliance to the decision of RB show cause was issued to firm vide letter No. 03-45/2022-QC dated 21-Nov-22 to which the firm replied and again called for appellate testing of their product namely "25% Dextrose Infusion" batch No. A042C21 declared substandard by CDL Karachi on 03-12-2021 and briefed that due to temperature issue pH decreased but still remained within limits and submitted CAPA in which they manufacture 3 trial batches i.e bulk manufacturing at 80&100^{o} & with addition of stabilizers that is showing stability after 8 months passed and they are going to change its label with indication "*Store below 25 degrees centigrade*".

Proceedings and Decision of 324th Meeting of Registration Board.

Decision:

Keeping in view position of firm narrated above, the Board decided that

i. **Risk based sampling of all the batches of said formulationwill be done.**

ii. **Call the firm for personal hearing under section 42 due to violation of Drug Act, 1976 and rules made thereunder.**

iii. **Product registration of 25% Dextrose Infusion Mfg by M/s. Otsuka Pakistan ltd., hub, Balochistan will remain suspended till personal hearing before next meeting of Registration Board and decision by the Board.**

Case No. 2: SUBSTANDARD NYLOZ CAPSULE MANUFACTURED BY M/S. ZEPHYR PHARMATEC (PVT) LTD. KARACHI.

Federal Government Analyst CDL Karachi vide test report No. F. 5-3(K)/2021-CDL/S-870 dated 30-07-2021 informed that the sample of product "Nyloz capsule (Esomeprazole 20mg)" Batch No. C01358 (Mfg. date 05-2021, Exp date 04-2023) sent to CDL Karachi by FID-II Karachi has been declared as of substandard quality. Details of the test report are given as under:

S. No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Hard gelatin capsule consist of yellow coloured body and green coloured cap containing white enteric coated pellets	Complies	Mfg. Specs
2.	Identification	Identification test must identify Esomeprazole Magnesium	Complies	USP 43
3.	Dissolution	Each unit is not less than 80%	Complies	USP 43
4.	Uniformity of dosage units by content uniformity	Acceptanc value of the 30 dosage units is less or equal L1% and no individual content of "any" dosage unit is less than [1-(0.01)(L2)]M not more than [1+(0.01(L2)]M	**L1=22.24 – Does not comply.**	USP 43
5.	**Assay.** Esomeprazole. (20mg/cap)	90.0% to 110.0%	Complies	USP 43

02. FID-II Karachi vide letter No. F. 000403/2018-FID-II (K) (Zephyr) dated 07-09-2021 forwarded the request of for appellate testing of Board's portion of sample of their product namely "Nyloz capsule" batch No. C01358 declared substandard by CDL Karachi on 30-07-2021.

03. Registration Board in its 313th meeting decided to fulfill the codal formalities. In complianceLetter vide No. F. 03-28/2021-QC dated 31-12-2022 was issued to M/s. Zephyr Pharmatech Karachi for submission of OOS investigation and complete testing record of the concerned batch and to Federal Government Analyst CDL Karachi for submission of OOS investigation and complete testing record of report vide No. F. 5-3(K)/2021-CDL-S-870 dated 30-07-2021.

Technical evaluation of OOS report by QC section:

05. M/s. Zephyr Pharmaceuticals Karachi vide letter ZP/0398/2022 dated 05-01-2022 provided the OOS investigation report. On technical evaluation of CDL Karachi OOS investigation report and OOS investigation report provided by manufacturer it was observed that both have performed the content uniformity test according to USP 43 specifications. However, the manufacturer claims the product to be of standard quality while CDL Karachi has reported the product to be substandard.

The case has been deferred due to paucity of time in 320th meeting

06. Decision of 321st meeting Keeping in view position narrated above, the Board did not accede the firm's request of appellate testing and decided to issue show cause notice and called them for personal hearing before Registration Board.

07. In compliance to the decision of RB show cause was issued to firm vide letter No. 03-45/2022 QC dated 21-nov-22 to which M/s. Zephyr Pharmaceuticals Karachi vide letter ZP/0435/2022 dated 22-11-2022 has requested for personal hearing

Proceedings and Decision of 324th Meeting of Registration Board.

Mr Asif Khitab (Sr. Manager Regulatory Affairs) along with QC Manager, Mr Zubair Ahmed Khushhali appeared before the Board for Personal hearing. They reiterated the same stance submitted earlier and requested to send the Board's portion for Appellate testing The Board after considering the facts of the case and thorough deliberations decided as follows:

i. **Registration of "Nyloz capsule (Esomeprazole 20mg)" Mfg by M/s. Zephyr Pharmatec (pvt) ltd. Karachi shall remain suspended for a period of six months or till satisfactory Product Specific Inspection report and verification of CAPA by panel (constituted by Director QA&LT) whichever is later.**

Case No. 3: SUBSTANDARD DELMOL SUSPENSION MANUFACTURED BY M/S. DELTA PHARMA (PVT.) LTD., NOWSHERA.

FGA CDL Karachi vide test report No. F. 5-3(P)/2021-CDL/S-967 dated 17-08-2021 sample of product "Delmol Suspension (Paracetamol 120mg/5ml)" Batch No. 151 (Mfg. date 05-2021, Exp date 05-2023) sent to CDL Karachi by FID-I Peshawar has been declared as of substandard quality. Details of the test report are given as under:

S. No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Pink colored suspension in amber color glass bottle	Complies	Mfg. specs
2.	Identification	The identification test must identify Acetaminophen (Paracetamol)	Complies	USP 43
3.	pH	4.0 to 6.9	Complies	USP 43
4.	**Assay** Acetaminophen (Paracetamol) (Label claim 120mg/5ml)	90.0% to 110.0%	**74.1% - Does not comply**	USP 43

02. FID-II Karachi vide letter No. F. 10-7/2021-Delta-DRAP-3665 dated 21-09-2021 forwarded the request of M/s. Delta Pharma (Pvt.) Ltd., Nowshera dated 27-08-2021 for appellate testing of Board's portion of sample of their product namely "Delmol suspension" batch No. 151 declared substandard by CDL Karachi on 17-08-2021.

03. Registration Board in its 313th meeting decided to fulfill the codal formalities In complianceLetter vide No. F. 03-32/2021-QC dated 22-12-2022 was issued to M/s. Delta Pharma (Pvt.) Ltd., Nowshera for submission of OOS investigation and complete testing record of the concerned batch & to Federal Government Analyst CDL Karachi for submission of OOS investigation and complete testing record of report vide No. F. 5-3(K)/2021-CDL-S-870 dated 30-07-2021.

Technical evaluation of OOS report by QC section:

05. M/s. Delta Pharma Nowshera vide letter No. 22/DP/2021 dated 22-12-2021 provided OOS investigation report wherein they provided a non-pharmacopeial UV Photometric test report, manufacturing process of product and sample preparation method for test/analysis. Review of documents revealed that firm had performed the assay test on non-pharmacopeial method while CDL performed as per USP 43. Moreover, the report provided was not a controlled document and no reference for testing method were provided.

06. The case has been deferred due to paucity of time in 320th meeting

07. Decision of 321st meeting Keeping in view position narrated above, the Board did not accede the firm's request of appellate testing and decided to issue show cause notice and called them for personal hearing before Registration Board."

08. In compliance to the decision of RB show cause was issued to firm vide letter No. 03-45/2022 QC dated 21-nov-22 to which M/s. Delta Pharma (Pvt.) Ltd., Nowshera vide letter 999/Q.C/DRAP dated 23-11-2022 has requested for personal hearing and briefed that their sample was also tested by DTL KPK and their assay in that report was 92.6%. However when that report was analyzed it was found that DTL KPK has also declared that product Sub-Standard on presence of visible crystals.

Proceedings and Decision of 324th Meeting of Registration Board.

Mr Ashfaq parveiz (C.E.O) along with QC Manager, Mr kashif Ali appeared before the Board for Personal hearing. They reiterated the same stance submitted earlier that their product is also tested by DTL Peshawar

and although declared substandard but assay was 92.6% in that particular report and requested to send the Board's portion for Appellate testing. The Board after considering the facts of the case and thorough deliberations decided as follows:

ii. **Registration of "Delmol Suspension (Paracetamol 120mg/5ml)" Mfg by M/s. Delta Pharma (pvt.) Ltd., Nowshera shall remain suspended for a period of six months or till satisfactory Product Specific Inspection report and verification of CAPA by panel (constituted by Director QA&LT) whichever is later.**

Case No. 4: **MANUFACTURE AND SALE OF SUBSTANDARD REM-D 100MG/20ML IV INFUSION MANUFACTURED BY M/S. LIVEN PHARMACEUTICALS, KASUR.**

Federal Government Analyst CDL Karachi vide test report No. F. 5-3(LHR)/2021-CDL/S-1304 dated 03-11-2021 wherein it was informed that the sample of product "REM-D Infusion (Remdesivir 100mg/20ml)" Batch No. RD109 (Mfg. date 09-2021, Exp date 09-2022) sent to CDL Karachi by FID-II Lahore has been declared as of substandard quality. Details of the test report are given as under:

S. No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Clear, colorless solution in glass vial	Complies	Innovator's Specs.
2.	Identification	The identification test must identify Remdisivir	Complies	Innovator's Specs.
3.	pH	3.0 to 4.0	4.0 Complies	Innovators Specs.
4.	Bacterial Sterility	Must be sterile	**Does not comply**	USP 43
5.	Bacterial Endotoxin	Not more than 1.0 EU per mg	Complies	USP 43
6.	**Assay** Remdesivir, (Label claim 5mg/ml)	90.0% to 110.0%	97.4% Complies	Innovator's Specs.

02. FID-II Lahore vide letter No. 17406/2021-DRAP(L-II) dated 19-11-201 forwarded the request of M/s. Liven Pharmaceuticals Kasur dated 05-11-2021 for appellate testing of Board's portion of sample of their product namely "REM-D Infusion" batch No. RD109 declared substandard by CDL Karachi on 03-11-2021.

03. Registration Board in its 313th meeting decided to fulfill the codal formalities. In the light of decision of Registration Board, a letter vide No. F. 03-42/2021-QC dated 23-12-2021 was issued to M/s. Liven Pharmaceuticals Kasur for submission of OOS investigation and complete testing record of the concerned batch of product REM-D Infusion along with scientific justifications/grounds with the request of Appellate testing under section 22(4) of the Drugs Act 1976 and to Federal Government Analyst CDL Karachi for submission of OOS investigation and complete testing record of report vide No. F. 5-3(LHR)/2021-CDL-S-1304 dated 03-11-2021.

Technical evaluation of OOS report by QC section:

05. M/s. Liven Pharmaceuticals Kasur vide letter dated 29-12-2021 provided OOS investigation repot of their product REM-D Infusion (Batch No. RD109). On evaluation of OOS investigation provided by Firm and CDL it was observed that CDL Karachi has performed Sterility testing as per USP 43. USP 43 method advises to use 2% or 20 (Whichever is less) containers if batch size is more than 500 units. The batch size of product is question is 1000 units. However, the firm has not provided the reference of method for sterility testing and has not provided the information regarding the numbers of units used for sterility testing.

06. Decision of 320th meeting Keeping in view position narrated above, the Board did not accede the firm's request, as the firm is conducting bacterial sterility of the products on a non-pharmacopoeial method which is not validated and decided to issue show cause notice and called them for personal hearing before Registration Board in its forthcoming meeting.

07. In compliance to the decision of RB show cause was issued to firm vide letter No. 03-43/2022 QC dated 6th-Oct-22 to which M/s. Liven Pharmaceuticals Kasur vide letter dated 12-10-2022 has requested for personal hearing.

Proceedings and Decision of 324th Meeting of Registration Board.

Mr Kashif Hussain (C.E.O) appeared before the Board for Personal hearing. He pleaded that firm has performed testing as per USP 43, however he could not present the data of out of specification investigation details regarding batch size and other requirements as mentioned in USP 43 he failed to present the evidence The Board after considering the facts of the case and thorough deliberations decided as follows:

i. **Registration of "REM-D Infusion (Remdesivir 100mg/20ml)" mfg by M/s. Liven Pharmaceuticals, Kasur shall remain suspended for a period of six months or till satisfactory report of Product Specific Inspection and verification of CAPA by panel (constituted by Director QA&LT) whichever is later.**

Case No. 5: CANCELLATION/SUSPENSION OF REGISTRATION OF WATER FOR INJECTION 2ml (REGISTRATION NO. Q24873) MANUFACTURED BY M/S AMSON VACCINES PHARMA (PVT) LTD, PLOT #154, INDUSTRIAL TRIANGLE KAHUTA ROAD, ISLAMABAD.

FID I Islamabad along-with Assistant Director QA-I, inspected the premises of M/s Amson Vaccines & Pharma (Pvt)Ltd 113 Industrial Triangle Kahuta Road Islamabad on 16th June 2022 to review the GMP compliance of the firm. During the course of inspection, the panel came to know that the firm is carrying out manufacturing of the subject mentioned product whereas they do not have approved section for manufacturing of the said item i.e. Liquid Injectable Vial-SVP (general) from the CLB. Chairman CLB vide letter no. F.l-26/94-Lic(PtVol-I) dated 30th June allowed renewal of tablet section (General), Capsule section (General), Oral Liquid section (General), Liquid Ampoule injection (vaccine), Liquid vial injection (Vaccine / Sera) Dry powder injection (Steroid), Quality control Laboratory and warehouse.

02. FID I reported that the firm is currently manufacturing their Water for Injection in the Vaccine facility. Moreover, the filling of WFI is being done on the same filling machine as their other vaccines without undertaking Cleaning validation as for all of these vaccines limit of detectability is not available.

03. The firm is utilizing their water for Injection only for inclusion as reconstitution medium in their product Inj. Hyzonate (powder for reconstitution) whereas the Registration letter of Inj. Hyzonate does not specifically mention that only WFI manufactured by M/s Amson Vaccines & Pharma has to be included.

04. After the subject mentioned inspection, the firm submitted letter No. F. l-26/94-Lic(Pt-l) dated 14th December 2021 regarding Approval of layout plan for regularization/revised/new sections under DML No. 000393 (Formulation) issued by the Licensing wherein approval for Tablet (Psychotropic), Liquid injectable Vial-SVP, Dry powder for injection (Steroid), Quality control lab and Warehouse. Additionally, the firm submitted an undertaking that they will finish construction of Liquid Injectable Vial-SVP (general) within one year which clearly indicates without a doubt that as of right now the firm does not have approved section for manufacturing of Water for injection 2ml registration No.024873.

05. FID I reported that the panel advised the firm that they should get Approval of Liquid Injectable Vial-SVP (general) for manufacturing of Water for Injection in the existing facility in the interim period till construction/completion of the new building, the feasibility of which had been pointed/laid out to the firm in the closing meeting of the inspection. The firm however, point blank refused to consider the possibility even though it was made clear to the firm that they are undertaking an illegal activity. Furthermore, the firm was verbally directed to immediately stop production until the approval of Liquid Injectable Vial-SVP (general) from CLB, the firm however, adamantly and willfully refused to comply with the instructions and insisted on illegal manufacturing whereby, the firm stands in obstruction of Power of the Inspector granted under Section 18(l)(j) & punishable under Section 27(3) of Drugs Act,1976 read with Schedule-Ill (3) of DRAP Act, 2012

06. Keeping in view the above-mentioned facts of the case, FID I has recommended following actions against M/s. Amsons Vaccine and Pharma Islamabad:

i. Cancellation/Suspension of Registration of Water for injection 2ml registration No.024873 until the firm either completes the new building or gets section approval from CLB in the existing facility since as of today the firm M/s Amson Vaccines & Pharma (Pvt) l td do not have the requisite section approval from CLB

ii. Permission for prosecution against M/s Amson Vaccines & Pharma (Pvt) Ltd plot# 154 Industrial TriabngleKahuta Road, Islamabad through its management Mr. Abbas Khan S/O Dilawar Khan, Mr. Shamim Ahmad S/O Abdul Majeed. Mr. Saleem Asghar S/O Ali Sagheer, its Plant Manager Mr. Amanullah Sial, its Production In-charge Mr. Sajjad Hussain S/O M. Bashir & bits QC Incharge Mr. MuammadMuddassir S/O Noor Muhammad under Section 27(3) of Drugs Act, 1976 read with Schedule-Ill (3) of DRAP Act, 2012.

07. Proceedings and Decision of 320th meeting, "The case has been deferred due to paucity of time".

08. Decision of 321st meeting Keeping in view position narrated above. Board decided: "To issue show cause notice to M/s. Amson Vaccines & Pharma (Pvt) Ltd, Islamabad for suspension/cancellation/ prosecution in Drug Court, Islamabad for manufacturing of Water for injection 2ml registration No.024873

in vaccine manufacturing facility and called them for personal hearing before Registration Board as per clause 5.2 of Schedule B under Drugs (L, R & A) Rules, 1976.& Advised to proceed as per Section 27 (3) of Drugs Act, 1976 regarding obstruction in official duties as it does not pertain to Registration Board."

09. In compliance to the decision of RB show cause was issued to firm vide letter No. 03-45/2022 QC dated 15-11-22 to which M/s. Amsons Vaccine and Pharma Islamabad vide letter AVP/1222/WFI02 dated 23-12-2022 & letter AVP/1222/WFI01 dated 13-12-2022 has briefed that their layout for aseptic filling activity for WFI in vacant room in this sterile section has been approved and they need 4-6 months for its operation and till then aseptic filling of WFI 2ml after appropriate decontamination, cleaning, and on basis of cleaning validations may please be allowed in existing area.

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided:

i. **"Suspension of Registration of "Water for injection 2ml registration No.024873" of M/S Amson Vaccines Pharma till establishment and approval of separate section by Licensing Division, DRAP for manufacturing of this product with immediate effect."**

Case No. 06: CASE REFERED BY PQCB, PUNJAB REGARDING REGULATORY METHOD OF ANALYSIS OF HEMOROSE-F TABLETS SUBMITTED BY M/S NEOMEDIX PHARMA.

01. The Secretary, Provincial Quality Control Board, Punjab vide reference No. PQCB/F-Isu-Bwp-05/06/19 dated 20-02-2019 has informed that Director DTL Faisalabad vide letter no. 8054/DTL/FSD dated 26-01-2019 stated that the lab has received sample of Tab. Hemorose-F (iron polymaltose complex + Folic acid) manufactured by M/S Neomedix bearing batch No. 484 from Drug Inspector Aziz Bhatti Shaheed Teaching Hospital Gujrat on 27-12-2018.

02. That requests for the provision of method was sent to manufacturer vide letter no. 6007/DTL/FSD dated 29-12-2018 and 23-01-2019 respectively. The method of analysis was found to be not workable for folic acid as the mentioned concentration (0.00007 mg/ml) for both sample and standard was below the limit of identification and quantification on UV at 280nm.

PROCEEDINGS AND DECISION:

03. Subject issue was considered by the Committee of the Provincial Quality Control Board, under section 11 of the Drugs Act 1976 in its 6th meeting held on 20-02-2019. Secretary PQCB apprised the Committee about background of the subject matter which was discussed at length and directed Drugs Testing Laboratory, Faisalabad to file the above-mentioned case. The Board observed that all the manufacturers/ drug registration certificate holders are legally bound to provide product specification and method of analysis to the Government analyst/Drug Testing Laboratories. The need for product specifications /method of analysis becomes more critical when the drug is not available in official pharmacopoeias and/or the manufacturer has its own customized specifications/method for analysis. In such circumstances it becomes quite challenging and almost impossible for a Government Analyst to conduct testing of the drug sample on such method provided by the firm on which sample as well as standard is not responding. The Board expressed its serious concerns over casual behavior on the part of the firms in this regard.

04. The Committee after due discussion and deliberation unanimously decided to recommend DRAP for the cancellation of registration of the above-mentioned product as the manufacturer ignored the dissolution criteria of the official monograph and also provided a method to the Govt. Analyst which is full of mistakes.

Proceeding and Decision of 291st meeting of Registration Board.

05. The case was presented before the Registration Board in its 291st meeting held on 04th September, 2019 and the Board after detailed discussion decided as under:

"To issue the show cause notice and personal hearing to the firm/ responsible persons as provided by the provincial quality control board (PQCB), Lahore. You failed to fulfill the condition of registration as prescribed under the rules because the method of test/analysis method provided by you was non responsive for test analysis of Folic acid and is defective. (The method of analysis was found to be not workable for folic acid as the mentioned concentration (0.00007 mg/ml) for both sample and standard was below the limit of identification and quantification on UV at 280nm.). You are required to explain your position that why the registration of your product i.e. Tab. Hemorose-F (iron polymaltose complex + Folic acid) should not be suspended/cancelled."

06. Show cause notice was served to the firm as per decision of the Registration Board vide No.F.03-41/2019-QC (291st RB) dated 25-10-2019.

07. M/s Neomedix Pharma, Islamabad submitted their reply vide reference No. nil dated 06-11-2019 addressed to the Secretary, Registration Board regarding the subject of RE: Letter No.03-41/2019-QC Dated 25th October, 2019 wherein they have stated that "we would like to thank you for offering us the opportunity to be heard in person. Kindly give us a suitable date and time so we pay appear to your kind office and explain our case in detail."

Proceedings of 293rd meeting of the Registration Board.

08. Malik Shahid GM, (37405-4576435-1) and Ghulam of M/s Neomedix Pharma appeared on behalf of M/s Neomedix Pharma for instant case and stated that Quality Control Manager of the firm at that time submitted the method of analysis to the Provincial Quality Control Board which was not was not working/responding. Later on they submitted a new & validated method to the Provincial Quality Control Board but they told that it's too late now.

Decision of 293rd meeting of Registration Board.

09. Registration Board in its 293rd meeting after detailed discussion decided as under:

i. Suspension of the Registration of the said product for six (06) months or till the verification of root cause analysis, Corrective and preventive action (CAPA) by the firm, product development data and verification of aforementioned points and Product Specific Inspection by following panel whichever is later.
   - Dr. Qurban Ali, Member Registration Board
   - Area Federal Inspector of Drugs.
   - Mr. Haseeb Tariq AD PEC

10. The decision of the Board was communicated to the panel vide letter No. 03-65/219-QC-(293rd RB) dated 21-04-2020 wherein the Federal Inspector of Drugs-II Islamabad submitted as under:

> *"Kindly refer to the subject cited above and letter No.03-65/2019-QC- (293rd RB) dated 21-04-2020. It is submitted that a panel comprising of following members namely Dr. Qurban Ali Member Registration Board area FID and Mr. Haseeb Tariq AD, PEC was constituted with a direction to area FID-II implement the decision of the in letter in spirit and delivery of letter to the firm.*
>
> *02. The letter has been delivered to the firm and case was discussed with members of the panel who opined that if the firm provides the CAPA then inspection may not be necessary. The firm on 07-08-2020 provided a CAPA report along with all Batch history of batch No. 484 in 2018 and 2020 and same has been forwarded to members with the points raised for PSI. The firm complied with the documentary evidence of CAPA and batch record. The members of the panel in consonance with the member registration Board (Dr. Qurban Ali). The panel in the light of evaluation of submitted documents (CAPA) by the firm is of opinion that the inspection may not be necessary for the said product. The same copy of the CAPA has already been submitted AD QC-II. The firm provided the report (BMR) and the test analysis reports dated May 2020 July 2020 same has been provided and sent to the members for perusal and directions. No directions/comments received from the members so letter is being sent to the Secretary Registration Board for record please."*

11. In the above-mentioned reply, FID-II Islamabad has stated that the firm submitted CAPA to the panel members. The panel members were of opinion that in the light of submitted CAPA, the inspection may not be necessary.

12. Contrary to the statement of FID-II Islamabad, no such reply/comment/consonance has been received from the other panel members and also as per available record in the section no CAPA has been received from neither the firm nor FID-II Islamabad.

13. FID-II Islamabad vide letter No. F. 03-13/2005-FID-I(Isd) dated 14-06-2021 submitted the request of firm for resumption of production as under:

> *"In continuation of this office letter of even No. dated 20th August 2020 (Copy enclosed). The subject matter has been discussed with the members of panel, regarding the product namely Hemorose-F Tablet which had been suspended since more than six months as per decision of Registration Board taken before in its 293rd meeting held on 06-08th January 2020 (Copy enclosed). The firm had not manufactured the subject product since more than six months (copy enclosed).*
>
> *02. In view of directions of the Registration Board the firm had complied with the decision of the Board and now requesting for resumption of production of Hemorose-*

F Tablet (Copy enclosed) which had been suspended. The panel members had also been kept on Board and agreed to the decision/ directions of Registration Board."

Proceedings and Decision of 312th meeting:

14. The Board after thorough deliberations and considering the reply of area Federal Inspector of Drugs discussed the matter with the other panel members i.e. Dr. Qurban Ali and Mr. Haseeb Tariq. Both members were unaware of such communication as stated by area Federal Inspector of Drugs. The Board showed serious concern over the reply of area Federal Inspector of Drugs and decided as under:

i. Suspension of the Registration of the said product till the verification of root cause analysis, Corrective and preventive action (CAPA) by the firm, product development data and verification of aforementioned points and Product Specific Inspection by following panel whichever is later.
   a. Dr. Qurban Ali, Member Registration Board
   b. Ms. Mehwish Tanveer, Assistant Director QA&LT
   c. Mr. Haseeb Tariq Assistant Director PEC

ii. Refer the case to Chief Executive Officer DRAP for taking disciplinary action against the area FID Islamabad for not complying Registration Board directions and mis-quoting other members of Registration Board.

15. In compliance to the decision of Registration Board, panel mentioned in para. 14 (i) visited the premises of M/s. Neomedix Pharmaceuticals Islamabad on 06-04-2022 for the purpose of verification of Root cause analysis, Corrective and preventatinve action and product development data for Hemorose-F tablet. Details of report as under:

"DETAILS OF INSPECTION

The firm was informed about the schedule of the inspection vide letter No. F. 15-1/2022-PRC dated 1st April 2022 by Assistant Director (PEC-III) after coordination with other panel members.

The panel visited the factory premises of M/s Neomedix located at Plot No. 05, N/5 National Industrial Zone, Islamabad on 06-04-2022. The following representatives / management of the firm were present at the premises:

1. *Mr. Faisal Muzamal (Partner)*
2. *Mr. Syed Talib Hussain Hashmi (Partner)*
3. *Ghulam Ghaus (QC Manager)*
4. *Muhammad Shoaib (Production Manager)*

The management of the firm informed the panel that they have recently purchased this unit and applied for change of management in Licensing Division DRAP in January 2022. The management informed that they have not yet got the complete possession of this unit and therefore no production activities are carried out. The firm also presented copy of letter for change of management of M/s Neomedix dated 4th July 2022 submitted to the Secretary Licensing Board (Annexure-I). The management further informed that since they have recently purchased the unit therefore they have not completed Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets.

The management submitted a written request for provision of some time for performing Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets (Annexure-II). The written request of the firm is as below:

Dear sir,

Referring to your letter No. F.15-1/2022-PEC dated 1st April 2022 and visit of inspection panel on 6th April, 2022, it is submitted that we have purchased this premises and submitted the letter of change of management in Licensing Division DRAP, in first week of January (Letter attached) and according to agreement, we will get complete possession of Neomedix in May 2022.

It is submitted that due to change of management and that till date we have not received full possession of premises, we have not completed Root Cause Analysis, CAPA and product development.

Kindly grant us 90 days after the full possession, so we could complete RCA, CAPA and product development in a better way.

Thanks and best regards,

For Neomedix,

Faisal Muzamal *Syed Talib Hussain*

(Partner) *(Partner)*

The management of the firm showed positive attitude for performing Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets. The request of the firm is submitted for consideration by the Registration Board."

16. Proceedings and Decision of 317th Meeting of Registration Board.

Registration Board after thorough discussion and deliberations and considering the report of PSI and firm's request decided to advise panel for inspection of the firm in June 2022 for verification of CAPA and submit a report for consideration of the Board.

17. In compliance to the decision of the Board, the panel once again visited M/s Neomedix Pharma, Islamabad and submitted the report as under:

"DETAIL OF INSPECTION

The panel visited the factory premises of M/s Neomedix located at Plot No. 05, N/5 National Industrial Zone, Islamabad on 30-06-2022. The following representatives / management of the firm were present at the premises:

1. *Mr. Faisal Muzamal (Partner)*
2. *Mr. Syed Talib Hussain Hashmi (Partner)*
3. *Ghulam Ghaus (QC Manager)*
4. *Muhammad Shoaib (Production Manager)*
5. *Tauqeer Zehra (QA Manager)*

The management of the firm informed the panel that they have not yet conducted the Root Cause Analysis, Corrective and Preventive Action (CAPA) and performed product development and stability studies, because they have got the complete possession in May 2022 and afterwards they have started to upgrade the QC lab and have placed an order for the purchase of new HPLC system. The firm's management informed that they have received HPLC which needs commissioning and training which may take 15 days, after which they will perform product development studies.

Since the firm had not yet conducted the Root Cause Analysis, Corrective and Preventive Action (CAPA), product development and stability studies therefore the panel could not verify any performance of above stated studies."

Proceedings and Decision of 320th meeting:

18. The case has been deferred due to paucity of time.

Proceedings and Decision of 321st Meeting of Registration Board.

19 The Registration Board after discussion, considering the facts of the case decided:

"To issue show cause notice to M/s. Neomedix Pharma, National Industrial Zone, Rawat under clause (c) and (d) of sub section 11 of section 7 of the Drugs Act 1976 for suspension/cancellation/ prosecution in Drug Court of the subject cited drug and called them for personal hearing before Registration."

20 In compliance to the decision of RB show cause was issued to firm vide letter No. 03-45/2022 QC dated 15-11-22 to which M/s. Neomedix Pharma, National Industrial Zone, Rawat vide letter dated 06-12-2022

21 M/s. Neomedix Pharma, National Industrial Zone, Rawat vide letter dated 06-12-2022 has briefed that previous management was responsible for manufacture and sale of this substandard drug they are under process of purchasing the firm but still are not the legal owner of firm, future management is under process of changing which still is awaited by honorable drug court and CLB. The matter of sub-standard drug is pending adjunction before the honorable drug court Rawalpindi and responsibility falls to previous management so new management may be exonerated.

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided:

i. **"Cancellation of Registration of Tab. Hemorose-F (iron polymaltose complex + Folic acid manufactured by M/S Neomedix Pharma), Registration number Reg No. 043985 ."**

AGENDA ITEM NO. 02 (ROUTINE CASES)

Case No. 7: MANUFACTURE & SALE OF SUB-STANDARD TEMPRIN TABLETS, BATCH NO. 055, MANUFACTURED BY M/S KOHS PHARMACEUTICAL (PVT.) LTD., HYDERABAD.

01. FID-VI, DRAP, Karachi inspected the premises of M/s. Hashmani Medicines, Shop No.4, Plot SB-1, Block-1, Madiha Square, Hussain abad, FB Area, Karachi on 21-11-2019 in light of NTF, wherein following sample of drug along with other drugs were taken for the purpose of test/analysis on prescribed Form-3. The sealed samples of above drugs were sent by the FID, DRAP, Karachi to Federal Government

Analyst, Central Drugs Laboratory, Karachi for test/analysis vide office memorandum No. ARS- 249-252/2019-FID-VI (K) dated 22-11-2019.Details are as under:

Temprin Tablet (Paracetamol 500mg) **Batch No:** 055 **Mfg date** 10/18 **Expiry Date:** 09/20 **Manufacturer**: M/s. KOHS Pharmaceuticals (Pvt.) Ltd., P/8, SITE Hyderabad

02. The sealed portion of the sample was also sent to Chairman, Registration Board vide letter No.F.249-252/2019-FID-VI (K) dated 22-11-19 as required under the provision of clause (b) (3) Schedule-V (Procedure for Inspector) of DRAP, Act, 2012.

03. M/s Hashmani Medicines, Karachi has produced the invoice/bill warranty No. 183 dated 25-09-2018 of M/s KOHS Pharmaceuticals (Pvt.) Ltd., P/8, SITE Hyderabad as a proof of their purchase of above said drug.

04. The Federal Government Analyst, Central Drug Laboratory, Karachi vide test report No.NTF.KQ.567/2019 dated 11-12-2019 declared the sample of above-named drug as "substandard" quality under the drugs Act, 1976, which is violation of Section 23 (1)(a)(v) of the drugs Act, 1976 and rules framed there under. Results of the test reports of CDL, Karachi are given as under;

Description	*White tablets, marked with "KOHS" on one side and line of bisection on the other*
Identification	*Paracetamol identified*
Dissolution test	***Does not comply***
Uniformity of Dosage Unit by Weight Variation	*Complies*
Assay for Paracetamol	*Determined amount/tablet: 501.3477mg (100.3%) Complies*

Remarks: - *The sample is of substandard quality under the Drugs Act. 1976.*

05. Letters dated 16-12-2019, 30-12-2019 and 14-02-2020 issued by the FID to M/s. KOHS Pharmaceuticals (Pvt.) Ltd., P/8, SITE Hyderabad for manufacturing, selling & distributing of above-mentioned substandard drug with directions to recall from the marketbut the firm had not replied. FID-VI, DRAP, Karachi further submitted that keeping in view of above stated facts, M/s. KOHS Pharmaceuticals, P/8, SITE, Hyderabad has violated Section 23(l)(a)(v) of Drug Act, 1976 and rules framed there under therefore, it is recommended that: -

i. The registration of said product may be suspended/cancelled in larger public interest after due deliberation of board concerned.
ii. It is also recommended that a detailed panel GMP inspection of the firm may be carried to find out the RCA of the problem and for final recommendations, please.
iii. The names of their Director and Technical persons may kindly be obtained from Licensing Division.

06. FID-VI, DRAP, Karachi vide reference No.F.ARS-249-252/2019-FID-VI (K)-NTF dated 26-02-2020 addressed to the Assistant Director (QC-II) wherein he enclosed the reply of M/s KOHS Pharmaceuticals (Pvt.) Ltd., and also provided the names of following technical persons;

Dayo Mal Daya Ram	MD (CNIC: 41306-33000997-5)
Mirza Salim Ullah	Production Incharge, (CNIC: 41303-1504590-5)
Miss Rakhshanda Parvenn	QC Incharge, (CNIC: 45304-9856804-2)

07. Drugs Licensing Division was requested to verify the names and they provided the following

Mr. Pardeep Kumar	Director
Saman Mal	Director
Mr. Mirza Saleem ullah	Production Incharge
Ms. Rakhshanda Parveen	Quality control Incharge

10. Show-cause notice was issued to the firm and above accused vide letter No.F.03-62/2029-QC dated 15-09-2020 for the following actions;

i. Prosecution in the Drug Court.
ii. Cancellation/Suspension of Drug Registration.
iii. Any other action the Board may deem fit.

11. M/s. KOHS Pharmaceuticals (Pvt.) Ltd., Hyderabad submitted their reply vide reference No.032KOHS/2020-2021 dated 02-10-2020 and is given as under;

"Regarding to our product Temprin 500mg tab (Batch No. 055) didn't comply in dissolution may be because of shop premises (Temperature & Humidity) not suitable for product or any atmosphere reason.
Here we perform dissolution of temprin 500mg tab of other batches (070, 072) in our lab, the result of batch is within the limit, attach lab report copies.
Kindly consider our lab report and give us one warning or to appear technical person in front of the Board."

12. The accused were called before the Registration Board for opportunity of personal hearing.
13. The case was presented in the 297th meeting of the Registration Board wherein decided as under:

"i. To issues show cause notice for cancelation/suspension of the registration of product Temprin (Reg. No. 070620) to the accused.
ii. The Board authorized Additional Director QA&LT to nominate a panel for inspectors to conduct the risk-based inspection of the firm including Dr. Rafiq Alam (Member Registration Board) and to take sample for test/analysis. Until satisfactory GMP inspection report and standard test report by CDL is obtained, the registration of product Temprin tablet will remain suspended."

14. The accused were issued show-cause notice and notice of suspension of production of product vide No. F. 03-56/2021-QC (Pt-I) (297-RB) dated 05-04-2021. The accused has replied vide ref. No. 065/21/KOHS dated 15-04-2021 which is given as under:

"In response to your letter for Temprin tablet Batch No: 055 MFG date OCT / 18 EXP: SEP / 20. It is submitted that according to test analysis report issued from CENTRAL DRUGS LABORATORY / GOVT ANALYSIS report No NTF, KQ 567/ 2019, the potency of the said product is declared (100.3%) and failed in dissolution test. Govt, analysis test report attached for your kind consideration. due to this reason it was declared as sub -standard. kindly consider this matter sympathically

We had not appeared before the board official due to some environmental problems occurring in the country since last months.Lastly it is requested that give us a chance for appearing before the Board regarding this matter."

15. The representatives of firm are called before the Board for personal hearing.
16. Proceedings and decision of 307th meeting of Registration Board, Mr. Rashid Mureed (Attorney) appeared before the Board on behalf of M/s. KOHS Pharmaceuticals, Hyderabad to plead the instant case. The Board after considering the facts of the case, stance of the firm and thorough deliberations decided as:
    i. The suspension of Registration of the Temprin tablet Registration No. 070620 remain intact till the PSI is conducted.
    ii. The data of Quality Control cases during last 2 years along with their fates will be presented before the Board.
17. In compliance to the decision of 307th meeting of Registration Board, data of Quality Control cases along with the fates of the cases of M/s. KOHS Pharmaceuticals, Hyderabad were obtained from CDL Karachi and Provincial Health Departments. Details are given as under:

01	**Tempramine suspension** **B No.** TM047 **Substandard** on Assay (65.20%) & physical description (sedimented cake) **DTL** Bahawalpur **TRA No. & date** 01-77002870 dated 2-27-2021	Firm has submitted evidence in contravention of DTL report. Request of the firm will be placed in upcoming meeting of PQCB scheduled to be held on 20th January
02	**Tempramine suspension** **B No.** TM047 **Substandard** on Assay (65.20%) & physical description (sedimented cake) **DTL** Bahawalpur **TRA No. & date** 01-77002960 dated 03-03-2021	Complete investigation report from Drug inspector has been received in PQCB Punjab
03	**Tempramine suspension** **Batch No.** 076 **Misbranded** (Section 3(iv) of the Drugs Act 1976) **DTL** Rawalpindi **TRA No. & date** 01-75000571 dated 03-03-2021	Complete investigation report Drug inspector is awaited by PQCB

18. Moreover, FID-IV Karachi has submitted report in compliance to the decision of Board. Details of proceedings of inspection area given under:

"Focus of inspection:
Risk based product specific inspection in compliance to DRAP, Islamabad letter No. F. 4-18/2006-QA dated 30th June, 2021.

Proceedings of current inspection:

The panel during the inspection reviewed the available documents of the product Batch in question and interviewed the technical staff. Related documents and traceability was established with the log books and the practices being followed in manufacturing and testing of the product.

Production Premises:

Firm has provided properly maintained visitors change room, male and females staff change room along with a buffer before entrance into the production premises. Material receiving bays, quarantine area, storage, dispensing areas were visited and their log documents were reviewed at the work stations.

Quality Control Laboratory

The laboratory is equipped with necessary equipments for carrying out test/ analysis of the focused Dosage form i.e. Tablet. Hardness tester, Disintegration apparatus, dissolution apparatus, analytical weighing Balance, pH meter, UV-Spectrophotometer, HPLC and other facilitating equipments required for test/ analysis of the product were seen available and utilized for investigation at time of inspection.

Quality Assurance/ Documentation System:

Firm has basic documentation system in place. Batch Manufacturing record of the product and batch in question was reviewed and it reveals that most parameters are not defined in details although followed/ are in practice.

Technical Areas:

The HVAC units of this section are placed on the rooftop. Since, production in this section is suspended therefore, was not in operation at the time of inspection, However, supply and exit ducts were seen properly installed.

Observations/ Findings:

Process validation and stability, studies as per requirements were not satisfactory.

Recommendation and Conclusion:

Based on the areas visited, processes reviewed and technical people interviewed, the panel is of the view to recommend resumption of suspension of product "Temprin 500mg" subjected to submission and verification of process re-validation studies and stability data of 3 Batches upon resumption of production by the area FID."

19. The case has been deferred due to paucity of time.in 320th meeting.
20. The Registration Board deferred the case for further deliberation in next meeting.in 321st meeting.

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided as under:

i. **"Registration of subject drug *Temprin 500mg tablet mfg by* M/s Kohs Pharmaceutical (Pvt.) ltd., Hyderabad shall remain suspended till completion of product development and 6 months accelerated and 12 months real time stability studies and satisfactory GMP report by a panel constituted by Director QA&LT Division."**

Case No. 8: NOT TO DISPOSE OF UNDER SECTION 18(1)(I) OF DRUGS ACT, 1976 – M/S. HAWK BIO PHARMACEUTICALS PVT LTD, PLOT NO.10, STREET NO. S-6, NATIONAL INDUSTRIAL ESTATE, RCCI RAWAT.

01. Federal Inspector of Drugs-III Islamabad, vide letter No. F.2-10/2011-FID-II dated 14th October, 2019, wherein FID requested Chairman, Drug Registration Board, for extension in order not to dispose of which was granted to FID-III Islamabad vide letter F. No. 13-195/2019-QC dated 30-12-2019 with instructions to complete the investigation. Details of the stock ordered not to dispose of are given as under:

S.#	Drug	Details	Reason
01.	Invermectin	**Batch No** 201808021 **Quantity** 1.7 Kg **Manufacteurer** Unknown	The Firm's management is unable to provide the import authorization/ clearance documents of material issued by (I&E) DRAP.
02.	Bismuth Subnitrate	Batch No 19030211 Quantity 4.1kg **Manufacteurer** Unknown	-Do-
03.	Ferrous Sulphate	Batch No 00118-060 Quantity 22.250Kg **Manufacteurer** Unknown	-Do-
04.	Copper Sulphate	Batch No RLFX87318 Quantity 19.90kg	-Do-

		Manufacteurer Unknown	
05	Zinc Sulphate	Batch No JXBHB2019-014 Quantity 17.7Kg **Manufacteurer** Unknown	-Do-
06	Magnesium Sulphate	**Batch No** Not Known **Quantity** 50Kg **Manufacteurer** Unknown	-Do-
07	Manganese Sulphate Mnso4	**Batch No** 10819-019 **Quantity** 2.4Kg **Manufacteurer** Unknown	-Do-

02. FID-III Islamabad vide letter No. F. 3-9/2010-FID-II (ISD) dated 15-09-2020 submitted as under; "Undersigned has inspected the premises of M/s Hawk Bio Pharmaceuticals (Pvt) Ltd, Plot No. 10, S-6, NIZ, RCCI Rawat, Islamabad on 10th October, 2019. During inspection following drugs were placed in warehouse of the firm premises due to the reason mentioned below in contravention of DRAP Act, 2012 under Drug Act, 1976 and rules framed ther under. Therefore, the below mentioned drugs were ordered not to dispose off for 28 days under schedule -V Section (1) (i) of DRAP Act, 2012 read with section (18) (1)(i) of the Drugs Act, 1976. (Annex-A).

S.#	Name of Drug	Batch & Quantity	Manufacturer	Reason
1	Invermectin	201808021 1.7Kg	Unknown	The firm's management is unable to provide the import authorization/ clearance document of material issued by (I&E) DRAP.
2	Bismuth	19030211 4.1 Kg.	-do-	-do-
3	Ferro Sulphate	00118-060 22.250Kg	-do-	-do-
4	Copper Sulphate	RLFX-873-18 19.90Kg	-do-	-do-
5	Zinc Sulphate	JXBHB2019-014 17.7Kg	-do-	-do-
6	Mangnesium Sulphate	Not know. 50Kg	-do-	-do-
7	Mangnesium Sulphate Mnso4	10819-019 2.4Kg.	-do-	-do-

i. M/s Hawk Bio Pharmaceuticals (Pvt) Ltd, Plot No. 10, S-6, NIZ, RCCI Rawat, Islamabad was directed vide this division letter of even number dated 14-10-2019, subsequent reminder dated 02- 01-2020under drugs Act, 1976 and rules framed there under, as required under section 32 (3) (b) (i) (ii) of Drug Act, 1976 under DRAP Act, 2012. (Annex-C).

i. *License/ permission certificate of said imported Raw Material.*
ii. *Clearance of Assistant director (I&E).*
iii. *Any written evidence of loan from another manufacturer*

ii. M/s Hawk Bio Pharmaceuticals (Pvt) Ltd, Plot No. 10, S-6, NIZ, RCCI Rawat, Islamabad intimated that they purchased quantity of 2Kg of Ivermectin and 25 Kg of Bismuth from local market to fulfill some urgent supply and presented or clarification about other drugs (photo copy enclosed) (Annexed-D)

iii. It is pertinent to mention that the firm failed to provide any evidence as asked for about in the said letter, hence the firm contravened Section 23 (1) (d)(e) read with Section 27 (1) (C) and 27 (4) of the Drug act, 1976 and rule 7 & 15 (1) of drug import and Export Rules, 1976. Following persons are involved in the said contravention and action mentioned below are being purposed: -

i. *Prosecution in the Drug Court.*
ii. *Cancellation/ suspension of registration of all the product where the said illegal raw material used.*
iii. *Cancellation/ suspension of DML of all the sections where the said illegal raw material used.*

	Name	***CNIC#***	***Designation***

1	*Dr. Javed Saeed*	*37405-0357375-7*	*Chief Executive of the firm.*
2	*Mr. Zia Hussain*	*3706-5184938-7*	*Production incharge.*
3	*Mr. Ajmal Zaman*	*37405-0438707-1*	*QC incharge.*

iv. Submitted for perusal under Section 19(7) to the competent authority as desired, please."

03. The case was presented before the Board in its **297th meeting** wherein it was decided as under:

"The Board after detailed deliberations and considering the facts of the case decided to issue show cause notice for cancelation/suspension of products to the accused."

04. In compliance to the decision of Registration Board, the accused was issued a show-cause notice vide No. F. 03-56/2021-QC (Pt-I) (297-RB) dated 05-04-2021. The accused has replied vide ref. No. HBP 4 / 2021 dated 15-04-2021 which is given as under:

> *"This refer to your letter no. F.03-56/2021-QC(Pt-I) (297-RB) dated April 05,2021 via ums services, which we received on dated April 12,2021 on Subject cited above. Please provide us an opportunity to be heard in person in response to above show cause notice. We want to submit justification / clarification in person."*

05. Keeping in view of above-mentioned reply, the representatives of the firm are called before the Board for personal hearing.

06. Proceedings and decision of 307th meeting of Registration Board:

Dr. Javed Saeed (CEO M/s. Hawk Bio Pharma, Islamabad) along with QC Manager, Mr. Ajmal and Production Manager, Mr. Zia Hussain appeared before the Board for Personal hearing. They pleaded that they have submitted evidence to FID that their imports were done as per legal procedures. They submitted a written reply and supporting documents. The Board after considering the facts of the case and thorough deliberations decided as follows:

i. Refer the case back to area FID for complete investigation.
ii. Suspend all registered products of the firm (as identified by area FID) that were manufactured by the raw materials in question.

07. In compliance to the decision of 307th meeting of the Registration Board, letter vide No. No.F.03-15/2021-QC (307-RB) (Pt-I) dated 03-08-2021 was issued to M/s. Hawk Bio Pharma Islamabad and area FID Islamabad for submission of complete investigation report. Area FID Islamabad vide letter No. F. 2-10/2011-FID-II (ISD) dated 05-01-2021 submitted as under:

08. In response to the decision of Registration Board taken in it's 307th meeting, the firm was called for investigation of case.

Investigation of Case:

*The firm was asked to submit the evidence of loan & proof of import clearance by DRAP. In response they submitted the loan request applications alongwith inward, outward Gate Pass & GRN of Ivermectin & Bismuth Subnitrate alongwith import clearance documents & COAs of both loaned & self-imported materials **(Annex-E)**. However, they could not provide the evidence of import of loaned material of Bismuth subnitrate. For which they have submitted that since they loaned it from M/s Mansoor Chemicals, Karachi who have informed them the given material was expired during 2020. Hence, they have disposed off the documents after expiry period **(Annex-F)**. Regarding Ferrous Sulphate, Copper Sulphate, Zinc Sulphate, Magnesium Sulphate and Manganese Sulphate, they have submitted clarification that these are considered as excipients. Hence no need of import authorization required. They have further informed that all the materials (except Magnesium Sulphate) have now been expired as details mentioned on COAs as per following details and they have hence requested for destruction of materials since the materials have been expired now and they shall be careful in future **(Annex-G)**:*

S.#	***Name of Drug***	***Batch & Quantity***	***Date of Expiry (As mentioned on COA)***	***Manufacturer***
1.	*Invermectin*	*201808021 1.7Kg*	*17th August 2020*	*Unknown*
2.	*Bismuth Subnitrate*	*19030211 4.1Kg.*	*27th October 2020*	*-do-*

3.	*Ferrous Sulphate*	*00118-060 22.250Kg*	*12th April 2018*	*-do-*
4.	*Copper Sulphate*	*RLFX-873-18 19.90Kg*	*11th November 2020*	*-do-*
5.	*Zinc Sulphate*	*JXBHB2019-014 17.7Kg*	*11th January 2021*	*-do-*
6.	*Magnesium Sulphate*	*Not mentioned on COA 50Kg*	*Not mentioned on COA*	*-do-*
7.	*Manganese Sulphate*	*10819-019 2.4Kg*	*11th May 2021*	*-do-*

11. In the light of above, it is concluded that the firm was involved in loaning practices which has no legal coverage. Regarding Ferrous Sulphate, Copper Sulphate, Zinc Sulphate, Magnesium Sulphate and Manganese Sulphate their clarification is not justified on scientific & legal grounds. The investigation of case and the request of firm for destruction of materials is submitted before Registration Board."

Proceedings and Decision of 320th meeting:

The case has been deferred due to paucity of time.

Proceedings and Decision of 321st Meeting of Registration Board.

The Registration Board deferred the case for further deliberation in next meeting.

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided as under:

i. **Import and export of raw materials does not fall under the mandate of Registration Board. Hence, the case is referred back to QA&LT Division to decide the case under the Drugs (import & Export) Rules, 1976 under Drugs Act, 1976. Till that decision, registration of all products shall remain suspended as per decision of the 307th meeting of Registration Board communicated vide letter No. No.F.03-15/2021-QC (307-RB) (Pt-I) dated 03-08-2021.**

Case No. 9: IMPORT OF REGISTERED PRODUCTS THROUGH FAKE/FORGED INVOICES BY M/S. BIOCURE PHARMACEUTICALS, LAHORE.

01. Assistant Director (I&E), Lahore vide letter No.5247/2019/DRAP(AD-CD) (I&E) dated 15-04-2019 informed that Assistant Collector-II, Model Customs Collectorate of Appraisement-West, Karachi has asked for the verification of genuineness of following ADC invoices;

Sr. No	Invoice No. & Date	Diary No. & date	Dispatch No. & Date
1	SBF/EXP/23-2019, dated 21-02-2019	4699/2019 DRAP dated 15-03-2019	3769/2019-DRAP, dated 19-03-2019
2	SBF/EXP/24-2018, dated 15-03-2018	4569 dated 26-03-2018	4451/2018-DRAP, dated 29-03-2018
3	SBF/EXP/28-2017, dated 29-03-2017	5982 dated 27-04-2017	5647/2017-DRAP, dated 28-04-2017
4	SBF/EXP/127-2015, dated 28-10-2015	13579 dated 23-11-2015	18835/2015-DRAP, dated 26-11-2015
5	SBF/EXP/128-2016, dated 27-12-2016	1524 dated 26-01-2017	1396/2017-DRAP, dated 27-01-2017

02. AD (I&E), DRAP, Lahore further informed that the genuineness of the endorsement of said invoices is not verified from the office record. In response to the submission of AD (I&E), DRAP, Lahore the division of QA&LT directed the Area FID vide letter F. No.13-125/2019-(QC)dated 16-05-2019 to investigate the matter and after completing all the legal formalities, submit a comprehensive report including all the requisite documents, if any, on priority basis for consideration of the Board.

03. Area Federal Inspector of Drugs Lahore vide letter No.7011/2021-DRAP (L-IV) dated 07-05-2021 submitted the complete investigation report and the reply of accused as under:

S.No.	Invoice No & Date	Diary No. & date	Dispatch No, & Date

1	SBF/EXP/23-2019, dated 21-02-2019	4699/2019 DRAP dated 15-03-2019	3769/2019-DRAP, dated 19-03-2019
2	SBF/EXP/24-2018, dated 15-03-2018	4569 dated 26-03-2018	4451/2018-DRAP, dated 29-03-2018
3	SBF/EXP/28-2017, dated 29-03-2017	5982 dated 27-04-2017	5647/2017-DRAP, dated 28-04-2017
4	SBF/EXP/127-2015, dated 28-10-2015	13579 dated 23-11-2015	18835/2015-DRAP, dated 26-11-2015
5	SBF/EXP/128-2016, dated 27-12-2016	1524 dated 26-01-2017	1396/2017-DRAP, dated 27-01-2017

2 Letter No. 12040/2019-DRAP (L-VI) dated, 17-09-2019, was sent from this office to M/s. Biocure Pharmaceuticals, to explain their position in this regard (copy attached annex-9).

3 Reply received from M/s. Biocure Pharmaceuticals, Jail Road, Lahore vide letter No. Nil, dated Nil received office on 02-10-2019 (copy attached annex-10), wherein they have informed that after coming to know of the above they launched FIR against the clearing agent, whom they had hired some time ago .The CEO of the firm further informed that he was shaken after knowing about this matter which caused severe tension, heart attack and cardiogenic shock. He has further requested that he may be granted relief on humanitarian basis. Previous import history of the firm as per this office record showing clearance certificates obtained from this office previously is also. But as per available record of this office the above said invoices were not cleared by this office.

4 The available data of this office reveals that the firm did not get prior clearance to import their products Eridoksin Registration No. 059185 and Roxine 25% Registration No. 059186 which is the violation of the Drugs Act 1976/DRAP Act 2012, so, it is recommended that the registration of the drugs / product in question may be suspended or cancelled or any other action may be taken as deemed fit by the Competent Authorities.

Submitted for information and further necessary action please."

04. Area FID Lahore in the above-mentioned report has recommended the cancellation/suspension of registration of products namely Eridoksin powder containing Erythromycin 40mg and Doxycycline 20mg (Reg. No. 059185) and Roxine 25% oral solution containing Enrofloxacin 250g (Reg. No. 059186) or any other action as may deem fit by the Board.

05. The Board in its 312th meeting decided to issue show cause notice to firm for cancellation/suspension of their registered product.

06. In compliance to the decision of 312th meeting of the Registration Board, the firm was issued show cause notice vide F.No.03-33/2021-QC (312-RB) dated 28-10-2021. Till date no reply has been received from the firm.

07. The representatives of the firm are called before the Board for personal hearing.

Proceedings and Decision of 313th meeting:

08. Jawad Ahmed (CEO) of M/s. Biocure Pharmaceuticals, Suite No. 211, 2nd Floor Khaleej Town, 38-A, Jail Road Lahore appeared before the Board and informed the Board that he had hired a clearing agent namely Muhammad Sadiq S/o Abdul Aziz R/o House No. 49-A, Street No. 139-C, Ittefaq street, Ghulam road, Ichhra Lahore who was responsible for submitting fake invoices to the custom authorities. Moreover, Mr. Jawad Ahmed also informed the Board that he was unaware of these illegal activities being carried out by his clearing agent and he also had lodged FIR against that clearing agent in Litton road Police Station Lahore.

09. The Board after thorugh deliberations, considering the facts of the case and submission of CEO of M/s. Biocure Pharmceuticals Lahore decided as under:

i. Suspend the Registration of the products namely Eridoksin Powder (Reg. No. 059185) and Roxine 25% oral solution (Reg. No. 059186) for (06) months.
ii. The division of QA&LT will conduct a detailed investigation of the matter and submit a comprehensive report before the Board within (02) months.

10. In the light of the decision of Registration Board, the accused were issued a letter for suspension of their products vide letter F. No. 03-43/2021-QC (313-RB) dated 16-12-2021. Moreover, brief facts of the case are given as under:

1) Assistant Director (I&E), Lahore vide letter No.5247/2019/DRAP(AD-CD)(I&E) dated 15-04-2019 informed that Assistant Collector-II, Model Customs Collectorate of Appraisement-West, Karachi has asked for the verification of genuineness of ADC invoices as mentioned in table of para 01.

2) The division of QA&LT directed the Area FID vide letter F. No.13-125/2019-(QC)dated 16-05-2019 to investigate the matter and submit a comprehensive report of the matter.
3) Area FID Lahore informed that the invoices provided by the Assistant Collector-II, Model Customs Collectorate of Appraisement-West, Karachi are forged and the firm did not get prior clearance to import their products and recommended that the registration of the drugs / product in question may be suspended or cancelled.
4) The Registration Board in its 312th meeting decided to issue Show cause notice and personal hearing to the management of M/s. Biocure Pharmaceuticals Lahore.
5) Jawad Ahmed (CEO) of M/s. Biocure Pharmaceuticals of the firm appeared before the Board in its 312th meeting and submitted that he had hired a clearing agent namely Muhammad Sadiq S/o Abdul Aziz R/o House No. 49-A, Street No. 139-C, Ittefaq street, Ghulam road, Ichhra Lahore and the fake invoices were submitted by him. The said person is not traceable and Jawad Ahmad (CRO) of M/s. Biocure Pharmaceuticals Lahore had lodged FIR against that person in Litton road Police Station Lahore. A Copy of FIR is also submitted by the CEO of M/s. Biocure Pharmaceuticals Lahore.
6) The invoices provided by Assistant Collector-II, Model Customs Collectorate of Appraisement-West, Karachi are dated 26-11-2015, 27-01-2017, 28-04-2017, 29-03-2018 and 19-03-2019 in her letter dated 15-04-2019 whereas the accused had lodged the FIR against his clearing agent on 22-06-2019.

10. The case has been deferred due to paucity of time in 320th meeting.
11. The Registration Board deferred the case in 321st meeting for further deliberation in next meeting

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided as under:

i. **"To refer the case to Legal Affairs Division for their opinion on the case."**

Case No. 10: **MANUFACTURE & SALE OF SUB-STANDARD BLOMOX FORTE SUSPENSION, REG. NO. 026072, BATCH NO. PF-045, MANUFACTURED BY M/S. BLOOM PHARMACEUTICALS (PVT) LTD., HATTAR.**

Details of sample:

Name of Product	Manufactured by	Reg. no.	Batch no.	Mfg. Date	Exp. Date	Remarks of CDL
Blomox Forte Suspension	Bloom Pharmaceutical (Pvt.) Ltd. Hattar	026072	PF-045	03-2021	02-2023	Substandard on the basis of Deliverable volume.

Details of CDL report:

S.No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Off white which reconstitute into off white suspension on mixing with water.	Complies.	Mfg. Specs.
2.	Identification	The identification test must identify Amoxicillin.	Complies.	USP 43
3.	**Deliverable Volume**	**Meets the requirement of general chapter <698>**	**Does not comply.**	**USP 43**
3.	pH	5.0 to 7.5	5.79-Complies	USP 43
4.	**Assay** Amoxicillin (Label Claim 250mg/5ml)	90.0% to 120.0%	113.74%- Complies.	USP 43

Remarks:*The sample is of **"Sub-Standard"** quality under the Drugs Act, 1976.*

Summary of the case:

i. Federal Inspector of Drugs-IV, DRAP Islamabad was taken the sample of Blomox forte suspension manufactured by Ms. Bloom Pharmaceuticals Pvt. Ltd., Hattar from the premises of M/s. Federal Government Polyclinic Hospital, Islamabad on 06-08-2021.

ii. FID also ordered not to dispose of the stock (3565 bottles) of Blomox forte suspension subject to report of test and analysis of the product for volume and content uniformity under clause (i) of section 18.

iii. The sample of drugs sent to Government Analyst, CDL for test and analysis on form-4 dated 09-08-2021. Federal Govt. Analyst CDL Karachi vide report No.R.IP.66/2021 dated 22-09-2021 has declared the sample as "Sub-standard" quality under the Drugs Act, 1976.

iv. FID directed firm to stop the sale and recall the said drug and explain their position.

v. Recall of product was initiated and reconciled by FID, it was revealed that batch size of product was 9300 packs and actual yield was 9010 packs+100 packs utilized by QC department. Ms. Bloom Pharma issued stock of 9000 bottles to its distributor Ms. Chaudhary Pharma, Rawalpindi which they issued to Ms. Biocare Enterprises and they supplied 9000 bottles to Polyclinic Hospital, Islamabad.

vi. M/s. Bloom Pharmaceutical Pvt. Ltd., Hattar replied to FID dated 21-10-2021 wherein they requested for retesting on the ground that

> ***"as per in-house testing performed by the Quality Control Department, the product complies all test specifications. Their Quality Control Department released the product for market after thorough tests and all specifications of the product were within limits and found no contravention of Drug Act, 1976."***

vii. Firm has been directed to submit scientific justification/evidence for retesting dated 25-11-2021.

viii. Firm replied dated 31-10-2021 where in their results of finished product and retained sample were as per specification. Firm has performed test on 10 containers which are in specification as per their documents

ix. As per decision of 313th meeting of Registration Board regarding appellate testing, CDL was asked for OOS investigation.

x. Federal Government Analyst, CDL Karachi submitted that

> ***"The sample in question was tested for Deliverable volume along with other quality test as per USP General Chapter<698> and as desired by the FID. The sample was declared as of substandard quality on the basis of the test performed. It is submitted that the test of deliverable volume requires thirty (30) containers and the quantity submitted to CDL, Karachi by the FID vide memorandum No. F.7-2/2011-FID-I (Vol-I) dated 09-08-2021, was only fifty (50) containers, therefore, No Systematic Out of Specification Investigation could be made for this sample."***

Proceedings and Decision of 324th Meeting of Registration Board.

The Registration Board deferred the case for further deliberation along with confirmation of Dry Powder Suspension (penicillin)

AGENDA ITEM NO. 03
APPELLATE TESTING CASES REPORTS FROM NIH

Case No. 12: **SUBSTANDARD MECONOR INJECTION MANUFACTURED BY M/S. NORTECH PHARMACEUTICALS (PVT.) LTD., ISLAMABAD.**

Federal Government Analyst CDL Karachi vide test report No. F. 5-3(I)/2021-CDL/S-803 dated 02-07-2021 it was informed that the sample of product "MecoNor Injection" Batch No. A-003 (Mfg. date 11-2020, Exp date 10-2022) sent to CDL Karachi by FID-I Islamabad has been declared as of substandard quality. Details of the test report are given as under:

S. No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Reddish pink coloured solution in amber glass ampoule.	Complies	Mfg. Specs.
2.	Identification	The identification test must identify Mecobalamin.	Complies	Mfg. Specs.
3.	pH	5.5 to 6.5	**4.98** **Does not comply**	Mfg. Specs.
4.	Bacterial Sterility	Must be sterile	Complies	BP 2020
5.	**Assay.** Mecobalamin.	92.5% to 108.5%	106.2% Complies	Mfg. Specs.

	(Label claim 500mcg/ampoule)			

02. FID-I Islamabad vide letter No. F. 3-4/2011-FID-I dated 23-09-2021 forwarded the request of M/s. Nortech Pharmaceuticals (Pvt.) Ltd., Islamabad dated 15-09-2021 for appellate testing of their sample of product namely "MecoNor Injection" batch No. A-003 declared substandard by CDL Karachi on 02-07-2021 (Report received by firm on 07-09-2021).

03. Registration Board in its 313th meeting decided to fulfill the codal formalities. In complianceLetter vide Therefore, in the light of decision of Registration Board, a letter vide No. F. 03-27/2021-QC dated 22-12-2022 was issued to M/s. NorTech Pharmaceuticals (Pvt.) Ltd., Islamabad for submission of OOS investigation and complete testing record of the concerned batch and to Federal Government Analyst CDL Karachi for submission of OOS investigation and complete testing record of report vide No. F. 5-3(I)/2021-CDL-S-803 dated 02-07-2021.

Technical evaluation of OOS report by QC section:

04. M/s. NorTech Pharmaceuticals Islamabad vide letter dated 03-01-2022 provided OOS investigation wherein they submitted the following:

- Testing method for pH of injection MecoNor (Mecobalamin) is non-pharmacopeial and the same was provided to CDL Karachi 23-06-2021.
- CDL Karachi concluded the test report while referring the controlled limits 5.5-6.5 of pH instead to limits provided by the firm i.e. 5.0-7.0.

06. However, on evaluation of the OOS report provided by the firm, it was observed that in Analysis report (Finished product) dated 24-12-2020, the pH of the batch in question of product Meconor injection was found to be 6.00 whereas in Analysis report (Finished product) dated 07-09-2021, the pH was found to be 5.7. It seems that product is not stable as evident from the variation of more than ±0.1 in pH values as determined by the manufacturer itself.

07. The matter was discussed in 320th meeting OOS investigation submitted by the firm and CDL Karachi were placed before the Board. The Board after thorough discussion and evaluation of the provided OOS investigation reports decided to accede with the request of M/s. Nortech Pharmaceuticals Islamabad to perform appellate test/analysis of Board's portion of sample for parameters that have been reported out of specifications (i.e. pH) by CDL Karachi of their product Meconr Injection Batch No. A-003 from NIH Islamabad**.**

08. In compliance to the decision of RB where board allowed appellate test for the said product so letter No. F.03-27/2021-QC dated 01-09-22 in compliance of which NIH has sent its report No 03-M/2022-DC&TMD dated 28-oct-22

PH TEST	Determined amount	Limits
Nomenclature Inj Meconor 500mcg **Batch No** A-003 **Mfg date** 11-20 **Exp date** 10-2022	5.4	5.0-7.0
Conclusion	The sample is of standard quality on basis of test performed	

Proceedings and Decision of 324th Meeting of Registration Board.

Registration Board after discussion, considering the facts of the case decided as under:

i) **Advised QA&LT Division, DRAP to approach NIH and CDL for provision of specifications of the said product as provided by the firm for further consideration by Registration Board.**

Item No.VI Additional Agenda

A. Pharmaceutical Evaluation & Registration Division:

Pharmaceutical Evaluation Cell (PEC)

Item No. I: Agenda of Evaluator PEC-X (Mst Najia Saleem)

Case No. 01: Registration applications of newly granted DML or New section (Veterinary)

a. New DML

New cases

I. **M/s Suave Pharmaceuticals Pvt. Ltd., Faisalabad. (New DML)**

CLB in its 288th meeting held on 18th October, 2022 has considered and granted approval for DML by way of formulation with the following sections.

Oral Powder (Penicillin)-Veterinary
Oral Liquid (General/ Antibiotic)-Veterinary
Oral Powder (General/ Antibiotic)-Veterinary
Liquid Injection (General/ Antibiotic)-Veterinary

Accordingly, firm has applied for following products for consideration by the Registration Board.

Section	No. of Products applied	No. of Molecules applied
Oral Powder (Penicillin)-Veterinary	03	02
Oral Liquid (General/ Antibiotic)-Veterinary	08	07
Oral Powder (General/ Antibiotic)-Veterinary	13	10
Liquid Injection (General/ Antibiotic)-Veterinary	08	08

Oral Powder (Penicillin)-Veterinary

(02 Molecules/ 03 products)

1.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Saple Sove E Oral Powder
	Composition	Each 1000gm Contains: Amoxicillin Trihydrate…200gm Lincomycin HCl…88gm Spectinomycin Sulphate…88gm Vitamin E Acetate…30gm
	Diary No. Date of R& I & fee	Dy.No 39352 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Lincoamox-Vet Powder of M/s Baariq Pharmaceuticals, Lahore. (Reg. No. 088643)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (Penicillin)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
2.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sovi Mox 50 Oral Powder
	Composition	Each 100gm Contains: Amoxicillin as Amoxicillin Trihydrate…50gm Colistin Sulphate…50 MIU
	Diary No. Date of R& I & fee	Dy.No 39346 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Moxywell Oral Powder of M/s Farm Aid Group, Haripur (Reg. No. 087187)

	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (Penicillin)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
3.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sovi Mox 20 Oral Powder
	Composition	Each 1000gm Contains: Amoxicillin as Amoxicillin Trihydrate…200gm Colistin Sulphate…800 MIU
	Diary No. Date of R& I & fee	Dy.No 39347 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Moxabect Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore. (Reg. No. 088642)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (Penicillin)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
Oral Liquid (General/ Antibiotic)-Veterinary (07 Molecules/ 08 products)		
4.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Encoli Sove 20 Oral Liquid
	Composition	Each 100ml Contains: Enrofloxacin…20gm Colistin Sulphate…50,000,000 IU
	Diary No. Date of R& I & fee	Dy.No 39343 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml,1000ml; Decontrolled
	Me-too status	Colistacin Liquid of M/s Bio-Labs (Pvt) Ltd., Islamabad. (Reg. No. 079714)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 The firm has submitted that 50MIU of Colistin Sulphate is equal to 4 grams.
	Decision: Approved.	
5.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Encoli Sove 10 Oral Liquid

	Composition	Each 100ml Contains: Enrofloxacin…10gm Colistin Sulphate…52 MIU
	Diary No. Date of R& I & fee	Dy.No 39349 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	520ml,1000ml; Decontrolled
	Me-too status	Bioenrocolis Liquid of M/s Elegance Pharmaceutical, Rawalpindi. (Reg. No. 073916)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 The firm has submitted that 52MIUof Colistin Sulphate is equal to 4.16 grams.
	Decision: Approved.	
6.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Bromint Sove Oral Liquid
	Composition	Each 1000ml Contains: Bromhexine HCl…50gm Menthol…40gm
	Diary No. Date of R& I & fee	Dy.No 39348 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 200ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Manster B 90 Oral Liquid of M/s Aamster Laboratories, Islamabad (Reg. No. 101499)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
7.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Bromo Sove Oral Liquid
	Composition	Each 1000ml Contains: Bromhexine HCl…50gm
	Diary No. Date of R& I & fee	Dy.No 39345 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Mucolytic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 200ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Brombar-5 Oral Liquid of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 073947)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	

8.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Floro Sove 23 Oral Liquid
	Composition	Each 1000ml Contains: Florfenicol…230gm
	Diary No. Date of R& I & fee	Dy.No 39344 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 500ml, 1000ml, 2500ml; Decontrolled
	Me-too status	Baflor-23 Oral Solution of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 071096)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
9.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Tilco Sove Oral Liquid
	Composition	Each 100ml Contains: Tilmicosin Phosphate Eq. to Tilmicosin…25gm
	Diary No. Date of R& I & fee	Dy.No 39340 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 150ml, 200ml, 250ml, 500ml, 1000ml; Decontrolled
	Me-too status	Tilcosin-25 Oral Solution of M/s Nawan Laboratories (Pvt) Ltd, Karachi (Reg. No. 058986)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
10.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Floro Col S 25 Oral Liquid
	Composition	Each ml Contains: Florfenicol…250mg Colistin Sulphate…0.5MIU
	Diary No. Date of R& I & fee	Dy.No 39332 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	100ml, 250ml, 500ml, 1000ml, 2500ml,5000ml; Decontrolled
	Me-too status	Poliflor Liquid of M/s Hawk Bio Pharma (Pvt) Ltd, Islamabad (Reg. No.078383)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022

		Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
11.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Entrim SS Oral Liquid
	Composition	Each 100ml Contains: Trimethoprim…2500mg Sulphamethazine…5000mg Sulphamethoxypyridazine…7500mg Enrofloxacin…7500mg
	Diary No. Date of R& I & fee	Dy.No 39359 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	500ml, 1000ml; Decontrolled
	Me-too status	Cinafas Oral Suspension of M/s Intervac (Pvt) Ltd., Lahore (Reg. No. 048264)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Liquid (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
Oral Powder (General/ Antibiotic)-Veterinary (10 Molecules/ 13 products)		
12.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Coli Sove 480 Oral Powder
	Composition	Each 100gm Contains: Colistin Sulphate…48,00,000 IU
	Diary No. Date of R& I & fee	Dy.No 2196 dated 23-01-2023 Rs.30,000/- dated 23-01-2023
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Bio-Colistin Water Soluble Powder of M/s M/s Bio-Labs (Pvt) Ltd., Islamabad. (Reg. No. 078291)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
13.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Coli Sove 500 Oral Powder
	Composition	Each 100gm Contains: Colistin Sulphate…500,000,000 IU
	Diary No. Date of R& I & fee	Dy.No 39333 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications

	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Colibect Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 075791)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
14.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sovi Dox 20 Oral Powder
	Composition	Each 1000gm Contains: Doxycycline HCl…200gm Tylosin Tartrate…100gm Colistin Sulphate…480 MIU Bromhexine HCl…5gm
	Diary No. Date of R& I & fee	Dy.No 39338 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Maxdox water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 087144)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	
15.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sovi Dox 40 Oral Powder
	Composition	Each 1000gm Contains: Doxycycline HCl…400gm Tylosin Taratrate…200gm Colistin Sulphate…1000 MIU Bromhexine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 39334 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Monodox Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 087142)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Provided conversion of Colistin Sulphate from MIU to grams. (19000IU = 1mg)
	Decision: Approved.	

16.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Neomy Sove 72 Oral Powder
	Composition	Each 100gm Contains: Neomycin Sulphate…72%
	Diary No. Date of R& I & fee	Dy.No 39336 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Nemobar-72 Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 071100)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
17.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Ampro Sove 90 Oral Powder
	Composition	Each 1000gm Contains: Amprolium HCl.....900gm
	Diary No. Date of R& I & fee	Dy.No 39335 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Amprobar Water Soluble Powder of M/s Baariq Pharmaceuticals, Lahore (Reg. No. 073955)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
18.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Amanta Sove 10 Oral Powder
	Composition	Each 100gm Contains: Amantadine HCl…10gm
	Diary No. Date of R& I & fee	Dy.No 39357 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Roxidine-10 Water Soluble Powder of M/s Vetrox Pharmaceutical Pvt Ltd, Toba Tek Singh (Reg. No. 112364)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in	

	view safety, efficacy and quality parameters.	
19.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Amanta Sove 98 Oral Powder
	Composition	Each 100gm Contains: Amantadine HCl…98gm
	Diary No. Date of R& I & fee	Dy.No 39358 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Vety Amantex 98% Oral Powder of M/s Leads Pharma Pvt Ltd, Islamabad (Reg. No. 094402)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
20.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Fosomin Sove Oral Powder
	Composition	Each 100gm Contains: Calcium Fosfomycin …20gm Tylosin Tartrate…10gm Fructose …18gm Sodium Phosphate…15gm Magnesium Sulphate…10gm
	Diary No. Date of R& I & fee	Dy.No 39351 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Fosomax Oral Powder of M/s Biogen Pharma, Rawat (Reg. No. 063808)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
21.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Lyzo Sove Oral Powder
	Composition	Each 1000gm Contains: Lysozyme HCl…400,000mg Vitamin E…100,000mg Vitamin C…50,000mg Sodium Selenite…100mg Zinc Sulphate…600mg Calcium Chloride…60,000mg Biotin…150mg Magnesium Sulphate…20,000mg

	Diary No. Date of R& I & fee	Dy.No 39342 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Immunity booster
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Magotin of M/s Leads Pharmaceuticals Could not be confirmed
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Shortcomings: Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm.
	Decision: Deferred for evidence of applied formulation/drug already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm	
22.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Paravit C Oral Powder
	Composition	Each 1000gm Contains: Paracetamol…200gm Vitamin C…50gm Potassium Carbonate…125gm Sodium Bicarbonate…125gm Vitamin E…125gm
	Diary No. Date of R& I & fee	Dy.No 39341 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Anti-inflammatory
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Parascorbic Powder of M/s Baariq Pharmaceuticals, Lahore. (Reg. No. 087140)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Shortcomings: Incorrect pharmacological group i.e. "Anti-inflammatory" was mentioned. Firm has now revised the pharmacological group to "Immune Booster". Firm shall submit fee of Rs.7500/- for correction in pharmacological group, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	
23.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Fnoxy Sove Oral Powder
	Composition	Each 1000gm Contains: Neomycin Sulphate…150gm Florfenicol…100gm

		Oxytetracycline HCl…300gm
	Diary No. Date of R& I & fee	Dy.No 39350 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Neoxflor Oral Powder of M/s Baariq Pharmaceuticals, Lahore. (Reg. No. 088638)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
24.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sovi Dox Oral Powder
	Composition	Each 1000gm Contains: Doxycycline HCl…200gm Tylosin Taratrate…100gm
	Diary No. Date of R& I & fee	Dy.No 2190 dated 23-01-2023 Rs.30,000/- dated 23-01-2023
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50gm, 100gm, 250gm, 450gm, 500gm, 1Kg, 2.5Kg, 5Kg, 10Kg, 15Kg, 20Kg, 25Kg; Decontrolled
	Me-too status	Tylohans-D20 Powder of M/s D-HAANS Pharmaceuticals, Azad Kashmir. (Reg. No. 106775)
	GMP status	New DML
	Remarks of the Evaluator X	Oral Powder (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022.
	Decision: Approved.	
Liquid Injection (General/ Antibiotic)-Veterinary (08 Molecules/ 08 products)		
25.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Sulphaton Solution for Injection
	Composition	Each ml Contains: Sulphadimidine Sodium…33.33%
	Diary No. Date of R& I & fee	Dy.No 39339 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Super Sulf Injection (50ml) of M/s Nawal Pharmaceuticals, Rawalpindi.(Reg. No. 074089)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
26.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad

	Brand Name +Dosage Form + Strength	Iverbil Solution for Injection
	Composition	Each ml Contains: Ivermectin…10mg
	Diary No. Date of R& I & fee	Dy.No 39337 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Anthelmintic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Ivoron Injection (50ml) of M/s Kayans Pharmaceuticals, Rawalpindi. (Reg. No. 112248)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
27.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Cyno-T Solution for Injection
	Composition	Each ml Contains: Cyanocobalamin…125mcg
	Diary No. Date of R& I & fee	Dy.No 39360 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Haemopoietic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Cyanofar Injection (50ml) of M/s Izfaar Pharmaceutical Industries, Lahore. (Reg. No. 074745)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
28.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Thylother-20 Solution for Injection
	Composition	Each 1ml Contains: Tylosin Tartrate…200mg
	Diary No. Date of R& I & fee	Dy.No 39361 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Tyrate -20% Injection (50ml) of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 109933)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
29.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Lidother Solution for Injection
	Composition	Each ml Contains: Lidocaine HCl…20mg

	Diary No. Date of R& I & fee	Dy.No 39356 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Local anaesthetic/Antiarrhythmic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Lignobak Injection (50ml) of M/s Attabak Pharmaceuticals Islamabad. (Reg. No.063830)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
30.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Oxymion Solution for Injection
	Composition	Each ml Contains: Oxytetracycline (HCl)…50mg
	Diary No. Date of R& I & fee	Dy.No 39355 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibiotics
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Levamycin-5% Injection (50ml) of M/s Biorise Pharmaceuticals Multan. (Reg. No. 113403)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Approved.	
31.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Genticin Solution for Injection
	Composition	Each 1ml Contains: Gentamycin Sulphate…100mg
	Diary No. Date of R& I & fee	Dy.No 39354 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antibacterial
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	10ml, 20ml, 50ml, 100ml; Decontrolled
	Me-too status	Gantasin-10% Injection (50ml, 100ml) of M/s Univet Pharmaceuticals, Rawalpindi. (Reg. No. 112218, 112219)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022 Shortcomings: The firm has applied for Gentamycin Sulphate 100mg/ml while the reference formulation is Each ml Contains: Gentamycin as Sulphate…100mg Firm shall submit fee of Rs.30000/- for correction in formulation, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021. Separate registration is granted to separate pack size/fill volume of injectable dosage form. However, multiple pack

		sizes of injectable dosage form are demanded in a single application. So clarification is required for which pack size/ fill volume you want to apply this dossier along with evidence of applied formulation/drug already approved by DRAP (generic / me-too status), with same fill volume/ pack size, alongwith registration number, brand name and name of firm.
	Decision: Approved as per following label claim: Each ml Contains: Gentamycin as Sulphate…100mg Firm shall submit fee of Rs.30000/- for correction in formulation, as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 alongwith selection of one fill volumeonly before issuance of registration letter.	
32.	Name and address of manufacturer / Applicant	M/s Suave Pharmaceuticals Pvt. Ltd. Plot No. 2-C, Value Addition City, Khurianwala, Faisalabad
	Brand Name +Dosage Form + Strength	Phenromion Solution for Injection
	Composition	Each ml Contains: Pheniramine Maleate…25mg
	Diary No. Date of R& I & fee	Dy.No 39353 dated 29-12-2022 Rs.30,000/- dated 29-12-2022
	Pharmacological Group	Antihistamine
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	50ml amber vial; Decontrolled
	Me-too status	Ann-Vil Injection (50ml) of M/s Venus Pharma, Lahore. (Reg. No. 035158)
	GMP status	New DML
	Remarks of the Evaluator X	Liquid Injection (General/Antibiotic)-Veterinary section granted vide letter No. F.1-9/2018 dated 10-11-2022
	Decision: Referred to Expert working Group to review therapeutic requirement keeping in view safety, efficacy and quality parameters.	

B. Item No. II: Agenda of Evaluator PEC-IV (Mst. Farzana Raja)

Export Facilitation cases

33.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 961 dated :11-01-2023
	Details of fee submitted	PKR 75,000/-: Deposit slip # 66569938007

	The proposed proprietary name / brand name	Linvesta-M 2.5/500mg Film Coated Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film coated Tablet contains: Linagliptin …….2.5mg Metformin HCl …….500mg
	Pharmaceutical form of applied drug	Yellow colored, biconvex oval shaped film coated tablet.
	Pharmacotherapeutic Group of (API)	Anti-Diabetic (Type-II)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	JENTADUETO 2.5/500mg Film Coated Tablet by Boehringer Ingelheim International GmbH (USFDA approved)
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 14-09-2022 and valid for two years.
	Name and address of API manufacturer.	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Linagliptin is not available in any official Pharmacopoeia & Official monograph of Metformin HCl is available in British Pharmacopoeia as well as in United States Pharmacopoeia. The API Manufacturer of Metformin HCl used B.P. Specifications & Manufacturer of Linagliptin used In-house Specifications. The firm as submitted both APIs details of nomenclature, structure, general properties, Solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of both drug substances.
	Stability studies of Drug substance	Linagliptin:

		Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (LI0316005, LI0316006, LI0316007) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (9002ML2RMl, 9003ML2RMl, 9004ML2RMl)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is JENTADUETO 2.5/500mg Tablets by Boehringer Ingelheim International GmbH by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Tragenta Duo 2.5/500mg Tablet by Boehringer Ingelheim International GmbH in Acid media (0.1N HCl) & Buffer (pH 4.5 & 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
API Lot No.	Linagliptin: LIFP21012 Metformin HCl: 21296ML2ARMI
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2×7's)
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 06th months Accelerated: 6th months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	NPD-PR21-039-T1S1	NPD-PR21-039-T1S2	NPD-PR21-039-T1S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	22-01-2022	22-01-2022	22-01-2022
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Linagliptin: Copy of GMP certificate No. L. Dis.No: 86097/TS/2022 issued by DRUGS CONTROL ADMINISTRATION, Government of Telangana valid till 08/05/2023. Metformin HCl: Copy of GMP certificate No. No.: NEW-WHO-GMP/CERT/AD/104179/2021/11/37725 issued by Food & Drugs Administration Maharashtra, India valid till 27/10/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Linagliptin: Firm has submitted copy of Form 6 from & invoice (invoice# 1269/LP/2021-22) Dated: 07-10-2021 cleared by DRAP Lahore office dated 13-10-2021 specifying import 4Kg Linagliptin (Batch# LIFP21012). Metformin HCl: Firm has submitted copy of Form 6 from & invoice (invoice# SMP2122/1630075) Dated: 25-08-2021cleared by DRAP Lahore office dated 02-09-2021.specifying import of Metformin HCl 25Kg (Batch# 21296ML2ARMI).
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.No	Section	Shortcomings Communicated	Reply
	2.3.R.1.1	Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3	Copies of Batch Manufacturing Record (BMR) for following 03 trial batches have already been provide Dossier:

Batch No	NPD-PR21-039-T1S1	NPD-PR21-039-T1S2	NPD-PR21-039-T1S3
Batch Size	2000 Tab.	2000 Tab.	2000 Tab.
Mfg. Date	01-2022	01-2022	01-2022

	3.2.S.4.4	The submitted COA of drug substance (Linagliptin) by drug substance manufacturer does not declare Enantiometric Content of S-Isomer.	According to Section S1 & Section S2 Version 1.0 Applicant part of Drug Master File (DMF) of Linagliptin, R-Enantiomer is the Drug substance which is being used in Drug Product. The same is recommended by "European Medicines Agency" for Innovator Brand manufactured by "Boehringer Ingelheim". All the intermediate related Compounds are also R-Intermediates either Carbamates or Dione.
	3.2.P.2.1.1	Justify the proposed quantity of Arginine in applied formulation	According to application filed by "Boehringer Ingelheim" vide application No. PCT/EP 2012/053910, equal ratio of Linagliptin with basic amino acid Arginine is effective and stable one. Therefore, in our formulation we stabilize Linagliptin component of our product by using 1:1 of Linagliptin and Arginine. Moreover, Stability studies up till now also showing & strengthening effectiveness of this ratio.
	3.2.P.2.2.1	Pharmaceutical equivalence and Comparative dissolution profile are performed against 2 different products. Justification is required.	Linvesta-M 2.5/500mg Film Coated Tablet is non-Pharmacopial product. The brand used in Comparative Dissolution Profile USP<1090> is from the innovator "Boehringer Ingelheim" under brand name "Trajenta Duo 2.5/500mg Tablet". The other brand of this formulation i.e. "Jentadueto 2.5/500mg" is manufactured by same innovator "Boehringer Ingelheim". The Comparative Dissolution Profile was performed as per the availability of the Boehringer Ingelheim product. Reference is as under: https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs992-annex8-who-comparators-multisource.pdf?sfvrsn=c5116e6_2&download=true
	3.2.P.5.1	Test for Quantification of Arginine by way assay as recommende by innovator product literature is not included in drug product specification. Justification shall be submitted.	We performed analytical Procedure for Linagliptin & Metformin through a single Test method but the procedure for Arginine is different & performed separately. COA is attached indicating quantification of Arginine. (However testing method for Arginine not submitted)

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.

34.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP)

		☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 475 dated :05-01-2023
	Details of fee submitted	PKR 75,000/-: Deposit slip # 4956932844
	The proposed proprietary name / brand name	Linvesta-M 2.5/1000mg Film Coated Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film coated Tablet contains: Linagliptin …….2.5mg Metformin HCl …….1000mg
	Pharmaceutical form of applied drug	Yellow colored, biconvex oval shaped film coated tablet.
	Pharmacotherapeutic Group of (API)	Anti-Diabetic (Type-II)
	Reference to Finished product specifications	Manufacturer's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	JENTADUETO 2.5/1000mg Film Coated Tablet by Boehringer Ingelheim International GmbH (USFDA approved)
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 14-09-2022 and valid for two years.
	Name and address of API manufacturer.	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Linagliptin is not available in any official Pharmacopoeia & Official monograph of Metformin HCl is available in British Pharmacopoeia as well as in United States Pharmacopoeia. The API Manufacturer of Metformin HCl used B.P. Specifications & Manufacturer of Linagliptin used In-house Specifications. The firm as submitted both APIs details of nomenclature, structure, general properties, Solubility's, physical form,

		manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of both drug substances.
	Stability studies of Drug substance	Linagliptin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (LI0316005, LI0316006, LI0316007) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (9002ML2RMl, 9003ML2RMl, 9004ML2RMl)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is JENTADUETO 2.5/1000mg Tablets by Boehringer Ingelheim International GmbH by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is Tragenta Duo 2.5/1000mg Tablet by Boehringer Ingelheim International GmbH in Acid media (0.1N HCl) & Buffer (pH 4.5 & 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.	
API Lot No.	Linagliptin: LIFP21012 Metformin HCl: 21296ML2ARMI	
Description of Pack	Alu-Alu blister packed in unit carton (2×7's)	

(Container closure system)				
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 06th months Accelerated: 6th months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		NPD-PR22-011-T1S1	NPD-PR22-011-T1S2	NPD-PR22-011-T1S3
Batch Size		2000 tab	2000 tab	2000 tab
Manufacturing Date		01-2022	01-2022	01-2022
Date of Initiation		14-01-2022	14-01-2022	14-01-2022
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)			
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Linagliptin: Copy of GMP certificate No. L. Dis.No: 86097/TS/2022 issued by DRUGS CONTROL ADMINISTRATION, Government of Telangana valid till 08/05/2023. Metformin HCl: Copy of GMP certificate No. No.: NEW-WHO-GMP/CERT/AD/104179/2021/11/37725 issued by Food & Drugs Administration Maharashtra, India valid till 27/10/2024.		
	Documents for the procurement of API with approval from DRAP (in case of import).	Linagliptin: Firm has submitted copy of Form 6 from & invoice (invoice# 1269/LP/2021-22) Dated: 07-10-2021 cleared by DRAP Lahore office dated 13-10-2021 specifying import 4Kg Linagliptin (Batch# LIFP21012). Metformin HCl: Firm has submitted copy of Form 6 from & invoice (invoice# SMP2122/1630075) Dated: 25-08-2021cleared by DRAP Lahore office dated 02-09-2021. specifying import of Metformin HCl 25Kg (Batch# 21296ML2ARMI).		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.		
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted		
Remarks OF Evaluator:				
S.No	Section	Shortcomings Communicated	Reply	

<table>
<tr><td></td><td>2.3.R.1.1</td><td>Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3</td><td>Copies of Batch Manufacturing Record (BMR) for following 03 trial batches have already been provided with Dossier:
<table><tr><td>Batch No</td><td>NPD-PR21-039-T1S1</td><td>NPD-PR21-039-T1S2</td><td>NPD-PR21-039-T1S3</td></tr><tr><td>Batch Size</td><td>2000 Tab.</td><td>2000 Tab.</td><td>2000 Tab.</td></tr><tr><td>Mfg. Date</td><td>01-2022</td><td>01-2022</td><td>01-2022</td></tr></table></td></tr>
<tr><td></td><td>3.2.S.4.4</td><td>The submitted COA of drug substance (Linagliptin) by drug substance manufacturer does not declare Enantiometric Content of S-Isomer.</td><td>According to Section S1 & Section S2 Version 1.0 Applicant part of Drug Master File (DMF) of Linagliptin, R-Enantiomer is the Drug substance which is being used in Drug Product. The same is recommended by “European Medicines Agency” for Innovator Brand manufactured by “Boehringer Ingelheim”. All the intermediate related Compounds are also R-Intermediates either Carbamates or Dione</td></tr>
<tr><td></td><td>3.2.P.2.1.1</td><td>Justify the proposed quantity of Arginine in applied formulation</td><td>According to application filed by “Boehringer Ingelheim” vide application No. PCT/EP 2012/053910, equal ratio of Linagliptin with basic amino acid Arginine is effective and stable one. Therefore, in our formulation we stabilize Linagliptin component of our product by using 1:1 of Linagliptin and Arginine. Moreover, Stability studies up till now also showing & strengthening effectiveness of this ratio</td></tr>
<tr><td></td><td>3.2.P.2.2.1</td><td>Pharmaceutical equivalence and Comparative dissolution profile are performed against 2 different products. Justification is required.</td><td>Linvesta-M 2.5/1000mg Film Coated Tablet is non-Pharmacopial product. The brand used in Comparative Dissolution Profile USP<1090> is from the innovator “Boehringer Ingelheim” under brand name “Trajenta Duo 2.5/1000mg Tablet”. The other brand of this formulation i.e. “Jentadueto 2.5/1000mg” is manufactured by same innovator “Boehringer Ingelheim”. The Comparative Dissolution Profile was performed as per the availability of the Boehringer Ingelheim product. Reference is as under:

https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs992-annex8-who-comparators-multisource.pdf?sfvrsn=c5116e6_2&download=true</td></tr>
<tr><td></td><td>3.2.P.5.1</td><td>Test for Quantification of Arginine by way of assay as recommended by innovator product literature is not included in drug product specification. Justification shall be submitted.</td><td>We performed analytical Procedure for Linagliptin & Metformin through a single Test method but the procedure for Arginine is different & performed separately. COA is attached indicating quantification of Arginine.
(However testing method for Arginine not submitted)</td></tr>
</table>

Decision: Approved with innovator’s specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Registration letter will be issued upon submission of fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.		
35.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 842 dated :10-01-2023
	Details of fee submitted	PKR 75,000/-: Deposit slip # 386416818
	The proposed proprietary name / brand name	Linvesta-M XR 2.5/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Extended Release Tablet contains: Linagliptin ……2.5mg Metformin HCl …….1000mg
	Pharmaceutical form of applied drug	Blue colored biconvex Oblong Extended Release Tablet
	Pharmacotherapeutic Group of (API)	Anti-Diabetic (Type-II)
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	JENTADUETO XR 2.5/1000mg Tablet by Boehringer Ingelheim International GmbH (USFDA approved)
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 14-09-2022 and valid for two years.
	Name and address of API manufacturer.	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls,

		impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Linagliptin is not available in any official Pharmacopoeia & Official monograph of Metformin HCl is available in British Pharmacopoeia as well as in United States Pharmacopoeia. The API Manufacturer of Metformin HCl used B.P. Specifications & Manufacturer of Linagliptin used In-house Specifications. The firm as submitted both APIs details of nomenclature, structure, general properties, Solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of both drug substances.
	Stability studies of Drug substance	Linagliptin: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (LI0316005, LI0316006, LI0316007) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (9002ML2RMl, 9003ML2RMl, 9004ML2RMl)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is JENTADUETO XR 2.5/1000mg Tablets by Boehringer Ingelheim International GmbH by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is JENTADUETO XR 2.5/1000mg Tablet by Boehringer Ingelheim International GmbH in Acid media (0.1N HCl) & Buffer (pH 4.5 & 6.8). The values for f1 and f2 are in the acceptable range.

	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.	
STABILITY STUDY DATA			
Manufacturer of API	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.		
API Lot No.	Linagliptin: LIFP21012 Metformin HCl: 21296ML2ARMI		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2×7's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 06th months Accelerated: 6th months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	NPD/PR21-045/T2/S1	NPD/PR21-045/T2/S2	NPD/PR21-045/T2/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	09-02-2022	09-02-2022	09-02-2022
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Linagliptin: Copy of GMP certificate No. L. Dis.No: 86097/TS/2022 issued by DRUGS CONTROL ADMINISTRATION, Government of Telangana valid till 08/05/2023. Metformin HCl: Copy of GMP certificate No. No.: NEW-WHO-GMP/CERT/AD/104179/2021/11/37725 issued by Food & Drugs Administration Maharashtra, India valid till 27/10/2024.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Linagliptin: Firm has submitted copy of Form 6 from & invoice (invoice# 1269/LP/2021-22) Dated: 07-10-2021 cleared by DRAP Lahore office dated 13-10-2021 specifying import 4Kg Linagliptin (Batch# LIFP21012). Metformin HCl: Firm has submitted copy of Form 6 from & invoice (invoice# SMP2122/1630075) Dated: 25-08-2021cleared by DRAP Lahore office dated 02-09-2021. specifying import of Metformin HCl 25Kg (Batch# 21296ML2ARMI).	

	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

S.No	Section	Shortcomings Communicated	Reply
	3.2.S.4.4	The submitted COA of drug substance (Linagliptin) by drug substance manufacturer does not declare Enantiometric Content of S-Isomer.	According to Section S1 & Section S2 Version 1.0 Applicant part of Drug Master File (DMF) of Linag R-Enantiomer is the Drug substance which is being in Drug Product. The same is recommended by "European Medicines Agency" for Innovator Brand manufactured by "Boehringer Ingelheim". All the intermediate related Compounds are also R-Interme either Carbamates or Dione as shown in Attachment
	3.2.P.2.1.1	Justify the proposed quantity of Arginine in applied formulation	According to application filed by "Boehringer Ingel vide application No. PCT/EP 2012/053910, equal ra Linagliptin with basic amino acid Arginine is effect and stable one. Therefore, in our formulation we sta Linagliptin component of our product by using 1:1 Linagliptin and Arginine. Moreover, Stability studie till now also showing & strengthening effectiveness this ratio.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

36.	Name, address of Applicant / Marketing Authorization Holder	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Name, address of Manufacturing site.	M/s Wilshire Laboratories Private Limited 124/1 Quaid-e-Azam Industrial Estate, Kot Lakhpat Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1179 dated :13-01-2023
	Details of fee submitted	PKR 75,000/-: Deposit slip # 7293841480

	The proposed proprietary name / brand name	Linvesta-M XR 5/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Extended Release Tablet contains: Linagliptin …….5mg Metformin HCl …….1000mg
	Pharmaceutical form of applied drug	Blue colored biconvex Oblong Extended Release Tablet
	Pharmacotherapeutic Group of (API)	Anti-Diabetic (Type-II)
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	JENTADUETO XR 5/1000mg Tablet by Boehringer Ingelheim International GmbH (USFDA approved)
	For generic drugs (me-too status)	Not Available
	GMP status of the Finished product manufacturer	cGMP certificate based on inspection conducted on 14-09-2022 and valid for two years.
	Name and address of API manufacturer.	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, Solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Linagliptin is not available in any official Pharmacopoeia & Official monograph of Metformin HCl is available in British Pharmacopoeia as well as in United States Pharmacopoeia. The API Manufacturer of Metformin HCl used B.P. Specifications & Manufacturer of Linagliptin used In-house Specifications. The firm as submitted both APIs details of nomenclature, structure, general properties, Solubility's, physical form, manufacturers, description of manufacturing process and controls, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of both drug substances.
	Stability studies of Drug substance	Linagliptin:

		Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (LI0316005, LI0316006, LI0316007) Metformin HCl: Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (9002ML2RMl, 9003ML2RMl, 9004ML2RMl)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is JENTADUETO XR 5/1000mg Tablets by Boehringer Ingelheim International GmbH by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form). CDP has been performed against the same brand that is JENTADUETO XR 5/1000mg Tablet by Boehringer Ingelheim International GmbH in Acid media (0.1N HCl) & Buffer (pH 4.5 & 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	Linagliptin: M/s Lee Pharma Limited, Survey No. 10/G-1, Gadda Potharam (Village) Jinnaram (Mandal), Sangareddy (District) Telangana, 502319, INDIA. Metformin HCl: M/S Ipca Laboratories Limited, H-4, M.LD.C., Waluj, Aurangabad (Maharashtra) Pin: 431 136, India.
API Lot No.	Linagliptin: LIFP21012 Metformin HCl: 21296ML2ARMI
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (2×7's)
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 06th months Accelerated: 6th months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	NPD/PR21-046/T2/S1	NPD/PR21-046/T2/S2	NPD/PR21-046/T2/S3
Batch Size	2000 tab	2000 tab	2000 tab
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	16-02-2022	16-02-2022	16-02-2022
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Linagliptin: Copy of GMP certificate No. L. Dis.No: 86097/TS/2022 issued by DRUGS CONTROL ADMINISTRATION, Government of Telangana valid till 08/05/2023. Metformin HCl: Copy of GMP certificate No. No.: NEW-WHO-GMP/CERT/AD/104179/2021/11/37725 issued by Food & Drugs Administration Maharashtra, India valid till 27/10/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Linagliptin: Firm has submitted copy of Form 6 from & invoice (invoice# 1269/LP/2021-22) Dated: 07-10-2021 cleared by DRAP Lahore office dated 13-10-2021 specifying import 4Kg Linagliptin (Batch# LIFP21012). Metformin HCl: Firm has submitted copy of Form 6 from & invoice (invoice# SMP2122/1630075) Dated: 25-08-2021cleared by DRAP Lahore office dated 02-09-2021. specifying import of Metformin HCl 25Kg (Batch# 21296ML2ARMI).
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks OF Evaluator:

S.No	Section	Shortcomings Communicated	Reply
	3.2.S.4.4	The submitted COA of drug substance (Linagliptin) by drug substance manufacturer does not declare Enantiometric Content of S-Isomer.	According to Section S1 & Section S2 Versi Applicant part of Drug Master File (DMF) o Linagliptin, R-Enantiomer is the Drug substa which is being used in Drug Product. The sa recommended by "European Medicines Age for Innovator Brand manufactured by "Boeh Ingelheim". All the intermediate related Compounds are also R-Intermediates either Carbamates or Dione as shown in Attachmer
	3.2.P.2.1.1	Justify the proposed quantity of Arginine in applied formulation	According to application filed by "Boehringe Ingelheim" vide application No. PCT/EP 2012/053910, equal ratio of Linagliptin with

			amino acid Arginine is effective and stable one. Therefore, in our formulation we stabilize Linagliptin component of our product by using 1:1 of Linagliptin and Arginine. Moreover, Stability studies up till now also showing & strengthening effectiveness of this ratio.

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

37.	Name and address of manufacturer / Applicant	"M/s Max Pharmaceuticals,Plot # 12, St. No. N-7, National Industrial Zone, Rawat, Islamabad"
	Brand Name +Dosage Form + Strength	Tamso Capsules 0.4mg
	Composition	"Each Capsule Contains: Tamsulosin HCL…0.4mg"
	Diary No. Date of R& I & fee	Form-5 Dy.No 41715 dated 07-12-2018 Rs.20,000/- Dated 06-12-2018
	Pharmacological Group	Alpha-adrenoreceptor antagonists. ATC code: G04C A02. Preparations for the exclusive treatment of prostatic disease.
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	1x10's, As per PRC.
	Approval status of product in Reference Regulatory Authorities.	USFDA Approved.
	Me-too status	050392: Brand Name: Tamsolin 0.4mg Capsule Manufacturer Name: Getz Pharma, Karachi
	GMP status	26-06-2019 Conclusion: The company is working at good level of GMP and record of raw material was found maintained along with SOP's the clearance of API's for imported sources are attached as of today. GMP is a continuous process of up gradation, the firm the advise to continue with up gradation and purchase the desired equipments are advised.
	Remarks of the Evaluator (V)	The strength on Form 5 mentions "Each tablet Contains:Tamsulosin 0.4mg" whereas, rest of the dossier mentions capsule. Source of pellets, along with stability studies data, GMP certificate of supplier and differential fee in case of import of pellets shall be submitted.
	Decision of 295th Meeting: Deferred for the following: Submit COA, GMP of pellets manufacturer and stability studies of three batches of pellets conducted in accordance with zone IV-A conditions. Submit fee challan for relevant formulation.	
	Remarks of Evaluator: The source of pellets is M/s Vision Pharmaceuticals. Firm has submitted fee of Rs, 7500/-. vide deposit slip# 268335179124	
	Decision: Approved.	

Item No. III: Agenda of Evaluator PEC-VI (Mr. Ishtiaq Shafique)

CASE NO. 1: M/S NABIQASIM INDUSTRIES (PVT) LTD., 17 / 24, KORANGI INDUSTRIAL AREA, KARACHI.

Assistant Director PR-I / EFD vide its letter No. F.1-6/2019-PR-I (EFD) dated 6th October 2022 informed that as per decision of 133rd meeting of DRAP Authority wherein it was decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicine (to a maximum of 15 such molecules) during a financial year.

In compliance to the above decision M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan. have achieved benchmark of more than 100,000 USD and submitted their applications for priority consideration including following application:

38.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan. (DML No. 000105)
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27741 dated 30/09/2022
	Details of fee submitted	PKR 30,000/-: dated 26/07/2022 (01479192711)
	The proposed proprietary name / brand name	Britam Tablets 10mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Brivaracetam ……..…10mg
	Pharmaceutical form of applied drug	Film coated tablet for oral use only.
	Pharmacotherapeutic Group of (API)	Antiepileptics, other antiepileptics.(N03AX23)
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	14's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	BRIVIACT 10mg Tablets (Brivaracetam) UCB Pharma Limited., United Kingdom (US FDA and MHRA).
	For generic drugs (me-too status)	Brivace Tablet 10mg by M/s Hilton Pharma (Pvt.) Ltd., Reg. No. 110124
	GMP status of the Finished product manufacturer	New GMP Certificate granted based on evaluation conducted on 27-05-2022, valid till 26-05-2024. Tablet section(General) approved vide letter no. F.2-20/85-Lic(Vol-V),dated 27-04-2020.
	Name and address of API manufacturer.	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of

		manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances [Individual impurity, Total impurities, Enantiomeric purity (RS 01, RS 02, RS 03)], specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (BRMVS001, BRMVS002, BRMVS003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Brivace Tablet 10mg (Brivaracetam), Hilton Pharma (Pvt.) Ltd., by performing quality tests (Description, Identification, Disintegration Time, Dissolution and Assay). CDP has been performed against the same brand that is Brivace Tablet 10mg (Brivaracetam) by Hilton Pharma (Pvt.) Ltd., in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (6.4). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India		
API Lot No.	BVMVU011		
Description of Pack (Container closure system)	Alu-Alu blister of 14's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	558DS01	558DS02	558DS03

Batch Size	3000 tablets	3000 tablets	3000 tablets
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	25-03-2022	25-03-2022	25-03-2022
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate of M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India, certificate no. E-1698616/DD/DCA/VSP/2022 issued by Drugs Control Administration, Government of Andhra Pradesh, India, valid till 20/05/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has provided invoice no 2804000336 dated 25/12/2021 duly attested by Assistant Director, DRAP, Karachi on 07/01/2022 specifying the import of 3 kg Brivaracetam (Batch no. BVMVU011) was provided.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

S. No.	Observations	Response of firm
01	Justification required for not including system suitability parameter in assay of drug substance i.e. Correlation factor (the correlation between two standards should be in the range of 0.98 to 1.02), in accordance with the analytical method of drug substance manufacturer)	Correlation factor between two standards is used to evaluate standard recovery (accuracy) between two standards. We have revised our API specifications for QC release, and incorporated correlation factor in accordance with the analytical method of drug substance manufacturer. We also conducted Analytical method verification studies of API, perform system suitability testing with only one standard and results of our verification parameters i.e. (specificity, accuracy, precision) found to meet the stated acceptance criteria.
02	Innovator has used 0.1 N HCl as disintegration medium of Brivaracetam tablet. However, in analytical method of drug product manufacturer it is water. Justification required.	While setting FP specifications, we follow general medium as water for Disintegration testing, however as your good-self inform us about innovator disintegration test medium as 0.1 N HCl media, we have revised our FP specifications of Brivaracetam Tablet Range for disintegration test and updated 0.1 N HCl as disintegration medium. Firm has submitted revised analytical method. However, fee for change in specifications not submitted. We have conducted Disintegration test using 0.1 N HCl medium on today basis, results are as follows:

Product Name	Disintegration Test (0.1 N HCl medium)specs.	Batch No.	Results

		Britam Tablet 10mg	NMT 10 minutes	558DS01	5 minutes	
		Britam Tablet 25mg	NMT 10 minutes	559DS01	5 minutes 30 sec.	
		Britam Tablet 50mg	NMT 10 minutes	560DS01	5minutes 21 sec	
		Britam Tablet 100mg	NMT 10 minutes	562DS01	5 mins 45 sec.	
03	Justification required for not including bioburden test in Brivaracetam tablet drug product specification and stability studies in accordance with the innovator.	We have revised our FP specifications for QC release commercial batches of Britam Tablet Range in accordance with innovator literature for microbiological limit test. However, fee for change in specifications not submitted.				
04	Justification required for not including absence of Salmonella Species test in specification of oral liquid dosage in accordance with the innovator.	Britam 10mg/mL oral solution have tested against USP General Chapter <1111> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS. According to this, for Oral aqueous solution, only the test of E. coli is recommended. (Enclosed for Ready Reference in Annexure-C) However, we have included the test of salmonella species in our revised specification to meet the innovator criteria for QC commercial release batches. However, fee for change in specifications not submitted.				
05	Justification of pH of oral solution (4.90-5.90) in light of the innovator product.	pH range of oral solution (4.90-5.90) is adapted from Australian Public Assessment Report for Biviact (Brivaracetam)Oral Solution, reference of same is submitted				
06	Provide the stability batch size of oral solution in terms of packs (i.e. amber glass bottles).	Britam 10mg/ml oral solution have batch size of 15.0 liters, in terms of packs the standard batch size is 125 packs containing 120 ml per bottle. The actual yield achieve on filling of britam 10 mg/ml oral solution is 97.0% in terms of packs it is 121 packs				

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.
Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

39.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale

		☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.27742 dated 30 /09/2022
	Details of fee submitted	PKR 30,000/- dated 26/07/2022(107916121)
	The proposed proprietary name / brand name	Britam Tablets 25mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Brivaracetam ……..…25mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Antiepileptics, other antiepileptics.
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	14's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	BRIVIACT 25mg Tablets (Brivaracetam) UCB Pharma Limited., United Kingdom (US FDA and MHRA).
	For generic drugs (me-too status)	Brivace Tablets 25mg by M/s Hilton Pharma (Pvt.) Ltd., Reg. No. 110125
	GMP status of the Finished product manufacturer	New GMP Certificate granted based on evaluation conducted on 27-05-2022, valid till 26-05-2024. Tablet section(General) approved vide letter no. F.2-20/85-Lic(Vol-V),dated 27-04-2020.
	Name and address of API manufacturer.	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances [Individual impurity, Total impurities, Enantiomeric purity (RS 01, RS 02, RS 03)], specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (BRMVS001, BRMVS002, BRMVS003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer

		medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Brivace Tablet 25mg (Brivaracetam)Hilton Pharma (Pvt.) Ltd., by performing quality tests (Description, Identification, Disintegration Time, Dissolution and Assay). CDP has been performed against the same brand that is Brivace Tablet 25mg (Brivaracetam) by Hilton Pharma (Pvt.) Ltd., in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (6.4). The values for f1 and f2 are in the acceptable range.		
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY STUDY DATA				
Manufacturer of API		M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India Mandal, Vizag - 531019 Andhra Pradesh, India		
API Lot No.		BVMVU011		
Description of Pack (Container closure system)		Alu-Alu blister of 14's tablets packed in unit carton.		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0,3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		559DS01	559DS02	559DS03
Batch Size		3000 tablets	3000 tablets	3000 tablets
Manufacturing Date		03-2022	03-2022	03-2022
Date of Initiation		25-03-2022	25-03-2022	25-03-2022
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate of M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India, certificate no. E-1698616/DD/DCA/VSP/2022 issued by Drugs Control Administration, Government of Andhra Pradesh, India, valid till 20/05/2023.		
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has provided invoice no 2804000336 dated 25/12/2021 duly attested by Assistant Director, DRAP, Karachi on 07/01/2022 specifying the import of 3 kg Brivaracetam (Batch no. BVMVU011) was provided.		

	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

<table>
<tr><th>S. No.</th><th>Observations</th><th>Response of firm</th></tr>
<tr><td>01</td><td>Justification required for not including system suitability parameter in assay of drug substance i.e. Correlation factor (the correlation between two standards should be in the range of 0.98 to 1.02), in accordance with the analytical method of drug substance manufacturer)</td><td>Correlation factor between two standards is used to evaluate standard recovery (accuracy) between two standards. We have revised our API specifications for QC release, and incorporated correlation factor in accordance with the analytical method of drug substance manufacturer.
We also conducted Analytical method verification studies of API, perform system suitability testing with only one standard and results of our verification parameters i.e. (specificity, accuracy, precision) found to meet the stated acceptance criteria.</td></tr>
<tr><td>02</td><td>Innovator has used 0.1 N HCl as disintegration medium of Brivaracetam tablet. However, in analytical method of drug product manufacturer it is water. Justification required.</td><td>While setting FP specifications, we follow general medium as water for Disintegration testing, however as your good-self inform us about innovator disintegration test medium as 0.1 N HCl media, we have revised our FP specifications of Brivaracetam Tablet Range for disintegration test and updated 0.1 N HCl as disintegration medium. Firm has submitted revised analytical method. However, fee for change in specifications not submitted.
We have conducted Disintegration test using 0.1 N HCl medium on today basis, results are as follows:
<table>
<tr><th>Product Name</th><th>Disintegration Test (0.1 N HCl medium)specs.</th><th>Batch No.</th><th>Results</th></tr>
<tr><td>Britam Tablet 10mg</td><td>NMT 10 minutes</td><td>558DS01</td><td>5 minutes</td></tr>
<tr><td>Britam Tablet 25mg</td><td>NMT 10 minutes</td><td>559DS01</td><td>5 minutes 30 sec.</td></tr>
<tr><td>Britam Tablet 50mg</td><td>NMT 10 minutes</td><td>560DS01</td><td>5minutes 21 sec</td></tr>
<tr><td>Britam Tablet 100mg</td><td>NMT 10 minutes</td><td>562DS01</td><td>5 mins 45 sec.</td></tr>
</table></td></tr>
<tr><td>03</td><td>Justification required for not including bioburden test in Brivaracetam tablet drug product specification and stability studies in accordance with the innovator.</td><td>We have revised our FP specifications for QC release commercial batches of Britam Tablet Range in accordance with innovator literature for microbiological limit test. However, fee for change in specifications not submitted.</td></tr>
<tr><td>04</td><td>Justification required for not including absence of Salmonella Species test in specification of oral</td><td>Britam 10mg/mL oral solution have tested against USP General Chapter <1111> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS. According to this, for Oral aqueous solution, only the test of</td></tr>
</table>

	liquid dosage in accordance with the innovator.	E. coli is recommended. (Enclosed for Ready Reference in Annexure-C) However we have included the test of salmonella species in our revised specification to meet the innovator criteria for QC commercial release batches. However, fee for change in specifications not submitted.
05	Justification of pH of oral solution (4.90-5.90) in light of the innovator product.	pH range of oral solution (4.90-5.90) is adapted from Australian Public Assessment Report for Biviact (Brivaracetam)Oral Solution, reference of same is submitted
06	Provide the stability batch size of oral solution in terms of packs (i.e. amber glass bottles).	Britam 10mg/ml oral solution have batch size of 15.0 liters, In terms of packs the standard batch size is 125 packs containing 120 ml per bottle. The actual yield achieve on filling of britam 10 mg/ml oral solution is 97.0% in terms of packs it is 121 packs

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

40.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27743 dated 30/09/ 2022
	Details of fee submitted	PKR 30,000/-: dated 26/07/2022(910657416)
	The proposed proprietary name / brand name	Britam Tablets 50mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Brivaracetam ……..…50mg
	Pharmaceutical form of applied drug	film coated tablet
	Pharmacotherapeutic Group of (API)	Antiepileptics, other antiepileptics. .(N03AX23)
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	14's tablets
	Proposed unit price	As per SRO

	The status in reference regulatory authorities	BRIVIACT 50mg Tablets (Brivaracetam) UCB Pharma Limited., United Kingdom (Approved by US FDA and MHRA).
	For generic drugs (me-too status)	Brivace Tablets 50mg by M/s Hilton Pharma (Pvt.) Ltd., Reg. No. 110126
	GMP status of the Finished product manufacturer	New GMP Certificate granted based on evaluation conducted on 27-05-2022, valid till 26-05-2024. Tablet section(General) approved vide letter no. F.2-20/85-Lic(Vol-V),dated 27-04-2020.
	Name and address of API manufacturer.	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Brivaracetam is present is as per In-house (Manufacturer's) specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances [Individual impurity, Total impurities, Enantiomeric purity (RS 01, RS 02, RS 03)], specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (BRMVS001, BRMVS002, BRMVS003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Brivace Tablet 50mg (Brivaracetam) Hilton Pharma (Pvt.) Ltd., by performing quality tests (Description, Identification, Disintegration Time, Dissolution and Assay). CDP has been performed against the same brand that is Brivace Tablet 50mg (Brivaracetam) by Hilton Pharma (Pvt.) Ltd., in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (6.4). The values for f1 and f2 are in the acceptable range.

	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY STUDY DATA				
Manufacturer of API		M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India		
API Lot No.		BVMVU011		
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton (1×14's).		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		560DS01	560DS02	560DS03
Batch Size		3000 tablets	3000 tablets	3000 tablets
Manufacturing Date		03-2022	03-2022	03-2022
Date of Initiation		25-03-2022	25-03-2022	25-03-2022
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate of M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India, certificate no. E-1698616/DD/DCA/VSP/2022 issued by Drugs Control Administration, Government of Andhra Pradesh, India, valid till 20/05/2023.		
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has provided invoice no 2804000336 dated 25/12/2021 duly attested by Assistant Director, DRAP, Karachi on 07/01/2022 specifying the import of 3 kg Brivaracetam (Batch no. BVMVU011) was provided.		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted		
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted		

Remarks of Evaluator:

S. No.	Observations	Response of firm
01	Justification required for not including system suitability parameter in assay of drug substance i.e. Correlation factor (the correlation between two standards should be in	Correlation factor between two standards is used to evaluate standard recovery (accuracy) between two standards. We have revised our API specifications for QC release, and incorporated correlation factor in accordance with the analytical method of drug substance manufacturer.

<table>
<tr><td></td><td>the range of 0.98 to 1.02), in accordance with the analytical method of drug substance manufacturer)</td><td>We also conducted Analytical method verification studies of API, perform system suitability testing with only one standard and results of our verification parameters i.e. (specificity, accuracy, precision) found to meet the stated acceptance criteria.</td></tr>
<tr><td>02</td><td>Innovator has used 0.1 N HCl as disintegration medium of Brivaracetam tablet. However, in analytical method of drug product manufacturer it is water. Justification required.</td><td>While setting FP specifications, we follow general medium as water for Disintegration testing, however as your good-self inform us about innovator disintegration test medium as 0.1 N HCl media, we have revised our FP specifications of Brivaracetam Tablet Range for disintegration test and updated 0.1 N HCl as disintegration medium. Firm has submitted revised analytical method. However, fee for change in specifications not submitted.
We have conducted Disintegration test using 0.1 N HCl medium on today basis, results are as follows:
<table>
<tr><td>Product Name</td><td>Disintegration Test (0.1 N HCl medium)specs.</td><td>Batch No.</td><td>Results</td></tr>
<tr><td>Britam Tablet 10mg</td><td>NMT 10 minutes</td><td>558DS01</td><td>5 minutes</td></tr>
<tr><td>Britam Tablet 25mg</td><td>NMT 10 minutes</td><td>559DS01</td><td>5 minutes 30 sec.</td></tr>
<tr><td>Britam Tablet 50mg</td><td>NMT 10 minutes</td><td>560DS01</td><td>5minutes 21 sec</td></tr>
<tr><td>Britam Tablet 100mg</td><td>NMT 10 minutes</td><td>562DS01</td><td>5 mins 45 sec.</td></tr>
</table></td></tr>
<tr><td>03</td><td>Justification required for not including bioburden test in Brivaracetam tablet drug product specification and stability studies in accordance with the innovator.</td><td>We have revised our FP specifications for QC release commercial batches of Britam Tablet Range in accordance with innovator literature for microbiological limit test. However, fee for change in specifications not submitted.</td></tr>
<tr><td>04</td><td>Justification required for not including absence of Salmonella Species test in specification of oral liquid dosage in accordance with the innovator.</td><td>Britam 10mg/mL oral solution have tested against USP General Chapter <1111> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS. According to this, for Oral aqueous solution, only the test of E. coli is recommended. (Enclosed for Ready Reference in Annexure-C)
However we have included the test of salmonella species in our revised specification to meet the innovator criteria for QC commercial release batches.
However, fee for change in specifications not submitted.</td></tr>
<tr><td>05</td><td>Justification of pH of oral solution (4.90-5.90) in light of the innovator product.</td><td>pH range of oral solution (4.90-5.90) is adapted from Australian Public Assessment Report for Biviact (Brivaracetam)Oral Solution, reference of same is submitted</td></tr>
<tr><td>06</td><td>Provide the stability batch size of oral solution in terms of packs (i.e. amber glass bottles).</td><td>Britam 10mg/ml oral solution have batch size of 15.0 liters, In terms of packs the standard batch size is 125 packs containing 120 ml per bottle.
The actual yield achieve on filling of britam 10 mg/ml oral solution is 97.0% in terms of packs it is 121 packs</td></tr>
</table>

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
41.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 27744 dated 30/09/2022
	Details of fee submitted	PKR 30,000/-: dated 26/07/2022(364327556245)
	The proposed proprietary name / brand name	Britam Tablets 100mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film-coated tablet contains: Brivaracetam ……..…100mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Antiepileptics, other antiepileptics.
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	14's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	BRIVIACT 100mg Tablets (Brivaracetam) UCB Pharma Limited., United Kingdom (Approved by US FDA and MHRA).
	For generic drugs (me-too status)	Brivace Tablets 100mg by M/s Hilton Pharma (Pvt.) Ltd., Reg. No. 110128
	GMP status of the Finished product manufacturer	New GMP Certificate granted based on evaluation conducted on 27-05-2022, valid till 26-05-2024. Tablet section(General) approved vide letter no. F.2-20/85-Lic(Vol-V),dated 27-04-2020.
	Name and address of API manufacturer.	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

		specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Brivaracetam is present is as per In-house (Manufacturer's) specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances [Individual impurity, Total impurities, Enantiomeric purity (RS 01, RS 02, RS 03)], specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (BRMVS001, BRMVS002, BRMVS003)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Brivace Tablet 100mg (Brivaracetam) is registered and being marketed by Hilton Pharma (Pvt.) Ltd., by performing quality tests (Description, Identification, Disintegration Time, Dissolution and Assay). CDP has been performed against the same brand that is Brivace Tablet 100mg (Brivaracetam) by Hilton Pharma (Pvt.) Ltd., in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (6.4). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA	
Manufacturer of API	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
API Lot No.	BVMVU011
Description of Pack (Container closure system)	Alu-Alu blister of 14's tablets packed in unit carton.
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	562DS01	562DS02	562DS03
Batch Size	3000 tablets	3000 tablets	3000 tablets
Manufacturing Date	03-2022	03-2022	03-2022
Date of Initiation	25-03-2022	25-03-2022	25-03-2022
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate of M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India, certificate no. E-1698616/DD/DCA/VSP/2022 issued by Drugs Control Administration, Government of Andhra Pradesh, India, valid till 20/05/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has provided invoice no 2804000336 dated 25/12/2021 duly attested by Assistant Director, DRAP, Karachi on 07/01/2022 specifying the import of 3 kg Brivaracetam (Batch no. BVMVU011) was provided.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S. No.	Observations	Response of firm
01	Justification required for not including system suitability parameter in assay of drug substance i.e. Correlation factor (the correlation between two standards should be in the range of 0.98 to 1.02), in accordance with the analytical method of drug substance manufacturer)	Correlation factor between two standards is used to evaluate standard recovery (accuracy) between two standards. We have revised our API specifications for QC release, and incorporated correlation factor in accordance with the analytical method of drug substance manufacturer. We also conducted Analytical method verification studies of API, perform system suitability testing with only one standard and results of our verification parameters i.e. (specificity, accuracy, precision) found to meet the stated acceptance criteria.
02	Innovator has used 0.1 N HCl as disintegration medium of Brivaracetam tablet. However, in analytical method of drug product manufacturer it is water. Justification required.	While setting FP specifications, we follow general medium as water for Disintegration testing, however as your good-self inform us about innovator disintegration test medium as 0.1 N HCl media, we have revised our FP specifications of Brivaracetam Tablet Range for disintegration test and updated 0.1 N HCl as disintegration medium. Firm has submitted revised analytical method. However, fee for change in specifications not submitted. We have conducted Disintegration test using 0.1 N HCl medium on today basis, results are as follows:

Product Name	Disintegration Test (0.1 N	Batch No.	Results

			HCl medium)specs.		
		Britam Tablet 10mg	NMT 10 minutes	558DS01	5 minutes
		Britam Tablet 25mg	NMT 10 minutes	559DS01	5 minutes 30 sec.
		Britam Tablet 50mg	NMT 10 minutes	560DS01	5minutes 21 sec
		Britam Tablet 100mg	NMT 10 minutes	562DS01	5 mins 45 sec.
03	Justification required for not including bioburden test in Brivaracetam tablet drug product specification and stability studies in accordance with the innovator.	We have revised our FP specifications for QC release commercial batches of Britam Tablet Range in accordance with innovator literature for microbiological limit test. However, fee for change in specifications not submitted.			
04	Justification required for not including absence of Salmonella Species test in specification of oral liquid dosage in accordance with the innovator.	Britam 10mg/mL oral solution have tested against USP General Chapter <1111> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS. According to this, for Oral aqueous solution, only the test of E. coli is recommended. (Enclosed for Ready Reference in Annexure-C) However we have included the test of salmonella species in our revised specification to meet the innovator criteria for QC commercial release batches. However, fee for change in specifications not submitted.			
05	Justification of pH of oral solution (4.90-5.90) in light of the innovator product.	pH range of oral solution (4.90-5.90) is adapted from Australian Public Assessment Report for Biviact (Brivaracetam)Oral Solution, reference of same is submitted			
06	Provide the stability batch size of oral solution in terms of packs (i.e. amber glass bottles).	Britam 10mg/ml oral solution have batch size of 15.0 liters, In terms of packs the standard batch size is 125 packs containing 120 ml per bottle. The actual yield achieve on filling of britam 10 mg/ml oral solution is 97.0% in terms of packs it is 121 packs			

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

42.	Name, address of Applicant / Marketing Authorization Holder	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Name, address of Manufacturing site.	M/s NABIQASIM INDUSTRIES (PVT) LTD. 17 / 24, Korangi Industrial Area, Karachi – Pakistan.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP)

		☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29744 dated 20/10 /2022
	Details of fee submitted	PKR 75,000/-: dated 16/08/2022(150691247)
	The proposed proprietary name / brand name	Britam Oral Solution 10mg / ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Brivaracetam ……..…10mg
	Pharmaceutical form of applied drug	Slightly viscous, clear and colorless to yellowish liquid.
	Pharmacotherapeutic Group of (API)	Antiepileptics, other antiepileptics.
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	Packed in 120ml amber glass bottle
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	BRIVIACT 10mg / ml Oral Solution (Brivaracetam) UCB Pharma Limited., United Kingdom (Approved by US FDA and MHRA).
	For generic drugs (me-too status)	Not available in Pakistan
	GMP status of the Finished product manufacturer	New GMP Certificate granted based on evaluation conducted on 27-05-2022, valid till 26-05-2024. Liquid syrup section(General) approved vide letter no. F.2-20/85-Lic(Vol-V),dated 27-04-2020.
	Name and address of API manufacturer.	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Monograph of Brivaracetam is present is as per In-house (Manufacturer's) specifications. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for related substances [Individual impurity, Total impurities, Enantiomeric purity (RS 01, RS 02, RS 03)], specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (BRMVS001, BRMVS002, BRMVS003)

	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Briviact 10mg/ml Oral Solution is being marketed by M/s UCB Pharma S.A., Belgium by performing quality tests (Description, Identification, pH, Assay and Microbial Tests)
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India		
API Lot No.	BVMVU011		
Description of Pack (Container closure system)	Packed in 120ml amber glass bottle in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	549DS01	549DS02	549DS03
Batch Size	15 Liters(125 packs)	15 Liters(125 packs)	15 Liters(125 packs)
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	03-03-2022	03-03-2022	03-03-2022
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted GMP certificate of M/s JPR Labs Private Limited, situated at Plot No. 74/A, J.N Pharma City, Thanam (V), Parwada(M), Visakhapatnam District-531019, Andhra Pradesh, India, certificate no. E-1698616/DD/DCA/VSP/2022 issued by Drugs Control Administration, Government of Andhra Pradesh, India, valid till 20/05/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has provided invoice no 2804000336 dated 25/12/2021 duly attested by Assistant Director, DRAP, Karachi on 07/01/2022 specifying the import of 3 kg Brivaracetam (Batch no. BVMVU011) was provided.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted

	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

<table>
<tr><th>S. No.</th><th>Observations</th><th>Response of firm</th></tr>
<tr><td>01</td><td>Justification required for not including system suitability parameter in assay of drug substance i.e. Correlation factor (the correlation between two standards should be in the range of 0.98 to 1.02), in accordance with the analytical method of drug substance manufacturer)</td><td>Correlation factor between two standards is used to evaluate standard recovery (accuracy) between two standards. We have revised our API specifications for QC release, and incorporated correlation factor in accordance with the analytical method of drug substance manufacturer.
We also conducted Analytical method verification studies of API, perform system suitability testing with only one standard and results of our verification parameters i.e. (specificity, accuracy, precision) found to meet the stated acceptance criteria.</td></tr>
<tr><td>02</td><td>Innovator has used 0.1 N HCl as disintegration medium of Brivaracetam tablet. However, in analytical method of drug product manufacturer it is water. Justification required.</td><td>While setting FP specifications, we follow general medium as water for Disintegration testing, however as your good-self inform us about innovator disintegration test medium as 0.1 N HCl media, we have revised our FP specifications of Brivaracetam Tablet Range for disintegration test and updated 0.1 N HCl as disintegration medium. Firm has submitted revised analytical method. However, fee for change in specifications not submitted.
We have conducted Disintegration test using 0.1 N HCl medium on today basis, results are as follows:
<table>
<tr><th>Product Name</th><th>Disintegration Test (0.1 N HCl medium)specs.</th><th>Batch No.</th><th>Results</th></tr>
<tr><td>Britam Tablet 10mg</td><td>NMT 10 minutes</td><td>558DS01</td><td>5 minutes</td></tr>
<tr><td>Britam Tablet 25mg</td><td>NMT 10 minutes</td><td>559DS01</td><td>5 minutes 30 sec.</td></tr>
<tr><td>Britam Tablet 50mg</td><td>NMT 10 minutes</td><td>560DS01</td><td>5minutes 21 sec</td></tr>
<tr><td>Britam Tablet 100mg</td><td>NMT 10 minutes</td><td>562DS01</td><td>5 mins 45 sec.</td></tr>
</table>
</td></tr>
<tr><td>03</td><td>Justification required for not including bioburden test in Brivaracetam tablet drug product specification and stability studies in accordance with the innovator.</td><td>We have revised our FP specifications for QC release commercial batches of Britam Tablet Range in accordance with innovator literature for microbiological limit test. However, fee for change in specifications not submitted.</td></tr>
<tr><td>04</td><td>Justification required for not including absence of Salmonella Species test in specification of oral liquid dosage in accordance with the innovator.</td><td>Britam 10mg/mL oral solution have tested against USP General Chapter <1111> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS. According to this, for Oral aqueous solution, only the test of E. coli is recommended. (Enclosed for Ready Reference in Annexure-C)
However we have included the test of salmonella species in our revised specification to meet the innovator criteria for QC commercial release batches.</td></tr>
</table>

		However, fee for change in specifications not submitted.
05	Justification of pH of oral solution (4.90-5.90) in light of the innovator product.	pH range of oral solution (4.90-5.90) is adapted from Australian Public Assessment Report for Biviact (Brivaracetam)Oral Solution, reference of same is submitted
06	Provide the stability batch size of oral solution in terms of packs (i.e. amber glass bottles).	Britam 10mg/ml oral solution have batch size of 15.0 liters, In terms of packs the standard batch size is 125 packs containing 120 ml per bottle. The actual yield achieve on filling of britam 10 mg/ml oral solution is 97.0% in terms of packs it is 121 packs

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

C. Case No.2; Priority Registration application as per Decision of 257th meeting of DRB on Form 5F (Import)

43.	Name, address of Applicant / Importer	M/s Lab Diagnostic Systems (SMC) Pvt Ltd Address: 36-A, PSIC, SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	License No: 01-374-0006-96845D Address: 36-A, PSIC, SIE, Taxila Rawalpindi Address of Godown: NA Validity: 04/08/2024 Status: License to sell drugs as distributor Renewal: n/a
	Name and address of marketing authorization holder (abroad)	NAPROD LIFE SCIENCES PVT. LTD 304, town centre, Andheri kurla road, andheri (east), Mumbai – 400 059 India. Factory address NAPROD LIFE SCIENCES PVT. Ltd G-17/1, M.I.D.C. Tarapur industrial area, Boisar, dist – thane – 401506 India.
	Name, address of manufacturer(s)	NAPROD LIFE SCIENCES PVT. LTD 304, town centre, Andheri kurla road, andheri (east), Mumbai – 400 059 India. Factory address NAPROD LIFE SCIENCES PVT. Ltd G-17/1, M.I.D.C. Tarapur industrial area, Boisar, dist – thane – 401506 India.
	Name of exporting country	India

	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has submitted copy of CoPP certificate (No. COPP/CERT/KD/119620/2022/11/42232/206429 dated 27/09/2022 issued by Food and Drug Administration Mahrashtra Estate Mumbai for Posaconazole Injection 300mg/16.7ml. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization certificate from Naprod Life Sciences Pvt. Ltd. The letter species that the manufacturer appoints M/s Lab Diagnostic Systems (SMC) Pvt Ltd. to register their products in Pakistan. The authorization letter is valid till 31/03/2027
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 33807 dated 23/11/2022
	Details of fee submitted	PKR 150,000/- dated 17/10/2022(341557646987)
	The proposed proprietary name / brand name	Posazole 300mg/16.7ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Posaconazole Injection 300mg/16.7ml
	Pharmaceutical form of applied drug	IV Infusion
	Pharmacotherapeutic Group of (API)	Antimycotics for systemic use, triazole derivatives, ATC code: J02A C04.
	Reference to Finished product specifications	In-house
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	NOXAFIL manufactured by MSD (Merck & Co. Inc.), Ireland UK MHRA Approved
	For generic drugs (me-too status)	n/a
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing

		process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Neuland Laboratories Limited. Address: Unit-I, Sy. No.: 347, 473,474,490/2, Veerabhadraswamy, Temple road, Bothapally Village, Gummadidala Mandal, Sangareddy District-502313 Telangana, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated (40±2°C/75± 5%RH) for 6 months as well as real time conditions. The real time stability data is conducted at 25±2°C. The stability study data is provided for 3 batches at 48 months. (Batch no. PZ213002A, PZ213003A, PZ213004A)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Submitted
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	USP type-I glass.
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 25± 2C & 60 ±5% RH for 6 months. The real time stability study data is conducted at 2-8 C. The real time stability study data of 3 batches is provided

STABILITY STUDY DATA	
Manufacturer of API	Neuland Laboratories Limited

	Address: Unit-I, Sy. No.: 347, 473,474,490/2, Veerabhadraswamy, Temple road, Bothapally Village, Gummadidala Mandal, Sangareddy District-502313 Telangana, India.		
Description of Pack (Container closure system)	USP Type I 20CC Vials		
Stability Storage Condition	Real time: 30°C ± 2°C / 60% ± 5%RH Accelerated: 2-8°C		
Time Period	Real time: 18 months Accelerated: 6 months		
Frequency	Accelerated: 0,1,2, 3, 6 (Months) Real Time: 0, 3, 6,9,12,12 (Months)		
Batch No.	NP0161	NP0161	NP0163
Batch Size	581 vials	581 vials	581 vials
Manufacturing Date	08-2022	08-2022	08-2022
Date of Initiation	26-09-2020	26-09-2020	26-09-2020
No. of Batches	03		

Evaluation by PEC:

Sr. No.	Sections	Observations	Response of firm
1.	1.3.3	Provide original, legalized notarized countersigned by embassy of Pakistan, Certificate of Pharmaceutical Product (CoPP) / Free Sale certificate and GMP certificate of the Manufacturer issued by relevant regulatory authority in the country of origin and name of exporting country. Provide original, notarized , sole agency agreement.	Firm has provided copy of COPP legalized notarized countersigned by embassy of Pakistan. Firm has provided copy of letter of authorization, which is not notorized.
2.	1.6.5	Valid Good Manufacturing Practice (GMP) certificate of the Drug Substance manufacturer issued by relevant regulatory authority of country of origin.	Firm has provided GMP certificate of Neuland Laboratories Limited. Address: Unit-I, Sy. No.: 347, 473,474,490/2, Veerabhadraswamy, Temple road, Bothapally Village, Gummadidala Mandal, Sangareddy District-502313 Telangana, India valid till 19-06-2025
3.	2.3.R.1.1	In BMR it is mention Posaconazole injection IH (For export) justification required.	The Posaconazole injection is meant for export in other countries as well as in Pakistan. The BMR provided is for the batch prepared for export purpose (to other country).
5.	3.2.S.4	Control of Drug Substance Specification Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required. Analytical procedures Detailed analytical procedures for the testing of drug substance	Firm has provided documents of Drug substance manufacturer. However, Documents of drug product manufacturer are required.

		performed by Drug Product manufacturer shall be provided. Validation of analytical procedures Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	
6.	3.2.P.2	Pharmaceutical equivalence of the applied drug shall be established with the innovator / reference/ comparator product and results of all the quality tests (mentioned in any official pharmacopoeia or section 3.2.P.5.1 of this application) of the developed formulation and the innovator / reference / comparator product shall be submitted and discussed.	Firm has submitted Pharmaceutical equivalence against Noxafil:
7	3.2.P.8	Provide accelerated stability data of batch number NP0163.	Firm has submitted stability data of batch number NP0163

Test Parameters	Test Product	Reference Product	
Batch No.	POSA/18/IN/S/19/04	T008836 (Noxafil®)	BV191004A (
Description	A clear colorless to yellow solution	A clear colorless to yellow solution	A clear colo yellow sol
Strength	300 mg/ 16.7ml vial	300 mg/ 16.7ml vial	300 mg/ 16.7
Manufactured by	Naprod	MSD (Merck & Co. Inc.), Ireland UK	Mylan Pharma
Label Claim	18 mg/ ml	18 mg/ ml	18 mg/
Dosage Form	Injection	Injection	Injecti
Related substance a) Individual impurity (NMT 0.2%) b) Total impurity (NMT 2.0%)	 0.07% 0.21%	 0.01% 0.05%	 ND ND
PH (2.0 to 3.0)	2.80	2.80	2.70
Assay (90.0% - 110.0%)	102.6%	98.8%	100.8

Decision: Approved as per policy of inspection of manufacturer abroad with innovator's specifications.

- **Firm shall submit documents for the drug substance specifications, analytical procedure and analytical method verification studies from the drug product manufacturer before issuance of registration letter.**
- **Furthermore, Registration Board was apprised regarding an e. mail received to Director PE&R Division from M/s Miles International India (authorized exclusive representative for the export of products manufactured by Naprod Life Sciences for the Pakistan region), wherein firm has requested to not consider any product registration applications made by any other party other than LDS as they will not be able to supply these products in the future.**
- **In context of above cited e.mail Registration Board decided that firm shall submit afresh notarized "Sole Agency Agreement" between M/s Lab Diagnostic System & M/s Naprod Life Sciences Pvt. Ltd before issuance of registration letter.**

D. Item No. IV: Agenda of Evaluator PEC-XI (Dr. Farhad Ullah)
Case No. 01: New application for registration of Human drugs on Form 5-F on export facilitation

Assistant director PR-I/EFD vide letter No.F.1-6/2019-PR-I (EFD) dated 12-01-2023 has informed that DRAP Authority in its 133rd meeting held on 13th April 2022, decided to grant registration on priority basis to the pharmaceutical i.e. one molecule for each 100,000 USD worth of export of medicines (to a maximum of 15 such molecules) during a fiscal year. In compliance to the aforementioned decision of the authority, the following firm have achieved the benchmark of more than 100,000 USD during the fiscal Year 2021-2022 and submitted their applications for priority consideration in lieu of export facilitation for Registration Board please.,

44.	Name, Address Of Applicant / Marketing Authorization Holder	M/s Bio-Labs (Pvt.) Ltd., Plot No. 145 Industrial Triangle Kahuta Road Islamabad.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot No. 145 Industrial Triangle Kahuta Road Islamabad.

	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 21-05-2019 based on inspection conducted on 23-04-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of grant of additional section letter No.F.1-12/98-Lic(Vol. II) dated 24-03-2007 which specifies Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 154 dated 03-01-2022
	Details of fee submitted	PKR 30,000/-: dated 23-11-2021 (Deposit slip#148278185261)
	The proposed proprietary name / brand name	Dapa-Met 5/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dapagliflozin propanediol monohydrate equivalent to Dapagliflozin…….5mg Metformin HCl……1000mg
	Pharmaceutical form of applied drug	Tablets
	Pharmacotherapeutic Group of (API)	Dapagliflozin; Sodium-glucose co-transporter 2 (SGLT2) inhibitors Metformin; Biguanides
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	2 x 7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XIGDUO (5mg/850mg; 5mg/1000mg) film coated tablet EMA Approved
	For generic drugs (me-too status)	Daplozmet 5mg/1000mg Tablets by M/s Highnoon Laboratories (Reg#96589)
	Name and address of API manufacturer.	Dapagliflozin: M/s Jiangsu Yungan Pharmaceutical CO., Ltd., No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu China Metformin HCl: Aarti Drugs Limited., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference

		standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Dapagliflozin propanediol monohydrate: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40 O ± 2 O C /75% ± 5% RH for 6 months. The real time stability data is conducted at 30OC ± 2 O C / 65% ± 5% RH for 36 months (Batches: 130401, 130402, 130501) Metformin Hydrochloride; Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40 O ± 2 O C /75% ± 5% RH for 6 months. The real time stability data is conducted at 30OC ± 2 O C / 65% ± 5% RH for 48 months (Batches; MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against innovator product Xigduo 5/1000mg Tablet of M/s AstraZeneca AB SE-151 85 Sodertalje - Sweden by performing quality tests (Description, identification, uniformity of dosage unit, Dissolution and Assay). CDP has been performed against the same brand that is Xigduo 5/1000mg Tablet of M/s AstraZeneca AB SE-151 85 Sodertalje - Sweden in Acid media (pH 1.2), acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values of f2 are in acceptable range.
	Analytical method validation/verification of product	Firm has submitted method validation studies including specificity, accuracy, precision,

		linearity & range, system suitability, ruggedness, LOD, LOQ.		
STABILITY STUDY DATA				
Manufacturer of API		Dapagliflozin: M/s Jiangsu Yungan Pharmaceutical CO., Ltd., No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu China Metformin HCl: Aarti Drugs Limited., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat India.		
API Lot No.		Dapagliflozin Propanediol Monohydrate: DGF-201902001 Metformin Hydrochloride: MEF/18122462		
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 12 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.		DAP-20-019	DAP-20-020	DAP-20-021
Batch Size		1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date		04-2020	04-2020	04-2020
Date of Initiation		02-05-2020	02-05-2020	02-05-2020
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	N/A		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Dapagliflozin propanediol monohydrate: The firm has submitted cGMP certificate to M/s Jiangsu Yongan Pharmaceutical Co., Ltd., China issued by Jiangsu Food and Drug Administration valid upto 03-03-2021 Metformin HCl: The firm has submitted GMP certificate for Aarti Drugs Limited India issued by Food & Drug Maharashtra State India. The certificate is valid till 01-11-2021		
	Documents for the procurement of API with approval from DRAP (in case of import).	Dapagliflozin propanediol monohydrate: Firm has submitted copy of Form 6 for import of 200g of Dapagliflozin propanediol Monohydrate in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Firm has submitted copy of invoice for import of 200g of Dapagliflozin propanediol Monohydrate (Batch No. DGF-201902001) in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Firm has also submitted copy of clearance certificate for import of 200g of Dapagliflozin		

		propanediol Monohydrate in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Metformin HCl: Firm has submitted copy of invoice No. EXP/2411/18-19 dated 21-02-2019 for import of 25kg of Metformin HCl (Batch No. MEF/18122462) in name of M/s Bio-Labs (Pvt.) Ltd., attested by AD (I&E) DRAP Islamabad dated 27-03-2019. Firm has submitted copy of clearance certificate for import of 25kg of Metformin HCl in name of M/s Bio-Labs (Pvt.) Ltd., attested by AD (I&E) DRAP Islamabad dated 27-03-2019.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail reports on product testing.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

Remarks of Evaluator XI:

Section	Observations	Response
1.3.5	Submit GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years	
1.6.5	Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer for dapagliflozin propanediol monohydrate and Metformin HCl issued by relevant regulatory authority of country of origin	
3.2.S.4	Justification is required for including assay test for metformin on titration method by drug product manufacturer and potentiometric method by drug substance manufacturer in analytical procedure instead of HPLC as recommended by USP. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) Metformin HCl for titration method is submitted. Clarification is required as the drug substance manufacturer has performed assay of drug substance Metformin HCl in batch analysis by potentiometric method instead of HPLC as recommended by USP.	
3.2.P.2	Justification is required for not considering one time-point after 85% dissolution has been reached in CDP studies or the dissolution should be conducted until an asymptote (plateau) has been reached	
3.2.P.5	Justification is required for not including test for disintegration test in finished product specification as recommended by innovator product review document. Submit numerical results for uniformity of dosage unit test in batch analysis for dapagliflozin and metformin. Clarification is required as you have mentioned innovator specification in module 1 section 1.5.6 while bio labs	

	specification in module 3 section 3.2.P.5 drug product specification		

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

45.	Name, Address Of Applicant / Marketing Authorization Holder	M/s Bio-Labs (Pvt.) Ltd., Plot No. 145 Industrial Triangle Kahuta Road Islamabad.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt.) Ltd., Plot No. 145 Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the Finished product manufacturer	Firm has submitted cGMP certificate issued on 21-05-2019 based on inspection conducted on 23-04-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of grant of additional section letter No.F.1-12/98-Lic(Vol. II) dated 24-03-2007 which specifies Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 2035 dated 21-01-2022
	Details of fee submitted	PKR 30,000/-: dated 23-11-2021 (Deposit slip#0805662855)
	The proposed proprietary name / brand name	Dapa-Met 5/850mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dapagliflozin propanediol monohydrate equivalent to Dapagliflozin…….5mg Metformin HCl……850mg
	Pharmaceutical form of applied drug	Tablets
	Pharmacotherapeutic Group of (API)	Dapagliflozin; Sodium-glucose co-transporter 2 (SGLT2) inhibitors Metformin; Biguanides
	Reference to Finished product specifications	Innovator's specifications
	Proposed Pack size	2 x 7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XIGDUO (5mg/850mg; 5mg/1000mg) film coated tablet EMA Approved
	For generic drugs (me-too status)	Daplozmet 5mg/850mg Tablets by M/s Highnoon Laboratories (Reg#96588)
	Name and address of API manufacturer.	Dapagliflozin: M/s Jiangsu Youngan Pharmaceutical CO., Ltd., No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu China Metformin HCl:

		Aarti Drugs Limited., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Dapagliflozin propanediol monohydrate: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40 O ± 2 O C /75% ± 5% RH for 6 months. The real time stability data is conducted at 30OC ± 2 O C / 65% ± 5% RH for 36 months (Batches: 130401, 130402, 130501) Metformin Hydrochloride; Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40 O ± 2 O C /75% ± 5% RH for 6 months. The real time stability data is conducted at 30OC ± 2 O C / 65% ± 5% RH for 48 months (Batches; MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence has been established against innovator product Xigduo 5/850mg Tablet of M/s AstraZeneca AB SE-151 85 Sodertalje - Sweden by performing

		quality tests (Description, identification, uniformity of dosage unit, Dissolution and Assay). CDP has been performed against the same brand that is Xigduo 5/850mg Tablet of M/s AstraZeneca AB SE-151 85 Sodertalje - Sweden in Acid media (pH 1.2), acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values of f2 are in acceptable range.		
	Analytical method validation/verification of product	Firm has submitted method validation studies including specificity, accuracy, precision, linearity & range, system suitability, ruggedness, LOD, LOQ.		
STABILITY STUDY DATA				
Manufacturer of API		Dapagliflozin: M/s Jiangsu Yungan Pharmaceutical CO., Ltd., No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu China Metformin HCl: Aarti Drugs Limited., Plot No. 211 - 213, Road No.2 G.I.D.C., Sarigam, Dist.: Valsad, Gujarat India.		
API Lot No.		Dapagliflozin Propanediol Monohydrate: DGF-201902001 Metformin Hydrochloride: MEF/18122462		
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 12 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.		DAP-20-016	DAP-20-017	DAP-20-018
Batch Size		1500 Tablets	1500 Tablets	1500 Tablets
Manufacturing Date		04-2020	04-2020	04-2020
Date of Initiation		26-04-2020	26-04-2020	26-04-2020
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	N/A		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Dapagliflozin propanediol monohydrate: The firm has submitted cGMP certificate to M/s Jiangsu Yongan Pharmaceutical Co., Ltd., China issued by Jiangsu Food and Drug Administration valid upto 03-03-2021 Metformin HCl: The firm has submitted GMP certificate for M/s Aarti Drugs Limited India issued by Food & Drug Maharashtra State India. The certificate is valid till 01-11-2021		
	Documents for the procurement of API with approval from DRAP (in case of import).	Dapagliflozin propanediol monohydrate:		

		Firm has submitted copy of Form 6 for import of 200g of Dapagliflozin propanediol Monohydrate in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Firm has submitted copy of invoice for import of 200g of Dapagliflozin propanediol Monohydrate (Batch No. DGF-201902001) in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Firm has also submitted copy of clearance certificate for import of 200g of Dapagliflozin propanediol Monohydrate in name of M/s Bio-Labs (Pvt.) Ltd. attested by AD (I&E) DRAP Islamabad dated 01-04-2019. Metformin HCl: Firm has submitted copy of invoice No. EXP/2411/18-19 dated 21-02-2019 for import of 25kg of Metformin HCl (Batch No. MEF/18122462) in name of M/s Bio-Labs (Pvt.) Ltd., attested by AD (I&E) DRAP Islamabad dated 27-03-2019. Firm has submitted copy of clearance certificate for import of 25kg of Metformin HCl in name of M/s Bio-Labs (Pvt.) Ltd., attested by AD (I&E) DRAP Islamabad dated 27-03-2019.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail reports on product testing.
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

Remarks of Evaluator XI:

Section	Observations	Response
1.3.5	Submit GMP inspection report/ GMP certificate of the manufacturing unit issued within the last three years	
1.6.5	Submit valid GMP certificate / Drug Manufacturing License of the Drug Substance manufacturer for dapagliflozin propanediol monohydrate and Metformin HCl issued by relevant regulatory authority of country of origin	
3.2.S.4	Justification is required for including assay test for metformin on titration method by drug product manufacturer and potentiometric method by drug substance manufacturer in analytical procedure instead of HPLC as recommended by USP. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) Metformin HCl for titration method is submitted. Clarification is required as the drug substance manufacturer has performed assay of drug substance Metformin HCl in batch analysis by potentiometric method instead of HPLC as recommended by USP.	

3.2.P.2	Justification is required for not considering one time-point after 85% dissolution has been reached in CDP studies or the dissolution should be conducted until an asymptote (plateau) has been reached		
3.2.P.5	Justification is required for not including test for disintegration test in finished product specification as recommended by innovator product review document. Submit numerical results for uniformity of dosage unit test in batch analysis for dapagliflozin and metformin. Clarification is required as you have mentioned innovator specification in module 1 section 1.5.6 while bio labs specification in module 3 section 3.2.P.5 drug product specification		

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Case No. 02: Deferred Registration applications of New Section of Human drugs on Form 5-F (Local)

M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.

The Central Licensing Board in its 276th meeting held on 3rd September, 2020 has considered and approved the following additional section of M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha. under Drug Manufacturing License No. 000609 (Formulation) vide approval letter No. F. 1-37/2003-Lic (Vol-I) dated 29th September 2020.

S No.	Section
1.	Capsule (General) Section (New)
2.	Sachet (General) Section (New)

Following applications have been submitted for registration by the firm.

46.	Name, address of Applicant / Marketing Authorization Holder	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29207 dated 26-10-2021
	Details of fee submitted	PKR 30,000/-: dated 20-10-2021
	The proposed proprietary name / brand name	PREQUAP 50 mg Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Pregabalin…….50 mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anticonvulsant
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA (25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg) Capsule USFDA Approved
	For generic drugs (me-too status)	Zeegap 50mg Capsule by M/s Hilton Pharmaceuticals (Reg# 047358)
	GMP status of the Finished product manufacturer	New sections
	Name and address of API manufacturer.	M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and

		its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Long-term stability studies were performed at a storage temperature of 30°C±2°C/65%±5% RH for 60 months. Accelerated stability studies were performed at a temperature of 40±2°C/75%±5% RH for 6 months. Batches: (D5248-14-002, D5248-14-003, D5248-14-004)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Lyrica 50 mg Capsule by Pfizer by performing quality tests (Description, Assay, Dissolution, weight variation). CDP has been performed against the same brand Lyrica 50 mg Capsule by Pfizer in Acid media 0.1N HCl (pH 1.2), Phosphate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision,.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China		
API Lot No.	D5248-19-069		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	T04	T05	T06
Batch Size	1500 Cap	1500 Cap	1500 Cap
Manufacturing Date	02-2021	02-2021	02-2021

Date of Initiation	05-02-2021	05-02-2021	05-02-2021
No. of Batches	03		
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm submitted that Quaper Pvt. Ltd is a new license facility hence no such inspection has been conducted	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP cetificate of M/s Zhejiang Huahai Pharmaceutical Co., Ltd Xunqiao, Linhai, Zhejiang is submitted while manufacturer is M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China	
	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted	
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm have submitted data of stability batches along with respective documents like chromatograms, COA, summary data sheets etc.	
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable. Our HPLC system are not 21CFR compliant	
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm have submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

Remarks of Evaluator XI:

Section	Observations	Response
1.5.15-1.5.20	Commitments not submitted as per the CTD guidance document	Commitments are not submitted
1.6.5	Drug Manufacturing License (DML) / Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin shall be submitted as the submitted GMP certificate is of different manufacturing site	Firm has submitted GMP certificate No. ZJ201 of M/s Zhejiang Huahai Pharmaceutical Co., Lt Xunqiao, Linhai, Zhejiang China valid upto 25- 2023 instead of M/s Zhejiang Huahai Pharmace Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China The submitted GMP certificate of the drug subs manufacturer of different manufacturing site.
3.2.S.4.2	Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug substance manufacturer is required. In analytical procedure in assay test you have mentioned the conc. Of standard and sample solution as 2mg/ml while in validation of analytical procedure you have mentioned the conc. Of standard and sample solution as 1mg/ml, justify?	Copies of the Drug substance analytical procedu used for routine testing of the Drug substance /A Pharmaceutical Ingredient by Drug substance manufacturer is not submitted. The firm submitted that the concentration of 1m is to cover the lower range of assay.
3.2.S.4.3	Results for specificity of drug substance not given by drug product manufacturer	Firm has submitted result of specificity test in analytical method verification studies for drug substance
3.2.S.5	The Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, clarify whether the same was used for test and analysis?	Firm has not submitted clarification regarding r date of Reference Standards or Materials. Howe firm has submitted COA of USP reference stan catalog No. 1559618.

3.2.P.2	Justification is required as Phosphate buffer ph 4.5 was used instead of acetate buffer ph 4.5 in CDP studies	The firm submitted that it was a typographical error, CDP was performed in Acetate buffer of pH 4.5 in addition to pH 1.2 and pH 6.8 buffers.
3.2.P.5.1	You have mentioned innovators specifications in module I section 1.5.6 while in house specifications in control of drug product section 3.2.P.5.1 and 3.2.P.5.4, clarify? Justify the acceptance criteria of dissolution test NLT Q in 45min in product specifications since FDA review documents specifies that dissolution criteria shall be NLT Q in 30 min for the applied product Justification is required as the registration board in its 293rd meeting decided that For rapidly dissolving as well as immediate release drug products, wherein the stability batches will be manufactured after 01-06-2020, variation from innovator /reference product with reference to dissolution specification will not be acceptable.	Te firm submitted that since the applied product was non pharmaopeial at the time of development at the time of development hence, we had applied for "innovator's specifications" as mentioned in section 1.5.6. The firm submitted that for dissolution test we adopted the general provision for immediate release dosage forms and both 30min and 45mn time point are admissible for immediate release dosage form. The firm submitted that we have revised the drug product specification as per latest BP monograph for "Pregabalin capsule" and same will be adopted for commercial batches and submit BP monograph for applied product.
3.2.P.5.2	Details of analytical method for drug substance has been submitted against the drug product. Justify the adoption of dissolution parameters including dissolution media (0.06N HCl)	Analytical method for drug product is not submitted. Te firm submitted that since the applied product was non pharmaopeial at the time of development at the time of development hence, we had applied for "innovator's specifications" but now on the issuance of BP monograph for "Pregabalin capsule" in latest edition, the same has been adopted. Same dissolution media (0.06M HCl) is mentioned in BP monograph.
3.2.P.5.3	Results for specificity of drug product not given by drug product manufacturer	Firm has submitted results of specificity test in method validation studies for applied product
3.2.P.5.4	In batch analysis acceptance criteria set for average weight of Batch No. T-05 is 225.00mg±7.5% while the results are 201.00mg, justify your results?	The firm submitted that it was a typographical error, the actual average weight is 200mg and limit for weight variation as 200.00mg±7.5 (Limit: 185mg-215mg) as evident from section 3.2.P.2.and COAs of other trial batches.
3.2.P.8	Submit Raw data sheets of stability studies containing calculation formula for both assay & dissolution test In COA for stability study acceptance criteria set for average weight of Batch No. T-04 is 225.00mg±7.5% (Limit; 208.125mg-241.875mg) while the results are 203.00mg at initial time point, 202.00mg at 3rd month time point of real time stability study, 200.00mg at 6th month time point real time stability study, justify your results? Furthermore, the acceptance criteria set for average weight of other batches are 200.00mg±7.5% (Limit; 185mg-215mg) The injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram, clarify?	The firm submitted that same calculation formulas have been applied in calculation of assay and dissolution results as given in drug product test method. However, Raw data sheets of stability studies containing calculation formula for both assay & dissolution test is not submitted The firm submitted that it was a typographical error, the actual average weight is 200mg and limit for weight variation as 200.00mg±7.5 (Limit: 185mg-215mg) as evident from section 3.2.P.2.and COAs of other trial batches. The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> Firm has submitted copy of invoice No# HH20200723R1 dated 12th December 2020 in name of M/s Quaper Pvt Ltd from M/s Zhejiang Huahai Pharmaceutical Co., Ltd for import of 1.114kg Pregabalin batch No#D5248-19-069. However, the invoice not attested by AD (I&E) DRAP field office.

	Submit documents for the procurement of API with approval from DRAP	The firm also submitted copy of goods decalaration certificate.

Previous Decision (323rd-DRB): Deferred for following:
Submission of commitments as per the Form5F guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin
250/100

Clarification whether the same Reference Standards or Materials was used for test and analysis of drug substance as the Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, while manufacturing date of drug substance was 23-02-3019.
Submission of complete analytical method for applied drug product
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.
Submission of copy of invoice attested by AD (I&E) DRAP field office.

Response of the firm:

Observations	Firm's response
Submission of commitments as per the Form5F guidance document	Firm has submitted commitments as per the Form 5F guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin	Firm has submitted Eudra GMP of M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China valid up to three years for date o inspection (date of inspection 30-09-2021)
Submission of copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer	Firm has submitted copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer
The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.	The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.
Submission of complete analytical method for applied drug product	Firm has submitted complete analytical method for applied drug product as per BP Monograph
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test	Firm has submitted raw data sheets of stability studies. However, calculation formula for both assay & dissolution test is not submitted
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.	The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> and it does not impact the result
Submission of copy of invoice attested by AD (I&E) DRAP field office.	The firm has submitted GD copy for procurement of Pregabalin

Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with calculation formula for both Assay and dissolution test of drug product, before issuance of registration letter.

• **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
47.	Name, address of Applicant / Marketing Authorization Holder	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29208 dated 26-10-2021
	Details of fee submitted	PKR 30,000/-: dated 20-10-2021
	The proposed proprietary name / brand name	PREQUAP 75 mg Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Pregabalin…….75 mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anticonvulsant
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA (25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg) Capsule USFDA Approved
	For generic drugs (me-too status)	Zeegap 75mg Capsule by M/s Hilton Pharmaceuticals (Reg# 047359)
	GMP status of the Finished product manufacturer	New sections
	Name and address of API manufacturer.	M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical

		form, manufacturers, description of manufacturing process and controls, tests for impurity, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Long-term stability studies were performed at a storage temperature of 30°C±2°C/65%±5% RH for 60 months. Accelerated stability studies were performed at a temperature of 40±2°C/75%±5% RH for 6 months. Batches: (D5248-14-002, D5248-14-003, D5248-14-004)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Lyrica 75 mg Capsule by Pfizer by performing quality tests (Description, Assay, Dissolution, weight variation). CDP has been performed against the same brand Lyrica 75 mg Capsule by Pfizer in Acid media 0.1N HCl (pH 1.2), Phosphate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China		
API Lot No.	D5248-19-069		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.	T19	T20	T21
Batch Size	1500 Cap	1500 Cap	1500 Cap
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	04-02-2021	04-02-2021	04-02-2021
No. of Batches	03		
Administrative Portion			

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm submitted that Quaper Pvt. Ltd is a new license facility hence no such inspection has been conducted
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate of M/s Zhejiang Huahai Pharmaceutical Co., Ltd Xunqiao, Linhai, Zhejiang is submitted while manufacturer is M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China
	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm have submitted data of stability batches along with respective documents like chromatograms, COA, summary data sheets etc.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable. Our HPLC system are not 21CFR compliant
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm have submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator XI:

Section	Observations	Response
1.5.15-1.5.20	Commitments not submitted as per the CTD guidance document	Commitments are not submitted
1.6.5	Drug Manufacturing License (DML) / Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin shall be submitted as the submitted GMP certificate is of different manufacturing site	Firm has submitted GMP certificate No. ZJ20180073 of M/s Zhejiang Huahai Pharmaceutical Co., Ltd Xunqiao, Linhai, Zh China valid upto 25-06-2023 instead of M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016 China The submitted GMP certificate of the drug substance manufacturer of different manufact site.
3.2.S.4.2	Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug substance manufacturer is required. In analytical procedure in assay test you have mentioned the conc. Of standard and sample solution as 2mg/ml (as per USP) while in validation of analytical procedure you have mentioned the conc. Of standard and sample solution as 1mg/ml, justify?	Copies of the Drug substance analytical proce used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug substance manufacturer is not submitted. The firm submitted that the concentration of 1mg/1ml is to cover the lower range of assay.
3.2.S.4.3	Results for specificity of drug substance not given by drug product manufacturer	Firm has submitted result of specificity test in analytical method verification studies for drug substance
3.2.S.5	The Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, clarify whether the same was used for test and analysis?	Firm has not submitted clarification regarding date of Reference Standards or Materials. Ho firm has submitted COA of USP reference sta catalog No. 1559618.

3.2.P.2	Justification is required as Phosphate buffer ph 4.5 was used instead of acetate buffer ph 4.5 in CDP studies	The firm submitted that it was a typographical error, CDP was performed in Acetate buffer of pH 4.5 in addition to pH 1.2 and pH 6.8 buffers.
3.2.P.5.1	You have mentioned innovators specifications in module I section 1.5.6 while in house specifications in control of drug product section 3.2.P.5.1 and 3.2.P.5.4, clarify? Justify the acceptance criteria of dissolution test NLT Q in 45min in product specifications since FDA review documents specifies that dissolution criteria shall be NLT Q in 30 min for the applied product Justification is required as the registration board in its 293rd meeting decided that For rapidly dissolving as well as immediate release drug products, wherein the stability batches will be manufactured after 01-06-2020, variation from innovator /reference product with reference to dissolution specification will not be acceptable.	Te firm submitted that since the applied product was non pharmaopeial at the time of development at the time of development hence, we had applied for "innovator's specifications" as mentioned in section 1.5.6. The firm submitted that for dissolution test we adopted the general provision for immediate release dosage forms and both 30min and 45min time point are admissible for immediate release dosage form. The firm submitted that we have revised the drug product specification as per latest BP monograph for "Pregabalin capsule" and same will be adopted for commercial batches and submit BP monograph for applied product.
3.2.P.5.2	Details of analytical method for drug substance has been submitted against the drug product. Justify the adoption of dissolution parameters including dissolution media (0.06N HCl)	Analytical method for drug product is not submitted. Te firm submitted that since the applied product was non pharmaopeial at the time of development at the time of development hence, we had applied for "innovator's specifications" but now on the issuance of BP monograph for "Pregabalin capsule" in latest edition, the same has been adopted. Same dissolution media (0.06M HCl) is mentioned in BP monograph.
3.2.P.5.3	Results for specificity of drug product not given by drug product manufacturer	Firm has submitted results of specificity test in method validation studies for applied product
3.2.P.8	Submit Raw data sheets of stability studies containing calculation formula for both assay & dissolution test The injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram, clarify Submit documents for the procurement of API with approval from DRAP	The firm submitted that same calculation formulas have been applied in calculation of assay and dissolution results as given in drug product test method. However, Raw data sheets of stability studies containing calculation formula for both assay & dissolution test is not submitted The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> Firm has submitted copy of invoice No# HH20200723R1 dated 12th December 2020 in name of M/s Quaper Pvt Ltd from M/s Zhejiang Huahai Pharmaceutical Co., Ltd for import of 1.114kg Pregabalin batch No#D5248-19-069. However, the invoice not attested by AD (I&E) DRAP field office. The firm also submitted copy of goods decalaration certificate.

Previous Decision (323rd-DRB): Deferred for following:
Submission of commitments as per the CTD guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin
Submission of copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer

Clarification whether the same Reference Standards or Materials was used for test and analysis of drug substance as the Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, while manufacturing date of drug substance was 23-02-3019.
Submission of complete analytical method for applied drug product
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.
Submission of copy of invoice attested by AD (I&E) DRAP field office.

Response of the firm:

Observations	Firm's response
Submission of commitments as per the Form5F guidance document	Firm has submitted commitments as per the Form 5F guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin	Firm has submitted Eudra GMP of M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China valid up to three years for date o inspection (date of inspection 30-09-2021)
Submission of copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer	Firm has submitted copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer
The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.	The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.
Submission of complete analytical method for applied drug product	Firm has submitted complete analytical method for applied drug product as per BP Monograph
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test	Firm has submitted raw data sheets of stability studies. However, calculation formula for both assay & dissolution test is not submitted
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.	The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> and it does not impact the result
Submission of copy of invoice attested by AD (I&E) DRAP field office.	The firm has submitted GD copy for procurement of Pregabalin

Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with calculation formula for both Assay and dissolution test of drug product, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

48.	Name, address of Applicant / Marketing Authorization Holder	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Name, address of Manufacturing site.	M/s Quaper (Pvt) Ltd. 26-A, Small Industrial Estate, Lahore Road, Sargodha.
	Status of the applicant	☒ Manufacturer ☐ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 29209 dated 26-10-2021
	Details of fee submitted	PKR 30,000/-: dated 20-10-2021
	The proposed proprietary name / brand name	PREQUAP 100 mg Capsule
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Pregabalin……100 mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Anticonvulsant
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	LYRICA (25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg) Capsule USFDA Approved
	For generic drugs (me-too status)	Zeegap 100mg Capsule by M/s Hilton Pharmaceuticals (Reg# 047360)
	GMP status of the Finished product manufacturer	New sections
	Name and address of API manufacturer.	M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Long-term stability studies were performed at a storage temperature of 30°C±2°C/65%±5% RH for 60 months. Accelerated stability studies were performed at a temperature of 40±2°C/75%±5% RH for 6 months.

		Batches: (D5248-14-002, D5248-14-003, D5248-14-004)		
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the Lyrica 100 mg Capsule by Pfizer by performing quality tests (Description, Assay, Dissolution, weight variation). CDP has been performed against the same brand Lyrica 100 mg Capsule by Pfizer in Acid media 0.1N HCl (pH 1.2), Phosphate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f2 are in the acceptable range.		
	Analytical method validation/verification of product	Method validation studies have been submitted including linearity, range, accuracy, precision.		
STABILITY STUDY DATA				
Manufacturer of API		M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China		
API Lot No.		D5248-19-069		
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.		T-01	T-02	T-03
Batch Size		1500 Cap	1500 Cap	1500 Cap
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		06-02-2021	06-02-2021	06-02-2021
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm submitted that Quaper Pvt. Ltd is a new license facility hence no such inspection has been conducted		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP certificate of M/s Zhejiang Huahai Pharmaceutical Co., Ltd Xunqiao, Linhai, Zhejiang is submitted while manufacturer is M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China		
	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted		

	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm have submitted data of stability batches along with respective documents like chromatograms, COA, summary data sheets etc.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable. Our HPLC system are not 21CFR compliant
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	The firm have submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)

Remarks of Evaluator XI:

Section	Observations	Response
1.5.15-1.5.20	Commitments not submitted as per the CTD guidance document	Commitments are not submitted
1.6.5	Drug Manufacturing License (DML) / Good Manufacturing Practice (GMP) certificate of the Drug Substance / API manufacturer issued by concerned regulatory authority of country of origin shall be submitted as the submitted GMP certificate is of different manufacturing site	Firm has submitted GMP certificate No. ZJ20 of M/s Zhejiang Huahai Pharmaceutical Co., L Xunqiao, Linhai, Zhejiang China valid upto 25 2023 instead of M/s Zhejiang Huahai Pharmac Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China The submitted GMP certificate of the drug sub manufacturer of different manufacturing site.
3.2.S.4.2	Copies of the Drug substance analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug substance manufacturer is required. In analytical procedure in assay test you have mentioned the conc. Of standard and sample solution as 2mg/ml (as per USP) while in validation of analytical procedure you have mentioned the conc. Of standard and sample solution as 1mg/ml, justify?	Copies of the Drug substance analytical proce used for routine testing of the Drug substance / Pharmaceutical Ingredient by Drug substance manufacturer is not submitted. The firm submitted that the concentration of 1mg/1ml is to cover the lower range of assay.
3.2.S.4.3	Results for specificity of drug substance not given by drug product manufacturer	Firm has submitted result of specificity test in analytical method verification studies for drug substance
3.2.S.5	The Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, clarify whether the same was used for test and analysis?	Firm has not submitted clarification regarding date of Reference Standards or Materials. How firm has submitted COA of USP reference star catalog No. 1559618.
3.2.P.2	Justification is required as Phosphate buffer ph 4.5 was used instead of acetate buffer ph 4.5 in CDP studies Specify the batch number of innovator product against which pharmaceutical equivalence and CDP was performed	The firm submitted that it was a typographical CDP was performed in Acetate buffer of pH 4. addition to pH 1.2 and pH 6.8 buffers. The firm has not submitted Batch number of innovator product against which pharmaceutic equivalence and CDP
3.2.P.5.1	You have mentioned innovators specifications in module I section 1.5.6 while in house specifications in control of drug product section 3.2.P.5.1 and 3.2.P.5.4, clarify? Justify the acceptance criteria of dissolution test NLT Q in 45min in product specifications since FDA review documents specifies that	Te firm submitted that since the applied produ non pharmaopeial at the time of development a time of development hence, we had applied fo "innovator's specifications" as mentioned in se 1.5.6. The firm submitted that for dissolution test we adopted the general provision for immediate re dosage forms and both 30min and 45min time are admissible for immediate release dosage fo

	dissolution criteria shall be NLT Q in 30 min for the applied product Justification is required as the registration board in its 293rd meeting decided that For rapidly dissolving as well as immediate release drug products, wherein the stability batches will be manufactured after 01-06-2020, variation from innovator /reference product with reference to dissolution specification will not be acceptable.	The firm submitted that we have revised the drug product specification as per latest BP monograph for "Pregabalin capsule" and same will be adopted for commercial batches and submit BP monograph for applied product.
3.2.P.5.2	Details of analytical method for drug substance has been submitted against the drug product. Justify the adoption of dissolution parameters including dissolution media (0.06N HCl)	Analytical method for drug product is not submitted. Te firm submitted that since the applied product was non pharmaopeial at the time of development at the time of development hence, we had applied for "innovator's specifications" but now on the issuance of BP monograph for "Pregabalin capsule" in latest edition, the same has been adopted. Same dissolution media (0.06M HCl) is mentioned in BP monograph.
3.2.P.5.3	Results for specificity of drug product not given by drug product manufacturer	Firm has submitted results of specificity test in method validation studies for applied product
3.2.P.8	Submit Raw data sheets of stability studies containing calculation formula for both assay & dissolution test The injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram, clarify? Submit documents for the procurement of API with approval from DRAP	The firm submitted that same calculation formulas have been applied in calculation of assay and dissolution results as given in drug product test method. However, Raw data sheets of stability studies containing calculation formula for both assay & dissolution test is not submitted The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> Firm has submitted copy of invoice No# HH20200723R1 dated 12th December 2020 in name of M/s Quaper Pvt Ltd from M/s Zhejiang Huahai Pharmaceutical Co., Ltd for import of 1.114kg Pregabalin batch No#D5248-19-069. However, the invoice not attested by AD (I&E) DRAP field office. The firm also submitted copy of goods decalaration certificate.

Previous Decision (323rd–DRB): Deferred for following:
Submission of commitments as per the CTD guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin
Submission of copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer
Clarification whether the same Reference Standards or Materials was used for test and analysis of drug substance as the Retest Date Mentioned on COA of Reference Standards or Materials is 07.2018, while manufacturing date of drug substance was 23-02-3019.
Submission of details of innovator product including batch number against which pharmaceutical equivalence and CDP studies is performed
Submission of complete analytical method for applied drug product
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.
Submission of copy of invoice attested by AD (I&E) DRAP field office.

Response of the firm:

Observations	Firm's response

Submission of commitments as per the Form5F guidance document	Firm has submitted commitments as per the Form 5F guidance document
Submission of GMP certificate / Drug Manufacturing License (DML) of the Drug Substance manufacturer issued by concerned regulatory authority of country of origin	Firm has submitted Eudra GMP of M/s Zhejiang Huahai Pharmaceutical Co., Ltd. Chuannan, Duqiao, Linhai, Zhejiang, 317016, China valid up to three years for date o inspection (date of inspection 30-09-2021)
Submission of copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer	Firm has submitted copies of the Drug substance analytical procedures used for routine testing of the Drug substance by Drug substance manufacturer
The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.	The firm stated that the COA of reference standard or materials with retest date of 07-2018 was erroneously submitted as it was part of the DMF, whereas COA of primary reference standard actually used for analysis is submitted.
Submission of complete analytical method for applied drug product	Firm has submitted complete analytical method for applied drug product as per BP Monograph
Submission of raw data sheets of stability studies containing calculation formula for both assay & dissolution test	Firm has submitted raw data sheets of stability studies. However, calculation formula for both assay & dissolution test is not submitted
Clarification since the injection volume mentioned in the submitted analytical method is 20µl while 10µl in the submitted chromatogram.	The firm submitted that change in injection volume is within permissible limits of USP general chapter <621> and it does not impact the result
Submission of copy of invoice attested by AD (I&E) DRAP field office.	The firm has submitted GD copy for procurement of Pregabalin

Decision: Approved with BP specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, along with calculation formula for both Assay and dissolution test of drug product, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

E. Item No. V: Agenda of Evaluator PEC-XIII (Mr. Shahid Nawaz)

Case No. 1: Priority Application as per 257th Registration Board Meeting

49.	Name, address of Applicant / Importer	M/s Graton Pharma, Office No. 501 & 502, 5th Floor Plot 42C/2 Lane No. 8 Bukhari commercial DHA Phase-6, Karachi.
	Details of Drug Sale License of importer	License No. 160 Address: Office no. 501 & 502, 5th floor Plot no 42C/2 Lane-08, Bukhari Commercial Phase-6, D.H.A Karachi, Pakistan. Address of Godown: NA Validity: 21-10-2023 Status: Drug License by way of whole sale.

	Name and address of marketing authorization holder (abroad)	M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name, address of manufacturer(s)	M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name of exporting country	India.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Detail of certificates attached (CoPP, GMP certificate) CoPP: Firm has submitted original, legalized copy of CoPP certificate (No: 1974295/TS/2021) dated 13-12-2021 issued by Drug Control Administration Government of Telangana, India for Doxorubicin hydrochloride for injection 10mg/vial (Lyophilized). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The name of importing country on CoPP is mentioned as Pakistan. Furthermore, the CoPP is valid till 18-12-2023. GMP: Copy of GMP certificate No. L. Dis No. 1967/E1/2020 dated 30-06-2020 issued by Drugs Control Administration Government of Telangana in the name of M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India wherein it is stated that the firm is following Good Manufacturing Practices as stipulated under the provisions of Schedule "M" of the Drugs and Cosmetics Rules, 1945. The certificate is valid till 29-06-2021.
	Details of letter of authorization / sole agency agreement	Firm has submitted notarized Authorization letter from M/s Jodas Expoim Pvt. ltd., wherein M/s Jodas Expoim confirms that M/s Graton Pharma, Office No. 501 & 502, 5th Floor Plot 42C/2 Lane No. 8 Bukhari commercial DHA Phase-6, Karachi is their agent for their products in Pakistan and they are fully authorized to register, market and sell the products. The authorization letter is valid till 31-12-2025. List of product has mentioned total of 28 products which include Doxorubicin hydrochloride 10mg and Doxorubicin hydrochloride 50mg.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging

		☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 35493: dated 07-12-2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 0663149488 dated 15-06-2021.
	The proposed proprietary name / brand name	Cixadin Injection 10mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains; Doxorubicin hydrochloride …….. 10mg
	Pharmaceutical form of applied drug	Lyophilized Powder for solution for injection.
	Pharmacotherapeutic Group of (API)	Antimitotic and cytotoxic (L01DB01)
	Reference to Finished product specifications	USP Specification.
	Proposed Pack size	10ml is filled in 30ml USP type I clear glass tubular vial.
	Proposed unit price	Not mentioned.
	The status in reference regulatory authorities	Doxorubicin Hydrochloride10mg Powder for Injection, Hospira UK Limited, MHRA approved.
	For generic drugs (me-too status)	Adriblastina 10mg, Pfizer Pakistan, Reg. No. 002580.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Sterling Biotech Limited, Jambusar State Highway, Village: Masar-391 421, Ta: Padra, Dist. Vadodara, Gujrat, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data regarding nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification studies, batch analysis (061503018, 061503019 & 061503020) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	24 months' real time stability data at 25°± 2°C / 60% RH ± 5% RH of 03 batches (2705, 2805 & 2905). 06 month accelerated stability data 40°C ± 2°C / 75% RH ± 5% RH of 03 batches. Batches (061403010, 061403011 & 061403012)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, formulation development, pharmaceutical development, manufacturer, batch formula, manufacturing process and process control, process validation protocols/report, specifications, analytical procedures, validation of analytical procedures, batch analysis (0070717001, 0070717002

		& 0070817003), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against Aderamycin by performing quality tests including identification, pH, Assay, water content & impurities. Results of both the applied as well as reference products are in acceptable range.
	Analytical method validation/verification of product	Submitted.
	Container closure system of the drug product	5ml clear tubular USP type I glass vial with 20mm bromobutyl rubber stoppers and 20mm aluminum flip off seals.
	Stability study data of drug product, shelf life and storage conditions	24-months real time stability data at 30°C ± 2°C / 75% ± 5% RH of 03 batches (0070817004, 0070817005 & 0070817006). 06-month accelerated stability data 40°C ± 2°C / 75% ± 5% RH of 03 batches (0070817004, 0070817005 & 0070817006).

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm
		Valid notarized and legalized copy of GMP certificate for of the finished product manufacturer shall be submitted.	
	1.1	Differential fee of 75000/- shall be submitted.	
	1.4.1.1	Authorization letter has mentioned the territory of Pakistan, while in module one section 1.4.1.1 has mentioned domestic and export sales. Clarification shall be submitted.	
	1.5.2	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit shall clearly be mentioned as this section has only mentioned 10mg.	
	1.6.5	Valid copy of GMP certificate of the drug substance manufacturer issued by the relevant/concerned regulatory authority shall be submitted.	
	3.2	Quality overall summary as per WHO QOS-PD template shall be submitted.	
	3.2.S.4.2	Chromatographic condition i.e. flow rate, injection volume, column temperature et. in the assay test by the drug substance manufacturer are different from USP while the specifications provided are as of USP. Clarification shall be submitted.	
	3.2.S.4.3	Analytical method verification studies performed by the drug product manufacturer shall be submitted.	
	3.2.S.4.4	COAs of the drug substance from drug product manufacturer shall be submitted.	
	3.2.S.7.3	Real time stability data of the drug substance as per Zone Iva or Zone IVb shall be submitted.	

	3.2.P.2.1	Provide information including type of diluent, its composition, quantity or volume, specifications (as applicable) and regulatory status in Pakistan (as applicable) for the diluent which is to be provided along with the applied drug.	
	3.2.P.2.2	Details of the reference product in CDP shall be submitted. i.e. firm name, batch number, mfg. Date & exp. Date etc.	
	3.2.P.5.4	COAs of the drug product for 10mg shall be submitted. COAs for 50mg is submitted instead of 10mg.	
	3.2.P.8.3	In use stability studies shall be submitted. Justification shall be submitted that submitted stability data is on solution form of powder form.	
		Justification shall be submitted whether finished Product shall be imported in combo pack or alone in powder form.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

50.	Name, address of Applicant / Importer	M/s Graton Pharma, Office No. 501 & 502, 5th Floor Plot 42C/2 Lane No. 8 Bukhari commercial DHA Phase-6, Karachi.
	Details of Drug Sale License of importer	License No. 160 Address: Office no. 501 & 502, 5th floor Plot no 42C/2 Lane-08, Bukhari Commercial Phase-6, D.H.A Karachi, Pakistan. Address of Godown: NA Validity: 21-10-2023 Status: Drug License by way of whole sale.
	Name and address of marketing authorization holder (abroad)	M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name, address of manufacturer(s)	M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India.
	Name of exporting country	India.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Detail of certificates attached (CoPP, GMP certificate) CoPP: Firm has submitted original, legalized copy of CoPP certificate (No: 1974296/TS/2021) dated 13-12-2021 issued by Drug Control Administration Government of Telangana, India for Doxorubicin hydrochloride for injection 50mg/vial (Lyophilized). The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year. The name of importing country on CoPP is mentioned as Pakistan. Furthermore, the CoPP is valid till 18-12-2023. GMP: Copy of GMP certificate No. L. Dis No. 1967/E1/2020 dated 30-06-2020 issued by Drugs Control Administration Government of Telangana in

		the name of M/s Jodas Expoim Pvt. Ltd., Plot No. 55, Phase-III, Biotech Park, Karkapatla (V), Markook (M), Siddipet (D) Telangana - 502279, India wherein it is stated that the firm is following Good Manufacturing Practices as stipulated under the provisions of Schedule "M" of the Drugs and Cosmetics Rules, 1945. The certificate is valid till 29-06-2021.
	Details of letter of authorization / sole agency agreement	Firm has submitted notarized Authorization letter from M/s Jodas Expoim Pvt. ltd., wherein M/s Jodas Expoim confirms that M/s Graton Pharma, Office No. 501 & 502, 5th Floor Plot 42C/2 Lane No. 8 Bukhari commercial DHA Phase-6, Karachi is their agent for their products in Pakistan and they are fully authorized to register, market and sell the products. The authorization letter is valid till 31-12-2025. List of product has mentioned total of 28 products which include Doxorubicin hydrochloride 10mg and Doxorubicin hydrochloride 50mg.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 35492: dated 07-12-2022.
	Details of fee submitted	PKR 75,000/-: vide slip No. 709969314 dated 15-06-2021.
	The proposed proprietary name / brand name	Cixadin Injection 50mg.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains; Doxorubicin hydrochloride …….. 50mg
	Pharmaceutical form of applied drug	Lyophilized Powder for solution for injection.
	Pharmacotherapeutic Group of (API)	Antimitotic and cytotoxic (L01DB01)
	Reference to Finished product specifications	USP Specification.
	Proposed Pack size	10ml is filled in 30ml USP type I clear glass tubular vial.
	Proposed unit price	Not mentioned.
	The status in reference regulatory authorities	Doxorubicin Hydrochloride 50mg Powder for Injection, Hospira UK Limited, MHRA approved.
	For generic drugs (me-too status)	Adriblastina 50mg, Pfizer Pakistan, Reg. No. 014606.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to

		nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Sterling Biotech Limited, Jambusar State Highway, Village: Masar-391 421, Ta: Padra, Dist. Vadodara, Gujrat, India.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data regarding nomenclature, structure, general properties, solubility, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification studies, batch analysis (061503018, 061503019 & 061503020) and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	24 months' real time stability data at 25°± 2°C / 60% RH ± 5% RH of 03 batches (2705, 2805 & 2905). 06 month accelerated stability data 40°C ± 2°C / 75% RH ± 5% RH of 03 batches. Batches (061403010, 061403011 & 061403012)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, formulation development, pharmaceutical development, manufacturer, batch formula, manufacturing process and process control, process validation protocols/report, specifications, analytical procedures, validation of analytical procedures, batch analysis (0070717001, 0070717002 & 0070817003), justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence is established against Aderamycin by performing quality tests including identification, pH, Assay, water content & impurities. Results of both the applied as well as reference products are in acceptable range.
	Analytical method validation/verification of product	Submitted.
	Container closure system of the drug product	30ml clear tubular USP type I glass vial with 20mm bromobutyl rubber stoppers and 20mm aluminum flip off seals.
	Stability study data of drug product, shelf life and storage conditions	24-months real time stability data at 30°C ± 2°C / 75% ± 5% RH of 03 batches (0070717001, 0070717002 & 0070717003). 06-month accelerated stability data 40°C ± 2°C / 75% ± 5% RH of 03 batches (0070717001, 0070717002 & 0070717003).

Evaluation by PEC:

Sr. No.	Section	Observation	Reply by the firm

		Valid notarized and legalized copy of GMP certificate for of the finished product manufacturer shall be submitted.	
	1.1	Differential fee of 75000/- shall be submitted.	
	1.4.1.1	Authorization letter has mentioned the territory of Pakistan, while in module one section 1.4.1.1 has mentioned domestic and export sales. Clarification shall be submitted.	
	1.5.2	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit shall clearly be mentioned as this section has only mentioned 50mg.	
	1.6.5	Valid copy of GMP certificate of the drug substance manufacturer issued by the relevant/concerned regulatory authority shall be submitted.	
	3.2	Quality overall summary as per WHO QOS-PD template shall be submitted.	
	3.2.S.4.2	Chromatographic condition i.e. flow rate, injection volume, column temperature et. in the assay test by the drug substance manufacturer are different from USP while the specifications provided are as of USP. Clarification shall be submitted.	
	3.2.S.4.3	Analytical method verification studies performed by the drug product manufacturer shall be submitted.	
	3.2.S.4.4	COAs of the drug substance from drug product manufacturer shall be submitted.	
	3.2.S.7.3	Real time stability data of the drug substance as per Zone Iva or Zone IVb shall be submitted.	
	3.2.P.2.1	Provide information including type of diluent, its composition, quantity or volume, specifications (as applicable) and regulatory status in Pakistan (as applicable) for the diluent which is to be provided along with the applied drug.	
	3.2.P.2.2	Details of the reference product in CDP shall be submitted. i.e. firm name, batch number, mfg. Date & exp. Date etc.	
	3.2.P.8.3	In use stability studies shall be submitted. Justification shall be submitted that submitted stability data is on solution form of powder form.	
		Justification shall be submitted whether finished Product shall be imported in combo pack or alone in powder form.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Item No. VI: Agenda of Evaluator PEC-XV (Mst. Saima Hussain)

Local manufacturing applications of priority categories defined by Registration Board in its 257th meeting

51.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharma Private Limited, Plot No 62 Quaid e Azam Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s CCL Pharma Private Limited, Plot No 62 Quaid e Azam Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.19741 dated 06/07/2022
	Details of fee submitted	PKR 75,000/-: dated 23/06/2022
	The proposed proprietary name / brand name	Eluxa Tablet 75mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Eluxadoline …….....75mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-propulsive / Mixed mu opioid receptor agonist/delta opioid receptor antagonist Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	5's, 10's, l4's, 20's, 28's, 30's, 50's and 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Viberzi Tablet by M/s Allergan Holdings USA. (USFDA Approved)
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	DML renewal Inspection conducted on 14.09.2020, 15.09.2020 and 21.10.2020. New DML granted on 08.06.2021 with effect from 21.07.2020. Tablet (General), Capsule (General), Oral Liquid, Dry Powder Suspension, Liquid Injectable & Capsule section (Steroid) approved. Ref. letter no. 819 4 /2022-DRAP (Addl.Dire) dated 07.07.2022 The Firm has applied for GMP Inspection. The application is under processes at DRAP Office and inspection will be done as per availability of Area FID. The firm's last GMP status is Compliant / Good.
	Name and address of API manufacturer.	M/s Jiangsu Yongan Pharmaceutical Co., Limited Address: No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China.

	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Eluxadoline is not present in Pharamcopoeia. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH (12 month) Accelerated: 40°C ± 2°C / 75% ± 5%RH (6 month) Batches: (20180101, 20180102, 20180201)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Viberzi tablet 75mg (Batch no. 3180416, EXP date: Sep-22) manufactured by M/s Allergen Holdings, USA by performing quality tests (Identification, Assay, Dissolution etc.) CDP has been performed against the same brand that is Viberzi tablet 75mg manufactured by M/s Allergen Holdings, USA in Acid media & Phosphate Buffer. The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Jiangsu Yongan Pharmaceutical Co., Limited		
API Lot No.	ELD-202107001		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (4×7's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.	T2-22	T3-22	T4-22
Batch Size	1000 Tab	1000 Tab	1000 Tab

Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	01-2022	01-2022	01-2022
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted the list of products previously approved with stability study data.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate of M/s. JIANGSU YONGAN PHARMACEUTICAL Co. Ltd. issued by Huai'an Pharmaceutical Industry Association, valid till 14/01/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Invoice having diary No.12869/2021/DRAP dated 27/08/2021 is submitted wherein the permission to import of API is granted.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings	Response of the Firm
	3.2.S.4.4	Justify for not including the test of particle size (laser diffraction) and steroisomeric purity (Chiral HPLC) in the release specification of drug substance since these tests are included in the specification of drug substance by innovator brand.	As per FDA chemistry review, particle size is not included in the drug substance specification. For purity, Drug substance and Drug product manufacturer have performed Assay by HPLC and Impurites testing for ensuring the quality. However, in the public assessment report of EMA approved innovator brand both of these test are included in the release specification of drug substance. Further, the drug substance used in applied formulation is different from the drug substance of innovator brand as evident from the chemical structure given in section 3.2.S.1.
	3.2.S.4.4	According drug substance documents α polymorphic form of drug substance is supplied by drug substance manufacturer while the review literature of innovator products reveal that Polymorphic form-I is the only non-solvated, crystalline form of the active substance which has been used in the formulation of innovator product, clarification is required either the Form α is similar to	Firm replied that "It is the same form, only notation is different i.e., Form 1 or Form Alpha".

		polymorphic Form-I of eluxadoline.	
	3.2.P.2.2.1	In compliance of notification no. 14-1/2022-PEC dated 16th January,2023 issued by DRAP, submit the image/picture/snapshot of innovator /reference/comparator pack against which Pharmaceutical equivalence/Comparative dissolution profile studies have been performed.	Submitted
	3.2.S.7	Justify for not including water content, stereoisomeric purity in the shelf life specification of the drug substance, since these tests are included in the shelf life specification of drug substance of innovator brand.	Firm replied that The API manufacturer (Vendor) claims that loss on drying test was run to determine the water content, in line with the instructions provided in the drug master file. For purity, Drug substance and Drug product manufacturer have performed Assay by HPLC and Impurites testing for ensuring the quality. Impurities testing mentioned in the stability data is not related to the chiral impurity testing of drug substance.
	3.2.S.7	Provide complete stability data of drug substance performed at both accelerated and long term condition till the claimed re-test date, since you have submitted real time data of only 12 month time period.	Submitted
	3.2.P.8	Justify for not including the test of water content and chiral purity in the shelf life specification of drug product ,since both of these critical test are included in the shelf life specification of innovator product.	As per US-FDA chemistry review, Life cycle management, these tests are not included in the Critical Quality Attributes. However, the tests are the part of shelf life specification of innovator brand as per the review literature.

Indication:
VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
DOSAGE AND ADMINISTRATION
The recommended dosage in adults is 100 mg twice daily taken with food.
The recommended dosage is 75 mg twice daily taken with food in patients
who do not have a gallbladder
are unable to tolerate the 100 mg dose
are receiving concomitant OATP1B1 inhibitors
have mild or moderate hepatic impairment
Discontinue VIBERZI in patients who develop severe constipation for more than 4 days.
If a dose is missed, take the next dose at the regular time; do not take 2 doses at once.

Decision: Deferred for scientific justification for following along with documented evidence:

- **Variation of the chemical structure of the drug substance, as evident from section 3.2.S.1, from that of the innovator.**
- **According drug substance documents α polymorphic form of drug substance is supplied by drug substance manufacturer while the review literature of innovator products reveal that Polymorphic form-I is the only non-solvated, crystalline form of the active substance which has been used in the formulation of innovator product, clarification is required either the Form α is similar to polymorphic Form-I of Eluxadoline.**

52.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharma Private Limited, Plot No 62 Quaid e Azam Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s CCL Pharma Private Limited, Plot No 62 Quaid e Azam Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.19742 dated 06/07/2022
	Details of fee submitted	PKR 75,000/-: vide slip no. 8459056839 dated 23/06/2022
	The proposed proprietary name / brand name	Eluxa Tablet 100mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Eluxadoline …….....100mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Anti-propulsive / Mixed mu opioid receptor agonist/delta opioid receptor antagonist Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	5's, 10's, l4's, 20's, 28's, 30's, 50's and 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Viberzi Tablet by M/s Allergan Holdings USA. (USFDA Approved)
	For generic drugs (me-too status)	NA
	GMP status of the Finished product manufacturer	DML renewal Inspection conducted on 14.09.2020, 15.09.2020 and 21.10.2020. New DML granted on 08.06.2021 with effect from 21.07.2020. Tablet (General), Capsule (General), Oral Liquid, Dry Powder Suspension, Liquid Injectable & Capsule section (Steroid) approved. Ref. letter no. 819 4 /2022-DRAP (Addl.Dire) dated 07.07.2022 The Firm has applied for GMP Inspection. The application is under processes at DRAP Office and inspection will be done as per availability of Area FID. The firm's last GMP status is Compliant / Good.
	Name and address of API manufacturer.	M/s Jiangsu Yongan Pharmaceutical Co., Limited Address: No. 18, 237 Provincial Road, Economic Development Zone, Huaian, Jiangsu, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description

		of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Eluxadoline is not present in any Pharmacopoeias. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH (12 month) Accelerated: 40°C ± 2°C / 75% ± 5%RH (6 month) Batches: (20180101, 20180102, 20180201)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator Viberzi tablet 100mg manufactured by M/s Allergan Holdings, USA (Batch no. 3195885 expiry date: Jan-2024) by performing quality tests (Identification, Assay, Dissolution) CDP has been performed against the same brand that is Viberzi tablet 100mg manufactured by M/s Allergan Holdings, USA in Acid media & Phosphate Buffer. The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Jiangsu Yongan Pharmaceutical Co., Limited		
API Lot No.	ELD-202107001		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (4×7's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12 (Months)		
Batch No.	T2-22	T3-22	T4-22
Batch Size	1000 Tab	1000 Tab	1000 Tab
Manufacturing Date	01-2022	01-2022	01-2022
Date of Initiation	01-2022	01-2022	01-2022

No. of Batches	03	
Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has submitted the list of products previously approved with stability study data.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate of M/s. JIANGSU YONGAN PHARMACEUTICAL Co. Ltd. issued by Huai'an Pharmaceutical Industry Association, valid till 14/01/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Invoice having diary No.12869/2021/DRAP dated 27/08/2021 is submitted wherein the permission to import of API is granted.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

S.no.	Sections	Observations/Deficiencies/ Short-comings	Response of the Firm
	3.2.S.4.4	Justify for not including the test of particle size (laser diffraction) and steroisomeric purity (Chiral HPLC) in the release specification of drug substance since these tests are included in the specification of drug substance by innovator brand.	As per FDA chemistry review, particle size is not included in the drug substance specification. For purity, Drug substance and Drug product manufacturer have performed Assay by HPLC and Impurites testing for ensuring the quality. However, in the public assessment report of EMA approved innovator brand both of these test are included in the release specification of drug substance. Further, the drug substance used in applied formulation is different from the drug substance of innovator brand as evident from the chemical structure given in section 3.2.S.1.
	3.2.S.4.4	According drug substance documents α polymorphic form of drug substance is supplied by drug substance manufacturer while the review literature of innovator products reveal that Polymorphic form-I is the only non-solvated, crystalline form of the active substance which has been used in the formulation of innovator product, clarification is required either the Form α is similar to polymorphic Form-I of eluxadoline.	Firm replied that "It is the same form, only notation is different i.e., Form 1 or Form Alpha".

	3.2.P.2.2.1	In compliance of notification no. 14-1/2022-PEC dated 16th January,2023 issued by DRAP, submit the image/picture/snapshot of innovator /reference/comparator pack against which Pharmaceutical equivalence/Comparative dissolution profile studies have been performed.	Submitted
	3.2.S.7	Justify for not including water content, stereoisomeric purity in the shelf life specification of the drug substance, since these tests are included in the shelf life specification of drug substance of innovator brand.	Firm replied that The API manufacturer (Vendor) claims that loss on drying test was run to determine the water content, in line with the instructions provided in the drug master file. For purity, Drug substance and Drug product manufacturer have performed Assay by HPLC and Impurites testing for ensuring the quality. Impurities testing mentioned in the stability data is not related to the chiral impurity testing of drug substance.
	3.2.S.7	Provide complete stability data of drug substance performed at both accelerated and long term condition till the claimed re-test date, since you have submitted real time data of only 12 month time period.	Submitted
	3.2.P.8	Justify for not including the test of water content and chiral purity in the shelf life specification of drug product ,since both of these critical test are included in the shelf life specification of innovator product.	As per US-FDA chemistry review, Life cycle management, these tests are not included in the Critical Quality Attributes. However, the tests are the part of shelf life specification of innovator brand as per the review literature.

Decision: Deferred for scientific justification for following along with documented evidence:

- **Variation of the chemical structure of the drug substance, as evident from section 3.2.S.1, from that of the innovator.**
- **According to drug substance documents α polymorphic form of drug substance is supplied by drug substance manufacturer while the review literature of innovator products reveal that Polymorphic form-I is the only non-solvated, crystalline form of the active substance which has been used in the formulation of innovator product, clarification is required either the Form α is similar to polymorphic Form-I of Eluxadoline.**

Item No. VII: Agenda of Evaluator PEC- XVII (Mr. Zia Ullah)

Case No.I Registration applications of locally manufactured (Human) drugs submitted on Form 5D (Requiring Stability data)

53.	Name and address of manufacturer / Applicant	M/s Werrick Pharmaceuticals, 216-217, I-10/3, Industrial Area, Islamabad.
	Brand Name +Dosage Form + Strength	LOXAM FLASH Tablets 8mg
	Composition	Each film coated tablet contains: Lornoxicam……8mg
	Diary No. Date of R& I & fee	Dy. No. 16560 dated 07-03-2019, Fee Rs: 20,000/- dated 07-03-2019 vide deposit slip No.1900334 dated 06-03-2019. "Duplicate dossier, R & I verified".
	Pharmacological Group	Non-Steroidal Anti-Inflammatory Drug (NSAID)
	Type of Form	Form 5

	Finished product Specifications	Innovator's specifications
	Pack size & Demanded Price	10's, 20's & 30's, As per SRO
	Approval status of product in Reference Regulator Authorities	Xefo Rapid Tablets 8mg film coated tablets Austria (EMA Approved)
	Me-too status	Xika Rapid Tablets 8mg film coated tablets of Hilton Pharma (Pvt)Ltd. Karachi. Registration No. 061612 (in database, the composition given as Each tablet contains……Lornoxicam….8mg)
	GMP status	GMP certificate issued on 22-08-2022, based on evaluation conducted on 12th August, 2022.
	Remarks of the Evaluator	

STABILITY STUDY DATA			
Manufacturer of API	M/s Pure Chem Pvt. Ltd. Plot # 4717, GIDC Estate, Ankleshwar 393 002 Gujrat, India.		
API Lot No.	LXM 180106P4		
Description of Pack (Container closure system)	Alu-Alu/ Alu-PVC blister packed in uni carton		
Stability Storage Condition	Real time: 30°C ± 2° C / 65% ± 5% RH Accelerated: 40 °C ± 2 °C / 75% ± 5%		
Time Period	Real time: throughout shelf life Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 6 (months) Real Time: 0,3, 6 (months)		
Batch No.	Trial # 01	Trial # 02	Trial # 03
Batch Size	1500 tablets	1500 tablets	1500 tablets
Manufacturing Date	07-2018	07-2018	07-2018
Date of Initiation	10-07-2018	11-07-2018	12-07-2018
No. of Batches	03		
Date of Submission	29-03-2019		

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr. No.	Documents to Be Provided	Status
	Reference of previous approval of applications with stability study data of the firm.	Firm has referred to onsite inspection report of their product "Cell-Tab 400mg (Sofosbuvir) Tablets", which was presented initially in 256th subsequently in 269th &finally in 276th meeting of Registration board. Registration Board decided to approve registration of above stated drug product of M/s. Werrick Pharmaceuticals. According to the report following points were confirmed. ●The firm has 21CFR compliant HPLC software. ●The firm has audit trail reports available.
	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Firm has submitted copy of CoA for Lornoxicam. (Batch# LXM 180106P4) of M/s Pure Chem Pvt. Ltd. Plot # 4717, GIDC Estate, Ankleshwar 393 002 Gujrat, India. 4717, GIDC Estate, Ankleshwar 393 002 Gujrat, India.
	Method used for analysis of API from both API Manufacturer and Finished Product Manufacturer	Only assay method of API from Finished Product Manufacturer submitted.
	Stability study data of API from API manufacturer	Firm has submitted stability study data of API as per zone IV-a. Stability study is conducted at Real time conditions; 30°C ± 2°C / 65% ± 5%RH for 24 months and at Accelerated conditions; 40°C ± 2°C / 75% ± 5%RH for 6 months at intervals 0, 3, 6, 9, 12, 18, 24 & 0, 1, 2, 3 & 6 months respectively.

<table>
<tr><td></td><td></td><td>Batches:(PCPL/LXM/01/B14, PCPL/LXM/02/B14, PCPL/LXM/03/B14)</td></tr>
<tr><td></td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Firm has submitted copy of GMP certificate No. S-GMP/18091018 issued to M/s. Pure Chem Pvt. Ltd. Plot # 4717, G.I.D.C Estate, Ankleshwar 393 002 Gujrat, India. Valid till 23-09-2020.</td></tr>
<tr><td></td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>The firm has submitted copy of invoice No. EXP /100/17-18 dated 28-03-2018 from exporter M/s Pure Chem Pvt. Ltd. India for import of 150gm of Lornoxicam (Batch No. LXM 180106P4) in name of M/s Werrick Pharmaceuticals 216-217, I-10/3, Industrial Area Islamabad, attested by AD (I&E) DRAP Islamabad dated 17-04-2018.</td></tr>
<tr><td></td><td>Protocols followed for conduction of stability study</td><td>Submitted</td></tr>
<tr><td></td><td>Method used for analysis of FPP</td><td>Submitted</td></tr>
<tr><td></td><td>Drug-excipients compatibility studies (where applicable)</td><td>Firm has used same excipients as that of the innovator’s product therefore compatibility studies are not required.
Qualitative composition of applied formulation is same as that of reference product.
Applicant is referring to handbook of Pharmaceutical excipients & stability studies as an evidence of Drug-excipients compatibility.</td></tr>
<tr><td></td><td>Complete batch manufacturing record of three stability batches.</td><td>The firm has submitted Batch Manufacturing record of following 03 Batches:
<table>
<tr><td>Batch No.</td><td>Batch Size</td><td>Mfg. Date</td></tr>
<tr><td>Trial # 01</td><td>1500 tablets</td><td>07-2020</td></tr>
<tr><td>Trial # 02</td><td>1500 tablets</td><td>07-2020</td></tr>
<tr><td>Trial # 03</td><td>1500 tablets</td><td>07-2020</td></tr>
</table></td></tr>
<tr><td></td><td>Record of comparative dissolution data (where applicable)</td><td>Not Submitted</td></tr>
<tr><td></td><td>Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td></td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing.</td><td>Submitted</td></tr>
<tr><td></td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted photocopies of data logger record temperature & humidity for chambers used in Real Time & Accelerated stability studies of applied product from 01-07-2018 to 31-01-2019.</td></tr>
<tr><td colspan="3">REMARKS OF EVALUATOR (PEC-XVII)
<table>
<tr><td>Deficiency/Observation</td><td>Response by Pharma.</td></tr>
<tr><td>Provide valid GMP certificate of API manufacturer.</td><td>Firm has submitted copy of GMP certificate No. 21012385 issued to M/s. Pure Chem Pvt. Ltd. Plot # 4717, G.I.D.C Estate, Ankleshwar 393 002 Gujrat, India. Valid till 03-01-2024.</td></tr>
<tr><td>Justify the dispensing of drug substance for trial batch manufacturing without potency adjustment.</td><td>Firm submitted as:
Results for trial batches ranges from 100.89% - 103.36%, whereas the release limits for finished drug product are 90.0% - 110.0%. as per manufacturer’s specifications.
The firm undertakes that they will adjust the potency of drug substance in formulation of commercial batches before launching of the product.</td></tr>
<tr><td>Submit CoA of API by drug product manufacturer.</td><td>Firm submitted CoA of API Lornoxicam, Batch No. LXM180106P4 by the Drug Product manufacturer.</td></tr>
</table></td></tr>
</table>

Submit complete analytical methods/procedures of API as per specifications from drug substance and drug product manufacturers as only assay method of API by the drug product manufacturer submitted.	Firm submitted analytical methods/procedures of API from the drug product manufacture only. Complete analytical method from drug substance manufacturer has not been submitted.
Submit complete drug product specifications along with analytical methods/procedures as only assay and dissolution methods of finished drug product are submitted.	Submitted
Please justify why Assay determination is by HPLC method while for dissolution UV method employed.	The firm submitted as: UV method for Dissolution Testing as per USP <1092> Subsection 3.4: Analytical Procedure adopted because spectrophotometric determination is faster, analysis is simpler and easier with fewer solvents needed. UV Spectrophotometric dissolution method is validated with all necessary parameters including Specificity, Linearity, Accuracy and Method Precision.
In analytical method validation of FPP, the column specifications given as 150 × 4.6mm, while in finished drug product method, given as 4.6mm × 25cm. The mobile phase ratio given as buffer to methanol as 60:40 in method validation, while in analytical method as 50:50.	The chromatographic conditions mentioned in the submitted method of FPP and method validation are the same. The shortcoming/deficiency mentioned here has misunderstanding between the analytical method of finished product and method of API. The mobile phase ratio (Beffer:Methanol, 50:50) and column 4.6 × 25 cm corresponds to analytical method of API while (Buffer: Methanol, 60:40) and column 150 × 4.6 mm corresponds to FPP. The submitted record was rechecked/re-verified and found to be correct. The firm submission is justified.
Please clarify as to why the content uniformity tests have not been performed for the trial batches.	The firm undertakes that they will perform Content Uniformity Tests before launching of product.
Comparative dissolution studies/profile not submitted.	It is submitted that When the product was applied, no Reference Product was available in Pakistan. Now the Reference Product is available in Pakistan so the firm will perform Comparative Dissolution Profile (CDP) before launching of product. The firm has not mentioned the reference product. Moreover, it needs to be ascertained that the various generic products locally manufactured like Xikafast 8mg (Registration No. 086503) & Xikafast 4mg (Registration No. 086498) of M/s Inventor Pharma, Karachi and Xika Rapid Tablets 8mg film coated tablets (Registration No. 061612) & Xika rapid 4mg film-coated tablet (Registration No. 061611) of Hilton Pharma Karachi have been granted approved as per reference product that is Xefo Rapid Tablets 8mg film coated tablets (Austria) as in reference regulatory authorities only the 8mg strength available as rapid film-coated tablet.
Justify the applied product finished drug product specifications comply innovator's product specifications (dissolution parameters, dissolution limits etc).	Firm submitted as follow: The dissolution method of innovator/reference product is not available in any official pharmacopoeia or reference regulatory authority. The firm has established it dissolution method and parameters as per USP Chapter <1092> THE DISSOLUTION PROCEDURE. Dissolution Medium & Volume: Dose solubility ratio was performed in pH 1.2, 4.5, 6.8 and 7.4 Phosphate

	buffer. Dose solubility ratio was found high in the Phosphate Buffer pH 7.4. USP type II apparatus & agitation: As per USP chapter <1092> Dissolution Limit (Q) and Time (T): As per USP chapter <1092> The drug substances are found to be soluble in physiological buffer pH 7.4 i.e., it shows more than 85% release within specified limit (45 minutes). Furthermore, all the results observed during stability studies are within limits.
Please clarify as to how the applied formulation is different than your Loxam 8mg film-coated tablet, as approved in 297th meeting of Drug Registration Board, in terms of pharmacokinetic profiles and also elaborate the in-vitro tests applied for establishing the said difference.	The ingredients used in Loxam Flash 8mg film-coated tablets are according to innovators brand: Xifo Rapid 8mg and different from Loxam tablet 8mg film-coated tablets. In Loxam Flash tablet, Sodium bicarbonate is used for rapid release. The disintegration time for Loxam Flash tablet 8mg is NMT 3 minutes, while in case of Loxam tablet 8mg it is NMT 30min. Composition of Xefo rapid 8mg film-coated tablet and Xefo 8mg film-coated tablet provided for reference: Xefo rapid 8mg tablet Microcrystalline cellulose, Sodium hydrogen carbonate, Calcium hydrogen phosphate (anhydrous), Low substituted hydroxyl propyl cellulose, Hydroxypropylcellulose, Calcium stearate. Xefo 8mg tablet Lactose monohydrate, microcrystalline cellulose, Povidone K30, Crosscarmellose sodium, Magnesium stearate.
Decision: Deferred for following: • **Evidence of separate market authorizations, by any reference regulatory authority adopted by Registration Board in its 275th meeting, for the Lornoxiam 8mg plain tablet & Lornoxicam rapid tablet along with comparison of their pharmaceutical & pharmacokinetic particulars.** • **Detailed comparison of the pharmaceutical & pharmacokinetic particulars of the applied formulation and previously registered "Weramed 8mg film coated tablet (Reg.#107168)" in name of applicant and also .**	

Item No. VIII: Agenda of Evaluator PEC-XX (Mst. Sana Kanwal)

Following applications have been considered on priority in the light of decision of Registration Board, 257th meeting:

54.	Name, address of Applicant / Marketing Authorization Holder	M/s Horizon Healthcare (Pvt.) Ltd. Plot no. 33 Punjab Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s Horizon Healthcare (Pvt.) Ltd. Plot no. 33 Punjab Industrial Estate Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐Domestic and Export sales
	Dy. No. and date of submission	Dy. No 12205 dated 19-05-2022
	Details of fee submitted	Rs.75,000/- dated 11-05-2022
	The proposed proprietary name / brand name	Imeglu Tablet 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated tablet contains: Imeglimin Hydrochloride.....500mg
	Pharmaceutical form of applied drug	Film coated tablet
	Pharmacotherapeutic Group of (API)	Anti-Diabetic
	Reference to Finished product specifications	As Per Innovator's specification
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Twymeeg Tablet 500mg approved by (PMDA Japan)
	For generic drugs (me-too status)	Not available
	GMP status of the Finished product manufacturer	Last inspection report dated 18.06.2020. certificate issued on 06.07.2020 concluded good level of cGMP compliance. Valid for 2 years Evidence for section approval (Tablet General section) provided dated 07.02.2014
	Name and address of API manufacturer.	AMI Life Sciences Pvt Ltd. Block No.82/B, ECP Road, At & Post: Kararkhadi- Tal- Padra, Dist: Baroda Gujrat India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to structure, general properties, Manufacturers, description of manufacturing process and controls, Characterization, Impurities, Specifications, Analytical procedures, Validation of analytical procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of General information, General properties, Manufacturers, description of manufacturing process and process controls, Characterization, Impurities, Control of drug substance, Reference standard or materials container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Imeglimin HCl: Batch No — Accelerated — Long Term IME/RD/30011221V — 6 Months — 60 Months IME/RD/30021221V — 6 Months — 60 Months IME/RD/30031221V — 6 Months — 60 Months

	Module-III (Drug Product):	The firm has submitted detail of Drug Products including Description and composition of drug product, Pharmaceutical Development, Manufacturing process development, Microbiological attribution, Manufacturer, Master formulations, Description of Manufacturing Process and Process Controls, Control of Critical Steps and Intermediates, Process Validation and/ or Evaluation, Control of Excipients with specification and Analytical methods, Control of Drug Products including Finished product specifications and test methods, validation of Analytical methods, Batch analysis , reference standard, Container closure and stabilities studies.	
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Twymeeg Tablets 500mg by BioPharma (Batch No 1001C) by performing quality tests (Identification, Assay, DT, Hardness, weight variation and Dissolution against test product Imeglimin HCl tablet (Batch No PTIM-001) CDP has been performed against the same brand that is in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.	
	Analytical method validation/verification of product	Method verification studies have submitted including Specificity, Accuracy, Precision, Linearity concentration and peak range.	
STABILITY STUDY DATA			
Manufacturer of API		AMI Life Sciences Pvt Ltd.	
API Lot No.		IME/RD/30051221V	
Description of Pack (Container closure system)		Alu-Alu Blisters with aluminum foil having leaflet and packed in unit carton	
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH	
Time Period		Real time: 3 months Accelerated: 3months	
Frequency		Accelerated: 0, 3 months Real Time: 0, 3 months	
Batch No.		IM-001	IM-002
Batch Size		5000 Tab	5000 Tab
Manufacturing Date		02-2022	02-2022
Date of Initiation		17-02-2022	18-02-2022
No. of Batches		02	
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product: EMPAZON 10mg Tablets, EMPAZON 25mg Tablets (Empagliflozin) Dayzol 30mg Capsules, Dayzol 60mg Capsules (Dexlansoprazole) which was conducted on 1st June, 2021 and was presented in 307th meeting of Registration Board held on 08-10th June , 2021. Registration Board decided to approve registration of EMPAZON 10mg Tablets, EMPAZON 25mg Tablets (Empagliflozin)	

<table>
<tr><td></td><td></td><td>Dayzol 30mg Capsules, Dayzol 60mg Capsules (Dexlansoprazole)</td></tr>
<tr><td></td><td>Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.</td><td>Firm had provided valid DML (No. G/25/1704) of AMI Life Sciences Pvt Ltd. Issued by Food and Drug Control Administration, Gujrat state India
DML Valid upto: 14- 06- 2025</td></tr>
<tr><td></td><td>Documents for the procurement of API with approval from DRAP (in case of import).</td><td>Copy of commercial invoice attested by AD I&E DRAP, Lahore, has been submitted
<table>
<tr><td>Batch No.</td><td>Invoice No.</td><td>Quantity Imported</td><td>Date of approval by DRAP</td></tr>
<tr><td>IME/RD/30051221V</td><td>ALPL/Sample-00251/20-21</td><td>6.00kgs</td><td>18-01-2022 Ref No 885/2022 DRAP</td></tr>
</table></td></tr>
<tr><td></td><td>Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.</td><td>Submitted</td></tr>
<tr><td></td><td>Compliance Record of HPLC software 21CFR & audit trail reports on product testing</td><td>Audit trail reports have been submitted.</td></tr>
<tr><td></td><td>Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)</td><td>Firm has submitted record of Digital data logger for temperature and humidity monitoring of stability chambers.</td></tr>
<tr><td colspan="3">Remarks of Assessor (AD-PECXX):
<table>
<tr><td>Sr.#</td><td>Observation</td><td>Reply</td><td>Remarks</td></tr>
<tr><td>1.</td><td>Data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc to be submitted at 6th month and onward.</td><td>Firm has provided 6th month stability data supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc to</td><td>Complied</td></tr>
</table></td></tr>
<tr><td colspan="3">Discussion & Decision: Registration Board was apprised regarding the CDP results of applied formulation from two different applicants i.e., M/s Horizon Healthcare and M/s NabiQasim Industries wherein conflicting results were reported despite of using same reference product i.e TWYMEEG Tablet 500mg. In the CDP data presented by M/s Horizon Healthcare maximum drug release was reported in phosphate buffer of pH 6.8 while the CDP data of M/s Nabiqasim Industries reported minimum drug release in phosphate buffer of pH 6.8.
On basis of above cited observation Board decided to defer the instant application for justification of the reported results of CDP studies, with reference to the innovator drug product literature.</td></tr>
<tr><td>55.</td><td>Name, address of Applicant / Marketing Authorization Holder</td><td>M/s NABIQASIM INDUSTRIES (PVT) LTD.
17 / 24, Korangi Industrial Area,
Karachi – Pakistan.</td></tr>
<tr><td></td><td>Name, address of Manufacturing site.</td><td>M/s NABIQASIM INDUSTRIES (PVT) LTD.
17 / 24, Korangi Industrial Area,
Karachi – Pakistan.</td></tr>
<tr><td></td><td>Status of the applicant</td><td>☒ Manufacturer
☐ Importer
☐ Is involved in none of the above (contract giver)</td></tr>
</table>

	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 19518 dated 04.07.2022 6th month stability data submitted on 02.09.2022 (Dy No. 24945)
	Details of fee submitted	PKR 75,000/- dated 21/06/2022
	The proposed proprietary name / brand name	MEGLIM Tablets 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet: Imeglimin Hydrochloride…..…500mg
	Pharmaceutical form of applied drug	White color oblong shape film coated tablet one side engraved NQ and other side is plain.
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, Other blood glucose lowering drugs, excl. insulins.
	Reference to Finished product specifications	Innovator's Specs.
	Proposed Pack size	10's, 14's, 20's,28's, 30's, 50's, 56's tablets
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	TWYMEEG Tablet 500mg (Imeglimin Hydrochloride) by Sumitomo Dainippon Pharma Co., Ltd., Japan (Approved by Pharmaceutical and Medical Devices Agency, Japan).
	For generic drugs (me-too status)	Not available in Pakistan
	GMP status of the Finished product manufacturer	GMP Certificate granted on 28/05/2022 based on inspection dated 19.09.2020. Evidence for Section approval is provided dated 27.04.2020. Tablet (General) section is approved.
	Name and address of API manufacturer.	M/s Anhui Haikang Pharmaceutical Co. Ltd. No. 21, Hauncheng West Road Anqing Anhui 246000, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification / validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official Monograph of Imeglimin Hydrochloride is not available hence In-house (Manufacturer's) specifications were adopted. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, tests for related substances (Single impurity, Total impurities), specifications, analytical procedures and its verification,

		batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 9 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (21061501, 21062201, 21062901)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is TWYMEEG Tablet 500mg (Imeglimin Hydrochloride) is being marketed by Sumitomo Dainippon Pharma Co., Ltd., Japan, (Batch No 1004F) by performing quality tests (Description, Identification, Disintegration, Dissolution, Impurities and Assay) against Meglim tablet 500mg (Batch No 538DS01) CDP has been performed against the same brand that is TWYMEEG Tablet 500mg (Imeglimin Hydrochloride) by Sumitomo Dainippon Pharma Co., Ltd., Japan, in Acid media (pH 1.2), Acetate Buffer (pH 4.5) & Phosphate Buffer (6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.

STABILITY STUDY DATA			
Manufacturer of API	M/s Anhui Haikang Pharmaceutical Co. Ltd. No. 21, Hauncheng West Road Anqing Anhui 246000, China		
API Lot No.	21112901		
Description of Pack (Container closure system)	Alu-Alu blister of 10's, 14's, 20's & 28's, 30's, 50's & 56's tablets packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	538DS01	538DS02	538DS03
Batch Size	650 tablets	650 tablets	650 tablets
Manufacturing Date	02-2022	02-2022	02-2022
Date of Initiation	20-02-2022	20-02-2022	20-02-2022
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Submitted.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by Anqing Biomedical Industry Association, China valid till 25/01/2025

	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice no WD202101004 dated 01/12/2021 duly attested by Assistant Director, DRAP, Karachi on 06/12/2021 was provided, confirming import of 2.1Kg Imeglimin HCl . Batch No 21112901
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Assesor (AD-PEC XX):

<table>
<tr><th>Sr.#</th><th>Observation</th><th>Reply</th><th>Remarks</th></tr>
<tr><td>1.</td><td>The proposed specification of Drug Substance includes residue on ignition as per Report on deliberation results of Twymeeg Tablets 500 mg by PMDA, same has not been tested by Drug substance manufacturer. Justify it
API</td><td>Reference to the “Report on deliberation results of Twymeeg Tablets 500mg by PMDA, we have conducted Residue on Ignition Test on retention sample of API and found below results :
<table><tr><th>S.No</th><th>Specifications</th><th>Results</th></tr><tr><td>01</td><td>Residue on ignition (NMT 0.1%)</td><td>0.07%</td></tr></table>
Revise API specifications for QC release having Residue on ignition test is provided</td><td>Complied

Firm has submitted revised analytical testing method and CoA, wherein “Residue on ignition” is tested, by Finished product manufacturer.</td></tr>
<tr><td>2.</td><td>The proposed specification of Drug Product includes uniformity of dosage units (mass variation test) as per Report on deliberation results of Twymeeg Tablets 500 mg by PMDA same has not been tested by finished product manufacturer. Justify it</td><td>We have previously submitted COAs of Imeglimin HCl Tablets 500mg at Initial testing having uniformity of dosage units by mass variation test same enclose in for ready reference.

We also conducted weight variation test as on today basis, results of the same are enclose in Annexure-B.</td><td>Complied

Uniformity of dosage units was performed at initial testing in stability studies , same was mentioned in CoA (NMT 15)</td></tr>
<tr><td>3.</td><td>3% overage is added to compensate water content as</td><td>In formulation of Imeglimin HCl Tablet, there is no bulking agent used for potency adjustment so potency calculation is set on basis of results of water content as Drug substance having</td><td></td></tr>
</table>

		mentioned in batch formula, need further deliberation.	maximum limit of 5% water content , we have set median limit of 3% water content in our batch formula to comply the product assay results on QC release specifications i.e. 95% - 105% of label claim to assure product quality for patient compliance.	

Discussion & Decision: Registration Board was apprised regarding the CDP results of applied formulation from two different applicants i.e., M/s Horizon Healthcare and M/s Nabiqasim Industries wherein conflicting results were reported despite of using same reference product i.e TWYMEEG Tablet 500mg.
In the CDP data presented by M/s Horizon Healthcare maximum drug release was reported in phosphate buffer of pH 6.8 while the CDP data of M/s Nabiqasim Industries reported minimum drug release in phosphate buffer of pH 6.8.
On basis of above cited observation Board decided to defer the instant application for justification of the reported results of CDP studies, with reference to the innovator drug product literature along with scientific justification of using 3%overage of drug substance in the drug product formulation.

Item No. IX: Agenda of Evaluator PEC-II (Mr. Ammar Ashraf Awan)
Case no. 01 Priority consideration of registration applications:
M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan has achieved the benchmark of more than 100,000 USD during the fiscal Year 2019-2020 and requested for priority consideration of following molecules.

56.	Name, address of Applicant / Marketing Authorization Holder	M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Name, address of Manufacturing site.	M/s Focus & Rulz Pharmaceuticals Pvt., Ltd. 44-Indutrial Triangle Kahuta Road Islamabad Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 12514 dated 23-05-2022
	Details of fee submitted	Rs.30,000/- dated 20-05-2022
	The proposed proprietary name / brand name	Ulfam dry Suspension 40mg/5ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains: Famotidine …… 40mg (USP Specifications)
	Pharmaceutical form of applied drug	Before Reconstitution: White to off-white granular powder. After Reconstitution: White colored thick suspension visually free from foreign particles.
	Pharmacotherapeutic Group of (API)	Histamine H2 receptor antagonist
	Reference to Finished product specifications	USP Spec's
	Proposed Pack size	60ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Pepcid 40mg/5ml Dry Suspension by M/s Salix Pharms USA.

	For generic drugs (me-too status)	Famlet 40mg/5ml Dry Suspension By M/s Winlet Pharmaceuticals Pvt., Ltd. Reg. No. 098322
	GMP status of the Finished product manufacturer	GMP inspection report conducted on 29-12-2020 concluding acceptable level of GMP compliance.
	Name and address of API manufacturer.	M/s Rakshit Pharmaceuticals Limited Plot No.68/A, Jawaharlal Nehru Pharma City, Parawada Mandal, Visakhapatnam District, Andhra Pradesh India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Famotidine is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 60 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (FM/08/00/017, FM/08/00/018, FM/08/00/019)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Famlet Dry Suspension 100mg/5ml by Winlet Pharmaceuticals Pvt., Ltd by performing quality tests. As the dissolution of famotidine for oral suspension is not described in USP, hence dissolution comparison was not performed for the product with innovator/ reference product.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
STABILITY STUDY DATA		
Manufacturer of API	M/s Rakshit Pharmaceuticals Limited Plot No.68/A, Jawaharlal Nehru Pharma City, Parawada Mandal, Visakhapatnam District, Andhra Pradesh India.	
API Lot No.	FT/21/025	

Description of Pack (Container closure system)	60ml amber colored glass bottle.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	21GT07	21GT08	21GT09
Batch Size	67 Bottles	67 Bottles	67 Bottles
Manufacturing Date	07-2021	07-2021	07-2021
Date of Initiation	10-08-2021	10-08-2021	10-08-2021
No. of Batches	03		

Administrative Portion

	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. E-1555174/DD/DCA/VSP/2021 issued by DCA Andhra Pradesh valid till 21-11-2022 submitted.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice No. RLP3721E0145, dated 29-09-2021 Famotidine 50 kg imported from Rakshit Pharmaceuticals Limited, attested by AD I&E DRAP dated 20-10-2021 is submitted.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Record of Digital data logger for temperature and humidity monitoring of stability chambers is submitted

Remarks of Evaluator:

Section#	Observation	
1.6.5	Valid GMP certificate of the drug substance manufacturer shall be submitted.	
3.2.S.7	Long term stability studies data of drug substance is not as per Zone IVa conditions.	
3.2.P.1	Details of accompanying reconstitution diluent shall be submitted.	
3.2.P.2.5	Submit data for test for content of antimicrobial preservative & efficacy of preservative, as recommended by ICH Q1 (R2) guidelines & USP chapter <51>.	
3.2.P.2.6	Compatibility studies with reconstitution diluent shall be submitted.	
3.2.P.5.1	Test for content of antimicrobial preservative & efficacy of preservative, as recommended by ICH Q1 (R2) guidelines & USP chapter <51>, has not been included in the finished product specifications. You are advised to submit justification in this regard.	

	Justification shall be submitted for not including test of "Content uniformity" & "Microbial Enumeration Tests" in the drug product specifications as recommended by USP monograph. Elaborate the sample preparation method including procedure of reconstitution in the Assay test method.	
3.2.P.5.4	Submitted drug product COAs & BMRs declare manufacturing date as of July, 2021, whereas the COA of Famotidine from drug substance manufacture mentions its date of manufacture as August 2021, while date of drug substance analysis in the COA from M/s Focus & Rulz declare date of analysis as 10-08-2021. Justification shall be submitted for the manufacturing of drug product stability batches prior to the date of manufacture of drug substance.	
3.2.P.8	Submit justification for not performing tests of content of antimicrobial preservative, efficacy of preservative, "Content uniformity" & "Microbial Enumeration Tests" during stability studies. In-use stability studies of reconstitution diluent have not been submitted.	

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Case no. 02 Registration applications on Form 5F (Human)

57.	Name, address of Applicant / Marketing Authorization Holder	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Name, address of Manufacturing site.	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 93 dated 03-02-2020
	Details of fee submitted	Rs.20,000/- dated 31-01-2020
	The proposed proprietary name / brand name	Nufen 400mg/4ml Infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	"Each ml Contains: Ibuprofen……100mg"
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	NSAID
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	4ml ampoule X 5's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Caldolor 400mg/4ml solution for injection, Seqirus Pty Ltd, Australia.
	For generic drugs (me-too status)	Xaleve Injection, Hudson Pharma

	GMP status	GMP certificate issued on basis of inspection conducted on 28-10-2020.
	Name and address of API manufacturer.	Ibuprofen: M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS –PD template
	Module-III Drug Substance:	Firm has submitted detailed drug substance data f related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability data of 3 batches of API at accelerated (6 months) and real time conditions (36 months) as per Zone IVa.
	Module-III Drug Product:	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence against the Xaleve injection of M/s Hudson Pharma has been submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation data.
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long term conditions

STABILITY STUDY DATA			
Manufacturer of API	M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind.		
API Lot No.	ZIBU19-014		
Description of Pack (Container closure system)	Glass ampoule		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,1, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No	NU-001	NU-002	NU-003
Batch Size	1000 ampoule	1000 ampoule	1000 ampoule
Manufacturing Date	06-2019	06-2019	06-2019

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr.#	Documents To Be Provided	Status
1.	COA of API	Submitted

2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Copy of GMP certificate issued by the Additional director DRAP, Lahore based upon inspection conducted 06-12-2018.
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
5.	Documents confirming import of API etc.	Copy of purchase order and delivery challan from M/s Zenith Chemical industries , Lahore has been submitted.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

58.	Name, address of Applicant / Marketing Authorization Holder	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Name, address of Manufacturing site.	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No 94 dated 03-02-2020
	Details of fee submitted	Rs.20,000/- dated 31-01-2020
	The proposed proprietary name / brand name	Nufen 400mg/100ml Infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	"Each ml Contains: Ibuprofen……4mg"
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	NSAID
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	100ml vial X 1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Ibuprofen B. Braun 400mg/100ml solution for infusion, B. Braun, approved by MHRA of UK.
	For generic drugs (me-too status)	Indrufen Infusion of M/s Indus pharma (Reg.#108826)
	GMP status	GMP certificate issued on basis of inspection conducted on 28-10-2020.
	Name and address of API manufacturer.	Ibuprofen: M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS –PD template

	Module-III Drug Substance:	Firm has submitted detailed drug substance data f related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability data of 3 batches of API at accelerated (6 months) and real time conditions (36 months) as per Zone IVa.
	Module-III Drug Product:	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence against the Inbufin infusion of M/s Searle IV solutions has been submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation data.
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long term conditions

STABILITY STUDY DATA			
Manufacturer of API	M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind.		
API Lot No.	ZIBU19-014		
Description of Pack (Container closure system)	Type II Glass Vial		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,1, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No	NUV-001	NUV-002	NUV-003
Batch Size	90 Vials	90 Vials	90 Vials
Manufacturing Date	06-2019	06-2019	06-2019

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr.#	Documents To Be Provided	Status
1.	COA of API	Submitted
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Copy of GMP certificate issued by the Additional director DRAP, Lahore based upon inspection conducted 06-12-2018.
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes

5.	Documents confirming import of API etc.	Copy of purchase order and delivery challan from M/s Zenith Chemical industries , Lahore has been submitted.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

59.	Name, address of Applicant / Marketing Authorization Holder	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Name, address of Manufacturing site.	"M/s Ameer & Adnan Pharmaceutical Pvt Ltd. Plot No.47, Sundar Industrial Estate, Lahore"
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 95 dated 03-02-2020
	Details of fee submitted	Rs.20,000/- dated 31-01-2020
	The proposed proprietary name / brand name	Nufen 600mg/100ml Infusion
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	"Each ml Contains: Ibuprofen……6mg"
	Pharmaceutical form of applied drug	Injection
	Pharmacotherapeutic Group of (API)	NSAID
	Reference to Finished product specifications	Innovator's specification
	Proposed Pack size	100ml vial X 1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Approved by MHRA of UK
	For generic drugs (me-too status)	Ubrof infusion of M/s Sami Pharmaceuticals (Reg.#105263)
	GMP status	GMP certificate issued on basis of inspection conducted on 28-10-2020.
	Name and address of API manufacturer.	Ibuprofen: M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS –PD template
	Module-III Drug Substance:	Firm has submitted detailed drug substance data f related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability data of 3 batches of API at accelerated (6 months) and real time conditions (36 months) as per Zone IVa.
	Module-III Drug Product:	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence against the Ibuprofen infusion 600mg/100ml of B Braun has been submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation data.
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long term conditions

STABILITY STUDY DATA			
Manufacturer of API	M/s Zenith Chemical Industries (Pvt) Limited Moza Dhonday ,jia Baga Raiwind – Kahna Road Raiwind.		
API Lot No.	ZIBU19-014		
Description of Pack (Container closure system)	Type II Glass Vial		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,1, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No	NUV-001	NUV-002	NUV-003
Batch Size	90 Vials	90 Vials	90 Vials
Manufacturing Date	06-2019	06-2019	06-2019

DOCUMENTS / DATA PROVIDED BY THE APPLICANT		
Sr.#	Documents To Be Provided	Status
1.	COA of API	Submitted
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Copy of GMP certificate issued by the Additional director DRAP, Lahore based upon inspection conducted 06-12-2018.
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
5.	Documents confirming import of API etc.	Copy of purchase order and delivery challan from M/s Zenith Chemical industries , Lahore has been submitted.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

Report on Verification of Authenticity of Stability Data submitted for Registration of Nufen 400mg/4ml, 400mg/100ml & 600mg/100ml injections

Name of Manufacturer	M/s Ameer & Adnan Pharmaceuticals Pvt Limited.
Physical Address	Plot no. 47, Sundar Industrial Estate, Lahore.
Drug Manufacturing License No. and validity	000787 by way of formulation Renewal date: 3-2-2019.
Date of Inspection.	23-11-2022
Purpose of Inspection	Verification of Authenticity of Stability Data for Purpose of Registration of Drugs with reference DRAP's letter No. F.15-1/2022-PEC dated 16-08-2022.
Name of Inspector	Mr. Iftikhar Ch. (Member, Registration Board Ms. Maham Misbah Assistant Director, DRAP, Lahore.
Name of firm Representatives present during the course of inspection	Mr. Adnan CEO. Mr. Hammad (R&D Manager) Mr. Adeel Akram(Production Incharge) Mr. Hafiz Umer Nisar (Quality Control Manager)

Sr. No.	Questions	Observations of the panel
	Do you have documents confirming the import of API including approval from DRAP?	Material was purchased locally from M/s Zenith Chemical Industries (Pvt.) Ltd, Jia Baga, Raiwind Road, Lahore. Pakistan.
	What was the rationale behind selecting the particular manufacturer of API?	The site had been visited and qualified by the firm. GMP certificate of the vendor was also available, as informed by the representative of the firm.
	Do you have documents confirming the import of reference standard and impurity standards?	Reference standards were not available. The firms management informed the panel that they had procured working standards from the vendor. Impurity standards were not available.
	Do you have certificate of Analysis of the API, reference standards and impurity standards?	COAs of API, Working Standards were available.
	Do you have GMP certificate of API manufacturer issued by regulatory authority of country of origin?	Yes
	Do you use API manufacturer method of testing for testing API?	API manufacturer had use phrmacopoeial method and same method used by the firm.
	Do you have stability studies reports on API?	Yes, stability studies reports were provided by the API manufacturer.

	If yes, whether the stability testing has been performed as per SIM method and degradation products have been quantified?	No.
	Do you have method for quantifying the impurities in the API?	Available.
	Do you have some remaining quantities of the API, its reference standard and impurities standards?	Remaining quantities of API and working standard were available.
	Have you used pharmaceutical grade excipients?	L-Arginine (analytical grade) excipient was used, according to documents shown to the panel. NaOH, HCl, Phosphate Buffer were also used as excipients and they were of analytical grade, according to the documents shown to the panel.
	Do you have documents confirming the import of the used excipients?	The firm had used locally purchased excipient.
	Do you have test reports and other records on the excipient used?	CoAs were available.
	Do you have written and authorized protocols for the development of applied product?	Yes
	Have you performed Drug-excipients compatibility studies?	No.
	Have you performed comparative dissolution studies?	Not Applicable
	Do you have product development (R&D) section	Firm did not have R&D section for injectables. Firm had used the commercial production area for manufacturing of product development and stability batches.
	Do you have necessary equipments available in product development section for development of applied product?	Commercial production facility was used.
	Are the equipments in product development section qualified?	Yes
	Do you have proper maintenance / calibration / re-qualification program for the equipment used in PD section?	Available for the equipment used.
	Do you have qualified staff in product development section with proper knowledge and training in product development?	Yes
	Have you manufactured three stability batches for the stability studies of applied product as required?	Yes.
	Do you have any criteria for fixing the batch size of stability batches?	According to the management of the firm, Batch size was developed according to the size of the production equipment and samples required for stability testing.

	Do you have complete record of production of stability batches?	BMRs were available. It was recommended to make them more comprehensive to include step by step procedure.
	Do you have protocols for stability testing of stability batches?	Yes firm had protocols for stability testing of stability batches
	Do you have developed and validated the method for testing of stability batches?	Firm had developed the method and validated it In-house. Validation documents were shown to the panel.
	Do you have method transfer studies in case when the method of testing being used by your firm is given by any other lab?	Not Applicable.
	Do you have documents confirming the qualification of equipments / instruments being used in the test and analysis of API and the finished drug?	Calibration certificates of all testing equipments were available.
	Is your method of analysis stability indicating?	Yes.
	Is your HPLC software is 21CFR compliant? (Details of Model, software, description/version (i.e. software validation report for 21 CFR Part 11 compliance including audit trail, password protection, date & time lock and user authorizations shall also be reported.)	No. Password protected accounts were enabled, date and time lock were available.
	Can you show Audit Trail reports on stability studies testing?	No.
	Do you have some remaining quantities of degradation products and stability batches?	Yes.
	Do you have stability batches kept on stability testing?	None at the time of inspection as the firm had completed real time stability studies for two years.
	Do you have valid calibration status for the equipments used in production and analysis?	Yes.
	Do proper and continuous monitoring and control are available for stability chamber?	Data loggers were placed in the chambers for monitoring. Accelerated Stability Chamber: Company: Binder Capacity: 500L Real Time Stability Chamber: Company: Supico Capacity: 750L
	Do related manufacturing area, equipment, personnel and utilities be rated as GMP compliant?	Firm had GMP compliance certificate issue by DRAP.

Remarks:
In addition to the details given in table above, the panel was also advised to verify the performance of sterility test performed lately on retention batches. According to the documents shown to the panel, the materials and testing facilities available at the premises at the time of inspection and the personnel interviewed, it seemed that the firm had conducted sterility testing on the retention batches.
Submitted for consideration and necessary action, please.

Decision: Registration Board approved the applications of Nufen 600mg/100ml Infusion, Nufen 400mg/100ml Infusion & Nufen 400mg/4ml Infusion

• **Manufacturer will place first three production batches of each strength on long term stability studies throughout proposed shelf life and on accelerated studies for six months.**		
60.	Name, address of Applicant / Marketing Authorization Holder	"M/s High-Q Pharmaceuticals. B-64 KDA-1, Karsaz Road Karachi,"
	Name, address of Manufacturing site.	M/s High-Q Pharmaceuticals. Plot No.224 & 225/1 Sector 23, Korangi Industrial Area, Karachi-Pakistan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 20558 dated 28-07-2021
	Details of fee submitted	PKR 30,000/-: dated 08-06-2021
	The proposed proprietary name / brand name	Ertagsa 5/100 mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: 6.48 mg ertugliflozin L-pyroglutamic acid equivalent to 5 mg of ertugliflozin and 128.5 mg sitagliptin phosphate monohydrate equivalent to 100 mg sitagliptin
	Pharmaceutical form of applied drug	Pink color, oval shaped, biconvex, film coated tablet with bisect line on one side and other side is plain.
	Pharmacotherapeutic Group of (API)	Ertugliflozin: Sodium-glucose co-transporter 2 (SGLT2) inhibitors Sitagliptin: Dipeptidyl peptidase-4 (DPP-4) inhibitors
	Reference to Finished product specifications	Manufacturer's Specification
	Proposed Pack size	10's, 14's, 20's, 28's & 30's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	"Steglujan 5/100mg Tablet" by Merck & Co., inc. Approved by US FDA
	For generic drugs (me-too status)	Ertuvia 5mg + 100mg Tablet by Ferozsons Laboratories Limited
	GMP status of the Finished product manufacturer	New license granted on 21st Dec, 2021 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	SITAGLIPTIN: Manufacturing facility name: Fuxin Long Rui Pharmaceutical CO.,Ltd Manufacturing facility address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China Exporting company name: Beijing Sino Hanson Import & Export Co. Ltd Exporting company Address: No 3, Zhonghe Road, Fengtai District, Beijing China 100070 ERTUGLIFLOZIN-LPGA:

		DMF Holder: Shanghai Pansopharm Technology Co., Ltd. Address:2F, Bldg. 7, 333# East Kangqiao Rd., Pudong, Shanghai, China Manufacturer: Chifeng Arker Pharmaceutical Technology Co., Ltd. Manufacturing Site: No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Ertugliflozin-LPGA & Sitagliptin are not present in any Pharmacopoeia and the firm has followed manufacturer's specification. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Ertugliflozin-LPGA: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 48 months Batches: (D84-161201, D84-161202, D84-170101) Sitagliptin: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH. The real time stability data is conducted at 30oC ± 2oC / 75% ± 5% RH. Batches: For Accelerated studies (M-20190127-D01-M06-06, M-20190316-D02-M06-07, M-20190127-D01-M06-08) For Real time studies (M-20190127-D01-M06-01, M-20181222-D06-M06-08, M-20181222-D06-M06-09)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard,

		container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	CDP studies against the reference product of Steglujan tablets, in three dissolution mediums has been submitted with acceptable level of f2 results (f2 ≥ 50).
	Analytical method validation/verification of product	Firm has submitted analytical method validation data

STABILITY STUDY DATA			
Manufacturer of API	SITAGLIPTIN: Fuxin Long Rui Pharmaceutical CO.,Ltd ERTUGLIFLOZIN-LPGA: DMF Holder: Shanghai Pansopharm Technology Co., Ltd. Manufacturer:Chifeng Arker Pharmaceutical Technology Co., Ltd.		
API Lot No.	Sitagliptin phosphate monohydrate: M-20191228-D07-M06-04 Ertugliflozin-LPGA: D84-191001		
Description of Pack (Container closure system)	Alu-Alu blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0,1,2,3 & 6 (Months) Real Time: 0, 3 & 6 (Months)		
Batch No.	5ESPD01/20	5ESPD02/20	5ESPD03/20
Batch Size	2500 tab	2500 tab	2500 tab
Manufacturing Date	04-2020	04-2020	04-2020
Date of Initiation	09-04-2020	09-04-2020	09-04-2020
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Attached
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Ertugliflozin-LPGA: Copy of GMP certificate issued by CFDA in the name of M/s Chifeng Arker Pharmaceutical Technology Co., Ltd., China provided Sitagliptin phosphate monohydrate: Copy of GMP Certificate issued by the CFDA in the name of M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Liaoning Province, China. valid upto May/25/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice attested by AD I&E DRAP, Karachi, has been submitted. Sitagliptin phosphate monohydrate: Batch No. / Invoice No. / Quantity Imported. / Date of approval by DRAP M-20191228-D07-M06-04 / MR200219-H / 200Kg / 26-02-2020 Ertugliflozin-LPGA:

		Batch No.	Invoice No.	Quantity Imported.	Date of approval by DRAP
		Not Available	PSPW-191025	1Kg	12-11-2019
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted			
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted			
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes			
	Name, address of Applicant / Marketing Authorization Holder	"M/s High-Q Pharmaceuticals. B-64 KDA-1, Karsaz Road Karachi,"			
	Name, address of Manufacturing site.	M/s High-Q Pharmaceuticals. Plot No.224 & 225/1 Sector 23, Korangi Industrial Area, Karachi-Pakistan			
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)			
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)			
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales			
	Dy. No. and date of submission	Dy.No 20559 dated 28-07-2021			
	Details of fee submitted	PKR 30,000/-: dated 08-06-2021			
	The proposed proprietary name / brand name	Ertagsa 15/100 mg Tablet			
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: 19.43mg Ertugliflozin L-pyroglutamic acid equivalent to 15 mg of Ertugliflozin and 128.5 mg Sitagliptin phosphate monohydrate equivalent to 100 mg Sitagliptin			
	Pharmaceutical form of applied drug	Brown colored, oval shaped, biconvex, film coated tablet with bisect line on one side and plain on other side			
	Pharmacotherapeutic Group of (API)	Ertugliflozin: Sodium-glucose co-transporter 2 (SGLT2) inhibitors Sitagliptin: Dipeptidyl peptidase-4 (DPP-4) inhibitors			
	Reference to Finished product specifications	Manufacturer's Specification			
	Proposed Pack size	10's, 14's, 20's, 28's & 30's			
	Proposed unit price	As per SRO			
	The status in reference regulatory authorities	"Steglujan 15/100mg Tablet" by Merck & Co., inc. Approved by US FDA			
	For generic drugs (me-too status)	Ertuvia 15mg + 100mg Tablet by Ferozsons Laboratories Limited			

	GMP status of the Finished product manufacturer	New license granted on 21st Dec, 2021 Tablet (General & General Antibiotic) section approved.
	Name and address of API manufacturer.	SITAGLIPTIN: Manufacturing facility name: Fuxin Long Rui Pharmaceutical CO.,Ltd Manufacturing facility address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China Exporting company name: Beijing Sino Hanson Import & Export Co. Ltd Exporting company Address: No 3, Zhonghe Road, Fengtai District, Beijing China 100070 ERTUGLIFLOZIN-LPGA: DMF Holder: Shanghai Pansopharm Technology Co., Ltd. Address:2F, Bldg. 7, 333# East Kangqiao Rd., Pudong, Shanghai, China Manufacturer: Chifeng Arker Pharmaceutical Technology Co., Ltd. Manufacturing Site: No. 8 Mysun Street, Hongshan Economic Development Zone, Chifeng, Inner Mongolia, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Ertugliflozin-LPGA & Sitagliptin are not present in any Pharmacopoeia and the firm has followed manufacturer's specification. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Ertugliflozin-LPGA: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 48 months. Batches: (D84-161201, D84-161202, D84-170101) Sitagliptin: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH. The real time stability data is conducted at 30oC ± 2oC / 75% ± 5% RH.

		Batches: For Accelerated studies (M-20190127-D01-M06-06, M-20190316-D02-M06-07, M-20190127-D01-M06-08) For Real time studies (M-20190127-D01-M06-01, M-20181222-D06-M06-08, M-20181222-D06-M06-09)		
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	CDP studies against the reference product of Steglujan tablets, in three dissolution mediums has been submitted with acceptable level of f2 results (f2 ≥ 50).		
	Analytical method validation/verification of product.	Firm has submitted analytical method validation data		
STABILITY STUDY DATA				
Manufacturer of API	SITAGLIPTIN: Fuxin Long Rui Pharmaceutical CO.,Ltd ERTUGLIFLOZIN-LPGA: DMF Holder: Shanghai Pansopharm Technology Co., Ltd. Manufacturer:Chifeng Arker Pharmaceutical Technology Co., Ltd.			
API Lot No.	Sitagliptin phosphate monohydrate: M-20191228-D07-M06-04 Ertugliflozin-LPGA: D84-191001			
Description of Pack (Container closure system)	Alu-Alu blister			
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH			
Time Period	Real time: 6 months Accelerated: 6 months			
Frequency	Accelerated: 0,1,2,3 & 6 (Months) Real Time: 0, 3 & 6 (Months)			
Batch No.	1ESPD01/20	1ESPD02/20	1ESPD03/20	
Batch Size	2380 Tablets	2380 Tablets	2380 Tablets	
Manufacturing Date	04-2020	04-2020	04-2020	
Date of Initiation	09-04-2020	09-04-2020	09-04-2020	
No. of Batches	03			
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	Attached		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Ertugliflozin-LPGA: Copy of GMP certificate issued by CFDA in the name of M/s Chifeng Arker Pharmaceutical Technology Co., Ltd., China provided		

		Sitagliptin phosphate monohydrate: Copy of GMP Certificate issued by the CFDA in the name of M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Liaoning Province, China. valid upto May/25/2024.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice attested by AD I&E DRAP, Karachi, has been submitted. Sitagliptin phosphate monohydrate: Batch No. | Invoice No. | Quantity Imported. | Date of approval by DRAP M-20191228-D07-M06-04 | MR200219-H | 200Kg | 26-02-2020 Ertugliflozin-LPGA: Batch No. | Invoice No. | Quantity Imported. | Date of approval by DRAP Not Available | PSPW-191025 | 1Kg | 12-11-2019
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes

Remarks of EvaluatorII:

Sr.#	Section#	Observation	Firm's response
	1.6.5	Valid GMP certificate of the manufacturer of Ertugliflozin L-PGA shall be submitted.	Submitted from Changzhou Pharmaceutical Profession Association wghich is not relevant regulatory authority.
Ertugliflozin L-Pyroglutamic acid			
	3.2.S.4	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Pro duct manufacturer is required. Submitted specifications and analytical procedure by drug substance manufacturer describes the test for content of "Ertugliflozin L-pyroglutamic acid, whereas the Innovator's product literature recommends test of "Ertugliflozin potency" in the drug substance specifications. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision)	Submitted. As per the manufacturer: Ertugliflozin potency = Ertugliflozin LPGA Assay - LPGA content. So, they have shown only two test results of them on the COA, instead of all three, because the third outcome can be calculated out. Analytical method verification report has been submitted. As per submitted analytical record various chromatograms have been analysed with retention time of 20 minutes whereas analytical procedure recommends gradient run time of 45 minutes. Submitted. Firm has submitted Revised CoA with Ertugliflozin content is submitted.

		performed by the Drug Product manufacturer shall be submitted. Analytical record i.e., Raw data sheet, FTIR spectrum, chromatograms etc., shall be submitted for the analysis of 'Ertugliflozin L-pyroglutamic Acid' performed by M/s High-Q Pharmaceuticals. COA from drug substance manufacturer does not declare the "Ertugliflozin potency" as recommended by the innovator product. COA from of drug substance from drug product manufacturer does not include test of L-Pyroglutamic acid content.	Revised CoA of material with test of L-pyroglutamic acid content is submitted. The test for L-PGA was performed after the submission, considering that theoretical factor calculated using molecular weights can serve the purpose for small size trial batches. This test has now been performed on the retention sample of API and included in the specification for routine testing of API for commercial batches of the product
	3.2. S.5	COA of reference standard of L-Pyroglutamic acid shall be submitted. Submitted COAs of reference standard of Ertugliflozin L-PGA does not mention any manufacturing date, validity date & batch no. Submitted COA of reference standard does not declare the content of L-pyroglutamic acid.	CoA of Reference standard of L-pyroglutamic acid is submitted. Updated CoA of Reference standard with L-pyroglutamic acid content is attached. Batch number: B34-191001 Mfg Date: Oct 26, 2019 Retest Date: Oct 25, 2021
	3.2. S.7	Justification shall be submitted for not performing test of L-PGA content throughout the stability studies.	Firm has submitted declaration from drug substance manufacturer: On the stability data of Ertugliflozin L-PGA, L-PGA content is only shown in month 0 and month 24, because L-PGA is very stable, and doesn't degrade within 3-4 years, so we tested it every two years in the stability studies initially. If customer insist to have L-PGA content data in each column, then we'll add the test results from next stability batch.
Sitagliptin phosphate monohydrate			
	3.2.S.4	Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required. Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted. Analytical record i.e., Raw data sheet, FTIR spectrum, chromatograms etc., shall be submitted performed by M/s High-Q Pharmaceuticals. Provide Certificate of Analysis (CoA) of relevant batch(es) of Drug Substance performed by Drug substance manufacturer used during	Firm has submitted specifications, analytical procedure, analytical method verification report, analytical record for Drug substance analysis and COAs.

	product development and stability studies.	
3.2.S.5	Submitted COA of working standard declares the expire date as 24-07-2018, whereas the drug substance analysis has been performed subsequent to this date.	Revised COA of working standard has been submitted with expiry date of 14-02-2023.
3.2.S.7	Long term stability studies have been submitted for 6 months only.	Long term stability data as per Zone IVa conditions has been submitted for 24 months.
3.2.P.1	Excipients used in the proposed formulation are different form that used by the Innovator. Justification shall be submitted in this regard. Clarification shall be submitted regarding composition of "Quick tab" used in the formulation.	Firm has referred to drug excipient compatibility study as justification. Quick Tab is a pre-mix used as Binder, filler and disintegrant.
3.2.P.3.5	Sampling plan of compression stage, presented in the submitted process validation protocol, does not include test of content uniformity. Justification shall be submitted in this regard.	Revised Process validation protocol submitted.
3.2. P.5.1	Drug substance specifications have been submitted instead of the drug product specifications. Dissolution parameters of apparatus (paddle instead of basket), dissolution medium (0.1N HCl instead of pH 4.5acetate buffer) & dissolution volume (1000ml instead of 900ml), proposed in analytical procedure, are different from that recommended by the US FDA in the innovator's product literature review. Justifications shall be submitted in this regard. You have applied Paddle speed = 100 rpm in dissolution parameters. You are advised to justify the speed of paddle apparatus with reference to USP general chapter <1092> (The Dissolution Procedure; Development and Validation). Submitted analytical procedure does not include test of content uniformity.	Firm has submitted drug product specifications. There was a typo error; the actual paddle speed is 50 rpm as mentioned in Comparative Dissolution Profile documents (Biowaiver Studies Protocol), already submitted. The testing was done following that procedure. The medium (0.1N HCI pH 1.2) was selected as both ertugliflozin and sitagliptin meet the requirements of BCS Class I drug due to high solubility across physiological pH range and high permeability. Ertugliflozin / sitagliptin tablets display rapid in vitro dissolution characteristics over the pH range of 1.2 — 6.8. The control methods of Ertagsa 5mg/100 mg & Ertagsa 15 mg/100 mg have been corrected to show Paddle speed as 50 rpm and Dissolution volume as 500 ml. The analysis of commercial batches shall be carried out according to the revised methods for Ertagsa 5mg/100mg & 10mg/10mg Tablets. The actual testing of trial batches were carried out with 1000 ml dissolution volume instead of 500 ml but since both the APIs are high solubility and the Tablets have low disintegration time, therefore, it can be assumed that dissolution results would not be significantly impacted. Dissolution medium and volume in revised drug product method is still not as per US FDA.
3.2. P.5.4	Test of content uniformity by way of Assay has not been performed during batch analysis.	Firm has submitted performance on the retention samples of all the three trial batches for content uniformity. The CoAs along with related chromatograms and work sheets

3.2. P.6	Dates of standardization of working standard of Sitagliptin & Ertugliflozin are April & August 2020, whereas the product analysis has also been performed prior to these dates. Clarification shall be submitted regarding reference standards applied for the analysis of product samples, performed prior to the date of standardization of working standards. Submitted COA of working standard of Ertugliflozin-LPGA does not declare the content of LPGA and also the potency in terms of Ertugliflozin has not been determined.	Sitagliptin USP, batch no. M-20191228-D07-M06-04, was received with expiry date as 14/02/2023. Same was standardized on 16/03/2020 against USP Reference Standard (Lot # R07630) and declared as working standard since the results were comparable with the RS. The re-standardization date given was 15/03/2021. Same lot was again tested on 27/07/2020 due to malfunctioning of the refrigerator, in which reference and working standards are stored, and since no change in potency and water contents observed therefore its re-standardization date revised accordingly as 26/07/2021 with no change in potency. In the documents submitted, the revised CoA was attached, by mistake. Ertugliflozin, batch no. D-84-191001, was received on 29/10/2019. Same was standardized on 17/01/2020 against Working Standard (B34-191001) supplied by the manufacturer. This lot was also qualified as Working Standard with re-standardization date as 16/01/2021. Same lot was again tested on 17/08/2020 due to consumption of entire quantity of working standard retained. A fresh sample was taken from the available material of batch no. D-84-191001 and standardized with re-standardization date as 16/08/2021 with no change in potency. In the documents submitted, the revised CoA was attached, by mistake. Reviewed COA of working standard has been submitted.
3.2. P.8	Submitted commercial invoice for Sitagliptin phosphate monohydrate does not reveal the name of manufacturer, hence Form 3 & 7 shall be submitted. Justification shall be submitted for applying the theoretical factor of LPGA, instead of applying the actual potency of Ertugliflozin in working standard. You are advised to justify the quantity of "Ertugliflozin-LPGA" dispensed for formulation of each trial, with reference to the %age content of	Firm has submitted Form 3 & Form 7 for the imported batch of Sitaglitpin form M/s Fuxin Long Rui., China. Theoretical factor was used as the actual contents of L-pyroglutamic acid were not determined at that time. The API has been retested (on 15/02/2022) in order to determine the potencies of Ertugliflozin L-PGA, Ertugliflozin and L-PGA separately to see the impact on quantity of Ertuglifolzin L-PGA used in trial batches. The difference between the theoretical and actual L-PGA contents as declared in the CoA from the supplier, is not that much that could significantly impact the quantity of Ertugliflozin L-PGA dispensed for small size trial batches. In commercial batches the quantity of Ertugliflozin L-PGA per batch shall be calculated on the basis of actual %age of L-PGA content in the API According to the data of potency determined in COA of Ertugliflozin-LPGA, the difference between quantity dispensed and the actual quantity that should have been dispensed, is nominal, however in

	"Ertugliflozin" in the drug substance of "Ertugliflozin-LPGA".	commercial batches the quantity of Ertugliflozin L-PGA per batch shall be calculated on the basis of actual %age of L-PGA content in the API in order to achieve the desired label claim of Ertugliflozin.

Decision of 320th meeting: Registration Board deliberated that the selected dissolution parameters for the applied products including apparatus, dissolution medium, volume etc. are different from the parameters described in the literature review of the product approved by US FDA. Therefore, the Board decided to defer the applications for Ertagsa 15/100 mg Tablet & Ertagsa 5/100 mg Tablet for submission of stability studies data of two batches of each strength at accelerated and long term conditions for initial and 1 month time point, wherein dissolution tests shall be performed as per the dissolution parameters recommended by US FDA in the literature review of innovator drug product i.e., Steglujan tablet.

Firm's response: Firm has submitted data for two new batches of each strength wherein Dissolution test has been performed as per recommendations of US FDA for innovator product.

	Batch No.	Batch size	Date of Mfg.	Duration of study
Ertagsa 5/100 mg Tablet	5ESPD04/22	2500 tablets	09-2022	0 & 1st month (Both accelerated and Long term conditions)
	5ESPD05/22	2500 tablets	09-2022	0 & 1st month (Both accelerated and Long term conditions)
Ertagsa 15/100 mg Tablet	1ESPD05/22	2380 tablets	10-2022	0 & 1st month (Both accelerated and Long term conditions)
	1ESPD04/22	2380 tablets	10-2022	0 & 1st month (Both accelerated and Long term conditions)

Decision of 324th meeting: Registration Board approved the applications of Ertagsa 15/100 mg Tablet & Ertagsa 5/100 mg Tablet with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for each strength for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

F.

61.	Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Ltd. Plot No. 29-30, Sector 30, Korangi Industrial Area, Islamabad.
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt) Ltd. Plot No. 29-30, Sector 30, Korangi Industrial Area, Islamabad.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the drug product manufacturer	Firm has submitted copy of GMP certificate dated 30-10-2019
	Evidence of approval of manufacturing facility	Firm has submitted copy of GMP certificate dated 30-10-2019 which specifies Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales

	Dy. No. and date of submission	Dy. No. 29986 dated 3/11/2021
	Details of fee submitted	PKR 30,000/-: vide deposit slip# 6117667857
	The proposed proprietary name / brand name	NILAP 20mg/ml solution for Infusion and oral solution
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1 ml ampoule contains; Caffeine Citrate 20 mg equivalent to Caffeine ……10mg
	Pharmaceutical form of applied drug	A clear colourless liquid, free from turbidity and foreign matter; filled in sterilized USP Type-1 ampoule.
	Pharmacotherapeutic Group of (API)	Anti-Hypertensive
	Reference to Finished product specifications	USP
	Proposed Pack size	1 ml x 1s, 1ml x 10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Peyona 20 mg/mL solution for infusion and oral solution (MHRA approved).
	For generic drugs (me-too status)	PEYONA SOLUTION FOR INFUSION. VIA ENRICO FERMI 1, 65020 ALANNO (PE), ITALY.
	Name and address of API manufacturer.	Hebei Guangxiang Pharmaceutical Co, Limited , Cangzhou City, Hebei Province, China by China Food and Drug Administration.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 6 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the comparator i.e. Peyona 20mg/ml solution for infusion and oral solution
	Analytical method validation/verification of product	Firm has submitted report of verification studies of analytical method of drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	Zhejiang Haisen Pharmaceutical Co Ltd. Liushi Street, Dongyang city, Zhejiang Province China.		
API Lot No.	B012006006		
Description of Pack (Container closure system)	1 ml Type 1 Glass Ampoule		
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	549DS01	549DS02	549DS03
Batch Size	2500 Ampoule	2500 Ampoule	2500 Ampoule
Manufacturing Date	03-09-2020	03-09-2020	03-09-2020
Date of Initiation	21-10-2020	21-10-2020	21-10-2020
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product for Mirab (Mirabegron) Extended Release Tablets 25mg & 50mg on 12th December 2017. Further, the said panel inspection report was discussed in 277th Drug Registration Board meeting held on 27th – 29th December 2017. The case was approved and the inspection report confirms following points: The HPLC software is 21CFR Compliant as per record available with the firm. Audit trail on the testing reports is available. Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP Certificate No. HE20190094 issued to manufacturer Hebei Guangxiang Pharmaceutical Co, Limited , Cangzhou City, Hebei Province, China by China Food and Drug Administration
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice specifying import of 075 Kg Caffine Anhydrous . The invoice was signed by AD (I&E) DRAP field office Karachi dated 13-08-2020.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted audit trail record of product testing of HPLC.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC:

Query Items	Getz Pharma Response
Submit label claim as per innovator product declaring the equivalent content of Caffeine citrate in terms of the base per unit ml.	Below is the label claim as per innovator product declaring the equivalent content of Caffeine citrate in terms of the base per unit ml. Each 1ml ampoule contains: Caffeine Citrate… 20mg (equivalent to 10mg Caffeine) Please refer to Annexure-1 for the SmPC of innovator product for label claim.
Submit microbial reports for the sterility testing of drug product during stability studies.	We would like to inform you that we have performed Bacterial Endotoxin Test, Sterility Test and Particulate Matter Test at the time of Release in line with ICH Q6 requirements which shows that NILAP is sterile. As per ICH Q1A, stability studies should include testing of those attributes that are susceptible to change during storage and are likely to influence quality, safety and/or efficacy. Since aforementioned tests can be affected by any breach in container closure system, therefore, we have replaced said tests with container closure integrity test during stability studies. Further, this is in line with US-FDA Guidelines "Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products" which states in VI. IMPLEMENTATION as follows: A container and closure system integrity test may replace sterility testing in a stability program at time points other than the product sterility test prior to release Container and closure system integrity tests do not replace sterility testing methods for product sterility testing prior to release. Please refer to Annexure-2 for reports of Bacterial Endotoxin Test, Sterility Test, Particulate Matter Test conducted at batch release and Container Closure Integrity Test at initial stability study interval.
USP monograph of "Caffeine citrate injection" mandates use of Theophylline in the standard solution for Assay test, whereas submitted drug product test method form M/s Getz does not include any such details. Justification shall be submitted in this regard.	This is to bring to your kind attention that in USP monograph of "Caffeine Citrate Injection" Theophylline is used only for resolution purpose between Theophylline and Caffeine and not for the calculation purpose. As per USP Theophylline is categorized as dangerous goods, therefore, we are unable to procure it. Further, in USP monograph RRT (relative retention time) of Theophylline is given which is 0.70, consequently Theophylline can easily be identified & reported through its relative retention time (RRT). In sample solution, peak of Theophylline is observed but it is below the reporting threshold (i.e. less than 0.05%) while the resolution between Theophylline (observed at RRT 0.73) and Caffeine is 7.05 (Greater than 6) which fulfills the requirement of USP resolution criteria.

	Please refer to Annexure-3 for sample chromatogram on enhanced scale showing resolution of 7.05 between Theophylline and Caffeine.
It is evident from the submitted analytical record for stability studies that standard solution preparation & system suitability parameter for Assay test has not been performed as per the recommendations of USP monograph of "Caffeine citrate Injection".	Please refer to above point for system suitability parameter justification.

Decision in 322nd meeting :

Registration Board deferred for clarification of following points:

• USP monograph of "Caffeine citrate injection" mandates use of Theophylline in the standard solution for Assay test, whereas submitted drug product test method from M/s Getz does not include any such details.

• Non-performance of sterility testing at the start and end of stability studies.

• Submitted Pharmacological group of applied formulation as "Anti-hypertensive".

Reply of the firm:

Query Items	Getz Pharma Response
USP monograph of "Caffeine citrate injection" mandates use of Theophylline in the standard solution for Assay test, whereas submitted drug product test method from M/s Getz does not include any such details.	This is to bring to your kind attention that in USP monograph of "Caffeine Citrate Injection" Theophylline is used only for resolution purpose between Theophylline and Caffeine and not for the calculation purpose. As per USP Theophylline is categorized as dangerous goods, therefore, we are unable to procure it. Further, in USP monograph RRT (relative retention time) of Theophylline is given which is 0.70, consequently Theophylline can easily be identified & reported through its relative retention time (RRT). In sample solution, peak of Theophylline is observed but it is below the reporting threshold (i.e. less than 0.05%) while the resolution between Theophylline (observed at RRT 0.73) and Caffeine is 7.05 (Greater than 6) which fulfills the requirement of USP resolution criteria. Please refer to Annexure-1 for sample chromatogram on enhanced scale showing resolution of 7.05 between Theophylline and Caffeine.
Non-performance of sterility testing at the start and end of stability studies.	We would like to inform you that we have performed Bacterial Endotoxin Test, Sterility Test and Particulate Matter Test at the time of Release in line with ICH Q6 requirements which shows that NILAP is sterile. As per ICH Q1A, stability studies should include testing of those attributes that are susceptible to change during storage and are likely to influence quality, safety and/or efficacy. Since aforementioned tests can be affected by any breach in container closure system, therefore, we have replaced said tests with container closure integrity test during stability studies. Further, this is in line with US-FDA Guidelines "Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products" which states in VI. IMPLEMENTATION as follows: A container and closure system integrity test may replace sterility testing in a stability program at time points other than the product sterility test prior to release

	Container and closure system integrity tests do not replace sterility testing methods for product sterility testing prior to release. Please refer to Annexure-2 for reports of Bacterial Endotoxin Test, Sterility Test, Particulate Matter Test conducted at batch release and Container Closure Integrity Test at initial stability study interval.
Submitted Pharmacological group of applied formulation as "Anti-hypertensive".	This is to inform you that Pharmacological group of applied formulation is Xanthine Derivatives.

Decision of 324th meeting: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in pharmacological group as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case no. 03Registration applications submitted along with stability studies data

62.	Name and address of manufacturer / Applicant	M/s PharmEvo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi
	Brand Name +Dosage Form + Strength	Lina 5mg Tablet
	Composition	Each film coated tablet contains: Linagliptin ……. 5mg
	Diary No. Date of R& I & fee	Dy. No.406 09-04-2014 Rs. 50,000/
	Pharmacological Group	Dipeptidyl peptidase-4 (DPP-4) inhibitors (Anti-diabetic)
	Type of Form	Form-5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	Rs. 80/- per tablet, Rs. 800/- for 10's Rs. 1,120/- for 14's Rs. 2,400/- for 30's
	Approval status of product in Reference Regulatory Authorities	TRADJENTA TABLET by M/s BOEHRINGER INGELHEIM, USFDA Approved.
	Me-too status (with strength and dosage form)	Linvesta 5 mg tablets by M/s, Wilshire Laboratories (Pvt.) Ltd.
	GMP status	GMP inspection conducted on 22-June-2022, GMP certificate grant on 22-August 2022. Tablet (General) section approved.
	Remarks of the Evaluator :	
	Now the firm has submitted stability data detailed as under:	
STABILITY STUDY DATA		
Drug		LINA 5MG TABLET
Name of Manufacturer		M/s Pharmevo Private Limited., Plot # A-29, North Western Industrial Zone, Port Qasim, Karachi.
Manufacturer of API		M/s Beijing Huikang Boyuan Chemical Tech Co., Ltd., China.
API Lot No.		160108
Description of Pack (Container closure system)		Alu-Alu Blister
Stability Storage Condition		Accelerated: 40°C ± 2°C & 75±5%RH Real Time: 30°C ± 2°C & 75±5%RH
Time Period		Accelerated: 26 Weeks Real Time: 26 Weeks
Frequency		Accelerated: 0,1,2,3,4,6,8,10,12,14,16,18,20,22,24 (Week)

	Real Time:0,1,2,3,4,6 (Month)		
Batch No.	16PD-1824-01-T	16PD-1825-02-T	16PD-1825-03-T
Batch Size	2,500 Tablets	2,500 Tablets	2,500 Tablets
Manufacturing Date	May 2016	May 2016	May 2016
Date of Initiation	May 2016	May 2016	May 2016
No. of Batches	03		
Date of Submission	20-03-2017 (Dy. No. 775)		

Sr. No.	Documents To Be Provided	Status
	COA of API	Yes
	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Copy of GMP Certificate is provided.
	Protocols followed for conduction of stability study and details of tests.	Yes
	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
	Documents confirming import of API etc.	Copy of License to Import API (Linagliptin) issued by ADC (Karachi) is provided.
	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
	Commitment to continue real time stability study till assigned shelf life of the product.	Yes
	Commitment to follow Drug Specification Rules, 1978.	Yes

Remarks of Evaluator:
The firm has provided 6 Months Accelerated and 6 Months Real Time Stability Data for 03 batches.
The acceptance criteria for Avg. weight mentioned in stability data sheets is 130mg + 5% whereas the minimum result at any time point obtained for weight of tablet is 302.57mg per tablet.
Appearance of tablet is mentioned as:
a. Light pink colored square shaped film coated tablet having bisect line on one side and plain on other side.
b. Light Green Colored round biconvex shaped coated tablet plain from both sides.
c. Blue colored round shaped coated tablet plain from both sides.
Significant Change (6.12%) in assay results was obtained between Initial time point (101.99%) and 24th week (95.87%) for accelerated studies conducted at Batch No. 16PD-1825-02-T.
Significant Change (5.52%) in assay results was obtained between Initial time point (101.35%) and 24th week (95.83%) for accelerated studies conducted at Batch No. 16PD-1825-03-T.
Acceptance criterion for thickness is mentioned as 3.10mm – 3.60mm whereas the minimum result at any time point obtained for thickness of tablet is 4.46mm.
Description of tablet is provided in Stability Data Sheets rather than the description of container closure system.
Firm has claimed Mfg. Specs. Supporting documents in the light of 267th RB Meeting should be provided for Finished Product Specifications.

REQUEST OF EXEMPTION FROM ON SITE INSPECTION

Upon communication of above observations firm has submitted stability studies data of 3 new trial batches with revised source of drug substance as per checklist approved in 293rd meeting of Registration Board for exemption from onsite inspection report.

STABILITY STUDY DATA

Manufacturer of API	M/s Jiangsu Yongan Pharmaceutical Co., Ltd., l8, 237 Provincial Road, Economic Development Zone, Huai'an, Jiangsu,China.
API Lot No.	7700-20200501
Description of Pack (Container closure system)	Alu-Alu Blister
Stability Storage Condition	Real time: 30°C ± 2° C / 75% ± 5% RH Accelerated: 40°C ± 2°C / 75% ± 5% RH
Time Period	Real time: 6 months Accelerated: 6 months

Frequency		Accelerated: 0,1,2,3,4,6,8,10,12,14,16,18,20,22,24 (Week) Real Time:0,1,2,3,4,6 (Month)		
Batch No.		20PD-3418-04-T	20PD-3419-05-T	20PD-3420-06-T
Batch Size		2500 tab	2500 tab	2500 tab
Manufacturing Date		10-2020	10-2020	10-2020
Date of Initiation		11-2020	11-2020	11-2020
No. of Batches		03		
Date of Submission		06-08-2021		
Documents To Be Provided		Status		
1	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their product Erli Plus XR Tablet 5/1000mg, 10/1000mg, 12.5/1000mg & 25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05th December, 2019 and were presented in 293rd meeting of Registration Board held on 6th -8th Jan, 2020. According to the report following points were confirmed. Firm has 21 CFR compliant HPLC software. Firm has audit trail reports available. Firm possesses stability chambers with digital data loggers.		
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Copy of COA of Linagliptin: (Batch# 7700-20200501) from M/s. Jiangsu Yongan Pharmaceutical Co. Ltd. & M/s PharmEvo (private) Limited is submitted.		
3	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Method of analysis for drug substance has been submitted from both drug substance and drug product manufacturer.		
4	Stability study data of API from API manufacturer	Submitted as per following conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20180201, 20180202, and 20180301)		
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of Drug Manufacturing License no. Su 20160324 issued by Jiangsu Drug Administration valid till 06-12-2025.		
6	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of commercial invoice No. ZY20060101G/W attested by AD I&E, DRAP dated 10-6-2020 for import of 500gm of Linagliptin along with license to Import drug from M/s Jiangsu Yongan Pharmaceutical Co., Ltd		
7	Protocols followed for conduction of stability study	Submitted		
8	Method used for analysis of FPP	Submitted.		
9	Drug-excipients compatibility studies (where applicable)	Same excipients used as used by innovator.		
10	Complete batch manufacturing record of three stability batches.	The firm has submitted copy of Trial batch manufacturing record. Details are as under: Batch no. — Batch Size — Mfg. date 20PD-3418-04-T — 2500 — 11-2020 20PD-3419-05-T — 2500 — 11-2020 20PD-3420-06-T — 2500 — 11-2020		
11	Record of comparative dissolution data (where applicable)	Firm has submitted Comparative dissolution study of their product with innovator product “TRADJENTA TABLET” The details are as follows: Feature — Reference Product — Product of PharmEvo Brand Name — TRADJENTA TABLET — LINA 5MG TABLET Batch No. — AB0294A — 20PD-3418-04-T Comparative dissolution studies have been performed in following mediums: 1. pH 1.2 HCl buffer		

		2. pH 4.5 Acetate buffer 3. pH 6.8 Phosphate buffer f2 factor not calculated since more than 85% dissolution achieved within 15 minutes in all time mediums.
12	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record including chromatograms, raw data sheets and COAs.
13	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Submitted
14	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted
Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP . • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**		

Case no. 04 PIC/S approval priority as per 157th meeting of Authority.

Authority in its 157th meeting held on 20th January, 2022 decided as under:

"For pharmaceutical manufcaturers who acquire GMP certification from any PIC/S member country, the Authority as an incentive approved the out of queue consideration of registration of 05 molecules, on CTD per calendar year during the valididty of the PIC/S country's issues GMP certificate to boost the pharmaceutical exports."

Accordingly following applications are presented for consideration of Board:

63.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 18751 dated 28/06/2022
	Details of fee submitted	PKR 30,000/-: dated 24/06/2022
	The proposed proprietary name / brand name	Gliflo-Met 12.5/500mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…….12.5mg Metformin HCl……...500mg
	Pharmaceutical form of applied drug	Immediate release Film coated tablet
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes (Combination of oral blood glucose lowering drugs)
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	As per SRO

	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Synjardy (12.5/500mg, 12.5/1000mg, 5/1000mg, 5/500mg) tablet, USFDA Approved.
	For generic drugs (me-too status)	Empagen 12.5/500 tablet by M/s Ferozsons.
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 29/2021-DRAP(FID-2065251-174) issued on the basis of inspection conducted on 26/03/2021. Tablet General Sectin
	Name and address of API manufacturer.	Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards container closure system and stability studies of drug substances.
	Stability studies	Empagliflozin: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20160301, 20160302, 20160303) Metformin HCl: 48 months real time stability studies conducted at 30°C ± 2°C / 65% ± 5%RH of 03 batches. 06 months accelerated stability studies conducted at 40°C ± 2°C / 75% ± 5%RH of 03 batches Batches: A-71411106004, A-71411106005, A-71411106006
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution profile is submitted against the reference product in all the three media that is

		0.1N HCl, Phosphate buffer and acetate buffer. Pharmaceutical Equivalence is established against the same product. Reference product: Synjardy 12.5/500mg tablet Bacth no.: C84684 Mfg by: Boehringer Ingelheim	
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity etc for drug substance and drug product is submitted.	
STABILITY STUDY DATA			
Manufacturer of API		Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.	
API Lot No.		Metformin: A-81411906039 Empagliflozin: 20060201	
Description of Pack (Container closure system)		Alu-Alu blister strips pack packed in unit carton with leaf insert	
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH	
Time Period		Real time: 6 months Accelerated: 6 months	
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)	
Batch No.		TDA-004	TDA-003
Batch Size		5000 tablets	5000 tablets
Manufacturing Date		10-2021	10-2021
Date of Initiation		30-10-2021	28-10-2021
No. of Batches		02	
Administrative Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)	Strength of 5/500mg of the same formulation was approved in 322nd meeting.	
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of drug manufacturing license no. 20190399 valid till 31/12/2025 is submitted. Metformin HCl: Copy of GMP certificate No. SD20190888 valid till 12/03/2024 is submitted by the applicant.	
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of attested invoice No. IND-19-0404, dy. No. 14544/2019DRAP dated 11-11-2019. Metformin HCl: Copy of attested invoice no. 419FK07Z057 dy. No. 11177/2019DRAP dated 22-08-2019.	
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted	

	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks oF Evaluator:

Sr. no.	Observations	Response
1	The official monograph of Metformin HCl (drug substance) is present in USP-43 wherein the HPLC method of analysis for assay of active has been described, whereas you have used titration method for the analysis. Therefore, a clarification is required for not performing the analysis by HPLC method or otherwise submit the said performance using HPLC method for analysis of Metformin drug substance.	The firm has stated that B.P monograph have been adopted for the said testing which is titration method by drug product manufacturer as well as by the drug substance manufacturer.
2	The test for specificity parameter of analytical method validation studies for drug product is performed by taking placebo solution while it should have been performed by spiking, please clarify.	We have done stressed studies using following conditions. Acid-Base Hydrolysis, oxidation and heat treatment If impurity or degradation product standards are not available, specificity testing may be demonstrated by comparing the test results of samples containing impurities or degradation products to a second well characterised procedure. This should include samples stored under relevant stress conditions that is light, heat, humidity, acid/base hydrolysis, oxidation (ICH Q1R2).
3	Provide the quantities (with rational) used for the preparation of 70%, 80%, 100%, 120% etc dilutions of sample solution for testing the accuracy/linearity parameters of validation studies for drug product.	

Empagliflozin (Linearity):

Concentration (%)	Concentration (ppm)
70	3.5
80	4
90	4.5
100	5
110	5.5
120	6
130	6.5

Metformin (Linearity):

Concentration (%)	Concentration (ppm)
70	700
80	800
90	900
100	1000
110	1100
120	1200
130	1300

Accuracy:

Concentration (%)	Concentration (mg) Empagliflozin	Concentration (mg) Metformin
80	4mg	800
100	5mg	1000
120	6mg	1200

*Each sample concentration was dissolved in 100mL of solvent.

4	Provide batch manufacturing record for the applied product.	Submitted.

Decision: Approved. • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		
64.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 18959 dated 29/06/2022
	Details of fee submitted	PKR 30,000/-: dated 10/03/2022
	The proposed proprietary name / brand name	Gliflo-Met 5/1000mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…….5mg Metformin HCl……...1000mg
	Pharmaceutical form of applied drug	Immediate release Film coated tablet
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes (Combination of oral blood glucose lowering drugs)
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Synjardy (12.5/500mg, 12.5/1000mg, 5/1000mg, 5/500mg) tablet, USFDA Approved.
	For generic drugs (me-too status)	Empator-M 5/1000mg by M/s MartinDow.
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 29/2021-DRAP(FID-2065251-174) issued on the basis of inspection conducted on 26/03/2021. Tablet General Sectin
	Name and address of API manufacturer.	Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form,

		manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards container closure system and stability studies of drug substances.
	Stability studies	Empagliflozin: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20160301, 20160302, 20160303) Metformin HCl: 48 months real time stability studies conducted at 30°C ± 2°C / 65% ± 5%RH of 03 batches. 06 months accelerated stability studies conducted at 40°C ± 2°C / 75% ± 5%RH of 03 batches Batches: A-71411106004, A-71411106005, A-71411106006
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution profile is submitted against the reference product in all the three media that is 0.1N HCl, Phosphate buffer and acetate buffer. Pharmaceutical Equivalence is established against the same product. Reference product: Synjardy 5/1000mg tablet Bacth no.: C43117 Mfg by: Boehringer Ingelheim
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity etc for drug substance and drug product is submitted.

STABILITY STUDY DATA	
Manufacturer of API	Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.
API Lot No.	20190703 Metformin: A-81411906039 Empagliflozin: 20060201
Description of Pack (Container closure system)	Alu-Alu blister strips pack packed in unit carton with leaf insert
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months

Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TDB-002	TDA-003	TDA-004
Batch Size	2500 tablets	2500 tablets	2500 tablets
Manufacturing Date	03-2021	04-2021	04-2021
Date of Initiation	29-04-2021	07-05-2021	07-05-2021
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Strength of 5/500mg of the same formulation was approved in 322nd meeting.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of drug manufacturing license no. 20190399 valid till 31/12/2025 is submitted. Metformin HCl: Copy of GMP certificate No. SD20190888 valid till 12/03/2024 is submitted by the applicant.
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of attested invoice No. IND-19-0404, dy. No. 14544/2019DRAP dated 11-11-2019. Metformin HCl: Copy of attested invoice no. 419FK07Z057 dy. No. 11177/2019DRAP dated 22-08-2019.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks oF Evaluator:

Sr. no.	Observations	Response
1	The official monograph of Metformin HCl (drug substance) is present in USP-43 wherein the HPLC method of analysis for assay of active has been described, whereas you have used titration method for the analysis. Therefore, a clarification is required for not performing the analysis by HPLC method or otherwise submit the said performance using HPLC method for analysis of Metformin drug substance.	The firm has stated that B.P monograph have been adopted for the said testing which is titration method by drug product manufacturer as well as by the drug substance manufacturer.
2	The test for specificity parameter of analytical method validation studies for drug product is performed by taking placebo solution while it should have been performed by spiking, please clarify.	We have done stressed studies using following conditions. Acid-Base Hydrolysis, oxidation and heat treatment If impurity or degradation product standards are not available, specificity testing may be demonstrated by comparing the test results of samples containing

<table>
<tr><td></td><td></td><td>impurities or degradation products to a second well characterised procedure. This should include samples stored under relevant stress conditions that is light, heat, humidity, acid/base hydrolysis, oxidation (ICH Q1R2).</td></tr>
<tr><td>3</td><td colspan="2">Provide the quantities (with rational) used for the preparation of 70%, 80%, 100%, 120% etc dilutions of sample solution for testing the accuracy/linearity parameters of validation studies for drug product.
Empagliflozin (Linearity):
<table>
<tr><th>Concentration (%)</th><th>Concentration (ppm)</th></tr>
<tr><td>70</td><td>3.5</td></tr>
<tr><td>80</td><td>4</td></tr>
<tr><td>90</td><td>4.5</td></tr>
<tr><td>100</td><td>5</td></tr>
<tr><td>110</td><td>5.5</td></tr>
<tr><td>120</td><td>6</td></tr>
<tr><td>130</td><td>6.5</td></tr>
</table>
Metformin (Linearity):
<table>
<tr><th>Concentration (%)</th><th>Concentration (ppm)</th></tr>
<tr><td>70</td><td>700</td></tr>
<tr><td>80</td><td>800</td></tr>
<tr><td>90</td><td>900</td></tr>
<tr><td>100</td><td>1000</td></tr>
<tr><td>110</td><td>1100</td></tr>
<tr><td>120</td><td>1200</td></tr>
<tr><td>130</td><td>1300</td></tr>
</table>
Accuracy:
<table>
<tr><th>Concentration (%)</th><th>Concentration (mg) Empagliflozin</th><th>Concentration (mg) Metformin</th></tr>
<tr><td>80</td><td>4mg</td><td>800</td></tr>
<tr><td>100</td><td>5mg</td><td>1000</td></tr>
<tr><td>120</td><td>6mg</td><td>1200</td></tr>
</table>
*Each sample concentration was dissolved in 100mL of solvent.</td></tr>
<tr><td>4</td><td>Provide batch manufacturing record for the applied product.</td><td>Submitted.</td></tr>
</table>

Decision: Approved with innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in pharmacological group as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

65.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Name, address of Manufacturing site.	M/s Dynatis Pakistan (Pvt.) Ltd. Plot No. 710, Sunder Industrial Estate, Lahore
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)

	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 18752 dated 28/06/2022
	Details of fee submitted	PKR 30,000/-: dated 24/06/2022
	The proposed proprietary name / brand name	Gliflo-Met 12.5/1000mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin…….12.5mg Metformin HCl……...1000mg
	Pharmaceutical form of applied drug	Immediate release Film coated tablet
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes (Combination of oral blood glucose lowering drugs)
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Synjardy (12.5/500mg, 12.5/1000mg, 5/1000mg, 5/500mg) tablet, USFDA Approved.
	For generic drugs (me-too status)	Xengu-Met 12.5/1000mg by Hilton Pharma.
	GMP status of the Finished product manufacturer	Copy of GMP certificate No. 29/2021-DRAP(FID-2065251-174) issued on the basis of inspection conducted on 26/03/2021. Tablet General Sectin
	Name and address of API manufacturer.	Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its complete validation studies, batch analysis and justification of specification, details of reference standards container closure system and stability studies of drug substances.
	Stability studies	Empagliflozin: Real time: 30°C ± 2°C / 65% ± 5%RH for 36 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (20160301, 20160302, 20160303) Metformin HCl:

		48 months real time stability studies conducted at 30°C ± 2°C / 65% ± 5%RH of 03 batches. 06 months accelerated stability studies conducted at 40°C ± 2°C / 75% ± 5%RH of 03 batches Batches: A-71411106004, A-71411106005, A-71411106006
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its validation studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Comparative dissolution profile is submitted against the reference product in all the three media that is 0.1N HCl, Phosphate buffer and acetate buffer. Pharmaceutical Equivalence is established against the same product. Reference product: Synjardy 12.5/1000mg tablet Bacth no.: C80105 Mfg by: Boehringer Ingelheim
	Analytical method validation/verification of product	Method validation / verification studies have submitted including accuracy/recovery, precision, specificity etc for drug substance and drug product is submitted.

STABILITY STUDY DATA			
Manufacturer of API	Empagliflozin: M/s Anhui Haikang Pharmaceutical Co., Ltd., No. 21 Huancheng west road, Anqing city, Anhui Province, 246000 China Metformin HCl: M/s Shouguang Fukang Pharmaceutical Co., Ltd., North East of Dongwaihuan road, Dongcheng Industrial Area, Shouguang city, Shandong Province, China.		
API Lot No.	Metformin: A-81411906039 Empagliflozin: 20060201		
Description of Pack (Container closure system)	Alu-Alu blister strips pack packed in unit carton with leaf insert		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	TDC-003	TDC-004	
Batch Size	5000 tablets	5000 tablets	
Manufacturing Date	11-2021	11-2021	
Date of Initiation	13-11-2021	13-11-2021	
No. of Batches	02		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	Strength of 5/500mg of the same formulation was approved in 322nd meeting.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of drug manufacturing license no. 20190399 valid till 31/12/2025 is submitted.

		Metformin HCl: Copy of GMP certificate No. SD20190888 valid till 12/03/2024 is submitted by the applicant.
	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Copy of attested invoice No. IND-19-0404, dy. No. 14544/2019DRAP dated 11-11-2019. Metformin HCl: Copy of attested invoice no. 419FK07Z057 dy. No. 11177/2019DRAP dated 22-08-2019.
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr. no.	Observations	Response
1	The official monograph of Metformin HCl (drug substance) is present in USP-43 wherein the HPLC method of analysis for assay of active has been described, whereas you have used titration method for the analysis. Therefore, a clarification is required for not performing the analysis by HPLC method or otherwise submit the said performance using HPLC method for analysis of Metformin drug substance.	The firm has stated that B.P monograph have been adopted for the said testing which is titration method by drug product manufacturer as well as by the drug substance manufacturer.
2	The test for specificity parameter of analytical method validation studies for drug product is performed by taking placebo solution while it should have been performed by spiking, please clarify.	We have done stressed studies using following conditions. Acid-Base Hydrolysis, oxidation and heat treatment If impurity or degradation product standards are not available, specificity testing may be demonstrated by comparing the test results of samples containing impurities or degradation products to a second well characterised procedure. This should include samples stored under relevant stress conditions that is light, heat, humidity, acid/base hydrolysis, oxidation (ICH Q1R2).
3	Provide the quantities (with rational) used for the preparation of 70%, 80%, 100%, 120% etc dilutions of sample solution for testing the accuracy/linearity parameters of validation studies for drug product. Empagliflozin (Linearity): Concentration (%) — Concentration (ppm) 70 — 3.5 80 — 4 90 — 4.5 100 — 5 110 — 5.5 120 — 6 130 — 6.5 Metformin (Linearity): Concentration (%) — Concentration (ppm) 70 — 700 80 — 800	

	90 900 100 1000 110 1100 120 1200 130 1300 Accuracy: Concentration (%) Concentration (mg) Empagliflozin Concentration (mg) Metformin 80 4mg 800 100 5mg 1000 120 6mg 1200 *Each sample concentration was dissolved in 100mL of solvent.	
4	Provide batch manufacturing record for the applied product.	Submitted.

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in pharmacological group as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Case no. 05 Registration Applications of Import drug products:
Priority applications as per 257th meeting of RB

66.	Name, address of Applicant / Importer	M/s The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd. Kalalwala Stop, 20Km Lahore- Jaranwala Road, District Sheikhupura, Pakistan.
	Details of Drug Sale License of importer	License No: 05-354-0076-059245D Address: Kalalwala Stop, 20Km Lahore- Jaranwala Road, District Sheikhupura, Pakistan. Validity: 25-09-2022 Status: License to sell drugs as distributor Renewal: Firm has submitted a receipt of renewal but it does not contain any date
	Name and address of marketing authorization holder (abroad)	M/s BDR Pharmaceuticals International Pvt. Ltd R.S.No. 578, Near Effluent Channel Road, Village: Luna, Ta: Padra, Dist : Vadodara– 391 440, (India).
	Name, address of manufacturer(s)	M/s BDR Pharmaceuticals International Pvt. Ltd R.S.No. 578, Near Effluent Channel Road, Village: Luna, Ta: Padra, Dist : Vadodara– 391 440, (India).
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized CoPP certificate (No. 022105) valid till 07-11-2019 issued by Food & Drugs Control Administration, Gujarat, India. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection every year.
	Details of letter of authorization / sole agency agreement	Firm has submitted letter of authorization certificate from M/s BDR Pharmaceuticals International Pvt. Ltd
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)

		☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 17603 dated 16-06-2022
	Details of fee submitted	PKR 75,000/- dated 13-04-2022
	The proposed proprietary name / brand name	Arbit Tablets USP 500mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet Contains: Abiraterone acetate …… 500mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Other hormone antagonists and related agents
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	ZYTIGA 500 mg Janssen-Cilag International NV USFDA Approved.
	For generic drugs (me-too status)	--
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	BDR Life Sciences Private Limited R.S.NO.578, Near Effluent, Channel Road, Village Luna – 391 440, Ta.Padra, Dist. VADODARA, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of

		drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence studies against the innovator product of Zytiga tablet 250mg while CDP studies have bene performed in three dissolution mediums of pH 1.2, 4.5 & 6.8 against the Zytiga 500mg tablet.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product as per USP monograph.
	Container closure system of the drug product	HDPE Container
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 40oC ±2oC / 75% ± 5% RH for 6 months. The real time stability study data is conducted at 30oC ±2oC / 75% ± 5% RH for 36 months.

Remarks of Evaluator:

Section#	Observation
1.1	Fee for registration has been submitted from header of DML instead of DSL. Submit valid copy of DSL.
1.3	Submit original legalized valid COPP since the submitted COPP was expired at the time of submission of registration application. Submit evidence of approval for the required manufacturing facility "Tablet (steroid)" for the applied formulation.
3.2.P.2.2.1	Submit justification for performing Pharmaceutical equivalence studies against the Zytiga 250mg tablet while the applied strength is 500mg.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Deferred cases:

67.	Name, address of Applicant / Marketing Authorization Holder	M/s Martin Dow Marker Limited, 7-Jail Road, Quetta	
	Name, address of Manufacturing site.	M/s Martin Dow Marker Limited, F-126, S. I. T. E., Karachi, Pakistan	
	Status of the applicant	☐Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver)	
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales	
	Dy. No. and date of submission	Dy.No 25930 dated 17/09/2021	
	Details of fee submitted	PKR 50,000/-: PKR 25,000/-:	dated 04/05/2020 dated 30/06/2021
	The proposed proprietary name / brand name	ADVITA 20,000 IU CAPSULES	

	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Soft gel Capsule contains: Cholecalciferol…...20,000 IU
	Pharmaceutical form of applied drug	Clear light-yellow oily liquid
	Pharmacotherapeutic Group of (API)	Vitamin D analogs
	Reference to Finished product specifications	USP
	Proposed Pack size	As per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Fultium 20,0000 IU Capsule by M/s Internis Pharmaceuticals Limited, MHRA Approved.
	For generic drugs (me-too status)	
	GMP status of the Finished product manufacturer	Certificate No: F.14-1/DRAP/GMP/MDM-2022 issued on 03rd Feb 2022 Soft Gelatin Capsule (General) Dispensing, Mixing, Drying, Granulation, Compression, Coating, Blistering & Packaging.
	Name and address of API manufacturer.	M/s DSM Nutritional Product, France
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 25°C ± 2°C / 60% RH ± 5% RH for 24 months Accelerated: 30°C ± 2°C / 65% RH ± 5% RH for 6 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure, verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that Fultium 20,0000 IU Capsule by M/s Internis Pharmaceuticals Limited. Since Vitamin D3 capsules are Fat soluble in nature so the dissolution in not recommended by any Pharmacopoeia & FDA dissolution guideline.

	Analytical method validation/verification of product	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY STUDY DATA				
Manufacturer of API		M/s DSM Nutritional Product, France		
API Lot No.		11F01901004		
Description of Pack (Container closure system)		Aluminum foil with PVC/PVDC blister (2×7's)		
Stability Storage Condition		Real time: 25°C ± 2°C / 60% ± 5%RH Accelerated: 30°C ± 2°C / 65% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		TR-007/20	TR-008/20	TR-009/20
Batch Size		10000 capsule	10000 capsule	10000 capsule
Manufacturing Date		02-2020	02-2020	02-2020
Date of Initiation		02-2022	02-2022	02-2022
No. of Batches		03		
Administrative Portion				
	Reference of previous approval of applications with stability study data of the firm (if any)	Acidex 60mg Capsule Dexlansoprazole was approved in 312th Registration Board meeting. Compliance Record of HPLC software 21CFR & audit trail reports on product testing were present		
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP Certificate No 18MPP077HFR02 issued by EUDRA . Period of validity is extended to 26.09.2023 in case of cholecalciferol .		
	Documents for the procurement of API with approval from DRAP (in case of import).	M/s DSM Nutritional Product, France ADC Invoice No: 2831239200, 29-08-2019		
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted record of testing of batches along with chromatograms, raw data sheets, COA and summary data sheets		
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted compliance record of HPLC software 21 CFR and copies of audit trail on testing of drug product.		
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.		
Remarks OF Evaluator:				
Decision of 320th meeting: Deferred for following points: Clarification of conditions of stability studies of drug substance and drug product. Justification why comparative dissolution profile studies are not performed against the innovator drug product.				
Firm's response: Cholecalciferol is sensitive & not stable when exposed to high temperature condtion so in the light of above condition stability performed at 25oC +2oC/60% RH +5%RH. SmPc of innovator product "Fultium-D3 20,000IU capsules" clearly instructed to store the product below 25oC.				

As Choleclaciferol is present in USP and its nature is fat soluble. Therefore, its dissolution is not recommended in any Pharmacopoeia as well as FDA dissolution guideline. While complete comparative analysis & Pharmaceutical equivalence with innovator has already been submitted with initial dossier.

Decision of 323rd meeting: Deferred for following:
Scientific justification for performing drug product stability studies on storage conditons different from that required by ICH/WHO guidelines for Zone IVA.
Submission of reference from pharmacopoeia/ innovator drug product literature regarding non-performance of dissolution test for applied formulation.

Firm's response:

S. No	Observation	Reply
1.	Scientific justification for performing drug product stability studies on storage conditions different from that required by ICH/WHO guidelines for Zone IVA.	Cholecalciferol (Vitamin D3) is a sensitive vitamin & not stable when exposed to high temperature conditions so in the light of above condition stability performed at 25°C ± 2°C / 60% RH ± 5% RH. Leaflet (enclosed) of innovator product "Fultium 20,000 IU Capsule" clearly instructed to store the product below 25°C.
2.	Submission of reference from pharmacopoeia/ innovator drug product literature regarding nonperformance of dissolution test for applied formulation.	Cholecalciferol (Vitamin D3) is present in USP pharmacopeia & its nature is fat soluble. Therefore, its dissolution is not recommended in any pharmacopeia as well as FDA dissolution guideline. USP Monograph of Cholecalciferol Capsule attached for reference. While complete comparative analysis and pharmaceutical equivalence with innovator has been done and already submitted with initial dossier.

Decision: Deferred for submission of following:

- **Justification of not performing stability studies as per Zone-IV A conditions since the MHRA Public Assessment Report of the innovator product i.e., Fultium –D3 20,000 IU capsule recommends storage condition as "Do no store above 30oC".**
- **Justification on the basis of analytical record and stability studies that at what time point the product is unstable when stored at Zone IVA conditions for stability studies.**

Item No. X: Agenda of Evaluator PEC-III (Dr. Muhammad Haseeb Tariq)
PICs Approval Priority as per 157th meeting of authority

68.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt) Ltd Plot No. 710, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt) Ltd 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement dated 14-11-2022
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s CCL Pharmaceuticals issued on the basis of inspection dated 30-04-2019. Firm has also submitted a copy of letter from Additional Director DRAP Lahore dated 07-07-2022 that the firm has applied for GMP inspection and the application is under process and will be done as per availability of FID. The firm's last GMP status if compliant / Good.

	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of Drug Manufacturing License (No. 000052) dated 08-06-2021 specifying Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 33639: 22-11-2022
	Details of fee submitted	PKR 75,000/-: 10-11-2022
	The proposed proprietary name / brand name	DAPAZIN MET XR 5mg/500mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dapagliflozin propanediol monohydrate eq to Dapagliflozin…….5mg Metformin HCl……500mg
	Pharmaceutical form of applied drug	Film coated double layer tablet
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering drugs
	Reference to Finished product specifications	As per innovator's product
	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's and 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	Xiga-Met XR Tablet of CCL
	Name and address of API manufacturer.	Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Dapagliflozin: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 24 months. Metformin HCl: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 72 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Innovator's product Xigduo Tablet XR 5/5000mg. Firm has submitted Comparative Dissolution Profile studies against Innovator's product Xigduo Tablet XR 5/5000mg.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.		
API Lot No.	Dapagliflozin: DG-20190727-D02-DG06-03 Metformin HCl: MT10890619		
Description of Pack (Container closure system)	Alu-Alu Blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 3, 6 (Months) Accelerated: 0, 3, 6 (Months)		
Batch No.	XMA T2-19	XMA T3-19	XMA T4-19
Batch Size	5000 Tablet	5000 Tablet	5000 Tablet
Manufacturing Date	11-2019	12-2019	12-2019
Date of Initiation	01-2020	01-2020	01-2020

No. of Batches	03	
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to their previous PSI inspection conducted for the product Dexlan DR Capsule 30 and 60mg conducted on 26-08-2019 which was considered by Registration Board in its 294th meeting. The Board approved the case and following things were noted in the inspection report: HPLC used in the stability studies of current products was gradient and not 21CFR 11 compliant. The audit trail was not active on the testing reports and log of data was available in the HPLCs. The data was also confirmed through record, chromatograms and logbooks.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Dapagliflozin: Firm has submitted copy of DML of the firm (No. Liao 20150233) issued by NMPA China. The certificate is valid till 17-11-2027. The certificate is verified from official database of NMPA China. Metformin HCl: Firm has submitted copy of License Retention Certificate (No. 2683/Stores/2018) of the firm issued by Drugs Control Administration Government of Andhra Pradesh dated 25-07-2018. The certificate is valid till 28-07-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Dapagliflozin: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 15-11-2019 specifying import 8 Kg Dapagliflozin propanediol monohydrate (batch# DG-20190727-D02-DG06-03). Metformin HCl: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 22-07-2019 specifying import of 12000 Kg Metformin HCl (Batch number MT10890619).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted by the firm
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

The applied product to be manufactured by M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore have already been approved by Registration Board (as a stability / exemption data case) in its 308th meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 308th meeting are as follows:

Applicant firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore
Manufacturer firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore

	Brand Name	Xiga-Met 5/500 XR Tablet
	Registration Board meeting	308th meeting of Registration Board

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

69.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt) Ltd Plot No. 710, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt) Ltd 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement dated 14-11-2022
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s CCL Pharmaceuticals issued on the basis of inspection dated 30-04-2019. Firm has also submitted a copy of letter from Additional Director DRAP Lahore dated 07-07-2022 that the firm has applied for GMP inspection and the application is under process and will be done as per availability of FID. The firm's last GMP status if compliant / Good.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of Drug Manufacturing License (No. 000052) dated 08-06-2021 specifying Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 33640: 22-11-2022
	Details of fee submitted	PKR 75,000/-: 10-11-2022
	The proposed proprietary name / brand name	DAPAZIN MET XR 5mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dapagliflozin propanediol monohydrate eq to Dapagliflozin…….5mg Metformin HCl……1000mg
	Pharmaceutical form of applied drug	Film coated double layer tablet
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering drugs
	Reference to Finished product specifications	As per innovator's product
	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's and 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved

	For generic drugs (me-too status)	Xiga-Met XR Tablet of CCL
	Name and address of API manufacturer.	Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Dapagliflozin: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 24 months. Metformin HCl: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 72 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Innovator's product Xigduo Tablet XR 5/5000mg.

		Firm has submitted Comparative Dissolution Profile studies against Innovator's product Xigduo Tablet XR 5/5000mg.		
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.		
STABILITY STUDY DATA				
Manufacturer of API		Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.		
API Lot No.		Dapagliflozin: DG-20190727-D02-DG06-03 Metformin HCl: MT10890619		
Description of Pack (Container closure system)		Alu-Alu Blister		
Stability Storage Condition		Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period		Real time: 6 Months Accelerated: 6 Months		
Frequency		Real Time: 0, 3, 6 (Months) Accelerated: 0, 3, 6 (Months)		
Batch No.		XMB T2-19	XMB T3-19	XMB T4-19
Batch Size		5000 Tablet	5000 Tablet	5000 Tablet
Manufacturing Date		12-2019	12-2019	01-2020
Date of Initiation		02-2020	02-2020	02-2020
No. of Batches		03		
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA				
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to their previous PSI inspection conducted for the product Dexlan DR Capsule 30 and 60mg conducted on 26-08-2019 which was considered by Registration Board in its 294th meeting. The Board approved the case and following things were noted in the inspection report: HPLC used in the stability studies of current products was gradient and not 21CFR 11 compliant. The audit trail was not active on the testing reports and log of data was available in the HPLCs. The data was also confirmed through record, chromatograms and logbooks.		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Dapagliflozin: Firm has submitted copy of DML of the firm (No. Liao 20150233) issued by NMPA China. The certificate is valid till 17-11-2027. The certificate is verified from official database of NMPA China. Metformin HCl: Firm has submitted copy of License Retention Certificate (No. 2683/Stores/2018) of the firm issued by Drugs Control Administration Government of Andhra Pradesh dated 25-07-2018. The certificate is valid till 28-07-2023.		

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Dapagliflozin: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 15-11-2019 specifying import 8 Kg Dapagliflozin propanediol monohydrate (batch# DG-20190727-D02-DG06-03). Metformin HCl: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 22-07-2019 specifying import of 12000 Kg Metformin HCl (Batch number MT10890619).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted by the firm
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

The applied product to be manufactured by M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore have already been approved by Registration Board (as a stability / exemption data case) in its 308th meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 308th meeting are as follows:

Applicant firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore
Manufacturer firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore
Brand Name	Xiga-Met 5/1000 XR Tablet
Registration Board meeting	308th meeting of Registration Board

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

70.	Name, address of Applicant / Marketing Authorization Holder	M/s Dynatis Pakistan (Pvt) Ltd Plot No. 710, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt) Ltd 62-Industrial Estate, Kot Lakhpat, Lahore.
	Status of the applicant	☐ Manufacturer ☐ Importer ☒ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement dated 14-11-2022
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s CCL Pharmaceuticals issued on the basis of inspection dated 30-04-2019. Firm has also submitted a copy of letter from Additional Director DRAP Lahore dated 07-07-2022 that the firm has applied for GMP inspection and the application is under process

		and will be done as per availability of FID. The firm's last GMP status if compliant / Good.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of Drug Manufacturing License (No. 000052) dated 08-06-2021 specifying Tablet (General) section.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 33641: 22-11-2022
	Details of fee submitted	PKR 75,000/-: 10-11-2022
	The proposed proprietary name / brand name	DAPAZIN MET XR 10mg/1000mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Dapagliflozin propanediol monohydrate eq to Dapagliflozin…….10mg Metformin HCl……1000mg
	Pharmaceutical form of applied drug	Film coated double layer tablet
	Pharmacotherapeutic Group of (API)	Combination of oral blood glucose lowering drugs
	Reference to Finished product specifications	As per innovator's product
	Proposed Pack size	5's, 10's, 14's, 20's, 28's, 30's, 50's and 100's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	Xiga-Met XR Tablet of CCL
	Name and address of API manufacturer.	Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container

		closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Dapagliflozin: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 24 months. Metformin HCl: Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30oC ± 2oC / 65% ± 5% RH for 72 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Innovator's product Xigduo Tablet XR 5/5000mg. Firm has submitted Comparative Dissolution Profile studies against Innovator's product Xigduo Tablet XR 5/5000mg.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	Dapagliflozin: M/s Fuxin Long Rui Pharmaceutical Co., Ltd., Flouride Industrial park, Fuxin City, Liaoning province, China. Metformin HCl: M/s Wanbury Limited., Doctor's Organic Chemical Division K Illindalaparru 534217 Iragavaram Mandal West Godavari District Andhra Pradesh, India.		
API Lot No.	Dapagliflozin: DG-20190727-D02-DG06-03 Metformin HCl: MT10890619		
Description of Pack (Container closure system)	Alu-Alu Blister		
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH		
Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 3, 6 (Months) Accelerated: 0, 3, 6 (Months)		
Batch No.	XMD T2-19	XMD T3-19	XMD T4-19
Batch Size	5000 Tablet	5000 Tablet	5000 Tablet

Manufacturing Date		11-2019	12-2019	12-2019
Date of Initiation		01-2020	01-2020	01-2020
No. of Batches		03		
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA				
1.	Reference of previous approval of applications with stability study data of the firm (if any)		Firm has referred to their previous PSI inspection conducted for the product Dexlan DR Capsule 30 and 60mg conducted on 26-08-2019 which was considered by Registration Board in its 294th meeting. The Board approved the case and following things were noted in the inspection report: HPLC used in the stability studies of current products was gradient and not 21CFR 11 compliant. The audit trail was not active on the testing reports and log of data was available in the HPLCs. The data was also confirmed through record, chromatograms and logbooks.	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Dapagliflozin: Firm has submitted copy of DML of the firm (No. Liao 20150233) issued by NMPA China. The certificate is valid till 17-11-2027. The certificate is verified from official database of NMPA China. Metformin HCl: Firm has submitted copy of License Retention Certificate (No. 2683/Stores/2018) of the firm issued by Drugs Control Administration Government of Andhra Pradesh dated 25-07-2018. The certificate is valid till 28-07-2023.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Dapagliflozin: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 15-11-2019 specifying import 8 Kg Dapagliflozin propanediol monohydrate (batch# DG-20190727-D02-DG06-03). Metformin HCl: Firm has submitted copy of invoice cleared by DRAP Lahore office dated 22-07-2019 specifying import of 12000 Kg Metformin HCl (Batch number MT10890619).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Firm has submitted analytical record of stability testing of 3 batches.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Submitted by the firm	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		Submitted by the firm	
Evaluation by PEC:				
The applied product to be manufactured by M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore have already been approved by Registration Board (as a stability / exemption data case) in its 308th meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 308th meeting are as follows:				

	Applicant firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore
	Manufacturer firm	M/s CCL Pharmaceuticals Pvt Ltd. 62 Industrial Estate, Kot Lakhpat, Lahore
	Brand Name	Xiga-Met 10/1000 XR Tablet
	Registration Board meeting	308th meeting of Registration Board

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Export Facilitation Priority

71.	Name, address of Applicant / Marketing Authorization Holder	M/s Brookes Pharma (Pvt) Ltd. Plot 58-59 Sector 15, Korangi Industrial Area Karachi.
	Name, address of Manufacturing site.	M/s Brookes Pharma (Pvt) Ltd. Plot 58-59 Sector 15, Korangi Industrial Area Karachi.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of inspection report dated 18-08-2020 which recommends renewal of DML.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of regularization of layout plan of M/s Brookes Pharma under Drug Manufacturing License (No. 000275) dated 16-04-2020 specifying Liquid injectable (SVP) section.
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 18403: 24-06-2022
	Details of fee submitted	PKR 75,000/-: 24-05-2022
	The proposed proprietary name / brand name	SUGA Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Sugammadex sodium eq to sugammadex… 100mg
	Pharmaceutical form of applied drug	Clear and colorless solution filled in glass ampoule
	Pharmacotherapeutic Group of (API)	Antidote-Selective relaxant binding agent
	Reference to Finished product specifications	As per innovator's product
	Proposed Pack size	2 ampoule of 2ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	USFDA Approved
	For generic drugs (me-too status)	NA

	Name and address of API manufacturer.	PLIVS Croatia Ltd. TAPI Croatia Production SM Prudnicka cesta 54 10291 Prigorje Brdovecko Croatia.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40oC ± 2oC / 75% ± 5% RH for 6 months. The real time stability data is conducted at 25oC ± 2oC / 60% ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted pharmaceutical equivalence against Bridion Injection.
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA	
Manufacturer of API	PLIVS Croatia Ltd. TAPI Croatia Production SM Prudnicka cesta 54 10291 Prigorje Brdovecko Croatia.
API Lot No.	7MPS02843901220
Description of Pack (Container closure system)	Glass ampoule
Stability Storage Condition	Real time: 30°C ± 2°C / 35% RH Accelerated: 40°C ± 2°C / 25% RH

Time Period	Real time: 6 Months Accelerated: 6 Months		
Frequency	Real Time: 0, 1, 3, 6 (Months) Accelerated: 0, 1, 3, 6 (Months)		
Batch No.	PD-PS-00111	PD-PS-00211	PD-PS-00411
Batch Size	1.5 L	1.5 L	1.5 L
Manufacturing Date	09-2021	09-2021	09-2021
Date of Initiation	21-09-2021	21-09-2021	15-09-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to previous inspection for their product Brofex IV Infusion for which PSI was conducted on 13-02-2020 and the report was presented in 295th meeting of RB. The reports confirms that the HPLc system was 21 CFR compliant and audit trail report was available.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate issued by Agency for medicinal products and medical devices of Croatia dated 23-08-2019 issued on the basis of inspection dated 10-05-2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted analytical record of stability testing of 3 batches.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted by the firm
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted by the firm

Evaluation by PEC:

Sr. No	Shortcomings communicated	Response by the firm
1.	Submit data in section 3.2.S.4.1 and 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."	Firm has submitted copies of the Drug substance specifications and analytical procedures by both Drug substance & Drug Product manufacturer.
2.	Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that "Analytical	Firm has submitted data of verification of analytical procedure of drug substance by drug product manufacturer.

	Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".	
3.	Submit COA of relevant batch of drug substance from API manufacturer as well as drug product manufacturer in section 3.2.S.4.4 which is actually used for manufacturing of three stability batches of drug product.	Firm has submitted COA of relevant batch of API
4.	Submit stability study data of the drug substance as per zone IV-A conditions.	Firm has submitted stability study data of drug substance as per zone IV-B conditions for 24 months.
5.	Provide details including the batch number, expiry date and manufacturer of the innovator's product against which pharmaceutical equivalence is conducted.	Firm has submitted picture of the vial of the innovator's product depicting details of lot number and expiry date.
6.	The applied brand name is Suga injection while the stability data of sudex injection is submitted. Clarification is required in this regard.	This is for your information that during the development stage of Sugammadex Injection 100mg/ml, the proposed brand name was previously selected as "Sudex Injection", hence few documents are with the name as "Sudex Injection (Sugammadex sodium eq. to sugammadex I00mg/ml)". However, due to resemblance of the name we have changed the proposed name of our product fom Sudex Injection in our submitted documents as "Suga Injection (Sugammadex sodium eq. to sugammadex l00mg/ml)".

Decision: Approved.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

Cases of New DML

Case No. 04: M/s Lakhani Pharma Private Limited, Sheikh Zayed Road, Rahim Yar Khan

Firm has submitted copy of issuance of DML by way of formulation to M/s Lakhani Pharma Private Limited dated 07-06-2021 from Secretary Central Licensing Board. The letter specifies that CLB in its 279th meeting held on 18th February 2021 has approved the grant of DML in the name of M/s Lakhani Pharma Private Limited for following section:

1. IV Infusion section (General)

Now the firm has submitted following applications as per the details mentioned in the table below:

	Previously considered		Freshly applied		Total	
Name of Section	No of molecules	No of products	No of molecules	No of products	No of molecules	No of products
IV Infusion section (General)	09	27	01	01	10	28

IV Infusion section (General): 04 Molecules / 5 Products

72.	Name, address of Applicant / Marketing Authorization Holder	M/s Lakhani Pharma Private Limited Sheikh Zayed Road, Rahim Yar Khan
	Name, address of Manufacturing site.	M/s Lakhani Pharma Private Limited Sheikh Zayed Road, Rahim Yar Khan
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	New license granted on 16/03/2021 (Inspection date 03/02/2021) IV Infusion section approved.
	Evidence of approval of manufacturing facility	Firm has submitted copy of issuance of DML by way of formulation to M/s Lakhani Pharma Private Limited dated 07-06-2021 from Secretary Central Licensing Board. The letter specifies that CLB in its 279th meeting held on 18th February 2021 has approved the grant of DML in the name of M/s Lakhani Pharma Private Limited for following section: 1. IV Infusion section (General)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 32156: 24-11-2021
	Details of fee submitted	PKR 20,000/-: 01-04-2021 PKR 10,000/-: 09-10-2021
	The proposed proprietary name / brand name	LAKSOL-CIPRO IV Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml contains: Ciprofloxacin (as lactate)……200mg
	Pharmaceutical form of applied drug	Intravenous Infusion
	Pharmacotherapeutic Group of (API)	Quinolone antibiotic
	Reference to Finished product specifications	USP
	Proposed Pack size	100ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	MHRA Approved. Ciprofloxacin 2 mg/ml Solution for Infusion
	For generic drugs (me-too status)	Otsuflox infusion 100ml by Otsuka (Reg#086880)
	Name and address of API manufacturer.	Shangyu Jingxin Pharmaceutical Co. Ltd. No. 31 Weisan Road, Hangzhou Bay Shangyu Economic and Technological Development Area, Shangyu, Zhejiang China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications,

		analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the comparator product 'Otsuflox infusion 100ml by Otsuka .
	Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA	
Manufacturer of API	Shangyu Jingxin Pharmaceutical Co. Ltd. No. 31 Weisan Road, Hangzhou Bay Shangyu Economic and Technological Development Area, Shangyu, Zhejiang China.
API Lot No.	DK 12-2010182-b
Description of Pack (Container closure system)	Low Density Polyethylene bag
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 1, 2, 3, 4, 5, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.	Ex-076	Ex-077	Ex-078
Batch Size	250 liters	100 liters	100 liters
Manufacturing Date	02-2021	02-2021	02-2021
Date of Initiation	27-02-2021	27-02-2021	27-02-2021
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not applicable since it is a newly established license.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate (No. ZJ20190157) issued by NMPA China. The certificate is issued on 30-11-2019. The certificate is valid till 29-11-2024.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted stability study data of 3 batches along with water loss test at each time point. Firm has submitted analytical report at each stability testing interval.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Evaluation by PEC:

The case was evaluated and the following observations were communicated to the firm vide letter dated 9th December, 2021.

Justify the manufacturing of batches before the issuance of Drug Manufacturing License.

Your label claim states that ciprofloxacin base is used while you have used ciprofloxacin lactate, revise your label claim along with submission of applicable fee.

You have submitted information regarding ciprofloxacin base in module 3 while the COA of API manufacturer states that the material is ciprofloxacin lactate.

Provide specifications and analytical method of drug substance manufacturer in section 3.2.S.4.1 and 3.2.S.4.2.

As per the COA of API submitted from API manufacturer, the material is not sterile and the test for bacterial endotoxin and sterility is also not performed. Justify how you have performed both of these tests.

Justify how the specification of USP have been applied for testing of drug substance while the API manufacturer has claimed in house specs. Furthermore, USP monograph is for ciprofloxacin base while the material is ciprofloxacin lactate.

As per the USP monograph the detector is UV 278nm with injection volume 10µL while as per your testing the analysis has been performed at UV 262nm with injection volume 5µL.

The innovator product as well as USP monograph specify that ciprofloxacin or ciprofloxacin hydrochloride could be used as starting material for the drug product and it should be prepared with the aid of lactic acid. Justify how you have prepared the formulation using ciprofloxacin lactate as starting material. The developed formulation does not fall in the definition of the generic drug.

Justify the pharmaceutical equivalence studies in which pH acceptance criteria is 4 to 5 while as per USP the pH should be 3.5 - 4.6. Justify how the results of pH above 4.6 in your pharmaceutical equivalence studies could be justified.

Justify the test of sodium chloride in your pharmaceutical equivalence studies since this test is only recommended when the injection is prepared in sodium chloride injection.

Justify why the test for lactic acid content is not performed in pharmaceutical equivalence studies.

Justify why the specifications applied in batch release are different from that mentioned in section 3.2.P.5.2.

Justify why the test of lactic acid content is not performed at batch release.

Provide CoA of reference standard / working standard used in the analysis of drug product and substance.
Describe the container closure system for applied product in detail, what is the exact material of construction, grade and density of the LDPE material along with its certificate of analysis. Also specify if the applied product is with Eurocap or not.
Submit evidence for the procurement of drug substances / API with approval from DRAP.
Submit raw data sheets including HPLC chromatograms for evidence of the product testing as per USP monograph.
Provide compliance Record of HPLC software including 21CFR & audit trail reports on product testing.
Provide record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)
The stability batches were released after sterility testing on 27-02-2021 while all the batches were manufactured on the same day as well. Justify how the batches were released and stability study was initiated before the result of sterility test.

The firm vide its letter Dy No. 32999 dated 17-11-2022 requests for inclusion of Lakadol 1g/100ml IV Infusion and withdrawl of Laksol-Cipro 200mg/100ml IV Infusion. The request of the firm is placed as under:

Sub: Inclusion (Lakadol 1g/100ml I.V. Infusion) and Withdrawal (Laksol-Cipro 200mg/100ml I.V. Infusion) Of Application (For Local Manufacturing).

Respected Sir/Madam,

We Lakhani Pharma (Pvt.) Limited, having our Registered Manufacturing Facility & Head office at Sheikh Zayed Road, Rahim Yar Khan, would like to grab your kind attention towards our already submitted application for Registration of following drug mentioned-below (For Local Manufacturing) on the basis of 10-Molecules per New Section Policy.

Product Name: Laksol-Cipro 200mg/100ml I.V. Infusion
Composition: Ciprofloxacin 200mg/100ml.
Pack Size: 100ml
Date of submission of application: 01-04-2021

Note: Copy of receiving is being enclosed for ready reference.
Sir, due to certain reason, we do request for withdrawal of submitted Application (Laksol- Cipro 200mg/100ml I.V. Infusion) out of 10-Molecules per New Section Policy.
Instead: We request you to kindly consider our submitted application for registration (Lakadol 1g/100ml I.V. Infusion) under 10-molecule Policy in place of above-mentioned application. Details are given below:
Product Name: Lakadol 1g/100ml I.V. Infusion
Composition: Paracetamol 1g/100ml
Pack Size: 100ml
Date of submission of application: 04-11-2022

The evaluation summary of the Lakadol 1g/100ml Infusion is placed below:

Name, address of Applicant / Marketing Authorization Holder	M/s Lakhani Pharma Private Limited Sheikh Zayed Road, Rahim Yar Khan
Name, address of Manufacturing site.	M/s Lakhani Pharma Private Limited Sheikh Zayed Road, Rahim Yar Khan
Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
GMP status of the firm	New license granted on 16/03/2021 (Inspection date 03/02/2021) IV Infusion section approved.

Evidence of approval of manufacturing facility	Firm has submitted copy of issuance of DML by way of formulation to M/s Lakhani Pharma Private Limited dated 07-06-2021 from Secretary Central Licensing Board. The letter specifies that CLB in its 279th meeting held on 18th February 2021 has approved the grant of DML in the name of M/s Lakhani Pharma Private Limited for following section: 1. IV Infusion section (General)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
Dy. No. and date of submission	Dy. No. 31971: 04-11-2022
Details of fee submitted	PKR 30,000/-: 27-10-2022
The proposed proprietary name / brand name	LAKADOL 1g/100ml IV Infusion
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml contains: Paracetamol…… 1g
Pharmaceutical form of applied drug	Sterile, Clear, Colorless or Slightly Yellowish, Non-Pyrogenic, Isotonic Solution, Practically Free from Particles Solution, in Low Density Polyethylene bottle.
Pharmacotherapeutic Group of (API)	Antipyretic / Analgesic
Reference to Finished product specifications	Manufacturer's Specs
Proposed Pack size	100ml
Proposed unit price	As per SRO
The status in reference regulatory authorities	USFDA Approved
For generic drugs (me-too status)	Provas 1g/100ml IV Infusion by Sami Pharma
Name and address of API manufacturer.	M/s Zenith Chemical Industries (Pvt.) Ltd. Moaza Dhonday, Jia Bagga, Raiwind Road, Lahore – Pakistan.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 30°C ± 2°C / 65% ± 5% RH for 24 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator product Provas infusion by Sami Pharma.
Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zenith Chemical Industries (Pvt.) Ltd. Moaza Dhonday, Jia Bagga, Raiwind Road, Lahore – Pakistan.		
API Lot No.	ZPAR21-258		
Description of Pack (Container closure system)	Low Density Polyethylene bag		
Stability Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 1, 2, 3, 4, 5, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	P-001	P-002	P-003
Batch Size	500 bottles	500 bottles	500 bottles
Manufacturing Date	04-2022	04-2022	04-2022
Date of Initiation	08-04-2022	11-04-2022	15-04-2022
No. of Batches	03		

DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not applicable since it is a newly established license.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate issued on the basis of inspection dated 06-12-2018. Firm has also submitted copy of DML of the firm for semi basic manufacturing (DML No. 000733) issued w.e.f. 15-06-2016 dated 07-05-2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice dated 23-12-2021 specifying 25kg Paracetamol.

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted stability study data of 3 batches along with water loss test at each time point. Firm has submitted analytical report at each stability testing interval.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	NA
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.
Evaluation by PEC:		
Firm has performed sterilization of the bottlepack product during manufacturing. Firm has also performed water loss testing of the drug product during stability studies which are performed as per zone IV-A conditions.		
Decision: Registration Board decided as follows: **Acceded to the firm's request of withdrawal and declared the application of LAKSOL-CIPRO IV Injection, submitted vide Dy. No. 32156 dated 24-11-2021 as disposed off.** **Approved LAKADOL 1g/100ml IV Infusion with Innovator's specifications. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.** • **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.** • **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**		

Item No. XI: Agenda of Evaluator XVI (Mr. Akbar Ali)
Priority applications as per 257th meeting of RB

73.	Name, address of Applicant / Importer	M/s BF Biosciences Ltd 5-KM Sunder Raiwind Road, Raiwind, District Lahore – Pakistan, Pakistan
	Details of Drug Sale License of importer	License No:05-352-0066-034461D Address: 5-KM Sunder Raiwind Road, Raiwind, District Lahore – Pakistan. Address of Godown: NA Validity: 29-06-2027. Status: License to sell drugs as distributor Renewal: NA
	Name and address of marketing authorization holder (abroad)	Bioprofarma Bagó S.A. Terrada 1270 - Autonomous City of Buenos Aires, Argentine Republic.
	Name, address of manufacturer(s)	Laboratorio Kemex S.A. Nazarre 3446/54 - Autonomous City of Buenos Aires, Argentine Republic.
	Name of exporting country	Argentine Republic
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized copy of CoPP certificate (No. IF-2022-09064835-APN-DFYGR#ANMAT) dated 04-01-2022 issued by National Institute of Drugs Avenida Caseros 2161 Ciudad Autonoma de Buenos Aires-Republica Argentina for Fulvestrant injection 250mg. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the

		manufacturing site through periodic inspection every year.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Bioprofarma Bagó S.A. The letter species that the manufacturer appoints M/s BF Biosciences Ltd. to register their products in Pakistan. The authorization letter is valid till 31-01-2023.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy.31009 dated No 01-11-2022
	Details of fee submitted	PKR 75,000/-:slip No. 04893286804 dated 25-04-2022
	The proposed proprietary name / brand name	DIMERE injection 250mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5 ml vial contains: Fulvestrant …….250mg
	Pharmaceutical form of applied drug	Solution for Injection
	Pharmacotherapeutic Group of (API)	oestrogen receptor antagonists (L02BA03)
	Reference to Finished product specifications	In house
	Proposed Pack size	2’s
	Proposed unit price	Rs 45,000 /- single dose vial
	The status in reference regulatory authorities	FASLODEX 250mg Injection (AstraZeneca UK Limited). (Pre Filled Syringe of 5 ml)
	For generic drugs (me-too status)	NA
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Farmabios S.p.A. Via Pavia, 1 27027 Gropello Cairoli, (PV) – Italy
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real time conditions. The real time stability data is conducted at 5oC ± 3oC. The stability study data is till 48 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Submitted.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	USP type-I glass
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 25 °C ± 2ºC/ 60% ± 5% RH for 6 months. The real time stability study data is conducted at 5 °C ± 3ºC. The real time stability study data of 3 batches is for 24 months

Evaluation by PEC:

Sr. No	Observations
01	DSL of Importer /applicant is expired till 29-06-2022.
02	Provided copy of GMP certificate of API/Drug substance manufacturer, I-e M/s Farmabiosa S.P.A Italy, issued by AIFA, Italy vide certificate No. IT-API/167/H/2020 based on inspection conducted on 20-09-2019 was valid for 30 months, which has been expired.
03	Justification of applied container closer system of finished drug product as glass vial whereas the innovator product Faslodox is prefilled syringe.
04	Justification of overage of 0.4 ml excess filling in vial during filling process in line with innovator product which is prefilled syringe.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.within six months		
74.	Name, address of Applicant / Importer	M/s Martin Dow Limited, Plot No. 37, Sector 19, Korangi Industrial Area, Karachi-74900, Pakistan.
	Details of Drug Sale License of importer	License No: 565 Address: Martin Dow Limited, Plot no. 37, Sector 19, Korangi Industrial Area, Karachi. Address of Godown: (a) 1st floor, Plot no. 211, Sector 23 Korangi Industrial Area, Karachi (b) Plot No 32, Sector 16, Korangi Industrial Area, Karachi Validity: 16-06-2024 Status: License to sell Drugs by way of Wholesale Renewal: Yes
	Name and address of marketing authorization holder (abroad)	EXELTIS HEALTHCARE, S.L. Av. Miralcampo 7 19200 Azuqueca de Henares (Guadalajara) España/Spain
	Name, address of manufacturer(s)	LABORATORIOS FARMALAN S.A. C/ La Vallina s/n, Edificio 2, Poligono Industrial Navatejera 24193 Villaquilambre (Leon) España/Spain
	Name of exporting country	Spain
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has submitted original, legalized copy of COPP certificate (No. 2022/02191) dated 10-07-2020 issued by AGENCIA ESPAÑOLA DEL MEDICAMENTO Y PRODUCTOS SANITARIOS, Spain. Firm has submitted second original, legalized copy of CoPP certificate (No. 5.8.1-2022-64806) dated 22-08-2022 issued by Swedish Medical Products Agency. The CoPP confirms free sale status of the product in Sweden with different marketing authorization holder. The name of importing country on CoPPs is mentioned as Pakistan.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of authorization from Chemo SA, Lugano branch. The letter specifies that Chemo SA, Lugano branch appoints M/s. Martin Dow Limited to register their products in Pakistan. The authorization letter is valid. Firm has also submitted a letter clarifying that Chemo has been entitled by the manufacturer and license holder to promote and distribute their product.
	Status of the applicant	☐ Manufacturer ☒ Importer

		☐ Is involved in none of the above (contract giver)
	Status of application	☒ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
	Dy. No. and date of submission	Dy. No. 31354 : 02-11-2022
	Details of fee submitted	PKR 150,000/-: 31-12-2021 ,Slip No.43533251754
	The proposed proprietary name / brand name	Vestant Solution for Injection in pre-filled syringe 250mg/5ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains: Fulvestrant…….50mg
	Pharmaceutical form of applied drug	Solution for Injection
	Pharmacotherapeutic Group of (API)	Anti-estrogens (ATC code: L02BA03)
	Reference to Finished product specifications	As per innovator
	Proposed Pack size	1's
	Proposed unit price	As per DPC
	The status in reference regulatory authorities	FASLODEX Injection of ASTRAZENECA (USFDA Approved).
	For generic drugs (me-too status)	Not available
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	Industriale Chimica s.r.l. Address: Via E. H. Grieg 13, 21047 Saronno (Varese), Italy
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated as well as real

		time conditions. The real time stability data is conducted at 5oC ± 3oC and accelerated at 25°C ± 2°C. The real time stability study data is till 5 years.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence has been established with reference product FASLODEX Pre filled syringe 250mg/5ml by establishing comparative study of critical quality attributes.
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
	Container closure system of the drug product	Syringe 5mL Glass Type – I and Plunger Stopper
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 25oC ±2oC / 60% ± 5% RH for 6 months. The real time stability study data is conducted at 5oC ±3oC. The real time stability study data of 3 batches is for 36 months.

Remarks of Evaluator:

Sr. No	Observations
01	COPP section 1.4 mentioned that this product is not actually on the market in the exporting country ,i-e Spain, please clarify.
02	Sole Agency agreement between Marketing Authorization Holder of Country of Export and Applicant, is required.
03	GMP certificate of API /Drug Substance manufacturer was granted by AIFA based on GMP inspection dated 21-09-2018 valid for 3 years, which is expired, valid copy is required please.

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

75.	Name, address of Applicant / Marketing Authorization Holder	Name: Pharmedic Laboratories (Pvt.) Ltd. Address: 16km Multan Road, Lahore-Pakistan Contact details: Tel: +92 42 37511861-65 Fax: (042) 37511396-37510498 Email: info@pharmedic.com
	Name, address of Manufacturing site.	Name: Shrooq Pharmaceuticals (Pvt.) Ltd. Address: 21-km Ferozpur Road, Lahore-Pakistan. Contact details: Tel: +92-42-35274026-30
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)

	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 1361 dated 16/01/2023
	Details of fee submitted	PKR 75,000/-: dated 26/01/2023 slip No .705919199860
	The proposed proprietary name / brand name	Onset Oral Solution 4mg/5ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains: Ondansetron hydrochloride Dihydrate equivalent to Ondansetron……4mg
	Pharmaceutical form of applied drug	Clear transparent solution
	Pharmacotherapeutic Group of (API)	Antiemetic and antinauseants. Serotonin (5HT3) antagonist
	Reference to Finished product specifications	USP Specification
	Proposed Pack size	25ml,50ml
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Zofran Oral Solution HPRA Ireland MHRA/EMA UK
	For generic drugs (me-too status)	Onseron Oral Solution by Indus Pharma (Pvt.) Ltd. Lahore
	GMP status of the Finished product manufacturer	Last GMP was granted on 10/02/2022
	Name and address of API manufacturer.	Name: M/s. ANUGRAHA CHEMICALS Address: No. D-47 to D-50 & C-62 to C-63, KSSIDC Industrial Estate, Doddaballapur, Bengaluru Rural District-561203. Tel: +919845939733 / +91-8277389023 Fax : 080-28563081 E-Mail: info@anugrahachemicals.in
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ondansetron as hydrochloride Dihydrate is present in (USP). The firm as submitted detail of nomenclature, structure, general properties, solubility, physical

		form, manufacturers, description of manufacturing process and controls, Test for Impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 12 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (060, 061, 062)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Onseron Oral Solution by Indus Pharma (Pvt.) Ltd. Lahore. by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form).
	Analytical method validation/verification of product	Method verification studies have submitted including Specificity, linearity, accuracy, precision (repeatability and Intermediate),.

STABILITY STUDY DATA			
Manufacturer of API	M/s. ANUGRAHA CHEMICALS		
API Lot No.	AOND-21015		
Description of Pack (Container closure system)	25ml& 50ml		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 36 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, 36, 48, 60 (Months)		
Batch No.	060	061	062
Batch Size	1000 L	1000 L	1000 L
Manufacturing Date	05.2022	06.2022	07.2022
Date of Initiation	05.2022	06.2022	07.2022
No. of Batches	03		

Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.

	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	GMP Certificate No: DCD/SPL-1/CR-1733/2021/02 Valid up to 30.01.2023 Issued BY: Govt. of Karnataka, Drug Control Department, India DML License No: KTK/25/549/2008 Valid up to: 13/02/2025 Issued BY: Govt. of Karnataka, Drug Control Department, India
	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator:

Sr#	Section	Observations
01	3.2.S.3.1	The Molecular weight of Drug substance (Ondansetron Hcl dehydrate) is mentioned as 329.82 g/mol whereas USP has mentioned molecular weight as 365.85. Clarification is required.
02	3.2.S.4	Drug substance analytical method verification studied conducted by drug substance manufacturer and Finished product manufacturer are missing, which are required. Provided copy of COA of Drug Substance Batch No AOND-21015 mentioned Ondansetron Hcl (Tablet grade) .please clarify.
03	3.2.P.1	Finished manufacturer has mentioned Glycerin and poly sucralose as excipients in their formulation which are not present in Reference product, Syp Zofran 4gm/5ml approved by MHRA. Please clarify.
04	3.2.P.8.3	Stability study data of 3 batches for real time and accelerated conditions for 6-month time point is missing which is required. Documents for the procurement of API with approval from DRAP (in case of import).

Decision: Registration Board was apprised that the letter of shortcoming has been initially issued to the firm, hence Board deferred the case for submission of reply to the above cited shortcomings within six months.

Item No. XII: Agenda of Registration Section R-II (Hafiz Tayyab) Registration-II
REPORT ON ASSESSMENT AND CONFIRMATION OF MANUFACTURING CAPACITY OF M/S IPRAM INTERNATIONAL, PLOT NO. 26, S.S. 3, NATIONAL INDUSTRIAL ZONE, RAWAT. (DML No. 000551).

Reference No: F.5-5/2022-Reg-II (M-321) (Misc.)
Inspection Date: 30th December, 2022.

Background: The inspection was conducted on 30.12.2022 in compliance to letter of Assistant Director (Reg-II) vide No. 5-5/2022-Reg-II(M-321) (Misc.) dated 01.11.2022

Composition of Panel:

Mr. Muneeb Ahmed Cheema, Deputy Director PE&R, DRAP Islamabad.

Mr. Adil Saeed, Assistant Director PEC-IX, DRAP Islamabad.

Scope of Inspection:

The inspection was conducted for assessment and confirmation of manufacturing capacity of Dry Powder Injection (Carbapenem) Section of M/s Ipram International Plot No. 26, S.S. 3 national Industrial Zone Rawat.

Manufacturing record/data of 1 year (1st July, 2021 to 30th June, 2022) was evaluated for aforementioned purpose. The details of capacity calculations are as under:

Registered Products	
Total registered products of manufacturer	5
Registered products on contract from the manufacturer	0

CAPACITY OF DRY VIAL INJECTION (CARBAPENEM) SECTION.

Manufacturer's total Registrations	Manufacturer's Pending applications	Contract Products Registrations	Contract products Pending applications
5	Nil	Nil	2

G.

STEP WISE CAPACITY OF EACH PROCESS				
	Process/Step 1: Vial Washing -	Process/step 2: Depyrogenation Capacity-	Process / step 3: Filling and Sealing Capacity –	Process/ Step 4: Packing Capacity –
Per day (8 hours working shift)	24,000	18,200	57,600	24,000
Per month (26 working days)	624,000	473,000	1,497,600	624,000

Capacity calculated with respect to the depyrogenation being capacity limiting step

QUARTER WISE CAPACITY UTILIZED			
Quarter	Actual Production	Capacity w.r.t capacity limiting step	Capacity utilized in %
1st (1st July – 30th Sept 21)	35,200	1,310,400	2.68%
2nd (1st Oct – 31st Dec 21)	72,770	1,310,400	5.55%
3rd (1st Jan – 31st March 22)	137,995	1,310,400	10.53%
4th (1st Apr – 30th June 22)	29,905	1,310,400	2.28%
Average Capacity Utilized			

Manufacturing Capacity Utilized (average): 5.26%

Manufacturing Capacity Available (average): 94.74%

CAPACITY OF QUALITY CONTROL DEPARTMENT

Quality Control Equipment Details			
S.No	Equipment	Quantity	Capacity per day
	HPLC	1	02
	UV Spectrophotometer	1	15
	pH Meter	1	25
	Balance	1	30
	Cold Incubator	1	200L
	Hot Incubator	1	200L

	Liquid Particle Counter (LPC)	1	40
	Stability Chamber (Accelerated)	1	400L
	Stability Chamber (Real time)	1	400L

1. HPLC Capacity Calculation Quarter Wise(Maximum 2 tests/day/HPLC)TOTAL No of HPLC= 1

QUARTER	Average Capacity of HPLC	Performed	Capacity Utilized %	Capacity Available %
1st (1st July – 30th Sept 21)	132	63	47%	53%
2nd (1st Oct – 31st Dec 21)	132	65	49%	51%
3rd (1st Jan – 31st March 22)	132	109	82%	18%
4th (1st Apr – 30th June 22)	132	81	61%	39%
Average capacity Available:				40.25%

2. Capacity Calculation for sterility testing Quarter Wise (Average 2 tests/day)

Quarter	Capacity	Test Performed	Capacity Utilized %	Capacity Available %
1st (1st July – 30th Sept 21)	156	70	49%	69%
2nd (1st Oct – 31st Dec 21)	156	85	54%	64%
3rd (1st Jan – 31st March 22)	156	120	78%	68%
4th (1st Apr – 30th June 22)	156	95	61%	66%
Average capacity available:				66.75%

3. Bacterial Endotoxin Test Capacity Calculation Quarter Wise (Average 50 tests / day)

Quarter	Capacity	Test Performed	Capacity Utilized %	Capacity Available %
1st (1st July – 30th Sept 21)	1500	468	31%	69%
2nd (1st Oct – 31st Dec 21)	1500	540	36%	64%
3rd (1st Jan – 31st March 22)	1500	480	32%	68%
4th (1st Apr – 30th June 22)	1500	515	34%	66%
Average capacity available:				66.75%

4. HOT INCUBATOR CAPACITY AND USAGE.

Item	Media capacity at a time for incubation	Estimated Media capacity REQUIRED at Maximum production load	Estimated Capacity required (%)	Estimated Capacity Available for expansion(%)
Media bottles	40	80	200%	-100%
Media plates	60	360	600%	-500%
Pre-Incubated				

5. COLD INCUBATOR CAPACITY AND USAGE.

Item	Media capacity at a time for incubation	Estimated Media capacity used at Maximum production load	Estimated Capacity required (%)	Estimated Capacity Available for expansion(%)
Media bottles	40	80	200%	-100%
Media plates	60	360	600%	-500%

Mr. Anees ur Rahman, Production Manager and Mr. Rashid ullah Khan QC Manager assisted during inspection. The carbapenem manufacturing facility was not dedicated, it was segregated section which shared common corridor with cephalosporin and steroidal section before the change rooms. The brief of inspection is given below;

Primary Change room: The primary change room was leading to corridor which had secondary change room before filling area. The primary change room was not provided with requisite pressure differential to contain the internal environment. The material entry towards RMS was also through this change room.

Raw Material Store: At the time of inspection, 55kg meropenem with sodium carbonate was present in RMS. The RMS was extremely congested (approximately 6x6 feet in size), even 2 persons cannot stand properly in the RMS. The material transfer to filling area was through UV hatch. The store in-charge was a non-technical person having degree in Mass Communication.

Production Area: The production line was semi-automatic. Vials were washed and then transferred to hot air oven. After depyrogenation and sterilization, vials were claimed to be transferred to filling line by placing them in a HEPA fitted trolley. The space was so congested, that door of cool room could

not be closed when HEPA trolley was brought in filling room. It appeared impossible to power the HEPA trolley to switch it on while shifting it from cooling area to filling line. The space for filling machine was also very constrained, hopper was very close to top of the LFH, making it difficult to fill it directly from the canisters. After filling, vials were sealed and collected for optical checking before packaging. The packaging was manual. The pressure differential gauge of the filling area was not deflecting when door between cooling area and filling area was opened or closed, indicating issues with pressure differentials of the filling area.

Finished Goods Store: The Finished Goods(FGS) Store had few cartons of finished products.

Production Practices:

The manufacturing practices were evaluated by reviewing multiple log books and material ledgers. The firm was not performing sterility testing on API and the technical team stated that as they are checking sterility of finished product so there is no need of sterility testing of API.

The log books showed that batch size varied greatly and firm did not have any uniform batch size and they are manufacturing the products as per demand from market. The batches varied from 22000 vials (Cilipenem 1g batch 22CP-037) to 4447 vials (Cilipenem 1g batch No. 22CP-041).

It was further observed that firm was manufacturing different strengths of same products in one go increasing chances of mix up of multiple strengths. For such different batches, single 10kg canister was being dispensed that was divided based on size of demanded batch (Cilipenem 500mg Batch No. 22CP-040 & Cilipenem 1g Batch No. 22CP-041 was manufactured from single canister of 10kg. 4kg was used in batch No. 22CP-040 and 6kg was used in batch No. 22CP-041).

The firm was manufacturing own water for injection Ampoules but product was being marketed without WFI (diluent).

It was also observed that same product Cilipenem 1g and 500mg had different registration numbers on different unit cartons of finished products. (on some registration number was 047724 and on some it was 082371). The API clearance was obtained on new registration number (082371) and BMRs and majority of packing material had old registration numbers having unclear registration status. The firm failed to give any justification of aforesaid practice. The firm was also asked to provide the registration status of products bearing registration No. 047724 & 082370, the firm informed that the application was submitted to the DRAP for regularization of registration under SRO.1005(I)/2017 for regularization of registration due to non-submission of renewal. But the firm failed to provide any evidence regarding regularization of their old registration of Cilipenem 500mg & 1g issued by DRAP.

Quality Control:

Main Quality Control Lab: The quality control lab had following major equipments;

HPLC
UV/Vis Spectrophotometer
Liquid Particle counter.
pH Meter
Analytical balance
Moisture balance

The firm did not had following equipment;

FTIR
Karlfisher titrator.

The Atomic Absorption spectrophotometer placed in QC lab was not functional. It was a very old model refurbished with Chinese parts not compatible with original instrument. Further only Iron, Cadmium, lead, and chromium lamps were available. The instrument was not repairable. TOC analyser was also out of order. There were no primary or secondary reference standards available.

The firm was releasing Carbapenem products on UV analysis rather than HPLC method as recommended by USP Pharmacopoeia, for instance batch No. 22CP-039 was released without testing on HPLC.

Microbiology Lab: The firm had hired a fresh graduate as microbiologist who had no experience of testing. A pharmacist with experience of 6 months was performing all activities of microbiology laboratory. Technically firm did not had a proper Microbiologist at time of inspection. The firm has 3 sterile sections currently in working (Ceph dry powder vial, liquid ampoule & carbapenem dry vial) and have established 3 more sections (dry powder steroids, Liquid ampoule steroids & liquid vial General) awaiting inspection from licensing division, the microbiology lab is not sufficient to even carry out complete testing for area monitoring and finished product sterility of current running sections.

The portable air particle counter was out of order. Beta lactamases and cephalosporinases were out of inventory.

CONCLUSION:

After inspecting the manufacturing, testing and storage facility of the firm M/s Ipram International Plot No. 26, SS, National Industrial Zone, Rawat of Carbapenem Dry Powder Injection, the panel is of the opinion that firm needs to address following points before contract manufacturing;

Dedication of Carbapenem facility (currently its segregated from ceph and steroid facility).

Improvement of practices in manufacturing like fixation of batch size based on validation studies and proper line clearance before manufacturing different strengths at same time.

Increase in storage space of RMS.

Increase in space of filling area to mitigate congestion & provision of sufficient space for operators, transfer of material to hopper, proper air circulation over the filling line and for placement of HEPA trolley.

Upgradation of QC lab including;

Purchase of 2 or more CFR21 compliant HPLC systems to fully test all APIs and finished products as per pharmacopoeial methods.

Provision of functional atomic absorption spectrophotometer & TOC.

Provision of FTIR for identity testing of raw materials.

Provision of Karlfisher titrator.

Upgradation of Microbiology Lab including;

Appointment of a full time microbiologist having prescribed qualification and experience.

Enhancement in capacity of hot and cold incubators to perform microbiological testing of products and area monitoring of all sterile areas.

Purchase of beta-lactamases and cephalosporinases for sterility testing of beta-lactam antibiotics.

Functionalization of portable air particle counter.

As the firm holds two registrations for same products Cilipenem 500mg (047725 & 082371) and Cilipenem 1gm (047724 & 082370), hence the firm shall be advised to approach relevant section for resolution of this issue.

Although the mandate of panel was capacity verification of Carbapenem section, during inspection water system of the firm was also observed as firm was also manufacturing WFI ampoules. The capacity of present water system was not sufficient to meet the requirements of the firm. The heating element of bulk WFI tank was not functional. The firm had a new larger vessel ready to be installed but it was not sealed and its lid was just placed over the tank exposing it to external environment. There was no agitator in the tank neither spray ball. The firm needs to purchase a GMP compliant bulk WFI manufacturing system.

Production and QC capacity utilized and available is summarized as follow:

Section name	Manufacturer total Registrations	Pending application for registration	Contract Products Registrations	Contract products Pending applications	Manufacturing Capacity Utilized (average)	Manufacturing Capacity Available (average)
Dry powder for injection (carbapenem)	5	Nil	Nil	2	5.25%	94.75%

QC Department:

1. HPLC Average Capacity Available:

Could not be verified as the firm is not using HPLC for testing of all products.

2. STERILITY TESTING Average Capacity Available:

It could not be verified as does not have sufficient space to incubate exposed plates of all the sterile manufacturing sections.

Submitted for consideration of the Board.

Decision: Registration Board on basis of the findings of above presented inspection report decided to defer the registratiobn applications of contract manufacturing from M/s Ipram International, Plot no. 26, s.s. 3, National Industrial Zone, Rawat till any further decision. Moreover, Registration Board decided to refer the above inspection report to QA&LT Division for further necessary action.

Item No. XII: Priority as Per 147th meeting of Authority for distribution of 15,000 Packs of Paracetamol (200's) in the market.

Authority in its 157th meetig held on 20th of January, 2023 while considering the agenda of "Consideration of one molecule out of queue on immediate production and sale of 15,000 packs (200's) of Paracetamol" decided as under:

"The Authority clarified that in light of ots decision taken in 147th meeting, only those manufcaturers are entitled for out of queue consideration of one molecule who have fulfilled the condition of manufacturing and sale of 15000 packs (200 tablets per pack) of Paracetamol tablets before 3rd November, 2022."

Jinnah Pharma has requested for the priority consideration of the following application against the submitted details of production and distribution of more than 15,000 packs (200's) of Jetemol 500mg tablet (Paraectamol) distriubuted from 29-09-2022 to 27-10-2022.

76.	Name, address of Applicant / Marketing Authorization Holder	M/s Jinnah Pharmaceuticals Pvt Ltd. 13 km, Lahore Road, Multan
	Name, address of Manufacturing site.	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	Dy. No. and date of submission	Dy.No 37578 dated 23-12-2022
	Details of fee submitted	PKR 30,000/-
	The proposed proprietary name / brand name	Tycal-D 5mg Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1ml ampoule contains: Cholecalciferol …….5mg
	Pharmaceutical form of applied drug	Liquid Injecatble
	Pharmacotherapeutic Group of (API)	Vitamin D
	Reference to Finished product specifications	Innovator
	Proposed Pack size	1ml×1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Vitamin D3 Good 200000 IU/ml (5mg/ml) by M/s Bouchara-Recordati, ANSM France Approved.
	For generic drugs (me-too status)	Indrop-D 5mg/ml by M/s Neutro Pharma (Pvt) Ltd. Reg. No. 023170
	GMP status of the Finished product manufacturer	New Section for liquid ampoule (SVP) General was granted after inspection vide letter No.F. 1-19/2014-Lic (Vol-1) Dated: 18/12/2020
	Name and address of API manufacturer.	M/s Zhejiang NHU Company Ltd. No.418 Xinchang Dadao West Road, Qixing Street, Xinchang County CHINA.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure

		system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability studies	Stability study conditions: Real time: 5°C ± 3°C for 24 months Accelerated: 25°C ± 2°C / 60% ± 10%RH for 06 months
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Indrop-D 5mg/ml injection by Neutro Pharma
	Analytical method validation/verification of product	Method validation studies have been submitted.

STABILITY STUDY DATA			
Manufacturer of API	M/s Zhejiang NHU Company Ltd. No.418 Xinchang Dadao West Road, Qixing Street, Xinchang County CHINA		
API Lot No.	01201103VD		
Description of Pack (Container closure system)	USP Type-I clear Glass ampoules in PVC Tray, packed in unit carton (1ml×1's)		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	21ARn055	21ARn056	21ARn057
Batch Size	2500 ampoules	2500 ampoules	2500 ampoules
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	24-05-2021	24-05-2021	24-05-2021
No. of Batches	03		
Administrative Portion			

	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate No. ZJ20180077 issued by PRC valid till 23/07/2023.
	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of letter No.14850/2020/DRAP-AD-VIII (I&E) dated 16/10/2020 is submitted wherein the permission to import different APIs including Cholecalciferol for the purpose of test/analysis and stability studies is granted. AirWay Bill No. 607-91230053 Dated: 02/12/2020
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	--
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

Remarks of Evaluator: Differential fee of Rs. 45,000/- shall be paid for the contract manufacturing application.

The applied formulation has already been approved in name of M/s Islam Pharmaceuticals for self-manufacturing, on Form 5F on the basis of stability studies data of same batches as presented in instant application. The details of previous approval of applied formulation in name of M/s Islam Pharmaceuticals is as under:

Applicant firm	M/s Islam Pharmaceuticals 7Km Pasrur Road Sialkot
Manufacturer firm	M/s Islam Pharmaceuticals 7Km Pasrur Road Sialkot
Brand Name	Care-D 5mg/ml Injection
Case No.	661
Batch No. of drug product	21ARn055, 21ARn056, 21ARn057
Registration Board meeting	316th meeting of Registration Board

Decision: Approved with innovator's specifications.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**

M/s Don Valley Pharmaceuticals (Pvt) Ltd 31 Km, Main Ferozepur Road, Lahore has requested (dated 07 November, 2022) to consider Priority evaluation and registration of following products, Form 5F (CTD):

Gutain capsules 60mg 2. Gutain capsules 30mg

Firm has submitted details for the Manufacturing and distributing data of Tylol Tablet (Paracetamol 500 mg) for 38 batches accounting for about 38,000 packs (200's) manufactured from September, 2022 to October, 2022.

77.	Name, address of Applicant / Marketing Authorization Holder	M/s Don Valley Pharmaceuticals (Pvt) Ltd 31 Km, Main Ferozepur Road, Lahore.

	Name, address of Manufacturing site.	M/s Don Valley Pharmaceuticals (Pvt) Ltd 31 Km, Main Ferozepur Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 19359 (dated: 01-07-2022)
	Details of fee submitted	PKR 30,000/-: dated: 10-03-2022 (deposit slip# 52512115288)
	The proposed proprietary name / brand name	Gutain capsules 60mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Dexlansoprazole…… 60 mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	2x7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Dexilant capsules (USFDA approved).
	For generic drugs (me-too status)	Dexxoo 60mg capsule (M/s Weatherfold pharma) Reg No 088380
	GMP status of the Finished product manufacturer	Firm has submitted GMP certificate issued on dated 06-08-2019. Section approval letter issued on 23.06.2009
	Name and address of API manufacturer.	M/s Vision Pharmaceutical Industrial Triangle Islamabad.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph for drug is not present in any pharmacopoeia. The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification

		of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (DLP283, DLP284, DLP285)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	The firm has submitted results of pharmaceutical equivalence for all the quality tests for their product as per specification and comparative study against the comparator product i.e. Dexilant 60mg capsule by Takeda Pharma (Batch No 508308) by performing quality tests (Average weight, content uniformity, Assay, Dissolution). CDP has been performed against the same brand that is Dexilant 60mg capsule by Takeda Pharma (Batch No 508308) in pH 1.2, pH 5.5, (after 1 hour), pH 7.0 (after 40 min)
	Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product including system suitability, specificity, accuracy, , repeatability, intermediate precision, linearity, range & robustness.

STABILITY STUDY DATA			
Manufacturer of API	M/s Vision Pharmaceutical Industrial triangle Islamabad Pakistan		
API Lot No.	Not provided		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 0, 3 (Months) Real Time: 0, 3 (Months)		
Batch No.	T-HF-21-01	T-HF-21-02	T-HF-21-03
Batch Size	5000 caps.	5000 caps.	5000 caps.
Manufacturing Date	11 – 2021	11 – 2021	11 – 2021
Date of Initiation	09-11-2021	09-11-2021	09-11-2021

No. of Batches		03
Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Evaluator:

Dissolution testing performed by finished product manufacturer on DDR pellets were as follows:

Dissolution parameters	Specification
Acid stage (Stage I)	
Apparatus	USP I
Medium	0.1N HCl
Volume	500ml
RPM	100
Sample interval	120 minutes
Analysis technique	UV
Limit	NMT 10%
Buffer stage (Stage II)	
Apparatus	USP I
Medium	pH 5.5
Volume	900ml
RPM	100
Sample interval	60 minutes
Analysis technique	UV
Limit	NMT 15-40%
Buffer stage (Stage II)	
Apparatus	USP I
Medium	pH 7.0
Volume	900ml
RPM	100
Sample interval	120 minutes
Analysis technique	UV
Limit	NLT 75%

Dissolution parameters of innovator product (Dexilant) are as follows:

Media	Acid Stage: 0.1 N HCl Buffer Stage 1: pH 6.0 Phosphate buffer with 5mM Sodium Lauryl Sulfate Buffer Stage 2: pH 7.4 Phosphate buffer with 5mM Sodium Lauryl Sulfate
Volume	Acid Stage: 500 mL Buffer Stage 1: 700 mL Buffer Stage 2: 900 mL
USP Apparatus	USP II (Paddle)
Speed	75 rpm
Specifications	Acid Stage: NMT (b)(4)% in 120 minutes Buffer Stage 1: NLT (b)(4)% in 30 minutes NMT (b)(4)% in 60 minutes Buffer Stage 2: NLT (b)(4)% in 60 minutes

Sr.#	Observations	Reply/Remark
1.	Justification to be provided for selection of dissolution parameters i.e dissolution medium, volume of dissolution medium, sampling interval and rpm etc.	We have selected dissolution parameters as per manufacturer specifications
	Detailed analytical procedures for the testing of drug substance (pellets) to be provided by Drug Product manufacturer	Provided
	Provide results of analysis of relevant batch(es) of Drug Substance (pellets) performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of batch No DLP 793 from FPP manufacturer is submitted however CoA of same Lot No is not provided from pellets manufacturer.
	Approval of API/ DML/GMP certificate of API (pellet) manufacturer to be provided	Provided
	In CDP report differentiation factor/similarity factor (f1, f2) has not been calculated. Moreover, sampling interval for dissolution testing at acid stage has not been defined.	Complied f2 value has been calculated in each medium. which was within acceptable range. Sampling interval for dissolution testing at acid stage is 120 min
	Data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc to be submitted at 6th month.	Complied
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not provided	Complied
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is not provided.	Complied

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufcaturer shall adopt specifications for dissolution test as recommended by innovator drug product for commercial batches.**

78.	Name, address of Applicant / Marketing Authorization Holder	M/s Don Valley Pharmaceuticals (Pvt) Ltd 31 Km, Main Ferozepur Road, Lahore.
	Name, address of Manufacturing site.	M/s Don Valley Pharmaceuticals (Pvt) Ltd 31 Km, Main Ferozepur Road, Lahore.
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 19358 (dated: 01-07-2022)
	Details of fee submitted	PKR 30,000/-: dated: 10-03-2022 (deposit slip# 23207259)
	The proposed proprietary name / brand name	Gutain capsules 30mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Dexlansoprazole…… 30 mg
	Pharmaceutical form of applied drug	Capsule
	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Innovator's
	Proposed Pack size	4x7's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Dexilant capsules (USFDA approved).
	For generic drugs (me-too status)	Dexxoo 30mg capsule (M/s Weatherfold pharma) Reg No 088381
	GMP status of the Finished product manufacturer	Firm has submitted GMP certificate issued on dated 06-08-2019. Section approval letter issued on 23.06.2009
	Name and address of API manufacturer.	M/s Vision Pharmaceutical Industrial Triangle Islamabad.
	Module-II (Quality Overall Summary)	The firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph for drug is not present in any pharmacopoeia. The firm has submitted detail of nomenclature, structure, general properties, solubility, physical form, manufacturers, description of manufacturing process and controls, specifications,

		analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: 30°C ± 2°C / 65% ± 5%RH for 18 months Accelerated: 40°C ± 2°C / 75% ± 5%RH for 6 months Batches: (DLP283, DLP284, DLP285)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	The firm has submitted results of pharmaceutical equivalence for all the quality tests for their product as per specification and comparative study against the comparator product i.e. Dexilant 30mg capsule by Takeda Pharma (Batch No 507728) by performing quality tests (Average weight, content uniformity, Assay, Dissolution). CDP has been performed against the same brand that is Dexilant 30mg capsule by Takeda Pharma (Batch No 507728) in pH 1.2, pH 5.5, (after 1 hour), pH 7.0 (after 60 min, 105 min and 120min)
	Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product including system suitability, specificity, accuracy, , repeatability, intermediate precision, linearity, range & robustness.

STABILITY STUDY DATA			
Manufacturer of API	M/s Vision Pharmaceutical Industrial triangle Islamabad Pakistan		
API Lot No.	Not provided		
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton.		
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 3 months Accelerated: 3 months		
Frequency	Accelerated: 0, 3 (Months) Real Time: 0, 3 (Months)		
Batch No.	T-HE-21-01	T-HE-21-02	T-HE-21-03
Batch Size	5000 caps.	5000 caps.	5000 caps.
Manufacturing Date	11 – 2021	11 – 2021	11 – 2021
Date of Initiation	13-11-2021	13-11-2021	13-11-2021

No. of Batches	03	
Administrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Not provided
	Documents for the procurement of API with approval from DRAP (in case of import).	Not provided
	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not provided
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Not provided

Remarks of Evaluator:

Dissolution testing performed by finished product manufacturer on DDR pellets were as follows:

Dissolution parameters	Specification
Acid stage (Stage I)	
Apparatus	USP I
Medium	0.1N HCl
Volume	500ml
RPM	100
Sample interval	120 minutes
Analysis technique	UV
Limit	NMT 10%
Buffer stage (Stage II)	
Apparatus	USP I
Medium	pH 5.5
Volume	900ml
RPM	100
Sample interval	60 minutes
Analysis technique	UV
Limit	NMT 15-40%
Buffer stage (Stage II)	
Apparatus	USP I
Medium	pH 7.0
Volume	900ml
RPM	100
Sample interval	120 minutes

Analysis technique	UV
Limit	NLT 75%

Dissolution parameters of innovator product (Dexilant) are as follows:

Media	Acid Stage: 0.1 N HCl Buffer Stage 1: pH 6.0 Phosphate buffer with 5mM Sodium Lauryl Sulfate Buffer Stage 2: pH 7.4 Phosphate buffer with 5mM Sodium Lauryl Sulfate
Volume	Acid Stage: 500 mL Buffer Stage 1: 700 mL Buffer Stage 2: 900 mL
USP Apparatus	USP II (Paddle)
Speed	75 rpm
Specifications	Acid Stage: NMT (b)(4)% in 120 minutes Buffer Stage 1: NLT (b)(4)% in 30 minutes NMT (b)(4)% in 60 minutes Buffer Stage 2: NLT (b)(4)% in 60 minutes

Sr.#	Observations	Reply/ Remark
1.	Justification to be provided for selection of dissolution parameters i.e dissolution medium, volume of dissolution medium, sampling interval and rpm etc	We have selected dissolution parameters as per manufacturer specifications
	Detailed analytical procedures for the testing of drug substance (pellets) to be provided by Drug Product manufacturer	Provided
	Provide results of analysis of relevant batch(es) of Drug Substance (pellets) performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (COA) of the same batch from Drug Substance / API manufacture.	CoA of batch No DLP 793 from FPP manufacturer is submitted however CoA of same lot No is not provided from pellets manufacturer.
	Approval of API/ DML/GMP certificate of API (pellet) manufacturer to be provided	Provided
	In CDP report differentiation factor/similarity factor (f1, f2) has not been calculated. Moreover, sampling interval for dissolution testing at acid stage has not been defined.	Complied f2 value has been calculated in each medium. which was within acceptable range. sampling interval for dissolution testing at acid stage is 120 min
	Data of stability batches supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc to be submitted at 6th month.	complied
	Compliance Record of HPLC software 21CFR & audit trail reports on product testing is not provided	complied
	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated) is not provided.	complied

Decision: Approved. The firm shall submit fee of Rs. 7,500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021, before issuance of registration letter.

- **Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.**
- **Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.**
- **Manufcaturer shall adopt specifications for dissolution test as recommended by innovator drug product for commercial batches.**

Item No. XIII: Import of Finished Pharmaceutical Products.

Registration Board deliberated that registration of finished pharmaceutical drug products are done as per Drugs (L R & A) Rules, 1976 and Policy for Import of Finished product as approved by DRAP's Policy Board. As per aforementioned provisions, many drug products (human and veterinary) are being registered for finished import despite of the being manufactured locally by national pharmaceutical manufacturers. Registration Board deliberated the matter in detail and decided to seek guidance from Authority, regarding the imposition of any restriction or putting of technical barriers on the import of finished drugs (for human use and also for veterinary products), which are sufficiently produced by the local pharma companies in Pakistan.

Item No. XIV: Formulations containing Linagliptin & Metformin Hydrochloride

Linagliptin is available as fixed dose combination with metformin in following formulations:

i. Linagliptin + Metformin HCl Immediate release film coated tablet.
ii. Linagliptin + Metformin HCl + Empagliflozin modified release tablet wherein Metformin HCl is available as extended release core while Linagliptin and Empagliflozin are available as immediate release layer of active coating.

The Public assessment report from various reference regulatory authorities of innovator products have reported that initial compatibility studies with the active substances showed degradation of Linagliptin when combined with Metformin hydrochloride, hence Arginine is included in the formulation as stabilizer and test of "Arginine content" is also included in the drug product specifications.

Submitted drug product development and stability studies data of above cited formulations need to be evaluated for the inclusion Arginine in the drug product formulation and its analysis of its contents in drug product.

Decision: Registration Board considered the above presented information and advised PE&R Division to present an agenda for further deliberation and review of formulations of drug product containing Linagliptin & Metformin for the inclusion of Arginine along with its role, limits and analysis in finish drug product.

Item No. XV: Enantiomeric purity of Linagliptin.

Linagliptin is a selective, orally administered, xanthine-based DPP-4 inhibitor. GLP-1 lowers blood glucose levels by augmenting the glucose-stimulated insulin release. The EMA assessment report for innovator product i.e., Trajenta tablet has reported that Linagliptin has one chiral centre at the 3-aminopiperidine moiety. The public assessment reports of Innovator product i.e., Trajenta tablet of M/s Boehringer Ingelheim, from various reference regulatory authorities have reported that the active substance corresponds to the R-enantiomer and the S-isomer is controlled as an impurity. The drug substance specifications of innovator drug product literature have also included test of "Enantiomeric purity" to confirm the enantiomeric form of Linagliptin.

It has been observed during the review of applications of "Linagliptin containing formulations" that the various drug substance manufacturers have reported enantiomeric purity of Linagliptin in different manners, briefed as under:

i. Test of Enantiomeric purity.
ii. Test for S-isomer.
iii. Test for Isomer.

The particular tests and limits required to establish the "Enantiomeric form" of Linagliptin, needs to be identified yet.

Decision: Registration Board considered the above presented information and advised PE&R Division to present an agenda for the "tests and Limits for "Enantiomeric purity of Linagliptin" in upcoming Board meeting.

B. Biological Drugs Division.

Case No. 01: Products Lumpyvac vaccine and Teylovac vaccine applied by M/s Huzaifa International, Sargodha

The following products of M/s Huzaifa International, Sargodha were approved in various meetings of Registration Board. The details are as under:

Product name and composition	Document Details	Decisions of RB
Lumpyvac (Lumpy Skin Disease vaccine with Diluent) Each 2 ml Dose contains: Attenuated Lumpy skin disease virus (Neethling strain) …. $\geq 10^{3.5}$ $TCID_{50}$	• Original Legalized Free Sale certificate dated 24-02-2022 • Legalized copy of GMP certificate dated 12-02-2019	**Decision of 316th meeting:** Keeping in view legalized GMP certificate and Legalized Free Sale Certificate indicating product availability in country of origin; Registration Board approved the product with "As per Innovator Specifications" subject to compliance of current Import Policy for finished drugs.
TEYLOVAC Vaccine Live attenuated Freeze dried Theileria Annulata cells based vaccine with diluent Each dose of vaccine contains Theileria annulata…...…….$\geq 1x10^7$ cells	Legalized Certificate of Pharmaceutical Product (CoPP) NoB028634. issued by Ministry of Agriculture and Forestry, Turkey, dated.01-10-2019 valid till. 10-11-2024.	**Decision of 313th meeting** Registration Board approved the product namely TEYLOVAC Vaccine as product is highly needed for veterinary use in Pakistan.

The firm M/s Huzaifa International, Sargodha has already been granted registration of Lumpyvac Vaccine having Registration No.111128 vide letter No. F.1-5/2022-AD(BD)(M316) dated 25th March 2022, however as per decision of Policy Board in its 41st meeting, the inspection exemption of manufacturer abroad i.e., M/s Vetal Animal Health Products, Turkey was granted for six months to M/s Huzaifa International, Sargodha. The six months' time period has been completed, hence the virtual inspection was conducted.

The virtual inspection of manufacturing facility abroad namely M/s Vetal Hayvan Sagligi Urunleri A.S. Turkey was conducted on 3rd – 4th November, 2022 by the panel of inspectors vide DRAP's letter No. F.8-1/2022-(I&V-I) dated 24th October, 2022. The conclusion and recommendations are as under:

Conclusion

Keeping in view the proceedings of virtual inspection conducted by the panel of inspectors, it was observed that *due to inadequate communication/ weak tools such as internet connectivity, inappropriate cameras, as mostly mobile cameras were used. Proper inspection cameras, borescopes, fiberscopes (communicated vide DRAP letter No.F.3-2/2005-Reg-I(Vol-II) dated 27th September, 2022) were not utilized, hence on this remote virtual inspection the basic system such as manufacturing facility/ Q.C etc were seen but actual manufacturing proceeding, Q.C testing, HVAC system functioning etc could not be verified.*

Moreover, it was also observed that Mr. Asim Rauf, the then Additional Director (E&M) Lahore, DRAP and Mr. Abdullah, Additional Director (PE&R), DRAP (co-opted member) had visited the same unit from 24th to 26th September, 2018 when it was newly built, while on official inspection of another unit of M/s Vetal Animal Health Products in Turkey.

It was highlighted in that inspection report that the newly built unit was a state of the art facility in which trial batches were being manufactured and QC testing of vaccines were performed.

Recommendations:

Based on the proceedings of virtual inspection, documents reviewed and videos of the unit seen, the panel has reached to the conclusion that the firm has basic systems to manufacture veterinary vaccines and appeared to comply the GMP requirements. *Hence, the panel recommends that the Registration Board may grant the registration of applied products namely Teylovac and Lumpyvac vaccines to M/s Huzaifa International, Sargodha for six months. However, the panel strongly recommends on-site inspection in order to verify/ ascertain the Good Manufacturing Practices (GMP) of the firm within six months' time period.*

a. As per inspection report, the filling area of both Lumpyvac and Teylovac vaccine was same, as Teylovac is a live protozoal vaccine while Lumpyvac is a live viral vaccine. The firm informed that cleaning validation procedures are performed for same filling line.
The same was discussed and it was decided to send emails to EMA, FAO and USDA dated 29-11-2022 regarding manufacturing requirements of live viral and live protozoal vaccines to be manufactured for animals in the same filling line. Accordingly, emails were sent to relevant authorities and the responses received did not address the query so far, therefore the case may be submitted for further directions if any.
b. As per recommendation of the panel, the Registration of the products namely Teylovac and Lumpyvac vaccines may be granted for six months only (the details are given above).

Previous Decision: Registration Board after thorough deliberation decided to defer the case of Teylovac Vaccine and advised to seek following clarifications **(M-323)**:

- Manufacturing requirements of live protozoal and live viral vaccines in the same filling line as outlined in the inspection report of the firm and also send emails to Turkish veterinary authority i.e., Directorate-General for Animal Health and Veterinary Medicines and OIE –World Organization for Animal Health.
- Legal Affair Division regarding issuance of registration letter for 6 months' time till onsite inspection by the panel.

Evaluation by BE&R: Email for clarification of manufacturing requirements of live protozoal and live viral vaccines was sent to the manufacturer, Turkish veterinary authority and OIE. The response received from M/s Vetal Animal Health Inc. enclosed following documents:

- SOP for fumigation process procedure
- SOP for Teylovac formulation and filling procedures
- SOP for cleaning validation protocol for live filling machine
- SOP for Search of Mycoplasma in Bulk and final containers

Response also received from EMA is as below:
We advise you to have a look at annex 5 of the EU GMP guide which is dedicated to the manufacturing of immunological veterinary medicinal products (https://health.ec.europa.eu/system/files/2016-11/anx05en200408_en_0.pdf).
Also in general, the EU GMP Guide, Part I, mentions in Chapter 3 and 5 several requirements for having dedicated facilities and measures to avoid (cross-)contamination (https://health.ec.europa.eu/system/files/2016-11/chapter_3_0.pdf) and https://health.ec.europa.eu/system/files/2016-11/chapter_5_0.pdf). A risk assessment including the toxicological considerations as defined in the Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different_en.pdf) should evidence the absence of risks of cross-contamination.

Discussion: Registration Board discussed the manufacturing of immunological veterinary medicinal products in the light of response received from European Medicine Agency (EMA). EMA has referred to Annex 5 of EU GMP Guide (https://health.ec.europa.eu/system/files/2016-11/anx05en200408_en_0.pdf) wherein it is categorically mentioned regarding filling of live biological agents:

- With the exception of blending and subsequent filling operations (or when totally enclosed systems are used,) only one live biological agent may be handled within a production room at any given time. Production rooms must be effectively disinfected between the handling of different live biological agents.
- Careful consideration should be given to the validation of methods for sterilization, disinfection, virus removal and inactivation.
- Filling should be carried out as soon as possible following production. Containers of bulk product prior to filling should be sealed, appropriately labelled and stored under specified conditions of temperature.

Decision: Keeping in view above, Registration Board decided as under:

- **Approved the registration of TEYLOVAC Vaccine (Live attenuated Freeze dried Theileria Annulata cells based vaccine with diluent). Manufacturer will follow above mentioned guidelines for manufacturing of vaccines**
- **Recommended the conduction of virtual inspection again of the manufacturer abroad for further verification of *manufacturing procedures, Q.C testing, HVAC system functioning etc* which could not be verified due to inadequate communication/ weak tools such as internet connectivity, inappropriate cameras during previous virtual inspection.**

Case No. 02: Application for the grant of Additional Pack of 1000ml of Locally Manufactured Veterinary Vaccine diluent namely VAXI-DROP by M/s Grand pharma (Pvt). Ltd, Rawat.

Following product of M/s Grand Pharma Pvt Ltd, Lahore was deferred in various meetings of Registration Board in 313th, 316th, 320th meeting of RB as per following details;

1.	**Name and address of product manufacturer (Applicant)**	**M/s Grand Pharma Pvt Ltd** Plot # 5-A, Street No.N-5, RCCI Estate, Rawat, Islamabad
	Brand Name +Dosage Form + Strength	Vaxi-drop 1000ml
	Type of Form, Diary No. Date of R& I & fee	Form-5 Dy. No.20999 Date:21-8-2020 Rs. 20,000/- Date: 19-8-2020
	Composition	Each ml contains: Monobasic Potassium Phosphate: 0.37 mg Disodium Phosphate Dihydrate: 0.72 mg Sodium Chloride : 7.65mg
	Pharmacological Group	Diluent for live Avian vaccines
	Finished Product Specification	Manufacturer' Spec
	Shelf Life	2 Years (15°C -25°C)
	Document Details	All the undertaking has been submitted by the firm. Copy of DML Copy of inspection report for GMP for viral vaccines section (killed) & Bacterial killed vaccine section.
	Pack size & Demanded Price	0.30ml per bird **Decontrolled**
	Products already registered in Pakistan	*MS Bac* (M/s Hi-Tech Pharma, Lahore)
	Remarks of Evaluator	

Previous Decisions:

Decision of 313th Meeting:

Deferred for submission of method of administration of vaccine and container closer system of diluent.

Decision of 316th Meeting:

Deferred for confirmation of manufacturing facility for the diluents

Decision of 320th Meeting:

Deferred for confirmation of international practices regarding the manufacturing sections requirement for manufacturing of vaccine diluents

In response, the firm has submitted following:

a. The vaccines diluents are sterile water preparations used for diluting & dispensing live vaccines of poultry and livestock which are presented in lyophilized form in a vial of 12-5ml capacity, containing 1000-5000 doses of a live vaccine. The vaccines for livestock and poultry are available in multiple doses format, therefore, to dispense these live vaccines a sterile water-based Diluent preparation is required. These diluents are available in separate packing and already a number of imported and local products have been registered 36ml (1000 doses) for eye-drop usage or 25ml and 50ml (25-50 doses) for sub/ cut injection or 200ml (1000 doses) for sub/ cut injection.
b. The container closure system comprises of an autoclavable polypropylene bottle having rubber caps with aluminum seals.
c. The required equipment for producing and filling / packing of proposed 1000ml pack size is already available in the production facility of Grand Pharma.
d. The following vaccine diluents are already registered with DRAP:

Vaccine Type	Presentation of Approved Diluents	Administration Route	Doses per vaccine vial	Company
NDV/ IBD/ IBV Live	36ml	Eye Drop/ Spray Drinking water	1000	- Lead pharma (local) - MSD - Elanco
NDV/ IBDV/ IBV live	Bulk RO water	Drinking water	-	Normal Field practice
MD/ CAV Live	200ml	Sub-Cut	1000	- MSD

				- CEVA
LSD Live	50ml	Sub-Cut	25 & 50	- MSD - Arriah

e. Regarding international practices for the production of diluents, the firm submitted that as per literature, diluents are produced in injectable facilities of a Pharma or Biologics production unit.

Based on the above, it is pointed out that although all types of queries from DRAP in this case have been responded accordingly, however, it has taken more than 2 years to reach to any decision in this case. Such delays are badly affecting our production plans for this product. It is therefore requested that all the queries raised during its evaluation by the Drug Registration Board, so approval may please be granted at the earliest for production of VAXI-Drop (1000 ml pack size) at Grand Pharma (Pvt) Ltd., Rawat Islamabad, accordingly.

Previous Decision: Registration Board deferred the case and advised BE&R Division to compile data of all such registrations granted to M/s Grand Pharma and place before Registration Board for its consideration **(M-323)**.

Evaluation by BE&R: The firm has already registered product (diluent in 36 ml packing) vide Registration # 087070 dated 28-05-2018. And the VAXI-DROP is used to dilute live avian vaccines through spray or Eye drop.

Decision: Registration Board deferred the case and advised to deliberate the case with Licensing Division regarding manufacturing requirements of diluents for vaccine.

Item No VII. Miscellaneous cases:

Case No. 1: Request of PPMA for Extension in Time for Submission of Stability Data of Form 5

Registration Board in its 320th meeting considered the case of "Applications submitted on Form 5 / 5-D requiring submission of stability data" and decided as under:

> ***Registration Board deliberated the matter in detail and observed that these applications are pending for submission of stability data/product development data by the applicants since many years. Keeping in view the pendency, the Board deliberated the matter in detail and also took opinion of PPMA and then decided that the firms shall initiate the product development and stability studies of submitted applications and intimate to Pharmaceutical Evaluation Cell (PEC) regarding procurement of raw material, initiation of product development and initiation of stability studies, by 31st December 2022. For all those applications for which Pharmaceutical Evaluation Cell will not receive any intimation regarding initiation of product development and stability studies, will be placed before the Board for decision.***

The above decision of the Board was notified vide letter No. No. 320-DRB/ 2022(PE&R) dated 17-10-2022.

Now, Pakistan Pharmaceutical Manufacturers' Association through its Chairman (North) vide its letter No. PPMNAM-03312022 dated 30-12-2022 has requested for Extension in Time for Submission of Stability Data of Form 5. The request of PPMA is placed below:

> *Respected Sir,*
> *Please accept heartiest compliments and best wishes from Pakistan Pharmaceuticals Manufacturers' Association.*
> *This refer to the above subject that Drug Regulatory Authority of Pakistan has instructed that Pharma Manufacturer companies will submit Stability Data of Form 5 / Form 5-D Files till December 31,2022 to DRAP otherwise the Files shall be considered withdrawal. The decision was taken in 320th DRB Meeting held on 29th July to 1st August, 2022.*
> *In this regard, it is submitted that our member companies are requested that the time period for Submission of Stability Data of Form 5 (31.12.2022) is not enough in current circumstances as there are hindrances in Import of Materials due to current economic condition of country.*
> *Therefore, you are requested to* ***kindly extend the time for Six Months for the submission of Stability Data of Form 5*** *and oblige.*

Decision: Registration Board while considering the above cited request of PPMA reiterated that that the numerous applications are pending for submission of stability data/product development data

by the applicants since many years causing by an un due backlog for the PE&R Division. Board also discussed that previously, opinion of PPMA was also taken while giving an opportunity to the firms to submit an intimation regarding initiation of product development & stability studies had been given to firms for submission of any had already been given a time period till by 31st December 2022. Keeping in view the above deliberation Board decided to refer the case to Authority for seeking guidance regarding timelines for submission of Stability Data of Form 5 / Form 5-D Files.

Case No. 2: Request of PPMA for Registration of Semaglutide Tablet for export purpose only

PPMA vide its letter dated 16-01-2023 has submitted the following request.

"Our member companies are receiving inquiries for providing Semaglutide Tablets from various countries. PPMA is under discussion with DRAP for deliberation regarding registration of this important drug for local population. In meantime, it is being earnestly requested to please process export registrations of member companies so that they can start to export and earn valuable foreign exchange which is the dire need during current hard times."

Decision: Registration Board referred the case to the "Working Group for deliberation regarding Semaglutide" with advise to take up the matter in upcoming meeting of the working group.

Case No. 3: Regulatory submissions for registration of pharmaceutical drug products on Form 5F.

Registration Board discussed the following proposals in lieu of the existing procedure for dossier submission and deliberated that it will not only facilitate the registration applicants in submission of their applications on Form 5F but will also also streamline the assessment process without compromising on safety, efficacy and quality aspects of applied products. Registration Board decided that relevant guidelines be revised in light of the decisions made in instant cases.

Observers / stakeholders *viz.* Pakistan Pharmaceutical Manufacturers Association, Pharma Bureau and Pakistan Chemist & Druggist Association appreciated the proposals and decisions of Registration Board.

a. Submission of Form 5F (Hard copy and digital submission).

The pharmaceutical companies submit applications for registration of pharmaceuticals and biological products on Form 5F which usually contains large volume of technical data usually comprising of multiple volumes of papers. Internationally, due to enormous volume of data, most of such submissions have been shifted to online submission which is convenient both for applicant and regulatory authority.

In this regard, the main issues at the applicant's side are:

- Handling and Transportation of manual files through couriers or in-person submissions,
- Hefty printing and logistic cost,
- Compilation of data files, etc.

Similarly, at the side of DRAP which receives thousands of registration dossiers annually, challenges are:

- Human labour for handling and archiving of a large number of manual files,
- An unending need for vast space for storage management.

Goal:

Like all progressive organizations which are embracing new technologies and adopting modern "way of doing things", Drug Regulatory Authority of Pakistan (DRAP) has implemented technological approaches for its various regulatory processes including online fee challan generation system, PIRIMS, Online import export application system (OIES), E-Governance (e-Office) etc. With the deployment of all these technological systems, DRAP has made itself more visible for stakeholders, and also witnessed enhanced level of efficiency and effectiveness.

Similarly, in context to the current challenge, DRAP proposes a procedural shift from conventional method of dossier submission through manual files to electronic submission process. Keeping in view the practicality, usability and reliability, we hereby propose following procedure which also ensures the sanctity of the regulatory data.

Proposal:

DRAP proposes to add another option for regulatory submissions via hybrid mode, where minimum submission will be required in hard copy and all the scientific studies and related data may be submitted in the non-editable digital format. Applicants may submit application dossier for registration of drug in following manner:

Content of Form 5F	Type of Submission
i. Covering Letter ii. Signed Application on Form 5F iii. Fee Challan(s) iv. Module 1	Hard Copy
i. Module 1 ii. Module 2 iii. Module 3 iv. Module 4 v. Module 5	Non-Editable & Non printable Digital submission

DRAP also recommends that applicant shall use a watermark of their companies in page background to maintain the sanctity of the data. In addition, applicants will also maintain data repository of all regulatory submission at their premises.

Advantages:

- Efficient document management at the level of applicant and regulatory body.
- Economical and eco-friendly. (less paper consumption and printing).
- Reduced physical storage space and cost.
- Increased working quality and efficiency.

Decision: **Registration Board endorsed the above presented proposals for provisions of data submission on digital format for Form 5F of Pharmaceutical drug registration applications and recommended to proceed further for its notification by DRAP. However, applicant may use existing process of submission in hard format, if desired so.**

Case no. 04: Proposals for data requirements of Form 5-F:

a. Data requirements of Form 5-F for pharmaceutical drug products having multiple strengths / fill volumes.

Several drug products are available in multiple strengths or fill volumes and in such cases the drug substance part of Form 5F remains the same, if the source has not been changed between the strengths of fill volumes. For such cases the applicants had to submit volume of data comprising of same information of drug substance along with application of every strength.

Proposal: For such drug products, having multiple strengths multiple strengths or fill volumes complete Form 5F may be submitted for only one of the strength/fill volume or one of the strengths while for remaining strengths/fill volumes the 3.2.S part of CTD will be optional and applicant may refer to its complete dossier for this data.

Conditions:

i. All strengths/fill volumes shall be manufactured by same source of drug substance.

Decision: Registration Board decided to approve the proposal with following conditions and recommended to proceed further for its notification by DRAP.

i. An undertaking by the applicant that all strengths/fill volumes shall be manufactured by same source of drug substance.

ii. If different Lot/Batch no. of same source of drug substance has been used in manufacturing of various strengths/fill volumes of applied product, then Certificate of Analysis of such lots / batch nos. of drug substance (by drug substance and drug product manufacturers) will be submitted by the applicant.

b. Applications for contract manufacturing.

Applications of any drug product in particular strength and dosage form for contract manufacturing may require submission of complete dossier. If approved by the Registration Board, thereafter, only Module I may be required for the rest of the applicants who are willing to get registration of the same drug product from the same contract manufacturer following submission may be required only:

i. Covering Letter
ii. Signed Application on Form 5F
iii. Fee Challan(s)
iv. Module 1

Conditions:

i. Applicants shall submit declaration that they are willing to adopt the same source of drug substance, drug product formulation, specifications and container closure as approved in previous application of the contract manufacturer.

ii. Applicant shall refer along with extract of relevant minutes of Registration Board for the previous approval of the applied drug product on Form 5F from same manufacturer.

Decision: Registration Board decided that applicant may submit application of contract manufacturing of Human Pharmaceutical drug products with covering letter, fee challan, filled and signed Form 5F and Module 1. For remaining modules (2-5), the applicant instead of submission of data shall refer to previous approval of Registration Board (on Form 5F) of same formulation with the product development and stability studies data from same manufacturing site with the condition that:

- **Applicant shall submit declaration that they will adopt the same source of drug substance drug product formulation, specifications and container closure**
- **In case of any post-registration variation by contract manufacturer, same shall be immediately applied by applicant/ registration holder for requisite approval by Registration Board as per "Post Registration Variation Guideline for Pharmaceutical and Biological Products", available on DRAP's official website**
- **Applicant shall refer along with extract of relevant minutes of Registration Board for the previous approval of the applied drug product on Form 5F from same manufacturer.**

Meeting ended with vote of thanks to and from the chair.

End of document